<?xml version='1.0' encoding='UTF-8' ?><Trials_downloaded_from_ICTRP>
  <Trial>
    <Internal_Number>2452965</Internal_Number>
    <TrialID>EUCTR2004-001298-24-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>An open-label, randomized, multicenter, parallel group study to demonstrate correction of anemia using intravenous injections of RO0503821 in patients with chronic kidney disease who are on dialysis</Public_title>
    <Scientific_title>An open-label, randomized, multicenter, parallel group study to demonstrate correction of anemia using intravenous injections of RO0503821 in patients with chronic kidney disease who are on dialysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>F. Hoffmann-La Roche Ltd</Primary_sponsor>
    <Date_registration3>20040628</Date_registration3>
    <Date_registration>28/06/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001298-24                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>01/07/2004</Date_enrollement>
    <Target_size>168</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Baseline predialysis (for HD patients) Hb concentration 8-11 g/dL determined from the mean of 2 screening values with at least one day between measurements&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Previous therapy with recombinant human erythropoetin or any other erythropoeitc substance within 12 weeks prior to screening. If epoetin treatment has been interrupted for at least 12 weeks, the patient may be enrolled in the study. Ongoing epoetin treatment should not be discontinued to allow participation in the trial.&lt;br&gt;</Exclusion_Criteria>
    <Condition>anemia in chronic kidney patients who are in dialysis</Condition>
    <Intervention>&lt;br&gt;Product Name: cera&lt;br&gt;Product Code: RO 0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;Trade Name: Neorecormon&lt;br&gt;Product Name: Neorecormon&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Epoetin beta&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50000-&lt;br&gt;INN or Proposed INN: epoetin beta&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100000-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To demonstrate the efficay of IV RO 0503821;Secondary Objective: - To asses time to response&lt;br&gt;- To asses the safety and tolerability of multiple doses of RO 0503821 during the correction and extension periods in this patient population&lt;br&gt;- To asses long term safety with RO 0503821 in this patient population&lt;br&gt;- To investigate the farmachokinetics and the concentration-effect relationships after IV administration of RO 0503821 in this patient population;Primary end point(s): To demonstrate the efficay of IV RO 0503821 treatment for correction of anemia in patients with kidney chronic disease who are on dialysis</Primary_outcome>
    <Secondary_ID>BA16736</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453174</Internal_Number>
    <TrialID>EUCTR2004-002160-22-HU</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety of MK-0431
Monotherapy in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Control - MK-0431 Monotherapy Study in Patients With Type 2 DM and Chronic Renal Insufficiency</Public_title>
    <Scientific_title>A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety of MK-0431
Monotherapy in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Control - MK-0431 Monotherapy Study in Patients With Type 2 DM and Chronic Renal Insufficiency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Merck &amp; Co., Inc.</Primary_sponsor>
    <Date_registration3>20041012</Date_registration3>
    <Date_registration>12/10/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002160-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/11/2004</Date_enrollement>
    <Target_size>90</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;a.	Patient has type 2 diabetes mellitus (T2DM). &lt;br&gt;b.	Patient has moderate, severe, or end-stage renal insufficiency as indicated by a ‘yes’ answer to one or more of the following :&lt;br&gt;1)	Creatinine clearance =30 to &lt; 50 mL/min&lt;br&gt;2)	Creatinine clearance &lt; 30 mL/min&lt;br&gt;3)	Patient receiving dialysis&lt;br&gt;c.	Patient is =18 years of age.&lt;br&gt;d.	Patient has an understanding of the study procedures and agrees to participate in the study by giving written informed consent.&lt;br&gt;e.	Patient is not pregnant or breast-feeding and does not plan to become pregnant for the duration of the study and poststudy follow-up period.&lt;br&gt;f.	Patient is a male, or a female who is highly unlikely to conceive.&lt;br&gt;g.	HbA1c =6.5% and =10% measured at, or within 2 weeks prior to, Visit 3.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;a.	Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis&lt;br&gt;b.	Patient has an ALT or AST &gt;2.0-fold the Upper Limit of Normal (ULN)&lt;br&gt;c.	Patient has acute or rapidly progressive renal disease, or a history of renal transplant.&lt;br&gt;d.	Patient has any of the following disorders within the past 6 months: &lt;br&gt;•	Acute coronary syndrome (e.g., MI or unstable angina).&lt;br&gt;•	Coronary artery intervention (e.g., CABG or PTCA).&lt;br&gt;•	Worsening congestive heart failure (e.g., worsening symptoms or increase in pharmacologic therapy).&lt;br&gt;•	Stroke or transient ischemic neurological disorder.&lt;br&gt;e.	Patient has new or worsening signs or symptoms of coronary heart disease within the past 3 months.&lt;br&gt;f.	Patient has a BMI &lt;20 kg/m2 or &gt;43 kg/m2&lt;br&gt;g.	Patient has a positive urine pregnancy test&lt;br&gt;h.	Patient has any other condition or therapy which, in the opinion of the investigator or Merck medical monitor, might pose a risk to the patient or make participation not in the patient’s best interest.&lt;br&gt;i.	Patient has poor mental function or any other reason to expect that the patient may have difficulty in complying with the requirements of the study.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Type 2 Diabetes Mellitus

Chronic Renal Insufficiency [MedDRA classification code:  10050441] &lt;br&gt;MedDRA version: 7.0
Level: LLT
Classification code 10045242
</Condition>
    <Intervention>&lt;br&gt;Product Name: MK-0431   25-mg Tablet&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Current Sponsor code: MK-0431&lt;br&gt;Other descriptive name: L-000224715&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Glibinese [Glipizide 5-mg scored tablets]&lt;br&gt;Product Name: Glibinese 5-mg scored tablets&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: glipizide&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: In patients with type 2 diabetes mellitus and chronic renal insufficiency with inadequate glycemic control&lt;br&gt;&lt;br&gt;Primary:  To assess the safety and tolerability of MK-0431 after 12 weeks.&lt;br&gt;;Secondary Objective: In patients with type 2 diabetes mellitus and chronic renal insufficiency with inadequate glycemic control&lt;br&gt;&lt;br&gt;To assess the safety and tolerability of MK-0431 over 54 weeks.;Primary end point(s): N/A</Primary_outcome>
    <Secondary_ID>0431-028</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453243</Internal_Number>
    <TrialID>EUCTR2004-000587-26-HU</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A 24-month Extension to a one-year, multicentre, double-blinded, double-dummy, randomized study to evaluate the safety and efficacy of two doses of FTY720 combined with full-dose Neoral and steroids versus Cellcept combined with full-dose Neoral and steroids, in de novo adult renal transplant recipients.</Public_title>
    <Scientific_title>A 24-month Extension to a one-year, multicentre, double-blinded, double-dummy, randomized study to evaluate the safety and efficacy of two doses of FTY720 combined with full-dose Neoral and steroids versus Cellcept combined with full-dose Neoral and steroids, in de novo adult renal transplant recipients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Novartis Pharma Services AG</Primary_sponsor>
    <Date_registration3>20041110</Date_registration3>
    <Date_registration>10/11/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000587-26                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>01/02/2005</Date_enrollement>
    <Target_size>690</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: Partially double blinded, partially open&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;a)	The patient has given written informed consent to participate in the extension study.&lt;br&gt;b)	The patient has completed the core study (through 12 months post-transplantation, either being maintained on study medication or having attended the Follow-up visits up to Month 12 after being discontinued from study medication).  &lt;br&gt;c)	Females capable of becoming pregnant are required to practice a medically approved method of birth control as long as they are on study medication and for a period of 3 months following discontinuation of study medication.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients with any medical or psychosocial condition which the investigator believes would hinder compliance with the study requirements.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Prophylaxis of kidney allograft rejection in de novo adult renal transplant recipients &lt;br&gt;MedDRA version: 7.0
Level: LLT
Classification code 10023439
</Condition>
    <Intervention>&lt;br&gt;Product Name: FTY720&lt;br&gt;Product Code: FTY720&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: CellCept&lt;br&gt;Product Name: Mycophenolate Mofetil&lt;br&gt;Product Code: RS-61443&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun Neoral&lt;br&gt;Product Name: Ciclosporin for microemulsion&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The objective of this extension is to assess long-term safety and efficacy data of two doses of FTY720 (2.5 or 5.0 mg) combined with full dose Neoral and steroids versus MMF combined with full dose Neoral and steroids in de novo adult renal transplant recipients beyond 12 months post-transplantation.;Secondary Objective: To provide continued treatment for patients who have completed the 12-month core study on study medication.;Primary end point(s): Biopsy-proven acute rejection, graft loss, death or discontinuation from study</Primary_outcome>
    <Secondary_ID>CFTY720A2218E1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453302</Internal_Number>
    <TrialID>EUCTR2004-004416-22-SE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Platelet function in diabetic patients without and with renal impairment, and the effects of lipid-lowering treatment</Public_title>
    <Scientific_title>Platelet function in diabetic patients without and with renal impairment, and the effects of lipid-lowering treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Karolinska Institutet, Dept of Medicine, Clinical Pharmacology Unit</Primary_sponsor>
    <Date_registration3>20041206</Date_registration3>
    <Date_registration>06/12/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-004416-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>05/01/2005</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: yes&lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Diabetes mellitus type 2&lt;br&gt;&lt;br&gt;With or without established microalbuminuria (urinary albumin excretion of 30-299 µg/mg creatinine in a spot sample) Two out of three specimens collected within a 3-6 month period should be abnormal before the diagnosis can be settled. &lt;br&gt;&lt;br&gt;Glomerular filtration rate (GFR) between 15-50 ml/min (measured the last 6 months) or GFR &gt;75ml/min. GFR will be established by 24-hour Iohexolclearence.&lt;br&gt;&lt;br&gt;Age 18-80 years&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Definite history of myocardial infarction, coronary revascularisation procedure or stroke. (i.e, a strong clinical indication for statin treatment) &lt;br&gt;&lt;br&gt;Functioning renal transplant, or living donor-related transplant planned.&lt;br&gt;&lt;br&gt;Patients on dialysis.&lt;br&gt;&lt;br&gt;Poor metabolic control, i.e HbA1c &gt; 9%&lt;br&gt;&lt;br&gt;Definite history of chronic liver disease, or abnormal liver function (i.e ALT &gt;1,5 x ULN or, if ALT not available, AST &gt; 1,5 x ULN). &lt;br&gt;&lt;br&gt;Evidence of active inflammatory muscle disease (e.g dermatomyositis, polymyositis), or CK&gt;3 x ULN&lt;br&gt;&lt;br&gt;Definite previous adverse reaction to a statin or to ezetimibe&lt;br&gt;&lt;br&gt;Definite previous adverse reaction to acetylsalicylic acid.&lt;br&gt;&lt;br&gt;Definite previous adverse reaction to an ACE-inhibitor.&lt;br&gt;&lt;br&gt;Need for concomitant treatment with a strong inhibitor of CYP3A4, such as itrokonazole, ketokonazole, erythromycin, clarithromycin, HIV-protease inhibitors or nefazodone (i.e. agents that may markedly elevate simvastatin levels).&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Diabetes mellitus type 2, without or with renal impairment
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Zocord  R&lt;br&gt;Product Name: Zocord  R&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Simvastatin&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 40-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Ezetrol&lt;br&gt;Product Name: Ezetrol  R&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: ezetimibe&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 10-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the effects of simvastatin + ezetimibe with those of simvastatin alone, on thrombogenic mechanisms, in patients with diabetes mellitus type 2.;Secondary Objective: a) Compare the effects of simvastatin alone with those of placebo (baseline data) on thrombogenic mechanisms&lt;br&gt;b) Compare the effects of simvastatin + ezetimibe with those of simvastatin alone, and simvastatin alone with placebo on inflammatory variables.&lt;br&gt;c) Assess how the treatment effects relate to renal function.  &lt;br&gt;;Primary end point(s): ADP stimulated platelet P-selectin expression (flow cytometry in whole blood).&lt;br&gt;Other flow cytometric platelet variables related to the primary end point are (a) circulating platelet-platelet aggregates, (b) circulating platelet-leukocyte aggregates, (c) single platelet counts.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>DMK001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453351</Internal_Number>
    <TrialID>EUCTR2004-002032-26-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>An open-label, multi-center study to document the efficacy, safety and tolerability of long-term administration of RO0503821 in patients with chronic renal anemia</Public_title>
    <Scientific_title>An open-label, multi-center study to document the efficacy, safety and tolerability of long-term administration of RO0503821 in patients with chronic renal anemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>F. Hoffmann-La Roche Ltd.</Primary_sponsor>
    <Date_registration3>20041112</Date_registration3>
    <Date_registration>12/11/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002032-26                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>23/12/2004</Date_enrollement>
    <Target_size>1000</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Aranesp, NeoRecormon&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	1.	Written informed consent&lt;br&gt;2.	Adult patients (equal or more than 18 years old) with chronic renal anemia&lt;br&gt;3.	Continuous maintenance erythropoietic therapy with RO0503821 or a protocol-specified reference medication (epoetin alfa formulated with human albumin,  epoetin beta or darbepoetin alfa) in one of the following studies: BA16528, BA16285, BA16286, BA16736, BA16738, BA16739, BA16740, BA17283 and BA17284&lt;br&gt;4.	Hemoglobin concentration between 10.5 and 13.0 g/dL &lt;br&gt;5.	Adequate iron status defined as serum ferritin equal or more than 100 ng/mL or TSAT equal or more than 20% (or percentage of hypochromic RBCs &lt; 10%)&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;6.	Poorly controlled hypertension necessitating interruption of erythropoietin treatment in the 6 months before screening&lt;br&gt;7.	Epileptic seizure in the  6 months before screening&lt;br&gt;8.	Platelets  &gt; 500 x 10 9/L&lt;br&gt;9.	Pure red cell aplasia &lt;br&gt;10.	Chronic congestive heart failure (New York Heart Association Class IV)&lt;br&gt;11.	High likelihood of early withdrawal or interruption of the study (e.g., myocardial infarction, severe or unstable coronary artery disease, stroke, severe liver disease within the 12 weeks before screening)&lt;br&gt;12.	Active malignant disease (except non-melanoma skin cancer)&lt;br&gt;13.	Life expectancy less than 12 months&lt;br&gt;14.	Pregnancy or breast-feeding&lt;br&gt;15.	Women of childbearing potential without effective contraception&lt;br&gt;16.	Administration of another investigational drug planned during the study period&lt;br&gt;17.	Known hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any constituent of the study or reference drug  formulations&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patient with chronic renal anaemia</Condition>
    <Intervention>&lt;br&gt;Product Name: N/A&lt;br&gt;Product Code: RO0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: not available yet&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;INN or Proposed INN: not available yet&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;INN or Proposed INN: not available yet&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: not available yet&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;INN or Proposed INN: not available yet&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;Trade Name: NeoRecormon&lt;br&gt;Product Name: NeoRecormon &lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;INN or Proposed INN: Epoetin beta&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50.000-&lt;br&gt;INN or Proposed INN: Epoetin beta&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100.000-&lt;br&gt;&lt;br&gt;Trade Name: Aranesp&lt;br&gt;Product Name: Aranesp&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Darbepoetin alfa&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 15-&lt;br&gt;INN or Proposed INN: Darbepoetin alfa&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;INN or Proposed INN: Darbepoetin alfa&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;INN or Proposed INN: Da</Intervention>
    <Primary_outcome>Main Objective: To document that RO0503821 administered for prolonged periods is efficacious, safe and well tolerated in patients treated for  chronic renal anemia;Secondary Objective: N/A;Primary end point(s): Analysis of Efficacy&lt;br&gt;No formal efficacy assessment will be performed. Efficacy parameters such as hemoglobin will be reported descriptively using means, standard deviations and percentiles.&lt;br&gt;&lt;br&gt;Analysis of Safety &lt;br&gt;All patients who have received at least one dose of RO0503821 or of reference medication and a safety follow-up, whether withdrawn prematurely or not, will be included in the safety analysis. The safety parameters will be vital signs, AEs and the safety laboratory parameters. &lt;br&gt;All safety parameters will be summarized descriptively. Vital signs and laboratory data will be assessed for clinically relevant abnormalities.&lt;br&gt;Frequencies and incidence rates of AEs will be tabulated.  The goal of the statistical evaluation of AE data is a standardized tabulation of the frequencies and incidence rates of all observed AEs. These will be calculated on a per-patient basis rather than on an event basis. &lt;br&gt;Brief narratives will describe each death, each drug related SAE, premature withdrawals arising from AEs, and other significant AEs that are judged to be of special interest because of clinical importance. &lt;br&gt;All safety parameters will be summarized descriptively. Vital signs and laboratory data will be assessed for clinically relevant abnormalities.</Primary_outcome>
    <Secondary_ID>BH 18387</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453504</Internal_Number>
    <TrialID>EUCTR2004-002310-10-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Study to Investigate Cinacalcet Treatment in Haemodialysis Patients with Secondary Hyperparathyroidism - SENSOR</Public_title>
    <Scientific_title>Study to Investigate Cinacalcet Treatment in Haemodialysis Patients with Secondary Hyperparathyroidism - SENSOR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Amgen Development Europe</Primary_sponsor>
    <Date_registration3>20041110</Date_registration3>
    <Date_registration>10/11/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002310-10                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/11/2004</Date_enrollement>
    <Target_size>800</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- CKD patients requiring dialysis (HD, HDF, HF) for at least 1 month before enrolment&lt;br&gt;- Males or females = 18 years of age at the time of informed consent. &lt;br&gt;- Men and women participating in this study must agree to use, in the opinion of the principal investigator, highly effective contraceptive measures throughout the study.  Females must have a negative serum pregnancy test (or definitive evidence to demonstrate lack of pregnancy) within 30 days before randomisation, unless there is a definite history of amenorrhoea.&lt;br&gt;- An iPTH determination within 14 days before randomisation must be = 300 pg/mL (biPTH = 150 pg/mL).  &lt;br&gt;- A serum calcium determination (corrected for calcium) within 14 days before randomisation must be = 8.4 mg/dL [2.1 mmol/L].  &lt;br&gt;- Signed the Independent Ethics Committee (IEC) approved Informed Consent document, before any study specific procedures are initiated &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Have an unstable medical condition, defined as having been hospitalised, other than for dialysis vascular access revision, within 30 days before day 1, or otherwise unstable in the judgment of the investigator.&lt;br&gt;- Are currently breast-feeding.&lt;br&gt;- Are performing peritoneal dialysis&lt;br&gt;- Have had a parathyroidectomy in the 3 months before day 1.&lt;br&gt;- Are currently enrolled in, or have not yet completed at least 30 days before day 1 other invasive investigational device or investigational drug trials, or are receiving other investigational agents (experimental dialysis machines are acceptable).&lt;br&gt;- Have a gastrointestinal disorder that may be associated with impaired absorption of orally administered medications or an inability to swallow tablets.&lt;br&gt;- Have a disorder that would interfere with understanding and giving informed consent or compliance with protocol requirements&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis</Condition>
    <Intervention>&lt;br&gt;Product Name: Cinacalcet&lt;br&gt;Product Code: AMG 073&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Cinacalcet&lt;br&gt;CAS Number: 364782-34-3&lt;br&gt;Current Sponsor code: AMG 073&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;&lt;br&gt;Product Name: Cinacalcet&lt;br&gt;Product Code: AMG 073&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Cinacalcet&lt;br&gt;CAS Number: 364782-34-3&lt;br&gt;Current Sponsor code: AMG 073&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 60-&lt;br&gt;&lt;br&gt;Product Name: Cinacalcet&lt;br&gt;Product Code: AMG 073&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Cinacalcet&lt;br&gt;CAS Number: 364782-34-3&lt;br&gt;Current Sponsor code: AMG 073&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 90-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To demonstrate that the efficacy of cinacalcet when co-administered with the first meal after dialysis is comparable (non-inferior) to the efficacy of cinacalcet when administered during the dialysis study visit.;Secondary Objective: To evaluate the safety of cinacalcet when co-administered with the first major meal after dialysis.&lt;br&gt;To evaluate a predefined strategy to manage nausea/vomiting during the study&lt;br&gt;;Primary end point(s): The proportion of subjects with a mean iPTH £ 300 pg/mL at weeks 11 and 13</Primary_outcome>
    <Secondary_ID>20040143</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453669</Internal_Number>
    <TrialID>EUCTR2004-004488-31-NO</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Does cyclosporine A reduce the insulin secretion from the pancreas?</Public_title>
    <Scientific_title>Does cyclosporine A reduce the insulin secretion from the pancreas?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Rikshospitalet University Hospital, University of Oslo</Primary_sponsor>
    <Date_registration3>20050201</Date_registration3>
    <Date_registration>01/02/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-004488-31                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement />
    <Target_size>16</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;Other trial design description: Therapy followed by wash out&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Dialysis patients planned to be kidney transplanted and not treated with steroids&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Age above 75 years or below 18 years&lt;br&gt;Pregnancy&lt;br&gt;Lactating mothers&lt;br&gt;Diabetes mellitus&lt;br&gt;Less than 2 months of dilayses&lt;br&gt;Coronary heart disease&lt;br&gt;Ongoing corticosteroid treatment&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Kidney failure / dialysis patients / transplantation</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sandimmun Neoral&lt;br&gt;Product Name: Sandimmun Neoral&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Current Sponsor code: NOVARTIS&lt;br&gt;Other descriptive name: Sandimmun Neoral&lt;br&gt;Concentration unit: µg/l microgram(s)/litre&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 150-200&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Other descriptive name: cyclosporine A&lt;br&gt;Concentration unit: µg/l microgram(s)/litre&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 150-200&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Test the effect of cyclosporine A on insulin release;Secondary Objective: Test the effect of cyclosporine A on insulin action, endothelial function. Test the useage of pretransplant cyclosporine A pharmacokinetics detrminations for dose individualisation at the time of transplantation;Primary end point(s): Change in insulin secretion&lt;br&gt;</Primary_outcome>
    <Secondary_ID>S-02005</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453918</Internal_Number>
    <TrialID>EUCTR2004-001608-11-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Multi-centre, Open Label, Randomised, Parallel Group Pilot Study to assess the Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease</Public_title>
    <Scientific_title>A Multi-centre, Open Label, Randomised, Parallel Group Pilot Study to assess the Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Shire Pharmaceutical Development Ltd</Primary_sponsor>
    <Date_registration3>20050303</Date_registration3>
    <Date_registration>03/03/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001608-11                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/11/2004</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Male or female patients greater than or equal to 18 years of age receiving haemodialysis for end stage renal disease with a level of serum phosphate&gt;5.9mg/dL (1.9mmol/L) after washout or sub-optimally treated with current phosphate binder. Patients (including those who have undergone renal transplantation in the past) must have received haemodialysis for chronic renal failure three times per week for at least the previous two months. &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Pregnant or lactating women. Patients with screening calcium below 8.8mg/dL (2.2mmol/L) or with significant abnormal laboratory values (excluding markers of pathologies associated with chronic renal failure), which in the opinion of the investigator should exclude the patient from the study. Patients with clinically significant uncontrolled concurrent illness a life threatening malignancy or current multiple myeloma or known to be HIV positive. Patients with any significant bowel obstruction, active inflammatory disease, gastrointestinal (GI) motility disorders, abnormal or irregular bowel motion or a history of major GI surgery within the last 6 mnths. Patients who have been in any other clinical trial within the last 30 days or who have previously taken lanthanum carbonate in the last year. &lt;br&gt;</Exclusion_Criteria>
    <Condition>Hyperphosphataemia in Patients Receiving Haemodialysis for End Stage Renal Disease</Condition>
    <Intervention>&lt;br&gt;Product Name: Lanthanum Carbonate &lt;br&gt;Product Code: SPD 405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate &lt;br&gt;Current Sponsor code: SPD 405&lt;br&gt;Other descriptive name: Lanthanum carbonate hydrate&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Product Name: Lanthanum Carbonate &lt;br&gt;Product Code: SPD 405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate &lt;br&gt;Current Sponsor code: SPD 405&lt;br&gt;Other descriptive name: Lanthanum carbonate hydrate&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Product Name: Lanthanum Carbonate &lt;br&gt;Product Code: SPD 405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate &lt;br&gt;Current Sponsor code: SPD 405&lt;br&gt;Other descriptive name: Lanthanum carbonate hydrate&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 750-&lt;br&gt;&lt;br&gt;Product Name: Lanthanum Carbonate &lt;br&gt;Product Code: SPD 405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate &lt;br&gt;Current Sponsor code: SPD 405&lt;br&gt;Other descriptive name: Lanthanum carbonate hydrate&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;Trade Name: Renagel 800mg Film Coated Tablets &lt;br&gt;Product Name: Renagel &lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Sevelamer &lt;br&gt;Concentration unit: mg/g milligram(s)/gram&lt;br&gt;Concentration number: 800-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess phosphate reduction and control (3.5-5.5mg/dL [1.1-1.8mmol/L]) in patients with End Stage Renal Disease (ESRD) following administration of lanthanum carbonate or sevelamer hydrochloride;Secondary Objective: To assess: &lt;br&gt;The effects of lanthanum carbonate and sevelamer hydrochloride on serum calcium and calcium phosphate product levels&lt;br&gt;The percentage of patients achieving a reduction in serum calcium-phosphate product to less than or equal to 4.4 (mmol/L)2 (54.56mg2/dL2) following administration of lanthanum carbonate or sevelamer hydrochloride&lt;br&gt;Average daily pill burden, dose levels and compliance&lt;br&gt;The safety and tolerability of lanthanum carbonate&lt;br&gt;Patient satisfaction with treatment ;Primary end point(s): Serum phosphate reduction and control rate (defined as 3.5-5.5mg/dL [1.1-1.8 mmol/L])</Primary_outcome>
    <Secondary_ID>SPD405-310</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2454519</Internal_Number>
    <TrialID>EUCTR2005-000087-12-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos, en fase IV, para comparar los efectos renales del medio de contraste no iónico isosmolar, iodixanol 320 mg I/ml (VisipaqueTM), con el medio de contraste no iónico de baja osmolaridad, iopamidol 300 mg I/ml, en sujetos con insuficiencia renal y diabetes mellitus sometidos a TC helicoidal multidetector.</Public_title>
    <Scientific_title>Estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos, en fase IV, para comparar los efectos renales del medio de contraste no iónico isosmolar, iodixanol 320 mg I/ml (VisipaqueTM), con el medio de contraste no iónico de baja osmolaridad, iopamidol 300 mg I/ml, en sujetos con insuficiencia renal y diabetes mellitus sometidos a TC helicoidal multidetector.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Amersham Health S.A. (parte de GE Healthcare Ltd y sus filiales)</Primary_sponsor>
    <Date_registration3>20050608</Date_registration3>
    <Date_registration>08/06/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-000087-12                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>16/08/2005</Date_enrollement>
    <Target_size>500</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.) The subject is at least 18 years old.&lt;br&gt;2.) The subject has diabetes mellitus (type I or II), treated with insulin or oral antidiabetic agents for at least 1 year.&lt;br&gt;3.) The subject has a pre-study serum creatinine = 1.7 mg/dl (150 µmol/l) if a man, or = 1.5 mg/dl (133 µmol/l) if a woman,&lt;br&gt;or an estimated pre-study glomerular filtration rate (eGFR) = 50 mL/min/1.73m2 according to the Modification of Diet in Renal Disease (MDRD) equation.*&lt;br&gt;The pre-study serum creatinine value must not be older than 3 months and any acute causes of impaired renal function have to be ruled out.&lt;br&gt;* the four-component MDRD equation provides estimates of GFR standardised for body surface, based on the variables serum creatinine concentration (SCr), age, race, and sex:&lt;br&gt;eGFR (mL/min/1.73m2) = 186 x SCr-1.154 x age-0.203 (x 0.742 if female) (x 1.210 if black)&lt;br&gt;Pre-study serum creatinine has to be expressed in milligrams per decilitre, age in years.&lt;br&gt;4.) The subject is referred for a contrast-enhanced MDCT examination, using a standardised CM volume of 1.5 mL per kilogram of body weight and an injection rate of 4 mL/s (in cases with inadequate venous access, a flow of 3 mL/s may be applied). For subjects with a body weight exceeding 100 kilogram, a total CM volume of 150 mL should be administered.&lt;br&gt;5.) The subject is a man, or a woman who is either surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (with cessation of menses for more than 1 year), or, if of child-bearing potential, the result of a urine or serum ?-HCG pregnancy test conducted at screening must be known to be negative before IMP administration.&lt;br&gt;6.) The subject is able and willing to comply with study procedures.&lt;br&gt;7.) Signed and dated (i.e., date and time) written informed consent is obtained.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.) The subject is pregnant or lactating.&lt;br&gt;2.) The subject was previously included in this study.&lt;br&gt;3.) The subject has received another IMP within 30 days before or is scheduled to receive one within 7 days after IMP administration.&lt;br&gt;4.) The subject has received iodinated contrast medium within 7 days before or will receive one within 7 days after IMP administration.&lt;br&gt;5.) The subject has a history of serious hypersensitivity reaction to iodinated contrast media.&lt;br&gt;6.) The subject has non-compensated heart failure (NYHA III or IV).&lt;br&gt;7.) The subject has manifest thyrotoxicosis.&lt;br&gt;8.) The subject is in acute renal failure or in acute on chronic renal failure.&lt;br&gt;9.) The subject has undergone kidney transplantation.&lt;br&gt;10.) The subject is on haemodialysis or peritoneal dialysis.&lt;br&gt;11.) The subject has liver cirrhosis with ascites.&lt;br&gt;12.) The subject has multiple myeloma.&lt;br&gt;13.) The subject is haemodynamically unstable pre-study.&lt;br&gt;14.) The subject is scheduled for major surgery within 7 days after IMP administration.&lt;br&gt;15.) The subject has received or will receive any of the following potentially nephroprotective drugs from 3 days before until 7 days after IMP administration:&lt;br&gt;n-acetylcysteine, fenoldopam, dopamine, or hydration with sodium bicarbonate. Concurrent medication with other drugs that are potentially nephroprotective, like calcium channel blockers or theophylline, are permitted provided they are used for the subject’s underlying disease (e.g., cardiac disease, arterial hypertension, bronchial asthma).&lt;br&gt;16.) The subject has received nephrotoxic drugs within 7 days before or will receive such drugs within 7 days after IMP administration. Respective nephrotoxic drugs include antibiotics (e.g., aminoglycosides, vancomycin, amphotericin B), antineoplastic agents (e.g., methotrexate, cisplatin), and immunosuppressants (e.g., cyclosporine).&lt;br&gt;17.) The subject has received nonsteroidal anti-inflammatory drugs (NSAID) within 3 days before or will receive such drugs within 7 days after IMP administration, with the exception of low dose aspirin (up to 325 mg per day). However, subjects who are on a stable NSAID regimen may be enrolled.&lt;br&gt;18.) The subject has had or is planned to have the initiation, discontinuation, or change in dose of any of the following from 3 days before until 7 days after IMP administration: trimethoprim, cimetidine, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers.&lt;br&gt;&lt;br&gt;19.) The subject is on metformin treatment at the time of the study procedure: metformin administration has to be discontinued prior to IMP administration, according to local guidelines, withheld for at least 48 hours, and resumed only if renal function / serum creatinine did not worsen compared to the baseline values.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Subjects with a combination of diabetes mellitus (type I or II), and impaired renal function.

 &lt;br&gt;MedDRA version: 7.0
Level: Pt
Classification code 10061835
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Visipaque 320 mgI/ml &lt;br&gt;Product Name: Visipaque 320 mg I/ml&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Iodixanol&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 320 mg I/ml-&lt;br&gt;&lt;br&gt;Trade Name: Iopamiro 300 mg I/ml&lt;br&gt;Product Name: Iopamiro&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Iopamidol&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 300 mg I/ml-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate and compare the effects of two different contrast media, iodixanol 320 mg I/mL and iopamidol 300 mg I/mL, on renal function;Secondary Objective: To evaluate and compare the safety profile of iodixanol 320 mg I/mL and iopamidol 300 mg I/mL&lt;br&gt;To evaluate and compare the efficacy of iodixanol 320 mg I/mL and iopamidol 300 mg I/mL&lt;br&gt;;Primary end point(s): The primary endpoint will be the incidence rate of contrast-induced nephropathy (CIN), defined as an intra-individual increase in serum creatinine of at least 44.2 µmol/l (0.5 mg/dl) from baseline up to day 3.&lt;br&gt;&lt;br&gt;</Primary_outcome>
    <Secondary_ID>DXV406</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2454536</Internal_Number>
    <TrialID>EUCTR2005-001231-29-SE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A PROSPECTIVE, RANDOMISED, PLACEBO CONTROLLED, MULTI-CENTER STUDY 
OF THE EFFICACY AND SAFETY OF RITUXIMAB AS INDUCTION THERAPY TOGETHER WITH TACROLIMUS, MYCOPHENOLATE MOFETIL AND STEROIDS FOR PATIENTS UNDERGOING RENAL TRANSPLANTATION
</Public_title>
    <Scientific_title>A PROSPECTIVE, RANDOMISED, PLACEBO CONTROLLED, MULTI-CENTER STUDY 
OF THE EFFICACY AND SAFETY OF RITUXIMAB AS INDUCTION THERAPY TOGETHER WITH TACROLIMUS, MYCOPHENOLATE MOFETIL AND STEROIDS FOR PATIENTS UNDERGOING RENAL TRANSPLANTATION
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Dept of Transplantation Surgery B 56, Karolinska University Hospital, Huddinge</Primary_sponsor>
    <Date_registration3>20050705</Date_registration3>
    <Date_registration>05/07/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001231-29                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>08/09/2005</Date_enrollement>
    <Target_size>140</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients aged 18 years or above&lt;br&gt;Recipients of first or second renal transplant&lt;br&gt;Recipients from living or cadaveric donors&lt;br&gt;Single organ recipients (kidney only)&lt;br&gt;Patients providing written informed consent&lt;br&gt;Patients cooperative and able to complete all the assessment procedures&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;HLA-identical siblings&lt;br&gt;Patients receiving immunosuppressive therapy within the preceding 28 days&lt;br&gt;PRA &gt;50% within 6 months prior to enrolment&lt;br&gt;Previous exposure to murine antibodies&lt;br&gt;History of malignancy (except localised non-melanotic skin cancer) or the presence of any active malignancy at the time of transplant&lt;br&gt;Active infection (HCV, HBV, HIV)&lt;br&gt;Pregnant or lactating females &lt;br&gt;Women of child bearing potential not willing to use reliable form of contraception                                                                                                       &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic renal failure patients who are receiving a kidney transplant.  Different immunosuppressive protocls are awailable. However, current strategies for the medical management of transplant patients are largely focused on the prevention and treatment of T-cell mediated processes. However, there is an increasing evidence that B cells may significantly contribute to post-transplant morbidity in addition to their role in acute humoral rejection.</Condition>
    <Intervention>&lt;br&gt;Trade Name: MabThera&lt;br&gt;Product Name: Mabthera&lt;br&gt;Product Code: RO 45-2294/V02&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of the study is to determine the effect of one dose of rituximab as induction therapy together with a conventional tacrolimus, mycophenolate mofetil, prednisolone immunosuppressive protocol on the incidence of treatment failure (biopsy-proven acute rejection, graft loss or death) at 6 months post transplant. &lt;br&gt;&lt;br&gt;;Secondary Objective: To assess the effect of rituximab induction on renal function at 6 months post transplant, measured as creatinine clearance. &lt;br&gt;&lt;br&gt;To assess the incidence and severity of  infections (CMV, BKV, fungal and bacterial) in the two groups. &lt;br&gt;Creatinine clearance determined by the iohexol technique at 6 months &lt;br&gt;Incidence of opportunistic infections (CMV, BK, fungus)&lt;br&gt;Incidence of urinary tract infections and septicemia &lt;br&gt;Incidence of rituximab-related adverse events&lt;br&gt;Incidence of malignancies &lt;br&gt;All adverse events including clinically significant abnormalities and clinical and laboratory parameters&lt;br&gt;&lt;br&gt;Additional parameters to be assessed peroperatively and at 6 months&lt;br&gt;Number of CD19+, CD20+ lymphocytes in blood &lt;br&gt;Immunoglobulin G and M levels&lt;br&gt;Anti-tetanus IgG&lt;br&gt;Anti-CMV IgG&lt;br&gt;Cystatin C &lt;br&gt;Iohexol clearance (at 6 months only)&lt;br&gt;Transplant biopsy&lt;br&gt;&lt;br&gt;&lt;br&gt;;Primary end point(s): The primary endpoint will be a composite endpoint defined as treatment failure,&lt;br&gt;including the occurrence of any of the following: biopsy-proven acute rejection, graft loss or death during the first 6 months following transplantation. &lt;br&gt;</Primary_outcome>
    <Secondary_ID>2005-01-02</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2454693</Internal_Number>
    <TrialID>EUCTR2004-002973-22-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Epidemiological open-label study to evaluate the frequency of helicobacter Pylori infections prior to and after equimolar switch from therapy with MMF to enteric-coated Mycophenolic Acid (MYFORTIC-ERL080) in stable renal transplant patients</Public_title>
    <Scientific_title>Epidemiological open-label study to evaluate the frequency of helicobacter Pylori infections prior to and after equimolar switch from therapy with MMF to enteric-coated Mycophenolic Acid (MYFORTIC-ERL080) in stable renal transplant patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>AZIENDA UNIVERSITARIA OSPEDALE POLICLINICO UMBERTO I</Primary_sponsor>
    <Date_registration3>20050801</Date_registration3>
    <Date_registration>01/08/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002973-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>28/04/2004</Date_enrollement>
    <Target_size>250</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;</Exclusion_Criteria>
    <Condition>Profilaxis of rejection in stable renal transplant patients &lt;br&gt;MedDRA version: 6.1
Level: PT
Classification code 10046694
</Condition>
    <Intervention>&lt;br&gt;Product Name: NA&lt;br&gt;Product Code: NA&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Mycophenolic acid&lt;br&gt;CAS Number: 115007-34-6&lt;br&gt;Current Sponsor code: ERL080&lt;br&gt;Other descriptive name: NA&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 180-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: ;Secondary Objective: ;Primary end point(s): </Primary_outcome>
    <Secondary_ID>CERL080AIT03</Secondary_ID>
    <Secondary_Sponsor>AZIENDA POLICLINICO UMBERTO I</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2454739</Internal_Number>
    <TrialID>EUCTR2005-000855-14-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Multicenter, not controlled, prospectic clinical phase IV study: safety and efficacy of an immunosuppressive regimen with Thymoglobuline and Rapamune in patients receiving a renal transplantation from a marginal donor.</Public_title>
    <Scientific_title>Multicenter, not controlled, prospectic clinical phase IV study: safety and efficacy of an immunosuppressive regimen with Thymoglobuline and Rapamune in patients receiving a renal transplantation from a marginal donor.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>AZIENDA OSPEDALIERA DI PADOVA</Primary_sponsor>
    <Date_registration3>20050810</Date_registration3>
    <Date_registration>10/08/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-000855-14                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/07/2005</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;</Exclusion_Criteria>
    <Condition>Acute rejection prophylaxis after single-double kidney transplantation from marginal donors making use of a not nephrotoxic immunosuppressive regimen. &lt;br&gt;MedDRA version: 6.1
Level: PT
Classification code 10023439
</Condition>
    <Intervention>&lt;br&gt;Trade Name: RAPAMUNE*1MG 100 CPR&lt;br&gt;Product Name: NA&lt;br&gt;Product Code: NA&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: RAPAMUNE*2MG 30 CPR&lt;br&gt;Product Name: NA&lt;br&gt;Product Code: NA&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;&lt;br&gt;Trade Name: RAPAMUNE*OS 60 ML 1 MG&lt;br&gt;Product Name: NA&lt;br&gt;Product Code: NA&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: THYMOGLOBULINE*IV 1F 25MG +F&lt;br&gt;Product Name: NA&lt;br&gt;Product Code: NA&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Antithymocyte immunoglobulin (rabbit)&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: ;Secondary Objective: ;Primary end point(s): </Primary_outcome>
    <Secondary_ID>01-865-2005</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2454772</Internal_Number>
    <TrialID>EUCTR2005-002380-90-DK</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Effekten af intravenøs infusion af n-3 polyumættede fedtsyrer på risikomarkører for pludselig hjertedød hos hæmodialysepatienter</Public_title>
    <Scientific_title>Effekten af intravenøs infusion af n-3 polyumættede fedtsyrer på risikomarkører for pludselig hjertedød hos hæmodialysepatienter                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Nyremedicinsk afdeling, Aalborg Sygehus</Primary_sponsor>
    <Date_registration3>20050824</Date_registration3>
    <Date_registration>24/08/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-002380-90                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/09/2005</Date_enrollement>
    <Target_size>70</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: yes&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients with chronic renal failure undergoing haemodialysis treatment three times a week&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Allergy to fish or egg protein. Age &lt; 18 yrs. Body Weight &lt; 50 kg. Chronic supraventricular arrhythmias. Implanted pacemaker. Myocardial infarction or stroke within the past 6 months. Tendency to significant drop in bloodpressure during haemodialysis. Ongoing infection. Other serious illness. Fasting triglycerides &gt; 3 mmol/L. &lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic renal failure</Condition>
    <Intervention>&lt;br&gt;Trade Name: Omegaven&lt;br&gt;Product Name: Omegaven&lt;br&gt;Pharmaceutical Form: Emulsion for infusion&lt;br&gt;Pharmaceutical form of the placebo: Intravenous infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To investigate the effect of intravenous infusion of an emulsion rich on n-3 polyunsaturated fatty acids on heart rate variability and the occurence of arrhythmias in relation to haemodialysis treatment;Secondary Objective: To determine the content of n-3 polyunsaturated fatty acids in plasma and cell membranes before and after infusion;Primary end point(s): The effect on heart rate variability and arrhythmias</Primary_outcome>
    <Secondary_ID>IVN3DIALYSE;N/A</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2454985</Internal_Number>
    <TrialID>EUCTR2004-005002-68-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio multicéntrico, aleatorizado, doble ciego, paralelo y de fase IV para comparar los efectos en la función renal del medio de contraste no iónico, isosmolar, iodixanol 320 mgI/ml (VisipaqueTM) con el medio de contraste no iónico, de baja osmolalidad, iopamidol 370 mgI/ml, en sujetos con función renal disminuida y diabetes mellitus sometidos a una angiografía coronaria con o sin intervención coronaria percutánea (ICP).</Public_title>
    <Scientific_title>Estudio multicéntrico, aleatorizado, doble ciego, paralelo y de fase IV para comparar los efectos en la función renal del medio de contraste no iónico, isosmolar, iodixanol 320 mgI/ml (VisipaqueTM) con el medio de contraste no iónico, de baja osmolalidad, iopamidol 370 mgI/ml, en sujetos con función renal disminuida y diabetes mellitus sometidos a una angiografía coronaria con o sin intervención coronaria percutánea (ICP).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Amersham Health SA (Parte de GE Healthcare Ltd. y sus filiales)</Primary_sponsor>
    <Date_registration3>20050922</Date_registration3>
    <Date_registration>22/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-005002-68                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>03/11/2005</Date_enrollement>
    <Target_size>450</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;(1) The subject is over 18 years of age. &lt;br&gt;(2) The subject is referred for coronary angiography with or without PCI.&lt;br&gt;(3) The subject has diabetes mellitus I or II, treated with insulin or oral antiglycemics for at least 1 year.&lt;br&gt;(4) The subject has renal impairment of non-acute aetiology:&lt;br&gt;SCr measurement not older than 6 months ?150 µmol/L (1.7 mg/dL) for men and  ?133 µmol/L (1.5 mg/dL) for women or a creatinine clearance = 50 mL/min calculated according to Cockcroft-Gault formula. &lt;br&gt;(5) The subject is able and willing to comply with study procedures including hydration protocol and signed and dated (i.e. date and time) informed consent is obtained.&lt;br&gt;(6) The subject is male, or a female who is either surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (cessation of menses for more than 1 year), or non-lactating, or if of childbearing potential the results of a serum or urine human chorionic gonadotropin pregnancy test, performed at screening, with the result known before IMP administration, must be negative.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;(1) The subject was previously included in this study. &lt;br&gt;(2) The subject has participated in any IMP study within 30 days prior to study enrolment.&lt;br&gt;(3) The subject received iodinated contrast medium within 7 days before IMP administration or is scheduled to receive one within the study period.&lt;br&gt;(4) The subject is planned to undergo major surgery (CABG, CEA, vascular bypass) within 3 days after the IMP administration.&lt;br&gt;(5) The subject is planned to undergo selective renal angiography.&lt;br&gt;(6) The subject has a history of serious hypersensitivity reaction to iodinated contrast media.&lt;br&gt;(7) The subject has severe liver or haematologic disease, multiple myeloma or manifest thyrotoxicosis.&lt;br&gt;(8) The subject has severe heart failure requiring intravenous therapy with diuretics, inotropes, and/or vasodilators.&lt;br&gt;(9) The subject is planned to receive an intravenous diuretic or intravenous mannitol in connection to the IMP administration.&lt;br&gt;(10) The subject is haemodynamically unstable pre-study (i.e., inability to sustain systolic blood pressure above 90 mmHg within 48 hours before IMP-administration without pressor or balloon support).&lt;br&gt;(11) The subject is on haemodialysis or peritoneal dialysis, and/or is in acute renal failure. &lt;br&gt;(12) The subject has undergone kidney transplantation. &lt;br&gt;(13) The subject has received or will receive any of the following potentially nephroprotective drugs within 3 days before or 3 days after IMP administration; n-acetylcysteine, fenoldopam, dopamine or hydration with sodium bicarbonate (NaHCO3).  Potentially nephroprotective drugs such as Ca-channel blockers, theophylline etc, are allowed provided they are used for treatment of the subject’s chronic underlying disease. &lt;br&gt;(14) The subject has received or is planned to receive any of the following nephrotoxic drugs within 7 days before or 3 days after IMP administration; aminoglycosides, vancomycin, amphotericin B, cyclosporin, methotrexate, cisplatin.  &lt;br&gt;(15) The subject has received or is planned to receive nonsteroidal anti-inflammatory drugs (NSAID) within 3 days before or 3 days after IMP administration, with the exception of low dose acetyl salicylic acid (up to 325 mg per day, and at a single occasion in connection with PCI up to 500 mg).  However, subjects who are on a stable NSAID regimen may be enrolled.&lt;br&gt;(16) The subject has had or is planned to have the initiation, discontinuation, or change in dose within 3 days before or 3 days after IMP administration of any of the following: trimethoprim, cimetidine, angiotensin converting enzyme inhibitors (ACEI), or angiotensin receptor blockers (ARB).&lt;br&gt;(17) The subject is on metformin (e.g., Glucophage?) at the time of coronary angiography/intervention.  Metformin must be discontinued according to local guidelines, and stopped no later than the time of IMP administration, withheld for at least 48 hours, until the subject’s SCr has been evaluated and it is deemed safe to resume metformin.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Subjects with impaired renal function and diabetes mellitus undergoing coronary angiography.
 &lt;br&gt;MedDRA version: 8.0
Level: Pt
Classification code 10061835
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Visipaque 320 mg I/ml&lt;br&gt;Product Name: Visipaque&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Iodixanol&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 320 mg I/ml-&lt;br&gt;&lt;br&gt;Trade Name: Iopamiro 370 mg I/ml&lt;br&gt;Product Name: Iopamiro&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Iopamidol&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 370 mg I/ml-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate and compare the effects of two different contrast media, the iso-osmolar contrast medium (IOCM), iodixanol 320 mgI/mL, and the low-osmolar contrast medium (LOCM) iopamidol 370 mgI/mL, on renal function.;Secondary Objective: - To evaluate and compare the safety profile of iodixanol 320 mgI/mL and iopamidol 370 mgI/mL.&lt;br&gt;- To evaluate and compare the efficacy of iodixanol 320 mgI/mL and iopamidol 370 mgI/mL.&lt;br&gt;;Primary end point(s): - The peak increase in SCr from baseline up to day 3.&lt;br&gt;- The incidence of CIN, defined as number of subjects with an increase in SCr of at least 44.2 µmol/L (0.5 mg/dL) from baseline up to day 3.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>DXV405</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455044</Internal_Number>
    <TrialID>EUCTR2005-002372-16-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Multicenter, open-label, single-arm, safety, tolerability, efficacy and pharmacokinetic study of RAD001 in pediatric de novo renal transplant patients

Estudio multicéntrico, abierto, con un grupo de tratamiento, para evaluar la eficacia, la tolerabilidad, la seguridad y la farmacocinética de RAD001, en pacientes pediátricos receptores de un trasplante renal de novo - RAD351</Public_title>
    <Scientific_title>Multicenter, open-label, single-arm, safety, tolerability, efficacy and pharmacokinetic study of RAD001 in pediatric de novo renal transplant patients

Estudio multicéntrico, abierto, con un grupo de tratamiento, para evaluar la eficacia, la tolerabilidad, la seguridad y la farmacocinética de RAD001, en pacientes pediátricos receptores de un trasplante renal de novo - RAD351                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Novartis Farmaceútica S.A</Primary_sponsor>
    <Date_registration3>20050906</Date_registration3>
    <Date_registration>06/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-002372-16                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>11/10/2005</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;a.Male and female patients ? 16 years of age.&lt;br&gt;b.Patients receiving a primary cadaveric or non-HLA identical living donor (related or unrelated) renal transplant.&lt;br&gt;c.The graft must be functional within 48 hours post transplantation. A functional graft is defined at the investigator’s determination by a 50 % fall of serum creatinine from the pre-transplant value. In the event of dialysis immediately preceding transplantation, the pre-dialysis serum creatinine value may be used.&lt;br&gt;d.Females capable of becoming pregnant must have a negative pregnancy test (qualitative dip stick test on urine) immediately prior to study entry. Females of child bearing potential must practice an approved method of birth control for the one year duration of the study and for a period of three months following discontinuation of study medication.&lt;br&gt;e.Patients who are willing and able to participate in the whole course of the study and for whom written informed consent has been obtained from the parent(s) or legal guardian.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;a.Cold ischemia time &gt; 40 hours.&lt;br&gt;b.Patients who are recipients of multiple solid organ transplants, including dual and en bloc kidneys, or who have previously received transplanted organs.&lt;br&gt;c.Patients with non-diarrhea associated hemolytic-uremic syndrome.&lt;br&gt;d.Recipients of donor specific transfusions.&lt;br&gt;e.Patients with panel reactive T cell antibodies of 50 % or higher at the last assessment before transplantation.&lt;br&gt;f.Patients unable to undergo renal biopsies post-transplant. &lt;br&gt;g.Induction therapy with ALG, ATG and OKT3.&lt;br&gt;h.Use of anti-fungal azoles such as ketoconazole, itraconazole and fluconazole.&lt;br&gt;i.Patients requiring treatments with rifampin, carbamazepine, phenobarbital, phenytoin at the time of entry in the study.&lt;br&gt;j.The use of any investigational drug within 4 weeks prior to administration of the initial dose of study medication.&lt;br&gt;k.Patients who have received an investigational immunosuppressive agent within 4 months prior to administration of the initial dose of study medication.&lt;br&gt;l.Presence of any severe allergy (within 4 weeks prior to administration of the initial dose of study medication) requiring acute or chronic treatment; or hypersensitivity to drugs similar to RAD001 (e.g., erythromycin or other macrolide antibiotics) or to any component of the formulation.&lt;br&gt;m.Patients with any known contraindication to CsA.&lt;br&gt;n.Patients with severe or unstable medical conditions likely to affect patient safety or the objectives of this study. Other social circumstances that prevent full compliance with the protocol.&lt;br&gt;o.Patients with a history of alcohol or drug abuse, or signs of alcohol-induced organ damage, mental dysfunction or other factors limiting their ability to cooperate fully with the study.&lt;br&gt;p.Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug. The investigator should be guided by evidence of any of the following:&lt;br&gt;presence of inflammatory bowel syndrome, or gastrointestinal bleeding;&lt;br&gt;history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection (bladder augmentations and feeding tubes are acceptable).&lt;br&gt;q.Patients who are Hepatitis C positive, HIV positive, or Hepatitis B surface antigen positive. Laboratory results obtained within 6 months prior to administration of the initial dose of study medication are acceptable. Recipients of organs from donors who test positive for Hepatitis B surface antigen, Hepatitis C or HIV.&lt;br&gt;r.Evidence of liver injury as indicated by abnormal liver tests (AST or ALT &gt; 3 times ULN, total bilirubin &gt; 2 mg/dL).&lt;br&gt;s.Presence of uncontrolled hypercholesterolemia ( =350 mg/dL, = 9.1 mmol/L) or hypertriglyceridemia (= 500 mg/dL, = 5.6 mmol/L).&lt;br&gt;t.White blood cell count = 4500/mm3 or platelet count = 100,000/mm3.&lt;br&gt;u.Patients with severe systemic infections.&lt;br&gt;v.Patients with any past or present malignancy (other than excised basal cell carcinoma).&lt;br&gt;w.History of splenectomy.&lt;br&gt;x.Patients with any history of significant coagulopathy or medical condition requiring long term systemic anticoagulation after transplantation which would interfere with obtaining biopsies. Low dose aspirin is allowed.&lt;br&gt;y.Abnormal physical or laboratory findings of clinical significance which would interfere with the objectives of the study.&lt;br&gt;z.Females who are breast feeding.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>pediatric de novo renal trasplant &lt;br&gt;MedDRA version: 7.0
Level: LLT
Classification code 10050432
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican 0.1mg fast-dispersable tablets&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001B&lt;br&gt;Pharmaceutical Form: Dispersible tablet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 1.5mg/day-&lt;br&gt;&lt;br&gt;Trade Name: Certican 0.25mg fast-dispersable tablets&lt;br&gt;Product Name: certican&lt;br&gt;Product Code: RAD001B&lt;br&gt;Pharmaceutical Form: Dispersible tablet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 1.5mg/day-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: 1. To evaluate the safety and tolerability of RAD001 administered b.i.d. in combination with Neoral® and corticosteroids in pediatric de novo renal transplant recipients, and to provide additional safety data (quantitative protein/creatinine ratio in urine).;Primary end point(s): To evaluate the safety and tolerability of RAD001 administered b.i.d. in combination with Neoral® and corticosteroids in pediatric de novo renal transplant recipients;Secondary Objective: 1.To evaluate the efficacy of RAD001 administered b.i.d. in combination with Neoral® and corticosteroids as measured by the incidence of biopsy proven acute allograft rejection episodes, graft loss or death at 6 and 12 months after initial dose of study medication.&lt;br&gt;2.To characterize the multiple dose pharmacokinetics of RAD001 administered b.i.d.&lt;br&gt;3.To evaluate the efficacy of RAD001 administered b.i.d. in combination with Neoral® and corticosteroids in the prevention of chronic allograft rejection (chronic graft dysfunction) at 12 months post-transplantation.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>CRAD001B351</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455172</Internal_Number>
    <TrialID>EUCTR2005-001854-25-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio comparativo de tacrolimus y rapamicina para evaluar la función renal en pacientes mayores de 50 años, receptores de un riñón de donante mayor de 55 años, en un régimen inmunosupresor de daclizumab y micofenolato mofetil. - ALHAMBRA</Public_title>
    <Scientific_title>Estudio comparativo de tacrolimus y rapamicina para evaluar la función renal en pacientes mayores de 50 años, receptores de un riñón de donante mayor de 55 años, en un régimen inmunosupresor de daclizumab y micofenolato mofetil. - ALHAMBRA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Sociedad Andaluza de Trasplante de Órganos y Tejidos</Primary_sponsor>
    <Date_registration3>20051010</Date_registration3>
    <Date_registration>10/10/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001854-25                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>05/12/2005</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Pacientes de ambos sexos cuya edad sea mayor o igual a 50 años, y que sean receptores primarios de aloinjerto renal proveniente de donante mayor o igual a 55 años.&lt;br&gt;2. Pacientes que hayan otorgado su consentimiento de manera previa a su participación en el estudio.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Pacientes receptores de trasplante multiorgánico.&lt;br&gt;2. Pacientes que reciben trasplante de donante cadáver con un tiempo de isquemia fría mayos de 30 horas.&lt;br&gt;3. Pacientes con un PRA mayor del 20% en los 6 meses anteriores a la inclusión.&lt;br&gt;4. Mujeres en periodo de lactancia, embarazadas o en edad fértil, que no usen un método anticonceptivo fiable antes de comenzar la terapia con el fármaco en estudio, durante la terapia, y durante los 4 meses siguientes a la última dosis de los fármacos administrados dentro de este estudio clínico.&lt;br&gt;5. Pacientes con recuento leucocitario menor de 2,5 x 109/L, recuento de plaquetas menor de 100 x 109/L, o hemoglobina inferior a 6 g/dL en el momento de ser incluido en el estudio,&lt;br&gt;6. Pacientes con evidencia de enfermedad hepática activa.&lt;br&gt;7. Pacientes con úlcera péptica activa.&lt;br&gt;8. Pacientes con diarrea grave o cualquier otro trastorno intestinal que pudiera interferir en la capacidad de absorción de medicación oral, incluyendo pacientes diabéticos con gastroenteropatía diabética diagnosticada previamente,&lt;br&gt;9. Pacientes con evidencia de infección sistémica activa que requiera el uso continuado de antibióticos, o evidencia de infección por VIH, o presencia de hepatitis B (HBs-Ag positiva) o C crónica activa,&lt;br&gt;10. Pacientes con historia de malignidad (excepto cáncer de piel no melanocítico localizado, tratado satisfactoriamente y carcinoma “in situ” de cervix),&lt;br&gt;11. Pacientes con una historia de enfermedad, o afección psicológica, que interfiera en la capacidad del paciente para comprender los requisitos del estudio,&lt;br&gt;12. Pacientes en quienes el investigador considera necesario un tratamiento con la siguiente medicación: &lt;br&gt;a.	-Azatioprina,&lt;br&gt;b.	Metotrexato,&lt;br&gt;c.	Ciclofosfamida&lt;br&gt;d.	-Anticuerpos antilinfocitos policlonales y monoclonales (por ejemplo, OKT3, ATG), usados para la inducción en pacientes de alto riesgo inmunológico,&lt;br&gt;e.	Basiliximab,&lt;br&gt;f.	Otros fármacos en investigación,&lt;br&gt;&lt;br&gt;13. Hipersensibilidad conocida o contraindicación absoluta de cualquiera de las medicaciones administradas en el contexto del estudio, o cualquier otra sustancia presente en las medicaciones del  estudio.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Trasplante renal en pacientes mayores de 50 años, receptores de un riñón de donante mayor de 55 años.</Condition>
    <Intervention>&lt;br&gt;Trade Name: PROGRAF&lt;br&gt;Product Name: tacrolimus&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: RAPAMUNE&lt;br&gt;Product Name: SIROLIMUS&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Comparar la función renal (creatinina sérica a los 6 meses) en la entrada tardía del tratamiento con tacrolimus o rapamicina basados en regímenes con daclizumab, micofenolato mofetil y esteroides en pacientes mayores de 50 receptores de un injerto de donante mayor de 55 años.;Secondary Objective: 1. Eficacia:&lt;br&gt;Comparar los datos relativos al retraso en la función del injerto.&lt;br&gt;Comparar los datos relativos al rechazo.&lt;br&gt;Comparar la supervivencia del paciente y del injerto tras 6 meses de tratamiento.&lt;br&gt;Comparar los datos relativos al fallo de tratamiento a los 6 meses.&lt;br&gt;2. Seguridad:&lt;br&gt;Describir la incidencia de acontecimientos adversos entre ambos brazos a lo largo de 6 meses de tratamiento.;Primary end point(s): creatinina sérica a los 6 meses</Primary_outcome>
    <Secondary_ID>SATOT42005</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455280</Internal_Number>
    <TrialID>EUCTR2004-000520-32-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A MULTICENTRE, RANDOMISED, OPEN CLINICAL STUDY TO COMPARE THE EFFICACY AND SAFETY OF A COMBINATION OF TACROLIMUS AND MYCOPHENOLATE MOFETIL BASED REGIMEN WITH OR WITHOUT INDUCTION IN ELDERLY RECIPIENTS UNDERGOING KIDNEY TRANSPLANTATION
 - SENIOR (Safety and Efficacy with kNown Immunosuppression in Older Recipients)</Public_title>
    <Scientific_title>A MULTICENTRE, RANDOMISED, OPEN CLINICAL STUDY TO COMPARE THE EFFICACY AND SAFETY OF A COMBINATION OF TACROLIMUS AND MYCOPHENOLATE MOFETIL BASED REGIMEN WITH OR WITHOUT INDUCTION IN ELDERLY RECIPIENTS UNDERGOING KIDNEY TRANSPLANTATION
 - SENIOR (Safety and Efficacy with kNown Immunosuppression in Older Recipients)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Fujisawa GmbH</Primary_sponsor>
    <Date_registration3>20051102</Date_registration3>
    <Date_registration>02/11/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000520-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/01/2005</Date_enrollement>
    <Target_size>230</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: different drug combination regimen&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1 Male or female patients minimum 60 years of age&lt;br&gt;2 Patient has end stage kidney disease and is a suitable candidate for primary renal transplantation or retransplantation&lt;br&gt;3. Patient is receiving a kidney transplant, from a cadaveric or living donor (not HLA identical) with compatible ABO blood type&lt;br&gt;4. Patient has been fully informed and has given written informed consent according to ICH-GCP. Patient unable to write and/or read but who fully understands the oral information given by the investigator (or nominated representative) has given oral informed consent witnessed by an independent person&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Patient has an immunological high risk, defined as a PRA grade &gt;50% &lt;br&gt;2. Cold ischemia time of the donor kidney greater than 30 hours&lt;br&gt;3. Patient has significant liver disease, defined as having during the past 30 days continuously elevated ASAT (SGOT) and/or ALAT (SGPT) levels greater than 2 times the upper value of the normal range of the investigational site or is receiving a graft from a hepatitis C or B positive donor&lt;br&gt;4. Patient is allergic or intolerant to corticosteroids, macrolide antibiotics, mycophenolate mofetil, mycophenolic acid, tacrolimus, basiliximab or to the excipients of the study medication&lt;br&gt;5. Patient requires ongoing dosing with corticosteroids &lt;br&gt;6. Patient requires initial sequential or parallel therapy with immunosuppressive antibody preparation(s) or prohibited medication (see section 7.4 of protocol)&lt;br&gt;7. Patient or donor is known to be HIV positive&lt;br&gt;8. Patient with malignancy or history of malignancy, except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully&lt;br&gt;9. Patient has significant, uncontrolled concomitant infections and/or severe diarrhoea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer&lt;br&gt;10. Patient is participating or has participated in another clinical trial and/or is taking or has been taking an investigational drug in the past 30 days&lt;br&gt;11. Patient has previously received or is receiving an organ transplant other than kidney&lt;br&gt;12. Patient has been previously enrolled in this study&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with end stage kidney disease who will undergo primary renal transplantion or retransplantation &lt;br&gt;MedDRA version: 7.0
Level: LLT
Classification code 10014646
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Prograf&lt;br&gt;Product Code: FK506&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;CAS Number: 109581-93-3&lt;br&gt;Current Sponsor code: FK506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Prograf&lt;br&gt;Product Code: FK506&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;CAS Number: 109581-93-3&lt;br&gt;Current Sponsor code: FK506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.0-&lt;br&gt;&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Prograf&lt;br&gt;Product Code: FK506&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;CAS Number: 109581-93-3&lt;br&gt;Current Sponsor code: FK506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5.0-&lt;br&gt;&lt;br&gt;Trade Name: CellCept&lt;br&gt;Product Name: CellCept&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Mycophenolate mofetil&lt;br&gt;CAS Number: 116680-01-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Trade Name: Simulect&lt;br&gt;&lt;br&gt;Product Name: Simulect&lt;br&gt;Pharmaceutical Form: Powder for solution for injection&lt;br&gt;INN or Proposed INN: Basiliximab  &lt;br&gt;CAS Number: 179045-86-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20.00-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare renal function as well as incidence of renal dysfunction, patient death, graft loss or first biopsy proven acute rejection within the first 6 months after transplantation for the two therapy regimens (Arm 1: Delayed Tacrolimus + MMF+ Basiliximab + Corticosteroids (1 week), Arm 2: Tacrolimus + MMF + Corticosteroids (3 months)). The aim is to demonstrate that Arm 1 is non-inferior to Arm 2 with regard to the primary endpoint.;Secondary Objective: To compare the efficacy and safety profiles of the two therapy regimens (Arm 1: Delayed Tacrolimus + MMF+ Basiliximab + Corticosteroids (1 week), Arm 2: Tacrolimus + MMF + Corticosteroids (3 months)). &lt;br&gt;;Primary end point(s): A two step testing strategy will be applied for the two primary endpoints. The first primary efficacy endpoint of this study will be the renal function measured by calculated creatinine clearance at month 6, determined from the serum creatine using the Cockcroft formula.&lt;br&gt;&lt;br&gt;If the result of the test for the first primary endpoint is statistically significant, then the composite endpoint can also be tested in a confirmatory way.&lt;br&gt;&lt;br&gt;The composite endpoint is the incidence of death, graft loss or acute rejection within the first 6 months after transplantation and incidence of renal dysfunction defined as a calculated creatinine clearance value of =40 ml/min/1.73 m2 at month 6. &lt;br&gt;</Primary_outcome>
    <Secondary_ID>FG-506-02-42</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455320</Internal_Number>
    <TrialID>EUCTR2004-001270-77-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio piloto para evaluar la eficacia y seguridad de Valsartán para el control de la progresión de la insuficiencia renal y la morbimortalidad cardiovascular en pacientes con trasplante renal funcionante con proteinuria e insuficiencia renal leve o moderada.</Public_title>
    <Scientific_title>Estudio piloto para evaluar la eficacia y seguridad de Valsartán para el control de la progresión de la insuficiencia renal y la morbimortalidad cardiovascular en pacientes con trasplante renal funcionante con proteinuria e insuficiencia renal leve o moderada.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Equipo de doctores: Dr. Amado Andrés y Dr. Manuel Praga</Primary_sponsor>
    <Date_registration3>20051103</Date_registration3>
    <Date_registration>03/11/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001270-77                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>01/03/2005</Date_enrollement>
    <Target_size>178</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Hombres y mujeres con edad entre 18 y 70 años de edad, con un trasplante renal funcionante de más de 1 año, sea cual sea la causa de la insuficiencia renal terminal que lo haya motivado (nefropatía diabética o no diabética)&lt;br&gt;2.	Insuficiencia renal leve o moderada, definida como una creatinina sérica &gt; 1,3 mg/dl en las mujeres y &gt; 1,5 mg/dl en los  varones y &lt; 3 mg/dl en ambos casos. &lt;br&gt;3.	Proteinuria &gt; 0,5 g/24 h en al menos 3 determinaciones previas al inicio del estudio y &lt; 3, 5 g /24 h.&lt;br&gt;4.	En el momento de la aleatorización y durante las 6 semanas previas a la misma, los pacientes no estarán tomando IECA o ARAII como tratamiento antihipertensivo.&lt;br&gt;5.	Se incluirá a los pacientes con estos criterios independientemente de su presión arterial, es decir, podrán ser incluidos tanto pacientes normotensos como hipertensos. No obstante, la presencia de una hipertensión de difícil control constituirá un criterio de  exclusión.&lt;br&gt;6.	No será requisito necesario la realización de biopsia renal antes del inicio del estudio. Si se hubiera realizado, los pacientes podrán ser incluidos independientemente del diagnóstico establecido (rechazo crónico, glomerulonefritis de novo o de recidiva...) siempre que cumplan los criterios de inclusión/exclusión.&lt;br&gt;&lt;br&gt;&lt;br&gt;7.	La inmunosupresión empleada en estos pacientes estará basada en Ciclosporina A y los pacientes no deben estar incluidos en ningún otro protocolo de estudio en el momento de su reclutamiento.&lt;br&gt;8.	Las mujeres potencialmente fértiles deberán presentar una prueba de embarazo negativa antes de la aleatorización y deberán practicar un método anticonceptivo probado médicamente durante todo el ensayo. &lt;br&gt;9.	El paciente ha de otorgar su consentimiento informado por escrito para participar en el estudio.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Diagnóstico de más de 2 episodios de rechazo agudo hasta el inicio del estudio.&lt;br&gt;2.	Presencia de uropatía obstructiva no resuelta.&lt;br&gt;3.	Presencia de estenosis de arteria renal del injerto no resuelta&lt;br&gt;4.	Hepatopatía severa&lt;br&gt;5.	Enfermedad sistémica o deterioro general que haga previsible la imposibilidad de su seguimiento regular.&lt;br&gt;6.	Embarazo o lactancia&lt;br&gt;7.	Alteraciones psiquiátricas&lt;br&gt;8.	Hipersensibilidad conocida a los antagonistas de receptores de angiotensina (ARAII)&lt;br&gt;9.	Potasio sérico superior a 5.5 mEq/l en ausencia de fármacos que lo justifiquen.  &lt;br&gt;10.	Creatinina sérica &gt; 3.0 mg/dl o proteinuria &gt; 3,5 g/24h.&lt;br&gt;11.	Pacientes que hayan utilizado cualquier fármaco en investigación en las 6 semanas previas.&lt;br&gt;12.	Antecedentes de abuso de alcohol o de drogas no resuelto.&lt;br&gt;13.	Pacientes receptores de trasplantes de múltiples órganos sólidos o trasplantados previamente con cualquier otro órgano.&lt;br&gt;14.	Pacientes con alguna enfermedad maligna durante los últimos 5 años, excepto carcinoma de células basales o escamosas extirpado o carcinoma de cérvix in situ tratado adecuadamente.&lt;br&gt;15.	Estar participando en el momento de inclusión en otros protocolos de estudio.&lt;br&gt;16.	Hipertensión arterial de difícil control.&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Pacientes varones y mujeres de 18 a 70 años con trasplantes renales funcionantes de más de 1 año de evolución y una insuficiencia renal leve o moderada (creatinina sérica &gt; 1,3 mg/dl en mujeres y &gt; 1,5 mg/dl en varones y &lt; 3 mg/dl en ambos casos) y proteinuria (&gt;0,5 g/24 h y &lt; 3,5 g/24 h).</Condition>
    <Intervention>&lt;br&gt;Trade Name: DIOVAN&lt;br&gt;Product Name: Diovan&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: VALSARTÁN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 80-160&lt;br&gt;&lt;br&gt;Product Name: HIPOTENSORES&lt;br&gt;Product Code: C02&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Product Name: DIURETICOS&lt;br&gt;Product Code: C03&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Product Name: VASODILATADORES PERIFÉRICOS&lt;br&gt;Product Code: C04&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Product Name: BETABLOQUEANTES&lt;br&gt;Product Code: C07&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Product Name: CALCIO ANTAGONISTAS&lt;br&gt;Product Code: C08&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluar la eficacia de Valsartán en comparación con el tratamiento estándar para el control de la progresión de la insuficiencia renal, definida como un incremento de la creatinina sérica igual o superior al 50% del valor basal, en pacientes con trasplantes renales funcionantes con proteinuria e insuficiencia renal leve o moderada.;Secondary Objective: 1.	La reducción de la proteinuria&lt;br&gt;2.	Tolerabilidad de valsartán, evaluada mediante la frecuencia, tipo y gravedad de los acontecimientos adversos observados durante el estudio.  Se valorará la seguridad mediante exploraciones físicas, parámetros de laboratorio hematológicos y bioquímicos (incluyendo la determinación de creatinina y potasio) y medición de las constantes vitales.&lt;br&gt;3.	La morbimortalidad cardiovascular, evaluada mediante la incidencia global y específica de cada uno de los siguientes parámetros:&lt;br&gt;-	infarto agudo de miocardio o angina de pecho&lt;br&gt;-	necesidad de revascularización coronaria&lt;br&gt;-	episodios de insuficiencia cardiaca&lt;br&gt;-	accidente vascular cerebral&lt;br&gt;-	amputación y/o revascularización de extremidades inferiores&lt;br&gt;-	muerte de causa cardiovascular&lt;br&gt;;Primary end point(s): Porcentaje de pacientes con progresión de la insuficiencia renal, definida como un incremento de la creatinina sérica igual o superior al 50% del valor basal.	&lt;br&gt;</Primary_outcome>
    <Secondary_ID>TRASVAL</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455462</Internal_Number>
    <TrialID>EUCTR2004-000655-41-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A one-year, multicenter, open-label, feasibility study to evaluate the safety and the efficacy of FTY720 5mg introduction and CNI elimination in adult maintenance renal transplant reicpients maintained on a triple immunosuppressive regimen with either MPA or mTOR inhibitor</Public_title>
    <Scientific_title>A one-year, multicenter, open-label, feasibility study to evaluate the safety and the efficacy of FTY720 5mg introduction and CNI elimination in adult maintenance renal transplant reicpients maintained on a triple immunosuppressive regimen with either MPA or mTOR inhibitor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Novartis Farmacéutica S.A</Primary_sponsor>
    <Date_registration3>20051201</Date_registration3>
    <Date_registration>01/12/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000655-41                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/02/2005</Date_enrollement>
    <Target_size>88</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;male and female adults between 6 and 60 months post renal transplantation, maintained for the last 6 months on the same triple immunussupressive regimen : CNI + MPA + corticosteroids or CNI + mTOR + corticosteroids&lt;br&gt;stable renal function and no history of rejection&lt;br&gt;PRA &lt;10% pre-transplantation&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;patient at high immunological risk of rejection&lt;br&gt;pulse rate &lt; 50bpm at screening&lt;br&gt;presence or history of second or third degree AV block&lt;br&gt;history of cardiac arrest&lt;br&gt;history of malignancy&lt;br&gt;systemic infection within 2 weeks prior to start study medication&lt;br&gt;HIV or hepatitis B surface Ag positive&lt;br&gt;</Exclusion_Criteria>
    <Condition>prevention of acute rejection in maintenance renal transplant recipients &lt;br&gt;MedDRA version: 7.0
Level: LLT
Classification code 10023439
</Condition>
    <Intervention>&lt;br&gt;Product Name: FTY720&lt;br&gt;Product Code: FTY720&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Not applicable&lt;br&gt;Current Sponsor code: FTY720&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 2.5-5&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluate whether FTY720 can be safely introduced in a maintenance renal transplant population and can allow for CNI elimination resulting in an improvement of the renal function ;Secondary Objective: Validate discharge criteria following the first administration of FTY720;Primary end point(s): improvement of the renal function 12 months after FTY720 introduction, measured by the change in estimated glomerular filtration rate (Cockroft-Gault formula)</Primary_outcome>
    <Secondary_ID>CFTY720A2308</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455483</Internal_Number>
    <TrialID>EUCTR2005-004299-19-CZ</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>New Possibilities of TDM of Cyclosporine A and its metabolites after kidney transplantation</Public_title>
    <Scientific_title>New Possibilities of TDM of Cyclosporine A and its metabolites after kidney transplantation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>University Hospital Ostrava</Primary_sponsor>
    <Date_registration3>20051007</Date_registration3>
    <Date_registration>07/10/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004299-19                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/10/2005</Date_enrollement>
    <Target_size>375</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;renal transplant patients on standart therapy with cyclosporine A&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;end of treatment with cyclosporine A, disagreement of patients&lt;br&gt;</Exclusion_Criteria>
    <Condition>patient on standart immunusupresive therapy with cyclosporine A after renal transplantation</Condition>
    <Intervention>&lt;br&gt;Trade Name: not fixed in the protocol&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: CICLOSPORINUM&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The target of this project is to clarify the importance of TDM of CsA and its principal metabolites by LC-MS in lymphocytes when compared with currently used methods C through, AUC, and C2. ;Secondary Objective: We further wish for detection the role of the lipofile metabolite AM4N in imunosupresion and toxicity, and alternatively other metabolites analyzed by LC-MS.;Primary end point(s): to clarify the importance of TDM of CsA and its principal metabolites by LC-MS in lymphocytes when compared with currently used methods C through, AUC, and C2. We further wish for detection the role of the lipofile metabolite AM4N in imunosupresion and toxicity, and alternatively other metabolites analyzed by LC-MS.&lt;br&gt;to find the therapeutic range for safety and effective therapy with CsA</Primary_outcome>
    <Secondary_ID>1A/8655-5</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455503</Internal_Number>
    <TrialID>EUCTR2005-003383-39-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A randomized, open-label, multi-center study comparing a steroid sparing regimen versus standard steroid regimen in combination with daclizumab, mycophenolate mofetil and sirolimus in the prevention of acute renal allograft rejection.Estudio abierto, aleatorizado, multicéntrico, nacional, comparando un régimen libre de esteroides frente a un régimen de esteroides estándar, en combinación con Daclizumab, Micofenolato Mofetil y Sirolimus, en la prevención del rechazo agudo en trasplante renal.</Public_title>
    <Scientific_title>A randomized, open-label, multi-center study comparing a steroid sparing regimen versus standard steroid regimen in combination with daclizumab, mycophenolate mofetil and sirolimus in the prevention of acute renal allograft rejection.Estudio abierto, aleatorizado, multicéntrico, nacional, comparando un régimen libre de esteroides frente a un régimen de esteroides estándar, en combinación con Daclizumab, Micofenolato Mofetil y Sirolimus, en la prevención del rechazo agudo en trasplante renal.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Roche Farma S.A.</Primary_sponsor>
    <Date_registration3>20051111</Date_registration3>
    <Date_registration>11/11/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-003383-39                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>29/12/2005</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;–	Patients who are males or non-pregnant females &gt; 18 years old.&lt;br&gt;–	Patients who are recipients of primary kidney allografts.&lt;br&gt;–	Patients who are single-organ recipients (kidney only).&lt;br&gt;–	Patients with PRA &lt;20%&lt;br&gt;–	If patients are women of childbearing potential, they must have a negative pregnancy test, and use a reliable form of contraception&lt;br&gt;–	Patients and their guardians must be capable of understanding the purpose and risks of the study.&lt;br&gt;–	Patients who are willing to give written informed consent.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;–	Patients previously treated with Daclizumab, MMF or SRL.&lt;br&gt;–	Patients who require in addition to the study immunosuppresive regimen anti-lymphocyte preparations for induction therapy.&lt;br&gt;–	Women lactating, pregnant or of childbearing potential not using a reliable contraceptive method during the study.&lt;br&gt;–		Patients with severe gastrointestinal disorders that interfere with  &lt;br&gt;Their ability to receive or absorb oral medication and patients with severe diarrhoea.&lt;br&gt;–	Patients who are expected than to require oral corticosteroids post-transplant (i.e. patients suffering autoinmune diseases).&lt;br&gt;–	Patients with active peptic ulcer disease.&lt;br&gt;–	Patients receiving bile-acid sequestrants.&lt;br&gt;–	Patients with severe anemia (Hb&lt;6 g/dl), leucopenia (WBC&lt;2500/mm3) or thrombocytopenia (Tc&lt;100’000/mm3)&lt;br&gt;–	Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study.&lt;br&gt;–	HIV positive donor or patient&lt;br&gt;–	Patients with history of malignancy within the last 5 years, except localised and treated non melanoma skin cancer, treated and without recidive evidence.	&lt;br&gt;–	Patients for whom the investigator considers a treatment with the following medications necessary:&lt;br&gt;?	Azathioprine,&lt;br&gt;?	methotrexate&lt;br&gt;?	cyclophosphamide,&lt;br&gt;?	Cyclosporine&lt;br&gt;?	Tacrolimus&lt;br&gt;?	Everolimus&lt;br&gt;?	Mycophenolate sodium&lt;br&gt;?	polyclonal and monoclonal anti-lymphocyte antibodies other than daclizumab (e.g. OKT3, ATG, basiliximab) &lt;br&gt;–	Known hypersensitivity or absolute contraindications to any of the medications administered in the context of the study or any other substances present in the study medications&lt;br&gt;–		Patients who require concomitant treatment with other investigational or prohibited drugs.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal Transplant</Condition>
    <Intervention>&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: Rapamune&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: Rapamune&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;INN or Proposed INN: sirolimus&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: ZENAPAX&lt;br&gt;Product Name: Daclizumab&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Daclizumab&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the efficacy of a steroid free regimen against normal doses of corticosteroids for prevention of acute rejection, when given in conjunction with daclizumab, mycophenolate mofetil (MMF) and sirolimus as maintenance therapy in the management of renal allograft recipients.;Secondary Objective: To assess clinical efficacy and safety of  the two treatment regimens&lt;br&gt;;Primary end point(s): Proportion of patients experiencing a biopsy proven acute rejection episode 6 months post-randomization</Primary_outcome>
    <Secondary_ID>ML18690</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455613</Internal_Number>
    <TrialID>EUCTR2005-004431-21-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio abierto, multicéntrico, aleatorio, con el objetivo de evaluar la eficacia y la seguridad de la inmunosupresión tras un primer trasplante renal cadavérico a corazón latiente basado la utilización de suero anti-linfocitos T de conejo, tacrolimus y micofenolato, libre de corticoesteroides concomitantes desde el inicio. - IBERICA</Public_title>
    <Scientific_title>Estudio abierto, multicéntrico, aleatorio, con el objetivo de evaluar la eficacia y la seguridad de la inmunosupresión tras un primer trasplante renal cadavérico a corazón latiente basado la utilización de suero anti-linfocitos T de conejo, tacrolimus y micofenolato, libre de corticoesteroides concomitantes desde el inicio. - IBERICA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Fresenius Biotech GmbH</Primary_sponsor>
    <Date_registration3>20051219</Date_registration3>
    <Date_registration>19/12/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004431-21                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/02/2006</Date_enrollement>
    <Target_size>160</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Triple terapia Tacro/MMF/Corticosteroides&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Varón o mujer adulto, candidato para un primer transplante cadavérico, hasta los 70 años.&lt;br&gt;Las mujeres que se encuentren en edad fértil deberán utilizar métodos anticonceptivos seguros a lo largo de todo el estudio.&lt;br&gt;Donante a corazón latiente hasta los 65 años de edad, con de isquemia fría &lt;36 horas.&lt;br&gt;El paciente que haya recibido la información relativa al estudio y prestado su consentimiento informado por escrito.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Embarazo actual o en período de lactancia. &lt;br&gt;Mujeres que hayan tenido más de 3 embarazos (incluidos abortos). &lt;br&gt;Paciente con riesgo inmunológico considerado alto, definido por la presencia de un porcentaje de anticuerpos anti-HLA (PRA) ³25 %.&lt;br&gt;Hipersensibilidad a las proteínas del conejo (¿test cutáneo?) o alergias conocidas a cualquier componente de la inmunosupresión prevista. &lt;br&gt;Paciente/Donante HCV+, HBV+, HIV+&lt;br&gt;Paciente en tratamiento inmunosupresor pretransplante.&lt;br&gt;Paciente con neoplasia maligna actual o con antecedentes de neoplasia maligna, a excepción de cánceres basocelulares o espinocelulares en remisión. &lt;br&gt;Paciente sometido algún tipo de trasplante previo o candidato a trasplante múltiple (p.ej SKP).&lt;br&gt;Leucocitos &lt;2000/mm3 y/o plaquetas &lt;50 000/mm3 antes de iniciar el trasplante&lt;br&gt;</Exclusion_Criteria>
    <Condition>Trasplante renal de donante cadavérico</Condition>
    <Intervention>&lt;br&gt;Trade Name: ATeGe Fresenius&lt;br&gt;Product Name: ATeGe-Fresenius&lt;br&gt;Product Code: ATG&lt;br&gt;Pharmaceutical Form: Concentrate for solution for injection&lt;br&gt;INN or Proposed INN: Inmunoglobulina de conejo anti-linfocitos T humanos&lt;br&gt;Other descriptive name: ATG Fresenius&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Incidencia de rechazo subclínico y rechazo agudo (demostrados por biopsia).&lt;br&gt;   incidencia y lapso de tiempo hasta su manifestación&lt;br&gt;   gravedad histológica (BANFF)&lt;br&gt;   incidencia de resistencia a los corticoesteroides;Secondary Objective: Incidencia y duración de retraso inicial función injerto.&lt;br&gt;Función renal a los 1, 3, 6, 12 meses.&lt;br&gt;Porcentaje de pacientes proteinúricos y cantidad de proteína secretada&lt;br&gt;Porcentaje de pacientes con hipertensión arterial y en tratamiento hipotensor.&lt;br&gt;Porcentaje de pacientes hiperlipidémicos y en tratamiento hipolipemiante&lt;br&gt;Porcentaje de diabetes mellitas post-trasplante&lt;br&gt;Fallo de tratamiento y porcentaje de pacientes libres de esteroides al año.&lt;br&gt;Incidencia de complicaciones infecciosas bacterianas, víricas, fúngicas o parasitarias al año.  &lt;br&gt;Incidencia de neoplasias y enfermedad linfoproliferativa post-trasplante al año&lt;br&gt;Incidencia de cataratas&lt;br&gt;Incidencia de fracturas y osteoporosis diagnosticada densitometría osea al año&lt;br&gt;Incidencia de complicaciones cardiovasculares al año&lt;br&gt;Supervivencia total de pacientes al año&lt;br&gt;Supervivencia del injerto al año&lt;br&gt;Histología renal al año ;Primary end point(s): Evaluación de eficacia: La eficacia será valorada por la observación de eventos de rechazo agudo y rechazo agudo subclínico.&lt;br&gt;Evaluación de seguridad/tolerancia:La seguridad y tolerancia será determinada por la observación de graves efectos adversos. La evaluación incluirá pruebas clínicas y de laboratorio (exploración física, constantes vitales, hematología, bioquímica  y análisis de orina).</Primary_outcome>
    <Secondary_ID>IBERICA</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455627</Internal_Number>
    <TrialID>EUCTR2005-005664-88-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Prospective Study of Mycobacterium Tuberculosis Specific Cellular immune Responses in Iatrogenically Immunosuppressed Patients: those undergoing TNF-alpha blockade or Awaiting Renal Trasnplants: A Potential New Method For Accurate Diagnosis of Latent Tuberculosis Infection in Clinical Practice - Diagnosis of Latent TB Infection in Anti-TNF alpha or Dialysis</Public_title>
    <Scientific_title>Prospective Study of Mycobacterium Tuberculosis Specific Cellular immune Responses in Iatrogenically Immunosuppressed Patients: those undergoing TNF-alpha blockade or Awaiting Renal Trasnplants: A Potential New Method For Accurate Diagnosis of Latent Tuberculosis Infection in Clinical Practice - Diagnosis of Latent TB Infection in Anti-TNF alpha or Dialysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>University of Oxford</Primary_sponsor>
    <Date_registration3>20051215</Date_registration3>
    <Date_registration>15/12/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005664-88                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>08/12/2006</Date_enrollement>
    <Target_size>520</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: The RD1 based ex vivo enzyme linked immunospot assay&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients in chronic renal failure who are potential transplant recipients &lt;br&gt;OR &lt;br&gt;Patients with a rheumatological condition who are potential recipients of Tumour Necrosis Factor alpha blockade&lt;br&gt;&lt;br&gt;AND &lt;br&gt;adult (over 18)&lt;br&gt;AND&lt;br&gt;able to give written informed consent&lt;br&gt;AND &lt;br&gt;with risk factors for tuberculosis:&lt;br&gt;-[renal arm] from collaborating units in high prevalence areas of the UK&lt;br&gt;-[anti TNF alpha arm] patients who would be considered for tuberculin skin testing under current anti-TNFalpha treatment guidelines, including past history of exposure or disease, immigrant from high prevalence area, CXR changes suggestive of prior TB, grade 2 heaf test or above&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Children&lt;br&gt;Current active tuberculosis&lt;br&gt;Unable to give written informed consent&lt;br&gt;Hypersensitivity to tuberculin&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal failure and iatrogenic immunosuppression associated with solid organ transplantation or TNF alpha blockade in rheumatoid arthritis
ICD 10 codes included: N18 Z94.0 M05 M06 M07 M45</Condition>
    <Intervention>&lt;br&gt;Trade Name: Tuberculin PPD RT 23 SSI for mantoux testing&lt;br&gt;Product Name: Tuberculin PPD RT 23 SSI for mantoux testing&lt;br&gt;Product Code: 1&lt;br&gt;Pharmaceutical Form: Injection*&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To validate the use of the RD1 based Exvivo IFNy ELISpot in the immunodiagnosis of tuberculosis in iatrogenically immunosuppressed populations by calculation of positive and negative predictive values for the assay and for a comparator: the tuberculin based mantoux test;Secondary Objective: To investigate potential immune correlates of latency and active disease in tuberculosis and identify potential markers of prognosis and disease progression in tuberculosis.;Primary end point(s): Development of active tuberculosis</Primary_outcome>
    <Secondary_ID>HB996</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455632</Internal_Number>
    <TrialID>EUCTR2005-001714-41-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio multicéntrico, abierto, randomizado,  de doce meses de duración,  sobre la seguridad, tolerabilidad y eficacia de Certican®, administrado junto a un antagonista del receptor IL-2, corticoesteroides y dos niveles de exposición diferentes de tacrolimus, en pacientes con trasplante renal de novo

</Public_title>
    <Scientific_title>Estudio multicéntrico, abierto, randomizado,  de doce meses de duración,  sobre la seguridad, tolerabilidad y eficacia de Certican®, administrado junto a un antagonista del receptor IL-2, corticoesteroides y dos niveles de exposición diferentes de tacrolimus, en pacientes con trasplante renal de novo

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Novartis Farmacéutica, S.A.</Primary_sponsor>
    <Date_registration3>20051205</Date_registration3>
    <Date_registration>05/12/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001714-41                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/05/2006</Date_enrollement>
    <Target_size>230</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;El investigador debe asegurarse de que cada paciente cumple todos los criterios de inclusión al momento de ingresar en el estudio (basal), inmediatamente antes de la aleatorización: &lt;br&gt;- Hombre o mujeres entre 18 y 65 años de edad.&lt;br&gt;- Paciente que haya recibido un primer trasplante de riñón de un donante cadavérico, de un donante vivo no emparentado o de un donante vivo emparentado con HLA no idéntico.&lt;br&gt;- Receptor de un riñón con un tiempo de isquemia fría (TIF) &lt; 30 horas.&lt;br&gt;- Receptor de un riñón procedente de un donante que tiene entre 10 y 65 años de edad.&lt;br&gt;- Paciente capaz de recibir la primera dosis de tacrolimus dentro de las 24 horas de efectuada la reperfusión del injerto.&lt;br&gt;- Mujeres con capacidad de procrear deben tener una prueba de embarazo negativa, y es necesario que utilicen un método anticonceptivo médicamente probado durante el estudio y por un periodo de tres meses tras la discontinuación del fármaco en investigación.&lt;br&gt;- Paciente dispuesto y capaz de dar consentimiento informado escrito para participar en el estudio y capaz de participar en el estudio durante 12 meses.&lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;El paciente que cumpla con alguno de los siguientes criterios al momento de ingresar al estudio (basal) justo antes de la aleatorización no podrá participar en el estudio:&lt;br&gt;- Paciente que anteriormente haya recibido un trasplante de órgano.&lt;br&gt;- Receptor de trasplante múltiple de órganos.&lt;br&gt;- Receptor de un trasplante de riñón de un donante a corazón parado .&lt;br&gt;- Receptor con transfusiones específicas del  donante&lt;br&gt;- Receptor de un trasplante A-B-O incompatible o trasplante con cross-match para células T positivo.&lt;br&gt;- Paciente con un nivel actual con Panel de Anticuerpos Reactivos (PRA) = 50%.&lt;br&gt;- Receptor de un riñón de un donante con  antígeno de superficie positivo de la hepatitis B o anticuerpos contra hepatitis C .&lt;br&gt;- Paciente positivo para el virus de inmunodeficiencia humano (HIV).&lt;br&gt;- Paciente con serología positiva para hepatitis C, o que es positivo para el antígeno de superficie de la hepatitis B con evidencia de daño hepático indicado por niveles de AST/ALT = 2.5 veces el LSN. Se aceptan los resultados de serología viral obtenidos dentro de los 6 meses previos a la administración de la primera dosis de Certican®.&lt;br&gt;- Paciente con hipercolesterolemia severa ( = 350 mg/dl, 9.1 mmol/dl) o hipertrigliceridemia severa     ( = 500 mg/dl, 5.6 mmol/l).&lt;br&gt;- Paciente con recuento de glóbulos blancos (WBC) &lt; o = 3.000/mm3 o recuento plaquetario &lt; o =  75,000/mm3&lt;br&gt;- Paciente con alguna alergia severa que requiere tratamiento agudo (dentro de las 4 semanas anteriores al examen basal) o crónico, o que presenta hipersensibilidad a fármacos similares a Certican® (Ej. macrólidos).&lt;br&gt;- Paciente que ha recibido tratamiento con un fármaco inmunosupresor o un fármaco en investigación dentro de las 4 semanas previas a la administración de la primera dosis de Certican®.&lt;br&gt;- Paciente con infección no controlada.&lt;br&gt;- Paciente con alguna condición médica o quirúrgica, distinta del actual trasplante, que a criterio del investigador impida la participación en este ensayo.&lt;br&gt;- Paciente con una neoplasia conocida, o antecedentes de neoplasia en los últimos 5 años, excepto carcinoma cutáneo localizado de células basales o escamosas que haya sido tratado con éxito.&lt;br&gt;- Hallazgos anormales de importancia clínica, ya sea en las evaluaciones físicas o en las pruebas de laboratorio, efectuados en las 2 semanas previas a la administración de la primera dosis de Certican® y que, a juicio del investigador, podrían interferir con los objetivos del estudio.&lt;br&gt;- Mujeres en periodo de lactancia.&lt;br&gt;- Paciente con síntomas de enfermedad somática o mental significativa, o con historia no resuelta de abuso de drogas o alcohol.&lt;br&gt;- Paciente que no coopera ni se comunica con el investigador.&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Transplante renal de novo

de novo kidney transplantation</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001  &lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.25-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001&lt;br&gt;Pharmaceutical Form: Dispersible tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,1-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001  &lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.50-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001  &lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001&lt;br&gt;Pharmaceutical Form: Dispersible tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: El objetivo primario es determinar si la reducción de la dosis de tacrolimus puede preservar la función renal en pacientes receptores de trasplantes renales de novo que reciben tacrolimus además de Certican®, AR IL-2 y corticosteroides. Este objetivo se valorará comparando la función renal evaluada a los 12 meses de realizado el trasplante a través de una tasa de filtrado glomerular (GFR) calculada (fórmula MDRD) entre dos grupos de pacientes que reciben dos diferentes niveles de exposición al tacrolimus.&lt;br&gt;&lt;br&gt;;Secondary Objective: El objetivo secundario principal es evaluar la eficacia de los dos regímenes. Esto se evaluará con la comparación entre los dos grupos de la incidencia de rechazo agudo confirmado por biopsia (RACB), desde el Mes 4 hasta el Mes 12 después del trasplante. &lt;br&gt;Los otros objetivos secundarios son evaluar la eficacia y la seguridad de los dos regímenes. Esto se evaluará a los 12 meses, efectuando una comparación entre los dos grupos.&lt;br&gt;;Primary end point(s): La función renal se evaluará a los doce meses post-transplante por la creatinina sérica, el aclaramiento de creatinina calculado (fórmula de Cockcroft-Gault), la GFR calculada (fórmula de MDRD y fórmula de Nankivell). También se evaluará la proteinuria cuantitativa. </Primary_outcome>
    <Secondary_ID>CRAD001A2426</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456453</Internal_Number>
    <TrialID>EUCTR2005-005972-34-DK</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Retrograd intrarenal stenkirurgi. En metode til behandling af den ESWL-resistente nyresten - Retrograde intrarenal Stone Surgery</Public_title>
    <Scientific_title>Retrograd intrarenal stenkirurgi. En metode til behandling af den ESWL-resistente nyresten - Retrograde intrarenal Stone Surgery                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Fredericia Hospital</Primary_sponsor>
    <Date_registration3>20060105</Date_registration3>
    <Date_registration>05/01/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005972-34                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/03/2006</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: saline irrigation fluid as usually used in this kind of procedures &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Stone surgery required&lt;br&gt;Age &gt; 18 years&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Previous coronary infarct&lt;br&gt;Use of alpha-blocking or beta-blocking drugs&lt;br&gt;Untreated hypertension&lt;br&gt;Ureteral stone&lt;br&gt;Malignant disase in the upper urinary tract&lt;br&gt;Pregnancy&lt;br&gt;</Exclusion_Criteria>
    <Condition>kidney stone</Condition>
    <Intervention>&lt;br&gt;Trade Name: Isoprenalin&lt;br&gt;Product Name: isoprenalin&lt;br&gt;Product Code: 5115&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;Current Sponsor code: HJ1&lt;br&gt;Other descriptive name: isoprenalin&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,1-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To lower the intrarenal pelvic pressure during retrograde intrarenal stone surgery by adding isoprenalin to the irrigation fluid during the operation.;Secondary Objective: To shorten surgical time in retrograde intrarenal stone surgery whilst optimizing security and quality of the procedure. To spare the kidney parenchyma  from high pressures.;Primary end point(s): Lowering of the renal pelvic pressure.&lt;br&gt;Making the procedure easier for the surgeon (=shorter duration of operation time, fewer complications)</Primary_outcome>
    <Secondary_ID>HJ1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456484</Internal_Number>
    <TrialID>EUCTR2006-000753-22-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A phase I/II feasability trial to assess the safety, immunological activity and efficacy of TroVax plus interferon alpha in patients with advanced or metastatic renal cell cancer.</Public_title>
    <Scientific_title>A phase I/II feasability trial to assess the safety, immunological activity and efficacy of TroVax plus interferon alpha in patients with advanced or metastatic renal cell cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Oxford MioMedica UK Ltd.</Primary_sponsor>
    <Date_registration3>20060410</Date_registration3>
    <Date_registration>10/04/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-000753-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>04/05/2006</Date_enrollement>
    <Target_size>10</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Locally advanced or metastatic, histologically proven clear cell or papillary cell renal&lt;br&gt;carcinoma.&lt;br&gt;&lt;br&gt;If previously treated at least four weeks from any previous therapy (except Interferon a) for renal cancer includi,ng surgery chemotherapy, immunotherapy, or radiotherapy. (Patients receiving interferon a whose renal cancer is stable may also be included in the study)&lt;br&gt;&lt;br&gt;Newly diagnosed or progressive of stable measurable disease as defined by the&lt;br&gt;RECIST criteria&lt;br&gt;&lt;br&gt;Patients receiving first or second line treatment for locally advanced or metastatic renal cancer.&lt;br&gt;&lt;br&gt;Patients on stable doses of bisphosphonates that show subsequent tumor progression may continue on this medication; however, patients are not allowed to initiate bisphosphonate therapy within one month prior to starting therapy or throughout the study.&lt;br&gt;&lt;br&gt;Patients must be well enough to tolerate first or second line immunotherapy with&lt;br&gt;interferon alpha.&lt;br&gt;&lt;br&gt;Measurable disease.&lt;br&gt;&lt;br&gt;Aged 18 years or more.&lt;br&gt;&lt;br&gt;Patients must comply with 2 out of 3 of the following:&lt;br&gt;a. Karnofsky score greater than or equal to  80%.&lt;br&gt;b. Haemoglobin concentration greater than or equal to  13g/dL (males) or 11.5 g/dL (females)&lt;br&gt;c. Corrected calcium less than or equal to 10 g/dL (2.5 mmols/L).&lt;br&gt;&lt;br&gt;Clinically immunocompetent.&lt;br&gt;&lt;br&gt;Free of clinically apparent autoimmune disease (including no prior confirmed diagnosis or treatment for autoimmune disease including Systemic Lupus Erythematosis, Grave's disease, Hashimoto's thyroiditis, multiple sclerosis, insulin dependant diabetes mellitus or systemic (non-joint) manifestations of rheumatoid disease).&lt;br&gt;&lt;br&gt;Total white cell count greater than or equal to 3 x 10e9/L and lymphocyte count greater than or equal to 1 x 10e9/dL.&lt;br&gt;&lt;br&gt;Serum creatinine up to 1.5 times upper limit of normal.&lt;br&gt;&lt;br&gt;ALT, AST and bilirubin &lt; 2 times the upper limit of normal.&lt;br&gt;&lt;br&gt;Able to give written informed consent and to comply with the protocol.&lt;br&gt;&lt;br&gt;Women must be either post menopausal, or rendered surgically sterile or, if of child&lt;br&gt;bearing potential, must have been practising a reliable form of contraception (oral&lt;br&gt;contraception + a barrier method) for at least three months prior to the first dose of&lt;br&gt;TroVax and must continue while they are being treated with TroVax. Men must&lt;br&gt;practise a reliable form of contraception while they are being treated with TroVax.&lt;br&gt;&lt;br&gt;No acute changes on 12-lead ECG.&lt;br&gt;&lt;br&gt;No clinical suspicion that cardiac ejection fraction is less than 45% (If clinically&lt;br&gt;suspicion exists the ejection fraction should be measured according to local site&lt;br&gt;procedures)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Serious infections within the 28 days prior to entry to the trial.&lt;br&gt;&lt;br&gt;Prior TroVax&lt;br&gt;&lt;br&gt;Patients that initiate bisphosphonate therapy within one month prior to starting therapy or throughout the study.&lt;br&gt;&lt;br&gt;Already completed prior second line therapy for advanced or metastatic renal cancer.&lt;br&gt;(Note however that patients currently receiving interferon as second line therapy for&lt;br&gt;advanced or metastatic renal cancer who are stable (ie do not demonstrate response or progression by RECIST criteria) may enter the study)&lt;br&gt;&lt;br&gt;Major surgery or radiation therapy completed less than or equal to 4 weeks prior to enrollment.&lt;br&gt;&lt;br&gt;Prior radiopharmaceuticals (strontium, samarium) within 8 weeks prior to enrollment.&lt;br&gt;&lt;br&gt;Participation in any other clinical trial of a licensed or unlicensed drug within the&lt;br&gt;previous 30 days. (except sorafanib or sutnitinib who may enter the study after 7 days discontinuation)&lt;br&gt;&lt;br&gt;Cerebral metastesis on MRI scan&lt;br&gt;&lt;br&gt;"Currently active" second malignancy, other than non-melanoma skin cancer. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at least less than 30% risk of relapse.&lt;br&gt;&lt;br&gt;Serious intercurrent infections or nonmalignant medical illnesses that are uncontrolled.&lt;br&gt;&lt;br&gt;Psychiatric illnesses/social situations that would limit compliance with protocol&lt;br&gt;requirements.&lt;br&gt;&lt;br&gt;Creatinine 21.5 x ULN.&lt;br&gt;&lt;br&gt;Chronic oral corticosteroid use unless prescribed as replacement therapy in the case&lt;br&gt;of adrenal insufficiency.&lt;br&gt;&lt;br&gt;Clinical indication of reduced cardiac function or an ejection fraction of r 40%.&lt;br&gt;&lt;br&gt;Requirement for radiotherapy (this is a sign of disease progression and is classed as a withdrawal criterion).&lt;br&gt;&lt;br&gt;Concurrent chemotherapy, immunotherapy and radiation therapy&lt;br&gt;&lt;br&gt;No investigational or commercial agents or therapies other than those included in protocol treatment may be administered with the intent to create regression of the&lt;br&gt;patient's malignancy.&lt;br&gt;&lt;br&gt;Life threatening illness unrelated to cancer.&lt;br&gt;&lt;br&gt;Cerebral metastases on MRI scan.&lt;br&gt;&lt;br&gt;History of allergic response to previous vaccinia vaccinations.&lt;br&gt;&lt;br&gt;Participation in any other clinical trial of a licensed or unlicensed drug within the&lt;br&gt;previous 30 days or during the course of this trial.&lt;br&gt;&lt;br&gt;Previous malignancies within the last 10 years other than successfully treated&lt;br&gt;squamous carcinoma of the skin or in situ carcinoma of the cervix treated with cone&lt;br&gt;biopsy.&lt;br&gt;&lt;br&gt;Previous history psychosis or of major a psychiatric disorder requiring hospitalization or any current psychiatric disorder that would impede the patient's ability to provide&lt;br&gt;informed consent or to comply with the protocol.&lt;br&gt;&lt;br&gt;Known allergy to egg proteins.&lt;br&gt;&lt;br&gt;Known to test positive for HIV or hepatitis B or C.&lt;br&gt;&lt;br&gt;Pregnancy or lactation.&lt;br&gt;&lt;br&gt;Prior history of organ transplantation.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Advanced or Metastatic Renal Cell Cancer</Condition>
    <Intervention>&lt;br&gt;Product Name: TroVax&lt;br&gt;Product Code: TV&lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;Current Sponsor code: TroVax&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1.58 x 10e8-1.58 x 10e9&lt;br&gt;&lt;br&gt;Trade Name: Roferon-A&lt;br&gt;Product Name: Roferon-A&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Interferon A&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 18 x 10e6-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Secondary Objective: Though this is a phase I/II feasibility study to assess the safety and immunological&lt;br&gt;activity of TroVax combined with IFN-a, tumour response in each patient will also&lt;br&gt;be evaluated using RECIST criteria.;Main Objective: To evaluate whether IFN-a markedly increases the cellular or humoral anti-5T4&lt;br&gt;response to TroVax compared to that observed in previous studies using TroVax&lt;br&gt;alone, in combination with IL-2 or with chemotherapy.;Primary end point(s): Immunology endpoints&lt;br&gt;Antibody response to 5T4 as measured by ELISA&lt;br&gt;Cellular response to 5T4 antigen as measured by lFN gamma Elispot&lt;br&gt;&lt;br&gt;Primary safety endpoints&lt;br&gt;Assessment of the number of adverse events and serious adverse events&lt;br&gt;Assessment of safety by analysis of clinical laboratory variables (complete blood&lt;br&gt;count and chemistry panel).&lt;br&gt;&lt;br&gt;Efficacy endpoint&lt;br&gt;Tumour outcomes will be reported according to RECIST criteria.</Primary_outcome>
    <Secondary_ID>TV2/003/06</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456489</Internal_Number>
    <TrialID>EUCTR2005-005809-38-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Does prophylactic N acetylcysteine reduce the incidence of contrast nephropathy in patients undergoing peripheral angiography - NAC as a Nehroprotective agent in Peripheral Angiography</Public_title>
    <Scientific_title>Does prophylactic N acetylcysteine reduce the incidence of contrast nephropathy in patients undergoing peripheral angiography - NAC as a Nehroprotective agent in Peripheral Angiography                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Research &amp; Development Department, Addenbrookes Hospital</Primary_sponsor>
    <Date_registration3>20060110</Date_registration3>
    <Date_registration>10/01/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005809-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>08/12/2006</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Any patient undergoing peripheral angiography in the Cambridge Vascular Unit, Addenbrooke’s Hospital, Cambridge who consents to participation&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Any patient undergoing peripheral angiography in Cambridge Vascular Unit, &lt;br&gt;Any patient that does not consent to participation in the study.&lt;br&gt;Any patient under the age of 18 years&lt;br&gt;Any patient with established renal failure on renal replacement therapy (dialysis).&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>We will use N acetylcystiene prophylactically in patient undergoing peripheral angiography at the Cambridge Vascular Unit at Addenbrooke's Hospital in order to prevent renal injury. Patients undergoing peripheral angiography have large quanities of contrast medium injected intravenously, contrast medium is a nephrotoxic substance. Thge drug will be administrated prophylactically to aviod acute renal failure.</Condition>
    <Intervention>&lt;br&gt;Trade Name: Fluimucil&lt;br&gt;Pharmaceutical Form: Effervescent tablet&lt;br&gt;INN or Proposed INN: N acetylcysteine&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 600-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To investigate the role of N acetylcysteine as a nephroprotective agent in patients undergoing peripheral angiography at Addenbrooke’s Hospital, Cambridge.&lt;br&gt;&lt;br&gt;Primarily we are looking for a reduction in the elevation of serum creatinine and also of other markers of renal damage in urine (retinol binding protein and albumin)&lt;br&gt;&lt;br&gt;A reduction in the mortality and morbidity related to renal failure that may result from a contrast medium induced nephropathy.&lt;br&gt;;Secondary Objective: ;Primary end point(s): To obtain eveidence that shows prophylactic use of N acetylcysteine is significantly nephroprotective for patients undergoing peripheral angiography</Primary_outcome>
    <Secondary_ID>NACP1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456539</Internal_Number>
    <TrialID>EUCTR2004-002852-33-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>a randomised, open clinical trial to study the efficacy of risedronate 35 mg/week in prevention of bone mass loss and vascular calcifications after kidney transplantation
Ensayo aleatorio, abierto para estudiar la eficacia de risedronato 35mg/semanal en la prevención de pérdida de masa ósea y calcificaciones vasculares post-trasplante renal - PREVENOS</Public_title>
    <Scientific_title>a randomised, open clinical trial to study the efficacy of risedronate 35 mg/week in prevention of bone mass loss and vascular calcifications after kidney transplantation
Ensayo aleatorio, abierto para estudiar la eficacia de risedronato 35mg/semanal en la prevención de pérdida de masa ósea y calcificaciones vasculares post-trasplante renal - PREVENOS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Dr. Jose Vicente Torregrosa Prats (fundacio clinic)</Primary_sponsor>
    <Date_registration3>20060124</Date_registration3>
    <Date_registration>24/01/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002852-33                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>13/04/2005</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: same treatment (calcium carbonate and cholecalciferol) without risedronato&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Male and female aged 18-75 years old; chronic renal failure's patients on dialysis that have had a kidney transplant; patients who have been fully informed and have given written informed consent&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Hyperimmunized patients (PRA ›75%); multiorganic transplant; diabetes mellitus patients on insulin treatment at the transplant moment; parathyroidectomised patients with parathyroid hormone values ‹ 50 pg/ml; patients that have received fluorine, biphosphonates or hormone replacement therapy in the previous 6 months, antiepileptic or calcitonin treatment in the previous 3 months, patients with biphosphonate allergy history, dyspepsia or reflux history and pregnant patients or nursing mothers.&lt;br&gt;</Exclusion_Criteria>
    <Condition>bone metabolic pathology associated to kidney transplantation &lt;br&gt;MedDRA version: 7.1
Level: LLT
Classification code 10058972
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Actonel semanal&lt;br&gt;Product Name: Actonel semanal&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: risedronate&lt;br&gt;Other descriptive name: risedronic acid&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 35-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: study the efficacy of risedronate 35 mg/week to reduce the bone mass loss in patients after kidney transplantation;Secondary Objective: study the efficacy of risedronate 35 mg/week in bone fractures prevention and in the vascular calcifications of kidney graft recipients. Safety evaluation;Primary end point(s): bone masses evolutions through bone densitometry tests: basal and after 6 and 12 months</Primary_outcome>
    <Secondary_ID>TOR-RIS-2004-01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456630</Internal_Number>
    <TrialID>EUCTR2005-005155-18-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Study on the effectiveness of a treatment with statine in reducing the morbility and cardiovascular mortality in patients with moderate-strict renal insufficiency. - ND</Public_title>
    <Scientific_title>Study on the effectiveness of a treatment with statine in reducing the morbility and cardiovascular mortality in patients with moderate-strict renal insufficiency. - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI</Primary_sponsor>
    <Date_registration3>20060125</Date_registration3>
    <Date_registration>25/01/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005155-18                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/02/2004</Date_enrollement>
    <Target_size>350</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: yes&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients of age 18-80 years, with moderated light renal insufficiency, identified from a VFG calculated with formula of Cockcoft and Gault between the 60 and 20 ml/min.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients for which the cardiovascular risk is much elevated  40  .  Patients already in treatment with statine.&lt;br&gt;</Exclusion_Criteria>
    <Condition>patients with moderate-strict renal insufficiency &lt;br&gt;MedDRA version: 6.1
Level: PT
Classification code 10038474
</Condition>
    <Intervention>&lt;br&gt;Trade Name: TORVAST 10 10 CPR 10 MG&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Atorvastatin&lt;br&gt;CAS Number: 134523-03-8&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To verify in a population of patients with moderate-strict IR that an aggressive treatment of cholesterolemia  target   the levels of cholesterol LDL   100 mg/dL  meaningfully reduces the entity of a end point composite, constituted from mortality and cardiovascular morbility.;Secondary Objective: To verify in a population of patients with moderate-strict IR that an aggressive treatment of cholesterolemia  target   the levels of cholesterol LDL   100 mg/dL  meaningfully reduces the entity of a end point composite, constituted from mortality and cardiovascular morbility.;Primary end point(s): A composite of serious cardiovascular events  infarct, ictus, intestinal infarct, thrombosis renal arteries  and cardiovascular mortality.</Primary_outcome>
    <Secondary_ID>61/2003/O</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456830</Internal_Number>
    <TrialID>EUCTR2005-005770-72-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>RAPSODY - RANDOMIZED, PROSPECTIVE TRIAL OF TWO SCHEDULES OF SORAFENIB 800 mg DAILY AND INTERFERON ALPHA IN METASTATIC RENAL CELL CARCINOMA  MRCC   A GOIRC PHASE II STUDY - RAPSODY</Public_title>
    <Scientific_title>RAPSODY - RANDOMIZED, PROSPECTIVE TRIAL OF TWO SCHEDULES OF SORAFENIB 800 mg DAILY AND INTERFERON ALPHA IN METASTATIC RENAL CELL CARCINOMA  MRCC   A GOIRC PHASE II STUDY - RAPSODY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>GRUPPO ONCOLOGICO ITALIANO DI RICERCA</Primary_sponsor>
    <Date_registration3>20060217</Date_registration3>
    <Date_registration>17/02/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005770-72                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>13/01/2006</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Sorafenib 800 mg/die   interferone alfa 2a 9MU TIW&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.Signed informed consent  2.Histologically or cytologically documented Clear Cell Renal Carcinoma  RCC . In the case of a mixed histology the presence of a documented component of clear cell histology   61619; 50  is mandatory . Other variants are excluded  3.Prior Nephrectomy for primary site  conservative approaches are allowed   4.In cases with initial diagnosis of RCC of more than 2 years  RFS   2 years  a histological/cytological confirmation of renal cell carcinoma origin of actual metastases is mandatory  5.Metastatic measurable disease  at least one uni-dimensional measurable lesion by CT-scan or MRI  according to RECIST criteria  reported in Appendix   6.ECOG performance status   8804;2  ECOG scale reported in Appendix   7.Age   8805; 18 years  8.Life expectancy   8805; 3 months  9.Prior Surgery and/or Radiation Therapy  to less or equal than 25  of the bone marrow  are allowed. However, at least 4 weeks must have been elapsed since surgery or completion of radiation therapy and the patient must has recovered from side effects  10.ANC   8805;1.5 x 109/L; PLT   8805;100 x 109/L; Hb   8805;10 g/dl  11.Adequate hepatic function  Total bilirubin  1.5 times the UNL ; ALT and AST  2.5 times the UNL   5 UNL in presence of liver metastases   12.Amylase and lipase  1.5 x the UNL  13.Serum creatinine  2.0 x the UNL  14.PT or INR and PTT  1.5 times the UNL  Note  patients who receive anti-coagulation treatment will be allowed to participate provided that no evidence of abnormality in these parameters exists   15.Patients must be accessible for treatment and follow up   UNL   upper normal limit of the institution.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.CNS metastases  2.Previous malignancy except for basal cell skin cancer and cervical carcinoma in situ adequately treated, or any other cancer from which the patient has been disease-free for   61619; 5 years  3.Any of the concomitant illness or medical condition indicated below     Serious respiratory or cardiovascular disease such as  congestive heart failure    NYHA Class II -refer to Appendix- ; previous history  within 6 months  of myocardial infarction, angina pectoris or cardiac arrhythmias requiring anti-arrythmics  excluding beta blockers or digoxin . Active coronary artery disease, uncontrolled hypertension  4.Unstable diabetes mellitus, significant neurological or psychiatric disorders or seizure disorder requiring medication  such as anti-epileptics   5.Active clinically serious bacterial or fungal infections    grade 2 NCI-CTC, Version 3  or active human immunodeficiency virus  HIV  infection or chronic hepatitis B or C  6.Previous treatment  chemotherapy, Immunotherapy or experimental drugs  for advanced disease  adjuvant immnunotherapy could be allowed in the case of a relapse free survival   6 months   7.Prior isotope treatment  e.g. strontium or samarium   8.Participation in clinical trials with other experimental agents within 30 days of study entry or concomitant treatment with other experimental drug  9.Concomitant treatment with bisphosphonates or any other anti-cancer therapy  10.Concomitant treatment with ketoconazole or itraconazole  11.Pregnant or breast-feeding patients.  Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug.  Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial  12.History of organ allograft or autologous bone marrow transplant or stem cell rescue within four months of start of study drug   13.Prior use of Raf-kinase inhibitors  RKI , MEK or Farnesyl transferase inhibitors  14.Known or suspected allergy to the investigational agent or any agent given in association with this trial&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with histologically- or cytologically-confirmed, metastatic, clear cell renal cell cancer  RCC &lt;br&gt;MedDRA version: 6.1
Level: PT
Classification code 10050513
</Condition>
    <Intervention>&lt;br&gt;Product Name: Sorafenib&lt;br&gt;Product Code: BAY 43-9006&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Sorafenib&lt;br&gt;CAS Number: 284461-73&lt;br&gt;Current Sponsor code: BAY 43-9006&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Product Name: Sorafenib&lt;br&gt;Product Code: BAY43-9006&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Sorafenib&lt;br&gt;CAS Number: 284461-73&lt;br&gt;Current Sponsor code: BAY 43-9006&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Aim of this study is to evaluate if the combination of Sorafenib 800 mg daily plus low-dose frequent interferon  total weekly dose 15 MU  has an increased antiangiogenic activity, and  a consequent possible increased activity, than Sorafenib 800 mg daily plus interferon in the classic schedule  total weekly dose 27 MU . Serum surrogate markers will be evaluated to eventually support clinical results of the study.;Secondary Objective: A pharmacoeconomic evaluation of the two treatment  schedules  Sorafenib same schedule and dosage, IFN total weekly dose 27 MU in Arm A vs  15 MU in ArmB  will be performed.;Primary end point(s): Primary end-point of the study is to determine the Progression Free Survival  PFS  rates in the two arms.</Primary_outcome>
    <Secondary_ID>0681</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456841</Internal_Number>
    <TrialID>EUCTR2005-005695-32-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Ensayo clínico aleatorizado, controlado y abierto, para evaluar la eficacia (biocompatibilidad peritoneal) de la adición de bemiparina a la solución de icodextrina, en pacientes en diálisis peritoneal con trastornos del trasporte peritoneal. - Bemidextrina</Public_title>
    <Scientific_title>Ensayo clínico aleatorizado, controlado y abierto, para evaluar la eficacia (biocompatibilidad peritoneal) de la adición de bemiparina a la solución de icodextrina, en pacientes en diálisis peritoneal con trastornos del trasporte peritoneal. - Bemidextrina                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Fundación Renal Iñigo Álvarez de Toledo</Primary_sponsor>
    <Date_registration3>20060216</Date_registration3>
    <Date_registration>16/02/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005695-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/03/2006</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Sin tratamiento experimental&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Pacientes mayores de 18 años de ambos sexos, que hayan otorgado su consentimiento informado para participar en el estudio.&lt;br&gt;- Pacientes en tratamiento estable con diálisis peritoneal durante más de 6 semanas que presenten trastorno funcional peritoneal definido por capacidad de ultrafiltración estandarizada (glucosa 3.86% mantenida 4 horas en peritoneo) menor de 600 ml y/o transporte de creatinina elevado (definido por D/P de creatinina mayor de 0.65 a las 4h de permanencia). &lt;br&gt;- Pacientes con tratamiento con solución de icodextrina para diálisis peritoneal durante al menos un mes previo a su inclusión.&lt;br&gt;- Pacientes en los que el resto de líquidos dializantes que emplean en su DP contengan glucosa y PDG (productos de degradación de glucosa).&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Peritonitis en los últimos 2 meses.&lt;br&gt;- Pacientes con hemorragia en el momento de la inclusión, o pacientes con antecedentes de episodios hemorrágicos clínicamente evidentes y/o con incremento del riesgo de sangrado debido a cualquier alteración de la hemostasia que contraindique la terapia anticoagulante, y/o que en los dos últimos meses hayan presentado, al menos, alguna de las siguientes situaciones: hemorragia activa o lesiones orgánicas susceptibles de sangrar (ej.: úlcera péptica activa, accidente cerebrovascular hemorrágico, aneurismas).&lt;br&gt;- Cirugía mayor en el último mes. &lt;br&gt;- Hipersensibilidad conocida a las HBPM, a la heparina o sustancias de origen porcino.&lt;br&gt;- Hipersensibilidad conocida a icodextrina.&lt;br&gt;- Pacientes tratados con anticoagulación sistémica.&lt;br&gt;- Pacientes con diátesis hemorrágica congénita o adquirida. &lt;br&gt;- Daños o intervenciones quirúrgicas en el sistema nervioso central, ojos y oídos dentro de los 6 meses previos. &lt;br&gt;- Endocarditis bacteriana aguda y endocarditis lenta. &lt;br&gt;- Pacientes con historia de trombocitopenia asociada a heparina. &lt;br&gt;- Pacientes con insuficiencia hepática (con valores de AST y/o ALT &gt; 5 veces el valor normal establecido en los rangos de referencia del laboratorio local del hospital).&lt;br&gt;&lt;br&gt;- Hipertensión arterial grave (presión arterial sistólica mayor de 200 mmHg y/o presión arterial diastólica mayor de 120 mmHg).&lt;br&gt;- Pacientes con sospecha o incapacidad para cumplir el tratamiento y/o seguimiento del estudio.&lt;br&gt;- Pacientes que estén participando en otro ensayo clínico o lo hayan hecho en los últimos 30 días. &lt;br&gt;- Pacientes que tengan una esperanza de vida inferior a 6 meses.&lt;br&gt;- Mujeres embarazadas o en edad fértil que no utilicen un método anticonceptivo eficaz o mujeres en periodo de lactancia. &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Pacientes con insuficiencia renal en tratamiento con diálisis peritoneal y trastornos de la función peritoneal. &lt;br&gt;Classification code 10051055
</Condition>
    <Intervention>&lt;br&gt;Trade Name: HIBOR® 3.500 UI anti Xa&lt;br&gt;Product Name: HIBOR®&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Bemiparina sodica&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 17500-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluar si la adición de bemiparina (3500 Ul/día), una vez al día en la solución de icodextrina para la diálisis peritoneal durante 16 semanas, aumenta la capacidad peritoneal de ultrafiltración y/o disminuye la de transporte de creatinina de pacientes en diálisis peritoneal que presenten trastornos funcionales de tipo déficit de ultrafiltración y/o alto transporte.;Secondary Objective: Evaluar si la adición de bemiparina (3500 Ul/día), una vez al día en la solución de icodextrina para la diálisis peritoneal durante 16 semanas, modifica algunos biomarcadores del efluente peritoneal relacionados con los procesos de regeneración tisular.;Primary end point(s): La función peritoneal definida mediante la capacidad de ultrafiltración estandarizada (glucosa 3,86%, 4 horas de permanencia i.p.) y/o el transporte peritoneal de creatinina estimado por D/P y coeficiente de transferencia de masas o MTC durante el periodo de tratamiento aleatorizado (desde el día 1 al día 112).</Primary_outcome>
    <Secondary_ID>FRIAT-BEM-2005-01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456879</Internal_Number>
    <TrialID>EUCTR2006-000607-42-CZ</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Treatment of borderline changesin protocol biopsy 3 months after renal transplantation</Public_title>
    <Scientific_title>Treatment of borderline changesin protocol biopsy 3 months after renal transplantation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Institute for clinical and experimental Medicine</Primary_sponsor>
    <Date_registration3>20060208</Date_registration3>
    <Date_registration>08/02/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-000607-42                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/02/2006</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: no treatment&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;a. 3 months after kidney transplantation&lt;br&gt;b. stabilised graft function with serum creatinine under 300 umol/l&lt;br&gt;c.  borderline changes according to Banff classification in protocol biopsy&lt;br&gt;d. signed  informed consent&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;a. Graft dysfunction due to rejection or to other reasons less than 1 month before biopsy&lt;br&gt;b. reduced graft function with serum creatinine 300 umol/l or higher &lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with transplanted kidney and stabilised graft function</Condition>
    <Intervention>&lt;br&gt;Trade Name: SOLU-MEDROL inj.&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: methylprednisolon&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Impact of antirejection treatment with Solu-Medrol on graft function development&lt;br&gt;in patients with borderline changes in 3-months protocol graft biopsy.;Secondary Objective: Impact of antirejection treatment with Solu-Medrol on acute rejection prevalence and  graft survival in patients  with borderline changes in 3-months protocol graft biopsy ;Primary end point(s): Graft function assessed by serum creatinine and glomerular filtration rate calculated by Cockroft-Gault formula and MDRD at 1 and 2 years posttransplant</Primary_outcome>
    <Secondary_ID>KN-1/06</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2457059</Internal_Number>
    <TrialID>EUCTR2004-000678-30-CZ</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>An Evaluation of the Efficacy of Epo-Omega in Treatment of Anaemia in ESRD Patients When Administered by Thrice Weekly Intravenous Injection: A Dose Dependency Evaluation. - Epomax (3 x week i.v.) A dose dependency evaluation</Public_title>
    <Scientific_title>An Evaluation of the Efficacy of Epo-Omega in Treatment of Anaemia in ESRD Patients When Administered by Thrice Weekly Intravenous Injection: A Dose Dependency Evaluation. - Epomax (3 x week i.v.) A dose dependency evaluation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Baxter Healthcare S.A.</Primary_sponsor>
    <Date_registration3>20040910</Date_registration3>
    <Date_registration>10/09/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000678-30                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/11/2004</Date_enrollement>
    <Target_size>105</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Patients who have provided written informed consent.&lt;br&gt;2. Patients with stable Hb &lt;10.5g/dL (stable = at least two Hb measurements &lt;10.5g/dL, a minimum of 7 days apart, in a 42 day period prior to formal screening for the study.  &lt;br&gt;3. Haemodialysis 3X/W for a minimum of 3 months and with delivered Kt/V =1.20/session (renal clearance to be added to K in case of residual renal function (RRF) [urine volume &gt;100mL] and renal urea clearance &gt;0.5mL/min). In the case that Kt/V determinations are not possible, a urea reduction rate (URR) of &gt; 65% will be accepted.&lt;br&gt;4. Patients 18-75 years of age (inclusive).&lt;br&gt;5. Patients with an adequate iron status defined as serum ferritin =100µg/L and transferrin saturation =20% at the screening visit.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Patients with uncontrolled hypertension (diastolic BP &gt;100 mm Hg determined during two separate pre-dialysis measurements, preferably the second session of the week).&lt;br&gt;2.	Patients with Vit B12 deficiency (&lt;200 ng/L) or folic acid deficiency (&lt;3.0µg/L).&lt;br&gt;3.	Patients receiving treatment for cancer.&lt;br&gt;4.	Patients with haemolytic anaemia or anaemia due to other diseases.&lt;br&gt;5.	Patients with clinically persistent blood loss (e.g. gastrointestinal).&lt;br&gt;6.	Patients with known epilepsy.&lt;br&gt;7.	Patients with severe hyperparathyroidism and/or indication for parathyroidectomy.&lt;br&gt;8.	Pregnant or lactating patients. &lt;br&gt;N.B. Female patients of childbearing potential must have a negative serum pregnancy test at the time of screening and will be required to use a medically acceptable means of contraception during their participation in this study.&lt;br&gt;9.	Patients who have received Interferon or Ribavirin within 30 days prior to the screening visit.&lt;br&gt;10.	Patients who have received Epoetin (Alpha, Beta) or darbepoetin alfa treatment, androgens or transfusions within the last 90 days prior to screening.&lt;br&gt;11.	Patients with acute infection(s).&lt;br&gt;12.	Patients with inflammatory status (CRP &gt;30mg/L).&lt;br&gt;13.	Patients with HIV.&lt;br&gt;14.	Patients with chronic hepatitis C or chronic hepatitis B (with transaminases &gt;2X upper limit).&lt;br&gt;15.	 Patients who have received cytotoxic agents, immunosuppressives or radiation therapy within 30 days prior to the screening visit.&lt;br&gt;16.	Patients participating in another interventional study.&lt;br&gt;17.	Patients who have received investigational drug within 30 days prior to the screening visit.&lt;br&gt;18.	Patients with known hypersensitivity to Epoetin, mammalian cell line products or human serum albumin.&lt;br&gt;19.	Patients with a history of pure red cell aplasia (any cause).&lt;br&gt;20.	Patients with a serum albumin &lt; 30 g/L.&lt;br&gt;21.	Patients with a life expectancy &lt; 6 months.&lt;br&gt;Patients who have had a renal transplant are allowed to participate in the study, as are those who are on the transplant waiting list.  Those who are scheduled to have a living related donor operation within the next 3 months must be excluded.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Anaemia in End Stage Renal Disease  (ESRD) hemodialyzed Patients
 &lt;br&gt;MedDRA version: 7.0
Level: LLT
Classification code 10009120
</Condition>
    <Intervention>&lt;br&gt;Trade Name: NeoRecormon Multidose 50,000IU Powder and solvent for solution for injection&lt;br&gt;Product Name: NEORECORMON &lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;INN or Proposed INN: epoetin beta&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50000-&lt;br&gt;&lt;br&gt;Product Name: EPOMAX 5000 IU, solution for injection&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: epoetin omega&lt;br&gt;Current Sponsor code: rHu-EPO&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5000-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The objective of this study is to evaluate the dose dependency of the effects of Epoetin-Omega administered by thrice weekly intravenous (i.v.) injection on erythropoiesis in anaemic renal patients on haemodialysis.;Secondary Objective: The trial will also evaluate the dose dependency of possible untoward effects.;Primary end point(s): 1.       Response rate. The Response Rate is the proportion of “responders”, where response to the assigned dose is defined as Packed Red Cell (PRC)   transfusion-independent attainment of Hb levels during the trial that meet one of the  following criteria: a) two consecutive weekly Hb values &gt;1.5 g/dL higher than the baseline Hb (HbB); b) Hb level is &gt;13.0 g/dL at least once, c) reduction in Epoetin dose due to a too rapid increase in Hb (i.e. &gt; 2.5 g/dL/2 weeks).&lt;br&gt;The baseline Hb level is defined as the average value of three Hb concentrations determined at the Screening Visit, in between the  screening visit and visit 0, and at visit 0.&lt;br&gt;2.       The weekly change in Hb until the end of the study. This parameter is defined as the weekly consecutive differences in Hb for each patient  (Hbi - Hbi-1, where i is the visit number and may range from 1 to 12).  For Visit 1, the value Hbi-1 is the baseline Hb value. The duration of  the observed period is from enrolment until one of the following events (whichever occurs first).&lt;br&gt;a)	The Hb level &gt; 13 g/dL.&lt;br&gt;b)	Patient requires an Epoetin dose increase.&lt;br&gt;c)	Patient requires an Epoetin dose decrease.&lt;br&gt;d)	Patient receives a PRC transfusion.&lt;br&gt;e)	Patient drops out of the study and Hb values are no longer available.&lt;br&gt;f)	The planned end of the study (completed 12 weeks).</Primary_outcome>
    <Secondary_ID>PRO-RENAL-REG-056</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2457194</Internal_Number>
    <TrialID>EUCTR2005-004052-12-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio abierto, aleatorizado y controlado sobre las propiedades antiinflamatorias de sevelamer (Renagel®) en pacientes sometidos a hemodiálisis crónica</Public_title>
    <Scientific_title>Estudio abierto, aleatorizado y controlado sobre las propiedades antiinflamatorias de sevelamer (Renagel®) en pacientes sometidos a hemodiálisis crónica                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Asociación Científica para la investigación Nefrológica (ACINEF)</Primary_sponsor>
    <Date_registration3>20060330</Date_registration3>
    <Date_registration>30/03/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004052-12                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>13/06/2006</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Sujetos de ambos sexos, con edad igual o superior a 18 años; Sujetos sometidos a hemodiálisis durante un período igual o superior a 3 meses;	Sujetos que otorguen su consentimiento informado por escrito.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Sujetos que padezcan algún tipo de enfermedad inflamatoria, infecciosa o tumoral; Sujetos que hayan presentado algún episodio de enfermedad cardiovascular en los 3 meses previos a su inclusión en el estudio; Sujetos con enfermedad gastrointestinal severa (disfagia, gastroparesia activa no tratada, problemas de motilidad gastrointestinal, cirugía intestinal...); Sujetos con antecedentes de alcoholismo o abuso de tóxicos; Sujetos con antecedentes de vasculitis; Sujetos con diabetes mellitus y/o hipertensión mal controlada;	Sujetos que estén tomando fármacos con propiedades antiinflamatorias o inmunosupresores (corticoides, AINEs, inmunosupresores o inmunomoduladores, cualquier principio activo en cuya ficha técnica aparezca reflejado efecto alguno sobre la síntesis y/o liberación de citoquinas)&lt;br&gt;</Exclusion_Criteria>
    <Condition>Enfermedad renal terminal (ESRD)</Condition>
    <Intervention>&lt;br&gt;Trade Name: Renagel 800 mg&lt;br&gt;Product Name: Renagel&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Sevelamer&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 800-&lt;br&gt;&lt;br&gt;Product Name: Acetato cálcico&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Acetato cálcico&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Determinar la influencia del tratamiento con sevelamer en los niveles séricos de citoquinas pro-inflamatorias (TNF-alfa, IL-1beta, IL-6, IL-18), antiinflamatorias (IL-10) y de proteína C reactiva (PCR) en pacientes sometidos a hemodiálisis crónica.;Secondary Objective: Determinar la relación entre el metabolismo fosfocálcico y el estado inflamatorio.;Primary end point(s): Concentraciones séricas de citoquinas pro-inflamatorias (TNF-alfa, IL-1beta, IL-6, IL-18) y anti-inflamatorias (IL-10) en pacientes sometidos a hemodiálisis crónica.</Primary_outcome>
    <Secondary_ID>CAN-NEFRO-2005-01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2457243</Internal_Number>
    <TrialID>EUCTR2006-000830-11-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A randomised prospective trial of tacrolimus-based steroid avoidance in renal transplantation with either alemtuzumab induction or, basiliximab induction and mycophenolate mofetil maintenance therapy - SALAMI</Public_title>
    <Scientific_title>A randomised prospective trial of tacrolimus-based steroid avoidance in renal transplantation with either alemtuzumab induction or, basiliximab induction and mycophenolate mofetil maintenance therapy - SALAMI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Leeds Teaching Hospitals NHS Trust</Primary_sponsor>
    <Date_registration3>20060403</Date_registration3>
    <Date_registration>03/04/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-000830-11                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/07/2006</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Male and female patients who must be over age 18 years.&lt;br&gt;•	Patients must be recipients of heart-beating cadaveric, non-heart beating or living donors.&lt;br&gt;•	Patients receiving a 2nd or subsequent grafts must have maintained their primary graft for a minimum of 6 months, except if graft failure was due to technical reasons.&lt;br&gt;•	Written Informed consent&lt;br&gt;•	Women at risk of pregnancy must have a negative pregnancy test before commencing the trial and agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months after discontinuing the trial.  The manufacturer of Alemtuzumab advises effective contraception for 6 months after administration to men or women.  Advice will be given to patients to discuss with the transplant medical staff if a pregnancy is planned. &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	Regional patients from Hull Royal Infirmary (due to the logistical difficulties in following these patients up from Leeds).&lt;br&gt;•	High Risk Recipients - defined as recipients who have one or more of the following; 2 HLA-DR mismatch, previous immunologically mediated graft loss in less than 6 months, Preoperative donor specific antibodies&lt;br&gt;•	Known hypersensitivity to the IMP including the standard drugs.&lt;br&gt;•	Prohibited prior or concomitant medications&lt;br&gt;•	Pregnant women or nursing mothers. &lt;br&gt;•	WBC count &lt; 3000/mm3 or platelets &lt; 75,000/mm3 at time of study entry&lt;br&gt;•	Any other concurrent cardiovascular, gastrointestinal, pulmonary or haematological conditions that would restrict the administration of study drugs in the opinion of the investigator.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>MabCampath / Alemtuzumab will be used as part of the immunosuppression regime following renal transplant.</Condition>
    <Intervention>&lt;br&gt;Trade Name: MabCampath&lt;br&gt;Product Name: MabCampath&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;&lt;br&gt;Trade Name: Simulect&lt;br&gt;Product Name: Simulect&lt;br&gt;Pharmaceutical Form: Powder for injection*&lt;br&gt;&lt;br&gt;Trade Name: CellCept&lt;br&gt;Product Name: CellCept&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The purpose of this study is to compare the efficacy of two tacrolimus-based steroid avoidance immunosuppressive regimens.&lt;br&gt;The primary objective of this study is to determine whether we can use a regime of immunosuppression that is both as effective as our standard regime and that offers advantages in terms of a lack of some of the specific side effects of our standard regime and one that is simpler and more cost effective.;Secondary Objective: Secondary endpoints can be categorised: 1- contains a number of standard clinical variables anticipated to be similar in both study groups, including rejection rates, patient and graft survival rates and rates of delayed graft function.  2- comprises a number of surrogate markers for cardiovascular outcome which are particularly important in this setting of studying steroid-free patients.  These include 24 hour blood pressure monitoring, pulse wave analysis and metabolic studies including glucose tolerance.  3- various socioeconomic endpoints with quality of life assessment, adherence monitoring and a cost analysis.  4- follows a number of scientific endpoints capitalising on the various expertise available both on and off site&lt;br&gt;;Primary end point(s): 1.	DTPA Isotopic Glomerular Filtration Rate (GFR) at 12 months </Primary_outcome>
    <Secondary_ID>RL05/7239</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2457397</Internal_Number>
    <TrialID>EUCTR2004-002376-42-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>PHASE II TRIAL OF SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH CAPECITABINE PLUS INTERFERON ALPHA2a FOLLOWED BY IL-2 IN PATIENTS WITH METASTATIC KIDNEY CANCER</Public_title>
    <Scientific_title>PHASE II TRIAL OF SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH CAPECITABINE PLUS INTERFERON ALPHA2a FOLLOWED BY IL-2 IN PATIENTS WITH METASTATIC KIDNEY CANCER                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST</Primary_sponsor>
    <Date_registration3>20060421</Date_registration3>
    <Date_registration>21/04/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002376-42                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/01/2005</Date_enrollement>
    <Target_size>36</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;</Exclusion_Criteria>
    <Condition>TREATMENT OF METASTATIC KIDNEY CANCER &lt;br&gt;MedDRA version: 6.1
Level: PT
Classification code 10050018
</Condition>
    <Intervention>&lt;br&gt;Trade Name: XELODA 120 CPR RIV. 500MG&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Capecitabine&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: ;Secondary Objective: ;Primary end point(s): </Primary_outcome>
    <Secondary_ID>ASL603LIOM02</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2457519</Internal_Number>
    <TrialID>EUCTR2006-001265-41-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A comparison of Sirolimus versus Tacrolimus as a delayed treatment of recipients of non heart beating donor kidneys after anti-IL2 monoclonal antibody - Sirolimus vs Tacrolimus for NHBD Kidney Recipients after IL-2 mAb</Public_title>
    <Scientific_title>A comparison of Sirolimus versus Tacrolimus as a delayed treatment of recipients of non heart beating donor kidneys after anti-IL2 monoclonal antibody - Sirolimus vs Tacrolimus for NHBD Kidney Recipients after IL-2 mAb                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Newcastle upon Tyne Hospitals NHS Trust</Primary_sponsor>
    <Date_registration3>20060418</Date_registration3>
    <Date_registration>18/04/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-001265-41                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>16/06/2006</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Recipients of kidneys from non heart beating donors&lt;br&gt;&lt;br&gt;Age 18-75&lt;br&gt;&lt;br&gt;Written informed consent obtained from the patient after receiving a comprehensive explanation&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Pregnant women&lt;br&gt;&lt;br&gt;Recipients of multiple transplants (e.g. Both kidneys from one donor transplanted into one recipient or a simultaneous kidney and liver or kidney and pancreas transplant)&lt;br&gt;</Exclusion_Criteria>
    <Condition>Kidney transplantation from non heart beating donors for end-stage renal disease</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sirolimus (Rapamune)&lt;br&gt;Product Name: Sirolimus&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the effects of sirolimus and tacrolimus on kidney function following non heart beating donor kidney transplantation into adult recipients.;Secondary Objective: To determine if the drugs have different effects on patient survival, survival of the transplanted kidney, acute rejection, chronic rejection and complications following surgery.;Primary end point(s): The primary end points are creatinine and calculated GFR (glomerular filtration rate) at monthly intervals from the date of transplant to 12 months.</Primary_outcome>
    <Secondary_ID>200621</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2457646</Internal_Number>
    <TrialID>EUCTR2004-005241-36-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Phase II clinical trial of Cisplatin, Gemcitabine and Trastuzumab (Herceptin®) as first line treatment of advanced irresectable transitional-cell urothelial carcinoma with overexpression of C-erbB-2 - UROTELIALHER2</Public_title>
    <Scientific_title>Phase II clinical trial of Cisplatin, Gemcitabine and Trastuzumab (Herceptin®) as first line treatment of advanced irresectable transitional-cell urothelial carcinoma with overexpression of C-erbB-2 - UROTELIALHER2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>ACROSS Group</Primary_sponsor>
    <Date_registration3>20060508</Date_registration3>
    <Date_registration>08/05/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-005241-36                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>21/06/2005</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Histologically proven diagnosis of urothelial adenocarcinoma of bladder, ureter and renal pelvis with overexpression of C-erbB-2 determined by IHC (+++) or FISH/CISH (in IHC ++) &lt;br&gt;- Non-resectable metastasic or locally advanced disease at the time of inclusion. Any T, any N and M1; T4b, N0, M0 or any T , N1,2 or 3, M0 &lt;br&gt;- Presence of at least one dimensionally measurable target on a CT-scan available for external review, with at least one diameter &gt; or = 2 cm, in a non-irradiated area&lt;br&gt;- Adequate cardiac function (LVEF &gt; or = 50%)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Prior therapy for advanced disease. Adjuvant or Neoadjuvant therapy or chemo-radiotherapy for primary local disease are permitted if at least 6 months have elapsed&lt;br&gt;- Congestive heart failure (NYHA class II, III, IV) or history of  documented congestive heart failure, unstable angina pectoris, myocardial infarction in the last 6 months, poorly controlled hypertension (systolic &gt;180 mmHg or diastolic &gt;100 mmHg), clinically significant valvular heart disease, or high-risk uncontrolled arrhythmias&lt;br&gt;- Patients with dyspnoea at rest due to malignant or other disease or who require supportive oxygen therapy&lt;br&gt;</Exclusion_Criteria>
    <Condition>Advanced irresectable transitional-cell urothelial carcinoma, that includes cancer of the bladder, ureter and renal pelvis</Condition>
    <Intervention>&lt;br&gt;Trade Name: Trastuzumab (Herceptin)&lt;br&gt;Product Name: Trastuzumab (Herceptin)&lt;br&gt;Product Code: 903674&lt;br&gt;Pharmaceutical Form: Powder for infusion*&lt;br&gt;INN or Proposed INN: TRASTUZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 21-&lt;br&gt;&lt;br&gt;Trade Name: Gemcitabine&lt;br&gt;Product Name: Gemcitabine&lt;br&gt;Pharmaceutical Form: Powder for infusion*&lt;br&gt;INN or Proposed INN: GEMZITABINE&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 38-&lt;br&gt;&lt;br&gt;Trade Name: Cisplatin&lt;br&gt;Product Name: Cisplatin&lt;br&gt;Pharmaceutical Form: Powder for infusion*&lt;br&gt;INN or Proposed INN: CISPLATIN&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine the efficacy to the combination of Cisplatin, Gemcitabine and Trastuzumab in terms of response rate in patients with advance urothelial carcinoma, that includes the cancer of bladder, of ureter and of renal pelvis with overexpression of C-erbB-2&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;;Secondary Objective: To determine the progression-free interval, the duration of the response, the toxicity profile and the overall survival in patients with advance urothelial carcinoma&lt;br&gt;;Primary end point(s): The principal variable of valoration will be the number of response rates in patientes treated with the combination </Primary_outcome>
  </Trial>
  <Trial>
    <Internal_Number>2457678</Internal_Number>
    <TrialID>EUCTR2005-000380-26-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A 12 month, multicenter, randomized, parallel, open-label study, to evaluate renal function and efficacy of Certican® (everolimus) with Simulect® (basiliximab) and cyclosporine discontinuation at 3 month post-transplant vs minimization, in de novo kidney transplant recipients - CERTES02</Public_title>
    <Scientific_title>A 12 month, multicenter, randomized, parallel, open-label study, to evaluate renal function and efficacy of Certican® (everolimus) with Simulect® (basiliximab) and cyclosporine discontinuation at 3 month post-transplant vs minimization, in de novo kidney transplant recipients - CERTES02                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Novartis Farmacéutica S.A.</Primary_sponsor>
    <Date_registration3>20060509</Date_registration3>
    <Date_registration>09/05/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-000380-26                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/05/2005</Date_enrollement>
    <Target_size>168</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: The control arm is the no drug discont of one of the drugs,and the changes of the trial drug dosages&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Each patient must meet all of the following inclusion criteria:&lt;br&gt;1. Male or female patients between 18 and 65 years of age&lt;br&gt;2. Male or female patients who are recipients of a first renal transplant from a primary cadaveric or non-HLA identical living related donor .&lt;br&gt;3. The renal cold ischemic time (CIT) must be &lt; 36 hours&lt;br&gt;4. The age of the donor must be &lt; 65 years&lt;br&gt;5. Females of childbearing potential must have a negative pregnancy test at baseline and are required to practice an approved method of birth control for the duration of the study and for a period of three months following discontinuation of study medication. &lt;br&gt;6. Patients who have given written informed consent to participate in the study&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients meeting any of the following criteria at baseline will be excluded from study participation.&lt;br&gt;1. Patients who are recipients of  multiple organ transplants including any organ other than kidney&lt;br&gt;2. Patients who have been previously transplanted with any organ other than a kidney&lt;br&gt;3. Recipients of non heart-beating donor organs&lt;br&gt;4. Patients with current or past panel reactive T-cell antibodies (PRA) titers of &gt;50%&lt;br&gt;5. Patients that had been treated with any investigational drug 4 weeks before the baseline period&lt;br&gt;6. Presence of any severe allergy requiring acute (within 4 weeks of baseline) or chronic treatment, or hypersensitivity to drugs similar to RAD001 (e.g. macrolides)&lt;br&gt;7. Existence of any surgical or medical condition, other than the current transplant, which in the opinion of the investigator, precludes enrollment in this trial&lt;br&gt;8. Evidence of liver dysfunction as indicated by an abnormal liver profile (AST, ALT, alkaline phosphatase or total bilirubin = 3 times ULN) before transplantation&lt;br&gt;9. Patients who are known to have a positive hepatitis C serology, who are human immunodeficiency virus (HIV) or hepatitis B surface antigen positive.  Laboratory  results obtained within 6 months prior to randomization are acceptable. Recipients of organs from donors who test positive for Hepatitis B surface antigen or Hepatitis C are excluded.&lt;br&gt;10. Patients with symptoms of significant somatic or mental illness. Unresolved history of drug or alcohol abuse&lt;br&gt;11. Presence of revascularized ischemic heart disease or AMI, (or any cardiac disease  considered to be unsafe for the study by the investigator)&lt;br&gt;12. Presence of severe hypercholesterolemia (= 350 mg/dL, 9.1 mmoL/dL) or hypertriglyceridemia (= 500mg/dL, 5.6 mmoL/L). Patients with controlled hyperlipidemia are acceptable&lt;br&gt;13. White blood cell (WBC) count= 3,500/mm3, or platelet count = 100,000/mm3 &lt;br&gt;14.  Patients with severe systemic infections&lt;br&gt;15. Patients with current or past malignancies (except for successfully treated localized basal cell carcinoma of the skin)&lt;br&gt;16. Patients who are recipients of A-B-O incompatible transplants or T-cell cross-match positive transplants &lt;br&gt;17. Patients with coagulopathy or any medical condition requiring long-term anticoagulation after transplantation (low  dose aspirin is allowed)&lt;br&gt;18. Abnormal physical or laboratory findings of clinical significance within 2 weeks prior to baseline visit, which at investigators discretion would interfere with the objectives of the study&lt;br&gt;19. Breast feeding women&lt;br&gt;20. Inability to cooperate or communicate with the investigator &lt;br&gt;21. Patients who have been treated with non-protocol immunosuppressive drug or treatment within 4 weeks prior to baseline visit&lt;br&gt;&lt;br&gt;Exclusion criteria for randomization at the end of month 3 (week 12):&lt;br&gt;&lt;br&gt;1. Any episode of acute rejection grade IIb/III (Banff classification) or a vascular acute rejection in the previous 4 weeks or any episode of acute rejection episode during the month prior to randomization.&lt;br&gt;2. Patients depending on dialysis&lt;br&gt;3. Serum creatinine &gt;3 mg/dL and/or more than 30% elevated during the previous month. &lt;br&gt;4. Patients who do not tolerate any increase in Certican ®  dose.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal Transplant &lt;br&gt;MedDRA version: M15
Classification code 10023438
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican®  &lt;br&gt;Product Name: Certican®&lt;br&gt;Product Code: RAD001&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: EVEROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.50-&lt;br&gt;&lt;br&gt;Trade Name: Certican®  &lt;br&gt;Product Name: Certican®&lt;br&gt;Product Code: RAD001&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: EVEROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.75-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective is to compare renal function in the two treatment groups at month 12 post-transplant, as measured by calculated GFR (Nankivell), serum creatinine and calculated creatinine clearance (Cockroft- Gault).&lt;br&gt;Intra-group change in GFR , as determined by Nankivell’s formula, and the GFR’s slope in the period between visits 6 and 12 months will also be determined.&lt;br&gt;;Secondary Objective: The secondary objectives of this study are:&lt;br&gt;•	To evaluate the incidence of biopsy-proven acute rejection (BPAR) episodes, graft loss, death or loss to follow-up after 12 months in both groups.&lt;br&gt;•	To evaluate the incidence of graft loss, death, BPAR episodes, antibody treated acute rejection episodes, clinically confirmed acute rejection episodes, clinically confirmed chronic rejection episodes and biopsy-proven chronic allograft nephropathy after 12 months in both groups.&lt;br&gt;•	To evaluate the safety of Certican® in combination with Simulect® and steroids, with either Neoral® discontinuation at 3 months post-transplant, or  Neoral® minimization.&lt;br&gt;;Primary end point(s): The GFR value is calculated using the Nankivell formula. This is the end point in witch sample size is based. </Primary_outcome>
    <Secondary_ID>CERTES02 (Ce-PoP-RAD001A2419)</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2458046</Internal_Number>
    <TrialID>EUCTR2006-001504-37-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>SUBCUTANEOUS INOCULATION OF ALLOGENEIC GENE-MODIFIED TUMOR CELLS  ACHN-IL2  MIXED TO AUTOLOGOUS TUMOR CELLS  CT-AUT  IN PATIENTS WITH METASTATIC RENAL CARCINOMA. - ND</Public_title>
    <Scientific_title>SUBCUTANEOUS INOCULATION OF ALLOGENEIC GENE-MODIFIED TUMOR CELLS  ACHN-IL2  MIXED TO AUTOLOGOUS TUMOR CELLS  CT-AUT  IN PATIENTS WITH METASTATIC RENAL CARCINOMA. - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI</Primary_sponsor>
    <Date_registration3>20060623</Date_registration3>
    <Date_registration>23/06/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-001504-37                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/05/2006</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Terapie standard a base di Interleuchina2 e cellul&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1  documented Diagnosis of metastatic renal carcinoma; 2  Performance status  Karnofsky  80-100  and one prognosis quoad vitam advanced to 4 months;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1  Performance status  Karnofsky   80-100  and one prognosis quoad vitam inferior to 4 months;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Metastatic Kidney Cancer &lt;br&gt;MedDRA version: 6.1
Level: PT
Classification code 10050018
</Condition>
    <Intervention>&lt;br&gt;Product Name: ACHN-IL2&lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;Current Sponsor code: ACHN-IL2&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10000000-&lt;br&gt;&lt;br&gt;Product Name: CT-AUT&lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;Current Sponsor code: CT-AUT&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5000000-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: appraisal of the survival and quality of the life;Secondary Objective: clinical regression of the lesions;Primary end point(s): appraisal of the survival</Primary_outcome>
    <Secondary_ID>30/2006/O/Sper</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2458152</Internal_Number>
    <TrialID>EUCTR2006-000231-95-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A PHASE II STUDY OF BAY 43-9006 IN COMBINATION WITH WEEKLY GEMCITABINE FOR THE TREATMENT OF METASTATIC RCC EITHER UNSUITABLE FOR OR REFRACTORY TO PRIOR TREATMENT WITH CYTOKINES - TAGUSG6</Public_title>
    <Scientific_title>A PHASE II STUDY OF BAY 43-9006 IN COMBINATION WITH WEEKLY GEMCITABINE FOR THE TREATMENT OF METASTATIC RCC EITHER UNSUITABLE FOR OR REFRACTORY TO PRIOR TREATMENT WITH CYTOKINES - TAGUSG6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO</Primary_sponsor>
    <Date_registration3>20060622</Date_registration3>
    <Date_registration>22/06/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-000231-95                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>13/02/2006</Date_enrollement>
    <Target_size>43</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Written informed consent  - Advanced, histologically confirmed, RCC  - ECOG PS 0-2  - Age 18 years  - UISS 3 cathegory  see appendix  or immunotherapy refractory disease  indipendently of UISS cathegory .  - Presence of measurable disease  - Adequate blood counts  WBC  3.000/ml; HB  10 gr/dl; Ptl  100.000/ml  liver  Transaminases  2N; bilirubin  2N  and kidney  creatinine  2 ng/ml  function tests.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Brain metastasis  - Comorbid conditions which could represent a contraindication to receive the drugs on study or to jeopardize patient compliance  - Unstable diabetes; active coronary disease; active serious infections  - Recent gastrointestinal bleeding&lt;br&gt;</Exclusion_Criteria>
    <Condition>METASTATIC RENAL CANCER CELL &lt;br&gt;MedDRA version: 8.1
Level: PT
Classification code 10050018
Term: Renal cancer metastatic
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Nexavar&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Current Sponsor code: Bay 43-9006&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Gemzar*1g Polv ev 1fl&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Gemcitabine&lt;br&gt;CAS Number: 122111-03-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 800-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: - To evaluate the response  expressed as  clinical benefit   to the combination of Gemcitabine and BAY 43-9006 in women and men with metastatic RCC either unsuitable for or refractory to prior treatment with cytokines.;Secondary Objective: - To evaluate progression-free survival, overall survival, response duration, time to response.  - To evaluate the combined regimen with respect to change in QoL status.  - To evaluate the possible predictive value of baseline phosho ERK  pERK , VEGFr 2 and 3 in tumour cells and of VEGF serum levels in determining tumor response.;Primary end point(s): To evaluate the response  expressed as  clinical benefit   to the combination of Gemcitabine and BAY 43-9006 in women and men with metastatic RCC either unsuitable for or refractory to prior treatment with cytokines.</Primary_outcome>
    <Secondary_ID>TAGUSG6</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2458281</Internal_Number>
    <TrialID>EUCTR2006-001935-23-DE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Real-time contrast-enhanced sonography of renal transplant recipients accurately predicts vascular allograft nephropathy</Public_title>
    <Scientific_title>Real-time contrast-enhanced sonography of renal transplant recipients accurately predicts vascular allograft nephropathy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>University of Heidelberg</Primary_sponsor>
    <Date_registration3>20061024</Date_registration3>
    <Date_registration>24/10/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-001935-23                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/10/2006</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients who have had stable renal allograft function for at least three months. &lt;br&gt;Patients with a written informed consent.&lt;br&gt;Patients over 18 years.&lt;br&gt;Patients of the Department of Nephrology; University Heidelberg (D).&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Allograft recipients with lymphocele (&gt;100ml),&lt;br&gt;Patients with significant renal transplant artery stenosis (&gt;70%) &lt;br&gt;Patients with hydronephrosis of grade 2 (dilatation of the renal pelvis and the calyces, with or without a dilatation of the proximal ureter) or more.&lt;br&gt;Patients with a familiar incompatibility against SonoVue TM &lt;br&gt;Patients with pregnancy.&lt;br&gt;Patients are allergic to proteins.&lt;br&gt;Patients with pulmonary hypertension.&lt;br&gt;Patients wirh a thrombotic diathesm&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Vascular allograft nephropathy represents the main cause of renal allograft loss after 1 yr of transplantation. The trial shall find a way for early diagnostics.
</Condition>
    <Intervention>&lt;br&gt;Trade Name: SonoVue 8 Mikroliter/ml Pulver und Lösungsmittel&lt;br&gt;zur Herstellung einer Dispersion&lt;br&gt;zur Injektion&lt;br&gt;&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: SonoVue 8 Mikroliter/ml Pulver und Lösungsmittel&lt;br&gt;CAS Number: 2551-62-4&lt;br&gt;Concentration unit: µl/ml microlitre(s)/millilitre&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Real-time contrast enhanced sonography can assess microvascular tissue perfusion using gas-filled microbubbles. The study shall evaluate the feasibility of RT-CES in detecting vascular allograft nephropathy  in comparison to colour Doppler ultrasonography.;Secondary Objective: ;Primary end point(s): to evaluate the feasibility of RT-CES in detecting vascular allograft nephropathy  in comparison to colour Doppler ultrasonography</Primary_outcome>
    <Secondary_ID>NZHD02</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2458376</Internal_Number>
    <TrialID>EUCTR2006-002851-33-AT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Sorafenib and Bevacizumab as first- line treatment in patients with advanced renal cell carcinoma</Public_title>
    <Scientific_title>Sorafenib and Bevacizumab as first- line treatment in patients with advanced renal cell carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Univ. Prof. Dr. Manuela Schmidinger</Primary_sponsor>
    <Date_registration3>20060816</Date_registration3>
    <Date_registration>16/08/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002851-33                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/08/2006</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Age greater or equal to 18 years&lt;br&gt;•	Histologically confirmed renal cell carcinoma (primary tumour or biopsy/surgery of metastases)&lt;br&gt;•	Radiologically confirmed metastatic disease&lt;br&gt;•	Surgically removed primary tumour so feasible (nephrectomy or nephron-sparing surgery as indicated) &lt;br&gt;•	ECOG status of 0 or 1 &lt;br&gt;•	Life expectancy of at least 12 weeks&lt;br&gt;•	Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 14 days prior to treatment start:&lt;br&gt;o	Hemoglobin &gt; 9.0 g/L&lt;br&gt;o	Leucocytes greater than or equal to 3000/µL&lt;br&gt;o	Absolut neutrophil count &gt; or equal 1,500 µL&lt;br&gt;o	Platelet count above &gt; or equal 100,000 /µL&lt;br&gt;o	Total bilirubin &gt; or equal 1.5 x upper limit normal&lt;br&gt;o	Serum creatinine &lt; 2.5 x upper limit normal &lt;br&gt;o	ALT and AST &lt; 2.5 x upper limit normal (&lt; 5 x upper limit normal for patients with liver involvement of their cancer&lt;br&gt;o	PT or INR and PTT&lt; 1.5 x upper limit normal&lt;br&gt;•	Women of childbearing potential and men must agree to use adequate contraception &lt;br&gt;•	Signed informed consent&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	Prior systemic treatment for advanced renal cell carcinoma&lt;br&gt;•	Previous or concurrent malignancy that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis and T1) or any cancer curatively treated &gt; 5 years prior to study entry.&lt;br&gt;•	Complete renal shut down requiring hemo-or peritoneal dialysis&lt;br&gt;•	History of cardiac disease: congestive heart failure &gt; NYHA class 2, active cardiovascular disease (MI less than 6 months prior to study entry), cardiac arrhythmia requiring anti-arrhythmic therapy (beta-blockers and digoxins are permitted), uncontrolled hypertension or history of poor compliance with antihypertensive treatment&lt;br&gt;•	Active clinically serious bacterial or fungal infection (&gt; grade 2 NCI-CTCAE, Version 3)&lt;br&gt;•	Known history of human immunodeficiency virus (HIV) infection or chronic hepatitis B/C &lt;br&gt;•	Evidence of spinal cord compression or brain metastases. A CT or MRI of the brain must be performed within 4 weeks prior to enrolment if the presence of metastases at these sites is suspected.&lt;br&gt;•	History or evidence upon physical/neurological examination of CNS disease unrelated to cancer, unless adequately treated with standard medical therapy e.g. uncontrolled seizures.&lt;br&gt;•	Patients with evidence or history of bleeding diathesis, coagulopathy, or thromboembolic event&lt;br&gt;•	Substance abuse, medical, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results&lt;br&gt;•	Known or suspected allergy to any agent given in association with this trial&lt;br&gt;•	Any condition that is unstable or which could jeopardize the safety of the patient and his compliance in the study (e.g. uncontrolled diabetes mellitus, pancreatitis, acute or chronic liver disease etc).&lt;br&gt;•	Investigational drug therapy outside this trial during or within 4 weeks of the study entry&lt;br&gt;•	Prior use of inhibitors of Ras/Raf-, MEK-, AKT kinase- and mTOR-signaling pathway or of Farnesyl transferase inhibitors&lt;br&gt;•	Prior use investigational or licensed angiogenesis inhibitors&lt;br&gt;•	Concomitant Rifampicin&lt;br&gt;•	Significant surgery within 4 weeks prior to study entry&lt;br&gt;•	Female patients who are pregnant or breast feeding&lt;br&gt;•	Proteinuria defined as a 24-hour urine protein excretion greater than 1000 mg. Urine dipstick proteinuria of 2+ or greater will require a 24 hour urine to determine eligibility for enrollment&lt;br&gt;•	Impairment of the gastrointestinal (GI) function or GI disease that may significantly alter the absorption of Sorafenib&lt;br&gt;•	Therapeutic anticoagulation with coumadin, heparins or heparinoids&lt;br&gt;•	Current or recent (within 10 days of first dose of study treatment) daily use of aspirin (&gt;325 mg/day) or other NSAID &lt;br&gt;•	Thrombic or embolic events within the past 6 months&lt;br&gt;•	Hypertension defined as systolic blood pressure greater than 140 mm/Hg or diastolic pressure greater than 90 mm/Hg despite optimal management&lt;br&gt;•	Serious non-healing wounds, acute or non-healing ulcers, or bone fractures&lt;br&gt;•	Evidence of bleeding diathesis&lt;br&gt;•	History of hemoptysis or high grade varices&lt;br&gt;•	Primary tumor surgically removable&lt;br&gt;•	Solitary, surgically removable metastases&lt;br&gt;•	Patient unwilling or unable to give informed consent&lt;br&gt;•	Pregnancy or breast feeding&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with advanced renal cell carcinoma</Condition>
    <Intervention>&lt;br&gt;Product Name: Sorafenib&lt;br&gt;Product Code: Bay 43-9006&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Sorafenib&lt;br&gt;CAS Number: 284461-73-0&lt;br&gt;Current Sponsor code: Bay 43-9006&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Product Name: Bevacizumab&lt;br&gt;Product Code: Ro4876646&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Bevacizumab&lt;br&gt;Current Sponsor code: Ro4876646&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: •	To assess the combination of Sorafenib and Bevacizumab with respect to progression free survival &lt;br&gt;;Secondary Objective: •	To assess the safety of Sorafenib and Bavacizumab when used in combination&lt;br&gt;•	To assess disease control rate (DCR)&lt;br&gt;•	To estimate response rate&lt;br&gt;•	To evaluate time to progression (TTP)&lt;br&gt;•	To evaluate overall survival (OS)&lt;br&gt;•	To evaluate Quality of Life&lt;br&gt;•	To compare VEGF plasma levels before and during the treatment&lt;br&gt;;Primary end point(s): Clinical response measured according to standard criteria&lt;br&gt;•	Progression free survival	&lt;br&gt;•	clinical adverse events&lt;br&gt;•	laboratory parameters</Primary_outcome>
    <Secondary_ID>12197</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2458575</Internal_Number>
    <TrialID>EUCTR2006-003001-49-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Anti-inflammatory effects of rosiglitazone in patients with stage 4 and 5 chronic kidney disease - Hercules</Public_title>
    <Scientific_title>Anti-inflammatory effects of rosiglitazone in patients with stage 4 and 5 chronic kidney disease - Hercules                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Leiden University Medical Center</Primary_sponsor>
    <Date_registration3>20060601</Date_registration3>
    <Date_registration>01/06/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-003001-49                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>07/08/2006</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Willing and able to provide written consent;&lt;br&gt;- Patients must 18 years of age or older;&lt;br&gt;- Well-defined CKD&lt;br&gt;   for stage 4: GFR 15-30 ml/min/1.73m2 according to the abbreviated MDRD formula &lt;br&gt;   for stage 5: haemodialysis or peritoneal dialysis according to the K/DOQI guidelines&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- A diagnosis of diabetes mellitus for which the patient uses insulin;&lt;br&gt;- Significant co-morbidities which, according to the treating nephrologists, makes it unlikely that the patient will be able to complete the foreseen study period;&lt;br&gt;- Significant cardiovascular co-morbidities which are likely to interfere with the objectives of the study (morbid obesity, family history of dyslipidemia, etc.); at the discretion of the treating nephrologists or the principal investigator;&lt;br&gt;- Allergy for PPAR’s;&lt;br&gt;- Cardiac disease with marked limitation of functional capacity (New York Heart Association III or IV clinical status);&lt;br&gt;- Use of immunosuppressant agents;&lt;br&gt;- History of renal transplant;&lt;br&gt;- Hepatic insufficiency (defined as transaminase concentrations above &gt; 2.5 times the upper limit of normal for the laboratories);&lt;br&gt;- A history of alcohol abuse or excessive alcohol use defined as more than 21 consumptions per week;&lt;br&gt;- For female patients: pregnancy, the intention to become pregnant within the study period, or lactating patients.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic kidney disease</Condition>
    <Intervention>&lt;br&gt;Trade Name: Avandia&lt;br&gt;Product Name: Rosiglitazon&lt;br&gt;Product Code: 1360&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objectives of the study are to assess the effect of rosiglitazone in patients with severe renal impairment on the change of carotid artery intima media thickness (IMT) and carotid artery calcifications and to assess the tolerability of rosiglitazone in this patient population.;Secondary Objective: Secondary objectives are to study the effects on (a) inflammation determined by measurement of the serum levels of inflammatory markers, nutrition state, erythropoietin resistance, insulin resistance and peritoneal membrane function in peritoneal dialysis patients and (b) the change of arterial stiffness determined by pulse wave velocity measurements over 48 weeks and (c) the drug safety profile (liver function parameters, weight changes, adverse events, etc.).;Primary end point(s): Intima-media thickness carotid artery</Primary_outcome>
    <Secondary_ID>P05.020</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2458668</Internal_Number>
    <TrialID>EUCTR2006-002913-11-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Randomised controlled, double blinded single centre trial to assess the effects of peri-operative dopexamine on morbidity after major abdominal surgery in patients with low anaerobic threshold. - Peri-operative effects of dopexamine in patients with low AT</Public_title>
    <Scientific_title>Randomised controlled, double blinded single centre trial to assess the effects of peri-operative dopexamine on morbidity after major abdominal surgery in patients with low anaerobic threshold. - Peri-operative effects of dopexamine in patients with low AT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>York Hospitals NHS Trust</Primary_sponsor>
    <Date_registration3>20060930</Date_registration3>
    <Date_registration>30/09/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002913-11                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>31/07/2006</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients undergoing scheduled resection for carcinoma of the colon, rectum, bladder, pancreas, stomach or kidney, who, after routine CPX testing at the Pre-assessment Clinic, have been found to have an Anaerobic Threshold (AT) less than or equal to 11.0 ml/min/m2 as measured by the V-slope method15, or with an AT of 11.0 -14.0 ml/min/m2 and ischaemic changes on ECG monitoring during testing or with a significant history of ischaemic heart disease (NYHA classification III and IV).&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients less than 60 years of age unless they have significant co morbidities (ASA 3 or greater), patients having emergency or vascular procedures, those who are ASA grade 5, and patients who refuse or are unable to give informed consent&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients undergoing scheduled resection for carcinoma of the colon, rectum, bladder, pancreas, stomach or kidney, who, after routine CPX testing at the Pre-assessment Clinic, have been found to have an Anaerobic Threshold (AT) less than or equal to 11.0 ml/min/m2 as measured by the V-slope method15, or with an AT of 11.0 -14.0 ml/min/m2 and ischaemic changes on ECG monitoring during testing or with a significant history of ischaemic heart disease (NYHA classification III and IV).</Condition>
    <Intervention>&lt;br&gt;Trade Name: Dopacard&lt;br&gt;Product Name: Dopexamine hydrochloride&lt;br&gt;Pharmaceutical Form: Intravenous infusion&lt;br&gt;INN or Proposed INN: DOPEXAMINE HYDROCHLORIDE&lt;br&gt;CAS Number: 86484915&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;Pharmaceutical form of the placebo: Intravenous infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess morbidity at 1,3, 5, 8,10, 12 and 15 days using POMS score;Secondary Objective: To identify differences in&lt;br&gt;&lt;br&gt;1.	Length of stay in hospital after surgery&lt;br&gt;2.	Recovery parameters (drinking, eating, mobilising)&lt;br&gt;3.	Incidence of post-operative complications&lt;br&gt;4.	Peri-operative haemodynamic variables (heart rate, blood pressure, CVP)&lt;br&gt;5.	POSSUM score for surgical risk assessment.&lt;br&gt;6.	Oxygen delivery&lt;br&gt;;Primary end point(s): 1.	Morbidity at 1,3,5,8 10,12 and 15 days</Primary_outcome>
    <Secondary_ID>DOP 06;33549216</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2458848</Internal_Number>
    <TrialID>EUCTR2006-003746-42-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Immunotherapy vs immuno-chemotherapy in patients with metastatic kidney carcinoma - ND</Public_title>
    <Scientific_title>Immunotherapy vs immuno-chemotherapy in patients with metastatic kidney carcinoma - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>OSPEDALE ONCOLOGICO DI BARI</Primary_sponsor>
    <Date_registration3>20061003</Date_registration3>
    <Date_registration>03/10/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-003746-42                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>11/02/2003</Date_enrollement>
    <Target_size>210</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: immunoterapia chemioterapia vs immunoterapia&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Histologic diagnosis of kidney carcinoma  2. Presence of metastases and/or  locally advanced primary tumour  3. Age   18 years old&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Severe infections  2. Previous treatment with IL-2  3. Brain metastasis  4. Pregnancy&lt;br&gt;</Exclusion_Criteria>
    <Condition>metastatic kidney carcinoma &lt;br&gt;MedDRA version: 6.1
Level: HLT
Classification code 10038408
</Condition>
    <Intervention>&lt;br&gt;Trade Name: PROLEUKIN*EV 1FL 18MUI 5ML &lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Aldesleukin&lt;br&gt;CAS Number: 110942-02-4&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 18000000-&lt;br&gt;&lt;br&gt;Trade Name: GEMZAR*INFUS 1FL 1G POLV &lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Gemcitabine&lt;br&gt;CAS Number: 122111-03-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;Trade Name: NAVELBINE 50*IV 50MG 5ML &lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Vinorelbine&lt;br&gt;CAS Number: 122111-03-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To estimate if the addition of Gemcitabine and Navelbine leads to  increase of activity and therapeutic efficacy with respect to immunotherapy alone;Secondary Objective: 1. To estimate the toxicity of the two treatments  2. To estimate the treatment impact on the patient s life quality  3. To find the meaning of some predictive factors  VES, PCR, LDH, total lymphocytes ;Primary end point(s): To estimate if immunotherapy with IL-2, Gemcitabina e Navelbine is more effective with respect to immunotherapy alone in patients with kidney carcinoma</Primary_outcome>
    <Secondary_ID>om 145</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2459275</Internal_Number>
    <TrialID>EUCTR2006-005294-22-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Performance de l’équation MDRD corrigée par la cimétidine chez le patient transplanté rénal</Public_title>
    <Scientific_title>Performance de l’équation MDRD corrigée par la cimétidine chez le patient transplanté rénal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>CHU Saint-Etienne</Primary_sponsor>
    <Date_registration3>20061207</Date_registration3>
    <Date_registration>07/12/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005294-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>29/12/2006</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- &gt; 18 years&lt;br&gt;- Kidney transplantation &gt; 1 year &lt;br&gt;- Patient with immunosuppressant treatment of TACROLIMUS (PROGRAF?)&lt;br&gt;- Creatinine clearance &gt; 30 ml/min/1,73m2 within 3 months before inclusion&lt;br&gt;- Written informed consent&lt;br&gt;- Patient affiliated to social insurance&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Unstable renal fonction defined by serum creatinine (J0) &gt; 25% serum creatinine realised in 3 mois&lt;br&gt;- Treatment: Bactrim®, Fansidar®, Cimetidine arrow® withing the week before inclusion&lt;br&gt;- Contraindication listed in in the labeling of Cimetidine arrow® (absolue, relative et médicaments nécessitant des précautions d’emploi cf ficheVidal en annexe 3)&lt;br&gt;- Last residual rate of Tacrolimus &gt; 12 ng/ml.&lt;br&gt;- Treatment : carvedilol, phenytoïne (intercation with cimetidine)&lt;br&gt;- Serious hepatic insuffisancy&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Estimating glomerular filtration rate in kidney transplantation: a comparison between inulin clearance and MDRD equation with cimetidin (block of secretion renal tubule) &lt;br&gt;MedDRA version: 8.1
Level: PT
Classification code 10018355
Term: Glomerular filtration rate
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Cimetidine arrow&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: compare performance of inulin clearance and MDRD with or no block of secretion renal tubule with cimetidin,  in kidney transplantation;Secondary Objective: ? Performance of different prediction equations for estimating renal function in kidney transplantation with or no block of secretion renal tubule with cimetidin : &lt;br&gt;- Walser equation&lt;br&gt;- Nankivell equation &lt;br&gt;- Cockcroft and Gault equation&lt;br&gt;&lt;br&gt;? comparison between inulin clearance and cystatin C ;Primary end point(s): Performance of different prediction equation : accuracy -30%, ie defined by proportion of patients with a estimation of glomerular filtration glomerular is include in - 30 % et + 30 % of  inulin clearance value. &lt;br&gt;&lt;br&gt;</Primary_outcome>
    <Secondary_ID>060890</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2459410</Internal_Number>
    <TrialID>EUCTR2006-006491-38-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Sunitinib  prior to nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ</Public_title>
    <Scientific_title>Sunitinib  prior to nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>NKI-AVL</Primary_sponsor>
    <Date_registration3>20061222</Date_registration3>
    <Date_registration>22/12/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006491-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>16/04/2007</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Histologically confirmed metastatic renal cell cancer of clear-cell subtype with a resectable  asymptomatic primary in situ. Asymptomatic primary  is defined as the absence of symptoms which can be exclusively assigned to the primary tumor such as flank pain and/or gross hematuria necessitating blood transfusion. As paraneoplastic symptoms cannot be assigned to the primary tumor alone in metastatic disease, they are not included in this definition. Unless the diagnosis of a clear-cell subtype has been established after histological examination of a resected metastatic lesion, all patients need to undergo a transcutaneous tru-cut needle biopsy of the primary tumor.&lt;br&gt;2.	Extensive metastatic disease which is defined as 3 or more non-resectable metastases in case of 1 metastatic site, using the RECIST criteria,  or 2 or more metastatic sites.&lt;br&gt;3.	Age: 18 to 65 years&lt;br&gt;4.	Life expectancy &gt; 3 months&lt;br&gt;5.	WHO performance status 0 or 1&lt;br&gt;6.	Written informed consent obtained from the patient after having been informed about the objectives of the study and the medication used.&lt;br&gt;7.	Blood counts: Leucocytes &gt; 3.0 x 109/l, platelets &gt; 100 x 109/l, hemoglobin &gt; 6.0 mmol/l.&lt;br&gt;8.	Serum bilirubin, ASAT, ALAT and creatinin within 1.5 times of upper limit of reference values of laboratory.&lt;br&gt;9.	No prior systemic treatment with biological response modifiers, tyrosine-kinase inhibitors, monoclonal antibodies or chemotherapy. Patients who receive local radiotherapy for bone lesions can be included. &lt;br&gt;10.	An intermediate MSKCC risk profile&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Symptomatic primary necessitating nephrectomy. For definition see Inclusion criteria.&lt;br&gt;2.	Irresectable primary tumor&lt;br&gt;3.	Patients in whom complete surgical remission can be achieved by removing metastatic sites at nephrectomy or by delayed surgery.&lt;br&gt;4.	Previous nephrectomy&lt;br&gt;5.	Low metastatic burden (2 or less non-resectable metastases at 1 metastatic site) &lt;br&gt;6.	Metastatic RCC to the bone only. Bone metastases are considered truly non measurable.&lt;br&gt;7.	Current cardiovascular disease, hematopoetic, pulmonary, hepatic or renal dysfunction or WHO performance status &gt; 1.&lt;br&gt;8.	Previous immunotherapy, therapy with tyrosine-kinase inhibitors, monoclonal antibodies or chemotherapy.&lt;br&gt;9.	Presence of autoimmune disease, HIV and hepatitis.&lt;br&gt;10.	Corticosteroid and/ or other immunosuppressive therapies.&lt;br&gt;11.	Prior malignancies. In case of NED the period should be &gt; 5 years.&lt;br&gt;12.	Central nervous system metastases.&lt;br&gt;13.	non-clear cell subtype.&lt;br&gt;14.	Poor or good prognosis according to MSKCC risk assessment&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>metastatic renal cell carcinoma and the primary tumor in situ

</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sutent&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: sunitinib&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To investigate the response rate of the primary tumor following pretreatment with sunitinib;Secondary Objective: Cancer specific survival and morbidity, overall response at metastatic sites and duration of metastatic response will be assessed. (Duration of overall survival; duration of hospital stay; percentage of withdrawal from nephrectomy due to sunitinib-related reduction of performance; response at metastatic sites; progression to irresectability of the primary tumor during initial treatment). &lt;br&gt;Immunomonitoring in the peripheral blood at different time intervals and the primary tumor after nephrectomy.&lt;br&gt;Imaging with CT and dynamic MRI scan prior to treatment with sunitinib and prior to nephrectomy to identify potential response criteria other than RECIST in association with histopathology.&lt;br&gt;;Primary end point(s): The main end point of this study is any objective response in the primary tumor according to RECIST criteria .</Primary_outcome>
    <Secondary_ID>N06SUN</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2459416</Internal_Number>
    <TrialID>EUCTR2005-004024-39-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Título completo del ensayo: Estudio multicéntrico, aleatorizado, abierto, de 12 semanas de duración, para determinar el efecto del  tratamiento con Myfortic® (micofenolato sódico) en términos de calidad de vida en pacientes con síntomas gastrointestinales (GI) en tratamiento con MMF (micofenolato mofetilo) después de un trasplante renal. - MYVIDA2</Public_title>
    <Scientific_title>Título completo del ensayo: Estudio multicéntrico, aleatorizado, abierto, de 12 semanas de duración, para determinar el efecto del  tratamiento con Myfortic® (micofenolato sódico) en términos de calidad de vida en pacientes con síntomas gastrointestinales (GI) en tratamiento con MMF (micofenolato mofetilo) después de un trasplante renal. - MYVIDA2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Novartis Farmacéutica, S.A.</Primary_sponsor>
    <Date_registration3>20060306</Date_registration3>
    <Date_registration>06/03/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004024-39                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>25/04/2006</Date_enrollement>
    <Target_size>250</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•Pacientes que hayan sido sometidos a un trasplante renal.&lt;br&gt;•Que estén recibiendo un régimen inmunosupresor que incluya MMF antes de la inclusión en el estudio. &lt;br&gt;•Que sufran efectos secundarios GI relacionados con la dosis estandar de MMF, o bien pacientes en tratamiento con una dosis reducida de MMF para controlar dichos efectos secundarios GI.&lt;br&gt;•Con edad = 18 años.&lt;br&gt;•Capaces de entender la información sobre el estudio y de otorgar su consentimiento informado por escrito.&lt;br&gt;•Que puedan cumplir todos los requisitos del estudio incluyendo la realización de los cuestionarios, y la asistencia a las 3 visitas del estudio.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•Que se conozca o se asuma que los síntomas GI no están causados por el tratamiento con ácido micofenólico (MPA, principio activo de Cellcept®) (por ejemplo, diarrea infecciosa inducida por bisfosfonatos orales).&lt;br&gt;•Rechazo agudo &lt; 1 semana antes de la inclusión en el estudio.&lt;br&gt;•Mujeres físicamente fértiles que tengan previsto quedarse embarazadas, estén embarazadas y/o en periodo de lactancia, o bien que no deseen utilizar un método anticonceptivo eficaz.&lt;br&gt;•Presencia de enfermedad psiquiátrica (como esquizofrenia, depresión mayor) que, a juicio del investigador, pudiese interferir con los requerimientos del estudio.&lt;br&gt;•Que estén siendo sometidos a intervención médica por patología aguda o que estén hospitalizados.&lt;br&gt;•Cualquier otra condición médica que, a juicio del investigador basándose en el recuerdo o en la revisión de historiales clínicos, pudiese afectar a la finalización del estudio, incluyendo, pero no limitado a problemas visuales o deterioro cognitivo.&lt;br&gt;•Que estén recibiendo cualquier fármaco en investigación o lo hayan recibido durante los 30 días previos a la inclusión en el estudio.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Trasplante renal</Condition>
    <Intervention>&lt;br&gt;Trade Name: Myfortic ®&lt;br&gt;Product Name: Myfortic®&lt;br&gt;Product Code: ERL080&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Trade Name: CellCept ®&lt;br&gt;Product Name: CellCept®&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Determinar el efecto del uso de la formulación de comprimidos gastrorresistentes con película de MPA (Myfortic®) en la calidad de vida de los pacientes que requieran una disminución de la dosis de MMF debido a los síntomas gastrointestinales provocados por dicha medicación. ;Secondary Objective: El objetivo secundario será determinar si la formulación de comprimidos gastrorresistentes con película de MPA (Myfortic®) permite la administración con buena tolerancia de dosis más altas de MPA, comparado con el tratamiento estándar de MMF, en pacientes con susceptibilidad demostrada a efectos secundarios gastrointestinales.;Primary end point(s): La variable principal de valoración será la puntuación total de la escala GIQLI. Se hará una estadística descriptiva para la puntuación total de la escala GIQLI en las tres visitas del estudio. El análisis primario determinará los cambios en la puntuación total para dicha escala entre los dos grupos de tratamiento.</Primary_outcome>
    <Secondary_ID>CERL080AES06</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2460281</Internal_Number>
    <TrialID>EUCTR2006-002338-39-DE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Pharmakokinetik von Linezolid bei Dialyse
(pharmacokinetics of linezolid under dialysis) - LINUS</Public_title>
    <Scientific_title>Pharmakokinetik von Linezolid bei Dialyse
(pharmacokinetics of linezolid under dialysis) - LINUS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Universitätsklinikum Heidelberg</Primary_sponsor>
    <Date_registration3>20060817</Date_registration3>
    <Date_registration>17/08/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002338-39                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/12/2006</Date_enrollement>
    <Target_size>15</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: dialysis and not dialysis&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- The receipt of linezolid in the normal treatment of care&lt;br&gt;- acute renale failure with a dialysis-therapy or sepsis without acute renale failure&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- hypersensivity against linezolid&lt;br&gt;- newborn, children, adolescent, pregnant women, nursing women, pre-menopausal women&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>acute renal failure and infection or sepsis without acute renal failure</Condition>
    <Intervention>&lt;br&gt;Trade Name: Zyvoxid (R) 2mg/ml Infusionslösung&lt;br&gt;Product Name: Zyvoxid (R)2 mg/ml Infusionslösung&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: pharmacokinetic of Linezolid under dialysis;Secondary Objective: influence of sepsis alone without dialysis;Primary end point(s): no end points because it is only an accompanying pharmocokinetic-study</Primary_outcome>
  </Trial>
  <Trial>
    <Internal_Number>2460365</Internal_Number>
    <TrialID>EUCTR2007-005401-22-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Effect of Aliskiren on Muscle Sympathetic Nerve Activity in hypertensive patients with chronic kidney disease - Aliskiren and sympathetic activity</Public_title>
    <Scientific_title>Effect of Aliskiren on Muscle Sympathetic Nerve Activity in hypertensive patients with chronic kidney disease - Aliskiren and sympathetic activity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>University Medical Center Utrecht</Primary_sponsor>
    <Date_registration3>20071019</Date_registration3>
    <Date_registration>19/10/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005401-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/02/2009</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: no treatment&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients with stable CKD and hypertension: i.e. using antihypertensive drugs and/or blood pressure &gt;145/90mmHg when off medication. &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-	Patients on renal replacement therapy&lt;br&gt;-	Diabetes mellitus &lt;br&gt;-	Pregnancy&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Hypertension and chronic kidney disease</Condition>
    <Intervention>&lt;br&gt;Product Name: Aliskiren (Rasilez)&lt;br&gt;Product Code: ATC-code: C09XA02&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective is to investigate the effect on MSNA by Aliskiren in hypertensive patients with CKD. We hypothesize that there will be a (substantial) decrease in MSNA as result of chronic treatment (6 weeks) of Aliskiren. ;Secondary Objective: Secondary objective is to assess whether MSNA normalizes after chronic treatment (6 weeks) of Aliskiren in hypertensive patients with CKD. &lt;br&gt;Furthermore, we will study the effect of Aliskiren on blood pressure, heart rate, kidney function and PRA in hypertensive patients with CKD.&lt;br&gt;;Primary end point(s): Primary endpoint: the effect of Aliskiren on MSNA&lt;br&gt;&lt;br&gt;Secondary parameters: Effect of aliskiren on blood pressure, heart rate, PRA and kidney function &lt;br&gt;- Comparison of the effect on MSNA after treatment with aliskiren with the effects on ACEi and ARB  as comared to the previous studies and assessment whether normalization of MSNA is obtained after treatment with aliskiren &lt;br&gt;</Primary_outcome>
    <Secondary_ID>24092007</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2460545</Internal_Number>
    <TrialID>EUCTR2006-004857-86-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A multi-centre, open-label, phase II study of the safety, efficacy and pharmacokinetic (PK) profile of CAP-232 administered through continuous intravenous infusion in patients with metastatic kidney cancer</Public_title>
    <Scientific_title>A multi-centre, open-label, phase II study of the safety, efficacy and pharmacokinetic (PK) profile of CAP-232 administered through continuous intravenous infusion in patients with metastatic kidney cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Caprion Pharmaceuticals Inc.</Primary_sponsor>
    <Date_registration3>20061128</Date_registration3>
    <Date_registration>28/11/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004857-86                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/01/2007</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1) Patients must have histologically confirmed stage IV kidney clear cell carcinoma.  &lt;br&gt;&lt;br&gt;2) Patients must have progressive disease after receiving a previous systemic therapy. &lt;br&gt;&lt;br&gt;3) Patient must have progressive disease confirmed by 2 CT Scans or MRI performed within 6 months. &lt;br&gt;&lt;br&gt;4) Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as &gt;20 mm with conventional techniques or as &gt;10 mm with spiral CT scan.  &lt;br&gt;&lt;br&gt;5) Patients must have an age &gt;18 years.  &lt;br&gt;&lt;br&gt;6) Patients must have life expectancy of greater than 3 months.&lt;br&gt;&lt;br&gt;7) Patient must be at least 5 years free of any other cancer(s). Basal cell carcinoma, provided that is neither infiltrating nor sclerosing and carcinoma in situ of the cervix, is acceptable.&lt;br&gt;&lt;br&gt;8) Patients must have ECOG performance status ? ?2 (Karnofsky 60%).&lt;br&gt;&lt;br&gt;9) Patients must have normal organ and marrow function as defined below:&lt;br&gt;•	Leukocytes &gt;3,000/mm3&lt;br&gt;•	Absolute neutrophil count &gt;1,500/mm3&lt;br&gt;•	Platelets &gt;100,000/ mm3&lt;br&gt;•	Total bilirubin within normal institutional limits&lt;br&gt;•	AST(SGOT)/ALT(SGPT) ?2.5 X institutional upper limit of normal &lt;br&gt;•	Calculated creatinine clearance &gt;30 mL/min/1.73 m2 &lt;br&gt;&lt;br&gt;10) Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.  Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.&lt;br&gt;&lt;br&gt;11) Patients or the patient’s legal guardian must be able to understand and have the willingness to sign a written informed consent document.&lt;br&gt;&lt;br&gt;12) Patients must have the ability to receive central vein access catheter and manage an infusion pump.&lt;br&gt;&lt;br&gt;13) Women of child bearing potential must have a negative serum pregnancy test. &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;11) Patients who have received any known medical treatment targeting cancer within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.&lt;br&gt;&lt;br&gt;2) Patients may not be receiving any other investigational agents at least 30 days prior to enrollment in the study or/and participate in another clinical trial.&lt;br&gt;&lt;br&gt;3) Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.&lt;br&gt;&lt;br&gt;4) Patients with a history of allergic reactions attributed to compounds of similar composition to CAP-232.  CAP-232 consists of a heptapeptide (active ingredient) in an acetate buffered saline solution with mannitol (0.2 M sodium acetate, 0.2 M acetic acid, 3% mannitol). &lt;br&gt; &lt;br&gt;5) Patient with past or current cancer other than kidney cancer, except for:&lt;br&gt;•	Curatively treated non-melanoma skin cancer&lt;br&gt;•	In situ carcinoma of the cervix&lt;br&gt;•	Other cancer curatively treated and with no evidence of disease for at least 10 years&lt;br&gt;&lt;br&gt;6) Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.&lt;br&gt;&lt;br&gt;7) Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAP-232, breastfeeding should be discontinued if the mother is treated with CAP-232.&lt;br&gt;&lt;br&gt;8) Patients that have previously been enrolled into this study and subsequently withdrawn must also be excluded.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>metastatic kidney cancer &lt;br&gt;MedDRA version: 8.1
Level: LLT
Classification code 10023405
Term: Kidney cancer stage IV
</Condition>
    <Intervention>&lt;br&gt;Product Name: CAP 232&lt;br&gt;Product Code: CAP 232&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: synthetic peptide CAP-232 acetate&lt;br&gt;Other descriptive name: formerly known as TT-232&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of this study is to evaluate the efficacy of CAP-232 as a monotherapy (each 28-day cycle consists of 21 days continuous IV infusion of CAP-232 at 0.5 mg/kg/day followed by a 7-day rest period) in patients with metastatic kidney cancer.  The primary efficacy parameter will be the response rate based on RECIST criteria.;Secondary Objective: Secondary objectives include:&lt;br&gt;&lt;br&gt;•	Safety (through clinical and biological evaluations)&lt;br&gt;•	Other efficacy parameters (progression-free survival rate, time to progression and overall survival)&lt;br&gt;•	Pharmacokinetic (PK) characteristics of the first 15 recruited patients&lt;br&gt;•	Quality of life&lt;br&gt;•	Biological modulation (through potential blood and/or urine biomarkers including M2PK)&lt;br&gt;&lt;br&gt;;Primary end point(s): The primary safety endpoints will include the occurrence of AEs, clinical laboratory parameters, vital signs, ECGs and physical examination variables. &lt;br&gt;&lt;br&gt;The primary efficacy endpoints will: &lt;br&gt;- determine the M2PK plasma levels during the course of treatment&lt;br&gt;- determine disease state using RECIST criteria at the end of 2 cycles&lt;br&gt;- determine progression-free survival rate&lt;br&gt;- determine time to progression and overall survival&lt;br&gt;&lt;br&gt;Other endpoints will:&lt;br&gt;- evaluate the quality of life during each cycle&lt;br&gt;- determine the pharmacokinetic (PK) characteristics of CAP-232&lt;br&gt;- determine potential blood and/or urine biomarkers for predicting efficacy&lt;br&gt;&lt;br&gt;&lt;br&gt;</Primary_outcome>
    <Secondary_ID>CTP_CAP001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2460676</Internal_Number>
    <TrialID>EUCTR2006-003364-64-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A phase IV, open-label, multi-centre trial evaluating the conversion from standard phosphate binder therapy to Fosrenol in chronic kidney disease stage 5 patients on haemodialysis</Public_title>
    <Scientific_title>A phase IV, open-label, multi-centre trial evaluating the conversion from standard phosphate binder therapy to Fosrenol in chronic kidney disease stage 5 patients on haemodialysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Shire Development Inc</Primary_sponsor>
    <Date_registration3>20070105</Date_registration3>
    <Date_registration>05/01/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-003364-64                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>08/05/2007</Date_enrollement>
    <Target_size>760</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Aged 18 or over and receiving stable regimen of haemodialysis (three times a week) for CKD (stage 5) for at least 2 months prior to screening.&lt;br&gt;&lt;br&gt;Females must be non-pregnant and non-lactating.&lt;br&gt;&lt;br&gt;On a stable phosphate binder dose (no change in medication or dose for one month) with screening serum phosphorus levels of between 5.6 and 7.5 mg/dL inclusive.  &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Subjects with a corrected serum calcium level &lt;2.2mmol/L (8.8mg/dL).&lt;br&gt;&lt;br&gt;Subjects with an intact parapthyroid hormone level &gt;500pg/ml or a history of parathyroidectomy within 12 months of screening.&lt;br&gt;&lt;br&gt;Any significant GI disorders (including bowel obstruction, active, inflammatory bowel disease, GI motility disorders, abnormal or irregular bowel motion, major GI surgery in last 6 months.&lt;br&gt;&lt;br&gt;Subjects receiving aluminium, magnesium, or combination therapy other than sevelamer HCl and calcium as a phosphate binder.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Hyperphosphataemia in patients with end-stage renal disease receiving haemodialysis &lt;br&gt;MedDRA version: 8.1
Level: LLT
Classification code 10020712
Term: Hyperphosphatemia
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Fosrenol 750mg Chewable Tablets&lt;br&gt;Product Name: Lanthanum Carbonate&lt;br&gt;Product Code: SPD405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate&lt;br&gt;CAS Number: 54451-24-0&lt;br&gt;Current Sponsor code: SPD405&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 750-&lt;br&gt;&lt;br&gt;Trade Name: Fosrenol 1000mg Chewable Tablets&lt;br&gt;Product Name: Lanthanum Carbonate&lt;br&gt;Product Code: SPD405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate&lt;br&gt;CAS Number: 54451-24-0&lt;br&gt;Current Sponsor code: SPD405&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;Trade Name: Fosrenol 500mg Chewable Tablets&lt;br&gt;Product Name: Lanthanum Carbonate&lt;br&gt;Product Code: SPD405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate&lt;br&gt;CAS Number: 54451-24-0&lt;br&gt;Current Sponsor code: SPD405&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess the percentage of subjects who have serum phosphorus levels controlled to &lt;or= 1.78mmol/L (&lt;or=5.5mg/dl) following treatment with Fosrenol compared to their previous phosphate binder;Primary end point(s): The percentage of subjects acheiving serum phosphorus levels of less than or equal to 1.78mmol/L following treatment with Fosrenol at week 12 compared to treatment with their previous phosphate binder therapy.;Secondary Objective: To assess the following:&lt;br&gt;&lt;br&gt;If Fosrenol can maintain serum phosphorus levels in subjects converting to Fosrenol from their previous phosphate binder therapy.&lt;br&gt;&lt;br&gt;If Fosrenol can reduce serum phosphorus levels in subjects converting to Fosrenol from their previous phosphate binder therapy.&lt;br&gt;&lt;br&gt;To assess the control of serum calcium-phosphorus product.&lt;br&gt;&lt;br&gt;To assess the average dose of Fosrenol.&lt;br&gt;&lt;br&gt;To assess the safety and tolerability of Fosrenol</Primary_outcome>
    <Secondary_ID>SPD405-403</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2460686</Internal_Number>
    <TrialID>EUCTR2006-005604-14-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A randomized, prospective, multicenter trial to compare the effect on chronic allograft nephropathy prevention of  mycophenolate mofetil versus azathioprine as the sole immunosuppressive therapy for kidney transplant recipients - MAMMOUTH</Public_title>
    <Scientific_title>A randomized, prospective, multicenter trial to compare the effect on chronic allograft nephropathy prevention of  mycophenolate mofetil versus azathioprine as the sole immunosuppressive therapy for kidney transplant recipients - MAMMOUTH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>IST. DI RICERCHE FARMACOLOG. M. NEGRI</Primary_sponsor>
    <Date_registration3>20070105</Date_registration3>
    <Date_registration>05/01/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005604-14                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/12/2006</Date_enrollement>
    <Target_size>224</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Males and females aged 18-60 years;  - First single kidney transplant from living or deceased donors;  - Written informed consent.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Specific contraindications to RATG therapy such as severe leucopenia  WBC 2000/mm3 ;  - High immunological risk   such as second transplant recipients or those who have a panel reactivity   10 ;  - history of malignancy  except non metastatic basal or squamous cell carcinoma of the skin that has been treated successfully;  - Evidence of active hepatitis C virus, hepatitis B virus or human acquired immunodeficiency virus infection;  - Any chronic clinical conditions that may affect completion of the trial or confound data interpretation;  - Pregnancy or lactating;  - Women of childbearing potential without following a scientifically accepted form of contraception;  - Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequence of the trial;  - Evidence of an uncooperative attitude;  - Any evidence that patient will not be able to complete the trial follow-up.&lt;br&gt;</Exclusion_Criteria>
    <Condition>kidney transplant &lt;br&gt;MedDRA version: 6.1
Level: PT
Classification code 10023439
</Condition>
    <Intervention>&lt;br&gt;Trade Name: CELLCEPT*50CPR 500MG&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Trade Name: AZATIOPRINA WELL*50CPR RIV50MG &lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the incidence of CAN in kidney transplant patients receiving induction therapy with basiliximab and low-dose RATG and maintenance immunosuppression with low-dose MMF or AZA monotherapy.;Secondary Objective: - To evaluate whether MMF may exert an higher activity against acute allograft rejection as  compared to AZA when used as the sole immunosuppressive agent.   - To evaluate the relationships between acute rejection episodes and subsequent  occurrence of CAN, and long-term graft function/survival. Should the study demonstrate the superiority of any of the two drugs in preventing CAN, patients will be put on the more effective immunosuppressive treatment. This will allow assessing whether the lesions of CAN may recover in those patients who are shifted from the less to the more effective treatment. The extension phase of the study will be aimed at assessing the long-term patient and graft survival.;Primary end point(s): Incidence of biopsy-proven CAN at 3 years follow-up  end phase B .</Primary_outcome>
    <Secondary_ID>AIFA TX</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2460833</Internal_Number>
    <TrialID>EUCTR2006-004959-38-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A prospective multicenter, open-label, randomised, cross-over study to compare the efficacy and safety of Fosrenol and Sevelemer Hydrochloride in patients receiving hemodialysis for end stage renal disease</Public_title>
    <Scientific_title>A prospective multicenter, open-label, randomised, cross-over study to compare the efficacy and safety of Fosrenol and Sevelemer Hydrochloride in patients receiving hemodialysis for end stage renal disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Shire Development Inc</Primary_sponsor>
    <Date_registration3>20070101</Date_registration3>
    <Date_registration>01/01/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004959-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/05/2007</Date_enrollement>
    <Target_size>214</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Aged 18 or over&lt;br&gt;Females must be non-pregnant&lt;br&gt;Must have ESRD and have been receiving haemodialysis three times a week for at least 2 months&lt;br&gt;Being treated with a monotherapy calcium based phosphate binder or a combination therapy not containing Fosrenol or sevelamer hydrochloride and is sub-optimally controlled with screening serum phosphorus levels of greater or equal 5.6 to less than or equal 7.5 mg/dL.  Treatment naiive patients are permitted to enter study providing serum phosphorus levels are greater or equal 6.0 mg/dL (1.92 mmol/L)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients who require treatment with cinacalcet hydrochloride, or with compounds containing phosphorus, magnesium, aluminium or  calcium (except as indicated in section 6.4.1 of the protocol) that are used as a phosphate binder.&lt;br&gt;&lt;br&gt;Any significant GI surgery or GI disorders (including active, uncontrolled peptic ulcer, Crohns disease, GI bleed in last 6 months, past or present GI malignancy&lt;br&gt;&lt;br&gt;Cirrhosis or other clinically relevant liver disease&lt;br&gt;&lt;br&gt;Intact PTH &gt;500 pg/ml&lt;br&gt;&lt;br&gt;Serum calcium &lt;8.8 mg/dL&lt;br&gt;&lt;br&gt;Life threatening malignancy or current multiple myeloma&lt;br&gt;&lt;br&gt;HIV positive&lt;br&gt;&lt;br&gt;Hypersensitivity to investigational products&lt;br&gt;&lt;br&gt;Alcohol or substance abuse 1 year prior to screening&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Hyperphosphataemia in patients with end-stage renal disease receiving haemodialysis &lt;br&gt;MedDRA version: 8.1
Level: LLT
Classification code 10020712
Term: Hyperphosphatemia
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Fosrenol 750mg Chewable Tablets&lt;br&gt;Product Name: Lanthanum Carbonate&lt;br&gt;Product Code: SPD405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate&lt;br&gt;CAS Number: 54451-24-0&lt;br&gt;Current Sponsor code: SPD405&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 750-&lt;br&gt;&lt;br&gt;Trade Name: Fosrenol 1000mg Chewable Tablets&lt;br&gt;Product Name: Lanthanum Carbonate&lt;br&gt;Product Code: SPD405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate&lt;br&gt;CAS Number: 54451-24-0&lt;br&gt;Current Sponsor code: SPD405&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;Trade Name: Renagel 800mg film-coated tablets&lt;br&gt;Product Name: sevelamer hydrochloride &lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: SEVELAMER HYDROCHLORIDE&lt;br&gt;CAS Number: 182683007&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 800-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the efficacy of Fosrenol and sevelamer hydrochloride in the reduction of serum phosphorus levels from baseline;Secondary Objective: To assess the following:&lt;br&gt;&lt;br&gt;the percentage of patients acheiving KDOQI target for serum phosphorus (3.5-5.5mg/dL) following treatment with Fosrenol and sevelamer hydrochloride&lt;br&gt;&lt;br&gt;the percentage of responders, defined as &gt; or = 25% decrease in serum phosphorus from baseline following treatment with Fosrenol and sevelamer hydrochloride&lt;br&gt;&lt;br&gt;the effects of Fosrenol and sevelamer hydrochloride on calcium-phosphate product and parathyroid hormone (PTH)&lt;br&gt;&lt;br&gt;compliance&lt;br&gt;&lt;br&gt;safety and tolerability of Fosrenol and sevelamer hydrochloride;Primary end point(s): The change from baseline in serum phosphorus levels</Primary_outcome>
    <Secondary_ID>SPD405-319</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2460943</Internal_Number>
    <TrialID>EUCTR2006-004606-97-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A MULTICENTER, SINGLE-ARM, OPEN, CONVERSION STUDY FROM A CYCLOSPORINE (CyA) BASED IMMUNOSUPPRESSIVE REGIMEN TO A TACROLIMUS MODFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS - CONCERTO</Public_title>
    <Scientific_title>A MULTICENTER, SINGLE-ARM, OPEN, CONVERSION STUDY FROM A CYCLOSPORINE (CyA) BASED IMMUNOSUPPRESSIVE REGIMEN TO A TACROLIMUS MODFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS - CONCERTO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Astellas Pharma GmbH</Primary_sponsor>
    <Date_registration3>20070125</Date_registration3>
    <Date_registration>25/01/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004606-97                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/02/2007</Date_enrollement>
    <Target_size>380</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: 1-way conversion&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Age = 18 years.&lt;br&gt;2. Kidney transplant at least 12 months prior to enrollment.&lt;br&gt;3. Received a CyA-based immunosuppressive regimen since last transplantation. The dose of CyA has remained unchanged during the last four weeks prior to enrollment.&lt;br&gt;4. Immunosuppressive regimen (combination of medications) remained unchanged for a minimum of four weeks prior to enrollment.&lt;br&gt;5. Experienced at least one of the following CyA-related adverse events at enrollment:&lt;br&gt;a) Gingival hyperplasia where, in the opinion of the investigator, therapeutical intervention is required.&lt;br&gt;b) Hypertrichosis/hirsutism where, in the opinion of the investigator, therapeutical intervention is required.&lt;br&gt;c) Arterial hypertension (with the exception of known pre-transplant malignant nephrosclerosis) stages I-III (systolic blood pressure &gt; 140 mmHg and/or diastolic blood pressure &gt; 90mmHg) despite treatment with at least one anti-hypertensive medication. The anti-hypertensive medication(s) has been prescribed at least 4 weeks prior to enrollment.&lt;br&gt;d) Hyperlipidemia defined as total cholesterol higher than 220 mg/dl despite treatment with lipid-lowering medication(s) requires therapeutical intervention. The lipid-lowering medication(s) has been prescribed at least four weeks prior to enrollment.&lt;br&gt;6. Serum creatinine &lt; 200 µmol/l (&lt; 2.3 mg/dl) at enrollment.&lt;br&gt;7. Female subject of childbearing potential must have a negative serum pregnancy test at enrollment and must agree to maintain effective birth control during the study.&lt;br&gt;8. Capable of understanding the purpose and risks of the study, has been fully informed and has given written informed consent (signed Informed Consent has been obtained).&lt;br&gt;9. Clinically stable in the opinion of the investigator.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Previously received an organ transplant other than a kidney.&lt;br&gt;2. Acute rejection episode within 12 weeks prior to enrollment, or an acute rejection episode within the 24 weeks prior to enrollment that required anti-lymphocyte antibody therapy.&lt;br&gt;3. Diagnosis of new-onset malignancy after transplantation, with the exception of basocellular or squamous cell carcinoma of the skin which had been treated successfully.&lt;br&gt;4. Known to have FSGS or MPGN Type II as an underlying disease.&lt;br&gt;5. Proteinuria &gt; 2 g / 24 hrs.&lt;br&gt;6. “Creeping creatinine” (defined as an increase of 20% within the 6 months prior to enrollment and at Baseline).&lt;br&gt;7. Elevated SGPT/ALT and/or SGOT/AST and/or Total Bilirubin levels = 2 times the upper value of the normal range of the investigational site.&lt;br&gt;8. Liver cirrhosis.&lt;br&gt;9. Pregnant woman or breast-feeding mother.&lt;br&gt;10. HIV positive.&lt;br&gt;11. Known allergy or intolerance to tacrolimus, macrolide antibiotics, steroids, additional concomitant immunosuppressive medication or to the excipients of the study medication.&lt;br&gt;12. Any unstable medical condition that could interfere with the study objectives in the opinion of the investigator.&lt;br&gt;13. Receiving prohibited concomitant therapy, or received prohibited concomitant therapy within 28 days prior to enrollment.&lt;br&gt;14. Currently participating in another clinical trial, and/or has taken an investigational drug within 28 days prior to enrollment.&lt;br&gt;15. Any form of substance abuse, psychiatric disorder or condition which, in the opinion of the investigator, may complicate communication with the investigator.&lt;br&gt;16. Unlikely to comply with the visits scheduled in the protocol.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Stable, adult kidney transplant recipients (at least 12 months post transplant) who are currently treated with cyclosporine and who meet the Inclusion and Exclusion Criteria will be enrolled. &lt;br&gt;MedDRA version: 8.1
Level: LLT
Classification code 10023438
Term: Kidney transplant
</Condition>
    <Intervention>&lt;br&gt;Product Name: FK506E (MR4)&lt;br&gt;Product Code: FK506E (MR4)&lt;br&gt;Pharmaceutical Form: Prolonged-release capsule, hard&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Current Sponsor code: FK506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Product Name: FK506E (MR4)&lt;br&gt;Product Code: FK506E (MR4)&lt;br&gt;Pharmaceutical Form: Prolonged-release capsule, hard&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Current Sponsor code: FK506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Product Name: FK506E (MR4)&lt;br&gt;Product Code: FK506E (MR4)&lt;br&gt;Pharmaceutical Form: Prolonged-release capsule, hard&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Current Sponsor code: FK506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Primary objective is to assess the changes in kidney function in kidney transplant subjects converted from a CyA-based immunosuppressive regimen to a tacrolimus modified release, FK506E (MR4), based immunosuppressive regimen.;Secondary Objective: The secondary objective is to assess the safety and the efficacy of a MR4-based immunosuppressive regimen in kidney transplant subjects converted from a CyA-based immunosuppressive regimen experiencing CyA-related side effects.;Primary end point(s): Change in creatinine clearance, calculated according to Cockcroft and Gault formula, between Baseline (Day 1) and week 24 (End of Study) for each specific CyA-related side-effect group (hypertrichosis/hirsutism, gingival hyperplasia, hyperlipidemia, arterial hypertension).</Primary_outcome>
    <Secondary_ID>PMR-EC-1209</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2461728</Internal_Number>
    <TrialID>EUCTR2007-001048-32-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Prospective, multicentre, open-label study evaluating Fondaparinux (1,5 mg/day) in venous thromboembolic events prevention in patients with renal impairment defined by a creatinin clearance between 20 and 50 ml/min and undergoing a major orthopaedic surgery (hip fracture, total hip replacement and total knee replacement)</Public_title>
    <Scientific_title>Prospective, multicentre, open-label study evaluating Fondaparinux (1,5 mg/day) in venous thromboembolic events prevention in patients with renal impairment defined by a creatinin clearance between 20 and 50 ml/min and undergoing a major orthopaedic surgery (hip fracture, total hip replacement and total knee replacement)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>CHU SAINT-ETIENNE</Primary_sponsor>
    <Date_registration3>20070329</Date_registration3>
    <Date_registration>29/03/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001048-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>15/09/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patient affiliated with or a beneficiary of a social security category:&lt;br&gt;•	age &gt; 18 years old,&lt;br&gt;•	requiring a major orthopaedic surgery (THR, TKR, HF) whatever procedure techniques are used, 1st indication or resumption,&lt;br&gt;•	requiring an antithrombotic prophylaxis,&lt;br&gt;•	presenting a renal impairment defined by a creatinin clearance (CrCl) between 20 and 50 ml/min calculated by Cockcroft and Gault’s formula, &lt;br&gt;•	having signed the inform consent form.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	contra-indications to fondaparinux,&lt;br&gt;•	history of heparin inducted thrombopenia (HIT), &lt;br&gt;•	history of venous thromboembolic event,&lt;br&gt;•	Haemorrhagic diathesis, &lt;br&gt;•	PT &lt; 50 %, aPTT &gt; 1,5 of control value, platelets &lt; 100 G/l.&lt;br&gt;                incapacity to understand protocol&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with renal impairment defined by a creatinin clearance between 20 and 50 ml/min and undergoing a major orthopaedic surgery (hip fracture, total hip replacement and total knee replacement) &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038474
Term: Renal insufficiency
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10020100
Term: Hip fracture
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10023476
Term: Knee osteoarthritis
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10049909
Term: Venous thromboembolism prophylaxis
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10020108
Term: Hips osteoarthritis
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Arixtra 1,5 mg/0,3 ml&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Fondaparinux&lt;br&gt;CAS Number: 114870-03-0&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: to evaluate between D5 and D10, the incidence of major bleedings after a daily subcutaneous injection of fondaparinux 1,5 mg during at least 5 days for prevention of venous thromboembolic events after major orthopaedic surgery (TKR, THR and HF) in patients with a CrCl between 20 and 50 ml/min (estimated by Cockcroft and Gault formula). ;Secondary Objective: to evaluate: &lt;br&gt;•	The incidence of major bleedings at 1 month ± 5 days&lt;br&gt;•	The incidence of clinically significative bleedings between D5 and D10 and at 1 month ± 5 days&lt;br&gt;•	The incidence of symptomatic venous thromboembolic events (DVT and PE) between D5 and D10 and at 1 month ± 5 days&lt;br&gt;•	Pharmacodynamic parameters based on Xa activity (absorption half-life and elimination clearance of distribution volume and their variability) of fondaparinux based on a non-linear model at mixed effect and to compare the observed real clinical data with those simulated and described in MA file.&lt;br&gt;•	Estimation of haemorrhagic and thromboembolic risk factors.&lt;br&gt;•	Estimation of inter-laboratories variability in the measure of anti-Xa activity with fondaparinux;Primary end point(s): •	Major bleeding (occuring between D5 and D10) is defined by: &lt;br&gt;-	an exteriorised bleeding with a bleeding index &gt; 2 (g/dl of haemoglobin decrease + number of units transfused)&lt;br&gt;-	a bleeding needing a resumption surgery&lt;br&gt;-	a bleeding affecting a critical organ (ocular, retroperitoneal, pericardial, intra-cranial, intra-medullary, intramuscular with compression)&lt;br&gt;-	a fatal bleeding&lt;br&gt;</Primary_outcome>
    <Secondary_ID>0701017</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2461957</Internal_Number>
    <TrialID>EUCTR2006-007021-32-DE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Multi-center, open-label, prospective, randomized, parallel group, long-term study investigating a standard regimen in de novo kidney transplant patients versus a CNI-free regimen and a CNI-low dose regimen - HERAKLES</Public_title>
    <Scientific_title>Multi-center, open-label, prospective, randomized, parallel group, long-term study investigating a standard regimen in de novo kidney transplant patients versus a CNI-free regimen and a CNI-low dose regimen - HERAKLES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Novartis Pharma GmbH</Primary_sponsor>
    <Date_registration3>20070417</Date_registration3>
    <Date_registration>17/04/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-007021-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>29/05/2007</Date_enrollement>
    <Target_size>450</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: different treatment regimen&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Males or females, aged 18 – 70 years&lt;br&gt;2.	Recipients of de novo cadaveric, living unrelated or living related kidney transplants&lt;br&gt;3.	Females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at Baseline visit 1, and are required to practice an approved method of birth control for the duration of the study and for a period of 6 weeks following discontinuation of study medication, even where there has been a history of infertility&lt;br&gt;4.	Patients who are willing and able to participate in the study and from whom written informed consent has been obtained&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	More than one previous renal transplantation&lt;br&gt;2.	Multi-organ recipients (e.g., kidney and pancreas) or previous transplant with any other organ, different from kidney&lt;br&gt;3.	Patients receiving a kidney from a non-heart beating donor&lt;br&gt;4.	Donor age: &lt; 5 years or &gt; 70 years &lt;br&gt;5.	Graft loss due to immunological reasons in the first year after transplantation (in case of secondary transplantation) &lt;br&gt;6.	Patients who are recipients of A-B-O incompatible transplants&lt;br&gt;7.	Patients with a historical or current peak PRA of &gt; 25% (current = 3 months)&lt;br&gt;8.	Patients with already existing antibodies against the HLA-type of the receiving transplant&lt;br&gt;9.	Patients with any known hypersensitivity to Simulect®, Certican®, mycophenolic acid, cyclosporine A, other drugs similar to Certican® (e.g., macrolides), or other components of the formulations (e.g. lactose)&lt;br&gt;10.	Patients who have received an investigational immunosuppressive drug within four weeks prior to study entry (Baseline visit 1)&lt;br&gt;11.	Patients with thrombocytopenia (platelets &lt; 75,000/mm³), with an absolute neutrophil count of &lt; 1,500/mm³ or leucopenia (leucocytes &lt; 2,500/mm³), or hemoglobin &lt; 6 g/dL&lt;br&gt;12.	Patients with symptoms of significant somatic or mental illness. Inability to cooperate or communicate with the investigator, who are unlikely to comply with the study requirements, or who are unable to give informed consent&lt;br&gt;13.	Patients with a history of malignancy during the last five years, except squamous or basal cell carcinoma of the skin&lt;br&gt;14.	Patients who are HIV, HCV, or Hepatitis B surface antigen positive &lt;br&gt;15.	Evidence of severe liver disease (incl. abnormal liver enzyme profile, i.e. AST, ALT or total bilirubin &gt; 3 times UNL)&lt;br&gt;16.	Females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, who are unwilling to use effective means of contraception&lt;br&gt;17.	Presence of a clinically significant infection requiring continued therapy, severe diarrhea, active peptic ulcer disease, or uncontrolled diabetes mellitus that in the opinion of the investigator would interfere with the appropriate conduct of the study&lt;br&gt;18.	Evidence of drug or alcohol abuse&lt;br&gt;19.	Patients receiving drugs known to strongly interact with CsA and/or everolimus according to the list provided in Appendix 3 to this protocol should be excluded, if in the opinion of the investigator this drug interaction interferes with the objectives of the study, namely a clinical meaningful potentiation of renal dysfunction and/or maintenance of adequate immunosuppressive drug levels&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>de novo kidney transplant patients &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10023439
Term: Kidney transplant rejection
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican Tabletten&lt;br&gt;Product Name: Certican&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Current Sponsor code: RAD001&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Trade Name: Certican Tabletten&lt;br&gt;Product Name: Certican&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Current Sponsor code: RAD001&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.75-&lt;br&gt;&lt;br&gt;Trade Name: Simulect 20 mg&lt;br&gt;Product Name: Simulect 20 mg&lt;br&gt;Pharmaceutical Form: Intravenous infusion&lt;br&gt;INN or Proposed INN: Basiliximab&lt;br&gt;CAS Number: 179045-86-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Trade Name: Myfortic 180 mg/ -360 mg Filmtabletten&lt;br&gt;Product Name: Myfortic 180 mg/- 360 mg Filmtabletten&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Mycophenolate sodium&lt;br&gt;CAS Number: 24280-93-1&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 180-&lt;br&gt;&lt;br&gt;Trade Name: Myfortic 180 mg/ -360 mg Filmtabletten&lt;br&gt;Product Name: Myfortic 180 mg/- 360 mg Filmtabletten&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Mycophenolate sodium&lt;br&gt;CAS Number: 24280-93-1&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 360-&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun Optoral&lt;br&gt;10 mg, 25 mg, 50 mg, 100 mg Kapseln&lt;br&gt;Product Name: Sandimmun Optoral&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Ciclosporin&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun Optoral&lt;br&gt;10 mg, 25 mg, 50 mg, 100 mg Kapseln&lt;br&gt;Product Name: Sandimmun Optoral&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Ciclosporin&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun Optoral&lt;br&gt;10 mg, 25 mg, 50 mg, 100 mg Kapseln&lt;br&gt;Product Name: Sandimmun Optora</Intervention>
    <Primary_outcome>Main Objective: The primary objective of this trial is to demonstrate superiority of a CNI-free regimen respect to the renal function at Month 12 post Tx assessed by glomerular filtration rate – Nankivell method – as compared to the standard regimen in de novo kidney transplant patients.;Secondary Objective: •	to assess renal function by glomerular filtration rate at Month 12 post Tx of the CNI-low dose regimen compared to the standard regimen&lt;br&gt;•	to assess renal function by glomerular filtration rate at Month 12 post Tx&lt;br&gt;•	to assess renal function by serum creatinine at month 12 post Tx&lt;br&gt;•	to assess efficacy at Month 6 and 12&lt;br&gt;•	to asses occurrence of treatment failures up to or at Month 12&lt;br&gt;•	to assess evolution of renal function between Month 3 and 12 &lt;br&gt;•	to assess safety and tolerability at Month 12:	&lt;br&gt;- AE/SAE	&lt;br&gt;- incidence of infections (with special emphasis on CMV) 	&lt;br&gt;- tumor incidence	&lt;br&gt;- cardiovascular risk (changes in Framingham score)	&lt;br&gt;- occurrence of proteinuria&lt;br&gt;•	to assess efficacy, safety and tolerability at Follow-up visits at month 18, 24, 36, 48, and 60&lt;br&gt;;Primary end point(s): The primary aim of this study is to demonstrate superior renal function under the CNI-free regimen as compared to the Standard regimen.&lt;br&gt;The primary variable for assessment of renal function is the glomerular filtration rate (GFR) at Month 12, as assessed by the Nankivell method.</Primary_outcome>
    <Secondary_ID>CRAD001ADE13</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2461961</Internal_Number>
    <TrialID>EUCTR2006-002455-33-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of AZD2171 45mg Versus Placebo following 12 Weeks of Treatment in Patients with Metastatic or Recurrent Renal Cell Carcinoma who have had no Previous Anti-VEGF Therapy.</Public_title>
    <Scientific_title>A Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of AZD2171 45mg Versus Placebo following 12 Weeks of Treatment in Patients with Metastatic or Recurrent Renal Cell Carcinoma who have had no Previous Anti-VEGF Therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>AstraZeneca AB</Primary_sponsor>
    <Date_registration3>20060823</Date_registration3>
    <Date_registration>23/08/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002455-33                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>13/11/2006</Date_enrollement>
    <Target_size>65</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;Other trial design description: After double blind phase all patients are offered open label study drug&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Provision of informed consent	&lt;br&gt;2.	Males or females aged 18 years and older 	&lt;br&gt;3.	Histological/cytological confirmation of metastatic or recurrent renal cell clear cell/adenocarcinoma  &lt;br&gt;4.	One or more measurable lesions at least 10mm in the longest diameter by spiral computed tomography scan or 20mm with conventional techniques (RECIST criteria) 	&lt;br&gt;5.	WHO performance status 0-2 	&lt;br&gt;6.	Life expectancy = 12 weeks&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Previous anti-VEGF therapy  &lt;br&gt;2.	More than one previous type of immunotherapy &lt;br&gt;3.	Prior cytotoxic chemotherapy intended to treat RCC&lt;br&gt;4.	Surgery scheduled within 12 weeks after entry to the study.  &lt;br&gt;5.	Treatment with an investigational drug within 30 days prior to the first dose of  AZD2171.&lt;br&gt;6.	Other concomitant anti-cancer therapy (including LHRH agonists), except steroids&lt;br&gt;7.	Untreated unstable brain or meningeal metastases.  Patients with radiological evidence of stable brain metastases are eligible providing that they are asymptomatic and either do not require corticosteroids or have been treated with corticosteroids, with clinical and radiological evidence of stabilisation at least 10 days after discontinuation of steroids.&lt;br&gt;8.	History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within 5 years, unless the patient has been disease free for 2 years and there is a tissue diagnosis of renal cell carcinoma from a target lesion.  &lt;br&gt;9.	Inadequate bone marrow reserve as demonstrated by an absolute neutrophil count =1.5 x 10(to power 9)/L or platelet count =100 x 10 (to power 9)/L or requiring regular blood transfusions to maintain haemoglobin &gt;9g/dL&lt;br&gt;10.	Serum bilirubin = 1.5 x ULRR&lt;br&gt;11.	ALT or AST = 2.5 x ULRR.  If liver metastases are present, ALT or AST &gt; 5 x ULRR&lt;br&gt;12.	Serum creatinine &gt; 1.5 x ULRR or a creatinine clearance of = 50mL/min calculated by Cockcroft-Gault&lt;br&gt;13.	Greater than +1 proteinuria on two consecutive dipsticks taken no less than 1 week apart unless urinary protein &lt; 1.5g in a 24 hr period.&lt;br&gt;14.	History of significant gastrointestinal impairment, as judged by the investigator, that would significantly affect the absorption of AZD2171, including the inability to swallow the tablet whole.&lt;br&gt;15.	Patients with a history of poorly controlled hypertension with resting blood pressure &gt;150/100 in the presence or absence of a stable regimen of anti-hypertensive therapy.&lt;br&gt;16.	Known hypersensitivity to AZD2171 or any of its excipients&lt;br&gt;17.	Any evidence of severe uncontrolled diseases e.g. unstable or uncompensated respiratory, cardiac (including arrhythmias), hepatic or renal disease.&lt;br&gt;18.	Unresolved toxicity &gt; CTCAE grade 2 from previous anti-cancer therapy except alopecia (if applicable)&lt;br&gt;19.	Mean QTc with Bazetts correction &gt;470msec in screening ECG or history of familial long QT syndrome.&lt;br&gt;20.	Significant haemorrhage (&gt;30mL bleeding/episode in previous 3 months) or haemoptysis (&gt;5mL fresh blood in previous 4 weeks)&lt;br&gt;21.	Recent (&lt;14 days) major surgery prior to entry into the study, or a surgical incision that is not fully healed&lt;br&gt;22.	Pregnant or breast-feeding women or women of childbearing potential with a positive pregnancy test prior to receiving study medication&lt;br&gt;23.	Known infection with hepatitis B or C or HIV&lt;br&gt;24.	Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)&lt;br&gt;25.	Previous enrolment or randomisation of treatment in the present study.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal cell carcinoma &lt;br&gt;MedDRA version: 8.1
Level: LLT
Classification code 10038410
Term: Renal cell carcinoma recurrent
</Condition>
    <Intervention>&lt;br&gt;Product Name: AZD2171&lt;br&gt;Product Code: AZD2171&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;Current Sponsor code: AZD2171&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Product Name: AZD2171&lt;br&gt;Product Code: AZD2171&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;Current Sponsor code: AZD2171&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 15-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Product Name: AZD2171&lt;br&gt;Product Code: AZD2171&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;Current Sponsor code: AZD2171&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Determine the efficacy of AZD2171 compared to the efficacy of placebo in patients with metastatic or recurrent renal cell carcinoma by comparing changes in tumour size after 12 weeks of therapy (or upon progression if this occurs before 12 weeks).  ;Secondary Objective: To determine the efficacy of AZD2171 compared to the efficacy of placebo by assessment of RECIST data in patients with metastatic or recurrent renal cell carcinoma.&lt;br&gt;To determine the steady-state pharmacokinetic (PK) parameters of AZD2171 in patients with metastatic or recurrent renal cell carcinoma.&lt;br&gt;To determine the safety and tolerability of AZD2171 in patients with metastatic or recurrent renal cell carcinoma.&lt;br&gt;To assess the effect of AZD2171 on angiogenesis biomarkers.&lt;br&gt;;Primary end point(s): Determine the efficacy of AZD2171 compared to the efficacy of placebo in patients&lt;br&gt;with metastatic or recurrent renal cell carcinoma by comparing changes in tumour&lt;br&gt;size after 12 weeks of therapy (or upon progression if this occurs before 12 weeks).</Primary_outcome>
    <Secondary_ID>D8480C00030</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2462099</Internal_Number>
    <TrialID>EUCTR2007-002109-32-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>USE OF FENOLDOPAM TO IMPROVE  GLOMERULAR FILTRATION RATE  IN EARLY RENAL DYSFUNCTION AFTER LIVER TRANSPLANTATION - ND</Public_title>
    <Scientific_title>USE OF FENOLDOPAM TO IMPROVE  GLOMERULAR FILTRATION RATE  IN EARLY RENAL DYSFUNCTION AFTER LIVER TRANSPLANTATION - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>AZIENDA SANITARIA OSPEDALIERA  S. GIOVANNI BATTISTA DI TORINO</Primary_sponsor>
    <Date_registration3>20070424</Date_registration3>
    <Date_registration>24/04/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-002109-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/05/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;adult liver transplanted patients  age &gt;  18 years , with  pre-transplantation  normal renal function  creatinine clearance &gt;  1ml/kg/min , characterized  in the first week after liver transplantation by   increase of serum creatinine more than 1,5 times compared to pre-operative value or  urine out-put reduction    0,5 ml/kg/h  for over 6 hours period without loop diuretics administration and after  cardiovascular  performance optimization  hemodynamic stability defined as stable values of systemic systolic blood pressure    100 mmHg over the 6-hr period  immediately preceding the enrollment  low doses  of vasopressor drugs are allowed .&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;life expectancy  &gt;  48 hrs  renal dysfunction requiring  renal  replacement therapies  hemodynamic instability  sepsis  urgent surgery need during the study  administration of loop diuretic drugs  furosemide    250 mg/24 hrs&lt;br&gt;</Exclusion_Criteria>
    <Condition>Adult liver transplanted patients  age   &gt; 18 years , with  pre-transplantation  normal renal function  creatinine clearance   1ml/kg/min &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038436
Term: Renal failure acute
</Condition>
    <Intervention>&lt;br&gt;Trade Name: CORLOPAM 1F 2ML 20MG/2ML&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: to  evaluate, in patients with early renal dysfunction after liver transplantation, the efficacy of fenoldopam mesylate in preserving/improving renal function  glomerular filtration rate .;Secondary Objective: to evaluate  if cystatin-C can be a reliable marker of  glomerular filtration  GFR  changes  in critically  ill patient  to evaluate  if cystatin-C level  may detect  the changes in renal function due to vasoactive drugs as fenoldopam;Primary end point(s): to  evaluate, in patients with early renal dysfunction after liver transplantation, the efficacy of fenoldopam mesylate in preserving/improving renal function  glomerular filtration rate .</Primary_outcome>
    <Secondary_ID>CORL2007</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2462123</Internal_Number>
    <TrialID>EUCTR2006-006815-62-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Does N-Acetylcysteine (Parvolex) prophylaxis reduce the incidence of renal impairment after on pump Coronary artery bypass surgery?   A prospective randomised controlled trial.</Public_title>
    <Scientific_title>Does N-Acetylcysteine (Parvolex) prophylaxis reduce the incidence of renal impairment after on pump Coronary artery bypass surgery?   A prospective randomised controlled trial.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>University Hospitals of South Manchester NHS Foundation Trust</Primary_sponsor>
    <Date_registration3>20070417</Date_registration3>
    <Date_registration>17/04/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006815-62                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/05/2007</Date_enrollement>
    <Target_size>224</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt; Patients undergoing elective coronary artery bypasssurgery at Wythenshawe Hospital Manchester&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Urgent and emergency cases&lt;br&gt;Patients with history of hypersensitivity to N-Acetylcysteine&lt;br&gt;Patients already taking N-Acetylcysteine&lt;br&gt;Patients with existing renal failure (creatinine more than 120mmol/l –upper limit of normal range in our laboratory&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal impairment after coronary artery byapass surgery &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10006894
Term: CABG
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Parvolex&lt;br&gt;Product Name: Acetylcysteine&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intravenous drip use (Noncurrent)&lt;br&gt;&lt;br&gt;Trade Name: Parvolex&lt;br&gt;Product Name: Acetylcysteine&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To find out whether prophylactic use of N-Acetylcysteine decreases the incidence of renal impairment after cardiac surgery;Secondary Objective: To find out whether prophylactic N-Acetylcysteine has effect on the length of ICU/HDU stay;Primary end point(s): serum creatinine levels first 48 hrs</Primary_outcome>
    <Secondary_ID>NAC/CT/2006.</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2462381</Internal_Number>
    <TrialID>EUCTR2007-000229-23-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>RENAL SAFETY EVALUATION AFTER DOTAREM-ENHANCED  MRA COMPARED WITH NON-ENHANCED MRI IN PATIENTS AT HIGH RISK OF DEVELOPING CONTRAST MEDIUM INDUCED NEPHROPATHY.</Public_title>
    <Scientific_title>RENAL SAFETY EVALUATION AFTER DOTAREM-ENHANCED  MRA COMPARED WITH NON-ENHANCED MRI IN PATIENTS AT HIGH RISK OF DEVELOPING CONTRAST MEDIUM INDUCED NEPHROPATHY.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>GUERBET</Primary_sponsor>
    <Date_registration3>20070604</Date_registration3>
    <Date_registration>04/06/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-000229-23                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/08/2007</Date_enrollement>
    <Target_size>134</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: comparative descriptive &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Comparator will be an examination without contrast media injection(unenhanced-MRI)&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;·Male or female, aged = 55 years;&lt;br&gt;·Patient presenting with a known stable stage III to stage IV renal insufficiency according to the K/DOQI definition, i.e., 15 &lt; estimated GFR &lt; 60 ml/min/1.73m² according to MDRD formula for 2 consecutive values (within 10% of each other) obtained over at least one week apart with the most recent value having been obtained within 24 hours prior to the study procedure;&lt;br&gt;·Patient scheduled to undergo a contrast enhanced MR Angiography or unenhanced MRI examination to specify a diagnosis;&lt;br&gt;·Patient able to understand and provide written informed consent to participate in the trial;Patient for whom blood samples can be obtained in the 24 hours preceding the procedure and 72 hours after the examination.   &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;·Patient with a contraindication to MRI (e.g., pacemaker, aneurysm clip, severe claustrophobia, metallic joint replacement or others according to the imaging laboratory's standard practice);&lt;br&gt;·Patient who has a diagnosis of a hemodynamic instability (cardiogenic shock – persistent systolic pressure &lt; 90 requiring inotropic support) or acute myocardial infraction within 15 days prior the inclusion;&lt;br&gt;·Patient who needs hemodialysis; &lt;br&gt;·Patient with known allergy to gadolinium chelates (only applicable for patient undergoing Dotarem-enhanced MRA);&lt;br&gt;·Patient receiving medications known to be nephrotoxic or to cause increases in serum creatinine level (i.e. selective inhibitors of cyclo-oxygenase 2, anti-Vascular Endothelium Growth Factors, Vancomycine, Aciclovir, aminoglycosides, amphotericin B, polymixin, platinium complexes and non-steroidal anti-inflammatory treatment except Acetyl Salicylic Acid) within 24 hours before first blood sample and during 72 hours after the procedure;&lt;br&gt;·Patients for whom the dosage of diuretic has been modified during the month prior the inclusion or should be modified during the 3 days after the imaging procedure&lt;br&gt;·Patients planned to either undergo surgery or receive chemotherapy within 72 hours post-procedure (i.e: before the blood test 72 hours post-procedure);&lt;br&gt;·Patient having an imaging procedure (with contrast media or not ) within 7 days of entering this protocol;&lt;br&gt;·Patient with a planned imaging procedure (with contrast media or not ) within 72 hours post-procedure;&lt;br&gt;·Patient with newly discovered unstable diabetes;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients suffering from renal insufficiency and scheduled for contrast enhanced-MR angiography or unenhanced-MRI &lt;br&gt;MedDRA version: 10.0
Level: LLT
Classification code 10038474
Term: &lt;Manually entered code. Term in E.1.1&gt;
</Condition>
    <Intervention>&lt;br&gt;Trade Name: DOTAREM 0.5 mmol/ml&lt;br&gt;Product Name: DOTAREM 0.5mmol/m, solution for injection&lt;br&gt;Product Code: Not applicable&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Gadoteric Acid (corresponding to DOTA+gadolinium oxide)&lt;br&gt;Other descriptive name: 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid, Gadolinium complex&lt;br&gt;Concentration unit: mmol/ml millimole(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess in at risk patients (patients with at least moderate renal insufficiency) the frequency of contrast-induced nephropathy after Dotarem-enhanced MRA, in comparison with the frequency of nephropathy after unenhanced MRI and to observe an equivalence between both procedures regarding these frequencies.;Secondary Objective: -To confirm the clinical and biological safety of DOTAREM® by assessing vital signs, laboratory parameters and adverse events through a 72±12 hours post treatment (DOTAREM®) or post procedure follow-up period.&lt;br&gt;-To assess the serum creatinine level fluctuation in term of mean difference between baseline and 72 ±12 hours after examination.&lt;br&gt;-To evaluate the estimated Glomerular Filtration Rate fluctuation in term of percentage and mean difference between baseline and 72 ±12 hours after examination. Estimated GFR will be assessed using the MDRD study equation.&lt;br&gt;-If possible, to assess the potential influence of hydration protocol and/or prophylactic treatment on the renal function&lt;br&gt;In case of rise in Serum creatinine level at 72±12 hours of at least 25% or 0.5mg/dl (44.2µmol/l), to observe the percentage of patients returned at baseline level within 14 days after the last blood sample (at 72hours).&lt;br&gt;&lt;br&gt;;Primary end point(s): The evaluation of the renal tolerance after both procedures (MRI and DOTAREM®-MRA) will be done by assessing the serum creatinine levels from blood sampling taken within 24 hours before the imaging procedure and at 72 ±12 hours after the procedure. &lt;br&gt;&lt;br&gt;This study will calculate in the two groups the percentage of patients presenting with a significant creatinine level increase according to the approach described hereafter. &lt;br&gt;&lt;br&gt;Significant creatinine level increase (Nephrotoxicity) will be defined as a rise in serum creatinine level at 72±12 hours of at least 25% or 0.5mg/dl (=44.2µmol/l) compared to baseline.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>DGD 44-044;not applicable</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2462410</Internal_Number>
    <TrialID>EUCTR2007-001857-24-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Phase IIa, open-label, dose-titration, multicentre study to assess the safety and preliminary efficacy of NI-0401 in patients with acute cellular renal allograftt rejection</Public_title>
    <Scientific_title>A Phase IIa, open-label, dose-titration, multicentre study to assess the safety and preliminary efficacy of NI-0401 in patients with acute cellular renal allograftt rejection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>NovImmune S.A.</Primary_sponsor>
    <Date_registration3>20070531</Date_registration3>
    <Date_registration>31/05/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001857-24                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>25/07/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Men and women = 18 and = 70 years of age.&lt;br&gt;2.	Recipient of a kidney graft (first or second) from a deceased or living donor (non-HLA-identical).&lt;br&gt;3.	Rise in SCr concentration by &gt; 20% compared to baseline, defined as the most recent creatinine level measured prior to rejection but after transplantation.&lt;br&gt;4.	Allograft biopsy showing evidence of acute cellular rejection, according to Banff 97 criteria.&lt;br&gt;5.	Men and women of childbearing potential must use adequate birth control measures until 6 months after receiving study drug. Therefore, women of childbearing potential and their partners are required to use two forms of contraception. Men with partners of childbearing potential are required to use barrier contraception, in addition to their partners using another method. Acceptable forms of contraception are as follows: &lt;br&gt;-	Barrier methods: condoms, diaphragms, cervical caps;&lt;br&gt;-	Hormonal contraceptives: combination or progesterone only;&lt;br&gt;	Includes depot contraceptives;&lt;br&gt;-	Intrauterine methods: intrauterine devices or systems.&lt;br&gt;6.	The screening laboratory tests must meet the following criteria:&lt;br&gt;a.	Hb ³ 8.5 g/dL (4.5 mmol/L)&lt;br&gt;b.	WBC ³ 2.5 x 109/L&lt;br&gt;c.	Neutrophils ³ 1.5 x 109/L&lt;br&gt;d.	Platelets ³ 100 x 109/L&lt;br&gt;e.	SGOT (AST) and alkaline phosphatase levels must be within 3 times the upper limit of normal range.&lt;br&gt;7.	Patients must be able to adhere to the study visits and protocol requirements.&lt;br&gt;8.	Patients must be able to give written informed consent.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Patients who have received therapy with anti-CD3 mAb (OKT3) or anti-lymphocytes polyclonal antibodies (ATG, Atgam) in the past.&lt;br&gt;2.	Patients with cardiac insufficiency or fluid overload (to be excluded by a chest X ray). &lt;br&gt;3.	Severe HLA sensitization (&gt;50% panel reactive antibodies prior to transplantation).&lt;br&gt;4.	Evidence of delayed renal graft function.&lt;br&gt;5.	Have received or are planned to receive immunization with a live vaccine within 6 weeks prior to receiving study drug and 12 weeks after treatment cessation.&lt;br&gt;6.	Concomitant disease:&lt;br&gt;a.	Current signs or symptoms of severe, progressive or uncontrolled disease. Patients with cardiac (e.g. recent myocardial infarction or symptomatic ischemic heart disease); pulmonary (e.g. chronic obstructive pulmonary disease); or neurologic disease (e.g. seizure disorder or head trauma).&lt;br&gt;b.	Previous diagnosis of, or known, malignancies, except for completely excised basal cell carcinoma.&lt;br&gt;c.	Ongoing severe infections, such as hepatitis or pneumonia, or any active infection (requiring therapy).&lt;br&gt;d.	History of opportunistic infections such as herpes zoster within 2 months prior to screening. History of active tuberculosis (TB) or currently undergoing treatment for TB.&lt;br&gt;e.	Evidence of acute CMV (or D+/R-) or EBV infection.&lt;br&gt;f.	Serum anti HCV positive, serum HBsAg positive, serum anti-HIV positive. &lt;br&gt;g.	Patients with BK Virus nephropathy.&lt;br&gt;7.	Patients with any history of coagulopathy or medical condition requiring long-term anticoagulation after transplantation (low-dose of aspirin treatment is allowed).&lt;br&gt;8.	Female patients who are pregnant or breast feeding.&lt;br&gt;9.	A psychiatric, addictive, or any other disorder that compromises the ability to give truly informed written consent for participation in this study.&lt;br&gt;10.	Suspected hypersensitivity to any component of the drug product.&lt;br&gt;11.	Has undergone or is undergoing treatment with another investigational drug or approved therapy for investigational use within 3 months prior to entry in this study. Has previously participated in this study.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Acute cellular renal allograft rejection.</Condition>
    <Intervention>&lt;br&gt;Product Code: NI-0401&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess safety and tolerability of NI-0401&lt;br&gt;To determine whether NI-0401 can reverse BpACR;Secondary Objective: To assess changes in renal function overtime, as measured by serum creatinine.&lt;br&gt;To establish NI-0401 pharmacokinetics in patients with BpACR.&lt;br&gt;To assess pharmacodynamics of NI-0401.&lt;br&gt;To quantify the level of recurrent rejections, their severity and response to treatment.&lt;br&gt;To assess the incidence of anti-NI-0401 antibodies.&lt;br&gt;;Primary end point(s): Adverse events (nature, frequency, intensity, causality, seriousness, treatability and outcome).&lt;br&gt;The percentage of patients demonstrating a complete normalization of SCr at study day 14. Complete normalization is defined as a return of the SCr concentration to &lt; 120% of baseline value.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>NI-0401-02</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2462418</Internal_Number>
    <TrialID>EUCTR2006-005916-29-DE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>IFEROS – Influence of intravenous iron therapeutics on oxidative stress in hemodialysis patients - IFEROS</Public_title>
    <Scientific_title>IFEROS – Influence of intravenous iron therapeutics on oxidative stress in hemodialysis patients - IFEROS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Westpfalz-Klinikum GmbH</Primary_sponsor>
    <Date_registration3>20070605</Date_registration3>
    <Date_registration>05/06/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005916-29                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>29/10/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: yes&lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;stable hemodialysis patients at least three months on HD&lt;br&gt;age &gt;  18 years&lt;br&gt;adequate hemodialysis with kt/v &gt; 1,3&lt;br&gt;adequate iron stores with Serum-Ferritin &gt;100 µg/dl and TSAT &gt;20% or hypochrome erythrocytes &lt; 10%&lt;br&gt;CRP &lt; 30 mg/l&lt;br&gt;Hemoglobin &gt;10 g/dl&lt;br&gt;stable on erythropoeitin: erythropoetin-dose  50 – 150 IU/kg/Woche and no change of erythropoeitin-dose &gt; 30% in the last 8 weeks&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;·clinical signs of relevant inflammation or CRP &gt; 30 mg/l &lt;br&gt;Hemoglobin &lt; 10 g/dl or Hemoglobin &gt;13g/dl&lt;br&gt;Serum-Ferritin &lt;100 µg/dl or Serum-Ferritin &gt; 800 µg/dl&lt;br&gt;TSAT  &gt; 50%&lt;br&gt;weekly iron substitition &gt; 100 mg &lt;br&gt;hematologic systemic disease&lt;br&gt;immunsuppressive or cytostatic therapy&lt;br&gt;therapy with vitamin C, vitamin E or Acetylcystein&lt;br&gt;pregnany&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>stable patients on hemodialysis with renal anemia &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10019480
Term: Hemodialysis
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10058132
Term: Renal anemia
</Condition>
    <Intervention>&lt;br&gt;Trade Name: CosmoFer&lt;br&gt;Pharmaceutical Form: Injection*&lt;br&gt;CAS Number: 9004664&lt;br&gt;Other descriptive name: IRON DEXTRAN&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Ferrlecit&lt;br&gt;Pharmaceutical Form: Injection*&lt;br&gt;CAS Number: 8500011872&lt;br&gt;Other descriptive name: SODIUM-IRON-GLUCONATE COMPLEX&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 62,5/5-&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration number: 62,5/5-&lt;br&gt;&lt;br&gt;Trade Name: Venofer&lt;br&gt;Pharmaceutical Form: Injection*&lt;br&gt;CAS Number: 8047674&lt;br&gt;Other descriptive name: IRON SUCROSE&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100/5-&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration number: 100/5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: investigate the influence of different iro preparations on oxidative stress and apoptotic changes of peripheral blood leukocytes in hemodialysis patients;Secondary Objective: none;Primary end point(s): measurement of oxidative stress and apoptotic changes in peripheral blood leukocytes:&lt;br&gt;- Malondialdehyd&lt;br&gt;- DNA-damage (Comet-test)&lt;br&gt;- Glutathion&lt;br&gt;- changes of mitochondrial membran potential&lt;br&gt;&lt;br&gt;</Primary_outcome>
    <Secondary_ID>IFEROS V5-1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2462439</Internal_Number>
    <TrialID>EUCTR2007-000416-91-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Phase I/II, Ascending, Multi-Dose Study of BMS-663513, An Agonistic Anti-CD137
Monoclonal Antibody, Administered Every Three Weeks to Patients with Metastatic or
Locally Advanced Solid Malignancies.

Revised Protocol Number 07, incorporating Amendments 01, 02, 03, 04, 05, 06, 07 and Administrative Letter Dated 10-Mar-2006.
</Public_title>
    <Scientific_title>A Phase I/II, Ascending, Multi-Dose Study of BMS-663513, An Agonistic Anti-CD137
Monoclonal Antibody, Administered Every Three Weeks to Patients with Metastatic or
Locally Advanced Solid Malignancies.

Revised Protocol Number 07, incorporating Amendments 01, 02, 03, 04, 05, 06, 07 and Administrative Letter Dated 10-Mar-2006.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Bristol-Myers Squibb International Corporation</Primary_sponsor>
    <Date_registration3>20070611</Date_registration3>
    <Date_registration>11/06/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-000416-91                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/07/2007</Date_enrollement>
    <Target_size>110</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: patients will be randomized to receive 1, 3 or 10 mg/kg of BMS-663513 in a 1:1:1 ratio&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Signed written informed consent&lt;br&gt;&lt;br&gt;- Target population&lt;br&gt;a) Able to comply with visits/procedures required by the protocol&lt;br&gt;b) Life expectancy of at least 3 months&lt;br&gt;c) ECOG performance status score 0 - 1 (Protocol Appendix 4).&lt;br&gt;d) Patients with histologic or cytologic diagnosis of an advanced solid malignancy&lt;br&gt;who have failed, refused or are unable to receive standard treatment.&lt;br&gt;NOTE: Patients enrolled after Amendment 7 is IRB approved are limited to:&lt;br&gt;• Melanoma (must be anti-CTLA-4 naive),&lt;br&gt;• Renal (clear cell) carcinoma, or&lt;br&gt;• Epithelial carcinoma arising from the ovary, fallopian tube or peritoneum.&lt;br&gt;e) At least 1 site of measurable disease (excluding epithelial carcinoma who must&lt;br&gt;have at least 1 site of “evaluable” disease)&lt;br&gt;f) A tumor paraffin embedded tissue block or 5 - 15 unstained slides from the tumor&lt;br&gt;tissue block (from the primary or a metastatic tumor) must be provided for&lt;br&gt;biomarker and predictive marker analyses. Note: If the tumor tissue block or unstained slides are not available or insufficient, additional fresh tumor tissue&lt;br&gt;could be collected during the optional pretreatment biopsy to satisfy this criteria&lt;br&gt;g) At least 4 weeks must have elapsed since the last chemotherapy, immunotherapy,&lt;br&gt;hormonal therapy, radiotherapy or major surgery, &amp; the 1st day of BMS-663513 therapy. At least 6 weeks for nitrosoureas, mitomycin C &amp; liposomal doxorubicin&lt;br&gt;h) Toxicities related to prior therapy must either have returned to = Grade 1, baseline or deemed irreversible&lt;br&gt;&lt;br&gt;-Age and Sex&lt;br&gt;a) Men and women, who are at least 18 years of age.&lt;br&gt;- Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the study in such a manner that the risk of pregnancy is minimized. WOCBP include any female who has experienced menarche &amp; who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea &gt;= 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level &gt; 35 IU/mL. Even women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as an&lt;br&gt;intrauterine device or barrier methods (diaphragm, condoms, spermicides) to&lt;br&gt;prevent pregnancy or practicing abstinence or where partner is sterile (eg,&lt;br&gt;vasectomy), should be considered to be of child bearing potential.&lt;br&gt;- WOCBP must have a negative pregnancy test [minimum sensitivity 25 IU/L&lt;br&gt;or equivalent units of beta-human chorionic gonadatrophin (ßHCG)] within&lt;br&gt;72-hours prior to the start of study medication.&lt;br&gt;&lt;br&gt;- Physical and laboratory test findings:&lt;br&gt;a) Adequate bone marrow function defined as:&lt;br&gt;Absolute neutrophil count (ANC) &gt;= 1,500 cells/mm³&lt;br&gt;Platelet count &gt;= 100,000 cells/mm³&lt;br&gt;Hemoglobin &gt;= 9.0 g/dl&lt;br&gt;b) Adequate hepatic function defined as:&lt;br&gt;Total bilirubin =&lt; 1.5 times the institutional upper limit of normal (IULN)&lt;br&gt;ALT, AST and alkaline phosphatase =&lt; 2.5 times the IULN&lt;br&gt;c) Adequate renal function defined as:&lt;br&gt;Serum creatinine =&lt; 1.5 times the IULN or&lt;br&gt;Calculated creatinine clearance of &gt;= 60 mL/min/1.73m²&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Sex and Reproductive Status&lt;br&gt;a) WOCBP who are unwilling or unable to use an acceptable method to avoid&lt;br&gt;pregnancy for the entire study period and for up to 12 weeks after the study.&lt;br&gt;b) WOCBP using a prohibited contraceptive method.&lt;br&gt;c) Women who are pregnant or breastfeeding.&lt;br&gt;d) Women with a positive pregnancy test on enrollment or prior to study drug&lt;br&gt;administration.&lt;br&gt;e) Sexually active fertile men, whose partners are WOCBP, who are unwilling or&lt;br&gt;unable to use an acceptable method of birth control from the time of enrollment&lt;br&gt;and for 12 weeks after participation in the study.&lt;br&gt;&lt;br&gt;- Medical History and Concurrent Diseases&lt;br&gt;a) Active infection or uncontrolled significant acute or chronic medical illness other&lt;br&gt;than current cancer that would prohibit safe administration of BMS-663513.&lt;br&gt;b) Any concurrent malignancy other than adequately treated basal or squamous cell&lt;br&gt;skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix.&lt;br&gt;Patients with a previous malignancy but without evidence of disease for &gt;= 5 years&lt;br&gt;will be allowed to enter the trial.&lt;br&gt;c) History of autoimmune diseases including rheumatoid arthritis, lupus&lt;br&gt;erythermatosus, uveitis and autoimmune inflammatory eye disease, psoriasis,&lt;br&gt;multiple sclerosis, inflammatory bowel diseases, etc. Type I diabetes mellitus is&lt;br&gt;allowed.&lt;br&gt;d) Known or suspected human immunodeficiency virus (HIV) positive.&lt;br&gt;e) Any current condition requiring the continued use of systemic or topical steroids&lt;br&gt;or the use of immunosuppressive agents (eg, cyclosporine and its analog, or&lt;br&gt;chemotherapy agents). All corticosteroid use must have been discontinued&lt;br&gt;&gt;= 4 weeks prior to Day 1 of treatment.&lt;br&gt;f) Active/symptomatic brain metastasis. Patients with signs or symptoms suggestive&lt;br&gt;of brain metastasis are not eligible unless brain metastases are ruled out by&lt;br&gt;computerized axial tomography (CT) scan or magnetic resonance imaging (MRI).&lt;br&gt;Patients with stable brain metastasis and those who were previously treated with&lt;br&gt;radiotherapy or surgery must have no current evidence of active/symptomatic&lt;br&gt;brain metastasis and are off steroid therapy for at least 4 weeks prior to Day 1 of&lt;br&gt;treatment.&lt;br&gt;g) Uncontrolled or significant cardiovascular disease including myocardial infarction&lt;br&gt;within 6 months, uncontrolled angina, Class III-IV New York Heart Association&lt;br&gt;(NYHA) congestive heart failure (Appendix 5) and clinically significant&lt;br&gt;ventricular arrhythmias.&lt;br&gt;h) Any other sound medical, psychiatric and/or social reason, which in the opinion&lt;br&gt;of the principal investigator, would prohibit the understanding of the informed&lt;br&gt;consent and/or make the administration of study drug hazardous or obscure the&lt;br&gt;interpretation of adverse events.&lt;br&gt;i) History of hepatitis B or C, or alcohol induced liver disease.&lt;br&gt;&lt;br&gt;- Physical and Laboratory Test Findings&lt;br&gt;a) Evidence of organ dysfunction or any clinically significant deviation from normal&lt;br&gt;in physical examination, vital signs, ECG or clinical laboratory determinations.&lt;br&gt;b) Positive blood screen for hepatitis B surface antigen, or hepatitis C antibody.&lt;br&gt;&lt;br&gt;- Allergies and Adverse Drug Reactions&lt;br&gt;a) History of allergy to BMS-663513 or related compounds.&lt;br&gt;&lt;br&gt;- Prohibited Therapies and/or Medications&lt;br&gt;a) Exposure to any investigational products within 4 weeks prior to Day 1 of&lt;br&gt;treatment.&lt;br&gt;b) Use of any immunosuppressing treatments including corticosteroids,&lt;br&gt;cyclosporine, mycophenolate mofetil (CellCept®), chemotherapy, radiation, etc,&lt;br&gt;within 4 weeks prior to Day 1 of treatment.&lt;br&gt;&lt;br&gt;-Other Exclusion Criteria&lt;br&gt;a) Prisoners or patients w</Exclusion_Criteria>
    <Condition>Patients with Metastatic or Locally Advanced Solid Malignancies &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10025650
Term: Malignant melanoma
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038395
Term: Renal carcinoma
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10033131
Term: Ovarian carcinoma
</Condition>
    <Intervention>&lt;br&gt;Product Name: Anti-CD137&lt;br&gt;Product Code: BMS-663513&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;Current Sponsor code: BMS-663513&lt;br&gt;Other descriptive name: Anti-CD137&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess the safety and tolerability of BMS-663513 in the range of 0.3 mg/kg to&lt;br&gt;15 mg/kg administered once every 3 weeks to patients with metastatic or locally advanced solid malignancies in the dose escalation portion of the study. To estimate the reversible Grade 3-4 toxicity rate in the expanded dose cohorts of melanoma, ovarian and renal carcinoma patients at each of the 3 selected doses (1, 3 and 10 mg/kg).;Secondary Objective: •Assess the PK of BMS-663513&lt;br&gt;•Assess BMS-663513 dose &amp; biologic effect relationships using:&lt;br&gt; -Flow cytometry to quantitate subsets of immune cells (CD3, CD4, CD8, CD19, &amp; &lt;br&gt;   CD16/56)&lt;br&gt; -Flow cytometry to measure subsets of T cells (activated, memory)&lt;br&gt; -QRT-PCR to measure changes in RNA expression in peripheral blood&lt;br&gt; -ELISA to measure changes in levels of cytokines &amp;/or other biomolecules&lt;br&gt;•Screen for anti-tumor activity of single agent BMS-663513&lt;br&gt;•Assess the effect of BMS-663513 on immune response to non-cancer vaccines (influenza, tetanus, pneumoccocal)&lt;br&gt;•Assess the immunogenic potential of BMS-663513&lt;br&gt;•Assess the effect of BMS-663513 on intratumoral immune response pre and post treatment using immunohistochemistry&lt;br&gt;•Obtain fresh &amp; paraffin embedded tumor samples, &amp; blood, to identify potential predictive markers of biological response utilizing ribonucleic acid (RNA) profiling, protein profiling, single nucleotide polymorphism (SNP) analysis, &amp; other techniques;Primary end point(s): • Primary Safety Outcome Measures: &lt;br&gt;Safety assessments will be based on medical review of adverse event (AE) reports and the results of vital sign measurements, EKG/ECG, physical examinations, and clinical laboratory tests. AEs will be recorded using Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 and the incidence will be tabulated and reviewed for potential significance and clinical importance.&lt;br&gt;&lt;br&gt;• Pharmacokinetic Measures: &lt;br&gt;PK parameters (Cmax, Cmin, Tmax, AUC(INF), AUC(TAU), T1/2, CLT, Vss, and ?x) may be derived from serum concentration versus time for BMS-663513.&lt;br&gt;&lt;br&gt;• Efficacy Measures: &lt;br&gt;Tumor response will be determined for all patients using a modified form of the WHO criteria. These assessments will be made at week 12 and every 6 weeks thereafter or more frequently if indicated.&lt;br&gt;&lt;br&gt;• Pharmacodynamic Measures: &lt;br&gt;Exploratory research to assess dose and biologic effect relationships will be assessed by measurement of changes in peripheral T cell subsets using flow cytometry, changes in RNA expression in peripheral blood using QRT-PCR and changes in cytokines or other biomolecules using ELISA. Anti-influenza, anti-pneumoccocal and anti-tetanus antibody titers may be measured 3 to 4 weeks after immunization. Exploratory research to discover predictive markers of response will be performed using RNA profiling, SNP analysis and IHC of tumor tissue.</Primary_outcome>
    <Secondary_ID>CA186001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2462502</Internal_Number>
    <TrialID>EUCTR2004-004947-23-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Eficacia de rapamicina en prevención secundaria de tumores cutáneos en trasplantados renales. Estudio abierto, aleatorizado, comparando rapamicina con inhibidores de calcineurina. - Tumorapa-1</Public_title>
    <Scientific_title>Eficacia de rapamicina en prevención secundaria de tumores cutáneos en trasplantados renales. Estudio abierto, aleatorizado, comparando rapamicina con inhibidores de calcineurina. - Tumorapa-1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Hospices Civils de Lyon</Primary_sponsor>
    <Date_registration3>20070524</Date_registration3>
    <Date_registration>24/05/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-004947-23                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>05/06/2007</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;patient aged 18 year old or more with kidney transplant with immunosuppressive treatment with calcineurines inhibitor recurrence of spinocellular carcinoma&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;patient aged les tha 18 year old&lt;br&gt;metastatic carcinoma&lt;br&gt;previous treatment with rapamycine&lt;br&gt;pregnant woman&lt;br&gt;</Exclusion_Criteria>
    <Condition>Comparar el efecto de dos estrategias inmunosupresoras sobre la incidencia de nuevos carcinomas espinocelulares en pacientes con trasplante renal que hayan desarrollado un primer carcinoma espinocelular.


To evaluate the impact of two imnosupressive regimens on the incidence of skin cancers among patients who has a first spinocellular skin cancer after renal transplantation &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038533
Term: Renal transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Neoral&lt;br&gt;Product Name: Cyclosporine&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: cyclosporine&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;INN or Proposed INN: cyclosporine&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;INN or Proposed INN: Cyclosporine&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;INN or Proposed INN: cyclosporine&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: Rapamune&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Tacrolimus&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: Cellcept&lt;br&gt;Product Name: Micofenolato mofetilo&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Micofenolato mofetilo&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;INN or Proposed INN: Micofenolato mofetilo&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Trade Name: Imurel&lt;br&gt;Product Name: Azatioprina&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Azatioprina&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Rapapmycine replacement of calcineurines inhibitor could reduce the risk of a new kin cancer by 40% or more while preserving graft function;Secondary Objective: ;Primary end point(s): to analyse the annual incidence of spinocellular carcinoma</Primary_outcome>
    <Secondary_ID>Tumorapa-1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2462629</Internal_Number>
    <TrialID>EUCTR2005-004509-27-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Utilidad de la Rapamicina para la prevención secundaria de tumores cutáneos en trasplantados renales con recidiva de carcinoma espinocelular - Tumorapa-N</Public_title>
    <Scientific_title>Utilidad de la Rapamicina para la prevención secundaria de tumores cutáneos en trasplantados renales con recidiva de carcinoma espinocelular - Tumorapa-N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Hospices Civils de Lyon</Primary_sponsor>
    <Date_registration3>20070622</Date_registration3>
    <Date_registration>22/06/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004509-27                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/07/2007</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;patient aged 18 year old or more with kidney transplant &lt;br&gt;with immunusuppressive treatment with calcineurines inhibitor&lt;br&gt;recurrence of spinocellular carcinoma&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;patient aged less than 18year old&lt;br&gt;metastatic carcinoma&lt;br&gt;previous treatment with rapamycine&lt;br&gt;pregnant woman&lt;br&gt;</Exclusion_Criteria>
    <Condition>El objetivo principal consiste en comparar el efecto de dos estrategias inmunosupresoras, sobre la incidencia de carcinomas espinocelulares nuevos en pacientes receptores de trasplante renal que hayan desarrollado más de un carcinoma espinocelular.

To evaluate the impact of two immunosuppressive regimens on the incidence of skin cancers among patients who have had previously a first spinocellulaire skin cancer after transplantation</Condition>
    <Intervention>&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: Rapamune&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Tacrolimus&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: Cellcept&lt;br&gt;Product Name: Micofenolato Mofetilo&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Micofenolato mofetilo&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;INN or Proposed INN: Micofenolato mofetilo&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Trade Name: Imurel&lt;br&gt;Product Name: Azatioprina&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Azatioprina&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Neoral&lt;br&gt;Product Name: Cyclosporine&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: Cyclosporine&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;INN or Proposed INN: Cyclosporine&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;INN or Proposed INN: Cyclosporine&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;INN or Proposed INN: Cyclosporine&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Rapamycine replacement of calcineurines inhibitor could reduce the risk of a new skin cancer by  40% or more while preserving graft function;Secondary Objective: ;Primary end point(s): to analyse the annual incidence of spinocellular carcinoma</Primary_outcome>
    <Secondary_ID>Tumorapa-N</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2462737</Internal_Number>
    <TrialID>EUCTR2007-003045-33-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Fenoldopam and renal insufficiency - ND</Public_title>
    <Scientific_title>Fenoldopam and renal insufficiency - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>OSPEDALE S. RAFFAELE</Primary_sponsor>
    <Date_registration3>20070702</Date_registration3>
    <Date_registration>02/07/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-003045-33                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>25/08/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;patients undergoing heart surgery developing, in any moment during post surgery hospitalization in Intensive Care Unit, renal problems named as "R" of RIFLE score&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;glaucoma,discharge from Intensive Care Unit within 24 hours,renal substitutive treatment,possible exitus,inclusion in other studies,age under 18,lack of informed consent,patients treated with fenoldopam in prevoius month,pre surgery dialisis&lt;br&gt;</Exclusion_Criteria>
    <Condition>patients undergoing heart surgery developing, in any moment during post surgery hospitalization in Intensive Care Unit, renal problems named as "R" of RIFLE score &lt;br&gt;MedDRA version: 9.1
Level: SOC
Classification code 10038359
Term: Renal and urinary disorders
</Condition>
    <Intervention>&lt;br&gt;Trade Name: CORLOPAM&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Fenoldopam&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: to evaluate if Fenoldopam use versus placebo may improve the renal outcome in patients undergoing heart surgery;Secondary Objective: to evaluate if Fenoldopam use versus placebo may improve the renal outcome in patients undergoing heart surgery;Primary end point(s): prevention of placement of renal substitutive treatment</Primary_outcome>
    <Secondary_ID>FENO HSR</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2462899</Internal_Number>
    <TrialID>EUCTR2007-000033-19-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>An open study to investigate the effect of 4 instead of 2 daily dosing mycophenolate mofetil (MMF) in renal transplant patients on diarrhea - 4xMMF</Public_title>
    <Scientific_title>An open study to investigate the effect of 4 instead of 2 daily dosing mycophenolate mofetil (MMF) in renal transplant patients on diarrhea - 4xMMF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>UMC Utrecht</Primary_sponsor>
    <Date_registration3>20070302</Date_registration3>
    <Date_registration>02/03/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-000033-19                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>05/06/2007</Date_enrollement>
    <Target_size>10</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: administartion of 4 daily dosing Cellcept is compared with 2 daily dosing&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Male or female &gt; 18 years old&lt;br&gt;Renal transplantation &gt; 6 months with stable renal function (serum creatinine &lt; 250 mumol/L)&lt;br&gt;Use of MMF (Cellcept®) 2 times daily&lt;br&gt;History of diarrhea (&gt; 1 month = 3 times a day loose/ watery stool in at least 75% of the cases)&lt;br&gt;Willing and capable to give written informed consent&lt;br&gt;Able to communicate and cooperate with the investigators&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Usage of morfinomimetics, anti-diarretics, laxans or other drugs that are known to induce diarrhea.&lt;br&gt;Recent use of antibiotics (&lt; 4 weeks before study)&lt;br&gt;Gastro-intestinal infections (Yersinea, Campylobacter, Shigella, Salmonella, Clostridium difficile toxin, CMV)&lt;br&gt;Known gastro-intestinal diseases or recent major gastro-intestinal surgery&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Diarrhea in renal transplanted patients which use Cellcept® &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10021176
Term: Iatrogenic diarrhea
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10023438
Term: Kidney transplant
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10054980
Term: Immunosuppressant drug therapy
</Condition>
    <Intervention>&lt;br&gt;Trade Name: CellCept® (mycophenolate mofetil)&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: MYCOPHENOLATE MOFETIL&lt;br&gt;CAS Number: 115007346&lt;br&gt;Current Sponsor code: mmf4dd&lt;br&gt;Other descriptive name: 4xMMF&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 1-3&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The main objective is to find out if dividing the daily oral dose prevents diarrhea without increasing risk of graft failure.;Secondary Objective: Increasing the quality of life and effect on intestinal permeability.;Primary end point(s): - Stool frequency and faeces weight&lt;br&gt;- Incidence of acute graft rejection (according to BANFF 1997 criteria)</Primary_outcome>
    <Secondary_ID>4xmmf</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2462980</Internal_Number>
    <TrialID>EUCTR2007-002562-35-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>ffet de l’Epoetin Beta sur la fonction rénale et l’anémie dans les trente jours suivant une transplantation rénale - Etude Neo-PDGF</Public_title>
    <Scientific_title>ffet de l’Epoetin Beta sur la fonction rénale et l’anémie dans les trente jours suivant une transplantation rénale - Etude Neo-PDGF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>CHU AMIENS</Primary_sponsor>
    <Date_registration3>20070723</Date_registration3>
    <Date_registration>23/07/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-002562-35                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/09/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Comparaison à l'absence de traitement&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Patient d’âge compris entre 18 et 75 ans ayant délivré un consentement de participation libre et éclairé&lt;br&gt;- Patient devant être transplanté rénal bénéficiant d’une 1ère ou 2ème transplantation&lt;br&gt;- Patient anciennement traité par dialyse péritonéale ou par hémodialyse&lt;br&gt;- Patient recevant un greffon à risque de reprise retardée de fonction (score &gt; 7 combinant age du donneur, durée d’ischémie, ethnie du receveur et cause du décès)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Femme enceinte ou allaitante&lt;br&gt;- Déficience ne permettant pas une bonne compréhension des impératifs de l’essai&lt;br&gt;- Patient recevant des doses d’epoetin bêta ou alpha &gt; 30000 UI/semaine avant la transplantation&lt;br&gt;- Patient ayant participé à un essai clinique au cours du dernier mois &lt;br&gt;- Patient sous sauvegarde de justice, sous tutelle ou curatelle&lt;br&gt;- Patient bénéficiant d’une troisième greffe ou hyperimmunisé ou ayant un cross-match positif&lt;br&gt;- Greffon provenant d’un donneur vivant&lt;br&gt;- Greffon avec 3 artères ou plus&lt;br&gt;- Patient ayant une insuffisance cardiaque sévère, une cardiopathie ischémique instable ou ayant eu un événement coronarien majeur &lt; 6 mois, un AVC &lt; 6 mois ou une AOMI symptomatique&lt;br&gt;- Patient ayant une infection virale active : hépatites B, C ou HIV&lt;br&gt;- Patient ayant des antécédents d’anémie érythroblastopénique&lt;br&gt;- Patient recevant un traitement anticoagulant (AVK) avant la Tx rénale&lt;br&gt;- Patient ayant un taux d’Hb préopératoire &gt; 14 g/dL (avant ultrafiltration)&lt;br&gt;- Patient présentant une hypersensibilité connue au produit à l’essai&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients insuffisants rénaux chroniques, au stade terminal de leur affection, traités en dialyse. Patients, hommes ou femmes, agés de 18 à 75 ans, devant bénéficier d'une transplantation rénale à partir d'un donneur en coma dépassé et étant à risque de récupération lente de la fonction du greffon. Randomisés pour recevoir 4 injections de 30000 UI de NeoRecormon (Epoetin bêta) avant le déclampage, 12 heures après la greffe et à J7 et J14 (Groupe A), ou aucun traitement (Groupe B). &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10058116
Term: Nephrogenic anaemia
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10009120
Term: Chronic renal failure anaemia
</Condition>
    <Intervention>&lt;br&gt;Trade Name: NeoRecormon® 30 000 UI&lt;br&gt;Product Name: NeoRecormon®&lt;br&gt;Product Code: RO 2053859&lt;br&gt;Pharmaceutical Form: Injection*&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluer l’effet de l’Epoetin bêta sur le débit de filtration glomérulaire (DFG) estimée 30 jours après transplantation rénale. Le DFG sera évaluer par la formule MDRD simplifiée;Secondary Objective: Comparer entre les 2 groupes à tous les temps de J0 à J90 :&lt;br&gt;- L’évolution de la fonction rénale&lt;br&gt;- La survie des patients et des greffons&lt;br&gt;- Le délai de survenue et l’incidence d’un rejet aigu prouvé par biopsie&lt;br&gt;- La correction de l’anémie&lt;br&gt;- Les besoins transfusionnels&lt;br&gt;- Les besoins en EPO&lt;br&gt;- La qualité de vie&lt;br&gt;- La tolérance du traitement;Primary end point(s): Evaluation de la fonction rénale à J30 mesurée par le débit de filtration glomérulaire estimé (formule MDRD simplifiée)</Primary_outcome>
    <Secondary_ID>P107 - Pr CHOUKROUN</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2463028</Internal_Number>
    <TrialID>EUCTR2007-001904-18-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>An open label randomised controlled study to compare the efficacy, safety and tolerability of once every four weeks administration of subcutaneous C.E.R.A. versus darboepoetin alfa for the maintenance of haemoglobin levels in predialysis patients with chronic renal anaemia.

Estudio abierto, randomizado, controlado para comparar la eficacia, seguridad y tolerancia de la administración una vez cada cuatro semanas de C.E.R.A. por vía subcutánea frente a darbepoetina alfa para el mantenimiento de las concentraciones de hemoglobina en pacientes con anemia renal crónica que no están en diálisis.</Public_title>
    <Scientific_title>An open label randomised controlled study to compare the efficacy, safety and tolerability of once every four weeks administration of subcutaneous C.E.R.A. versus darboepoetin alfa for the maintenance of haemoglobin levels in predialysis patients with chronic renal anaemia.

Estudio abierto, randomizado, controlado para comparar la eficacia, seguridad y tolerancia de la administración una vez cada cuatro semanas de C.E.R.A. por vía subcutánea frente a darbepoetina alfa para el mantenimiento de las concentraciones de hemoglobina en pacientes con anemia renal crónica que no están en diálisis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>ROCHE FARMA S.A.</Primary_sponsor>
    <Date_registration3>20070730</Date_registration3>
    <Date_registration>30/07/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001904-18                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>27/08/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Darbepoetina alfa&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;• Consentimiento informado por escrito&lt;br&gt; &lt;br&gt;• Pacientes adultos (&gt;18 años) con enfermedad renal crónica en estadio 3 (VSGc 30-59 ml/min) o 4 (VSGc 15-29 ml/min) que no precisen diálisis&lt;br&gt; &lt;br&gt;• Concentración de hemoglobina basal entre 10,5 y 12,5 g/dl (media de los valores de hemoglobina semanales determinados en las semanas -4 a -1)&lt;br&gt;&lt;br&gt;• Estado de hierro adecuado (concentración de ferritina sérica &gt;100 ng/ml O TSAT &gt;20% O porcentaje de  hematíes hipocrómicos &lt;10%)&lt;br&gt; &lt;br&gt;• Tratamiento de mantenimiento continuo con darbepoetina alfa subcutánea utilizando la misma pauta de administración (una vez cada 2 semanas) durante los 2 meses previos.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) &lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) &lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;• Transfusiones de hematíes durante los 2 meses previos&lt;br&gt;• Hipertensión mal controlada, es decir, tensión arterial en posición sentada superior a 170/100 a pesar de la medicación, que haya requerido hospitalización o la interrupción del tratamiento con darbepoetina alfa en los 6 meses previos. &lt;br&gt;• Hemorragias agudas o crónicas significativas, tales como hemorragias gastrointestinales manifiestas&lt;br&gt;• Enfermedad maligna activa (excepto cáncer de piel no melanoma)&lt;br&gt;• Hemólisis &lt;br&gt;• Hemoglobinopatías (p. ej. anemia drepanocítica homocigótica, cualquier tipo de talasemia)&lt;br&gt;•	Deficiencia de ácido fólico &lt;br&gt;•	Deficiencia de vitamina B12 &lt;br&gt;•	Recuento de plaquetas &gt;500 x 109/l o &lt;100 x 109l&lt;br&gt;•	Aplasia eritrocítica pura&lt;br&gt;•	Ataques epilépticos durante los 6 meses previos &lt;br&gt;•	Insuficiencia cardíaca congestiva (Clase IV NYHA)&lt;br&gt;•	Infarto de miocardio o ictus, arteriopatía coronaria severa o inestable, enfermedad hepática severa de acuerdo con el criterio del investigador, durante los 3 meses previos&lt;br&gt;•	Hiperparatiroidismo secundario no controlado o sintomático (se podría definir como una concentración de PTH &gt; 1000 pg/ml en el ensayo de PTH intacta o de &gt;500 pg/ml en el ensayo de PTH completa).&lt;br&gt;•	Mujeres embarazadas o en período de lactancia&lt;br&gt;•	Mujeres potencialmente fértiles que no utilicen métodos anticonceptivos eficaces&lt;br&gt;•	Participación en un ensayo clínico o administración de un compuesto en investigación o un tratamiento experimental durante las 4 últimas semanas previas.&lt;br&gt;•	Cirugía programada (con fecha) durante el período de estudio, a excepción de &lt;br&gt;?	cirugía por cataratas&lt;br&gt;?	cirugía de acceso vascular&lt;br&gt;•	Hipersensibilidad confirmada a eritropoyetina recombinante humana, polietilenglicol o a cualquiera de los componentes de la medicación del estudio &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Anemia en insuficiencia renal crónica &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10058124
Term: Nephrogenic anemia
</Condition>
    <Intervention>&lt;br&gt;Product Name: C.E.R.A.&lt;br&gt;Product Code: RO0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: proposed: pegzerepoetin alfa&lt;br&gt;CAS Number: 67734-53-7&lt;br&gt;Current Sponsor code: RO0503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;&lt;br&gt;Trade Name: Aranesp®&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: darbepoetin alfa&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;&lt;br&gt;Product Name: C.E.R.A.&lt;br&gt;Product Code: RO0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: proposed: pegzerepoetin alfa&lt;br&gt;CAS Number: 67734-53-7&lt;br&gt;Current Sponsor code: RO0503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Product Name: C.E.R.A.&lt;br&gt;Product Code: RO0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: proposed: pegzerepoetin alfa&lt;br&gt;CAS Number: 67734-53-7&lt;br&gt;Current Sponsor code: RO0503821&lt;br&gt;Concentration unit: µg/µl microgram(s)/microlitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 60-&lt;br&gt;&lt;br&gt;Product Name: C.E.R.A.&lt;br&gt;Product Code: RO0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: proposed: pegzerepoetin alfa&lt;br&gt;CAS Number: 67734-53-7&lt;br&gt;Current Sponsor code: RO0503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 75-&lt;br&gt;&lt;br&gt;Product Name: C.E.R.A.&lt;br&gt;Product Code: RO0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: proposed: pegzerepoetin alfa&lt;br&gt;CAS Number: 677324-53-7&lt;br&gt;Current Sponsor code: RO0503821&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Name: C.E.R.A.&lt;br&gt;Product Code: RO0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: proposed: pegzerepoetin alfa&lt;br&gt;CAS Number: 67734-53-7&lt;br&gt;Current Sponsor code: RO0503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 120-&lt;br&gt;&lt;br&gt;Product Name: C.E.R.A.&lt;br&gt;Product Code: RO0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or </Intervention>
    <Primary_outcome>Main Objective: • Comparar el mantenimiento a largo plazo de las concentraciones de hemoglobina con la administración subcutánea una vez cada cuatro semanas de C.E.R.A. frente a darbepoetina alfa subcutánea en pacientes con anemia renal crónica que no están en diálisis. ;Secondary Objective: • Comparar la seguridad y tolerancia de la administración de C.E.R.A una vez cada cuatro semanas para el tratamiento de la anemia en pacientes con enfermedad renal crónica ;Primary end point(s): Las variables principales se evaluarán durante las 8 semanas siguientes al período de corrección de dosis de 16 semanas, es decir, durante el período de evaluación de la eficacia (PEE).&lt;br&gt;La concentración de hemoglobina de referencia se define como la media de las cuatro determinaciones registradas durante el PVE (semanas -4,-3,-2,-1)&lt;br&gt;A los efectos de la evaluación de la eficacia, el rango diana de la concentración de hemoglobina se definirá como ± 1 g/dl de la concentración de hemoglobina de referencia O un valor que esté dentro del rango de 10,5 – 12,5 g/dl. &lt;br&gt;&lt;br&gt;Variable de eficacia principal &lt;br&gt;• Proporción de pacientes en los que se mantiene la concentración media de hemoglobina dentro del rango diana durante el período  PEE&lt;br&gt;</Primary_outcome>
    <Secondary_ID>ML21059</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2463257</Internal_Number>
    <TrialID>EUCTR2006-001812-65-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A randomized, double-blind, placebo-controlled, parallel
group, multicenter study to evaluate the effect of valsartan
on proteinuria and glomerular filtration rate in children with
Chronic Kidney Disease who are receiving a standardized
dose of angiotensin converting enzyme inhibitor therapy</Public_title>
    <Scientific_title>A randomized, double-blind, placebo-controlled, parallel
group, multicenter study to evaluate the effect of valsartan
on proteinuria and glomerular filtration rate in children with
Chronic Kidney Disease who are receiving a standardized
dose of angiotensin converting enzyme inhibitor therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Novartis Pharma Services AG</Primary_sponsor>
    <Date_registration3>20070801</Date_registration3>
    <Date_registration>01/08/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-001812-65                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/08/2006</Date_enrollement>
    <Target_size>314</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;(For Full list, see protocol)&lt;br&gt;• Pediatric outpatients, 5-17 years of age, with a history of chronic kidney disease.&lt;br&gt;• Male and female patients with body weight = 15 kg and = 100 kg are eligible.&lt;br&gt;• Must be able to swallow tablets.&lt;br&gt;• Must be receiving a standardized dose of an ACEI for at least for 2 months, for the treatment of proteinuria, without known ACEI-suspected adverse effects which could prevent the patient from continuing to receive the same dose of the ACEI for an additional 18 months.&lt;br&gt;• Urine dipstick for protein = trace at Visit 1.&lt;br&gt;• Proteinuria demonstrated in 2 of 3 early morning void urine specimen collections at Visit 2 (UPCR = 500 mg/g).&lt;br&gt;• GFR = 30 ml/min/1.73m2 and = 90 ml/min/1.73m2, as estimated by the Schwartz formula using the Visit 1 serum creatinine value.&lt;br&gt;• MSSBP/MSDBP must be &lt; 95th percentile, for age, gender and height, at Visit 2, by office blood pressure measurement.&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;(For full list, see protocol):&lt;br&gt;Renal transplant patients&lt;br&gt;• Renal artery stenosis.&lt;br&gt;• Patients with active systemic disease(s) (e.g. diabetes, amyloidosis, vasculitis, lupus nephritis) defined as those with current, recent (in the past two months) or frequent (= 2 episodes in the past 12 months) exacerbations of disease activity, and those in whom immunosuppressive medication was increased within two months prior to screening &lt;br&gt;• Patients who are currently or within two months prior to screening on the following medications. [Note: Patients on maintenance immunosuppressive therapy (CsA, FK 506, MMF or azathioprine), administered at unchanged dose in the past 2 months pior to screening, and expected to remain unchanged throughout the study, are allowed.]:&lt;br&gt;               • Intraveous or oral cyclophosphamide&lt;br&gt;               • Intravenous or oral steroid pulse therapy&lt;br&gt;               • Oral steroid therapy &gt;0.5 mg/kg/d&lt;br&gt;• Serum potassium &lt; 3.5 or &gt; 5.3 mEq/L.&lt;br&gt;• Hemoglobin &lt; 8 gm/dL.&lt;br&gt;• WBC &lt; 3000/mm3.&lt;br&gt;• Patients currently on Angiotensin II type-1 Receptor Blocker (ARB) therapy&lt;br&gt;• Patients are not medically able or willing to discontinue aldosterone receptor antagonist and/or potassium sparing diuretic medications for the duration of the study.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic kidney disease is characterized by a progressive decline of glomerular
filtration rate (GFR), which occurs irrespectively of the cause of the renal damage once a critical nephron mass has been lost.</Condition>
    <Intervention>&lt;br&gt;Trade Name: Diovan 40 mg film-coated tablet&lt;br&gt;Product Name: Valsartan&lt;br&gt;Product Code: VAL489&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Valsartan&lt;br&gt;Current Sponsor code: VAL489&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 40-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Diovan 80 mg film-coated tablet&lt;br&gt;Product Name: Valsartan&lt;br&gt;Product Code: VAL489&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Valsartan&lt;br&gt;Current Sponsor code: VAL 489&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 80-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate the efficacy, safety and tolerability of valsartan versus placebo in&lt;br&gt;children with Chronic Kidney Disease (CKD) manifested by persistent proteinuria (&gt; 500 mg/g) while receiving a standardized dose of ACEI therapy to provide important prescribing information to the pediatrician on the use of valsartan in children with CKD.;Primary end point(s): Period 1 : Change from baseline in log (UPCR) month 4&lt;br&gt;&lt;br&gt;Period 1 + Period 2 : Chronic slope of GFR over time, month 2 to 18   ;Secondary Objective: • Evaluate the proportion of patients who have their UPCR reduced by = 50% from baseline to end of Period 1.&lt;br&gt;• Evaluate the proportion of patients who have their urine albumin/creatinine ratio (UACR) reduced by = 50% from baseline to end of Period 1.&lt;br&gt;• Evaluate proteinuria reduction as measured by UACR from baseline to end of Period 1 &lt;br&gt;Entire study : To Evaluate: &lt;br&gt;• Proportion of patients who have their UPCR reduced by = 50% from baseline to end of Period 2.&lt;br&gt;• Proportion of patients who have their urine albumin/creatinine ratio (UACR) reduced&lt;br&gt;by = 50% from baseline to end of Period 2.&lt;br&gt;• Proteinuria reduction as measured by UPCR and UACR from baseline to end of&lt;br&gt;Period 2.&lt;br&gt;• Proportion of patients with = 25% GFR loss from baseline at end of Period 2.&lt;br&gt;• Change in GFR (difference in slope) from baseline to end of treatment Period 2.&lt;br&gt;• To evaluate the overall safety and tolerability of valsartan in this population.</Primary_outcome>
    <Secondary_ID>CVAL489K2301;Not applicable</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2463276</Internal_Number>
    <TrialID>EUCTR2006-006652-35-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A pilot study to evaluate of the impact on bone density during treatment with mycophenolate mofetil, daclizumab in combination with ciclosporin converted to sirolimus with steroid as mainstay immunosuppression, in comparison to current standard immunosuppression (daclizumab,mycophenolate, ciclosporin and corticosteroids) in renal transplantation. - Bone Protection study</Public_title>
    <Scientific_title>A pilot study to evaluate of the impact on bone density during treatment with mycophenolate mofetil, daclizumab in combination with ciclosporin converted to sirolimus with steroid as mainstay immunosuppression, in comparison to current standard immunosuppression (daclizumab,mycophenolate, ciclosporin and corticosteroids) in renal transplantation. - Bone Protection study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Queen Mary University of London</Primary_sponsor>
    <Date_registration3>20070731</Date_registration3>
    <Date_registration>31/07/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006652-35                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>28/09/2007</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;The enrolled patients must fulfil the following inclusion criteria:&lt;br&gt;1.	Male and female patients between 18 and 75 years of age&lt;br&gt;2.	Patients scheduled for a single-organ, renal transplantation from living or deceased donors. Patient receiving second renal transplants can be included, provided that the previous graft was not lost from acute rejection within the first year. &lt;br&gt;3.	Patients capable of understanding the purposes and risks of the study, who give written informed consent and who are willing to participate to and comply with the study.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;The following groups of patients will not be included in the study:&lt;br&gt;1.	Women lactating, pregnant or of childbearing potential not using a reliable contraceptive method before beginning study drug therapy, during therapy and for 4 months following their last dose of the drugs administered within this clinical study.&lt;br&gt;2.	Patients receiving the third or higher renal transplant.&lt;br&gt;3.	Patients with severe diarrhea or other gastrointestinal disorders that might interfere with their ability to absorb oral medication, including diabetic patients with previously diagnosed diabetic gastroenteropathy.&lt;br&gt;4.	Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study.&lt;br&gt;5.	Patients with evidence of an active systemic infection requiring the continued use of antibiotics or evidence of an HIV infection, or the presence of a chronic active hepatitis B (HBs-Ag positive) or C.&lt;br&gt;6.	Patients with history of malignancy (except successfully treated localized non-melanistic skin cancer).&lt;br&gt;7.	Patients with active peptic ulcer disease.&lt;br&gt;8.	Patients with evidence of an active liver disease &lt;br&gt;9.	Patients with severe anemia (Hb&lt;6 g/dl) leucopenia (WBC&lt;2500/mm3), thrombocytopenia (Tc &lt;100’000/mm3)&lt;br&gt;10.	Patients for whom the investigator considers a treatment with the following medications necessary:&lt;br&gt;-	azathioprine,&lt;br&gt;-	methotrexate,&lt;br&gt;-	cyclophosphamide,&lt;br&gt;-	polyclonal and monoclonal anti-lymphocyte antibodies (e.g. OKT3, ATG), e.g. used for induction in immunological high-risk patients,&lt;br&gt;-	basiliximab,&lt;br&gt;-	mycophenolate - sodium&lt;br&gt;-	other investigational drugs.&lt;br&gt;11.	Known hypersensitivity or absolute contraindications to any of the medications administered in the context of the study or any other substances present in the study medications&lt;br&gt;12.	Panel Reactive Antibody (PRA) &gt; 30% within 6 months prior to enrollment; &lt;br&gt;13.	Cold ischemia time of the graft of more than 30 hours; &lt;br&gt;14.	Patients who had received an investigational new drug within the last three months.&lt;br&gt;15.	Patients previously treated with daclizumab or basiliximab.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal Transplantation &lt;br&gt;MedDRA version: 9.1
Level: PT
Classification code 10038533
Term: Renal transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: Rapamune&lt;br&gt;Product Code: Not available&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: SIROLIMUS&lt;br&gt;CAS Number: 53123889&lt;br&gt;Current Sponsor code: Not available&lt;br&gt;Other descriptive name: N/A&lt;br&gt;Concentration unit: IU/mg international unit(s)/milligram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 6-&lt;br&gt;&lt;br&gt;Trade Name: Zenapax&lt;br&gt;Product Name: Zenapax&lt;br&gt;Product Code: Ro 24-7375&lt;br&gt;Pharmaceutical Form: Intravenous infusion&lt;br&gt;INN or Proposed INN: DACLIZUMAB&lt;br&gt;CAS Number: 152923563&lt;br&gt;Current Sponsor code: Ro-24-7375&lt;br&gt;Other descriptive name: N/A&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: Cellcept&lt;br&gt;Product Name: Cellcept&lt;br&gt;Product Code: Ro 106-1443&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: MYCOPHENOLATE MOFETIL&lt;br&gt;CAS Number: 115007346&lt;br&gt;Current Sponsor code: Ro-106-1443&lt;br&gt;Other descriptive name: MMF&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Trade Name: Sandimune&lt;br&gt;Product Name: Sandimune&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865133&lt;br&gt;Other descriptive name: CsA&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of the present investigation is to evaluate the effect of sirolimus (converted from ciclosporin at 6 weeks) compared to cicolsporin, as part of a standard immunosuppressive regimen, on the severity of bone loss at 12 months post transplant.  .  Current standard immunosuppression (group A: mycophenolate mofetil, dacluzimab, ciclosporin and corticosteroids) will be compared to a CNI conversion regimen (group B: mycophenolate mofetil, dacluzimab, ciclosporin converted to sirolimus at 6 weeks, and corticosteroids).;Secondary Objective: Secondary objectives are:&lt;br&gt;•	To assess the tolerability of patients to the regimens, by recording the % of patients remaining CNI free at 12 months.&lt;br&gt;•	Evaluate the incidence of biopsy proven, type and severity of rejection &lt;br&gt;•	To characterize the safety (hypertension, hyperlipidemia, opportunistic infections, post transplant and diabetes mellitus) of the immunosuppressant combinations at 6 and 12 months.&lt;br&gt;•	To evaluate the renal function as expressed by the calculated creatinine clearance over the course of the study.&lt;br&gt;•	Assess the impact of CNI conversion to sirolimus on MPA AUC in 10 patients in group B.&lt;br&gt;;Primary end point(s): The primary efficacy parameter of the study is to compare the change in bone density between 6 weeks and 12 month post transplant between groups A &amp; B.</Primary_outcome>
    <Secondary_ID>ML 20958</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2463301</Internal_Number>
    <TrialID>EUCTR2007-003369-42-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Etude de phase II randomisée, multicentrique, en ouvert, évaluant l'efficacité de l’association Avastin (bevacizumab) + Torisel (temsirolimus) versus Sutent (sunitinib) versus Avastin+ Roféron(interféron alpha-2a) en première ligne de traitement du cancer du rein métastatique

 - TORAVA</Public_title>
    <Scientific_title>Etude de phase II randomisée, multicentrique, en ouvert, évaluant l'efficacité de l’association Avastin (bevacizumab) + Torisel (temsirolimus) versus Sutent (sunitinib) versus Avastin+ Roféron(interféron alpha-2a) en première ligne de traitement du cancer du rein métastatique

 - TORAVA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>CENTRE LEON BERARD</Primary_sponsor>
    <Date_registration3>20070820</Date_registration3>
    <Date_registration>20/08/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-003369-42                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/10/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1) Homme ou femme âgé de 18 ans ou plus&lt;br&gt;&lt;br&gt;2) Patient porteur d’un adénocarcinome du rein métastatique de toute forme histologique, sauf papillaire. Une preuve cytologique ou histologique, comprenant le grade de Fürhman, est obligatoire&lt;br&gt;&lt;br&gt;3) Patient n’ayant pas subi de traitement systémique antérieur (chimiothérapie, immunothérapie, traitement anti-angiogénique, traitement en cours d’investigation) pour cancer du rein métastatique&lt;br&gt;&lt;br&gt;4) Patient ne présentant pas de métastase cérébrale attestée par une imagerie par résonance magnétique (IRM) ou un scanner dans les 28 jours précédant la randomisation. (Les patients avec des antécédents de métastases cérébrales traitées par chirurgie +/- irradiation cérébrale et présentant une IRM cérébrale normale peuvent être inclus)&lt;br&gt;&lt;br&gt;5) Performance Status Eastern Cooperative Oncology Group (ECOG) &lt; 2&lt;br&gt;&lt;br&gt;6) Maladie mesurable ou non mesurable selon les critères Response Evaluation Criteria in Solid Tumours (RECIST)&lt;br&gt;&lt;br&gt;7) Patient présentant, dans les 7 jours précédant la randomisation, des constantes hématologiques, paramètres fonctionnels rénaux et hépatiques tels que les numérations sanguines ou taux sériques, conformes aux valeurs suivantes :&lt;br&gt;• Hémoglobine &gt; 8 g/dL,&lt;br&gt;• Polynucléaires neutrophiles (PN) &gt; 1,5 G/L,&lt;br&gt;• Plaquettes &gt; 100 G/L,&lt;br&gt;• Créatinine sérique &lt; 200 µmol/L,&lt;br&gt;• Bilirubine totale &lt; 1,5 fois la limite supérieure de la normale (LSN),&lt;br&gt;• Alanine Amino Transférase (ALAT) et Spartate Amino Transférase (ASAT) &lt; 2,5 fois la LSN ou &lt; 5 fois la LSN pour les patients avec métastases hépatiques,&lt;br&gt;• Taux de prothrombine (TP) ou International Normalized Ratio (INR) &lt; 1,5 fois la limite supérieure à la normale en l’absence de traitement anticoagulant. (Les patients sous traitement anticoagulant à titre préventif peuvent être inclus)&lt;br&gt;&lt;br&gt;8) Patient ne présentant pas de protéinurie attestée par bandelette urinaire. Si le test par bandelette est positif au moins 2 fois, la protéinurie sera mesurée sur recueil des urines de 24 heures (le taux de protéines doit être &lt; 1 g/L)&lt;br&gt;&lt;br&gt;9) Pour les femmes en âge de procréer, une méthode contraceptive fiable (contraception hormonale, dispositif intra-utérin, double barrière) est nécessaire&lt;br&gt;&lt;br&gt;10) Patient affilié à un régime de sécurité sociale&lt;br&gt;&lt;br&gt;11) Patient ayant daté et signé le consentement éclairé de participation&lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1) Patient porteur d’un carcinome du rein à forme papillaire pure&lt;br&gt;&lt;br&gt;2) Patient ayant subi un traitement systémique antérieur pour cancer du rein métastatique&lt;br&gt;&lt;br&gt;3) Patient présentant des antécédents d’autre cancer hormis un cancer in situ du col utérin, ou un carcinome cutané basocellulaire traité de manière curative, ou tout autre cancer traité de manière curative et sans signe de récidive pendant au moins 5 ans&lt;br&gt;&lt;br&gt;4) Patient porteur de métastase cérébrale après contrôle tomodensitométrique ou par IRM réalisé dans les 28 jours précédant la randomisation. (Les patients avec antécédents de métastases cérébrales traitées par irradiation cérébrale exclusive ne peuvent être inclus, même avec une IRM cérébrale normale)&lt;br&gt;&lt;br&gt;5) Patient souffrant d’affection cardiovasculaire significative de type insuffisance cardiaque congestive &gt; classe 2 de la New York Heart Association (NYHA), infarctus du myocarde dans les 6 mois précédant la randomisation, angor instable, troubles du rythme graves, accident vasculaire cérébral dans les 6 mois précédant la randomisation, antécédents thromboemboliques sévères dans les 6 mois précédant la randomisation, allongement de l'intervalle QT, bradycardie, troubles électrolytiques, hypertension artérielle non contrôlée par un traitement adapté (PAsystolique = 160 mm Hg et/ou PAdiastolique = 90 mm Hg), (La méthode recommandée pour la mesure de la pression artérielle est la mesure par la méthode auscultatoire, au moyen d'un sphygmomanomètre à mercure, le patient étant depuis plusieurs minutes en position assise ou couchée. La mesure devra être systématiquement répétée au minimum 2 fois)&lt;br&gt;&lt;br&gt;6) Patient souffrant d’affection hépatique de type hépatite chronique évoluée et décompensée, cirrhose hépatique ou hépatite chronique récemment traitée ou en cours de traitement par des agents immunosuppresseurs, hépatite auto-immune ou antécédent de maladie auto-immune&lt;br&gt;&lt;br&gt;7) Patient ayant subi une intervention chirurgicale lourde, une biopsie ouverte, ou porteur d’une plaie non complètement cicatrisée dans les 28 jours précédant la randomisation&lt;br&gt;&lt;br&gt;8) Patient présentant une hypercalcémie non contrôlée par un traitement adapté&lt;br&gt;&lt;br&gt;9) Patient présentant une hypercholestérolémie ou hypertriglycéridémie non contrôlée&lt;br&gt;&lt;br&gt;10) Patient traité par anti-vitamine K au long cours&lt;br&gt;&lt;br&gt;11) Patient traité par inhibiteurs puissants du CYP3A4&lt;br&gt;&lt;br&gt;12) Patient porteur d'une maladie neuropsychiatrique grave ou souffrant de comitialité&lt;br&gt;&lt;br&gt;13) Patient participant à un autre essai thérapeutique, à l’exception des essais de soins de support&lt;br&gt;&lt;br&gt;14) Femme enceinte ou allaitante (un test de grossesse sérique ou urinaire doit être négatif au moment de l’entrée dans l’étude pour toutes les femmes en âge de procréer)&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patient en 1ère ligne de traitement d'un cancer du rein métastique. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050076
Term: Metastatic renal carcinoma
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Avastin&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;&lt;br&gt;Trade Name: TORISEL&lt;br&gt;Product Name: TEMSIROLIMUS&lt;br&gt;Product Code: CCI-779&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;&lt;br&gt;Trade Name: SUTENT&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;&lt;br&gt;Trade Name: ROFERON&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Estimer, chez des patients traités en première ligne d’un cancer du rein métastatique par l’association bevacizumab et temsirolimus, le taux de non progression 48 semaines après le début du traitement;Secondary Objective: Pour les 3 stratégies thérapeutiques :	&lt;br&gt;- estimer les taux de réponse objective et de régression tumorale,&lt;br&gt;- estimer la durée de réponse,&lt;br&gt;- Estimer précocement la réponse tumorale par échographie de contraste avec quantification de la perfusion tumorale (uniquement dans certains centres sélectionnés),&lt;br&gt;- estimer la survie sans progression et la survie globale,&lt;br&gt;- évaluer leur profil de tolérance,&lt;br&gt;- étudier la qualité de vie des patients.&lt;br&gt;&lt;br&gt;;Primary end point(s): 48 SEMAINES APRES LE DEBUT DU TRAITEMENT</Primary_outcome>
    <Secondary_ID>ET2007-035</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2463355</Internal_Number>
    <TrialID>EUCTR2007-004069-16-BE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Hepatic and intestinal CYP3A4/5 activity in renal transplantation.

A study assessing in vivo hepatic and intestinal CYP3A4/5 activity at different time-points and in different clinical settings after renal transplantation and its relationship with genotype, pharmacokinetics and metabolism of Tacrolimus and outcome.</Public_title>
    <Scientific_title>Hepatic and intestinal CYP3A4/5 activity in renal transplantation.

A study assessing in vivo hepatic and intestinal CYP3A4/5 activity at different time-points and in different clinical settings after renal transplantation and its relationship with genotype, pharmacokinetics and metabolism of Tacrolimus and outcome.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Department of Nephrology and Renal Transplantation, KU Leuven</Primary_sponsor>
    <Date_registration3>20071003</Date_registration3>
    <Date_registration>03/10/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004069-16                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/10/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- De novo primary renal allograft recipients.&lt;br&gt;- Chronic stable renal allograft recipients.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Age &lt; 18 years. &lt;br&gt;- Females with child bearing potential, not using an acceptable method of birth control. &lt;br&gt;- Nursing and pregnant women. Pregnancy tests will be performed before drug administration.&lt;br&gt;- Known allergy or intolerance to either Erythromycin or Midazolam.&lt;br&gt;- Concomitant treatment with opioid- or antipsychotic drugs. &lt;br&gt;- Severe chronic lung disease and chronic respiratory insufficiency. &lt;br&gt;- Chronic heart failure. &lt;br&gt;- Severe liver disease. &lt;br&gt;- Anaemia (haemoglobin &lt; 11 g/dL).&lt;br&gt;- Hypoalbuminemia (&lt; 25 g/L).&lt;br&gt;- Combined organ transplants.&lt;br&gt;- Known non-compliance.&lt;br&gt;- Alcohol intake &gt; 7 units/week.&lt;br&gt;- Smoking.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Effect of genetic (single nucleotide polymorphisms of genes encoding  drug metabolising enzymes and drug transporters) and non-genetic factors (e.g. age, time after transplantation, concommitant medication, renal function, liver dysfunction) on in vivo hepatic and intestinal CYP3A4 and 5 activity in renal allograft recipients. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038533
Term: Renal transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Dormicum 5mg/5ml&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: MIDAZOLAM HYDROCHLORIDE&lt;br&gt;CAS Number: 59467968&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Primary end point(s): The effect of genetic and non-genetic factors on the disposition of Midazolam, as a marker of in vivo CYP3A4 and 5 activity, in renal allograft recipients.;Main Objective: To asses in vivo hepatic and intestinal CYP3A4 and 5 activity in renal allograft recipients at different time-points and in different clinical settings after renal transplantation.  ;Secondary Objective: To asses the relationship of in vivo hepatic and intestinal CYP3A4 and 5 activity in renal allograft recipients with:&lt;br&gt;- the recipients genotype.&lt;br&gt;- pharmacokinetics and metabolism of immunosuppressive drugs.&lt;br&gt;- outcome. </Primary_outcome>
    <Secondary_ID>CYP3A4/5RenalTx</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2463391</Internal_Number>
    <TrialID>EUCTR2007-002208-17-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Phase IIa, Multi-Center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DNB-001 in Patients with Angina Pectoris and Moderate Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention</Public_title>
    <Scientific_title>A Phase IIa, Multi-Center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DNB-001 in Patients with Angina Pectoris and Moderate Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Danube Pharmaceuticals</Primary_sponsor>
    <Date_registration3>20070809</Date_registration3>
    <Date_registration>09/08/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-002208-17                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>14/08/2007</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•Males and sterile/post-menopausal = 1 year females aged 18 to 80 years inclusive.&lt;br&gt;&lt;br&gt;•Scheduled for elective percutaneous coronary intervention for angina pectoris (angioplasty with or without stents).&lt;br&gt;&lt;br&gt;•Planned administration of an iodine based contrast agent.&lt;br&gt;&lt;br&gt;•Angina pectoris as classified by the CCS grading system.&lt;br&gt;&lt;br&gt;•Stage III chronic kidney failure as defined by the National Kidney Foundation (NKF).&lt;br&gt;             *	eGFR calculated by the MDRD equation of 30 to 59 mL/min/1.73 m2.&lt;br&gt;&lt;br&gt;•Provide written informed consent.&lt;br&gt;&lt;br&gt;•Ability to return for all trial visits.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•Emergency cardiac catheterization.&lt;br&gt;&lt;br&gt;•Hemodynamic instability (Systolic Blood Pressure &lt; 80 mm Hg, or &gt; 200 mm Hg; Heart Rate &lt; 50 bpm, or &gt; 120 bpm).&lt;br&gt;&lt;br&gt;•Hemodynamic instability (SBP &lt; 80, or &gt; 200; HR &lt; 50, or &gt; 120).&lt;br&gt;&lt;br&gt;•Cardiac biomarkers (cTnI, cTnT) out of reference ranges at the time of screening.&lt;br&gt;&lt;br&gt;•Severe/unstable diabetes requiring emergency room or inpatient therapy for control of diabetes within previous 30 days.&lt;br&gt;&lt;br&gt;•Patients with liver function enzymes (AST, ALT, GGT) out of the normal range at the time of screening.&lt;br&gt;&lt;br&gt;•Serum creatinine greater than 5 mg/dL for males or greater than 4 mg/dL for females.&lt;br&gt;&lt;br&gt;•End-stage renal disease requiring dialysis.&lt;br&gt;&lt;br&gt;•Known acute renal failure at the time of screening.&lt;br&gt;&lt;br&gt;•Acute pulmonary edema.&lt;br&gt;&lt;br&gt;•Administration of contrast agent within previous 48 hours.&lt;br&gt;&lt;br&gt;•Planned re-administration of contrast agent for 28 days post-PCI.&lt;br&gt;&lt;br&gt;•Known allergy to the planned contrast agent.&lt;br&gt;&lt;br&gt;•Planned administration of dopamine, mannitol, or fenoldopam during study.&lt;br&gt;&lt;br&gt;•New therapy or change in dose of a diuretic, ACE inhibitor, or ARB within previous 14 days or during the study.&lt;br&gt;&lt;br&gt;•Planned new therapy or titration of dose of a diuretic, ACE inhibitor, or ARB within previous 14 days, or during the study, EXCEPT as indicated for the periprocedural period.&lt;br&gt;&lt;br&gt;•Any treatment with an investigational agent in the past 60 days for any condition.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Angina pectoris and renal insufficiency whilst undergoing percutaneous coronary intervention (PCI). &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10063886
Term: Renal insufficiency aggravated
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10002384
Term: Angina pectoris aggravated
</Condition>
    <Intervention>&lt;br&gt;Product Name: DNB-001&lt;br&gt;Product Code: DNB-001&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;Current Sponsor code: DNB-001&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 750-&lt;br&gt;Pharmaceutical form of the placebo: Capsule*&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The objective of this study will be to evaluate the potential efficacy and safety of BID dosing of DNB-001 (750 mg) given over 72 hours in patients with angina pectoris and chronic kidney disease undergoing elective PCI. The primary objectives include:&lt;br&gt;&lt;br&gt;•	To evaluate the cardio-protective efficacy of DNB-001 versus placebo, as measured by the change in cardiac biomarkers of myonecrosis (cTnI) from baseline to peak levels post-PCI.&lt;br&gt;&lt;br&gt;•	To evaluate the safety of DNB-001 when used in a patient population with angina pectoris and moderate chronic kidney disease undergoing elective percutaneous coronary intervention (angioplasty +/- stent deployment).&lt;br&gt;&lt;br&gt;;Secondary Objective: •To evaluate the renal-protective efficacy of DNB-001 versus placebo, as measured by the change in SCr (renal function) from baseline to peak level post-PCI. &lt;br&gt;&lt;br&gt;•Composite endpoint of death, MI, or re-hospitalization for acute coronary syndrome within 28 days of treatment.&lt;br&gt;&lt;br&gt;•To evaluate the difference in additional potential biomarkers (CKMB).;Primary end point(s): •The change in cardiac cTnI between the active and placebo arms of the trial from baseline to peak levels post-PCI &lt;br&gt;&lt;br&gt;•The change in renal function (SCr) between the active and placebo arms of the trial from baseline to peak levels post-PCI&lt;br&gt;</Primary_outcome>
    <Secondary_ID>DNB-001-CT002</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2463518</Internal_Number>
    <TrialID>EUCTR2007-002763-27-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A multi-center, randomized, controlled trial with programmed introduction of Sirolimus-based, Calcineurin inhibitor free immunosuppression in recipients of non-heart-beating donor kidney grafts. - PRINS study</Public_title>
    <Scientific_title>A multi-center, randomized, controlled trial with programmed introduction of Sirolimus-based, Calcineurin inhibitor free immunosuppression in recipients of non-heart-beating donor kidney grafts. - PRINS study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Erasmus MC</Primary_sponsor>
    <Date_registration3>20070809</Date_registration3>
    <Date_registration>09/08/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-002763-27                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/09/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Age = 18 years.&lt;br&gt;2.	Acceptable renal function (eGFR Nankivell &gt; 30ml, Proteinuria &lt; 1.0 g/day)&lt;br&gt;3.	3-4 months post renal transplantation with a NHBD graft&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Banff grade &gt; 2 acute or vascular rejection at any time during this transplant pre-randomization&lt;br&gt;2.	Multiple organ transplants (i.e., prior or concurrent transplantation of any organs other than renal transplant)..&lt;br&gt;3.	Evidence of active systemic or localized major infection.&lt;br&gt;4.	Use of any investigational drug or treatment up to 4 weeks prior to transplantation.&lt;br&gt;5.	Planned use of agents with a known interaction with any of the following: sirolimus or its derivatives, macrolide antibiotics, corticosteroids,  tacrolimus, or IMPDH inhibitor. &lt;br&gt;6.	Immunosuppressive therapies other than those described above&lt;br&gt;7.	Planned treatment with voriconazole, cisapride, or ketoconazole, that will not be discontinued prior to randomization.&lt;br&gt;8.	Treatment with aminoglycosides, amphotericin B, cisplatin, or other drugs associated with renal dysfunction that is not discontinued prior to enrolment.&lt;br&gt;9.	Subjects with a screening/baseline total white blood cell count  &lt; 2,000/mm3 or ANC &lt; 1000, platelet count &lt; 100,000/mm3.&lt;br&gt;10.	 Fasting triglycerides &gt; 400 mg/dL (&gt; 4.5 mmol/L) or fasting total cholesterol &gt; 300 mg/dL (&gt; 7.8 mmol/L) despite optimal lipid-lowering therapy.&lt;br&gt;11.	Subjects who are known to be HIV positive and/or subjects with active Hepatitis B or   active Hepatitis C.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Recipients of a renal allograft from a non-heart-beating donor, three months after transplantation. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10023438
Term: Kidney transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: Sirolimus&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: SIROLIMUS&lt;br&gt;CAS Number: 53123889&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1-2&lt;br&gt;&lt;br&gt;Trade Name: Prograft&lt;br&gt;Product Name: Tacrolimus&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987113&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 0.5-5&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the safety and efficacy of a programmed introduction of a Sirolimus-based, Calcineurin inhibitor free, maintenance immunosuppressive regime, three months after renal transplantation in recipients of a non-heart-beating donor kidney graft on: graft function as determined by eGFR and biopsy proven acute rejection rates at twelve months post randomization to programmed Sirolimus introduction&lt;br&gt;;Secondary Objective: Graft and patient survival. Infection rate. Malignancy rate. Dyslipidaemia. Proteinuria rate. Change in selectivity index of proteinuria. Blood pressure. Number of antihypertensive drugs. Cardiovascular event rate.;Primary end point(s): eGFR as determined by Nankivell at month 12 post randomization </Primary_outcome>
    <Secondary_ID>PRINS study</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2463554</Internal_Number>
    <TrialID>EUCTR2007-003092-39-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Pharmacokinetics of colistimethate and colistine after a 60 minutes intravenous infusion of colistimethate 1 million UI (80 mg) in 12 healthy volunteers</Public_title>
    <Scientific_title>Pharmacokinetics of colistimethate and colistine after a 60 minutes intravenous infusion of colistimethate 1 million UI (80 mg) in 12 healthy volunteers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>CHU DE POITIERS</Primary_sponsor>
    <Date_registration3>20070918</Date_registration3>
    <Date_registration>18/09/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-003092-39                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/11/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;-	Subjects aged from 18 to 65, male&lt;br&gt;-	Without major known disease,&lt;br&gt;-	Non smokers or moderate smokers (&lt; 15 cigarettes p. day), &lt;br&gt;-	During the study, subjects accepted to drink 250 ml p. hour during the 4th first hours, then 100 ml p. hour next hours,&lt;br&gt;-	Subjects accepted to feed only with the collations which are proposed to them,&lt;br&gt;-	Non pathologic blood pressure and heart rate,&lt;br&gt;-	A written assent must be signed.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-	Hypersensitivity to colistine or polymyxines,&lt;br&gt;-	Familial or personal known myasthenia,&lt;br&gt;-	Renal, hepatic, cardiac, hematologic, neurologic, psychiatric or digestive known disease &lt;br&gt;-	Asthma or severe allergy ,&lt;br&gt;-	Surgical operation during the previous month,&lt;br&gt;-	Drug or alcohol addiction,&lt;br&gt;-	Previous administration of colistine or other medication. Other planned administration of any medication during the study.&lt;br&gt;-	Blood gift during the previous month&lt;br&gt; -	Positive HIV, HBV et HCV serological status.&lt;br&gt;</Exclusion_Criteria>
    <Condition>kidney infection
genital infection &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10023424
Term: Kidney infection
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10018152
Term: Genital infection bacterial NOS
</Condition>
    <Intervention>&lt;br&gt;Trade Name: COLIMYCINE&lt;br&gt;Product Name: COLIMYCINE&lt;br&gt;Product Code: J01XB01&lt;br&gt;Pharmaceutical Form: Powder for injection*&lt;br&gt;INN or Proposed INN: COLISTIMETHATE SODIQUE&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1,6 -&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Plasmatic and urinary concentrations, pharmacokinetics parameters of colistine and colistimethate. ;Secondary Objective: Evaluation of safety. ;Primary end point(s): Plasmatic and urinary concentrations, pharmacokinetics parameters of colistine and colistimethate. </Primary_outcome>
    <Secondary_ID>PHARMACOLIS</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2463756</Internal_Number>
    <TrialID>EUCTR2007-002102-22-BE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Multicenter, prospective, randomized, open-label study of the safety and efficacy of a Certican® -based regimen versus a calcineurin inhibitor (CNI)-based regimen in maintenance heart transplant recipients with CNI-related renal insufficiency - CeCaRi</Public_title>
    <Scientific_title>Multicenter, prospective, randomized, open-label study of the safety and efficacy of a Certican® -based regimen versus a calcineurin inhibitor (CNI)-based regimen in maintenance heart transplant recipients with CNI-related renal insufficiency - CeCaRi                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Gasthuisberg Leuven</Primary_sponsor>
    <Date_registration3>20070921</Date_registration3>
    <Date_registration>21/09/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-002102-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/10/2007</Date_enrollement>
    <Target_size>150</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Male or female over 18 years old&lt;br&gt;•	Patients who have undergone a heart transplantation at least 12 months ago&lt;br&gt;•	Patients with a calculated GFR (MDRD formula) = 60 ml/min and = 30 ml/min/1.73m2 (CKD stage 3) &lt;br&gt;•	Patients who are willing and capable to participate in the study for 12 months and who have given written informed consent.&lt;br&gt;•	Females capable of becoming pregnant must have a negative pregnancy test within 7 days prior to randomization and are required to practice a medically approved method of birth control for the duration of the study.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	Dialysed patients&lt;br&gt;•	Patients with any treated acute rejection within 6 months prior to randomization&lt;br&gt;•	Patients with an identifiable cause of renal dysfunction other than CNI toxicity&lt;br&gt;•	Patients with platelet count = 75.000/mm3 or white blood cell count = 2.500/mm3 or  hemoglobin value = 8 g/dL&lt;br&gt;•	Patients with proteinuria = 0.8 g/24h&lt;br&gt;•	Presence of a severe hypercholesterolemia (total cholesterol ? 9 mmol/l; ? 350mg/dl) or hypertriglyceridemia (? 8.5 mmol/l, ? 750 mg/dl) despite lipid lowering therapy&lt;br&gt;•	Patients with a current severe systemic infection&lt;br&gt;•	Patients with any history(within the past 5 years) or currently suffering from a malignancy, with an expected life-span of less than 2 years&lt;br&gt;•	Patients currently being treated with a mTOR inhibitor&lt;br&gt;•	Patients with a known intolerance or hypersensitivity to Certican®  (everolimus) or similar drugs.&lt;br&gt;•	Severe hepatic disorders&lt;br&gt;•	Patients suffering from chronic hepatitis C  (PCR positive) or who are HIV- or HBsAg-positive. The result of a laboratory test performed within the 6 months preceding the inclusion must be available.&lt;br&gt;•	Patients with a significant mental illness, which in the opinion of the investigator may interfere with patients’ ability to comply with the protocol.&lt;br&gt;•	Women who are pregnant or breastfeeding&lt;br&gt;•	Patients who have received an investigational drug within 4 weeks prior to study enrolment&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>This study is designed to evaluate whether Certican® initiation, together with discontinuation of calcineurin inhibitors (CNIs) will have a beneficial effect on the renal function in maintenance heart transplant recipients with CNI-related renal impairment, while maintaining efficacy.</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: •	Change in renal function assessed by mGFR  from baseline to month 12 after randomization between the group of patients receiving Certican® and the control group with unchanged CNI-based immunosuppressive treatment.  ;Secondary Objective: •	Incidence of treated acute rejection episodes  &lt;br&gt;•	Proteinuria (protein/creatinine ratio, measured in first morning urine sample)&lt;br&gt;•	Incidence of graft loss/retransplantation&lt;br&gt;•	Patient survival&lt;br&gt;•	Ultrasound left ventricular ejection fraction&lt;br&gt;•	Incidence of MACEs. MACEs include:  acute myocardial infarction, congestive heart failure, percutaneous coronary intervention (PCI), automatic implanted cardiac defibrillator (AICD), coronary artery bypass graft surgery (CABG), cerebral vascular accident, and peripheral vascular disease.  &lt;br&gt;•	Calculated GFR (cGFR n-MDRD formula) change from baseline.&lt;br&gt;•	Ambulatory 24h blood pressure monitoring&lt;br&gt;•	Safety parameters including: hypertension, diabetes mellitus, hyperlipidemia, anemia, infections and malignancies&lt;br&gt;•	Incidence of discontinuations, AEs and SAEs&lt;br&gt;;Primary end point(s): •	Change in renal function assessed by mGFR  from baseline to month 12 after randomization between the group of patients receiving Certican® and the control group with unchanged CNI-based immunosuppressive treatment.  </Primary_outcome>
    <Secondary_ID>CeCaRi </Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2463927</Internal_Number>
    <TrialID>EUCTR2007-005079-32-AT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Treatment of secondary renal amyloidosis A with the Intereleukin – 1 antagonist anakinra</Public_title>
    <Scientific_title>Treatment of secondary renal amyloidosis A with the Intereleukin – 1 antagonist anakinra                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Medical University of Vienna</Primary_sponsor>
    <Date_registration3>20071031</Date_registration3>
    <Date_registration>31/10/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005079-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>04/12/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Biopsy proven renal amyoidosis&lt;br&gt;2.	Serum Amyloid A concentration greater than 25mg/l&lt;br&gt;3.	Estimated GFR between 30 to 90ml/min&lt;br&gt;4.	Men or women aged &gt;18years&lt;br&gt;5.	Provision of informed consent&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Estimated GFR &lt; 30ml/min&lt;br&gt;2.	Kidney disease other than renal amyloidosis&lt;br&gt;3.	Child bearing potential with lack of a reliable method of contraception.&lt;br&gt;4.	Poor compliance&lt;br&gt;5.	Medical history that might limit the individual’s ability to take the trial treatment for the duration of the study. &lt;br&gt;6.	Simultanous administration of TNF-blocking agents (etanercept, adalimumab, and infliximab)&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal Amyloidosis</Condition>
    <Intervention>&lt;br&gt;Trade Name: Kineret&lt;br&gt;Product Name: Kineret&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Secondary Objective: ;Main Objective: Outcome assessment at the end of the study &lt;br&gt;The primary end point  is measurement of kidney function by the estimated glomerular filtration rate and extent of proteinuria as 24h urinary excretion and fractional protein excretion. The results will be compared with the change of eGFR during the preceeding six months, and the mean of two protein excretion measurements at study entry. Progresssion of disease is defined as a significant more rapid decline of eGFR compared to pretreatment values, or a significant higher protein excretion. Improvement of both markers is defined as improvement of the disease, and no change as disease beeing stable. &lt;br&gt;;Primary end point(s): The primary end point  is measurement of kidney function by the estimated glomerular filtration rate and extent of proteinuria as 24h urinary excretion and fractional protein excretion. The results will be compared with the change of eGFR during the preceeding six months, and the mean of two protein excretion measurements at study entry. Progresssion of disease is defined as a significant more rapid decline of eGFR compared to pretreatment values, or a significant higher protein excretion. Improvement of both markers is defined as improvement of the disease, and no change as disease beeing stable. </Primary_outcome>
    <Secondary_ID>00001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2463941</Internal_Number>
    <TrialID>EUCTR2007-005627-15-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Evaluation de l'échographie de contraste pour l'appréciation précoce de l'effet d'un traitement anti-angiogénique sur le carcinome rénal avancé</Public_title>
    <Scientific_title>Evaluation de l'échographie de contraste pour l'appréciation précoce de l'effet d'un traitement anti-angiogénique sur le carcinome rénal avancé                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>CHRU de TOURS</Primary_sponsor>
    <Date_registration3>20071031</Date_registration3>
    <Date_registration>31/10/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005627-15                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/12/2007</Date_enrollement>
    <Target_size>50</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Adénocarcinome rénal métastatique devant recevoir un traitement anti-angiogénique&lt;br&gt;•	Présence d’une lésion cible visible, localisable et mesurable en échographie conventionnelle et scanner / IRM &lt;br&gt;•	Signature du consentement éclairé&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	contre-indication aux traitements anti-angiogéniques&lt;br&gt;•	contre-indication au produit de contraste &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>adenocarcinome rénal métastatique à cellule claire &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050018
Term: Renal cancer metastatic
</Condition>
    <Intervention>&lt;br&gt;Trade Name: SONOVUE&lt;br&gt;Product Name: hexafluorure de soufre&lt;br&gt;Pharmaceutical Form: Powder and solvent for suspension for injection&lt;br&gt;&lt;br&gt;Trade Name: SUTENT&lt;br&gt;Product Name: Sunitinib&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;&lt;br&gt;Trade Name: NEXAVAR&lt;br&gt;Product Name: Sorafénib&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Trade Name: AVASTIN&lt;br&gt;Product Name: Bevacizumab&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Montrer que l’étude fonctionnelle par échographie de contraste de la microvascularisation d’une lésion primitive ou secondaire de patients atteints d’un adénocarcinome rénal, permet d’évaluer précocement l’effet pharmacodynamique d’un traitement antiangiogénique afin de prédire l’efficacité anti-tumorale définie par les critères RECIST;Secondary Objective: - Etudier l'association entre la réponse précoce objectivée au niveau de la lésion cible à partir des paramètres de l’échographie de contraste et la survie sans progression&lt;br&gt;- Etudier l'association entre la réponse précoce objectivée au niveau de la lésion cible à partir des paramètres de l’échographie de contraste et la survie globale&lt;br&gt;- Décrire la tolérance au traitement anti-angiogénique par le suivi des effets indésirables survenant au cours de l’étude.&lt;br&gt;&lt;br&gt;En cas de lésions mesurables multiples : &lt;br&gt;- Etudier l’association  entre les paramètres échographiques mesurés au niveau de la lésion cible  et la réponse au niveau des autres lésions, définie par les critères RECIST.&lt;br&gt;;Primary end point(s): Paramètres mesurés à l’échographie de contraste (à chacun des temps) :&lt;br&gt;•	Seront ainsi déterminés à chaque examen :&lt;br&gt;o	Taille de la lésion : plus grand diamètre, volume global&lt;br&gt;o	Temps d’arrivée de l’agent de contraste dans la lésion&lt;br&gt;o	Temps jusqu’au pic de rehaussement&lt;br&gt;o	Paramètre ß de l’exponentielle de rehaussement&lt;br&gt;o	Densité de microvaisseaux au pic du rehaussement&lt;br&gt;o	Rapport de rehaussement entre la lésion et le parenchyme voisin au pic&lt;br&gt;o	Volumes nécrotique et viable&lt;br&gt;&lt;br&gt;Paramètre de réponse :&lt;br&gt;La réponse tumorale sera évaluée par les critères RECIST&lt;br&gt;&lt;br&gt;</Primary_outcome>
    <Secondary_ID>CIT07-FB/CREIN;CREIN </Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2464016</Internal_Number>
    <TrialID>EUCTR2007-002378-68-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio piloto de Selección de la Inmunosupresión basado en un régimen basado en inhibidores de CNI o libre de CNI dependiendo de la aloreactividad donante-especifica mediante el ensayo ELISPOT en receptores de un injerto renal e bajo riesgo - SIRES</Public_title>
    <Scientific_title>Estudio piloto de Selección de la Inmunosupresión basado en un régimen basado en inhibidores de CNI o libre de CNI dependiendo de la aloreactividad donante-especifica mediante el ensayo ELISPOT en receptores de un injerto renal e bajo riesgo - SIRES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>SERVICIO NEFROLOGIA HOSPITAL BELLVITGE</Primary_sponsor>
    <Date_registration3>20071024</Date_registration3>
    <Date_registration>24/10/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-002378-68                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>30/10/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.Age of donor and recipient  between 18 and 65 years.&lt;br&gt;2.End-stage renal disease and scheduled to receive a primary or secondary renal allograft from a cadaveric, a living-unrelated, or a living-related donor. Patients scheduled for a second transplant must have maintained their primary graft for at least 6 months after transplantation, with the exception of graft failure due to technical reasons.&lt;br&gt;3.PRA = 20%&lt;br&gt;4.Negative cytotoxic T-cell cross-match.&lt;br&gt;5.Women of childbearing potential must have a negative serum pregnancy test before randomization.&lt;br&gt;6.Women of childbearing potential must agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months following discontinuation of assigned treatment.  &lt;br&gt;7.Signed and dated informed consent prior to transplantation.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.Multiple organ transplants &lt;br&gt;2.Recipients of adult or pediatric en bloc kidney transplants or dual transplantation or non-heart beating donors.&lt;br&gt;3.Evidence of active systemic or localized major infection.&lt;br&gt;4.Evidence of infiltrate, cavitation, or consolidation on chest x-ray obtained during the screening/baseline evaluation.&lt;br&gt;5.Use of any investigational drug or treatment up to 4 weeks prior to transplantation.&lt;br&gt;6.Treatment with voriconazole, ketoconazole, itraconazole, fluconazole, clotrimazole, astemizole, pimozide, terfenadine, erythromycin, clarithromycin, telithromycin, troleandomycin, rifampin, rifabutin, or St. John’s Wort that is not discontinued prior to randomization.&lt;br&gt;7.Treatment with aminoglycosides, amphotericin B, cisplatin, cisapride, metoclopramide, cimetidine, bromocriptine, danazol, or other drugs associated with renal dysfunction that are not discontinued prior to randomization.&lt;br&gt;8.Subjects with a screening/baseline total white blood cell count &lt; 2,000/mm3 or ANC &lt; 500, platelet count &lt; 100,000/mm3.&lt;br&gt;9.Fasting triglycerides &gt; 400 mg/dL (&gt; 4.6 mmol/L) or fasting total cholesterol &gt; 300 mg/dL (&gt; 7.8 mmol/L) despite optimal lipid-lowering therapy.&lt;br&gt;10.History of malignancy within 2 years of enrollment (except for adequately treated basal cell or squamous cell carcinoma of the skin).&lt;br&gt;11.Auto-inmune diseases in active inmunosupressive treatment ( 3 months prior to inclusion).&lt;br&gt;12.Patients with psiquiatric disorders that could be non-compliance for the treatment.&lt;br&gt;13. Active peptic ulcers that could produce intestinal absortion disorders.&lt;br&gt;14. Subjects who are known to be HIV or HBV positive ( surface antigen, HBV DNA, or e antigen positive).  Patients with HCV positive should be excluded if PCR positive or transaminates values are =2UNV.&lt;br&gt;15. Diabetic patients.&lt;br&gt;16. Body mass index (BMI) higher than 30 Kg/m2. (See Attachment 5: Nomogram for Determining Body Mass Index).&lt;br&gt;17. Recipients of kidneys from deceased donor after a cardiac arrest.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>PATIENTS THAT RECEIVE A FIRST RENAL ALLOGRAFT TRANSPLANTATION.
 It has been shown that the assessment of the donor specific T-cell alloimmune response can be successfully performed by using new tools, such as the Elispot assay. The aim of this protocol is to make use of the pre-transplant donor specific cellular alloreactivity assessment by the Elispot assay, in order to evaluate if low aloresponders patients can be safely managed with a CNI-free immunosuppression regimen &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10023438
Term: Kidney transplant
</Condition>
    <Intervention>&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: SIROLIMUS&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;INN or Proposed INN: SIROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;INN or Proposed INN: SIROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;INN or Proposed INN: SIROLIMUS&lt;br&gt;CAS Number: 53123889&lt;br&gt;&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,5-&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987113&lt;br&gt;&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: MICOFENOLATO MOFETIL&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;INN or Proposed INN: MICOFENOLATO MOFETIL&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;INN or Proposed INN: MICOFENOLATO MOFETIL&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;INN or Proposed INN: MICOFENOLATO MOFETIL&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;INN or Proposed INN: MYCOPHENOLATE MOFETIL&lt;br&gt;CAS Number: 115007346&lt;br&gt;&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: TIMOGLOBULINA&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To describe cumulative biopsy-confirmed acute rejection at month 6th and month 12th  in both groups by intention to treat analysis.;Secondary Objective: 1.To describe the percentage of steroid-sensitive and resistent acute rejections episodes at month 6 and 12 in both groups by intention to treat analysis.&lt;br&gt;2.To describe renal function measured by MDRD at month 12 and 24 in both groups.&lt;br&gt;4.To describe proteinuria in g/day at month 6and 12 in both groups.&lt;br&gt;5.To describe histology at month 6 in both groups .&lt;br&gt;6.To describe percentage of patients with negative ELISPOT at 6 and 12 months in both groups-&lt;br&gt;7.To describe the percentage of patients in group A requiring CNI introduction. &lt;br&gt;8.To describe adverse events in the whole group.&lt;br&gt;9. To assess if low pre-transplantation donor specific T-cell reactive patients measured by ELISPOT can be safely managed with CNI-free SRL-based immunossuppression.&lt;br&gt;10.To assess if post-transplant donor specific T-cell alloresponse monitoring together with graft histology assessment could be useful for minimization or strengthen the immunosuppressive therapy in month 6.;Primary end point(s): To describe cumulative biopsy-confirmed acute rejection at month 6th after transplantation and month 12th  in both groups by intention to treat analysis.</Primary_outcome>
    <Secondary_ID>SIRES</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2464056</Internal_Number>
    <TrialID>EUCTR2007-001394-29-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Multi-center, prospective trial to demonstrate Improved Metabolic control of PPEN vs DDDD in DIAbetic CAPD patients -The IMPENDIA Trial - IMPENDIA</Public_title>
    <Scientific_title>Multi-center, prospective trial to demonstrate Improved Metabolic control of PPEN vs DDDD in DIAbetic CAPD patients -The IMPENDIA Trial - IMPENDIA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Baxter Healthcare Corporation</Primary_sponsor>
    <Date_registration3>20071120</Date_registration3>
    <Date_registration>20/11/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001394-29                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>28/12/2007</Date_enrollement>
    <Target_size>236</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Dianeal&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients who meet ALL of the following criteria at both Screening and randomization are eligible for the study:&lt;br&gt;1.	Male or female patients who are at least 18 years of age&lt;br&gt;2.	Patients who have read, understood and given written Informed Consent after the nature of the study has been explained&lt;br&gt;3.	Patients who have a diagnosis of ESRD (GFR = 15 mL/min)&lt;br&gt;4.	Patients performing CAPD using only Dianeal, a daily prescription including at least 1 exchange of Dianeal 2.5% or 4.25% dextrose (2.27% or 3.86% glucose, respectively), for at least 30 days prior to Screening and who have no prescribed dry time&lt;br&gt;5.	Patients who are in a stable clinical condition in the judgment of the treating physician and as demonstrated by medical history, physical examination, and laboratory testing&lt;br&gt;6.	Incident and prevalent patients with diagnosed diabetes (Type 1 and Type 2), as verified by the treating physician, and who have received glycemic-control medication, i.e., insulin and/or oral hypoglycemic agents, for at least 90 days prior to Screening&lt;br&gt;7.	Patients with an HbA1c &gt; 6.0% but = 10.0% (to be determined at the Screening visit using regional central laboratories and reported according to the Diabetes Control and Complications Trial (DCCT)/National Glycohemoglobin Standardization Program (NGSP) standard)&lt;br&gt;8.	Patients who have a blood hemoglobin concentration = 9.0 g/dL, but = 13.0 g/dL (to be determined at screening visit using local lab)&lt;br&gt;9.	Patients with a total Kt/V = 1.7 at Screening&lt;br&gt;10.	Patients who are expected to remain on CAPD for at least 6 months&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients who have any of the following at the time of either Screening or randomization are not eligible for enrollment in this study.&lt;br&gt;1.	Patients performing Automated Peritoneal Dialysis (APD)&lt;br&gt;2.	Female patients who are pregnant, lactating or planning to become pregnant during the study period.  Note:  Female patients of childbearing potential must not be pregnant and not lactating.  They must also have a negative serum human chorionic gonadotropin (hCG) pregnancy test result prior to receiving any dose of study medication (14 day window).  Women of childbearing potential are defined as women less than 55 years old who have not had a partial or full hysterectomy or oophorectomy.  Patients are required to use medically acceptable means of contraception during their participation in this study.&lt;br&gt;3.	Patients with concomitant participation in any other interventional study &lt;br&gt;4.	Patients who have used any investigational device or received any investigational drug, biologic within five half-lives of the physiological action (if drug or biologic) or 30 days prior to Screening, whichever is longer&lt;br&gt;5.	Patients who have previously participated in this study&lt;br&gt;6.	Patients who have previously participated in the PRePEND study&lt;br&gt;7.	Patients who have had an acute myocardial infarction (MI) with hospitalization, coronary bypass surgery, or acute coronary ischemia with percutaneous transluminal coronary angioplasty (PTCA)/stent within the last 90 days&lt;br&gt;8.	Patients who have had a failed kidney transplant without nephrectomy of the graft&lt;br&gt;9.	Patients who have a history of abdominal fistulae, tumors, open wounds, herniae, or other conditions, which compromised the integrity of the abdominal wall, abdominal surface, or intra-abdominal cavity, within the last 30 days&lt;br&gt;10.	Patients who have undergone abdominal surgery within the last 30 days except for PD catheter insertion&lt;br&gt;11.	Patients who are receiving or have received Calcineurin inhibitors (e.g., cyclosporin) or corticosteroids within the last 90 days&lt;br&gt;12.	Patients who have any other serious acute or active conditions that in the investigator’s opinion would preclude their participation in the study&lt;br&gt;13.	Patients who have a history of drug, or alcohol abuse in the last six months&lt;br&gt;14.	Patients who have active liver disease such as cirrhosis of the liver, active hepatitis or other active liver disease as evidenced by biopsy, laboratory (unstable liver enzymes over the last 90 days) or clinical examination&lt;br&gt;15.	Patients who have active infectious conditions, including but not limited to septicemia and pneumonia, within the last 90 days&lt;br&gt;16.	Patients who have ongoing clinically significant congestive heart failure (New York Heart Association [NYHA] class III or IV)&lt;br&gt;17.	Patients who have malignancy or other severe co-morbidity associated with a life expectancy of less than 1 year&lt;br&gt;18.	Patients who have had an episode of life threatening systemic infection, or other serious disease, such as active, or previously treated, residual malignancy (exceptions - malignant free for two years or life threatening systemic infection free for 90 days)&lt;br&gt;19.	Patients who have any medical condition that, in the judgment of the Investigator, would jeopardize the patient’s safety following exposure to the study drugs, or in the judgment of the Investigator, will not be able to tolerate one of the solution regimens (i.e., DDDD or PPEN)&lt;br&gt;20.	Patients who are allergic to starch-based polymers&lt;br&gt;21.	Patients who have glycogen storage disease&lt;br&gt;22.	</Exclusion_Criteria>
    <Condition>End stage renal disease patients with Diabetes Type I and II on Continuous Ambulatory Peritoneal Dialysis &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10012660
Term: Diabetic end stage renal disease
</Condition>
    <Intervention>&lt;br&gt;Trade Name: EXTRANEAL, solution pour dialyse péritonéale&lt;br&gt;Product Name: EXTRANEAL&lt;br&gt;Pharmaceutical Form: Solution for peritoneal dialysis&lt;br&gt;INN or Proposed INN: Icodextrin&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 75.0-&lt;br&gt;INN or Proposed INN: Sodium chloride&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5.40-&lt;br&gt;INN or Proposed INN: Calcium chloride dihydrate&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.257-&lt;br&gt;INN or Proposed INN: Magnesium chloride hexahydrate&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.051-&lt;br&gt;INN or Proposed INN: Sodium lactate solution&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 4.50-&lt;br&gt;&lt;br&gt;Trade Name: NUTRINEAL PD4 à 1.1% d'acides aminés, solution pour dialyse péritonéale&lt;br&gt;Product Name: NUTRINEAL&lt;br&gt;Pharmaceutical Form: Solution for peritoneal dialysis&lt;br&gt;INN or Proposed INN: L-alanin&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.951-&lt;br&gt;INN or Proposed INN: L-arginin&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.071-&lt;br&gt;INN or Proposed INN: L-glycin&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.51-&lt;br&gt;INN or Proposed INN: L-histidin&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.714-&lt;br&gt;INN or Proposed INN: L-isoleucin&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.850-&lt;br&gt;INN or Proposed INN: L-leucin&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.020-&lt;br&gt;INN or Proposed INN: L-lysin chlorydrate&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.955-&lt;br&gt;INN or Proposed INN: L-methionin&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.850-&lt;br&gt;INN or Proposed INN: </Intervention>
    <Primary_outcome>Main Objective: The primary objective of this study is to demonstrate that use of glucose-sparing prescriptions (PPEN vs DDDD) in diabetic (Type 1 and Type 2) Continuous Ambulatory Peritoneal Dialysis (CAPD) patients leads to improved metabolic control as measured by the magnitude of change from the baseline value for HbA1c levels.;Secondary Objective: The secondary objectives of the study are to demonstrate that use of glucose-sparing (i.e., 2nd generation) PD solutions prescriptions (PPEN vs DDDD) in diabetic (Type 1 and Type 2) CAPD patients leads to lower glycemic-control medication requirements, decreased incidence of severe hypoglycemic events requiring medical intervention, improved metabolic control, improved nutritional status, and improvement in Quality of Life.  In a subgroup of patients, the impact of glucose-sparing PD solutions (PPEN vs DDDD) on abdominal fat and left ventricular (LV) structure and function will be assessed.&lt;br&gt;The exploratory objectives of the study are to assess the impact of glucose-sparing PD solutions prescriptions (PPEN vs DDDD) in the study population on advanced glycation end-products (AGEs) and fructosamine, on insulin action, on markers of systemic inflammation, and on markers of membrane status.;Primary end point(s): The primary efficacy assessment is change from the baseline value of HbA1c at Months 2, 4, and 6, which will be measured using a Tina-quant® immunological assay for HbA1c (Roche Diagnostic) suitable for samples from ESRD patients and with icodextrin metabolites or equivalent.  HbA1c analysis for primary efficacy assessment will be performed at Baxter’s Clinical Laboratory Services, Technology Resources, Round Lake, IL.</Primary_outcome>
    <Secondary_ID>31998</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2464120</Internal_Number>
    <TrialID>EUCTR2007-005757-28-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Etude française multi-centrique évaluant le maintien du taux d’hémoglobine avec une administration sous-cutanée mensuelle de C.E.R.A. (activateur continu du récepteur de l’érythropoïétine) chez des patients insuffisants rénaux chroniques non dialysés - PRADO</Public_title>
    <Scientific_title>Etude française multi-centrique évaluant le maintien du taux d’hémoglobine avec une administration sous-cutanée mensuelle de C.E.R.A. (activateur continu du récepteur de l’érythropoïétine) chez des patients insuffisants rénaux chroniques non dialysés - PRADO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Roche</Primary_sponsor>
    <Date_registration3>20071126</Date_registration3>
    <Date_registration>26/11/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005757-28                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/01/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Relatifs à la population :&lt;br&gt;•Patient ayant délivré un consentement de participation écrit&lt;br&gt;•Patient apte selon l'investigateur à se plier aux impératifs de l'étude&lt;br&gt;•Patient affilié à un régime de sécurité sociale ou bénéficiaire d'un tel régime&lt;br&gt;•Patient adulte âgé de plus de 18 ans&lt;br&gt;&lt;br&gt;Relatifs à la pathologie :&lt;br&gt;•Patient atteint d’une insuffisance rénale chronique stade 3 = clairance créatinine (CrCl)/Taux de filtration glomérulaire (GFR) &lt; 60 mL/min et = 30 mL/min (calculée et corrigée selon Cockcroft-Gault) ou stade 4 = CrCl/GFR &lt; 30 mL/min et = 15 mL/min (calculée et corrigée selon Cockcroft-Gault) confirmée à la valeur de baseline soit à la semaine -4 associée à une anémie, et non dialysé &lt;br&gt;•Patient ayant un taux moyen d’hémoglobine (Hb) compris entre [10;12] g/dL sur les 3 valeurs de la période de baseline (semaines -4, -2 et J0)&lt;br&gt;•Patient ayant un traitement de maintenance continu en sous-cutané par epoetin beta ou darbepoetin alfa avec la même fréquence d’administration et sans modification de la dose totale hebdomadaire (calculée) dans les 4 semaines avant et pendant la période de baseline &lt;br&gt;•Patient ayant un statut martial adéquat: ferritine sérique &gt; 100 ng/mL et TSAT &gt; 20% (ou pourcentage de globules rouges hypochromes &lt; 10%) &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Relatifs à la population :&lt;br&gt;•Femme enceinte ou allaitant&lt;br&gt;•Femme en période d’activité génitale sans contraception efficace&lt;br&gt;•Patient atteint d’une déficience ne lui permettant pas une bonne compréhension des impératifs de l’essai&lt;br&gt;•Patient ayant déjà été inclus dans le présent essai&lt;br&gt;•Patient participant ou ayant participé à un essai clinique dans les 3 derniers mois&lt;br&gt;&lt;br&gt;Relatifs au traitement à l’essai :&lt;br&gt;•Patient présentant un saignement aigu ou chronique significatif, comme un saignement d’origine gastro-intestinale &lt;br&gt;•Patient recevant une ou plusieurs transfusion de culots globulaires dans les 8 semaines précédant la période de baseline&lt;br&gt;•Patient ayant une dose hebdomadaire d’epoetin beta &gt; 16000UI ou une dose hebdomadaire de darbepoetin alfa &gt; 80µg dans les 4 semaines avant et pendant la période de baseline (soit 8 semaines avant l’inclusion)&lt;br&gt;•Patient présentant un greffon allogénique en place&lt;br&gt;•Patient présentant une hémoglobinopathie (anémie falciforme homozygote, thalassémie de tous types)&lt;br&gt;•Patient présentant une hémolyse (haptoglobine &lt; 30mg/dL ou autre test d’hémolyse)&lt;br&gt;•Patient présentant une maladie maligne active dans les 5 dernières années (excepté les cancers cutanés hors mélanome) &lt;br&gt;•Patient ayant un déficit connu en Vitamine B12 &lt;br&gt;•Patient ayant un déficit connu en acide folique &lt;br&gt;•Patient ayant une hyperparathyroïdie secondaire non contrôlée ou symptomatique &lt;br&gt;•Patient présentant une hypertension artérielle mal contrôlée, c’est-à-dire une pression artérielle assise &gt; 170/100 mmHg et nécessitant une interruption de traitement par ASE  dans les 6 mois précédant la période de baseline&lt;br&gt;•Patient présentant une crise d’épilepsie dans les 6 mois précédant la période de baseline&lt;br&gt;•Patient présentant un infarctus du myocarde, un accident vasculaire cérébral, une coronaropathie sévère ou instable, une maladie hépatique sévère dans les 12 semaines précédant la période de baseline&lt;br&gt;•Patient présentant une insuffisance cardiaque congestive (stade III-IV de la New York Heart Association)&lt;br&gt;•Patient présentant un nombre de plaquettes &gt; 500 x 10 9/L ou &lt; 100 x   10 9/L&lt;br&gt;•Patient présentant une érythroblastopénie&lt;br&gt;•Patient ayant une chirurgie planifiée pendant la durée de l’étude excepté pour la cataracte et pour la voie d’abord vasculaire&lt;br&gt;•Patient présentant une hypersensibilité connue à une érythropoïétine recombinante, au polyéthylène glycol ou tout autre constituant du traitement à l’étude&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Anémie symptomatique de l'insuffisance rénale chronique &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10054353
Term: Chronic renal failure anemia
</Condition>
    <Intervention>&lt;br&gt;Trade Name: MIRCERA&lt;br&gt;Product Code: RO 503821/F03&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyéthylène glycol-epoetin bêta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: MIRCERA&lt;br&gt;Product Code: RO 503821/F04&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyéthylène glycol-epoetin bêta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 75-&lt;br&gt;&lt;br&gt;Trade Name: MIRCERA&lt;br&gt;Product Code: RO 503821/F05&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyéthylène glycol-epoetin bêta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Code: RO 503821/F21&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyéthylène glycol-epoetin bêta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 120-&lt;br&gt;&lt;br&gt;Trade Name: MIRCERA&lt;br&gt;Product Code: RO 503821/F06&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyéthylène glycol-epoetin bêta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 150-&lt;br&gt;&lt;br&gt;Trade Name: MIRCERA&lt;br&gt;Product Code: RO 503821/F07&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyéthylène glycol-epoetin bêta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: MIRCERA&lt;br&gt;Product Code: RO 503821/F08&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyéthylène glycol-epoetin bêta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-</Intervention>
    <Primary_outcome>Main Objective: Evaluer le maintien du taux d’hémoglobine avec une administration sous-cutanée mensuelle de C.E.R.A. chez des patients insuffisants rénaux chroniques non dialysés.;Secondary Objective: Evaluer la variabilité de l’hémoglobine avec une administration sous-cutanée mensuelle de C.E.R.A. dans cette population de patients.&lt;br&gt;&lt;br&gt;Evaluer la tolérance avec une administration sous-cutanée mensuelle de C.E.R.A. dans cette population de patients.&lt;br&gt;;Primary end point(s): Proportion de patients maintenant un taux d’hémoglobine moyen dans l’intervalle [10;12] g/dL pendant la période d’évaluation (S16 à S24)</Primary_outcome>
    <Secondary_ID>ML21146</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2464121</Internal_Number>
    <TrialID>EUCTR2007-003114-34-BE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>The impact of oral curcumin (Curcuma longa) on mycophenolic acid and metabolite pharmacokinetics in stable renal allograft recipients: exploratory investigation of the role of intestinal uridine-diphosphate-glucuronosyltransferases (UGTs) in in vivo mycophenolic acid disposition.</Public_title>
    <Scientific_title>The impact of oral curcumin (Curcuma longa) on mycophenolic acid and metabolite pharmacokinetics in stable renal allograft recipients: exploratory investigation of the role of intestinal uridine-diphosphate-glucuronosyltransferases (UGTs) in in vivo mycophenolic acid disposition.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Department of Nephrology and Renal Transplantation, University Hospitals Leuven</Primary_sponsor>
    <Date_registration3>20071126</Date_registration3>
    <Date_registration>26/11/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-003114-34                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>29/11/2007</Date_enrollement>
    <Target_size>12</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Primary and secondary renal allograft recipients.&lt;br&gt;Stable (clinically and biochemically) renal transplant patients.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Age &lt; 18 yrs of age.&lt;br&gt;Combined solid organ transplantations.&lt;br&gt;History of medical or surgical diseases of the gastrointestinal and hepato-biliary tract.&lt;br&gt;Recipients with active infectious or inflammatory disease as well as anti-infectious or anti-inflammatory treatment for at least 2 weeks prior to enrolment.&lt;br&gt;Severe hypoalbuminemia (&lt; 25 g/L).&lt;br&gt;Severe anemia (&lt; 8 g/dL).&lt;br&gt;Patients with documented non-compliance.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Stable renal allograft recipients</Condition>
    <Intervention>&lt;br&gt;Trade Name: C3 Complex&lt;br&gt;Product Name: Curcumin&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;Other descriptive name: Curcumin longa&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: not less then&lt;br&gt;Concentration number: 95%-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Assessing the impact of oral curcumin (Curcuma longa) on mycophenolic acid and metabolite pharmacokinetics in stable renal allograft recipients. ;Secondary Objective: Investigate the role of intestinal uridine-diphosphate-glucuronosyltransferases (UGTs) in in vivo mycophenolic acid disposition. ;Primary end point(s): Differences in mycophenolic acid and metabolite pharmacokinetics in stable renal allograft recipients before and after 7 days administration of Curcumin longa.</Primary_outcome>
    <Secondary_ID>CUR001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2464203</Internal_Number>
    <TrialID>EUCTR2007-004875-21-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Phase II, Multi-centre, Open-label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Intrapatient Dose Escalation of Sorafenib as First Line Treatment for Metastatic Renal Cell Carcinoma</Public_title>
    <Scientific_title>A Phase II, Multi-centre, Open-label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Intrapatient Dose Escalation of Sorafenib as First Line Treatment for Metastatic Renal Cell Carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Bayer Healthcare AG, D-51368 Leverkusen, Germany</Primary_sponsor>
    <Date_registration3>20071207</Date_registration3>
    <Date_registration>07/12/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004875-21                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>21/01/2008</Date_enrollement>
    <Target_size>90</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Age &gt; 18 years. &lt;br&gt;•	Histological or cytological documentation of metastatic and/or unresectable clear cell RCC is required&lt;br&gt;•	Subjects with at least one uni-dimensional measurable lesion. Lesions must be measured by CT-scan or MRI according to Response Evaluation Criteria in Solid Tumours (RECIST).&lt;br&gt;•	ECOG Performance Status of 0 or 1&lt;br&gt;•	MSKCC good or intermediate category&lt;br&gt;•	Life expectancy of at least 12 weeks.&lt;br&gt;•	Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:&lt;br&gt;•	Hemoglobin &gt; 9.0 g/dl &lt;br&gt;•	Absolute neutrophil count (ANC) &gt;1,500/mm3  &lt;br&gt;•	Platelet count ? 100,000/?l &lt;br&gt;•	Total bilirubin &lt; 1.5 times the upper limit of normal &lt;br&gt;•	ALT and AST &lt; 2.5 x upper limit of normal (&lt; 5 x upper limit of normal for subjects with liver involvement of their cancer)&lt;br&gt;•	Alkaline phosphatase &lt;  2.5 x ULN &lt;br&gt;	PT-INR/PTT &lt; 1.5 x upper limit of normal.  Subjects who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists. For subjects on warfarin, close monitoring of at least weekly evaluations will be performed until INR is stable based on a measurement at pre dose, as defined by the local standard of care (exluding subjects being anticaogulated for deep vein thrombosis and/or pulmonary embolus occurring  within 12 months of the start of treatment).&lt;br&gt;•	Serum creatinine &lt; 1.5 x upper limit of normal &lt;br&gt;•	Signed informed consent must be obtained prior to any study specific procedures.&lt;br&gt;•	Subjects must have received no prior systemic anticancer therapy for the treatment of their renal cell carcinoma&lt;br&gt;•	Prior nephrectomy&lt;br&gt;•	Prior palliative radiotherapy to metastatic lesion(s) is permitted&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) &lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) &lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	History of cardiac disease;&lt;br&gt;•	congestive heart failure &gt;NYHA class 2&lt;br&gt;•	active CAD (MI more than 6 mo prior to study entry is allowed)&lt;br&gt;•	 cardiac arrhythmias requiring  anti-arrhythmic therapy( beta blockers or digoxin are permitted) &lt;br&gt;•	uncontrolled hypertension (defined as blood pressure &gt;160mmHg systolic and/or &gt; 90mmHg diastolic on medication) &lt;br&gt;•	History of HIV infection or chronic hepatitis B or C &lt;br&gt;•	Active clinically serious infections (&gt; grade 2 NCI-CTCAE version 3.0) &lt;br&gt;•	Symptomatic metastatic brain or meningeal tumors unless the subject is &gt; 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry.  Also the subject must not be undergoing acute steroid therapy or taper therapy (chronic steroid therapy is acceptable provided that the dose is stable for one month prior to and following screening radiographic studies) &lt;br&gt;•	Subjects with seizure disorder requiring medication (such as steroids or anti-epileptics)&lt;br&gt;•	History of organ allograft &lt;br&gt;•	Subjects with evidence or history of bleeding diathesis&lt;br&gt;•	Deep vein thrombosis and/or pulmonary embolus within 12 months of the start of treatment.&lt;br&gt;•	Delayed healing of wounds, ulcers or bone fractures&lt;br&gt;•	Subjects with pre-existing thyroid abnormality whose thyroid function cannot be maintained within the normal range by medication &lt;br&gt;•	Subjects undergoing renal dialysis&lt;br&gt;•	Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis &amp; T1] or any cancer curatively treated &gt; 3 years prior to study entry.&lt;br&gt;•	Any condition that is unstable or could jeopardize the safety of the subject and their compliance in the study&lt;br&gt;•	Pregnant or breast-feeding subjects.  Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment.  Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and three months after the completion of trial. The investigator is requested to advise the subject how to achieve an adequate contraception.    &lt;br&gt;&lt;br&gt;•	Subjects unable to swallow oral medications. This applies to subjects with severe obstruction of upper GI that require gavage.&lt;br&gt;Excluded therapies and medications, previous and concomitant:&lt;br&gt;•	Any prior systemic anticancer therapy including cytotoxic therapy, targeted agents, experimental therapy (adjuvant or neo-adjuvant therapy including IFN-IL2-5FU is permitted).&lt;br&gt;•	Prior adjuvant sorafenib is excluded.&lt;br&gt;•	Radiotherapy during study or within 3 weeks of start of study drug&lt;br&gt;•	 Major surgery within 4 weeks of start of study &lt;br&gt;•	Autologous bone marrow transplant or stem cell rescue within 4 months of study &lt;br&gt;•	Use of biologic response modifiers, such as G-CSF, within 3 week of study entry. [G-CSF and other hematopoietic growth factors may be used in the management of acute toxicity such as febrile neutropenia when clinically indicated or at the discretion of the investigator, however they may not be substituted for a required dose reduction.]  Subjects taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within 2 months prior to the study or during the study.&lt;br&gt;•	Investigational drug therapy outside of this trial during or within 4 weeks of study entry&lt;br&gt;•	Subst</Exclusion_Criteria>
    <Condition>renal cell carcinoma &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050513
Term: Metastatic renal cell carcinoma
</Condition>
    <Intervention>&lt;br&gt;Trade Name: NEXAVAR&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: sorafenib&lt;br&gt;CAS Number: 28844-1-73-1&lt;br&gt;Current Sponsor code: BAY 43-9006&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The objective of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of intrapatient dose escalation in previously untreated subjects with mRCC.  The initial dose of sorafenib will be 400mg bid administered orally, on a continuous basis.  Intrapatient dose escalation will occur as defined in the table below, providing no grade 3 or 4 toxicities (except for alopecia, nausea and vomiting) are observed. &lt;br&gt;&lt;br&gt;The primary objective is to assess the response rates (by independent assessment)  observed in subjects treated with a continuous, daily dose of 400 mg bid sorafenib dose escalated up to 800mg bid. ;Secondary Objective: The secondary objectives are to assess the following:&lt;br&gt;•	Safety and tolerability&lt;br&gt;•	Pharmacokinetics &lt;br&gt;•	Progression free survival (PFS)&lt;br&gt;•	Time to progression (TTP)&lt;br&gt;	;Primary end point(s): Primary end point is to assess the response rates observed for patients treated with continuous daily dose of sorafenib escalated from 400mg to 600mg to a maximum of 800mg bid.</Primary_outcome>
    <Secondary_ID>BAY 43-9006 / 12913</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2464205</Internal_Number>
    <TrialID>EUCTR2007-001755-19-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A double-blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy - Benfotiamine in Diabetic Nephropathy</Public_title>
    <Scientific_title>A double-blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy - Benfotiamine in Diabetic Nephropathy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>UMCG</Primary_sponsor>
    <Date_registration3>20071026</Date_registration3>
    <Date_registration>26/10/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001755-19                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>15/11/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;• Diabetes mellitus, with onset of disease after the age of 40 years&lt;br&gt;• Age: 50-70 years&lt;br&gt;• Patients are on treatment with angiotensin converting enzyme inhibitors (ACEi) and/or angiotensin II antagonists (AIIA) in an unchanged dose for at least 3 months&lt;br&gt;• Active diabetic nephropathy as indicated by presence of microalbuminuria (30-300 mg/24 h urine) in at least two samples within 2-6 weeks in advance of inclusion in the trial&lt;br&gt;• HbA1c &lt; 8.5%, a higher HbA1c ? 9.5% is acceptable if the treating physician and the patient have accepted that striving for lower values is an unreachable goal (patients with high HbA1c values are the ones that one would expect to be benefit most from treatment with benfotiamine)&lt;br&gt;• eGFR (estimated by MDRD formula) &gt; 30 ml/min&lt;br&gt;• Males and postmenopausal females&lt;br&gt;• Written informed consent&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;• Renal impairment by other causes than diabetes&lt;br&gt;• Stage of the disease more severe than indicated in "Inclusion criteria"&lt;br&gt;(macroalbuminuria or renal insufficiency)&lt;br&gt;• Severe hypoglycemia during the last 3 months, needing help from another person&lt;br&gt;• Severe hepatopathy (liver function enzymes about three times higher than normal)&lt;br&gt;• Endocrine disorders, e.g. hyper-/hypothyroidism&lt;br&gt;• Blood pressure &gt; 160/90 mmHg&lt;br&gt;• Severe cardiac function disturbances and severe heart rhythm disturbances&lt;br&gt;• Neoplasm&lt;br&gt;• Severe general diseases or mental disorders making the participation in the study&lt;br&gt;impossible&lt;br&gt;• Drug abuse&lt;br&gt;• Female patients during pregnancy and lactation period and female patients with active menses during the past year&lt;br&gt;• Hypersensitivity to benfotiamine or other constituents of the study medication&lt;br&gt;• HbA1c &gt;9.5%&lt;br&gt;• Use of vitamin B containing supplements during the last 3 months&lt;br&gt;• Use of NSAIDs more than 3x per week (including self-medication)&lt;br&gt;• Participation in another study within one month before joining the benfotiamine&lt;br&gt;study&lt;br&gt;</Exclusion_Criteria>
    <Condition>Diabetic nephropathy is a serious complication of diabetes mellitus, which is the leading cause of end-stage renal disease (ESRD).
Benfotiamine has been shown to reduce diabetic nephropathy and retinopathy in animal experimental models. 
We investigate the effect of benfotiamine supplementation in patients with diabetic nephropathy, and hypothesize that it will slow down the progression to ESRD.</Condition>
    <Intervention>&lt;br&gt;Trade Name: Milgamma mono 300&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To investigate whether short-term treatment (3 months) with benfotiamine leads to a reduction in urinary excretion of ß2-microglobulin and albumin.;Secondary Objective: To investigate whether short-term treatment (3 months) with benfotiamine leads to reduction in urinary excretion of markers of renal tubulointerstitial damage and inflammation (Kidney Injury Molecule-1, Monocyte Chemo-attractant Protein-1, Macrophage Inhibiting Factor, Complement factor C3d);Primary end point(s): Change in urinary excretion of (measured in 24-hour urine):&lt;br&gt;• ß2-microglobulin&lt;br&gt;• Albumin</Primary_outcome>
    <Secondary_ID>BENFO-1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2464331</Internal_Number>
    <TrialID>EUCTR2007-005083-28-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio de fase II, aleatorizado, abierto, multicéntrico, para evaluar la eficacia de sorafenib solo y sorafenib en combinación con interferón alfa-2a a dosis bajas como tratamiento de segunda línea tras el fracaso a sunitinib en pacientes con carcinoma metastásico de células renales (CCR) 
(A Phase II, Randomized, Open-label, MultiCenter, Study Evaluating the Efficacy of SOrafenib AloNe and Sorafenib in Combination with Low DosE InterfeRon Alpha-2a as Second-line Treatment of Sunitinib Failure in Patients with Metastatic Renal Cell Carcinoma (RCC))
 - CONCERT</Public_title>
    <Scientific_title>Estudio de fase II, aleatorizado, abierto, multicéntrico, para evaluar la eficacia de sorafenib solo y sorafenib en combinación con interferón alfa-2a a dosis bajas como tratamiento de segunda línea tras el fracaso a sunitinib en pacientes con carcinoma metastásico de células renales (CCR) 
(A Phase II, Randomized, Open-label, MultiCenter, Study Evaluating the Efficacy of SOrafenib AloNe and Sorafenib in Combination with Low DosE InterfeRon Alpha-2a as Second-line Treatment of Sunitinib Failure in Patients with Metastatic Renal Cell Carcinoma (RCC))
 - CONCERT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Bayer Healthcare AG, Leverkusen</Primary_sponsor>
    <Date_registration3>20071228</Date_registration3>
    <Date_registration>28/12/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005083-28                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>27/02/2008</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Sorafenib with or without low dose interferon alpha-2a&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Disease progression as defined by RECIST criteria following documented stable disease or better after at least 8 weeks of sunitinib as first-line treatment (or two cycles of 4 weeks on and 2 weeks off treatment)&lt;br&gt;•	And/or patients who have discontinued sunitinib treatment at any point due to toxicity&lt;br&gt;•	Study entry at least 2 weeks after treatment with sunitinib but up to a maximum of 8 weeks&lt;br&gt;•	MSKCC prognostic score low or intermediate&lt;br&gt;•	ECOG Performance Status of 0 or1&lt;br&gt;•	Patient must have histologically confirmed metastatic renal cell carcinoma with predominant clear cell histology (clear cell component more than 50%)&lt;br&gt;•	Age &gt; 18 years&lt;br&gt;•	Life expectancy of at least 12 weeks&lt;br&gt;•	Patients with at least one measurable lesion.  Lesions must be measured by CT-scan or MRI (Magnetic Resonance Imaging) according to Response Evaluation Criteria in Solid Tumors (RECIST, see Appendix 10.5 )&lt;br&gt;•	Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:&lt;br&gt;•	Hemoglobin &gt; 9.0 g/dl&lt;br&gt;•	Absolute neutrophil count (ANC) &gt;1,500/mm3 &lt;br&gt;•	Platelet count ? 100,000/µl &lt;br&gt;•	Total bilirubin &lt; 1.5 times the upper limit of normal &lt;br&gt;•	ALT and AST &lt; 2.5 x upper limit of normal (&lt; 5 x upper limit of normal for patients with liver involvement of their cancer)&lt;br&gt;•	Alkaline phosphatase &lt; 4 x ULN&lt;br&gt;•	PT or INR and PTT &lt; 1.5 x upper limit of normal (patients who receive anti-coagulation treatment with an agent such as coumarin derivates or heparin will be allowed to participate.  For patients on coumarin derivates , close monitoring of at least weekly evaluations will be performed until INR is stable based on a measurement at pre dose, as defined by the local standard of care).&lt;br&gt;•	Serum creatinine &lt; 2.0 x upper limit of normal.&lt;br&gt;•	Ability to understand and the willingness to sign a written informed consent.  A signed informed consent must be obtained prior to performing any study specific procedures.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	Patient should be excluded if they have unresolved chronic toxicity grade &gt; 1 and related to prior therapy with sunitinib.&lt;br&gt;•	History of cardiac disease: &lt;br&gt;o	Congestive heart failure NYHA (New York Heart Association) class &gt; 2&lt;br&gt;o	Active CAD (Coronary artery disease) or MI (Myocardial Infarction) more than 6 months prior to study entry is allowed)&lt;br&gt;o	Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) &lt;br&gt;o	Uncontrolled hypertension defined as systolic blood pressure &gt; 150 mmHg or diastolic pressure &gt; 90 mmHg, despite optimal medical management.&lt;br&gt;•	Known history of HIV (Human immunodeficiency virus) infection or chronic Hepatitis B or C &lt;br&gt;•	Active clinically serious infections (grade &gt; 2 National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE Version 3.0))&lt;br&gt;•	Patients with seizure disorder requiring medication (such as steroids or anti-epileptics)&lt;br&gt;•	Symptomatic metastatic brain or meningeal tumors unless the patient is &gt; 6 months from definitive therapy, has a negative brain imaging study within &lt;br&gt;4 weeks of study entry and is clinically stable , with respect to CNS metastases, at the time of study entry.  Also the patient must not be undergoing acute steroid therapy or taper (chronic steroid therapy is acceptable provided that the dose is stable for one month prior to and following screening radiographic studies)&lt;br&gt;•	History of organ allograft &lt;br&gt;•	Patients with evidence or history of bleeding diathesis or coagulopathy&lt;br&gt;•	Patients undergoing renal dialysis&lt;br&gt;•	Previous or concurrent cancer that is distinct in primary site or histology form the renal cell carcinoma EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, or superficial bladder tumors [Ta (Noninvasive tumor), Tis (Carcinoma in situ) &amp; T1 (Tumor invades lamina propria)] or any cancer curatively treated &gt; 3 years prior to study entry&lt;br&gt;•	Any hemorrhage/bleeding event grade &gt; 3 within 4 weeks of first dose of study drug&lt;br&gt;•	Serious, non-healing wound, ulcer, or bone fracture &lt;br&gt;•	Pregnant or breast-feeding patients.  Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment.  Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and two weeks after the completion of trial.  The investigator is requested to advise the patient how to achieve an adequate contraception.    &lt;br&gt;•	Substance abuse, medical, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results&lt;br&gt;•	Known or suspected allergy to the investigational agent or any agent given in association with this trial &lt;br&gt;•	Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study&lt;br&gt;•	Patients unable to swallow oral medications &lt;br&gt;•	Any malabsorption condition &lt;br&gt;Excluded therapies and medications, previous and concomitant:&lt;br&gt;•	Any anticancer therapy during the study &lt;br&gt;•	Radiotherapy during study or within 3 weeks of start of study drug.  (Palliative radiotherapy will be allowed as described in the Prior and concomitant Therapy section)&lt;br&gt;•	Major surgery, or significant traumatic injury within 4 weeks of the first dose of study drug &lt;br&gt;•	Autologous bone marrow transplant or stem cell rescue&lt;br&gt;•	Investigational drug therapy outside of this trial during or within 4 weeks of study entry&lt;br&gt;•	Use of biologic response modifiers, such as</Exclusion_Criteria>
    <Condition>Carcinoma metastásico de células renales (Advanced renal cell cancer.) &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038407
Term: Renal cell cancer
</Condition>
    <Intervention>&lt;br&gt;Trade Name: NEXAVAR&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: sorafenib&lt;br&gt;CAS Number: 28844-1-73-1&lt;br&gt;Current Sponsor code: BAY 43-9006&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Roferon-A &lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: interferon alpha-2a&lt;br&gt;CAS Number: 76543-88-9&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 3-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The aim of the study is to evaluate if the addition of low doses of IFN alpha-2a to sorafenib would be beneficial, by estimating the median PFS, in patients who have previously either progressed or are intolerant to sunitinib.  &lt;br&gt;&lt;br&gt;The primary end-point is the PFS before dose escalation.&lt;br&gt;;Secondary Objective: Secondary variables include response rate, time to progression, duration of response and overall survival.;Primary end point(s): After progression the dose of sorafenib can be increased in both arms.&lt;br&gt;&lt;br&gt;The primary end-point is the first PFS time which will be described using Kaplan-Meier curves for each treatment group.  The median PFS time and the percentage of patients progression-free at 3, 6, and 12 months will be displayed with their 95% confidence intervals for each treatment group.  In addition, the Hazard Ratio will be presented with its 95% confidence interval.  &lt;br&gt;&lt;br&gt;For the PFS time after dose escalation to 600 mg BID, the medians will be estimated with their 95% confidence interval.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>BAY 43-9006 / 12782</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2464371</Internal_Number>
    <TrialID>EUCTR2007-005546-20-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Systemic effects of mild renal insufficiency: the relation between forearm blood flow and ADMA.</Public_title>
    <Scientific_title>Systemic effects of mild renal insufficiency: the relation between forearm blood flow and ADMA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>academisch ziekenhuis Maastricht</Primary_sponsor>
    <Date_registration3>20071010</Date_registration3>
    <Date_registration>10/10/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005546-20                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>01/02/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;hypertension (without medication BP &gt;140/90 mmHg and &lt;180/110 mmHg)&lt;br&gt;creatinine clearance 60-90 ml/min&lt;br&gt;microalbuminuria (30-300 mg albumin/24 hour)&lt;br&gt;age 18-75&lt;br&gt;total cholesterol &gt;4,5 mmol/l&lt;br&gt;BMI between 18 and 30 kg/m2&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;diabetes mellitus&lt;br&gt;contra-indication for use of an angiotensin-II-receptorblocker or statin&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>hypertension
mild renal insufficiency</Condition>
    <Intervention>&lt;br&gt;Trade Name: Crestor&lt;br&gt;Product Name: Rosuvastatine&lt;br&gt;Product Code: ZD4522&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 287714414&lt;br&gt;Current Sponsor code: ZD4522&lt;br&gt;Other descriptive name: ROSUVASTATIN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Trade Name: Olmetec&lt;br&gt;Product Name: Olmetec&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 144689-24-7&lt;br&gt;Other descriptive name: OLMESARTAN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 40-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine the relation between systemic effects of ADMA and mild renal dysfunction. ;Secondary Objective: -;Primary end point(s): forearm blood flow</Primary_outcome>
    <Secondary_ID>2605</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2464443</Internal_Number>
    <TrialID>EUCTR2007-001604-20-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A PROSPECTIVE RANDOMIZED STUDY ON THE EFFICACY AND SAFETY OF THE PROPHYLACTIC USE OF RITUXIMAB, ADDED TO STANDARD IMMUNOSUPPRESSIVE TREATMENT IN COMPARISON WITH STANDARD IMMUNOSUPPRESSIVE TREATMENT ALONE IN RENAL TRANSPLANTATION - Rituximab in renal transplantation</Public_title>
    <Scientific_title>A PROSPECTIVE RANDOMIZED STUDY ON THE EFFICACY AND SAFETY OF THE PROPHYLACTIC USE OF RITUXIMAB, ADDED TO STANDARD IMMUNOSUPPRESSIVE TREATMENT IN COMPARISON WITH STANDARD IMMUNOSUPPRESSIVE TREATMENT ALONE IN RENAL TRANSPLANTATION - Rituximab in renal transplantation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Radboud University Nijmegen Medical Center</Primary_sponsor>
    <Date_registration3>20070627</Date_registration3>
    <Date_registration>27/06/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001604-20                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/09/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: yes&lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. All renal transplant recipients older than 18 years&lt;br&gt;2. All female patients at risk for pregnancy must have a negative serum pregnancy test before randomization. Female patients at risk for pregnancy must agree to use a medically acceptable method of contraception throughout the treatment period and for 12 weeks after discontinuation of study medication.&lt;br&gt;3. Signed, dated, and witnessed institutional review board (IRB) approved informed consent before screening and before any tests are performed that are specific to the protocol.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Recipients of a kidney from a living donor, who is HLA identical.&lt;br&gt;2. Patients with hemolytic uremic syndrome as original kidney disease.&lt;br&gt;3. Patients with focal segmental glomerulosclerosis that had recurred in a previous graft&lt;br&gt;4. Recipients with more than two previously failed grafts and/or PRA &gt; 85%&lt;br&gt;5. Previous treatment with anti-CD20 antibodies.&lt;br&gt;6. Diabetes mellitus that is currently not treated with insulin&lt;br&gt;7. Total white blood cell count &lt;3,000/mm3 or platelet count &lt;75,000/mm3.&lt;br&gt;8. Active infection with hepatitis B, hepatitis C, or HIV.&lt;br&gt;9. History of tuberculosis.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>prophylaxis of acute rejection after renal transplantation</Condition>
    <Intervention>&lt;br&gt;Trade Name: MabThera&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;Pharmaceutical form of the placebo: Intravenous infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine the incidence and severity of biopsy-confirmed acute rejection within the first six months after transplantation.;Secondary Objective: To analyze:&lt;br&gt;-Renal function as estimated by the endogenous creatinine clearance at 6 months&lt;br&gt;-Occurrence of chronic allograft nephropathy at 6 months&lt;br&gt;-Cumulative incidence of  infections and malignancies at 6 months&lt;br&gt;-Medical costs during the first 6 months after transplantation&lt;br&gt;-Patient and graft survival&lt;br&gt;;Primary end point(s): The incidence and severity of biopsy-confirmed acute rejections within the first six months after transplantation.</Primary_outcome>
    <Secondary_ID>RRT6</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2464744</Internal_Number>
    <TrialID>EUCTR2007-005985-10-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Análisis del Efecto Renoprotector de la Pentoxifilina en Pacientes con Enfermedad Renal Crónica Secundaria a Nefropatía Diabética - Pentoxifilina y renoprotección</Public_title>
    <Scientific_title>Análisis del Efecto Renoprotector de la Pentoxifilina en Pacientes con Enfermedad Renal Crónica Secundaria a Nefropatía Diabética - Pentoxifilina y renoprotección                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Juan Francisco Navarro González</Primary_sponsor>
    <Date_registration3>20080121</Date_registration3>
    <Date_registration>21/01/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005985-10                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>03/03/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: yes&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: No tratamiento activo ni placebo en el grupo control.&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Edad superior a 35 años.&lt;br&gt;2. Diabetes mellitus tipo 2 con un tiempo de diagnóstico superior a 10 años.&lt;br&gt;3. Diagnóstico clínico compatible con nefropatía diabética establecida tras exclusión de acuerdo con la práctica clínica habitual de otras posibles etiologías de la ERC y sin precisar confirmación histológica.&lt;br&gt;4. ERC estadio 3 ó 4 (filtrado glomerular estimado entre 15 y 60 ml/min).&lt;br&gt;5. Tratamiento con fármacos bloqueadores del sistema renina-angiotensina durante al menos los 6 meses previos a la inclusión en el estudio.&lt;br&gt;6. Ausencia de terapéutica inmunosupresora en los 6 meses previos a la inclusión en el estudio.&lt;br&gt;7. Obtención del consentimiento por parte del paciente.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. HTA severa (definida con una PAS mayor o igual a 180 mmHg y/o una PAD mayor o igual a 110 mmHg) y/o HbA1c &gt; 10%.&lt;br&gt;2. Padecer enfermedades sistémicas (LES, vasculitis, amiloidosis, etc) o tumorales activas.&lt;br&gt;3. Presencia de enfermedad renal no diabética.&lt;br&gt;4. Agudización de la insuficiencia renal crónica por proceso intercurrente en los últimos 6 meses.&lt;br&gt;5. Necesidad de tratamiento concomitante con glucocorticoides o antiinflamatorios no esteroideos en los 3 meses previos a la inclusión en el estudio.&lt;br&gt;6. Tratamiento con antagonistas de la aldosterona y bloqueo doble del sistema renina-angiotensina.&lt;br&gt;7. Mujeres en edad fértil que no utilizan medidas anticonceptivas.&lt;br&gt;8. Mujeres en período de lactancia.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Enfermedad renal crónica secundaria a nefropatía diabética. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10061835
Term: Diabetic nephropathy
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Hemovas 600 mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: PENTOXIFYLLINE&lt;br&gt;CAS Number: 6493056&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 600-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluar el efecto renoprotector aditivo de la terapéutica con pentoxifilina en pacientes diabéticos tipo 2 con nefropatía diabética tratados con bloquedores del sistema renina-angiotensina. Se analizará la progresión de la insuficiencia renal crónica mediante la valoración de la tasa media de progresión de la creatinina sérica (Crs) expresada en mg/dl/mes y/o  1/Crs con el tiempo, así como mediante el análisis del filtrado glomerular estimado a través de la ecuación abreviada del estudio MDRD (Modification of Diet in Renal Disease), la ecuación que hoy en día es recomendada por la gran mayoría de las sociedades científicas para la estimación del filtrado glomerular.;Secondary Objective: •	Porcentaje de pacientes que duplican su Crs, llegan a diálisis o trasplante renal.&lt;br&gt;•	Evolución de la albuminuria.&lt;br&gt;•	Influencia de presión arterial, albuminuria, anemia, dislipemia y alteraciones del metabolismo  calcio-fósforo, e influencia del tratamiento con PTF. &lt;br&gt;•	Análisis de la sensibilidad a la insulina, su relación con la progresión de la enfermedad renal y la influencia del tratamiento con PTF.&lt;br&gt;•	Evolución de los niveles de TNFa, interleukina 18 e interelukina 10. &lt;br&gt;•	Morbi-mortalidad cardiovascular (muerte de causa cardiovascular, hospitalización por insuficiencia cardiaca, coronariografía y/o revascularización coronaria, accidente cerebrovascular, amputación y/o revascularización de miembros inferiores).&lt;br&gt;•	Seguridad y tolerancia del tratamiento combinado con PTF y bloqueadores del sistema renina-angiotensina.&lt;br&gt;;Primary end point(s): - Tasa media de progresión de la creatinina sérica.&lt;br&gt;- Evolución del filtrado glomerular estimado.&lt;br&gt;- Porcentaje de pacientes que duplican su Crs durante el estudio, llegan a diálisis o trasplante renal.&lt;br&gt;- Evolución de la excreción urinaria de albúmina.&lt;br&gt;- Morbi-mortalidad cardiovascular (muerte de causa cardiovascular, hospitalización por insuficiencia cardiaca, coronariografía y/o revascularización coronaria, accidente cerebrovascular, amputación y/o revascularización de miembros inferiores).</Primary_outcome>
    <Secondary_ID>PTF-REN-001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2464760</Internal_Number>
    <TrialID>EUCTR2007-005648-25-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Carcinome rénal à cellules claires (CRCC) traité par molécules antiangiogéniques en situation adjuvante: valeur pronostique et thérapeutique des altérations du gène VHL et de l’expression plasmatique et intratumorale des molécules impliquées dans la voie VHL/HIF/VEGF. - S-TRAC</Public_title>
    <Scientific_title>Carcinome rénal à cellules claires (CRCC) traité par molécules antiangiogéniques en situation adjuvante: valeur pronostique et thérapeutique des altérations du gène VHL et de l’expression plasmatique et intratumorale des molécules impliquées dans la voie VHL/HIF/VEGF. - S-TRAC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>C.H.U. de RENNES</Primary_sponsor>
    <Date_registration3>20071217</Date_registration3>
    <Date_registration>17/12/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005648-25                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>31/01/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Les sujets devront répondre à tous les critères d'inclusion suivants pour pouvoir être inclus dans l'étude :&lt;br&gt;1.	les sujets doivent signer et dater le consentement éclairé approuvé par le comité d'éthique ; &lt;br&gt;2.	Âge = 18 ans ; &lt;br&gt;3.	indice de performance ECOG 0 – 2 avant la néphrectomie ;&lt;br&gt;4.	un des diagnostics suivants doit être posé selon le système de stadification UISS :&lt;br&gt;a.	T3 N0 ou Nx, M0, grade de Fuhrman ³ 2 et indice de performance ECOG ³ 1, ou &lt;br&gt;b.	T4 N0 ou Nx, M0, grade de Fuhrman quelconque et indice de performance ECOG quelconque, ou&lt;br&gt;c.	Tout T, N1-2, M0, grade de Fuhrman quelconque et indice de performance ECOG quelconque ;&lt;br&gt;5.	le diagnostic de carcinome rénal (cancer du rein à cellules claires) doit être confirmé par histologie ;&lt;br&gt;6.	aucune preuve de maladie macroscopique résiduelle ou de maladie métastatique ne doit être mise en évidence. Les sujets présentant des preuves de maladie microscopique (R1) sont acceptés ;&lt;br&gt;7.	les sujets ne doivent avoir reçu aucun traitement médical systémique spécifique antérieur pour le cancer du rein ; &lt;br&gt;8.	les sujets ne doivent pas avoir reçu un traitement anti-angiogénique antérieur ; &lt;br&gt;9.	les sujets doivent avoir reçu la première dose orale de sunitinib pas plus de 10 semaines après la date de la néphrectomie ; &lt;br&gt;10.	les sujets doivent présenter des fonctions organiques adéquates définies de la manière suivante : &lt;br&gt;a.	plaquettes ³ 100 x 109/l, hémoglobine ? 8 g/dl, numération absolue des neutrophiles ? 1,5 x 109/l ;&lt;br&gt;b.	bilirubine ? 3 mg/dl,  aspartate transaminase (ASAT) et alanine transaminase (ALAT) £ 2,5 fois la limite supérieure de la normale ;&lt;br&gt;c.	International Normalized Ratio (INR) £ 1,7 ou temps de Quick £ 6 s de plus que le témoin ; &lt;br&gt;d.	clairance de la créatinine calculée = 30 ml/mn.&lt;br&gt;11.	Fonction d’éjection ventriculaire gauche suffisante définie par une valeur = 50 %, 3 à 10 semaines après la date de la néphrectomie sur la base d'un échocardiogramme bidimensionnel (ECHO) ou d’une ventriculographie isotopique (MUGA) ; &lt;br&gt;12.	les femmes et les hommes doivent utiliser des méthodes de contraception adéquates au cours de l'étude. Les méthodes de contraception adéquates comprennent les implants, les produits injectables, les contraceptifs oraux associés, les dispositifs intra-utérins efficaces, l'abstinence sexuelle ou un partenaire vasectomisé ou une vasectomie ;&lt;br&gt;13.	la volonté et la capacité de se rendre aux visites programmées, et de se conformer aux programmes thérapeutiques, aux analyses biologiques et aux autres procédures de l'étude.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Les sujets répondant à l'un des critères suivants ne seront pas inclus dans l'étude : &lt;br&gt;1.	carcinome non différencié sur le plan histologique ou carcinome des tubes collecteurs, lymphome, sarcome ou sujets présentant des sites métastatiques rénaux ; &lt;br&gt;2.	hémorragie de grade 3 (NCI CTCAE) moins de 4 semaines après la date de la randomisation ; &lt;br&gt;3.	diagnostic d'une affection maligne secondaire quelconque dans les 5 ans suivant la date de randomisation, à l'exception d'un épithélioma basocellulaire, d'un épithélioma spinocellulaire ou d'un cancer in situ du col de l'utérus traité de manière adéquate et sans signe de récidive pendant 12 mois ;&lt;br&gt;4.	angor sévère/instable, infarctus du myocarde, pontage coronaire, insuffisance cardiaque congestive symptomatique, accident vasculaire cérébral, y compris accidents ischémiques transitoires ou embolie pulmonaire, survenus dans les 12 mois précédents l’administration du traitement à l’étude ;&lt;br&gt;5.	traitement concomitant avec des inhibiteurs et des inducteurs puissants connus de l'isoenzyme CYP3A4 et/ou administration de ces médicaments 7 et 12 jours avant la date de la randomisation (par exemple respectivement kétoconazole, rifampicine, etc.) ;&lt;br&gt;6.	arythmie cardiaque en cours de grade NCI CTCAE ³ 2, fibrillation auriculaire de tout grade, ou allongement de l'intervalle QTc &gt; 500 ms ;  &lt;br&gt;7.	hypertension non contrôlée par des médicaments ; &lt;br&gt;8.	traitement par des anticoagulants et traitement à doses thérapeutiques par la warfarine en cours ou au cours des deux semaines précédant le premier jour de l'administration du sunitinib. L'administration de warfarine à faible dose pour une prophylaxie de la thrombose veineuse profonde est autorisée (jusqu'à 2 mg/jour). L'administration d'héparine de bas poids moléculaire ou d'aspirine est autorisée ; &lt;br&gt;9.	incapacité à avaler des médicaments oraux, ou présence d'une maladie inflammatoire chronique de l'intestin, d’une occlusion intestinale partielle ou complète ou d'une diarrhée chronique ; &lt;br&gt;10.	infection connue par le virus de l'immunodéficience humaine (VIH) ou d'une pathologie liée au syndrome d'immunodéficience acquise (SIDA) ; &lt;br&gt;11.	hépatite active connue ;&lt;br&gt;12.	grossesse ou allaitement. Toutes les femmes en âge de procréer doivent présenter un test de grossesse négatif (sur sérum ou urine) dans les 7 jours précédant la date de la randomisation ; &lt;br&gt;13.	tout autre affection médicale ou psychiatrique ou anomalie biologique sévère aiguë ou chronique susceptible d'augmenter le risque associé à la participation à l'étude ou à l'administration du médicament à l'étude, ou pouvant interférer avec l'interprétation des résultats de l'étude, et susceptible de rendre l'inclusion du sujet dans l'étude inappropriée selon l'avis de l'investigateur ; &lt;br&gt;14.	administration de toute substance oncologique expérimentale ou anti-angiogénique autorisée ou expérimentale avant l'entrée dans l'étude ; &lt;br&gt;15.	traitement en cours dans un autre essai clinique thérapeutique. Les essais portant sur les traitements de soutien ou les essais non thérapeutiques, par exemple les études portant sur les méthodes d'évaluation des résultats notifiés par les patients, sont autorisés.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Carcinome rénal à cellules claires (CRCC) traité par molécules antiangiogéniques en situation adjuvante &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10001326
Term: Adrenal carcinoma
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10001327
Term: Adrenal carcinoma NOS
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038395
Term: Renal carcinoma
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038396
Term: Renal carcinoma recurrent
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038397
Term: Renal carcinoma stage I
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038398
Term: Renal carcinoma stage II
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038399
Term: Renal carcinoma stage III
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038400
Term: Renal carcinoma stage IV
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050076
Term: Metastatic renal carcinoma
 &lt;br&gt;MedDRA version: 9.1
Level: PT
Classification code 10001326
Term: Adrenal carcinoma
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sutent&lt;br&gt;Product Name: Sunitinib&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: sunitinib&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;Pharmaceutical form of the placebo: Capsule*&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: L’objectif principal de ce projet est de déterminer dans les CRCC,  si les facteurs suivants sont prédictifs de la réponse (définie par la survie sans cancer) ou de la non réponse aux thérapies antiangiogéniques de type inhibiteur de l’activité tyrosine kinase (Sunitinib) :&lt;br&gt;- statut VHL (présence de mutations, délétions, d’hyperméthylation du promoteur) &lt;br&gt;- taux circulants ou expression intratumorale de molécules impliquées dans la voie VHL/HIF/VEGF.&lt;br&gt;;Secondary Objective: Les objectifs secondaires sont de :&lt;br&gt;- déterminer si les facteurs listés ci-dessus sont pronostiques de la survie sans cancer et de la survie globale,&lt;br&gt;- Explorer l’association entre le statut VHL et les biomarqueurs de la voie VHL/HIF/VEGF.&lt;br&gt;;Primary end point(s): Critère de jugement principal :&lt;br&gt;Relation entre les marqueurs biologiques et moléculaires explorés dans cette étude ancillaire et la réponse au Sunitinib&lt;br&gt;•	anomalies du gène VHL (mutations, délétions ou hyperméthylation du promoteur)&lt;br&gt;•	taux plasmatiques de VEGF-A et C, de VEGFR1 et R2, bFGF, SDF-1, PDGF AA, PDGF AB, PDGF BB, des précurseurs endothéliaux circulants, des cellules endothéliales circulantes, des microparticules endothéliales et des microparticules plaquettaires.&lt;br&gt;•	expression intratumorale de VEGF-A, B, C, D, de VEFG-R1, R2, R3, PDGFR,  HIF1?, HIF2, CAIX, p53, PTEN, et pVHL.&lt;br&gt;&lt;br&gt;Critères de jugement secondaires :&lt;br&gt;•	Relation entre les marqueurs biologiques et moléculaires explorés dans cette étude ancillaire, la survie sans cancer et la survie globale&lt;br&gt;•	Relations entre le statut VHL, les marqueurs biologiques et tissulaires explorés et les caractéristiques histo-pronostiques des tumeurs.&lt;br&gt;&lt;br&gt;</Primary_outcome>
    <Secondary_ID>PHRC/07-03/RENNES</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2465162</Internal_Number>
    <TrialID>EUCTR2005-004360-23-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Randomised controlled study of “physiological” peritoneal dialysis solutions. - Physiological PD</Public_title>
    <Scientific_title>Randomised controlled study of “physiological” peritoneal dialysis solutions. - Physiological PD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Barts and The London NHS Trust</Primary_sponsor>
    <Date_registration3>20060611</Date_registration3>
    <Date_registration>11/06/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004360-23                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>03/07/2006</Date_enrollement>
    <Target_size>250</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;All incident patients selected to use a PD system that has physiological and standard solutions available.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-	Patients unable to provide informed consent &lt;br&gt;-	Patients where the use of a certain solution is indicated or contra-indicated for medical reasons (e.g. known allergy).&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>End stage renal failure</Condition>
    <Intervention>&lt;br&gt;Product Name: Physioneal PD solutions&lt;br&gt;Pharmaceutical Form: Solution for peritoneal dialysis&lt;br&gt;INN or Proposed INN: glucose&lt;br&gt;Concentration unit: % (W/V) percent weight/volume&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1.36-3.86&lt;br&gt;Pharmaceutical form of the placebo: Solution for peritoneal dialysis&lt;br&gt;Route of administration of the placebo: Intraperitoneal use&lt;br&gt;&lt;br&gt;Product Name: Dineal&lt;br&gt;Product Code: Dianeal&lt;br&gt;Pharmaceutical Form: Solution for peritoneal dialysis&lt;br&gt;INN or Proposed INN: glucose&lt;br&gt;Concentration unit: % (W/V) percent weight/volume&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1.36-3.86&lt;br&gt;Pharmaceutical form of the placebo: Solution for peritoneal dialysis&lt;br&gt;Route of administration of the placebo: Intraperitoneal use&lt;br&gt;&lt;br&gt;Product Name: Balance&lt;br&gt;Product Code: Balance&lt;br&gt;Pharmaceutical Form: Solution for peritoneal dialysis&lt;br&gt;INN or Proposed INN: glucose&lt;br&gt;Concentration unit: % (W/V) percent weight/volume&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1.5-3.5&lt;br&gt;Pharmaceutical form of the placebo: Solution for peritoneal dialysis&lt;br&gt;Route of administration of the placebo: Intraperitoneal use&lt;br&gt;&lt;br&gt;Product Name: CAPD/DPCA staysafe&lt;br&gt;Product Code: CAPD/DPCA staysafe&lt;br&gt;Pharmaceutical Form: Solution for peritoneal dialysis&lt;br&gt;INN or Proposed INN: glucose&lt;br&gt;Concentration unit: % (W/V) percent weight/volume&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1.5-3.5&lt;br&gt;Pharmaceutical form of the placebo: Solution for peritoneal dialysis&lt;br&gt;Route of administration of the placebo: Intraperitoneal use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the outcome of peritoneal dialysis when "standard" or "biocompatible" solutions are used. Primary end-point is: peritonitis rate. ;Secondary Objective: Secondary Endpoints:&lt;br&gt;·	Patients using physiological solutions will have better preservation of residual kidney function.&lt;br&gt;·	Patients using physiological solutions will have smaller changes in peritoneal membrane function assessed by PET than control&lt;br&gt;·	Patients using physiological solutions will have reduced composite end-point of mortality and PD failure defined by transfer to HD&lt;br&gt;·	Patients using physiological solutions will have better quality of life assessed by SF-36&lt;br&gt;;Primary end point(s): Primary aim is to compare peritonitis. However, some patients may have more than 1 episode</Primary_outcome>
    <Secondary_ID>P-03-235</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2465175</Internal_Number>
    <TrialID>EUCTR2006-000674-73-HU</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, THREE-ARM,
PARALLEL-GROUP, MULTICENTER, MULTINATIONAL SAFETY AND
EFFICACY TRIAL OF 300 MG AND 900 MG OF ABETIMUS SODIUM IN
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS WITH A HISTORY OF
RENAL DISEASE</Public_title>
    <Scientific_title>A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, THREE-ARM,
PARALLEL-GROUP, MULTICENTER, MULTINATIONAL SAFETY AND
EFFICACY TRIAL OF 300 MG AND 900 MG OF ABETIMUS SODIUM IN
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS WITH A HISTORY OF
RENAL DISEASE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>La Jolla Pharmaceutical Company</Primary_sponsor>
    <Date_registration3>20060615</Date_registration3>
    <Date_registration>15/06/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-000674-73                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>11/08/2006</Date_enrollement>
    <Target_size>730</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Each patient must meet all the following criteria in order to participate in&lt;br&gt;this trial:&lt;br&gt;&lt;br&gt;2.1.1 Males or females between 12 and 70 years old, inclusive.&lt;br&gt;2.1.2 Female patients must be non-pregnant and non-lactating and have a negative serum pregnancy test result prior to enrollment in the study. Female patients of childbearing potential (including peri-menopausal women who have had a menstrual period within 1 year) must be using appropriate birth control (defined as a method which results in a low failure rate of less than 1% per year, when used consistently and correctly, for example oral contraceptives, contraceptive patch, implants,&lt;br&gt;injectables, some intrauterine contraceptive devices [IUDs], or sexual abstinence) during the entire duration of the study. Males enrolled in the trial must have no plans to father a child during the course of the trial and agree to use adequate birth control methods.&lt;br&gt;2.1.3. Diagnosis of SLE for purposes of this trial utilize the 1996 Revised Criteria for the Classification of SLE as defined by the American College of Rheumatology (ACR) where a diagnosis of SLE is established when = 4 of the 11 criteria are met (refer to Section 8.2 of protocol).&lt;br&gt;2.1.4 At least one documented episode of active SLE renal disease within 4 years prior to randomization at study Visit 3 as defined by at least one of the following:&lt;br&gt;- A renal biopsy showing active lesions of SLE, Morphologic Classification of Lupus Nephritis defined by the World Health Organization (WHO) Class III, IV or V (refer to Section 8.3 of protocol)&lt;br&gt;- Increase in serum creatinine:&lt;br&gt;• by greater than 0.3 mg/dL if previous value was less than 2.0 mg/dL&lt;br&gt;• by greater than 0.4 mg/dL if previous value was 2.0 mg/dL to 5.0 mg/dL&lt;br&gt;• AND either hematuria OR a C3, C4 or CH50 below lower limits of normal or at least 25% lower than a previous value.&lt;br&gt;Patients with hereditary C4 deficiency cannot qualify on the C4 or CH50 criterion alone.&lt;br&gt;-Increase in proteinuria:&lt;br&gt;• to greater than 1000 mg/24 hr if the previous value was &lt; 200 mg/24 hr&lt;br&gt;• to greater than 2000 mg/24 hr if the previous value was = 200 mg/24 hr and = 1000 mg/24 hr&lt;br&gt;• to greater than 2 times the previous value if that value was &gt; 1000 mg/24 hr&lt;br&gt;- Use of cyclophosphamide to treat lupus nephritis that is documented in clinical or hospital records.&lt;br&gt;2.1.5 Elevated anti-dsDNA antibody concentration at pre-screening Visit 0 (= 10 IU/mL) as measured by the Farr assay at the regional central laboratory.&lt;br&gt;2.1.6. Ability to communicate meaningfully with the investigational staff, competence to give written informed consent, and ability to comply with the entire study procedure.&lt;br&gt;2.1.7 Duly executed, written, informed consent obtained from the patient, next of kin, or other legal representative.&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Any of the following will exclude a patient from this trial:&lt;br&gt;&lt;br&gt;2.2.1 Active SLE renal disease in the 3 months prior to Visit 3 as evidenced by:&lt;br&gt;- Increase in serum creatinine:&lt;br&gt;• by greater than 0.3 mg/dL if previous value was less than 2.0 mg/dL&lt;br&gt;• by greater than 0.4 mg/dL if previous value was 2.0 mg/dL to 5.0 mg/dL&lt;br&gt;• AND either hematuria OR a C3, C4 or CH50 below lower limits of normal or at least 25% lower than a previous value.&lt;br&gt;- Reproducible increase in proteinuria:&lt;br&gt;• to greater than 1000 mg/24 hr if the previous value was &lt; 200 mg/24 hr&lt;br&gt;• to greater than 2000 mg/24 hr if the previous value was = 200 mg/24 hr and = 1000 mg/24 hr&lt;br&gt;• to greater than 2 times the previous value if that value was &gt; 1000 mg/24 hr&lt;br&gt;2.2.2 An increase in the anti-dsDNA antibody concentration of more than 50% with an incremental increase of at least 50 units in anti-dsDNA antibody concentration by Farr assay between the samples taken at Visit 0 and Visit 1 during the screening period. &lt;br&gt;2.2.3 Use of the following therapeutics:&lt;br&gt;- Prednisone &gt; 20 mg/day within 1 month prior to Visit 1&lt;br&gt;- Any use of the following therapies or therapeutics within 2 months prior to randomization or 1 month prior to Visit 1:&lt;br&gt;• alkylating agents (e.g., cyclophosphamide)&lt;br&gt;• TNF inhibitors (e.g., etanercept, infliximab)&lt;br&gt;• cyclosporine&lt;br&gt;• plasmapheresis&lt;br&gt;• intravenous immunoglobulin&lt;br&gt;• prosorba column&lt;br&gt;- Any use of mycophenolate mofetil that exceeds 1000 mg/day 1 month prior to Visit 1&lt;br&gt;- Any use of azathioprine that exceeds 100 mg/day within 1 month prior to Visit 1&lt;br&gt;- Any use of methotrexate that exceeds 10 mg/week within 1 month prior to Visit 1&lt;br&gt;- Any use of leflunomide that exceeds 10 mg/day within 1 month prior to Visit 1&lt;br&gt;- Any use of rituximab within 5 months prior to Visit 1&lt;br&gt;- Previous or concurrent medications and other therapies or devices that in the judgment of the Investigator are likely to confound the evaluation of the safety or efficacy of abetimus sodium. Examples include:&lt;br&gt;- immunosuppressants or immunomodulatory drugs other than those therapies specifically noted above to include new immunomodulatory agents that may become commercially available during the course of the study&lt;br&gt;- drugs that have the potential to induce SLE (e.g., isoniazid, phenytoin, hydralazine, procainamide, etc.)&lt;br&gt;- radiation therapy within 1 year.&lt;br&gt;- If the Investigator has any question concerning a particular medication, he/she should discuss this with the Medical Monitor prior to enrollment.&lt;br&gt;- Patient has received any investigational new drug or device within 30 days prior to screening or 5 half-lives of the agent (whichever is longer), or any investigational new drug with a long-term effect.&lt;br&gt;- Prior participation in study LJP 394-90-14&lt;br&gt;2.2.4 Exclusionary laboratory values:&lt;br&gt;• leukocyte count &lt; 2,000 cells/mm3&lt;br&gt;• platelet count &lt; 50,000 cells/mm3&lt;br&gt;• hemoglobin &lt; 8.5 gm/dL&lt;br&gt;• serum hepatic transaminases = 3X the upper limit of normal&lt;br&gt;• serum creatinine &gt; 3.5 mg/dL within the 2 months prior to randomization&lt;br&gt;2.2.5 Malignant disease or immunodeficiency syndrome within 5 years, excepting patients with basal cell or squamous cell carcinoma of the skin with complete excision and clean borders.&lt;br&gt;2.2.6 Evidence of current abuse of drugs or alcohol.&lt;br&gt;2.2.7 History of poor procedural compliance in previous investigational studies.&lt;br&gt;2.2.8 History of serious cardiac disease or functional classification New York Heart Association Class III or IV.&lt;br&gt;2.2.9 Patient has previously undergone organ transplantation.&lt;br&gt;2.2.10 Other medical c</Exclusion_Criteria>
    <Condition>Systemic lupus erythematosus patients with a history of renal disease &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10042945
Term: Systemic lupus erythematosus
</Condition>
    <Intervention>&lt;br&gt;Product Name: Abetimus sodium&lt;br&gt;Product Code: LJP 394&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Abetimus Sodium&lt;br&gt;CAS Number: 167362-48-3&lt;br&gt;Current Sponsor code: LJP 394&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of this trial is to determine whether abetimus&lt;br&gt;sodium is more effective than placebo in delaying the time to renal flare in SLE&lt;br&gt;patients with a history of SLE renal disease. The safety and efficacy of abetimus&lt;br&gt;sodium in SLE patients will be evaluated at weekly doses of 300 and 900 mg&lt;br&gt;over the intended 52-week exposure period.&lt;br&gt;;Secondary Objective: The secondary objectives of the trial are to determine whether treatment with&lt;br&gt;abetimus sodium is more effective than placebo&lt;br&gt;--in reducing proteinuria&lt;br&gt;--in delaying time to all major SLE flares;Primary end point(s): 4.13.1. The primary efficacy endpoint, time to first renal flare, will be based on laboratory data from the central laboratory and confirmed by supporting data as stipulated in section 4.13.2. and other relevant sections. &lt;br&gt;For renal flare, laboratory data leading to the primary endpoint will be considered valid for defining the endpoint only after causes other than increased activity of SLE renal disease have been excluded and the Principal Investigator, with concurrence of the Medical Monitor, has attributed the changes in laboratory values to an SLE-related renal flare. An independent Renal Events Committee will review renal flare data to adjudicate the attribution of renal flares to SLE prior to the data from the trial being unblinded. &lt;br&gt;Patients reaching a renal flare endpoint are encouraged to stay in the study and receive weekly administration of study drug until they complete the one-year evaluation period. Patients experiencing a renal flare may be treated with prednisone, cyclophosphamide, and//or other immunosuppressive agents as needed.&lt;br&gt;&lt;br&gt;4.13.2. .... A renal flare endpoint will have been reached if one or the other of the following criteria, or both, are met following a renal flare signal as outlined in the protocol.&lt;br&gt;Either:&lt;br&gt;A reproducible increase in serum creatinine of &gt; 20% OR at least 0.3&lt;br&gt;mg/dL, whichever is greater. This endpoint cannot be met using this&lt;br&gt;criterion unless this increase is documented by two consecutive tests&lt;br&gt;from two different days and each consecutive test continues to meet the&lt;br&gt;endpoint increase in serum creatinine and each of the consecutive tests&lt;br&gt;is accompanied by the presence of clinically significant proteinuria&lt;br&gt;(&gt; 1000 mg/24 h) and/or red cell casts.&lt;br&gt;Or:&lt;br&gt;A reproducible increase in 24-hr urine protein:&lt;br&gt;• to greater than 1000 mg/24 hr if the screening value was&lt;br&gt;&lt; 200 mg/24 hr&lt;br&gt;• to greater than 2000 mg/24 hr if the screening value was&lt;br&gt;= 200 mg/24 hr and = 1000 mg/24 hr &lt;br&gt;• to greater than 2 times the screening value if that value was&lt;br&gt;&gt; 1000 mg/24 hr&lt;br&gt;AND the documentation of increased urinary protein is reproducible and&lt;br&gt;is based on specimens from 2 different days. This will require at least two&lt;br&gt;24-hr urine collections. &lt;br&gt;&lt;br&gt;4.13.3 Subsequent Flares&lt;br&gt;A subsequent flare (second flare, third flare, etc.) will be considered to have occured if the first flare has resolved, i.e., the parameters responsible for the first flare have returned to baseline and remain at baseline for at least 3 months. The primary endpoint, time to renal flare, will be based exclusively on the occurence of the first on-study renal flare.&lt;br&gt;&lt;br&gt;Safety and tolerability Endpoints:&lt;br&gt;Adverse experiences, laboratory parameters, reasons for premature&lt;br&gt;study termination, and cause(s) of death will be collected and assessed&lt;br&gt;as measures of safety and tolerability.&lt;br&gt;All patients who receive at least one dose of study drug will be included in&lt;br&gt;analyses of safety and tolerability.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>LJP 394-90-14</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2465537</Internal_Number>
    <TrialID>EUCTR2006-005774-50-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Protocol for taking pharmacogenetic testing of tacrolimus into the clinical arena: patient tailored anti-rejection therapy</Public_title>
    <Scientific_title>Protocol for taking pharmacogenetic testing of tacrolimus into the clinical arena: patient tailored anti-rejection therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Central Manchester &amp; Manchester Children's University Hospitals NHS Trust</Primary_sponsor>
    <Date_registration3>20061221</Date_registration3>
    <Date_registration>21/12/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005774-50                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/05/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: &lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Subjects who have undergone a kidney transplant and are receiving oral tacrolimus as part of their clinical management&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Any form of substance abuse (including drug or alcohol abuse) psychiatric disorder or condition which, in the opinion of the investigator, may invalidate the patient's ability to give informed consent.&lt;br&gt;</Exclusion_Criteria>
    <Condition>The study is to determine whether MDR-1 genotyping correlates with tacrolimus dose in individual patients and could therefore be used in future to predict tacrolimus dose.  All patients will have undergone or be about to undergo a kidney transplant and require treatment with tacrolimus immunosuppression. &lt;br&gt;MedDRA version: 8.1
Level: LLT
Classification code 10021510
Term: Immunosuppression NOS
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Prograf&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine in a well-powered study whether MDR-1 genotyping correlates with tacrolimus dose in individual patients and could therefore be used in future to predict tacrolimus starting dose.;Secondary Objective: ;Primary end point(s): The MDR-1 genotype of 400 patients taking tacrolimus.  This information will be used to predict whether the patients are on standard, intermediate or reduced therapy dose.</Primary_outcome>
    <Secondary_ID>9834p</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2465755</Internal_Number>
    <TrialID>EUCTR2006-006137-41-DE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Prospective, randomized, open, 2-arm national multi-center study to 
evaluate the value of Rituximab in humoral chronic rejection 
after renal transplantation
 - Rituximab 2006</Public_title>
    <Scientific_title>Prospective, randomized, open, 2-arm national multi-center study to 
evaluate the value of Rituximab in humoral chronic rejection 
after renal transplantation
 - Rituximab 2006                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Medizinische Fakultät der Technischen Universität München, vertreten durch den Dekan</Primary_sponsor>
    <Date_registration3>20070326</Date_registration3>
    <Date_registration>26/03/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006137-41                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>07/08/2007</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;GFR &gt; 25 ml/min x 1,73m2 (MDRD)Time after transplantation &gt;3 months &lt;br&gt;Age &gt;18 yearsInformed consent&lt;br&gt;Biopsy proven CAN with C4d+ and/or plasma-cell and/or B-Lymphocyte (CD20+ cells) within the last 4 weeks before inclusion&lt;br&gt;ACE/AT1 blocker started more than 1 week before inclusion&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Hepatitis B, HIV &lt;br&gt;Signs of acute cellular rejection&lt;br&gt;Proteinuria &gt;4g/24h&lt;br&gt;History of malignancy within the last 5 years (except non-metastatic basal or squamous cell carcinoma of the skin)&lt;br&gt;Systemic infection&lt;br&gt;Leukopenia&lt;br&gt;Pregnancy &lt;br&gt;Participation in another investigational drug study&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal transplant patients beyond 1 year post Tx, suffering from CAN and histologically proven C4d deposits and/or plasma cell and/or B-Lymphocyte (CD20+ cells) infiltration of their grafts</Condition>
    <Intervention>&lt;br&gt;Trade Name: MabThera 100mg&lt;br&gt;Product Name: MabThera®&lt;br&gt;Pharmaceutical Form: Intravenous infusion&lt;br&gt;INN or Proposed INN: Rituximab&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 375-&lt;br&gt;&lt;br&gt;Trade Name: Prograf Hartkapseln&lt;br&gt;Product Name: Prograf&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Prograf&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: see D.3.5, D.3.6-&lt;br&gt;&lt;br&gt;Trade Name: CellCept®&lt;br&gt;Product Name: CellCept®&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: CellCept&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 2,0 g -&lt;br&gt;&lt;br&gt;Trade Name: Urbason® solubile&lt;br&gt;Product Name: Urbason® solubile&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Urbason solubile&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100 mg-&lt;br&gt;&lt;br&gt;Trade Name: Decortin H &lt;br&gt;Product Name: Decortin H &lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Decortin H&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 40 mg-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate the benefit of Rituximab in patients with CAN with histologically proven C4d deposits and/or plasma cell and/or B-Lymphocyte (CD20+ cells) infiltration of their grafts.;Secondary Objective: Renal function at 1 year&lt;br&gt;Tolerability/ safety &lt;br&gt;Graft survival at 1 and 2 years;Primary end point(s): Serum creatinine level 12 month </Primary_outcome>
    <Secondary_ID>VAL-518-HEE-0200-S</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2465811</Internal_Number>
    <TrialID>EUCTR2008-000088-40-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Pharmacocinétique de l’association pipéracilline-tazobactam chez les patients septiques, en insuffisance rénale oligo-anurique, traités par hémodiafiltration veino-veineuse continue</Public_title>
    <Scientific_title>Pharmacocinétique de l’association pipéracilline-tazobactam chez les patients septiques, en insuffisance rénale oligo-anurique, traités par hémodiafiltration veino-veineuse continue                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>CHU de TOULOUSE</Primary_sponsor>
    <Date_registration3>20080527</Date_registration3>
    <Date_registration>27/05/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000088-40                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>09/04/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Patient (homme ou femme) âgé de plus de 18 ans&lt;br&gt;- Durée attendue de survie &gt; à 7 jours&lt;br&gt;- Patient oligo-anurique (diurèse &lt; 20cc/heure) devant bénéficier d’une CVVHDF (présentant une insuffisance rénale aiguë ou une poussée d’insuffisance rénale aiguë sur une insuffisance rénale chronique sous jacente ou habituellement traité par  hémodialyse intermittente chronique)&lt;br&gt;- Patient présentant une infection*, déjà colonisé ou non, de localisation variable,  à germe non identifié supposé sensible à l’association pipéracilline-tazobactam&lt;br&gt;- Au stade de sepsis sévère* ou de choc septique*&lt;br&gt;- Consentement éclairé du patient ou, s’il est sédaté du fait de la gravité de son état clinique et ainsi hors d’état d’exprimer son consentement, d’un membre de sa famille ou de la personne de confiance désignée dans son dossier médical.&lt;br&gt;- Patient affilié à un régime de sécurité sociale&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Antécédents d’allergie aux Bêta-lactamines&lt;br&gt;- Isolement d’un germe résistant à l’association pipéracilline-tazobactam&lt;br&gt;- Insuffisance hépatocellulaire sévère aiguë ou chronique avec un score de Child &gt; 9&lt;br&gt;- Contre-indication à une héparinothérapie curative&lt;br&gt;- Présence d’une fonction rénale résiduelle&lt;br&gt;- Femme enceinte (test de grossesse au moment de l’inclusion positif) ou allaitant&lt;br&gt;- Personne sous sauvegarde de justice, sous tutelle ou sous curatelle&lt;br&gt;- Refus de signer le consentement par le patient ou la personne de confiance désignée dans son dossier médical si le patient est hors d’état d’exprimer lui-même son consentement.&lt;br&gt;- Interruption du traitement par pipéracilline-tazobactam et / ou hémodiafiltration au cours de l’étude.&lt;br&gt;- Participation du patient à un autre protocole de recherche clinique.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>patient septique hospitalisé en réanimation présentant  une infection, déjà colonisé ou non, de localisation variable,  à germe non identifié supposé sensible à l’association pipéracilline-tazobactam. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10022519
Term: Intensive care
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10040580
Term: Shock septic
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038435
Term: Renal failure
</Condition>
    <Intervention>&lt;br&gt;Trade Name: TAZOCILLINE&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for infusion&lt;br&gt;INN or Proposed INN: piperacilline&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 4-&lt;br&gt;INN or Proposed INN: tazobactam&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: L’objectif principal est d’évaluer chez les patients de réanimation septiques en insuffisance rénale oligo-anurique, l’impact d’une épuration rénale extra corporelle continue par CVVHDF sur la pharmacocinétique de l’association pipéracilline-tazobactam.&lt;br&gt;Pour cet antibiotique, l’activité bactéricide est temps-dépendante. L’efficacité est donc conditionnée par la valeur de sa concentration résiduelle plasmatique qui doit être un multiple de la CMI (à peu près 5 fois la CMI).&lt;br&gt;;Secondary Objective: L’objectif secondaire est purement observationnel et consiste à évaluer l’épuration de la pipéracilline-tazobactam par la mesure des clairances combinées diffusive et convective que l’on rapportera à la clairance totale des 2 molécules étudiées.;Primary end point(s): Le critère principal de jugement sera donc la comparaison, au cours de la séance de CVVHDF, des concentrations plasmatiques de pipéracilline et tazobactam à la CMI documentée à partir du germe identifié.</Primary_outcome>
    <Secondary_ID>07 300 02</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2466128</Internal_Number>
    <TrialID>EUCTR2005-005745-18-BE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Levamisole treatment for children with steroid sensitive nephrotic syndrome. A multi-centre, double-blind, placebo-controlled, randomised trial. - Levamisol Trial</Public_title>
    <Scientific_title>Levamisole treatment for children with steroid sensitive nephrotic syndrome. A multi-centre, double-blind, placebo-controlled, randomised trial. - Levamisol Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Emma Children's Hospital-AMC</Primary_sponsor>
    <Date_registration3>20070910</Date_registration3>
    <Date_registration>10/09/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005745-18                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/10/2007</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Frequently relapsing idiopathic SSNS with or without steroid dependency&lt;br&gt;- Age between 2 and 18 years&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Patient previously treated with Levamisole&lt;br&gt;- Patients unresponsive to Cyclosporine or MMF&lt;br&gt;- Nephrotic Syndrome due to specific kidney disease&lt;br&gt;- Patients presenting with leucopenia, convulsions or with hepatic diseases&lt;br&gt;</Exclusion_Criteria>
    <Condition>Steroid Sensitive Nephrotic Syndrome (SSNS) &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10029172
Term: Nephrotic syndrome with unspecified pathological lesion in kidney
</Condition>
    <Intervention>&lt;br&gt;Product Name: Levamisole Hydrochloride&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Levamisole Hydrochloride&lt;br&gt;CAS Number: 14769734&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess the efficacy of one year of alternate days Levamisole treatment in a dose of 2.5mg/kg in the prevention of relpases and prolonging the time to relapse after cessation of corticosteroids treatment in children with SNSS;Secondary Objective: - Evaluation whether the effect of Levamisole varies with disease status&lt;br&gt;- Evaluation whether the effect of Levamisole varies with prior treatment with Cyclosphosphamide.&lt;br&gt;- Assessment of steroid sparing effect of Levamisole treatment as well as the sparing effect of other immunosuppressive drugs&lt;br&gt;- Determination whether the effectiveness of Levamisole remains constant or wanes over time&lt;br&gt;- Assessment of pharmacokinetics of Levamisole in the target population&lt;br&gt;- Assessment of the safety of treatment with Levamisole;Primary end point(s): Time to relapse</Primary_outcome>
    <Secondary_ID>EUDRACT 2005-005745-18</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2466449</Internal_Number>
    <TrialID>EUCTR2007-004403-34-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Eficacia y seguridad del telmisartan en pacientes hipertensos con insuficiencia renal crónica en hemodiálisis</Public_title>
    <Scientific_title>Eficacia y seguridad del telmisartan en pacientes hipertensos con insuficiencia renal crónica en hemodiálisis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Fundació Puigvert</Primary_sponsor>
    <Date_registration3>20071204</Date_registration3>
    <Date_registration>04/12/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004403-34                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>16/04/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Pacientes de ambos sexos con edad &gt; de 18 años con insuficiencia renal en programa de hemodiálisis crónica (más de 6 meses) en nuestro centro.&lt;br&gt;- Pacientes diagnosticados de HTA no controlada entendida como cifras de PA sistólica = 130 mmHg y/o PA diastólica = 80 mmHg medida con aparato automático de PA homologado y calibrado a las 24 horas de la sesión de hemodiálisis según las recomendaciones de la Sociedad Española de HTA (21) y habiendo previamente asegurado que se encuentra en su peso seco. Se realizaran tres medidas de PA a intervalos de 1 minuto y se calculará la media.&lt;br&gt;- Presencia de una MAPA de 48 horas patológica en la visita basal. Definido MAPA patológica según los criterios de la Sociedad Europea de HTA: media diurna (actividad) de la PA sistólica/PA diastólica &gt; de 135/85 mmHg o la media nocturna (ciclo de descanso) &gt; de 120/70 mmHg.&lt;br&gt;- El sujeto comprende y acepta los procedimientos del ensayo y otorga por escrito su consentimiento informado.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Hipervolemia definida como presencia de edemas maleolares o insuficiencia cardiaca.&lt;br&gt;- Pacientes con patología terminal y pronóstico de vida inferior a un año.&lt;br&gt;- Historia clínica con alergia o intolerancia confirmada o probable a alguno de los principios activos usados en el estudio.&lt;br&gt;- Embarazo o periodo de lactancia&lt;br&gt;- Trastornos obstructivos biliares o insuficiencia hepática grave&lt;br&gt;- Historia de incumplimiento de tratamiento médico o no disposición a cumplir con el protocolo del estudio.&lt;br&gt;- Consumidores de alcohol o drogas.&lt;br&gt;- HTA severa (grado 3 según criterios de la Sociedad Europea de HTA, PA sistólica = 180 mmHg y/o PA diastólica = 110 mmHg)&lt;br&gt;- Tratamiento con un ARA-II en los 15 días previos del inicio del estudio.&lt;br&gt;-Cualquier enfermedad o alteración analítica que a criterio del investigador contraindique la participación del paciente en el estudio.&lt;br&gt;-Pacientes que hayan participado en otro ensayo clínico, o donado sangre durante los 3 meses anteriores al inicio del presente estudio. &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Pacientes con insuficiencia renal crónica en programa de hemodiálisis</Condition>
    <Intervention>&lt;br&gt;Trade Name: Micardis&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Telmisartan&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 40 o 80-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluar la eficacia del telmisartan en el control de la PA en pacientes con insuficiencia renal en programa crónico de hemodiálisis a través de la reducción de la PA sistólica y diastólica medida por MAPA a las 16 semanas comparando respecto al basal.;Secondary Objective: Evaluar la eficacia del telmisartan en la reducción de la PA medida mediante esfingomanometría&lt;br&gt;&lt;br&gt;Evaluar el % de pacientes que responden y/o normalizan la PA&lt;br&gt;&lt;br&gt;Evaluar la eficacia del telmisartan en el control de la PA media durante el periodo de día-actividad y la PA media durante el periodo de noche-descanso.&lt;br&gt;&lt;br&gt;Evaluar la seguridad del telmisartan en esta población de pacientes.&lt;br&gt;;Primary end point(s): El criterio de valoración principal de este estudio es la reducción de la PA sistólica y diastólica medida por MAPA a las 16 semanas comparando respecto a visita basal.</Primary_outcome>
    <Secondary_ID>FP 2007/01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2466454</Internal_Number>
    <TrialID>EUCTR2007-004284-21-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A prospective randomized study of antibiotic prophylaxis for renal transplantation: short term vs standard treatment - ND</Public_title>
    <Scientific_title>A prospective randomized study of antibiotic prophylaxis for renal transplantation: short term vs standard treatment - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI</Primary_sponsor>
    <Date_registration3>20080104</Date_registration3>
    <Date_registration>04/01/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004284-21                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>06/07/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;renal transplantation - age 18-65 years&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;increased risk for infections for diabetes, BMI &gt;30Kg/m2,WBC &lt; 3500, age&gt;65 years and &lt;18years&lt;br&gt;</Exclusion_Criteria>
    <Condition>antibiotic prophylaxis for renal tranplantation &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038533
Term: Renal transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: CEFAZOLINA TEVA&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;INN or Proposed INN: Cefazolin&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Superiority of single dose - same incidence of infectious complications;Secondary Objective: Incidence of infections - use of antibiotics (dose and days of treatment) - mean hospitalization;Primary end point(s): low incidence of infections - low toxicity - low costs</Primary_outcome>
    <Secondary_ID>987</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2466840</Internal_Number>
    <TrialID>EUCTR2008-000102-36-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Immunosoppressive protocol based on everolimus and calcineurin inhibitor low doses in lung transplant recipients with moderate-severe kidney disease after standard immnuotherapy. - ND</Public_title>
    <Scientific_title>Immunosoppressive protocol based on everolimus and calcineurin inhibitor low doses in lung transplant recipients with moderate-severe kidney disease after standard immnuotherapy. - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>OSPEDALE POLICLINICO S. MATTEO</Primary_sponsor>
    <Date_registration3>20080220</Date_registration3>
    <Date_registration>20/02/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000102-36                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>21/02/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;eta' &gt; 18 anni Maschi o femmine seguiti in follow-up presso il nostro centro in regime ambulatoriale, trapianto, di polmone singolo o doppio o cuore polmone, da almeno 6 mesi alla data di inclusione nello studio, valori di creatinina persistentemente (per la durata del periodo di screening) &gt;/= a 1.50 mg/dl, quadro istologico di nefrotossicita' cronica da ciclosporina &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Saranno esclusi pazienti con, ad esame istologico, presenza di nefropatia primitiva o secondaria (ad es. nefrite interstiziale, glomerulosclerosi diabetica, glomerulosclerosi ipertensiva con ialinosi arteriolare intimale), riscontro di proteinuria significativa &gt; di 0.6 gr/24 ore, riceventi di trapianto renale, riceventi di trapianto polmonare (polmone singolo o doppio, o cuore polmone) da meno di 6 mesi all’atto del reclutamento, portatori nel post-trapianto di una patologia neoplastica sia cutanea che viscerale o ematologica, con significativo grado di compromissione tossica midollare (&gt;/= a 2: secondo i criteri del NCI corrispondenti ad una conta nel sangue periferico di neutrofili &lt;/= 1500/mcl e/o di piastrine &lt;/= 75.000 /mcl), con evidenza di infezione o colonizzazione cronica delle vie aeree o dei seni paranasali da parte di batteri multireristenti o funghi, con infezione cronica da Virus epatite B o C, con persistente incremento di EBVDNA-emia &gt; 5000 gEq/100.000 cellule mononucleate controllate a tempo -3 e 0, con un declino funzionale del graft tale da configurare una diagnosi di rigetto cronico (sindrome da bronchiolite obliterante) di grado &gt;2 (sulla base delle recenti linee guida ISHLT), con stenosi significative a livello delle anastomosi bronchiali complicate da evidenza di cronica colonizzazione batterica o fungina, gia' inclusi in altri protocolli di trattamento sperimentali, con nota ipersensibilita' o che abbiano presentato reazioni avverse con tacrolimus o everolimus. &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>kidney disease after pulmonary transplant &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038474
Term: Renal insufficiency
</Condition>
    <Intervention>&lt;br&gt;Trade Name: CERTICAN&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: .5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: to obtain a significative reduction of slope of curve after one year of treatment;Secondary Objective: to evaluate graft immunological and infective complications;Primary end point(s): significative reduction of slope of curve after one year of treatment.</Primary_outcome>
    <Secondary_ID>Everopolm</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2467207</Internal_Number>
    <TrialID>EUCTR2007-004014-13-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Etude française, randomisée, controlée, parallèle, en ouvert, multicentrique, comparant le maintien du taux d’hémoglobine avec une administration mensuelle de C.E.R.A. (activateur continu du récepteur de l’érythropoïétine) versus epoetin beta ou darbepoetin alfa chez des patients insuffisants rénaux chroniques hémodialysés. - HELYS</Public_title>
    <Scientific_title>Etude française, randomisée, controlée, parallèle, en ouvert, multicentrique, comparant le maintien du taux d’hémoglobine avec une administration mensuelle de C.E.R.A. (activateur continu du récepteur de l’érythropoïétine) versus epoetin beta ou darbepoetin alfa chez des patients insuffisants rénaux chroniques hémodialysés. - HELYS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>ROCHE</Primary_sponsor>
    <Date_registration3>20080401</Date_registration3>
    <Date_registration>01/04/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004014-13                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>27/05/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;• Patient ayant délivré un consentement de participation écrit&lt;br&gt;• Patient adulte âgé de plus de 18 ans&lt;br&gt;• Patient atteint d’une insuffisance rénale chronique associée à une anémie, hémodialysé régulièrement avec la même technique de dialyse et à la même fréquence (3 fois par semaine) depuis au moins 12 semaines&lt;br&gt;• Patient ayant un Kt/V = 1.2 (ou URR = 70%)&lt;br&gt;• Patient ayant un taux moyen d’hémoglobine (Hb) compris entre [10 ; 12] g/dL sur les 3 valeurs de la période de baseline (semaines -4, -2 et J0)&lt;br&gt;• Patient ayant un traitement de maintenance continu en sous-cutané ou en intraveineux par epoetin beta, une, deux ou trois fois, par semaine, ou par darbepoetin alfa, une fois par semaine ou une fois toutes les deux semaines, avec la même fréquence d’administration et sans modification de la dose totale hebdomadaire dans les 4 semaines avant et pendant la période de baseline.&lt;br&gt;• Patient ayant un statut martial adéquat : ferritine sérique &gt; 100 ng/mL et TSAT &gt; 20% (ou pourcentage de globules rouges hypochromes &lt; 10%)&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;• Patient présentant un saignement aigu ou chronique significatif, comme un saignement d’origine gastro-intestinale&lt;br&gt;• Patient recevant une ou plusieures transfusion de culots globulaires dans les 8 semaines précédant la période de baseline&lt;br&gt;• Patient ayant une dose hebdomadaire d’epoetin beta &gt; 16000 UI ou une dose hebdomadaire de darbepoetin alfa &gt; 80 µg dans les 4 semaines avant et pendant la période de baseline (soit 8 semaines avant l’inclusion)&lt;br&gt;• Patient présentant un greffon allogénique en place&lt;br&gt;• Patient présentant une hémoglobinopathie (anémie falciforme homozygote, thalassémie de tous types)&lt;br&gt;• Patient présentant une hémolyse&lt;br&gt;• Patient présentant une maladie maligne active dans les 5 dernières années (excepté les cancers cutanés hors mélanomes) &lt;br&gt;• Patient ayant un déficit connu en Vitamine B12&lt;br&gt;• Patient ayant un déficit connu en acide folique&lt;br&gt;• Patient ayant une hyperparathyroïdie secondaire on controlée ou symptomatique&lt;br&gt;• Patient présentant une hypertension artérielle mal contrôlée, c’est-à-dire une pression artérielle assise &gt; 170/100 mmHg et nécessitant une interruption de traitement par epoetin beta/darbepoetin alfa dans les 6 mois précédant la période de baseline&lt;br&gt;• Patient présentant une crise d’épilepsie dans les 6 mois précédant la période de baseline&lt;br&gt;• Patient présentant un infarctus du myocarde, un accident vasculaire cérébral, une coronaropathie sévère ou instable, une maladie hépatique sévère dans les 12 semaines précédant la période de baseline&lt;br&gt;• Patient présentant une insuffisance cardiaque congestive (stade III-IV de la New York Heart Association)&lt;br&gt;• Patient présentant un nombre de plaquettes &gt; 500 x 10.9/L ou &lt; 100 x 10.9/L&lt;br&gt;• Patient présentant une érythroblastopénie&lt;br&gt;• Patient ayant une chirurgie planifiée pendant la durée de l’étude excepté pour la cataracte et pour la voie d’abord vasculaire&lt;br&gt;• Femme enceinte ou allaitant&lt;br&gt;• Femme en période d’activité génitale sans contraception efficace&lt;br&gt;• Patient participant ou ayant participé à un essai clinique dans les 3 derniers mois&lt;br&gt;• Patient présentant une hypersensibilité connue à une érythropoïétine recombinante, au polyethylène glycol ou tout autre constituant du traitement à l’étude&lt;br&gt;•Patient ayant un catheter de dialyse temporaire non tunnélisé&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients insuffisants rénaux chroniques hémodialysés &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10054353
Term: Chronic renal failure anemia
</Condition>
    <Intervention>&lt;br&gt;Product Code: RO503821/F03&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F04&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 75-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F05&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F21&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 120-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F06&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 150-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F07&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F08&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Trade Name: NeoRecormon&lt;br&gt;Product Code: RO2053859&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Epoet</Intervention>
    <Primary_outcome>Main Objective: Comparer le maintien du taux d'hémoglobine avec une administration mensuelle sous-cutanée ou intraveineuse de C.E.R.A. versus l'administration sous-cutanée ou intra-veineuse d'epoetin beta ou de darbepoetin alfa chez des patients insuffisants rénaux chroniques hémodialysés;Secondary Objective: * Evaluer la variabilité de l’hémoglobine avec une administration mensuelle sous cutanée ou intraveineuse de C.E.R.A. dans cette population de patients.&lt;br&gt;* Evaluer la tolérance avec une administration mensuelle sous-cutanée ou intraveineuse de C.E.R.A. dans cette population de patients.&lt;br&gt;;Primary end point(s): Proportion de patients maintenant un taux d’hémoglobine moyen dans l’intervalle [10 ; 12] g/dL pendant la période d’évaluation (S16 à S24)&lt;br&gt;</Primary_outcome>
    <Secondary_ID>ML21145</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2467343</Internal_Number>
    <TrialID>EUCTR2008-000948-13-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Etude de phase II, multicentrique, en ouvert, évaluant l'efficacité d'un traitement par Sutent (sunitinib) chez des patients porteurs de métastases cérébrales d'origine rénale non traitées antérieurement ou en reprise évolutive après radiothérapie ou chirurgie
 - Sutent Métastases cérébrales</Public_title>
    <Scientific_title>Etude de phase II, multicentrique, en ouvert, évaluant l'efficacité d'un traitement par Sutent (sunitinib) chez des patients porteurs de métastases cérébrales d'origine rénale non traitées antérieurement ou en reprise évolutive après radiothérapie ou chirurgie
 - Sutent Métastases cérébrales                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Institut Claudius Regaud</Primary_sponsor>
    <Date_registration3>20080414</Date_registration3>
    <Date_registration>14/04/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000948-13                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>04/07/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;-               Homme ou femme âgé(e) de 18 ans ou plus.&lt;br&gt;&lt;br&gt;-	Patient porteur d’un adénocarcinome du rein métastatique de toute forme histologique. Preuve cytologique ou histologique, avec grade de Fürhman, obligatoire.&lt;br&gt;	Strate 1 : présence de métastases cérébrales non traitées, non symptomatiques ou avec symptomatologie contrôlée (non évolutive depuis au moins 2 semaines sous traitement) ;&lt;br&gt;                Strate 2 : présence de métastases cérébrales en reprise évolutive après radiothérapie ou chirurgie (récidive sur le site du traitement).&lt;br&gt;&lt;br&gt;-	Patient non traité par sunitinib. Les patients antérieurement traités par sunitinib peuvent être inclus si un intervalle libre d’au moins 6 mois entre la fin du traitement et l’inclusion est respecté.&lt;br&gt;&lt;br&gt;-	PS ECOG. £ 2 (échelle OMS), sauf si parésie liée à métastase cérébrale.&lt;br&gt;&lt;br&gt;-	Maladie mesurable selon les critères RECIST (au moins une lésion mesurable).&lt;br&gt;&lt;br&gt;-	Patient présentant, dans les 7 jours précédant l’inclusion, des constantes hématologiques, paramètres fonctionnels rénaux et hépatiques tels que les numérations sanguines ou taux sériques, conformes aux valeurs suivantes :&lt;br&gt;•	Hémoglobine &gt; 8 g/dL,&lt;br&gt;•	Polynucléaires neutrophiles &gt; 1,5 G/L,&lt;br&gt;•	Plaquettes &gt; 100 G/L,&lt;br&gt;•	Créatinine sérique &lt; 200 µmol/L,&lt;br&gt;•	Bilirubine totale &lt; 1,5 fois la LSN,&lt;br&gt;•	ALAT et ASAT &lt; 2,5 fois la LSN ou &lt; 5 fois la LSN pour les patients avec métastases hépatiques,&lt;br&gt;•	TP ou INR &lt; 1,5 fois la limite supérieure à la normale en l’absence de traitement anticoagulant.(Les patients sous traitement anticoagulant à titre préventif peuvent être inclus)&lt;br&gt;&lt;br&gt;-	Homme et femme en âge de procréer utilisant une méthode de contraception efficace avant d’entrer dans l’étude et ce jusqu’à 30 jours après l’administration du dernier traitement à l’essai.&lt;br&gt;&lt;br&gt;-	Patient affilié à un régime de sécurité sociale.&lt;br&gt;&lt;br&gt;-	Patient capable de comprendre, de lire et d’écrire le français.&lt;br&gt;&lt;br&gt;-	Patient ayant daté et signé un consentement éclairé.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-               Métastase cérébrale révélée par une hémorragie.&lt;br&gt;&lt;br&gt;-	Présence d’une métastase cérébrale unique &lt; 2 cm, accessible à une prise en charge chirurgicale ou par radio-chirurgie.&lt;br&gt;&lt;br&gt;-	Patient présentant des antécédents d’autre cancer hormis un cancer in situ du col utérin, ou un carcinome cutané basocellulaire traité de manière curative, ou tout autre cancer traité de manière curative et sans signe de récidive pendant au moins 5 ans.&lt;br&gt;&lt;br&gt;-	Traitement antinéoplasique antérieur dont l’intervalle libre entre la fin du traitement et l’inclusion est inférieur à 6 mois pour le sunitinib et 4 semaines pour les autres traitements.&lt;br&gt;&lt;br&gt;-	Administration de facteurs de croissance hématopoïétiques (G-CSF, GM-CSF) dans les 3 semaines précédant l’inclusion.&lt;br&gt;&lt;br&gt;-	HTA non contrôlée par un traitement adapté (PAsystolique = 160 mm Hg et/ou PAdiastolique = 90 mm Hg).[La méthode recommandée pour la mesure de la pression artérielle est la mesure par la méthode auscultatoire, au moyen d'un sphygmomanomètre à mercure, le patient étant depuis plusieurs minutes en position assise ou couchée. La mesure devra être systématiquement répétée au minimum 2 fois]&lt;br&gt;&lt;br&gt;-	Affection cardiovasculaire significative (insuffisance cardiaque congestive &gt; classe 2 de la NYHA, IDM dans les 6 mois précédant l’inclusion, angor instable, troubles du rythme graves, AVC dans les 6 mois précédant l’inclusion, antécédents thromboemboliques sévères dans les 6 mois précédant l’inclusion).&lt;br&gt;&lt;br&gt;-	Patient traité par anti-vitamine K à doses curatives ou par anti-aggrégant.&lt;br&gt;&lt;br&gt;-	Patient porteur d'une maladie neuropsychiatrique grave.&lt;br&gt;&lt;br&gt;-	Femme enceinte ou allaitante (test de grossesse sérique ou urinaire &lt;br&gt;négatif au moment de l'entrée dans l'étude pour toutes les femmes en âge de procréer).&lt;br&gt;&lt;br&gt;-	Patient privé de liberté par décision de justice ou administrative.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients porteurs de métastases cérébrales d'origine rénale non traitées antérieurement ou en reprise évolutive après radiothérapie ou chirurgie &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10028979
Term: Neoplasia renal
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sutent 12.5mg gélules&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: sunitinib malate&lt;br&gt;CAS Number: 341031-54-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 25-50&lt;br&gt;&lt;br&gt;Trade Name: Sutent 25mg gélules&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: sunitinib malate&lt;br&gt;CAS Number: 341031-54-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 25-50&lt;br&gt;&lt;br&gt;Trade Name: Sutent 50mg gélules&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: sunitinib malate&lt;br&gt;CAS Number: 341031-54-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Déterminer dans chacune des strates de l’étude l’efficacité du sunitinib dans le traitement des métastases cérébrales du cancer du rein en estimant le taux de réponses objectives sur l’encéphale après 2 cycles de traitement, réponse évaluée par IRM et définie selon les critères RECIST.;Secondary Objective: Evaluer dans les 2 strates : &lt;br&gt;§	la durée de la réponse&lt;br&gt;§	la réponse objective sur les cibles hors SNC&lt;br&gt;§	le temps jusqu’à progression de la maladie&lt;br&gt;§	la survie sans progression &lt;br&gt;§	la survie globale &lt;br&gt;§	l’évolution des symptômes neurologiques liés à la tumeur&lt;br&gt;§	la faisabilité et la tolérance globale du traitement ;Primary end point(s): Déterminer dans chacune des strates de l’étude l’efficacité du sunitinib dans le traitement des métastases cérébrales du cancer du rein en estimant le taux de réponses objectives sur l’encéphale après 2 cycles de traitement, réponse évaluée par IRM et définie selon les critères RECIST (comité centralisé de relecture des IRM).</Primary_outcome>
    <Secondary_ID>07URO02</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2467479</Internal_Number>
    <TrialID>EUCTR2007-005844-26-BE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Multicentre, prospective, randomized, open-label, controlled study in de novo kidney transplant recipients to evaluate the impact of cyclosporine or steroid withdrawal at 3 months on graft function, patient and graft survival, and cardiovascular surrogate markers during the first five years after transplantation. - Cistcert</Public_title>
    <Scientific_title>Multicentre, prospective, randomized, open-label, controlled study in de novo kidney transplant recipients to evaluate the impact of cyclosporine or steroid withdrawal at 3 months on graft function, patient and graft survival, and cardiovascular surrogate markers during the first five years after transplantation. - Cistcert                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Antwerp University Hospital</Primary_sponsor>
    <Date_registration3>20080425</Date_registration3>
    <Date_registration>25/04/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005844-26                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>16/06/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;?	Male or female recipients of a de novo kidney transplant, aged above 18 yrs.&lt;br&gt;?	Women of childbearing potential must have a negative serum or urine pregnancy test with sensitivity equal to at least 50 mIU/ml.&lt;br&gt;?	Patients must be capable of understanding the purpose and risks of the study, and must sign an informed consent form&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;?	Multiple organ transplantation (e.g. Kidney-pancreas, kidney-heart, kidney-liver,…)&lt;br&gt;?	Transplantation of a patient who got another organ transplant previously&lt;br&gt;?	Recipients of a HLA-identical living-related renal transplant&lt;br&gt;?	Patients with PRA &gt; 30%, patients who have lost a first graft from rejection within two years after transplantation, and African European patients.&lt;br&gt;?	Patients with primary renal disease at risk for recurrence: FSGS, MPGN, HUS&lt;br&gt;?	Pregnant or lactating women&lt;br&gt;?	WBC &lt; 2.5 x 109/l (IU), platelet count &lt; 100 x 109/l (IU), or Hb &lt; 6 g/dl at the time of entry into the study&lt;br&gt;?	Active peptic ulcer&lt;br&gt;?	Severe diarrhea or other gastrointestinal disorder, which might interfere with their ability to absorb oral medication, including diabetic patients with previously diagnosed diabetic gastroenteropathy&lt;br&gt;?	Known HIV-1 or HTLV-1 positive tests&lt;br&gt;?	The use of investigational drugs or other immunosuppressive drugs, as those specified in this protocol&lt;br&gt;?	Patients receiving bile acid sequestrants&lt;br&gt;?	Psychological illness or condition, interfering with the patient’s compliance or ability to understand the requirements of the study.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Preservation of renal function after kidney transplantation in a 5-year, multicentre, prospective, randomized, open-label, controlled study

Patients will be randomized within 24 hours prior to transplantation.

?	Group 1: Simulect + Neoral + Myfortic + steroid stop at 3 months

?	Group 2: Simulect + Neoral (decrease dose in one week at mo 3 and replace by Certican) + Myfortic + steroid maintenance.  



</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican 0.25 mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: EVEROLIMUS&lt;br&gt;CAS Number: 159351696&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.25-&lt;br&gt;&lt;br&gt;Trade Name: Certican 0.50 mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: EVEROLIMUS&lt;br&gt;CAS Number: 159351696&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.50-&lt;br&gt;&lt;br&gt;Trade Name: Certican 0.75 mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: EVEROLIMUS&lt;br&gt;CAS Number: 159351696&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.75-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess if superior graft function (GFR difference of 10 ml/min) will be achieved at 1 year after transplantation in cohorts of de novo kidney transplant patients treated with Myfortic-Certican plus steroids compared to Myfortic-Neoral.   ;Secondary Objective: 1.	Efficacy variables:&lt;br&gt;To compare the evolution of graft function during the first 5 years post transplantation.&lt;br&gt;To compare the evolution of intragraft lesions (subclinical rejections, fibrosis, vasculopathy, and glomerular lesions) in protocol biopsies at baseline, and at one year.&lt;br&gt;To compare the number and severity of BPAR.&lt;br&gt;To compare patient and graft survival. &lt;br&gt;&lt;br&gt;2.	Safety variables:&lt;br&gt;To compare the incidence of malignancy.&lt;br&gt;To compare the incidence of MACES.&lt;br&gt;To compare the progression of atherosclerosis by means of exploration of carotid artery with doppler echography (thickness of intima/media, IMT).&lt;br&gt;To compare the evolution of left ventricular mass by echocardiography.&lt;br&gt;To compare the development of proteinuria.&lt;br&gt;To compare the safety profile by assessing the incidence of hypertension, hyperlipidemia, diabetes mellitus, infections and bone marrow toxicity. &lt;br&gt;;Primary end point(s): graft function (GFR measured by 51 CrEDTA clearance) at 1 year </Primary_outcome>
    <Secondary_ID>Cistcert</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2467736</Internal_Number>
    <TrialID>EUCTR2007-001503-38-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>effect of everolimus on adult polycystic nephropaty; a study pilot - PolEver</Public_title>
    <Scientific_title>effect of everolimus on adult polycystic nephropaty; a study pilot - PolEver                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>AZIENDA OSPEDALIERA PROVINCIALE DI LECCO</Primary_sponsor>
    <Date_registration3>20080603</Date_registration3>
    <Date_registration>03/06/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001503-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>05/06/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;male and female ADPKD mayor 18 , estimated GFR between 30 and 60 mil/min/1.73 mq, almost 1 creatinine value/year in the previous 2 years, progressive renal insufficiency&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;female of childbearing potential who is planning to become pregnant. granulocytopenia or thrombocytopenia,hyperlipidemia&lt;br&gt;</Exclusion_Criteria>
    <Condition>Autosomal Dominant Plycystic Kidney Disease &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10010607
Term: Congenital renal cyst
</Condition>
    <Intervention>&lt;br&gt;Trade Name: CERTICAN&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: .75-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: the aim of the study is to investigate wheter everolimus ratards cyst growth and slow renal funcional deterioration in patients with ADPKD;Secondary Objective: a positiv influence of everolimus on ADPKD in adults;Primary end point(s): glomerular filtration rate at any visit</Primary_outcome>
    <Secondary_ID>PolEver</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2467754</Internal_Number>
    <TrialID>EUCTR2006-001787-23-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A 12-week, open label, multicenter, titration study, with a 9-month maintenance treatment extension, to demonstrate efficacy of SBR759 compared to sevelamer HCl in lowering serum phosphate levels in Chronic Kidney Disease patients on hemodialysis</Public_title>
    <Scientific_title>A 12-week, open label, multicenter, titration study, with a 9-month maintenance treatment extension, to demonstrate efficacy of SBR759 compared to sevelamer HCl in lowering serum phosphate levels in Chronic Kidney Disease patients on hemodialysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Novartis Pharma Services AG</Primary_sponsor>
    <Date_registration3>20080606</Date_registration3>
    <Date_registration>06/06/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-001787-23                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>04/08/2008</Date_enrollement>
    <Target_size>378</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: Stratified per serum phosphorus levels (&lt;or&gt;= to 75.mg/dL)&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Patients must give written informed consent before any assessment is performed.&lt;br&gt;2. Men or women of at least 18 years old.&lt;br&gt;3. Patient must be treated with a stable maintenance hemodialysis (i.e. no change in dialysis material and parameters) 3 times per week for &gt; 3 months before screening and planned to be maintained the same throughout the study duration.&lt;br&gt;4. Patient must be on restricted phosphate diet at screening and throughout the study.&lt;br&gt;5. Patient has a controlled serum phosphate &gt; 3.0 mg/dL (&gt; 0.97 mmol/L) and &lt; 6.0 mg/dL (&lt; 1.9 mmol/L), as indicated by the average of the 2 latest pre-dialysis laboratory values reported prior to screening, if currently under phosphate binder therapy.&lt;br&gt;6. Patient has a serum phosphate level &gt; 6.0 mg/dL (&gt; 1.9 mmol/L), obtained from central laboratory, prior to study treatment initiation.&lt;br&gt;7. Patient must have a Urea Reduction Ratio of &gt; 65% (obtained within 2 weeks prior to screening).&lt;br&gt;8. If patient has a history of parathyroidectomy, iPTH and calcium-phosphate product levels should be stable within 30 days prior to screening.&lt;br&gt;9. Patient must be on a stable phosphate binder dose (i.e. No change in prescribed dose) for at least 30 days prior to screening, or is newly diagnosed with hyperphosphatemia and has not initiated treatment with phosphate binder yet.&lt;br&gt;10. Patient must, in the investigator’s opinion, be compliant with prescribed phosphate binders.&lt;br&gt;11. If patient is currently being treated with calcimimetics, the prescribed dose must be constant for at least 30 days prior to screening and should remain constant during the total core study duration.&lt;br&gt;12. If patient is currently being treated with vitamin D, the prescribed dose must be constant for at least 30 days prior to screening and should remain constant during the total core study duration.&lt;br&gt;13. If patient is currently being treated with IV iron, the prescribed dose must be constant for at least 30 days prior to screening and should remain constant during the total core study duration.&lt;br&gt;14. If patient is currently being treated for osteoporosis, the prescribed dose must be constant for at least 30 days prior to screening and during the total core study duration.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Patient is on peritoneal dialysis or a non-conventional hemodialysis technique (e.g.&lt;br&gt;hemofiltration, hemodiafiltration)&lt;br&gt;2. Patient has a parathyroidectomy or transplant scheduled during the study.&lt;br&gt;3. Patient has an uncontrolled hyperparathyroidism (i.e. intact PTH &gt; 800 pg/mL within 30 days prior to study screening)&lt;br&gt;4. Patient has a history of hemochromatosis or ferritin &gt; 800 µg/L.&lt;br&gt;5. Patient has a clinically significant GI disorder (i.e. swallowing disorder, active dysphagia, bowel obstruction, severe GI motility disorder)&lt;br&gt;6. Patient has a chronic unstable GI disorder (e.g. Irritable Bowel Syndrome, Inflammatory Bowel Disease, chronic abdominal pain, chronic diarrhea)&lt;br&gt;7. Patient has an history of major gastrointestinal tract surgery such as gastrectomy,&lt;br&gt;gastroenterostomy, or bowel resection.&lt;br&gt;8. Patient has a clinically significant unstable medical condition (e.g. uncontrolled diabetes, etc.), other than Chronic Kidney Disease.&lt;br&gt;9. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.&lt;br&gt;10. Patient is known to currently have a drug or alcohol abuse problem.&lt;br&gt;11. Patient has a known history of immunodeficiency disease, e.g. existing positive HIV (ELISA or Western blot) test result.&lt;br&gt;12. Patient is / has been treated with sevelamer HCl monotherapy or SBR759 within 3 months prior to screening.&lt;br&gt;13. History of intolerance to sevelamer HCl.&lt;br&gt;14. Patient is currently being treated with oral iron.&lt;br&gt;15. Patient currently has an active infection or is being treated with antibiotics (within 14 days prior to screening).&lt;br&gt;16. Patient currently has an active antiviral treatment for Hepatitis B and/or C (within 30 days prior to screening).&lt;br&gt;17. Patient is currently being treated with anti-seizure medications for the control of a seizure disorder (i.e. phenobarbital, valproate, carbamazepine)&lt;br&gt;18. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 halflives of enrollment, whichever is longer&lt;br&gt;19. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes&lt;br&gt;20. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation&lt;br&gt;21. Women of child-bearing potential, defined as all women physiologically capable of&lt;br&gt;becoming pregnant. UNLESS they are using a highly effective method of birth control&lt;br&gt;(i.e. one that results in a less than 1% per year failure rate when used consistently and correctly, such as implants, injectables, combined oral contraceptives, and some&lt;br&gt;intrauterine devices (IUDs). Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) are not acceptable.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Hyperphosphataemia in patients with Chronic Kidney Disease (CKD) on hemodialysis &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10020712
Term: Hyperphosphatemia
</Condition>
    <Intervention>&lt;br&gt;Product Name: SBR759 &lt;br&gt;Product Code: SBR759&lt;br&gt;Pharmaceutical Form: Powder for oral suspension&lt;br&gt;INN or Proposed INN: not yet established&lt;br&gt;Current Sponsor code: SBR759-NXA 001&lt;br&gt;Other descriptive name: Fe(OH)+ Starch + saccharose complex&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000 mg -&lt;br&gt;&lt;br&gt;Product Name: SBR759 &lt;br&gt;Product Code: SBR759&lt;br&gt;Pharmaceutical Form: Powder for oral suspension&lt;br&gt;INN or Proposed INN: not yet established&lt;br&gt;Current Sponsor code: SBR759-NXA 001&lt;br&gt;Other descriptive name: Fe(OH)+ Starch + saccharose complex&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1500 mg-&lt;br&gt;&lt;br&gt;Trade Name: Renagel &lt;br&gt;Product Name: RENAGEL&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: sevelamer hydrochloride&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 800mg-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: This study is designed to demonstrate superior or at least non-inferior&lt;br&gt;efficacy of SBR759 in phoshate binding,  versus sevelamer HCl and evaluate safety over a long term exposure. Efficacy will be measured by the number of patients with a serum phosphate level below or equal to 5.5 mg/dl (i.e. 1.78 mmol/L) at 12 weeks;Primary end point(s): To demonstrate superior efficacy or at least non-inferiority of SBR759 compared to sevelamer HCl, as measured by the number of patients with a serum phosphate level below or equal to 5.5 mg/dl (i.e. 1.78 mmol/L) at 12 weeks.;Secondary Objective: To evaluate safety and tolerability of SBR759 compared to sevelamer HCl over a 12-week period.&lt;br&gt;To evaluate whether SBR759 has superior efficacy at week 12 compared to sevelamer HCl, as measured by the number of patients with a serum calcium-phosphate product levels below or equal to 55 mg2/dL2.&lt;br&gt;to evaluate whether SBR759 is associated with less increase in serum iPTH levels compared to sevelamer HCl at 12 weeks&lt;br&gt;to evaluate whether SBR759 has an equivalent rate of hypercalcemia events at 12 weeks compared to sevelamer HCl as measured by serum calcium levels&lt;br&gt;to evaluate changes in patient-reported gasrointestinal symptom burden, using gastrointestinal symptom rating scale (GSRS) total and subscales scores, in patients treated with SBR759 compared to patients treated with sevelamer HCl</Primary_outcome>
    <Secondary_ID>CSBR759A2201</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2468037</Internal_Number>
    <TrialID>EUCTR2008-001204-23-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio comparativo de mupirocina versus acido fusidico tópico en la erradicación de portadores nasales de Staphylococcus aureus en pacientes con insuficiencia renal crónica en hemodiálisis por cateter permanente</Public_title>
    <Scientific_title>Estudio comparativo de mupirocina versus acido fusidico tópico en la erradicación de portadores nasales de Staphylococcus aureus en pacientes con insuficiencia renal crónica en hemodiálisis por cateter permanente                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Dra. Beatriz Sanchez Sobrino</Primary_sponsor>
    <Date_registration3>20080702</Date_registration3>
    <Date_registration>02/07/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-001204-23                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>01/09/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;-El rango de edad estará comprendido entre los 18 y los 80 años. &lt;br&gt;-Insuficiencia renal crónica estadio 5 en programa de hemodiálisis cuyo acceso vascular sea catéter permanente.&lt;br&gt;-Consentimiento informado escrito, conforme a ICH/GCP y a la legislación local, obtenido antes de cualquier procedimiento de estudio.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-Rechazo o incapacitación para otorgar el consentimiento informado por escrito.&lt;br&gt;-Embarazo o lactancia en curso.&lt;br&gt;-Alergia conocida a medicamentos del estudio (mupirocina y/ó ácido fusídico).&lt;br&gt;-Pacientes con cualquier valor analítico anormal clínicamente significativo según la opinión del investigador médico en la selección. &lt;br&gt;-Participación en otros ensayos clínicos con fármacos en los 3 meses previos.&lt;br&gt;-Donación de sangre en los tres meses previos al comienzo del estudio.&lt;br&gt;-Incapacidad para cumplir los procedimientos del protocolo.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Pacientes con insuficiencia renal crónica estadio 5 en Hemodialisis que se encuentren realizando la técnica mediante un acceso vascular tipo catéter central permanente tunelizado portadores nasales de Pacientes con insuficiencia renal crónica estadio 5 en Hemodialisis que se encuentren realizando la técnica mediante un acceso vascular tipo catéter central permanente tunelizado portadores nasales de Staphylococcus aureus.</Condition>
    <Intervention>&lt;br&gt;Trade Name: FUCIDINE POMADA&lt;br&gt;Product Name: FUCIDINE POMADA&lt;br&gt;Pharmaceutical Form: Ointment&lt;br&gt;INN or Proposed INN: FUSIDICO ACIDO&lt;br&gt;CAS Number: 6990-06-3&lt;br&gt;Other descriptive name: FUSIDIC ACID&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 15-&lt;br&gt;&lt;br&gt;Trade Name: BACTROBAN NASAL, pomada&lt;br&gt;Product Name: BACTROBAN NASAL, POMADA&lt;br&gt;Pharmaceutical Form: Nasal ointment&lt;br&gt;INN or Proposed INN: MUPIROCINA CALCICA&lt;br&gt;Other descriptive name: MUPIROCIN CALCIUM&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 3-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Comparar la eficacia del tratamiento tópico con mupirocina versus acido fusidico en pacientes portadores de S aureus con insuficiencia renal crónica estadio 5 en programa de hemodiálisis cuyo acceso vascular sea catéter permanente;Secondary Objective: -Evaluar la seguridad y tolerabilidad de la administración tópica de los fármacos a estudio.&lt;br&gt;-Conocer la prevalencia de portador nasal de Staphylococcus aureus en el Área a estudio. &lt;br&gt;-Establecer un protocolo de profilaxis de infecciones en los sujetos portadores nasales de Staphylococcus aureus;Primary end point(s): La variable principal de eficacia será la tasa de erradicación a las 48 horas desde la finalización del tratamiento</Primary_outcome>
    <Secondary_ID>MUFU001-SA-01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2468173</Internal_Number>
    <TrialID>EUCTR2007-003649-34-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>RENAL RESCUE IMMUNOSUPPRESSION FOLLOWING HEART TRANSPLANTATION - RRescue Trial</Public_title>
    <Scientific_title>RENAL RESCUE IMMUNOSUPPRESSION FOLLOWING HEART TRANSPLANTATION - RRescue Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>University Hospital of South Manchester NHS Foundation Trust</Primary_sponsor>
    <Date_registration3>20080627</Date_registration3>
    <Date_registration>27/06/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-003649-34                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>08/08/2008</Date_enrollement>
    <Target_size>56</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Stable patients more than 6 months after heart transplantation, receiving immunosuppression based on cyclosporine or tacrolimus.&lt;br&gt;2.	Moderate renal impairment - serum creatinine 150-220 micro mol/l or GFR (glomerular filtration rate) 30-59, in the 3 months period prior to enrolment in the study.&lt;br&gt;3.	Patients who have given written informed consent to take part in the study.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Acute rejection (grade 3a or above from the ISHLT criteria) requiring treatment in the last 3 months.&lt;br&gt;2.	Alternative causes for renal dysfunction (e.g. renal obstruction, small kidneys or other gross abnormalities).&lt;br&gt;3.	Females of childbearing potential who are planning to become pregnant, who are pregnant who are unwilling to use effective means of contraception. Patients should use a reliable medically approved method of contraception during the trial period. If unwilling or unable to use a medically approved reliable form of contraception then patients should abstain from penetrative sex. &lt;br&gt;It is recommended that MMF or Myfortic therapy should not be initiated until a negative pregnancy test has been obtained. Effective contraception must be used before beginning MMF / Myfortic therapy, during therapy, and for six weeks following discontinuation of therapy. Patients should be instructed to consult their physician immediately should pregnancy occur. &lt;br&gt;The use of MMF / Myfortic is not recommended during pregnancy and should be reserved for cases where no more suitable alternative treatment is available. MMF / Myfortic should be used in pregnant women only if the potential benefit outweighs the potential risk to the foetus. There are no adequate data from the use of MMF / Myfortic in pregnant women. Studies in animals have shown reproductive toxicity. The potential risk for humans is unknown. &lt;br&gt;Mycophenolate mofetil has been shown to be excreted in the milk of lactating rats. It is not known whether this substance is excreted in human milk. Because of the potential for serious adverse reactions to mycophenolate mofetil in breast-fed infants, MMF / Myfortic are contraindicated in nursing mothers.&lt;br&gt;4.	Pre-existing severe cardiac allograft dysfunction (LVEF &lt; 40%).&lt;br&gt;5.	Hb persistently (on 3 consecutive occasions) &lt; 10 g/dl, white cell count persistently (on 3 consecutive occasions) &lt; 4.0 x 109/l.&lt;br&gt;6.	Platelets persistently (on 3 consecutive occasions) &lt; 100 x 109/l&lt;br&gt;7.	Heavy proteinuria without any evidence of urinary infection (&gt;1g/24hrs)&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal impairment following heart transplantation &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10010184
Term: Complications of transplanted heart
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Myfortic&lt;br&gt;Product Name: Mycophenolic acid&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 180-360&lt;br&gt;&lt;br&gt;Trade Name: Neoral&lt;br&gt;Product Name: Ciclosporin&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 10-100&lt;br&gt;&lt;br&gt;Trade Name: Neoral&lt;br&gt;Product Name: Ciclosporin&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Tacrolimus&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 0.5-5&lt;br&gt;&lt;br&gt;Product Name: Azathioprine&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 25-50&lt;br&gt;&lt;br&gt;Trade Name: Cellcept&lt;br&gt;Product Name: Mycophenolate mofetil&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Trade Name: Cellcept&lt;br&gt;Product Name: Mycophenolate mofetil&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Improvement of kidney function 6 months following the introduction of trial medication.&lt;br&gt;;Secondary Objective: •	Efficacy: improvement of renal function at 12 months, treated acute rejection episodes.&lt;br&gt;•	Safety of the trial medications by reduction in adverse events (including infection, haematological and gastrointestinal effects, bleeding, skin rash, pneumonitis, any cause of hospitalization for treatment, death), cardiovascular risk factors, and standard laboratory assessments&lt;br&gt;;Primary end point(s): To show an improvment in renal function at 6 months following the introduction of trial medication ( in the low dose ciclosporin group).</Primary_outcome>
    <Secondary_ID>RRT001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2468205</Internal_Number>
    <TrialID>EUCTR2008-000738-39-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>EFFECTS ON INCIDENCE OF CARDIOVASCULAR EVENTS OF THE ADDITION OF PIOGLITAZONE AS COMPARED WITH A SULFONYLUREA IN TYPE 2 DIABETIC PATIENTS INADEQUATELY
CONTROLLED WITH METFORMIN
Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents (TOSCA) - TOSCA Study</Public_title>
    <Scientific_title>EFFECTS ON INCIDENCE OF CARDIOVASCULAR EVENTS OF THE ADDITION OF PIOGLITAZONE AS COMPARED WITH A SULFONYLUREA IN TYPE 2 DIABETIC PATIENTS INADEQUATELY
CONTROLLED WITH METFORMIN
Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents (TOSCA) - TOSCA Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Societa' Italiana di Diabetologia</Primary_sponsor>
    <Date_registration3>20080716</Date_registration3>
    <Date_registration>16/07/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000738-39                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>02/03/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;-Patients with type 2 diabetes (WHO criteria) of at least 2 years duration&lt;br&gt;-Males and females&lt;br&gt;-Age 50-75 years&lt;br&gt;-BMI 20-40 Kg/m2&lt;br&gt;-Stable treatment for the last three months with metformin in monotherapy&lt;br&gt;-Glycated haemoglobin (HbA1c) &gt;7.0% and &lt;9.0%&lt;br&gt;-Potentially childbearing women must use a reliable contraceptive method&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-Type 1 diabetes&lt;br&gt;-Previous or current use of insulin (if not on pregnancy or for surgery or for intercurrent acute illness).&lt;br&gt;-Current use of glucose lowering therapies other than metformin&lt;br&gt;-Contraindication/intolerance to metformin or sulphonylureas or thiazolidinediones&lt;br&gt;-Chronic use of glucocorticoids&lt;br&gt;-Documented coronary or cerebrovascular events in the previous 6 months&lt;br&gt;-Serum creatinine &gt;1.5 mg/dl&lt;br&gt;-Proliferative retinopathy&lt;br&gt;-Ischemic ulcer or gangrene&lt;br&gt;-History of congestive heart failure, NYHA (New York Heart Association ) class I or higher&lt;br&gt;-Liver cirrhosis or severe hepatic dysfunction (2.5 times the upper limit of normal concentration of alanine aminotransferase)&lt;br&gt;-Pregnancy or breast feeding&lt;br&gt;-Cancer, substance abuse, any health problem that may interfere with the compliance to study protocol or limit life expectancy&lt;br&gt;</Exclusion_Criteria>
    <Condition>diabetes mellitus &lt;br&gt;MedDRA version: 9.1
Level: HLT
Classification code 10012654
Term: Diabetic complications cardiovascular
 &lt;br&gt;MedDRA version: 9.1
Level: HLT
Classification code 10012658
Term: Diabetic complications renal
</Condition>
    <Intervention>&lt;br&gt;Product Name: Pioglitazone&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Pioglitazone&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 15-&lt;br&gt;&lt;br&gt;Product Name: Glibenclamide&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Glibenclamide&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Product Name: Gliclazide&lt;br&gt;Pharmaceutical Form: Modified-release capsule, hard&lt;br&gt;INN or Proposed INN: Gliclazide&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;&lt;br&gt;Product Name: Glimepiride&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Glimepiride&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Our aim is to ascertain whether in patients with type 2 diabetes poorly controlled with the maximal tolerated dose of metformin, the addition of pioglitazone reduces the rate of cardiovascular events as compared with the addition of a SU. Glucose control, major CV risk factors, safety, tolerability and economic costs with the two therapeutic regimens will also be compared. Sample size and study power are calculated on the primary efficacy outcome.;Secondary Objective: PRINCIPAL secondary outcome:&lt;br&gt;-	A composite ischemic end point of: sudden death, fatal and non fatal MI (including silent MI), fatal and non fatal stroke, major leg amputation (above the ankle), endovascular or surgical interventions on the coronary, leg or carotid arteries&lt;br&gt;&lt;br&gt;OTHER secondary outcomes:&lt;br&gt;-	a composite cardiovascular endpoint including the primary endpoint plus  heart failure - by the full version of the Boston criteria - endovascular or surgical intervention on the coronary, leg or carotid arteries, angina - by WHO criteria and confirmed by a new electrocardiogram abnormalities - intermittent claudication with an ankle/brachial index &lt; 0.85;&lt;br&gt;-	glycemic control (changes from baseline in HbA1c, time to failure of oral hypoglycaemic therapy, i.e., HBA1c &gt;8.0% on two consecutive occasions three months apart); &lt;br&gt;-	major cardiovascular risk factors (lipids, blood pressure, microalbuminuria, inflammation markers, waist circumference);&lt;br&gt;-	a microvascular composite e;Primary end point(s): A composite endpoint including: all-causes mortality, non fatal myocardial infarction (MI) - including silent MI- , non fatal stroke, unplanned coronary revascularization</Primary_outcome>
    <Secondary_ID>FARM6T9CET</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2468332</Internal_Number>
    <TrialID>EUCTR2008-000928-71-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>?TWIST?. RANDOMIZED PROSPECTIVE PHASE II STUDY OF TEMSIROLIMUS WITH OR WITHOUT LOW-DOSE INTERFERON ALPHA IN METASTATIC NON-CLEAR RENAL CELL CARCINOMA: GOIRC STUDY 02/2008 - TWIST</Public_title>
    <Scientific_title>?TWIST?. RANDOMIZED PROSPECTIVE PHASE II STUDY OF TEMSIROLIMUS WITH OR WITHOUT LOW-DOSE INTERFERON ALPHA IN METASTATIC NON-CLEAR RENAL CELL CARCINOMA: GOIRC STUDY 02/2008 - TWIST                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>GRUPPO ONCOLOGICO ITALIANO DI RICERCA</Primary_sponsor>
    <Date_registration3>20080710</Date_registration3>
    <Date_registration>10/07/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000928-71                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>14/11/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Stesso farmaco piu' altro farmaco&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Signed informed consent  Histologically or cytologically documented non-clear Cell Renal Carcinoma (with centralized review of histological specimens). In the case of a mixed histology the presence of a documented component of clear cell histology &lt;50% is mandatory. Urothelial upper urinary tract tumors are excluded.  In cases with initial diagnosis of non-clear RCC of more than 2 years (RFS &gt;2 years) a histological/cytological confirmation of renal cell carcinoma origin of actual metastases is mandatory.  Metastatic measurable disease (at least one uni-dimensional measurable lesion by CT-scan or MRI) according to RECIST criteria (reported in Appendix  Karnofsky performance status (KPS) &amp;#8805; 70 (KPS scale reported in Appendix)  Age &amp;#8805; 18 years§  Life expectancy &amp;#8805; 3 months  Prior Surgery and/or Radiation Therapy (to less or equal than 25% of the bone marrow) are allowed. However, at least 4 weeks must have been elapsed since surgery or completion of radiation therapy and the patient must has recovered from side effects  ANC &amp;#8805;1.5 x 109/L; PLT &amp;#8805;100 x 109/L; Hb &amp;#8805; 9 g/dl  Adequate hepatic function: Total bilirubin &amp;#8804;1.5 times UNL*; ALT and AST &amp;#8804;2.5 times UNL (&amp;#8804;5 UNL in presence of liver metastases)  Serum creatinine &amp;#8804;2.0 x the UNL. Serum cholesterol &amp;#8804;350 mg/dL; serum triglycerides &amp;#8804; 300 mg/dL  Patients must be accessible for treatment and follow up&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;CNS metastases  Previous malignancy except for basal cell skin cancer and cervical carcinoma in situ adequately treated, or any other cancer from which the patient has been disease-free for &gt;=5 years  Any of the concomitant illness or medical condition indicated below: Serious respiratory or cardiovascular disease such as: congestive heart failure (³ NYHA Class II -refer to Appendix-); previous history (within 6 months) of myocardial infarction, angina pectoris or cardiac arrhythmias requiring anti-arrythmics (excluding beta blockers or digoxin). Active coronary artery disease, uncontrolled hypertension  Unstable diabetes mellitus, significant neurological or psychiatric disorders or seizure disorder requiring medication (such as anti-epileptics). Uncontrolled hypertension (systolic pressure ³ 160 mm Hg and/or diastolic ³ 90mm Hg) while receiving chronic medication.  Active clinically serious bacterial or fungal infections (&gt; grade 2 NCI-CTC, Version 3) or active human immunodeficiency virus (HIV) infection or chronic hepatitis B or C  Previous or concomitant treatment with antiangiogenic agents (e.g.: bevacizumab, sorafenib, sunitinib) or m-TOR inhibitors. Previous treatment with chemotherapy, immunotherapy (IFN and/or Interleukin-2) for advanced disease is allowed  Prior isotope treatment (e.g. strontium or samarium)  Participation in clinical trials with other experimental agents within 30 days of study entry or concomitant treatment with other experimental drug  Use of immunosuppressive agents including systemic steroids). History of organ allograft or autologous bone marrow transplant or stem cell rescue within four months of start of study drug  Pregnant or breast-feeding patients.  Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug.  Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial  Known or suspected allergy to the investigational agent or any agent given in association with this trial&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with advanced non-clear Cell Renal Carcinoma. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050513
Term: Metastatic renal cell carcinoma
 &lt;br&gt;MedDRA version: 9.1
Level: PT
Classification code 10038458
Term: Renal granular cell carcinoma
 &lt;br&gt;MedDRA version: 9.1
Level: PT
Classification code 10038414
Term: Renal cell carcinoma stage IV
</Condition>
    <Intervention>&lt;br&gt;Trade Name: ROFERON A&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Interferon alfa-2a&lt;br&gt;Concentration unit: million IU million international units&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 3-&lt;br&gt;&lt;br&gt;Product Name: Temsirolimus&lt;br&gt;Product Code: CCI-779&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: temsirolimus&lt;br&gt;CAS Number: 162635-04-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Progression Free Survival (PFS);Secondary Objective: Overall Response Rate (RECIST Criteria); Time to Progression (TTP); Safety; Overall Survival (OS).;Primary end point(s): Progression Free Survival (PFS) rates in the two arms.</Primary_outcome>
    <Secondary_ID>GOIRC02/2008-TWIST</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2468370</Internal_Number>
    <TrialID>EUCTR2008-002177-13-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Intérêt de la mesure de l’activité calcineurine dans le suivi thérapeutique du tacrolimus chez des patients transplantés rénaux</Public_title>
    <Scientific_title>Intérêt de la mesure de l’activité calcineurine dans le suivi thérapeutique du tacrolimus chez des patients transplantés rénaux                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)</Primary_sponsor>
    <Date_registration3>20080805</Date_registration3>
    <Date_registration>05/08/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-002177-13                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/10/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Adultes (&gt;= 18 ans) ayant bénéficié d'une transplantation rénale de novo;&lt;br&gt;Patients bénéficiant d'une couverture immunosuppressive principale par tacrolimus associé aux coritcoïdes et au Cellcept avec ou sans induction;&lt;br&gt;Patients affiliés au régime de la sécurité sociale.(bénéficiaire ou ayant droit)&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients présentant un risque avéré de non observance (principalement antécédent de toxicomanie, troubles psychiatriques intercurrents, etc.) ;&lt;br&gt;Greffes multiorganes ;&lt;br&gt;Patients bénéficiant d'une couverture immunosuppressive complémentaire par sirolimus -RAPAMUNE  ou everolimus ;&lt;br&gt;Patients infectés par le VIH.&lt;br&gt;Femmes enceintes&lt;br&gt;Femmes  allaitantes&lt;br&gt;Majeurs sous tutelle&lt;br&gt;Refus de consentement&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal Transplant &lt;br&gt;MedDRA version: 8.1
Level: PT
Classification code 10038533
Term: Transplantation rénale
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Prograf&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Prograf&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Prograf&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Trade Name: Advagraf&lt;br&gt;Product Name: Advagraf&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Advagraf&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: Advagraf&lt;br&gt;Product Name: Advagraf&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Advagraf&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: Advagraf&lt;br&gt;Product Name: Advagraf&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Advagraf&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Etudier la relation entre l'activité calcineurine résiduelle et la survenue d'un rejet aigu, chez les transplantés rénaux traités par tacrolimus au cours des 3 premiers mois suivant la transplantation. &lt;br&gt;;Secondary Objective: Déterminer à l'aide d'une courbe ROC, le seuil d'activité le plus performant pour prédire la survenue du rejet;&lt;br&gt;Etudier les variations entre la mesure de l'activité calcineurine dans les PBMC et les concentrations sanguines de tacrolimus; &lt;br&gt;Comparer l'activité calcineurine chez les sujets en rejet aigu et ceux présentant un rejet borderline diagnostiqué sur la PBR systématique à M3. ;Primary end point(s): Evaluation du rejet du greffon rénal se fait grace à la pharmacocinétique, par la mesure d'une part de l'activité calcineurine et d'autre part par le dosage du Tacrolimus dans le sang.</Primary_outcome>
    <Secondary_ID>P071004</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2468589</Internal_Number>
    <TrialID>EUCTR2008-002807-21-AT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>VITA-D: Cholecalciferol substitution in vitamin D deficient kidney transplant recipients: A randomized, placebo-controlled study to evaluate the posttransplant outcome - VITA-D</Public_title>
    <Scientific_title>VITA-D: Cholecalciferol substitution in vitamin D deficient kidney transplant recipients: A randomized, placebo-controlled study to evaluate the posttransplant outcome - VITA-D                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>MUW, Universitätsklinik für Innere Medizin III, Abteilung für Nephrologie und Dialyse</Primary_sponsor>
    <Date_registration3>20080904</Date_registration3>
    <Date_registration>04/09/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-002807-21                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>15/10/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Age &gt;18&lt;br&gt;Deceased donor kidney transplant recipients &lt;br&gt;Only kidney transplant recipients &lt;br&gt;Vitamin D deficiency defined as 25OHD &lt;50nmol/l &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Re-transplantation for the second time if the patient is highly immunized and therefore included in the apheresis program&lt;br&gt;Re-transplantation for the third time or more often&lt;br&gt;Significant impaired intestinal resorption: malabsorption due to celiac sprue, systemic scleroderma; maldigestion due to chronic pancreatitis, pancreatic insufficiency, pancreas resection, mukoviscidosis,  Zollinger-Ellison-syndrom&lt;br&gt;History of inflammatory bowel disease: Crohn’s disease, Ulcerative Colitis&lt;br&gt;Previouse gastrectomy, small bowel or large bowel resection, intestinal bypass surgery &lt;br&gt;Severe liver disease: cirrhosis &lt;br&gt;HIV positive  (HAART enhances Vitamin D catabolism) &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Vitamin D deficiency in kidney transplant recipients &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10047626
Term: Vitamin D deficiency
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10023438
Term: Kidney transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Oleovit D3 Tropfen&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;Pharmaceutical form of the placebo: Oral solution&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: 1. Does vitamin D3 substitution in vitamin D deficient kidney transplant recipients influence the posttransplant outcome compared to placebo?&lt;br&gt;&lt;br&gt;Hypothesis 1a&lt;br&gt;Vitamin D3 substitution improves graft function compared to placebo analysed by means of serum creatinine within the first year after transplantation. Another surrogate marker used to evaluate the immunomodulatory properties of vitamin D3 is the incidence of acute rejection episodes within the first year after kidney transplantation.&lt;br&gt;&lt;br&gt;Hypothesis 1b&lt;br&gt;Vitamin D3 substitution reduces the frequency and severity (analysed by means of CRP) of posttransplant infections compared to placebo within the first year after kidney transplantation.&lt;br&gt;;Secondary Objective: 2. Does vitamin D3 substitution influence renal osteopathy analysed using absolute bone mineral density?&lt;br&gt;&lt;br&gt;Hypothesis 2&lt;br&gt;Vitamin D3 substitution prevents the usual decline in bone mineral density within the first year after transplantation;Primary end point(s): The immunologic effects of vitamin D3 substitution in vitamin D deficient kidney transplant recipients will be evaluated by means of &lt;br&gt;- serum creatinine levels within the first year after transplantation, &lt;br&gt;- number of acute rejection episodes within the first year after transplantation,&lt;br&gt;- number of infections within the first year after transplantation,&lt;br&gt;- and CRP levels within the first year after transplantation.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>VitaD-1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2468591</Internal_Number>
    <TrialID>EUCTR2008-004158-33-BE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>CYP3A4/5 and PGP activity in renal transplantation.

A study assessing in vivo hepatic and intestinal CYP3A4/5 and PGP activity in kidney transplant recipients and its relationship with genetic and non-genetic variables and the pharmacokinetics and metabolism of Tacrolimus.</Public_title>
    <Scientific_title>CYP3A4/5 and PGP activity in renal transplantation.

A study assessing in vivo hepatic and intestinal CYP3A4/5 and PGP activity in kidney transplant recipients and its relationship with genetic and non-genetic variables and the pharmacokinetics and metabolism of Tacrolimus.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Department of Nephrology and Renal Transplantation, KU Leuven</Primary_sponsor>
    <Date_registration3>20080909</Date_registration3>
    <Date_registration>09/09/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-004158-33                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/09/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Chronic stable renal allograft recipients (&gt; 1 year after transplantation) treated with Tacrolimus (Prograft® or Advagraf®).&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Age &lt; 18 years. &lt;br&gt;- Females with child bearing potential, not using an acceptable method of birth control. &lt;br&gt;- Nursing and pregnant women. Pregnancy tests will be performed before drug administration.&lt;br&gt;- Known allergy or intolerance to either Erythromycin, Midazolam or Fexofenadine.&lt;br&gt;- Concomitant treatment with opioid- or antipsychotic drugs. &lt;br&gt;- Severe chronic lung disease and chronic respiratory insufficiency. &lt;br&gt;- Chronic heart failure. &lt;br&gt;- Severe liver disease. &lt;br&gt;- Anaemia (haemoglobin &lt; 11 g/dL).&lt;br&gt;- Hypoalbuminemia (&lt; 25 g/L).&lt;br&gt;- Combined organ transplants.&lt;br&gt;- Known non-compliance.&lt;br&gt;- Alcohol intake &gt; 7 units/week.&lt;br&gt;- Smoking.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Effect of genetic (single nucleotide polymorphisms of genes encoding drug metabolising enzymes and drug transporters) and non-genetic factors (e.g. age, time after transplantation, concommitant medication, renal function, liver dysfunction) on in vivo hepatic and intestinal CYP3A4 and 5 and PGP activity in renal allograft recipients. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038533
Term: Renal transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Dormicum 5 mg/5ml&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: MIDAZOLAM HYDROCHLORIDE&lt;br&gt;CAS Number: 59467968&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: Telfast 180 mg&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: FEXOFENADINE HYDROCHLORIDE&lt;br&gt;CAS Number: 8000051492&lt;br&gt;Other descriptive name: FEXOFENADINE HYDROCHLORIDE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 180-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To asses in vivo hepatic and intestinal CYP3A4 and 5 and PGP activity in renal allograft recipients.;Secondary Objective: To asses the relationship of in vivo hepatic and intestinal CYP3A4 and 5 and PGP activity in renal allograft recipients with:&lt;br&gt;- the recipients genotype.&lt;br&gt;- potential non-genetic determinants of in vivo CYP3A4 and 5 and PGP activity (e.g. concomittant medication, renal function, liver function, age, gender, .....)&lt;br&gt;- pharmacokinetics and metabolism of immunosuppressive drugs.;Primary end point(s): The effect of genetic and non-genetic factors on the disposition of Midazolam and Fexofenadine, as markers of, respectively,  in vivo CYP3A4/5 and PGP activity in renal allograft recipients.</Primary_outcome>
    <Secondary_ID>CYP3A4/5+PGPinRenalTx</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2468776</Internal_Number>
    <TrialID>EUCTR2008-005657-38-IE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Transversus Abdominis Plane Block for Analgesia in Renal Transplantation: A Randomised Controlled Trial</Public_title>
    <Scientific_title>Transversus Abdominis Plane Block for Analgesia in Renal Transplantation: A Randomised Controlled Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Royal College of Surgeons Ireland</Primary_sponsor>
    <Date_registration3>20080909</Date_registration3>
    <Date_registration>09/09/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005657-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/11/2008</Date_enrollement>
    <Target_size>62</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: TAP Block with saline&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Renal transplantation surgery&lt;br&gt;Age 18 years or over&lt;br&gt;ASA I-III&lt;br&gt;No allergy to bupivacaine&lt;br&gt;No allergy to morphine&lt;br&gt;Able to use a PCA device&lt;br&gt;Informed consent obtained&lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Aged under 18 years&lt;br&gt;ASA IV-V&lt;br&gt;Allergy to bupivavcaine&lt;br&gt;Allergy to morphine&lt;br&gt;Unable to use a PCA device&lt;br&gt;No consent obtained&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Condition to be investigated - Analgesia requirements in patients having renal transplant surgery. 
The study proposes to reduce current requirements for morphine post-operatively by the use of a Tranversus Abdominis Plane (TAP) Block. This is a technique of depositing local anaesthetic (bupivacaine) into the plane between the transversus abdominis and internal oblique muscles of the abdominal wall, thus providing analgesia to the area in which the surgery takes place. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10036276
Term: Postoperative analgesia
</Condition>
    <Intervention>&lt;br&gt;Product Name: bupivacaine&lt;br&gt;Product Code: bupivacaine&lt;br&gt;Pharmaceutical Form: Injection*&lt;br&gt;INN or Proposed INN: BUPIVACAINE HYDROCHLORIDE&lt;br&gt;CAS Number: 18010407&lt;br&gt;Concentration unit: % percent&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 0.25-0.5&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Not mentioned (Noncurrent)&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To demonstrate, in a renal transplantation population, a reduction in morphine use postoperatively in patients who have received a Transversus Abdominis Plane (TAP) block compared with those who received a placebo block.;Secondary Objective: To measure pain scores at rest and on movement, incidence of post-operative nausea and vomiting, incidence of sedation and incidence of respiratory depression for 24 hrs post-operatively and compare them between the TAP group versus the placebo group.;Primary end point(s): The primary endpoint is total morphine consumption in 24hrs.  We expect the group who receive a TAP block to have a reduction in morphine requirements compared with those who receive a placebo block.</Primary_outcome>
    <Secondary_ID>TAPprotocol12008</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2468831</Internal_Number>
    <TrialID>EUCTR2008-000889-22-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A randomised controlled comparison of standard release Tacrolimus vs extended-release Tacrolimus as baseline maintenance monotherapy for kidney transplantation after induction with Campath 1-H. - TAESR</Public_title>
    <Scientific_title>A randomised controlled comparison of standard release Tacrolimus vs extended-release Tacrolimus as baseline maintenance monotherapy for kidney transplantation after induction with Campath 1-H. - TAESR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Imperial College Healthcare NHS Trust</Primary_sponsor>
    <Date_registration3>20081003</Date_registration3>
    <Date_registration>03/10/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000889-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>11/11/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Adults undergoing live donor or deceased donor kidney transplantation who are able to give written informed consent to the study.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Patients who would not be treated with Campath 1-H under current renal unit protocols:&lt;br&gt;a. Patents with prior exposure to potent anti-proliferative or myelosuppressive agents.&lt;br&gt;b. Patients with previous malignancy.&lt;br&gt;c. Patients with chronic hepatitis B hepatitis C or HIV infection.&lt;br&gt;2. Patients receiving non-heart-beating deceased donor kidney transplants.&lt;br&gt;3. Patients receiving simultaneous kidney/pancreas transplants.&lt;br&gt;4. Patients undergoing desensitization for ABO incompatible or positive cross-match transplantation&lt;br&gt;5. Women of child-bearing age who would not be treated with Alemtuzumab because they are unable or unwilling to use effective contraception during therapy and continue its use for 6 months following the last dose of Alemtuzumab.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Prevention of allograft rejection after renal transplantation &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10023439
Term: Kidney transplant rejection
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Prograf&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;&lt;br&gt;Trade Name: Advagraf&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare outcomes of kidney transplantation after induction with Alemtuzumab/short course steroids, followed by maintenance with either standard release Tacrolimus (Prograf) monotherapy, or extended-release tacrolimus (Advagraf) monotherapy.&lt;br&gt;&lt;br&gt;Primary outcome measures: Survival with a functioning graft at 1 year and 3 years.;Secondary Objective: Secondary outcomes: Rejection rate / Time to achievement of target Tacrolimus levels / Inter-visit variance in Tacrolimus trough level / Lymphocyte subset recovery rates after Campath / Donor-specific ?-IFN producing lymphocyte frequency and phenotype / Functional Calcineurin inhibition levels.;Primary end point(s): Survival with a functioning graft at 1 and 3 years.</Primary_outcome>
    <Secondary_ID>ICKTI08TX01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2469007</Internal_Number>
    <TrialID>EUCTR2008-005727-28-SE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>BK viremi efter njurtransplantation: Screening, tidig diagnostik, tidig reduktion av immunhämning samt behandling med leflunomid (Arava®) - BK Viremia</Public_title>
    <Scientific_title>BK viremi efter njurtransplantation: Screening, tidig diagnostik, tidig reduktion av immunhämning samt behandling med leflunomid (Arava®) - BK Viremia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Karolinska Universitetssjukhuset</Primary_sponsor>
    <Date_registration3>20081021</Date_registration3>
    <Date_registration>21/10/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005727-28                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/12/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Recipienter&lt;br&gt;-	Skriftligt informerat samtycke&lt;br&gt;-	Vuxna mottagare av njurtransplantat&lt;br&gt;-	Man eller kvinna =18 år&lt;br&gt;&lt;br&gt;&lt;br&gt;Donatorer (levande eller avlidna donatorer)&lt;br&gt;-	Skriftligt informerat samtycke (från levande donator eller anhörig till avliden donator)&lt;br&gt;-	Njurdonator&lt;br&gt;-	Man eller kvinna =18 år&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Recipienter&lt;br&gt;För screeningfasen: Inga studiespecifika.&lt;br&gt;För behandling med reducerad immunosuppression: Inga studiespecifika. &lt;br&gt;För behandling med leflunomid&lt;br&gt;- Kontraindikationer för leflunomid (Arava?) (enligt produktresumén)&lt;br&gt;- Gravida eller ammande kvinnor&lt;br&gt;Donatorer&lt;br&gt;Inga exklusionskriterier&lt;br&gt;&lt;br&gt;För de recipienter som under studien blir aktuella för Arava-behandling tillkommer följande kriterier för Arava-behandling:&lt;br&gt;-	Kvinnor i fertil ålder måste använda tillförlitlig kontraception under Arava-behandling och under upp till 2 år efter avslutad behandling.&lt;br&gt;-	Män i fertil ålder måste använda tillförlitlig kontraception under behandling med Arava och en viss tid efter behandlingen enligt riktlinjer i produktresumén för Arava.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>BK Virusinfektion vid Njurtransplantation &lt;br&gt;MedDRA version: 9.1
Level: PT
Classification code 10055181
Term: BK virus infection
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10023438
Term: Kidney transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Arava 20 mg filmdragerade tabletter&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Leflunomid&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Kan leflunomid användas säkert i behandlingen av BK viremi och förstärka/förbättra den antivirala effekten hos patienter där reducerad immunosuppression är otillräckligt?;Secondary Objective: 1) Kan screening, tidig diagnostik samt tidig minskning av immunhämningen vara av värde vid behandlingen BK virus infektion?&lt;br&gt;&lt;br&gt;2) Påverkar graden av immunhämning förekomsten av BK virus infektion och resultatet av behandlingen samt det kliniska förloppet?&lt;br&gt;&lt;br&gt;3) Föreligger en korsneutralisation hos antikroppar riktade mot olika subtyper av BK virus och kan BKV subtypsspecifika neutraliserande antikroppar hos donator och recipient före njurtransplantation utgöra ett diagnostiskt verktyg för att förebygga BKVAN hos recipienten?&lt;br&gt;&lt;br&gt;4) Vilken är förekomsten av BK viremi samt BK virus nefropati efter njurtransplantation?&lt;br&gt;;Primary end point(s): Primär endpoint&lt;br&gt;Transplantatöverlevnad eller transplantatförlust ett år efter diagnos (transplantatförlust = åter i dialys)&lt;br&gt;&lt;br&gt;&lt;br&gt;Sekundära endpoints&lt;br&gt;•	Patientöverlevnad ett år efter diagnos &lt;br&gt;•	Akut avstötning under studieperioden&lt;br&gt;•	Kronisk allograft neuropati ett år efter diagnos&lt;br&gt;•	Banff klassifikation vid histopatologisk undersökning av biopsi från den transplanterade njuren&lt;br&gt;•	Transplantatfunktion 1 år efter diagnos (P-Kreatinin, GFR – beräknat enligt Cockroft Gault)&lt;br&gt;•	Kvoten: P-Kreatinin efter 1 månad/P-Kreatinin efter 12 månader&lt;br&gt;•	Biverkningar vid leflunomid (Arava®) -behandling&lt;br&gt;•	Hematologi (Hb, LPK, TPK)&lt;br&gt;•	Infektioner&lt;br&gt;•	Malignitet&lt;br&gt;</Primary_outcome>
    <Secondary_ID>2008-005727-28</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2469112</Internal_Number>
    <TrialID>EUCTR2008-002191-98-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>"Efecto del ARA-II Olmesartan sobre el metabolismo del potasio en pacientes con insuficiencia renal crónica"</Public_title>
    <Scientific_title>"Efecto del ARA-II Olmesartan sobre el metabolismo del potasio en pacientes con insuficiencia renal crónica"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Servicio de Nefrologia-Hospital Universitario Vall d'Hebron</Primary_sponsor>
    <Date_registration3>20081023</Date_registration3>
    <Date_registration>23/10/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-002191-98                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>27/11/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: enalapril&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Insuficiencia renal crónica con aclaramientos entre 30 y 60 ml/minuto por MDRD.&lt;br&gt;Hipertensión arterial leve - moderada.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Niveles de potasio superiores a 5 mEq/l&lt;br&gt;Hipertensión arterial secundaria&lt;br&gt;Alergia a cualquiera de los dos fármacos&lt;br&gt;</Exclusion_Criteria>
    <Condition>Microalbuminúria, hipertensión arterial y renoprotección en la insuficiencia renal crónica.</Condition>
    <Intervention>&lt;br&gt;Trade Name: Openvas&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: olmesartan&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 10-20&lt;br&gt;&lt;br&gt;Trade Name: Enalapril&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: enalapril&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 10-20&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Comparar el efecto de la administración de un inhibidor del enzima de conversión del angiotensina con un antagonista de los receptores AT1 de la angiotensina, sobre los niveles de potasio plasmáticos.;Secondary Objective: Valorar los efectos de ambos fármacos sobre la función renal y sobre los niveles de renina, angiotensina y aldosterona.;Primary end point(s): Niveles de potasio en sangre, creatinina en sangre y microalbuminúria.</Primary_outcome>
    <Secondary_ID>PREVARENAL-08</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2469116</Internal_Number>
    <TrialID>EUCTR2008-000627-26-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Conversion from cyclosporine to tacrolimus followed by randomized C0 or Bayesian monitoring using the C4 timepoint The effect on kidney function - FK04-study</Public_title>
    <Scientific_title>Conversion from cyclosporine to tacrolimus followed by randomized C0 or Bayesian monitoring using the C4 timepoint The effect on kidney function - FK04-study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Leiden University Medical Center</Primary_sponsor>
    <Date_registration3>20080529</Date_registration3>
    <Date_registration>29/05/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000627-26                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>29/09/2008</Date_enrollement>
    <Target_size>50</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: First pase uncontrolled, second phase parrallel group &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Standard TDM vs Baysian monitoring&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Livertransplant recipients at least 18 years of age at least 6 months past last transplantation on a stable calcineurin inhibitor based immunosuppressive regimen capable of understanding the purpose and risk of the study. &lt;br&gt;&lt;br&gt; &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Multi-organ transplant recipients&lt;br&gt;Allergy/intollerance to the study drugs&lt;br&gt;Patients with a serum creatinine &gt;200 umol/l&lt;br&gt;Pregnant or breastfeading mother&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Effect of immunosuppressive medication on renal function following livertransplantation &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10024716
Term: Liver transplantation
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Prograf(t)&lt;br&gt;Product Name: Prograft&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987113&lt;br&gt;Current Sponsor code: FK506&lt;br&gt;Other descriptive name: Prograf(t)&lt;br&gt;Concentration unit: µg/l microgram(s)/litre&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 4-8&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Change in cratinine clearance measured by creatinine clearence in 24 hours urine collection and serum creatinine between baseline and week 12, week 12 and 14, and baseline and week 24   ;Secondary Objective: - Changes in mean arterial blood pressure and number and dose of antihypertensive medications used between baseline and week 12 and baseline and week 24&lt;br&gt;&lt;br&gt;- Tacrolimus pharmacokinetics&lt;br&gt;&lt;br&gt;- Changes in mean lipid levels (total cholesterol, TG, LDL, HDL), and the number and &lt;br&gt;dose of lipid-lowering medications between baseline and week 12 and week 24&lt;br&gt;&lt;br&gt;- Subject and graft survival&lt;br&gt;&lt;br&gt;- Creatinine clearance calculated by BSA corrected Cockcroft and GAult and MDRD&lt;br&gt;&lt;br&gt;- Biopsy proven treated graft rejection&lt;br&gt;&lt;br&gt;- Side effects;Primary end point(s): Change in renal function, as measured by:&lt;br&gt;Creatinine clearance, measured by creatinine clearance in a 24 hour urine collection and serum creatinine between: 1) baseline and week 12, 2) week 12 and week 24 and 3) baseline and week 24 &lt;br&gt;Creatinine clearance calculated by BSA adjusted Cockcroft and Gault and MDRD</Primary_outcome>
    <Secondary_ID>FK04</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2469124</Internal_Number>
    <TrialID>EUCTR2008-000628-25-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>The effectiveness of intensive treatment on sympathetic hyperactivity. A randomized, cross-over trial in patients with chronic kidney disease and hypertension</Public_title>
    <Scientific_title>The effectiveness of intensive treatment on sympathetic hyperactivity. A randomized, cross-over trial in patients with chronic kidney disease and hypertension                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>UMC Utrecht</Primary_sponsor>
    <Date_registration3>20080529</Date_registration3>
    <Date_registration>29/05/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000628-25                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>13/05/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients with stable chronic kidney disease and hypertension: i.e. using antihypertensive drugs and/or blood pressure &gt;145/90mmHg when off medication. &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients with diabetes mellitus and patients on renal replacement therapy are excluded. In addition, patients with severe liver insufficiency, biliary cirrhosis and cholestasis, pregnant patients and patients in lactation are excluded as Valsartan is contra-indicated for these patients.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Sympathetic nerve system in hypertensive patients with chronic kidney disease</Condition>
    <Intervention>&lt;br&gt;Trade Name: Diovan&lt;br&gt;Product Name: Valsartan&lt;br&gt;Product Code: RVG34472&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective is to investigate if there is an incremental inhibiting effect on MSNA by increasing dosage valsartan above the presently advised dosage. We hypothesize that there will be a further decrease in MSNA as compared to the MSNA during standard dosage valsartan.;Secondary Objective: econdary objective is to assess whether MSNA normalizes after application of higher than usual dosage of valsartan. The second secondary objective is to study the effect of higher than usual dosage of valsartan on blood pressure.;Primary end point(s): Primary endpoint: Change in MSNA during higher than usual dosage valsartan as compared to MSNA during standard dosage &lt;br&gt;Primary expected outcome: further decrease in MSNA as compared to the MSNA during standard dosage &lt;br&gt;&lt;br&gt;Secondary endpoint: Assess whether normalization of MSNA occurs during higher than usual dosage of valsartan&lt;br&gt;Secondary expected outcome: normalization of MSNA after application of higher than usual dosage of valsartan&lt;br&gt;Secondary endpoint: assessment of effect of higher than usual dosage valsartan on blood pressure&lt;br&gt;Secondary expected outcome: higher than usual dosage of valsartan will cause no changes in blood pressure&lt;br&gt;</Primary_outcome>
    <Secondary_ID>23012008</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2469320</Internal_Number>
    <TrialID>EUCTR2008-006014-20-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Effects of the dose of erythropoiesis stimulating agents on cardiac-cerebrovascular outcomes and quality of life in hemodialysis patients. The DOSe of Erythropoietins (DOSE) trial. - C.E. DOSE</Public_title>
    <Scientific_title>Effects of the dose of erythropoiesis stimulating agents on cardiac-cerebrovascular outcomes and quality of life in hemodialysis patients. The DOSe of Erythropoietins (DOSE) trial. - C.E. DOSE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>CONSORZIO MARIO NEGRI SUD</Primary_sponsor>
    <Date_registration3>20081121</Date_registration3>
    <Date_registration>21/11/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-006014-20                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/01/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator:  - same IMP used at different dosage&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Male or female, age&gt;=18, with end stage kidney disease and anemia, treated with hemodialysis for renal replacement therapy, with no contraindications to erythropoietin stimulating agents (ESA) or already treated with ESA&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients with Hb levels &gt;10 g/dl without ESA&lt;br&gt;</Exclusion_Criteria>
    <Condition>End stage kidney disease and anemia, treated with hemodialysis for renal replacement therapy &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10014647
Term: End stage renal failure
</Condition>
    <Intervention>&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2000-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 6000-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate the benefits and harms of high versus low EPOS doses for major patient-level outcomes (mortality, cardiac and cerebrovascular events, safety),quality of life and costs in a population of prevalent outpatient hemodialysis patients;Secondary Objective: xxx;Primary end point(s): composite of all-cause mortality, fatal and non fatal myocardial infarction, fatal and non fatal stroke, hospitalizations due to acute coronaric syndrome, transitory ischemich attacs, not planned coronaric revascularization, periferic revascularization.</Primary_outcome>
    <Secondary_ID>FARM6X822T</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2469342</Internal_Number>
    <TrialID>EUCTR2008-002696-27-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>An open label, single-arm, baseline-controlled, multicenter study to evaluate the efficacy, safety and immunogenicity of subcutaneous HX575 administered once a week (qw) and once every two weeks (q2w) in the treatment of anemia associated with chronic kidney disease in pre-dialysis and dialysis subjects
 - SWEEP Study</Public_title>
    <Scientific_title>An open label, single-arm, baseline-controlled, multicenter study to evaluate the efficacy, safety and immunogenicity of subcutaneous HX575 administered once a week (qw) and once every two weeks (q2w) in the treatment of anemia associated with chronic kidney disease in pre-dialysis and dialysis subjects
 - SWEEP Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Hexal AG</Primary_sponsor>
    <Date_registration3>20081125</Date_registration3>
    <Date_registration>25/11/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-002696-27                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/11/2008</Date_enrollement>
    <Target_size>500</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;• Male and female CKD subjects with or without dialysis treatment&lt;br&gt;• Age &gt; 18 years&lt;br&gt;• Subjects under documented stable maintenance therapy with rHuEPO, once, twice or thrice weekly, s.c., for at least 3 months with a total weekly dose of = 300 IU/kg/week&lt;br&gt;• Subjects with controlled symptomatic anemia, defined as Hb level between 10.0 g/dL and 12.0 g/dL, based on four Hb measurements during the four-week baseline period&lt;br&gt;• Adequate iron status, serum ferritin = 100 µg/L or transferrin saturation = 20%&lt;br&gt;• Confirmed negative anti-EPO antibody assay from sample taken at screening visit -4&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;• Systemic cyclosporine or any other drugs known to adversely affect the Hb level&lt;br&gt;• History of PRCA or aplastic anemia&lt;br&gt;• History of anti-EPO antibodies&lt;br&gt;• Uncontrolled hypertension&lt;br&gt;</Exclusion_Criteria>
    <Condition>Anemia associated with chronic kidney disease in pre-dialysis and dialysis subjects &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10009120
Term: Chronic renal failure anaemia
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Binocrit (referred in the protocol to as HX575)&lt;br&gt;Product Name: HX575 epoetin alfa (registered as Binocrit®)&lt;br&gt;Product Code: HX575&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Epoetin alfa&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000 IU/0.5ml-&lt;br&gt;INN or Proposed INN: Epoetin alfa&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2000 IU/1 ml-&lt;br&gt;INN or Proposed INN: Epoetin alfa&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 4000 IU/0.4 ml-&lt;br&gt;INN or Proposed INN: Epoetin alfa&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 6000 IU/0.6 ml-&lt;br&gt;INN or Proposed INN: Epoetin alfa&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 8000 IU/0.8 ml-&lt;br&gt;INN or Proposed INN: Epoetin alfa&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10000 IU/1 ml-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To demonstrate that HX575 administered s.c. qw and q2w maintains the correction of anemia associated with CKD.;Secondary Objective: To document the safety and immunogenicity of HX575.&lt;br&gt;To determine the optimal dosing regimen of HX575 s.c. administration.;Primary end point(s): Successful 1:1 conversion from rHuEPO to weekly HX575, and from weekly HX575 to fortnightly HX575, as assessed by the mean absolute change in Hb levels.</Primary_outcome>
    <Secondary_ID>HX575-304;not applicable</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2469357</Internal_Number>
    <TrialID>EUCTR2008-007017-76-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio prospectivo, randomizado para comparar paratiroidectomía subtotal versus cinacalcet en el tratamiento del hiperparatiroidismo secundario persistente post trasplante renal. 


 - 01PTHi</Public_title>
    <Scientific_title>Estudio prospectivo, randomizado para comparar paratiroidectomía subtotal versus cinacalcet en el tratamiento del hiperparatiroidismo secundario persistente post trasplante renal. 


 - 01PTHi                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Josep M Cruzado</Primary_sponsor>
    <Date_registration3>20081126</Date_registration3>
    <Date_registration>26/11/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-007017-76                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/03/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: subtotal parathyroidectomy&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Inclusion criteria: &lt;br&gt;1.Functionning renal allograft, estimated GFR = 30 ml/min&lt;br&gt;2.More than 6 m after transplantation&lt;br&gt;3.PTHi =15 pmol/L&lt;br&gt;4.Calcemia =2.7 mmol/L with phosphatemia =1.2 mmol/L&lt;br&gt;5.MIBI &lt;br&gt;6.Written informed consent &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Exclusion criteria: &lt;br&gt;1.Surgical contraindication&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Hiperparatiroidismo secundario post trasplante renal




 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10020708
Term: Hyperparathyroidism secondary
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Mimpara&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: CINACALCET&lt;br&gt;CAS Number: 364782-34-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To study the percentage of patients with normocalcemia at 1 year after treatment with cinacalcet versus subtotal parathyreidectomy;Secondary Objective: Percentage of patients with PTHi according guidelines, renal function, economic cost study, incidence of cardiovascular events and graft and patient survival at year 1;Primary end point(s): percentage of patients with normocalcemia at year 1</Primary_outcome>
    <Secondary_ID>01PTHi</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2469383</Internal_Number>
    <TrialID>EUCTR2008-005110-41-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Circadian Influence on Renal Clearance of Aminoglycosides in cystic fibrosis patients 
 - CIRCA</Public_title>
    <Scientific_title>Circadian Influence on Renal Clearance of Aminoglycosides in cystic fibrosis patients 
 - CIRCA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>not applicable</Primary_sponsor>
    <Date_registration3>20081210</Date_registration3>
    <Date_registration>10/12/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005110-41                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>09/12/2008</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: dosing tobramycin in the morning vs. evening&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: controlled by comparing morning arm to evening arm&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Inclusion criteria :&lt;br&gt;-	Age: = 18 years&lt;br&gt;-	a diagnosis of cystic fibrosis (ie, sweat chloride _60 mmol/L or a genotype associated with cystic fibrosis) &lt;br&gt;-	chronic infection with Pseudomonas aeruginosa with the most recently isolated organism showing sensitivity to tobramycin.&lt;br&gt;-	Pulmonary exacerbation as defined by Fuchs and colleagues&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-	use of nephrotoxic drugs (NSAID´s, furosemide, vancomycin)&lt;br&gt;-	allergy for aminoglycosides&lt;br&gt;-	granulocytopenia (&lt;1,0 x 109/L)&lt;br&gt;-	pregnancy&lt;br&gt;-	calculated GFR &lt; 40 ml/min &lt;br&gt;-	pre-existing hearing impairment (_20 dB hearing level at any two frequencies between 2kHz and 8 kHz on the standard audiogram)&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Repeated or extended dosing of aminoglycosides may cause damage to the proximal tubuli, resulting in renal impairment. Renal impairment affects up to 40 % of adult CF patients, measured after estimation using an appropriate formula. The true number is probably even greater.</Condition>
    <Intervention>&lt;br&gt;Pharmaceutical Form:</Intervention>
    <Primary_outcome>Main Objective: To compare renal elimination constant in CF patients receiving a daily intravenous dose of tobramycin in the morning compared to patients receiving a daily intravenous dose of tobramycin in the evening.;Secondary Objective: To compare biochemical signs of nephrotoxicity in patients who receive their dose of aminoglycoside in the morning against patients who receive their dose of aminoglycoside in the evening.;Primary end point(s): The primary end point will be a significant or non-significant difference in the rate elimination constant (Kelm) between CF patients receiving a daily intravenous dose of tobramycin in the morning and CF patients receiving a daily intravenous dose of tobramycin in the evening.</Primary_outcome>
    <Secondary_ID>9999999999999999999;not available</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2469465</Internal_Number>
    <TrialID>EUCTR2008-006798-33-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Medical optimization of TORisel (MoTOR): MULTICENTER, PHASE II EVALUATION OF TORISEL AS II-LINE TREATMENT FOR METASTATIC RCC PATIENTS PROGRESSING AFTER CYTOKINE THERAPY, TYROSINE KINASE, OR ANGIOGENESIS INHIBITORS - MOTOR</Public_title>
    <Scientific_title>Medical optimization of TORisel (MoTOR): MULTICENTER, PHASE II EVALUATION OF TORISEL AS II-LINE TREATMENT FOR METASTATIC RCC PATIENTS PROGRESSING AFTER CYTOKINE THERAPY, TYROSINE KINASE, OR ANGIOGENESIS INHIBITORS - MOTOR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>CONSORZIO ONCOTECH</Primary_sponsor>
    <Date_registration3>20081215</Date_registration3>
    <Date_registration>15/12/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-006798-33                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/11/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Study subjects must have a histologically/cytologically confirmed diagnosis of metastatic RCC (regardless of nephrectomy status) with well-documented progressive disease (PD) after any of the following: cytokines (± chemotherapy), sunitinib, sorafenib, or bevacizumab (± IFN).&lt;br&gt;&lt;br&gt;2.	No more than one prior systemic treatment for advanced disease is allowed.&lt;br&gt;&lt;br&gt;3.	At least 2 weeks since prior systemic treatment, palliative radiation therapy, and/or surgery must have elapsed and resolution of all toxic effects of prior therapy to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE, version 3.0) Grade &amp;amp;#61603;1 must be observed prior to inclusion. &lt;br&gt;&lt;br&gt;4.	At least 1 measurable lesion that can be accurately measured in at least 1 dimension with the longest diameter &amp;amp;#61619; 10 mm when measured by spiral computerized tomography (CT, 5-mm slice thickness contiguous) or &amp;amp;#61619; 20 mm when measured by conventional CT (10-mm slice thickness contiguous).  Lesion must be &amp;amp;#61619; 2 times the size of the slice thickness per Response Evaluation Criteria in Solid Tumors (RECIST).&lt;br&gt;&lt;br&gt;5.	Age &gt; 18 years.&lt;br&gt;&lt;br&gt;&lt;br&gt;6.	Screening laboratory values within the following limits:&lt;br&gt;&amp;amp;#61607;	ANC  &gt;=1500/mL &lt;br&gt;&amp;amp;#61607;	Platelet count  &gt;=100,000/mL&lt;br&gt;&amp;amp;#61607;	Leukocyte count &gt;=2000/uL&lt;br&gt;&amp;amp;#61607;	Hemoglobin  &gt;= 8.0 g/dL (80g/L) without transfusion within 2 weeks of first dose of test article&lt;br&gt;&amp;amp;#61607;	Serum creatinine  &lt;= 2.0 X ULN&lt;br&gt;&amp;amp;#61607;	Total bilirubin  &lt;= 1.5 X ULN&lt;br&gt;&amp;amp;#61607;	AST and ALT &lt;=3 X ULN [&amp;amp;#61603;5 X ULN if liver metastases are present]&lt;br&gt;&amp;amp;#61607;	Fasting serum cholesterol &lt;=350 mg/dL (9.0 mmol/L)&lt;br&gt;&amp;amp;#61607;	Fasting serum triglycerides &lt;=400 mg/dL (4.56 mmol/L)&lt;br&gt;&amp;amp;#61607;	Fasting hemoglobin A1c (HbA1c) &lt; 10% (therapy permitted)&lt;br&gt;&amp;amp;#61607;	PTT/INR or PT &lt; 1.3 x ULN&lt;br&gt;&amp;amp;#61607;	Urinalysis within normal limits&lt;br&gt;&lt;br&gt;6.	Metabolic, thyroid, and pancreatic function within laboratory limits of normal&lt;br&gt;&lt;br&gt;7.	Adequate cardiac (left ventricular ejection fraction &gt;=40%) as assessed by electrocardiogram (ECG), echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan&lt;br&gt;&lt;br&gt;8.	Eastern Cooperative Oncology Group (ECOG) performance status 0-2&lt;br&gt;&lt;br&gt;9.	Life expectancy of at least 3 months&lt;br&gt;&lt;br&gt;10.	Written, signed, dated, and witnessed IRB or IEC approved informed consent form (ICF)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	History of a central nervous system (CNS) malignancy or metastatic disease to the CNS or known, active CNS malignancy (primary or metastatic).&lt;br&gt;2.	More than one prior systemic therapy for mRCC other than sunitinib.  &lt;br&gt;3.	Subjects receiving known strong CYP3A4 isoenzyme inhibitors and/or inducers.  Subjects taking CYP3A4 isoenzyme inhibitors and/or inducers not listed in Appendix are eligible, provided they have been on a stable regimen for at least 4 weeks prior to enrollment.&lt;br&gt;4.	Subjects with a non-healing wound or ulcer.&lt;br&gt;5.	Grade &gt;=3 hemorrhage within the past month.&lt;br&gt;6.	Systolic blood pressure of  &gt; 160 mm Hg and/or diastolic pressure &gt; 100 mg Hg (anti-hypertensive medications permitted).&lt;br&gt;7.	AHA Class 3/4 heart disease.&lt;br&gt;8.	QTc interval &gt; 450 msec for males and &gt; 470 msec for females and/or any ventricular arrhythmia and/or any uncontrolled atrial arrhythmia.  &lt;br&gt;9.	Subjects receiving anticoagulation with warfarin (therapeutic doses of warfarin for catheter patency are permitted).  Low molecular weight (LMW) heparin is permitted.&lt;br&gt;10.	Glycosylated hemoglobin A1c (HbA1c) &gt; 10% despite therapy.  &lt;br&gt;11.	History of pulmonary hypertension or interstitial lung disease.&lt;br&gt;12.	Subjects receiving immunosuppressive agents within 4 weeks of the screening visit.  Replacement doses of corticosteroids and topical/inhaled steroids are permitted.   &lt;br&gt;13.	Chronic viral/bacterial/fungal illnesses such as human immunodeficiency virus (HIV), hepatitis B, or hepatitis C. &lt;br&gt;14.	Active infection(s), active antimicrobial therapy or serious intercurrent illness.&lt;br&gt;15.	Subjects with a ?currently active? second malignancy other than non-melanoma skin cancers.  Subjects are not considered to have a ?currently active? malignancy if they have completed anti-cancer therapy and are considered by their physician to be at less than 30% risk of relapse.  &lt;br&gt;16.	Pregnant or nursing women, women who are of childbearing potential  (biologically capable of becoming pregnant) who are not using a medically acceptable contraceptive method, or men who are not using a medically acceptable contraceptive method with partners of childbearing potential.&lt;br&gt;17.	Subjects who do not agree to use medically acceptable contraceptive methods for 3 months after their last dose of Torisel therapy.&lt;br&gt;18.	Any other major illness that, in the investigator?s judgment, will substantially increase the risk associated with the subject?s participation in this study.&lt;br&gt;19.	Known hypersensitivity to any of the components in the Torisel infusion products or other medical reasons for not being able to receive adequate premedication (for example, antihistamines).&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with metastatic RCC &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050018
Term: Renal cancer metastatic
</Condition>
    <Intervention>&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TEMSIROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: PFS rate at 6 months;Secondary Objective: ORR (RECIST criteria)&lt;br&gt;Duration of response&lt;br&gt;Duration of stable disease&lt;br&gt;Toxicity&lt;br&gt;PFS&lt;br&gt;OS&lt;br&gt;Quality of life (EORTC QLQ C-30)&lt;br&gt;Biological/molecular correlates (TBD);Primary end point(s): 	Medical history&lt;br&gt;	Physical Examination&lt;br&gt;	CBC (including WBC with differential)&lt;br&gt;	Serum electrolytes&lt;br&gt;	Serum chemistry&lt;br&gt;	Coagulation tests&lt;br&gt;	HbA1c&lt;br&gt;	Routine urinalysis&lt;br&gt;	CT of chest, abdomen and pelvis&lt;br&gt;	ECG/ECHO or MUGA&lt;br&gt;	Chest x-ray&lt;br&gt;	Vital signs&lt;br&gt;	Adverse events&lt;br&gt;	Concomitant medications</Primary_outcome>
    <Secondary_ID>MOTOR</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2469553</Internal_Number>
    <TrialID>EUCTR2008-008235-28-FI</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Parasetamolin käyttö oheiskipulääkkeenä oksikodonin kanssa ohitusleikkauksen jälkeisen kivun hoidossa 

Paracetamol as Adjuctive Treatment for Postoperative Pain after Off-Pump Bypass Surgery
 - PARA-CABG-01</Public_title>
    <Scientific_title>Parasetamolin käyttö oheiskipulääkkeenä oksikodonin kanssa ohitusleikkauksen jälkeisen kivun hoidossa 

Paracetamol as Adjuctive Treatment for Postoperative Pain after Off-Pump Bypass Surgery
 - PARA-CABG-01                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Vesa Pakanen</Primary_sponsor>
    <Date_registration3>20081210</Date_registration3>
    <Date_registration>10/12/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-008235-28                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>28/01/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;</Exclusion_Criteria>
    <Condition>Patient with chronic ischemic heart disease ongoing elective coronary artery bypass grafting. Any major organ failures like  heart, kidney, liver  failures are excluded.
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10008937
Term: Chronic ischemic heart disease, unspecified
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Perfalgan&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: PARACETAMOL&lt;br&gt;CAS Number: 103902&lt;br&gt;Pharmaceutical form of the placebo: Intravenous infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: ;Secondary Objective: ;Primary end point(s): </Primary_outcome>
    <Secondary_ID>82772673</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2469669</Internal_Number>
    <TrialID>EUCTR2008-007881-45-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A double-blind, placebo-controlled, randomized trial investigating the safety and efficacy of Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction - ARIANA-CHF-RD</Public_title>
    <Scientific_title>A double-blind, placebo-controlled, randomized trial investigating the safety and efficacy of Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction - ARIANA-CHF-RD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>University Medical Center Groningen</Primary_sponsor>
    <Date_registration3>20081209</Date_registration3>
    <Date_registration>09/12/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-007881-45                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/03/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Out patients = 18  years of age, male or female.&lt;br&gt;•	Patients with a diagnosis of chronic heart failure (NYHA Class II – IV)&lt;br&gt;•	LVEF = 45% at visit 1 (local measurement, measured within the past 6 months assessed by  echocardiogram, MUGA or ventricular angiography)&lt;br&gt;•	Estimated GFR between 30 and 60 ml/min/1.73m2 as measured by the MDRD formula&lt;br&gt;•	Patients must be treated with an ACE inhibitor at a stable dose (enalapril 10 mg daily at least or any other ACE inhibitor, e.g. ramipril, quinapril, lisinopril, fosinopril, perindopril, trandolapril; on equivalent doses, or maximum tolerated dose) or if intolerant to ACE inhibitors with ARB therapy (Candesartan 32 mg daily or any other ARB in equivalent dose, or maximum tolerated dose) for at least 4 weeks prior to visit 1.&lt;br&gt;•	Patients must be treated with a beta blocker unless contraindicated or not tolerated at a stable dose for at least 4 weeks prior to visit 1 (for patients not on target dose or in absence of that medication, the reason should be documented). &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	History of hypersensitivity to any of the study drugs including history or allergy to ACEi’s as well as known or suspected contraindications to the study drugs or previous history of intolerance to high doses of ACEi’s during up titration process.&lt;br&gt;•	Patients treated concomitantly with both ARB and aldosterone antagonist.&lt;br&gt;•	Current acute decompensated heart failure (HF). &lt;br&gt;•	Symptomatic hypotension and/ or less than 90 mmHg SBP at randomisation&lt;br&gt;•	Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or major vascular surgery, percutaneous coronary intervention (PCI) or carotid angioplasty, within the past 3 months.&lt;br&gt;•	Coronary or carotid artery disease likely to require surgical or PCI.&lt;br&gt;•	Right heart failure due to severe pulmonary disease.&lt;br&gt;•	Diagnosis of peripartum or chemotherapy induced cardiomyopathy within the last year. &lt;br&gt;•	Patients with a history of heart transplant or who are on a transplant list or with LVAD device (left ventricular assistance device). &lt;br&gt;•	Documented ventricular arrhythmia with syncopal episodes within past 3 months that is untreated.&lt;br&gt;•	Documented history of ventricular tachycardia or ventricular fibrillation without ICD.&lt;br&gt;•	Symptomatic bradycardia, or second or third degree heart block without a pacemaker.&lt;br&gt;•	Implantation of a CRT (cardiac resynchronization therapy) device within prior 3 months. &lt;br&gt;•	Presence of hemodynamically significant mitral and /or aortic valve disease, except mitral regurgitation secondary to left ventricular dilatation. &lt;br&gt;•	Presence of hemodynamically significant obstructive lesions of left ventricular outflow tract, including aortic stenosis.&lt;br&gt;•	Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs including, but not limited to, any of the following:&lt;br&gt;•	Any history of pancreatic injury, pancreatitis or evidence of impaired pancreatic function/injury as indicated by abnormal lipase or amylase.&lt;br&gt;•	Primary liver disease considered to be life threatening.&lt;br&gt;•	Currently active gastritis, duodenal or gastric ulcers, or gastrointestinal/rectal bleeding during the 3 months prior to Visit 1.&lt;br&gt;•	Serum potassium =  5.2 mEq/L at randomisation visit.&lt;br&gt;•	History or presence of any other diseases (i.e. including malignancies) with a life expectancy of &lt; 5 years.&lt;br&gt;•	Current double-blind treatment in HF trials.&lt;br&gt;•	Participation in an investigational drug study at the time of enrollment or within the past 30 days or 5 half lives of enrollment whichever is longer.&lt;br&gt;•	Any surgical or medical condition that in the opinion of the investigator or medical monitor would jeopardize the evaluation of efficacy or safety.&lt;br&gt;•	History of noncompliance to medical regimens and patients who are considered potentially unreliable.&lt;br&gt;•	Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive Human Chorionic Gonadotropin (hCG) laboratory test (&gt; 5 mIU/ml).&lt;br&gt;•	Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum Follicle Stimulating Hormone (</Exclusion_Criteria>
    <Condition>Patients with chronic heart failure and reduced glomerular filtration rate. &lt;br&gt;MedDRA version: 9.1
Level: HLT
Classification code 10038443
Term: Renal failure and impairment
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10008908
Term: Chronic heart failure
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Rasilez&lt;br&gt;Product Name: Aliskiren&lt;br&gt;Product Code: SPP100&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 173334571&lt;br&gt;Other descriptive name: ALISKIREN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 150-300&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of this study is to test if add-on therapy with aliskiren improves RBF in patients with CHF (NYHA Class II - IV) and RD treated with renin-angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II type 1 receptor blockers (ARB).;Secondary Objective: Secondary objectives are to examine the effect of addition of aliskiren on RD expressed as glomerular filtration rate(GFR) as measured by clearance of 125I-Iothalamate, filtration fraction(FF) as measured by GFR/Effective Renal Plasma Flow, circulating plasma values of markers of renin-angiotensin (RAS) system activity, including plasma renin activity, angiotensin II, angiotensin converting enzyme activity and chymase activity, levels of N Terminal-proBrain Natriuretic Peptides, left ventricular ejection fraction as measured by radionucleotide ventriculography, urinary levels of markers of glomerular and tubular damage, including urinary albumin ecretion (UAE), N-acetyl-beta-D-glucosaminidase (NAG), neutrophil gelatinase associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1), NYHA Association class, Patient’s and Physician’s global assessment score’s and on heart rate, systolic and diastolic blood pressure.;Primary end point(s): Change in Renal Blood Flow from baseline to 26 weeks with additive renin-inhibition with aliskiren</Primary_outcome>
    <Secondary_ID>SPP100ANL02T</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2470033</Internal_Number>
    <TrialID>EUCTR2005-005124-14-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>The unlicensed and off-label use of diclofenac in paediatric patients: Pharmacokinetic, pharmacodynamic and pharmacogenomic evlauations - Diclofenac in Paediatrics</Public_title>
    <Scientific_title>The unlicensed and off-label use of diclofenac in paediatric patients: Pharmacokinetic, pharmacodynamic and pharmacogenomic evlauations - Diclofenac in Paediatrics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Joint Sponsor: University of Glasgow with NHS greater Glasgow and Clyde</Primary_sponsor>
    <Date_registration3>20070516</Date_registration3>
    <Date_registration>16/05/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005124-14                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/07/2007</Date_enrollement>
    <Target_size>80</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Age 6m-12y&lt;br&gt;Weight 5-50kg&lt;br&gt;Undergoing elective surgery where diclofenac would routinely be used&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;&lt;6m&lt;br&gt;&lt;5kg&lt;br&gt;&gt;50kg&lt;br&gt;Dehydration&lt;br&gt;Renal impairment&lt;br&gt;High risk of bleeding&lt;br&gt;Receiving anticoagluants&lt;br&gt;Allergy to NSAIDs&lt;br&gt;Poorly controlled asthma&lt;br&gt;Emergency surgery&lt;br&gt;Receiving diazepam, barbiturates, rifampicin, azole antifungals and any other drugs which may induce or block the metabolic pathway related to diclofenac&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Children undergoing surgery for orthapaedic, ENT, renal or abdominal conditions &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10042609
Term: Surgery
</Condition>
    <Intervention>&lt;br&gt;Product Name: Diclofenac Sodium 50mg/5ml Oral Suspension&lt;br&gt;Pharmaceutical Form: Oral suspension&lt;br&gt;INN or Proposed INN: Diclofenac&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine population pharmacokinetics of diclofenac in children aged 6m-12y;Secondary Objective: To determine proportion of children with each of the three genotypes relevant to metabolism of diclofenac (CYP2C8, CYP2C9 and UGT2B7) .&lt;br&gt;To correlate pharmacokinetics with pharmacogenetic profile and pharmacodynamic effects.;Primary end point(s): Population pharmacokinetics of diclofenac&lt;br&gt;Pharmacogenetic subtypes for diclofenac metabolism</Primary_outcome>
    <Secondary_ID>2005DICPAED</Secondary_ID>
    <Secondary_Sponsor>Joint Sponsor: University of Glasgow with NHS Greater Glasgow and Clyde</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2470035</Internal_Number>
    <TrialID>EUCTR2006-002328-40-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A phase I safety and tolerability study of infusing the autologous progeny of an adult CD34+ subset into patients with type I diabetes mellitus and a successful renal transplant. - Stem cell and diabetes study</Public_title>
    <Scientific_title>A phase I safety and tolerability study of infusing the autologous progeny of an adult CD34+ subset into patients with type I diabetes mellitus and a successful renal transplant. - Stem cell and diabetes study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Imperial College London</Primary_sponsor>
    <Date_registration3>20060723</Date_registration3>
    <Date_registration>23/07/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002328-40                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/05/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Male or female patients aged from 16 to 65 years of age&lt;br&gt;Patient with Type I diabetes mellitus plus:&lt;br&gt;Successful previous kidney transplant. &lt;br&gt;Good kidney allograft function /no episodes of rejection &lt;br&gt;for at least one year post-transplant&lt;br&gt;Not taking steroids as part of standard  immuno-suppression&lt;br&gt;Has a WHO performance score of less than 2&lt;br&gt;Has a life expectancy of at least 3 months&lt;br&gt;Ability to give written consent&lt;br&gt;Women of childbearing potential may be included, but must use a reliable and appropriate contraceptive method&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients below the age of 16 or above the age of 65 years&lt;br&gt;Patients with chronic pancreatitis and poor exocrine pancreatic function&lt;br&gt;Pregnant or lactating women&lt;br&gt;Patients with recent recurrent GI bleeding or spontaneous bacterial peritonitis&lt;br&gt;Patients with evidence of HIV or other life threatening infection&lt;br&gt;Patients unable to give written consent&lt;br&gt;Patients with a history of hypersensitivity to G-CSF &lt;br&gt;Patients who have been included in any other clinical trial within the previous month&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Diabetes mellitus type 1 and succesful renal transplant &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10012638
Term: Diabetes with renal manifestations
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038533
Term: Renal transplant
</Condition>
    <Intervention>&lt;br&gt;Product Name: Autologous CD34+ stem cell subset&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess the safety and tolerance of a high dose of autologous expanded progeny of adult CD34+ stem cell subset (InsulinCytes) when introduced into either the body or tail of the pancreas.  ;Secondary Objective: To assess improvement in endocrine pancreatic function as measured by serological and biochemical analysis and determine any symptomatic improvements as they are reported by the patients.;Primary end point(s): To assess the safety and tolerance of a high dose of autologous expanded progeny of adult CD34+ stem cell subset (InsulinCytes) when introduced into either the body or tail of the pancreas.  </Primary_outcome>
    <Secondary_ID>HHSC/005</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2470136</Internal_Number>
    <TrialID>EUCTR2006-002770-22-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>The effects of oral sodium bicarbonate on extracellular water in patients with chronic renal failure - Sodium bicarbonate use in renal patients</Public_title>
    <Scientific_title>The effects of oral sodium bicarbonate on extracellular water in patients with chronic renal failure - Sodium bicarbonate use in renal patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>York Hospital NHS Trust</Primary_sponsor>
    <Date_registration3>20060918</Date_registration3>
    <Date_registration>18/09/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002770-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/09/2006</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients with chronic renal failure defined as stage 3-5 CKD (an estimated glomerular filtration rate (MDRD GFR) of &lt;60 ml/min). Using a serum creatinine &gt;180 µmol/l will mean that nearly all subjects will actually have stage 4/5 CKD (MDRD GFR &lt;30 ml/min). &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients on dialysis; already on sodium bicarbonate; poorly controlled hypertension (systolic BP &gt; 160 mmHg; diastolic BP &gt; 90 mmHg); peripheral oedema on clinical assessment; active nephrotic syndrome; history of congestive cardiac failure and/or pulmonary oedema.&lt;br&gt;</Exclusion_Criteria>
    <Condition>We will investiagte the use of sodium bicarbonate on extracellular water in patients with CHRONIC RENAL FAILURE</Condition>
    <Intervention>&lt;br&gt;Product Name: sodium bicarbonate&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;CAS Number: 144-55-8&lt;br&gt;Current Sponsor code: SOB06&lt;br&gt;Other descriptive name: Sodium Bicarbonate&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;Pharmaceutical form of the placebo: Capsule*&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: This is a double blind placebo controlled trial of oral sodium bicarbonate against placebo in patients with chronic renal failure.  The aim of the trial is to determine the effects of oral sodium bicarbonate on extracellular fluid volumes and blood pressure in patients with renal failure.;Secondary Objective: To determine whether or not biometric impedence monitoring will detect changes demonstrated by gold standard techniques of body water measurements.;Primary end point(s): Change in the ratio Vecf/Vtbw&lt;br&gt;Change in body weight/blood pressure. Agreement between gold standard and bioimpedance measurements of Vecf/Vtbw.</Primary_outcome>
    <Secondary_ID>SOB06</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2470366</Internal_Number>
    <TrialID>EUCTR2006-006948-65-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>The effect of acidosis correction and exercise on tissue wasting and immune function in renal patients</Public_title>
    <Scientific_title>The effect of acidosis correction and exercise on tissue wasting and immune function in renal patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>University Hospitals of Leicester NHS Trust</Primary_sponsor>
    <Date_registration3>20070126</Date_registration3>
    <Date_registration>26/01/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006948-65                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>29/11/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Lower dose of sodium bicarbonate&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Chronic kidney disease patients at CKD  stages 4 to 5 &lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Physical disability sufficient to preclude participating in an exercise programme&lt;br&gt;Age less than 18 years&lt;br&gt;Pregnancy&lt;br&gt;Congestive heart failure&lt;br&gt;Live cirrhosis&lt;br&gt;&lt;br&gt;The Summary of Product Characteristics also recommends caution in the use of sodium bicarbonate in those with impaired renal function , hypertension, and dietary sodium restriction. These features characterise all subjects recruited to this study. Due caution will be exercised based on the expert clinical knowledge and experience of the investigators.&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic kidney disease</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sodium bicarbonate 500mg capsules&lt;br&gt;Product Name: Sodium bicarbonate&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The interaction between exercise and metabolic acidosis in chronic kidney disease has never been investigated. Important questions to be answered are:&lt;br&gt;•	What influence does correcting acidosis have on exercise tolerance? &lt;br&gt;•	Are the expected beneficial effects of exercise and acidosis correction additive?&lt;br&gt;           OR&lt;br&gt;•	Does exercise (which generates lactic acid in muscle) worsen the acidosis problem? This may be important in kidney patients because the level of exercise needed to generate lactic acid  (the lactate threshold) is low. &lt;br&gt;•	Does correcting acidosis allow an improved response to exercise in those kidney patients who currently respond poorly to exercise therapy alone? &lt;br&gt;;Secondary Objective: ;Primary end point(s): Muscle mass and ability to perform exercise&lt;br&gt;Signals in muscle which control protein synthesis&lt;br&gt;Blood pressure, pulse wave velocity, finometry&lt;br&gt;Quality of life using Leicester uraemic symptoms score&lt;br&gt;</Primary_outcome>
    <Secondary_ID>Version 4</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2470481</Internal_Number>
    <TrialID>EUCTR2006-004511-21-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Upfront Sunitinib (SU011248)® therapy followed by surgery in patients with metastatic renal cancer: a pilot Phase II study [SuMR] - SuMR</Public_title>
    <Scientific_title>Upfront Sunitinib (SU011248)® therapy followed by surgery in patients with metastatic renal cancer: a pilot Phase II study [SuMR] - SuMR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Queen Mary University London</Primary_sponsor>
    <Date_registration3>20070309</Date_registration3>
    <Date_registration>09/03/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004511-21                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>01/08/2007</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Histopathologically confirmed renal cell carcinoma (clear cell) with measurable metastases on CT/ imaging.Patients with suspicion of renal cancer on radiology must have a biopsy to confirm diagnosis of clear cell, taken as part of the study.&lt;br&gt;2.	Judged by the treating physician to have the potential to derive clinical benefit form sunitinib treatment&lt;br&gt;3.	Male or Female, 18 years of age or older&lt;br&gt;4.	Adequate organ function as defined by the following criteria:&lt;br&gt;•	Total serum bilirubin =2 x ULN (patients with Gilbert’s disease exempt)&lt;br&gt;•	Serum transaminases &lt;5 x ULN&lt;br&gt;•	Serum creatinine =2 x ULN&lt;br&gt;•	Absolute neutrophil count (ANC) =1000/mm3 without growth factor support&lt;br&gt;•	Platelets = 75,000/mm3&lt;br&gt;5.	Signed and dated informed consent document indicating that the patient has been informed of all the pertinent aspects of the trial prior to enrolment.&lt;br&gt;6.	Willingness and ability to comply with scheduled visits, treatment plans and laboratory tests and other study procedures&lt;br&gt;7.	ECOG performance status of 0,1 or 2.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Congestive heart failure, myocardial infarction or coronary artery bypass graft in the previous six months, ongoing severe or unstable arrhythmia requiring medication.&lt;br&gt;2.	Previous treatment  for renal cancer. &lt;br&gt;3.	Pregnancy or breastfeeding.  Patients must be surgically sterile or be postmenopausal, or must agree to use adequate contraception during the period of therapy.  The definition of effective contraception will be based on the judgement of the principal investigator or a designated associate.  Male patients must be surgically sterile or agree to use adequate contraception.&lt;br&gt;5.	Other severe acute or chronic medical or psychiatric condition, or laboratory abnormally that would impart, in the judgement of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgement of the investigator, would make the patient inappropriate for entry into this study&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>The current standard treatment in patients with metastatic renal cancer includes nephrectomy followed by immune therapy with either interleukin 2 (rIL-2) or interferon (IFN-a).  Unfortunately, responses occur in only approximately 15% of patients, with less than 5% benefiting from a durable remission. Treatment options for patients who progress on this treatment remain very limited. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050018
Term: Renal cancer metastatic
</Condition>
    <Intervention>&lt;br&gt;Product Name: Sunitinib Malate&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Sutent-H-687-00-00&lt;br&gt;CAS Number: 557795-19-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 50, 25 &amp; 12.5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective is to determine the effect of three months pre-operative treatment with SUNITINIB in patients with operable and inoperable metastatic renal cancer.;Secondary Objective: 1.	To establish if there is a correlation between PET response and overall survival in these patients.  Additionally changes in gene suppression &lt;br&gt;&lt;br&gt;2.	To investigate if changes in growth factor and growth factor receptor expression at a tissue level before and after treatment are associated response &lt;br&gt;&lt;br&gt;3.	Assess tumour response using sequential micro-array&lt;br&gt;&lt;br&gt;4.	To determine the proportion of patients that are deemed to be inoperable that will become operable with SU011248.&lt;br&gt;&lt;br&gt;5.	To evaluate the safety and tolerability profile&lt;br&gt;;Primary end point(s): The primary endpoint is time to radiological progression.  </Primary_outcome>
    <Secondary_ID>RC-2007-01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2470615</Internal_Number>
    <TrialID>EUCTR2006-005373-22-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Erythropoietin and Delayed Graft Function in Renal Allografts from Extended Criteria Donors.

 - EPO and DGF</Public_title>
    <Scientific_title>Erythropoietin and Delayed Graft Function in Renal Allografts from Extended Criteria Donors.

 - EPO and DGF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Central Manchester and Manchester Children's University Hospitals NHS Trust</Primary_sponsor>
    <Date_registration3>20070530</Date_registration3>
    <Date_registration>30/05/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005373-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>23/07/2007</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Men and women aged = or &gt; 18 years&lt;br&gt;2.	The subject is willing to provide signed written informed consent.&lt;br&gt;3.	The subject is the recipient of a deceased donor kidney transplant.&lt;br&gt;4.	The donor and/or donor kidney meet at least one of the following extended criteria for organ donation from either (a) or (b) as described below:&lt;br&gt;a)&lt;br&gt;&lt;br&gt;Donor condition	Donor age categories&lt;br&gt;	                 50-59 years	&gt;or=60 years&lt;br&gt;CVA+HTN+SCr&gt;1.5	eligible	eligible&lt;br&gt;CVA+HTN	                    eligible	eligible&lt;br&gt;CVA+SCr&gt;1.5	eligible	eligible&lt;br&gt;HTN+SCr&gt;1.5	eligible	eligible&lt;br&gt;CVA	                      no	eligible&lt;br&gt;HTN	                      no              eligible&lt;br&gt;SCr&gt;1.5	                      no	eligible&lt;br&gt;None 	                      no	eligible&lt;br&gt;&lt;br&gt;b)	Additional criteria&lt;br&gt;	i)	anticipated CIT  = or &gt; 24hrs&lt;br&gt;	ii)	donor with cardiac death&lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Women who are pregnant or breastfeeding.&lt;br&gt;2. Women with a positive pregnancy test on enrolment.&lt;br&gt;3. Subjects with any active infection that would normally exclude &lt;br&gt;    transplantation.&lt;br&gt;4. Subjects who have used any other investigational drug within 30 days prior to &lt;br&gt;    transplantation.&lt;br&gt;5. Subjects with a haemoglobin level = or &gt; 15g/dl&lt;br&gt;6. Subjects with a diastolic blood pressure &gt; 100 mm/Hg pre-transplantation.&lt;br&gt;7. Subjects previously intolerant of NeoRecormon.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Transplantation of renal allografts from extended criteria donors</Condition>
    <Intervention>&lt;br&gt;Trade Name: NeoRecormon&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The principal objective of this study is to investigate whether giving erythropoietin (EPO) to patients at the time of kidney transplantation reduces the incidence and/or severity of delayed graft function, when compared to patients who receive a placebo.;Secondary Objective: 1.	To monitor and compare kidney function in both patient groups post-operatively and at 3, 6, 9 and 12 months&lt;br&gt;2.	To record number and severity of acute rejection episodes.     &lt;br&gt;3.	To measure biomarkers involved in ischaemia/reperfusion injury and compare the findings in the EPO group with the placebo group&lt;br&gt;4.	The longer term outcome (at 1 year and 2 years) of the patients in both groups will be followed to compare the incidence of chronic allograft nephropathy. &lt;br&gt;;Primary end point(s): The primary end point of the trial is the comparison between plasma levels and gene expression of biomarkers between the two arms of the trial at the specified time points.</Primary_outcome>
    <Secondary_ID>10322</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2470806</Internal_Number>
    <TrialID>EUCTR2007-002914-20-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Calcineurin Inhibitor Minimisation in Renal Transplant Recipients with Stable Allograft Function: A Prospective Randomised Controlled Trial - CNIM-SRT</Public_title>
    <Scientific_title>Calcineurin Inhibitor Minimisation in Renal Transplant Recipients with Stable Allograft Function: A Prospective Randomised Controlled Trial - CNIM-SRT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>University Hospital Birmingham NHS Foundation Trust</Primary_sponsor>
    <Date_registration3>20070731</Date_registration3>
    <Date_registration>31/07/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-002914-20                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/09/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;To be included in the study the patient must be an adult recipient of a first kidney transplant, and have:&lt;br&gt;•A functioning kidney allograft (with estimated (e)GFR by MDRD &gt;30ml/min/1.73m2) and be between 1 and 10 years post transplantation&lt;br&gt;•Stable allograft function, as defined by no greater than 10% rise in serum creatinine in the preceding 6 months, on ciclosporin and azathioprine immunosuppression&lt;br&gt;•Minimal proteinuria, evidenced as urine albumin:creatinine ratio &lt;50mg/mmol&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;The presence of any of the following will preclude patient inclusion&lt;br&gt;&lt;br&gt;• &lt;18 years of age&lt;br&gt;• Pregnancy or suspicion of pregnancy confirmed by positive b-HCG pregnancy test&lt;br&gt;• Female patients unwilling to take effective contraception for study duration&lt;br&gt;• Untreated ureteric obstruction on ultrasound of allograft&lt;br&gt;• Recurrent urosepsis&lt;br&gt;• Severe systemic infection&lt;br&gt;• Untreated significant (&gt;50%) renal artery stenosis on magnetic resonance       angiography performed prior to study.&lt;br&gt;• History of acute allograft rejection &lt;br&gt;• History of myocardial infarction&lt;br&gt;• History of malignancy in previous 5 years (excluding non-melanomatous tumours limited to skin)&lt;br&gt;• Symptomatic ischaemic heart disease&lt;br&gt;• Hepatitis B surface antigen positive, Hepatitis C positive or HIV positive. &lt;br&gt;• Recipient of combined organ transplantation (e.g. pancreas/kidney; liver/kidney) &lt;br&gt;• Recipient of ABO-incompatible kidney&lt;br&gt;• Greater than 1 HLA mismatch at either the “B” or “DR” locus&lt;br&gt;• Peak HLA antibody Panel Reactivity (PRA) greater than 10% &lt;br&gt;• Recipient who underwent HLA desensitisation procedure prior to transplantation&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal Transplantation &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10010185
Term: Complications of transplanted kidney
 &lt;br&gt;MedDRA version: 9.1
Level: HLT
Classification code 10052779
Term: Transplant rejections
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Neoral&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865133&lt;br&gt;Current Sponsor code: RRK3367&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Trade Name: Neoral&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865133&lt;br&gt;Current Sponsor code: RRK3367&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Neoral&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865133&lt;br&gt;Current Sponsor code: RRK3367&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Trade Name: Neoral&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865133&lt;br&gt;Current Sponsor code: RRK3367&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine whether complete calcineurin inhibitor withdrawal offers benefits over partial withdrawal (minimisation) in delaying the progression of histological graft damage, in patients with stable short-term allograft function, but who are at risk for progressive histological damage.;Secondary Objective: •To compare patient and graft survival between withdrawal and minimisation groups&lt;br&gt;•To compare renal function between groups&lt;br&gt;•To assess the incidence of allograft rejection (clinical and sub-clinical) between groups&lt;br&gt;•To evaluate effect on proteinuria, where present&lt;br&gt;•To compare changes in anti-HLA antibody profiles between groups&lt;br&gt;•To compare lymphocyte function between groups&lt;br&gt;•To compare cardiovascular risk profile between groups&lt;br&gt;•To compare the incidence of viral and bacterial infection between groups&lt;br&gt;;Primary end point(s): To compare renal allograft markers of damage and evolving injury in biopsies immediately pre study and at the end of the study. The primary tissue assessments will comprise:&lt;br&gt;&lt;br&gt;1) Index of chronic damage (an objective measure of the amount of chronic damage, shown to be a powerful indicator of prognosis in non-allograft renal biopsies )&lt;br&gt;2)Interstitial fibrosis quantification by Sirius Red staining&lt;br&gt;3)TGF-beta expression&lt;br&gt;4)P-selectin expression and leukocyte infiltration (macrophage).&lt;br&gt;5)Fibroblast function&lt;br&gt;6)Epithelial mesenchymal transformation markers&lt;br&gt;7)Markers of apoptosis&lt;br&gt;8)Electron Microscopy&lt;br&gt;&lt;br&gt;</Primary_outcome>
    <Secondary_ID>RRK3367;ISRCTN60081949</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2471541</Internal_Number>
    <TrialID>EUCTR2008-001747-18-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Etude multicentrique évaluant le maintien du taux d’hémoglobine avec une administration sous-cutanée mensuelle de C.E.R.A. (activateur continu du récepteur de l’érythropoïétine) chez des patients insuffisants rénaux chroniques sous dialyse péritonéale - MISTRAL</Public_title>
    <Scientific_title>Etude multicentrique évaluant le maintien du taux d’hémoglobine avec une administration sous-cutanée mensuelle de C.E.R.A. (activateur continu du récepteur de l’érythropoïétine) chez des patients insuffisants rénaux chroniques sous dialyse péritonéale - MISTRAL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>ROCHE</Primary_sponsor>
    <Date_registration3>20080513</Date_registration3>
    <Date_registration>13/05/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-001747-18                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>05/06/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Relatifs à la population : &lt;br&gt;1. Patient adulte (= 18 ans) ayant délivré un consentement de participation écrit &lt;br&gt;2. Patient apte selon l’investigateur à se plier aux impératifs de l’étude &lt;br&gt;3. Patient affilié à un régime de sécurité sociale ou bénéficiaire d'un tel régime&lt;br&gt;&lt;br&gt;Relatifs à la pathologie : &lt;br&gt;4. Patient atteint d’insuffisance rénale chronique associée à une anémie, sous dialyse péritonéale depuis au moins 3 mois avant la période de sélection &lt;br&gt;5. Patient chez lequel un minimum de 36 litres de dialysat est infusé par semaine &lt;br&gt;6. Patient ayant un Kt/V total (rénal + dialytique) hebdomadaire = 1.7 et/ou une clairance hebdomadaire totale (rénale + dialytique) &gt; 50 litres &lt;br&gt;7. Patient ayant un taux moyen d’Hb compris entre [10; 12] g/dl pendant la période de sélection (moyenne de 3 valeurs d’Hb mesurées à S-4, S-2 et J0) &lt;br&gt;8. Patient recevant un traitement de maintenance continu en sous-cutané par epoetin ou darbepoetin alfa avec une fréquence d’administration identique pendant la période de sélection et pendant les 4 semaines précédentes &lt;br&gt;9. Patient ayant une dose d’ASE stable pendant la période de sélection (aucun changement de la dose hebdomadaire n’est autorisé) &lt;br&gt;10. Patient ayant un statut martial adéquat (mesuré sur une valeur durant la période de sélection): ferritine sérique &gt; 100 ng/ml et TSAT &gt; 20% (ou pourcentage de globules rouges hypochromes &lt; 10%)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Relatifs à la population : &lt;br&gt;1. Femme enceinte ou allaitant &lt;br&gt;2. Femme en période d’activité génitale sans contraception efficace &lt;br&gt;3. Patient atteint d’une déficience ne lui permettant pas une bonne compréhension des impératifs de l’essai&lt;br&gt;4. Patient ayant déjà été inclus dans le présent essai &lt;br&gt;5. Patient participant à un essai clinique, ou ayant reçu un autre médicament expérimental moins de 3 mois avant la sélection&lt;br&gt;Relatif au traitement à l’essai : &lt;br&gt;6. Au moment de la sélection : patient pour lequel un transfert en hémodialyse est prévu pendant la période de l’étude &lt;br&gt;7. Patient présentant un ou des saignements aigus ou chroniques significatifs notamment gastro-intestinaux dans les 8 semaines précédant la période de sélection &lt;br&gt;8. Patient recevant une ou plusieurs transfusions sanguines (globules rouges) pendant la période de sélection et pendant les 8 semaines précédentes &lt;br&gt;9. Patient recevant un traitement immunosuppresseur (autre que corticoïdes pour une affection chronique, cyclosporine, et anticorps monoclonaux/polyclonaux) pendant la période de sélection et pendant les 8 semaines précédentes &lt;br&gt;10. Patient recevant une dose hebdomadaire d’epoetin &gt; 16000 UI ou dose hebdomadaire de darbepoetin alfa&gt; 80 µg pendant la période de sélection et pendant les 8 semaines précédentes &lt;br&gt;11. Patient ayant un changement de voie d’administration de l’epoetin ou de la darbepoetin alfa pendant la période de sélection &lt;br&gt;12. Patient présentant une hémoglobinopathie (anémie falciforme, thalassémies) &lt;br&gt;13. Patient présentant une hémolyse &lt;br&gt;14. Patient présentant une maladie maligne active dans les 5 dernières années (excepté les cancers cutanés hors mélanome) &lt;br&gt;15. Patient présentant un déficit sérique connu en Vitamine B12 ou en acide folique 16. Patient présentant une hyperparathyroïdie secondaire non contrôlée ou symptomatique &lt;br&gt;17. Patient présentant une péritonite active ou toute autre infection sévère et/ou syndrome inflammatoire nécessitant une antibiothérapie (orale, intraveineuse ou intra péritonéale) pendant la période de sélection &lt;br&gt;18. Patient présentant une hypertension artérielle mal contrôlée, c’est-à-dire une pression artérielle (PAS/PAD) assise &gt; 170/100 mmHg et nécessitant une interruption de traitement par ASE dans les 6 mois précédant la période de sélection&lt;br&gt;19. Patient présentant une crise d’épilepsie dans les 6 mois précédant la période de sélection &lt;br&gt;20. Patient présentant un infarctus du myocarde, coronaropathie sévère ou instable, accident vasculaire cérébral, ou hépatopathie sévère survenant dans les 12 semaines précédant la période de sélection &lt;br&gt;21. Patient présentant un nombre de plaquettes &gt; 500 x 109/L ou &lt; 100 x 109/L &lt;br&gt;22. Patient présentant une insuffisance cardiaque congestive sévère (stade IV de la New York Heart Association) &lt;br&gt;23. Patient présentant ou ayant présenté une érythroblastopénie &lt;br&gt;24. Patient ayant une chirurgie planifiée pendant la durée de l’étude à l’exception d’une intervention pour : cataracte, photocoagulation laser, révision/création d’une voie d’abord vasculaire et chirurgie ambulatoire mineure ne nécessitant pas d’hospitalisation &lt;br&gt;25. Patient présentant une hypersensibilité connue à une érythropoïétine recombinante, au polyéthylène glycol ou à tout autre constituant du traitement à l’étude&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients insuffisants rénaux chroniques sous dialyse péritonéale &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10054353
Term: Chronic renal failure anemia
</Condition>
    <Intervention>&lt;br&gt;Product Code: RO503821/F03&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F04&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 75-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F05&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F21&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 120-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F06&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 150-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F07&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F08&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F23&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glyco</Intervention>
    <Primary_outcome>Main Objective: Evaluer le maintien du taux d'hémoglobine avec une administration sous-cutanée mensuelle de  C.E.R.A. chez des patients insuffisants rénaux chroniques sous dialyse péritonéale;Secondary Objective: Evaluer la variabilité du taux d'hémoglobine avec une administration sous-cutanée mensuelle de C.E.R.A. dans cette population de patients&lt;br&gt;&lt;br&gt;Evaluer la tolérance d'une administration sous-cutanée mensuelle de C.E.R.A. dans cette population de patients&lt;br&gt;&lt;br&gt;Evaluer le statut nutritionnel des patients&lt;br&gt;&lt;br&gt;Evaluer la qualité de vie (QdV) des patients;Primary end point(s): Proportion de patients maintenant un taux moyen* d’hémoglobine dans l’intervalle cible [10; 12] g/dl pendant la période d’évaluation d’efficacité (PEE)&lt;br&gt;* Moyenne de 3 valeurs d’Hémoglobine mesurées aux semaines 16, 20 et 24</Primary_outcome>
    <Secondary_ID>ML 21421 </Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2471896</Internal_Number>
    <TrialID>EUCTR2008-008895-15-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Influence de l'introduction du sirolimus sur la balance inflammatoire chez le transplanté rénal - SIRILYGRE</Public_title>
    <Scientific_title>Influence de l'introduction du sirolimus sur la balance inflammatoire chez le transplanté rénal - SIRILYGRE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Hospices Civils de Lyon</Primary_sponsor>
    <Date_registration3>20090318</Date_registration3>
    <Date_registration>18/03/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-008895-15                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>16/02/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- âge &gt; ou égale à 18 ans&lt;br&gt;- patients transplantés rénaux depuis plus de 3 mois,&lt;br&gt;- suivis dans les Centres Hospitaliers Universitaires de Lyon et Grenoble,&lt;br&gt;- pour lesquels est décidée l’introduction du sirolimus en remplacement des anticalcineurines (quelque soit la cause de ce changement thérapeutique).&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- âge &lt; 18 ans, &lt;br&gt;- greffe rein-pancréas, &lt;br&gt;- date de la greffe &lt; 3 mois, &lt;br&gt;- rejet en cours ou mal contrôlé, &lt;br&gt;- suivi de 3 mois non possible, &lt;br&gt;- hypersensibilité au sirolimus ou à l’un des excipients,&lt;br&gt;- absence de contraception efficace chez la femme non ménauposée&lt;br&gt;- absence de consentement éclairé&lt;br&gt;- patient non affilié à un régime de sécurité sociale.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Transplantation rénale &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038533
Term: Renal transplant
</Condition>
    <Intervention>&lt;br&gt;Product Name: sirolimus&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: SIROLIMUS&lt;br&gt;CAS Number: 53123889&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1-2&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Secondary Objective: ;Primary end point(s): - Effets secondaires rattachés au sirolimus : &lt;br&gt;   * effets cliniques, évalués indépendamment par le médecin et par le patient à l’aide d’un questionnaire qui lui sera remis&lt;br&gt;   * effets biologiques&lt;br&gt;- Dosage de cytokines plasmatiques impliquées dans la balance pro / anti inflammatoire&lt;br&gt;- Génotypage du cytochrome P450 3A5&lt;br&gt;;Main Objective: - Déterminer le profil des manifestations inflammatoires cliniques et biologiques après conversion d’un inhibiteur de la calcineurine au sirolimus ;&lt;br&gt;- Déterminer si ces manifestations inflammatoires corrèlent avec une exposition différente à la molécule (relation dose effet, génotype du cytochrome 3A5) ;&lt;br&gt;- Valider l’hypothèse avancée chez les patients anémiques que les manifestations inflammatoires du sirolimus dépendent d’un blocage de la boucle d’autorégulation IL-10 dépendante de l’inflammation.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>HCL/P 2008.537/38</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2472146</Internal_Number>
    <TrialID>EUCTR2008-007235-40-AT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Development of Varicella-zoster virus (VZV)-specific CD4+ T cells on primary VZV infection or vaccination in renal transplant (RTX) recipients and healthy donors - VZV-specific CD4+ T cells</Public_title>
    <Scientific_title>Development of Varicella-zoster virus (VZV)-specific CD4+ T cells on primary VZV infection or vaccination in renal transplant (RTX) recipients and healthy donors - VZV-specific CD4+ T cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Department für Pädiatrie, Medizinische Universität Innsbruck</Primary_sponsor>
    <Date_registration3>20090330</Date_registration3>
    <Date_registration>30/03/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-007235-40                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/06/2009</Date_enrollement>
    <Target_size>180</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients listed for renal transplantation:&lt;br&gt;Patients with renal failure (meeting the criterias for transplantion listing; renal failure stage 4 or 5, glomerular filtration rate &lt; 29ml/min/1.73m2); age 24 months to 80 years; routine VZV vaccination (Varivax)&lt;br&gt;Healthy subjects (according to WHO definition): age 24 months to 80 years; routine VZV vaccination with Varivax&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients listed for renal transplantation:&lt;br&gt;Positive VZV IgG antibody levels at time point 0; immunosuppression at time of vaccinations; malignancies; rheumatic diseases; loss of immunoglobulins; proteinuria; blood transfusion or treatment with intravenous immunglobulin or plasma products in the last 6 months; pregnancy (validated by urine beta-HCG)&lt;br&gt;Healthy subjects: Positive VZV IgG antibody levels at time point 0; malignancies; rheumatic diseases; immunosuppression; cortisone therapy in the last 6 months; cytostatic therapy; blood transfusion or treatment with intravenous immunglobulin or plasma products in the last 6 months; pregnancy&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients (aged 24 months to 80 years) listed for renal transplantation
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Varivax&lt;br&gt;Product Name: Varivax&lt;br&gt;Product Code: 2-00300&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The proposed study is aimed to investigate the kinetics and maintenance of CD4+ T cell memory by evaluating VZV-specific CD4+ T cells after two-dose VZV vaccination in RTX recipients compared to two control groups of healthy age-matched children after VZV wildtype infection or after VZV vaccination, prospectively. Additionally, VZV IgG antibody levels and IgG avidity are monitored over 18 months in RTX recipients and healthy age-matched controls to assess humoral immunity against VZV. &lt;br&gt;Main objective: percentage of VZV-specific CD4+ T cells;Secondary Objective: VZV-specific IgG antibodies (U/ml) and relative avidity index of VZV-specific IgG antibodies;Primary end point(s): Drop-out criteria for vaccination:&lt;br&gt;Transplantation, immunosuppression, wish of patient, wish of doctor&lt;br&gt;Drop-out criteria for blood withdrawal: &lt;br&gt;wish of patient, wish of doctor&lt;br&gt;</Primary_outcome>
    <Secondary_ID>2008-007235</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2472516</Internal_Number>
    <TrialID>EUCTR2008-006772-30-AT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Evaluation of HCV clearance by hemodialysis</Public_title>
    <Scientific_title>Evaluation of HCV clearance by hemodialysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Medical University of Graz</Primary_sponsor>
    <Date_registration3>20090204</Date_registration3>
    <Date_registration>04/02/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-006772-30                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/03/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Consecutive hemodialysed patients with end-stage renal disease and documented presence of HCV RNA in serum over a period of ?6 months&lt;br&gt;- Age &gt;18 years&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- HCV/HBV or HCV/HIV co-infection&lt;br&gt;- Hematologic disease&lt;br&gt;- Sepsis&lt;br&gt;- Pregnancy&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic hepatitis C in patients with chronic renal failure &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10008912
Term: Chronic hepatitis C
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10066622
Term: Chronic hemodialysis
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Pegasys&lt;br&gt;Pharmaceutical Form: Injection*&lt;br&gt;&lt;br&gt;Trade Name: Copegus&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine HCV RNA clearance at different time points during hemodialysis;Primary end point(s): HCV RNA level;Secondary Objective: 1. To assess cellular and humoral immunologic parameters in peripheral blood before and after hemodialysis&lt;br&gt;2. To correlate HCV RNA levels, HCV RNA clearance, and cellular and humoral immunological parameters&lt;br&gt;3. To compare different hemodialysis methods (low flux hemodialysis versus high flux hemodiafiltration) on HCV RNA levels, HCV RNA clearance, and cellular and humoral immunological parameters&lt;br&gt;4. To assess sustained virological response (SVR) to antiviral treatment with peginterferon plus ribavirin&lt;br&gt;5. To relate SVR to HCV clearance and cellular and humoral immunological parameters&lt;br&gt;</Primary_outcome>
    <Secondary_ID>20-026</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2472575</Internal_Number>
    <TrialID>EUCTR2007-004590-25-AT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Determination of immune response after sequential pneumococcal vaccination using the 7-valent conjugate pneumococcal and the 23-valent pneumococcal polysaccharide vaccine in renal transplant recipients</Public_title>
    <Scientific_title>Determination of immune response after sequential pneumococcal vaccination using the 7-valent conjugate pneumococcal and the 23-valent pneumococcal polysaccharide vaccine in renal transplant recipients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Medical University of Vienna</Primary_sponsor>
    <Date_registration3>20090127</Date_registration3>
    <Date_registration>27/01/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004590-25                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/03/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Adult patients will be recruited at the transplant center of the Medical University of Vienna.&lt;br&gt;Patients will be eligable if between 6 months and 3 years had passed since their kidney transplant and if they have stable allograft function, as evidenced by creatinine level &lt; 250 µl for 1 month prior involvement&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;splenectomy, pneumococcal vaccination within preceeding 5 years, any acute febrile illness in the 2 weeks prior to or at time of enrollment, use of intravenous immunoglobulis within precceding 6 months, history of severe allergic reaction or anaphylaxis, hemoglobin value &lt; 10 g/dl at the time of inclusion &lt;br&gt;</Exclusion_Criteria>
    <Condition>Immunisation of renal transplant patients against streptococcus pneumoniae by conjugated or non conjugated pneumococcal vaccination</Condition>
    <Intervention>&lt;br&gt;Trade Name: Pneumo 23; &lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;&lt;br&gt;Trade Name: Prevenar&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To find an optimal vaccination schedule for tranplant patients;Secondary Objective: ;Primary end point(s): The aim of the study is to compare the quantitative antibody response of PPV23 with those of a sequential schedule of PCV7 followed by PPv23 12 months later in adult renal transplant recipients by measuring the concentrations of serotype-specific IgI in sera using ELISA recommended by the WHO.</Primary_outcome>
    <Secondary_ID>0/0</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2472747</Internal_Number>
    <TrialID>EUCTR2008-007786-23-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>ESTUDIO EN FASE 2 ALEATORIZADO Y DOBLE CIEGO DE AXITINIB (AG-013736) CON O SIN AJUSTE DE LA DOSIS EN PACIENTES CON CANCER DE CELULAS RENALES METASTASICO

RANDOMIZED, DOUBLE-BLIND PHASE 2 STUDY OF AXITINIB (AG-013736) WITH OR WITHOUT DOSE TITRATION IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA</Public_title>
    <Scientific_title>ESTUDIO EN FASE 2 ALEATORIZADO Y DOBLE CIEGO DE AXITINIB (AG-013736) CON O SIN AJUSTE DE LA DOSIS EN PACIENTES CON CANCER DE CELULAS RENALES METASTASICO

RANDOMIZED, DOUBLE-BLIND PHASE 2 STUDY OF AXITINIB (AG-013736) WITH OR WITHOUT DOSE TITRATION IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Pfizer, S.A.</Primary_sponsor>
    <Date_registration3>20090217</Date_registration3>
    <Date_registration>17/02/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-007786-23                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>23/04/2009</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. CCRm confirmado mediante estudio histológico con un componente histológico de células claras.&lt;br&gt;2. Ningún tratamiento sistémico previo para el CCRm (ni ningún tratamiento adyuvante ni neoadyuvante previo)&lt;br&gt;3. Si el paciente ha recibido radioterapia o una operación quirúrgica previa, ha transcurrido al menos 1 semana desde el final de la radioterapia y al menos 4 semanas desde la cirugía mayor. Toda la toxicidad previa relacionada con el tratamiento deberá haber mejorado a un grado &lt;= de los CTCAE del NCI, versión 3.0, o hasta el valor basal, salvo la alopecia. &lt;br&gt;4. Presencia de enfermedad mensurable (es decir, &gt;= 1 masa tumoral maligna que pueda medirse exactamente en al menos 1 dimensión que tenga un tamaño  &gt;=20 mm con tomografía computadorizada [TC] convencional o resonancia magnética [RM], o  &gt;=10 mm con TC helicoidal usando un algoritmo de reconstrucción de bloques contiguos de 5 mm o más pequeños). No se consideran mensurables las lesiones óseas, ascitis, carcinomatosis peritoneal o lesiones biliares, derrames pleurales o pericárdicos, diseminación linfangítica a la piel o el pulmón, lesiones quísticas o lesiones radiadas. Se permite la radioterapia paliativa previa para las lesiones metastásicas, siempre que persista al menos una lesión mensurable que no haya sido radiada.&lt;br&gt;5. Ausencia de hipertensión no controlada, documentada por dos mediciones basales de la presión arterial obtenidas con una diferencia de al menos 1 hora: las mediciones basales de la presión arterial sistólica deben ser &lt;=140 mm Hg y las mediciones basales de la presión arterial diastólica deben ser &lt;=90 mm Hg. &lt;br&gt;6. Función orgánica adecuada según lo definido por los criterios siguientes:&lt;br&gt;? Recuento absoluto de neutrófilos (RAN)  &gt;=1.500/mm3&lt;br&gt;? Plaquetas  &gt;= 75.000 células/mm3&lt;br&gt;? Hemoglobina  &gt;= 9,0 g/dl.&lt;br&gt;? AST y ALT &lt;= 2,5 veces el límite superior de la normalidad (LSN); si existen metástasis hepáticas, AST y ALT &lt;= 5,0 x LSN;&lt;br&gt;? Bilirrubina total &lt;= 1,5 x LSN;&lt;br&gt;? Creatinina sérica &lt;= 1,5 x LSN o aclaramiento de creatinina calculado &gt;=60 ml/min;&lt;br&gt;? Proteinuria &lt;2+ medida con tira reactiva. Si la tira reactiva es &gt;=2+, se medirá la proteinuria en la orina de 24 horas y los resultados deberán mostrar &lt;2 g por 24 horas.&lt;br&gt;7. Varones o mujeres de edad  &gt;=18 años.&lt;br&gt;8. Estado funcional del ECOG de 0 ó 1.&lt;br&gt;9. Esperanza de vida &gt;= 12 semanas.&lt;br&gt;10. Las mujeres (o sus parejas) deberán estar esterilizadas por métodos quirúrgicos o ser posmenopáusicas, o deberán acceder a usar un método anticonceptivo eficaz mientras reciban el tratamiento del estudio y por lo menos durante 3 meses después (o durante 6 meses, si así lo exige la normativa local). Todas las mujeres en edad fértil deberán dar negativo en una prueba de embarazo (suero/orina) en las 72 horas anteriores al inicio del tratamiento. Los varones (o sus parejas) deberán estar esterilizados por métodos quirúrgicos o deberán acceder a usar un método anticonceptivo eficaz mientras reciban el tratamiento del estudio y por lo menos durante 3 meses después (o durante 6 meses, si así lo exige la normativa local). La definición de un método anticonceptivo eficaz deberá cumplir la normativa local y se basará en el criterio del investigador principal o de un colaborador designado. En este estudio no podrán participar las mujeres lactantes.&lt;br&gt;11. Documento de consentimiento informado firmado y fechado en el que se indique que el paciente (o su representante legal) ha sido informado de todos los aspectos pertinentes del estudio antes de su </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Uso concurrente de más de 2 antihipertensivos. &lt;br&gt;2. Uso previo de axitinib (AG-013736).&lt;br&gt;3. Alteraciones del aparato digestivo como incapacidad para tomar medicación oral; necesidad de alimentación intravenosa; procedimientos quirúrgicos previos que afecten a la absorción, incluida la resección gástrica total; tratamiento por úlcera péptica activa en los 6 meses anteriores; hemorragia digestiva activa no relacionada con el cáncer demostrada por hematemesis, hematoquecia o melena en los 3 meses anteriores sin pruebas de resolución documentada por endoscopia o colonoscopia; síndromes de malabsorción.&lt;br&gt;4. Uso actual o necesidad prevista de tratamiento con fármacos que son inhibidores potentes de la enzima CYP3A4 (p. ej., zumo de pomelo, verapamilo, ketoconazol, miconazol, itraconazol, eritromicina, telitromicina, claritromicina, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir y delavirdina).&lt;br&gt;5. Uso actual o necesidad prevista de tratamiento con fármacos que son inductores de las enzimas CYP3A4 o CYP1A2 (p. ej., carbamazepina, dexametasona, felbamato, omeprazol, fenobarbital, fenitoína, amobarbital, nevirapina, primidona, rifabutina, rifampicina e hipérico).&lt;br&gt;6. Necesidad actual o reciente (en los 10 días previos al comienzo del tratamiento) de dosis terapéuticas completas de anticoagulantes orales o parenterales o de tratamiento diario crónico con ácido acetilsalicílico (&gt;325 mg/día) o clopidogrel (&gt;75 mg/día). &lt;br&gt;7. Trastorno convulsivo o signos de metástasis cerebrales, compresión de la médula espinal o meningitis carcinomatosa. &lt;br&gt;8. Cualquiera de los trastornos siguientes en los 12 meses previos a la administración del fármaco del estudio: infarto de miocardio, angina grave o inestable, injerto de derivación de arterias coronarias o periféricas, insuficiencia cardíaca congestiva sintomática, accidente cerebrovascular o accidente isquémico transitorio, y en los 6 meses previos en caso de trombosis venosa profunda o embolia pulmonar. &lt;br&gt;9. Infección bacteriana, fúngica o vírica activa; enfermedad relacionada con el virus de la inmunodeficiencia humana (VIH) o el síndrome de inmunodeficiencia adquirida (sida). &lt;br&gt;10. Antecedentes de neoplasia maligna (diferente del cáncer de células renales) excepto en los pacientes tratados con intención curativa por cáncer de piel distinto del melanoma, cáncer de mama o cervicouterino in situ, o aquellos tratados con intención curativa por otro cáncer que no hayan tenido signos de enfermedad durante 2 años.&lt;br&gt;11. Demencia o alteración importante del estado mental que impediría la comprensión o la concesión del consentimiento informado y el cumplimiento de los requisitos de este protocolo.&lt;br&gt;12. Cualquier otro trastorno médico o psiquiátrico grave, agudo o crónico, o cualquier anomalía de laboratorio que pueda aumentar el riesgo asociado a la participación en el ensayo o a la administración del fármaco del estudio o interferir en la interpretación de los resultados del estudio y, en opinión del investigador, impedir la participación en este ensayo.&lt;br&gt;</Exclusion_Criteria>
    <Condition>CCR metastásico

Metastatic RCC &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050513
Term: Metastatic renal cell carcinoma
</Condition>
    <Intervention>&lt;br&gt;Product Name: Axitinib&lt;br&gt;Product Code: AG-013736&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Axitinib&lt;br&gt;CAS Number: 319460-85-0&lt;br&gt;Current Sponsor code: AG-013736&lt;br&gt;Other descriptive name: Benzamide, N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Product Name: Axitinib&lt;br&gt;Product Code: AG-013736&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Axitinib&lt;br&gt;CAS Number: 319460-85-0&lt;br&gt;Current Sponsor code: AG-013736&lt;br&gt;Other descriptive name: Benzamide, N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Comparar la tasa de respuesta objetiva (TRO) en los pacientes que reciben axitinib con o sin ajuste de la dosis (grupos A y B);Secondary Objective: Evaluar el perfil de seguridad, otros parámetros de eficacia, la farmacocinética, las relaciones entre los biomarcadores o el perfil de expresión génica con el resultado clínico o la medición de la PA en pacientes que reciben axitinib con o sin ajuste de la dosis (grupos A y B). Aunque la principal comparación del estudio se realiza entre los grupos A y B, la información adicional como la referente a la seguridad y la relación entre el perfil de biomarcadores/expresión génica y los resultados clínicos también se evaluará en el grupo no aleatorizado, el grupo C.;Primary end point(s): TRO (grupos A frente a B)</Primary_outcome>
    <Secondary_ID>A4061046</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2472802</Internal_Number>
    <TrialID>EUCTR2009-010920-24-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio para evaluar la eficacia de Rapamicina en pacientes con Poliquistosis Renal Autosómica Dominante (PQRAD)</Public_title>
    <Scientific_title>Estudio para evaluar la eficacia de Rapamicina en pacientes con Poliquistosis Renal Autosómica Dominante (PQRAD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Fundación para la Investigación Biomédica del Hospital Universitario La Paz</Primary_sponsor>
    <Date_registration3>20090312</Date_registration3>
    <Date_registration>12/03/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-010920-24                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>07/08/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Medicación convencional&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Edad igual o mayor de 18 años.&lt;br&gt;2.	Pacientes con antecedentes familiares de PQRAD y/o diagnóstico confirmado de PQRAD tipo1.&lt;br&gt;3.	Serán incluidos los pacientes con una Tasa de Filtración Glomerular (aclaramiento de creatinina) &gt; 70 ml/min.&lt;br&gt;4.	Haber dado su consentimiento informado por escrito.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Embarazo y lactancia.   &lt;br&gt;2.	Pacientes con aclaramiento de creatinina &lt; de 70 ml/min.&lt;br&gt;3.	Pacientes con proteinuria &gt; 500 mg/ 24 h.&lt;br&gt;4.	Administración conjunta de medicamentos inductores o inhibidores del CYP 3A4.&lt;br&gt;5.	Hiperlipemia.&lt;br&gt;6.	Infección severa en el momento de entrar al estudio.&lt;br&gt;7.	Hipersensibilidad a la Rapamicina conocida.&lt;br&gt;8.	Pacientes en quienes no se haya documentado, a través de técnicas de imagen, crecimiento del volumen renal en los 6 meses previos a la aleatorización.&lt;br&gt;9.	Antecedentes de neoplasias en los últimos 2 años excepto cáncer de cérvix o cáncer cutáneo tratado.&lt;br&gt;10.	Participación en otro ensayo clínico.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Poliquistosis Renal Autosómica Dominante (PQRAD)</Condition>
    <Intervention>&lt;br&gt;Trade Name: RAPAMUNE 2 mg comprimidos recubiertos&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: SIROLIMUS&lt;br&gt;Other descriptive name: SIROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Primary end point(s): Para evaluar la eficacia de la Rapamicina se comparará el porcentaje de variación del volumen renal (lo mismo hepático) a los 12 meses entre ambos grupos.;Secondary Objective: ?	Monitorizar la evolución de la presión arterial cada 3 meses. &lt;br&gt;?	Monitorizar la aparición de proteinuria cada 3 meses.&lt;br&gt;?	Analizar la evolución de los quistes hepáticos a lo largo del estudio.;Main Objective: Evaluar la eficacia, seguridad y tolerabilidad de Rapamicina para retrasar y/o enlentecer el crecimiento de los quistes y del volumen renal y para prevenir la pérdida de la función renal en pacientes con PQRAD con función renal conservada, midiendo los volúmenes de los riñones por RMN y la función renal durante un periodo de 1 año.</Primary_outcome>
    <Secondary_ID>FLP-RAP-2009-01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2473082</Internal_Number>
    <TrialID>EUCTR2008-006210-14-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Phase 2 Open-Label Single-Arm, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination with AMG 386 as First Line or Second Line Therapy for Subjects with Metastatic Renal Cell Carcinoma</Public_title>
    <Scientific_title>Phase 2 Open-Label Single-Arm, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination with AMG 386 as First Line or Second Line Therapy for Subjects with Metastatic Renal Cell Carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Amgen Inc</Primary_sponsor>
    <Date_registration3>20090324</Date_registration3>
    <Date_registration>24/03/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-006210-14                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>27/04/2009</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Sunitinib Malate historical data&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Disease Related&lt;br&gt;• Subjects must have a histologically confirmed metastatic RCC with a clear cell component&lt;br&gt;• Low or intermediate risk according to the Memorial Sloan Kettering Cancer Center (MSKCC) prognostic risk classification defined as meeting between 0 and 2 of the following risk factors:&lt;br&gt;o Karnofsky performance status &lt; 80%&lt;br&gt;o Time from diagnosis of RCC to first systemic treatment &lt; 1 year&lt;br&gt;o Serum lactate dehydrogenase &gt; 1.5 x upper limit of normal (ULN)&lt;br&gt;o Serum hemoglobin &lt; lower limit of normal (LLN) for their institution&lt;br&gt;o Serum calcium (corrected) &gt; 10 mg/dL&lt;br&gt;*For the corrected calcium value, the following formula should be used:&lt;br&gt;Corrected calcium = Total serum calcium [mg/dL] + (0.8 x (4 – serum albumin [g/dL]))&lt;br&gt;Note: If the units of calcium measurement are in mmol/L (or mmoles/L or mM), then the conversion to mg/dL is as follows:&lt;br&gt;?? Calcium (mmol/L) x 4 = Calcium (mg/dL)&lt;br&gt;?? Calcium (mg/dL) x 0.25 = Calcium (mmol/L)&lt;br&gt;• Measurable disease with at least one unidimensionally measurable lesion per RECIST (see Appendix E).&lt;br&gt;• Left ventricular ejection fraction (LVEF) = 45% as measured by Muga scan or ECHO within 28 days prior to enrollment&lt;br&gt;Demographic&lt;br&gt;• Men or women &gt; 18 years old&lt;br&gt;• ECOG of 0 or 1&lt;br&gt;Laboratory&lt;br&gt;• Adequate organ and hematological function as evidenced by the following laboratory studies within 14 days of enrollment:&lt;br&gt;• Hematological function, as follows:&lt;br&gt;o Absolute neutrophil count (ANC) = 1.5 x 109/L&lt;br&gt;o Platelet count = 100 x 109/L&lt;br&gt;o Hemoglobin = 9 g/dL&lt;br&gt;• Renal function, as follows:&lt;br&gt;o Calculated creatinine clearance &gt; 50 mL/min according to the Cockcroft- Gault formula&lt;br&gt;o Urinary protein quantitative value of &lt; 30 mg in urinalysis or &lt; 1+ on dipstick, unless quantitative protein is &lt; 1000 mg in a 24 hour urine sample&lt;br&gt;• Hepatic function, as follows:&lt;br&gt;o Aspartate aminotransferase (AST) &lt; 2.5 x upper limit of normal (ULN) (if liver metastases are present, = 5 x ULN)&lt;br&gt;o Alanine aminotransferase (ALT) &lt; 2.5 x ULN (if liver metastases are present, = 5 x ULN)&lt;br&gt;o Alkaline phosphatase &lt; 2.0 x ULN (if bone or liver metastases are present, = 5 x ULN)&lt;br&gt;o Bilirubin &lt; 2.0 x ULN&lt;br&gt;• Hemostatic function, as follows:&lt;br&gt;o International Normalized Ratio (INR) &lt; 1.5 per institutional laboratory range&lt;br&gt;o Partial thromboplastin time (PTT) or activated partial thromboplastin (aPTT) = 1.5 x ULN per institutional laboratory range&lt;br&gt;General&lt;br&gt;• Able to tolerate infusions and self-administer oral medications&lt;br&gt;• Competent to comprehend, sign, and date an institutional review board (IRB)/ Independent Ethics Committee (IEC) -approved informed consent form&lt;br&gt;• Subject plans to begin protocol directed therapy within 7 days of enrollment&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Disease Related&lt;br&gt;• Primary tumor in situ&lt;br&gt;o Subjects must have their primary tumor resected to be eligible for this study&lt;br&gt;• Any existing tumor thrombus must be removed before enrollment&lt;br&gt;• Known history of central nervous system metastases. An MRI or CT scan of the brain or head will be performed within 28 days of enrollment.&lt;br&gt;• History of arterial or venous thromboembolism within 12 months prior to enrollment&lt;br&gt;• History of clinically significant bleeding within 6 months prior to enrollment&lt;br&gt;• Previous treatment (excluding surgery, prior cytokine-based immunotherapy and palliative radiotherapy) for advanced or metastatic renal cell carcinoma&lt;br&gt;• Focal radiation therapy for palliation of pain from bony metastases within 14 days of enrollment.&lt;br&gt;• Subjects who received radiation therapy must have recovered from all radiation induced toxicities prior to enrollment&lt;br&gt;Medications&lt;br&gt;• Currently or previously treated with sunitinib or other small molecule inhibitors of VEGF including, but not limited to AMG 706 (motesanib), SU11248 (sunitinib), sorafenib, PTK787 (vatalinib), AZD 2171 (recentin), AEE-788&lt;br&gt;• Currently or previously treated with agents that neutralizing VEGF such as bevacizumab, or VEGF-TRAP&lt;br&gt;• Currently or previously treated with AMG 386, or other molecules that inhibit the angiopoietins or Tie2 receptor including but not limited to, XL-820, XL-184, or CVX- 060/PF-4856884&lt;br&gt;• Currently or previously treated with agents inhibiting the mammalian target of rapamycin (mTOR)&lt;br&gt;• Current or within 30 days prior to enrollment treatment with immune modulators such as cyclosporine and tacrolimus&lt;br&gt;• Concomitant or previous use within 30 days prior to enrollment of any strong inducer of CYP3A4 including, but not limited to, rifampin, St. John’s wort, phenytoin, carbamazepine, phenobarbital and dexamethasone&lt;br&gt;• Concomitant or previous use within 30 days prior to enrollment of any strong inhibitors of CYP3A4 including, but not limited to, ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit, and grapefruit juice&lt;br&gt;• Concomitant or previous use of amiodarone within 6 months prior to enrollment&lt;br&gt;General Medical&lt;br&gt;• Known ongoing pancreatitis&lt;br&gt;• Clinically significant cardiovascular disease within 12 months prior to enrollment, including myocardial infarction, unstable angina, grade 2 or greater peripheral vascular disease, cerebrovascular accident, transient ischemic attack, congestive heart failure, or arrhythmias not controlled by outpatient medication, percutaneous transluminal coronary angioplasty/stent&lt;br&gt;• History of allergic reactions to bacterially produced proteins&lt;br&gt;• Pregnant (i.e., positive beta-human chorionic gonadotropin test) or is breast feeding&lt;br&gt;• Subjects with history of prior malignancy, except:&lt;br&gt;?? Malignancy treated with curative intent and with no known active disease present for = 3 years before enrollment and felt to be at low risk for recurrence by treating physician&lt;br&gt;?? Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease&lt;br&gt;?? Adequately treated cervical carcinoma in situ without evidence of disease&lt;br&gt;?? Prostatic intraepithelial neoplasia without evidence of prostate cancer&lt;br&gt;• Major surgery within 28 days prior to enrollment or still recovering from prior surgery&lt;br&gt;• Minor surgical procedures, placement of central venous access device (except PICC or peripherally inserted central catheter), or fine needle aspiration </Exclusion_Criteria>
    <Condition>Metastatic renal cell carcinoma &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050513
Term: Metastatic renal cell carcinoma
</Condition>
    <Intervention>&lt;br&gt;Product Name: AMG 386&lt;br&gt;Product Code: AMG 386&lt;br&gt;Pharmaceutical Form: Intravenous infusion&lt;br&gt;INN or Proposed INN: AMG 386&lt;br&gt;Current Sponsor code: AMG 386&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective is to determine the safety and tolerability of AMG 386 in combination with sunitinib in subjects with metastatic renal cell carcinoma;Secondary Objective: • To estimate the efficacy (as measured by objective response rate [ORR], disease control rate [DCR], duration of response [DOR], progression free survival [PFS], overall survival [OS]) and change in continuous measures of tumor burden) of AMG 386 10 mg/kg IV QW in combination with sunitinib (50 mg PO QD) in subjects with metastatic renal cell cancer.&lt;br&gt;• To evaluate the pharmacokinetics (PK) of AMG 386 and sunitinib and its primary active metabolite when used in combination (only in a sub-group of subjects at selected sites outside of Europe for sunitinib and its primary active metabolite) &lt;br&gt;• To determine the incidence of occurrence of anti-AMG386 antibody formation ;Primary end point(s): The primary endpoint is safety and tolerability, as measured by the incidence of adverse events, dose interruptions due to adverse events, dose reductions of sunitinib during the first 12 weeks of study treatment and significant laboratory abnormalities.</Primary_outcome>
    <Secondary_ID>20080579</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2473104</Internal_Number>
    <TrialID>EUCTR2008-006072-30-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Mycophénolate sodic in graded increased doses in the first 3 months of renal transplantation _  Pharmacokinetic descriptive Pilot study</Public_title>
    <Scientific_title>Mycophénolate sodic in graded increased doses in the first 3 months of renal transplantation _  Pharmacokinetic descriptive Pilot study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>CHU Saint-Etienne</Primary_sponsor>
    <Date_registration3>20090324</Date_registration3>
    <Date_registration>24/03/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-006072-30                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/01/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- &gt;18 years&lt;br&gt;- Receveurs d’une greffe rénale à partir d'un donneur décédé ou vivant.&lt;br&gt;- Renal transplant from a dead or alive donor.&lt;br&gt;-  Patients treated by initial quadritherapy with basiliximab, tacrolimus, stéroïdes et mycophénolate sodique&lt;br&gt;- Test de grossesse ßHCG négatif à l’initiation du traitement Myfortic®&lt;br&gt;- Contraception efficace pendant le traitement et jusqu’à 6 semaines après le traitement par Myfortic®&lt;br&gt;&lt;br&gt;	&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Patient at high risk of rejection of a transplant&lt;br&gt;- IMC &gt; ou = 30&lt;br&gt;- Platelets &lt; 75000 / mm3 et/ou neutrophiles &lt; 1500 / mm3 et/ou leucocytes &lt; 2500/ mm3 et/ou hémoglobine &lt; 6 g/dL.&lt;br&gt;- Patient requiring a anti-CMV prophylaxis  by valganciclovir.&lt;br&gt;- Pregnant women or allaitantes.&lt;br&gt;</Exclusion_Criteria>
    <Condition>renal transplantation &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038533
Term: Renal transplant
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050436
Term: Prophylaxis against renal transplant rejection
</Condition>
    <Intervention>&lt;br&gt;Product Name: MYFORTIC®&lt;br&gt;Pharmaceutical Form: Cachet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Describe the pharmacokinetics of the MYFORTIC ® ( MPA) with graded increased doses first 3 months of the renal transplantation;Secondary Objective: Determine the parameters of pharmacokinetic modelling of the MPA at renal transplanted patients treated by MYFORTIC ®.;Primary end point(s): Area under the curve (AUC0 - 12 hours) of the MPA and its métabolites MPAG and Ac-MPAG</Primary_outcome>
    <Secondary_ID>0808100</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2473450</Internal_Number>
    <TrialID>EUCTR2008-008852-18-AT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Profile of soluble and cellular biomarkers and of functional imaging during antiangiogenic therapies in cancer patients - PRAEMARKERAAT08</Public_title>
    <Scientific_title>Profile of soluble and cellular biomarkers and of functional imaging during antiangiogenic therapies in cancer patients - PRAEMARKERAAT08                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Medizinische Universität Innsbruck Innere Medizin V</Primary_sponsor>
    <Date_registration3>20090422</Date_registration3>
    <Date_registration>22/04/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-008852-18                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/06/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Histological confirmed Tumor specimen RCC, HCC, CRC or NSCLC &lt;br&gt;Measurable disease according to RECIST criteria                  &lt;br&gt;Age: 18-80 years                                                                     &lt;br&gt;Antiangiogenic Monotherapy (Avastin, Nexavar or Sutent)&lt;br&gt;WHO 0-2                                                                                 &lt;br&gt;Life expectancy of more than 3 months                                  &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Prior or concurrent antitumor therapy (&lt;3 weeks)&lt;br&gt;Pregnant or lactating patients                   &lt;br&gt;Preconditions in which MRI is contraindicated (claustrophopia, certain metal implants, others)                 &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>The present project is an academic clinical trial in which patient suffering from hepatocellular carcinoma, non-small cell lung cancer, renal cell cancer and colorectal cancer treated routinely with antiangiogenic agents. The study protocol intends to include ten patients per tumour entitity (n=40), treated either with Sorafenib (Nexavar), Bevacizumab (Avastin) or Sunitinib (Sutent), which are all approved antiangiogenic drugs in Austria in one of the cancer types defined above.</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sutent&lt;br&gt;Product Name: Sutent&lt;br&gt;Product Code: H-C-687   &lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Sunitinib&lt;br&gt;&lt;br&gt;Trade Name: Nexavar&lt;br&gt;Product Name: Nexavar&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Sorafenib&lt;br&gt;&lt;br&gt;Trade Name: Avastin&lt;br&gt;Product Name: Avastin&lt;br&gt;Pharmaceutical Form: Concentrate and solvent for solution for injection&lt;br&gt;INN or Proposed INN: Bevacizumab&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Secondary Objective: ;Primary end point(s): Evaluation of biomarker analyses;Main Objective: Biomarker evaluation under antiannagiogenic therapy with Nexavar, Sutent and Avastin. Eligible patients are suffering from hepatocellular carcinoma, non small cell lung cancer, renal cell cancer and colorectal cancer routinely treated with the abov mentioned antiangiogenic agents.</Primary_outcome>
    <Secondary_ID>PRAEMARKERAAT08</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2473469</Internal_Number>
    <TrialID>EUCTR2009-011497-15-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>PILOT CLINICAL TRIAL WITH MIRCERA (methoxy polyethylene glycol-epoetin beta) IN DIALYSIS UNIT OF A.O. SAN GIOVANNI BATTISTA DI TORINO - ND</Public_title>
    <Scientific_title>PILOT CLINICAL TRIAL WITH MIRCERA (methoxy polyethylene glycol-epoetin beta) IN DIALYSIS UNIT OF A.O. SAN GIOVANNI BATTISTA DI TORINO - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"</Primary_sponsor>
    <Date_registration3>20090422</Date_registration3>
    <Date_registration>22/04/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011497-15                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>07/05/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;no evidence of clinical problems with influence on blood crasis (i.e. Infections, bleedings, surgical procedures) in the last 6 months&lt;br&gt;- stable hemoglobin values into NKF-DOKI range (11-12g/dl) or more for minimum three months before study inclusion&lt;br&gt;epoetin alfa, epoetin beta, darbopoetin therapy with modifications inferior to 25% of the dose for minimum three months before study inclusion&lt;br&gt;therapy with ferrum or B12 vitamin or folinic acid administration without any modification for minimum three months before study inclusion&lt;br&gt;last available PTHi value &lt; 500pg/ml&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Drug controindications to MIRCERA: ipersensivity reactions to drug formulation or non controlled arterial hypertension&lt;br&gt;Neoplasia or drug therapy or radioteraphy for previous neoplasia&lt;br&gt;</Exclusion_Criteria>
    <Condition>End stage renal patients in hemodialysis or peritoneal dialysis treatment &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10014647
Term: End stage renal failure
</Condition>
    <Intervention>&lt;br&gt;Trade Name: MIRCERA*IV SC FL 200MCG 1ML&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: noninferiority and safety evaluation of MIRCERA versus conventional epoetin theapy in hemodiaysis and peritoneal dialysis population in Dialysis Unit of A.O. San Giovanni Battista di Torino;Secondary Objective: evaluation of hemoglobin values stability, reticolocytes values stability, sideremia and vitamin status stability and number of therapy modification before and after shift from conventional epoetin therapy to MIRCERA;Primary end point(s): noninferiority and safety evaluation of MIRCERA versus conventional epoetin theapy in hemodiaysis and peritoneal dialysis population in Dialysis Unit of A.O. San Giovanni Battista di Torino</Primary_outcome>
    <Secondary_ID>CERA</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2473554</Internal_Number>
    <TrialID>EUCTR2007-004012-31-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>The effects of improving oxygen concentration in the reduction of dialysis induced myocardial stunning – A pilot study - Oxygenation and myocardial stunning</Public_title>
    <Scientific_title>The effects of improving oxygen concentration in the reduction of dialysis induced myocardial stunning – A pilot study - Oxygenation and myocardial stunning                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Derby Hospitals NHS Foundation Trust</Primary_sponsor>
    <Date_registration3>20090416</Date_registration3>
    <Date_registration>16/04/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004012-31                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>06/07/2009</Date_enrollement>
    <Target_size>24</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: yes&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Other specify the comparator: room air&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Patients on HD treatment at least 3times/week.&lt;br&gt;2.	Willing to provide consent.&lt;br&gt;3.	Male and female, age&gt;18 years old.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Dialysis for &lt;4 months	&lt;br&gt;2.	Unable to obtain echocardiographic data of sufficient quality to allow analysis&lt;br&gt;3.	Cardiac transplant recipients&lt;br&gt;4.	NYHA IV heart failure&lt;br&gt;5.	Chronic obstructive airway disease, other chronic/acute lung condition exacerbating hypoxia and/or unable to tolerate O2 therapy.&lt;br&gt;6.	Patients on long term oxygen therapy (LTOT).&lt;br&gt;7.      Pregnant women or female subjects in childbearing age.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic renal failure patients who are receiving haemodialysis treatment &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10066623
Term: Chronic haemodialysis
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Oxygen&lt;br&gt;Product Name: Oxygen&lt;br&gt;Pharmaceutical Form: Inhalation gas&lt;br&gt;CAS Number: 7782447&lt;br&gt;Other descriptive name: OXYGEN&lt;br&gt;Concentration unit: l litre(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 4 litres-per minute&lt;br&gt;&lt;br&gt;Trade Name: Oxygen&lt;br&gt;Product Name: Oxygen&lt;br&gt;Pharmaceutical Form: Inhalation gas&lt;br&gt;CAS Number: 7782447&lt;br&gt;Other descriptive name: OXYGEN&lt;br&gt;Concentration unit: l litre(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 4 litres-per minute&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Test if increasing inhaled O2 concentration at 4 litre/minute via nasal cannulae, reduces dialysis related myocardial stunning.&lt;br&gt;;Primary end point(s): The response to O2 administration at 4 litre/minute during HD on the frequency and severity of myocardial stunning, measured by the number of the new Regional Wall Motion Abnormalities (RWMA) and the reduction in the myocardial contractility in each of the segment affected by RWMAs respectively ;Secondary Objective: 1.      Observe the difference in the haemodynamic variables during HD including the frequency and severity of intradislytic hypotension and pulse rate in response to inhaled O2 at 4litre/min. &lt;br&gt;2.	Observe the difference in the global left ventricular ejection fraction with and without inhaled O2 at 4litre/min, pre and post dialysis.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>RD 5130-009-07</Secondary_ID>
    <Secondary_Sponsor>The University of Nottingham-Research innovation services</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2473601</Internal_Number>
    <TrialID>EUCTR2009-011473-33-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Etude prospective, multicentrique, randomisée, en ouvert, évaluant la progression de la fibrose rénale selon le profil de transition épithélio-mésenchymateuse chez des patients adultes transplantés rénaux de novo traités par une immunosuppression sans inhibiteur de la calcineurine associant Certican® et Myfortic® versus une immunosuppression standard associant Néoral® et Myfortic® (Etude CERTITEM). - CERTITEM</Public_title>
    <Scientific_title>Etude prospective, multicentrique, randomisée, en ouvert, évaluant la progression de la fibrose rénale selon le profil de transition épithélio-mésenchymateuse chez des patients adultes transplantés rénaux de novo traités par une immunosuppression sans inhibiteur de la calcineurine associant Certican® et Myfortic® versus une immunosuppression standard associant Néoral® et Myfortic® (Etude CERTITEM). - CERTITEM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Novartis Pharma S.A.S.</Primary_sponsor>
    <Date_registration3>20090515</Date_registration3>
    <Date_registration>15/05/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011473-33                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/06/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: single group from transplantation to randomisation (between months 3 and 4)&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Critères d'inclusion à la transplantation:&lt;br&gt;1.Patient, homme ou femme, âgé de 18 à 70 ans.&lt;br&gt;2.Patient receveur d’une première ou deuxième greffe rénale d’un donneur décédé ou vivant apparenté ou non et devant recevoir une thérapie d’induction par basiliximab. &lt;br&gt;3.Temps d’ischémie froide &lt; 30 heures.&lt;br&gt;4.Pour les femmes en âge de procréer, test de grossesse négatif dans les 7 jours précédant la sélection ou au moment de la sélection et utilisation d’une méthode de contraception reconnue et fiable pendant toute la durée de l’étude et pendant 2 mois après l’arrêt du traitement de l’étude, même en cas d’antécédents de stérilité.&lt;br&gt;5.Patient souhaitant et étant capable de participer à l’intégralité de l’étude et ayant donné son consentement par écrit.&lt;br&gt;6.Patient affilié à un régime de sécurité sociale ou bénéficiaire d’un tel régime.&lt;br&gt;&lt;br&gt;Critères d’éligibilité à la randomisation (entre 3 et 4 mois post-tx):&lt;br&gt;1.Biopsie du greffon rénal réalisée à M3 et matériel histologique adéquat adressé pour détermination de la TEM.&lt;br&gt;2.Pour les femmes en âge de procréer, utilisation d’une méthode de contraception reconnue et fiable pendant toute la durée de l’étude et pendant 2 mois après l’arrêt du traitement de l’étude, même en cas d’antécédents de stérilité.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) &lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) &lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Critères de non inclusion à la transplantation&lt;br&gt;1.Patient receveur d’une greffe multi-organes y compris des deux reins ou ayant précédemment reçu une greffe autre que rénale.&lt;br&gt;2.Patient receveur d’un greffon d’un donneur à cœur arrêté.&lt;br&gt;3.Taux d’anticorps anti-HLA = 20% dans les 3 derniers mois précédant l’inclusion.&lt;br&gt;4.Greffon ABO incompatible ou ayant un cross match T positif.&lt;br&gt;5.Hyperlipidémie sévère : cholestérol total = 9,1 mmol/L (= 350 mg/dL) et/ou triglycérides = 8,5 mmol/l (= 750 mg/dL) malgré un traitement hypolipémiant adapté.&lt;br&gt;6.Hypersensibilité ou contre-indications connues à l’acide mycophénolique, à la ciclosporine ou au lactose.&lt;br&gt;7.Hypersensibilité ou contre-indications connues aux macrolides ou aux médicaments de la classe des inhibiteurs des m-TORs.&lt;br&gt;8.Séropositivité pour le VIH, ou hépatites B (Ag HBs) ou C chroniques actives. Les résultats obtenus au cours des 6 mois précédant l’inclusion sont acceptables. Les receveurs de donneurs positifs pour les hépatites B ou C seront exclus.&lt;br&gt;9.Patient ayant une thrombopénie (= 75 000 /mm3), une neutropénie (= 1500 /mm3), une leucopénie (= 2500 /mm3) et/ou une hémoglobine &lt; 8 g/dl à la visite d’inclusion.&lt;br&gt;10.ASAT, ALAT ou bilirubine totale = 3 LNS.&lt;br&gt;11.Infection sévère non contrôlée, allergie sévère nécessitant un traitement aigu ou chronique.&lt;br&gt;12.Patient ayant une pathologie maligne ou des antécédents de pathologie maligne au cours des 5 dernières années, à l’exception d’un carcinome basocellulaire ou spinocellulaire excisé et d’un cancer in situ du col utérin traité.&lt;br&gt;13.Condition médicale ou chirurgicale, à l'exception de la transplantation, qui pourrait exclure le patient selon l'avis de l'investigateur.&lt;br&gt;14.Femme enceinte, allaitante ou en âge de procréer et refusant ou étant incapable d’utiliser une méthode de contraception reconnue et fiable.&lt;br&gt;15.Patient présentant des symptômes de pathologie mentale ou somatique significative. Incapacité à coopérer ou à communiquer avec l'investigateur.&lt;br&gt;16.Patient sous tutelle ou curatelle ou tout patient protégé par la loi.&lt;br&gt;&lt;br&gt;Critères de non éligibilité à la randomisation&lt;br&gt;1.Rejet aigu histologiquement prouvé entre la transplantation et la randomisation (lecture locale).&lt;br&gt;2.Rejet aigu infraclinique (à l’exception d’une lésion borderline) diagnostiqué sur la biopsie de M3 (lecture locale). &lt;br&gt;3.Anticorps anti-donneur positifs à M3.&lt;br&gt;4.Débit de filtration glomérulaire estimé &lt; 30 ml/min/1,73m² (MDRDa).&lt;br&gt;5.Protéinurie = 1 g/24h.&lt;br&gt;6.Hyperlipidémie sévère : cholestérol total = 9,1 mmol/L (= 350 mg/dL) et/ou triglycérides = 8,5 mmol/l (= 750 mg/dL) malgré un traitement hypolipémiant adapté.&lt;br&gt;7.Thrombopénie (= 75 000 /mm3), neutropénie (= 1500 /mm3), leucopénie (= 2500 /mm3) et/ou hémoglobine &lt; 8 g/dl.&lt;br&gt;8.ASAT, ALAT ou bilirubine totale = 3 LNS.&lt;br&gt;9.Condition médicale ou chirurgicale qui serait apparue et pourrait exclure le patient selon l'avis de l'investigateur.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal Transplantation</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Current Sponsor code: RAD001&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.25-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Current Sponsor code: RAD001&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Current Sponsor code: RAD001&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.75-&lt;br&gt;&lt;br&gt;Trade Name: Néoral&lt;br&gt;Product Name: Néoral&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: Ciclosporin&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;Trade Name: Néoral&lt;br&gt;Product Name: Néoral&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: Ciclosporin&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Trade Name: Néoral&lt;br&gt;Product Name: Néoral&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: Ciclosporin&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Néoral&lt;br&gt;Product Name: Néoral&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: Ciclosporin&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Trade Name: Myfortic&lt;br&gt;Product Name: Myfortic&lt;br&gt;Pharmaceutical Form: Gastro-resistant tablet&lt;br&gt;INN or Proposed INN: mycophenolic acid&lt;br&gt;Current Sponsor code: ERL 080&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 180-&lt;br&gt;&lt;br&gt;Trade Name: Myfortic&lt;br&gt;Product Name: Myfortic&lt;br&gt;Pharmaceutical Form: Gastro-resistant tablet&lt;br&gt;INN or Proposed INN: mycophenolic acid&lt;br&gt;Current Sponsor code: ERL 080&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentr</Intervention>
    <Primary_outcome>Main Objective: Comparer la progression de la fibrose rénale entre le 3ème et le 12ème  mois post-transplantation selon le profil de transition épithélio-mésenchymateuse (TEM) chez des patients transplantés rénaux de novo recevant soit un traitement immunosuppresseur sans inhibiteur de la calcineurine associant Certican® et Myfortic®, soit un traitement immunosuppresseur standard associant Néoral® et Myfortic®.&lt;br&gt;Cet objectif principal comportera une comparaison principale des groupes de patients TEM+ Néoral® et TEM+ Certican®. &lt;br&gt;Trois comparaisons secondaires porteront sur les paires suivantes : &lt;br&gt;- groupe de patients TEM+ Néoral® versus groupe de patients TEM- Néoral®&lt;br&gt;- groupe de patients TEM- Néoral® versus groupe de patients TEM- Certican®&lt;br&gt;- groupe de patients TEM+ Certican® versus groupe de patients TEM- Certican®&lt;br&gt;;Primary end point(s): Le critère principal est un critère histologique qui consistera à comparer la progression de la fibrose du greffon rénal sur la base du nombre de patients ayant une augmentation =1 du score de FI/AT entre 3 et 12 mois post-transplantation en tenant compte du profil TEM entre les 2 groupes de traitement. ;Secondary Objective: Histologie&lt;br&gt;•Fibrose du greffon à 3 et 12 mois post-transplantation&lt;br&gt;•TEM à 3 et 12 mois post-transplantation&lt;br&gt;•Valeur prédictive de la TEM à 3 mois sur la fibrose du greffon à 12 mois&lt;br&gt;•Incidence des rejets aigus infracliniques et borderline à 3 mois&lt;br&gt;•Autres lésions histologiques&lt;br&gt;&lt;br&gt;Efficacité&lt;br&gt;•Fonction rénale à 6 et 12 mois post-transplantation&lt;br&gt;•Echecs de traitement (RAPB, perte de greffon, perdu de vue ou décès) à 6 et 12 mois post-transplantation&lt;br&gt;•RAPB et rejets traités à 6 et 12 mois post-transplantation&lt;br&gt;•Survies du patient et du greffon à 12 mois post-transplantation&lt;br&gt;&lt;br&gt;Tolérance&lt;br&gt;•Evènements indésirables, EI graves&lt;br&gt;•Arrêts prématurés de l’étude et du traitement à l’étude et raisons d’arrêt&lt;br&gt;•Paramètres métaboliques&lt;br&gt;•Doses et concentrations résiduelles (C0) de Certican&lt;br&gt;•Doses et concentrations sanguines (C0 et C2) de Néoral&lt;br&gt;•Doses et variations de doses (réduction, augmentation, interruption) de Myfortic&lt;br&gt;</Primary_outcome>
    <Secondary_ID>CRAD001AFR10</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2473624</Internal_Number>
    <TrialID>EUCTR2006-004822-97-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Phase I / II Trial to Evaluate the Combination of Infliximab and Sorafenib in the Treatment of Renal Cell Carcinoma - Combination Infliximab and Sorafenib in RCC</Public_title>
    <Scientific_title>A Phase I / II Trial to Evaluate the Combination of Infliximab and Sorafenib in the Treatment of Renal Cell Carcinoma - Combination Infliximab and Sorafenib in RCC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>The Royal Marsden NHSF Trust</Primary_sponsor>
    <Date_registration3>20090508</Date_registration3>
    <Date_registration>08/05/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004822-97                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>09/01/2007</Date_enrollement>
    <Target_size>51</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.&lt;br&gt;&lt;br&gt;2. The presence of one or more clinically or radiologically measurable lesions&lt;br&gt;&lt;br&gt;3. ECOG performance status 0 or 1&lt;br&gt;&lt;br&gt;4. Life expectancy greater than 12 weeks&lt;br&gt;&lt;br&gt;5. At least 21 days since major surgery and 7 days since skin/tumour biopsy&lt;br&gt;&lt;br&gt;6. The capacity to understand the patient information sheet and the ability to provide written informed consent&lt;br&gt;&lt;br&gt;7. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures&lt;br&gt;&lt;br&gt;8. Male or female, age 18 or greater&lt;br&gt;&lt;br&gt;9. Women must be postmenopausal (no menstrual period for a minimum of 1 year) or have a negative serum pregnancy test on entry in the study (even if surgically sterilized).  Men and women of childbearing potential must use adequate birth control measures (e.g. abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, implantable or injectable contraceptives or surgical sterilization) for the duration of the study and should continue such precautions for 6 months after receiving the last study treatment&lt;br&gt;&lt;br&gt;10. Serum aspartate transaminase (AST) and alanine transaminase (ALT) =2.5 x upper limit of normal (ULN) &lt;br&gt;&lt;br&gt;11. Total serum bilirubin =1.5 x ULN &lt;br&gt;&lt;br&gt;12. Serum creatinine =1.5 x ULN &lt;br&gt;&lt;br&gt;13. Haemoglobin =9.0 g/dL&lt;br&gt;&lt;br&gt;14. Absolute neutrophil count =1.5 x 109/L &lt;br&gt;&lt;br&gt;15. Platelets =100 x 109/L  &lt;br&gt;&lt;br&gt;16. Prothrombin time (PT) =1.5 x ULN &lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Previous treatment with monoclonal antibodies or antibody fragments, or known hypersensitivity to any murine proteins or other infliximab components&lt;br&gt;&lt;br&gt;2. Known infection with human immunodeficiency virus (HIV) and / or hepatitis B surface antigen or hepatitis C&lt;br&gt;&lt;br&gt;3. Known history of serious infections (e.g. hepatitis, pneumonia or pyelonephritis) in the previous 3 months&lt;br&gt;&lt;br&gt;4. Opportunistic infections (e.g. herpes zoster (shingles), cytomegalovirus, active pneumocystis carinii, aspergillosis, histoplasmosis, or atypical mycobacteria infection other than TB) within the last 6 months&lt;br&gt;&lt;br&gt;5. History of lymphoproliferative disease, including lymphoma or signs suggestive of possible lymphoproliferative disease such as lymphadenopathy of unusual size or location (e.g. nodes in the posterior triangle of the neck, infraclavicular, epitrochlear, or periaortic area) or splenomegaly#&lt;br&gt;&lt;br&gt;6. Current signs or symptoms of severe progressive or uncontrolled hepatic, haematologic, gastrointestinal, endocrine, pulmonary or cardiac disease other than directly related to RCC&lt;br&gt;&lt;br&gt;7. Intracranial disease, unless there has been radiological evidence of stable intracranial disease &gt; 6 months. In the case of a solitary brain metastasis, evidence of a disease-free interval of at least 3 months post surgery.  All patients previously treated for brain metastases must be stable off corticosteroid therapy for at least 28 days&lt;br&gt;&lt;br&gt;8. Previous treatment with a tyrosine kinase inhbitor or anti-angiogenic agent (licensed or investigational) such as sunitinib or bevacizumab&lt;br&gt;9. Any drug (licensed or investigational) that targets the RAS or EGFR pathway&lt;br&gt;&lt;br&gt;10. Any chemotherapy, immunotherapy or hormonal treatment over the last 4 weeks. Palliative radiotherapy to symptomatic disease sites is permitted&lt;br&gt;&lt;br&gt;11. Women who are pregnant, nursing, or planning pregnancy within 6 months after the last treatment (this includes men who plan to father a child within 6 months of the last treatment)&lt;br&gt;&lt;br&gt;12. Chest radiograph at screening that shows evidence of malignancy, infection, or any abnormalities suggestive of TB as described in Appendix C&lt;br&gt;&lt;br&gt;13. Ineligibility according to the TB eligibility assessment, screening, and early detection of reactivation rules (see Appendix C)&lt;br&gt;&lt;br&gt;14. Malignancy other that the condition being treated or a history of malignancy within the previous 5 years, with the exception of basal cell or squamous cell carcinoma of the skin that has been fully excised with no evidence of recurrence&lt;br&gt;&lt;br&gt;15. Use of any investigational drug within 30 days prior to screening or within 50 days of infliximab infusion&lt;br&gt;&lt;br&gt;16. Presence of a transplanted solid organ (with the exception of a corneal transplant) &gt; 3 months prior to screening&lt;br&gt;&lt;br&gt;17. History of alcohol or substance abuse within the preceding 6 months that, in the opinion of the investigator, may increase the risks associated with study participation or study agent administration, or may interfere with interpretation of results&lt;br&gt;&lt;br&gt;18. Peripheral neuropathy greater than grade 1 according to the Common Terminology Criteria (CTC) criteria&lt;br&gt;&lt;br&gt;19. Concomitant diagnosis or history of congestive heart failure as assessed by the investigator&lt;br&gt;&lt;br&gt;20. Uncontrolled hypertension or hypertension treated with 2 or more anti-hypertensive agents&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Metastatic Renal Cell Carcinoma (RCC) &lt;br&gt;MedDRA version: 8.1
Level: HLT
Classification code 10038408
Term: Renal cell carcinomas
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Remicade&lt;br&gt;Pharmaceutical Form: Powder for solution for infusion&lt;br&gt;&lt;br&gt;Trade Name: Nexavar&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Primary end point(s): Phase I: Doses of infliximab and sorafenib in combination that are safe and tolerable&lt;br&gt;&lt;br&gt;Phase II: Proportion of patients progression free at six months&lt;br&gt;;Main Objective: This is a phase I / II design. &lt;br&gt;The objective of the phase I section is to define a safe and tolerable dose of infliximab and sorafenib in combination and to assess its pharmacokinetics and pharmacodynamics.&lt;br&gt;&lt;br&gt;The objective of the phase II section is to assess safety and efficacy of the combination in a Simon 2 stage design. The primary efficacy variable will be the proportion of patients progression free after 6 months of treatment.&lt;br&gt;;Secondary Objective: Secondary efficacy variables will be &lt;br&gt;1.  Pharmacokinetics of the combination of infliximab and sorafenib &lt;br&gt;2. Changes in predictive biomarkers and pharmacodynamic markers induced by the combination of  infliximab and sorafenib&lt;br&gt;3. Response rate at 12 weeks of treatment and best response to therapy  &lt;br&gt;4. Overall survival median and 95% Confidence Interval, CI; also PFS median and 95% CI.&lt;br&gt;5. Correlation of biological markers in original nephrectomy specimen (if available) or on-study biopsies with clinical outcome and serum biomarkers such as TNF?? IL-6 and CCL2&lt;br&gt;</Primary_outcome>
    <Secondary_ID>EU-RD-001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2473732</Internal_Number>
    <TrialID>EUCTR2009-011505-16-AT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Pharmacokinetics of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without peritonitis</Public_title>
    <Scientific_title>Pharmacokinetics of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without peritonitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Medizinische Universität Wien,KIM I,Klinische Abteilung für Infektionen u.Tropenmedizin</Primary_sponsor>
    <Date_registration3>20090526</Date_registration3>
    <Date_registration>26/05/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011505-16                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>21/01/2010</Date_enrollement>
    <Target_size>8</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Male or female, aged between 18 and 85 years&lt;br&gt;•	Patients on APD using Icodextrin (Extraneal) for the long daytime dwell &lt;br&gt;•	Willingness and ability to comply with the protocol&lt;br&gt;•	Signed informed consent&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	any systemic infection&lt;br&gt;•	peritonitis or catheter-related infection which required antibiotic treatment within 2 months prior to the start of the study .&lt;br&gt;•	Allergy or hypersensitivity against study drug.&lt;br&gt;•	Severe hepatic impairment (Child-Pugh Class C)&lt;br&gt;•	Pregnancy, or women of child bearing potential not willing to apply adequate contraception during study period&lt;br&gt;•	Any disease considered relevant for proper performance of the study or risks to the patient, at the discretion of the investigator&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>A total of 8 patients with renal insufficiency and treatment with automated peritoneal dialysis (APD) will be enrolled into this study evaluating the pharmacokinetics of fosfomycin in this special patient group. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10034660
Term: Peritoneal dialysis
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Fosfomycin&lt;br&gt;Product Name: Fosfomycin&lt;br&gt;Pharmaceutical Form: Powder for infusion*&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: 1. Determination of concentrations of fosfomycin in plasma and dialysate after single intraperitoneal or intravenous application in APD-patients&lt;br&gt;&lt;br&gt;  ;Secondary Objective: 2. Calculation of PK/PD indices to estimate target site efficacy of fosfomycin. &lt;br&gt;;Primary end point(s): AUC, Cmax, Half-life (t1/2), time to reach maximum drug concentration (tmax)</Primary_outcome>
    <Secondary_ID>3.0</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2473747</Internal_Number>
    <TrialID>EUCTR2009-012010-52-DK</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Bevacizumab, Interleukin-2 and Interferon-alpha in metastathic renal cell carcinoma - mRCC</Public_title>
    <Scientific_title>Bevacizumab, Interleukin-2 and Interferon-alpha in metastathic renal cell carcinoma - mRCC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Department of Oncology, Aarhus University Hospital</Primary_sponsor>
    <Date_registration3>20090528</Date_registration3>
    <Date_registration>28/05/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-012010-52                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>04/08/2009</Date_enrollement>
    <Target_size>118</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Avastin, IL-2, IFN alpha vs IL-2, IFN alpha alone&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Signed written informed consent obtained prior to any study specific screening procedures.&lt;br&gt;2.	Patient must be willing and able to comply with the protocol.&lt;br&gt;3.	Age ? 18.&lt;br&gt;4.	Histologic og cytologic biopsy proven locally advanced or metastatic renal cell carcinoma, considered non-candidates for curative surgery. Nephrectomy is not mandatory.&lt;br&gt;5.	Patient with renal cell carcinoma (RCC) with a clear-cell histologic component confirmed by local pathology review. (Patient with true papillary, sarcomatoid features without any clear cell component, chromophobe, oncocytoma, collecting duct tumours, Bellini tumours and transitional cell carcinoma are not allowed.)&lt;br&gt;6.	If metastatic disease is diagnosed more than two years from the date of the initial diagnosis of RCC, histological or cytological confirmation of renal cell carcinoma (clear cell type) origin of the metastatic lesion(s) is mandatory.&lt;br&gt;7.	Females with a negative serum pregnancy test unless childbearing potential can be otherwise excluded (postmenopausal, hysterectomy or oophorectomy) and not lactating.&lt;br&gt;8.	Fertile women of childbearing potential (&lt;2 years after last menstruation) and men must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgical sterilisation).&lt;br&gt;9.	Memorial-Sloan-Kettering-Cancer-Centre favourable- and intermediate prognostic group.&lt;br&gt;10.	Measurable or non-measurable disease (as per RECIST criteria) &lt;br&gt;11.	Karnofsky Performance status ? 70%.&lt;br&gt;12.	Life expectancy greater than 4 months.&lt;br&gt;13.	The required laboratory values at baseline are as follows:&lt;br&gt;14.	Haematology: &lt;br&gt;15.	WCC = 3.0 x 109/L, Platelet count = 100 x 109/L, Haemoglobin = 6.2 mmol/l, International Normalized Ratio (INR) = 1.5, APTT = 1.5 x ULN&lt;br&gt;16.	Biochemistry:&lt;br&gt;Total bilirubin = 1.5 x upper limit of normal (ULN), AST, ALT = 2.5 x ULN in patients without liver metastases, = 5 x ULN in patients with liver metastases, Serum Creatinine  = 150 ?mol/L&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Prior systemic treatment for metastatic RCC disease (including neo-adjuvant therapy).&lt;br&gt;2.	Major surgical procedure, open surgical biopsy, or significant traumatic injury within 28 days prior to randomization.&lt;br&gt;3.	Serious non-healing wound, ulcer or bone fracture.&lt;br&gt;4.	Evidence of current central nervous system (CNS) metastases or spinal cord compression. Patient must undergo an MRI or CT scan of the brain (with contrast, if possible) within 28 days prior to randomization. &lt;br&gt;5.	Seizure(s) not controlled with standard medical therapy.&lt;br&gt;6.	Dipstick urine test of protein = 2+.&lt;br&gt;7.	Other malignancies within 5 years prior to randomization (other than curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix).&lt;br&gt;8.	Evidence of bleeding diathesis or coagulopathy.&lt;br&gt;9.	Ongoing or recent (within 10 days prior to study treatment start) need for full therapeutic dose of oral anticoagulants or chronic daily treatment with aspirin. Low molecular weight heparin are allowed&lt;br&gt;10.	Uncontrolled hypertension (? 160 mm Hg systolic and/or ? 100 mm Hg diastolic) while receiving chronic medication.&lt;br&gt;11.	Clinically significant (i.e. active) cardiovascular disease, for example cerebrovascular accidents (= 6 months before randomisation), myocardial infarction (= 6 months before randomisation), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication.&lt;br&gt;12.	Recent (within the 30 days prior to randomization) treatment with another investigational drug or participation in another investigational study. &lt;br&gt;13.	Chronic treatment with corticosteroids (dose of = 10 mg/day methylprednisolone equivalent), excluding inhaled steroids.&lt;br&gt;14.	History or presence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or patient at high risk from treatment complications.&lt;br&gt;15.	Known hypersensitivity to interleukin-2, Inferferon, alpha or bevacizumab.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patient with previously untreated Metastatic Renal Cell Carcinoma &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050513
Term: Metastatic renal cell carcinoma
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Avastin&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Bevacizumab&lt;br&gt;CAS Number: 216974-75-3&lt;br&gt;Current Sponsor code: RO4876646&lt;br&gt;Other descriptive name: rhuMAb VEGF, anti-VEGF &lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Avastin as monotherapy has effect in mRCC. Avastin in combination with interferon-alfa (IFN-a) has significant efficacy in mRCC and has been approved by EMEA. &lt;br&gt;The present study will assess whether the combination of Interleukin-2 (IL-2) and IFN-a with Avastin may add efficacy in patients with mRCC with a tolerable safety profile.&lt;br&gt;Progression Free Survival;Secondary Objective: Response rate, overall survival (OS), duration of response, time to progression, time to treatment failure, tolerability, frequency of surgical resection of residual disease and frequency of no evidence of disease (NED). To explore the immunomodulatory effect of therapy in serial blood samples and serial tumor core biopsies and to correlate these biomarkers with outcome. To assess dynamic contrast-enhanced imaging as a potential biomarker;Primary end point(s): Primary objective&lt;br&gt;•	To determine the efficacy of the combination of interleukin-2 / interferon alfa-2b plus bevacizumab as compared with interleukin-2 /interferon-alfa 2b in patients with metastatic RCC, based on progression free survival (PFS).&lt;br&gt;</Primary_outcome>
    <Secondary_ID>mRCC</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2473764</Internal_Number>
    <TrialID>EUCTR2009-012673-35-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Etude pharmacocinétique et pharmacodynamique comparant deux posologies différentes de la Thymoglobuline® en transplantation rénale. - THYMO</Public_title>
    <Scientific_title>Etude pharmacocinétique et pharmacodynamique comparant deux posologies différentes de la Thymoglobuline® en transplantation rénale. - THYMO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>CHRU de TOURS</Primary_sponsor>
    <Date_registration3>20090528</Date_registration3>
    <Date_registration>28/05/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-012673-35                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>03/07/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: 2 different doses&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;-	Patient âgé(e) de plus de 18 ans,&lt;br&gt;-	Première ou seconde transplantation rénale,&lt;br&gt;-	Patient avec PRA (Panel Reactive Antibody) &lt; 20% et un cross-match négatif&lt;br&gt;-	Patient pour lequel un suivi d’au moins un an est prévu&lt;br&gt;-	Patient ayant donné son consentement éclairé et écrit pour participer à l’essai clinique.&lt;br&gt;-	Patient affilié à la sécurité sociale&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-	Patient ayant reçu une induction par Thymoglobuline® ou par un autre ATG lors d’une transplantation antérieure,&lt;br&gt;-	Patient ayant un poids = 50 kg ou = 85 kg&lt;br&gt;-	Temps d’ischémie froide avec un risque de reprise retardée de la fonction du greffon (DGF) (c'est-à-dire avec une IF&gt; 24 h)&lt;br&gt;-	Femme en période d’activité génitale sans contraception efficace, &lt;br&gt;-	Patient avec greffes d’organes multiples &lt;br&gt;-	Patient avec une infection active, ou avec une suspicion d’infection par VIH, VHB ou VHC, ou de tuberculose&lt;br&gt;-	Patient pour lequel est prévue une vaccination dans l'année&lt;br&gt;-	Patient atteint d’une déficience ne lui permettant pas une bonne compréhension des impératifs de l’essai, &lt;br&gt;-	Patient sous sauvegarde de justice, sous tutelle ou curatelle, &lt;br&gt;-	Patient présentant une contre-indication à la Thymoglobuline® (hypersensibilité connue aux protéines de lapin ou à l'un des composants de la préparation)&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal transplantation &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038533
Term: Renal transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: THYMOGLOBULINE® 5 mg/ml&lt;br&gt;Pharmaceutical Form: Powder for solution for infusion&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Comparer les paramètres pharmacocinétiques et pharmacodynamiques de 2 posologies d’immunoglobulines anti-thymocytes de lapin (rATG Thymoglobuline®) à la dose standard sur 4 jours ou à dose élevée sur 2 jours, en association avec le MMF, un retrait précoce des corticoïdes et l’introduction retardée du tacrolimus, chez 2 groupes de patients transplantés rénaux.;Secondary Objective: * Évaluer l’influence du polymorphisme génétique du récepteur Fc?RIIIa sur les paramètres pharmacocinétiques et pharmacodynamiques.&lt;br&gt;* Évaluer la tolérance de l’induction par 2 posologies de Thymoglobuline® par :&lt;br&gt;•	le recours à la dialyse durant la première semaine définissant la reprise retardée de fonction du greffon&lt;br&gt;•	la créatininémie à J5, une créatininémie supérieure à 250 µmol/L en l’absence de dialyse définissant une reprise lente de fonction rénale&lt;br&gt;•	l’évolution de la fonction rénale selon Cockroft à 3 mois et à 1 an&lt;br&gt;•	le taux de rejet aigu sur les 3 premiers mois et à 1 an&lt;br&gt;•	la survie des patients et des greffons à 1 an &lt;br&gt;•	l’incidence des infections en particulier à CMV, de la maladie sérique et des syndromes lymphoprolifératifs&lt;br&gt;;Primary end point(s): - Paramètres pharmacocinétiques de la Thymoglobuline® et de la Thymoglobuline® active :&lt;br&gt;o	concentration totale et active&lt;br&gt;o	demi-vie d’élimination&lt;br&gt;o	aire sous la courbe des concentrations en fonction du temps (AUC)&lt;br&gt;o	Paramètres pharmacocinétiques correspondant à un modèle à 2 compartiments (CLc, CLp, Vc, Vp)&lt;br&gt;&lt;br&gt;- Paramètres pharmacodynamiques :&lt;br&gt;o	Évolution des numérations lymphocytaires : lymphocytes totaux CD4, CD8, CD56, CD19&lt;br&gt;o	Évolution de l’expression des marqueurs des populations de cellules T régulatrices (Treg): CD4+ CD25+ CD127- FoxP3+&lt;br&gt;o	Évolution de l’expression des marqueurs des cellules T naïves et mémoires : CD4 CD45 RA, CD4 CD45 RO, CD27, CD62L&lt;br&gt;&lt;br&gt;- Polymorphisme génétique :&lt;br&gt;o	Polymorphisme génétique du récepteur Fc?RIIIa&lt;br&gt;&lt;br&gt;&lt;br&gt;</Primary_outcome>
    <Secondary_ID>PHAO08-YL/THYMO</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2473772</Internal_Number>
    <TrialID>EUCTR2008-006438-82-DK</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Vitamin D og kronisk nyreinsufficiens</Public_title>
    <Scientific_title>Vitamin D og kronisk nyreinsufficiens                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Odense Universitetshospital, Nyremedicinsk Afd. Y</Primary_sponsor>
    <Date_registration3>20090602</Date_registration3>
    <Date_registration>02/06/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-006438-82                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>15/06/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Chronic kidney disease (CKD 3-5 and renal transplanted patients)&lt;br&gt;- Age &gt; 18 years&lt;br&gt;- Vitamin D insufficiency or deficiency (25-OHD &lt; 50nmol/l, 3 months before project start)&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Treatment with vitamin D2/D3 (dose more than 10000 IU within the last 3 months)&lt;br&gt;- hypercalcæmi (Ca-ion &gt; 1.35 mmol/L) more than 4 weeks despite missing intake of calcium containing preparations and aktivated vitamin D&lt;br&gt;- uncontrolled hyperphosphatæmia (S-phosphat &gt; 2.2 mmol/L &lt;br&gt;- Sarcoidose&lt;br&gt;- Malignant disease &lt;br&gt;- psychotic disorders&lt;br&gt;- Pregnancy and lactation&lt;br&gt;- Allergy to soya&lt;br&gt;</Exclusion_Criteria>
    <Condition>Investigating the effects of treatment with not activated vitamin D (cholecalciferol) in chronic kidney disease petients with vitamin D deficiency.</Condition>
    <Intervention>&lt;br&gt;Trade Name: Dekristol&lt;br&gt;Product Name: Cholecalciferol&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CHOLECALCIFEROL&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Pharmaceutical form of the placebo: Capsule, soft&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Purpose of the experiment is to investigate the effect of treatment with not activated vitamin D (cholecalciferol) compared with placebo in a trial including chronic kidney disease patients with vitamin D deficiency. Multible biological variables are monitored in order to assess any effect on the biological system (calcium-phosphat metabolism, bone and endotel markers, inflammation and muscle function);Secondary Objective: ;Primary end point(s): - Calcium phosphate associated metabolites&lt;br&gt;- Bone markers&lt;br&gt;- Endotel markers&lt;br&gt;- Inflammation&lt;br&gt;- Muscle function</Primary_outcome>
    <Secondary_ID>001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2474119</Internal_Number>
    <TrialID>EUCTR2008-004746-81-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Effect of amiloride on lithium-induced chronic nephropathy.
Comparing discontinuation of lithium treatment to adding amiloride while continuing lithium treatment.</Public_title>
    <Scientific_title>Effect of amiloride on lithium-induced chronic nephropathy.
Comparing discontinuation of lithium treatment to adding amiloride while continuing lithium treatment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Parnassia-BAVO groep</Primary_sponsor>
    <Date_registration3>20090213</Date_registration3>
    <Date_registration>13/02/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-004746-81                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/07/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Group 1 stops lithium (control), group 2 continues lithium with amiloride added&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients are eliglible for participation in case of&lt;br&gt;&lt;br&gt;Long-term use of lithium treatment, defined as having used lithium for at least five years prior to inclusion.&lt;br&gt;progressive renal faillure defined as an increase of plasma creatinine levels of at least 10umol/l/year for at least five years. with r2 &gt;/= 0.85 and a maximal serum creatinine level of 200umol/L.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;patients with either hyper or hypotension. Use of antihypertensive medication is allowed.&lt;br&gt;not being able to provide informed consent for participation&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal failure due to long-term use of lithium salts in patients with bipolar disorders. &lt;br&gt;MedDRA version: 9.1
Level: HLT
Classification code 10004938
Term: Bipolar disorders
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10009121
Term: Chronic renal failure worsened
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Modamide&lt;br&gt;Product Name: amiloride (modamide)&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: AMILORIDE (Modamide)&lt;br&gt;CAS Number: 2016-88-8 &lt;br&gt;Current Sponsor code: not available&lt;br&gt;Other descriptive name: not available&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: determining the effect on kidney functioning of addition of amiloride to continuing lithium treatment in patients with lithium induced renal failure.&lt;br&gt;&lt;br&gt;&lt;br&gt;;Secondary Objective: Comparing the effect of addition of amiloride treatment to continuing lithium treatment with discontinuation of lithium treatment in patients with renal failure;Primary end point(s): a decrease in renal faillure defined as a decrease in plasma creatinine level of at least 50% in nine months.&lt;br&gt;&lt;br&gt;Creatinine clearance (estimated by using MDRD), lithium serum level, blood pressure  and potasium levels will be monitored with three month intervals during a two year follow-up period. In addition patients` psychiatric condition will be evaluated.</Primary_outcome>
    <Secondary_Sponsor>St. Elisabeth Ziekenhuis;University Medical Center Utrecht</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2474360</Internal_Number>
    <TrialID>EUCTR2009-013547-11-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Sodium Bicarbonate for the prevention of Contrast Induced Nephropathy in patients undergoing CTPA - The Nephros Study</Public_title>
    <Scientific_title>Sodium Bicarbonate for the prevention of Contrast Induced Nephropathy in patients undergoing CTPA - The Nephros Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Leids Universitair Medisch Centrum</Primary_sponsor>
    <Date_registration3>20090715</Date_registration3>
    <Date_registration>15/07/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-013547-11                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>16/07/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Doing nothing&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;-estimated glomerular filtration rate (eGFR) &lt; 60 ml/min&lt;br&gt;- clinical suspected acute pulmonary embolism with an indication for CTPA with intravenous administration of iso osmolar contrast media.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Age &lt; 18 years&lt;br&gt;- Exposure to radiographic contrast media within 7 days&lt;br&gt;- Pregnancy&lt;br&gt;- Systolic bloodpressure &lt; 100 mmHg&lt;br&gt;- Allergy for contrast media&lt;br&gt;</Exclusion_Criteria>
    <Condition>The prevention of Contrast Induced Nephropathy is under investigation.
Contrast induced nephropathy (CIN) can occur after injecting radiographic iso osmolair contrast media. Patients with a renal impairment or a decreased renal function and aspecially in combination with diabetis mellitus are at risk for developing CIN.
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10037790
Term: Radiocontrast nephropathy
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Natriumwaterstofcarbonaat 1,4%&lt;br&gt;Product Name: Natriumwaterstofcarbonaat&lt;br&gt;Product Code: N.A.&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;CAS Number: 0&lt;br&gt;Other descriptive name: SODIUM HYDROGEN CARBONATE&lt;br&gt;Concentration unit: % percent&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.4-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Primary end point(s): - Mean increase in serum creatinine 2-4 days after CTPA;Main Objective: -Evaluation of the mean increase in serum creatinine following CTPA (CT- pulmonary angiography) without prehydration compaired to a short prehydration regime with sodium bicarbonate during one hour.;Secondary Objective: -Evaluation of the incidence of CIN following CTPA without prehydration compaired to a short prehydration regime with sodium bicarbonate during one hour.&lt;br&gt;-Furthermore, the risk of developing CIN after CTPA with iso-osmolair contrast media is studied for both patient groups</Primary_outcome>
    <Secondary_ID>09-059</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2474478</Internal_Number>
    <TrialID>EUCTR2008-005806-38-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A multiple ascending dose study to evaluate the safety, tolerability and effect on tumor response of the mTOR inhibitor (RAD001) in combination with the IGF-1R antagonist (R1507) in patients with advanced solid tumors</Public_title>
    <Scientific_title>A multiple ascending dose study to evaluate the safety, tolerability and effect on tumor response of the mTOR inhibitor (RAD001) in combination with the IGF-1R antagonist (R1507) in patients with advanced solid tumors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>F.Hoffmann-La Roche Ltd.</Primary_sponsor>
    <Date_registration3>20090806</Date_registration3>
    <Date_registration>06/08/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005806-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>23/10/2009</Date_enrollement>
    <Target_size>134</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. [Phase Ib] Patients must have histologically confirmed recurrent or refractory advanced solid malignancy with no known standard of care according to the judgment of the investigator (including Hodgkin’s and non-Hodgkin’s lymphoma)&lt;br&gt;&lt;br&gt;[Phase II] Patients must have histologically confirmed:&lt;br&gt;• Advanced metastatic renal cell carcinoma (RCC) with evidence of progressive disease despite prior VEGFr- TKI therapy.&lt;br&gt;• Advanced low- to intermediate grade metastatic or unresectable locoregional pancreatic neuroendocrine tumors (pNET) and carcinoid tumors who have failed standard therapy and have evidence of progressive disease. Patients with either carcinoid or islet cell tumors&lt;br&gt;will be included in this cohort.&lt;br&gt;&lt;br&gt;2. Measurable disease according to RECIST in Phase II&lt;br&gt;&lt;br&gt;3. Male and female patients, = 18 years age &lt;br&gt;&lt;br&gt;5. Patients with treated, asymptomatic, stable CNS metastases are eligible for enrollment only if:&lt;br&gt;• Patient has received prior treatment  to the site(s) of CNS metastatic disease at least 4 weeks prior to treatment&lt;br&gt;• Patient has no requirement for glucocorticoids (discontinued at least 3 weeks prior to treatment) &lt;br&gt;• Patient is not taking anticonvulsants (discontinued at least 3 weeks prior to treatment)&lt;br&gt;• Patient has no overt evidence of neurological deficit&lt;br&gt;&lt;br&gt;6. ECOG performance status 0-2 &lt;br&gt;&lt;br&gt;7. Patients must have adequate organ and marrow function &lt;br&gt;&lt;br&gt;8. Negative pregnancy test (serum ß-HCG) within 7 days of startingStudy treatment in women of childbearing potential (both premenopausal women and women &lt; 2 years after the onset of menopause).&lt;br&gt;&lt;br&gt;10. HbA1c = 7% at screening.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Prior treatment with agents that act via inhibition of the IGF-1R&lt;br&gt;pathway.&lt;br&gt;&lt;br&gt;2. Prior treatment with agents that act via mTOR inhibition (e.g. sirolimus, temsirolimus, everolimus) for the phase II portion only.&lt;br&gt;&lt;br&gt;3. Patients with untreated CNS metastases.&lt;br&gt;&lt;br&gt;5. Previous or current anti cancer therapy: Patients who are currently receiving any anti cancer therapy (other than those administered on this study) or who have received:&lt;br&gt;• Radiotherapy = 4 weeks prior to enrollment&lt;br&gt;• Chemotherapy (including biologic therapy) = 4 weeks prior to enrollment&lt;br&gt;• Patients who have received therapy more than 4 weeks prior to enrollment who have not recovered adverse events to = grade 1, (excluding alopecia)&lt;br&gt;&lt;br&gt;7. History of allogeneic bone marrow transplantation or organ transplantation.&lt;br&gt;&lt;br&gt;11. Patients who are pregnant or breastfeeding.&lt;br&gt;&lt;br&gt;12. Fertile men and women of childbearing potential not employing an effective method of birth control throughout the trial and for 3 months after last study drug administration in both sexes. Women of childbearing potential must have a negative pregnancy test (serum ß- HCG) within the 7 days prior to study drug administration.&lt;br&gt;&lt;br&gt;13. Known hypersensitivity to R1507 or its excipients or to RAD001 or compounds of similar chemical or biologic composition to RAD001.&lt;br&gt;&lt;br&gt;14. Any known severe and/or uncontrolled medical conditions&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>PIb: solid malignancy that is metastatic or unresectable 
PII: C 1: Advanced metastatic renal cell carcinoma 
C 2: Advanced low- to intermediate grade metastatic or unresectable locoregional pancreatic neuroendocrine tumors + carcinoid tumors &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050076
Term: Metastatic renal carcinoma
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10065147
Term: Malignant solid tumor
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10052399
Term: Neuroendocrine tumour
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10026664
Term: Malignant pancreatic islet neoplasm
</Condition>
    <Intervention>&lt;br&gt;Product Name: huMab IGF1-R&lt;br&gt;Product Code: RO4858696/F05&lt;br&gt;Pharmaceutical Form: Powder for concentrate for solution for infusion&lt;br&gt;Current Sponsor code: RO4858696&lt;br&gt;Other descriptive name: R1507 (CHO)&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 125-&lt;br&gt;&lt;br&gt;Trade Name: AFINITOR&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Current Sponsor code: 3745429.013&lt;br&gt;Other descriptive name: RAD001&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Primary end point(s): The primary endpoints are defined according to the cohort in which a patient is entered into the study:&lt;br&gt;– Progression-free survival rate at 24 weeks after start of therapy in the advanced renal cell carcinoma cohort&lt;br&gt;– Progression-free survival rate at 24 weeks in the advanced NET cohort.&lt;br&gt;;Main Objective: P Ib:&lt;br&gt;• To characterize the safety and tolerability of R1507 administered every 3 weeks in combination with daily RAD001 and to determine the maximum-tolerated dose (MTD) of RAD001 administered orally daily, in combination with R1507 administered intravenously every 3 weeks in patients with advanced solid malignancies, and to determine the recommended dose of RAD001 for the phase II study of the combined regimen.&lt;br&gt;P II:&lt;br&gt;• To assess the clinical activity of combination R1507 and RAD001 in two cohorts of patients, defined by:&lt;br&gt;• PFS rate at 24 weeks, in a cohort of patients with advanced stage renal cell carcinoma [RCC cohort],&lt;br&gt;• PFS rate at 24 weeks, in a cohort of patients with advanced low to intermediate grade metastatic or unresectable locoregional pancreatic neuroendocrine tumors (pNET) and carcinoid tumors, [NET cohort].&lt;br&gt;• NOTE: the NET cohort will be comprised of equal numbers of patients of 2 tumor subgroups, (pancreatic islet cell tumors and carcinoid tumors);Secondary Objective: Phase Ib:  &lt;br&gt;• To describe the tolerability and adverse event profile of the combination of R1507 and RAD001 in patients with advanced solid tumors. &lt;br&gt;• To describe pharmacokinetics (PK) of the combination of RAD001 and R1507 using a population PK approach&lt;br&gt;• To evaluate preliminary anti-tumor activity of the combination.&lt;br&gt;&lt;br&gt;Phase II:  &lt;br&gt;• To determine the overall objective response rate, response duration, progression-free survival and overall survival in two cohorts of patients 1) patients with advanced stage renal cell carcinoma (RCC) cohort, and 2) patients with advanced low- to intermediate grade metastatic or unresectable locoregional neuroendocrine tumors (NET) cohort.&lt;br&gt;• To determine the tolerability and adverse event profile of combination R1507 and RAD001 in patients with advanced solid tumors. &lt;br&gt;• To describe pharmacokinetics (PK) of the combination of RAD001 and R1507 using a population PK approach.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>NO21884</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2474744</Internal_Number>
    <TrialID>EUCTR2009-013541-28-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Intérêt de l’utilisation d’un inhibiteur de la mTor (everolimus) pour la minimisation des anticalcineurines dans les transplantations rénales de type « old for old » (receveur &gt; 60 ans recevant un greffon &gt; 60 ans) - EVEROLD</Public_title>
    <Scientific_title>Intérêt de l’utilisation d’un inhibiteur de la mTor (everolimus) pour la minimisation des anticalcineurines dans les transplantations rénales de type « old for old » (receveur &gt; 60 ans recevant un greffon &gt; 60 ans) - EVEROLD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>CHU de Brest</Primary_sponsor>
    <Date_registration3>20090929</Date_registration3>
    <Date_registration>29/09/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-013541-28                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>27/10/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;• première ou deuxième transplantation rénale d’un patient de 60 ans ou plus&lt;br&gt;• recevant un greffon rénal de 60 ans ou plus &lt;br&gt;• immunisation prégreffe &lt; 30 %&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;• troisième greffe ou plus&lt;br&gt;• immunisation supérieure à 30%&lt;br&gt;• bi greffe ou greffe multiorgane&lt;br&gt;• greffe à donneur vivant&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Candidat de 60 ans et plus à une greffe rénale et bénéficiant d'un greffon de donneur de 60 ans et plus &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10038533
Term: Renal transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: SIMULECT&lt;br&gt;Pharmaceutical Form: Concentrate and solvent for solution for injection&lt;br&gt;&lt;br&gt;Trade Name: THYMOGLOBULINE&lt;br&gt;Pharmaceutical Form: Powder for solution for injection&lt;br&gt;&lt;br&gt;Trade Name: NEORAL&lt;br&gt;Product Name: Ciclosporine&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;&lt;br&gt;Trade Name: CERTICAN&lt;br&gt;Product Name: Everolimus&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Primary end point(s): Fonction rénale calculée à un an par la formule MDRD simplifiée;Main Objective: Etudier l'intérêt sur la fonction rénale à un an du remplacement de la ciclosporine par Everolimus  soit d"emblée soit après un mois de greffe chez les transplantés rénaux de plus de 60 ans recevant un greffon rénal de plus de 60 ans;Secondary Objective: •	Comparer les trois stratégies immunosuppressives en terme de survie patient et greffon, incidence de rejet, sortie d’étude, effets secondaires.&lt;br&gt;•	Promouvoir un programme de greffe de type old for old sur l’ensemble du territoire français. &lt;br&gt;•	Étudier les caractéristiques immunologiques du sujet âgé.&lt;br&gt;•	Étudier la pharmacocinétique et pharmacogénétique de l’everolimus&lt;br&gt;</Primary_outcome>
    <Secondary_ID>RB 09.074</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2474748</Internal_Number>
    <TrialID>EUCTR2007-006274-29-SE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Sympathetic activation, microcirculation, haemostasis and inflammation in diabetic and non-diabetic kidney disease: disease modification by vitamin D receptor activation - VDRA and CKD</Public_title>
    <Scientific_title>Sympathetic activation, microcirculation, haemostasis and inflammation in diabetic and non-diabetic kidney disease: disease modification by vitamin D receptor activation - VDRA and CKD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Karolinska Institutet at Danderyd University Hospital</Primary_sponsor>
    <Date_registration3>20090922</Date_registration3>
    <Date_registration>22/09/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006274-29                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/11/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Man or woman above 20 years of age.&lt;br&gt;If woman in reproductive age: not nursing and not pregnant (preseting a negative pregnancy test), and on anticonception therapy.&lt;br&gt;Calculated GFR between 15-59 mL/min/1.73m2 using MDRD  &lt;br&gt;S-Ca2+ &lt;2.6 mmol/L&lt;br&gt;iPTH between 35-500 pg/mL &lt;br&gt;Serum albumin &gt; 3.0 g/dL &lt;br&gt;Signed informed consent&lt;br&gt;&lt;br&gt;For inclusion in the diabetes study group:&lt;br&gt;•	Diagnosed type II diabetes, and treated with peroral antidiabetics or insulin the last 12 months&lt;br&gt;•	HbA1c &lt;= 12% &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Changes in ACE-inhibitor medication or ARB within 8 weeks before start of the study. &lt;br&gt;&lt;br&gt;Nefrotic syndrome&lt;br&gt;Expected need for dialysis within 6 months after study start&lt;br&gt;Vitamin D treatment within 6 months before start of the study.&lt;br&gt;Poorly controlled hypertension with blood pressure &gt;150/100 mmHg (repeated measurements after 15 minutes rest)&lt;br&gt;Concomitant treatment with drugs affecting bone and calcium metabolism such as kalcitonin, cinacalcet (Mimpara or Parareg), and high dose corticosteroids. &lt;br&gt;Concomitant treatment with drugs inhibiting or inducing Cytokrom P450 3A.&lt;br&gt;Known hypersensitivity to any of the substances in study drug or placebo.&lt;br&gt;Diabetic nefropathy and concurrent glomerulonefritis or nefritis&lt;br&gt;Acute renal failure within 12 weeks before screening&lt;br&gt;Other severe chronic disease (AIDS/HIV-positive, cancer, severe heart failure etc.)&lt;br&gt;Known kidney artery stenosis&lt;br&gt;Known kidney stone disease&lt;br&gt;Intake of other investigational medicinal product within 30 days before screening.&lt;br&gt;Known alcohol or drug abuse&lt;br&gt;Known low compliance&lt;br&gt;Not suitable for participation for other reason according to investigators opinion.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with mild to moderate chronic renal failure (CRF; GFR 15-60ml/min; n=26)
Patients with mild to moderate CRF and coexisting Diabetes Mellitus (n=26)

 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10064848
Term: Chronic kidney disease
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10045242
Term: Type II diabetes mellitus
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Zemplar&lt;br&gt;Product Name: Zemplar&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: paricalcitol&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;Pharmaceutical form of the placebo: Capsule*&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The major goal of this study is to develop an enhanced understanding of the disturbances involved in how a progressive loss of kidney function cause increased cardiovascular disturbance, disease and ultimately death, and if some of these disturbances can be ameliorated and modified by treatment with a VDRA. Furthermore, evidence suggest that Diabetic kidney disease constitute a separate entity with certain characteristics that may respond differently to treatment with VDRA. Thus we intend to compare diabetic kidney disease with non-diabetic.&lt;br&gt;As kidney disease is characterized by increased neurohormonal activation and sympathetic overactivity, the primary outcome variable will be a change (reduction) in sympathetic activity as measured by a tungsten microelectrode inserted percutaneously into a fascicle of the peroneal nerve at the level of the fibular head (muscle sympathetic nerve activity: MSNA).&lt;br&gt;;Secondary Objective: A) 	To determine whether sympathetic overactivity cause sympathovagal imbalance, reflected in altered heart rate variability, disturbed baroreflex regulation, and altered transfer-function between blood pressure and sympathetic nerve activity? May these disturbances be ameliorated by treatment with VDRA?&lt;br&gt;B)	Endothelial dysfunction and increased arterial stiffness are common features in severe renal failure, and have been shown even before diagnosis in DM-II. To which degrees are they present in mild to moderate CKD, and how do they correlate with other physiological changes? May these disturbances be modified by treatment with VDRA?&lt;br&gt;C/	Several factors involved in haemostasis and inflammation are independent risk factors for mortality in patients with end stage renal disease. Is the haemostasis disturbed in mild to moderate CKD, and if so, is this correlated to sympathetic activation and impaired microcirculatory control? May these disturbances be ameliorated by treatment with VDRA?;Primary end point(s): Sympathetic activation measured by microneurography at the conclusion of the 12 weeks treatment period.</Primary_outcome>
    <Secondary_ID>ZEMPLAR</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2474907</Internal_Number>
    <TrialID>EUCTR2009-011236-35-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A post-marketing safety study in patients with moderate renal insufficiency who receive Omniscan (Gadodiamide Injection) for contrast enhanced magnetic resonance imaging (MRI)

Estudio de seguridad poscomercialización en pacientes con insuficiencia renal moderada a los que se les administra OMNISCAN (inyección de gadodiamida) para la adquisición de imágenes de RM (IRM) realzada con contraste.</Public_title>
    <Scientific_title>A post-marketing safety study in patients with moderate renal insufficiency who receive Omniscan (Gadodiamide Injection) for contrast enhanced magnetic resonance imaging (MRI)

Estudio de seguridad poscomercialización en pacientes con insuficiencia renal moderada a los que se les administra OMNISCAN (inyección de gadodiamida) para la adquisición de imágenes de RM (IRM) realzada con contraste.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>GE Healthcare Limited and its Affiliates</Primary_sponsor>
    <Date_registration3>20091013</Date_registration3>
    <Date_registration>13/10/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011236-35                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>13/10/2009</Date_enrollement>
    <Target_size>600</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;(1) The subject is 18 years of age or older at time of study entry.&lt;br&gt;(2) The subject is physically able and willing to comply with study procedures and a signed and dated informed consent is obtained.&lt;br&gt;(3) The subject has been referred for a clinically indicated MRI examination with a gadolinium-based contrast agent (GBCA).&lt;br&gt;(4) The subject has known or suspected chronic kidney disease with an eGFR &gt;30 and &lt;60 mL/min/1.73m2 as measured within 30 days prior to the planned index OMNISCAN administration.&lt;br&gt;(5) The subject agrees to be contacted for follow-up for 24 months.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;(1) Patients with known or suspected NSF based on biopsy confirmation or the onset of signs and symptoms of NSF lasting at least  7 days as follows: (a) skin - swelling, hardening and tightening; reddened or darkened patches; burning or itching ; (b) eyes - yellow raised spots on whites of eyes; or (c) bones and muscle - stiffness in joints; difficulty in moving or straightening of arms,&lt;br&gt;hands, legs or feet; bone pain especially in hips and ribs or muscle weakness.&lt;br&gt;(2) Patients allergic to any GBCA.&lt;br&gt;(3) Patients with chronic renal disease with a GFR &lt;30 mL/min/1.73m2 as measured within 30 days prior to the planned index OMNISCAN administration.&lt;br&gt; (4) Patients with acute renal insufficiency of any severity due to the hepato-renal syndrome&lt;br&gt;or in the peri-operative liver transplantation period.&lt;br&gt;(5) Patients that were exposed to any GBCA within a period of 12 months prior the planned index administration of OMNISCAN.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with moderate renal insufficiency (estimated eGFR &gt; 30 and &lt;60 mL/min/1.73m2).

Pacientes con insuficiencia renal moderada (tasa de filtración glomerular [TFG] &gt;estimada 30 y &lt;60 ml/min/1,73 m2). &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10064499
Term: Nephrogenic fibrosing dermopathy
</Condition>
    <Intervention>&lt;br&gt;Trade Name: OMNISCAN  0,5 mmol/ml solución inyectable&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: GADODIAMIDA&lt;br&gt;CAS Number: 122795-43-1&lt;br&gt;Other descriptive name: GADODIAMIDE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 287-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To capture post-marketing safety information on patients with moderate renal insufficiency (eGFR &gt;30 and &lt;60 mL/min/1.73m2) undergoing routine contrast-enhanced MRI with OMNISCAN in order to assess the risk of developing nephrogenic systemic fibrosis (NSF).;Secondary Objective: Not applicable.;Primary end point(s): The primary endpoint will be the development of NSF, whether or not confirmed histologically.</Primary_outcome>
    <Secondary_ID>GE-041-075</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2475063</Internal_Number>
    <TrialID>EUCTR2009-014997-16-AT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Identification of patients with high probability of not or poorly responding to therapy with mycophenolic acid pro-drugs.</Public_title>
    <Scientific_title>Identification of patients with high probability of not or poorly responding to therapy with mycophenolic acid pro-drugs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Medizinische Universität Wien, Abteilung für Nephrologie und Dialyse</Primary_sponsor>
    <Date_registration3>20091021</Date_registration3>
    <Date_registration>21/10/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-014997-16                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>08/04/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;de novo kidney graft&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;highly immunized patients (due to previous transplantations etc) with PRA levels &gt;40%&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with a de novo kidney transplantation &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10023438
Term: Kidney transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Myfortic&lt;br&gt;Product Name: Mycophenolate sodium&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Detection of functionally relevant SNPs in IMPDH 2 gene.;Secondary Objective: The association of detected SNPs in inosine monophosphate dehydrogenase-2 transcript or high IMPDH 2 activity with biopsy proven rejection reactions in the first year after transplantation.;Primary end point(s): Biopsy proven rejection</Primary_outcome>
    <Secondary_ID>MPASNP1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2475112</Internal_Number>
    <TrialID>EUCTR2009-016797-32-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Phase 2/3, twelve-month, multicenter, intra-subjectcontrolled
(retrospective-prospective), open-label,
active-treatment study to evaluate the efficacy, safety,
tolerability and pharmacokinetics of cinacalcet
hydrochloride for the treatment of secondary
hyperparathyroidism in paediatric subjects with chronic
kidney disease on dialysis, followed by 12-month study
extension. - Cinacalcet in paediatric secondary HPT due to CKD</Public_title>
    <Scientific_title>Phase 2/3, twelve-month, multicenter, intra-subjectcontrolled
(retrospective-prospective), open-label,
active-treatment study to evaluate the efficacy, safety,
tolerability and pharmacokinetics of cinacalcet
hydrochloride for the treatment of secondary
hyperparathyroidism in paediatric subjects with chronic
kidney disease on dialysis, followed by 12-month study
extension. - Cinacalcet in paediatric secondary HPT due to CKD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>ISTITUTO GIANNINA GASLINI</Primary_sponsor>
    <Date_registration3>20091102</Date_registration3>
    <Date_registration>02/11/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-016797-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>23/11/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: controllo intra-paziente retrospettivo-prospettico&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Other specify the comparator: controllo intra-paziente con terapia standard&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;To be eligible for inclusion into this study, the subjects must fulfill all of the following&lt;br&gt;criteria at study entry:&lt;br&gt;- Parents/guardian written informed consent, and childs assent given before any studyrelated&lt;br&gt;procedure not part of the subjects normal medical care, with the understanding&lt;br&gt;that consent may be withdrawn by the subject at any time without prejudice to his or her&lt;br&gt;future medical care.&lt;br&gt;- Age &gt; 2 and &lt;18 years;&lt;br&gt;- A dry body weight (BW) &gt;10.49 Kg in males and &gt;9.95 Kg in females, respectively;&lt;br&gt;- Inpatient or outpatient status at the time of enrolment;&lt;br&gt;- Males or females. Female subjects sexually active must be neither pregnant nor breastfeeding,&lt;br&gt;and must lack childbearing potential from screening visit to the end of the&lt;br&gt;safety follow-up, as defined by using an effective form of contraception (i.e. condoms,&lt;br&gt;oral contraceptives or intra-uterine device-IUD). Medically approved contraception&lt;br&gt;could include abstinence. Oral contraception will be accompanied by a barrier method.&lt;br&gt;A negative serum pregnancy test is required prior to initiation of treatment with study&lt;br&gt;medication.&lt;br&gt;- On stable hemodialysis (HD) or peritoneal dialysis (PD) for their CKD for at least one&lt;br&gt;month before entering the 6-month pre-treatment period;&lt;br&gt;- Plasma iPTH levels &gt; 300 pg/mL, AND&lt;br&gt;- Plasma calcium (Ca) levels &gt; 9.4 mg/dL (with normal serum albumin level), AND&lt;br&gt;- Plasma phosphorus (P) levels &lt;6.5 mg/dL in patients younger than 6 years, or &lt;6.0&lt;br&gt;mg/dL in older patients, OR&lt;br&gt;- &amp;#61531;Ca x P&amp;#61533; product &gt; 60;&lt;br&gt;- Records availability for the following parameters 6 months prior to study entry:&lt;br&gt;demographic information, physical examination, height and dry weight,&lt;br&gt;auxological/anthropometric indices, blood pressure values, Kt/V urea, plasma iPTH,&lt;br&gt;calcium, phosphorus, and alkaline phosphatase levels, blood pH and bicarbonate,&lt;br&gt;serum creatinine/urea, C reactive protein (CRP) levels, liver function tests, blood&lt;br&gt;count, blood 25(OH) vitamin D3 level.&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;To be eligible for inclusion in this study the subjects must not meet any of the following&lt;br&gt;criteria at study entry:&lt;br&gt;- The following laboratory values: Hb&lt;9.0 g/dL, WBC&lt;2000/mm3 (2x109/L), platelets&lt;br&gt;&lt;150,000/mm3 (150x109/L) only in subjects who are otherwise eligible for PK/PD&lt;br&gt;assessments; abnormal liver function, defined by a total bilirubin &amp;#8805;2 times the upper&lt;br&gt;limit of normal values, aspartate aminotransferase, alanine aminotransferase or &amp;#947; &lt;br&gt;glutamyltranspeptidase (&amp;#947;-GT) levels &amp;#8805;2 times the upper limit of normal values.&lt;br&gt;- Any other lab values that in the opinion of the investigator might place the subject at&lt;br&gt;unacceptable risk for participation in the study.&lt;br&gt;- History of malignancy (active malignancy, or off therapy since less than 1 year)&lt;br&gt;- History of diseases causing hypercalcemia (primary hyperparathyroidism; parathyroid&lt;br&gt;carcinoma; Williams syndrome; prolonged immobilization)&lt;br&gt;- Chronic inflammatory diseases (C-Reactive Protein-CRP &gt;2 times the upper limit of&lt;br&gt;normal values) requiring a concomitant corticosteroid or immunosuppressive therapy&lt;br&gt;- History of infectious diseases (including opportunistic infections) within 4 weeks&lt;br&gt;prior to study entry&lt;br&gt;- Evidence as assessed by the Investigator of active or latent bacterial, viral or fungal&lt;br&gt;infections at the time of potential enrollment, including subjects with evidence of&lt;br&gt;Human Immunodeficiency virus (HIV) infection.&lt;br&gt;- Hepatitis-B surface antigen-positive subjects only in subjects who are otherwise&lt;br&gt;eligible for PK/PD assessments&lt;br&gt;- Hepatits C antibody-positive subjects who are also PCR-positive or RIBA positive&lt;br&gt;only in subjects who are otherwise eligible for PK/PD assessments&lt;br&gt;- Use of recombinant human growth hormone therapy&lt;br&gt;- Use of tricyclic antidepressant use&lt;br&gt;- Use of drugs that interact with cinacalcet disposition, such as ketoconazole,&lt;br&gt;itraconazole, telythromycin, voryconazole, ritonavir, rifampin&lt;br&gt;- Previous use of cinacalcet&lt;br&gt;- History of hypersensitivity to any of the ingredients of the study drug.&lt;br&gt;- Use of any investigational drug, device or biologic within 4 weeks prior to study entry&lt;br&gt;or during the study.&lt;br&gt;</Exclusion_Criteria>
    <Condition>secondary
hyperparathyroidism in paediatric subjects with chronic
kidney disease &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10020708
</Condition>
    <Intervention>&lt;br&gt;Trade Name: MIMPARA&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Cinacalcet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;&lt;br&gt;Trade Name: MIMPARA&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Cinacalcet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 60-&lt;br&gt;&lt;br&gt;Trade Name: MIMPARA&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Cinacalcet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 90-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: -To determine the efficacy of cinacalcet HCl plus standard therapy for SHPT in paediatric&lt;br&gt;subjects with CKD on dialysis by assessing the response to treatment (e.g., a reduction from&lt;br&gt;baseline &gt;25% in mean intact parathyroid hormone (iPTH) levels with concomitant values&lt;br&gt;for P&lt;6 mg/dL and Ca between 8.4-10.5 mg/dL or &amp;#61531;Ca x P&amp;#61533; product &lt;60) after 6 months&lt;br&gt;compared to standard therapy alone intra-subject;&lt;br&gt;AND&lt;br&gt;- To evaluate the overall safety and tolerability of cinacalcet HCl plus standard therapy for&lt;br&gt;SHPT in paediatric patients with CKD on dialysis over 6 months compared to standard&lt;br&gt;therapy alone intra-subject.;Secondary Objective: -to determine the efficacy of cinacalcet HCl plus standard therapy in the target population&lt;br&gt;by assessing the response to treatment during the induction period over 6 months, and during&lt;br&gt;the maintenance period over 12 months;&lt;br&gt;- To evaluate the overall safety and tolerability of cinacalcet HCl plus standard therapy in the&lt;br&gt;target population over 18 months;&lt;br&gt;- To evaluate the effects of cinacalcet HCl on bone growth by measuring anthropometric&lt;br&gt;indices (Height-for-Age, Weight-for-Age, Weight-for-Height, Body Mass Index-for-Age)&lt;br&gt;and subject growth velocity over 18 months;&lt;br&gt;- In a subset of adolescent subjects (12-18 yrs), to assess the pharmacokinetics&lt;br&gt;(PK)/pharmacodynamic (PD) profile of cinacalcet HCl and its correlation with iPTH target&lt;br&gt;levels and testosterone level when applicable;&lt;br&gt;- In a subset of children (2-11 yrs), to explore the population clinical pharmacology of&lt;br&gt;cinacalcet HCl.;Primary end point(s): The primary study endpoint (EP) will be the proportion of recruited patients who will have a&lt;br&gt;reduction from baseline of at least 25% in mean iPTH levels with concomitant values for&lt;br&gt;plasma P &lt;6 mg/dL and Ca between 8.4 and 10.5 mg/dL or the &amp;#61531;Ca x P&amp;#61533; product &lt;60 during&lt;br&gt;the 6-month, intra subject-controlled, efficacy-assessment phase.</Primary_outcome>
    <Secondary_ID>IGG_ev_003</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2475361</Internal_Number>
    <TrialID>EUCTR2009-010827-23-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio nacuinal, multicéntrico, abierto, de tratamiento de inducción con VELCADE y Dexametasona en pacientes con mieloma múltiple e insuficiencia renal no tratados previamente</Public_title>
    <Scientific_title>Estudio nacuinal, multicéntrico, abierto, de tratamiento de inducción con VELCADE y Dexametasona en pacientes con mieloma múltiple e insuficiencia renal no tratados previamente                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Fundación PETHEMA</Primary_sponsor>
    <Date_registration3>20091210</Date_registration3>
    <Date_registration>10/12/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-010827-23                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>02/02/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- El paciente se encuentra, en opinión del investigador, dispuesto y capacitado para cumplir con los requisitos del protocolo.&lt;br&gt;- El paciente o su representante legal ha otorgado voluntariamente su consentimiento informado por escrito antes de la realización de cualquiera de los procedimientos relacionados con el estudio, que no forman parte de la atención médica normal, entendiendo que dicho consentimiento puede ser retirado por parte del paciente en cualquier momento sin que ello suponga un perjuicio en su atención médica futura.&lt;br&gt;- Edad mayor o igual de 18 años.&lt;br&gt;- Se trata de un paciente con diagnóstico reciente de mieloma múltiple sintomático, según  los criterios estándar y que no ha recibido ningún tratamiento anterior con quimioterapia para el mieloma múltiple.&lt;br&gt;- El paciente presenta una enfermedad medible, definida como sigue:&lt;br&gt;          - Para el mieloma múltiple secretor, la enfermedad medible se define como  valores de proteína monoclonal cuantificables en suero de IgG&gt;10g/l o IgA&gt;5g/l  y, si procede, excreción de cadena ligera en orina mayor o igual a 200 mg/24 horas.&lt;br&gt;          - Para el mieloma múltiple oligosecretor o no secretor, la enfermedad medible se define por la presencia plasmocitomas de tejido blando (no óseo), determinados en el examen clínico o radiológico pertinente (p.ej. MRI, CT-Scan). En pacientes con mieloma múltiple oligosecretor, las mediciones de proteína M en suero y/o en orina son muy bajas y de difícil seguimiento para la evaluación de la respuesta. En los pacientes con mieloma múltiple no secretor, no se detecta proteína M en suero o en orina mediante inmunofijación.&lt;br&gt;- El paciente posee un estado funcional de ECOG menor o igual a 2.&lt;br&gt;- El paciente posee una esperanza de vida superior a 3 meses.&lt;br&gt;- Filtrado glomerular determinado por MDRD &lt;50 ml/min&lt;br&gt;- El paciente presenta los siguientes valores de laboratorio en los 14 días anteriores a la administración del fármaco en estudio:&lt;br&gt;          - Recuento plaquetario mayor o igual a 50x109/l.&lt;br&gt;          - Recuento absoluto de neutrófilos (ANC) igual o superior a 0.75 x 10 9/ L.&lt;br&gt;          - Calcio en suero corregido (ver anexo 15) menor o igual a 14mg/dl.&lt;br&gt;          - Aspartato transaminasa (AST): inferior o igual a 2,5 x el límite superior normal.&lt;br&gt;          - Alanintransaminasa (ALT): menor o igual a 2,5 x el límite superior normal.&lt;br&gt;          - Bilirrubina total: inferior o igual a 1,5 x el límite superior normal.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Filtrado glomerular determinado por MDRD &amp;#8805; 50ml/min&lt;br&gt;- MM asintomático con insuficiencia renal atribuible a otras causas&lt;br&gt;- Paciente que anteriormente ha recibido tratamiento con VELCADE&lt;br&gt;- Paciente que anteriormente ha recibido tratamiento para el mieloma múltiple&lt;br&gt;- Paciente sometido a cirugía mayor en las 4 semanas anteriores al reclutamiento.&lt;br&gt;- Paciente con recuento plaquetario menor de 50x10 9/l en los 14 días anteriores al reclutamiento.&lt;br&gt;- Paciente con recuento absoluto de neutrófilos menor de 0,75x10 9/l en los 14 días anteriores al reclutamiento. &lt;br&gt;- Paciente con neuropatía periférica mayor o igual a Grado 2 en los 14 días anteriores al reclutamiento.&lt;br&gt;- Paciente con hipersensibilidad frente a bortezomib, ácido bórico o manitol.&lt;br&gt;- Paciente que ha recibido otros fármacos en investigación en los 14 días anteriores al reclutamiento.&lt;br&gt;- Paciente con seropositividad conocida frente al virus de la inmunodeficiencia humana (VIH).&lt;br&gt;- Paciente que ha sufrido un infarto de miocardio en los 6 meses anteriores al reclutamiento o que presenta una insuficiencia cardiaca de cualquier clase (III ó IV según la Asociación de Cardiología de Nueva York &lt;NYHA&gt;), angina inestable, arritmias ventriculares graves no controladas o evidencia electrocardiográfica de isquemia aguda, anomalías del sistema de conducción activas o cualquier otra condición o dolencia cardiológica que, a juicio del especialista, suponga un factor de riesgo para desarrollar insuficiencia cardiaca, digno a tener en cuenta.&lt;br&gt;- Paciente que participa en otro estudio de investigación clínica y/o está siendo tratado con un producto en investigación por cualquier motivo.&lt;br&gt;- Paciente con enfermedad pulmonar difusa y/o enfermedad pericárdica&lt;br&gt;- Embarazo, lactancia o mujeres potencialmente fértiles que no utilizan ni utilizarán durante el estudio un método anticonceptivo efectivo aprobado médicamente desde la selección hasta al menos 30 días después de finalizar el último ciclo de tratamiento. Si es varón, el sujeto se compromete a usar un método anticonceptivo de barrera aceptable desde la selección hasta como mínimo 30 días después de recibir el último ciclo de tratamiento.&lt;br&gt;- Historia previa de otras enfermedades malignas diferentes al mieloma (excepto para carcinoma basal o escamoso de la piel, o carcinoma in situ de cérvix o mama) a menos que el paciente se encuentre libre de enfermedad más allá de 5 años&lt;br&gt;- Hipertensión arterial o diabetes mellitus mal controladas o cualquier otra enfermedad orgánica grave que suponga un riesgo excesivo para el paciente o cualquier alteración psiquiátrica que interfira con la comprensión del consentimiento informado.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Mieloma Múltiple e insuficiencia renal no tratados previamente &lt;br&gt;MedDRA version: 9
Level: LLT
Classification code 10028228
Term: Multiple myeloma
</Condition>
    <Intervention>&lt;br&gt;Trade Name: VELCADE 3,5 mg, polvo para solución inyectable&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: BORTEZOMIB&lt;br&gt;Other descriptive name: BORTEZOMIB&lt;br&gt;Concentration unit: mg/m2 milligram(s)/square meter&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 1.3-&lt;br&gt;&lt;br&gt;Trade Name: FORTECORTIN 8 mg comprimidos&lt;br&gt;Product Name: FORTECORTÍN&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: DEXAMETASONA&lt;br&gt;CAS Number: 50-02-2&lt;br&gt;Other descriptive name: DEXAMETHASONE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 8-&lt;br&gt;&lt;br&gt;Trade Name: FORTECORTIN 4 mg comprimidos&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: DEXAMETASONA&lt;br&gt;CAS Number: 50-02-2&lt;br&gt;Other descriptive name: DEXAMETHASONE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 4-&lt;br&gt;&lt;br&gt;Trade Name: FORTECORTIN 1 mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: DEXAMETASONA&lt;br&gt;CAS Number: 50-02-2&lt;br&gt;Other descriptive name: DEXAMETHASONE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Estudiar la eficacia en términos de tasa de respuesta;Secondary Objective: - Estudiar la rapidez y grado de respuesta (variación en la cuantía del componente M en suero y orina) tras cada ciclo de bortezomib/dexametasona.&lt;br&gt;- Reversibilidad de la insuficiencia renal.&lt;br&gt;- Proporción de pacientes uq epueden discontinuar la diálisis.&lt;br&gt;- Valor predictivo de la determinación de cadenas ligeras para respuesta y reversibilidad de la insuficiencia renal.&lt;br&gt;- Mortalidad precoz (menos de 2 meses).&lt;br&gt;- Supervivencia libre de progresión.&lt;br&gt;- Supervivencia global.&lt;br&gt;- Determinar la seguridad y tolerabilidad de VELCADE asociado a Dexametasona, medido en función de la incidencia de toxicidades clínicas y de laboratorio.;Primary end point(s): La variable principal de eficacia es:&lt;br&gt;- Tasa de respuesta (RC, RP) a VELCADE/DEXA.&lt;br&gt;La variable principal de seguridad es:&lt;br&gt;- Incidencias de toxicidades clínicas y de laboratorio.</Primary_outcome>
    <Secondary_ID>RENVEL</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2475502</Internal_Number>
    <TrialID>EUCTR2009-014562-26-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>?Estudio multicéntrico, aleatorizado, abierto de maximización de micofenolato sódico (MFS) versus micofenolato mofetilo (MMF) para minimizar la dosis de tacrolimus en pacientes trasplantados renales en mantenimiento. Estudio Maximiza.?. - MAXIMIZA</Public_title>
    <Scientific_title>?Estudio multicéntrico, aleatorizado, abierto de maximización de micofenolato sódico (MFS) versus micofenolato mofetilo (MMF) para minimizar la dosis de tacrolimus en pacientes trasplantados renales en mantenimiento. Estudio Maximiza.?. - MAXIMIZA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Novartis Farmacéuitica S.A</Primary_sponsor>
    <Date_registration3>20091223</Date_registration3>
    <Date_registration>23/12/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-014562-26                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/02/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;?	Receptores de trasplante renal &amp;#8805; 1 año y &lt;5 años previos1 a la inclusión en el estudio.&lt;br&gt;?	Que estén recibiendo un régimen inmunosupresor que incluya MMF &lt;1000 mg/día y &amp;#8805;250 mg/día (mínimo durante un mes) y Prograf®1 (niveles &amp;#8805;7 ng/ml). &lt;br&gt;?	Pacientes que hayan mantenido el actual régimen de inmunosupresión con MMF a dosis estables como mínimo en los últimos 3 meses 2&lt;br&gt;?	Los pacientes incluidos deberán estar en unos niveles de Prograf &amp;#8805; 7mg/ml durante como mínimo un mes antes de su inclusión en el ensayo 2&lt;br&gt;?	Pacientes con bajo riesgo inmunológico, según criterio del investigador.&lt;br&gt;?	Pacientes con una tasa de filtrado glomerular estimado por la fórmula MDRD &gt; 30 mL/min x 1.73m2 1&lt;br&gt;?	Pacientes mayores de 18 años 1&lt;br&gt;?	Capaces de entender la información sobre el estudio y de otorgar su consentimiento informado de forma escrita.&lt;br&gt;?	Que puedan cumplir todos los requisitos del estudio incluyendo la realización de los cuestionarios y la asistencia a las visitas del estudio.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;?	Que se conozca o asuma que tiene síntomas GI no causados por el tratamiento con ácido micofenólico (MPA) (por ejemplo, diarrea infecciosa inducida por bisfosfonatos orales).&lt;br&gt;?	Pacientes con enfermedad inflamatoria intestinal crónica.&lt;br&gt;?	Pacientes diabéticos.&lt;br&gt;?	Rechazo agudo &lt; 1 mes previo a la inclusión en el estudio. &lt;br&gt;?	Pacientes con leucopenia (&lt;3.500 cel/mm3) o plaquetopenia (&lt;100.000 cel/mm3)&lt;br&gt;?	Mujeres físicamente fértiles que tengan previsto quedarse embarazadas, estén embarazadas y/o en periodo de lactancia, o bien que no deseen utilizar un método anticonceptivo eficaz [anticonceptivos hormonales (implantación, parches, oral), y métodos de doble barrera (cualquier combinación doble de: DIU, profilácticos masculinos o femeninos con gel espermicida, diafragma, esponja anticonceptiva, capuchón cervical)]. &lt;br&gt;?	Presencia de enfermedad psiquiátrica (como esquizofrenia, depresión mayor) que, a juicio del investigador, pudiese interferir con los requerimientos del estudio.&lt;br&gt;?	Que estén siendo sometidos a intervención médica por patología aguda o que estén hospitalizados.&lt;br&gt;?	Cualquier otra condición médica que, a juicio del investigador basándose en el recuento o en la revisión de historiales clínicos, pudiese afectar a la realización del estudio, incluyendo, pero no limitado a problemas visuales o deterioro cognitivo.&lt;br&gt;?	Que estén recibiendo cualquier fármaco en investigación o lo hayan recibido durante los 30 días previos a la inclusión en el estudio.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Profilaxis del rechazo agudo en trasplante alogénico renal. Minimizar la dosis de tacrolimus en pacientes trasplantados renales en mantenimiento &lt;br&gt;MedDRA version: 9
Level: LLT
Classification code 10000952
Term: Acute on chronic renal failure
 &lt;br&gt;MedDRA version: 9
Level: LLT
Classification code 10001041
Term: Acute renal failure
</Condition>
    <Intervention>&lt;br&gt;Trade Name: MYFORTIC 180 mg comprimidos gastrorresistentes recubiertos con película&lt;br&gt;Pharmaceutical Form: Gastro-resistant tablet&lt;br&gt;INN or Proposed INN: MICOFENOLICO ACIDO&lt;br&gt;Other descriptive name: MYCOPHENOLIC ACID&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 180-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: El objetivo principal demostrar que Myfortic&amp;#61650; permite una dosis óptima más alta que MMF lo que conduce a una minimización de Prograf®1 en el mantenimiento de los pacientes con trasplante renal.;Secondary Objective: ?	Comparar la eficacia entre los dos grupos de tratamiento en función de BPAR, pérdida de injerto, muerte y pérdida de seguimiento.&lt;br&gt;?	Comparar la calidad de vida entre los dos regimenes inmunosupresores en función del impacto de los síntomas GI, mediante la escala SIGIT-QoL. Asimismo, se evaluará la gravedad de los síntomas utilizando la escala de clasificación de síntomas gastrointestinales (GSRS).&lt;br&gt;?	Comparar la seguridad entre los dos regimenes inmunosupresores mediante la evaluación de acontecimientos adversos (AAs), exploración física, constantes vitales y los resultados de los análisis de laboratorio y del PRA;Primary end point(s): La variable principal será la proporción de pacientes que alcanzan al menos dos dosis mayores de MPA y consiguen reducir la dosis de Prograf®1 al finalizar el estudio (visita final) con respecto a la dosis basal.</Primary_outcome>
    <Secondary_ID>CERL080AES08</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2475506</Internal_Number>
    <TrialID>EUCTR2009-014268-20-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>VZV vaccination to prevent herpes zoster after transplantation - Vaccination to prevent herpes zoster</Public_title>
    <Scientific_title>VZV vaccination to prevent herpes zoster after transplantation - Vaccination to prevent herpes zoster                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Erasmus MC</Primary_sponsor>
    <Date_registration3>20090721</Date_registration3>
    <Date_registration>21/07/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-014268-20                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/12/2009</Date_enrollement>
    <Target_size>80</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: same VZV vaccin&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Age of patient and donor is 50 years or older&lt;br&gt;- Patients on waitinglist for living-related kidney transplantation and their donors&lt;br&gt;- Patients at least 1 month prior to to kidney transplantation&lt;br&gt;- Patient is VZV seropositive before vaccination&lt;br&gt;- Patient is capable of understanding the purpose and risks of the study, fully informed and given written informed consent&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Use of immunosuppresion (inhalation corticosteroids are allowed)&lt;br&gt;- Neomycine allergy&lt;br&gt;- Fever&lt;br&gt;- Immunodeficiency due to e.g. acute/chronic, lymphoma or HIV&lt;br&gt;- Active tuberculosis&lt;br&gt;</Exclusion_Criteria>
    <Condition>Herpes Zoster &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10019974
Term: Herpes zoster
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10036897
Term: Prophylactic vaccination
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10023438
Term: Kidney transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Zostavax&lt;br&gt;Product Name: Zostavax&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;INN or Proposed INN: shingles (herpes zoster) vaccine (live)&lt;br&gt;CAS Number: 0&lt;br&gt;Other descriptive name: VARICELLA VIRUS OKA/MERCK STRAIN (LIVE, ATTENUATED)&lt;br&gt;Concentration unit: ml millilitre(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.65-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To study if there is a role for prophylactic VZV vaccination prior to transplantation to boost the patients B- and T-cell repertoire and thereby reducing the incidence and morbidity associated with herpes zoster.;Secondary Objective: none;Primary end point(s): VZV-specific IgG and IgM levels from baseline to endpoint (1 year after vaccination).&lt;br&gt;VZV-specific T-cell reactivity using flow cytometry specific from baseline to endpoint.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>VZV01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2475528</Internal_Number>
    <TrialID>EUCTR2007-006198-98-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Pain management in renal colic; The efficacy of continuous intravenous administration of tramadol versus butylscopolamine. A double blinded, randomized placebo controlled, prospective multicenter trial. - TraBu-trial</Public_title>
    <Scientific_title>Pain management in renal colic; The efficacy of continuous intravenous administration of tramadol versus butylscopolamine. A double blinded, randomized placebo controlled, prospective multicenter trial. - TraBu-trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Isala klinieken Zwolle</Primary_sponsor>
    <Date_registration3>20090901</Date_registration3>
    <Date_registration>01/09/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006198-98                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>05/10/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;The participants are 18 years and older and are able to make a will. Participants presenting with clinical signs and symptoms of renal colic, as ajudged by a urologist or resident in urology, are included after oral an written informed consent.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-pregnancy or lactation&lt;br&gt;-chronic tramadol use&lt;br&gt;-severe renal failure, GFR less than 10 ml/min&lt;br&gt;-severe hepatic failure&lt;br&gt;-allergic reactions to opioids / NSAID's&lt;br&gt;-concommitent use of MAO-inhibitor, or less than 2 weeks after stop MAO-inhibitor&lt;br&gt;-narrow-angle glaucoma&lt;br&gt;-use of NSAID's 8 hours before admittance&lt;br&gt;-use of drugs or alcohol 8 hours before admittance&lt;br&gt;-hydronephrotic kidney combined with fever&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal colic pain based on kidney or ureteric stones in patients of 18 years and older.</Condition>
    <Intervention>&lt;br&gt;Trade Name: Tramadol&lt;br&gt;Product Name: Tramadol&lt;br&gt;Product Code: Tramadol&lt;br&gt;Pharmaceutical Form: Intravenous infusion&lt;br&gt;Pharmaceutical form of the placebo: Intravenous infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;Trade Name: Buscopan&lt;br&gt;Product Name: Buscopan&lt;br&gt;Pharmaceutical Form: Intravenous infusion&lt;br&gt;Pharmaceutical form of the placebo: Intravenous infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Can a difference between the change in the perception of pain over time(0-60minutes) between tramadol and butylscopolamine in renal colic be proven?;Secondary Objective: -Can a difference in the decline in VAS-score over time (0-240min) between the tramadol group and the butylscopolamine group be proven?&lt;br&gt;-Can the therapeutic efficacy of butylscopolamine compared to placebo over time (0-240min) be proved?&lt;br&gt;-Can the therapeutic efficacy of tramadol compared to placebo over time (0-240min) be proved?&lt;br&gt;-What are the side effects of continuous intravenous administered tramadol and to what extend do they occur?&lt;br&gt;-Is a difference in the need for of rescue-medication seen between the tramadol and butylscopolamine group?;Primary end point(s): Efficacy of treatment is defiend as a decline of 10mm or more on the horizontal Visual Analogue Scale. Differences between the tramadol and butylscopolamine groups wil be calculated with change in VAS-score between T0 and T3 ( 60min ).</Primary_outcome>
    <Secondary_ID>99976</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2475603</Internal_Number>
    <TrialID>EUCTR2009-014436-38-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A prospective, open, randomized, single center study comparing the effects of duo therapy with Everolimus and steroids versus triple treatment of low dose calcineurin inhibitor, low-dose MMF and steroids at least one year after renal transplantation.
Effects on renal function, tolerability, chronic allograft damage, cardiovascular parameters and malignancies.
 - STER</Public_title>
    <Scientific_title>A prospective, open, randomized, single center study comparing the effects of duo therapy with Everolimus and steroids versus triple treatment of low dose calcineurin inhibitor, low-dose MMF and steroids at least one year after renal transplantation.
Effects on renal function, tolerability, chronic allograft damage, cardiovascular parameters and malignancies.
 - STER                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>UMCG</Primary_sponsor>
    <Date_registration3>20090713</Date_registration3>
    <Date_registration>13/07/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-014436-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>25/09/2009</Date_enrollement>
    <Target_size>130</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Female or male, aged between 18 and 70 years.&lt;br&gt;•	Recipient of a kidney graft from a deceased donor or living (non-HLA identical) donor.&lt;br&gt;•	The patient understands the purpose and risks of the study and has given written informed consent to participate in the study.&lt;br&gt;•	Acceptable renal function, eGFR &gt; 40 ml/min, Proteinuria = 1, 0   g/24hr. &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	Patients with multi-organ transplants.&lt;br&gt;•	Patients who have been receiving a second or subsequent transplant.&lt;br&gt;•	Patients with very low function at 1 year post-transplant, GFR &lt; 40.&lt;br&gt;•	Proteinuria &gt; 1, 0   g/24 hr.&lt;br&gt;•	Patients with a screening/baseline total white blood cell count  &lt; 2,0 10Eg/l or ANC &lt; 1,0 10Eg/l,  platelet count &lt; 100 10Eg/l.&lt;br&gt;•	Patients with baseline fasting triglycerides &gt; 4.5 mmol/l or fasting total cholesterol  &gt; 7.8 mmol/l despite optimal lipid-lowering therapy.&lt;br&gt;•	Presence of sub clinical rejection (Borderline or Banff score &gt;1a) in biopsy taken at approximately month 12&lt;br&gt;•	Vascular or Acute rejection (Banff score = 2a) six months preceding randomization.&lt;br&gt;•	Female patients who are pregnant or unwilling to use adequate contraception during the study.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal transplantation.</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Trade Name: Neoral&lt;br&gt;Product Name: Neoral&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;&lt;br&gt;Trade Name: Prograft&lt;br&gt;Product Name: Prograft&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;&lt;br&gt;Trade Name: Mycofenolaat mofetil CF 500&lt;br&gt;Product Name: Mycofenolaat mofetil&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;&lt;br&gt;Trade Name: Prednisolon 5 PCH&lt;br&gt;Product Name: Prednisolon 5 PCH&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Secondary Objective: ;Primary end point(s): •	Renal function&lt;br&gt;•	The percentage of patients that need reconversion to their original therapy (tolerability).&lt;br&gt;&lt;br&gt;;Main Objective:  &lt;br&gt;To investigate the safety and efficacy of a therapy consisting Everolimus and &lt;br&gt;corticosteroids maintenance immunosuppressive regime twelve months after renal transplantation &lt;br&gt;in recipients of donor kidney graft on graft function and acute rejection rates. The other group will&lt;br&gt;receive a low-dose regimen consisting a low-dose calcineurin inhibitor, low dose MMF and corticosteroids. &lt;br&gt;</Primary_outcome>
    <Secondary_ID>2009/07</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2475607</Internal_Number>
    <TrialID>EUCTR2009-015558-40-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Abatacept treatment in patients with primary Sjögren’s syndrome</Public_title>
    <Scientific_title>Abatacept treatment in patients with primary Sjögren’s syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>University Medical Center Groningen</Primary_sponsor>
    <Date_registration3>20091223</Date_registration3>
    <Date_registration>23/12/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-015558-40                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>28/07/2010</Date_enrollement>
    <Target_size>15</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;?	pSS according to the revised European – U.S. criteria(22).&lt;br&gt;?	Male or female  ? 18 years.&lt;br&gt;?	Stimulated whole saliva secretion ? 0.15 ml/min. &lt;br&gt;?	Positive autoantibodies (IgM-Rf ?10 and SS-A and/or SS-B).&lt;br&gt;?	Parotid gland biopsy  (paraffin material and fresh frozen tissue) with characteristic features of SS performed at time of inclusion (no longer than 12 months ago).&lt;br&gt;?	In female patients: use of reliable method of contraception during the study and at least until 14 weeks after the last infusion, in women of child bearing potential. &lt;br&gt;?	In male patients: use of reliable method of contraception during the study and at least until 14 weeks after the last infusion by partner of patient, in case the partner of the patient is a female of child bearing potential.&lt;br&gt;?	Written informed consent.&lt;br&gt;?	Patients are allowed to continue artificial tears and/or artificial saliva provided that the dosage and schedule regime are stable, and that the usage will be stopped one day prior to each evaluation. &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;?	Disease duration ? 5 years.&lt;br&gt;?	The presence of any other connective tissue disease.&lt;br&gt;?	Clinically significant serious abnormalities on electrocardiography or chest X ray.&lt;br&gt;?	Lab abnormalities:&lt;br&gt;o	Serum creatine &gt; 2.8 mg/dl (250 ?mol/l);&lt;br&gt;o	ASAT or ALAT outside 1.5 x upper normal range of the laboratory;&lt;br&gt;o	Hb &lt; 9 g/dl (5.6 mmol/l) for males and 8.5 g/dl (5.3 mmol/l) for females;&lt;br&gt;o	Neutrophil granulocytes less than 0.5 x 109/l;&lt;br&gt;o	Platelet count less than 50 x 109/l.&lt;br&gt;?	Underlying cardiac, pulmonary, metabolic, renal or gastrointestinal conditions, chronic or latent infectious diseases (e.g., patients with hepatitis B or C, patent tuberculosis or latent tuberculosis non-adequately treated) or immune deficiency which places the patient at an unacceptable risk for participation in the study. &lt;br&gt;?	History of cancer, including mucosa associated lymphoid tissue (MALT) lymphoma in the preceding 5 years (except adequately treated basal cell carcinoma of the skin and carcinoma in situ of the skin).&lt;br&gt;?	Positive pregnancy test or breast-feeding.&lt;br&gt;?	Planned major surgery (e.g. joint replacement) within the duration of the treatment period of the study. &lt;br&gt;?	Serious infections in the preceding month. &lt;br&gt;?	Opportunistic infection in the preceding 3 months.&lt;br&gt;?	Subjects with evidence of active or latent bacterial infections at the time enrollment, including subjects with evidence of Human Immunodeficiency Virus (HIV) infection.&lt;br&gt;?	Subjects with current clinical or laboratory evidence of active tuberculosis (TB).&lt;br&gt;?	Subjects with a history of active TB treated within the last 3 years.&lt;br&gt;?	Subjects who received treatment for active TB greater than 3 years ago may be eligible for inclusion in this study if there is documentation of the prior anti-TB treatment confirming that it was appropriate in duration and type. &lt;br&gt;?	Subjects with latent TB which was not successfully treated.&lt;br&gt;?	Subjects with a positive TB screening test indicative of latent TB will not be eligible for this study unless active TB infection has been ruled out and they have been initiated treatment for latent TB with isoniazid (INH) for at least 4 weeks prior to dosing of Abatacept and they have a negative chest x-ray for  active TB at enrollment. Such subjects should complete 9 months of INH treatment.&lt;br&gt;?	Subjects with herpes zoster that resolved less than 2 months prior to enrollment.&lt;br&gt;?	Preceding treatment with anti-TNF, rituximab or other monoclonal antibodies&lt;br&gt;?	Use of prednisone and/or pilocarpine less than 2 weeks ago&lt;br&gt;?	The use of hydroxychloroquine, azathioprine, cyclofosphamide, cyclosporine, MTX and other DMARDs should be discontinued at least 1 month prior to the first infusion of abatacept.&lt;br&gt;?	History of alcohol or drug abuse.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Sjögren’s syndrome (SS) is a chronic, systemic, lymphoproliferative autoimmune disease affecting the exocrine glands. The salivary and lacrimal glands are most commonly affected, resulting in dry mouth and dry eyes. Extraglandular involvement can occur in SS, and includes, amongst others, pulmonary disease, renal disease and vasculitis. Moreover, almost all patients suffer from restricting fatigue. &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10040767
Term: Sjogren's syndrome
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Orencia&lt;br&gt;Pharmaceutical Form: Powder for concentrate for solution for infusion&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluation of efficacy (as assessed by the stimulated whole saliva flow rate at 24 weeks) and safety of abatacept treatment in 15 patients with pSS. &lt;br&gt;;Secondary Objective: Evaluation of efficay of abatacept treatment in 15 patients with pSS on objective signs and subjective complains.;Primary end point(s): primary endpoint:&lt;br&gt;- Stimulated whole salivary gland function at week 24&lt;br&gt;&lt;br&gt;secundary endpoints:&lt;br&gt;- functional parameters (clinical glandular and extraglandular examination)&lt;br&gt;- laboratory parameters (e.g. B and T cell subsets, IgM-Rf)&lt;br&gt;- subjective parameters (VAS scores, MFI, SF-36)&lt;br&gt;- histological/molecular parameters</Primary_outcome>
    <Secondary_ID>ABACEPT1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2475617</Internal_Number>
    <TrialID>EUCTR2009-016159-23-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Vitamin D in addition to RAAS blockade and dietary sodium for the Treatment of Urinary Excretion of albumin: the ViRTUE-study - ViRTUE</Public_title>
    <Scientific_title>Vitamin D in addition to RAAS blockade and dietary sodium for the Treatment of Urinary Excretion of albumin: the ViRTUE-study - ViRTUE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>University Medical Center Groningen (UMCG)</Primary_sponsor>
    <Date_registration3>20091008</Date_registration3>
    <Date_registration>08/10/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-016159-23                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/10/2011</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Male and female patients&lt;br&gt;- Non-diabetic renal disease as established by history, serum biochemistry tests and/or renal biopsy&lt;br&gt;- Age = 18 and = 75 years &lt;br&gt;- Residual proteinuria &gt; 1,0 g/day and &lt; 8 g/day during conventional treatment of at least 8 weeks with ACE-inhibitor or ARB  at the maximum recommended dose &lt;br&gt;- Stable renal function (creatinine clearance of &gt; 30 ml/min/1.73m2; with &lt; 6 ml/min per year decline)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Inability to meet inclusion criteria&lt;br&gt;- uncontrolled hypertension, hyperkalemia (potassium &gt;6.0 mmol/l, cardiovascular disease (myocardial infarction, unstable angina, percutanous transluminal coronary angioplasty, coronary artery bypass grafting, or stroke within last 6 months, heart failure NYHA III-IV), Diabetes Mellitus &lt;br&gt;- epilepsy&lt;br&gt;- liver disease resulting in liverfunction aberrations (zemplar bevat ethanol))&lt;br&gt;- Previously treated (within 3 months of screening) with paricalcitol or vitamin D&lt;br&gt;- contraindication to ACEi, high/low sodium diet or paricalcitol&lt;br&gt;- medication interacting with ACEi or paricalcitol &lt;br&gt;- frequent NSAID use (&gt;2 doses/week)&lt;br&gt;- Immunosuppressive medication&lt;br&gt;- Digoxine use&lt;br&gt;- secondary or tertiary hyperparathyreoidie &lt;br&gt;- active malignancy &lt;br&gt;- any bowel disorder resulting in fat malabsorption&lt;br&gt;- Pregnant or nursing (lactating) women, where pregnancy is defined as a state of a female after conception and until the termination of gestation, confirmed by a positive ß-hCG laboratory test (&gt;5 mIU/ml).&lt;br&gt;- incompliance with diet or study medication&lt;br&gt;- any psychiatric condition or psychofarmacon use&lt;br&gt;- drug or alcohol abuse&lt;br&gt;</Exclusion_Criteria>
    <Condition>chronic kidney disease &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10064848
Term: Chronic kidney disease
</Condition>
    <Intervention>&lt;br&gt;Trade Name: paricalcitol&lt;br&gt;Product Name: paricalcitol&lt;br&gt;Product Code: RVG 100436&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;Pharmaceutical form of the placebo: Capsule*&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: ramipril&lt;br&gt;Product Name: ramipril&lt;br&gt;Product Code: RVG28004&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Does paricalcitol have an additive antiproteinuric respons to RAAS blockade and low sodium diet?;Secondary Objective: Does paricalcitol prevent the reactive rise in renin during RAAS-blockade?;Primary end point(s): proteinuria</Primary_outcome>
    <Secondary_ID>ViRTUE-2009</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2475621</Internal_Number>
    <TrialID>EUCTR2008-004548-35-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>PHASE II STUDY OF LUTETIUM-177 LABELED CHIMERIC MONOCLONAL ANTIBODY cG250 (177Lu-DOTA-cG250) IN PATIENTS WITH ADVANCED RENAL CANCER
 - Phase II Lutetium</Public_title>
    <Scientific_title>PHASE II STUDY OF LUTETIUM-177 LABELED CHIMERIC MONOCLONAL ANTIBODY cG250 (177Lu-DOTA-cG250) IN PATIENTS WITH ADVANCED RENAL CANCER
 - Phase II Lutetium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Radboud university nijmegen medical centre</Primary_sponsor>
    <Date_registration3>20091130</Date_registration3>
    <Date_registration>30/11/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-004548-35                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/08/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients with proven advanced and progressive renal cell carcinoma of the clear cell type&lt;br&gt;At least one evaluable lesion less than 5 cm&lt;br&gt;Performance status: Karnofsky &gt; 70 % &lt;br&gt;Laboratory values obtained less than 14 days prior to registration:&lt;br&gt;White blood cells (WBC) &gt; 3.5 x 109/l&lt;br&gt;Platelet count &gt; 100 x 109/l&lt;br&gt;Hemoglobin &gt; 6 mmol/l &lt;br&gt;Total bilirubin &lt; 2 x upper limit of normal (ULN) &lt;br&gt;ASAT, ALAT &lt; 3 x ULN (&lt; 5 x ULN if liver metastases present)&lt;br&gt;Serum creatinine &lt; 2 x ULN&lt;br&gt;Negative pregnancy test for women of child¬bearing potential (urine or serum)&lt;br&gt;Age over 18 years &lt;br&gt;Ability to provide written informed consent&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Known metastases to the brain&lt;br&gt;Untreated hypercalcemia&lt;br&gt;Metastatic disease limited to the bone&lt;br&gt;Pre-exposure to murine/chimeric antibody&lt;br&gt;Chemotherapy, external beam radiation, immunotherapy or angiogenesis inhibitors within 4 weeks prior to study. Limited field external beam radiotherapy to prevent pathological fractures is allowed, when unirradiated, evaluable lesions elsewhere are present.&lt;br&gt;Cardiac disease with New York Heart Association classification of III or IV &lt;br&gt;Patients who are pregnant, nursing or of reproductive potential and are not practicing an effective method of contraception&lt;br&gt;Any unrelated illness, e.g. active infection, inflammation, medical condition or laboratory abnormalities, which in the judgment of the investigator will significantly affect patients’ clinical status &lt;br&gt;Life expectancy shorter than 6 months&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with metastatic clear cell renal cell carcinoma &lt;br&gt;MedDRA version: 9.1
Level: PT
Classification code 10050513
Term: Metastatic renal cell carcinoma
</Condition>
    <Intervention>&lt;br&gt;Product Name: cG250&lt;br&gt;Product Code: cG250&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine the clinical efficacy of multiple doses of 177Lu-DOTA-cG250 at MTD in patients with advanced renal cancer using RECIST criteria;Secondary Objective: To determine the toxicity of the treatment as defined by NCI Common Terminology Criteria for Adverse Events (CTCAE v3.0)&lt;br&gt;To determine the targeting and dosimetry of 111In-DOTA-cG250 in patients with advanced renal cancer, as a surrogate for 177Lu-DOTA-cG250 &lt;br&gt;;Primary end point(s): After all 9 patients have finished the study (up to three treatment cycles) the efficacy of the treatment will be determined.</Primary_outcome>
    <Secondary_ID>15081982</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2475872</Internal_Number>
    <TrialID>EUCTR2006-002420-41-AT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Randomized, Open-Label Study to Compare the Safety and Efficacy of Conversion
From a Calcineurin Inhibitor to Sirolimus Versus Continued Use of a Calcineurin
Inhibitor in Cardiac Transplant Recipients With Mild to Moderate Renal Insufficiency</Public_title>
    <Scientific_title>A Randomized, Open-Label Study to Compare the Safety and Efficacy of Conversion
From a Calcineurin Inhibitor to Sirolimus Versus Continued Use of a Calcineurin
Inhibitor in Cardiac Transplant Recipients With Mild to Moderate Renal Insufficiency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Wyeth Research, Division of Wyeth Pharmaceuticals, Inc.</Primary_sponsor>
    <Date_registration3>20060811</Date_registration3>
    <Date_registration>11/08/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002420-41                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>27/09/2006</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Cardiac transplant recipients aged = 18 years. &lt;br&gt;2. Receiving CsA or TAC as part of the maintenance immunosuppressive regimen since the time of transplantation.  &lt;br&gt;3. = 12 Months after cardiac transplantation but = 96 months after transplantation at the time of screening.&lt;br&gt;4. GFR &gt; 40 mL/min but &lt; 90 mL/min/1.73m2 (calculated by the Cockcroft-Gault equation and adjusted for body surface area [BSA] using the Mosteller formula) with stable renal function (as defined by no decrease in &gt; 20% of GFR) over the previous 3 months.&lt;br&gt;5. Left ventricular ejection fraction by echocardiogram (ECHO) = 40%.&lt;br&gt;6. Women of childbearing potential (CBP) must have a negative urine pregnancy test before randomization.&lt;br&gt;7. Women of CBP and men with sexual partners of CBP must agree to use a medically acceptable method of contraception throughout the treatment period.  &lt;br&gt;8. Women of CBP and men with sexual partners of CBP must agree to use a medically acceptable method of contraception for 3 months after discontinuation of assigned treatment. &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Secondary cardiac transplant recipients (subjects who have lost 1 or more previous cardiac transplant).&lt;br&gt;2. Multiple-organ transplant recipients (such as heart-lung, heart-kidney, or heart-after-kidney transplant recipients).&lt;br&gt;3. Treatment of acute rejection within 3 months.&lt;br&gt;4. Evidence of active systemic or localized major infection at the time of randomization.&lt;br&gt;5. Evidence of infiltrate, cavitation or consolidation on chest x-ray film obtained within 3 months before or at the time of the screening evaluation.&lt;br&gt;6. Use of any investigational drug or treatment up to 4 weeks before random assignment.&lt;br&gt;7. Spot urine protein-to-creatinine ratio &gt; 0.5 or proteinuria &gt; 500 mg/day.&lt;br&gt;8. Subjects maintained on CNI monotherapy.&lt;br&gt;9. Prior or current use of mammalian target of rapamycin (mTOR) inhibitors unless administration was part of a "CNI holiday" (a planned temporary switch from a CNI to an mTOR inhibitor to limit exposure to CNIs) lasting no more than 10 days.&lt;br&gt;10. Known hypersensitivity to sirolimus or its derivatives or macrolide antibiotics.&lt;br&gt;11. Treatment with voriconazole, cisapride, or ketoconazole, which are all known to interact with sirolimus, that is not discontinued before randomization.&lt;br&gt;12. Treatment with aminoglycosides, amphotericin B, cisplatin, or other drugs associated with renal dysfunction that is not discontinued before randomization.&lt;br&gt;13. Subjects with screening baseline white blood cell (WBC) count &lt; 3000/mm3, platelet count &lt; 100,000/mm3, fasting triglyceride level &gt; 400 mg/dL (4.5 mmol/L), or total cholesterol level &gt; 300 mg/dL (7.6 mmol/L).&lt;br&gt;14. History of malignancy within 3 years before enrollment (except for adequately treated basal-cell or squamous-ell carcinoma of the skin).&lt;br&gt;15. Planned used of agents with a known major interaction with sirolimus or CNIs.&lt;br&gt;16. Subjects who are known to be positive for human immunodeficiency virus (HIV).&lt;br&gt;</Exclusion_Criteria>
    <Condition>Cardiac transplant recipients with mild to moderate renal insufficiency. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050432
Term: Prophylaxis against heart transplant rejection
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: Rapamune&lt;br&gt;Product Code: Rapamune&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: Rapamune&lt;br&gt;Product Code: Rapamune&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To demonstrate the superiority of converting from CNI therapy to sirolimus therapy to continuing CNI therapy with respect to renal function in cardiac transplant recipients with mild to moderate renal dysfunction.;Secondary Objective: To evaluate the safety of conversion from CNI therapy to sirolimus therapy in this patient population.&lt;br&gt;To explore the effect of conversion from CNI therapy to sirolimus therapy on surrogate markers of cardiovascular risk.;Primary end point(s): Change from baseline calculated creatinine clearance (using the Cockcroft-Gault equation and adjusted for BSA using the Mosteller formula) at 52 weeks. </Primary_outcome>
    <Secondary_ID>0468E7-408</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2476533</Internal_Number>
    <TrialID>EUCTR2007-003847-66-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Dose Finding and Randomized, Multicenter, Placebo-Controlled, Phase 2 Study of Enzastaurin and Sunitinib versus Placebo and Sunitinib in Patients with Metastatic Renal Cell Carcinoma - N/A</Public_title>
    <Scientific_title>Dose Finding and Randomized, Multicenter, Placebo-Controlled, Phase 2 Study of Enzastaurin and Sunitinib versus Placebo and Sunitinib in Patients with Metastatic Renal Cell Carcinoma - N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Eli Lilly and company</Primary_sponsor>
    <Date_registration3>20080108</Date_registration3>
    <Date_registration>08/01/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-003847-66                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>28/03/2008</Date_enrollement>
    <Target_size>122</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: Part 1 of the trial : Open   /// Part 2 of the trial : Randomised, Double Blind, Parrallel group&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;[1]	Patients with metastatic RCC who have not received prior treatment with systemic (adjuvant or neoadjuvant) therapy for RCC (including targeted therapy such as tyrosine kinase inhibitors or bevacizumab, immunotherapy, chemotherapy, hormonal, or investigational therapy)&lt;br&gt;[2]	Histologically confirmed RCC with metastases with a component of clear (conventional) cell histology&lt;br&gt;[3]	Evidence of unidimensionally measurable disease (=1 malignant tumor mass that can be accurately measured in at least 1 dimension =20 mm with conventional computed tomography (CT) or magnetic resonance imaging (MRI) scan, or =10 mm with spiral CT scan.  (If spiral CT scan is used, minimum lesion size should be twice the reconstruction interval used.  For example, if reconstruction size is 7 mm, lesion size should be =14 mm).  CT/MRI should be performed within 4 weeks prior to study entry&lt;br&gt;Note:  Bone lesions, ascites, peritoneal carcinomatosis or miliary lesions, pleural or pericardial effusions, lymphangitis of the skin or lung, cystic lesions, or irradiated lesions are not considered measurable.&lt;br&gt;[4]	Primary tumor has been surgically removed by nephrectomy or nephron-sparing surgery&lt;br&gt;[5]	ECOG performance status score of 0 or 1 (see Protocol Attachment S061.5)&lt;br&gt;[6]	Have adequate bone marrow, liver, and renal function, as assessed by the following laboratory requirements, to be conducted within 7 days prior to treatment:  (ULN/LLN = upper/lower limit of normal)&lt;br&gt;?	Hemoglobin &gt;9.0 g/dL&lt;br&gt;?	Absolute neutrophil count (ANC) =1.5 x 103 µL&lt;br&gt;?	Platelet count =100 x 103/µL&lt;br&gt;?	Total bilirubin =1.5 x ULN&lt;br&gt;?	Serum calcium within 10% of normal range?&lt;br&gt;?	Serum creatinine =2 x ULN&lt;br&gt;?	Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =3 x ULN (or &lt;5 x ULN for patients with liver involvement of their cancer)&lt;br&gt;?	Prothrombin Time (PT) or International Normalized Ratio (INR) and activated Partial Thromboplastin Time (aPTT) = 1.5 x ULN&lt;br&gt;?	Left ventricular ejection fraction (LVEF) = LLN as defined by the institution performing the scan, as assessed by Multiple Gated Acquisition (MUGA) scan, or from echocardiogram&lt;br&gt;[7]	Estimated life expectancy of at least 12 weeks&lt;br&gt;[8]	Patient compliance and geographic proximity that allow for adequate follow-up&lt;br&gt;[9]	Patients must sign an informed consent document&lt;br&gt;[10]	Patients must be at least 18 years of age&lt;br&gt;[11]	Women of childbearing potential (not surgically sterilized and between menarche and 1 year postmenopause) must test negative for pregnancy within 7 days prior to or at the time of enrollment, based on either a serum or urine pregnancy test.  Both male and female patients of reproductive potential must agree to use a reliable method of birth control, as determined by the patient and his or her health-care team, during the study and for 3 months following the last dose of study treatment&lt;br&gt;[12]	No prior malignancies for =5 years with the exception of cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis, and T1) or any cancer curatively treated =5 years prior to study entry.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;[13]	Have received prior treatment with sunitinib or enzastaurin&lt;br&gt;[14]	Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry&lt;br&gt;[15]	Have had any of the following within 12 months prior to study drug administration:  myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (CHF), cerebrovascular accident, transient ischemic attack, or pulmonary embolism&lt;br&gt;Note:  Ongoing treatment with therapeutic doses of Coumadin? (warfarin) or a derivative of Coumadin or phenprocoumon is not allowed, but prophylactic, low-dose Coumadin (= 2 mg daily) for deep vein thrombosis is allowed.  In such cases, PT/INR should be very closely monitored as clinically indicated.&lt;br&gt;[16]	Ongoing cardiac arrhythmias &gt;New York Health Association Class II (Protocol Attachment S061.6), atrial fibrillation of any grade, or prolongation of the QTc interval to &gt;450 msec for males or &gt;470 msec for females&lt;br&gt;[17]	Have uncontrolled hypertension (&gt;150/100 mm/Hg despite optimal medical therapy), or history of poor compliance with antihypertensive treatment&lt;br&gt;[18]	Have active, clinically serious bacterial or fungal infection more than NCI CTCAE Grade 2 &lt;br&gt;[19]	Have known history of human immunodeficiency virus (HIV) infection or chronic hepatitis B/C&lt;br&gt;[20]	Have history of or known brain metastases, spinal cord compression, carcinomatous meningitis, or evidence of brain or leptomeningeal disease on screening CT or MRI scan&lt;br&gt;[21]	Have history of documented central nervous system disease unrelated to cancer; for example, uncontrolled seizures, unless adequately treated with standard medical therapy&lt;br&gt;[22]	Have evidence of bleeding diathesis, NCI CTCAE Grade 3 hemorrhage &lt;4 weeks of starting the study treatment, coagulopathy, or thromboembolic event&lt;br&gt;[23]	Have medical, psychological, or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results or have a history of substance abuse&lt;br&gt;[24]	Have known or suspected allergy to any agent given in association with this trial&lt;br&gt;[25]	Have any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study (for example, uncontrolled diabetes mellitus, pancreatitis, acute or chronic liver disease), and preexisting thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication&lt;br&gt;[26]	Require concomitant use of potent CYP3A4 inducer, for example, rifampicin or potent CYP3A inhibitors, such as ketoconazole.&lt;br&gt;Note:  Protocol Attachment S061.4 provides an extensive list of CYP3A4 inhibitors or inducers&lt;br&gt;[27]	Significant surgery or radiation therapy &lt;4 weeks of starting study treatment.  Prior palliative radiotherapy to metastatic lesion(s) is/are permitted, provided there is at least 1 measurable lesion that has not been irradiated&lt;br&gt;[28]	Patients who are pregnant or breast feeding&lt;br&gt;[29]	Have impairment of the gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug&lt;br&gt;[30]	Current or recent (within 10 days of first dose of study treatment) daily use of aspirin (&gt;325 mg/day)&lt;br&gt;[31]	Have serious nonhealing wounds, acute or nonhealing ulcers, or bone fractures&lt;br&gt;[32]	Are unable or unwilling to discontinue use of carbamazepine, phenobarbital, or phenytoin at least 14 days prior to study therapy&lt;br&gt;[33]	Are unable to swallow tablets.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal cell carcinoma</Condition>
    <Intervention>&lt;br&gt;Product Name: enzastaurin&lt;br&gt;Product Code: LY317615&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Enzastaurin Hydrochloride&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 125-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Sutent&lt;br&gt;Product Name: Sutent&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: sunitinib&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50 mg -&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of this Phase 2 study is to compare the progression-free survival in enzastaurin and sunitinib therapy versus sunitinib and placebo in the first-line setting for patients with metastatic clear-cell RCC;Secondary Objective: The secondary objectives of the study are:&lt;br&gt;•	to compare the following time-to-event efficacy variables between treatment arms: &lt;br&gt;-	time to tumor progression (TTP)&lt;br&gt;-	overall survival (OS)&lt;br&gt;-	to estimate duration of overall response in each treatment arm &lt;br&gt;•	to compare the objective response rate (complete response [CR] + partial response [PR]) between treatment arms&lt;br&gt;•	to compare the rate of clinical benefit (CR + PR + stable disease [SD]) between treatment arms&lt;br&gt;•	to assess the safety and adverse events in both treatment arms&lt;br&gt;•	to characterize the pharmacokinetics (PK) of enzastaurin and sunitinib when administered in combination&lt;br&gt;•	to assess biomarkers (for example, PKCß, GSK3ß, S6K, PTEN, CREB) relevant to enzastaurin and disease state, and their correlation to clinical outcome.&lt;br&gt;;Primary end point(s): The primary endpoint for Part 1 (Safety lead in) is to evaluate the safety of the combination of enzastaurin plus sunitinib.&lt;br&gt;The primary endpoint for Part 2 is to compare progression-free survival (PFS) between the two arms of treatment. &lt;br&gt;</Primary_outcome>
    <Secondary_ID>H6Q-MC-S061</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2477363</Internal_Number>
    <TrialID>EUCTR2007-005721-30-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral Tonapofylline in Patients with Heart Failure and Renal Insufficiency - POSEIDON</Public_title>
    <Scientific_title>A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral Tonapofylline in Patients with Heart Failure and Renal Insufficiency - POSEIDON                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Biogen Idec</Primary_sponsor>
    <Date_registration3>20090611</Date_registration3>
    <Date_registration>11/06/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005721-30                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/10/2009</Date_enrollement>
    <Target_size>300</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Must give written informed consent and any authorizations required by local law (e.g., Protected Health Information).&lt;br&gt;2. Must be 18 years of age or older.&lt;br&gt;3. Must have a previous diagnosis of HF with symptoms of HF present at screening (i.e., subjects must be graded as NYHA Class II, III, or IV).&lt;br&gt;4. Must meet the following criteria (subjects graded as NYHA Class III or IV at screening must meet one of the following, while subjects graded as NYHA Class II at screening must meet both of the following):&lt;br&gt;• history of hospitalization for HF &gt;1 month and =12 months prior to the screening&lt;br&gt;visit, or documented, unscheduled outpatient treatment with intravenous (IV)&lt;br&gt;diuretics, IV vasodilators, or IV inotropic medications &gt;1 month and =12 months&lt;br&gt;prior to the screening visit&lt;br&gt;• documented BNP =150 pg/mL, or NTproBNP =500 pg/mL, within the 12 months&lt;br&gt;prior to Day 1.&lt;br&gt;5. Must have renal insufficiency as defined by a reduced estimated glomerular filtration rate (eGFR) at the time of screening =20 and =70 mL/min/1.73 m2, as determined by the Modification of Diet in Renal Disease (MDRD) equation (abbreviated version).&lt;br&gt;6. Must be on an oral loop diuretic for at least the 4 weeks prior to Day 1. Dose&lt;br&gt;adjustments are allowed within the 4 weeks prior to Day 1, but the dose on Day 1 must be within 50% to 200% of the dose the subject was receiving at 4 weeks prior to Day 1.&lt;br&gt;The introduction or withdrawal of any other class of diuretic (i.e., thiazide diuretics) is&lt;br&gt;not allowed within the 4 weeks prior to Day 1&lt;br&gt;7. Subjects with a reduced LVEF (=40%) documented during screening must be on a&lt;br&gt;pharmacological treatment regimen for HF for at least the 4 weeks prior to Day 1. The&lt;br&gt;HF regimen must include:&lt;br&gt;• treatment with a beta-blocker, unless contraindicated due to intolerance, and&lt;br&gt;• treatment with an angiotensin converting enzyme (ACE) inhibitor or angiotensin&lt;br&gt;receptor blocker (ARB), unless contraindicated due to intolerance.&lt;br&gt;Note: The dose of any of the HF medications listed above may be adjusted once within the 4 weeks prior to Day 1. This restriction also applies to subjects with LVEF &gt;40% if they are receiving treatment with beta-blockers, ACE inhibitors, and/or ARBs.&lt;br&gt;8. Women of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 2 months after their last dose of study treatment. For further details of contraceptive requirements for this study, please refer to Section 15.5.3. All female subjects of childbearing potential must have a negative pregnancy test on Screening Day and Day 1.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. History of an allergic reaction to any xanthine-containing compound.&lt;br&gt;2. History of seizure within the past 10 years or use of any medication for the suppression of seizures within the past 5 years.&lt;br&gt;3. Within the past 2 years, history of head injury with loss of consciousness, stroke, or transient ischemic attack.&lt;br&gt;4. History of multiple sclerosis, Alzheimer’s disease, mental retardation,&lt;br&gt;meningitis/encephalitis, brain surgery, or penetrating head trauma.&lt;br&gt;5. History of, or prior neuroimaging evidence of, intracranial pathology known to increase the risk of seizure such as brain tumors of any kind (including meningioma),&lt;br&gt;arteriovenous malformation, cerebral cavernous malformation, hydrocephalus, or&lt;br&gt;encephalomalacia.&lt;br&gt;6. History consistent with illicit use of drugs or alcohol abuse within 6 months prior to&lt;br&gt;Day 1.&lt;br&gt;7. Hospitalization for HF within 30 days of Day 1.&lt;br&gt;8. Myocardial infarction (MI) within 30 days of Day 1.&lt;br&gt;9. Hemodynamically destabilizing arrhythmia (e.g., ventricular tachycardia or ventricular fibrillation) within 30 days of Day 1.&lt;br&gt;10. Cardiac surgery within 60 days prior to Day 1.&lt;br&gt;11. Uncorrected hemodynamically significant primary valvular disease.&lt;br&gt;12. Known obstructive or restrictive cardiomyopathy.&lt;br&gt;13. Currently receiving chronic renal replacement therapy (e.g., hemodialysis or peritoneal dialysis).&lt;br&gt;14. Receiving adenosine or xanthine-based agents (e.g., aminophylline, theophylline,&lt;br&gt;pentoxifylline, or dyphylline).&lt;br&gt;15. Receiving clozapine or metronidazole within 5 days of screening, during the screening period, or anticipated use during study drug treatment.&lt;br&gt;16. Regular consumption of excessive amounts of caffeinated beverages (e.g., &gt;72 ounces [2.13 liters or 9 cups] of coffee/day).&lt;br&gt;17. Initiation of cardiac resynchronization treatment within 30 days prior to Day 1.&lt;br&gt;18. Serious systemic infection (e.g., septicemia) or major surgical procedures within the 30 days prior to Day 1.&lt;br&gt;19. Fever, with body temperature &gt;38oC, within the 48 hours prior to first dose.&lt;br&gt;20. Evidence of malignancy within 6 months prior to Day 1. Subjects with a history of&lt;br&gt;stable prostate cancer, basal cell carcinomas, or fewer than 3 squamous cell carcinomas are eligible.&lt;br&gt;21. Likelihood, in the Investigator’s opinion, of undergoing cardiac transplantation, left ventricular assist device (LVAD) or other device implantation, or other cardiac surgerywithin next 3 months; or of requiring continuous IV inotropic treatment, or referral for hospice or end of life treatment.&lt;br&gt;22. Sustained systolic blood pressure &gt;170 or &lt;90 mmHg at Screening Day or Day 1.&lt;br&gt;23. Screening laboratory findings as follows (Screening laboratory tests should be&lt;br&gt;performed at the central laboratory):&lt;br&gt;• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =3 times the&lt;br&gt;upper limit of normal, or&lt;br&gt;• Total bilirubin &gt;2.0 mg/dL.&lt;br&gt;24. Nursing mothers, pregnant women, or women planning on becoming pregnant during&lt;br&gt;the study.&lt;br&gt;25. Participation in any other investigational study of drugs or devices within 30 days prior&lt;br&gt;to Day 1.&lt;br&gt;26. Unwillingness to comply with protocol-required procedures.&lt;br&gt;27. Presence of any clinically significant (as determined by the Investigator)&lt;br&gt;endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary,&lt;br&gt;neurologic, dermatologic, psychiatric, and/or other major disease that might interfere&lt;br&gt;with optimal safe participation in this study.&lt;br&gt;28. Other unspecified reasons that, in the opinion of the Investigator or Biogen Idec, make the subject un</Exclusion_Criteria>
    <Condition>Heart Failure and Renal Insufficiency. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038474
Term: Renal insufficiency
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10019279
Term: Heart failure
</Condition>
    <Intervention>&lt;br&gt;Product Name: Adentri&lt;br&gt;Product Code: Tonapofylline&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;CAS Number: 340021-17-2&lt;br&gt;Current Sponsor code: Tonapofylline&lt;br&gt;Other descriptive name: Adentri&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 7.5-&lt;br&gt;Pharmaceutical form of the placebo: Capsule, hard&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Product Name: Adentri&lt;br&gt;Product Code: Tonapofylline&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;CAS Number: 340021-17-2&lt;br&gt;Current Sponsor code: Tonapofylline&lt;br&gt;Other descriptive name: Adentri&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 37.5-&lt;br&gt;Pharmaceutical form of the placebo: Capsule, hard&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of this study is to assess the safety and tolerability of Tonapofylline administered to subjects with heart failure and renal insufficiency;Secondary Objective: The secondary objectives of this study are to assess the effect of Tonapofylline on the following in subjects with heart failure and renal insufficiency:&lt;br&gt;• Quality of life as assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ)&lt;br&gt;• Exercise capacity as measured by 6-minute walk distance&lt;br&gt;• Renal function as assessed by serum creatinine and Cystatin-C&lt;br&gt;• Concomitant medications used to treat heart failure;Primary end point(s): The safety and tolerability of Tonapofylline administered to subjects with stable heart failure and renal insufficiency. This objective will be evaluated by the incidence of AEs and SAEs, clinically abnormal physical examinations and vital signs, shifts to outside the normal ranges in laboratory parameters, and electrocardiogram results.</Primary_outcome>
    <Secondary_ID>161HF201</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2477996</Internal_Number>
    <TrialID>EUCTR2008-008676-13-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Phase II Study Of Sunitinib And Low Dose Metronomic Cyclophosphamide In Advanced Renal Cell Cancer - SUN-CYCL (Sunitinib + Cyclophosphamide in RCC)</Public_title>
    <Scientific_title>A Phase II Study Of Sunitinib And Low Dose Metronomic Cyclophosphamide In Advanced Renal Cell Cancer - SUN-CYCL (Sunitinib + Cyclophosphamide in RCC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>The Royal Marsden NHS Foundation Trust</Primary_sponsor>
    <Date_registration3>20090626</Date_registration3>
    <Date_registration>26/06/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-008676-13                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>04/08/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Patients with advanced renal cell carcinoma suitable for 1st line therapy with sunitinib&lt;br&gt;2. Histologically or cytologically confirmed advanced renal cell carcinoma&lt;br&gt;3. The presence of one or more clinically or radiographically measurable lesions&lt;br&gt;4. ECOG performance status 0 or 1&lt;br&gt;5. Life expectancy greater than 12 weeks&lt;br&gt;6. At least 14 days since major surgery and 7 days since skin/tumour biopsy&lt;br&gt;7. The capacity to understand the patient information sheet and the ability to provide written informed consent&lt;br&gt;8. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures&lt;br&gt;9. Male or female, age 18 or greater&lt;br&gt;10. Women must be postmenopausal (no menstrual period for a minimum of 1 year) or have a negative serum pregnancy test on entry in the study (even if surgically sterilized).  Men and women of childbearing potential must use adequate birth control measures (e.g. abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, implantable or injectable contraceptives or surgical sterilization) for the duration of the study and should continue such precautions for 6 months after receiving the last study treatment&lt;br&gt;11. Serum aspartate transaminase (AST) and alanine transaminase (ALT) =2.5 x upper limit of normal (ULN) &lt;br&gt;12. Total serum bilirubin =1.5 x ULN &lt;br&gt;13. Serum creatinine =1.5 x ULN &lt;br&gt;14. Haemoglobin =9.0 g/dL&lt;br&gt;15. Absolute neutrophil count =1.5 x 109/L &lt;br&gt;16. Platelets =100 x 109/L  &lt;br&gt;17. Prothrombin time (PT) =1.5 x ULN &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Current signs or symptoms of severe progressive or uncontrolled hepatic, haematologic, gastrointestinal, endocrine, pulmonary or cardiac disease other than directly related to RCC&lt;br&gt;2. Intracranial disease, unless there has been radiological evidence of stable intracranial disease &gt; 6 months. In the case of a solitary brain metastasis, evidence of a disease-free interval of at least 3 months post surgery.  All patients previously treated for brain metastases must be stable off corticosteroid therapy for at least 28 days&lt;br&gt;3. Previous systemic treatment for metastatic renal cell carcinoma.  Palliative radiotherapy to symptomatic disease sites is permitted&lt;br&gt;4.  Women who are pregnant, nursing, or planning pregnancy within 6 months after the last treatment (this includes men who plan to father a child within 6 months of the last treatment) &lt;br&gt;5. Malignancy other than the condition being treated or a history of malignancy within the previous 5 years, with the exception of basal cell or squamous cell carcinoma of the skin that has been fully excised with no evidence of recurrence&lt;br&gt;6. Use of any investigational drug within 30 days prior to screening &lt;br&gt;7. History of alcohol or substance abuse within the preceding 6 months that, in the opinion of the investigator, may increase the risks associated with study participation or study agent administration, or may interfere with interpretation of results &lt;br&gt;8. Uncontrolled hypertension or hypertension treated with 2 or more anti-hypertensive agents&lt;br&gt;</Exclusion_Criteria>
    <Condition>Metastatic Renal Cell Carcinoma &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050513
Term: Metastatic renal cell carcinoma
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sutent&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Sunitinib&lt;br&gt;CAS Number:  341031-54-7&lt;br&gt;Current Sponsor code: Sunitinib&lt;br&gt;Other descriptive name: Sutent&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Cyclophosphamide&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: CYCLOPHOSPHAMIDE&lt;br&gt;CAS Number: 50180&lt;br&gt;Current Sponsor code: CYCLOPHOSPHAMIDE&lt;br&gt;Other descriptive name: CYCLOPHOSPHAMIDE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50.0-&lt;br&gt;&lt;br&gt;Trade Name: Sutent&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Sunitinib&lt;br&gt;CAS Number:  341031-54-7&lt;br&gt;Current Sponsor code: Sunitinib&lt;br&gt;Other descriptive name: Sutent&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 12.5-&lt;br&gt;&lt;br&gt;Trade Name: Sutent&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Sunitinib&lt;br&gt;CAS Number:  341031-54-7&lt;br&gt;Current Sponsor code: Sunitinib&lt;br&gt;Other descriptive name: Sutent&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Maximum tolerated dose (MTD) of the combination of sunitinib and cyclophosphamide and response rate (complete and partial response);Secondary Objective: 1) Toxicity of treatment&lt;br&gt;2) Progression-free and overall survival&lt;br&gt;3) Correlation between biological markers in original nephrectomy specimen (if available) or on-study biopsies with clinical outcome and serum biomarkers including circulating tumour cells&lt;br&gt;4) CT and PET assessment of tumour blood flow / disease activity&lt;br&gt;5) Recrudescence of symptoms/signs during the 2 week interval off sunitinib&lt;br&gt;;Primary end point(s): Maximum tolerated dose (MTD) of the combination of sunitinib and cyclophosphamide and response rate (complete and partial response)</Primary_outcome>
    <Secondary_ID>CCR3164</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2478268</Internal_Number>
    <TrialID>EUCTR2009-009516-44-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A randomised, open label, parallel group Phase II study comparing the
efficacy and tolerability of BIBF 1120 versus sunitinib in previously
untreated patients with Renal Cell Cancer. - BIBF 1120 in 1st line Renal Cell Carcinoma</Public_title>
    <Scientific_title>A randomised, open label, parallel group Phase II study comparing the
efficacy and tolerability of BIBF 1120 versus sunitinib in previously
untreated patients with Renal Cell Cancer. - BIBF 1120 in 1st line Renal Cell Carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Boehringer Ingelheim</Primary_sponsor>
    <Date_registration3>20090901</Date_registration3>
    <Date_registration>01/09/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009516-44                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>27/10/2009</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Patients with unresectable or metastatic Renal Cell Cancer, who have &lt;br&gt;                received no previous systemic anti-cancer treatment.&lt;br&gt;•	Histological-confirmed diagnosis of renal cell cancer with clear cell &lt;br&gt;                component.&lt;br&gt;•	Age = 18 years.  &lt;br&gt;•	ECOG Performance Score 0 or 1.&lt;br&gt;•	Life expectancy of at least 3 months&lt;br&gt;•	Must have measurable disease according to RECIST, i.e. presence of at &lt;br&gt;                least  one target lesion according to RECIST criteria in a previously &lt;br&gt;                non-irradiated area&lt;br&gt;•	Serum creatinine &lt; 2 x ULN.&lt;br&gt;•	Written informed consent consistent with ICH-GCP guidelines.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	Serious illness or concomitant non-oncological disease such as neurologic, &lt;br&gt;                psychiatric, infectious disease or active ulcers (gastro-intestinal tract, &lt;br&gt;                skin) or laboratory abnormality that may increase the risk associated with &lt;br&gt;                study participation or study drug administration and in the judgment of     &lt;br&gt;                the investigator would make the patient inappropriate for entry into the &lt;br&gt;                study.&lt;br&gt;•	Major injuries, bone fracture and/or surgery within past 4 weeks or/ and &lt;br&gt;                planned surgical procedures during the study period.&lt;br&gt;•	Hypersensitivity to BIBF 1120, sunitinib or the excipients of the study &lt;br&gt;                drugs.&lt;br&gt;•	Significant cardiovascular diseases (i.e. uncontrolled hypertension, &lt;br&gt;                unstable angina, history of infarction within past 12 months, congestive &lt;br&gt;                heart failure &gt; NYHA II, serious cardiac arrhythmia).&lt;br&gt;•	LV-EF (left ventricular ejection fraction) by ECHO or MUGA below local &lt;br&gt;                 limits of normal.&lt;br&gt;•	Hepatic function: total bilirubin outside of normal limits; ALT and &lt;br&gt;                AST &gt; 1.5x upper limit of normal (ULN) in patients without liver metastasis.&lt;br&gt;                For patients with liver metastasis: total bilirubin outside of normal &lt;br&gt;                limits, ALT and AST &gt; 2.5x ULN.  &lt;br&gt;•	Coagulation parameters: international normalised ratio (INR) &gt; 2,&lt;br&gt;                prothrombin time (PT) and partial thromboplastin time (PTT) &gt; 50% of &lt;br&gt;                deviation of institutional ULN. &lt;br&gt;•	Absolute neutrophil count (ANC) &lt; 1500/ml, Platelets &lt;100000/ml, &lt;br&gt;                Haemoglobin &lt;9.0 g/dl.  &lt;br&gt;•	History of clinically significant haemorrhagic or thromboembolic event in  &lt;br&gt;                the past 6 months. &lt;br&gt;•	Known inherited predisposition to bleeds or to thrombosis.&lt;br&gt;•	History of clinically significant haemoptysis within the last 3 months (more&lt;br&gt;                than one tea-spoon of fresh blood per day)&lt;br&gt;•	Therapeutic anticoagulation (except low-dose heparin and/or heparin flush &lt;br&gt;                as needed for maintenance of an in-dwelling intravenous device) or anti-&lt;br&gt;                platelet therapy (except for low-dose therapy with acetylsalicylic acid &lt;br&gt;                &lt; 325mg per day).&lt;br&gt;•	Previous treatment for RCC with targeted agents (in particular including &lt;br&gt;                any antibody and any VEGF/VEGFR, EGFR and mTOR inhibitors), &lt;br&gt;                immunotherapy [Interferon (IFNa) or Interleukin-2 (IL-2)] or chemotherapy.&lt;br&gt;•	Treatment with other investigational drugs or participation in another &lt;br&gt;                clinical study within the past 4 weeks before start of therapy or &lt;br&gt;                concomitantly with this study.&lt;br&gt;•	Patients unable to comply with the protocol.&lt;br&gt;•	Pregnancy or breast feeding.&lt;br&gt;•	Active alcohol or drug abuse.&lt;br&gt;•	Women of child bearing potential, or men who are able to father a child, &lt;br&gt;                unwilling to use a medically acceptable form of contraception during the &lt;br&gt;                study period.&lt;br&gt;•	Symptomatic central nervous system (CNS) metastatis or leptomeningeal &lt;br&gt;                disease as documented by CT, MRI or analysis of cerebrospinal fluid &lt;br&gt;                requiring radiotherapy, steroids or anticonvulsive treatment.&lt;br&gt;•	Radiotherapy within the previous 4 weeks.&lt;br&gt;•	QTcF interval &gt; 500 ms at screening&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Advanced unresectable or metastatic Renal Cell Cancer in patients who have received no previous systemic anti-cancer treatment. &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10050513
Term: Metastatic renal cell carcinoma
</Condition>
    <Intervention>&lt;br&gt;Product Name: N/A&lt;br&gt;Product Code: BIBF 1120&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;CAS Number: 656247-18-6&lt;br&gt;Current Sponsor code: BIBF 1120&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Code: BIBF 1120&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;CAS Number: 656247-18-6&lt;br&gt;Current Sponsor code: BIBF 1120&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 150-&lt;br&gt;&lt;br&gt;Trade Name: Sutent&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: SUNITINIB&lt;br&gt;CAS Number: 557795-19-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 12.5-&lt;br&gt;&lt;br&gt;Trade Name: Sutent&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: SUNITINIB&lt;br&gt;CAS Number: 557795-19-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the efficacy and safety of BIBF 1120 and sunitinib to treat patients with Renal Cell Cancer. An additional objective of the 1199.26 study is to assess the effects of BIBF 1120 treatment on the QTcF interval.&lt;br&gt;&lt;br&gt;;Secondary Objective: Efficacy&lt;br&gt;- Progression Free Survival.&lt;br&gt;- Objective tumour response.&lt;br&gt;- Duration of Objective Response.&lt;br&gt;- Overall Survival.&lt;br&gt;- Time to treatment failure.&lt;br&gt;- Time to progression.&lt;br&gt;&lt;br&gt;ECG - BIBF 1120 patients only&lt;br&gt;- Change of the QTcF interval from baseline to each patients maximum dose of BIBF 1120 concentration.&lt;br&gt;- Time averaged QTcF interval over 1 to 12 hours.&lt;br&gt;&lt;br&gt;Safety&lt;br&gt;- Frequency of all Adverse Events, including laboratory parameters, graded by NCI-CTCAEv3.&lt;br&gt;- Dose related dose reductions and discontinuation rates.&lt;br&gt;- Number and duration of hosptal stays due to Adverse Events.&lt;br&gt;&lt;br&gt;Pharmacokinetics&lt;br&gt;- PK characteristics of BIBF 1120 after a single dose and at steady state (Day 15).;Primary end point(s): 1. Progression Free Survival in patients treated with either sunitinib or BIBF 1120.&lt;br&gt;&lt;br&gt;2. For patients treated with BIBF 1120 only - Change from baseline to endpoint (day 15) of the QTcF interval at each point in time.</Primary_outcome>
    <Secondary_ID>1199.26</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2478421</Internal_Number>
    <TrialID>EUCTR2009-013219-37-HU</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma</Public_title>
    <Scientific_title>A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>AVEO Pharmaceuticals, Inc.</Primary_sponsor>
    <Date_registration3>20091013</Date_registration3>
    <Date_registration>13/10/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-013219-37                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>02/02/2010</Date_enrollement>
    <Target_size>500</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. = 18-years of age.&lt;br&gt;&lt;br&gt;2. Subjects with recurrent or metastatic RCC.&lt;br&gt;&lt;br&gt;3. Subjects must have undergone prior nephrectomy (complete or partial) for excision of the primary tumor.&lt;br&gt;&lt;br&gt;4. Histologically or cytologically confirmed RCC with a clear cell component (subjects with pure papillary cell tumor or other non-clear cell histologies, including collecting duct, medullary, chromophobe, mixed tumor containing predominantly sarcomatoid cells, and unclassified RCC are excluded).&lt;br&gt;&lt;br&gt;5. Measurable disease per the RECIST criteria Version 1.0 (see Appendix A). Measurable disease must be verified by an independent radiologist prior to randomization.&lt;br&gt;&lt;br&gt;6. Treatment naïve subjects or subjects who have received no more than one prior systemic treatment (immunotherapy, including interferon-alfa or interleukin-2 based therapy, chemotherapy, hormonal therapy or an investigational agent) for metastatic RCC. Postoperative or adjuvant systemic therapy will not be counted as a prior therapy unless recurrence is detected within 6 months of completion of treatment, in which case it will be counted as a prior therapy for metastatic disease.&lt;br&gt;&lt;br&gt;7. ECOG performance status of 0 or 1, and life expectancy = 3 months (see Appendix B).&lt;br&gt;&lt;br&gt;8. If female and of childbearing potential, documentation of negative pregnancy test prior to enrollment.&lt;br&gt;&lt;br&gt;9. Ability to give written informed consent and comply with protocol requirements.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Any prior VEGF-directed therapy including VEGF antibody (eg, bevacizumab), VEGF receptor tyrosine kinase inhibitor (eg, sunitinib, sorafenib, axitinib, pazopanib, etc.), VEGF trap (eg, aflibercept), or any other agent or investigational agent targeting the VEGF pathway.&lt;br&gt;&lt;br&gt;2. Any prior therapy with an agent targeting the mTOR pathway (eg, temsirolimus, everolimus, etc)&lt;br&gt;&lt;br&gt;3. Primary CNS malignancies or symptomatic CNS metastases; subjects with previously treated brain metastasis will be allowed if the brain metastasis have been stable without steroid treatment for at least 3 months following prior treatment (radiotherapy or surgery).&lt;br&gt;&lt;br&gt;4. Any listed hematologic abnormalities&lt;br&gt;&lt;br&gt;5. Any listed serum chemistry abnormalities&lt;br&gt;&lt;br&gt;6. Significant cardiovascular disease&lt;br&gt;&lt;br&gt;7. Non-healing wound, bone fracture, or skin ulcer.&lt;br&gt;&lt;br&gt;8. Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other gastrointestinal condition with increased risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to administration of first dose of study drug&lt;br&gt;&lt;br&gt;9. Serious/active infection or infection requiring parenteral antibiotics.&lt;br&gt;&lt;br&gt;10. Inadequate recovery from any prior surgical procedure or major surgical procedure within 4 weeks prior to administration of first dose of study drug.&lt;br&gt;&lt;br&gt;11. Significant thromboembolic or vascular disorders within 6 months prior to administration of first dose of study drug, including but not limited to: Deep vein thrombosis Pulmonary embolism Cerebrovascular accident (CVA) or transient ischemic attach (TIA) Peripheral arterial ischemia &gt; Grade 2 Coronary or peripheral artery bypass graft.&lt;br&gt;&lt;br&gt;12. Significant bleeding disorders within 6 months prior to administration of first dose of study drug, including but not limited to. Hematemesis, hematochezia, melena or other gastrointestinal bleeding Grade =2 Hemoptysis or other pulmonary bleeding Grade =2 Hematuria or other genitourinary bleeding Grade =2&lt;br&gt;&lt;br&gt;13. Currently active second primary malignancy, including hematologic malignancies (leukemia, lymphoma, multiple myeloma, etc.), other than non-melanoma skin cancers, non-metastatic prostate cancer, in situ cervical cancer and ductal or lobular carcinoma in situ of the breast. Subjects are not considered to have a currently active malignancy if they have completed anti-cancer therapy and have been disease free for &gt;2 years.&lt;br&gt;&lt;br&gt;14. Pregnant or lactating females.&lt;br&gt;&lt;br&gt;15. History of genetic or acquired immune suppression disease such as HIV; subjects on immune suppressive therapy for organ transplant.&lt;br&gt;&lt;br&gt;16. Life-threatening illness or organ system dysfunction compromising safety evaluation.&lt;br&gt;&lt;br&gt;17. Requirement for hemodialysis or peritoneal dialysis.&lt;br&gt;&lt;br&gt;18. Inability to swallow pills, malabsorption syndrome or gastrointestinal disease that severely affects the absorption of tivozanib or sorafenib, major resection of the stomach or small bowel, or gastric bypass procedure.&lt;br&gt;&lt;br&gt;19. Psychiatric disorder or altered mental status precluding informed consent or necessary testing.&lt;br&gt;&lt;br&gt;20. Sexually active pre-menopausal female subjects (and female partners of male subjects) must use adequate contraceptive measures, while on study and for at least 50 days after the last dose of study drug. Sexually active male subjects must use adequate contraceptive measures, while on study and for at least 90 days after the last dose of study drug. All fertile male and female subjects must agree to use a h</Exclusion_Criteria>
    <Condition>Advanced Renal Cell Carcinoma &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10038410
Term: Renal cell carcinoma recurrent
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10050513
Term: Metastatic renal cell carcinoma
</Condition>
    <Intervention>&lt;br&gt;Product Name: AV-951&lt;br&gt;Product Code: Tivozanib&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;CAS Number: 682745-41-1&lt;br&gt;Current Sponsor code: Tivozanib (AV-951)&lt;br&gt;Other descriptive name: KRN951&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.0-&lt;br&gt;&lt;br&gt;Product Name: Tivozanib (AV-951)&lt;br&gt;Product Code: 1.5 mg&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;CAS Number: 682745-41-1&lt;br&gt;Current Sponsor code: Tivozanib (AV-951)&lt;br&gt;Other descriptive name: KRN951&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.5-&lt;br&gt;&lt;br&gt;Trade Name: Nexavar&lt;br&gt;Product Name: Nexavar&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: SORAFENIB&lt;br&gt;CAS Number: 284461-73-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the progression-free survival (PFS) of subjects with advanced renal cell cancer (RCC) randomized to treatment with tivozanib or sorafenib;Secondary Objective: To compare the overall survival (OS) of subjects randomized to treatment with tivozanib or sorafenib &lt;br&gt;&lt;br&gt;To compare objective response rate (ORR) and duration of response (DR) of subjects randomized to treatment with tivozanib or sorafenib &lt;br&gt;&lt;br&gt;To compare the safety and tolerability of tivozanib and sorafenib &lt;br&gt;&lt;br&gt;To compare kidney-specific symptoms and health outcome measurements in subjects randomized to treatment with tivozanib or sorafenib &lt;br&gt;&lt;br&gt;To evaluate the pharmacokinetics (PK) of tivozanib;Primary end point(s): To compare the progression-free survival (PFS) of subjects with advanced renal cell cancer (RCC) randomized to treatment with tivozanib or sorafenib</Primary_outcome>
    <Secondary_ID>AV-951-09-301</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2478483</Internal_Number>
    <TrialID>EUCTR2009-016088-13-FI</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Pregabaliinin vaikutus leikkauskipuun ja toipumiseen munuaisensiirtopotilailla</Public_title>
    <Scientific_title>Pregabaliinin vaikutus leikkauskipuun ja toipumiseen munuaisensiirtopotilailla                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Kirurgisen sairaalan munuaisensiirtoihin liittyvän kivun hoidon tutkimusryhmä</Primary_sponsor>
    <Date_registration3>20091020</Date_registration3>
    <Date_registration>20/10/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-016088-13                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>31/12/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Kaikkien tutkimuksen aikana munuaisensiirtoleikkausta varten HYKS Kirurgisen sairaalan osastolle 9 kutsuttujen potilaiden mahdollinen sopivuus tutkimuspotilaiksi arvioidaan.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Krooninen opioidilääkitys, krooninen gabapentinoidien käyttö, kyvyttömyys kommunikoida suomen tai ruotsin kielellä, anestesialääkärin arvioima potilaan kyvyttömyys käyttää PCA (patient controlled analgesia) kivunhoitomenetelmää leikkauksen jälkeen, kyvyttömyys käyttää NRS (numeral rating scale) kivunmittausmenetelmää, allergia pregabaliinille, oksikodonille, propofolille tai remifentaniilille, tai potilaan paino &lt; 40 kg tai &gt; 120 kg.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients who receive kidney transplant &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10023438
Term: Kidney transplant
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10054711
Term: Postoperative pain
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10054048
Term: Postoperative ileus
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10028818
Term: Nausea postoperative
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10061243
Term: Post procedural nausea
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10036238
Term: Postoperative vomiting
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10047707
Term: Vomiting postoperative
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10039897
Term: Sedation
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10040760
Term: Situational anxiety
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10002855
Term: Anxiety
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Lyrica&lt;br&gt;Product Name: Lyrica&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;CAS Number: 148553-50-8&lt;br&gt;Other descriptive name: PREGABALIN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 150-300&lt;br&gt;&lt;br&gt;Trade Name: Diapam&lt;br&gt;Product Name: Diapam&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;CAS Number: 439-14-5&lt;br&gt;Other descriptive name: DIAZEPAM&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 7,5-15&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Tämän prospektiivisen, randomisoidun, kaksoissokkoutetun tutkimuksen tarkoituksena on tutkia pregabaliiniesilääkityksen vaikutusta opioidin kulutukseen 24 tuntia leikkauksen jälkeen, mikä on tutkimuksen päälopputulosmuuttuja. Hypoteesina on että pregabaliinia esilääkkeeksi saaneet potilaat tarvitsevat vähemmän opioideja postoperatiivisesti kuin diatsepaamilla esilääkityt, jolloin opioidien sivuvaikutukset kuten pahoinvointi ja ummetus vähenevät.;Secondary Objective: Lisäksi tutkitaan pregabaliinin vaikutusta jännittyneisyyteen ja väsymykseen ennen leikkausta sekä kipuun, pahoinvointiin, oksenteluun, huimaukseen, väsymykseen, toimin-takykyyn, mielialaan, katetrin aiheuttamaan virtsarakon ärsytykseen ja suolen toimintaan leikkauksen jälkeen. Koska pregabaliini eliminoituu normaalisti munuaisten kautta, määritetään lisäksi sen pitoisuus annostelun jälkeen sen farmakokinetiikan muutosten selvittämiseksi. Hypoteesina on että pregabaliinia esilääkkeeksi saaneet potilaat tarvitsevat vähemmän opioideja postoperatiivisesti kuin diatsepaamilla esilääkityt, jolloin opioidien sivuvaikutukset kuten pahoinvointi ja ummetus vähenevät. Näiden esiintymistä seurataan 14 vuorokauden ajan.;Primary end point(s): Opioidin (PCA-laitteella annostellun oksikodonin) kulutus 24 tuntia leikkauksen jälkeen.</Primary_outcome>
    <Secondary_ID>Kirkipu 09-1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2478485</Internal_Number>
    <TrialID>EUCTR2009-012198-36-DE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Einfluss von Rituximab-Induktion und Lebendspende auf Immunregulation und Viruskontrolle nach Nierentransplantation - eine prospektive Pilotstudie</Public_title>
    <Scientific_title>Einfluss von Rituximab-Induktion und Lebendspende auf Immunregulation und Viruskontrolle nach Nierentransplantation - eine prospektive Pilotstudie                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Universitätsklinikum Giessen und Marburg - Standort Giessen</Primary_sponsor>
    <Date_registration3>20091023</Date_registration3>
    <Date_registration>23/10/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-012198-36                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/01/2010</Date_enrollement>
    <Target_size>75</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: different immunosuppressive regimen are compared&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patienten, die in die Studie aufgenommen werden sollen, müssen die folgenden Einschlusskriterien erfüllen:&lt;br&gt;&lt;br&gt;•	Nierentransplantationen nach postmortaler Spende (Vermittlung über Eurotransplant) und nach Lebendspende (Blutgruppen-kompatibel und Blutgruppen-inkompatibel)&lt;br&gt;•	Erst-, Zweit- und Dritttransplantationen&lt;br&gt;•	immunisierte und nicht immunisierte Transplantatempfänger&lt;br&gt;•	Alter der Empfänger mindestens 18 Jahre&lt;br&gt;•	Negativer Schwangerschaftstest vor Transplantation bei Frauen im gebärfähigen Alter&lt;br&gt;•	Bei Frauen im gebärfähigen Alter: während der ersten 2 Jahre nach Nierentransplantation muss eine anerkannte Kontrazeptionsmethode  wie orale Kontrazeptiva und zusätzliche Barrieremethode durchgeführt werden. Jenseits der 2 Jahre sollte grundsätzlich nur in Absprache mit dem behandelnden Arzt eine Schwangerschaft geplant werden (vorheriges Absetzen von dann kontraindizierten Medikamenten wie Myfortic®, ACE-Hemmer erforderlich, vorherige individuelle Risikoevaluierung) &lt;br&gt;•	Schriftliche Einwilligung zur Teilnahme an der klinischen Prüfung inklusive datenschutzrechtlicher Einwilligung&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patienten, für die eines oder mehrere der folgenden Ausschlusskriterien zutreffen, dürfen nicht in die Studie aufgenommen werden:&lt;br&gt;&lt;br&gt;•	Kontraindikationen gegen die Gabe von Tacrolimus (Tacr) oder Mycophenolsäure (MPS) &lt;br&gt;•	Kontraindikationen gegen die Gabe von Rituximab in der Blutgruppen-inkompatiblen Lebendtransplantations-Gruppe (LD ABOi) &lt;br&gt;•	chronische Infektion mit Hepatitis B-, C- oder HI-Viren&lt;br&gt;•	Anamnese rekurrierender Infektionen&lt;br&gt;•	Z.n. Hepatitis B, falls keine prophylaktische Virustatikagabe erfolgt&lt;br&gt;•	Z.n. Tuberkulose&lt;br&gt;•	Hb&lt;8,5g/dl, Thrombozyten&lt;80.000/ul oder Leukozyten&lt;3000/ul&lt;br&gt;•	Impfung mit Lebendvakzine innerhalb von 4 Wochen vor Transplantation&lt;br&gt;•	Erhebliche gastrointestinale Vorerkrankungen wie z.B. Divertikulitiden (Kontraindikation gegen MPS)&lt;br&gt;•	Kinder und Jugendliche&lt;br&gt;•	Stillende Mütter oder bestehende Schwangerschaft &lt;br&gt;•	Ablehnung einer effektiven Empfängnisverhütung bei Frauen im gebärfähigen Alter &lt;br&gt;•	Kombinierte Transplantationen wie z.B. simultane Nieren-/Inseltransplantationen&lt;br&gt;•	Minderjährige Personen oder volljährige Personen, die nicht in der Lage sind, Wesen, Bedeutung und Tragweite der klinischen Prüfung zu erkennen und ihren Willen hiernach auszurichten (gemäß § 40 Abs. 4 und § 41 Abs. 2 und Abs. 3 AMG)&lt;br&gt;•	Gleichzeitige Teilnahme an anderen klinischen Prüfungen oder Teilnahme in den letzten drei Monaten&lt;br&gt;•	Fehlende Bereitschaft oder Unfähigkeit zur schriftlichen Einwilligung &lt;br&gt;•	Jeder andere klinische Zustand, der nach Ansicht des Prüfarztes die Teilnahme des Patienten bzw. den Abschluss der Therapie in Frage stellen könnte.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Living donor and deceased donor kidney transplantation.
ABO compatible and ABO incompatible kidney transplantation.

</Condition>
    <Intervention>&lt;br&gt;Trade Name: MabThera 100mg&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: RITUXIMAB&lt;br&gt;CAS Number: 174722-31-7&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;Trade Name: MabThera 500mg&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: RITUXIMAB&lt;br&gt;CAS Number: 174722-31-7&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: 1.	Beeinflussung von für das Transplantatoutcome relevanten Immunparametern durch Rituximab bzw. Lebendspende&lt;br&gt;2.	Ausmaß der B-Zell-Elimination durch Rituximab und Verteilung der B-Zell-Subpopulationen in peripherem Blut und iliakalen Lymphknoten &lt;br&gt;3.	Beeinflussung der Virusreplikation (Polyomaviren, EBV, CMV) durch Rituximab bzw. Lebendspende und damit einhergehendes Risiko für eine Polyomavirusnephropathie im Transplantat, ein Posttransplantationslymphom bzw. eine CMV-Erkrankung &lt;br&gt;4.	Beeinflussung der Inzidenz akuter Abstoßungen und einer chronischen Transplantatdysfunktion durch Rituximab bzw. Lebendspende&lt;br&gt;5.	Sicherheit von Rituximab &lt;br&gt;;Secondary Objective: 1.	Patienten- und Transplantatüberleben&lt;br&gt;2.	Transplantatfunktion (Serum-Kreatinin, gemessene Kreatininclearance, ggf. kalkulierte Kreatininclearance)&lt;br&gt;3.	Proteinurie-Ausmaß (quantitative Proteinurie und SDS-PAGE)&lt;br&gt;4.	Inzidenz von akuten Rejektionen (Schweregrad nach Banff, steroidsensitive und –resistente Rejektionen)&lt;br&gt;5.	Inzidenz einer chronischen Transplantatdysfunktion (allmähliche Funktionsverschlechterung &gt;6 Monate nach NTx, in der Regel assoziiert mit arterieller Hypertonie und Proteinurie, möglichst durch Transplantatbiopsie (mit Immunfluoreszenz, d.h. Nachweis von C4d und B-Zellen/Plasmazellen) zu bestätigen; insbesondere Ausschluss anderer Ursachen der Funktionsverschlechterung wie Transplantatnierenarterienstenose (Duplexuntersuchung, ggf. MR-Angiographie) und Rekurrenz der Grunderkrankung)&lt;br&gt;;Primary end point(s): Primäre Endpunkte:&lt;br&gt;1.	Beeinflussung von für das Auftreten einer akuten Rejektion oder chronischen Transplantatdysfunktion prognostisch relevanten immunologischen Parametern (CD4-Helferaktivität, CD4-Zell-IL-4- und –IL-10-Antwort, sCD30, Plasma-Neopterin, IgG-, IgA-anti-Fab, nTreg) &lt;br&gt;2.	Beeinflussung der B-Zell-Antwort (ebenfalls prognostisch relevant), insbesondere durch Rituximab  &lt;br&gt;a.	Donor-spezifische HLA-Antikörper (Assoziation mit chronischer Transplantatdysfunktion und Transplantat-Outcome)&lt;br&gt;b.	B-Zell-Antwort gegen Recall-Antigene (HBs-Antigen, Masern, Varizellen)&lt;br&gt;c.	Mitogenstimulierte B-Zell-Antwort (PWM, SAC I) &lt;br&gt;d.	Inzidenz einer de-novo monoklonalen Gammopathie nach NTx&lt;br&gt;3.	Dosis-Wirkungs-Beziehung von Rituximab (Hauptziel: Verhinderung von Drop-outs bei der ABO-inkompatiblen Lebendnierentransplantation durch Optimierung der Rituximab-Dosierung)&lt;br&gt;a.	Analyse von B-Zell-Subpopulationen vor RTx-Gabe hinsichtlich einer möglichen Assoziation zwischen Verteilung dieser Subpopulationen (z.B. CD19+CD20-CD22+ B-Zellen) und Erreichen einer kompletten B-Zell-Depletion (&lt;8 B-Zellen/µl) im peripheren Blut durch einmalige Rituximab-Gabe (375mg/m2)  &lt;br&gt;b.	Ausmaß der B-Zell-Elimination in iliakalen Lymphknoten und Effekte auf die Verteilung der verschiedenen B-Zell-Subpopulationen &lt;br&gt;c.	Kinetik der Repopulation der B-Zell-Subpopulationen im peripheren Blut (voraussichtlich ca. 1,5 Jahre nach Gabe von  Rituximab)  &lt;br&gt;d.	Assoziation zwischen den erwähnten zu messenden Parametern (B-Zell-Subpopulatinen im peripheren Blut vor RTx-Gabe, B-Zellen und -Subpopulationen in iliakalen Lymphknoten) und der klinischen Wirkung, d.h. &lt;br&gt;•	effektiver Senkung der Isoagglutinintiter gegen die Spenderblutgruppe, zu messen anhand der Zahl benötigter Immunadsorptionen bezogen auf den Ausgangs-Isoagglutinintiter&lt;br&gt;•	Ausbleiben von behandlungsbedürftigen Isoagglutinintiteranstiegen in der 14-tägigen Posttransplantationsperiode&lt;br&gt;4.	Beeinflussung der Virusreplikation (Polyomaviren, EBV, CMV; insbesondere durch Rituximab und damit einhergehendes Risiko für Polyomavirusnephropathie, PTLD und CMV-Erkrankung&lt;br&gt;•	Inzidenz von Polyomavirämie (positive PCR im Plasma) und Virämie-Kinetik im Urin, ggf. Inzidenz von Polyomavirusnephropathie im Transplantat (histologisch zu sichern)&lt;br&gt;•	Kinetik von EBV- und CMV-Virämie im Plasma&lt;br&gt;5.	Sicherheit von Rituximab (Inzidenz von schweren Infektionen (definiert als Notwendigkeit einer stationären Therapie), CMV-Infektionen (einschließlich CMV-Syndrom) und Tumoren; Inzidenz sonstiger  Nebenwirkungen während Verabreichung und danach im Verlauf vor und nach NTx; Inzidenz eines Immunglobulinmangels im Serum)&lt;br&gt;</Primary_outcome>
    <Secondary_ID>NTx-RTx-LD-001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2478496</Internal_Number>
    <TrialID>EUCTR2009-012260-14-SE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>An open, non-randomized phase-2 study of efficacy and safety of treatment with 177Lutetium-DOTA0-Tyr3-octreotate in patients with neuroendocrine tumors</Public_title>
    <Scientific_title>An open, non-randomized phase-2 study of efficacy and safety of treatment with 177Lutetium-DOTA0-Tyr3-octreotate in patients with neuroendocrine tumors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Department of Endocrine Oncology</Primary_sponsor>
    <Date_registration3>20091028</Date_registration3>
    <Date_registration>28/10/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-012260-14                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>27/08/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: yes&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Patients either with carcinoids originating from lung, thymus, stomach, duodenum, small bowel, large bowel, rectum, or&lt;br&gt;•	Patients with endocrine pancreatic tumours, or &lt;br&gt;•	Patients with malignant pheochromocytoma/paraganglioma&lt;br&gt;•	Uptake at least grade 3 according to Krenning sckale (0–4) at OctreoScan, (i.e. somatostatin receptor expression higher than normal liver), not older than 6 months&lt;br&gt;•	Life exspektancy more than 3 months &lt;br&gt;•	WBC &gt;3,0x109/L&lt;br&gt;•	Neutrophils &gt;1,5x109/L&lt;br&gt;•	Platelet count &gt;100x109/L&lt;br&gt;•	Bilirubin &lt;40 µmol/L&lt;br&gt;•	Albumin &gt;25 g/L&lt;br&gt;•	ASAT/ALAT =5 times upper reference limit&lt;br&gt;•	Creatinine &lt;110 µmol/L&lt;br&gt;•	GFR =50 ml/min/1,73&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	Tumors accessible to surgery or radiofrequency ablation&lt;br&gt;•	Decreased renal function: Creatinine &gt;110 µmol/L and/or GFR &lt;50 ml/min/1,73&lt;br&gt;•	Platelet count &lt;100x109/L&lt;br&gt;•	WBC &lt;3,0x109/L&lt;br&gt;•	Neutrophils &lt;1,5x109/L&lt;br&gt;•	Moderately/severely impaired liver function&lt;br&gt;•	Very large tumour load in the liver with high uptake on OctreoScan&lt;br&gt;•	Pregnancy&lt;br&gt;•	Inability to manage the personal hygiene&lt;br&gt;•	Inablity to be isolated for 24 hours&lt;br&gt;•	Proliferation &gt;20–30% (Ki67-positive tumour cells) &lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with malignant neuroendocrine tumours, not amenable to surgical treatment or radiofrequency ablation. Renal, bone marrow and liver function must be sufficient.</Condition>
    <Intervention>&lt;br&gt;Trade Name: 177-LuDOTA-Tyr3-Octreotate&lt;br&gt;Product Name: 177-LuDOTA-Tyr3-Octreotate&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Clarify the effect of the treatment with 177-Lu-DOTA-octreotate, regarding a) tumour size b) biochemical response, c) prognostic factors such as proliferation markers and LD/ALP and type of tumour, d) quality of life, e) survival and f) progression free survival.;Secondary Objective: Optimize the treatment based on a dosimetry protocol developed in Uppsala. Is it possible to safely administer more than the four treatments from the Rotterdam protocol based on this dosmetry model, and can the therapeutic effect be further improved over time?;Primary end point(s): Radiological response rate according to RECIST criteria</Primary_outcome>
    <Secondary_ID>20050418</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2478706</Internal_Number>
    <TrialID>EUCTR2009-016595-77-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Efecto de la combinación estatinas-aspirina versus estatinas-pentoxifilina sobre la lesión aterosclerótica en pacientes con enfermedad renal crónica. - Pentoxifil</Public_title>
    <Scientific_title>Efecto de la combinación estatinas-aspirina versus estatinas-pentoxifilina sobre la lesión aterosclerótica en pacientes con enfermedad renal crónica. - Pentoxifil                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Juan Francisco Navarro González</Primary_sponsor>
    <Date_registration3>20091215</Date_registration3>
    <Date_registration>15/12/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-016595-77                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/03/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Sin tratamiento experimental&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.Edad superior a 18 años.&lt;br&gt;2.ERC estadio 3 ó 4 (FG estimado mediante la expresión MDRD-4 entre 15 y 60 ml/min).&lt;br&gt;3.Presión arterial (PA) &lt; 140/90 mmHg.&lt;br&gt;4.Ausencia de antecedentes clínicos de ECV.&lt;br&gt;5.Tratamiento con estatinas al menos durante los 6 meses previos a la inclusión en el estudio.&lt;br&gt;6.Ausencia de terapéutica inmunosupresora en los 6 meses previos a la inclusión en el estudio.&lt;br&gt;7.Obtención del consentimiento del paciente.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.ECV previa (angina o infarto agudo de miocardio, accidente isquémico transitorio, infarto cerebral  isquémico y/o hemorrágico, claudicación intermitente).&lt;br&gt;2.Enfermedad intercurrente que presuponga ausencia de seguimiento o expectativa de supervivencia menor a 1 año, a juicio del investigador.&lt;br&gt;3.Cirugía previa de las arterias carótidas.&lt;br&gt;4.Haber recibido previamente un trasplante de órganos.&lt;br&gt;5.HTA no controlada, definida como una PA sistólica mayor o igual a 140 mmHg y/o una PA diastólica mayor o igual a 90 mmHg). &lt;br&gt;6.Padecer enfermedades sistémicas (LES, vasculitis, amiloidosis, etc) o tumorales.&lt;br&gt;7.Agudización de la IR crónica por proceso intercurrente en los últimos 6 meses.&lt;br&gt;8.Necesidad de tratamiento concomitante con glucocorticoides o antiinflamatorios no esteroideos en los 3 meses previos a la inclusión en el estudio.&lt;br&gt;9.Mujeres en edad fértil que no utilicen medidas anticonceptivas.&lt;br&gt;10.Mujeres en período de lactancia.&lt;br&gt;11.Aquellos casos en los que el AAS esté contraindicado según ficha técnica (úlcera gastroduodenal activa, crónica o recurrente, y molestias gástricas de repetición; antecedentes de hemorragia o perforación gástrica tras el tratamiento con ácido acetilsalicílico u otros antiinflamatorios no esteroideos; asma; historial de hipersensibilidad a ácido acetilsalicílico, a antiinflamatorios no esteroideos o a tartrazina (reacción cruzada); enfermedades que cursen con trastornos de la coagulación, principalmente, hemofilia o hipoprotrombinemia; insuficiencia hepática grave; pólipos nasales asociados a asma que sean inducidos o exacerbados por ácido acetilsalicílico).&lt;br&gt;12.Aquellos casos en los que el AAS esté contraindicado según ficha técnica ((hipersensibilidad a la pentoxifilina o a otras metilxantinas; hemorragia grave; hemorragia retiniana extensa (riesgo de aumento de la hemorragia); infarto de miocardio reciente).&lt;br&gt;</Exclusion_Criteria>
    <Condition>Enfermedad aterosclerótica en la Enfermedad renal crónica</Condition>
    <Intervention>&lt;br&gt;Product Name: Pentoxifilina&lt;br&gt;Product Code: PTF&lt;br&gt;Pharmaceutical Form: Prolonged-release tablet&lt;br&gt;INN or Proposed INN: Pentoxifilina&lt;br&gt;CAS Number: 6493-05-6&lt;br&gt;Current Sponsor code: PTF&lt;br&gt;Other descriptive name: Pentoxifilina&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 600-&lt;br&gt;&lt;br&gt;Product Name: Acido acetilsalicílico&lt;br&gt;Product Code: AAS&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Acido acetilsalicílico&lt;br&gt;CAS Number: 50-78-2&lt;br&gt;Current Sponsor code: AAS&lt;br&gt;Other descriptive name: Aspirina&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Analizar en pacientes con enfermedad renal crónica, las propiedades anti-ateroscleróticas de 3 regímenes de tratamiento: estatinas, estatinas combinadas con AAS y estatinas combinadas con PTF, mediante la evaluación del grosor íntima-media carotídeo.;Secondary Objective: ·Analizar la potencial repercusión clínica de estos regímenes terapéuticos mediante la evaluación del índice tobillo-brazo.&lt;br&gt;·Estudiar la relación de las concentraciones séricas de biomarcadores inflamatorios con la severidad de la lesión aterosclerótica y su modificación con los regímenes terapéuticos utilizados.&lt;br&gt;·Analizar la expresión de genes de citoquinas pro- y anti-inflamatorias en células mononucleares de sangre periférica y evaluar su relación con la severidad de la lesión aterosclerótica y su modificación con el tratamiento.&lt;br&gt;·Estudiar diversos polimorfimos genéticos de estas citoquinas para valorar su potencial relación con la severidad de la lesión y la respuesta al tratamiento.;Primary end point(s): Grosor del complejo íntima-media carotídeo, siendo considerado éste como la distancia entre la línea ecogénica interna, que representa la interfase luz vascular-íntima, y la línea ecogénica externa, que representa la interfase de la adventicia media, en la vista longitudinal de la carótida  mediante ecografía.</Primary_outcome>
    <Secondary_ID>PTF-AAS-TR-2009</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2478985</Internal_Number>
    <TrialID>EUCTR2009-014732-38-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Ensayo clínico fase IV.II para el análisis de los factores moleculares de pronóstico de respuesta y beneficio clínico en pacientes con cáncer renal metastásico o avanzado, tratados con bevacizumab e interferón como primera línea de tratamiento - REVAMARK</Public_title>
    <Scientific_title>Ensayo clínico fase IV.II para el análisis de los factores moleculares de pronóstico de respuesta y beneficio clínico en pacientes con cáncer renal metastásico o avanzado, tratados con bevacizumab e interferón como primera línea de tratamiento - REVAMARK                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>SOGUG</Primary_sponsor>
    <Date_registration3>20100127</Date_registration3>
    <Date_registration>27/01/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-014732-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/03/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Pacientes que hayan otorgado su consentimiento informado por escrito antes de realizar cualquier procedimiento de selección específico del estudio.&lt;br&gt;2. Pacientes de ambos sexos con edad igual o superior a 18 años.&lt;br&gt;3. Pacientes con esperanza de vida mayor de 12 semanas.&lt;br&gt;4. Pacientes con capacidad de ajustarse al programa de visitas, los tratamientos planeados y las pruebas requeridas.&lt;br&gt;5. Pacientes con cáncer renal metastásico o avanzado (estadio IV o recurrente) confirmado histológica o citológicamente, cuyo componente principal sea el tipo convencional de células claras. Los tumores de histologías mixtas han de ser categorizados por el tipo celular más predominante.&lt;br&gt;6. Pacientes con cáncer renal metastático (estadio IV) o localmente avanzado e inoperable (estadio III) no tratado previamente.&lt;br&gt;7. Pacientes con pronóstico bueno o intermedio definido por la puntuación de Motzer.&lt;br&gt;8. Pacientes con adecuada función hematológica definida por un recuento de neutrófilos absoluto de &gt; o = 1,5x10e9/L y un recuento de plaquetas de &gt; o = 100 x10e9/L.&lt;br&gt;9. Pacientes con valores de hemoglobina &gt; o = 8 g/dL (los pacientes pueden ser transfundidos para el cumplimiento del presente criterio).&lt;br&gt;10. Pacientes con una adecuada función hepática definida por valores de asparragina aminotransferasa (AST) y alanino aminotransferasa (ALT) &lt; 2,5 x LSN o &lt;5 x LSN en pacientes con metástasis de hígado y bilirrubina total &lt; 1,5 x 10e9 x LSN.&lt;br&gt;11. Función renal adecuada: creatinina &lt; o = 1,5 x LSN y proteinuria (test de dipstick) &lt;2+. Los pacientes que tengan proteinuria por el test de dipstick &gt; o = 2+ deberán someterse a una muestra de orina en las 24 horas siguientes  y deben demostrar un descenso de &lt;1 g de proteína a las 24 horas.&lt;br&gt;12. International Normalized Ratio (INR) &lt; o = 1,5; aPTT &lt; o = 1,5xULN.&lt;br&gt;13. Mujeres en edad potencialmente fértil con test de embarazo negativo o que no se encuentren en período de lactancia.&lt;br&gt;14. Pacientes que accedan a usar un método anticonceptivo clínicamente aceptado durante su participación en el estudio y hasta 90 días después de recibir la última dosis de la medicación de estudio.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Pacientes que esten participando en otro ensayo clínico o vayan a participar durante el período del estudio.&lt;br&gt;2. Pacientes pretratados con citoquina o terapia antiangiogénica en primera línea (se permite el tratamiento adyuvante con interferón si la última dosis se recibió al menos 4 meses antes de la inclusión en el estudio).&lt;br&gt;3. Pacientes que hayan sufrido una cirugía mayor (incluida biopsia abierta) o radioterapia en los 28 días previos a la inclusión en el estudio. (Radioterapia paliativa para las lesiones dolorosas de hueso es permitido hasta 14 días previos a la inclusión). El sujeto debe haberse recuperado de la cirugía previa (&gt;28 días) y/o la radiación (&gt;28 días o 14 días) en el momento de la inclusión en el estudio.&lt;br&gt;4. Biopsia excisional u otro procedimiento quirúrgico menor, excluyendo la implantación de un dispositivo de acceso vascular, en los 7 días previos al inicio del tratamiento.&lt;br&gt;5. Pacientes con metástasis cerebrales demostradas radiológicamente (la realización de TAC craneal previo a la entrada en el estudio solamente está indicada si existe sospecha clínica de afectación del SNC).&lt;br&gt;6. Los sujetos con predominancia de rasgos papilares o sarcomatosos, y sujetos con células cromófobas, oncocitomas, tumores del ducto colector, tumores de Bellini o carcinomas de células transicionales.&lt;br&gt;7. Control inadecuado de la hipertensión, definido como un valor de la presión arterial sistólica (PAS) &gt; 150 mmHg y/o &gt; 100 mmHg de la presión arterial diastólica (PAD) con medicación antihipertensiva, o historia previa de crisis antihipertensiva o encefalopatia hipertensiva.&lt;br&gt;8. Historial pasado o actual (dentro de los 5 años previos al comienzo del tratamiento) de otra enfermedad neoplásica excepto cáncer renal(los pacientes con carcinomas curados de células basales y escamosas de la piel o carcinoma de cérvix in situ son eligibles).&lt;br&gt;9. Enfermedad cardiovascular clínicamente significativa, por ejemplo, aneurisma aórtico, disección aórtica, accidente cerebro vascular (ACV), infarto de miocardio, angina inestable, insuficiencia cardiaca congestiva de grado II o superior de la New York Heart Association (NYHA) , fallo cardiaco congestivo, arritmia que requiera medicación, tromboembolismo recurrente  (más de un episodio), coagulopatia o diátesis hemorrágica dentro de los 6 meses anteriores al comienzo del tratamiento.&lt;br&gt;10. Pacientes bajo tratamiento crónico diario de ácido acetil salicílico &gt; 325 mg/día o clopidogrel &gt; 75 mg/día, o de cualquier otro AINE dentro de los 10 días previos a la primera dosis de tratamiento del estudio.&lt;br&gt;11. Historia de fístula abdominal o traqueoesofágica, perforación gastrointestinal o abceso intra-abdominal en los 6 meses previos a la inclusión en el estudio.&lt;br&gt;12. Pacientes con sintomatología grave de heridas no curadas, úlceras o fracturas.&lt;br&gt;13. Hipersensibilidad conocida a alguno de los medicamentos del estudio.&lt;br&gt;14. Serología positiva para VIH (Virus de la Inmunodeficiencia Humana) o pacientes inmunocomprometidos por otro motivo.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Cáncer renal metastásico o avanzado &lt;br&gt;MedDRA version: 9
Level: LLT
Classification code 10050018
Term: Renal cancer metastatic
</Condition>
    <Intervention>&lt;br&gt;Trade Name: AVASTIN 25 mg/ml concentrado para solución para perfusión&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: BEVACIZUMAB&lt;br&gt;Other descriptive name: BEVACIZUMAB&lt;br&gt;Concentration unit: mg/l milligram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Trade Name: ROFERON- A 9 M.U.I. solución inyectable en jeringa precargada&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: INTERFERON ALFA2A&lt;br&gt;CAS Number: 76543-88-9&lt;br&gt;Other descriptive name: INTERFERON ALFA2A&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 9000000-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluar la posible relación entre la supervivencia libre de progresión (SLP) y los patrones de expresión molecular;Secondary Objective: 1. Comparar el valor pronóstico de los diferentes patrones de expresión molecular frente a la clasificación de factores pronóstico de Motzer.&lt;br&gt;2. Establecer las correlaciones entre los diferentes patrones de expresión molecular y la supervivencia global. &lt;br&gt;3. Establecer las correlaciones entre los diferentes patrones de expresión molecular y la respuesta obtenida (RECIST).&lt;br&gt;4. Supervivencia global.&lt;br&gt;5. Tasa de respuesta global, evaluado con los criterios de evaluación de la respuesta en tumores sólidos (RECIST).&lt;br&gt;6. Tiempo hasta la respuesta.&lt;br&gt;7. Duración de la respuesta.&lt;br&gt;8. Número de pacientes que han necesitado reducciones de dosis de cualquiera de los fármacos.&lt;br&gt;9. Perfil de seguridad de los tratamientos;Primary end point(s): El parámetro principal de eficacia es la SLP, definido como el tiempo desde el inicio del tratamiento, hasta que se objetiva enfermedad progresiva según los criterios RECIST.&lt;br&gt;La variable principal del presente estudio se correlacionará con la determinación de los patrones de expresión de HIF, S6, VEGF y de CA IX.</Primary_outcome>
    <Secondary_ID>ML25042</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2479092</Internal_Number>
    <TrialID>EUCTR2009-014249-10-FI</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A randomised double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment naïve locally advanced or metastatic renal cell carcinoma.</Public_title>
    <Scientific_title>A randomised double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment naïve locally advanced or metastatic renal cell carcinoma.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>GlaxoSmithKline Research &amp; Development Ltd</Primary_sponsor>
    <Date_registration3>20100217</Date_registration3>
    <Date_registration>17/02/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-014249-10                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/04/2010</Date_enrollement>
    <Target_size>160</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients eligible for enrolment in the study must meet all of the following criteria:&lt;br&gt;1.Patients must provide written informed consent prior to performance of any study-specific procedures or assessments and must be willing to comply with treatment and follow up. Procedures conducted as part of the patient’s routine clinical management (e.g. blood count, imaging study) and obtained prior to signing of informed consent may be utilised for screening or baseline purposes provided these procedures are conducted as specified in the protocol.&lt;br&gt;2.Received no prior systemic therapy (including interleukin-2, interferon-a, chemotherapy, bevacizumab, mTOR inhibitor, sunitinib, sorafenib or other VEGF TKI) for advanced or metastatic RCC. Patients who received adjuvant treatment with a cancer vaccine are eligible.&lt;br&gt;3.Locally advanced (defined as disease not amenable to curative surgery or radiation therapy) or metastatic renal cell carcinoma of any histology (equivalent to Stage IV RCC according to AJCC staging). Patients with non-measurable disease are allowed if metastatic disease can be confirmed.&lt;br&gt;4.ECOG PS of 0 or 1&lt;br&gt;5.Age =18 years&lt;br&gt;6.A female is eligible to enter and participate in this study if she is of:&lt;br&gt;Non-childbearing potential (i.e. physiologically incapable of becoming pregnant)Childbearing potential, including any female who has had a negative serum pregnancy test within two weeks prior to the first dose of study treatment, preferably as close to the first dose as possible and agrees to use adequate contraception (A list of GSK acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of the physician, are given in the appendix 11.4 of the protocol).&lt;br&gt;7.Adequate organ system functions as defined in Table 2 of the protocol.&lt;br&gt;8.Total serum calcium concentration &lt;12.0mg/dL&lt;br&gt;9.Left ventricular ejection fraction (LVEF) =lower limit of institutional normal (LLN) as assessed by echocardiography (ECHO) or multigated acquisition (MUGA) scan. The same modality used at baseline must be applied for subsequent evaluations.&lt;br&gt;10.Patient is able to swallow and retain oral tablets&lt;br&gt;Patients in France: A patient will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category or of a health insurance valid in France.&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.Poor MSKCC risk group&lt;br&gt;2.History of another malignancy.&lt;br&gt;Note: Patients who have had another malignancy and have been disease-free for 3 years or patients with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible.&lt;br&gt;3.History or clinical evidence of central nervous system (CNS) metastases.&lt;br&gt;Note: Patients who have previously-treated CNS metastases (surgery ± radiotherapy, radiosurgery, or gamma knife) and meet all 3 of the following criteria are eligible:&lt;br&gt;a.Are asymptomatic,&lt;br&gt;b.Have had no evidence of active CNS metastases for =6 months prior to enrolment ,&lt;br&gt;c.Have no requirement for steroids or enzyme-inducing anticonvulsants (EIAC).&lt;br&gt;4.Any clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding or affect absorption of investigational product including, but not limited to:&lt;br&gt;a.Malabsorption syndrome&lt;br&gt;b.Major resection of the stomach or small bowel that could affect the absorption of study drug&lt;br&gt;c.Active peptic ulcer disease&lt;br&gt;d.Inflammatory bowel disease&lt;br&gt;e.Ulcerative colitis, or other gastrointestinal conditions with increased risk of perforation&lt;br&gt;f.History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 28 days prior to beginning study treatment.&lt;br&gt;5.Presence of uncontrolled infection.&lt;br&gt;6.Corrected QT interval (QTc) &gt;480 msecs using Bazett’s formula&lt;br&gt;7.History of one or more of the following cardiovascular conditions within the past 6 months:&lt;br&gt;a.Cardiac angioplasty or stenting&lt;br&gt;b.Myocardial infarction&lt;br&gt;c.Unstable angina &lt;br&gt;d.Coronary artery bypass graft surgery&lt;br&gt;e.Symptomatic peripheral vascular disease&lt;br&gt;f.Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA)&lt;br&gt;8.Poorly controlled hypertension (defined as systolic blood pressure (SBP) of &gt; 150mmHg or diastolic blood pressure (DBP) of &gt; 90mmHg) at baseline.&lt;br&gt;Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. Blood pressure must be re-assessed on two occasions that are separated by a minimum of 1 hour within a visit. The mean SBP/DBP values from each blood pressure assessment must be =150/90mmHg in order for a patient to be eligible for the study. &lt;br&gt;9.History of cerebrovascular accident (CVA) including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.&lt;br&gt;Note: Patients with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible.&lt;br&gt;10.Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major).&lt;br&gt;11.Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels.&lt;br&gt;12.Evidence of active bleeding or bleeding diathesis.&lt;br&gt;13.Significant haemoptysis within 6 weeks prior to first dose of study drug.&lt;br&gt;14.Any serious and/or unstable pre-existing medical, psychiatric, or other conditions that could interfere with patient’s safety, obtaining informed consent or compliance to the study.&lt;br&gt;15.Use any prohibited medications within 14 days of the first dose of study medication.&lt;br&gt;16.Use of an investigational agent, including an investigational anti-cancer agent, within 28 days or 5 half-lives, whichever is longer, prior to the first dose of study drug.&lt;br&gt;17.Radiation therapy, surgery or tumour embolisation within 14 da</Exclusion_Criteria>
    <Condition>Locally Advanced and/or Metastatic Renal Cell Carcinoma &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10050513
Term: Metastatic renal cell carcinoma
</Condition>
    <Intervention>&lt;br&gt;Product Name: Pazopanib&lt;br&gt;Product Code: GW786034&lt;br&gt;Pharmaceutical Form: Over encapsulated tablet&lt;br&gt;INN or Proposed INN: Pazopanib&lt;br&gt;CAS Number: 635702-64-6&lt;br&gt;Current Sponsor code: GW786034B&lt;br&gt;Other descriptive name: Pazopanib Hydrochloride&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Sutent&lt;br&gt;Pharmaceutical Form: Over encapsulated tablet&lt;br&gt;INN or Proposed INN: SUNITINIB&lt;br&gt;CAS Number: 557795-19-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 12.5-&lt;br&gt;Pharmaceutical form of the placebo: Over encapsulated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Product Name: Pazopanib&lt;br&gt;Product Code: GW786034&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Pazopanib&lt;br&gt;CAS Number: 635702-64-6&lt;br&gt;Current Sponsor code: GW786034B&lt;br&gt;Other descriptive name: Pazopanib Hydrochloride&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess how the tolerability and safety differences between pazopanib and sunitinib translate into patient preference.;Primary end point(s): •Patient preference (pazopanib vs. sunitinib) as assessed by patient preference questionnaire;Secondary Objective: •To evaluate the reason for patient preference as assessed by a patient preference questionnaire&lt;br&gt;•To evaluate fatigue as assessed by FACIT-Fatigue and quality of life as assessed by EuroQoL EQ-5D. &lt;br&gt;•To evaluate dose modifications and time to dose modification &lt;br&gt;•To evaluate the safety and tolerability (including AEs, SAEs, withdrawal of treatment due to AE, vital signs, ECG and clinical laboratory).&lt;br&gt;</Primary_outcome>
    <Secondary_ID>VEG113046</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2479140</Internal_Number>
    <TrialID>EUCTR2009-017387-16-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>To assess ease of use, acceptability and preference of  Norditropin  NordiFlex®  in subjects on prescribed growth hormone therapy</Public_title>
    <Scientific_title>To assess ease of use, acceptability and preference of  Norditropin  NordiFlex®  in subjects on prescribed growth hormone therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Novo Nordisk Pharmaceutique S.A.S</Primary_sponsor>
    <Date_registration3>20100223</Date_registration3>
    <Date_registration>23/02/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-017387-16                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>31/08/2010</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Only children whom Norditropin® treatment is indicated in accordance with labelling will be included in this study&lt;br&gt;•	Children receiving growth hormone therapy for at least one year&lt;br&gt;•	Age = 6 years&lt;br&gt;written informed consent&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	Contraindications to Norditropin® growth hormone therapy as stated in the summary of product characteristics.&lt;br&gt;•	Patients who have previously been enrolled in this study.      &lt;br&gt;•	The receipt of any investigational medicinal product within 3 months prior to this trial.&lt;br&gt;•	Suffer from a life threatening disease &lt;br&gt;</Exclusion_Criteria>
    <Condition>children aged 6 years or more receiving growth hormone therapy for the following approved indications (according to Norditropine SPC)
-GHD
-Turner Syndrome
-small for gestational age
-chronic renal insufficiency</Condition>
    <Intervention>&lt;br&gt;Trade Name: Norditropine NordiFleX&lt;br&gt;Product Name: Norditropine NordiFleX&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: somatropin&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 6.7-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of this study is to investigate how easy/difficult patients/parents assess growth hormone injection using Norditropin NordiFlex® by quantifying the proportion of patients that find growth hormone injection using Norditropin NordiFlex® easy or very easy as assessed by patient/parent questionnaire at the end of study.;Secondary Objective: •	Patient/parent overall acceptance/convenience of Norditropin NordiFlex® as assessed by questionnaire at the end of study.&lt;br&gt;•	Patients’/parents’ preference to use Norditropin NordiFlex® in comparison to the previous delivery systems.&lt;br&gt;•	Influence of NordiFlex PenMate® on overall acceptability/convenience&lt;br&gt;•	Compliance to treatment as assessed by patient/parent diary and drug accountability at the end of study &lt;br&gt;•	Ease of teaching how to use Norditropin NordiFlex® as assessed by nurse questionnaires at baseline visit.&lt;br&gt;•	Evaluation of tolerability, when using Norditropin NordiFlex® by collecting adverse events, serious adverse events, MESI and Clinical Technical Complaints.&lt;br&gt;;Primary end point(s): is to investigate how easy/difficult patients/parents assess growth hormone injection using Norditropin NordiFlex® by quantifying the proportion of patients that find growth hormone injection using Norditropin NordiFlex® easy or very easy as assessed by patient/parent questionnaire at the end of study.</Primary_outcome>
    <Secondary_ID>GH-3826</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2479352</Internal_Number>
    <TrialID>EUCTR2006-003515-44-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Cardioprotective effect of sevoflurane versus propofol used during anesthesia and the postoperative period in patients undergoing coronary bypass surgery. Impact on critical care unit stay. A double-blind, randomized, controlled, prospective clinical study.
Efecto cardioprotector del sevoflurano frente al propofol, utilizados durante la anestesia y el periodo postoperatorio en pacientes sometidos a cirugía de bypass coronario. Repercusión sobre la estancia en la unidad de críticos. Estudio clínico, prospectivo, controlado, randomizado y doble ciego.</Public_title>
    <Scientific_title>Cardioprotective effect of sevoflurane versus propofol used during anesthesia and the postoperative period in patients undergoing coronary bypass surgery. Impact on critical care unit stay. A double-blind, randomized, controlled, prospective clinical study.
Efecto cardioprotector del sevoflurano frente al propofol, utilizados durante la anestesia y el periodo postoperatorio en pacientes sometidos a cirugía de bypass coronario. Repercusión sobre la estancia en la unidad de críticos. Estudio clínico, prospectivo, controlado, randomizado y doble ciego.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>FRANCISCO JAVIER BELDA</Primary_sponsor>
    <Date_registration3>20100305</Date_registration3>
    <Date_registration>05/03/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-003515-44                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/12/2006</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Signed informed consent (patient or relatives)&lt;br&gt;2. Aged 18 years or older &lt;br&gt;3. Minimum postoperative sedation of 4 hours&lt;br&gt;4. Patients scheduled for elective coronary surgery.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Prior coronary or valvular surgery&lt;br&gt;2. Combined surgery (simultaneous carotid endartectomy, valvular repair, left ventricular aneurysmectomy)&lt;br&gt;3. Unstable angina&lt;br&gt;4. Valvular insufficiency&lt;br&gt;5. Myocardial infarction in the last 6 weeks&lt;br&gt;6. Active congestive heart failure&lt;br&gt;7. Hemodynamic instability requiring pharmacologic or mechanical support&lt;br&gt;8. Renal dysfunction: Creatinine &gt; 1.5 mg/dL&lt;br&gt;9. Hepatic dysfunction: GOT, GPT &gt; 150 U/L&lt;br&gt;10. Severe chronic obstructive pulmonary disease (FEV1 &lt; 50% or &lt; 2 L)&lt;br&gt;11. History of chronic enolism or neurological disease&lt;br&gt;12. Pregnant or lactating women&lt;br&gt;</Exclusion_Criteria>
    <Condition>This study will evaluate the cardioprotective effects of sevoflurane versus propofol during anesthesia and sedation of patients undergoing coronary bypass surgery in terms of maintenance of cardiac function and reduction of stay in these units.

Secondary Objectives:
1. To compare the possible advantages and disadvantages of both regimens in terms of preservation/improvement or pulmonary, hepatic and renal side effects. &lt;br&gt;MedDRA version: 8.1
Level: LLT
Classification code 10002323
Term: Anesthesia general
</Condition>
    <Intervention>&lt;br&gt;Trade Name: SEVORANE&lt;br&gt;Pharmaceutical Form: Inhalation vapour, liquid&lt;br&gt;INN or Proposed INN: SEVOFLURANO&lt;br&gt;Other descriptive name: SEVOFLURANO&lt;br&gt;Concentration unit: % percent&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;Pharmaceutical form of the placebo: Emulsion for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;Trade Name: DIPRIVAN  1%, JERINGA PRECARGADA&lt;br&gt;Pharmaceutical Form: Emulsion for injection&lt;br&gt;INN or Proposed INN: PROPOFOL&lt;br&gt;CAS Number: 2078-54-8&lt;br&gt;Other descriptive name: PROPOFOL&lt;br&gt;Concentration unit: % percent&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;Pharmaceutical form of the placebo: Intravenous infusion&lt;br&gt;Route of administration of the placebo: Inhalation use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate the cardioprotective effects of sevoflurane versus propofol during anesthesia and sedation of patients undergoing coronary bypass surgery in terms of maintenance of cardiac function and reduction of stay in these units.;Secondary Objective: 1. To compare the quality of the anesthesia and sedation obtained with sevoflurane versus that obtained with propofol in terms of control of anesthesia and sedation, rapidity and predictability of emergence in critical care patients. &lt;br&gt;2. To determine the mean alveolar concentration of sevoflurane required to obtain an adequate level of anesthesia and sedation in these patients.&lt;br&gt;3. To compare the possible advantages and disadvantages of both regimens in terms of preservation/improvement or pulmonary, hepatic and renal side effects.;Primary end point(s): To evaluate the cardioprotective effects of sevoflurane versus propofol during anesthesia and sedation of patients undergoing coronary bypass surgery in terms of maintenance of cardiac function and reduction of stay in these units.</Primary_outcome>
    <Secondary_ID>ACA-SPAI-04-22</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2479401</Internal_Number>
    <TrialID>EUCTR2007-006253-60-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Eficacia de la profilaxis antibiótica en dosis única nocturna frente al control clínico y tratamiento precoz de las infecciones urinarias para prevenir secuelas parenquimatosas y pielonefritis de repetición en niños afectos de reflujo vesicoureteral primario de grado III a V. - Eficacia de la profilaxis antibiótica en dosis única nocturna frente al control clínico</Public_title>
    <Scientific_title>Eficacia de la profilaxis antibiótica en dosis única nocturna frente al control clínico y tratamiento precoz de las infecciones urinarias para prevenir secuelas parenquimatosas y pielonefritis de repetición en niños afectos de reflujo vesicoureteral primario de grado III a V. - Eficacia de la profilaxis antibiótica en dosis única nocturna frente al control clínico                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>MAR ESPINO HERNANDEZ</Primary_sponsor>
    <Date_registration3>20100301</Date_registration3>
    <Date_registration>01/03/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006253-60                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>11/04/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Seguimiento y tratamiento precoz de cada episodio de infección urinaria.&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Edad: entre 0 y 5 años, diagnosticados de reflujo vesicoureteral por cistoureterografía miccional seriada convencional.&lt;br&gt;&lt;br&gt;GRUPO 1 Pacientes con reflujo de grado 3, 4 y 5 detectados al realizar el estudio de la hidronefrosis congénita con o sin afectación en la gammagrafia inicial.&lt;br&gt;GRUPO 2 Pacientes con reflujo de grado 3, 4 y 5 tras un primer episodio de pielonefritis.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patología urológica refluyente y obstructiva, obstructiva, válvulas de uretra, ureterocele, vejiga neurógena, trastorno funcional vesical comprobado mediante estudio urodinámico, insuficiencia renal moderada o severa y reflujo vesicoureteral bilateral de grado V.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Demostrar que en los reflujos de alto grado (de III a V de la Clasificación Internacional del Reflujo) no hay menos incidencia de cicatrices renales ni de pielonefritis con el uso de la dosis única nocturna de antibiótico profiláctico si lo comparamos con un seguimiento clínico con diagnóstico y tratamiento precoz de cada episodio de infección urinaria. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10047371
Term: Vesicoureteral reflux
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10066700
Term: Prophylaxis urinary tract infection
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10065144
Term: Renal scarring
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10037596
Term: Pyelonephritis
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Duracef suspensión&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;INN or Proposed INN: CEFADROXIL&lt;br&gt;CAS Number: 50370122&lt;br&gt;Other descriptive name: DURACEF&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50 mg/ml-&lt;br&gt;&lt;br&gt;Trade Name: Fosfocina suspensión&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;INN or Proposed INN: FOSFOMYCIN&lt;br&gt;CAS Number: 23155024&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50 mg/ml-&lt;br&gt;&lt;br&gt;Trade Name: TEDIPRIMA SUSPENSION&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;INN or Proposed INN: TRIMETHOPRIM&lt;br&gt;CAS Number: 738705&lt;br&gt;Other descriptive name: TEDIPRIMA&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 16 MG/ML-&lt;br&gt;&lt;br&gt;Trade Name: SETPRIM SUSPENSION PEDIATRICA&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;INN or Proposed INN: TRIMETHOPRIM SULFAMETOXAZOL&lt;br&gt;CAS Number: 8064902&lt;br&gt;Other descriptive name: CO-TRIMOXAZOLE&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 8 mg/ml-40 mg/ml&lt;br&gt;&lt;br&gt;Trade Name: SETPRIM pediatrico comprimidos&lt;br&gt;Pharmaceutical Form: Orodispersible tablet&lt;br&gt;INN or Proposed INN: TRIMETROPRIM/SULFAMETHOXAZOLE&lt;br&gt;CAS Number: 8064902&lt;br&gt;Other descriptive name: CO-TRIMOXAZOLE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 80 mg/comprimido-400 mg/comprimi&lt;br&gt;&lt;br&gt;Trade Name: AMOXI-GOBENS&lt;br&gt;Pharmaceutical Form: Oral suspension&lt;br&gt;INN or Proposed INN: AMOXICILLIN&lt;br&gt;CAS Number: 26787780&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50 mg/ml-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Demostrar si la profilaxis antibiótica nocturna en el reflujo vesicoureteral primario primario de alto grado (RVU) es igual que la vigilancia clínica de aparición de infección del tracto urinario y tratamiento precoz de cada episodio diagnosticado para disminuir la incidencia de daño renal (valorado gammagrafia renal con DMSAtc-99m en :&lt;br&gt; * Grupo 1: pacientes con RVU primario de grado III, IV y V diagnosticado tras estudio de alteración ecográfica prenatal sin infección del tracto urinario (ITU) previa con y sin alteración en el estudio gammagráfico inicial.&lt;br&gt;* Grupo 2: pacientes con RVU primario de grado III, IV y V diagnosticado tras ITU febril.&lt;br&gt;;Secondary Objective: 2º.- Demostrar si la profilaxis antibiótica nocturna en RVU primario es igual de eficaz que la vigilancia clínica de aparición de Infección del Tracto Urinario y tratamiento precoz de cada episodio diagnosticado para disminuir la incidencia de ITU febril:&lt;br&gt;* Grupo 1: pacientes con RVU primario de grado III, IV y V diagnosticado tras estudio de alteración ecográfica prenatal sin infección del tracto urinario (ITU) previa con y sin alteración en el estudio gammagráfico inicial.&lt;br&gt;* Grupo 2: pacientes con RVU primario de grado III, IV y V diagnosticado tras ITU febril.&lt;br&gt;3º.- Incidencia de cicatrices renales en ambos grupos.&lt;br&gt;4º.-  Diferencias en la resolución espontánea de RVU a los dos años de inicio del estudio en los dos grupos de pacientes citados.&lt;br&gt;5º-  Incidencia de ITU afebril.&lt;br&gt;6º.- Determinar la incidencia de Bacteriuria asintomática en todos los grupos.&lt;br&gt;7º.- Repercusión sobre el filtrado glomerular.&lt;br&gt;&lt;br&gt;;Primary end point(s): Afectación aguda en gammagrafia renal con DMSA: hipocaptación difusa sin pérdida del contorno, realizada en un periodo inferior a 10 días desde el debut de la clínica.  &lt;br&gt;&lt;br&gt;Afectación crónica Gammagrafia renal con DMSA o cicatriz renal: &lt;br&gt;- pérdida contorno renal o afectación difusa con FUR menor 40%, se utilizará la clasificación de Goldraich. Se realizará tras un periodo libre de infecciones mínimo de 9 a 12 meses. Si presentará nuevas infecciones se repetirá a los 9 meses de la última y se realizará un nuevo control a los 2 años de seguimiento si existe alteración.  &lt;br&gt;&lt;br&gt;Pielonefritis: presencia de hipocaptación en gammagrafia renal realizada en un periodo inferior a 10 días desde el inicio de los síntomas con urocultivo con un recuento de colonias significativo para la técnica (cualquier recuento en punción suprapúbica, más de 10.000 colonias por sondaje o más de 100.000 colonias por micción media) con fiebre, leucocitosis, desviación izquierda y aumento reactantes de fase aguda.&lt;br&gt;&lt;br&gt;Infección del tracto urinario febril: ausencia de hipocaptación en gammagrafia renal realizada en un periodo inferior a 10 días desde el inicio de los síntomas con urocultivo con un recuento de colonias significativo para la técnica (cualquier recuento en punción suprapúbica, más de 10.000 colonias por sondaje o más de 100.000 colonias por micción media) con fiebre, leucocitosis, desviación izquierda y aumento reactantes de fase aguda.&lt;br&gt;&lt;br&gt;Infección del tracto urinario afebril: sintomatología miccional con urocultivo con un recuento de colonias significativo para la técnica (cualquier recuento en punción suprapúbica, más de 10.000 colonias por sondaje o más de 100.000 colonias por micción media) sin fiebre, con alteración del sedimento urinario.&lt;br&gt;&lt;br&gt;Bacteriuria asintomática: colonización del tracto urinario  por un número significativo de gérmenes en dos urocultivos, con el paciente asintomático, ausencia de síntomas urinarios ni generales, ni alteración en el sedimento.  &lt;br&gt;&lt;br&gt;&lt;br&gt;Reflujo vesicoureteral: ascenso de orina de vejiga a uréteres y pelvis renal. Clasificación Internacional del reflujo vesicoureteral  &lt;br&gt;- grado I uréter&lt;br&gt;- grado II uréter y pelvis sin dilatación&lt;br&gt;- grado III uréter y pelvis con dilatación del cáliz&lt;br&gt;- grado IV uréter dilatado con dilatación de calices y deformidad.&lt;br&gt;- grado V uréter muy tortuoso con dilatación cálices, deformidad y atrofia. &lt;br&gt;&lt;br&gt;Filtrado glomerular estimado por la talla  &lt;br&gt;	Lactantes  0.45 x talla/ creat p&lt;br&gt;	Niños 0.55 x talla/ creat p&lt;br&gt;	Normal 120-80 ml/min/1.73m2&lt;br&gt;	Insuficiencia renal leve 80-60 ml/min/1.73m2&lt;br&gt;</Primary_outcome>
    <Secondary_ID>EC07/90847</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2479519</Internal_Number>
    <TrialID>EUCTR2005-004523-19-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Phase II clinical trial to evaluate the efficacy and safety in the use of pancreatic islets cells from cadaver donors for the treatment of Type-I Diabetes Mellitus in renal transplant  patients.</Public_title>
    <Scientific_title>Phase II clinical trial to evaluate the efficacy and safety in the use of pancreatic islets cells from cadaver donors for the treatment of Type-I Diabetes Mellitus in renal transplant  patients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Área de Trasplante y Terapia Celular - Hospital Central de Asturias</Primary_sponsor>
    <Date_registration3>20100315</Date_registration3>
    <Date_registration>15/03/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004523-19                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>08/02/2008</Date_enrollement>
    <Target_size>10</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;. Type-I diabetes mellitus patients with renal transplantation and good renal function (serum creatinine &lt; 2 mg/dl, creatinine clearance &gt; 40 ml/min and proteinuria &lt; 1 gr/day).&lt;br&gt;.  Patients who were indicated a renal but not a pancreas transplantation because of the high-risk for surgery. For these patients renal and pancreatic islet cells transplant will be performed at the same time.          &lt;br&gt;. Patients between 18 and 65 years of age.&lt;br&gt;. C-peptide levels &lt; 0.48 ng/ml.&lt;br&gt;. Body Mass Index (BMI) &lt; 28 kg/m2&lt;br&gt;. Time of renal transplantantion of at least 6 months.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;. Deliberate desire not to take part in the trial.&lt;br&gt;. Negative to sign the informed consent, essetial to take part in the Trial.&lt;br&gt;. Presence of higher cardiovascular risks: ischemic cardiopathy, peripheral vasculopathy (amputation and/or intermittent claudication) and left ventricular dysfunction (LVEF left ventricular ejection fraction &lt;30%).&lt;br&gt;. Consumption of alcohol or any other substance abuse, including tobacco (abstinence is required for a period of at least 6 months). &lt;br&gt;. Active infections (hepatitis B and C, HIV, tuberculosis, etc.). &lt;br&gt;. Presence of neoplasia within 5 years prior to the transplantation, excluding nonmelanoma skin carcinomas.&lt;br&gt;. Hepatic disease or hepatic disorders (ie. portal hypertension detected by ecographic control). &lt;br&gt;. Presence of motor neuropathy or autonomic impairment.  &lt;br&gt;. Presence of coagulation disorders.&lt;br&gt;. Presence of Leukopenia &lt;3000/mm3 or thrombopenia &lt;100.000/mm3.&lt;br&gt;. Renal failure (creatinine clearance &lt;60 ml/min or macroalbuminuria), except when performed together with the renal transplant.&lt;br&gt;. Non-treated proliferative retinopathy .&lt;br&gt;. Women who are pregnant or breast-feeding, or women with child-bearing potential who are not using effective contraceptive methods.&lt;br&gt;. Daily insulin requirement &gt; 0.7 U/kg/day.&lt;br&gt;. HbA1c &gt; 12%.&lt;br&gt;. Uncontrolled hyperlipidemia.&lt;br&gt;. Obesity.&lt;br&gt;. Any other medical situation which in the investigator’s opinion could interfere with optimum participation in the trial or cause significant risk for the patient. &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Type-I Diabetes Mellitus in renal trasplant patients &lt;br&gt;MedDRA version: 8.1
Level: pt
Classification code 10061835
</Condition>
    <Intervention>&lt;br&gt;Product Name: Pancreatic islets cells in suspension from cadaver donor &lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective:  To evaluate the efficacy and safety of the pancreatic islet cells transplantation from a cadaver donor, in the glycemic control of patients with Type-I Diabetes Mellitus and renal transplant,  through its implantation into the liver by percutaneous portal vein catheterization. ;Secondary Objective: To evaluate "the dose of pancreatic islet cells" in the use of such therapy.;Primary end point(s): . Proportion of patients who get the control of gylcemic levels without the administration of any exogenous insulin in the post-transplant period, in Type-I diabetes mellitus patients with renal transplantation.&lt;br&gt;&lt;br&gt;&lt;br&gt;. Correlation between pre-trasplant and post-transplant blood glucose levels, and the control of insulin secretion in response to blood glucose after pancreatic islets transplant.</Primary_outcome>
    <Secondary_ID>TIP0305</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2479664</Internal_Number>
    <TrialID>EUCTR2010-018377-38-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Immune respons after inactivated oral cholera vaccin (Dukoral) in renal transplant recipients

Mucosal response in ImmunoCompromised Host (MICH)
 - MICH</Public_title>
    <Scientific_title>Immune respons after inactivated oral cholera vaccin (Dukoral) in renal transplant recipients

Mucosal response in ImmunoCompromised Host (MICH)
 - MICH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Leiden University Medical Centre</Primary_sponsor>
    <Date_registration3>20100120</Date_registration3>
    <Date_registration>20/01/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-018377-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/03/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Age = 18 years&lt;br&gt;- Creatinin clearance = 40 ml/min&lt;br&gt;- Stable renal function for 1 year prior to inclusion&lt;br&gt;- Stabe immunosuppressive medication for 3 months prior to inclusion, consisting of prednisone in combination with either a calcineurine inhibitor, mycophenolate mofetil or an mTOR inhibitor&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- A chronic disease which may influence the immune system, other than the renal transplant and accompanying immunosupressive medication &lt;br&gt;- Chronic infection&lt;br&gt;- Treatment for graft rejection in the year prior to inclusion&lt;br&gt;- Prior vaccination with Dukoral or another oral cholera or ETEC vaccine.&lt;br&gt;- Prior Vibrio cholerae infection&lt;br&gt;- Travellers' diarrhea 6 months prior to inclusion&lt;br&gt;- Known allergy to the vaccine or to one of the vaccine components&lt;br&gt;- History of an anaphylactic reaction following vaccination&lt;br&gt;- Treatment with plasma or blood products in the 3 months prior to inclusion&lt;br&gt;- Pregnancy or breast feeding&lt;br&gt;- Immunosuppressive medication other than prednisone, a calcineurine inhibitor, mycophenolate mofetil or an mTOR inhibitor&lt;br&gt;</Exclusion_Criteria>
    <Condition>Single centre, interventional, non-parallel-group trial. 
Aim: To assess the immunogenicity of inactivated oral cholera vaccine (Dukoral) in renal transplant recipients and healthy controls.</Condition>
    <Intervention>&lt;br&gt;Trade Name: DUKORAL&lt;br&gt;Product Name: Dukoral&lt;br&gt;Pharmaceutical Form: Oral suspension&lt;br&gt;CAS Number: 0&lt;br&gt;Other descriptive name: VIBRIO CHOLERAE O1 INABA, EL TOR BIOTYPE (FORMALIN INACTIVATED)&lt;br&gt;Concentration unit: million organisms million organisms&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25000-&lt;br&gt;CAS Number: 0&lt;br&gt;Other descriptive name: VIBRIO CHOLERAE O1 INABA, CLASSICAL BIOTYPE (HEAT INACTIVATED)&lt;br&gt;Concentration unit: million organisms million organisms&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25000-&lt;br&gt;CAS Number: 0&lt;br&gt;Other descriptive name: VIBRIO CHOLERAE O1 OGAWA, CLASSICAL BIOTYPE (HEAT INACTIVATED)&lt;br&gt;Concentration unit: million organisms million organisms&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25000-&lt;br&gt;CAS Number: 0&lt;br&gt;Other descriptive name: VIBRIO CHOLERAE O1OGAWA, CLASSICAL BIOTYPE (FORMALIN INACTIVATED)&lt;br&gt;Concentration unit: million organisms million organisms&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25000-&lt;br&gt;CAS Number: 0&lt;br&gt;Other descriptive name: CHOLERA TOXIN B SUBUNIT RECOMBINANT(RCTB) (PRODUCED IN V. CHOLERAE O1 INABA, CLASSICAL BIOTYPE STRAIN 213)&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess the immunogenicity of inactivated oral cholera vaccine (Dukoral) in renal transplant recipients who use prednisone in combination with either a calcineurin inhibitor, or mycophenolate mofetil or an mTOR-inhibitor.;Secondary Objective: To compare the between-group differences in the immunogenicity of inactivated oral cholera vaccine (Dukoral) in renal transplant recipients who use prednison in combination with either a calcineurin inhibitor, or mycophenolate mofetil or an mTOR-inhibitor.&lt;br&gt;&lt;br&gt;To compare the immunogenicity of inactivated oral cholera vaccine (Dukoral) between renal transplant recipients and healthy controls.;Primary end point(s): Seroconversion rate.&lt;br&gt;Seroconversion is defined as a =2-fold rise in the anti-rCTB IgA en IgG titer at day 28. measured using an Enzyme Immuno Assay (EIA) or a =2-fold rise in th number of IgA- or IgG secreting peripheral blood lymphocytes (PBMC), with an obligatiry minimum of 10 per 10 million PBMC.</Primary_outcome>
    <Secondary_ID>MICH</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2479776</Internal_Number>
    <TrialID>EUCTR2009-016531-35-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Proof of Concept, Phase 2a, Double-blind, Parallel Group, Randomised, Placebo controlled Study to Assess the Effect of Lanthanum Carbonate on intact FGF23 in Normo-phosphataemic Subjects with Stage 3 Chronic Kidney Disease</Public_title>
    <Scientific_title>A Proof of Concept, Phase 2a, Double-blind, Parallel Group, Randomised, Placebo controlled Study to Assess the Effect of Lanthanum Carbonate on intact FGF23 in Normo-phosphataemic Subjects with Stage 3 Chronic Kidney Disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Shire Pharmaceutical Development Ltd</Primary_sponsor>
    <Date_registration3>20100329</Date_registration3>
    <Date_registration>29/03/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-016531-35                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/05/2010</Date_enrollement>
    <Target_size>45</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1) Male or female subjects =18 years old, who have been in the care of a physician for CKD for &gt;2 months, and are not expected to begin dialysis for at least 6 months&lt;br&gt;2) Screening c-terminal FGF23 &gt; 50RU/mL&lt;br&gt;3) Screening estimated glomerular filtration rate (eGFR) of 30-59mL/min/1.73m2 using the formula derived from the Modification of Diet in Renal Disease (MDRD)&lt;br&gt;4) Screening normal serum phosphate (0.808-1.55mmol/L) and endogenous 25-hydroxy Vitamin D levels &gt;20ng/mL&lt;br&gt;5) Adequate protein diet (includes 2-3 portions of protein rich food per day).&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1) Subjects who require Vitamin D supplementation, or compounds containing calcium, phosphate, aluminium or magnesium, subjects with acute renal failure, and subjects with rapidly progressing glomerulonephritis&lt;br&gt;2) Vegetarian diet&lt;br&gt;3) Known allergy to iodine.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic Kidney Disease &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10064848
Term: Chronic kidney disease
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Fosrenol (Lanthanum Carbonate)&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: lanthanum (III) carbonate hydrate&lt;br&gt;CAS Number: 54451240&lt;br&gt;Other descriptive name: LANTHANUM CARBONATE HYDRATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;Pharmaceutical form of the placebo: Chewable tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess the effects of 12 weeks of treatment with lanthanum carbonate compared with placebo on serum intact Fibroblast Growth Factor 23 (FGF23) levels;Secondary Objective: 1. To assess the effects of lanthanum carbonate treatment on serum intact parathyroid hormone (iPTH) and 1,25-dihydroxy Vitamin D.&lt;br&gt;2. To assess the urinary fractional excretion of phosphate following treatment with lanthanum carbonate.&lt;br&gt;3. To assess serum phosphate, serum total calcium, and calcium-phosphate product following treatment with lanthanum carbonate.&lt;br&gt;4. To monitor the safety and tolerability of lanthanum carbonate compared with placebo in Stage 3 Chronic Kidney Disease (CKD) subjects.&lt;br&gt;;Primary end point(s): Serum intact FGF23 level at week 12</Primary_outcome>
    <Secondary_ID>SPD405-703</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2479802</Internal_Number>
    <TrialID>EUCTR2009-017600-89-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Ensayo intrapaciente de biodisponibilidad relativa de dos formulaciones de tacrolimus: Prograf (comprimidos de liberación normal) y Advagraf (comprimidos de liberación sostenida) en niños trasplantados de riñón</Public_title>
    <Scientific_title>Ensayo intrapaciente de biodisponibilidad relativa de dos formulaciones de tacrolimus: Prograf (comprimidos de liberación normal) y Advagraf (comprimidos de liberación sostenida) en niños trasplantados de riñón                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Asociación para la investigación de Nefrología Infantil</Primary_sponsor>
    <Date_registration3>20100406</Date_registration3>
    <Date_registration>06/04/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-017600-89                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/06/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: Estudio intrapaciente de transferencia&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;? Edad de 4 a 18 años de edad.&lt;br&gt;? Capacidad de tragar cápsulas.&lt;br&gt;? Pacientes con trasplante renal en tratamiento estable con tacrolimus en los últimos 30 días.&lt;br&gt;? Capacidad  de comprensión de las indicaciones del tratamiento.&lt;br&gt;? Posibilidad de administración controlada de Prograf y Advagraf por parte de padres/tutores, de acuerdo a lo establecido en este protocolo.&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;? Haber presentado un episodio de rechazo dentro de los 90 días anteriores al estudio.&lt;br&gt;? Introducción de fármacos que alteren la cinética de tacrolimus en las dos semanas previas&lt;br&gt;</Exclusion_Criteria>
    <Condition>Transplante renal</Condition>
    <Intervention>&lt;br&gt;Trade Name: ADVAGRAF 0,5 mg cápsulas duras de liberación prolongada&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;Other descriptive name: TACROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Trade Name: ADVAGRAF 1 mg cápsulas duras de liberación prolongada&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;Other descriptive name: TACROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: ADVAGRAF 1 mg cápsulas duras de liberación prolongada&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;Other descriptive name: TACROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: ADVAGRAF 5 mg cápsulas duras de liberación prolongada&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;Other descriptive name: TACROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: ADVAGRAF 3 mg cápsulas duras de liberación prolongada&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;Other descriptive name: TACROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 3-&lt;br&gt;&lt;br&gt;Trade Name: PROGRAF  0,5 mg cápsulas duras&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;Other descriptive name: TACROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Trade Name: PROGRAF 5 mg cápsulas duras&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;Other descriptive name: TACROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: PROGRAF 1 mg cápsulas duras&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;Other descriptive name: TACROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: ?	Conocer la biodisponibilidad relativa de la formulación de Tacrolimus de liberación sostenida (Advagraf) tras la administración única diaria respecto a la formulación de Tacrolimus de liberación normal (Prograf) administrada dos veces al día, en pacientes pediátricos con trasplante renal y en tratamiento estable con tacrolimus que son transferidos a tacrolimus de libración sostenida.;Secondary Objective: 1. Conocer el perfil cinético de tacrolimus tras la administración de Advagraf en pacientes con transplante renal menores de 18 años de edad.&lt;br&gt;2. Evaluar la correlación entre las concentraciones valle de tacrolimus y el AUC0-24 tras la administración de Advagraf.&lt;br&gt;3. Explorar la correlación entre el AUC0-24 de Advagraf y diferentes AUC parciales, con el objetivo de definir el AUC abreviada que mejor refleje la exposición a tacrolimus tras la administración de Advagraf.&lt;br&gt;4. Evaluar las diferencias circadianas de tacrolimus tras la administración de Prograf.&lt;br&gt;5. Evaluar el impacto de las variantes genéticas de transportadores y enzimas metabolizadoras (especialmente Glicoproteina ?p? y del CYP3A4) en la farmacocinética de tacrolimus tras la administración de Prograf y de Advagraf.&lt;br&gt;6.Evaluación de la tolerabilidad.;Primary end point(s): Para el análisis de biodisponibilidad relativa entre las dos formulaciones, la variable principal será el área bajo la curva (AUC0-24) calculada a partir de las concentraciones plasmáticas de Tacrolimus.&lt;br&gt;También se tendrán en cuenta la concentración máxima (Cmax) y el tiempo en el que aparece (Tmax), la vida media aparente y la oscilación pico-valle.</Primary_outcome>
    <Secondary_ID>FC/hulp003</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2480021</Internal_Number>
    <TrialID>EUCTR2009-018189-36-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Prévention chez le receveur avec néphropathie à IgA primaire (NIGA) de la Récidive Après Transplantation rénale: ATG-F versus Basiliximab, comme traitements immunosuppresseurs d’induction.  
Etude PIRAT: A vs B
 - PIRAT</Public_title>
    <Scientific_title>Prévention chez le receveur avec néphropathie à IgA primaire (NIGA) de la Récidive Après Transplantation rénale: ATG-F versus Basiliximab, comme traitements immunosuppresseurs d’induction.  
Etude PIRAT: A vs B
 - PIRAT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>CHU Saint-Etienne</Primary_sponsor>
    <Date_registration3>20100409</Date_registration3>
    <Date_registration>09/04/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-018189-36                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/05/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Patient aged = 18 and &lt;75 years &lt;br&gt;- Free, informed, express and written.&lt;br&gt;- Diagnosis of native kidney primary IgA glomerulonephritis biopsy-proven&lt;br&gt;- First kidney transplantation (one kidney)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-Panel Reactive Antibody (PRA PRA global or class I or class II PRA) over 50% on a serum before transplantation&lt;br&gt;-Multi-organ graft&lt;br&gt;-Transplants using donor limits or sub-optimal: donor age = 70 years, donors in the study BIGRAS or taken heart beating donors (tested on computer infusion) or other restriction factors&lt;br&gt;- IgA glomerulonephritis  secondary to HSP (Henoch-Schonlein purpura) or Systemic Lupus Erythematosus (SLE) or alcoholic cirrhosis&lt;br&gt;- History of cancer older than 5 years or with advanced cancer, but except for non-recurrent skin cancers&lt;br&gt;- Infectious diseases scalable: tuberculosis, HIV, HBV or HCV infection with viral replication and / or chronic hepatitis&lt;br&gt;- Allergy to rabbit proteins&lt;br&gt;- Severe thrombocytopenia (&lt;50,000 platelets / ul)&lt;br&gt;- Bacterial infection, viral and fungal uncontrolled therapeutically&lt;br&gt;- Pregnancy and lactation&lt;br&gt;</Exclusion_Criteria>
    <Condition>IgA glomerulonephritis and first transplant &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10018367
Term: Glomerulonephritis chronic
 &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10023438
Term: Kidney transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: GLOBULINES ANTILYMPHOCYTAIRES FRESENIUS&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;&lt;br&gt;Trade Name: SIMULECT&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Demonstration of a protective effect of ATG-Fresenius against the clinical and histological recurrence of IgA nephropathy after primary first kidney transplant and compared to simulect;Primary end point(s): Clinico-histological recurrence of IgA  in monitoring a first transplant;Secondary Objective: For the efficacy, Comparison in the 2 groups :&lt;br&gt;- histological recurrence confirmed by renal biopsy at 5 years &lt;br&gt;- graft loss &lt;br&gt;- quality of graft function at 5 years &lt;br&gt;- cumulative incidence of acute rejection and / or chronic rejection proved by renal biopsy to 5 years &lt;br&gt;- onset of hypertension&lt;br&gt;- survival of grafts and patients up to 5 years &lt;br&gt;For the safety, comparison in the 2 goups :&lt;br&gt;- infection and CMV disease at 1 year &lt;br&gt;- other microbial infections at 1 year post-transplant. &lt;br&gt;- incidence of cancers up to 5 years with 3 topics: skin cancer, cancers of organs (solid) and lymphomas. &lt;br&gt;</Primary_outcome>
    <Secondary_ID>0908143</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2480022</Internal_Number>
    <TrialID>EUCTR2010-018917-30-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A SINGLE-CENTER PHARMACOGENETIC STUDY OF DONOR AND RECIPIENT TO IMPROVE THE EFFICACY AND REDUCE THE NEPHROTOXICITY OF TACROLIMUS AFTER KIDNEY TRANSPLANTATION - CYP3A5 for dosing tacrolimus</Public_title>
    <Scientific_title>A SINGLE-CENTER PHARMACOGENETIC STUDY OF DONOR AND RECIPIENT TO IMPROVE THE EFFICACY AND REDUCE THE NEPHROTOXICITY OF TACROLIMUS AFTER KIDNEY TRANSPLANTATION - CYP3A5 for dosing tacrolimus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Erasmus Medical Center</Primary_sponsor>
    <Date_registration3>20100210</Date_registration3>
    <Date_registration>10/02/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-018917-30                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>08/04/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: tacrolimus dosing based on genotype&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Adult recipients (18 years or older) who are to receive an ABO-compatible single-organ kidney transplant from a living donor (related or unrelated) will be eligible for entry into the study.  &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients receiving immunosuppressive therapy (except steroid treatment) within the preceding 28 days except for pretransplant immunosuppressive medication (up to 48 hr before transplantation) will not be included. In addition, patients using medication known to have a pharmacokinetic interaction with tacrolimus will not be asked to participate in the study.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Kidney transplantation &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10038474
Term: Renal insufficiency
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Prograft&lt;br&gt;Product Name: Prograft&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Prograft&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Current Sponsor code: 18107&lt;br&gt;Other descriptive name: tacrolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 0.15-0.30&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Current Sponsor code: 18107&lt;br&gt;Other descriptive name: tacrolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 0.15-0.30&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: First we will investigate whether a CYP3A5 genotype-based tacrolimus dosing strategy will result in improved clinical outcomes as compared with a standard tacrolimus dosing regimen based on bodyweight. ;Secondary Objective: Second, we will investigate if ABCB1 and CYP3A5 and single-nucleotide polymorphisms (SNPs) in their encoding genes are associated with the development of tacrolimus-induced nephrotoxicity after kidney transplantation.;Primary end point(s): The primary endpoint of the study is the proportion of patients reaching target levels (10-15 ng/ml) on day 3 and day 7 after transplantation. </Primary_outcome>
    <Secondary_ID>RB01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2480202</Internal_Number>
    <TrialID>EUCTR2009-010541-31-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Efecto de la inhibición de la diana de rapamicina  (mTor) sobre el metabolismo y rendimiento en el ejercicio físico - EXETOR</Public_title>
    <Scientific_title>Efecto de la inhibición de la diana de rapamicina  (mTor) sobre el metabolismo y rendimiento en el ejercicio físico - EXETOR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Servicio Nefrología Hospital Universitario de Bellvitge</Primary_sponsor>
    <Date_registration3>20100512</Date_registration3>
    <Date_registration>12/05/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-010541-31                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/10/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;a. Paciente trasplantado renal, edad &gt;18 años y &lt; a 60 años.&lt;br&gt;b. Frecuencia cardíaca en pulso radial y en sedestación entre 50 y 100 ppm.&lt;br&gt;c. Tensión arterial entre 100 y 140 para sistólica y entre 50 y 90 para diastólica.&lt;br&gt;d. Inexistencia de cualquier cuadro clínico físico,&lt;br&gt;psicológico o psiquiátrico que pueda impedir un&lt;br&gt;seguimiento estricto del protocolo descrito.&lt;br&gt;e. Filtrado glomerular estimado superior a 40 ml/min.&lt;br&gt;f. Proteinuria &lt; 0.5 g/d.&lt;br&gt;g. Trasplante renal realizado cómo mínimo hace 6 meses.&lt;br&gt;h. Inmunosupresión basada en inhibidores de calcineurina.&lt;br&gt;i. Hemoglobina &gt; 11 g/dl.&lt;br&gt;j. BMI &lt; 35 kg/m2.&lt;br&gt;k. Indicación de conversión a everolimus y otorgación del consentimiento informado por escrito.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;a. Participación en cualquier ensayo clínico en los últimos 30 días previos a su inclusión.&lt;br&gt;b.Cualquier otra enfermedad física, psicológica o&lt;br&gt;psiquiátrica que impida el seguimiento por parte del sujeto.&lt;br&gt;c. Diabetes mellitus.&lt;br&gt;d.Tratamiento con agentes estimulantes de la eritropoyesis.&lt;br&gt;e.Tratamiento con &amp;#946;-bloqueantes.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Pacientes trasplantados renales a los que por indicación clínica se les va a realizar un cambio de un fármaco anti-calcineurínico (Ciclosporina o Tacrolimus) a un inhidor de la diana de rapamicina (everolimus). &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10038533
Term: Renal transplant
</Condition>
    <Intervention>&lt;br&gt;Product Name: EVEROLIMUS&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Estudiar si la inhibición de mTOR reduciría la utilización muscular de glucosa a la vez que aumentaría la oxidación de ácidos grasos, aumentando la capacidad de esfuerzo físico en pacientes trasplantados renales.;Secondary Objective: Ninguno;Primary end point(s): 1-Análisis antropométrico (peso, talla, diametros, pliegues y diametros)&lt;br&gt;2-Análisis de la fuerza (fuerza de contracción palmar y resistencia a la fuerza).&lt;br&gt;3- Análisis metabólico  y test de sobrecarga oral de glucosa.&lt;br&gt;4- Análisis de paramentros cardiovasculares ( Presión arterial, MAPA y velocidad de la onda de pulso).</Primary_outcome>
    <Secondary_ID>MTOR-METAB</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2480405</Internal_Number>
    <TrialID>EUCTR2010-020415-36-NO</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>En åpen, randomisert cross over studie av fosfatbinder (sevelamer) eller aktivt vitamin D hos pasienter med kronisk nyresvikt i stadium 3b (eGFR 30-45 ml/min/1,73 m2) for evaluering av fibroblast like growth factor 23 (FGF 23) og parathyroidea hormon (PTH) – en pilotstudie.</Public_title>
    <Scientific_title>En åpen, randomisert cross over studie av fosfatbinder (sevelamer) eller aktivt vitamin D hos pasienter med kronisk nyresvikt i stadium 3b (eGFR 30-45 ml/min/1,73 m2) for evaluering av fibroblast like growth factor 23 (FGF 23) og parathyroidea hormon (PTH) – en pilotstudie.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Stavanger University Hospital</Primary_sponsor>
    <Date_registration3>20100615</Date_registration3>
    <Date_registration>15/06/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-020415-36                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>15/07/2010</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Chronic renal failure stage 3B.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Stable therapy with bisphosphonate and corticosteroides.&lt;br&gt;Unstable medical condition.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic renal failure, stage 3B.</Condition>
    <Intervention>&lt;br&gt;Trade Name: Renvela&lt;br&gt;Product Name: Renvela&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Trade Name: Etalpha&lt;br&gt;Product Name: Etalpha&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate the effects on the plasma level of FGF 23 of early pharmaceutical intervention with Renagel vs Etalpha. A pilot study.;Secondary Objective: None defined;Primary end point(s): Plasma level of FGF 23.</Primary_outcome>
    <Secondary_ID>SUS2010GOLA01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2480444</Internal_Number>
    <TrialID>EUCTR2010-021075-89-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A MULTICENTER, THREE ARM, RANDOMIZED, OPEN LABEL  CLINICAL STUDY TO COMPARE RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS RECEIVING AN IMMUNOSUPPRESSIVE REGIMEN OF ADVAGRAF® (IMMEDIATELY OR DELAYED POST-TRANSPLANT) AND MMF WITH OR WITHOUT A MONOCLONAL ANTI-IL2R ANTIBODY (BASILIXIMAB) - Short Title: DIAMOND FRANCE Study</Public_title>
    <Scientific_title>A MULTICENTER, THREE ARM, RANDOMIZED, OPEN LABEL  CLINICAL STUDY TO COMPARE RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS RECEIVING AN IMMUNOSUPPRESSIVE REGIMEN OF ADVAGRAF® (IMMEDIATELY OR DELAYED POST-TRANSPLANT) AND MMF WITH OR WITHOUT A MONOCLONAL ANTI-IL2R ANTIBODY (BASILIXIMAB) - Short Title: DIAMOND FRANCE Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Astellas Pharma Europe Ltd.</Primary_sponsor>
    <Date_registration3>20100614</Date_registration3>
    <Date_registration>14/06/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-021075-89                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>25/08/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;A subject is eligible for the study if all of the following apply:&lt;br&gt;1.	Age = 18 years.&lt;br&gt;2.	Undergoing orthotopic liver or split liver allograft transplantation.&lt;br&gt;3.	Female subject of childbearing potential must have a negative serum or urine pregnancy test at enrollment and must agree to maintain effective birth control during the study and during 6 weeks after cellcept is stopped&lt;br&gt;4.	Capable of understanding the purpose and risks of the study, fully informed and given written informed consent (signed Informed Consent has been obtained).&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;A subject will be excluded from participation if any of the following apply:&lt;br&gt;1.	Receiving a multi-organ transplant or having previous received an organ transplant (including liver re-transplantation). &lt;br&gt;2.	Receiving an auxiliary graft or in whom a bio-artificial liver (cell system) has been used.&lt;br&gt;3.	Receiving ABO incompatible graft or a graft from a non heart beating donor.&lt;br&gt;4.	Ongoing dosing with systemic corticosteroids.&lt;br&gt;5.	Subjects with systemic infection requiring treatment except viral hepatitis.&lt;br&gt;6.	Diagnosis of new-onset malignancy prior to transplantation, with the exception of basocellular or squamous cell carcinoma of the skin which had been treated successfully. However, subjects with primary liver carcinoma can be included if they meet the following criteria:&lt;br&gt;•	&lt; or = 3 nodules&lt;br&gt;•	no node larger than 5 cm&lt;br&gt;•	no metastases&lt;br&gt;•	no vascular tumoral invasion&lt;br&gt;7.	Significant, uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer.&lt;br&gt;8.	Subject or donor known to be HIV positive. &lt;br&gt;9.	Known allergy or intolerance to tacrolimus, macrolide antibiotics, corticosteroids, Basiliximab or mycophenolate mofetil or any of the product excipients.&lt;br&gt;10.	Pregnant woman or breast-feeding mother.&lt;br&gt;11.	Currently participating in another clinical trial, and/or has taken an investigational drug within 28 days prior to enrollment.&lt;br&gt;12.	Unlikely to comply with the visits scheduled in the protocol.&lt;br&gt;13.	Any unstable medical condition that could interfere with the study objectives in the opinion of the investigator.&lt;br&gt;14.	Receiving prohibited concomitant therapy, or received prohibited concomitant therapy within 28 days prior to enrollment.&lt;br&gt;15.	Any form of substance abuse, psychiatric disorder or condition which, in the opinion of the investigator, may complicate communication with the investigator.&lt;br&gt;.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS RECEIVING AN IMMUNOSUPPRESSIVE REGIMEN OF ADVAGRAF® (IMMEDIATELY OR DELAYED POST-TRANSPLANT) AND MMF WITH OR WITHOUT SIMULECT &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10024716
Term: Liver transplantation
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Advagraf&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987113&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Trade Name: Advagraf&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987113&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.0-&lt;br&gt;&lt;br&gt;Trade Name: Advagraf&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987113&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5.0-&lt;br&gt;&lt;br&gt;Trade Name: Simulect&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;Other descriptive name: BASILIXIMAB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of this study is to compare the three therapy regimens with regard to renal function.;Secondary Objective: The secondary objective is to compare the safety and efficacy profiles of the three therapy regimens with each other.;Primary end point(s): Renal function assessed by eGFR (MDRD4 formula: estimates GFR using four variables: serum creatinine, age, race, and gender) at 24 weeks after transplantation is the primary endpoint of the study. </Primary_outcome>
    <Secondary_ID>PMR-EC-1107</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2480455</Internal_Number>
    <TrialID>EUCTR2009-016835-36-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>ESTUDIO CLÍNICO MULTICÉNTRICO,  PROSPECTIVO, ALEATORIZADO, ABIERTO Y CONTROLADO, PARA LA PREVENCIÓN DE LA INFECCIÓN DEL ORIFICIO EXTERNO (IOE) DEL CATÉTER PERITONEAL CON UNA PASTA ANTIBIÓTICA TÓPICA - PREVIOE-DP</Public_title>
    <Scientific_title>ESTUDIO CLÍNICO MULTICÉNTRICO,  PROSPECTIVO, ALEATORIZADO, ABIERTO Y CONTROLADO, PARA LA PREVENCIÓN DE LA INFECCIÓN DEL ORIFICIO EXTERNO (IOE) DEL CATÉTER PERITONEAL CON UNA PASTA ANTIBIÓTICA TÓPICA - PREVIOE-DP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Fundación Investigación Biomédica Hospital Príncipe de Asturias</Primary_sponsor>
    <Date_registration3>20100611</Date_registration3>
    <Date_registration>11/06/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-016835-36                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>21/06/2011</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Cuidados diarios habituales del orificio peritoneal&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Pacientes adultos (18 años o más). &lt;br&gt;2. Prevalentes o incidentes en la técnica de diálisis peritoneal por insuficiencia renal crónica, según la realicen desde más de tres meses o menos, respectivamente.&lt;br&gt;3. Orificios externos curados (más de 6 semanas desde la implantación). &lt;br&gt;4. Ausencia de infección activa del orificio externo ni haberla presentado en los 3 meses previos.&lt;br&gt;5. Los pacientes deben disponer de un PET (Test de Equilibrio Peritoneal)  al menos 3 meses antes de su inclusión.&lt;br&gt;6. Consentimiento informado y aceptación de la estrategia de tratamiento por parte del paciente.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Peritonitis aguda en los dos meses previos. &lt;br&gt;2. Ausencia de otro problema asociado (fuga de líquido peritoneal, extrusión del dacron externo, costras).&lt;br&gt;3. Historia previa de alergia a alguno de los componentes de la pasta.&lt;br&gt;4.  Embarazo o lactancia.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Prevención de la infección del orificio externo (IOE) del catéter peritoneal en pacientes sometidos a diálisis peritoneal por insuficiencia renal crónica. &lt;br&gt;MedDRA version: 11
Level: LLT
Classification code 10008831
Term: Dialisis peritoneal crónica ambulatoria
 &lt;br&gt;MedDRA version: 11
Level: LLT
Classification code 10032857
Term: Otras peritonitis especificadas
</Condition>
    <Intervention>&lt;br&gt;Product Name: Pasta Antibiótica Tópica (PAT)&lt;br&gt;Pharmaceutical Form: Cutaneous paste&lt;br&gt;Other descriptive name: Anfotericina&lt;br&gt;Concentration unit: % percent&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;Other descriptive name: Colistina&lt;br&gt;Concentration unit: % percent&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;Other descriptive name: Tobramicina&lt;br&gt;Concentration unit: % percent&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;Other descriptive name: Vancomicina&lt;br&gt;Concentration unit: % percent&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 4-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluar si el empleo de la pasta antibiótica reduce la incidencia acumulada de la IOE al menos en un 30% y aumenta el tiempo en que el paciente permanece libre de infección.&lt;br&gt;Se empleará como definición de IOE, acordada con todos los centros participantes, la siguiente: al menos uno de los criterios clínicos de infección (eritema, edema o dolor) con secreción purulenta del orificio y  un cultivo positivo del exudado del orificio.;Secondary Objective: 1.- Evaluar si se disminuye en al menos un 30% el número de peritonitis, tanto de la incidencia de peritonitis global como de las asociadas a IOE (coincidencia del gérmen causal).  &lt;br&gt;2.-Demostrar que previene la aparición local de gérmenes resistentes y hongos sin producir irritación de la piel del orificio externo durante un periodo de empleo prolongado&lt;br&gt;3..- Evaluar si se disminuye la retirada del catéter peritoneal por infección y de la hospitalización. Los criterios de retirada del catéter, acordados con los centros participantes son: peritonitis refractaria, peritonitis por hongos, IOE refractaria o peritonitis recurrente por el mismo gérmen.&lt;br&gt;4.- Evaluar  una disminución de los costes: &lt;br&gt;- Estudio fármaco-económico con cálculo del coste del tratamiento antibiótico por IOE y peritonitis. &lt;br&gt;5.- Evaluar mediante el Test de Equilibrio Peritoneal los cambios de la función de la membrana peritoneal en los dos grupos de estudio y su posible relación con el número de peritonitis.;Primary end point(s): Variables cuantitativas&lt;br&gt;- Número de IOE;&lt;br&gt;- días libres de IOE;&lt;br&gt;- número de peritonitis;&lt;br&gt;- días de estancia hospitalaria;&lt;br&gt;- duración del tratamiento antibiótico;&lt;br&gt;- coste de hospitalización;&lt;br&gt;- coste del tratamiento antibiótico;&lt;br&gt;- coste de la transferencia a hemodiálisis; y&lt;br&gt;- cambio en los valores del PET (eficacia de la membrana peritoneal) pre y post-estudio.&lt;br&gt;&lt;br&gt;Variables cualiitativas&lt;br&gt;- Irritación del orificio;&lt;br&gt;- peritonitis asociada a IOE (coincidencia de gérmen causal);&lt;br&gt;- tipo de antibiótico empleado;&lt;br&gt;- aparición de gérmenes resistentes;&lt;br&gt;- aparición de signos de alergia a la pasta;&lt;br&gt;- retirada del catéter si/no;&lt;br&gt;- hospitalización si/no;&lt;br&gt;- transferencia a hemodiálisis; y&lt;br&gt;- éxitus.&lt;br&gt;&lt;br&gt;Adicionalmente a las variables específicas del proyecto, se registrará cualquier acontecimiento adverso relacionado o no con el tratamiento del estudio.</Primary_outcome>
    <Secondary_ID>PREVIOE-DP</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2480541</Internal_Number>
    <TrialID>EUCTR2010-019352-42-FI</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Effects of hypertonic saline-hydroxyethylstarch solution on extracellular water in cardiac surgery patients</Public_title>
    <Scientific_title>Effects of hypertonic saline-hydroxyethylstarch solution on extracellular water in cardiac surgery patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Heart Center Co. Tampere University Hospital</Primary_sponsor>
    <Date_registration3>20100622</Date_registration3>
    <Date_registration>22/06/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-019352-42                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: no&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/08/2010</Date_enrollement>
    <Target_size>50</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Fifty adult male patients undergoing coronary bypass surgery will be enrolled in this study.  Inclusion criteria are male gender and no need for pulmonary artery catheter (pulmonary hypertension or left ventricular ejection fraction &lt; 40%). &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Exclusion criterion is chronic hyponatremia and significant renal dysfunction.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Fifty adult male patients undergoing coronary bypass surgery will be enrolled in this study.  Inclusion criteria are male gender and no need for pulmonary artery catheter (pulmonary hypertension or left ventricular ejection fraction &lt; 40%). Exclusion criterion is chronic hyponatremia and significant renal dysfunction. &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10011078
Term: Coronary artery disease
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Hyperhaes&lt;br&gt;Product Name: Hyperhaes&lt;br&gt;Product Code: B05AA07&lt;br&gt;Pharmaceutical Form: Intravenous infusion&lt;br&gt;INN or Proposed INN: NaCl 7.2%/hydroxyethylstarch 200/0.5&lt;br&gt;&lt;br&gt;Trade Name: Natriumklorid Baxter 9 mg/ml&lt;br&gt;Product Name: Natriumklorid Baxter 9 mg/ml&lt;br&gt;Product Code: B05BB01&lt;br&gt;Pharmaceutical Form: Intravenous infusion&lt;br&gt;CAS Number: 7647-14-5&lt;br&gt;Other descriptive name: SODIUM CHLORIDE&lt;br&gt;Concentration unit: % percent&lt;br&gt;Concentration number: 0.9-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Primary endpoints are the changes in body weight and extracellular water from baseline to the first postoperative morning.  ;Secondary Objective: Secondary endpoints are the need of fluids and diuretic medication during the perioperative period.;Primary end point(s): Primary endpoints are the changes in body weight and extracellular water from baseline to the first postoperative morning.</Primary_outcome>
    <Secondary_ID>R09246M</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2480652</Internal_Number>
    <TrialID>EUCTR2009-017849-57-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Somatostatin analogues as a volume reducing treatment of polycystic livers - SOLVE</Public_title>
    <Scientific_title>Somatostatin analogues as a volume reducing treatment of polycystic livers - SOLVE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Radboud University Nijmegen Medical Centre</Primary_sponsor>
    <Date_registration3>20100113</Date_registration3>
    <Date_registration>13/01/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-017849-57                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/03/2011</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;• Patients with ADPKD with polycystic liver (&gt; 20 liver cysts)&lt;br&gt;• At least 18 years of age&lt;br&gt;• Informed consent, patients are willing and able to comply with the study drug regimen and all other study requirements&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;• Kidney transplantation&lt;br&gt;• Renal failure requiring hemodialysis&lt;br&gt;• Proteinuria of &gt; 1g/L at baseline&lt;br&gt;• Use of oral contraceptives or estrogen suppletion&lt;br&gt;• Women who are pregnant or breastfeeding&lt;br&gt;• History of cardiac/pulmonary disease; symptomatic gallstones, etc &lt;br&gt;• Intervention (aspiration or surgical intervention) within three months before baseline&lt;br&gt;• Mental illness that interferes with the patient ability to comply with the protocol&lt;br&gt;• Drug or alcohol abuse within one year of baseline&lt;br&gt;</Exclusion_Criteria>
    <Condition>Polycystic liver disease, due to isolated polycystic liver disease or polycystic kidney disease. &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10048834
Term: Polycystic liver disease
 &lt;br&gt;MedDRA version: 12.1
Level: PT
Classification code 10048834
Term: Polycystic liver disease
 &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10036045
Term: Polycystic kidney
 &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10036046
Term: Polycystic kidney, autosomal dominant
 &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10036048
Term: Polycystic kidney, unspecified type
</Condition>
    <Intervention>&lt;br&gt;Product Name: Sandostatin LAR&lt;br&gt;Product Code: unknown&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;&lt;br&gt;Product Name: Somatuline Autosolution&lt;br&gt;Product Code: unknown&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Reduction of liver volume;Secondary Objective: Reduction of kidney volume, symptom evaluation, monitoring of kidney function;Primary end point(s): reduction of liver volume</Primary_outcome>
    <Secondary_ID>PCLD004</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2480698</Internal_Number>
    <TrialID>EUCTR2010-021452-26-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Crise Rénale sclérodermique : amélioration du pronostic par adjonction de Bosentan au traitement de référence de la maladie - SCSREINBO</Public_title>
    <Scientific_title>Crise Rénale sclérodermique : amélioration du pronostic par adjonction de Bosentan au traitement de référence de la maladie - SCSREINBO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)</Primary_sponsor>
    <Date_registration3>20100709</Date_registration3>
    <Date_registration>09/07/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-021452-26                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/09/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Age &gt; ou = 18 ans&lt;br&gt;- Patient de sexe féminin ou masculin&lt;br&gt;- Patients présentant une ScS répondant aux critères diagnostiques de l'ACR et/ou de Leroy et Medsger &lt;br&gt;- Patients répondant aux critères de crise rénale sclérodermique&lt;br&gt;- Patient ayant donné son accord de participation et ayant signé le formulaire de consentement éclairé ou formulaire de consentement signé par un parent ou un proche si le patient est hors d'état d'exprimer son consentement&lt;br&gt;- Réalisation d'un examen médical préalable (résultats à communiquer au patient)&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Crise rénale sclérodermique survenant avant la date anniversaire de 18 ans&lt;br&gt;- Patients traités depuis plus d'un mois par bosentan pour une hypertension artérielle pulmonaire ou en prévention de récidive d'ulcères digitaux&lt;br&gt;- Autre traitement par antagoniste sélectif ou non sélectif des récepteurs à l'endothéline-1&lt;br&gt;- Insuffisance ventriculaire gauche avec fraction d'éjection inférieure à 40% évaluée par une échographie cardiaque&lt;br&gt;- Hypotension artérielle sévère PAS&lt;85mmHg&lt;br&gt;- Cancer(s) évolutif(s) ou considéré(s) comme guéri(s) depuis moins de 5 ans&lt;br&gt;- Antécédent d'intolérance au bosentan&lt;br&gt;- Infection évolutive sévère ou justifiant d'un traitement anti-infectieux prolongé (infection par le VIH, le VHC ou le VHB notamment)&lt;br&gt;- Insuffisance hépatique sévère, cirrhose non compensée&lt;br&gt;- Patientes enceintes, allaitant ou n'utilisant pas une contraception jugée efficace par l'investigateur (abstinence et/ou contraception orale ou mécanique)&lt;br&gt;- Patient dément ou non habilité pour des raisons psychiatriques ou de défaillance intellectuelle, à recevoir l'information sur le protocole et à donner un consentement éclairé&lt;br&gt;- Patients participant à un autre essai thérapeutique&lt;br&gt;- Refus de consentement ou incapacité d'obtention du consentement &lt;br&gt;- Absence d'affiliation au régime de la sécurité sociale (bénéficiaire ou ayant droit).&lt;br&gt;- Contre-indication(s) aux médicaments utilisés (bosentan ou IEC)&lt;br&gt;</Exclusion_Criteria>
    <Condition>Les patients inclus dans l'étude seront des patients atteints de sclérodermie systémique (définie selon les critères de la classification de l'ACR et/ou de Leroy et Medsger) et présentant une crise rénale sclérodermique aigue définie par une HTA sévère d'emblée et/ou d'aggravation progressive &gt;150/85mmHg obtenue  à deux reprises minimum en 24H, sans autre explication que la ScS et/ou une insuffisance rénale rapidement progressive, sans autre explication que la ScS. &lt;br&gt;MedDRA version: 8.1
Level: PT
Classification code 10062553
Term: scleroderma renal crisis 
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Tracleer&lt;br&gt;Product Name: Tracleer&lt;br&gt;Pharmaceutical Form: Buccal tablet&lt;br&gt;INN or Proposed INN: bosentan&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 62,5-&lt;br&gt;&lt;br&gt;Trade Name: Tracleer&lt;br&gt;Product Name: Tracleer&lt;br&gt;Pharmaceutical Form: Buccal tablet&lt;br&gt;INN or Proposed INN: Bosentan&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 125-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: L'objectif principal est de déterminer l'efficacité à un an du bosentan, prescrit durant 6 mois, chez des patients présentant une crise rénale sclérodermique venant d'être diagnostiquée. En l'absence de toute étude et de possibilité de réaliser à ce stade de nos connaissances une étude randomisée contre placebo, nous nous donnons l'objectif d'obtenir au cours de cette étude, au moins la même efficacité en terme de survie et de taux d'insuffisance rénale que ce qui est observé dans les études les plus récentes de la littérature.;Secondary Objective: L'objectif secondaire est d'évaluer la tolérance du bosentan, prescrit dans ces circonstances, en utilisant les normes définies par l'OMS.;Primary end point(s): Les critères d'évaluation de l'efficacité du traitement seront l'évolutivité de la fonction rénale (clairance de la créatinine et du débit de filtration glomérulaire, mesure du flux sanguin glomérulaire uniquement pour les patients inclus dans des groupes hospitaliers possédant un service d'explorations fonctionnelles rénales). La survie globale et la survie sans dialyse sera calculée à 12 mois (à la fin du suivi). Ces résultats seront comparés aux séries historiques de crises rénales sclérodermiques traités par IEC seuls.&lt;br&gt;&lt;br&gt;La tolérance du bosentan sera évaluée sur des critères cliniques et biologiques. Une surveillance des transaminases sera systématique tous les 15 jours le premier mois, puis tous les mois durant les 5 derniers mois de traitement.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>P081217</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2480705</Internal_Number>
    <TrialID>EUCTR2010-021355-85-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Etude nationale, multicentrique, prospective, évaluant la correction et le maintien du taux d’hémoglobine avec une administration sous-cutanée mensuelle de Mircera® chez des patients transplantés rénaux depuis plus de 6 mois présentant une anémie symptomatique traitée ou non par ASE - TRAMWAY</Public_title>
    <Scientific_title>Etude nationale, multicentrique, prospective, évaluant la correction et le maintien du taux d’hémoglobine avec une administration sous-cutanée mensuelle de Mircera® chez des patients transplantés rénaux depuis plus de 6 mois présentant une anémie symptomatique traitée ou non par ASE - TRAMWAY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>CHU AMIENS</Primary_sponsor>
    <Date_registration3>20100712</Date_registration3>
    <Date_registration>12/07/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-021355-85                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/10/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Relatifs à la population&lt;br&gt;—Patient adulte, âgé d’au moins 18 ans&lt;br&gt;—Patient apte selon l’investigateur à se plier aux contraintes de l’étude&lt;br&gt;—Patient ayant donné son consentement écrit de participation avant toute procédure de sélection dans l’étude&lt;br&gt;—Patient affilié à un régime de sécurité sociale ou bénéficiaire d’un tel régime&lt;br&gt;	&lt;br&gt;Relatifs à la pathologie&lt;br&gt;—Patient ayant bénéficié d’une transplantation rénale depuis plus de 6 mois&lt;br&gt;—Patient ayant un greffon fonctionnel sans signe clinique de rejet aigu&lt;br&gt;—Patient ayant une fonction rénale définie par un DFGe compris entre 60 et 15 ml/min&lt;br&gt;—Patient ayant un statut martial adéquat : coefficient de saturation de la transferrine &gt; 20% et/ou ferritinémie ? 50 mg/L lors de la visite de sélection&lt;br&gt;&lt;br&gt;—Groupe A : Patient naïf d’ASE ou patient n’étant plus traité par ASE depuis au moins 12 semaines avant la période de sélection et dont le taux d’hémoglobine est &lt; 11g/dL sur les 2 valeurs recueillies lors de la période de sélection (S-4 et J0 - 2 jours)&lt;br&gt;	OU&lt;br&gt;—Groupe B : Patient déjà traité par ASE par voie sous-cutanée (à l’exception de Mircera®), avec un rythme d’administration et une dose stable durant la période de sélection et sans variation du taux d’hémoglobine de plus de ± 1g/dL entre les 2 valeurs recueillies lors de la période de sélection&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Relatifs à la population&lt;br&gt;—Femme enceinte ou allaitant&lt;br&gt;—Femme en période d’activité génitale sans contraception efficace&lt;br&gt;—Patient ne souhaitant pas ou ne pouvant pas, selon l’investigateur, suivre les procédures de l’essai&lt;br&gt;—Patient ayant déjà été inclus dans le présent essai&lt;br&gt;—Patient participant (ou ayant participé) à un essai clinique ou recevant (ou ayant reçu) un traitement expérimental dans les 3 derniers mois&lt;br&gt;&lt;br&gt;Relatifs à la pathologie et au traitement étudié&lt;br&gt;—Patient traité par Mircera® au cours des 12 dernières semaines&lt;br&gt;—Patient présentant une insuffisance rénale sévère définie par un DFGe &lt; 15 mL/min au cours de la période de sélection&lt;br&gt;—Patient présentant une variation de la fonction rénale (DFGe) = 15% et / ou des signes cliniques de rejet aigu au cours de la période de sélection&lt;br&gt;—Patient avec greffe multi-organes&lt;br&gt;—Patient présentant un saignement aigu ou chronique significatif, comme une hémorragie gastro-intestinale &lt;br&gt;—Patient ayant reçu une ou plusieurs transfusions de culots globulaires dans les 8 semaines précédant la période de sélection et pendant cette période&lt;br&gt;—Patient présentant une hémoglobinopathie (anémie falciforme homozygote, thalassémie de tous types)&lt;br&gt;—Patient présentant une hémolyse (haptoglobine &lt; 30 mg/L)&lt;br&gt;—Patient ayant présenté une pathologie maligne active dans les 5 dernières années (excepté les cancers cutanés hors mélanome)&lt;br&gt;—Patient ayant un déficit connu en Vitamine B12&lt;br&gt;—Patient ayant un déficit connu en acide folique&lt;br&gt;—Patient présentant une maladie inflammatoire chronique &lt;br&gt;—Patient présentant une maladie infectieuse aiguë ou chronique &lt;br&gt;—Patient ayant une hyperparathyroïdie secondaire non contrôlée ou symptomatique&lt;br&gt;—Patient présentant une hypertension artérielle mal contrôlée, c’est-à-dire une pression artérielle en position assise &gt; 180/100 mm Hg&lt;br&gt;—Patient ayant présenté des crises d’épilepsie dans les 12 semaines précédant la période de sélection&lt;br&gt;—Patient ayant présenté un infarctus du myocarde, un accident vasculaire cérébral, une coronaropathie sévère ou instable, une pathologie hépatique sévère dans les 12 semaines précédant la période de sélection&lt;br&gt;—Patient présentant une insuffisance cardiaque congestive sévère (stade III ou IV de la New York Heart Association)&lt;br&gt;—Patient présentant un nombre de plaquettes &gt; 500 x 109/L ou &lt; 100 x 109/L&lt;br&gt;—Patient présentant une érythroblastopénie&lt;br&gt;—Patient ayant une chirurgie planifiée pendant la durée de l’étude excepté pour la cataracte et pour une chirurgie nécessitant un accès vasculaire &lt;br&gt;—Patient présentant une hypersensibilité connue à une érythropoïétine humaine recombinante, au polyéthylène glycol ou à tout autre constituant du traitement à l’étude &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Anémie symptomatique chez le patient transplanté rénal &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10054353
Term: &lt;Manually entered code. Term in E.1.1&gt;
</Condition>
    <Intervention>&lt;br&gt;Trade Name: MIRCERA&lt;br&gt;Product Code: RO 503821/F03&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyéthylène glycol-epoetin bêta&lt;br&gt;Current Sponsor code: RO 503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;INN or Proposed INN: methoxy polyéthylène glycol-epoetin bêta&lt;br&gt;Current Sponsor code: RO 503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;INN or Proposed INN: methoxy polyéthylène glycol-epoetin bêta&lt;br&gt;Current Sponsor code: RO 503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 75-&lt;br&gt;INN or Proposed INN: methoxy polyéthylène glycol-epoetin bêta&lt;br&gt;Current Sponsor code: RO 503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;INN or Proposed INN: methoxy polyéthylène glycol-epoetin bêta&lt;br&gt;Current Sponsor code: RO 503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 120-&lt;br&gt;INN or Proposed INN: methoxy polyéthylène glycol-epoetin bêta&lt;br&gt;Current Sponsor code: RO 503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 150-&lt;br&gt;INN or Proposed INN: methoxy polyéthylène glycol-epoetin bêta&lt;br&gt;Current Sponsor code: RO 503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: methoxy polyéthylène glycol-epoetin bêta&lt;br&gt;Current Sponsor code: RO 503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;INN or Proposed INN: methoxy polyéthylène glycol-epoetin bêta&lt;br&gt;Current Sponsor code: RO 503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 360-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: * Groupe A = Étude de correction de l’Hb : Patients transplantés rénaux non traités par ASE&lt;br&gt;Evaluer la correction de l’anémie, définie par un taux moyen d’Hb compris dans l’intervalle [11-12] g/dL, avec une administration sous-cutanée mensuelle de Mircera®.&lt;br&gt;&lt;br&gt;* Groupe B = Étude de maintien de l’Hb : Patients transplantés rénaux traités au préalable par ASE&lt;br&gt;Evaluer la stabilité du taux d’hémoglobine pendant la phase de maintien, avec une administration sous-cutanée mensuelle de Mircera®&lt;br&gt;;Secondary Objective: -Evaluer la variabilité du taux d’Hb avec une administration SC mensuelle de Mircera®&lt;br&gt;-Evaluer la dose de Mircera® nécessaire à la correction de l’anémie et au maintien du taux d’Hb dans les intervalles [10-11[ ; [11-12] g/dL&lt;br&gt;-Evaluer le recours aux transfusions sanguines&lt;br&gt;-Evaluer le taux d’hémoglobine en fonction du statut martial&lt;br&gt;-Evaluer l’impact de la correction de l’anémie sur la fonction rénale&lt;br&gt;-Evaluer la survie des patients et des greffons&lt;br&gt;- Evaluer la sécurité globale et la tolérance à Mircera®&lt;br&gt;-Décrire l’évolution de la qualité de vie&lt;br&gt;-Evaluer l’incidence et le délai de survenue d’un rejet aigu prouvé par biopsie&lt;br&gt;-Evaluer les modifications du traitement immunosuppresseur&lt;br&gt;;Primary end point(s): Critères principaux au cours de la période d’évaluation S16-S24 :&lt;br&gt;&lt;br&gt;Groupe A : Correction de l’anémie&lt;br&gt;Proportion de patients ayant un taux moyen d’hémoglobine compris dans l’intervalle [11-12] g/dL pendant la période d’évaluation&lt;br&gt;&lt;br&gt;Groupe B : Stabilité&lt;br&gt;Proportion de patients maintenant un taux d’hémoglobine stable, dans un intervalle de ± 1 g/dL par rapport au taux moyen de la période de sélection* [Hb moyenne sélection -1 g/dL ; Hb moyenne sélection + 1g/dL].&lt;br&gt;&lt;br&gt;* Valeur moyenne de la période de sélection = moyenne des 2 mesures d’Hb à S-4 et J0&lt;br&gt;&lt;br&gt;</Primary_outcome>
    <Secondary_ID>PI10</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2481022</Internal_Number>
    <TrialID>EUCTR2009-009427-11-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Efecto de la solución de diálisis peritoneal balance sobre la membrana peritoneal de pacientes tratados con diálisis peritoneal automatizada (DPA)
(The effect of balance peritoneal dialysis solution on the peritoneal membrane in patients on automated peritoneal dialysis (APD))</Public_title>
    <Scientific_title>Efecto de la solución de diálisis peritoneal balance sobre la membrana peritoneal de pacientes tratados con diálisis peritoneal automatizada (DPA)
(The effect of balance peritoneal dialysis solution on the peritoneal membrane in patients on automated peritoneal dialysis (APD))                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Fresenius Medical Care Deutschland GmbH</Primary_sponsor>
    <Date_registration3>20100805</Date_registration3>
    <Date_registration>05/08/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009427-11                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>13/10/2010</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Pacientes en DPA mayores de 18 años &lt;br&gt;- Pacientes prevalentes con por lo menos 3 meses de experiencia en DPA anterior a la inclusión en el estudio&lt;br&gt;- Paciente entrenados para el manejo de la cicladora sleep?safe para DPA y tratados con esta&lt;br&gt;- Pacientes tratados con DPA utilizando exclusivamente las soluciones convencionales CAPD 2, CAPD 3, CAPD 4, CAPD 17, CAPD 18 o CAPD 19 por lo menos durante las 8 semanas anteriores al estudio&lt;br&gt;- Pacientes bajo tratamiento diurético constante, p.ej. sin cambios en diuréticos en los últimos 30 días&lt;br&gt;- Consentimiento informado firmado y fechado por el paciente y el investigador&lt;br&gt;- Habilidad para entender la naturaleza y requerimientos del estudio&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Pacientes tratados por peritonitis durante las últimas 4 semanas&lt;br&gt;- Pacientes es tratados con la modalidad IPD &lt;br&gt;- Pacientes que sufren de alguna enfermedad maligna terminal&lt;br&gt;- Pacientes con articulaciones artificiales, amputaciones, stents o marcapasos &lt;br&gt;- Pacientes que sufren de cardiopatía isquémica o insuficiencia cardiaca NYHA III o mayor &lt;br&gt;- Pacientes con infecciones HBV o HCV activas&lt;br&gt;- Pacientes VIH positivos &lt;br&gt;- Pacientes que participaron en alguna investigación clínica en los 30 días anteriores al inicio de este estudio &lt;br&gt;- Pacientes que presentan alguna condición que puede interferir con su habilidad para cumplir con los requisitos del estudio&lt;br&gt;</Exclusion_Criteria>
    <Condition>Pacientes con enfermedad renal crónica tratados con diálisis peritoneal &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10014646
Term: End stage renal disease (ESRD)
</Condition>
    <Intervention>&lt;br&gt;Trade Name: BALANCE 1,5 % glucosa, 1,75 mmol/l de calcio, solución para diálisis peritoneal&lt;br&gt;Pharmaceutical Form: Solution for peritoneal dialysis&lt;br&gt;INN or Proposed INN: CALCIO CLORURO DIHIDRATO&lt;br&gt;CAS Number: 10035-04-8&lt;br&gt;Other descriptive name: CALCIUM CHLORIDE DIHYDRATE&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.2573-&lt;br&gt;INN or Proposed INN: GLUCOSA MONOHIDRATADA&lt;br&gt;CAS Number: 5996-10-1&lt;br&gt;Other descriptive name: GLUCOSE MONOHYDRATE&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 15-&lt;br&gt;INN or Proposed INN: LACTATO SODIO&lt;br&gt;CAS Number: 72-17-3&lt;br&gt;Other descriptive name: SODIUM LACTATE&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 3.925-&lt;br&gt;INN or Proposed INN: MAGNESIO CLORURO HEXAHIDRATO&lt;br&gt;CAS Number: 7791-18-6&lt;br&gt;Other descriptive name: MAGNESIUM CHLORIDE HEXAHYDRATE&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.1017-&lt;br&gt;INN or Proposed INN: SODIO CLORURO&lt;br&gt;CAS Number: 8026-10-6&lt;br&gt;Other descriptive name: SODIUM CHLORID&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5.640-&lt;br&gt;&lt;br&gt;Trade Name: BALANCE 2,3 % glucosa, 1,75 mmol/l de calcio, solución para diálisis peritoneal&lt;br&gt;Pharmaceutical Form: Solution for peritoneal dialysis&lt;br&gt;INN or Proposed INN: CALCIO CLORURO DIHIDRATO&lt;br&gt;CAS Number: 10035-04-8&lt;br&gt;Other descriptive name: CALCIUM CHLORIDE DIHYDRATE&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.2573-&lt;br&gt;INN or Proposed INN: GLUCOSA MONOHIDRATADA&lt;br&gt;CAS Number: 5996-10-1&lt;br&gt;Other descriptive name: GLUCOSE MONOHYDRATE&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 22.73-&lt;br&gt;INN or Proposed INN: LACTATO SODIO&lt;br&gt;CAS Number: 72-17-3&lt;br&gt;Other descriptive name: SODIUM LACTATE&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 3.925-&lt;br&gt;INN or Proposed INN: MAGNESIO CLORURO HEXAHIDRATO&lt;br&gt;CAS Number: 7791-18-6&lt;br&gt;Other descriptive nam</Intervention>
    <Primary_outcome>Secondary Objective: Mostrar la equivalencia de la solución de DP investigada (balance) y la solución de DP convencional en cuanto al estado de hidratación.&lt;br&gt;Investigar el efecto de la solución de DP balance sobre la inflamación y la formación de AGE sistémicos.;Main Objective: Investigar la biocompatibilidad de la solución de DP balance en comparación con la solución convencional para DP en pacientes tratados con la cicladora sleep?safe para  DPA.;Primary end point(s): - Tasa de aparición de CA125 en el efluente colectado durante 24 horas y estimación de la hidratación&lt;br&gt;- Acido hialurónico (HA) en el efluente colectado durante 24 horas&lt;br&gt;- Ultrafiltración&lt;br&gt;- CML, CRP yIL-6 en el suero</Primary_outcome>
    <Secondary_ID>PD-NL-04-EU</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2481207</Internal_Number>
    <TrialID>EUCTR2010-020401-32-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>IDENTIFICATION OF OXIDATIVE-STRESS AND MICROINFLAMMATION GENES MODULATED BY ERYTHROPOIETIN ADMINISTRATION IN PATIENTS WITH RENAL TRANSPLANT AND CHRONIC RENAL FAILURE. PERSPECTIVES FOR ERYTHROPOITIN PHARMACOGENOMICS. - ND</Public_title>
    <Scientific_title>IDENTIFICATION OF OXIDATIVE-STRESS AND MICROINFLAMMATION GENES MODULATED BY ERYTHROPOIETIN ADMINISTRATION IN PATIENTS WITH RENAL TRANSPLANT AND CHRONIC RENAL FAILURE. PERSPECTIVES FOR ERYTHROPOITIN PHARMACOGENOMICS. - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE</Primary_sponsor>
    <Date_registration3>20100906</Date_registration3>
    <Date_registration>06/09/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-020401-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>25/01/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: nessun trattamento; se necessario,terapia marziale&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;• Age 18 years or older  • Renal transplant &gt; 6 months prior to randomization   • Haemoglobin concentration between 11.5 and 12.5 g/dl at Baseline (mean of the two values obtained at week -4 and -2 during screening period)obtained with darbepoetin in the group A (group darbepoetin) and without any eritropoietin in the group B (group untreated)  • No ESA therapy during the 3 months prior to randomization  • Adequate iron status (serum ferritin =100 ng/mL as well as TSAT =20% or hypochromic red cells &lt;10% if serum transferrin or TIBC are unavailable). The mean of the two values obtained during screening period, at week -4 and -2, should be considered.  • GFR (estimated using the aMDRD equation) more then 30 mL/min during screening period (at week -4 and -2).&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;• Requirement for haemodialysis or peritoneal dialysis therapy within 3 months prior to randomization  ? mTOR inhibitors (Sirolimus, Everolimus) based Immunosuppression   • Change in haemoglobin concentration = 1.5 g/dL during the screening period (week -4 and -2)  • Change in GFR &gt;30% during the screening period  • Treatment for clinical acute rejection during screening period with GFR stability  below 30%  • Recipients of other solid organs in addition to kidney  • Patients planned to be switched from one immunosuppressive agent to another during study participation  • History of positive Anti-phospholipid antibodies  • Transfusion of red blood cells during the 3 months prior to randomization  • Poorly controlled hypertension as judged by the investigator, or requiring more than 3 antihypertensive drugs (excluding diuretics)  • Significant acute or chronic bleeding, such as overt gastrointestinal bleeding, i.e. requiring therapy within 3 months prior to randomization  • Active malignant disease (except non-melanoma skin cancer)  • Haemolysis  • Haemoglobinopathies (e.g. homozygous sickle-cell disease, thalassemia of all  types)  • Folic acid deficiency  • Vitamin B12 deficiency  • Platelet count &gt;500 x 109/L or &lt;100 x 109/L  • Pure red cell aplasia  • Epileptic seizure in the 6 months prior to randomization  • Congestive heart failure (NYHA Class IV)  • Myelofibrosis  • Active systemic lupus erythematosus  • Myocardial infarction or stroke, severe or unstable coronary artery disease, severe liver disease during 3 months prior to randomization  • Uncontrolled or symptomatic secondary hyperparathyroidism  • Women with positive pregnancy tests prior to randomization  • Women of childbearing potential without effective contraception or women in lactation period  • Participation in a clinical trial or receipt of investigational compound or treatment within the 3 months prior to randomization  • Planned elective surgery during the study period (except cataract surgery,  vascular access surgery, urethral stent removal, nephrostomy tube replacement, minor outpatient surgery not requiring hospitalization  • Known HIV infection  • Known hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any constituent of the study medication&lt;br&gt;</Exclusion_Criteria>
    <Condition>PATIENTS WITH RENAL TRANSPLANT AND CHRONIC RENAL FAILURE &lt;br&gt;MedDRA version: 9.1
Level: SOC
Classification code 10038359
</Condition>
    <Intervention>&lt;br&gt;Trade Name: ARANESP&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Darbepoetin alfa&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 150-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: 1) to assess whether ESA treatment may modulate inflammatory and oxidative stress genes in patients with renal transplant; 2) to identify genomic patterns able to explain the complex link among anemia, microinflammation and oxidative stress; 3) to identify ESA unresponsive subjects.;Secondary Objective: 1) to assess whether ESA treatment may modulate inflammatory and oxidative stress genes in patients with renal transplant; 2) to identify genomic patterns able to explain the complex link among anemia, microinflammation and oxidative stress; 3) to identify ESA unresponsive subjects.;Primary end point(s): Changes of the inflammatory and oxidative stress genes in patients with renal transplant with eritropoietin</Primary_outcome>
    <Secondary_ID>darbepoetina</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2481454</Internal_Number>
    <TrialID>EUCTR2010-019398-14-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>IMPROVEMENT OF RENAL FUNCTION BY CONVERSION OF TACROLIMUS TO EVEROLIMUS 3 MONTHS AFTER KIDNEY TRANSPLANTATION</Public_title>
    <Scientific_title>IMPROVEMENT OF RENAL FUNCTION BY CONVERSION OF TACROLIMUS TO EVEROLIMUS 3 MONTHS AFTER KIDNEY TRANSPLANTATION                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Erasmus Medical Center</Primary_sponsor>
    <Date_registration3>20100624</Date_registration3>
    <Date_registration>24/06/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-019398-14                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>07/10/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Adult patients (18 years or older) who have received an ABO-compatible single-organ kidney transplant from a living donor and who participated in study METC-2010-080 will be eligible for entry into the study.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients need to be on  immunosuppressive therapy with tacrolimus and mycophenolate mofetil at 3 months after transplantation.  &lt;br&gt;</Exclusion_Criteria>
    <Condition>Kidney Transplantation</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: everolimus&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Current Sponsor code: RAD-001&lt;br&gt;Other descriptive name: EVEROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 3.0-&lt;br&gt;&lt;br&gt;Trade Name: Prograft&lt;br&gt;Product Name: Prograft&lt;br&gt;Product Code: L04AD02&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Current Sponsor code: 18107&lt;br&gt;Other descriptive name: tacrolimus&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 0.15-0.30&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Primary end point(s): For this conversion study renal function is the primary endpoint. Mean MDRD clearances will be compared between tacrolimus and everolimus treated patients at month 12. Also changes in MDRD clearances within individual patients in the tacrolimus and everolimus treated patients between month 3 and 12 will be compared. ;Secondary Objective: Apart from renal function also changes in renal histology &lt;br&gt;following conversion of tacrolimus-based immunosuppression to everolimus-&lt;br&gt;based immunosuppression will be studied.&lt;br&gt;;Main Objective: The aim of this study is to investigate if conversion of tacrolimus-based &lt;br&gt;immunosuppression to everolimus-based immunosuppression results in &lt;br&gt;preservation of renal function as compared to continued tacrolimus-based &lt;br&gt;immunosuppression. </Primary_outcome>
    <Secondary_ID>RB02</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2481512</Internal_Number>
    <TrialID>EUCTR2010-020664-38-GR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Efficacy and safety of Bevacizumab/Temsirolimus combination after first-line Bevacizumab/IFN combination in advanced renal cell carcinoma</Public_title>
    <Scientific_title>Efficacy and safety of Bevacizumab/Temsirolimus combination after first-line Bevacizumab/IFN combination in advanced renal cell carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Hellenic Cooperative Oncology Group</Primary_sponsor>
    <Date_registration3>20101004</Date_registration3>
    <Date_registration>04/10/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-020664-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>28/09/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Adult patients (18th year of age completed).&lt;br&gt;Signed and dated written informed consent form prior to any procedures related to this protocol.&lt;br&gt;Histologically confirmed advanced clear cell renal cancer.&lt;br&gt;Measurable disease. &lt;br&gt;Failure of first line treatment of the combination bevacizumab and interferon A2 alpha.&lt;br&gt;Performace status 0-2, according to ECOG.&lt;br&gt;Satisfactory hematological parameters:&lt;br&gt;WBC &gt;4000mm3&lt;br&gt;PLT &gt;100000/mm3&lt;br&gt;ANC&gt;1200/mm3&lt;br&gt;Hemoglobin&gt;9,0 g/dL (can be achieved with red blood cell transfusion)&lt;br&gt;Satisfactory biochemical parameters:&lt;br&gt;Serum creatinine&lt;2xULN&lt;br&gt;AST&lt;2,5xULN&lt;br&gt;ALT&lt;2,5xULN&lt;br&gt;Bilirubin&lt;2xULN&lt;br&gt;(For female patients) Absence of pregnancy (negative pregnancy test for women of reproductive age before enrollment).&lt;br&gt;(For female patients) Non-lactating women.&lt;br&gt;Use of efficient contraceptive measures (women and men) to prevent possible pregnancy of female patient or female partner of a male patient during treatment and until 6 months after the end of treatment&lt;br&gt;&lt;br&gt;&lt;br&gt;	&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Prior treatment with mTOR inhibitor and/or TKI.&lt;br&gt;Major surgery (including open biopsy) or insufficient recovery or existence of major trauma within 4 weeks before enrollment.&lt;br&gt;Uncontrolled hypertension.&lt;br&gt;Active infection requiring systemic treatment within 4 weeks prior to enrollment.&lt;br&gt;Minor surgery (e.g. catheter replacement) within 2 days before enrollment.&lt;br&gt;Scheduled major surgery within the treatment period.&lt;br&gt;Medical history in the last 6 months prior to enrollment of significant cardiovascular disease, diabetes, cardiac infarction, unstable angina, uncontrolled arrhythmia or significant heart failure.&lt;br&gt;Indications of uncontrolled metastases or disease progression in CNS lesions (the suspicion of uncontrolled metastases or disease progression should be eliminated by imaging techniques within 14 days prior to enrollment).&lt;br&gt;Medical history in the last 5 years prior to enrollment of any other malignancies (excluding the basal or squamous skin cell carcinoma or in situ carcinoma of the cervix).&lt;br&gt;History of non-healing wound including active gastric ulcer.&lt;br&gt;History of fistula in the last 6 months prior to enrollment.&lt;br&gt;History of gastrointestinal perforation.&lt;br&gt;Patient incapacity (for psychiatric or social reasons) to conform to the protocol.&lt;br&gt;History of hemorrhagic predisposition.&lt;br&gt;History of hypersensitivity to the medications under investigation.&lt;br&gt;Significant proteinuria.&lt;br&gt;Prior immunotherapy within 4 weeks prior to enrollment.&lt;br&gt;Prior radiation treatment within 2 weeks prior to enrollment.&lt;br&gt;Concomitant medication with inducers or strong inhibitors of the coenzyme CYP3A4.&lt;br&gt;Concurrent participation in other interventional clinical trials with IMPs.&lt;br&gt;History of chronic interstitial lung disease. &lt;br&gt;</Exclusion_Criteria>
    <Condition>Advanced renal cancer &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10038390
Term: Renal cancer recurrent
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Torisel&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TEMSIROLIMUS&lt;br&gt;CAS Number: 162635-04-3&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;Trade Name: Avastin cs.sol.inf.25mg/ml&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: BEVACIZUMAB&lt;br&gt;CAS Number: 216974-75-3&lt;br&gt;Current Sponsor code: RO 4876646&lt;br&gt;Other descriptive name: rhuMAb VEGF, anti-VEGF&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluation of efficacy (6 month PFS);Secondary Objective: Progression Free Survival (PFS)&lt;br&gt;Overall Survival (OS)&lt;br&gt;Response Rate (RR)&lt;br&gt;Tumor shrinkage&lt;br&gt;Evaluation of safety&lt;br&gt;Adverse events with any causal relationship with the study IMPs&lt;br&gt;Serious adverse events with any causal relationship with the study IMPs&lt;br&gt;Quality of Life (QoL) evaluation using the QLQ C-30 questionnaire&lt;br&gt;Exploration of antiangiogenic parameters for response&lt;br&gt;;Primary end point(s): Evaluation of efficacy (6 month PFS)</Primary_outcome>
    <Secondary_ID>HE 21/10</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2481531</Internal_Number>
    <TrialID>EUCTR2010-021275-92-DE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Single center, open-label, cross-over study in maintenace kidney allograft recipients to evaluate the bioavailability of CellCept® (Mycophenolate mofetil) in comparison to Myfortic® (Enteric- coated  mycophenolate sodium) in combination with a proton pump inhibitor without co-medication. - Not available</Public_title>
    <Scientific_title>Single center, open-label, cross-over study in maintenace kidney allograft recipients to evaluate the bioavailability of CellCept® (Mycophenolate mofetil) in comparison to Myfortic® (Enteric- coated  mycophenolate sodium) in combination with a proton pump inhibitor without co-medication. - Not available                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Charité – Universitätsmedizin Berlin</Primary_sponsor>
    <Date_registration3>20101001</Date_registration3>
    <Date_registration>01/10/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-021275-92                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>16/09/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: yes&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator:  PR1, PR1+PR3, PR2, PR2+PR3&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Patients who are at least 18 years of age,&lt;br&gt;•	Willing to provide informed consent,&lt;br&gt;•	Suitable and willing to switch treatment according to the study plan,&lt;br&gt;•	Patients who are on stable immunosuppressive pre-treatment for at least one month with Cyclosporin A (C0-level of 75-150 ng/mL or C2-level of 400-900 ng/mL), Myfortic® or Cellcept® with or without corticosteroids  ,&lt;br&gt;•	 Renal transplantation, at least 6 months prior to study inclusion,&lt;br&gt;•	Women of childbearing potential must have a negative serum pregnancy test before study start, and effective contraception must be used (method with PEARL index &lt;1%).&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	Known anamnestic hypersensitivity to one of the investigational products or drugs with similar chemical structure and to other components of the investigational products, respectively,&lt;br&gt;•	Patients who are not on stable treatment with enzyme inductors or enzymes for one month before study start,&lt;br&gt;•	Patients with renal function &lt;30mL/min (using the Cockroft-Gault formula),&lt;br&gt;•	Patients on treatment with clopidogrel,&lt;br&gt;•	Acute rejection less than 1 month before study inclusion,&lt;br&gt;•	Patients who are HIV positive, HCV positive or HBsAg positive , &lt;br&gt;•	Patients with gastrointestinal disorders which could affect resorption,&lt;br&gt;•	Pregnancy and/or lactation,&lt;br&gt;•	Drug or alcohol abuse in the patient’s history,&lt;br&gt;•	(Patients with) insufficient co-operation with the clinical investigator (e.g. suspicion of non-compliance),&lt;br&gt;•	Patients with a history of psychological illness or condition such as to interfere with the patient’s ability to understand the requirements, the consequences and possible outcomes of the study and who are not willing to give a valid informed consent to the study.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Prophylaxis against renal transplant rejection

Renal transplant -&gt; immunosuppressant drug therapy &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10054980
Term: Immunosuppressant drug therapy
 &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10038533
Term: Renal transplant
 &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10050436
Term: Prophylaxis against renal transplant rejection
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Myfortic®&lt;br&gt;Product Name: Myfortic®&lt;br&gt;Pharmaceutical Form: Gastro-resistant tablet&lt;br&gt;INN or Proposed INN: MYCOPHENOLATE SODIUM&lt;br&gt;CAS Number: 37415-62-6&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 360-&lt;br&gt;&lt;br&gt;Trade Name: CellCept®&lt;br&gt;Product Name: CellCept®&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: MYCOPHENOLATE MOFETIL&lt;br&gt;CAS Number: 115007-34-6&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Trade Name: Pantozol®&lt;br&gt;Product Name: Pantozol®&lt;br&gt;Pharmaceutical Form: Gastro-resistant tablet&lt;br&gt;INN or Proposed INN: Pantoprazole (as sodium sesquihydrate)&lt;br&gt;CAS Number: 102625-70-7 &lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 40-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Primary end point(s): Evaluation of the bioavailability (as measured by area-under-the-concentration-curve (AUC)) of mycophenolic acid in stable renal transplant patients under immunosuppressive maintenance therapy after application of CellCept® alone or in combination with pantozol®; myfortic® alone or in combination with pantozol®.;Main Objective: Study objectives:&lt;br&gt;The objective of this pharmacokinetic trial is to analyze, whether the concomitant administration of a proton pump inhibitor influences the bioavailability of mycophenolic acid, applied as either mycophenolat mofetil or enteric-coated mycophenolic acid.&lt;br&gt;&lt;br&gt;Primary objective:&lt;br&gt;Evaluation of the bioavailability (as measured by area-under-the-concentration-curve (AUC)) of mycophenolic acid in stable renal transplant patients under immunosuppressive maintenance therapy after application of CellCept® alone or in combination with pantozol®; myfortic® alone or in combination with pantozol®.;Secondary Objective: •	Analysis of additional pharmacokinetic parameters, such as maximal concentration (Cmax), average concentration (Cavg), minimal concentration (Cmin), time to Cmax (Tmax), and apparent clearance (CL/F) of mycophenolic acid (MPA),&lt;br&gt;•	Analysis of the pharmacokinetic characteristics of the MPA metabolite MPAG,&lt;br&gt;•	Analysis of IMPH activity and the related pharmacodynamic (PD) parameters (maximal activity (Emax), minimal activity (Emax), average activity (Aavg), maximal inhibition),&lt;br&gt;•	Analysis of the safety and tolerability, in particular analysis of gastrointestinal discomfort (using standardized questionnaires), infections, leukopenia, anemia, thrombocytopenia, liver enzymes (AST, ALT), albumin- and protein content, gastrointestinal AEs incl. intensity, renal function using serum creatinine and GFR (according to Nanikvell and Cockroft-Gault), incidence of biopsy-proven acute rejections, and graft loss.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>CERL080ADE20T;Not available</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2481616</Internal_Number>
    <TrialID>EUCTR2010-019639-37-HU</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING RENAL FUNCTION IN AN ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT SIROLIMUS IN KIDNEY TRANSPLANT SUBJECTS. - ADHERE</Public_title>
    <Scientific_title>A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING RENAL FUNCTION IN AN ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT SIROLIMUS IN KIDNEY TRANSPLANT SUBJECTS. - ADHERE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Astellas Pharma Europe Ltd.</Primary_sponsor>
    <Date_registration3>20101022</Date_registration3>
    <Date_registration>22/10/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-019639-37                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>30/11/2010</Date_enrollement>
    <Target_size>772</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Age = 18 years. &lt;br&gt;2. End stage kidney disease and a suitable candidate for primary renal transplantation or re-transplantation (unless the graft was lost from rejection within 6 months). &lt;br&gt;3. Receiving a kidney transplant from a deceased or living (non Human Leukocyte Antigen identical) donor with compatible ABO blood type. &lt;br&gt;4. Female subject of childbearing potential has a negative serum or urine pregnancy test at enrollment. &lt;br&gt;5. Female and male subjects agree to maintain highly effective birth control during the study and for 90 days after discontinuation of dosing with study drugs. &lt;br&gt;6. Capable of understanding the purpose and risks of the study, fully informed and having given written informed consent (signed Informed Consent has been obtained). &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Receiving or having previously received an organ transplant other than a kidney.&lt;br&gt;2. Cold ischemia time of the donor kidney &gt; 30 hours.&lt;br&gt;3. Receiving a graft from a non-heart-beating donor other than of Maastricht category 3 (withdrawal of support awaiting cardiac arrest).&lt;br&gt;4. Panel Reactive Antibody &gt;20%.&lt;br&gt;5. Significant liver disease, defined as having continuously elevated SGPT/ALT and/or SGOT/AST and/or total bilirubin levels = 2 times the upper value of the normal range of the investigational site or is receiving a graft from a hepatitis C or B positive donor.&lt;br&gt;6. Requiring initial sequential or parallel therapy with immunosuppressive antibody preparation(s).&lt;br&gt;7. Requiring ongoing dosing with a systemic immunosuppressive drug prior to transplantation (other than minimal levels of immunosuppression following failure of previous transplantation without nephrectomy).&lt;br&gt;8. Significant, uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer.&lt;br&gt;9. Pregnant woman or breast-feeding mother.&lt;br&gt;10. Subject or donor known to be HIV positive.&lt;br&gt;11. Known allergy or intolerance to tacrolimus, macrolide antibiotics, corticosteroids, sirolimus, MMF or any of the product excipients or iodine.&lt;br&gt;12. Evidence of malignant disease within the last 5 years, not including non-malignant skin cancers. &lt;br&gt;13. Currently participating in another clinical trial, and/or has taken an investigational drug within 28 days prior to enrollment.&lt;br&gt;14. Any form of substance abuse, psychiatric disorder or condition which, in the opinion of the Investigator, may complicate communication with the Investigator.&lt;br&gt;15. Unlikely to comply with the visits scheduled in the protocol.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Prophylaxis of rejection in kidney allograft recipients (by immunosuppression) &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10050436
Term: Prophylaxis against renal transplant rejection
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Advagraf&lt;br&gt;Pharmaceutical Form: Prolonged-release capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Trade Name: Advagraf&lt;br&gt;Pharmaceutical Form: Prolonged-release capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: Advagraf&lt;br&gt;Pharmaceutical Form: Prolonged-release capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 3-&lt;br&gt;&lt;br&gt;Trade Name: Advagraf&lt;br&gt;Pharmaceutical Form: Prolonged-release capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: sirolimus&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: SIROLIMUS&lt;br&gt;CAS Number: 53123-88-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: sirolimus&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: SIROLIMUS&lt;br&gt;CAS Number: 53123-88-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the effect two immunosuppressive therapy regimens on Glomerular Filtration Rate (GFR) estimated by Iohexol clearance at Week 52 post kidney transplantation.&lt;br&gt;Arm 1: Advagraf® + MMF + Steroids&lt;br&gt;Arm 2: Advagraf® + MMF (withdrawn at Day 28) + Steroids + Sirolimus (introduced at Day 28). At Day 42 (Week 6) the Advagraf® dose will be reduced to achieve lower tacrolimus target levels.;Secondary Objective: To compare the safety and efficacy profiles of the two immunosuppressive therapy regimens with each other;Primary end point(s): GFR estimated by Iohexol clearance at Week 52 post kidney transplantation</Primary_outcome>
    <Secondary_ID>PMR-EC-1212</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2481698</Internal_Number>
    <TrialID>EUCTR2010-023455-28-FI</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Dexmedetomidine pharmacokinetics during continuous venovenous hemofiltration and hemodiafiltration in critically ill patients - Dexmedetomidine study</Public_title>
    <Scientific_title>Dexmedetomidine pharmacokinetics during continuous venovenous hemofiltration and hemodiafiltration in critically ill patients - Dexmedetomidine study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Maija Kaukonen</Primary_sponsor>
    <Date_registration3>20101103</Date_registration3>
    <Date_registration>03/11/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-023455-28                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>15/12/2010</Date_enrollement>
    <Target_size>10</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. age = 18&lt;br&gt;2. clinical need for sedation&lt;br&gt;3. acute kidney injury requiring renal replacement therapy (according to ICUs standard operating procedures, one or more of the following criteria)&lt;br&gt;        -oliguria (diuresis &lt; 200ml/12h) or anuria&lt;br&gt;        -severe acidosis (pH &lt; 7.1-7.2) or rapidly deteriorating acidosis&lt;br&gt;        -hyperpotassemia &lt;br&gt;        -urea &gt; 30 mmol/l and/or creatinine &gt;500 umol/l or uremic complications    (encephalopatia, pericarditis)&lt;br&gt;        -significant fluid retention (high IAP,  pulmonary oedema, severe peripheral oedema) &lt;br&gt;        -rhabdomyolysis&lt;br&gt;        -especially the combination of oliguria and deteriorating acidosis and/or hyperpotassemia is an indication for early initiation of renal replacement therapy&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Severe bradycardia (HR&lt;50/min)&lt;br&gt;2. AV conduction block II-III (unless pacemaker installed)&lt;br&gt;3. Severe hepatic impairment (bilirubin &gt;101 umol/l)&lt;br&gt;4. Pregnancy or lactation&lt;br&gt;5. Age &lt;18&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Intensive care patients with acute kidney injury requiring continuous renal replacement therapy with a clinical indication for sedation &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10069339
Term: Acute kidney injury
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Precedex&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: dexmedetomidine hydrochloride&lt;br&gt;CAS Number: 145108-58-3&lt;br&gt;Current Sponsor code: 11102010&lt;br&gt;Other descriptive name: DEXMEDETOMIDINE HYDROCHLORIDE&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine the pharmacokinetics of dexmedetomidine during continuous venovenous hemofiltration and hemodialfiltration  in critically ill patients.  The measured values will be Cltot, ClCVVH(DF), Vd, T½, the amount of dexmedetomidine in ultrafiltrate and urine.;Secondary Objective: none;Primary end point(s): This is a descriptive study aiming to determine dexmedetomidine clearance during continuous venovenous hemofiltration and hemodiafiltration.</Primary_outcome>
    <Secondary_ID>11102010</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2481808</Internal_Number>
    <TrialID>EUCTR2010-020925-42-AT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Phase II, Open-Label, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted from a Prograf® Based Immunosuppressive Regimen to a Tacrolimus Prolonged Release, Advagraf®  Based Immunosuppressive Regimen, Including a Long-Term Follow Up</Public_title>
    <Scientific_title>A Phase II, Open-Label, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted from a Prograf® Based Immunosuppressive Regimen to a Tacrolimus Prolonged Release, Advagraf®  Based Immunosuppressive Regimen, Including a Long-Term Follow Up                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Astellas Pharma Europe Ltd.</Primary_sponsor>
    <Date_registration3>20101111</Date_registration3>
    <Date_registration>11/11/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-020925-42                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>27/01/2011</Date_enrollement>
    <Target_size>80</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. The subject is at least 5 years and not older than 16 years of age, inclusive.&lt;br&gt;2. The subject must be able to swallow intact study medication capsules.&lt;br&gt;3. The subject received a single solid organ transplant at least 6 months prior to entry into the study.&lt;br&gt;4. The subject’s parent(s), or their legal representative(s), has been fully informed and has given written informed consent to participate in the study. The subject has given assent where applicable.&lt;br&gt;5. The subject has been receiving a Prograf® based immunosuppressive regimen for a minimum of 3 months.&lt;br&gt;6. Female subjects of child bearing potential must provide a negative urine or serum&lt;br&gt;pregnancy test prior to enrolment in the study&lt;br&gt;7. Male and female subjects that are sexually active must agree to practice effective birth control during the study. (An effective method of birth control is defined as those which result in a low failure rate (CPMP/ICH/286/95 modified) of less than 1% per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomized partner).&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. The subject has previously received a multiple organ transplant.&lt;br&gt;2. The subject has experienced any rejection episode within 3 months prior to enrolment in the study, any rejection episode within the last 6 months that required anti-lymphocyte antibody therapy, or 2 or more rejection episodes within the last 12 months.&lt;br&gt;3. The subject is currently receiving Rapamycin, Certican or MPA (Myfortic®).&lt;br&gt;4. The subject has a chronic dysfunction of the allograft, in the opinion of the Investigator.&lt;br&gt;5. The subject had major changes in their immunosuppressive regimen within the last 3 months prior to entry into the study (a major change in immunosuppressive medication would be defined as addition, removal or substitution of any immunosuppressive agent from the regimen, but would not include dose changes of current immunosuppressive medications).&lt;br&gt;6. The subject has any unstable medical condition that could interfere with the study&lt;br&gt;objectives in the opinion of the Investigator.&lt;br&gt;7. The subject is known to be positive for either HBV or HCV or HIV.&lt;br&gt;8. The subjects is required to be treated with medication or substances known to interfere with tacrolimus metabolism as listed in Appendix 1, or having taken such medication within 28 days prior to inclusion.&lt;br&gt;9. The subject is pregnant or breast feeding.&lt;br&gt;10. The subject has any form of substance abuse, psychiatric disorder or condition which, in the opinion of the Investigator, may complicate communication with the Investigator.&lt;br&gt;11. The subject is participating or has participated in another clinical trial and/or is taking or has taken an investigational/non-registered drug in the past 28 days.&lt;br&gt;12. The subject is unlikely to comply with the visits scheduled in the protocol.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Prophylaxis of primary liver, kidney, heart, lung, and intestinal organ transplant rejection &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10052062
Term: Prophylaxis against intestinal transplant rejection
 &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10050432
Term: Prophylaxis against heart transplant rejection
 &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10050433
Term: Prophylaxis against lung transplant rejection
 &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10050434
Term: Prophylaxis against liver transplant rejection
 &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10050436
Term: Prophylaxis against renal transplant rejection
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Advagraf&lt;br&gt;Pharmaceutical Form: Prolonged-release capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Trade Name: Prograf&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Trade Name: Advagraf&lt;br&gt;Pharmaceutical Form: Prolonged-release capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: Advagraf&lt;br&gt;Pharmaceutical Form: Prolonged-release capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 3-&lt;br&gt;&lt;br&gt;Trade Name: Advagraf&lt;br&gt;Pharmaceutical Form: Prolonged-release capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: Prograf&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: Prograf&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Secondary Objective: To observe the long-term safety and efficacy profile of tacrolimus for Advagraf® in stable pediatric allograft recipients after 1:1 (mg:mg) conversion from Prograf® to Advagraf® and to evaluate the relationship between AUC0-24h and C24 for Advagraf® and for Prograf® at each PK profile.;Primary end point(s): The steady state systemic exposure (AUC0-24h) of tacrolimus when administered as&lt;br&gt;Advagraf® or Prograf® in stable pediatric allograft recipients.;Main Objective: To compare the steady state AUC0-24h of tacrolimus for Advagraf® with that of Prograf® in stable pediatric allograft recipients after 1:1 (mg:mg) conversion from Prograf® to Advagraf®</Primary_outcome>
    <Secondary_ID>PMR-EC-1206</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2481935</Internal_Number>
    <TrialID>EUCTR2006-005238-19-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio fase II con inmunoterapia mediante células dendríticas y linfocitos infiltrantes de tumor en tumores sólidos</Public_title>
    <Scientific_title>Estudio fase II con inmunoterapia mediante células dendríticas y linfocitos infiltrantes de tumor en tumores sólidos                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Instituto Cientifico y Tecnologico de Navarra</Primary_sponsor>
    <Date_registration3>20101125</Date_registration3>
    <Date_registration>25/11/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005238-19                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/07/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Podrán ser incluidos en el estudio los pacientes que cumplan los siguientes requisitos:&lt;br&gt;1.	Edad superior a 18 años&lt;br&gt;2.	Diagnóstico confirmado histológicamente de:&lt;br&gt;-melanoma metastásico a nivel subcutáneo o partes blandas (estadios III no resecables o M1a) o metástasis pulmonares (M1b).&lt;br&gt;- carcinoma renal de células claras avanzado no susceptible de tratamiento curativo&lt;br&gt;- hepatocarcinoma no susceptible de tratamiento curativo, con función hepática estadio IB de Child o menor. Se podrán incluir pacientes en los que se haya realizado tratamiento con embolización si se considera necesario.&lt;br&gt;3.	Capacidad para otorgar consentimiento informado y expresar su deseo de cumplir todos los requisitos del protocolo durante el periodo de estudio.&lt;br&gt;4.	Enfermedad medible según los criterios RECIST (v. apéndice 3).&lt;br&gt;5.	Situación basal &lt;2 según la escala ECOG (v. apéndice 4)&lt;br&gt;6.	Adecuada función hepática, renal y medular, definidas por los siguientes parámetros obtenidos en los 14 días previos al inicio del tratamiento del estudio: &lt;br&gt;- Creatinina sérica &lt;1.5 x el límite superior de normalidad del laboratorio (LSN)&lt;br&gt;- SGOT y SGPT &lt;5 x LSN &lt;br&gt;- Bilirrubina sérica &lt;2 x LSN (confirmar si es aceptable para hepatocarcinoma)&lt;br&gt;- Leucocitos &gt;3000/ mm3, plaquetas &gt;5.000/ mm3.&lt;br&gt;7.	Pruebas serológicas negativas frente a VIH. &lt;br&gt;8.	Disponibilidad de tejido tumoral que permita madurar las células dendríticas y, en los casos en que se considere necesario, obtener células TIL. Si no existe tejido tumoral disponible, se valorará la realización de nuevas biopsias, pero teniendo en cuenta el carácter investigacional del tratamiento, no se propondrá la realización de biopsias que requieran cirugía mayor o de zonas que por su localización o por su proximidad a otras estructuras conlleven un riesgo considerable de hemorragia, perforación de víscera hueca, neumotórax u otras complicaciones relevantes.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Infección o enfermedades graves que desaconsejen la participación del paciente en el estudio, según el criterio del investigador.&lt;br&gt;2.	Participación en otro ensayo clínico. En el caso de que el paciente haya participado previamente en otro ensayo, se deberá esperar un tiempo de lavado y de recuperación determinado por el investigador, antes de tratar al paciente en este estudio. &lt;br&gt;3.	Administración concurrente de otro tratamiento antitumoral. En el caso de que el paciente haya recibido otro tratamiento previamente, se deberá esperar un tiempo de lavado, cuya duración la determinará el investigador.&lt;br&gt;4.	Pacientes diagnosticados de otras neoplasias, salvo carcinoma de células basales o escamosas de piel, carcinoma cervical in situ adecuadamente tratados, así como otros tumores que tratados de forma curativa sin recidiva durante al menos 3 años.&lt;br&gt;5.	Mujeres embarazadas o en período de lactancia. Mujeres que puedan quedar embarazadas durante el tratamiento.&lt;br&gt;6.	Pacientes que precisen medicación inmunosupresora.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Melanoma, renal cell carcinoma, hepatocarcinoma &lt;br&gt;MedDRA version: 8.1
Level: LLT
Classification code 10007050
Term: Cancer
</Condition>
    <Intervention>&lt;br&gt;Product Name: Autologous dendritic cells&lt;br&gt;Pharmaceutical Form: Injection*&lt;br&gt;INN or Proposed INN: Autologous dendritic cells&lt;br&gt;Concentration unit: EID50 50% Embryo Infective Dose&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 10000000-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Response rate;Secondary Objective: Immunologic response&lt;br&gt;Overall survival&lt;br&gt;Progression-free survival;Primary end point(s): Response rate</Primary_outcome>
    <Secondary_ID>CD-2007-01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2482279</Internal_Number>
    <TrialID>EUCTR2010-022994-32-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Effect of N-acetylcysteine on hydrogen sulfide in chronic kidney disease - Effect of NAC on H2S in CKD</Public_title>
    <Scientific_title>Effect of N-acetylcysteine on hydrogen sulfide in chronic kidney disease - Effect of NAC on H2S in CKD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>UMC Utrecht</Primary_sponsor>
    <Date_registration3>20101108</Date_registration3>
    <Date_registration>08/11/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-022994-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/06/2011</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Healthy volunteers:&lt;br&gt;-	Adult (&gt; 18 years and older)&lt;br&gt;-	Healthy, as assessed by medical history, blood pressure, plasma&lt;br&gt;	creatinine, and urine dipstick&lt;br&gt;-	No medication use&lt;br&gt;	&lt;br&gt;CKD patient:&lt;br&gt;-	Adult (&gt; 18 years and older)&lt;br&gt;-	CKD stage 3-4 (GFR 15-60 ml/min)&lt;br&gt;&lt;br&gt;Hemodialysis patient:&lt;br&gt;-	Adult (&gt; 18 years and older)&lt;br&gt;-	Hemodialysis patient&lt;br&gt;&lt;br&gt;Peritoneal dialysis patient:&lt;br&gt;-	Adult (&gt; 18 years and older)&lt;br&gt;-	Peritoneal dialysis patient&lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-	Unable to give informed consent&lt;br&gt;-	Hypersensitivity to NAC&lt;br&gt;-	Pregnancy&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic kidney disease
End stage renal disease &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10064848
Term: Chronic kidney disease
 &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10014646
Term: End stage renal disease (ESRD)
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Acetylcysteine&lt;br&gt;Product Name: Acetylcysteine&lt;br&gt;Pharmaceutical Form: Oral powder&lt;br&gt;INN or Proposed INN: ACETYLCYSTEINE&lt;br&gt;CAS Number: 616-91-1&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 600-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Investigate the effect of NAC on plasma H2S levels.;Secondary Objective: Investigate differences in plasma H2S levels between healthy volunteers, CKD patients, and dialysis patients.;Primary end point(s): H2S levels in plasma</Primary_outcome>
    <Secondary_ID>34009</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2482517</Internal_Number>
    <TrialID>EUCTR2008-005951-84-AT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Treat-to-target trial of basal insulin in Post-Transplant Hyperglycemia (TIP): Efficacy and safety of a novel protocol in renal transplant recipients receiving a tacrolimus-based immunosupprerssion - TIP</Public_title>
    <Scientific_title>Treat-to-target trial of basal insulin in Post-Transplant Hyperglycemia (TIP): Efficacy and safety of a novel protocol in renal transplant recipients receiving a tacrolimus-based immunosupprerssion - TIP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Medizinische Universität Wien, KIM III, Abteilung für Nephrologie</Primary_sponsor>
    <Date_registration3>20081027</Date_registration3>
    <Date_registration>27/10/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005951-84                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/11/2008</Date_enrollement>
    <Target_size>50</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Renal transplantation and immunosuppression with the standard protocol of our center (tacrolimus, mycophenolate mofetil, prednisone triple therapy without any induction therapy)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Any history of Diabetes Mellitus is an exclusion criterion.&lt;br&gt;</Exclusion_Criteria>
    <Condition>The medical condition to be investigated is post-transplant hyperglycemia in renal transplant recipients.</Condition>
    <Intervention>&lt;br&gt;Trade Name: Insulatard®&lt;br&gt;Product Name: Insulatard®&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;CAS Number: 11061-68-0&lt;br&gt;Other descriptive name: human insulin&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective is to demonstrate the superiority of long-acting insulin (Insulatard®) against post-transplant hyperglycemia, in comparison to conventional treatment, and as evaluated by HbA1c as well as repeated measures of capillary blood glucose levels.;Secondary Objective: •	To assess the average post-transplant glucose levels in renal transplant patients under conventional blood-glucose lowering therapy during a period of at least 14 days after transplantation by measuring the capillary blood glucose levels three times daily in both groups of patients (at 8:00, 14:00, 16:00)&lt;br&gt;•	To assess a full 48h glucose profile in patients treated with long-acting insulin (Insulatard®)&lt;br&gt;•	To detect the average number of hyperglycemic episodes in post-transplant patients&lt;br&gt;•	To assess the amount of long-acting insulin (Insulatard®,in units) needed in order to obtain a target capillary blood glucose level in the range of 90 mg/dl to 140 mg/dl before supper&lt;br&gt;•	To assess the safety of long-acting insulin in controlling post-transplant hyperglycemia&lt;br&gt;•	To assess the incidence of post-transplant diabetes&lt;br&gt;•	To assess the morbidity&lt;br&gt;•	To assess the renal outcome (creatinine levels, rejections)&lt;br&gt;;Primary end point(s): The primary endpoint is the difference in HbA1c between the two study arms.</Primary_outcome>
  </Trial>
  <Trial>
    <Internal_Number>2483403</Internal_Number>
    <TrialID>EUCTR2010-023746-67-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Tratamiento con inmunoglobulinas y rituximab en el rechazo crónico humoral en el trasplante renal: estudio multicéntrico, prospectivo, randomizado y controlado con placebo.

Treatment with intravenous immunoglobulins and rituximab in renal transplant recipients with chronic humoral rejection: a multicentre, prospective, randomized, placebo-controlled study.</Public_title>
    <Scientific_title>Tratamiento con inmunoglobulinas y rituximab en el rechazo crónico humoral en el trasplante renal: estudio multicéntrico, prospectivo, randomizado y controlado con placebo.

Treatment with intravenous immunoglobulins and rituximab in renal transplant recipients with chronic humoral rejection: a multicentre, prospective, randomized, placebo-controlled study.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Dr Daniel Serón. Servicio de Nefrología. Hospital Universitario Vall d'Hebron</Primary_sponsor>
    <Date_registration3>20110221</Date_registration3>
    <Date_registration>21/02/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-023746-67                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>14/06/2011</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Pacientes portadores de injerto renal funcionante realizado como mínimo seis meses antes de la inclusión con criterios diagnósticos de rechazo crónico humoral y estabilidad de la función renal&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Filtrado glomerular renal &lt; 20 mL/min/1.73m2, IF/TA grado III en la biopsia diagnóstica, neoplasia activa o antecedente de neoplasia durante los últimos 5 años, enfermedad infecciosa bacteriana, viral o fúngica activa, y antecedentes de reacción de hipersensibilidad a alguno de los productos suministrados.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Trasplate renal con rechazo crónico humoral 

Renal transplant with chronic humoral rejection &lt;br&gt;MedDRA version: 13
Level: PT
Classification code 10023439
Term: Rechazo del trasplante de riñón
 &lt;br&gt;MedDRA version: 13
Level: LLT
Classification code 10064682
Term: Rechazo de trasplante humoral
 &lt;br&gt;MedDRA version: 13
Level: LLT
Classification code 10038299
Term: Rechazo renal crónico
</Condition>
    <Intervention>&lt;br&gt;Trade Name: PRIVIGEN 100 mg/ml solución para perfusión&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: INMUNOGLOBULINA G HUMANA&lt;br&gt;Other descriptive name: INMUNOGLOBULINA G HUMANA&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;Pharmaceutical form of the placebo: Concentrate for solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;Trade Name: MABTHERA 100 mg concentrado para solución para perfusión&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: RITUXIMAB&lt;br&gt;CAS Number: 174722-31-7&lt;br&gt;Other descriptive name: RITUXIMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;Pharmaceutical form of the placebo: Concentrate for solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluar la función renal en pacientes con rechazo crónico humoral al año de tratamiento;Secondary Objective: Evaluar la proteinuria, la tasa de rechazo agudo, el inmunofenotipo del infiltrado renal en la biopsia renal, la supervivencia del paciente e injerto, y la seguridad de los tratamientos suministrados.;Primary end point(s): La variable principal es la variación del filtrado glomerular renal estimado al año de iniciado el tratamiento</Primary_outcome>
    <Secondary_ID>TRITON</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2483533</Internal_Number>
    <TrialID>EUCTR2010-024515-13-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Phase 1-2 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.</Public_title>
    <Scientific_title>Phase 1-2 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>VU University Medical Center</Primary_sponsor>
    <Date_registration3>20110105</Date_registration3>
    <Date_registration>05/01/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-024515-13                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/03/2011</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Patients with histologically or cytologically confirmed clear-cell mRCC with progressive disease and not amenable to or progressive on or within 6 months of stopping treatment with a VEGF receptor tyrosine kinase inhibitor (sunitinib (or pazopanib) ± sorafenib).&lt;br&gt;2. Prior therapy with cytokines (i.e. IL-2, interferon) and/or VEGF-ligand inhibitors (i.e. bevacizumab) is permitted.&lt;br&gt;3. Patients with brain metastases are eligible if they have been stable for at least two months post-radiation therapy or surgery.&lt;br&gt;4. Aged 18 years or older.&lt;br&gt;5. No other current malignant disease, except for basal cell carcinoma of the skin.&lt;br&gt;6. WHO performance status 0-2.&lt;br&gt;7. Life expectancy of at least 12 weeks.&lt;br&gt;8. Adequate hematologic function: ANC = 1.5 x 109/L, platelets = 100 x 109/L, Hb = 6.0 mmol/L.&lt;br&gt;9. Adequate hepatic function: serum bilirubin = 1.5 x ULN, ALT and AST = 2.5 x ULN (or = 5 times ULN if liver metastases are present).&lt;br&gt;10. Adequate renal function: calculated creatinine clearance = 50 ml/min.&lt;br&gt;11. Measurable or evaluable disease as defined by RECIST 1.1.&lt;br&gt;12. Patients with reproductive potential must use effective contraception. Female patients must have a negative pregnancy test.&lt;br&gt;13. Signed informed consent.	&lt;br&gt;14. Able to receive oral medication.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Patients currently receiving chemotherapy, immunotherapy, or radiotherapy or who have received these = 4 weeks prior to visit 1. The wash-out period for sunitinib or sorafenib is at least 2 weeks from the first dose of the study medication.&lt;br&gt;2. Known human immunodeficiency virus (HIV) or other major immunodeficiency.&lt;br&gt;3. Immunosuppressive agents within 3 weeks of study entry, except for low dose corticosteroids when given for disorders such as rheumatoid arthritis, asthma, or adrenal insufficiency. Topical or inhaled corticosteroids are permitted.&lt;br&gt;4. Patients with an active bleeding diathesis or on oral anti-vitamin K medication.&lt;br&gt;5. Patients with untreated CNS metastases with clinical symptoms or who have received treatment for CNS metastases within 2 months of study entry. Patients with treated CNS metastases, who are neurologically stable and off of corticosteroids for more than 2 months prior to study entry are eligible to enter the study.&lt;br&gt;6. Active infection or serious intercurrent illness, except asymptomatic bacteriuria.&lt;br&gt;7. Presence of unstable angina, recent myocardial infarction (within the previous 6 months), or use of ongoing maintenance therapy for life-threatening ventricular arrhythmia.&lt;br&gt;8. Macroscopic hematuria&lt;br&gt;9. Prior therapy with mTOR inhibitors.&lt;br&gt;10. Known hypersensitivity to everolimus or other rapamycins (sirolimus/temsirolimus) or to its excipients.&lt;br&gt;11. Pregnant or nursing women, or women who were of childbearing potential and who were not utilizing an effective contraceptive method. A woman of childbearing potential is defined as a female who is biologically capable of becoming pregnant. Men with partners of childbearing potential not using an effective method of contraception. (Use of effective contraceptives must continue for 3 months after the last dose of everolimus).&lt;br&gt;12. Presence of any significant central nervous system or psychiatric disorder(s) that would hamper the patient’s compliance.&lt;br&gt;13. Uncontrolled diabetes as defined by fasting serum glucose &gt; 2 ULN, severely impaired lung function.&lt;br&gt;14. Cirrhosis/chronic active hepatitis/chronic persistent hepatitis, history of HCV infection (for hepatitis screening indications see section 3.3).&lt;br&gt;15. Drug or alcohol abuse.&lt;br&gt;16. Any other major illness that, in the investigator’s judgment, substantially increased the risk associated with the subject’s participation in the study.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Metastatic renal cell cancer &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10050513
Term: Metastatic renal cell carcinoma
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Afinitor&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Trade Name: Endoxan&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Phase I part &lt;br&gt;1) Assessment of the recommended dosing and schedule for metronomic cyclophosphamide when administered in combination with fixed dose (10 mg) oral everolimus in patients with mRCC with respect to the selective induction of CD4+CD25+ regulatory T cell depletion. &lt;br&gt;2) Assessment of safety and tolerability for the combination of metronomic cyclophosphamide and fixed dose oral everolimus in patients with mRCC.&lt;br&gt;&lt;br&gt;In case no depletion of Tregs is observed during the phase 1 part of the study, we consider the absence of an increase in Treg as the minimally acceptable outcome for proceeding to the phase 2 part of the study.&lt;br&gt;&lt;br&gt;Phase II part &lt;br&gt;1) To investigate the proportion of patients with mRCC receiving everolimus and metronomic cyclophosphamide that is progression-free at 4 months.&lt;br&gt;2) Assessment of safety and tolerability for the combination of metronomic cyclophosphamide and fixed dose oral everolimus in patients with mRCC.&lt;br&gt;;Secondary Objective: 1) To assess the response rate, time to progression, and overall survival of the combination of metronomic cyclophosphamide and fixed dose oral everolimus in patients with mRCC.&lt;br&gt;2) Assessment of the immunological effects of combining metronomic cyclophosphamide with everolimus.&lt;br&gt;3) Assessment of the effect of the combination of metronomic cyclophosphamide and everolimus on selected angiogenesis parameters.&lt;br&gt;4) To assess whether intrapatient changes in thrombocyte numbers correlate with response rate and/or time to progression in patients using the combination of metronomic cyclophosphamide and fixed dose oral everolimus.&lt;br&gt;5) To asess the effects of the combination of metronomic cyclophosphamide and everolimus on tumor-infiltrating leukocytes.&lt;br&gt;6) To assess the effects of cyclophosphamide administration on the pharmacokinetics of everolimus.;Primary end point(s): Primary objectives Phase I&lt;br&gt;1) Assessment of the recommended dosing and schedule for metronomic cyclophosphamide when administered in combination with fixed dose (10 mg) oral everolimus in patients with mRCC with respect to the selective induction of CD4+CD25+ regulatory T cell depletion.&lt;br&gt;2) Assessment of safety and tolerability for the combination of metronomic cyclophosphamide and fixed dose oral everolimus in patients with mRCC.&lt;br&gt;&lt;br&gt;Primary objectives Phase II&lt;br&gt;1) To investigate the proportion of patients with mRCC receiving everolimus and metronomic cyclophosphamide that is alive and progression-free at 4 months.&lt;br&gt;2) Assessment of safety and tolerability for the combination of metronomic cyclophosphamide and fixed dose oral everolimus in patients with mRCC.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>VU-007</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2483537</Internal_Number>
    <TrialID>EUCTR2010-024425-20-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Phase III Randomized Double-blind Cross-over trial of Supersaturated Calcium-phosphate rinse (Caphosol®) versus NaCl 0.9% in the relief of Oral Mucositis in renal cell carcinoma, hepatocellular carcinoma, and gastrointestinal stromal tumor patients receiving Targeted Therapy - COMTT</Public_title>
    <Scientific_title>Phase III Randomized Double-blind Cross-over trial of Supersaturated Calcium-phosphate rinse (Caphosol®) versus NaCl 0.9% in the relief of Oral Mucositis in renal cell carcinoma, hepatocellular carcinoma, and gastrointestinal stromal tumor patients receiving Targeted Therapy - COMTT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Leiden University Medical Centre</Primary_sponsor>
    <Date_registration3>20110113</Date_registration3>
    <Date_registration>13/01/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-024425-20                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>14/03/2011</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: yes&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;?	Male and female subjects&lt;br&gt;?	=18 years of age&lt;br&gt;?	Histological proof of RCC, HCC or GIST&lt;br&gt;?	Oral adverse events &gt; grade 0 due to sunitinib, sorafenib, pazopanib, temsirolimus, or everolimus in mono therapy at study entry&lt;br&gt;?	Written informed consent&lt;br&gt;?	Eastern Co-operative Oncology Group (ECOG) performance status = 2&lt;br&gt;?	Able to perform oral rinsing&lt;br&gt;?	Able to complete questionnaires by themselves or with assistance&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;?	Subjects meeting any of the following criteria will be excluded from the study:&lt;br&gt;?	Any previous systemic antineoplastic treatment within 4 weeks of initiation of current targeted anticancer therapy&lt;br&gt;?	Current antineoplastic combination cytotoxic chemotherapy therapy&lt;br&gt;?	Physiologic condition that precludes the use of an oral rinse &lt;br&gt;?	Hypersensitivity to Caphosol ingredients &lt;br&gt;?	Use of palifermin, oral cryotherapy, low level laser therapy, topical oral steroids within 3 weeks of current targeted anticancer therapy&lt;br&gt;?	Oral abnormalities defined as baseline oral assessment of NCI-CTCAE v4.0 grade &gt; 0&lt;br&gt;?	Current use of agents that are known to be strong inducers or inhibitors of CYP3A4 that can not be stopped&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>oral mucositis in renal cell carcinoma, hepatocellular carcinoma, and gastrointestinal stromal tumor &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10028127
Term: Mucositis
 &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10042128
Term: Stomatitis
 &lt;br&gt;MedDRA version: 12.1
Level: PT
Classification code 10042128
Term: Stomatitis
 &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10031009
Term: Oral pain
 &lt;br&gt;MedDRA version: 12.1
Level: PT
Classification code 10031009
Term: Oral pain
 &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10013911
Term: Dysgeusia
 &lt;br&gt;MedDRA version: 12.1
Level: PT
Classification code 10013911
Term: Dysgeusia
 &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10013950
Term: Dysphagia
 &lt;br&gt;MedDRA version: 12.1
Level: PT
Classification code 10013950
Term: Dysphagia
 &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10013781
Term: Dry mouth
 &lt;br&gt;MedDRA version: 12.1
Level: PT
Classification code 10013781
Term: Dry mouth
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Caphosol&lt;br&gt;Product Name: supersaturated calcium phosphate rinse&lt;br&gt;Product Code: MDD93/42/CEE&lt;br&gt;Pharmaceutical Form: Oromucosal solution&lt;br&gt;INN or Proposed INN: calcium&lt;br&gt;CAS Number: 7440-70-2&lt;br&gt;Other descriptive name: calciumchloride 0.052&lt;br&gt;Concentration unit: % (W/W) percent weight/weight&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.052 -&lt;br&gt;INN or Proposed INN: PHOSPHATE&lt;br&gt;CAS Number: 98059-61-1&lt;br&gt;Other descriptive name: Dibasic Sodium Phosphate 0.032&lt;br&gt;Concentration unit: % (W/W) percent weight/weight&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.032 -&lt;br&gt;Other descriptive name: Monobasic Sodium Phosphate&lt;br&gt;Concentration unit: % (W/W) percent weight/weight&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.009-&lt;br&gt;Other descriptive name: Sodium Chloride &lt;br&gt;Concentration unit: % (W/W) percent weight/weight&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.569-&lt;br&gt;Pharmaceutical form of the placebo: Mouth wash&lt;br&gt;Route of administration of the placebo: Oromucosal use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Secondary Objective: None;Main Objective: To assess the effect of Caphosol® oral rinse on clinical outcomes of selected oral symptom burden (oral mucositis/stomatitis (aphthous-like), oral pain, taste change (dysgeusia), difficulty swallowing (dysphagia), difficulty oral intake, and dry mouth) associated with incidence of grade = 1 oral adverse events and the anticancer therapy cessation in patients treated with selected targeted anticancer therapy in selected tumors.;Primary end point(s): Assess the severity of patient-reported oral adverse events as determined by the change in the VHNSS2.0 score 3 times a week, from onset of oral mucositis, stomatitis (aphthous-like), oral pain, taste change (dysgeusia), difficulty swallowing (dysphagia), difficulty oral intake, or dry mouth during the active oral rinse period with Caphosol® oral rinse versus NaCl 0.9% oral rinse, 4 times daily, 2 minutes with 30 ml solution</Primary_outcome>
    <Secondary_ID>Esperanz-002</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2483671</Internal_Number>
    <TrialID>EUCTR2008-001491-77-SE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Randomized study comparing spinal anealgesia compared with epidural analgesia durinmg and postoperative nephrectomy dua to renal cell carcinoma</Public_title>
    <Scientific_title>Randomized study comparing spinal anealgesia compared with epidural analgesia durinmg and postoperative nephrectomy dua to renal cell carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Prof. Ola Winsö, Anesthesia and Intensive Care Medicine, Norrlands University Hospiatal</Primary_sponsor>
    <Date_registration3>20100416</Date_registration3>
    <Date_registration>16/04/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-001491-77                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>16/05/2011</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients planned to perform nephrectomy due to renal cell carcinoma, having a ASA score between I and III. &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Exclusion of patients having a ASA score more than III, or patients having a high risk for bleeding during surgery as vena caval thrombosis; Patients with chronic pain disorders; Patients with any abuse;  Patients younger than 18 years old and uncapable of understanding the consent form will not be eligible; Pregnant women or when pregnancy cannot be ruled out; All patients with any contraindication for epidural- or spinal analgesia will be excluded. As well as patients having a body weight less than 45 kg or more than 120 kg. &lt;br&gt;</Exclusion_Criteria>
    <Condition>Postoperative pain and mobilization after radical or nephronsparing nephrectomy in patients with renal cell carcinoma &lt;br&gt;MedDRA version: 13.1
Level: LLT
Classification code 10036236
Term: Postoperative pain relief
System Organ Class: 10042613 - Surgical and medical procedures
;Therapeutic area: Diseases [C] - Cancer [C04]</Condition>
    <Intervention>&lt;br&gt;Trade Name: Catapresan&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Clonidine HCL&lt;br&gt;CAS Number: 4205-91-8&lt;br&gt;Current Sponsor code: klonidin&lt;br&gt;Other descriptive name: CLONIDINE HYDROCHLORIDE&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 150-&lt;br&gt;&lt;br&gt;Trade Name: Marcain spinal tung 5 mg/ml&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: BUPIVACAINE HYDROCHLORIDE&lt;br&gt;CAS Number: 18010-40-7&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: Marcain adrenalin 2,5 mg/ml + 5 ug/ml&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: BUPIVACAINE HYDROCHLORIDE&lt;br&gt;CAS Number: 18010-40-7&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: Fentalyl 50 ug/ml&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: FENTANYL&lt;br&gt;CAS Number: 437-38-7&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: Morfin Special&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;CAS Number: 52-26-6&lt;br&gt;Other descriptive name: MORPHINE HYDROCHLORIDE&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.4-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The main object is to make the postoperative analgesia better and enhance the mobilization after nephrectomies due to renal cell carcinoma&lt;br&gt;&lt;br&gt;;Secondary Objective: Better analgesia and mobilization can give the patients earlier recover and shorter hospitalization. Furthermore the use of urinary catheters can be shortened as well as a lower use of analgesics. Other secondary objectives are that the spinal method can shorten the procedures in the operation theater and have lower costs. ;Primary end point(s): A better patients’ “mobility index” is expected in the group of patients with spinal analgesia. This motility index is based on: postoperative pain, unwell, need for intravenous fluid, and mobilization factors as: walking in corridor, flatulence, getting out of bed without help, urinary bladder catheter and eating in dining room.;Timepoint(s) of evaluation of this end point: 3rd day </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Motility index of days 1,2,4,5,6; 
&lt;br&gt;Daily pain according to the VAS scale
&lt;br&gt;Time to first postoperative rescue analgesic
&lt;br&gt;Time to surgery from entering the operation theater 
&lt;br&gt;Dosing of Fenylefrin during surgery.
&lt;br&gt;Time at postoperative unit
&lt;br&gt;Time to fist bowel delivery
&lt;br&gt;Time to discharge from hospital
&lt;br&gt;Difference in complications using the Clavian classification
&lt;br&gt;Any difference in oxygen concentration, median and systolic artery pressure will be evaluated from the surgery and in the postoperative unit.
&lt;br&gt;;Timepoint(s) of evaluation of this end point: depending on the study variable, se above</Secondary_outcome>
    <Secondary_ID>klonidin</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2483809</Internal_Number>
    <TrialID>EUCTR2006-003998-27-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Cardiovascular and functional consquences of chronic kidney disease in older people - consquences of chronic kidney disease in older people</Public_title>
    <Scientific_title>Cardiovascular and functional consquences of chronic kidney disease in older people - consquences of chronic kidney disease in older people                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Derby Hospitals NHS Foundation Trust</Primary_sponsor>
    <Date_registration3>20110331</Date_registration3>
    <Date_registration>31/03/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-003998-27                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>15/03/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Age &gt; 70&lt;br&gt;Chronic kidney disease 3, 4 or hypertensive (&gt; 130/80)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Likely to develop chronic kidney disease within one year&lt;br&gt;Poor mobility precluding completion of assessment&lt;br&gt;BP prior to antihypertensive withdrawl &gt; 160/90&lt;br&gt;diabetes&lt;br&gt;Severe peripheral vascular disease&lt;br&gt;Heart failure (BYHA III/IV) or other cause to prevent diuretic withdrawl&lt;br&gt;Atrial fibrillation (precludes PWV measurement)&lt;br&gt;AMT &lt;8&lt;br&gt;Recent acute illness (within the last 3 months)&lt;br&gt;IHD requiring beta-bloackade (nitrates/nicorandil are permitted)&lt;br&gt;Obstructive uropathy&lt;br&gt;Malignant hypertension&lt;br&gt;Involvement in another clinical trial with in 3 months&lt;br&gt;Attending day hospital or attanding Falls Reduction Services&lt;br&gt;Residents in nursing or residential homes&lt;br&gt;Renovascular disease precluding ACEi/ARB usage&lt;br&gt;Currently taking antihypertensive medication for which CTA has not been granted&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic Kidney Disease
Hypertension
Falls</Condition>
    <Intervention>&lt;br&gt;Product Name: Antiadrenergic agents, peripherally acting&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: DOXAZOSIN&lt;br&gt;CAS Number: 74191-85-8&lt;br&gt;&lt;br&gt;Product Name: Low Ceiling Diuretics, Thiazides&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: BENDROFLUMETHIAZIDE&lt;br&gt;CAS Number: 73-48-3&lt;br&gt;&lt;br&gt;Product Name: High Ceiling Diuretics&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: FUROSEMIDE&lt;br&gt;CAS Number: 54-31-9&lt;br&gt;&lt;br&gt;Product Name: Beta Blocking Agents&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: ATENOLOL&lt;br&gt;CAS Number: 29122-68-7&lt;br&gt;&lt;br&gt;Product Name: Selective Calcium Channel Blockers with mainly vascular effects&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: AMLODIPINE&lt;br&gt;CAS Number: 88150-42-9&lt;br&gt;&lt;br&gt;Product Name: Ace Inhibitors, Plain&lt;br&gt;Pharmaceutical Form: &lt;br&gt;CAS Number: 87333-19-5&lt;br&gt;Other descriptive name: RAMIPRIL&lt;br&gt;&lt;br&gt;Product Name: Angiotensin II antagonists, Plain&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: LOSARTAN&lt;br&gt;CAS Number: 114798-26-4&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The main objective is to try to answer the question "How does the change in baroreflex sensitivity alter in older people with chronic kidney disease with an optimal antihypertensitive strategy and over time?";Secondary Objective: To ascertain if the change in baroreflex sensitivity exhibited in older people with chronic kidney disease is different to that exhibited by older people who o not have chronic kidney disease. To identify abnormalities of cardiovascular function or functional ability that predict falls;Primary end point(s): change in baroreflex sensitivity with optimal hypertensive treatment and over time</Primary_outcome>
    <Secondary_ID>RD-5103-003-06</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2483972</Internal_Number>
    <TrialID>EUCTR2010-024175-58-CZ</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Comparison of two treatment regimen of high blood pressure in patients with transplanted heart.</Public_title>
    <Scientific_title>Comparison of two treatment options for hypertension in heart transplant recipients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>IKEM</Primary_sponsor>
    <Date_registration3>20110413</Date_registration3>
    <Date_registration>13/04/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-024175-58                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>30/06/2011</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients aged between 18-65 years ,who are undergoing heart transplantation, and who develop hypertension during the first 6 months, which will require treatment&lt;br&gt;2) A patient who understands the purpose of the study, which was fully informed and gave written consent to participate in the study&lt;br&gt;3) blood pressure&gt; 130/80 mmHg&lt;br&gt;4) The value of serum potassium &lt;5 mmol / l&lt;br&gt;5) Serum creatinine lower or equal than 150 micromol / l glomerular filtration rate &gt; 1.0 ml / s&lt;br&gt;6) No serious complications associated with surgery (graft failure ,hemodynamic instability, severe acute rejection, renal failure)&lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 40&lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1) Patient after heart transplantation more than 6 months&lt;br&gt; 2) The presence of serious complications after heart transplantation (graft failure,&lt;br&gt;     hemodynamic instability, severe acute rejection)&lt;br&gt;3) Hyperkalemia (serum potassium concentration&gt; 5.3 mmol / l)&lt;br&gt;4) Current use of potassium-sparing diuretics&lt;br&gt; 5) Patients with significant renal impairment defined as an increase creatinine higher or equal to 250 umol/l&lt;br&gt; 6) Patients with significantly elevated liver function tests (defined as AST and ALT &lt;br&gt;     increased to three times the normal values&lt;br&gt; 7) Anemia (hemoglobin &lt;90 g / l)&lt;br&gt; 8) Retransplantation or multiorgan transplantation&lt;br&gt; 9) Women who are unable or unwilling to use two barrier contraception&lt;br&gt; 10) Pregnant women or nursing mothers&lt;br&gt;11) Inability to take oral medication&lt;br&gt;12) Patients unable to give informed consent&lt;br&gt;13) Patients with mental disorder or condition, which in the opinion investigator might&lt;br&gt;      compromise communication with the investigator&lt;br&gt;14). Participation of patients in another clinical trial during the last 30 days&lt;br&gt;15). Patients with known sensitivity (sensitivity) of perindopril or losartan&lt;br&gt;        or a chemically related components&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Compensation of arterial hypertension in heart transplant recipients. 
Renal function and its changes in heart transplant recipients. &lt;br&gt;MedDRA version: 13.1
Level: HLT
Classification code 10038454
Term: Renal function analyses
System Organ Class: 10022891 - Investigations
 &lt;br&gt;MedDRA version: 13.1
Level: LLT
Classification code 10020775
Term: Hypertension arterial
System Organ Class: 10047065 - Vascular disorders
;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]</Condition>
    <Intervention>&lt;br&gt;Trade Name: PRESTARIUM Neo&lt;br&gt;Product Name: perindopril&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;CAS Number: 82834-16-0&lt;br&gt;Other descriptive name: PERINDOPRIL ARGININE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: LORISTA 25&lt;br&gt;Product Name: losartan&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;CAS Number: 124750-99-8&lt;br&gt;Other descriptive name: LOSARTAN POTASSIUM&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Product Name: perindopril&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: PERINDOPRIL&lt;br&gt;CAS Number: 82834-16-0&lt;br&gt;&lt;br&gt;Product Name: furosemid&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: FUROSEMIDE&lt;br&gt;CAS Number: 54-31-9&lt;br&gt;&lt;br&gt;Product Name: metoprolol&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 54163-88-1&lt;br&gt;Other descriptive name: METOPROLOL&lt;br&gt;&lt;br&gt;Product Name: amlodipin&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: AMLODIPINE&lt;br&gt;CAS Number: 88150-42-9&lt;br&gt;&lt;br&gt;Trade Name: PRESTARIUM Neo Forte&lt;br&gt;Product Name: perindopril&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;CAS Number: 82834-16-0&lt;br&gt;Other descriptive name: PERINDOPRIL ARGININE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;Trade Name: LORISTA 50&lt;br&gt;Product Name: losartan&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;CAS Number: 124750-99-8&lt;br&gt;Other descriptive name: LOSARTAN POTASSIUM&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: LORISTA 100&lt;br&gt;Product Name: losartan&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;CAS Number: 124750-99-8&lt;br&gt;Other descriptive name: LOSARTAN POTASSIUM&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Comparison of efficacy of treatment of hypertension in heart transplant recipients which is the combination of an ACE inhibitor and angiotensin II receptor antagonist (group A) with standard antihypertensive therapy used  in our department (group B). The measure of effectiveness is the achievement of blood pressure compensation.;Secondary Objective: Effect of dual blockade of the renin-angiotension system on renal function measuring by the glomerular filtration rate, proteinuria, microalbuminuria, and specific proteins (transferrin and alfa-1 microglobulin).;Primary end point(s): Compensentation of blood pressure.;Timepoint(s) of evaluation of this end point: 10 day, 30.day, 3., 6., 9. and 12 month after randomization</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Renal function measured by the glomerular filtration rate, proteinuria, microalbuminuria, and specific proteins (transferrin and alfa-1 microglobulin);Timepoint(s) of evaluation of this end point: 10 day, 30.day, 3., 6., 9. and 12 month after randomization</Secondary_outcome>
    <Secondary_ID>kardioIKEM2010</Secondary_ID>
    <Source_Support>IKEM</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2484151</Internal_Number>
    <TrialID>EUCTR2011-000644-16-EE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>High volume haemodiafiltration in treatment of severe sepsis -- impact on pharmacokinetics of doripenem and piperacillin tazobactam and inflammatory response</Public_title>
    <Scientific_title>High volume haemodiafiltration in treatment of severe sepsis -- impact on pharmacokinetics of doripenem and piperacillin tazobactam and inflammatory response                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>University of Tartu, Clinic of Anaesthesiology and Intensive Care</Primary_sponsor>
    <Date_registration3>20110324</Date_registration3>
    <Date_registration>24/03/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-000644-16                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>03/05/2011</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;age &gt;= 18 years&lt;br&gt;severe sepsis or septic shock as defined by the ACCP/SCC Consensus Conference&lt;br&gt;acute renal failure requiring renal replacement therapy&lt;br&gt;written informed consent signed by legal representative&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;contraindication for study drug use&lt;br&gt;life expectancy less than 6 h&lt;br&gt;</Exclusion_Criteria>
    <Condition>adult intensive care patient with severe sepsis or septic shock and acute renal failure  requiring renal replacement therapy &lt;br&gt;MedDRA version: 13.1
Level: PT
Classification code 10040047
Term: Sepsis
System Organ Class: 10021881 - Infections and infestations
 &lt;br&gt;MedDRA version: 13.1
Level: LLT
Classification code 10001041
Term: Acute renal failure
System Organ Class: 10038359 - Renal and urinary disorders
 &lt;br&gt;MedDRA version: 13.1
Level: PT
Classification code 10053879
Term: Sepsis syndrome
System Organ Class: 10021881 - Infections and infestations
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Doribax&lt;br&gt;Pharmaceutical Form: Powder for solution for infusion&lt;br&gt;&lt;br&gt;Trade Name: Tazocin&lt;br&gt;Pharmaceutical Form: Powder for solution for injection&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: describe the pharmacokinetics of doripenem and piperacillin-tazobactam during high volume haemofiltration;Secondary Objective: describe the whole body inflammatory response in conjunction with high volume haemofiltration;Primary end point(s): pharmacokinetic parameters of IMPs (T1/2; Cmax, Cmin, AUC0-8, T above MIC) during high volume haemofiltration therapy</Primary_outcome>
    <Secondary_ID>Dor1.0</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2485494</Internal_Number>
    <TrialID>EUCTR2010-021867-34-SI</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>An open, multicenter study to evaluate the urodynamic properties of a local implantation of autologous skeletal muscle-derived cells (SMDCs) in female patients with stress urinary incontinence - PD Study</Public_title>
    <Scientific_title>An open, multicenter study to evaluate the urodynamic properties of a local implantation of autologous skeletal muscle-derived cells (SMDCs) in female patients with stress urinary incontinence - PD Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Innovacell Biotechnologie AG - Life Science Center Innsbruck</Primary_sponsor>
    <Date_registration3>20110712</Date_registration3>
    <Date_registration>12/07/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-021867-34                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: no&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>07/12/2011</Date_enrollement>
    <Target_size>35</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Patients of =18 to 75 years,&lt;br&gt;2. Graded as moderate SUI at the screening visit, according to the classification based on the &lt;br&gt;    short pad test of Hahn and Fall (1991) Grade 2 (2 - 10 mL leakage) or Grade 3 (11 - &lt;br&gt;    50 mL leakage),&lt;br&gt;3. Diagnosed with SUI, predominantly intrinsic sphincter deficiency, confirmed by urodynamic    &lt;br&gt;    testing (filling cystometry, urethral pressure profile) at screening.&lt;br&gt;Patients will only be included in case of:&lt;br&gt;  - missing detrusor overactivity, i.e. involuntary detrusor contraction,&lt;br&gt;  - a cystometric capacity &gt;300 mL,&lt;br&gt;  - compliance of &gt;25 mL/cm H2O,&lt;br&gt;  - post void residual urine &lt;50 mL,&lt;br&gt;  - ability to void urine spontaneously,&lt;br&gt;  - maximum urethral closure pressure &lt;30 cm H2O and/or pressure transmission ratio &lt;75% in &lt;br&gt;    the midurethra,&lt;br&gt;  - fixed urethra (no or low hypermobility),&lt;br&gt;4. The SUI diagnosis has to be based on the patient’s medical history (including anamnestic &lt;br&gt;    complaints of involuntary leakage on effort or exertion or on sneezing or coughing) and a &lt;br&gt;    positive cough test (fixed volume) at the screening visit,&lt;br&gt;5. History of inefficient, insufficient, and/or refused PFMT,&lt;br&gt;6. Patients who have a negative urine test (dipstick) at visit 0,&lt;br&gt;7. Patients willing and able to comply with the study procedures,&lt;br&gt;8. Patients who are mentally competent and able to understand all study requirements,&lt;br&gt;9. Patients must agree to read and sign the Informed Consent (IC) form prior to any study-&lt;br&gt;    related procedures,&lt;br&gt;10. Female patients of childbearing potential willing to use acceptable methods of &lt;br&gt;     contraception (birth control pills, barriers, or abstinence).&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Pelvic organ prolapse &gt;Stage II (ICS-Classification: The most distal portion of the prolapse is &lt;br&gt;    more than 1 cm below the plane of the hymen, but protrudes no further than two centimeters &lt;br&gt;    less than the total vaginal length in cm) detected during the last 12 months prior to patient &lt;br&gt;    inclusion in the study,&lt;br&gt;2. Patients who have a medical history of uncontrolled overactive bladder (OAB) or urinary &lt;br&gt;    incontinence other than SUI (including anamnestic complaints on involuntary urine leakage &lt;br&gt;    accompanied by or immediately preceded by urgency, not stress induced),&lt;br&gt;3. Patients who have undergone a surgery in pelvis minor due to cancer,&lt;br&gt;4. Patients who have undergone any surgery for SUI, including midurethral slings, Burch &lt;br&gt;    colposuspension, or bulking agents,&lt;br&gt;5. Patients diagnosed with human immunodeficiency virus (HIV), acute or chronic viral hepatitis &lt;br&gt;    HCV, acute viral hepatitis HBV, and/or active Syphilis,&lt;br&gt;6. Patients diagnosed with any kind of skeletal muscle disease,&lt;br&gt;7. Patients who, according to the clinical judgment of the investigator, are not suitable for this &lt;br&gt;    study,&lt;br&gt;8. Patients who are currently participating or have participated in another clinical trial (testing &lt;br&gt;    medical device or drug) within 30 days prior to the study begin or have previously &lt;br&gt;    participated in the current clinical study,&lt;br&gt;9. Patients who are pregnant, lactating, or intending pregnancy in the near future, and those &lt;br&gt;    of childbearing potential who are not willing to use acceptable methods of contraception &lt;br&gt;    (birth control pills, barriers, or abstinence),&lt;br&gt;10. Patients with uncontrolled diabetes mellitus type I or II, or suffering from diabetic peripheral &lt;br&gt;     neuropathic pain,&lt;br&gt;11. Patients with compromised immune systems,&lt;br&gt;12. Patients complaining about symptoms of acute cystitis or urethritis at visit 0,&lt;br&gt;13. Patients who had previously undergone radiation of the pelvis,&lt;br&gt;14. Patients with coagulopathy and/or currently being under treatment with anticoagulant &lt;br&gt;     drugs. However, if the anticoagulant therapy may be changed to heparin treatment prior to &lt;br&gt;     the therapy, the patients can be included into the study,&lt;br&gt;15. Patients with chronic pelvic pain or complaining about pelvic pain syndrome and/or &lt;br&gt;     dyspareunia,&lt;br&gt;16. Patients with uncontrolled narrow-angle glaucoma,&lt;br&gt;17. Patients with severe myocardial disorders or irregular pulse, and those with an artificial &lt;br&gt;     pacemaker,&lt;br&gt;18. Patients with implantations of metal components in the electrical stimulation treatment &lt;br&gt;     area,&lt;br&gt;19. Patients dependent from the sponsor, CRO, or the investigator (e.g. employees, relatives, &lt;br&gt;     etc.),&lt;br&gt;20. Patients with a malignant disease not in remission for 5 years or more,&lt;br&gt;21. Patients with any persistent chronic bacterial infections as well as local infections as &lt;br&gt;     indicated by a high value of CRP and confirmed by bacteriological analysis,&lt;br&gt;22. Patients with known hypersensitivity to any component of the product (autologous cells, &lt;br&gt;     ringer’s lactate, human serum albumin, DMSO, bovine proteins, fibroblast growth factor).&lt;br&gt;</Exclusion_Criteria>
    <Condition>Stress urinary incontinence (SUI) in female patients with predominantly intrinsic sphincter deficiency of moderate severity (Grade 2 and Grade 3) &lt;br&gt;MedDRA version: 14.0
Level: PT
Classification code 10066218
Term: Stress urinary incontinence
System Organ Class: 10038359 - Renal and urinary disorders
</Condition>
    <Intervention>&lt;br&gt;Product Name: Skeletal Muscle Derived Cells&lt;br&gt;Product Code: SMDC&lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;Current Sponsor code: Skeletal Muscle Derived Cells (SMDC)&lt;br&gt;Concentration unit: Other&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10000000-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The objective of this study is to evaluate the functional status of the urethra and particularly the urethral rhabdosphincter by means of urodynamic measures after SMDCs implantation procedure in female patients with SUI.;Secondary Objective: Efficacy variables:&lt;br&gt;- Change from baseline of maximum urethral closure pressure,&lt;br&gt;- Change from baseline of the functional urethral length,&lt;br&gt;- Change from baseline of the area under the curve (AUC) of the urethral pressure curve at &lt;br&gt;   rest,&lt;br&gt;- Change from baseline of the IEF score (a response is defined as a reduction by 50% and &lt;br&gt;   75%),&lt;br&gt;- Change from baseline in the Visual Analogue Scale (VAS) score,&lt;br&gt;- Change from baseline in the short pad-test results,&lt;br&gt;- Change from baseline in the I-QoL score,&lt;br&gt;- Examinations based on the micturition diary records,&lt;br&gt;- Investigator’s Assessment by the Clinical Global Impression (CGI) score.&lt;br&gt;&lt;br&gt;Safety variables:&lt;br&gt;- Physical examination,&lt;br&gt;- Safety laboratory tests,&lt;br&gt;- AEs.;Primary end point(s): The primary endpoint of the current study is the change from baseline in the USP measured by the transmission ratio in percent in the midurethra.</Primary_outcome>
    <Secondary_ID>IC-01-01-5-006</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2485710</Internal_Number>
    <TrialID>EUCTR2011-000691-34-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Single-center study to evaluate the efficacy and safety of immunosuppressive regimens with lower risk of renal toxicity including ATeGe-Fresenius in patients with renal failure before liver transplantation</Public_title>
    <Scientific_title>Single-center pilot study, prospective, open-label, to evaluate the efficacy and safety of immunosuppression low nephrotoxicity, based on the use of ATeGe-Fresenius in patients with renal insufficiency pretransplant liver                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Dra Itxarone Bilbao. Servicio de Cirugía Hepatobiliopancreatica y Trasplantes. HUVH.</Primary_sponsor>
    <Date_registration3>20110721</Date_registration3>
    <Date_registration>21/07/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-000691-34                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>06/07/2011</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: Controles historicos&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 1&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Pacientes que vayan a ser sometidos a un primer trasplante hepático de 18-70 años de edad, sin contraindicación a priori para la realización de biopsias del aloinjerto, y con insuficiencia renal, que presenten niveles de creatinina sérica superiores a 1,5 mg/dl antes del trasplante hepático o valores de aclaramiento de creatinina estimado por MDRD &lt;60ml/min&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 20&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 10&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Pacientes receptores de trasplante de múltiples órganos o con antecedentes de trasplante previo de cualquier otro órgano, receptores de un trasplante hepático procedente de un donante en asistolia o con incompatibilidad ABO respecto al donante, con infecciones concomitantes no controladas significativas y/o diarrea, vómito o úlcera péptica activa graves, recepción de vacunas con virus atenuados en las semanas previas al trasplante, leucopenia, trombocitopenia, y recuento linfocitario CD2+/CD3+ inferior a 10 células/&amp;#956;l.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal failure in liver transplantation &lt;br&gt;MedDRA version: 14.0
Level: PT
Classification code 10024714
Term: Liver transplant
System Organ Class: 10042613 - Surgical and medical procedures
 &lt;br&gt;MedDRA version: 14.0
Level: LLT
Classification code 10022467
Term: Insufficiency renal
System Organ Class: 10038359 - Renal and urinary disorders
;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]</Condition>
    <Intervention>&lt;br&gt;Trade Name: ATeGe-Fresenius 20 mg/ml concentrado para solución para perfusión&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: INMUNOGLOBULINA CONEJO ANTI-LINFOCITOS T HUMANOS&lt;br&gt;Other descriptive name: INMUNOGLOBULINA CONEJO ANTI-LINFOCITOS T HUMANOS&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Product Name: metilprednisolona&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;INN or Proposed INN: METILPREDNISOLONA&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 8-&lt;br&gt;&lt;br&gt;Product Name: TACROLIMUS&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Product Name: MICOFENOLATO SODICO&lt;br&gt;Pharmaceutical Form: Gastro-resistant tablet&lt;br&gt;INN or Proposed INN: MICOFENOLATO SODICO&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 180-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluar la eficacia y seguridad de un régimen inmunosupresor de baja nefrotoxicidad, basado en ATeGe-Fresenius + esteroides + Tacrolimus a dosis bajas, en cuanto a su capacidad para preservar y recuperar la funcion renal durante los 3 primeros meses postrasplante;Primary end point(s): Mejoría y restauración de la funcion renal mediante los valores de creatinina y MDRD calculado en los días 1,3,5,7,15,30 y 90 días, así como, la incidencia de rechazo agudo probado por biopsia (BPAR) durante los primeros 3 meses después del trasplante hepático.;Timepoint(s) of evaluation of this end point: Mejoría y restauración de la funcion renal mediante los valores de creatinina y MDRD calculado en los días 1,3,5,7,15,30 y 90 días, así como, la incidencia de rechazo agudo probado por biopsia (BPAR) durante los primeros 3 meses después del trasplante hepático.;Secondary Objective: Evaluar la incidencia de rechazo agudo demostrado por biopsia en el primer año después del trasplante. &lt;br&gt;Analizar la supervivencia de pacientes e injertos durante el primer año postrasplante. &lt;br&gt;Evaluar la eficacia para estabilizar o mejorar la insuficiencia renal pretrasplante, a los 3, 6, 9, y 12 meses postrasplante hepático. &lt;br&gt;&lt;br&gt;Evaluar la relación entre las dosis de ATeGe-Fresenius, parámetros inmunológicos y acontecimientos clínicos. &lt;br&gt;Evaluar la incidencia y la gravedad de la recurrencia de la infección por el VHC al año de seguimiento o cuando esté clínicamente indicada.</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Rechazo agudo&lt;br&gt;Episodios de rechazo agudo confirmados con biopsia&lt;br&gt;Supervivencia del injerto&lt;br&gt;Supervivencia del paciente;Timepoint(s) of evaluation of this end point: 12 meses</Secondary_outcome>
    <Secondary_ID>ATG-IRA.HVH.10</Secondary_ID>
    <Source_Support>Dra Itxarone Bilbao. Servicio de Cirugía Hepatobiliopancreatica y Trasplantes. HUVH.</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2485865</Internal_Number>
    <TrialID>EUCTR2009-017939-18-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Phase 4 randomised, double-blind, placebo controlled, crossover trial Nitrofurantoin Macrocrystals 100 mg twice daily for six weeks in the treatment of  overactive bladder symptoms associated with a negative mid stream urine culture and pyuria in patients with Multiple Sclerosis. - Recurrent urine infection in MS</Public_title>
    <Scientific_title>A Phase 4 randomised, double-blind, placebo controlled, crossover trial Nitrofurantoin Macrocrystals 100 mg twice daily for six weeks in the treatment of  overactive bladder symptoms associated with a negative mid stream urine culture and pyuria in patients with Multiple Sclerosis. - Recurrent urine infection in MS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>UCLH/UCL Biomedical Research Unit</Primary_sponsor>
    <Date_registration3>20100827</Date_registration3>
    <Date_registration>27/08/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-017939-18                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>15/12/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Male or Female Patients suffering from MS and overactive bladder symptoms 2. Adults aged &gt;=18 years  3. Symptoms of frequency = 8 per day; urgency with or without urge incontinence.  4. Able to complete a bladder diary chart for at least three days in one week  5. Able to complete a symptom questionnaire  6. Pyuria on urinalysis showing =10 wbc µL-1 7. A negative result from culture of a midstream urine specimen on selective agar with a threshold of 105 cfu ml-1 8.      Able to give informed consent&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Age less than 18 years 2. Inability to consent 3. Bacteriuria of &gt;105 cfu ml-1 identified by conventional MSU culture  4. Negative urine microscopy identified by &lt; 10wbc/uL on a fresh, unspun sample of urine.  5. Known renal impairment - acute or chronic renal failure 6. Chronic lung disease 7. Allergy to Nitrofurantoin 8.      The patient must not have taken part in other research within the previous   six months and must not be participating in concurrent research. 9.     The patient must not have taken part in previous studies of Nitrofurantoin 10. Pregnant or lactating females (Contraception is required in females and males who participate)  11. Intolerance to lactose&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic urinary tract infection. &lt;br&gt;MedDRA version: 14.0
Level: LLT
Classification code 10059617
Term: Overactive bladder
System Organ Class: 10038359 - Renal and urinary disorders
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Nitrofurantoin&lt;br&gt;Product Name: Nitrofurantoin&lt;br&gt;Product Code: PL 12762/0049&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;INN or Proposed INN: Nitrofurantoin&lt;br&gt;CAS Number: 67-20-9&lt;br&gt;Other descriptive name: Nitrofurantoin&lt;br&gt;Concentration unit: Bq/mg becquerel(s)/milligram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;Pharmaceutical form of the placebo: Capsule&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The aim of this study is to determine whether treatment with Nitrofurantoin improves average voided volume in MS patients presenting with symptoms of overactive bladder and pyuria with a negative mid stream urine culture.;Secondary Objective: To determine whether treatment with Nitrofurantoin improves other symptoms of overactive bladder and indicators of infection and inflammation in MS patients presenting with symptoms of overactive bladder and pyuria with a negative mid stream urine culture:  1. 24-hr-urinary frequency  2. Incontinence episodes per 24-hrs 3. Urgency score {Al Buheissi, 2008 1182 /id} 4. Average voided volume  5. Quality of life (ICIQ)  6. Urinary pyuria,  7. Urinary bacterial culture  8. Urinary Il-6 levels 9. Urinary ATP levels  To determine whether pus cells are eliminated from the urine, &lt; 10 wbc/ uL, after long term treatment with Nitrofurantoin.   To record side effects of treatment;Primary end point(s): The primary outcome measure is the change in average voided volume.</Primary_outcome>
    <Secondary_ID>08/0316</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2485952</Internal_Number>
    <TrialID>EUCTR2007-003968-22-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast Nephropathy - Free light chain removal by extended haemodialysis.</Public_title>
    <Scientific_title>European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast Nephropathy - Free light chain removal by extended haemodialysis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>University Hospital Birmingham</Primary_sponsor>
    <Date_registration3>20080225</Date_registration3>
    <Date_registration>25/02/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-003968-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>04/02/2008</Date_enrollement>
    <Target_size>90</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: Randomised trial of a medical device (haemodialyser) not the IMP (Velcade). &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Standard dialysis&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Dialysis dependent acute renal failure (eGFR &lt;15mls/min/1.73m2)&lt;br&gt;•	Fulfils diagnostic criteria for the diagnosis of symptomatic de novo multiple myeloma1&lt;br&gt;•	Abnormal serum FLC ratio&lt;br&gt;•	Myeloma kidney demonstrated on a renal biopsy (cast nephropathy)&lt;br&gt;•	Ability to give informed consent to partake in study&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	Known advanced chronic renal failure (CKD stage IV; eGFR &lt;30mls/min/1.73m2) or evidence of significant chronic damage on renal biopsy&lt;br&gt;•	Amyloidosis or light chain deposition disease on renal biopsy&lt;br&gt;•	Previous treatment of multiple myeloma with chemotherapy&lt;br&gt;•	Haemodynamic instability that precludes unsupported dialysis &lt;br&gt;•	Significant cardiac disease (myocardial infarction with in 6 months; unstable angina; NYHA class III or IV heart failure; clinically significant pericardial disease; cardiac amyloidosis)&lt;br&gt;•	Advanced disease or significant co-morbidity: with poor short term prognosis, necessitating palliation and no active or disease specific treatment.&lt;br&gt;•	Inability to give informed consent&lt;br&gt;•	History of allergic reaction to compounds containing boron or mannitol&lt;br&gt;•	History of peripheral neuropathy or neuropathic pain (Grade 2 or Higher)&lt;br&gt;•	Clinically significant liver dysfunction (bilirubin &gt;1.8mg/dl (30umol/L)&lt;br&gt;•	Known HIV infection&lt;br&gt;•	Active uncontrolled infection&lt;br&gt;*              Pregnant and lactating women&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Multiple myeloma patients with acute dialysis dependent renal failure resulting from cast nephropathy. &lt;br&gt;MedDRA version: 14.0
Level: LLT
Classification code 10028566
Term: Myeloma
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
 &lt;br&gt;MedDRA version: 14.0
Level: LLT
Classification code 10028569
Term: Myelomatosis multiple
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
 &lt;br&gt;MedDRA version: 14.0
Level: PT
Classification code 10038436
Term: Renal failure acute
System Organ Class: 10038359 - Renal and urinary disorders
 &lt;br&gt;MedDRA version: 14.0
Level: PT
Classification code 10018875
Term: Haemodialysis
System Organ Class: 10042613 - Surgical and medical procedures
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Velcade&lt;br&gt;Pharmaceutical Form: Powder for solution for injection&lt;br&gt;INN or Proposed INN: Bortezomib&lt;br&gt;CAS Number: 179324-69-7&lt;br&gt;Current Sponsor code: 26866138&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 3.5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of the study is to address the hypothesis that extended HD, using the Gambro HCO 1100, increases the percentage of patients with cast nephropathy becoming independent of dialysis.;Secondary Objective: 1.  Investigation of the efficiency of extended HD using the Gambro HCO 1100 to result in sustained reductions in sFLC concentrations versus a standard dialysis. &lt;br&gt;&lt;br&gt;2	Comparison of the duration of HD before renal recovery&lt;br&gt;&lt;br&gt;&lt;br&gt;3	Investigation of multiple myeloma response to chemotherapy and suitability for stem cell transplantation.&lt;br&gt;&lt;br&gt;&lt;br&gt;4	Mortality&lt;br&gt;;Primary end point(s): The primary analysis for the trial is to compare the experimental treatment to the control treatment in terms of independence of dialysis at three months. The proportion of patients independent of dialysis will be compared using relative risks and chi-square tests. The analysis will be carried out on an intention-to-treat basis.</Primary_outcome>
    <Secondary_ID>ETFLCHD01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2486586</Internal_Number>
    <TrialID>EUCTR2011-002424-41-DE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>The trial is designed to determine the efficacy of OGX-427 Vs placebo in combination with Gemcitabine and Cisplatin in patients with Urinary tract cancer.</Public_title>
    <Scientific_title>A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination with OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>OncoGenex Technologies, Inc.</Primary_sponsor>
    <Date_registration3>20110824</Date_registration3>
    <Date_registration>24/08/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-002424-41                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/11/2011</Date_enrollement>
    <Target_size>180</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 3&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1) Age = 18 years at the time of consent.&lt;br&gt;2) Histologically documented metastatic or locally inoperable advanced TCC of the urinary tract (bladder, urethra, ureter and renal pelvis) (T4b, N2, N3 or M1 disease).&lt;br&gt;NOTE: Certain mixed histologies that are predominately (= 50%) TCC are eligible: squamous, adenocarcinoma, and undifferentiated. Mixed undifferentiated histology requires IHC consistent with a TCC origin. Mixed small-cell histologies are excluded.&lt;br&gt;3) Measurable disease defined as at least one target lesion that has not been irradiated and can be accurately measured in at least one dimension by RECIST 1.1 criteria.&lt;br&gt;4) No prior systemic chemotherapy with the following exceptions:&lt;br&gt;• Prior use of radiosensitizing single agent therapy is allowed.&lt;br&gt;• Prior neoadjuvant and adjuvant systemic chemotherapy are permissible if the interval from the end of therapy to the diagnosis of metastatic disease is at least 12 months.&lt;br&gt;5) Minimum of 21 days have elapsed since prior major surgery or radiation therapy, with recovery from any adverse events.&lt;br&gt;6) Karnofsky performance status =70%.&lt;br&gt;7) Required laboratory values at baseline:&lt;br&gt;• ANC = 1.5x10^9 cells/L&lt;br&gt;• platelet count = 125 x 10^9/L&lt;br&gt;• Calculated creatinine clearance =60 mL/minute (by modified Cockcroft-Gault formula).&lt;br&gt;• bilirubin = 1.5 x ULN (= 2.5 x ULN if secondary to Gilbert’s disease)&lt;br&gt;• AST and ALT = 3.0 x ULN&lt;br&gt;8) If of child-bearing potential, willing to use contraceptive measures during and for 3 months after completion of therapy.&lt;br&gt;9) willing to give written informed consent&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 150&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 30&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1) A candidate for potential curative surgery or radiotherapy.&lt;br&gt;2) Intravesical therapy within the last 3 months,&lt;br&gt;3) Documented brain metastasis or carcinomatous meningitis, treated or untreated. NOTE: Brain imaging is not required unless the patient has symptoms or physical signs of CNS disease.&lt;br&gt;4) Peripheral neuropathy =Grade 2.&lt;br&gt;5) Known serious hypersensitivity to gemcitabine, cisplatin or carboplatin.&lt;br&gt;6) Current serious, uncontrolled medical condition such as congestive heart failure, angina, hypertension, arrhythmia, diabetes mellitus, infection, etc. or any condition such as a psychiatric illness which in the opinion of the investigator would make the patient unacceptable for the protocol.&lt;br&gt;7) Cerebrovascular accident, myocardial infarction or pulmonary embolus within 6 months of randomization.&lt;br&gt;8) Active second malignancy (except non-melanomatous skin cancer): active secondary malignancy is defined as a current need for cancer therapy or a high possibility (&gt;30%) of recurrence during the study.&lt;br&gt;9) Pregnant or nursing (must have a negative serum or urine pregnancy test within 72 hours prior to randomization).&lt;br&gt;10) Participating in a concurrent clinical trial of an experimental drug, vaccine or device. Participation in an observational study is allowed.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Metastatic or locally inoperable, advanced (T4b, N2, N3 or M1) transitional cell carcinoma (TCC) of the urinary tract (bladder, urethra, ureter and renal pelvis) &lt;br&gt;MedDRA version: 14.0
Level: PT
Classification code 10005084
Term: Bladder transitional cell carcinoma
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
;Therapeutic area: Diseases [C] - Cancer [C04]</Condition>
    <Intervention>&lt;br&gt;Product Code: OGX-427&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Not applicable&lt;br&gt;CAS Number: 915443-09-3&lt;br&gt;Current Sponsor code: OGX-427&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To ascertain whether there is evidence of longer survival relative to the control arm for three comparisons: 600 mg OGX-427 Arm to control Arm; 1000 mg OGX-427 Arm to control Arm; and pooled 600 mg and 1000 mg OGX-427 Arms to control Arm.;Secondary Objective: • To compare the safety and tolerability of placebo, 600 mg of OGX-427, and 1000 mg of OGX-427 in combination with gemcitabine plus cisplatin.&lt;br&gt;• To select the optimal dose of OGX-427 (600 mg vs. 1000 mg) for Phase 3 studies based on the safety and efficacy (i.e., risk/benefit).&lt;br&gt;• To compare ORR (CR+PR), disease control rate (CR+PR+stable disease), duration of response, and PFS between the arms.&lt;br&gt;• To evaluate the effect of therapy with gemcitabine, cisplatin and OGX-427 on serum Hsp27 levels, serum clusterin levels and CTC counts.&lt;br&gt;• To evaluate and compare the number of circulating tumor cells (CTC) at baseline, the minimum CTC count during treatment and the maximum change in CTC count over time between arms.&lt;br&gt;• To evaluate the effect of repeat OGX-427 dosing on serum OGX-427 Cmax and trough levels.&lt;br&gt;• To evaluate for PTEN loss, translocation or deletion, along with downstream targets, in correlation with clinical response and changes in clusterin and Hsp27 levels.;Primary end point(s): The primary efficacy endpoint for each patient is overall survival time. ;Timepoint(s) of evaluation of this end point: The primary efficacy endpoint for each patient is overall survival time measured as time from the date of randomization to the date of death from any cause. For patients still alive at the time of analysis, overall survival time will be censored on the date of last contact.</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): The secondary efficacy objectives include evaluating the following:
&lt;br&gt;• Best response to therapy (CR, PR, SD, PD) will be summarized by treatment arm. In addition, the number (%) of patients with an overall response (CR or PR) and with disease control (PR or CR or SD) will be reported. Duration of responses will also be summarized.
&lt;br&gt;• Progression-free survival time (PFS) will be summarized by treatment arm. PFS is defined as the time from randomization to the date of disease progression or death, whichever occurs first, before or after treatment discontinuation. For those still on study and those who remain alive and have not progressed after treatment discontinuation, PFS will be censored on the date of the last tumor assessment.
&lt;br&gt;• Serum Hsp27 levels, serum clusterin levels and CTC counts will be summarized by treatment arm.
&lt;br&gt;• Serum OGX-427 Cmax and trough levels will be summarized by treatment arm.;Timepoint(s) of evaluation of this end point: Time from the date of randomization to the date of death from any cause or the date of last contact for alive patients. </Secondary_outcome>
    <Secondary_ID>OGX-427-02</Secondary_ID>
    <Source_Support>OncoGenex Technologies, Inc.</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2486713</Internal_Number>
    <TrialID>EUCTR2011-000624-16-DE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Infertility and inflammatory diseases of the urinary- and sex organs as a result of diabetes, hypertony, dislepidaemia and overweight (metabolic syndrome)
</Public_title>
    <Scientific_title>Infertility and inflammatory urogenital diseases as a result of the metabolic syndrome
Male infertility with infection and inflammation
-MIBIE-
 - MIBIE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Justus Liebig Universität Gießen</Primary_sponsor>
    <Date_registration3>20110905</Date_registration3>
    <Date_registration>05/09/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-000624-16                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: no&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>28/11/2011</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	age &gt; 18 years, male&lt;br&gt;•	metabolic syndrome according to International Diabetes Federation (IDF): &lt;br&gt;- adiposity: waist circumference &gt; 94 cm   (European), and 2 of the following criteria:&lt;br&gt;- triglyceride &gt; 150 mg/dl (fasting)&lt;br&gt;- HDL-cholesterol &lt; 40 mg/dl or treated by antilipemics (fasting)&lt;br&gt;- bloodpresssure &gt; 130/&gt; 85 mmHg or treated  hypertonia&lt;br&gt;- fasting blood sugar &gt; 100 mg/dl or&lt;br&gt;   known diabetes&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 50&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 10&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	noncompliance to criteria of metabolic syndrome (e.g. diabetes type 1)&lt;br&gt;•	Diseases, which might jeopardize patients safety&lt;br&gt;•	Condition after sterilisation or refertilization&lt;br&gt;•	Diseases or medicaments, which might obstruct the coduct of the trial (e.g. addiction, psychotic and tumourous diseases, systemic intake of glucocorticoids)&lt;br&gt;•	Participation in another trial according to AMG&lt;br&gt;</Exclusion_Criteria>
    <Condition>infertility and inflammatory urogenital diseases as a result of the metabolic syndrome &lt;br&gt;MedDRA version: 14.0
Level: PT
Classification code 10046694
Term: Urogenital disorder
System Organ Class: 10038359 - Renal and urinary disorders
 &lt;br&gt;MedDRA version: 14.0
Level: PT
Classification code 10052066
Term: Metabolic syndrome
System Organ Class: 10027433 - Metabolism and nutrition disorders
 &lt;br&gt;MedDRA version: 14.0
Level: PT
Classification code 10021926
Term: Infertility
System Organ Class: 10038604 - Reproductive system and breast disorders
;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]</Condition>
    <Intervention>&lt;br&gt;Product Name: Atorvastatin&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: ATORVASTATIN&lt;br&gt;CAS Number: 134523-00-5&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 10-20&lt;br&gt;&lt;br&gt;Product Name: Simvastatin&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Simvastatin&lt;br&gt;CAS Number: 79902-63-9&lt;br&gt;Other descriptive name: SIMVASTATIN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 5-80&lt;br&gt;&lt;br&gt;Product Name: Fenofibrat&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: FENOFIBRATE&lt;br&gt;CAS Number: 49562-28-9&lt;br&gt;Other descriptive name: FENOFIBRATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Product Name: Ramipril&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Ramipril&lt;br&gt;CAS Number: 87333-19-5&lt;br&gt;Other descriptive name: RAMIPRIL&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 2,5-5&lt;br&gt;&lt;br&gt;Product Name: Fosinopril&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: FOSINOPRIL&lt;br&gt;CAS Number: 97825-24-6&lt;br&gt;Other descriptive name: FOSINOPRIL&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 10-20&lt;br&gt;&lt;br&gt;Product Name: Carvediol&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: CARVEDILOL&lt;br&gt;CAS Number: 72956-09-3&lt;br&gt;Other descriptive name: CARVEDILOL&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 12,5-50&lt;br&gt;&lt;br&gt;Product Name: Valsartan&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Valsartan&lt;br&gt;CAS Number: 137862-53-4&lt;br&gt;Other descriptive name: Valsartan&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 20-160&lt;br&gt;&lt;br&gt;Product Name: Metformin&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: METFORMIN&lt;br&gt;CAS Number: 657-24-9&lt;br&gt;Other descriptive name: METFORMIN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 500-2400&lt;br&gt;&lt;br&gt;Product Name: Pioglitazon&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: PIOGLITAZONE&lt;br&gt;CAS Number: 111025-46-8&lt;br&gt;Other descriptive name: PIOGLITAZONE&lt;br&gt;Concen</Intervention>
    <Primary_outcome>Main Objective: Primary objective&lt;br&gt;Difference of spermatozoa concentration in the ejaculate between baseline and 12 months follow-up visit [millions/ml]&lt;br&gt;;Secondary Objective: Secondary objectives&lt;br&gt;•	Pregnancy rate primary/ secondary&lt;br&gt;•	Spermatozoa mobility (%)&lt;br&gt;•	Normal formed Spermatozoa (%)&lt;br&gt;•	Inflammation scores of ejaculate, consisting of cellular and humoral parameters&lt;br&gt;•	Change of the hormone levels of FSH, LH and testosterone in blood serum in the course of the study&lt;br&gt;•	Effects on the sonographic investigations of prostate gland and testicles&lt;br&gt;•	Influence of the age of the manifestation of the metabolic syndrome on fertility&lt;br&gt;•	Complaint scores, as Prostatitis questionnaire NIH-CPSI&lt;br&gt;•	Change of blood pressure, blood glucose, blood fat, body weight, sCRP&lt;br&gt;&lt;br&gt; &lt;br&gt;;Primary end point(s): Difference of spermatozoa concentration in the ejaculate between baseline and 12 months follow-up visit [millions/ml];Timepoint(s) of evaluation of this end point: end of study</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): •	Pregnancy rate primary/ secondary&lt;br&gt;•	Spermatozoa mobility (%)&lt;br&gt;•	Normal formed Spermatozoa (%)&lt;br&gt;•	Inflammation scores of ejaculate, consisting of cellular and humoral parameters&lt;br&gt;•	Change of the hormone levels of FSH, LH and testosterone in blood serum in the course of the study&lt;br&gt;•	Effects on the sonographic investigations of prostate gland and testicles&lt;br&gt;•	Influence of the age of the manifestation of the metabolic syndrome on fertility&lt;br&gt;•	Complaint scores, as Prostatitis questionnaire NIH-CPSI&lt;br&gt;•	Change of blood pressure, blood glucose, blood fat, body weight, sCRP&lt;br&gt;&lt;br&gt;;Timepoint(s) of evaluation of this end point: end of study</Secondary_outcome>
    <Secondary_ID>LOEWE_B4</Secondary_ID>
    <Source_Support>Justus Liebig Universität Gießen</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2486763</Internal_Number>
    <TrialID>EUCTR2011-000249-18-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>ACTION OF PARICALCITOL OVER PARAMETERS IN CHRONIC KIDNEY DISEASE</Public_title>
    <Scientific_title>ACCIÓN DEL PARICALCITOL SOBRE PARÁMETROS DE
INFLAMACIÓN Y ESTRÉS OXIDATIVO EN PACIENTES
CON ENFERMEDAD RENAL CRÓNICA ESTADIO Vd
PORTADORES DE CATÉTERES TUNELIZADOS PARA
HEMODIÁLISIS. - SENPARIC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>RICARDO MOUZO MIRCO</Primary_sponsor>
    <Date_registration3>20110915</Date_registration3>
    <Date_registration>15/09/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-000249-18                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>09/08/2011</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: atorvastatina&lt;br&gt;Number of treatment arms in the trial: 3&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;ERC Vd en HD durante un periodo igual o superior a tres meses.&lt;br&gt; Ser portadores de un catéter tunelizado permanente para hemodiálisis al menos&lt;br&gt;en los 6 meses previos al inicio del estudio.&lt;br&gt; Kt estable, mayor de 45 litros para ambos sexos.43-45&lt;br&gt; Estar en tratamiento previo con atorvastatina.&lt;br&gt; Sin procesos infecciosos o inflamatorios activos en las últimas 8 semanas.&lt;br&gt; Dos PTH consecutivas inferior a 400 pg/ml, Ca&lt;10.2 y P &lt;7.0 mg/dl.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 15&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 15&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Pacientes menores de 18 años.&lt;br&gt; Mujeres embarazadas.&lt;br&gt; Pacientes que hayan sido hospitalizados en las últimas 4 semanas previas al&lt;br&gt;inicio del tratamiento.&lt;br&gt; Recibir tratamiento inmunosupresor.&lt;br&gt;</Exclusion_Criteria>
    <Condition>ENFERMEDAD RENAL CRÓNICA ESTADIO VD.;Therapeutic area: Body processes [G] - Physical Phenomena [G01]</Condition>
    <Intervention>&lt;br&gt;Trade Name: PARICALCITOL&lt;br&gt;Product Name: PARICALCITOL&lt;br&gt;Product Code: PARICALCITOL&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: PARICALCITOL&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 40-&lt;br&gt;&lt;br&gt;Product Name: ATORVASTATINA&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: ATORVASTATINA&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Determinar la mejoría de parámetros de&lt;br&gt;inflamación y estrés oxidativo en pacientes&lt;br&gt;con ERC Vd portadores de catéteres&lt;br&gt;tunelizados permanentes para hemodiálisis,&lt;br&gt;tratados con paricalcitol oral.;Secondary Objective: Valorar la mejoría de los parámetros&lt;br&gt;nutricionales y de anemia.&lt;br&gt; Determinar la disminución de los&lt;br&gt;requerimientos de eritropoyetina.&lt;br&gt; Valorar los efectos beneficiosos sobre&lt;br&gt;marcadores inflamatorios con la asociación&lt;br&gt;entre paricalcitol + atorvastatina.;Primary end point(s): Parámetros de inflamación y estrés oxidativo en pacientes con ERC estadio Vd después de&lt;br&gt;12 semanas de tratamiento.;Timepoint(s) of evaluation of this end point: + 2 semanas después de tratamiento: 2º lavado.</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): ?Valorar la mejoría de los parámetros nutricionales y de anemia.&lt;br&gt;?Determinar la disminución de los requerimientos de eritropoyetina.&lt;br&gt;?Valorar la potención de efectos beneficiosos sobre marcadores inflamatorios con la asociación entre paricalcitol + atorvastatina;Timepoint(s) of evaluation of this end point: +2 semanas después de tratamiento</Secondary_outcome>
    <Secondary_ID>SENPARIC-2011-01</Secondary_ID>
    <Source_Support>FUNDACIÓN SENEFRO</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2486919</Internal_Number>
    <TrialID>EUCTR2010-024023-25-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>ENSAYO CLÍNICO, ABIERTO, DE GRUPOS PARALELOS, FASE III, PARA VALORAR EL EFECTO ANTIPROTEINÚRICO DE LOS DERIVADOS DE LA VITAMINA D EN PACIENTES CON ENFERMEDAD RENAL CRÓNICA E INSUFICIENCIA DE VITAMINA D.</Public_title>
    <Scientific_title>An open label, parallel groups, phase III, clinical trial to assess the antiproteinuric effects of the vitamin D derivates in patients with chronic kidney disease and vitamin D insufficiency. - Nefrovid2010                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Lorenzo Victor, PhD</Primary_sponsor>
    <Date_registration3>20110708</Date_registration3>
    <Date_registration>08/07/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-024023-25                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/09/2011</Date_enrollement>
    <Target_size>174</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: sólo el tratamiento standard&lt;br&gt;Number of treatment arms in the trial: 3&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 174&lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;</Exclusion_Criteria>
    <Condition> &lt;br&gt;MedDRA version: 14.0
Level: SOC
Classification code 10038359
Term: Renal and urinary disorders
System Organ Class: 10038359 - Renal and urinary disorders
;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]</Condition>
    <Intervention>&lt;br&gt;Trade Name: Zemplar&lt;br&gt;Product Name: zemplar&lt;br&gt;Product Code: 68022&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: D00930&lt;br&gt;CAS Number: 131918-61-1&lt;br&gt;Other descriptive name: PARICALCITOL&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: Hidroferol&lt;br&gt;Product Name: Hidroferol&lt;br&gt;Product Code: 53683&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;INN or Proposed INN: CALCIFEDIOL&lt;br&gt;CAS Number: 19356-17-3&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 266-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: ;Secondary Objective: ;Primary end point(s): </Primary_outcome>
    <Secondary_outcome>Timepoint(s) of evaluation of this end point: Está establecido en el apartado anterior para cada una de las variables.</Secondary_outcome>
    <Secondary_ID>Nefrovid2010</Secondary_ID>
    <Source_Support>Ministerio de Sanidad y Política Social (national health system)</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2487185</Internal_Number>
    <TrialID>EUCTR2011-002586-38-SE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A 12-week clinical double-blind, randomised study of vitamin D versus placebo in patients with chronic kidney disease stage 3-4 (CHICK).</Public_title>
    <Scientific_title>A 12-week clinical double-blind, randomised study of cholecalciferol versus placebo in patients with chronic kidney disease stage 3-4 (CHICK). - Vitamin D in chronic kidney disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Renapharma AB</Primary_sponsor>
    <Date_registration3>20110824</Date_registration3>
    <Date_registration>24/08/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-002586-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>14/10/2011</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Males or females aged 18-85 &lt;br&gt;•	A calculated GFR of 59 to 15 mL/min/1.73 m2 body surface according to the Modification of Diet in Renal Disease (MDRD) formula&lt;br&gt;•	Intact PTH above 6.8 pmol/L (70 pg/mL) &lt;br&gt;•	Calcidiol levels below 75 nmol/L (30 ng/mL) &lt;br&gt;•	Have signed informed consent to participate in the study &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 100&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 30&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	Assumed need for dialysis or renal transplantation within six months &lt;br&gt;•	Ionized calcium above 1.30 mmol/L &lt;br&gt;•	Ongoing acute infectious or inflammatory disease. Ongoing chronic inflammatory disease other than chronic glomerulonephritis or systemic diseases with renal involvement &lt;br&gt;•	Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods. &lt;br&gt;•	Kidney transplant, known granulomatous disease, malabsorption, primary hyperparathyroidism, malignancy or other disease with effect on mineral metabolism &lt;br&gt;•	Ongoing treatment with parakalcitol, calcimimetics or a daily intake of pharmaceutical preparations containing &gt;400 IE of vitamin D.&lt;br&gt;•	Planned vacation trip, during the study period, to a sunny country outside Sweden&lt;br&gt;•	Contraindication for Vitamin D3 Forte Renapharma®&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic renal failure, stage 3-4 &lt;br&gt;MedDRA version: 14.0
Level: PT
Classification code 10038444
Term: Renal failure chronic
System Organ Class: 10038359 - Renal and urinary disorders
;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]</Condition>
    <Intervention>&lt;br&gt;Trade Name: Detremin 20,000 I.U./ml oral drops, solution&lt;br&gt;Product Name: Vitamin D3 Forte Renapharma&lt;br&gt;Product Code: Vitamin D3 Forte Renapharma&lt;br&gt;Pharmaceutical Form: Oral drops, solution&lt;br&gt;Pharmaceutical form of the placebo: Oral solution&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;Pharmaceutical form of the placebo: Oral drops, solution&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To investigate whether there is a difference in the mean change from baseline of the blood levels of parathyroid hormone (PTH) between patients receiving cholecalciferol compared with patients receiving cholecalciferol placebo after 12 weeks’ treatment. ;Secondary Objective: The following secondary variable will be assessed after 6 weeks: &lt;br&gt;•	Mean change in blood levels of PTH.  &lt;br&gt;Further, the following secondary variables will be assessed after 6 and 12 weeks: &lt;br&gt;•	To Investigate whether there is a difference between the two treatment groups with respect to change in PTH levels after 6 weeks, and to investigate individual changes. Further to investigate differences between the two treatment in the change from baseline in musculoskeletal function and fatigue. &lt;br&gt;;Primary end point(s): Mean change from baseline in the levels of PTH after 12 weeks’ treatment&lt;br&gt;;Timepoint(s) of evaluation of this end point: After 12 weeks´ of treatment</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Secondary efficacy variables: Mean change from baseline after 6 to 12 weeks in the levels of grip strength, fatigue questionnaire, fatigue on visual analogue scale. Exploratory analyses: calcidiol and calcitriol levels, biointact (1-84) PTH, FGF23, ionized calcium, phosphate (Pi), GFR estimated from cystatin C levels, and renal fractional excretion (FE) of Ca and Pi. ;Timepoint(s) of evaluation of this end point: After 6 and 12 weeks respectively</Secondary_outcome>
    <Secondary_ID>RPH-1101</Secondary_ID>
    <Source_Support>Renapharma AB</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2487315</Internal_Number>
    <TrialID>EUCTR2009-015579-28-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>This study is to look at how well ferric carboxymaltose, an intravenous iron therapy (iron that is infused directly into your body through a vein), compares with iron sulphate capsules taken by mouth in the treatment of iron deficiency anaemia in subjects with non-dialysis-dependent chronic kidney disease</Public_title>
    <Scientific_title>An Open-label, Multicentre, Randomised, 3-arm Study to Investigate the Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (Ferinject® High- and Low-dosage Regimens) versus Oral Iron for the Treatment of Iron Deficiency Anaemia in Subjects with Non-dialysis-dependent Chronic Kidney Disease - The FIND-CKD Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Vifor Pharma Inc.</Primary_sponsor>
    <Date_registration3>20091001</Date_registration3>
    <Date_registration>01/10/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-015579-28                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/12/2009</Date_enrollement>
    <Target_size>1016</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 3&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. At least 18 years of age.&lt;br&gt;&lt;br&gt;2. NDD-CKD subjects with an estimated glomerular filtration rate (eGFR) =60  ml/min/1.73 m2 using modification of diet in renal disease (MDRD) calculation.&lt;br&gt;&lt;br&gt;3. NDD-CKD subjects with an eGFR loss =12 mL/min/1.73 m² per year and a predicted eGFR of =15 mL/min/1.73 m2 in 12 months.&lt;br&gt;The eGFR loss, defined as =12 mL/min/1.73 m2 per year, should be based on at least 2 appropriately representative values over at least 4 weeks prior to randomisation, ideally 3 values over at least 3 months. If this predicted eGFR decline is =12 mL/min/1.73 m2 per year then subject may be included (*).&lt;br&gt;The predicted eGFR of =15 mL/min/1.73 m2 in 12 months should be estimated based on previous eGFR values. If more than 3 eGFR values are available in the 2-year time period prior to randomisation, the predicted eGFR at 12 months should be calculated using 3 appropriately representative values (which will also be recorded in the case report form (CRF)).&lt;br&gt;&lt;br&gt;4. Any single Hb between 9 and 11 g/dL within 4 weeks of randomisation. Note: A value taken as part of routine medical care may be used.&lt;br&gt;&lt;br&gt;5. Any single serum ferritin &lt;100 mcg/L or &lt;200 mcg/L with TSAT &lt;20% within 4 weeks of randomisation. Note: Measurements taken as part of routine medical care may be used.&lt;br&gt;&lt;br&gt;6. ESA naïve (no exposure in last 4 months prior to randomisation).&lt;br&gt;&lt;br&gt;7. Females of child-bearing potential must have a negative pregnancy test (using any medically acceptable assessment) prior to randomisation. &lt;br&gt;&lt;br&gt;8. Before any study-specific procedure, the appropriate written informed consent must be obtained.&lt;br&gt;&lt;br&gt;(*) Criterion number 3 is aimed to minimise the likelihood that study participants go on to terminal renal failure (eGFR &lt;15 ml/min/1.73 m2) during the study.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 900&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 116&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. History of acquired iron overload.&lt;br&gt;&lt;br&gt;2. Known hypersensitivity reaction to any component of ferrous sulphate or FCM. Note: subjects with hypersensitivity to other forms of iron will be permitted to participate.&lt;br&gt;&lt;br&gt;3. Documented history of discontinuing oral iron products due to significant gastrointestinal distress.&lt;br&gt;&lt;br&gt;4. Screening TSAT &gt;40%.&lt;br&gt;&lt;br&gt;5. Known active infection, C-reactive protein &gt;20 mg/l, clinically significant overt bleeding, active malignancy (i.e., clinical evidence of current malignancy or not in stable remission for at least 5 years since completion of last treatment with exception of basal cell or squamous cell carcinoma of the skin, and cervical intraepithelial neoplasia).&lt;br&gt;&lt;br&gt;6. History of chronic alcohol abuse (alcohol consumption &gt;40 g/day).&lt;br&gt;&lt;br&gt;7. Chronic liver disease and/or screening alanine transaminase or aspartate transaminase above 3 times the upper limit of the normal range.&lt;br&gt;&lt;br&gt;8. Active human immunodeficiency virus/acquired immunodeficiency syndrome OR active hepatitis B or C virus infection (known positive serology to HIV antibodies OR hepatitis B antigen, hepatitis C antibody with clinical signs of active hepatitis).&lt;br&gt;&lt;br&gt;9. Anaemia due to reasons other than iron deficiency (e.g., haemoglobinopathy). Subject with treated Vitamin B12 or folic acid deficiency are permitted.&lt;br&gt;&lt;br&gt;10. Intravenous iron and/or blood transfusion in previous 30 days prior to screening (or during the screening period).&lt;br&gt;&lt;br&gt;11. Oral iron therapy at doses &gt;100 mg/day dosing must be discontinued at least 1 week prior to randomisation. If patient has received this therapy for greater than 3 months (at doses &gt;100 mg/day) then subject is not eligible. Note: Ongoing use of multivitamins containing iron are permitted.&lt;br&gt;&lt;br&gt;12. Immunosuppressive therapy that may lead to anaemia e.g., cyclophosphamide, azathioprine, mycophenolate mofetil, etc. Note: Steroid therapy is permitted.&lt;br&gt;&lt;br&gt;13. Currently requiring renal dialysis.&lt;br&gt;&lt;br&gt;14. Anticipated dialysis or transplant during the study.&lt;br&gt;&lt;br&gt;15. Anticipated need for surgery that may result in significant bleeding (&gt;100 ml).&lt;br&gt;&lt;br&gt;16. Currently suffering from chronic heart failure New York Heart Association (NYHA) Class IV.&lt;br&gt;&lt;br&gt;17. Poorly controlled hypertension (&gt;160 mmHg systolic pressure or &gt;100 mmHg diastolic pressure).&lt;br&gt;&lt;br&gt;18. Acute coronary syndrome or stroke within the 3 months prior to screening.&lt;br&gt;&lt;br&gt;19. Currently suffering from concomitant, severe psychiatric disorders or other conditions which, in the opinion of the Investigator, make participation unacceptable.&lt;br&gt;&lt;br&gt;20. Subject is not using adequate contraceptive precautions. Adequate contraceptive precautions are defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra-uterine devices, sexual abstinence or vasectomised partner. Non-childbearing potential includes being surgically sterilised at least 6 months prior to the study or post menopausal, defined as amenorrhea for at least 12 months.&lt;br&gt;&lt;br&gt;21. Subject of child-bearing potential is evidently pregnant (e.g., positive human chorionic gonadotropin test) or is breast feeding.&lt;br&gt;&lt;br&gt;22. Body weight &lt;35 kg.&lt;br&gt;&lt;br&gt;23. Subject currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(ies), or subject is receiving other investig</Exclusion_Criteria>
    <Condition>Iron deficiency anaemia in subjects with non-dialysis-dependent chronic kidney disease &lt;br&gt;MedDRA version: 14.0
Level: PT
Classification code 10022972
Term: Iron deficiency anaemia
System Organ Class: 10005329 - Blood and lymphatic system disorders
 &lt;br&gt;MedDRA version: 14.0
Level: LLT
Classification code 10064848
Term: Chronic kidney disease
System Organ Class: 10038359 - Renal and urinary disorders
;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]</Condition>
    <Intervention>&lt;br&gt;Trade Name: Ferinject®&lt;br&gt;Pharmaceutical Form: Infusion&lt;br&gt;INN or Proposed INN: Ferric carboxymaltose (FCM)&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Ferinject®&lt;br&gt;Pharmaceutical Form: Infusion&lt;br&gt;INN or Proposed INN: Ferric carboxymaltose (FCM)&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Plastufer®&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: Iron (II) sulphate&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 304.3-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Primary end point(s): Time to the initiation of other anaemia management (e.g., ESA or transfusion) using Kaplan-Meier survival analyses.&lt;br&gt;;Timepoint(s) of evaluation of this end point: End of Study;Main Objective: To evaluate the long-term efficacy of FCM (using targeted ferritin levels to determine dosing) or oral iron to delay and/or reduce erythropoiesis stimulating agent (ESA) use and/or other anaemia management options in NDD-CKD subjects with iron deficiency anaemia (IDA).;Secondary Objective: To evaluate the potential to reduce ESA requirement for subjects receiving FCM (using targeted ferritin levels to determine dosing) or oral iron.&lt;br&gt;&lt;br&gt;To evaluate the long-term safety and tolerability of Ferinject and oral iron in the treatment of NDD-CKD subjects with IDA.&lt;br&gt;&lt;br&gt;To evaluate the health resource utilisation, quality of life (QoL) effects and economic burden of the treatment of NDD-CKD subjects with IDA.</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): 1. Cumulative ESA requirement over the study period.
&lt;br&gt;
&lt;br&gt;2. Percentage of subjects requiring transfusion at anytime during the study.
&lt;br&gt;
&lt;br&gt;3. Cumulative iron requirements and number of iron administrations over the study period.
&lt;br&gt;
&lt;br&gt;4. Percentage of subjects with an increase of Hb =1 g/dL prior to any other anaemia management (e.g., ESA or transfusion).
&lt;br&gt;
&lt;br&gt;5. Value change from baseline to end of study (for each visit) for the following parameters:
&lt;br&gt;    - Haematological and iron parameters.
&lt;br&gt;    - eGFR as calculated with the MDRD formula.
&lt;br&gt;6. Percentage of subjects requiring dialysis at anytime during the study.
&lt;br&gt;
&lt;br&gt;7. Change in health-related QoL over the study period using the SF-36.
&lt;br&gt;
&lt;br&gt;8. Health resource utilisation over the study period calculated direct, indirect and total costs from 2 perspectives (payer’s and societal perspective).
&lt;br&gt;
&lt;br&gt;9. Cost effectiveness of treatment options using relevant effectiveness parameters.
&lt;br&gt;
&lt;br&gt;10. Percentage of subjects discontinuing the study drug due to intolerance.;Timepoint(s) of evaluation of this end point: 1. End of Study
&lt;br&gt;2. Duration of Study
&lt;br&gt;3. End of Study
&lt;br&gt;4. Every 4 weeks until Week 56
&lt;br&gt;5. Every 4 weeks until Week 56
&lt;br&gt;6. Duration of Study
&lt;br&gt;7. End of Study
&lt;br&gt;8. End of Study
&lt;br&gt;9. End of Study
&lt;br&gt;10. Duration of Study
&lt;br&gt;
&lt;br&gt;</Secondary_outcome>
    <Secondary_ID>FER-CKD-01;NCT00994318</Secondary_ID>
    <Source_Support>Vifor Pharma Inc.</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2487629</Internal_Number>
    <TrialID>EUCTR2011-003498-27-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A phase II open label study of cabazitaxel in patients with advanced or metastatic transitional cell carcinoma of the urothelium who have progressed ?12 months after a previous platinum based chemotherapy</Public_title>
    <Scientific_title>A phase II open label study of cabazitaxel in patients with advanced or metastatic transitional cell carcinoma of the urothelium who have progressed ?12 months after a previous platinum based chemotherapy.

?Estudio fase II de cabazitaxel en pacientes con cáncer avanzado o metastásico de células transicionales de urotelio que han progresado en un intervalo inferior a 12 meses después de una quimioterapia basada en cisplatino.? - N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Grupo Español de Tratamiento de Tumores Genitourinarios (SOGUG)-Spanish Genitourinary Oncologic Group</Primary_sponsor>
    <Date_registration3>20111028</Date_registration3>
    <Date_registration>28/10/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-003498-27                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/12/2011</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Histologically confirmed transitional carcinoma of the urothelium (bladder, urethra, ureter,&lt;br&gt;or renal pelvis). Patients with mixed histology are eligible if transitional carcinoma is&lt;br&gt;predominant component (i.e. &gt;50% of the pathologic specimen).&lt;br&gt;2. One previous cisplatin-based chemotherapy (with a minimum of 4 cycles).&lt;br&gt;a. Patients with unresectable locally advanced tumors or metastatic transitional cell&lt;br&gt;tumors of the urothelium who have progressed or relapsed after a maximum of 12&lt;br&gt;months since the last course of cisplatin-based chemotherapy.&lt;br&gt;b. Patients treated with adjuvant / neoadjuvant chemotherapy are eligible if their&lt;br&gt;relapse occurs ?12 months after the last cisplatin course; in this case, adjuvant or&lt;br&gt;neoadjuvant chemotherapy will be considered as the first line.&lt;br&gt;c. Patients with stable or responding disease at the end of first-line therapy should be&lt;br&gt;included only if they stabilization occurs after 6 cycles of chemotherapy.&lt;br&gt;3. Age ?18 years&lt;br&gt;4. Eastern Cooperative Oncology Group (ECOG) performance status of ?2.&lt;br&gt;5. Subjects must have signed an informed consent indicating that they understand the&lt;br&gt;purpose of and procedures required for the study and are willing to participate in the&lt;br&gt;study.&lt;br&gt;6. At least one measurable lesion (RECIST criteria, Version 1.1).&lt;br&gt;7. At least 4 weeks and recovery from effects of the last chemotherapy course, prior surgery,&lt;br&gt;prior radiotherapy, or other therapy with an approved or investigational agent.&lt;br&gt;8. Adequate hematologic, hepatic, and renal function: Hemoglobin ?9.0 g/dL (transfusion&lt;br&gt;allowed), Platelet count ?100,000/?L, absolute neutrophil count &gt; 1500/mm3, Serum&lt;br&gt;creatinine &lt;1.5 x upper limit of normal (ULN) or a calculated creatinine clearance ? 50&lt;br&gt;mL/min, &lt;br&gt;ALT, AST and bilirrubin &lt; 1.5 x ULN (&lt;5xULN if liver metastasis are present). In&lt;br&gt;patients with previously documented Glibert?s disease, the upper limit of serum bilirubin&lt;br&gt;allowed is 3 mg/dL).&lt;br&gt;9. In female with childbearing potential, a pregnancy test have to be negative within 72 hours&lt;br&gt;priors to first dose of study drug. If fertile, patient have to agree to use an effective&lt;br&gt;method of contraception to avoid pregnancy for the duration of the study.&lt;br&gt;10. Estimated life expectancy of &gt;12 weeks.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 105&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 105&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Any patient who relapse after more than 12 months since the last chemotherapy course.&lt;br&gt;Patients who have received more than one prior chemotherapeutic regimen. Adjuvant or&lt;br&gt;neoadjuvant chemotherapy will be considered to have been first line (in this case, patients&lt;br&gt;will be eligible only if progression occurs within 12 months of the last course).&lt;br&gt;Tumors with neuroendocrine differentiation or small cell histology in any percentage of the&lt;br&gt;specimen.&lt;br&gt; Non cisplatinum regimen as first chemotherapy.&lt;br&gt;Patients who received more than one cytotoxic chemotherapy regimen (either as adjuvant,&lt;br&gt;neoadjuvant or metastatic treatment).&lt;br&gt; Serious or uncontrolled coexistent nonmalignant disease, particularly active and&lt;br&gt;uncontrolled infection.&lt;br&gt; Neuropathy grade ? 2 (NCI CTC, Version 4.0), either post chemotherapy or secondary to a&lt;br&gt;different disease (diabetes, etc.).&lt;br&gt; Known metastasis or symptoms of metastasis to the central nervous system.&lt;br&gt; Clinically significant heart disease as evidenced by myocardial infarction, or arterial&lt;br&gt;thrombotic events in the past 6 months, severe or unstable angina, or New York Heart&lt;br&gt;Association (NYHA) Class III or IV heart disease or left ventricular ejection fraction (LVEF)&lt;br&gt;of &lt;50% at baseline.&lt;br&gt; Subjects with childbearing potential who are not willing to use a method of birth control&lt;br&gt;with adequate barrier protection as determined to be acceptable by the principal&lt;br&gt;investigator and sponsor during the study and for 13 weeks after last study drug&lt;br&gt;administration.&lt;br&gt; Pregnancy or lactancy.&lt;br&gt; Condition or situation which, in the investigator?s opinion, may put the subjects at&lt;br&gt;significant risk, may confound the study results, or may interfere significantly with&lt;br&gt;subject?s participation in the study.&lt;br&gt; Prior treatment with a taxane or other tubulin-targeted agent including a vinca alkaloid.&lt;br&gt; Need to continue any regularly-taken medication that is a potent inhibitor or inducer of the&lt;br&gt;CYP3A pathway.&lt;br&gt;</Exclusion_Criteria>
    <Condition>advanced or metastatic transitional cell carcinoma of the urothelium &lt;br&gt;MedDRA version: 14.0
Level: LLT
Classification code 10038498
Term: Renal pelvis and ureter transitional cell cancer metastatic
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
;Therapeutic area: Diseases [C] - Cancer [C04]</Condition>
    <Intervention>&lt;br&gt;Trade Name: JEVTANA 60 mg concentrado y disolvente para solución para perfusión.&lt;br&gt;Product Name: cabazitaxel&lt;br&gt;Pharmaceutical Form: Concentrate and diluent for solution for infusion&lt;br&gt;CAS Number: 183133-96-2&lt;br&gt;Other descriptive name: CABAZITAXEL&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 40-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate the efficacy of cabacitaxel as second line therapy for patients with tratnsitional&lt;br&gt;cell tumors of the urothelium who have relapsed after a maximum 12 month since the last&lt;br&gt;dose of a cisplatin-based chemotherapy, adjusting the result to the four prognostic&lt;br&gt;subgroups describe in these setting.;Primary end point(s): % of objective response ( RECIST v1.1).;Timepoint(s) of evaluation of this end point: every 3 cycles;Secondary Objective: To evaluate the efficacy of cabazitaxel separately in each subgroup.&lt;br&gt;To describe the toxicity of cabazitaxel in this setting.&lt;br&gt;To analyze QOL (optional).&lt;br&gt; To validate prospectively the recently published prognostic classification for these patients,&lt;br&gt;and to analyze the influence of time to progression to the first-line chemotherapy of ? 6&lt;br&gt;months vs 6 -12 months as an additional prognostic factor.</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): To evaluate the efficacy of cabazitaxel separately in each subgroup.&lt;br&gt; To describe the toxicity of cabazitaxel in this setting.&lt;br&gt; To analyze QOL (optional).&lt;br&gt;To validate prospectively the recently published prognostic classification for these patients,&lt;br&gt;and to analyze the influence of time to progression to the first-line chemotherapy of ? 6&lt;br&gt;months vs 6 -12 months as an additional prognostic factor.</Secondary_outcome>
    <Secondary_ID>JEVTCC-SOGUG-2011-04</Secondary_ID>
    <Source_Support>Sanofi;SOGUG</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2487764</Internal_Number>
    <TrialID>EUCTR2011-001113-14-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Pharmakokynetic and Pharmacodynamic study of Temsirolimus in Renal Cell Carcinoma Patients</Public_title>
    <Scientific_title>Pharmakokynetic and Pharmacodynamic study of Temsirolimus in Renal Cell Carcinoma Patients - PK/PD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Fundación Hospital Clinic i Provincial</Primary_sponsor>
    <Date_registration3>20111103</Date_registration3>
    <Date_registration>03/11/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-001113-14                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/12/2011</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 1&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Metastatic renal or locally advanced RCC histologically confirmed&lt;br&gt;- Patients who will received Temsirolimus as the habitual clinical practice.&lt;br&gt;- ECOG  &lt; 2&lt;br&gt;- Correct serum blood cell count and biochemistry&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 10&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 10&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Patients who do not met inclusion criteria&lt;br&gt;- Patients with active infection&lt;br&gt;- Patients with HIV infection&lt;br&gt;- Patients receiving high dose corticosteroids or other inmunosupressive agents&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal Cell Carcinoma Patients &lt;br&gt;MedDRA version: 14.0
Level: PT
Classification code 10067946
Term: Renal cell carcinoma
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
;Therapeutic area: Diseases [C] - Cancer [C04]</Condition>
    <Intervention>&lt;br&gt;Trade Name: TORISEL 30 mg, concentrado y disolvente para solución para perfusión.&lt;br&gt;Pharmaceutical Form: Concentrate and diluent for solution for infusion&lt;br&gt;INN or Proposed INN: TEMSIROLIMUS&lt;br&gt;CAS Number: 162635-04-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To describe the Pharmacokinetic profile of temsirolimus ?and sirolimus- after an intravenous 25 mg/week administration.;Secondary Objective: - To determine if micromolar levels are achieved and maintained, during the interval therapeutic range, in the tumor and/or surrogate tissue with a 25 mg/week IV administration. &lt;br&gt;-	To determine the relation lymphocyte levels and tissue/tumor levels.&lt;br&gt;-	To evaluate the correlation between TemSRL +SRL whole blood levels and TemSRL +SRL intracellular (Tcell) concentrations.&lt;br&gt;-	To evaluate the correlation between TemSRL +SRL whole blood levels and TemSRL +SRL tissue concentrations.&lt;br&gt;-	To establish a correlation between drug concentration and mTOR pathway inhibition &lt;br&gt;-	To establish a correlation between clinical response and drug concentration;Primary end point(s): To describe the Pharmacokinetic profile of temsirolimus ?and sirolimus- after an intravenous 25 mg/week administration.;Timepoint(s) of evaluation of this end point: 18 months</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): - To determine if micromolar levels are achieved and maintained, during the interval therapeutic range, in the tumor and/or surrogate tissue with a 25 mg/week IV administration. &lt;br&gt;-	To determine the relation lymphocyte levels and tissue/tumor levels.&lt;br&gt;-	To evaluate the correlation between TemSRL +SRL whole blood levels and TemSRL +SRL intracellular (Tcell) concentrations.&lt;br&gt;-	To evaluate the correlation between TemSRL +SRL whole blood levels and TemSRL +SRL tissue concentrations.&lt;br&gt;-	To establish a correlation between drug concentration and mTOR pathway inhibition &lt;br&gt;-	To establish a correlation between clinical response and drug concentration;Timepoint(s) of evaluation of this end point: 18 months</Secondary_outcome>
    <Secondary_ID>TEM-IIG-2</Secondary_ID>
    <Source_Support>Pfizer S.L.U.</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2488122</Internal_Number>
    <TrialID>EUCTR2011-001841-34-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>PLUTO - (pazopanib versus paclitaxel in relapsed urothelial tumours) A Randomised Phase II study investigating pazopanib vs weekly paclitaxel in relapsed or progressive Transitional Cell Carcinoma (TCC) of the urothelium</Public_title>
    <Scientific_title>A Randomised Phase II study investigating pazopanib vs weekly paclitaxel in relapsed or progressive Transitional Cell Carcinoma (TCC) of the urothelium. - PLUTO  (PAZOPANIB VERSUS PACLITAXEL IN RELAPSED UROTHELIAL TUMOURS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>NHS Greater Glasgow Health Board</Primary_sponsor>
    <Date_registration3>20111121</Date_registration3>
    <Date_registration>21/11/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-001841-34                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/01/2012</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.Histologically or cytologically confirmed TCC (bladder, renal pelvis, ureter, urethra), which is locally advanced or metastatic (T4b and/or N1-3 and/or M1). Patients with mixed or differentiation pattern pathology will be permitted entry providing that TCC is a component pathology. 2.Progressive disease during or after one prior platinum-based chemotherapy regimen for advanced disease or as peri-operative therapy for muscle-invasive / node positive disease (if completed &lt; 12 months prior to documented disease progression). The regimen must have included either cisplatin or carboplatin. Patients who have had two platinum containing regimens are eligible if one of these was given peri-operatively, and provided that there was a chemotherapy-free interval of at least 12 months between completing the 1st course and commencing the second course of chemotherapy. Chemotherapy given during radical radiotherapy as a radiosensitizer will not be considered as a chemotherapy treatment for the purposes of study eligibility. 3.Age = 18 years. 4.Measurable disease by RECIST 1.1.  5.Adequate organ function as defined by the following criteria: •Total serum bilirubin =1.5 x upper level of normal (ULN).  •Serum transaminases &lt;2.5 x ULN. Concomitant elevations of transaminases and bilirubin are not permitted. •Creatinine clearance  &gt;30ml/min (calculated by Cockcroft Gault equation) or Creatinine =1.5 x ULN. •Absolute neutrophil count (ANC) =1500/mm3 without growth factor support •Platelets = 100,000/mm3 •Urine protein to creatinine ratio (UPC) &lt; 110 mg/mmol (1g/g) (or total urinary protein &lt; 1g/24hrs) •Activated partial thromboplastin time (APTT) =1.2 x ULN •International normalised ratio (INR)= 1.2 6.Signed and dated informed consent indicating that the patient  has been informed of all the pertinent aspects of the trial prior to enrolment. 7.A negative pregnancy test for women of childbearing potential.  8.Life expectancy of 3 months or more. 9.Willingness and ability to comply with scheduled visits, treatment plans and laboratory tests and other study procedures. 10.ECOG performance status of 0 or 1.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: 0&lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 42&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 98&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.Congestive heart failure, myocardial infarction, coronary artery bypass graft or thrombotic cerebrovascular event in the previous six months, or ongoing severe or unstable arrhythmia requiring medication. Patients with rate controlled atrial fibrillation are permitted to enter the study. 2.History of clinically significant bleeding in the 6 months prior to study initiation (including haemoptysis, cerebrovascular bleed or haematemesis; patients with haematuria are permitted entry as long as there is no indication for intervention). 3.Major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any unhealed wound, fracture, or ulcer (procedures such as catheter placement not considered to be major surgery). 4.Cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or deep venous thrombosis (DVT) within the past 6 months.  Note:  Subjects with recent DVT who have been therapeutically anti-coagulated for at least 6 weeks are eligible. 5.History of another malignancy in the last 5 years (other than treated squamous/basal cell skin cancer, treated early stage cervical cancer or treated / biochemically stable, organ confined prostate cancer). 6.Ongoing major gastrointestinal disease including unstable inflammatory bowel disease or bleeding peptic ulcer disease. 7.Known endobronchial lesions which have a high risk of pulmonary haemorrhage . 8.Previously identified brain, or central nervous system (CNS) metastases at baseline, with the exception of those subjects who have previously-treated CNS metastases (surgery ± radiotherapy, radiosurgery, or gamma knife) and who meet both of the following criteria:  a) are asymptomatic and b) have no requirement for steroids or enzyme-inducing anticonvulsants in prior 28 days. 9.Pregnant or breastfeeding.  Patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy. Male patients must be surgically sterile or agree to use effective contraception.  10.Administration of any investigational drug within 28 days or 5 half lives, whichever is longer, prior to receiving the first dose of study treatment 11.Treatment with any of the following anti-cancer therapies: Radiation therapy, surgery or tumour embolisation within 14 days prior to the first dose of study medication Chemotherapy, immunotherapy, biologic therapy, investigational therapy within 28 days or 5 half-lives of a drug (whichever is longer) prior to the first dose of study medication. 12.Peripheral neuropathy of grade 2 or more.  13.Any on-going toxicity from prior anti-cancer therapy that is &gt;Grade 1 and/or that is progressing in severity, except alopecia. 14.Other severe or uncontrolled systemic disease or evidence of any other significant clinical disorder or lab finding that makes it undesirable for the patient to participate  in the study. 15.Any psychological, familial, sociological or geographical consideration  potentially hampering compliance with the study protocol and follow up schedule; those considerations should be discussed with the patient before registration in the trial. 16.Known HIV or other chronic immunosuppressive disease. 17. QTc that is immeasurable or &gt;480 msec on screening ECG. (Note: If a subject has a QTc interval &gt;480 msec on screening ECG, the screening ECG may be repeated twice (at least 24 hours apart). The average QTc from the three screening ECGs must be &lt;480 msec in orde</Exclusion_Criteria>
    <Condition>Relapsed or progressive Transitional Cell Carcinoma (TCC) of the urothelium &lt;br&gt;MedDRA version: 14.0
Level: LLT
Classification code 10044426
Term: Transitional cell carcinoma urethra
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
 &lt;br&gt;MedDRA version: 14.0
Level: LLT
Classification code 10044420
Term: Transitional cell carcinoma of the bladder stage unspecified
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
 &lt;br&gt;MedDRA version: 14.0
Level: PT
Classification code 10044407
Term: Transitional cell cancer of the renal pelvis and ureter
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
;Therapeutic area: Diseases [C] - Cancer [C04]</Condition>
    <Intervention>&lt;br&gt;Trade Name: Votrient&lt;br&gt;Product Name: Pazopanib Hydrochloride (Votrient)&lt;br&gt;Product Code: GW786034B&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Pazopanib Hydrochloride&lt;br&gt;CAS Number: 635702-64-6&lt;br&gt;Current Sponsor code: Not applicable&lt;br&gt;Other descriptive name: Not applicable&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: Pazopanib Hydrochloride&lt;br&gt;CAS Number: 635702-64-6&lt;br&gt;Current Sponsor code: Not applicable&lt;br&gt;Other descriptive name: Not applicable&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;&lt;br&gt;Product Name: Paclitaxel&lt;br&gt;Product Code: Not Applicable&lt;br&gt;Pharmaceutical Form: Concentrate for solution for injection/infusion&lt;br&gt;INN or Proposed INN: Paclitaxel&lt;br&gt;CAS Number: 33069-62-4&lt;br&gt;Current Sponsor code: Not applicable&lt;br&gt;Other descriptive name: Not applicable&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 6-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of the study is to investigate whether pazopanib increases the overall survival time for patients with relapsed or progressive disease; in comparison to the current standard treatment, paclitaxel.;Secondary Objective: The secondary objectives of the study are to measure the following for pazopanib in comparison to the current standard treatment, paclitaxel: -Toxicity -Clinical benefit at 12 weeks -Progression free survival time -Clinical benefit at 24 weeks -Quality of Life;Primary end point(s): Overall survival.;Timepoint(s) of evaluation of this end point: The primary endpoint is overall survival. Data relating to any patient death that occurs throughout the study period will be captured via the Case Report Form (CRFs), both during the treatment period and active follow up.</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): The secondary end points of the study are to measure the following for pazopanib in comparison to the current standard treatment, paclitaxel: -Toxicity -Clinical benefit at 12 weeks -Progression free survival time -Clinical benefit at 24 weeks -Quality of Life;Timepoint(s) of evaluation of this end point: -Toxicity will be assessed at all study visits while the patient is receiving treatment and until any ongoing toxicity is resolved. -Clinical benefit will be assessed after 12 and 24 weeks on treatment. Assessment will be  by CT scans/MRI as appropriate and the tumour response (stable disease (SD), partial response (PR) or complete response (CR) will be reported in accordance with RECIST 1.1. -Progression free survival will be assessed on an ongoing basis, by radiology and/or any other means of idenitification, or the opinion of the investigator. -Quality of Life (QoL)will be assessed continuously throughout the trial. QoL questionnaires will be collected at baseline (Week 1), and at Weeks 9, 17, 25, 37, 49, 61, 73, 85 and 97.</Secondary_outcome>
    <Secondary_ID>PLUTO2011</Secondary_ID>
    <Source_Support>GlaxoSmithKline Research &amp; Development Limited</Source_Support>
    <Secondary_Sponsor>University of Glasgow</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2495764</Internal_Number>
    <TrialID>EUCTR2009-016003-26-GB</TrialID>
    <Last_Refreshed_on>20 March 2012</Last_Refreshed_on>
    <Public_title>RANDOMISED PILOT TRIAL OF MYFORTIC FOR THE TREATMENT OF PRIMARY PROTEINURIC GLOMERULONEPHRITIS. - GloMY - Proteinuria in glomerulonephritis : Myfortic</Public_title>
    <Scientific_title>RANDOMISED PILOT TRIAL OF MYFORTIC FOR THE TREATMENT OF PRIMARY PROTEINURIC GLOMERULONEPHRITIS. - GloMY - Proteinuria in glomerulonephritis : Myfortic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>UHB NHS Foundation Trust</Primary_sponsor>
    <Date_registration3>20100317</Date_registration3>
    <Date_registration>17/03/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-016003-26                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>06/05/2010</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;. Inclusion Criteria &lt;br&gt;1.	Patients with new onset biopsy proven (within last year) primary FSGS with albumin lss than the normal laboratory reference range OR patients with primary IgAN with biopsy findings E1 or M1 using the Oxford classification (see Appendix 2) and a minimum of 8 glomeruli in the biopsy&lt;br&gt;AND&lt;br&gt;2.	Proteinuria (Protein Creatinine Ratio, PCR&gt;100mg/mmol or ACR&gt;66mg/mmol) following at least 4 weeks treatment with maximal blood pressure lowering therapy (to include angiotensin blockade) to target blood pressure &lt;130/80 mmHg&lt;br&gt;3.	If female and of childbearing potential, must:&lt;br&gt;•	Not be pregnant or breastfeeding&lt;br&gt;•	Agree to avoid pregnancy during and for 6 weeks following the last dose of study treatment&lt;br&gt;4.		If male with a partner of childbearing potential, must:&lt;br&gt;•	Agree to use adequate, medically approved, contraceptive precautions during and for 6 weeks following the last dose of study treatment&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: 0&lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 0&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 0&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Age &lt;18 years&lt;br&gt;2.	Secondary causes of FSGS&lt;br&gt;3.	Secondary IgAN&lt;br&gt;4.	Deteriorating renal function &gt;20µmol/l each week for 3 weeks or more&lt;br&gt;5.	estimated Glomerular Filtration Rate (eGFR) &lt;20 ml/min (using modification of diet in renal disease (MDRD) equation)&lt;br&gt;6.	Poor blood pressure control (e.g. blood pressure =140/90 mmHg)&lt;br&gt;7.	Previous treatment with immunosuppression therapies for renal disease&lt;br&gt;8.	Unable to receive immunosuppression treatments due to malignancy or active infection&lt;br&gt;9.	Patients with systemic infection unless specific anti-infective therapy is employed&lt;br&gt;10.	Diabetes&lt;br&gt;11.	Known to have Hepatitis B or C&lt;br&gt;12.	Known to be HIV positive&lt;br&gt;13.     Neutropenia&lt;br&gt;14.	Inability to give informed consent&lt;br&gt;15.     Greater than 2 weeks of steroid therapy for renal disease&lt;br&gt;</Exclusion_Criteria>
    <Condition>Primary Proteinuric Glomeruolnephritis 
Focal segmental glomeruloscerosis and IgA nephropathy &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10067757
Term: Focal segmental glomerulosclerosis
System Organ Class: 10038359 - Renal and urinary disorders
 &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10021263
Term: IgA nephropathy
System Organ Class: 10038359 - Renal and urinary disorders
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Myfortic&lt;br&gt;Product Name: Myfortic 360mg Tablets&lt;br&gt;Pharmaceutical Form: Gastro-resistant tablet&lt;br&gt;INN or Proposed INN: mycophenolic acid&lt;br&gt;CAS Number: 24280-93-1&lt;br&gt;Other descriptive name: mycophenolate sodium&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 360-&lt;br&gt;&lt;br&gt;Trade Name: Myfortic&lt;br&gt;Product Name: Myfortic 180mg Tablets&lt;br&gt;Pharmaceutical Form: Gastro-resistant tablet&lt;br&gt;INN or Proposed INN: mycophenolic sodium&lt;br&gt;CAS Number: 24280-93-1&lt;br&gt;Other descriptive name: mycophenolate sodium&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 180-&lt;br&gt;&lt;br&gt;Product Name: Prednisolone&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: prednisolone&lt;br&gt;CAS Number: 50-24-8&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1.0-25.0&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine the feasibility of running a full-scale randomised phase 3 trial of Myfortic plus short course steroids (prednisolone) versus standard care in patients with Focal segmental glomerulosclerosis (FSGS) or IgA nephropathy and to obtain preliminary comparative data on the efficacy of Myfortic plus short course steroids in inducing sustained response in patients with FSGS or IgAN.&lt;br&gt;&lt;br&gt;;Secondary Objective: To determine preliminary data on the effectiveness of myfortic plus short course steroids in inducing sustained remission, reducing proteinuria and preventing progression of chronic kidney disease.&lt;br&gt;&lt;br&gt;To determine treatment safety.&lt;br&gt;;Primary end point(s): The primary measure of efficacy will be the proportion of patients achieving complete or partial remission by 24 weeks sustained (relapse free) for 12 months.</Primary_outcome>
    <Secondary_ID>1.0;ISRCTN11937028</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2495812</Internal_Number>
    <TrialID>EUCTR2011-001211-31-GB</TrialID>
    <Last_Refreshed_on>20 March 2012</Last_Refreshed_on>
    <Public_title>A study of the effectiveness and safety of the drug Pazopanib for use in patients with advanced kidney cancer who are suffering symptoms from their illness.</Public_title>
    <Scientific_title>A study of pazopanib efficacy and safety in patients with advanced clear-cell renal cell carcinoma and ECOG Performance Status 2 (PaZ02) - Pazopanib in patients with renal cancer (PaZ02)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>University of Birmingham</Primary_sponsor>
    <Date_registration3>20120124</Date_registration3>
    <Date_registration>24/01/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-001211-31                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/02/2012</Date_enrollement>
    <Target_size>75</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 1&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1) Written informed consent 2) Histologically confirmed diagnosis of renal cell carcinoma with clear cell component 3) Locally advanced (defined as not amenable of curative surgery) or metastatic disease 4) Measurable disease as per RECIST Criteria 1.1 5) Performance Status 2 assessed using the ECOG scale.  6) No prior systemic therapy 7) Female patients of childbearing potential will be eligible if they agree to adequate contraception. Pregnancy test must be negative 1 week before first drug dose 8) Adequate organ function as defined by the following criteria:       o Total serum bilirubin =1.5 x ULN. Patients with Gilbert’s disease are eligible if the total; bilirubin is &lt;3.0 x ULN and direct bilirubin is =35%.       o Serum transaminases (AST and ALT) &lt;2.5 x ULN, unless liver metastases are documented in which case AST and ALT must be = 5 x ULN        oCalculated creatinine clearance =30mL/min (Cockroft Gault method)       oUrine Protein to Creatinine Ratio (UPC) &lt; 1. If UPC = 1 then a 24 hour urine protein must be assessed. Only patients with 24 hour urine protein &lt; 1g will be eligible       oTotal serum calcium concentration &lt; 2.9 mmol/l        oAbsolute neutrophil count (ANC) =1500/mm3       oHaemoglobin = 9g/dl        oPlatelets = 100,000/mm3       oINR (International Normalised ratio) = 1.2 x ULN. Subjects receiving anticoagulant therapy are eligible if their INR is stable and within the recommended range.  9) Age =18 10)Life expectancy = 12 weeks 11)Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: 0&lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 65&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 10&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1) Pregnant or lactating female patients. Patients who agree to discontinue nursing 14 days prior to commencing treatment and do not nurse throughout all the treatment period are eligible  2) Previous systemic treatment for RCC (licensed or investigational) including adjuvant or neo-adjuvant therapy 3) Major surgery or trauma &lt; 4 weeks or radiotherapy and/or presence of any non-healing wound, fracture, or ulcer. Radiotherapy  &lt; 2 weeks prior to starting treatment 4) History or clinical evidence of brain metastases or active seizure disorders 5) Previous malignancies within the last 5 years, with the exception of successfully treated superficial or in situ carcinomas and of invasive tumours treated with curative intent and in remission for at least 5 years 6) Current use of drugs which are known strong CYP4A inhibitors (7.10)  7) Use of any prohibited medications within 14 days of the first dose of study medication (7.11) 8) Uncontrolled hypertension defined as systolic blood pressure = 150 mm Hg or diastolic blood pressure = 95 mm Hg. Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry 9) Presence of uncontrolled infection 10)Prolongation of the QT interval (QTc) &gt; 480 msecs 11)History of malabsorption, major gastrointestinal tract resection or other pathology likely to affect study drug absorption 12)History of any one or more of the following cardiovascular conditions within the past 6 months:       o Cardiac angioplasty or stenting       o Myocardial infarction      o Unstable angina      o Coronary artery by-pass graft surgery      o Symptomatic peripheral vascular disease      o Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA) Functional Classification 13)History of cerebrovascular accident (CVA) including transient ischemic attack (TIA) within the past 12 months 14)History of pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months. Patients with recent DVT who have been treated with therapeutic anticoagulating agents for at least 6 weeks are eligible 15)Evidence of active bleeding or bleeding diathesis 16)Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels 17)Any serious and/or unstable pre-existing medical, psychiatric, or other conditions that could interfere with subject’s safety, obtaining informed consent or compliance to the study 18)Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drug chemically related to pazopanib&lt;br&gt;</Exclusion_Criteria>
    <Condition>Clear cell renal cell carcinoma &lt;br&gt;MedDRA version: 14.1
Level: LLT
Classification code 10038416
Term: Renal clear cell carcinoma
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
;Therapeutic area: Diseases [C] - Cancer [C04]</Condition>
    <Intervention>&lt;br&gt;Trade Name: Votrient&lt;br&gt;Product Name: pazopanib&lt;br&gt;Product Code: not applicable&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: pazopanib hydrochloride&lt;br&gt;CAS Number: 635702-64-6&lt;br&gt;Other descriptive name: Votrient&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The main objective of our clinical trial is to find out whether treatment with a drug called pazopanib is beneficial and safe for patients with advanced renal cancer and poor clinical condition (‘poor performance status’). These patients are often deemed not fit for treatment because of their poor prognosis and because of their perceived inability to withstand the side effects of the therapy. The treatments currently available cause severe side effects in two thirds of the patients and may require frequent hospital visits. By contrast pazopanib has demonstrated a significant efficacy and is well tolerated therefore it may represent a valuable treatment option for renal cancer patients with poor performance status. To assess treatment efficacy we will study in what percentage of patients pazopanib is able to prevent further tumour growth for at least 6 months; to assess safety we will study the ratio of patients who develop severe, drug induced, toxicity.;Secondary Objective: The secondary research objectives of our clinical trial are:   i) To study the duration of survival from the start of the treatment with pazopanib until death of renal cancer patients with poor performance status (technically called ‘Overall Survival’).   ii) To study the length of time over which pazopanib is able to block the growth of the renal cancer (technically called ‘Progression Free Survival’).  iii) To study the ability of pazopanib to induce a shrinkage of the tumour mass (technically called ‘Response Rate’).  iv) To study the entire profile of the side effects induced by pazopanib in the same group of patients.   v) To study the differences between the drug dose actually administered compared with the planned dose.;Primary end point(s): 1) Tolerability - will be assessed as the proportion of patients who have not developed grade 3 or 4 clinically relevant and drug related adverse events within 6-months from the date of entry into the trial. Any adverse event to be classified ‘Clinically Relevant’ and to be included in the analysis of the primary tolerability endpoint will need to satisfy all the following definitions:  • Adverse events which are Grade 3 or Grade 4 in severity according to the CTCAE version 4. • Adverse events which in the opinion of the Investigator are definitely related, probably related and possibly related to the drug treatment. Adverse events which are unrelated or unlikely to be related will not be included in the analysis.  • Adverse events which are symptomatic and in the opinion of the Investigator affect the patient’s wellbeing including but not limited to:  o Adverse events which result in  Serious Adverse Events  o Adverse events which lead to a permanent drug discontinuation o Adverse events which result in a decrease of the patient’s performance status  2) Efficacy - will be assessed as the proportion of all patients who entered the trial and who are progression free at 6 months. Disease Progression will be assessed as defined by RECIST Criteria 1.1.;Timepoint(s) of evaluation of this end point: The end of trial will be at the point when all patients have a minimum of 12 months follow-up from registration. This will allow sufficient time for the completion of protocol procedures, data collection and data input.  The Trials Office will notify the MHRA and main REC that the trial has ended and will provide them with a summary of the clinical trial report within 12 months of the end of trial.</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Progression free survival (PFS) will be measured at 12 months post registration as the number of whole days from the date of entry into trial until evidence of radiological disease progression or death by any cause, or censor date.  Overall survival (OS) will be measured at 12 months post registration as the number of whole days from date of entry into the trial until death by any cause or censor.  Response Rate will be defined as the proportion of patients who achieve either a complete or partial Radiological Response and Clinical benefit rate will be defined as the proportion of patients who achieve either a complete, partial or stable radiological response as defined by the RECIST 1.1 Criteria.  Duration of response will be measured as the number of whole days between date of first evidence of response (CR or PR) until date of Progression of the Disease (PD) or death as defined by the RECIST 1.1 Criteria.  Treatment safety is defined as the proportion of patients developing Adverse Events (AEs). Adverse Events will be collected from the date of entry in the trial until 28 days after drug discontinuation and graded according the NCI-CTC version 4. Adverse Events will be classified by causality, grade, type, duration and system involved.   Drug dose administered will be defined by dose intensity, incidences of dose reductions, interruptions, escalations and discontinuations.;Timepoint(s) of evaluation of this end point: As above</Secondary_outcome>
    <Secondary_ID>RG_10-177</Secondary_ID>
    <Source_Support>GlaxoSmithKline</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2495957</Internal_Number>
    <TrialID>EUCTR2010-019966-95-GB</TrialID>
    <Last_Refreshed_on>20 March 2012</Last_Refreshed_on>
    <Public_title>A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent
(Sunitinib) in Patients with Metastatic Non-Clear Cell Renal Cell
Carcinoma (ASPEN) - ASPEN</Public_title>
    <Scientific_title>A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent
(Sunitinib) in Patients with Metastatic Non-Clear Cell Renal Cell
Carcinoma (ASPEN) - ASPEN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Duke University</Primary_sponsor>
    <Date_registration3>20101008</Date_registration3>
    <Date_registration>08/10/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-019966-95                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>13/01/2011</Date_enrollement>
    <Target_size>108</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Sutent (Sunitinib)&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Histologically confirmed advanced RCC, with non-clear cell pathology. Pathology must consist predominantly (&gt; 50%) of papillary or chromophobe or undifferentiated histology. Mixtures of these non-clear cell variants are allowed.&lt;br&gt;2. RCC tumor tissue available for correlative sciences, from either primary or metastatic site or both.&lt;br&gt;3. At the time of screening, at least 4 weeks since prior palliative radiation therapy and/or major surgery, and resolution of all toxic effects of prior therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; version 3.0) Grade = 1.&lt;br&gt;4. Subject must have radiographic evidence of metastatic disease with at least 1 measurable per RECIST 1.1 criteria&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. subjects with a history of or active central nervous system (CNS) metastases. CNS metastases are allowed provided they have been treated and have been stable without new or growing lesions for 6 weeks.&lt;br&gt;2. Prior systemic therapy for RCC, including mTOR and anti-angiogenic therapy, chemotherapy, biologic or experimental therapy.&lt;br&gt;3. Collecting duct, medullary, small cell, oncocytoma, or lymphoma-type pathology is not allowed. Sarcomatoid variants of papillary or chromophobe carcinoma is permitted but not if clear cell features are predominant (&gt;50% involvement).&lt;br&gt;4. Subjects receiving known strong CYP3A4 isoenzyme inhibitors and/or inducers. Subjects on acceptable CYP3A4 isoenzyme inhibitors and/or inducers are eligible, provided they have been taking a stable regimen for at least 4 weeks prior to screening.&lt;br&gt;5. Major surgery, open biopsy, traumatic injury, or radiotherapy within 4 weeks of the screening visit.&lt;br&gt;6. Subjects who have not recovered from prior biopsy, surgery, traumatic injury, and/or radiation therapy.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Histologically confirmed advanced Renal Cell Carcinoma, with non-clear cell pathology. &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10038389
Term: Renal cancer
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sutent&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;CAS Number: 341031-54-7&lt;br&gt;Other descriptive name: SUNITINIB MALATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Afinitor&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Other descriptive name: EVEROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary endpoint will be a comparison of progression-free survival (PFS) between the treatment arms following therapy initiation. Disease progression is defined by documentation of progressive disease, a new primary malignancy, or death (whichever occurs first), censored at the last tumor evaluation date.  ;Secondary Objective: •	6-, 12- and 24-month rates of PFS i&lt;br&gt;•	(PFS) expressed compared to an historic control &lt;br&gt;•	compare the overall response rate &lt;br&gt;•	Compare Stable Disease and Clinical Benefit Rate  &lt;br&gt;•	Compare overall survival (OS) rates &lt;br&gt;•	Compare the best tumor shrinkage &lt;br&gt;•	Correlate clinical measures of response and PFS with baseline and time-dependent levels of biomarkers. &lt;br&gt;•	Evaluate ichanges in copy number, RNA expression, and immunohistochemical profiles between primary non-clear cell RCC tumors and metastatic samples.&lt;br&gt;•	Compare the median duration of response &lt;br&gt;•	Compare the median OS &lt;br&gt;•	Compare the time-to-new metastatic disease in each treatment arm&lt;br&gt;•	Compare change in quality-of-life&lt;br&gt;•	Assess toxicities associated with everolimus or sunitinib &lt;br&gt;;Primary end point(s): The primary endpoint will be a comparison of the rate of progression-free survival (PFS) between the treatment arms at 6 months following therapy initiation.</Primary_outcome>
    <Secondary_ID>CRAD001L2402T</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2495968</Internal_Number>
    <TrialID>EUCTR2011-002518-35-DK</TrialID>
    <Last_Refreshed_on>20 March 2012</Last_Refreshed_on>
    <Public_title>The effect of aldosterone on the development of chronic allograft nephropathy after kidney transplantation</Public_title>
    <Scientific_title>The effect of aldosterone on the development of chronic allograft nephropathy after kidney transplantation - CODE-CAN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Karl Emil Kristensen</Primary_sponsor>
    <Date_registration3>20120201</Date_registration3>
    <Date_registration>01/02/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-002518-35                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/02/2012</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Other specify the comparator: Furix&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;All the criteria must be fulfilled for inclusion &lt;br&gt;&lt;br&gt;•Men and women of 18 years or more, transplanted with a kidney from diseased or living donor, for between 1 and 3 years ago. Kidney function must be stable with a creatinine clearance at 30 ml/min or more. &lt;br&gt;&lt;br&gt;• Patients who have read and understood the conditions of participation of the study, as described in the patient information. &lt;br&gt;&lt;br&gt;• Patients, who can give an informed consent in regard to the patient information.&lt;br&gt;&lt;br&gt;•Patients, who are not expelled by the exclusion criteria. &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 60&lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•Patients, who are pregnant and/or breastfeeding or fertile women, who are not prepared to use safe contraceptives (P-pills, hormone spiral or depot gestagene) during the time of the investigation. Pregnancy should be ruled out in fertile women by a negative pregnancy tests or the use of safe contraceptive for at least 3 months before study entry. &lt;br&gt;&lt;br&gt;• Patients, who are HIV, HBV, HCV positive or suffer of other serious diseases. &lt;br&gt;&lt;br&gt;•Patients with diarrhea or gastrointestinal illness, which can prevent adequate absorption of the study drugs. &lt;br&gt;&lt;br&gt;•Patients with malignant diseases, except local dermal carcinoma, treated with success. &lt;br&gt;&lt;br&gt;•Patients with active systemic infections. &lt;br&gt;&lt;br&gt;•Patients with other chronic or acute, systemic or organ specific diseases, which are debilitating the patient, in such a way, that study entry cannot be defended by the investigating doctors. &lt;br&gt;&lt;br&gt;•Patients with plasma potassium &gt; 6,5 mmol/l &lt;br&gt;&lt;br&gt;•Patients, with any form of abuse of medical products, psychiatric disorders or other diseases, which may hamper the contacts between patient and the doctors. &lt;br&gt;&lt;br&gt;•Patients, enrolled in other projects involving administration of project medication or other treatment, which may affect the outcome. &lt;br&gt;&lt;br&gt;•Patients with allergic sensitization against the investigated drugs.&lt;br&gt;&lt;br&gt;•Patients treated with m-TOR blockade (sirolimus, everolimus)&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic allograft nephropathy in kidney transplants, defined as tubular atrophy and interstitial fibrosis in graft biopsy (Banff criteria) &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10063209
Term: Chronic allograft nephropathy
System Organ Class: 10022117 - Injury, poisoning and procedural complications
;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]</Condition>
    <Intervention>&lt;br&gt;Trade Name: inspra&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: EPLERENONE&lt;br&gt;CAS Number: 107724-20-9&lt;br&gt;Other descriptive name: EPLERENONE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Furix&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: FUROSEMIDE&lt;br&gt;CAS Number: 54-31-9 &lt;br&gt;Other descriptive name: FUROSEMIDE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To examine the possible renal graft protective effects of treatment with eplerenone in kidney transplanted patients in addition to a standard regimen, including studies in the progression of proteinuria and glomerular filtration. ;Secondary Objective: to reduce the velocety at witch the graft function is declining&lt;br&gt;;Primary end point(s): Primary endoints.&lt;br&gt;24 hour urine albumine excretion&lt;br&gt;&lt;br&gt;;Timepoint(s) of evaluation of this end point: The primery endpoint will be evaluated at 3 months and one year after initiation</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Ethiological studies in CAN:
&lt;br&gt;•	The ekspression of CYP11B2 
&lt;br&gt;•	The ekspressionen PAI-1, TGF-ß,
&lt;br&gt;
&lt;br&gt;surrogat messures of CAN
&lt;br&gt;•	Chrome EDTA clearance/Technetium DTPA renography
&lt;br&gt;•	Blood pressure
&lt;br&gt;•	weight
&lt;br&gt;;Timepoint(s) of evaluation of this end point: Secondary endpoints regarding ethiological reseach will be evaluated one at  initiation. 
&lt;br&gt;Secondary endpoints regarding surrogate endpoint will be evaluated at week 0, 12, 26, 48.</Secondary_outcome>
    <Secondary_ID>2011-402</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2496272</Internal_Number>
    <TrialID>EUCTR2010-022589-29-GB</TrialID>
    <Last_Refreshed_on>20 March 2012</Last_Refreshed_on>
    <Public_title>Study testing at how mTOR inhibiting drugs work in kidney cancer.</Public_title>
    <Scientific_title>Investigation of pathways regulating cell survival and early antiangiogenic response to single agent Everolimus or Rapamycin in renal cancer - Effects of mTOR Inhibition in renal cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>University of Oxford</Primary_sponsor>
    <Date_registration3>20110127</Date_registration3>
    <Date_registration>27/01/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-022589-29                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/03/2011</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Localised or metastatic renal cell cancer, any histological subtype, suitable for repeat sampling. Prior histological proof is not required, but scan appearances of newly diagnosed patients should be consistent with localised or metastatic RCC.&lt;br&gt;2.	Age &gt;=18 years. &lt;br&gt;3.	ECOG performance status 0-2&lt;br&gt;4.	Life expectancy &gt;3 months &lt;br&gt;5.	Either: scheduled for biopsy and nephrectomy, or metastatic disease, suitable for 2 CT-guided biopsies, including accessible deposits &gt;2cm in soft tissue or bone.&lt;br&gt;6.	Untreated or previously treated with systemic therapy including multi-kinase inhibitor (eg sunitinib, sorafenib), immunotherapy (eg interferon) or experimental therapy. Radiotherapy is acceptable provided lesion chosen for biopsy is outside the irradiated field.&lt;br&gt;7.	 Able to give written informed consent and cooperate with protocol.&lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: 0&lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 0&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 0&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Clinical or CT scan features inconsistent with RCC unless pathologically confirmed.&lt;br&gt;2.	Uncontrolled brain metastases.&lt;br&gt;3.	Radiotherapy, major surgery, significant traumatic injury, systemic anti-cancer therapy (including immunotherapy, kinase inhibitor or experimental therapy) during the four weeks prior to starting study treatment.&lt;br&gt;4.	Previous treatment with Rapamycin or Rapalogue (eg Everolimus, Temsirolimus).&lt;br&gt;5.	Current or recent (within 10 days of Rapamycin) use of full-dose oral or parenteral anticoagulants or thrombolytic agent for therapeutic purposes. Prophylactic use of anticoagulants is allowed. &lt;br&gt;6.	History or evidence of inherited bleeding diathesis or coagulopathy with risk of bleeding.&lt;br&gt;7.	Uncontrolled diabetes mellitus (HbA1c &gt;8%).&lt;br&gt;8.	Clinically significant (i.e. active) cardiovascular disease for example CVA (=6 months before enrolment), myocardial infarction (MI) (=6 months before enrolment) unstable angina, CHF NYHA Class =II study, cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin are permitted).&lt;br&gt;9.	Non-healing wound, active peptic ulcer or bone fracture.&lt;br&gt;10.	Known hypersensitivity to Rapamycin and any of its excipients. &lt;br&gt;11.	Other psychological, social or medical condition, physical examination finding or laboratory abnormality that the Investigator considers would make the patient a poor study candidate, or could interfere with protocol compliance or the interpretation of results.&lt;br&gt;12.	Co-administration of Rapamycin with strong inhibitors of CYP3A4 (such as ketoconazole, voriconazole, itraconazole, telithromycin or clarithromycin) or inducers of CYP3A4 (such as rifampin, rifabutin).  Low dose corticosteroids are permitted.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal cancer &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10038389
Term: Renal cancer
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
;Therapeutic area: Diseases [C] - Cancer [C04]</Condition>
    <Intervention>&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: Rapamune&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Rapamune&lt;br&gt;Other descriptive name: Rapamycin&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 6-&lt;br&gt;&lt;br&gt;Trade Name: Afinitor&lt;br&gt;Product Name: Afinitor&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: everolimus&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Drugs that inhibit the mTOR enzyme have clinical activity in renal cancer, causing significant delay in disease progression, although with a low incidence of objective tumour regressions. This trial aims to identify early indicators of disease response or resistance. ;Secondary Objective: To determine the levels of Rapamycin or everolimus in the blood before and 2hr after dosing with Rapamycin tablets.&lt;br&gt;&lt;br&gt;Assess the safety profile of 2 weeks mTOR inhibitor treatment in this patient population&lt;br&gt;&lt;br&gt;Evaluate whether changes in pharmacodynamic readouts pre- and post anti-mTOR therapy are associated with clinical outcome at 12 months&lt;br&gt;&lt;br&gt;(Exploratory) To store samples of blood and tumour surplus to diagnostic and study requirements in the Oxford Radcliffe Biobank (ORB), for use in future ethically approved research. ;Primary end point(s): The pharmacodynamic effects of two weeks’ administration of mTOR inhibitor treatment on cell signaling and intratumoral blood flow. THese will be measured by:&lt;br&gt;1) Compare baseline and induced changes in phosphorylation of Akt and S6, and on proliferation by Ki67 index, measured by immunohistochemistry).&lt;br&gt;&lt;br&gt;2) Assess changes in vascular volume and permeability by DCE MRI and perfusion CT imaging before and after Everolimus or Rapamycin.&lt;br&gt;&lt;br&gt;3) Assess correlation between Everolimus/ Rapamycin-induced changes in IHC with changes in vascular volume and permeability.;Timepoint(s) of evaluation of this end point: 14+-3 days following start of dosing with mTOR inibitor </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): 1) Determine circulating levels of Everolimus and Rapamycin &lt;br&gt;2) Assess the safety profile of 2 weeks mTOR inhibitor treatment in this patient population&lt;br&gt;3) Evaluate whether changes in pharmacodynamic readouts pre- and post anti-mTOR therapy are associated with clinical outcome at 12 months;Timepoint(s) of evaluation of this end point: 1 &amp; 2 will be assessed on or before the final study visit 4-6 weeks following second set of study scans and sample collection.&lt;br&gt;&lt;br&gt;3) Progression free and overall survival will be evaluated at the aniversary of the final study biopsy.</Secondary_outcome>
    <Secondary_ID>EP-TSC-624</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2496523</Internal_Number>
    <TrialID>EUCTR2011-002863-84-AT</TrialID>
    <Last_Refreshed_on>20 March 2012</Last_Refreshed_on>
    <Public_title>Calcitonin stimulation: pentagastrin vs. calcium gluconate - potency, feasibility and tolerance in chronic kidney disease. - CT- stimulation in CKD</Public_title>
    <Scientific_title>Calcitonin stimulation: pentagastrin vs. calcium gluconate - potency, feasibility and tolerance in chronic kidney disease. - CT- stimulation in CKD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Medizinische Universitaet Wien, AKH Wien, Innere Medizin III, klin.Abteilung fuer Nephrologie und Dialyse</Primary_sponsor>
    <Date_registration3>20120119</Date_registration3>
    <Date_registration>19/01/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-002863-84                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>02/03/2012</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: yes&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;&gt; 18 years; at least 3 months of chronic dialysis treatment (hemodiyalisis, peritoneal dialysis)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 15&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 5&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Cardiovascular interventions in the last 12 months; infarction; instable coronary heart disease; atrial fibrillation; cardiomyopath;, asthma; COPD (late stage); epilepsy; thyroidectomy; pregnancy; alcoholism; digitalis treatment;&lt;br&gt;</Exclusion_Criteria>
    <Condition>investigation of the presence/absence of C-cell abnormalities of the thyroid in chronic kidney disease.;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]</Condition>
    <Intervention>&lt;br&gt;Trade Name: Pentagastrin&lt;br&gt;Product Name: Peptavlon&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;INN or Proposed INN: PENTAGASTRIN&lt;br&gt;CAS Number: 5534-95-2&lt;br&gt;Current Sponsor code: -&lt;br&gt;Other descriptive name: -&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,25-&lt;br&gt;&lt;br&gt;Trade Name: Calcium gluconate&lt;br&gt;Product Name: Calcium Cluconat 10% Braun&lt;br&gt;Pharmaceutical Form: Solution for injection/infusion&lt;br&gt;INN or Proposed INN: calcium gluconate&lt;br&gt;CAS Number: 299-28-5&lt;br&gt;Current Sponsor code: -&lt;br&gt;Other descriptive name: CALCIUM GLUCONATE&lt;br&gt;Concentration unit: mmol/ml millimole(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,226-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Comparison of the two calcitonin stimulation tests pentagastrin and calcium gluconate regarding potency, feasibility and tolerance.;Secondary Objective: ;Primary end point(s): </Primary_outcome>
    <Source_Support>Medizinische Universitaet Wien, AKH Wien, Innere Medizin III, klin.Abteilung fuer Nephrologie und Dialyse</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2496814</Internal_Number>
    <TrialID>EUCTR2006-002330-38-GB</TrialID>
    <Last_Refreshed_on>20 March 2012</Last_Refreshed_on>
    <Public_title>Randomised Trial of Rituximab in C4d+ Chronic Renal Transplant Rejection</Public_title>
    <Scientific_title>Randomised Trial of Anti-CD20 in C4d+ Chronic Allograft Nephropathy - RituxiCAN-C4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>King's College London</Primary_sponsor>
    <Date_registration3>20061016</Date_registration3>
    <Date_registration>16/10/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002330-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/11/2006</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Standard optimal clinical care according to our unit protocol&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;To be included in the study the patient must have:&lt;br&gt;•A functioning kidney allograft (with estimated GFR by MDRD &gt;20) and be &gt;6/12 post-transplantation&lt;br&gt;•Either deteriorating allograft function as defined by linear regression of reciprocal creatinine plot. Deterioration will be defined as a negative slope over at least the preceding 3 months (with at least 6 creatinines included) with an adjusted r2 &gt;0.35 and a p value of =0.05 compared to horizontal baseline. Deterioration will be confirmed by Cockcroft Gault eGFR somparisons over same period to rule out body mass as a cause of change in creatinines&lt;br&gt;OR Significant proteinuria defined as a urine protein : creatinine ratio =50&lt;br&gt;OR Both deteriorating function and proteinuria&lt;br&gt;•CAN, by Banff ’97 criteria, or transplant glomerulopathy on renal allograft biopsy performed within 3/12 of enrolment &lt;br&gt;•Diffuse, linear C4d deposition on at least 25% of peritubular capillary (PTC) and/or glomerular EC of renal transplant biopsy when assessed by immunoperoxidase  OR &gt;50% of PTC (alone) when assessed by immunofluorescence.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 30&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 30&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;The presence of any of the following will preclude patient inclusion&lt;br&gt;&lt;br&gt;•&lt;18 years of age&lt;br&gt;•suspicion of pregnancy confirmed by positive HCG pregnancy test&lt;br&gt;•untreated ureteric obstruction on ultrasound of allograft&lt;br&gt;•history of acute allograft rejection in preceding 3/12&lt;br&gt;•history of MI in preceding 3/12&lt;br&gt;•history of malignancy in previous 5 years (excluding tumours limited to skin)&lt;br&gt;•symptomatic IHD&lt;br&gt;•recipient of simultaneous pancreas/kidney transplant&lt;br&gt;•recipient of ABO-incompatible kidney&lt;br&gt;•recipient who underwent an HLA desensitisation procedure prior to transplantation&lt;br&gt;•evidence, on examination of renal allograft biopsy specimen, of recurrent or de-novo disease (except IgA deposition in absence of mesangial proliferation) &lt;br&gt;• evidence, on examination of renal allograft biopsy specimen, of CNI toxicity IF ACCOMPANIED by mostly supra-therapeutic CNI trough levels in the 6 month period preceding biopsy.&lt;br&gt;• doumented allergy to mouse or chimeric human/mouse proteins&lt;br&gt;• HepBsAg+, HCV Ab+ or HIV+ or HepBcAb+ &lt;br&gt;• administration of lymphocyte depleting antibody within 3 months of enrolment&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal Transplant Rejection - chronic &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10023439
Term: Kidney transplant rejection
System Organ Class: 10021428 - Immune system disorders
;Therapeutic area: Body processes [G] - Immune system processes [G12]</Condition>
    <Intervention>&lt;br&gt;Trade Name: MabThera&lt;br&gt;Product Name: N/A&lt;br&gt;Product Code: N/A&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Rituximab&lt;br&gt;Other descriptive name: Anti-CD20 monoclonal Ab&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-50&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine whether anti-CD20 therapy can stabilise or improve renal function and/or proteinuria in patients with C4d+, chronic (humoral) rejection in whom standard therapeutic approaches have failed.&lt;br&gt;&lt;br&gt;;Secondary Objective: To compare patient and graft survival between control and rituximab-treated groups&lt;br&gt;To evaluate the adverse effect profile of rituximab in this group&lt;br&gt;To correlate changes in circulating B cell numbers, anti-HLA and non-HLA Ab profiles and titre with responses to standard therapy and / or rituximab&lt;br&gt;To correlate changes in T cell responsiveness to alloantigens with responses to standard therapy and / or rituximab;Primary end point(s): •Rate of deterioration in renal function, defined by slope of reciprocal creatinine plot, on samples taken in the preceding 3 months.&lt;br&gt;•Change in degree of proteinuria, where present;Timepoint(s) of evaluation of this end point: Determined 3-5 months post-randomisation</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): To compare patient and graft survival between control and rituximab-treated groups
&lt;br&gt;To evaluate the adverse effect profile of rituximab in this group
&lt;br&gt;To correlate changes in circulating B cell numbers, anti-HLA and non-HLA Ab profiles and titre with responses to standard therapy and / or rituximab
&lt;br&gt;To correlate changes in T cell responsiveness to alloantigens with responses to standard therapy and / or rituximab;Timepoint(s) of evaluation of this end point: Secondary endpoints will be determined at 3-5 months post-randomisation and at 1, 2 and 3 years post-recruitment</Secondary_outcome>
    <Secondary_ID>RituxiCAN-C4</Secondary_ID>
    <Source_Support>Roche</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2532587</Internal_Number>
    <TrialID>EUCTR2005-005791-32-GB</TrialID>
    <Last_Refreshed_on>3 April 2012</Last_Refreshed_on>
    <Public_title>Chemical Safety/Tolerability of HF0220 and its Effect on Biochemical Markers Relevant to Patients with a Diagnosis of Mild to Moderate Alzheimer's Disease.</Public_title>
    <Scientific_title>Chemical Safety/Tolerability of HF0220 and its Effect on Biochemical Markers Relevant to Patients with a Diagnosis of Mild to Moderate Alzheimer's Disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Hunter-Fleming Ltd</Primary_sponsor>
    <Date_registration3>20060217</Date_registration3>
    <Date_registration>17/02/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005791-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/04/2006</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.  Mild/moderate dementia as evidenced by a screening Mini-Mental State Examination (MMSE) score of 12-24 inclusive &lt;br&gt;&lt;br&gt;2. Capable of understanding written procedures and giving written informed consent. &lt;br&gt;&lt;br&gt;3. Male and Female outpatients with Alzheimer’s disease The diagnosis should be established in accordance with the NINCDS-ADRDA classification1 for probable Alzheimer’s disease. Patients living in residential homes for the elderly will be excluded &lt;br&gt;&lt;br&gt;4. Patients aged over 55 years &lt;br&gt;&lt;br&gt;5. Patients who live with or have at least daily visits from a responsible carer &lt;br&gt;This includes a friend or relative. The carer should be capable of assisting with the patient’s medication, prepared to attend with the patient for assessment and willing to provide information about the patient. There may be more than one carer, however, the same carer should assess the patient throughout the study, wherever possible. If there is a local requirement, the responsible carer will sign the carer informed consent form confirming they are willing to help the patient during the study and willing to visit with them for each assessment &lt;br&gt;&lt;br&gt;6. Written informed consent &lt;br&gt;Written consent should be obtained from the patient and responsible carer and countersigned by the responsible physician &lt;br&gt;&lt;br&gt;7. Depending on the biomarker results from Plan A, a decision will be made whether or not to include a biomarker as an entry criterion for Plan B. If a biomarker inclusion criterion is required, it will only be added after approval as a substantial protocol amendment. &lt;br&gt;&lt;br&gt;8. A negative screen for drugs of abuse, serum hepatitis B surface antigens, and hepatitis C &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Primary, secondary or pseudo- dementias&lt;br&gt;2. Concomitant medication, such as antipsychotics, anti-Parkinson’s drugs, anticonvulsants, cholinergic agents, NSAIDs, or Over-The-Counter medication other than approved by the Investigator&lt;br&gt;3. Excessive alcohol intake, malnourishment, use of antioxidant supplements; active smokers&lt;br&gt;4. Women of child-bearing potential or nursing mothers&lt;br&gt;5. Patients otherwise unsuitable for this study type, or feeling unable to comply with the restrictions required by the study&lt;br&gt;&lt;br&gt;(The full list is given in Section 7.3 of the Study Protocol)&lt;br&gt;</Exclusion_Criteria>
    <Condition>HF0220 experimentally appears to exert its potential beneficial effects within the CNS and possibly other tissues by attenuating the adverse effects of oxidative stress. It is believed that this mechanism has the potential to reduce disease progression in a wide range of disorders of the nervous system, e.g. Alzheimer's and Parkinson's disease, and brain damage due to acute stroke and head injury. It may also apply to the protection of peripheral tissues, such as the heart and/or kidney. &lt;br&gt;MedDRA version: 9.1
Level: HLT
Classification code 10001897
Term: Alzheimer's disease (incl subtypes)
</Condition>
    <Intervention>&lt;br&gt;Product Name: HF0220&lt;br&gt;Product Code: HF0220&lt;br&gt;Pharmaceutical Form: Powder for oral suspension&lt;br&gt;Current Sponsor code: HF0220&lt;br&gt;Other descriptive name: 7-beta-hydroxyepiandrosterone&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 0.001-0.22-&lt;br&gt;Pharmaceutical form of the placebo: Oral suspension&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate the safety and tolerability of HF0220 in a patient population.&lt;br&gt;&lt;br&gt;;Secondary Objective: To validate biochemical markers relevant to Alzheimer's disease as appropriate end-points in a future chronic clinical study of the neuroprotective effect of HF0220 in patients with a diagnosis of mild-to-moderate Alzheimer's Disease.&lt;br&gt;To assess the suitability of chosen dose levels for future studies. ;Primary end point(s): Candidate dose level and validation of biochemical markers indicative of HF0220 action. </Primary_outcome>
    <Secondary_ID>HF0220/003</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2532944</Internal_Number>
    <TrialID>EUCTR2006-005449-12-IT</TrialID>
    <Last_Refreshed_on>3 April 2012</Last_Refreshed_on>
    <Public_title>EVALUATION OF THE EFFICACY OF THE TREATMENT WITH ACE-INHIBITORS ON THE RENAL DAMAGE IN PATIENTS AFFECTED BY GLYCOGEN STORAGE DISEASE TYPE 1 AND OF THE VITAMINE E ON NEUTROPENIA OF PATIENTS WITH GSD1b - GSD1: study of specific therapeutic intervention</Public_title>
    <Scientific_title>EVALUATION OF THE EFFICACY OF THE TREATMENT WITH ACE-INHIBITORS ON THE RENAL DAMAGE IN PATIENTS AFFECTED BY GLYCOGEN STORAGE DISEASE TYPE 1 AND OF THE VITAMINE E ON NEUTROPENIA OF PATIENTS WITH GSD1b - GSD1: study of specific therapeutic intervention                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Dipartimento di Pediatria</Primary_sponsor>
    <Date_registration3>20070523</Date_registration3>
    <Date_registration>23/05/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005449-12                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>11/10/2006</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: farmaco versus non assunzione del farmaco&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Inclusion criteria will be represented by the demonstration of the diagnosis of GSD 1a-either by enzyme studies and/or mutation analysis-and GSD1b-either by enzyme studies and/or mutation analysis&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Exclusion criteria will be the inability to comply with the protocol and with the therapy.&lt;br&gt;&lt;br&gt;Pregnancy and breastfeeding&lt;br&gt;</Exclusion_Criteria>
    <Condition>As concern objective number 1:  Patients affected by glycogen storage disease (GSD) type 1a and patients affected by GSD1b with renal dysfunction including glomerular hyperfiltration, microalbuminuria and/or proteinuria   As concern objective number 2: Patients affected by GSD1b showing neutropenia &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10018464
Term: Glycogen storage disease type I
</Condition>
    <Intervention>&lt;br&gt;Trade Name: QUARK&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Ramipril&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2.5-&lt;br&gt;&lt;br&gt;Trade Name: EPHYNAL&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: Tocopherol (vit E)&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 300-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: are1) to perform a prospective study to analyse the effectiveness of ACE-inhibitors in improving the various manifestations of renal dysfunction (including hyperfiltration, microalbuminuria, proteinuria) and in delaying the progression of renal damage in both GSD1a and GSD1b patients, 2) to study the efficacy of vitamin E on the neutropenia, neutrophil dysfunction and IBD in GSD1b patients;Secondary Objective: 1.1 A reduction of the number of the patients needing dialysis and/or kidney transplantantion; 1.2 An improvement of patients' quality of life. 2.1 G-CSF therapy dose-reduction with consequent improvement of the G-CSF-related adverse effects. 2.2 Improvement of GSD1b patients' quality of life.;Primary end point(s): aim 1) 1.1 A 50% reduction of the value of glomerular hyperfiltration, microalbuminuria and proteinuria in patients treated with ACE-inibitors. 1.2 Lack of a progression of renal damage under  ACE-inibitors treatment. 1.3 A significant difference in renal function assessment between the sub-groups of treated and untreated patients after a two-year follow-up. 1.4 A significant difference in the progression of renal damage between the sub-groups of treated and untreated patients after a two-yaer follow-up.  Aim 2) 2.1 A 25% increase of neutrophil mean, median and nadir value(as compared to the previous year) under vitamin E supplemention; 2.2 A 25% reduction of the frequency of infections, frequency  of hospital admission and inflammatory bowel activity</Primary_outcome>
    <Secondary_ID>FARM5S3JT5</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2533369</Internal_Number>
    <TrialID>EUCTR2008-006729-15-IT</TrialID>
    <Last_Refreshed_on>3 April 2012</Last_Refreshed_on>
    <Public_title>OPEN PILOT STUDY, TWO ARMS, WITH HISTORIC CONTROL, MULTICENTRIC TO EVALUATE SAFETY AND EFFICACY OF ASSOCIATION WITH EVEROLIMUS AND LOW DOSES OF CYCLOSPORIN AND STEROIDS AFTER INDUCTION WITH MONOCLONAL ANTIBODY ANTI CD25 IN PEDIATRIC PATIENTS AFTER KIDNEY TRANSPLANTS - ND</Public_title>
    <Scientific_title>OPEN PILOT STUDY, TWO ARMS, WITH HISTORIC CONTROL, MULTICENTRIC TO EVALUATE SAFETY AND EFFICACY OF ASSOCIATION WITH EVEROLIMUS AND LOW DOSES OF CYCLOSPORIN AND STEROIDS AFTER INDUCTION WITH MONOCLONAL ANTIBODY ANTI CD25 IN PEDIATRIC PATIENTS AFTER KIDNEY TRANSPLANTS - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>ISTITUTO GIANNINA GASLINI</Primary_sponsor>
    <Date_registration3>20081219</Date_registration3>
    <Date_registration>19/12/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-006729-15                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>25/11/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: controllo storico&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: storico&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Age&lt;18 years at time of screening&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Systemic infection before starting everolimus&lt;br&gt;</Exclusion_Criteria>
    <Condition>pediatric patient after kidney transplant &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10023439
Term: Kidney transplant rejection
</Condition>
    <Intervention>&lt;br&gt;Trade Name: CERTICAN&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: .25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Efficacy;Secondary Objective: Safety;Primary end point(s): % failure</Primary_outcome>
    <Secondary_ID>IGG-GIFA-001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2533766</Internal_Number>
    <TrialID>EUCTR2009-016506-17-IT</TrialID>
    <Last_Refreshed_on>3 April 2012</Last_Refreshed_on>
    <Public_title>RIGOROUS NORMOXYA MAINTENANCE IN INTENSIVE CARE UNIT: RANDOMIZED CONTROLLED TRIAL. - ND</Public_title>
    <Scientific_title>RIGOROUS NORMOXYA MAINTENANCE IN INTENSIVE CARE UNIT: RANDOMIZED CONTROLLED TRIAL. - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>U.O. Terapia intensiva</Primary_sponsor>
    <Date_registration3>20091203</Date_registration3>
    <Date_registration>03/12/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-016506-17                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/04/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: yes&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Other specify the comparator:  - same IMP used at different dosage&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;All patients admitted to the intensive care unit of Policlinico di Modena in the study period from 01/12/2009 to 30/11/2011 with an expected lenght of stay of at least 3 days.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Patients age lower than 18  - Patients discharged from intensive care unit and than re-admitted during study period  - Patients partecipating to other prospective studies  - Expected survival &lt; 24 hours&lt;br&gt;</Exclusion_Criteria>
    <Condition>Critically ill patients because of chronic or acute respiratory, circulatory, neurologic, infective, metabolic, renal or hepatic pathologies. &lt;br&gt;MedDRA version: 9.1
Level: SOC
Classification code 10038738
 &lt;br&gt;MedDRA version: 9.1
Level: SOC
Classification code 10047065
 &lt;br&gt;MedDRA version: 9.1
Level: SOC
Classification code 10019805
 &lt;br&gt;MedDRA version: 9.1
Level: SOC
Classification code 10021881
</Condition>
    <Intervention>&lt;br&gt;Pharmaceutical Form: Inhalation gas&lt;br&gt;INN or Proposed INN: Oxygen&lt;br&gt;Concentration unit: l litre(s)&lt;br&gt;Concentration type: equal&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Main objective of the study is the assessment that a rigorous normoxia maintenance, avoiding hypoxia and hyperoxia states, can reduce intensice care unit mortality.;Secondary Objective: Secondary objectives are:  - reduction of new onset of organ failures (respiratory, circulatory, renal, hepatic) in intensive care unit  - reduction of new onset of infections in intensive care unit (pneumonia, blood) or in hospital (surgical site).;Primary end point(s): Mortality reduction in intensive care unit.</Primary_outcome>
    <Secondary_ID>OXYGEN-TIPO</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2534002</Internal_Number>
    <TrialID>EUCTR2010-019726-14-IT</TrialID>
    <Last_Refreshed_on>3 April 2012</Last_Refreshed_on>
    <Public_title>SORAFENIB IN ELDERLY PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (SERCC STIDY). IMPACT OF ADVERSE EVENTS MANAGEMENT IN ELDERLY mRCC PATIENTS TREATED WITH SORAFENIB. - SERCC</Public_title>
    <Scientific_title>SORAFENIB IN ELDERLY PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (SERCC STIDY). IMPACT OF ADVERSE EVENTS MANAGEMENT IN ELDERLY mRCC PATIENTS TREATED WITH SORAFENIB. - SERCC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO</Primary_sponsor>
    <Date_registration3>20100427</Date_registration3>
    <Date_registration>27/04/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-019726-14                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/09/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Nephrectomized, metastatic Clear Cell RCC patients not suitable for cytokines or anti-angiogenesis (bevacizumab or sunitinib) therapy as first line treatment &lt;br&gt;2.	Age = 65years &lt;br&gt;3.	ECOG Performance Status of 0 or 2 &lt;br&gt;4.	MSKCC prognostic score, Good or intermediate &lt;br&gt;5.	Life expectancy of at least 12 weeks. &lt;br&gt;6.	Subjects with at least one uni-dimensional (for RECIST) measurable lesion. Lesions must be measured by CT/MRI-scan. &lt;br&gt;7.	Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of therapy:&lt;br&gt;a.	Hemoglobin &gt; 9.0 g/dl &lt;br&gt;b.	Absolute neutrophil count (ANC) &gt;1,500/mm3 &lt;br&gt;c.	Platelet count  100,000/µl &lt;br&gt;d.	Total bilirubin &lt; 1.5 times the upper limit of normal &lt;br&gt;e.	ALT and AST &lt; 2.5 x upper limit of normal (&lt; 5 x upper limit of normal for patients with liver involvement of their cancer) &lt;br&gt;f.	Alkaline phosphatase &lt; 4 x upper limit of normal &lt;br&gt;g.	PT-INR/PT &lt; 1.5 x upper limit of normal [Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists.] &lt;br&gt;h.	Serum creatinine &lt; 1.5 x upper limit of normal. &lt;br&gt;&lt;br&gt;8.	Ability to take correctly oral drugs. &lt;br&gt;9.	Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.&lt;br&gt;10.	Written Informed Consent&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Previous first line treatment for metastatic RCC. No adjuvant or neoadjuvant treatments are allowed.&lt;br&gt;2.	Symptomatic metastatic brain or meningeal tumors (unless the patient is &gt; 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry) &lt;br&gt;3.	History of cardiac disease: congestive heart failure &gt;NYHA class 2; active CAD (MI more than 6 months prior to study entry is allowed); cardiac arrhythmias requiring antiarrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension. &lt;br&gt;4.	History of previous or present seizure disorder requiring medication (such as steroids or anti-epileptics), organ allograft, HIV infection or chronic hepatitis B or C&lt;br&gt;5.	Active clinically serious infections (&gt; grade 2 NCI-CTC version 3.0) &lt;br&gt;6.	Patients undergoing renal dialysis &lt;br&gt;7.	Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis &amp; T1] or any cancer curatively treated &gt; 3 years prior to study entry. &lt;br&gt;8.	Patients with evidence or history of bleeding diathesis &lt;br&gt;9.	Substance abuse, medical, psychological or social conditions that may interfere with the patient`s participation in the study or evaluation of the study results &lt;br&gt;10.	Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study &lt;br&gt;11.	Known allergy to sorafenib or one of its constituents&lt;br&gt;</Exclusion_Criteria>
    <Condition>PATIENTS WITH METASTATIC RENAL CELL CARCINOMA AGED &gt;/= 65 YRS &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038416
</Condition>
    <Intervention>&lt;br&gt;Trade Name: NEXAVAR*112CPR RIV 200MG&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary aim of this trial is the evaluation of the efficacy of a patient education  program in the reduction of HFSR.;Secondary Objective: TO asses:&lt;br&gt;•	The frequency of dose discontinuation, interruption and reduction &lt;br&gt;•	The incidence of any grade diarrhoea, and other adverse events&lt;br&gt;•	The overall Response Rate according to the RECIST criteria.&lt;br&gt;•	Progression free survival (PFR) in study population and comparison of PFS between age sub groups in the current study population;Primary end point(s): The primary aim of this study is to determine the efficacy of the patient education program in reducing the incidence of HFSR (all grades). The efficacy is measured in terms of percentage of HFSR-free.   &lt;br&gt;Simon’s methods will be used to calculate sample size (Simon R, 1989). Considering the optimal two-stage design for phase II, considering a difference p1-p0=20% between patients who undergo education program (p1=60%) and those who do not (p0=40%), and fixing error probabilities (?=0.05 and ?=0.20), the number of patients for the first step is 16. The trial will be terminated if less than 7 HFSR-free patients will be seen. Otherwise the accrual will continue up to a total of 46 patients.</Primary_outcome>
    <Secondary_ID>CRO-2010-01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2534204</Internal_Number>
    <TrialID>EUCTR2010-019086-28-IT</TrialID>
    <Last_Refreshed_on>3 April 2012</Last_Refreshed_on>
    <Public_title>Multicenter, no-profit, open, single sequence cross-over study on effectiveness and safety of anti-rejection therapy based on modified release Tacrolimus(Advagraf)and on patients quality of life and adhesion to therapeutical regimen improvement after switch from conventional BID(Prograf) Tacrolimus immunosuppressive therapy to mono-administration of modified release of Tacrolimus in stable kidney transplant recipient - ND</Public_title>
    <Scientific_title>Multicenter, no-profit, open, single sequence cross-over study on effectiveness and safety of anti-rejection therapy based on modified release Tacrolimus(Advagraf)and on patients quality of life and adhesion to therapeutical regimen improvement after switch from conventional BID(Prograf) Tacrolimus immunosuppressive therapy to mono-administration of modified release of Tacrolimus in stable kidney transplant recipient - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>UO Divisione Nefrologia, Dialisi e Trapianto renale</Primary_sponsor>
    <Date_registration3>20100914</Date_registration3>
    <Date_registration>14/09/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-019086-28                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>21/02/2011</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. both gender older than 18 years 2. one year kidney transplant 3.Prograf dosage unchanged in last 12 weeks before enrollement 4. Tacrolimus ematic levels stable within 5-15 ng/ml in last 12 weeks before enrollement 5.immunosuppressive regimen unchanged in last 12 weeks before enrollement 6. women in fertile ages with pregnancy test negative (performed in serum) with willing of using contraceptive methods all time study long 7. clinically stable patientsaccording to investigator opinion 8. patients capable of understanding and will, able to understand aims and risks of experimentation, who have signed informed consent at study enrollement&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. graft different from kidney 2. acute rejection episode within 12 weeks before enrollement or acute rejection episode within 24 weeks before enrollement, who required anti-lymphocity treatment 3. new onset malignat neoplasia after transplant 4. known allergy or hypersensitivity to one or both drugs components uesd in study 5. clinically unstable patients 6. history of drugs abuse or psychiatric issues which in investigator opinion could get difficolt patient-investigator comunication 7. patinets enrolled in an other clinical study 8. patients who have used or are using drugs non lcenesed in protocoll 9. pregnant or breastfeeding women 10.HIV positive pateints 11. patients who according to investigator opinion are not able to obey dadeline and procedures of protocol 12.proteinuria more than 2 g/24h 13. creatinine clearance mesured by Cockcroft-Gault formula &lt; 40 ml/min 14. sieric creatinine levels increased more than 20% in last 6 mouths before enrollement 15. GOT GPT increased or bilirubin level increased two times of normal range 16. Hepatic cyrrosis&lt;br&gt;</Exclusion_Criteria>
    <Condition>Kidney transplant patients &lt;br&gt;MedDRA version: 9.1
Level: PT
Classification code 10023439
</Condition>
    <Intervention>&lt;br&gt;Trade Name: ADVAGRAF*30CPS 0,5MG R.P.&lt;br&gt;Pharmaceutical Form: Modified-release tablet&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: ADVAGRAF*30CPS 1MG R.P.&lt;br&gt;Pharmaceutical Form: Modified-release tablet&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: ADVAGRAF*50CPS 5MG R.P.&lt;br&gt;Pharmaceutical Form: Modified-release tablet&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Comparison between Advagraf and Prograf of adherence index to the therapy with tacrolimus by patients who had an allogenic renal transplanation and who showed steadiness of hematic levels of tacrolimus. The dosage method will be the same for all centres taking part in the study.;Secondary Objective: To ass safety and effectivenessof anti-rejection therapy based on modified release Tacrolimus(Advagraf)in stable kidney transplant recipient after switch from conventional Tacrolimus BID therapy;Primary end point(s): Stability of plamsatic level of Tacrolimus after switch to Advagraf.  Stability of renal function parameters (serum creatinine, creatinine clearance misured, azotemia)after switch to Advagraf. Improvement of adhesion and comfort to therapy by patients, assessed by test</Primary_outcome>
    <Secondary_ID>AQUARIUS</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2534270</Internal_Number>
    <TrialID>EUCTR2010-021041-42-IT</TrialID>
    <Last_Refreshed_on>3 April 2012</Last_Refreshed_on>
    <Public_title>Use of Calcimimetics vs oral Paricalcitol in Renal transplant Patients affected with Persistent Secondary Hyperparathyroidism. A pilot study - ND</Public_title>
    <Scientific_title>Use of Calcimimetics vs oral Paricalcitol in Renal transplant Patients affected with Persistent Secondary Hyperparathyroidism. A pilot study - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA</Primary_sponsor>
    <Date_registration3>20101008</Date_registration3>
    <Date_registration>08/10/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-021041-42                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>28/01/2011</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1)Inclusion criteria in Lead-in:  Patient has received renal transplant more than 6 months before enrolment.  Persistent secondary hyperparathyroidism after  renal transplantation, intended as:  Serum PTH higher than reference KDOQI  range for the individual renal function.  Serum Ca level:&gt;10,5 mg/dL and &lt; 12,5 mg/dL.  GFR &gt;= 15 mL/min  2)Entry criteria at baseline (after 4 weeks cinacalcet lead-in):  Subjects should have a serum Ca level less than 10,2 mg/dL.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;&lt; 18 or &gt; 70 years of age.  Participant to other studies in the last 30 days.  Acute rejection.  Acute intercurrent illness.  Life expectancy &lt; 1 year for comorbid  conditions.  Any neoplasia.  Use of Cinacalcet, Paricalcitol, biphosphonates  or any form of vitamin D in the last 2 months  (multivitamin supplements containing &lt;=  400 IU of vitamin D are not restricted).Subject is currently receiving high doses (nonmaintenance  therapy) of steroids ( &gt;=10  mg/day of prednisone or equivalent)(except  topical or inhaled glucocorticoids).  Pregnant (confirmed by screening pregnancy  test) or lactating females.  Drugs intolerance.  For any reason, subject is considered by the  Investigator to be an unsuitable candidate to  receive paricalcitol capsules and/or cinacalcet  or is put at risk by study procedures.Subjects with serum Ca equal or greater than  10.2 mg/dL after the 4-week lead-in phase will  be excluded from the study&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal transplant patients &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10020708
</Condition>
    <Intervention>&lt;br&gt;Trade Name: ZEMPLAR&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: Paricalcitol &lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: MIMPARA&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Cinacalcet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate the efficacy of oral Paricalcitol in reduction of PTH levels in renal  transplant patients previously treated with Cinacalcet.;Secondary Objective: No Secondary objectives Specified;Primary end point(s): Proportion reduction of PTH levels with  respect to baseline</Primary_outcome>
    <Secondary_ID>25051954</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2541950</Internal_Number>
    <TrialID>EUCTR2005-002524-34-GB</TrialID>
    <Last_Refreshed_on>18 April 2012</Last_Refreshed_on>
    <Public_title>An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients with Advanced Renal Cell Carcinoma</Public_title>
    <Scientific_title>An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients with Advanced Renal Cell Carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>BAYER Healthcare AG</Primary_sponsor>
    <Date_registration3>20050824</Date_registration3>
    <Date_registration>24/08/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-002524-34                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>01/02/2006</Date_enrollement>
    <Target_size>1500</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: Open label, non-comparative&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.The patient must provide written informed consent prior to receiving BAY 43-9006.&lt;br&gt;2.The male or female patient must be at least 18 years of age.&lt;br&gt;3.The patient must have advanced Renal Cell Carcinoma.&lt;br&gt;4.The patient must have failed at least one prior systemic established therapy for advanced RCC (e. g., IL-2, IFN-alpha), or must have been unable to tolerate systemic therapy for advanced RCC, or is deemed by the Investigator to be unsuited for systemic therapy for advanced RCC.&lt;br&gt;5.A patient, who has received prior systemic and local therapies, must have completely recovered from acute toxicity (i. e., resolved back to CTCAE Grade 1 or less, or is considered as not going to resolve), if any, prior to study entry.&lt;br&gt;6.The patient must be, in the Investigator’s opinion, reasonably likely to benefit from treatment with BAY 43-9006 as a single agent.&lt;br&gt;7.The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.&lt;br&gt;8.The patient will not require other systemic anti-cancer chemotherapy, immunotherapy (including monoclonal antibodies), signal transduction inhibitors or hormonal therapy, except for bisphosphonates while taking BAY 43-9006.&lt;br&gt;9.Both male and female patients must use adequate barrier birth control methods (oral contraceptives, injectable contraceptives, intrauterine devices, condoms, sterilization) during their participation in the protocol. The birth control methods must be used for 4 weeks for female patients and for 3 months for male patients after discontinuation of treatment with BAY 43-9006.&lt;br&gt;10.For patients, who have had major surgery, the wound must be completely healed prior to receiving BAY 43-9006 treatment (4 weeks).&lt;br&gt;11. Patients with metastatic brain disease which is active or progressive despite previous radiation, radiosurgical or surgical therapy (including gamma knife) are eligible for this protocol, provided they have recovered from any treatment-related toxicity. Patients whose metastatic brain lesions have been surgically removed are also eligible for this protocol. Patients with brain metastases should be observed carefully for any central nervous system symptoms or signs of worsening. Brain metastases are excluded as target lesions for RECIST unless they are the only lesions being followed for the patient.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.Patients who have previously been enrolled in any other BAY 43-9006 clinical trial are not eligible for enrolment in this protocol. However, patients who are being treated with Bay 43-9006 in another trial can be enrolled in this study if the trial they are currently participating in is being discontinued, and if the patient has not already experienced progressive disease on sorafenib treatment.&lt;br&gt;2.Patients, who are eligible for or do have access to any other BAY 43-9006 clinical trial as to the knowledge of the Investigator.&lt;br&gt;3.Patients who have a life expectancy of less than 2 months.&lt;br&gt;&lt;br&gt;5.Patients are excluded who require any of the following:&lt;br&gt;a.Investigational drug therapy during the treatment with BAY 43-9006 or within 30 days prior to their first dose of BAY 43-9006.&lt;br&gt;Warfarin is allowed; however, for patients receiving concomitant warfarin therapy close monitoring of Prothrombin Time (PT) should be performed (please note that no laboratory data are collected in this study).&lt;br&gt;6.Women who are pregnant or breast feeding. Women of childbearing potential must have a negative pregnancy test performed within seven days of the start of study drug (please note that no laboratory data are collected in this study).&lt;br&gt;7.Patients with congestive heart failure greater than NYHA functional class II (symptomatic during ordinary activity)&lt;br&gt;8.Patients with cardiac arrhythmias greater than Grade 1 NCI CTCAE, Version 3.0 (conduction abnormality and supraventricular arrhythmia present but patient is asymptomatic; intervention not indicated, palpitations present and QTc &gt; 0.45 - 0.47 second).&lt;br&gt;9.Patients with active coronary artery disease or ischemia.&lt;br&gt;10.Patients with Child Pugh class C hepatic impairment.&lt;br&gt;11.Patients with severe renal impairment (calculated creatinine clearance of &lt; 30 ml/min) or who require dialysis.&lt;br&gt;12.Patients with active uncontrolled hypertension.&lt;br&gt;13.Patients with recent or active bleeding diathesis.&lt;br&gt;14.Patients with any medical condition which could jeopardize their safety while taking an investigational drug.&lt;br&gt;15. Severe hypersensitivity to sorafenib or any of the excipients.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Advanced Renal Cell Carcinoma</Condition>
    <Intervention>&lt;br&gt;Product Name: sorafenib&lt;br&gt;Product Code: BAY 43-9006&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: sorafenib&lt;br&gt;CAS Number: 28844-1-73-1&lt;br&gt;Current Sponsor code: BAY 43-9006&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The objective of this study is to make BAY 43-9006 available for patients with advanced RCC, who failed prior systemic therapy for advanced disease (i. e., require second line treatment), and who do not have access to or are not eligible for other clinical trials with BAY 43-9006.;Secondary Objective: In addition, safety data and limited efficacy data will be collected for BAY 43-9006 in the treatment of patients with advanced RCC, who failed prior systemic therapy for advanced disease (i. e., require second line treatment). All Drug Related Adverse Events, all Adverse Events NCI CTCAE Version 3.0 Grade 3 or higher, and all Serious Adverse Events regardless of causal relationship to study drug will be recorded in this study.&lt;br&gt;It is expected that, according to the oncological standards, radiological and other procedures will have been performed prior to enrolment of any patient, and, similarly, that the Investigator will be performing appropriate radiological and other procedures according to the local standard of care, although these procedures are not specifically defined within this study protocol.;Primary end point(s): Collection of additional safety data. &lt;br&gt;Time to progression (TTP) and progession free survival (PFS) will also be analysed for time to event data. </Primary_outcome>
    <Secondary_ID>011941</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2541967</Internal_Number>
    <TrialID>EUCTR2005-002817-19-GB</TrialID>
    <Last_Refreshed_on>18 April 2012</Last_Refreshed_on>
    <Public_title>A randomised, double blind, placebo controlled multicentre study of the efficacy and safety of up to 100 days of valganciclovir vs up to 200 days of valganciclovir for prevention of cytomegalovirus disease in high-risk kidney allograft recipients</Public_title>
    <Scientific_title>A randomised, double blind, placebo controlled multicentre study of the efficacy and safety of up to 100 days of valganciclovir vs up to 200 days of valganciclovir for prevention of cytomegalovirus disease in high-risk kidney allograft recipients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>F Hoffmann-La Roche Ltd</Primary_sponsor>
    <Date_registration3>20051129</Date_registration3>
    <Date_registration>29/11/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-002817-19                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/01/2006</Date_enrollement>
    <Target_size>316</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Valganciclovir&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.  Patient has received within the preceding ten days a primary or secondary renal allograft from a living or cadaveric donor.&lt;br&gt;2.  Patient is seronegative for CMV (confirmed within 30 days pre-transplant) and has received an allograft from a CMV seropositive donor.  A donor who is seropositive solely based on having received a CMV seropositive transfusion immediately prior to organ donation is not considered to be a seropositive donor in this study.&lt;br&gt;3.  Patient is 16 years of age or older.&lt;br&gt;4.  Patient has adequate hematological and renal function post-transplant defined as:&lt;br&gt;a)  Absolute neutrophil count (ANC) &gt;1000 cells/?L&lt;br&gt;b)  Platelet count &gt;25,000 cells/?L&lt;br&gt;c)  Hemoglobin &gt;8.0 g/dL&lt;br&gt;d)  Estimated creatinine clearance (calculated by the Cockcroft-Gault formula, see Section 6.1) of &gt;15 mL/min with evidence of improving renal function.&lt;br&gt;5.  Patient agrees to utilize contraceptive methods throughout the study period and for 90 days following discontinuation of the Study Drug. &lt;br&gt;6.  Females of childbearing potential will have a negative pregnancy test at screening.&lt;br&gt;7.  Patient is able to tolerate oral medication within 10 days post transplantation.  The day of completion of transplant surgery is defined as Day 0 post transplantation.&lt;br&gt;8.  Patient understands and signs the Informed Consent.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.  Patient is suspected of having CMV disease.&lt;br&gt;2.  Patient has received anti-CMV therapy within the past 30 days.  (Acyclovir, valacyclovir, or famciclovir may be used for up to 10 days, at the dose specified in the package insert, for treatment of acute herpes simplex or herpes zoster.)&lt;br&gt;3.  Patient is receiving a multi organ transplant (e.g. liver or pancreas in addition to kidney)&lt;br&gt;4.  Patient has received an investigational new drug within the past 30 days, except as approved by Roche Medical Science Representative &lt;br&gt;5.  Patient is simultaneously participating in another clinical trial except as approved by a Roche Medical Science Representative&lt;br&gt;6.  Patient has severe, uncontrolled diarrhea (multiple watery stools) or evidence of malabsorption&lt;br&gt;7.  Patient has exhibited in the past an allergic or other significant adverse reaction to acyclovir, valacyclovir, ganciclovir, or valganciclovir.&lt;br&gt;8.  Patient requires the use of any prohibited concomitant medications&lt;br&gt;9.  Patient is a lactating female who will not discontinue nursing prior to study entry&lt;br&gt;10.  Patient has liver function test results greater than 3 times the upper limit of normal (ULN)&lt;br&gt;11.  Patient is positive for HIV, Hepatitis B or Hepatitis C&lt;br&gt;12.  Patient with malignancies or history of malignancy except non metastatic basal or squamous cell carcinoma of the skin that has been treated sucessfully&lt;br&gt;13.  Male patients with a pregnant partner&lt;br&gt;14.  Patients with any form of substance abuse, psychiatric disorder or serious medical condition which, in the opinion of the investigator, may lead to non compliance, invalidate communication with teh investigator or lead to complexity in patient management&lt;br&gt;15.  Patient is unlikely to be available for follow-up for the full duration of the study (104 weeks)&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Prevention of cytomegalovirus (CMV) disease in kidney transplant recipients</Condition>
    <Intervention>&lt;br&gt;Product Name: Valganciclovir&lt;br&gt;Product Code: Ro 107-9070&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: 1.  To determine the comparative efficacy of up to 100 days valganciclovir (900 mg once daily) prophylaxis relative to up to 200 days valganciclovir (900 mg once daily) prophylaxis when given for the prevention of CMV disease in high risk (D+/R-) kidney allograft recipients.  The primary endpoint of the study will be the proportion of patients who develop CMV disease within the first 52 weeks (12 months) post-transplant.&lt;br&gt;&lt;br&gt;2.  To determine the comparative safety of up to 100 days valganciclovir (900 mg once daily) prophylaxis relative to up to 200 days valganciclovir (900 mg once daily) when given for the prevention of CMV disease in high risk (D+/R-) kidney allograft recipients.;Secondary Objective: 1.  Time to CMV disease&lt;br&gt;2.  Proportion of patients with CMV disease&lt;br&gt;3.  Proportion of patients with CMV viraemia&lt;br&gt;4.  Time to CMV viremia&lt;br&gt;5.  Proportion of patients experiencing biopsy proven acute rejection (BPAR)&lt;br&gt;6.  Proportion of patients with graft loss&lt;br&gt;7.  Proportion of patients surviving&lt;br&gt;8.  Proportion of patients with opportunistic infections&lt;br&gt;9.  Proportion of patients with seroconversion&lt;br&gt;10.  Time to seroconversion&lt;br&gt;11.  Proportion of patients with CMV harbouring genotypic changes associated with the development of CMV resistance to ganciclovir&lt;br&gt;13.  Proportion of patients experiencing post-transplant diabetes mellitus;Primary end point(s): The proportion of patients who develop CMV disease (defined as either CMV syndrome or tissue invasive CMV) within the first 12 months post-transplant</Primary_outcome>
    <Secondary_ID>NT18435</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2542081</Internal_Number>
    <TrialID>EUCTR2005-003233-41-GB</TrialID>
    <Last_Refreshed_on>18 April 2012</Last_Refreshed_on>
    <Public_title>An open label, dose titration study of sevelamer carbonate tablets dosed three times a day in hyperphosphatemic chronic kidney disease patients not on dialysis</Public_title>
    <Scientific_title>An open label, dose titration study of sevelamer carbonate tablets dosed three times a day in hyperphosphatemic chronic kidney disease patients not on dialysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Genzyme Europe BV</Primary_sponsor>
    <Date_registration3>20050909</Date_registration3>
    <Date_registration>09/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-003233-41                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>25/10/2005</Date_enrollement>
    <Target_size>28</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Men or women 18 years of age or older&lt;br&gt;2. If currently on phosphate binder(s), willing to stop this and enter a 2 week washout period&lt;br&gt;3. Willing to avoid any intentional changes in diet such as fasting or dieting&lt;br&gt;4. Have the following central laboratory measurement: &lt;br&gt;a) If not taking a phosphate binder, a serum phosphorus measurement = 5.5 mg/dL (1.76 mmol/L) at Screening (Visit 1).&lt;br&gt;b) If taking a phosphate binder at screening, a serum phosphorus measurement &gt; 5.5 mg/dL (1.76 mmol/L) after the two-week washout period at Visit 1a (Day 0).&lt;br&gt;5. At Screening (Visit 1), have the following central laboratory measurements:&lt;br&gt;a) 25-hydroxyvitamin D &gt;10 ng/mL. &lt;br&gt;b) iPTH = 800 pg/mL&lt;br&gt;6. Willing and able to take sevelamer carbonate alone as a phosphate binder for the duration of the study&lt;br&gt;7. Willing and able to maintain screening doses of lipid medication, 1,25 dihydroxyvitamin D, and/or cinacalcet for the duration of the study, except for safety reasons&lt;br&gt;8. Willing and able to avoid antacids and phosphate binders containing aluminum, magnesium, calcium or lanthanum for the duration of the study unless prescribed as an evening calcium supplement&lt;br&gt;9. If female and childbearing potential (pre-menopausal and not surgically sterile), willing to use an effective contraceptive method throughout study, which includes barrier methods, hormones, or IUDs&lt;br&gt;10. Expecting not to initiate dialysis for the duration of this study&lt;br&gt;11. Considered compliant with phosphate binders (if applicable)&lt;br&gt;12. Willing and able to provide informed consent&lt;br&gt;13. Has not participated in any other investigational drug studies within 30 days prior to enrollment&lt;br&gt;14. Level of understanding and willingness to cooperate with all visits and procedures as described by the study personnel&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Active bowel obstruction, dysphagia, swallowing disorder or severe gastrointestinal (GI) motility disorders&lt;br&gt;2. Active ethanol or drug abuse, excluding tobacco use&lt;br&gt;3. Use of anti-arrhythmic or anti-seizure medications for arrhythmia or seizure disorders.&lt;br&gt;4. In the opinion of the investigator, patient has poorly controlled diabetes mellitus, poorly controlled hypertension, active vasculitis, HIV infection, or any clinically significant unstable medical condition&lt;br&gt;5. Pregnant or breast-feeding&lt;br&gt;6. Evidence of active malignancy except for basal cell carcinoma of the skin&lt;br&gt;7. Unable to comply with the requirements of the study&lt;br&gt;8. Known hypersensitivity to sevelamer or any constituents of the study drug&lt;br&gt;9. Any other condition, which in the opinion of the investigator will prohibit the patient’s inclusion in the study&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic kidney disease &lt;br&gt;MedDRA version: 8.0
Level: LLT
Classification code 10009122
</Condition>
    <Intervention>&lt;br&gt;Product Name: sevelamer carbonate&lt;br&gt;Product Code: GT335-012 &lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: sevelamer&lt;br&gt;CAS Number: 845273-93-0&lt;br&gt;Current Sponsor code: GT335-012 &lt;br&gt;Other descriptive name: sevelamer carbonate&lt;br&gt;Concentration unit: mg/g milligram(s)/gram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 800-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: - Evaluate the efficacy of sevelamer carbonate tablets dosed three times a day (TID) with meals on control of serum phosphorus levels&lt;br&gt;&lt;br&gt;- Evaluate the safety and tolerability of sevelamer carbonate tablets dosed TID with meals;Primary end point(s): Change from baseline to Day 56/early termination in serum phosphorus;Secondary Objective: To evaluate sevelamer carbonate tablets dosed TID with meals on the following:&lt;br&gt;- serum calcium-phosphorus product &lt;br&gt;- serum lipid profile [total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein(LDL) cholesterol] &lt;br&gt;- percent responders [serum phosphorus between 2.7 and 4.6 mg/dL (0.86 and 1.47 mmol/L), inclusive] at Day 56/early termination&lt;br&gt;</Primary_outcome>
    <Secondary_ID>SVCARB00105</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2542128</Internal_Number>
    <TrialID>EUCTR2005-003871-19-GB</TrialID>
    <Last_Refreshed_on>18 April 2012</Last_Refreshed_on>
    <Public_title>A randomised control trial to identify the effects of cinacalcet on bone and cardiovascular health in end-stage renal disease - cinacalcet study</Public_title>
    <Scientific_title>A randomised control trial to identify the effects of cinacalcet on bone and cardiovascular health in end-stage renal disease - cinacalcet study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Salford Royal Hospital</Primary_sponsor>
    <Date_registration3>20051011</Date_registration3>
    <Date_registration>11/10/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-003871-19                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/09/2006</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;on renal replacement therapy&lt;br&gt;Corrected calcium &gt;2.2 mmol/l&lt;br&gt;Parathyroidhormone &gt; 300pg/ml&lt;br&gt;Age 18-75 yrs&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Contraindication to MR or CT scan&lt;br&gt;Atrial fibrillation&lt;br&gt;contraindication to cincalcet&lt;br&gt;moderate to severe liver disease (ALT x3 normal)&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Secondary hyperparathyroidism in renal failure</Condition>
    <Intervention>&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Cinacalcet is a new calcium sensing receptor agonist already licensed for use in secondary hyperparathyroidism. Our patients have a 20% mortality due to cardiovascular disease. We want to see if this drug affects vascular calcification, cardiac structure and bone density and therefore may help improve the mortality of our patients. We think this may occur as calcium receptors are present throughout the body. As it is too expensive to use in the general renal population we want to randomise our patients to compare this to standard treatment alone. We are going to do this in 40 patients, 20 in each cohort. We are then going to study vascular stiffness and calcification with CT and pulse wave velocity, cardiac structure with cardiac magnetic resonance scans and bone density using DEXA and CT. We will be comparing the change in these factors to serological markers of calcification. The patients will have investigations at the beginning and end of the 1 year study.;Secondary Objective: ;Primary end point(s): Percentage change in vascular calcification score as determined by the CT scan. </Primary_outcome>
    <Secondary_ID>srhths01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2542237</Internal_Number>
    <TrialID>EUCTR2005-000701-61-GB</TrialID>
    <Last_Refreshed_on>18 April 2012</Last_Refreshed_on>
    <Public_title>An open label trial of the dual specificity endothelin receptor antagonist bosentan in established scleroderma renal crisis - BIRD-1</Public_title>
    <Scientific_title>An open label trial of the dual specificity endothelin receptor antagonist bosentan in established scleroderma renal crisis - BIRD-1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>University College London</Primary_sponsor>
    <Date_registration3>20051027</Date_registration3>
    <Date_registration>27/10/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-000701-61                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>29/11/2005</Date_enrollement>
    <Target_size>15</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Historical controls&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients with scleroderma renal crisis, requiring both of &lt;br&gt;1. New onset blood pressure &gt;150/80 obtained twice over a 24 hour period&lt;br&gt;2. A documented decrease in renal function of at least 30% in the calculated glomerular filtration rate.&lt;br&gt;Patients with diffuse or limited systemic sclerosis of any disease duration&lt;br&gt;Age 18 or older&lt;br&gt;Women must be postmenopausal, surgically or naturally sterile, or use a reliable form of contraception during study treatment during and for three months after completion of the study. Hormone based contraception alone are not regarded as a reliable form of contraception.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Previous use of an endothelin receptor antagonist&lt;br&gt;Significant baseline abnormalities in liver function testing (biochemical markers more than 3 times upper limit of normal)&lt;br&gt;Patients with moderate or severe hepatic impairment i.e. Child-Pugh class B or C&lt;br&gt;Patients with body weight &lt;40kg&lt;br&gt;Patients with a systolic blood pressure &lt;85 mm Hg&lt;br&gt;Patients with conditions that prevent compliance with the protocol or failure to adhere to therapy&lt;br&gt;Patients with any other life threatening condition.&lt;br&gt;Patients with known hypersensitivity to bosentan, or any of the excipients of the formulation.&lt;br&gt;Patients receiving glibenclamide, cyclosporin A, or tacrolimus within 1 week prior to screening, or expecting to receive any of these agents during the study.&lt;br&gt;Patients who have received an investigational agent in the month preceding screening.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Scleroderma renal crisis</Condition>
    <Intervention>&lt;br&gt;Trade Name: Tracleer&lt;br&gt;Product Name: Bosentan&lt;br&gt;Product Code: N/A&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess efficacy, safety and tolerability of treating scleroderma renal crisis with bosentan.;Secondary Objective: To assess any difference in outcomes of those patients commenced on treatment within 10 days of onset of scleroderma renal crisis, compared with those treated later.;Primary end point(s): Creatinine clearance - baseline, minimum and at 6 and 12 months&lt;br&gt;24hr urinary protein - baseline, minimum and at 6 and 12 month&lt;br&gt;Serum creatinine - baseline, minimum and at 6 and 12 months&lt;br&gt;Dialysis duration&lt;br&gt;Time to achieve control of hypertension&lt;br&gt;Maintenance anti-hypertensive therapy at 6 and 12 months (number of anti-hypertensives)&lt;br&gt;</Primary_outcome>
    <Secondary_ID>BIRD-1 250705</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2542347</Internal_Number>
    <TrialID>EUCTR2005-004372-20-GB</TrialID>
    <Last_Refreshed_on>18 April 2012</Last_Refreshed_on>
    <Public_title>A randomised, prospective,open-label, multi-centre study comparing the efficacy and safety of conversion to Sirolimus in stable renal transplant recipients with a cutaneous squamous cell carcinoma. - RESCUE</Public_title>
    <Scientific_title>A randomised, prospective,open-label, multi-centre study comparing the efficacy and safety of conversion to Sirolimus in stable renal transplant recipients with a cutaneous squamous cell carcinoma. - RESCUE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Oxford Radcliffe Hospitals NHS Trust</Primary_sponsor>
    <Date_registration3>20051122</Date_registration3>
    <Date_registration>22/11/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004372-20                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>04/01/2006</Date_enrollement>
    <Target_size>180</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Kidney transplant recipient with ³1 biopsy-confirmed cutaneous SCC.&lt;br&gt;2. Age ³18 years and at least 12 months post-transplantation.&lt;br&gt;3. Stable graft function (estimated GFR ³20 ml/min) while on a maintenance regimen with a calcineurin inhibitor, azathioprine, mycophenolate mofetil or steroids for at least 12 weeks before randomization.&lt;br&gt;4. No acute rejection episode within 12 weeks prior to randomization.&lt;br&gt;5. Women of child-bearing potential must have a negative serum pregnancy test before randomization. Women of child-bearing potential must agree to use a medically acceptable method of contraception throughout the treatment period and for 12 weeks after discontinuation of study medication.&lt;br&gt;6. Total white blood cell count &gt;3,000/mm3, platelet count &gt;75,000/mm3.&lt;br&gt;7. Fasting triglycerides &lt;3.95 mmol/l, cholesterol &lt;7.8 mmol/l, with or without statins.&lt;br&gt;8. Signed and dated informed consent obtained before screening and before any tests are performed that are specific to the protocol. &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Metastatic cutaneous SCC.&lt;br&gt;2. Other malignancies (except for other skin cancers), documented after transplantation.&lt;br&gt;3. Serum creatinine at screening that has increased by &gt;30% above the last value obtained at least 12 weeks earlier.&lt;br&gt;4. Evidence of systemic infection at the time of randomization.&lt;br&gt;5. Prior or current use of Sirolimus or any of its derivatives.&lt;br&gt;6. Use of investigational agents £ 4 weeks before randomization, except for topical dermatological products as Aldara (imiquimod) or Efudix (5-fluoro-uracil).&lt;br&gt;7. Use of immunosuppressive agents at the time of randomization other than calcineurine inhibitor, azathioprine, mycophenolate mofetil or prednisone.&lt;br&gt;8. Current use of terfenadine, cisapride, astemizole, pimozide, or cimetidine; these drugs must be discontinued before randomization.&lt;br&gt;9. Positive past medical history for documented human immunodeficiency virus (HIV) infection.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Cutaneous squamous cell carcinoma after kidney transplantation</Condition>
    <Intervention>&lt;br&gt;Product Name: Sirolimus&lt;br&gt;Product Code: 1&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: sirolimus&lt;br&gt;Current Sponsor code: 1&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Product Name: Sirolimus&lt;br&gt;Product Code: 2&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: sirolimus&lt;br&gt;Current Sponsor code: 2&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;&lt;br&gt;Product Name: neoral&lt;br&gt;Product Code: 3&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: ciclosporin&lt;br&gt;Current Sponsor code: 3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25, 50, 100-&lt;br&gt;&lt;br&gt;Product Name: neoral&lt;br&gt;Product Code: 4&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: ciclosporin&lt;br&gt;Current Sponsor code: 4&lt;br&gt;Concentration unit: mg/g milligram(s)/gram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;Product Name: ciclosporin&lt;br&gt;Product Code: 3&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;INN or Proposed INN: ciclosporin&lt;br&gt;Current Sponsor code: 5&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Name: Tacrolimus&lt;br&gt;Product Code: 6&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;Current Sponsor code: 6&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Product Name: Mycophenolate Mofetil&lt;br&gt;Product Code: 7&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: mycophenolate mofetil&lt;br&gt;Current Sponsor code: 7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Product Name: Mycophenolate Mofetil&lt;br&gt;Product Code: 8&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: mycophenolate mofetil&lt;br&gt;Current Sponsor code: 8&lt;br&gt;Other descriptive name: mmf&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Product Name: azathioprine&lt;br&gt;Product Code: 9&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: azathioprine&lt;br&gt;Current Sponsor code: 9</Intervention>
    <Primary_outcome>Primary end point(s): Recurrence rate of biopsy-confirmed cutaneous SCC within 2 years after conversion to sirolimus-based maintenance therapy. &lt;br&gt;Difference between the two treatment arms for:&lt;br&gt;·	The time period to occurrence of the first biopsy-confirmed recurrent SCC lesion. A survival approach will be used in which the first recurrent lesion is the event under study.&lt;br&gt;·	The probability of having developed at least one recurrent biopsy-confirmed SCC lesion at 2 years after randomization. This is estimated from the survival curves.&lt;br&gt;·	The total amount of new biopsy-confirmed SCC lesions as an average over patients, per unit time.&lt;br&gt;·	Number of hyperkeratotic skin lesions, located on the dorsum of hands, the forearms or the head&lt;br&gt;;Main Objective: To determine the recurrence rate of biopsy-confirmed cutaneous SCC with sirolimus (SRL)-based immunosuppression over a 2 year period of follow-up.;Secondary Objective: Number of hyperkeratotic skin lesions, located on:	- the dorsum of the hands, the forearms, the head</Primary_outcome>
    <Secondary_ID>1.1(UK);98226084</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2542543</Internal_Number>
    <TrialID>EUCTR2005-004078-25-GB</TrialID>
    <Last_Refreshed_on>18 April 2012</Last_Refreshed_on>
    <Public_title>A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or Metastatic Renal Cell Carcinoma Who Have Progressed Following Cytokine-based First-line Treatment</Public_title>
    <Scientific_title>A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or Metastatic Renal Cell Carcinoma Who Have Progressed Following Cytokine-based First-line Treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>GlaxoSmithKline Research &amp; Development Limited</Primary_sponsor>
    <Date_registration3>20051223</Date_registration3>
    <Date_registration>23/12/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004078-25                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>16/03/2006</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;</Exclusion_Criteria>
    <Condition>Locally Advanced and/or metastatic renal carcinoma &lt;br&gt;MedDRA version: 8.1
Level: LLT
Classification code 10050076
</Condition>
    <Intervention>&lt;br&gt;Product Name: Pazopanib&lt;br&gt;Product Code: GW786034B&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Pazopanib&lt;br&gt;CAS Number: 635702-64&lt;br&gt;Current Sponsor code: GW786034B&lt;br&gt;Other descriptive name: Pazopanib Hydrochloride&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Product Name: Pazopanib&lt;br&gt;Product Code: GW786034B&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Pazopanib&lt;br&gt;CAS Number: 635702-64&lt;br&gt;Current Sponsor code: GW786034B&lt;br&gt;Other descriptive name: Pazopanib Hydrochloride&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: ;Secondary Objective: ;Primary end point(s): </Primary_outcome>
    <Secondary_ID>VEG105192</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2543659</Internal_Number>
    <TrialID>EUCTR2007-003955-35-FR</TrialID>
    <Last_Refreshed_on>18 April 2012</Last_Refreshed_on>
    <Public_title>A controlled open label randomised parallel group study to evaluate the efficacy, safety, and tolerability of subcutaneous MIRCERA, versus no ESA therapy, in the treatment of anaemia in CKD patients after kidney transplant.</Public_title>
    <Scientific_title>A controlled open label randomised parallel group study to evaluate the efficacy, safety, and tolerability of subcutaneous MIRCERA, versus no ESA therapy, in the treatment of anaemia in CKD patients after kidney transplant.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>F. Hoffmann-La Roche Ltd</Primary_sponsor>
    <Date_registration3>20071012</Date_registration3>
    <Date_registration>12/10/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-003955-35                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/10/2007</Date_enrollement>
    <Target_size>318</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Supportive treatment with regards to management of their anaemia&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;• Written informed consent&lt;br&gt;• Age 18 years or older&lt;br&gt;• Renal transplant =6 months and &lt;5 years prior to randomization (including re-transplant patients)&lt;br&gt;• Haemoglobin concentration between 9.5 and 10.5 g/dl at Baseline (mean of the two values obtained at week -4 and -2 during screening period).&lt;br&gt;• No ESA therapy during the 3 months prior to randomization&lt;br&gt;• Adequate iron status (serum ferritin =100 ng/mL AS WELL AS TSAT =20% OR Hypochromic red cells &lt;10% if serum transferrin or TIBC are unavailable) The mean of the two values obtained during screening period, at week -4 and -2, should be considered.&lt;br&gt;• GFR (estimated using the aMDRD equation) between 20 and 60 mL/min during screening period (at week -4 and -2).&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Requirement for haemodialysis or peritoneal dialysis therapy within 3 months prior to randomization&lt;br&gt;• Change in haemoglobin concentration = 1.5 g/dL during the screening period (week -4 and -2)&lt;br&gt;• Change in GFR &gt;30% during the screening period&lt;br&gt;Treatment for clinical acute rejection during screening period with GFR stability below 30%&lt;br&gt;• Recipients of other solid organs in addition to kidneys&lt;br&gt;• Patients planned to be switched from one immunosuppressive agent to another during study participation&lt;br&gt;• History of positive Anti-phospholipid antibodies&lt;br&gt;• Transfusion of red blood cells during the 3 months prior to randomization&lt;br&gt;• Poorly controlled hypertension as judged by the investigator, OR requiring more than 3 antihypertensive drugs (excluding diuretics)&lt;br&gt;• Significant acute or chronic bleeding, such as overt gastrointestinal bleeding, i.e. requiring therapy within 3 months prior to randomization&lt;br&gt;• Active malignant disease (except non-melanoma skin cancer).&lt;br&gt;• Haemolysis&lt;br&gt;• Haemoglobinopathies (e.g. homozygous sickle-cell disease, thalassemia of all types)&lt;br&gt;• Folic acid deficiency&lt;br&gt;• Vitamin B12 deficiency&lt;br&gt;• Platelet count &gt;500 x 10 exp9/L or &lt;100 x 10 exp9/L&lt;br&gt;• Pure red cell aplasia&lt;br&gt;• Epileptic seizure in the 6 months prior to randomization&lt;br&gt;• Congestive heart failure (NYHA Class IV)&lt;br&gt;• Myelofibrosis&lt;br&gt;• Active systemic lupus erythematosus&lt;br&gt;• Myocardial infarction or stroke, severe or unstable coronary artery disease, severe liver disease during the 3 months prior to randomization&lt;br&gt;• Uncontrolled or symptomatic secondary hyperparathyroidism&lt;br&gt;• Women with positive pregnancy tests prior to randomization&lt;br&gt;• Women of childbearing potential without effective contraception or women in lactation period&lt;br&gt;• Women of childbearing potential without effective contraception&lt;br&gt;• Participation in a clinical trial or receipt of investigational compound or treatment within the 3 months prior to randomization&lt;br&gt;• Planned elective surgery during the study period Exceptions are:&lt;br&gt;   • Cataract surgery&lt;br&gt;   • Vascular access surgery&lt;br&gt;   • Urethral stent removal&lt;br&gt;   • Nephrostomy tube replacement&lt;br&gt;   • Minor surgery not requiring hospitalisation&lt;br&gt;• Known HIV infection&lt;br&gt;• Known hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any constituent of the study medication&lt;br&gt;</Exclusion_Criteria>
    <Condition>post renal transplant anaemia patients. &lt;br&gt;MedDRA version: 9.1
Level: PT
Classification code 10058116
Term: Nephrogenic anaemia
</Condition>
    <Intervention>&lt;br&gt;Trade Name: MIRCERA®&lt;br&gt;Product Code: RO0503821/F03&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetin beta&lt;br&gt;Current Sponsor code: RO0503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: MIRCERA®&lt;br&gt;Product Code: RO0503821/F04&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetin beta&lt;br&gt;Current Sponsor code: RO0503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 75-&lt;br&gt;&lt;br&gt;Trade Name: MIRCERA®&lt;br&gt;Product Code: RO0503821/F05&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetin beta&lt;br&gt;Current Sponsor code: RO0503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Trade Name: MIRCERA®&lt;br&gt;Product Code: RO0503821/F06&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetin beta&lt;br&gt;Current Sponsor code: RO0503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 150-&lt;br&gt;&lt;br&gt;Trade Name: MIRCERA®&lt;br&gt;Product Code: RO0503821/F07&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetin beta&lt;br&gt;Current Sponsor code: RO0503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: MIRCERA®&lt;br&gt;Product Code: RO0503821/F08&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetin beta&lt;br&gt;Current Sponsor code: RO0503821/F08&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Trade Name: MIRCERA®&lt;br&gt;Product Code: RO0503821/F09&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetin beta&lt;br&gt;Current Sponsor code: RO0503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration </Intervention>
    <Primary_outcome>Main Objective: To assess the efficacy of subcutaneous administration of MIRCERA every two weeks, versus no ESA therapy, in CKD patients with anaemia after kidney transplant not currently treated with ESA.;Secondary Objective: To compare the Quality of Life in CKD patients with anaemia after kidney transplant who have received treatment with MIRCERA versus patients who do not have anaemia corrected (control).&lt;br&gt;&lt;br&gt;To investigate the effect of treatment of anaemia upon renal and other clinical outcomes (including cardiovascular events, cerebrovascular events, all cause hospitalization, need for transfusion and all cause mortality).&lt;br&gt;&lt;br&gt;To evaluate the safety and tolerability of MIRCERA administered every two weeks during the correction of anaemia in CKD patients after kidney transplant and then monthly for maintenance of Hb concentrations.&lt;br&gt;&lt;br&gt;Additional:&lt;br&gt;To explore associations between NT-proBNP levels and clinical outcomes observed during the study.;Primary end point(s): Change in haemoglobin concentration between baseline and the evaluation period (EEP haemoglobin – baseline haemoglobin), where:&lt;br&gt;• the baseline haemoglobin is defined as the mean of the two values recorded at weeks -4 and -2 during the screening period.&lt;br&gt;• the EEP haemoglobin is defined as the time adjusted average (see section 9.2.2) of the values recorded during the Efficacy Evaluation Period.</Primary_outcome>
    <Secondary_ID>MH21299</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2547618</Internal_Number>
    <TrialID>EUCTR2009-012436-32-DE</TrialID>
    <Last_Refreshed_on>18 April 2012</Last_Refreshed_on>
    <Public_title>Immunomonitoring by virus-specific T cells and evaluation as a prognostic marker for virus-induced diseases after kidney transplantation</Public_title>
    <Scientific_title>A multicenter, randomized, open-labeled study to steer immunsuppressive and antiviral therapy by measurement of virus- (CMV, ADV, HSV) specific T cells in addition to determination of trough levels of immunosuppressants in pediatric kidney allograft recipients.
An explorative study.
 - Everolimus-IVIST                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Medizinische Hochschule Hannover</Primary_sponsor>
    <Date_registration3>20090707</Date_registration3>
    <Date_registration>07/07/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-012436-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement />
    <Target_size>64</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: compared to standard treatment&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Patients who are males or non-pregnant females between the ages of 0 and 16 years.&lt;br&gt;2.	Patients after kidney transplantation. &lt;br&gt;3.	Patients who receive their first or second transplantation.&lt;br&gt;4.	Patients who are single-organ recipients.&lt;br&gt;5.	If patients are women of childbearing potential, they must have a negative serum pregnancy test with a sensitivity equal to at least 50 mIU/ml before transplantation.&lt;br&gt;6.	If patients are women of childbearing potential, they must use an effective form of contraception like birth control pill (except mini pill), hormonal depot injection, contraceptive hormonal patches, implanon, contraceptive hormone containing coil or hormon containing contraceptive vaginal ring, unless abstinence is the chosen method. In case of medical contraindication concerning the hormonal contraception, an intrauterine coil with a second contraceptive method (sondom, diaphragm, spermicide) can be used. Effective contraception must be used before transplantation, during therapy and for 6 weeks following discontinuation og immunosuppressive therapy.&lt;br&gt;7.	Patients’ guardians must be capable of understanding the purpose and risks of the study.&lt;br&gt;8.	Patients whose guardians are willing to give written informed consent and willing to participate in and comply with the study protocol. Patients above 7 years have to agree with the study in addition to the informed consent of the legally authorized representative.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: 64&lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Patients participating in other studies or participated within the last four weeks.&lt;br&gt;2.	Patients who are highly sensitized.&lt;br&gt;3.	Patients who have previously undergone two organ transplantations.&lt;br&gt;4.	Hypersensitivity to any of the components of the medication used.&lt;br&gt;5.	Patients from other centers, who are not followed in the outpatient unit of the Hannover Medical School or corresponding recruiting centers.&lt;br&gt;6.	Patients with a peak or current PRA of &gt;50%.&lt;br&gt;7.	Pregnant and/or lactating women and women of childbearing potential who are unwilling or unable to use contraception methods as specified. &lt;br&gt;8.	Patients whose guardians do not understand the requirements of the study.&lt;br&gt;9.	Patients with known positive HIV-1 or HCV test or the presence of HBsAg.&lt;br&gt;10.	Patients with malignancies or history of malignancy, despite Post Transplant Lymphoproliferative disease. &lt;br&gt;11.	Patients who are not eligible in the opinion of the physician.&lt;br&gt;12.	Significant medical history and/or treatments for cardiac, renal, neurological, hepatic, endocrine diseases, or any laboratory abnormality indicative of a significant underlying condition, that may interfere with patient’s safety, compliance, or study evaluations, according to the investigator’s opinion.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>After solid organ transplantation immunosuppressive treatment disrupts the individual balance between virus-replication and cellular immune response. This can lead to an elevated risk of severe viral complications.
1) Immunosuppressive therapy might better be steered by measuring of virus-specific T cells than by blood levels of immunosuppressants solely.
2) The antiviral treatment should be restricted to patients with high risk of viral diseases (high costs, severe side effects).
 &lt;br&gt;MedDRA version: 14.0
Level: PT
Classification code 10052279
Term: Renal and liver transplant
System Organ Class: 10042613 - Surgical and medical procedures
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sandimmun Optoral 10 mg Weichkapseln&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Other descriptive name: Cyclosporin A, Certican&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun Optoral 25 mg Weichkapseln&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Other descriptive name: Cyclosporin A, Certican&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun Optoral 50 mg Weichkapseln&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Other descriptive name: Cyclosporin A, Certican&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun Optoral 100 mg Weichkapseln&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Other descriptive name: Cyclosporin A, Certican&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun® Optoral 100 mg/ml Lösung zum Einnehmen&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Other descriptive name: Cyclosporin A, Certican&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Trade Name: Certican 0,1 mg Tabletten zur Herstellung&lt;br&gt;einer Suspension zum Einnehmen&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Other descriptive name: EVEROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,1-&lt;br&gt;&lt;br&gt;Trade Name: Certican 0,25 mg Tabletten zur Herstellung&lt;br&gt;einer Suspension zum Einnehmen&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Other descriptive name: EVEROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Prolongation of kidney function and reduced viral infections after solid organ transplantation by monitoring of virus-specific T cells followed by therapeutic intervention.;Secondary Objective: 1) Reduction of viral infections after solid organ transplantation&lt;br&gt;2) Optimization of the individual timing of antiviral therapy&lt;br&gt;3) Optimization of the immunosuppressive therapy&lt;br&gt;4) Reduction of nephrotoxic effects of CsA and antiviral agents by optimized dosing&lt;br&gt;5) Premature study discontinuations due to AEs&lt;br&gt;;Primary end point(s): GFR (Cystatin C, Filler) 2 years after transplantation.;Timepoint(s) of evaluation of this end point: Week 2, Week 6, Week 8, Week 10, Week 12, monthly months 6-14, bimonthly months 15-20, month 24</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): 1) Reduction of viral infections after solid organ transplantation&lt;br&gt;2) Optimization of the individual timing of antiviral therapy&lt;br&gt;3) Optimization of the immunosuppressive therapy&lt;br&gt;4) Reduction of nephrotoxic effects of CsA and antiviral agents by optimized dosing&lt;br&gt;5) Premature study discontinuations due to AEs&lt;br&gt;;Timepoint(s) of evaluation of this end point: Week 2, Week 6, Week 8, Week 10, Week 12, monthly months 6-14, bimonthly months 15-20, month 24</Secondary_outcome>
    <Secondary_ID>IVIST01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2548549</Internal_Number>
    <TrialID>EUCTR2006-003429-95-ES</TrialID>
    <Last_Refreshed_on>18 April 2012</Last_Refreshed_on>
    <Public_title>Treatment for renal cancer</Public_title>
    <Scientific_title>A phase II, multicenter, non randomized, clinical study of Gemcitabine, ,Capecitabine and Sorafenib (BAY 43-9006) combination for the treatment of non resectable and/or metastatic patients with renal cell carcinome.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>SOGUG, Grupo español para el estudio del cancer genitourinario</Primary_sponsor>
    <Date_registration3>20120329</Date_registration3>
    <Date_registration>29/03/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-003429-95                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/10/2006</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.  Patients who are able to give written informed consent.Patient informed constent must be obtained before any study specific procedure.&lt;br&gt;2.- Patients with non resectable and/or metastatic clear renal cell carcinoma histologically or citologically confirmed. papilares, cromófobos o histologias mixtas&lt;br&gt;3.- Patients who are not candidate to immunotherapy, according to predictive response factors or are intolerant to immunotherapy treatment.&lt;br&gt;4.- Patients with favorable or intermediate Motzer risk classification&lt;br&gt;5.- Age 18 years or older&lt;br&gt;6.- ECOG 0 to 1&lt;br&gt;7.- Measurable or evaluable disease &lt;br&gt;8.- Adequate hematopoietic (absolute neutrophil count &gt; or = 1.5 x 10(9)/L; platelet count &gt; or = 100 x 10(9) and hemoglobin &gt; or = 10 g/dl)&lt;br&gt;9.- Adequate hepatic and renal functions defined as: bilirubin &lt; 1.5 x ULN; GOT and GPT &lt; 2.5x ULN or &lt; 5.0 x ULN for subjects with hepatic metastases; amilase and lipase &lt; 1.5 ULN; Creatinine &lt; 1.5 x ULN; PT o INR and PTT &lt; 1.5 x ULN&lt;br&gt;10.- Patient must use an adequate contraception method while they are participating in the study and up to 4 weeks in women and during 3 moths in men after treatment discontinuation.&lt;br&gt;11.-Patients may have received radiotherapy. The lesion treated should not be the unique target lesion.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 30&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 10&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.- Papilar carcinoma, Bellini carcinoma, medular carcinoma and other less frequent renal cell carcinoma histologies.&lt;br&gt;Pacientes con subtipos poco comunes de CCR como tumor de células papilares puro, carcinoma de Bellini, carcinoma medular o tumores oncocíticos cromófobos y variantes sarcomatoides quedarán excluidos del estudio.&lt;br&gt;3.- Patients that due to their clinical characteristic it is expected to have a potential benefit with immunotherapy treatment.&lt;br&gt;4.- Patients with high risk Motzer classification2.- Concomitant treatment with other chemotherapy or immunotherapy&lt;br&gt;5.- No previous malignancy except cervical carcinoma in situ, adequately treated basal cell carcinoma,superficial bladder tumors, or other malignancies curatively treated &gt; 5 years before study entry.&lt;br&gt;6.- Previous history of congestive heart failure, active coronary disease or cardiac ischemia (Acute myocardial infartion within 6 previous months) or serious cardiac arrhythmias which require treatment.&lt;br&gt;7.- No history of HIV infection, cronic hepatitis B or C  or any active clinically serious infections requiring systemic therapy.&lt;br&gt;8.- No pregnacy or lactanting females7.- Patients with seizures who require anticonvulsivant treatment.&lt;br&gt;9.- Clinically suspected or history of leptomeningeal involvement.&lt;br&gt;10.- Uncontrolled hypertension defined as systolic blood pressure &gt; 150 mmHg ordiastolic pressure &gt; 90 mmHg, despite optimal medical management.&lt;br&gt;</Exclusion_Criteria>
    <Condition>NON RESECTABLE AND / OR METASTATIC RENAL CELL CARCINOMA &lt;br&gt;MedDRA version: 14.1
Level: LLT
Classification code 10038484
Term: Renal neoplasia
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
;Therapeutic area: Diseases [C] - Cancer [C04]</Condition>
    <Intervention>&lt;br&gt;Product Name: SORAFENIB&lt;br&gt;Product Code: BAY 43-9006&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: sorafenib&lt;br&gt;Current Sponsor code: bay 43-9006&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: XELODA 150 mg&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: CAPECITABINE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 150-&lt;br&gt;&lt;br&gt;Trade Name: GEMZAR 1GRAMO&lt;br&gt;Pharmaceutical Form: Powder for infusion&lt;br&gt;INN or Proposed INN: gemcitabine&lt;br&gt;CAS Number: 95058814&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;Trade Name: XELODA 500 mg&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: CAPECITABINE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Trade Name: GEMZAR 200mg&lt;br&gt;Pharmaceutical Form: Powder for infusion&lt;br&gt;INN or Proposed INN: gemcitabine&lt;br&gt;CAS Number: 95058814&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Progression free survival  defined as the time relapsed between first treatment administration and progressive disease (clinical o radiological) or death (any cause).;Secondary Objective: To evaluate toxicity profile &lt;br&gt;To evaluate response rate (CR and PR) and tumor growth control (CR + PR + SD)  Duration of response &lt;br&gt;Overall survival&lt;br&gt;Time to progression defined as the time elapse between first treatment  administration and progressive disease.;Primary end point(s): Progression free survival defined as the time elapsed between first treatment administration and progressive disease (clinical or radiological) or death (any cause).;Timepoint(s) of evaluation of this end point: End of the study</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Safety profile, Objective response index (CR/PR) and control of tumor growth (CR/PR/SD), Duration of the response, Overall survival, Time to progression;Timepoint(s) of evaluation of this end point: End of the study</Secondary_outcome>
    <Secondary_ID>SOGUG-02-06</Secondary_ID>
    <Source_Support>SOGUG, Grupo español para el estudio del cancer genitourinario</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2548764</Internal_Number>
    <TrialID>EUCTR2011-001995-20-IT</TrialID>
    <Last_Refreshed_on>18 April 2012</Last_Refreshed_on>
    <Public_title>evaluation of the compliance to immunosoppressive therapy in transplatation recipient.</Public_title>
    <Scientific_title>A pilot study on educational aproach to improve compliance to medical precriptions in transplantation recipients. - Single                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>AZIENDA OSPEDALIERA DI PADOVA</Primary_sponsor>
    <Date_registration3>20120410</Date_registration3>
    <Date_registration>10/04/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-001995-20                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>14/03/2011</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 4&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Aging more than 18  2.Liver or renal transplantation from at least 8 months  3. immunosuppressive regimen with tacrolimus bid (Prograf) which hasn`t been changed in the last 2 months before the enrolment and without counterindications for switch to monotherapy (Advagraf).  4. Clinically stable patients   5. Childbearing potential female patients with negative serum pregnancy test who agree in using medical acceptable contraception for the whole duration of the study.  6. Patients who are able to give their consent  7. AST and ALT &lt; 2 UNV (for liver transpantation)  8. Tacrolimus blood levels between 3-10 ng/ml and stable Prograf dosage in the 4-week period berfore enrolment.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: 0&lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 304&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 104&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Acute rejection episodes in the 6-month period before enrolment.  2. Known allergy or hypersensibility to one or more investigational drugs components.  3. Any substances abuse, psychiatric disorders or any condition that, in investigator`s opinion, might affect the comunication with investigators or might affect the compliance to the study.  4. Newly diagnosed neoplasy after transplantation (excepted skin neoplasy)-  5. Patient participating in other clinical trial or who ended another clinical trial in the last 3 monts.  6. patients who took any other experimental drug in the month before the enrolment.  7. HIV positive patients  8. pregnant women  9. creatinine&lt;30ml/min calculated by the Cockcroft and Gault`s formula (renal transpantation)  10. Increase of creatinine level over 20% in the last 6 months before enrolment (renal transplantation)  11. ASL/ALT &gt; 2 UNV and/or total bilirubine &gt;= 2 UNV (liver transplantation)&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients who underwent liver or renal transplantation;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]</Condition>
    <Intervention>&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Prolonged-release tablet&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The main objecive is splitted in evaluated by the connection between two parts: - Efficacy of the switch from double to single daily administration of the immunosuppressant drug (from Progrf to Advagraf)to reduce the non compliant patient's population. - Efficacy of Self Learning anc Patient's education to reduce the non compliant patient's population;Secondary Objective: The secondary objective is the evaluation of the patient's perception, measured by objective and subjective paramethers, of his quality of life.;Primary end point(s): The primary endpoint is the compliance to medical prescriptions, defined as the complete cocperation of the patient in the therapy, attend to the scheduled visits, perform blood exams and comply with the healthy way of life as indicated by the investigator.;Timepoint(s) of evaluation of this end point: 12 months</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): NA;Timepoint(s) of evaluation of this end point: NA</Secondary_outcome>
    <Secondary_ID>2205p</Secondary_ID>
    <Source_Support>Azienda Ospedaliera di Padova</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2551996</Internal_Number>
    <TrialID>EUCTR2005-000889-39-GB</TrialID>
    <Last_Refreshed_on>24 April 2012</Last_Refreshed_on>
    <Public_title>A Prospective, Randomized Controlled Study to Compare the Effects of a Fibrin Sealant(FS2) Versus Manual Compression on Haemostatic Efficacy During Vascular Surgical Procedures Utilising Polytetrafluorethylene Graft Material on an End-toSide Femoral or Upper Extremity Vascular Access Arterial Anastomosis. - FS2 in Vascular Surgery</Public_title>
    <Scientific_title>A Prospective, Randomized Controlled Study to Compare the Effects of a Fibrin Sealant(FS2) Versus Manual Compression on Haemostatic Efficacy During Vascular Surgical Procedures Utilising Polytetrafluorethylene Graft Material on an End-toSide Femoral or Upper Extremity Vascular Access Arterial Anastomosis. - FS2 in Vascular Surgery                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>OMRIX biopharmaceuticals Ltd</Primary_sponsor>
    <Date_registration3>20050504</Date_registration3>
    <Date_registration>04/05/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-000889-39                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>28/06/2005</Date_enrollement>
    <Target_size>150</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Manual compression&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Male and female patients, 18 years or older, requiring elective, primary or repeat vascular procedures with at least one end-to-side femoral or upper extremity vascular access arterial anastomosis (e.g.femoral-femoral, femoral-popliteal, femoral-tibial, ilio-femoral, aorto-bifemoral, abdominal aortic aneurysm, upper extremity vascular access for dialysis) using PTFE grafts, polypropylene sutures and 1:1 needle-to-thread ratio. &lt;br&gt;2. Following initial arterial clamp release, the study surgeon determines that adjunctive measures are needed to obtain haemostasis at the study anastomosis.&lt;br&gt;3. Patients must be willing to and capable of participating in the study, and provide written informed consent.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients are excluded due to the following criteria as these may influence obtaining haemostasis: re-vascularisation using autologous conduits (e.g. saphenous vein) or prosthetic material other than PTFE; Patients with autoimmune immunodeficiency diseases (including known HIV);  Patients who are  undergoing emergency surgery will be excluded as there would be insufficient time to obtain consent; Patients with any intra-operative findings may preclude conduct of the study procedure; In  order to protect vulnerable groups, patients who are current drug or alcohol abusers will be excluded;  Patients with known intolerance to heparin, blood products or to one of the components of the study products will be excluded to minimise the risk of allergic reaction;  Patients who are unwilling to receive blood products are also excluded as FS2 is produced from human plasma; Patients who have participated in another investigational drug or device research study within 30 days of enrollment will also be excluded;  As the safety of the product in human pregnancy has not been established, pregnant patients will be excluded from the study.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients undergoing vascular surgical procedures will be included in this study. This will include patients with peripheral vascular disease and also patients with renal disease who require vascular access for dialysis.</Condition>
    <Intervention>&lt;br&gt;Product Name: Fibrin Sealant 2 (FS2)&lt;br&gt;Product Code: FS2&lt;br&gt;Pharmaceutical Form: Sealant&lt;br&gt;INN or Proposed INN: Human Thrombin&lt;br&gt;CAS Number: 9002-4-4&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 800-1200&lt;br&gt;&lt;br&gt;Product Name: Fibrin Sealant 2 (FS2)&lt;br&gt;Product Code: FS2&lt;br&gt;Pharmaceutical Form: Sealant&lt;br&gt;INN or Proposed INN: Calcium Chloride&lt;br&gt;CAS Number: 10043-52-4&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 5.6-6.2&lt;br&gt;&lt;br&gt;Product Name: Fibrin Sealant 2 (FS2)&lt;br&gt;Product Code: FS2&lt;br&gt;Pharmaceutical Form: Sealant&lt;br&gt;INN or Proposed INN: Human Fibrinogen&lt;br&gt;CAS Number: 9001-32-5&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 55-85&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of this study is to evaluate whether the fibrin sealant (FS2) reduces time to haemostasis during vascular surgical procedures. Success rate of the FS2 group will be compared to success rate of the Manual Compression group. Success will be defined as the absence of bleeding at 4 minutes following randomisation.;Secondary Objective: The secondary objectives of this study are to compare the two treatment groups with respect to the following parameters:&lt;br&gt;Absence of bleeding at study anastomotic site 7 and 10 minutes following randomisation ; intra-operative blood loss from study anastomotic site following clamp removal; incidence of treatment failure; incidence of potential bleeding related complications up to Five Week Follow-Up; Adverse events up to Five Week Follow-Up.;Primary end point(s): bleeding at 4 minutes.</Primary_outcome>
    <Secondary_ID>400-05-001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2552012</Internal_Number>
    <TrialID>EUCTR2005-000817-37-GB</TrialID>
    <Last_Refreshed_on>24 April 2012</Last_Refreshed_on>
    <Public_title>A Study On The Efficacy Of Delta-9-Tetrahydrocannabinol (Dronabinol) In Renal Itch</Public_title>
    <Scientific_title>A Study On The Efficacy Of Delta-9-Tetrahydrocannabinol (Dronabinol) In Renal Itch                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Cardiff University</Primary_sponsor>
    <Date_registration3>20050527</Date_registration3>
    <Date_registration>27/05/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-000817-37                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>15/06/2005</Date_enrollement>
    <Target_size>24</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients with chronic renal failure treated with continuous ambulatory peritoneal dialysis (CAPD) with a history of pruritis for more than 8 weeks.&lt;br&gt;&lt;br&gt;Patients with haemoglobin level =11g/dl.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients with concomitant dermatological disease or another metabolic cause of itch.&lt;br&gt;Patients with history of poor concordance&lt;br&gt;Patients who are pregnant, planning to conceive or refuse to take adequate precaution to avoid pregnancy&lt;br&gt;History of psychotic illnesses, schizophrenia, and any other mental illnesses. Mild depression will not be exclude participation but severe depression requiring electroconvulsive therapy (ECT) or inpatient treatment will be excluded&lt;br&gt;Patients who refuse to abstain from driving during the study&lt;br&gt;Those with a history of allergy to delta-9-THC or its related compounds or constituents of dronabinol&lt;br&gt;Patients with unstable cardiac diseases such as uncontrolled hypertension, acute coronary syndrome and uncontrolled arrythmia as delta-9-THC may cause hypo- or hypertension and tachycardia. However, patients with stable cardiac conditions will not be excluded. &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Itch associated with chronic renal failure</Condition>
    <Intervention>&lt;br&gt;Trade Name: Marinol®&lt;br&gt;Product Name: Dronabinol&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;CAS Number: 1972-08-3&lt;br&gt;Other descriptive name: Delta-9-tetrahydrocannabinol&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2.5-&lt;br&gt;Pharmaceutical form of the placebo: Capsule*&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: : To assess the efficacy of oral delta-9-tetrahydrocannabinol (delta-9-THC) in patients with itch associated with chronic renal failure;Secondary Objective: To establish the pharmacokinetics of delta-9-THC in patients with chronic renal failure.;Primary end point(s): To demonstrate whether delta-9-THC is effective in treatment of renal itch when compared with placebo using a two-grouped t-test (statistical significance level p=0.05)</Primary_outcome>
    <Secondary_ID>SPON CU 081 Version 1 November 2004</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2552156</Internal_Number>
    <TrialID>EUCTR2005-001518-42-ES</TrialID>
    <Last_Refreshed_on>24 April 2012</Last_Refreshed_on>
    <Public_title>A six-month, prospective, multicenter, open label, parallel, randomized study of the safety, tolerability and efficacy of myfortic® (ERL080) with Simulect®, corticosteroids and two different levels of tacrolimus in de novo renal transplant recipients
</Public_title>
    <Scientific_title>A six-month, prospective, multicenter, open label, parallel, randomized study of the safety, tolerability and efficacy of myfortic® (ERL080) with Simulect®, corticosteroids and two different levels of tacrolimus in de novo renal transplant recipients
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Novartis Farmaceútica S.A</Primary_sponsor>
    <Date_registration3>20050629</Date_registration3>
    <Date_registration>29/06/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001518-42                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>15/09/2005</Date_enrollement>
    <Target_size>288</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.Male or female patients between 18 and 70 years of age&lt;br&gt;2.Male or female patients who are primary cadaveric, living unrelated or non- Human leukocyte antigen (HLA) identical living related donor renal transplant recipients&lt;br&gt;3.The renal cold ischemic time (CIT) must be &lt;30 hours&lt;br&gt;4.The age of the donor must be between 10 and 65 years &lt;br&gt;5.The patient has given written informed consent to participate in the study&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients meeting any of the following criteria at baseline will be excluded from study participation.&lt;br&gt;1.Patients who have previously received an organ transplant&lt;br&gt;2.Patients who are recipients of a multiple organ transplants&lt;br&gt;3.Recipients of non heart-beating donor organs&lt;br&gt;4.ABO incompatibility against the donor&lt;br&gt;5.Patients with panel reactive antibodies (PRA) of &gt;20% at most recent assessment prior to transplantation  &lt;br&gt;6.Patients who are known to have a positive hepatitis C serology, who are human immunodeficiency virus (HIV) or Hepatitis B surface antigen positive. Laboratory results obtained within 6 months prior to first dose of myfortic® are acceptable. Recipients of organs from donors who test positive for Hepatitis B surface antigen or Hepatitis C are excluded&lt;br&gt;7.Patients with thrombocytopenia (&lt; 75,000/mm3), with an absolute neutrophil count of &lt;1,500/mm3, and/or leukocytopenia (&lt; 2,500/mm3), or hemoglobin &lt; 6g/dL prior to randomization. &lt;br&gt;8.Presence of any severe allergy requiring acute (within 4 weeks of baseline) or chronic treatment, or history of hypersensitivity to any of the study drugs or to drugs with similar chemical structures&lt;br&gt;9.Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer&lt;br&gt;10.Existence of any surgical or medical condition, other than the current transplant, which in the opinion of the investigator might significantly alter the absorption, distribution, metabolism or excretion of study medication, and/or presence of severe diarrhea, active peptic ulcer disease, or uncontrolled diabetes mellitus&lt;br&gt;11.Patients with clinically significant systemic infection requiring continued therapy&lt;br&gt;12.Patients with a history of malignancy within the last five years, except for successfully excised squamous or basal cell carcinoma of the skin&lt;br&gt;13.Abnormal physical or laboratory findings of clinical significance within 2 weeks prior to first dose of myfortic® which at investigators discretion would interfere with the objectives of the study &lt;br&gt;14.Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive Human Chorionic Gonadotropin (hCG) laboratory test &lt;br&gt;15.Women of child-bearing potential (WOCBP), 16.	Patients with symptoms of significant somatic or mental illness. Unresolved history of drug or alcohol abuse&lt;br&gt;17.Inability to cooperate or communicate with the investigator or unable to complete self administered GI symptoms questionnaires&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>de novo renal transplant &lt;br&gt;Classification code 10023438
</Condition>
    <Intervention>&lt;br&gt;Trade Name: myfortic&lt;br&gt;Product Name: myfortic&lt;br&gt;Product Code: ERL080A&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: micofenolato de sodio&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 1440-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To demonstrate superior renal function at 6 months post-transplant in de novo renal transplant recipients who receive myfortic® and reduced tacrolimus levels (Group A) compared to those who receive myfortic® and reference tacrolimus levels (Group B) as measured by calculated glomerular filtration rate (GFR, Nankivell). Patients will also receive Simulect® (basiliximab) and corticosteroids as concomitant immunosuppressant therapy.  ;Secondary Objective: The secondary objectives are to compare the efficacy, safety, and tolerability of the combination of myfortic®, Simulect®, and corticosteroids with reduced levels of tacrolimus (Group A) versus reference levels of tacrolimus (Group B).&lt;br&gt;;Primary end point(s): Primary endpoint is renal function at 6 months measured by calculated glomerular filtration rate (GFR). </Primary_outcome>
    <Secondary_ID>CERL080A2409</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2552185</Internal_Number>
    <TrialID>EUCTR2005-003182-16-GB</TrialID>
    <Last_Refreshed_on>24 April 2012</Last_Refreshed_on>
    <Public_title>Blood Pressure Optimisation In Patients With Polycystic Kidney Disease And Hypertension By Rotation Through The Main Therapeutic Classes Of Antihypertensive Drugs.</Public_title>
    <Scientific_title>Blood Pressure Optimisation In Patients With Polycystic Kidney Disease And Hypertension By Rotation Through The Main Therapeutic Classes Of Antihypertensive Drugs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Addenbrooke's Hospital Trust</Primary_sponsor>
    <Date_registration3>20050729</Date_registration3>
    <Date_registration>29/07/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-003182-16                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/08/2005</Date_enrollement>
    <Target_size>42</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: yes&lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	patients who have given informed consent&lt;br&gt;•	male or female patients aged 18-65 years inclusive&lt;br&gt;•	normal renal function: defined as a creatinine clearance (ml/min/1.73m2) of &gt;=85 in men and &gt;=75 in women&lt;br&gt;•	either treated hypertensives on antihypertensive medication (no more than 2 agents) or untreated patients in whom initiation of treatment will follow the 1999 British Hypertension Society guidelines19 i.e. a seated BP &gt;160/100, OR &gt;140/90 with either end-organ changes or 10-year CHD risk of  &gt;15%&lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) &lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	pregnancy, lactation or child bearing potential and not using reliable contraception or who intend to become pregnant within the next year.&lt;br&gt;•	history of angina, unstable angina, myocardial infarction, heart failure or stroke within the previous six months&lt;br&gt;•	atrial fibrillation or other arrhythmias requiring medication&lt;br&gt;•	accelerated phase hypertension, untreated DBP &gt;120 or secondary hypertension (other than PKD)&lt;br&gt;•	clinically significant abnormal haematological or biochemical findings not attributed to underlying illness or therapy, or any illness such that in the investigator’s opinion the health of the patient would be prejudiced by inclusion in the study&lt;br&gt;•	serious adverse events, contraindications or history of allergy to any of the five treatments in the study&lt;br&gt;•	history of alcoholism, drug abuse or other emotional or intellectual problems likely to invalidate informed consent or limit the ability of the subject to comply with the protocol requirements.&lt;br&gt;•	donation or receipt of blood within one month before, during or for one month after study completion.&lt;br&gt;•	participation in any other studies involving investigational or marketed products within three months prior to this study or concomitantly with this study.&lt;br&gt;•	A BMI of &gt; 30&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Polycystic kidney disease</Condition>
    <Intervention>&lt;br&gt;Trade Name: CARDURA&lt;br&gt;Product Name: DOXAZOSIN&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Pharmaceutical form of the placebo: Capsule, hard&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: MONOCOR&lt;br&gt;Product Name: BISOPROLOL&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Pharmaceutical form of the placebo: Capsule, hard&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: ZESTRIL&lt;br&gt;Product Name: LISINOPRIL&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Pharmaceutical form of the placebo: Capsule, hard&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: ISTIN&lt;br&gt;Product Name: AMLODIPINE&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Pharmaceutical form of the placebo: Capsule, hard&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: AMIAS&lt;br&gt;Product Name: CANDESARTAN&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Pharmaceutical form of the placebo: Capsule, hard&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: APRINOX&lt;br&gt;Product Name: BENDROFLUMETHIAZIDE&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Pharmaceutical form of the placebo: Capsule, hard&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To identify best antihypertensive agent to control blood pressure;Secondary Objective: ;Primary end point(s): FALL IN SYSTOLIC AND DIASTOLIC BLOOD PRESSURE</Primary_outcome>
    <Secondary_ID>A07329</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2552204</Internal_Number>
    <TrialID>EUCTR2005-002982-35-GB</TrialID>
    <Last_Refreshed_on>24 April 2012</Last_Refreshed_on>
    <Public_title>The effect of Niaspan (slow release nicotinic acid) on plasma phosphate, and renal phosphate handling in patents with severe chronic kidney disease - Niaspan in CKD</Public_title>
    <Scientific_title>The effect of Niaspan (slow release nicotinic acid) on plasma phosphate, and renal phosphate handling in patents with severe chronic kidney disease - Niaspan in CKD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Barts and The London NHS Trust</Primary_sponsor>
    <Date_registration3>20050809</Date_registration3>
    <Date_registration>09/08/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-002982-35                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>21/11/2005</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients with CKD stages 4-5&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients unable to give informed consent.&lt;br&gt;Patients under the age of 18 years&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic renal failure (CKD stages 4 &amp;%)</Condition>
    <Intervention>&lt;br&gt;Trade Name: Niaspan&lt;br&gt;Product Name: Niaspan&lt;br&gt;Product Code: Niaspan&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;Trade Name: Phosex&lt;br&gt;Product Name: Phosex&lt;br&gt;Product Code: PL 14994/0001&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare Niaspan with Phosex at normalising renal tubular handling of phosphate.;Secondary Objective: To compare Niaspan with Phosex at reducing serum phosphorus and PTH concentrations.&lt;br&gt;To compare Niaspan with Phosex at increasing HDL:LDL ratio;Primary end point(s): Evaluation of TmPO4/GFR</Primary_outcome>
    <Secondary_ID>Niaspan in CKD</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2552262</Internal_Number>
    <TrialID>EUCTR2005-002212-13-GB</TrialID>
    <Last_Refreshed_on>24 April 2012</Last_Refreshed_on>
    <Public_title>A Phase II Study of GW786034 Using a Randomized Discontinuation Design in Subjects with Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma</Public_title>
    <Scientific_title>A Phase II Study of GW786034 Using a Randomized Discontinuation Design in Subjects with Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>GlaxoSmithKline Research &amp; Development Ltd</Primary_sponsor>
    <Date_registration3>20050815</Date_registration3>
    <Date_registration>15/08/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-002212-13                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>08/08/2006</Date_enrollement>
    <Target_size>230</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: yes&lt;br&gt;Other trial design description: randomised discontinuation design (open-label then double-blinded)&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: yes&lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Histologically or cytologically confirmed diagnosis of renal cell carcinoma of&lt;br&gt;predominantly clear-cell histology (excluding chromophobe, papillary, collecting&lt;br&gt;duct, and undifferentiated tumors) which is metastatic or locally recurrent.&lt;br&gt;- Either no prior systemic therapy or failed only 1 prior cytokine-based or&lt;br&gt;bevacizumab-based therapy (i.e. Interleukin-2 (IL-2), Interferon-alpha, or a&lt;br&gt;combination regimen of IL-2 and Interferon-alpha, or bevacizumab alone or in&lt;br&gt;combination with cytokine therapy). If subjects have received prior therapy, they&lt;br&gt;must have documented evidence by RECIST criteria of disease progression based on&lt;br&gt;radiographic imaging.&lt;br&gt;- Evidence of documented measurable disease by RECIST criteria (lesions that can be accurately measured in at least one dimension with longest diameter = 20 mm using conventional techniques or = 10 mm with spiral CT scan).&lt;br&gt;- Male or female at least 21 years of age.&lt;br&gt;A woman is eligible to enter and participate in the study if she is of:&lt;br&gt;a. Non-childbearing potential (i.e., physiologically incapable of becoming&lt;br&gt;pregnant), including any female who has had a hysterectomy, a bilateral ophorectomy (ovariectomy), a bilateral tubal ligation or is post-menopausal.  &lt;br&gt;b. Childbearing potential, has a negative serum pregnancy test at Screening Period&lt;br&gt;and Day1, and agrees to use adequate contraception (intrauterine device (IUD) with a documented failure rate of less than 1% per year, Vasectomized partner who is sterile prior to the female subject’s entry and is the sole sexual partner for that female,  Complete abstinence from sexual intercourse for 14 days before exposure to&lt;br&gt;investigation product, through the clinical trial, and for at least 21 days after the&lt;br&gt;last dose of investigational product, Double-barrier contraception (condom with spermicidal jelly, foam suppository, or film; diaphragm with spermicide; or male condom and diaphragm with spermicide).&lt;br&gt;A man with a female partner of childbearing potential, is eligible to enter and&lt;br&gt;participate in the study if he has either had a prior vasectomy or agrees to use&lt;br&gt;effective contraception during the study.&lt;br&gt;- ECOG Performance Status (PS) of 0 or 1.&lt;br&gt;- Adequate bone marrow function: ANC = 1,000/mm3 (1 X 109/L), Platelet count = 75,000/mm3 (75 X 109/L).&lt;br&gt;- Adequate hepatic function: total bilirubin = 1.5 X ULN, AST (SGOT) = 3.0 X ULN,&lt;br&gt;ALT (SGPT) = 3.0 X ULN.&lt;br&gt;- Adequate renal function as determined by the following tests: Calculated creatinine clearance = 40 mL/min as measured by Cockcroft and Gault Formula for estimated Creatinine Clearance (CLcr) and Urine protein &lt; 1.0 grams/24-hrs.&lt;br&gt;- PT/INR/PTT within 1.2 X ULN.&lt;br&gt;- Able to swallow and retain oral medications.&lt;br&gt;- before patient registration, written informed consent given .&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;A subject will not be eligible for inclusion in this study if any of the following criteria&lt;br&gt;apply:&lt;br&gt;1. Received prior non-cytokine or non-bevacizumab therapies (e.g., SU011248, PTK-&lt;br&gt;787, thalidomide, gefitinib, sorafenib (BAY 43-9006), or vaccines).&lt;br&gt;2. Received chemotherapy for renal cell carcinoma.&lt;br&gt;3. Has had any major surgery, radiotherapy, or immunotherapy within the last 28 days and/or not recovered from prior therapy. &lt;br&gt;4. History of hypercalcemia (corrected serum calcium above institution normal) within&lt;br&gt;two months of start of therapy.&lt;br&gt;5. Women who are pregnant or lactating.&lt;br&gt;6. Poorly controlled hypertension (SBP of 140 mmHg or higher, or DBP of 90 mmHg&lt;br&gt;or higher). Initiation or adjustment of BP medication is permitted prior to study&lt;br&gt;entry provided that subject has an averaged of three BP readings at a visit less than&lt;br&gt;140/90 mmHg. These readings need to be collected prior to enrolment.&lt;br&gt;7. QTc prolongation defined as a QTc interval greater than or equal to 480 msecs or&lt;br&gt;other significant ECG abnormalities.&lt;br&gt;8. Has Class II, III or IV heart failure as defined by the NYHA functional classification&lt;br&gt;system. A subject who has a history of Class II heart failure and is asymptomatic on&lt;br&gt;treatment may be considered eligible.&lt;br&gt;9. Any history of cerebrovascular accident [CVA].&lt;br&gt;10. History of myocardial infarction, admission for unstable angina, cardiac angioplasty or stenting within the last 12 weeks.&lt;br&gt;11. History of venous thrombosis in last 12 weeks.&lt;br&gt;12. Current use of therapeutic warfarin. Low molecular weight heparin and prophylactic low-dose warfarin are permitted. PT/PTT must meet the inclusion criteria.&lt;br&gt;13. Use of antiplatelet agents other than aspirin (= 325 mg/day).&lt;br&gt;14. Leptomeningeal or brain metastases.&lt;br&gt;15. Prior history of malignancies other than renal cell carcinoma (except for basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or the subject has been free of any other malignacies for &gt; 5 years).&lt;br&gt;16. Any serious and/or unstable pre-existing medical, psychiatric, or other condition&lt;br&gt;(including lab abnormalities) that could interfere with subject safety or obtaining&lt;br&gt;informed consent.&lt;br&gt;17. History of malabsorption syndrome, disease significantly affecting gastrointestinal&lt;br&gt;function or major resection of the stomach or small bowel that could affect&lt;br&gt;absorption, distribution, metabolism or excretion of study drugs. Has any unresolved&lt;br&gt;bowel obstruction or diarrhea.&lt;br&gt;18. Psychological, familial, sociological, or geographical conditions that do not permit&lt;br&gt;compliance with the protocol.&lt;br&gt;19. Is on any specifically prohibited medication or requires any of these medications&lt;br&gt;during treatment with GW786034.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma</Condition>
    <Intervention>&lt;br&gt;Product Name: GW786034&lt;br&gt;Product Code: GW786034&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Current Sponsor code: GW786034B (or SB-710468-A)&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: -100&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Product Name: GW786034&lt;br&gt;Product Code: GW786034&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Current Sponsor code: GW786034B (or SB-710468-A)&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: -500&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The principal objective of the trial is to compare the progressive disease rate at 16 weeks post-randomization of subjects receiving GW786034 or placebo and to determine the stable disease rate at 12 weeks in the Lead-in phase.&lt;br&gt;;Secondary Objective: - To Assess progression-free survival (PFS) and duration of response in subjects receiving GW786034.&lt;br&gt;- To Determine the objective response rate (complete and partial responses) at 12 weeks&lt;br&gt;in the Lead-in phase.&lt;br&gt;- To Evaluate the safety and tolerability of GW786034 in this subject population.&lt;br&gt;- To characterize the population pharmacokinetics (PK) parameters of GW786034&lt;br&gt;when administered daily in this population including an assessment of significant&lt;br&gt;covariates and to assess the potential relationships between the pharmacokinetics of GW786034 and relevant safety and efficacy endpoints.;Primary end point(s): • Progressive disease rate, defined as the percentage of all randomized subjects with progressive disease 16 weeks after randomization.&lt;br&gt;• Stable disease rate in the Lead-in Phase, defined as the number of subjects&lt;br&gt;having stable disease (SD) after 12 weeks of therapy, divided by the total number of&lt;br&gt;subjects enrolled. This endpoint will be assessed at the interim analysis.</Primary_outcome>
    <Secondary_ID>VEG102616</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2554034</Internal_Number>
    <TrialID>EUCTR2008-006840-20-ES</TrialID>
    <Last_Refreshed_on>24 April 2012</Last_Refreshed_on>
    <Public_title>Planned Transition to Sirolimus-based Therapy Versus Continued Tacrolimus-based
Therapy in Renal Allograft Recipients.
Transición programada a un tratamiento basado en sirolimus frente a la continuación de un tratamiento basado en tacrolimus en receptores de un alotrasplante renal</Public_title>
    <Scientific_title>Planned Transition to Sirolimus-based Therapy Versus Continued Tacrolimus-based
Therapy in Renal Allograft Recipients.
Transición programada a un tratamiento basado en sirolimus frente a la continuación de un tratamiento basado en tacrolimus en receptores de un alotrasplante renal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Wyeth Pharmaceuticals Inc</Primary_sponsor>
    <Date_registration3>20090922</Date_registration3>
    <Date_registration>22/09/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-006840-20                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/11/2009</Date_enrollement>
    <Target_size>300</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Critarios de inclusión para la selección&lt;br&gt;1.	Hombres o mujeres de como mínimo 18 años. &lt;br&gt;2.	Van a recibir o han recibido, a lo sumo 14 días antes del trasplante y no más de 2 días después del trasplante, un primer aloinjerto renal de donante vivo o muerto.&lt;br&gt;3.	Todas las mujeres y todos los hombres que sean biológicamente capaces de tener hijos deberán mostrar su conformidad y comprometerse en utilizar un método anticonceptivo fiable a lo largo del estudio y de los 3 meses siguientes a la última dosis del agente del estudio. Se considera que un sujeto es biológicamente capaz de tener hijos aunque él o ella estén utilizando anticonceptivos y su pareja sexual sea estéril o utilice anticonceptivos.&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;Para poder ser aleatorizados, los sujetos deberán cumplir todas las condiciones o características siguientes:&lt;br&gt;1.	Noventa (90) a 150 días postrasplante.&lt;br&gt;2.	Tratamiento con TAC y un inhibidor de IMPDH iniciado &amp;#8804; 30 días después del trasplante y haber permanecido con ambos medicamentos durante los 30 días previos a la aleatorización.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Se excluirán del estudio los sujetos con cualquiera de los siguientes procesos o características:&lt;br&gt;1.	Receptor de un trasplante multiorgánico (es decir, trasplante previo o concomitante de cualquier otro órgano además del trasplante renal).&lt;br&gt;2.	Receptor de un trasplante renal ?en bloc? de adulto o niño.&lt;br&gt;3.	Receptor que ha requerido o va a requerir protocolos de hiposensibilización.&lt;br&gt;4.	Antecedentes conocidos de glomerulosclerosis segmentaria focal (GESF) o glomerulonefritis membranoproliferativa (GNMP).&lt;br&gt;5.	Evidencia de infección sistémica o localizada importante activa, de acuerdo a la consideración del investigador.&lt;br&gt;6.	Recepción de cualquier medicamento o producto en fase de investigación &lt;= 30 días antes del trasplante.&lt;br&gt;7.	Alergia conocida o de sospecha a SRL, TAC, inhibidor de IMPDH, antibióticos macrólidos u otros productos relacionados con estas familias de medicamentos.&lt;br&gt;8.	Administración programada de tratamientos inmunosupresores distintos de los descritos en el protocolo.&lt;br&gt;9.	Antecedentes de neoplasia maligna &lt;= 3 años antes de la selección (excepto el carcinoma cutáneo de células basales o escamosas tratado adecuadamente).&lt;br&gt;10.	Receptor que se sabe que es positivo para el virus de la inmunodeficiencia humana (VIH). &lt;br&gt;11.	Mujer biológicamente capaz de tener hijos con un resultado positivo de una prueba de embarazo en orina o suero.&lt;br&gt;12.	Mujer que está amamantando.&lt;br&gt;&lt;br&gt;No se aleatorizarán los sujetos con cualquiera de los siguientes procesos o características:&lt;br&gt;1.	Toda enfermedad/proceso importante que, en opinión del investigador, pueda aumentar de manera sustancial el riesgo derivado de la participación del sujeto en y la finalización del estudio, o que pueda impedir la evaluación de la respuesta del sujeto.&lt;br&gt;2.	Tratamiento con inmunosupresores distintos de los descritos en el protocolo. &lt;br&gt;3.	Sujetos sometidos a la retirada o la evitación de los CS y que no recibieron inducción con anticuerpos en el momento del trasplante con globulina anti-timocitos (de conejo) (rATG) (Thymoglobulin®) o con alemtuzumab (Campath®).&lt;br&gt;4.	Sujetos que han abandonado los CS &lt;=30 días antes de la aleatorización.&lt;br&gt;5.	TFG calculada &lt; 40 mL/min/1,73m2 utilizando la fórmula del estudio Modification of Diet in Renal Disease (MDRD) (véase el Anexo 1: Ecuación para el cálculo de la tasa de filtración glomerular (TF)) &lt;= 2 semanas antes de la aleatorización.&lt;br&gt;6.	Cociente proteínas/creatinina en prueba rápida en orina (UPr/Cr) &gt;= 0.5 &lt;= 2 semanas antes de la aleatorización.&lt;br&gt;7.	Rechazo agudo mediado por células T de grado 2 o superior de Banff (2007) o cualquier rechazo agudo mediado por anticuerpos en cualquier momento después del trasplante (véase el Anexo 2: Criterios de Banff actualizados (2007) sobre el rechazo del aloinjerto renal).&lt;br&gt;8.	Todo rechazo agudo (confirmado por biopsia o presunto) &lt;= 30 días antes de la aleatorización.&lt;br&gt;9.	Más de un episodio de rechazo agudo (confirmado por biopsia o presunto).&lt;br&gt;10.	Fibrosis intersticial y atrofia tubular (FI/AT) de grado &gt;=2 de Banff (2007) (véase el Anexo 2: Criterios de Banff actualizados (2007) sobre el rechazo del aloinjerto renal) o enfermedad glomerular recurrente/de novo.&lt;br&gt;11.	Cirugía mayor &lt;= 2 semanas antes de la aleatorización.&lt;br&gt;12.	Complicación postoperatoria activa, por ejemplo, infección, retraso en la cicatrización de la herida quirúrgica.&lt;br&gt;13.	Recuento total de leucocitos &lt; 2.000/mm3 o recuento absoluto de neutrófilos (RAN) &lt; 1.000, recuento de plaquetas &lt; 100.000/mm3 &lt;= 2 semanas antes de la aleatorización.&lt;br&gt;14.	Val</Exclusion_Criteria>
    <Condition>Renal function in kidney transplant
Función renal en trasplantados renales &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050436
Term: Prophylaxis against renal transplant rejection
</Condition>
    <Intervention>&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: RAPAMUNE 1 mg comprimidos recubiertos&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: SIROLIMUS&lt;br&gt;Other descriptive name: SIROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: RAPAMUNE 2 mg comprimidos recubiertos&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: SIROLIMUS&lt;br&gt;Other descriptive name: SIROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluar si la transición planeada entre 90 y 150 días post-transplante a la terapia basada en SRL desde la terapia basada en TAC se asocia con una mejora clínicamente significativa en la función renal (&gt;= 5.0 ml/min/1.73 m2) comparado con la continuación de la terapia basada en TAC.;Primary end point(s): Porcentaje de sujetos que han demostrado una mejora &gt;= 5 ml/min/1.73m2 en el GFR medido desde la randomización hasta 24 mese post-transplante mediante análisis durante la terapia.;Secondary Objective: Evaluar la seguridad de una transición planeada entre 90 y 150 días post-trasplante a una terapia basada en SRL desde una terapia basada en TAC.&lt;br&gt;Para evaluar si la transición planeada entre 90 y 150 días post-transplante a una terapia basada en SRL desde una terapia basada en TAC se asocia con un grado clínicamente relevante de mejoría de la función renal (&gt;= 5.0 ml/min/1.73 m2) comparado con la continuación de la terapia basada en TAC.</Primary_outcome>
    <Secondary_ID>0468E8-4500</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2555641</Internal_Number>
    <TrialID>EUCTR2011-003081-32-NL</TrialID>
    <Last_Refreshed_on>24 April 2012</Last_Refreshed_on>
    <Public_title>Dabigatran, an anticoagulant drug in patients with impaired renal function</Public_title>
    <Scientific_title>DABIRENAL STUDY 
A study to investigate the pharmacokinetics and effects of Dabigatran in patients with stable severe chronic kidney disease - lumc-30706-IV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Leiden University Medical Center</Primary_sponsor>
    <Date_registration3>20120224</Date_registration3>
    <Date_registration>24/02/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-003081-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/04/2012</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: no comparator&lt;br&gt;Number of treatment arms in the trial: 1&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;• Age: 18 years and older&lt;br&gt;• Able and willing to give informed consent&lt;br&gt;• Impaired renal function defined as a stable MDRD and/or creatinine clearance &lt;br&gt;estimated using urinary excretion between 15-30 ml/min over the last 3 months &lt;br&gt;before study participation&lt;br&gt;• The single use of either aspirin or Vitamin K-antagonists&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 16&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 20&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-Instable renal function (i.e. an increase in serum creatinine &amp;gt; 20% in the last three months)&lt;br&gt;-Patients treated with two or more platelet aggregation inhibitors&lt;br&gt;-Use of or indication for therapeutic (low molecular weight) heparin&lt;br&gt;-Patients with mechanic heart valves &lt;br&gt;-Any known bleeding disorder or tendency&lt;br&gt;- Uncontrolled hypertension (systolic &gt;180mmHg or diastolic &gt;100mmHg)&lt;br&gt;- Diabetes mellitus with active retinopathy&lt;br&gt;- Pre-menopausal women not willing to use appropriate contraception (e.g. oral anti conceptive &lt;br&gt;drugs or intrauterine devices)&lt;br&gt;- Recent cerebral bleeding or cranio-cerebral trauma (within the last six months)&lt;br&gt;- Moderate to severe liver impairment (ALT &gt;2 ULN)&lt;br&gt;- Gastrointestinal surgery within the last three months (except for appendectomy, &lt;br&gt;cholecystectomy or herniotomy)&lt;br&gt;- Use of P-glycoprotein inhibitors &lt;br&gt;- Relevant acute infections (e.g. acute pneumonia)&lt;br&gt;- History of allergy or hypersensitivity (including drug allergies) deemed relevant by the &lt;br&gt;investigator&lt;br&gt;- Planned diagnostic or therapeutic procedures with potential for uncontrollable bleeding within &lt;br&gt;30 days before, during or after the trial&lt;br&gt;- Indication of past of present use of drugs or abuse&lt;br&gt;- Past history of alcoholism with clinical sequelae or present use of alcohol &amp;gt;3U daily (male) &lt;br&gt;or 2U daily (female) &lt;br&gt;- Participation in another drug trial&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic kidney disease and coagulation &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10038444
Term: Renal failure chronic
System Organ Class: 10038359 - Renal and urinary disorders
;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]</Condition>
    <Intervention>&lt;br&gt;Trade Name: Dabigatran Etexilate (pradaxa)&lt;br&gt;Product Name: Dabigatran Etexilate (pradaxa)&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;INN or Proposed INN: DABIGATRAN ETEXILATE&lt;br&gt;CAS Number: 211915-06-9&lt;br&gt;Current Sponsor code: lumc-30706-IV&lt;br&gt;Other descriptive name: n.a.&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 75-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To analyze the pharmacokinetics and dynamics of Dabigatran 75 mg twice daily in patients with  severe CKD (eGFR 15 - 30 ml/min) until steady state of the drug is established. ;Secondary Objective: - Effects of Dabigatran on D-dimer levels in patients with chronic kidney disease&lt;br&gt;- HAS-BLED en Chads-Vasc scores;Primary end point(s):  - Overall safety and tolerability profile (AEs, routine labs, vital signs)&lt;br&gt;- Pharmacodynamics: onset, maximal effect, overall (AUC per 24 hrs) effect for frequently measured coagulation parameters and &lt;br&gt;change from baseline when applicable (fibrinogen, AT) Hemoclot test&lt;br&gt;- Pharmacokinetics: Cmax, Tmax, AUC, T½ , CL/F, Vz/F, renal excretion (tbd: plasma protein binding, proportion of total dabigatran &lt;br&gt;excreted as glucuronides)  &lt;br&gt;;Timepoint(s) of evaluation of this end point: Lab sampling will be drawn at the following points in time:&lt;br&gt;•	Predose&lt;br&gt;•	.5&lt;br&gt;•	1&lt;br&gt;•	2&lt;br&gt;•	3&lt;br&gt;•	4&lt;br&gt;•	6&lt;br&gt;•	8&lt;br&gt;•	12&lt;br&gt;•	23.5&lt;br&gt;•	27.5&lt;br&gt;•	47.5&lt;br&gt;•	51.5&lt;br&gt;•	71.5&lt;br&gt;•	75.5&lt;br&gt;•	95.5&lt;br&gt;•	99.5&lt;br&gt;•	119.5&lt;br&gt;•	123, 5&lt;br&gt;•	167&lt;br&gt;•	168.5&lt;br&gt;•	169&lt;br&gt;•	170&lt;br&gt;•	171&lt;br&gt;•	172&lt;br&gt;•	174&lt;br&gt;•	176&lt;br&gt;•	180&lt;br&gt;•	192&lt;br&gt;•	216&lt;br&gt;•	240&lt;br&gt;This scheme requires a patient’s admission for two days of thirteen hours (predose -13 hours and 167-180 after the first intake). From day two until day six, two samples will be drawn each day, one prior and one after oral intake of dabigatran. For all blood drawings (accept those between 0-13 and 167-180 hours), the possibility of a visiting home nurse will be offered to all study patients.  &lt;br&gt;</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): - D-dimer levels
&lt;br&gt;- HAS-BLED and Chads-Vasc scores;Timepoint(s) of evaluation of this end point: Lab sampling will be drawn at the following points in time:
&lt;br&gt;•	Predose
&lt;br&gt;•	.5
&lt;br&gt;•	1
&lt;br&gt;•	2
&lt;br&gt;•	3
&lt;br&gt;•	4
&lt;br&gt;•	6
&lt;br&gt;•	8
&lt;br&gt;•	12
&lt;br&gt;•	23.5
&lt;br&gt;•	27.5
&lt;br&gt;•	47.5
&lt;br&gt;•	51.5
&lt;br&gt;•	71.5
&lt;br&gt;•	75.5
&lt;br&gt;•	95.5
&lt;br&gt;•	99.5
&lt;br&gt;•	119.5
&lt;br&gt;•	123, 5
&lt;br&gt;•	167
&lt;br&gt;•	168.5
&lt;br&gt;•	169
&lt;br&gt;•	170
&lt;br&gt;•	171
&lt;br&gt;•	172
&lt;br&gt;•	174
&lt;br&gt;•	176
&lt;br&gt;•	180
&lt;br&gt;•	192
&lt;br&gt;•	216
&lt;br&gt;•	240
&lt;br&gt;This scheme requires a patient’s admission for two days of thirteen hours (predose -13 hours and 167-180 after the first intake). From day two until day six, two samples will be drawn each day, one prior and one after oral intake of dabigatran. For all blood drawings (accept those between 0-13 and 167-180 hours), the possibility of a visiting home nurse will be offered to all study patients.  
&lt;br&gt;</Secondary_outcome>
    <Secondary_ID>lumc-30706-IV</Secondary_ID>
    <Source_Support>Leiden University Medical Center</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2577178</Internal_Number>
    <TrialID>EUCTR2004-005055-33-GB</TrialID>
    <Last_Refreshed_on>1 May 2012</Last_Refreshed_on>
    <Public_title>Evaluating the safety and efficacy of mycophenolate mofetil, daclizumab and a single, initial week of corticosteroids in combination with tacrolimus or sirolimus with continued steroid as mainstay immunosuppression in comparison to current standard immunosuppression (mycophenolate mofetil, tacrolimus and continued corticosteroids) in renal transplantation. - UK ELiTE</Public_title>
    <Scientific_title>Evaluating the safety and efficacy of mycophenolate mofetil, daclizumab and a single, initial week of corticosteroids in combination with tacrolimus or sirolimus with continued steroid as mainstay immunosuppression in comparison to current standard immunosuppression (mycophenolate mofetil, tacrolimus and continued corticosteroids) in renal transplantation. - UK ELiTE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Barts and the London NHS Trust</Primary_sponsor>
    <Date_registration3>20050215</Date_registration3>
    <Date_registration>15/02/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-005055-33                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>01/09/2005</Date_enrollement>
    <Target_size>180</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;The enrolled patients must fulfill the following inclusion criteria:&lt;br&gt;1.Male and female patients between 18 and 75 years of age&lt;br&gt;2.Patients scheduled for a single-organ, renal transplantation from living or cadaver donors. Patient receiving second renal transplants can be included, provided that the previous graft was not lost from acute rejection within the first year. &lt;br&gt;3.Patients capable of understanding the purposes and risks of the study, who give written informed consent and who are willing to participate to and comply with the study.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;The following groups of patients will not be included in the study:&lt;br&gt;1.Women lactating, pregnant or of childbearing potential not using a reliable contraceptive method before beginning study drug therapy, during therapy and for 4 months following their last dose of the drugs administered within this clinical study.&lt;br&gt;2.Patients receiving the third or higher renal transplant.&lt;br&gt;3.Patients with severe diarrhea or other gastrointestinal disorders that might interfere with their ability to absorb oral medication, including diabetic patients with previously diagnosed diabetic gastroenteropathy.&lt;br&gt;4.Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study.&lt;br&gt;5.Patients with evidence of an active systemic infection requiring the continued use of antibiotics or evidence of an HIV infection, or the presence of a chronic active hepatitis B (HBs-Ag positive) or C.&lt;br&gt;6.Patients with history of malignancy (except successfully treated localized non-melanocitic skin cancer).&lt;br&gt;7.Patients with active peptic ulcer disease.&lt;br&gt;8.Patients with evidence of an active liver disease &lt;br&gt;9.Patients with severe anemia (Hb&lt;6 g/dl) leucopenia (WBC&lt;2500/mm3), thrombocytopenia (Tc &lt;100’000/mm3)&lt;br&gt;10.Patients for whom the investigator considers a treatment with the following medications necessary:&lt;br&gt;-	azathioprine,&lt;br&gt;-	methotrexate,&lt;br&gt;-	cyclophosphamide,&lt;br&gt;-	polyclonal and monoclonal anti-lymphocyte antibodies (e.g. OKT3, ATG), e.g. used for induction in immunological high-risk patients,&lt;br&gt;-	basiliximab,&lt;br&gt;-	other investigational drugs.&lt;br&gt;11.Known hypersensitivity or absolute contraindications to any of the medications administered in the context of the study or any other substances present in the study medications&lt;br&gt;12.Panel Reactive Antibody (PRA) &gt; 50%  within 6 months prior to enrollment; &lt;br&gt;13.Cold ischemia time of the graft of more than 30 hours; &lt;br&gt;14.Patients who had received an investigational new drug within the last three months.&lt;br&gt;15.Patients previously treated with daclizumab or basiliximab.&lt;br&gt; &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal Transplantation &lt;br&gt;MedDRA version: 7.1
Level: PT
Classification code 10038533
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Zenapax&lt;br&gt;Product Name: Zenapax&lt;br&gt;Product Code: Ro 24-7375&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: daclizumab&lt;br&gt;CAS Number: Ro-7375&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5mg-1ml&lt;br&gt;&lt;br&gt;Trade Name: Cellcept&lt;br&gt;Product Name: Cellcept&lt;br&gt;Product Code: Ro 106-1443&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: mycophenylate mofetil&lt;br&gt;Current Sponsor code: Ro 106-1443&lt;br&gt;Other descriptive name: MMF&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Prograf&lt;br&gt;Product Code: Not available&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5mg-&lt;br&gt;&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: Rapamune&lt;br&gt;Product Code: Not available&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2mg-&lt;br&gt;&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Prograf&lt;br&gt;Product Code: Not available&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: Cellcept&lt;br&gt;Product Name: Cellcept&lt;br&gt;Product Code: Ro 106-1443&lt;br&gt;Pharmaceutical Form: Powder for infusion*&lt;br&gt;INN or Proposed INN: mycophenylate mofetil&lt;br&gt;Current Sponsor code: Ro 106-1443&lt;br&gt;Other descriptive name: MMF&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 6-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of the present investigation is to compare the incidence or avoidance of corticosteroid use, as a measure of the decreased incidence of acute rejection episodes 6 and 12 months after primary renal transplantation in patients receiving three different immunosuppressive treatments. Current standard immunosuppression (group A: mycophenolate mofetil, tacrolimus and corticosteroids) will be compared to regimens with mycophenolate mofetil, daclizumab and a single week of corticosteroids as mainstay immunosuppression in combination with tacrolimus (group B) or (group C) where sirolimus, MMF and steroids will be continued.;Secondary Objective: Secondary objectives are:&lt;br&gt;•to determine the patient and graft survival rates at 12 months and the proportion of patients experiencing treatment failure at 12 months,&lt;br&gt;•to evaluate the renal function as expressed by the serum creatinine and the calculated GFR over the course of the study, and &lt;br&gt;•to characterize the safety (including hypertension, hyperlipidemia, etc.) of these combinations at 6 and 12 months posttransplant.&lt;br&gt;•To  specifically evaluate the impact of steroid use on bone density with the use of DEXA scanning at 3 and 12 months.&lt;br&gt;&lt;br&gt;;Primary end point(s): Primary Aim&lt;br&gt;The primary aims of this study are to compare to incidence or avoidance of corticosteroid use in patients receiving three different immunosuppressive treatments. &lt;br&gt;Primary Efficacy Parameter&lt;br&gt;The primary efficacy parameter of the study is the incidence of reinitialisation of steroid or CNI ( calcineurin inhibitor) as a result of acute rejection episodes at 12 months.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>ML17443;N/A</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2577209</Internal_Number>
    <TrialID>EUCTR2004-004590-28-GB</TrialID>
    <Last_Refreshed_on>1 May 2012</Last_Refreshed_on>
    <Public_title>Efficacy and safety of 40 mg, 80 mg and 160 mg KUC 7483 BS administered twice daily and 160 mg administered once a day over 8 weeks in patients with overactive bladder syndrome (a double-blind, placebo-controlled, parallel groups, dose-ranging study)</Public_title>
    <Scientific_title>Efficacy and safety of 40 mg, 80 mg and 160 mg KUC 7483 BS administered twice daily and 160 mg administered once a day over 8 weeks in patients with overactive bladder syndrome (a double-blind, placebo-controlled, parallel groups, dose-ranging study)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Boehringer Ingelheim Limited</Primary_sponsor>
    <Date_registration3>20050223</Date_registration3>
    <Date_registration>23/02/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-004590-28                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>06/04/2005</Date_enrollement>
    <Target_size>425</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Urinary frequency of more or equal 8 micturitions/ 24 hours, &lt;br&gt;Urgency and/or urge urinary incontinence episodes more or equal 1/24 hours&lt;br&gt;Is a male or a female outpatient more or equal 18 years and less or equal 75 years of age.&lt;br&gt;Has had symptoms of overactive bladder syndrome with symptoms of frequency, with or without nocturia, and urgency with or without urge urinary incontinence, for a minimum of 6 consecutive months prior to the study entry&lt;br&gt;Has no language or cognitive barriers, &lt;br&gt;Agrees to comply with the requirements of the protocol&lt;br&gt;Has signed a written informed consent document prior to entry into the study. &lt;br&gt;Is able to use a toilet independently and without difficulty.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Has known neurologic lesions or conditions (for example, multiple sclerosis, spinal cord lesions, Parkinson’s disease, myasthenia gravis) or local lesions (for example, bladder stones, tumours) that could cause the bladder overactivity&lt;br&gt;Has incontinence with significant stress factor (&gt;50% of incontinence episodes due to stress on the bladder diary collected at Visit 3)&lt;br&gt;Has active or chronically recurring urinary tract infection (4 or more urinary tract infections per year)&lt;br&gt;Had a lower urinary tract surgery within the past 6 months&lt;br&gt;Has a significant haematuria (dipstick test ++ or +++)&lt;br&gt;Has a current diagnosis of :&lt;br&gt;a. urethral pain syndrome (defined by the ICS as an occurrence of recurrent episodic urethral pain usually on voiding, with daytime frequency and nocturia, in the absence of proven infection or other obvious pathology), &lt;br&gt;b. interstitial cystitis,&lt;br&gt;c. ureteric, bladder, urethral, or rectal fistula&lt;br&gt;d. uncorrected congenital abnormality leading to urinary incontinence&lt;br&gt;Has a current sign of significant vesical obstruction which in the opinion of the investigator could cause symptoms of urgency&lt;br&gt;Has PVR volume = 100 mL within 15 minutes of a spontaneous void.&lt;br&gt;Has a current diagnosis or a history of urogenital cancer&lt;br&gt;Has a diagnosis of voluminous uterine fibroma or ovarian cyst which in the opinion of investigator could cause symptoms of urgency&lt;br&gt;Had continence surgery including periurethral bulk injections or received bladder neck bulking agent therapy, including collagen injections for incontinence, within 6 months prior to Screening Visit (Visit 1)&lt;br&gt;Began pelvic floor muscle exercises (for example, Kegel or biofeedback) or a behavioral bladder training program within 3 months prior to Screening Visit (Visit 1)&lt;br&gt;Had previous pelvic irradiation&lt;br&gt;Has indwelling catheter or intermittent catheterization&lt;br&gt;Had received local administration of botulinium toxin within twelve months prior to Screening (Visit 1)&lt;br&gt;Risk of increased bleeding or full anticoagulation.&lt;br&gt;Is pregnant or nursing women&lt;br&gt;Is a woman of childbearing potential (last menstruation equal or less 1 year prior to signing informed consent) not using a medically approved means of contraception for the previous three months (i.e. intra uterine device, oral contraceptives, diaphragm or subdermal implants) &lt;br&gt;Has a current diagnosis of diabetes mellitus type I or II&lt;br&gt;Has an history of myocardial infarction or any cardiac ischemic condition &lt;br&gt;Has an history of known valvular disorders&lt;br&gt;Has a tachycardia defined as heart rate at rest above 90 bpm measured twice at 15 to 30 minutes interval&lt;br&gt;Has a symptomatic arrhythmia despite antiarrhythmic medication, uncontrolled angina, or a significant abnormality on ECG at Visit 1 that, in the opinion of the investigator, requires investigation or intervention &lt;br&gt;Has a history of GI bleeding within the past 5 years or current evidence of GI bleeding (visible or positive FOB test), with the exception of hemorroids&lt;br&gt;Has an inflammatory bowel disease, a Crohn disease, an ulcerative colitis, an oesophagitis, a gastritis or a peptic ulcer&lt;br&gt;Has a history of and/or active significant alcohol or drug abuse &lt;br&gt;Has taken an investigational drug within one month or six half-lives (whichever is greater) prior to Screening (Visit 1)&lt;br&gt;Currently participates in another study&lt;br&gt;Had previously been randomized in this study&lt;br&gt;Has a significant disease other than OAB, which in the opinion of the investigator may either put the patient at risk because of participation in the study or whic</Exclusion_Criteria>
    <Condition>Patients aged 18-75 years, of both sexes with symptoms of overactive bladder syndrome for at least 6 months.

Lower level term (LLT): Overactive bladder (10059617)
System Organ Class: Renal and Urinary Disorders
Preferred term: Hypertonic bladder" &lt;br&gt;MedDRA version: 7.1
Level: LLT
Classification code 10059617
</Condition>
    <Intervention>&lt;br&gt;Product Name: not available&lt;br&gt;Product Code: KUC 7483&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: n.a.&lt;br&gt;CAS Number: 476333-91-2&lt;br&gt;Current Sponsor code: KUC 7483&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 40-&lt;br&gt;Pharmaceutical form of the placebo: Capsule*&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Product Name: not available&lt;br&gt;Product Code: KUC 7483&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: n.a.&lt;br&gt;CAS Number: 476333-91-2&lt;br&gt;Current Sponsor code: KUC 7483&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 80-&lt;br&gt;Pharmaceutical form of the placebo: Capsule*&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The purpose of this trial is to investigate efficacy, safety and dose response relationship of different oral doses (40 mg, 80 mg and 160 twice daily and 160 mg once-daily) of KUC 7483 BS given over a 8 weeks period when compared to placebo in patients with overactive bladder.;Secondary Objective: 1.	Other endpoints derived from bladder diary&lt;br&gt;2.	Quality of life&lt;br&gt;3.	Safety (details in section 5.2 of the protocol)&lt;br&gt;4.	Population pharmacokinetic analysis of KUC 7322 ZW including exploratory&lt;br&gt;                covariate screening&lt;br&gt;;Primary end point(s): The primary efficacy endpoint will be the change from baseline to Visit 7 (week 8) in average number of micturitions per 24 hour period as recorded during a 7 day period in the bladder diary, compared to placebo.</Primary_outcome>
    <Secondary_ID>1207.5</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2577283</Internal_Number>
    <TrialID>EUCTR2004-005071-42-IE</TrialID>
    <Last_Refreshed_on>1 May 2012</Last_Refreshed_on>
    <Public_title>A study of the effect of conversion to Myfortic on quality of life in patients with gastrointestinal (GI) symptoms related to MMF therapy after renal transplantation (MYQOL). - MYQOL</Public_title>
    <Scientific_title>A study of the effect of conversion to Myfortic on quality of life in patients with gastrointestinal (GI) symptoms related to MMF therapy after renal transplantation (MYQOL). - MYQOL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Novartis Pharmaceuticals UK Limited</Primary_sponsor>
    <Date_registration3>20050311</Date_registration3>
    <Date_registration>11/03/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-005071-42                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>06/05/2005</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Current therapy - Cellcept&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Patients that have received a kidney transplant;&lt;br&gt;2. Receiving immunosuppressive regimen that includes MMF;&lt;br&gt;3. Patients suffering GI side effects related to standard MMF doses or patients on reduced dose MMF with existing but tolerated/controlled GI side effects.&lt;br&gt;4. At least 18 years of age;&lt;br&gt;5. Willing to provide written informed consent;&lt;br&gt;6. Able to meet all study requirements and completing three study visits.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Patients with GI symptoms assumed or known not to be caused by MPA therapy (e.g. oral bisphosphonate induced, infectious diarrhea); &lt;br&gt;2. Acute rejection &lt; 1 week prior to study enrollment;&lt;br&gt;3. Women of child-bearing potential who are planning to become pregnant or are pregnant and/or lactating who is unwilling to use effective means of contraception;&lt;br&gt;4. Presence of psychiatric illness (i.e., schizophrenia, major depression) that, in the opinion of the site investigator, would interfere with study requirements;&lt;br&gt;5. Undergoing acute medical intervention or hospitalization;&lt;br&gt;6. Any other medical condition that, in the opinion of the site investigator based on recall or chart review would interfere with completing the study, including but not limited to, visual problems or cognitive impairment.&lt;br&gt;7. Receiving any investigational drug or have received any investigational drug within 30 days prior to study enrollment.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal transplantation</Condition>
    <Intervention>&lt;br&gt;Trade Name: Myfortic 360mg film-coated gastro-resistant tablets&lt;br&gt;Product Name: Myfortic 360mg film-coated gastro-resistant tablets&lt;br&gt;Product Code: ERL080&lt;br&gt;Pharmaceutical Form: Gastro-resistant tablet&lt;br&gt;INN or Proposed INN: mycophenolic acid&lt;br&gt;CAS Number: 24280-93-1&lt;br&gt;Current Sponsor code: ERL080&lt;br&gt;Other descriptive name: mycophenolate sodium&lt;br&gt;Concentration unit: mg/g milligram(s)/gram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 360-&lt;br&gt;&lt;br&gt;Trade Name: Myfortic 180mg film-coated gastro-resistant tablets&lt;br&gt;Product Name: Myfortic 180mg film-coated gastro-resistant tablets&lt;br&gt;Product Code: ERL080&lt;br&gt;Pharmaceutical Form: Gastro-resistant tablet&lt;br&gt;INN or Proposed INN: mycophenolic acid&lt;br&gt;CAS Number: 24280-93-1&lt;br&gt;Current Sponsor code: ERL080&lt;br&gt;Other descriptive name: mycophenolate sodium&lt;br&gt;Concentration unit: mg/g milligram(s)/gram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 180-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Primary end point(s): The primary efficacy assessment will be based on the proportion of patients who are maintained at Visit 4 on a dose that is at least one dosage step greater than at baseline (Visit 2). Table 6.1 shows the dosage steps corresponding to 25%, 50% and 100% of the target therapeutic dose for each drug.&lt;br&gt;&lt;br&gt;The main secondary efficacy assessment of GI complaints will be based on changes from baseline to Visits 3 and 4 in the diarrhoea and indigestion subscales of the GSRS instrument and compared  between the Myfortic and standard therapy groups. For GSRS, a higher score represents greater impairment of quality of life due to GI symptoms. The comparisons between the groups will be based on confidence interval as well as hypothesis testing approaches. An analysis of covariance (ANCOVA) model will be fitted including terms for treatment, dose level (expressed as a proportion of the target therapeutic dose), baseline GSRS, and centre. The possibility of a treatment by centre interaction, or a treatment by baseline GSRS interaction will be examined, although the interaction terms will not be included in the primary analysis model. The least squares mean (“adjusted mean”) change from baseline for each treatment group, the difference in the least squares mean changes between the two treatment groups (Myfortic - MMF), and the two-sided 95% confidence interval for the difference will be obtained from the primary analysis model and presented. As a guide to aid interpretation, the minimum clinically important difference on the GSRS is 0.50.  Bristol stool chart: Summary statistics will be provided for the frequencies in each category of the chart and changes from baseline presented.&lt;br&gt;;Main Objective: The primary objective of this study is to assess whether treatment with an enteric coated formulation of mycophenolic acid (MPA) permits higher MPA doses to be maintained, than treatment with standard MMF therapy, in patients with demonstrated susceptibility to gastro intestinal side effects;Secondary Objective: The secondary objectives are to determine the effect of the use of the enteric coated formulation of MPA on patient reported outcomes, in patients who warrant conversion from MMF or require a reduced dose of MMF because of GI side effects. Symptom severity is assessed by the Gastrointestinal Symptom Rating Scale (GSRS) and Bristol stool form chart; HRQL is assessed by the Gastrointestinal Quality of Life Index (GIQLI) and SF-36.</Primary_outcome>
    <Secondary_ID>CERL080AGB03</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2578261</Internal_Number>
    <TrialID>EUCTR2007-001984-31-FR</TrialID>
    <Last_Refreshed_on>1 May 2012</Last_Refreshed_on>
    <Public_title>A PHASE 2 RANDOMIZED, MULTICENTER, ACTIVE COMPARATOR-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF COADMINISTRATION OF CP-690,550 AND MYCOPHENOLATE MOFETIL / MYCOPHENOLATE SODIUM IN DE NOVO KIDNEY ALLOGRAFT RECIPIENTS - N/A</Public_title>
    <Scientific_title>A PHASE 2 RANDOMIZED, MULTICENTER, ACTIVE COMPARATOR-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF COADMINISTRATION OF CP-690,550 AND MYCOPHENOLATE MOFETIL / MYCOPHENOLATE SODIUM IN DE NOVO KIDNEY ALLOGRAFT RECIPIENTS - N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Pfizer Inc. 235 East 42nd Street, New York, NY10017</Primary_sponsor>
    <Date_registration3>20070618</Date_registration3>
    <Date_registration>18/06/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001984-31                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>08/08/2007</Date_enrollement>
    <Target_size>300</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: partially blinded, open label to the sponsor&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Subjects must have end-stage renal disease, have been on renal replacement therapy (eg, dialysis) for =1 month or have eGFR (estimated by the Cockcroft-Gault equation) =10 mL/min, and are scheduled to receive a primary kidney transplant from a cadaveric donor, a living-related HLA-mismatched donor, or a living-unrelated HLA-mismatched donor;&lt;br&gt;&lt;br&gt;2. Between the ages of 18 and 70 years, inclusive;&lt;br&gt;&lt;br&gt;3. Either female (including women of childbearing potential) or male adults;&lt;br&gt;&lt;br&gt;4. Subjects must have no known contraindications to the administration of IL-2 receptor antagonist induction, MMF, corticosteroids, or CsA;&lt;br&gt;&lt;br&gt;5. Subjects must be willing and able to provide written informed consent with evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study;&lt;br&gt;&lt;br&gt;6. Subjects must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Subjects who have current PRA &gt;30%, or who have undergone desensitization treatment;&lt;br&gt;2. Subjects who are recipients of or scheduled for non-renal transplants;&lt;br&gt;3. Subjects scheduled for double kidney transplantation;&lt;br&gt;4. Subjects with evidence of active infection;&lt;br&gt;5. Subjects with clinically significant infections within the past 3 months (eg, those requiring hospitalization, or as judged by the Investigator);&lt;br&gt;6. Subjects with a first-degree relative with a history of hereditary immunodeficiency (eg, severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome, X-linked&lt;br&gt;agammaglobinemia);&lt;br&gt;7. Subjects with a history of malignancies with the exception of excised non-metastatic basal cell carcinoma or squamous cell cancer of the skin, or adequately treated cervical carcinoma in situ (preinvasive). Subjects with a history of monoclonal gammopathy of undetermined significance (MGUS) will be excluded;&lt;br&gt;8. Subjects who have a history of allergy to iodine, betadine, iohexol or other iodinated contrast media;&lt;br&gt;9. Subjects who have a history of multiple allergies or severe allergy (eg, anaphylaxis) to any substance;&lt;br&gt;10. Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of trial medication;&lt;br&gt;11. Subjects who are unwilling to refrain from consumption of grapefruit or grapefruit containing juices for the duration of trial medication period;&lt;br&gt;12. Subjects receiving or are expected to receive concomitant medications on the list of prohibited medications (Appendix A);&lt;br&gt;13. Subjects with known positive results of the following serological tests: HIV-1 Ab, hepatitis B virus (HBV) surface antigen (HBsAg), or anti-hepatitis C virus antibody (anti-HCV Ab).&lt;br&gt;Viral load monitoring (HBV DNA PCR and HCV RNA PCR) will be performed by the&lt;br&gt;central laboratory on a blood sample collected prior to dosing of CP-690,550 or CsA to detect active infection. Positive results in these viral load tests will require subject&lt;br&gt;discontinuation;&lt;br&gt;14. Subjects with mental dysfunction or inability to cooperate with the trial;&lt;br&gt;15. Subjects with the following laboratory parameters at screening: absolute neutrophil count (ANC) &lt;1800/µL or hemoglobin (Hgb) &lt;8 g/dL;&lt;br&gt;16. Subjects with any condition that may significantly affect drug absorption (eg, gastrectomy or insufficiently treated diabetic gastroenteropathy);&lt;br&gt;17. Body weight &lt;90 lbs (&lt;41 kg) or subjects who are morbidly obese at the time of transplant with a body mass index BMI &gt;40 (Appendix B);&lt;br&gt;18. History of alcohol abuse with less than 6 months of sobriety, or history of drug abuse within the past 5 years;&lt;br&gt;19. Males who are unwilling to abstain from sexual intercourse or use a condom with pregnant or lactating women. Non-vasectomized males unwilling to use a condom in addition to having their female partner use another form of contraception such as an IUD, diaphragm with spermicide, oral contraceptive, injectable progesterone, sub-dermal implant or a tubal ligation if the female partner could become pregnant from the time of the first dose of trial medication until completion of follow-up procedures;&lt;br&gt;20. Women of childbearing potential who are either pregnant, lactating, planning to become pregnant in the next 12 months, or with a positive serum or urine pregnancy test. Women of childbearing potential must be willing to agree to contraceptive practices;&lt;br&gt;21. Subjects with evidence of clinically significant disease (eg, gastrointestinal or hepatic disorders) that pla</Exclusion_Criteria>
    <Condition>Prevention of kidney allograft rejection &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10066543
Term: Acute allograft rejection
</Condition>
    <Intervention>&lt;br&gt;Product Name: CP-690,550&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 540737-29-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;Current Sponsor code: CP-690,550&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Product Name: CP-690,550&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 540737-29-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;Current Sponsor code: CP-690,550&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Neoral&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: Cyclosporine&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Trade Name: Neoral&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: Cyclosporine&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: 1) To compare the incidence of clinical biopsy-proven acute rejection (BPAR) (as interpreted by the central blinded pathologist) of combination regimens of CP-690,550 and mycophenolate mofetil (MMF) / mycophenolate sodium (MPS) versus a cyclosporine (CsA)-based regimen in recipients of first renal allografts at Month 6 posttransplant&lt;br&gt;&lt;br&gt;2) To compare glomerular filtration rate (GFR), as measured by iohexol serum clearance, of combination regimens of CP-690,550 and MMF/MPS versus a CsA-based regimen at Month 12 posttransplant;Secondary Objective: 1) To evaluate the safety and tolerability of combination regimens of CP-690,550 and&lt;br&gt;MMF/MPS, including adverse events, clinically significant infections, malignancies, incidence and duration of delayed graft function, safety laboratory tests and estimated GFR.&lt;br&gt;2) To compare GFR, as measured by iohexol serum clearance, of combination regimens of CP-690,550 and MMF/MPS vs a CsA-based regimen at Month 6 posttransplant&lt;br&gt;3) To compare the progression of chronic allograft lesions of combination regimens of&lt;br&gt;CP-690,550 and MMF/MPS versus a CsA-based regimen at Month 12 posttransplant&lt;br&gt;4) To evaluate the efficacy of combination regimens of CP-690,550 and MMF/MPS,&lt;br&gt;including clinical BPAR at Month 12, treated clinical acute rejection, combined Banff rejection categories, graft loss, subject death, and treatment failure&lt;br&gt;5) To evaluate the PK of CP-690,550 and mycophenolic acid&lt;br&gt;6) To evaluate the effects of CP-690,550 on lymphocyte subsets and on health outcome assessment;Primary end point(s): 1) First clinical BPAR episode (as interpreted by the central blinded pathologist) within&lt;br&gt;6 months posttransplant. Clinical BPAR is defined as a BPAR associated with an&lt;br&gt;increase in serum creatinine of =0.3 mg/dL and =20% from pre-rejection baseline.&lt;br&gt;&lt;br&gt;2) GFR, measured by iohexol serum clearance, at Month 12.</Primary_outcome>
    <Secondary_ID>A3921030;N/A</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2579404</Internal_Number>
    <TrialID>EUCTR2007-000573-29-BE</TrialID>
    <Last_Refreshed_on>1 May 2012</Last_Refreshed_on>
    <Public_title>A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism.</Public_title>
    <Scientific_title>A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Amgen Inc</Primary_sponsor>
    <Date_registration3>20090722</Date_registration3>
    <Date_registration>22/07/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-000573-29                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>16/10/2009</Date_enrollement>
    <Target_size>190</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Received a kidney transplant = 9 weeks at time of Screening and = 12 months before first dose (ie, subjects may receive first dose of investigational product no sooner than 12 weeks post-transplant and no later than 12 months post-transplant); may be the first kidney transplant or a repeat kidney transplant.&lt;br&gt;&lt;br&gt;Subjects with a functional, stable kidney transplant, defined as MDRD estimated glomerular filtration rate (eGFR) = 30 mL/min/1.73 m2 (CKD Stage 3 or better) at Screening.&lt;br&gt;Estimated GFR (mL/min/1.73 m2) will be calculated by the Interactive Voice Response System (IVRS) using the MDRD equation&lt;br&gt;&lt;br&gt;SI Units:&lt;br&gt;eGFRMDRD = 175 x [SCr/88.4]-1.154 x [age]-0.203 x [0.742 if subject is female] x&lt;br&gt;[1.212 if subject is African American]&lt;br&gt;Conventional Units:&lt;br&gt;eGFRMDRD = 175 x [SCr]-1.154 x [age]-0.203 x [0.742 if subject is female] x&lt;br&gt;[1.212 if subject is African American]&lt;br&gt;&lt;br&gt;where SCr is the serum creatinine.&lt;br&gt;&lt;br&gt;Men or women = 18 years at the start of screening (ie, time of informed consent).&lt;br&gt;&lt;br&gt;Corrected total serum calcium &gt; 10.5 mg/dL (2.63 mmol/L), defined as the mean of 2 values during the screening period.&lt;br&gt;&lt;br&gt;iPTH &gt; 100 pg/mL (10.6 pmol/L), during the Screening period (obtained at Screen 1 or Screen 2).&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Subjects will be ineligible for the study if they fulfill any of the following criteria:&lt;br&gt;&lt;br&gt;Received cinacalcet therapy post-transplant (Note: This does not exclude pre-transplant use of cinacalcet).&lt;br&gt;&lt;br&gt;Anticipated parathyroidectomy within 6 to12 months after randomization.&lt;br&gt;&lt;br&gt;Ongoing therapy with bisphosphonates or use within 6 months prior to screening.&lt;br&gt;&lt;br&gt;Ongoing use of 1,25-dihydroxyvitamin D3 (including other active vitamin D metabolites or analogues) or use within 30 days prior to screening.&lt;br&gt;&lt;br&gt;Ongoing use of calcium supplements or use within 30 days prior to screening.&lt;br&gt;&lt;br&gt;Ongoing use of phosphate binders (calcium or non-calcium containing) or use within 30 days prior to screening.&lt;br&gt;&lt;br&gt;Ongoing use of a thiazide diuretic.&lt;br&gt;&lt;br&gt;Current enrollment in or fewer than 30 days has passed since subject has completed another investigational device or drug study(s); or subject is receiving other investigational agent(s) [ie, less than 30 days prior to randomization].&lt;br&gt;&lt;br&gt;Refuse to use highly effective contraceptive measures (as determined by the investigator) throughout the study.&lt;br&gt;&lt;br&gt;Evidently pregnant (eg, positive HCG test) or is breast feeding.&lt;br&gt;&lt;br&gt;Known sensitivity to any of the products to be administered during dosing.&lt;br&gt;&lt;br&gt;Current gastrointestinal disorder that may be associated with impaired absorption of orally administered medications or an inability to swallow tablets.&lt;br&gt;&lt;br&gt;Will not be available for follow-up assessment.&lt;br&gt;&lt;br&gt;Any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures.&lt;br&gt;&lt;br&gt;Subjects with a history of seizures who had a seizure within the 3 months prior to randomization, which required adjustments to the seizure medication.&lt;br&gt;&lt;br&gt;Acute Kidney Injury (AKI) within 6 weeks prior to screening, defined by creatinine increase greater than or equal to 35.36 µmol/L&lt;br&gt;&lt;br&gt;Renal biopsy within 6 weeks prior to Screening, unless it is an institutional protocol-driven biopsy.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal transplant recipients with hypercalcemia and autonomous hyperparathyroidism &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10020587
Term: Hypercalcemia
</Condition>
    <Intervention>&lt;br&gt;Product Name: Cinacalcet&lt;br&gt;Product Code: AMG 073&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Cinacalcet&lt;br&gt;Current Sponsor code: AMG 073&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Product Name: Cinacalcet&lt;br&gt;Product Code: AMG 073&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Cinacalcet&lt;br&gt;Current Sponsor code: AMG 073&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 60-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Product Name: Cinacalcet&lt;br&gt;Product Code: AMG 073&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Cinacalcet&lt;br&gt;Current Sponsor code: AMG 073&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 90-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To demonstrate the efficacy of cinacalcet for correcting hypercalcemia in kidney transplant recipients with autonomous hyperparathyroidism (HPT).;Secondary Objective: To assess the efficacy of cinacalcet for increasing bone mineral density at the femoral neck&lt;br&gt;To evaluate the efficacy of cinacalcet for raising serum phosphorus levels&lt;br&gt;&lt;br&gt;Other&lt;br&gt;&lt;br&gt;To evaluate the impact of cinacalcet on kidney transplant function&lt;br&gt;To evaluate the efficacy of cinacalcet for reducing corrected total serum calcium levels&lt;br&gt;To evaluate the efficacy of cinacalcet for reducing plasma intact parathyroid hormone (iPTH) levels&lt;br&gt;To assess the impact of cinacalcet on urinary calcium and phosphorus excretion&lt;br&gt;To assess the safety and tolerability of cinacalcet (including evaluations of adverse events, acute rejection, kidney transplant failure, incidence of parathyroidectomy and hypocalcemia);Primary end point(s): The primary endpoint is the achievement of a mean corrected total serum calcium value &lt; 10.2 mg/dL (2.55 mmol/L) during the EAP. For each subject, the mean of all corrected total serum calcium values available from weeks 21 to 26 will be calculated. A responder is defined as a subject whose mean corrected total serum calcium value is &lt; 10.2 mg/dL (2.55 mmol/L). For subjects with no data during weeks 21 to 26, the mean of the last 2 available post-baseline corrected total serum calcium values will be used to calculate the endpoint. If only 1 post-baseline corrected total serum calcium value is available, this single value will be used.</Primary_outcome>
    <Secondary_ID>20062007</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2580597</Internal_Number>
    <TrialID>EUCTR2011-005606-30-GB</TrialID>
    <Last_Refreshed_on>1 May 2012</Last_Refreshed_on>
    <Public_title>Preventing patients with multiple sclerosis from developing side effects following treatment with alemtuzumab (Campath-1H).</Public_title>
    <Scientific_title>Keratinocyte Growth Factor - promoting thymic reconstitution and preventing autoimmunity after alemtuzumab (Campath-1H) treatment of multiple sclerosis. CAM-THY - CAM-THY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Cambridge University Hospitals NHS Foundation Trust and University of Cambridge</Primary_sponsor>
    <Date_registration3>20120402</Date_registration3>
    <Date_registration>02/04/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-005606-30                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>25/04/2012</Date_enrollement>
    <Target_size>86</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;To be included in the trial the patient must have/be:  • Male or non-pregnant, non-lactating female patients  • Aged between 18 and 50 years inclusive • Diagnosis of MS using McDonald’s criteria, including diagnostic MRI  • Onset of first MS symptoms within 10 years • EDSS score 0.0 to 5.0 (inclusive) at screening • At least 2 clinical episodes of MS in the 2 years prior to study entry, with at least 1 attack within 12 months, which may have occurred whilst on disease-modifying therapy, such as beta interferon therapy or glatiramer acetate. • Serum IL-21 =230pg/mL.  Apart from the IL-21 inclusion criterion, the details of patient selection are identical to those adopted in the phase 3 trials of alemtuzumab (CARE MS1 and MS2). This ensures that the results of this trial can be generalised to these patient groups.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: 0&lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 86&lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range 0&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;The presence of any of the following will preclude patient inclusion:  •Any progressive form of multiple sclerosis •Previous thymectomy •Previous treatment with alemtuzumab, mitoxantrone, cyclophosphomide, cladribine, rituximab or any other immunosuppressant or cytotoxic therapy (other than steroids) •History of malignancy •Personal history of clinically significant autoimmune disease, other than multiple sclerosis  (including but not limited to: thyroid disease, immune cytopenias, inflammatory bowel disease, diabetes, lupus, severe asthma) •Intolerance of pulsed corticosteroids, especially a history of steroid psychosis •Major systemic disease or other illness that would, in the opinion of the investigator, compromise patient safety or interfere with the interpretation of study results. •Seropositivity for human immunodeficiency virus (HIV) •Past or present hepatitis B infection (positive hepatitis B serology) •Pregnant women or male and female patients who do not agree to use effective contraception during the study. Reliable and effective contraceptive method(s) include: intrauterine device (IUD), hormonal based contraception, surgical sterilisation, abstinence, or double barrier contraception i.e. condom and occlusive cap (diaphragm or cervical cap with spermicide). • Medical, psychiatric, cognitive or other conditions that, in the investigator's opinion, compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol, or to complete the study.&lt;br&gt;</Exclusion_Criteria>
    <Condition>This trial will test the efficacy of Kepivance in the prevention of new autoimmune diseases in patients who have multiple sclerosis (MS)who are being treated with alemtuzumab. &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10058948
Term: Nephritis autoimmune
System Organ Class: 10038359 - Renal and urinary disorders
 &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10049046
Term: Autoimmune thyroiditis
System Organ Class: 10014698 - Endocrine disorders
 &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10061664
Term: Autoimmune disorder
System Organ Class: 10021428 - Immune system disorders
 &lt;br&gt;MedDRA version: 14.1
Level: LLT
Classification code 10068004
Term: Autoimmune hyperthyroidism
System Organ Class: 10014698 - Endocrine disorders
 &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10050245
Term: Autoimmune thrombocytopenia
System Organ Class: 10005329 - Blood and lymphatic system disorders
;Therapeutic area: Diseases [C] - Immune System Diseases [C20]</Condition>
    <Intervention>&lt;br&gt;Trade Name: Kepivance&lt;br&gt;Product Name: Kepivance&lt;br&gt;Pharmaceutical Form: Powder for solution for injection&lt;br&gt;INN or Proposed INN: Palifermin&lt;br&gt;CAS Number: 162394-19-6&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;Trade Name: MabCampath&lt;br&gt;Product Name: Alemtuzumab&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Alemtuzumab&lt;br&gt;CAS Number: 216503-57-0&lt;br&gt;Other descriptive name: anti-CD52 monoclonal antibody&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of this trial is to determine if Kepivance can prevent patients with multiple sclerosis from developing new autoimmune diseases after treatment with alemtuzumab.;Secondary Objective: Our secondary objective is to determine if Kepivance can boost the function of the thymus in adult humans.  The thymus is a gland that sits in the neck. Its function is to make new immune cells. If Kepivance can boost the function of the thymus gland this has important implications for a number of patient groups - for example patients who have reduced numbers of immune cells due to HIV infection, or because of treatment with chemotherapy drugs.;Primary end point(s): The primary endpoint is incidence of clinical autoimmunity within 30 months of starting treatment with alemtuzumab.;Timepoint(s) of evaluation of this end point: Patients will be assessed for development of autoimmunity at all routine study visits - Months 1,3 6,9,12,13, 15,18,21,24,27,30. In addition patients will have monthly full blood counts to screen for the development of immune thrombocytopenia.   The primary endpoint will be assessed once all patients have completed 30 months on study.</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): • Percentage of naive T cells  • Safety outcomes - incidence and nature of adverse events  • Percentage of central memory T cells, effector memory T cells and T effector memory RA cells  - as determined by flow cytometry  • Frequency of recent thymic emigrants (defined by co-expression of CD45RA and CD31 in CD4+ T cells, and by CD45RA and CD103 in CD8+ T cells) - as determined by flow cytometry  • T cell receptor (TCR) clonality - as determined by CDR3 spectratyping  • Thymic function - as determined by measuring TRECs • Thymic volume and density - as assessed by non-contrast helical CT scans of the thymus performed at baseline, then again at 6 months following treatment. The scans will be analysed by a blinded thoracic radiologist who will perform a quantitative computer based analysis in order calculate thymic volume and density.;Timepoint(s) of evaluation of this end point: Safety assessment and recording of all adverse events will be performed throughout the study, and reviewed at all study visits- Months 1,3 6,9,12,13, 15,18,21,24,27, and 30.  CT scans  of the chest, to measure thymic volume and density, will be performed at baseline and month 6.  Immunological assays of thymic function will be performed at baseline and again at months 1,3 6,9,12,13, 15,18,21,24,27, and 30.</Secondary_outcome>
    <Secondary_ID>CAM-THY</Secondary_ID>
    <Source_Support>Medical Research Council (MRC);Moulton Charitable Trust</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2584164</Internal_Number>
    <TrialID>EUCTR2008-003835-18-GB</TrialID>
    <Last_Refreshed_on>8 May 2012</Last_Refreshed_on>
    <Public_title>A phase 2, open-label test-retest study to assess the reproducibility of quantitative measurements of 18F uptake by solid tumours using PET imaging following intravenous administration of AH111585 (18F) Injection</Public_title>
    <Scientific_title>A phase 2, open-label test-retest study to assess the reproducibility of quantitative measurements of 18F uptake by solid tumours using PET imaging following intravenous administration of AH111585 (18F) Injection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>GE Healthcare Ltd</Primary_sponsor>
    <Date_registration3>20090428</Date_registration3>
    <Date_registration>28/04/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-003835-18                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>21/04/2009</Date_enrollement>
    <Target_size>45</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;The subject has been diagnosed with at least 1 solid primary or metastatic tumor at least 2.0 cm in diameter, including but not limited to NSCLC, RCC, GBM, melanoma, sarcoma, H&amp;N, and breast cancers.&lt;br&gt;The subject is undergoing therapy for a malignant tumour with non-curative intent.&lt;br&gt;The subject has received clinical routine imaging diagnostic work-up (e.g., CT with or without contrast, magnetic resonance imaging [MRI] with or without contrast, bone scintigraphy, X-ray, Mammography, [18F] FDG PET) within 8 weeks prior to the first [18F]AH111585 PET scan.&lt;br&gt;The subject has the following baseline serum biochemisty and haematology values:  blood urea nitrogen (BUN) value and serum creatinine (sCr) value of less or equal to 1.5 of the upper normal limit; prothrombin time (PTT) and activated partial thromboplastin time (aPTT) within normal limits; haemoglobin value of more than 9 g/dL; and platelet count of more than 75,000 x 10E+6/L.&lt;br&gt;The subject has a clinically acceptable (as judged by the investigator) physical examination at screening and is capable of self-care, i.e. Eastern Cooperative Oncology Group (ECOG) performance status is 0 to 2.&lt;br&gt;Endocrine therapy is permitted provided that it has been initiated for more than a month prior to first AH111585 imaging session and treatment continues at least through the second AH111585imaging session.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;The subject has received another IMP within 30 days before the first administration of AH111585 (18F) Injection, will receive another IMP during or between the 2 administrations of AH111585 (18F) Injection or plans to receive an IMP within 1 week after the second administration of AH111585 (18F) Injection. &lt;br&gt;The subject has known hyper- or hypo-coagulation syndromes.  Such coagulopathies include but are not limited to Von Willebrand disease, Protein C deficiency, Protein S deficiency, Haemophilia A/B/C, Factor-V Leiden, and Bernard-Soulier syndrome.&lt;br&gt;The subject has received chemotherapy within 2 weeks, or received radiotherapy, surgery or any other treatment against cancer (with the exception of endocrine therapy) within 4 weeks prior to the first [18F]AH111585 PET scan.&lt;br&gt;The subject is scheduled to undergo chemotherapy, radiotherapy, surgery or any other treatment against cancer between the first and second [18F]AH111585 PET scans.&lt;br&gt;The subject’s target tumour has been biopsied less than 4 weeks prior to the first [18F]AH111585 PET scan (not applicable for the immuno-histochemistry group) or is scheduled to undergo biopsy for the target tumour between the first and second [18F]AH111585 PET scans.  Subjects in the immuno-histochemistry group may not have had the target tumour biopsied less than or equal to 1 week prior to the first [18F]AH111585 PET scan.&lt;br&gt;The subject has intra-hepatic tumour(s) only (without extra-hepatic tumour).&lt;br&gt;The subject has known diagnosis of human immunodeficiency virus (HIV) infection or hepatitis B or C type virus infection.&lt;br&gt;The subject is being treated with heparin or warfarin&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Adult subjects with solid primary or metastatic tumours 2 cm or more in diameter.  Malignancies may include but are not limited to non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), glioblastoma multiforme (GBM), melanoma, sarcoma, head and neck (H&amp;N), and breast cancers.</Condition>
    <Intervention>&lt;br&gt;Product Name: AH111585 (18F) Injection&lt;br&gt;Product Code: AH111585&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess the test-retest reproducibility of [18F]AH111585 uptake by solid tumours following intravenous administration of AH111585 (18F) Injection.;Secondary Objective: (1) To assess the image quality and lesion detectability of [18F]AH111585 as a function of administered activity, by temporal segmentation &lt;br&gt;(2) To assess the safety of 2 or more administrations, each of a maximum of 370 MBq, AH111585 (18F) Injection in subjects with solid primary or metastatic tumours. &lt;br&gt;(3) To assess the relationship between 18F uptake by solid tumours and avb3 expression and other histological markers of angiogenesis in pre- or post- imaging biopsy material.&lt;br&gt;;Primary end point(s): Efficacy: Assessment of the test-retest reproducibility will be based on measurements obtained for each targeted tumour lesion and the extent of the difference between Standardized Uptake Value (SUV) measurements of [18F]AH111585 uptake following AH111585 (18F) Injection administration and PET imaging on 2 separate days within an interval of 3-8 days.&lt;br&gt;&lt;br&gt;Safety: Physical examinations, Vital signs, Serum biochemistry, Haematology, Coagulation parameters, 12 lead ECG, Anti-AH111585 antibody evaluation, Pre-treatment and Post treatments events (AEs and SAEs).</Primary_outcome>
    <Secondary_ID>GE-135-004</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2584820</Internal_Number>
    <TrialID>EUCTR2010-021137-32-BE</TrialID>
    <Last_Refreshed_on>8 May 2012</Last_Refreshed_on>
    <Public_title>Efficacy and safety of SAF312 in patients with urinary incontinence (malfunctioning bladder) due to spinal cord injury.</Public_title>
    <Scientific_title>A multi-center, double-blind, randomized, placebocontrolled, cross-over study to evaluate the efficacy, safety and tolerability of SAF312 in subjects with neurogenic detrusor overactivity due to spinal cord lesions who are inadequately managed by antimuscarinic therapy - Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Novartis Pharma Services AG</Primary_sponsor>
    <Date_registration3>20101019</Date_registration3>
    <Date_registration>19/10/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-021137-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>14/03/2011</Date_enrollement>
    <Target_size>72</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Patients with neurogenic detrusor overactivity due to spinal cord lesions&lt;br&gt;- Patients are inadequately managed by antimuscarinic medication and present with a cystometric bladder capacity of max. 300 mL&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 72&lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Chronic inflammation such as interstitial cystitis, bladder stones, hematuria of unknown origin, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs&lt;br&gt;- Pelvic or genitourinary tract anomalies including surgery or bladder disease other than detrusor overactivity impacting on bladder function&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Neurogenic detrusor overactivity due to spinal cord injury &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10020853
Term: Hypertonic bladder
System Organ Class: 10038359 - Renal and urinary disorders
;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]</Condition>
    <Intervention>&lt;br&gt;Product Name: SAF312&lt;br&gt;Product Code: SAF312&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Not known yet&lt;br&gt;CAS Number: 871814-52-7&lt;br&gt;Current Sponsor code: SAF312&lt;br&gt;Other descriptive name: 4-(7-Hydroxy-2-isopropyl-4-oxo-4Hquinazolin-3-yl)benzonitrile&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2.5-&lt;br&gt;Pharmaceutical form of the placebo: Capsule, hard&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Product Name: SAF312&lt;br&gt;Product Code: SAF312&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Not known yet&lt;br&gt;CAS Number: 871814-52-7&lt;br&gt;Current Sponsor code: SAF312&lt;br&gt;Other descriptive name: 4-(7-Hydroxy-2-isopropyl-4-oxo-4Hquinazolin-3-yl)benzonitrile&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;Pharmaceutical form of the placebo: Capsule, hard&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Product Name: SAF312&lt;br&gt;Product Code: SAF312&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Not known yet&lt;br&gt;CAS Number: 871814-52-7&lt;br&gt;Current Sponsor code: SAF312&lt;br&gt;Other descriptive name: 4-(7-Hydroxy-2-isopropyl-4-oxo-4Hquinazolin-3-yl)benzonitrile&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;Pharmaceutical form of the placebo: Capsule, hard&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Assessment of the change in maximum cystometric capacity (MCC) following one week of treatment versus baseline ;Primary end point(s): Change in maximum cystometric capacity (MCC) following one week of treatment versus baseline;Secondary Objective: - Evaluation of the safety, tolerability and pharmacokinetics of oral SAF312 administered with a b.i.d. regimen for 1 week&lt;br&gt;- Assessment of the relationship between pharmacokinetics and pharmaco-dynamics of SAF312&lt;br&gt;- Evaluation of the effects of SAF312 on additional parameters examined during filling cystometry following one week of treatment versus baseline measurements&lt;br&gt;- Changes from baseline with respect to micturition or catheterization frequency as measured by daily diaries&lt;br&gt;- Changes from baseline with respect to incontinence episodes as measured by daily diaries&lt;br&gt;;Timepoint(s) of evaluation of this end point: After 1 week of treatment </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): - Safety, tolerability and pharmacokinetics of SAF312 
&lt;br&gt;- Relationship between pharmacokinetics and pharmacodynamics of SAF312
&lt;br&gt;- Additional parameters examined during filling cystometry following one week of treatment versus baseline measurements
&lt;br&gt;- Changes from baseline with respect to micturition or catheterization frequency as measured by daily diaries
&lt;br&gt;- Changes from baseline with respect to incontinence episodes as measured by daily diaries
&lt;br&gt;;Timepoint(s) of evaluation of this end point: - Safety, tolerability and pharmacokinetics of SAF312: over the entire study duration
&lt;br&gt;- Relationship between pharmacokinetics and pharmacodynamics of SAF312: for a week after treatment administration
&lt;br&gt;- Additional parameters examined during filling cystometry following one week of treatment versus baseline measurements: after 1 week of treatment
&lt;br&gt;- Changes from baseline with respect to micturition or catheterization frequency and changes from baseline with respect to incontinence episodes: daily for a week</Secondary_outcome>
    <Secondary_ID>CSAF312A2202;Not applicable</Secondary_ID>
    <Source_Support>Novartis Pharma Services AG</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2585324</Internal_Number>
    <TrialID>EUCTR2009-016675-29-GB</TrialID>
    <Last_Refreshed_on>8 May 2012</Last_Refreshed_on>
    <Public_title>A Phase II Study Investigating Upfront Pazopanib in Metastatic Clear Cell Renal Cancer [PANTHER] - PANTHER (version 6, 23 March 2012)</Public_title>
    <Scientific_title>A Phase II Study Investigating Upfront Pazopanib in Metastatic Clear Cell Renal Cancer [PANTHER] - PANTHER (version 6, 23 March 2012)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Queen Mary university of London</Primary_sponsor>
    <Date_registration3>20100317</Date_registration3>
    <Date_registration>17/03/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-016675-29                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>29/04/2010</Date_enrollement>
    <Target_size>95</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;• Histopathologically confirmed clear cell carcinoma with measurable metastases on CT/MRI imaging (by RECIST). Only a component of clear cell is required. &lt;br&gt;• No prior systemic treatment or nephrectomy for RCC. Palliative radiotherapy is acceptable to non target lesions.&lt;br&gt;• Adequate organ function as defined by the following criteria:&lt;br&gt;i.	Total serum bilirubin =1.5 x uln (patients with gilbert’s disease exempt)&lt;br&gt;ii.	Serum transaminases (ALT) &lt;3 x uln&lt;br&gt;iii.	Calculated creatinine clearance &gt;30ml/min &lt;br&gt;iv.	Absolute neutrophil count (ANC) =1000/mm3 without growth factor support&lt;br&gt;v.	Platelets = 75,000/mm3&lt;br&gt;• Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrolment.&lt;br&gt;• Willingness and ability to comply with scheduled visits, treatment plans and laboratory tests and other study procedures&lt;br&gt;• ECOG performance status of 0, 1 or 2.&lt;br&gt;• 18 years or above (no upper age limit)&lt;br&gt;• Male or female&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;• Congestive heart failure (class III or IV NYHA), myocardial infarction or coronary artery bypass graft/ stenting or stroke in the previous six months, ongoing severe or unstable arrhythmia requiring medication.&lt;br&gt;• Previous treatment for renal cancer&lt;br&gt;• Pregnancy or breastfeeding.  Female patients must be surgically sterile, be postmenopausal, or must agree to use adequate contraception during the period of therapy.  &lt;br&gt;• Male patients must be surgically sterile or agree to use adequate contraception during the period of therapy.&lt;br&gt;• Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would in the judgement of the investigator, impart excess risk associated with study participation or study drug administration, or which, in the judgement of the investigator, would make the patient inappropriate for entry into this study&lt;br&gt;• Prolonged QT interval &gt;480msecs&lt;br&gt;• Ongoing major gastrointestinal disease including ulcerative colitis, bleeding peptic ulcer disease or inflammatory bowel disease.&lt;br&gt;• Bleeding diathesis&lt;br&gt;• Current uncontrolled hypertension&lt;br&gt;• Another malignancy requiring treatment within the last 5 years. Local prostate cancer not requiring hormone therapy or an asymptomatic raised PSA is acceptable. &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Metastatic Renal Cell Carcinoma</Condition>
    <Intervention>&lt;br&gt;Trade Name: Votrient&lt;br&gt;Product Name: Pazopanib&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: PAZOPANIB HYDROCHLORIDE&lt;br&gt;CAS Number: 635702-64-6&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine the clinical benefit of giving 14 weeks pazopanib to patients with metastatic kidney cancer prior to surgery to remove the cancerous kidney (nephrectomy). ;Secondary Objective: 1) To evaluate surgical complications (blood loss, post operative complications,&lt;br&gt;hospital stay)&lt;br&gt;2) To evaluate the local response of the primary tumour to pazopanib&lt;br&gt;3) To evaluate progression free survival&lt;br&gt;4) To evaluate overall survival&lt;br&gt;5) To evaluate translational endpoints;Primary end point(s): The primary outcome measure is to determine the proportion of patients who benefit clnically from 14 weeks of pre-operative pazopanib therapy. This will be assessed with CT scans. </Primary_outcome>
    <Secondary_ID>RC200902</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2590500</Internal_Number>
    <TrialID>EUCTR2010-018792-17-DE</TrialID>
    <Last_Refreshed_on>15 May 2012</Last_Refreshed_on>
    <Public_title>Single-center, single-armed, open-label, prospective  study assessing efficacy and safety of a conversion of kidney allograft recipients suffering from Chronic Allograft Nephropathy (CAN) assessed by GFR-slope analysis to an Everolimus-based regimen to improve renal function - ProCAN</Public_title>
    <Scientific_title>Single-center, single-armed, open-label, prospective  study assessing efficacy and safety of a conversion of kidney allograft recipients suffering from Chronic Allograft Nephropathy (CAN) assessed by GFR-slope analysis to an Everolimus-based regimen to improve renal function - ProCAN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Kliniken der Stadt Koeln gGmbH, Klinikum Merheim</Primary_sponsor>
    <Date_registration3>20101228</Date_registration3>
    <Date_registration>28/12/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-018792-17                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>04/07/2011</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Males or females, aged &gt;18 years&lt;br&gt;2. Renal transplant recipients suffering from Chronic Allograft Nephropathy (CAN) defined as having a statistically evident decrease in the GFR-slope at least 6 months prior to baseline. GFR-slope is calculated for the period from the day of TX until baseline (at least 6 months post transplantation) or at least 6 months before baseline and must have a significant negative slope as calculated by described statistic method (chapter 10.4.2). At least 5 GFR-values have to be present for slope-calculation. A renal biopsy at Baseline Visit will be performed to confirm the presence of CAN. This renal bisopsy may be taken within three months before Baseline visit&lt;br&gt;3. Allowed time interval between renal transplantation and Baseline Visit is = 6 months&lt;br&gt;4. Patients receiving Myfortic® / MMF and a CNI (Sandimmun® Optoral or Prograf®) with or without corticosteroids as part of their immunosuppressive regimen for at least 1 month before baseline&lt;br&gt;5. Females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at baseline, and are required to practice an approved method of birth control for the duration of the study and for a period of 6 weeks following discontinuation of study medication, even where there has been a history of infertility (see also chapter 8.2)&lt;br&gt;6. Patients who are willing and able to participate in the study and from whom written informed consent has been obtained&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. More than one previous renal transplantation&lt;br&gt;2. Multi-organ recipients (e.g., kidney and pancreas) or previous transplant with any other organ, different from kidney&lt;br&gt;3. Patient with proteinuria &gt; 1g/day total Protein in Urine or &gt; 500mg/day Albumin in Urine at baseline&lt;br&gt;4. Patients with hypersensitivity to Certican®, mycophenolic acid, or other components of the formulation (e.g. lactose; see also SPCs)&lt;br&gt;5. Patients who have received an investigational drug within four weeks prior to baseline&lt;br&gt;6. Patients who suffered from severe rejection (more than or equal to BANFF II acute rejection), recurrent acute rejection, or steroid resistant rejection within 6 months of enrollment in this trial (baseline). A renal biopsy at Baseline Visit will be performed to exclude any signs of rejection. This renal biopsy may taken within 3 month before Baseline visit  &lt;br&gt;7. Patients with thrombocytopenia (platelets &lt; 100,000/mm³), with an absolute neutrophil count of &lt; 1,500/mm³ or leucopenia (leucocytes &lt; 4,000/mm³), or hemoglobin &lt; 8 g/dL&lt;br&gt;8. Abnormal physical or laboratory findings of clinical significance within 2 weeks of study inclusion (baseline) which at investigator discretion would interfere with the objectives of the study&lt;br&gt;9. Patients with symptoms of significant somatic or mental illness. Inability to cooperate or communicate with the investigator, who are unlikely to comply with the study requirements, or who are unable to give informed consent&lt;br&gt;10. Patients with a history of malignancy during the last five years, except squamos or basal cell carcinoma of the skin&lt;br&gt;11. Patients who are HIV positive, or Hepatitis C-, or Hepatitis B surface antigen positive&lt;br&gt;12. Evidence of severe liver disease (incl. abnormal liver enzyme profile, i.e. AST, ALT or total bilirubin &gt; 3 times UNL)&lt;br&gt;13. Females of childbearing potential who are planning to become pregnant, who are pregnant or lactating and/or who are unwilling to use effective means of contraception &lt;br&gt;14. Presence of a clinically significant infection requiring continued therapy, severe diarrhea, active peptic ulcer disease or uncontrolled diabetes mellitus that in the opinion of the investigator would interfere with the appropriate conduct of the study&lt;br&gt;15. Evidence of drug or alcohol abuse&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>This study is designed to assess whether a conversion from a CNI-based therapy to a CNI-free therapy with Certican® and Myfortic® in renal transplant patients with Chronic Allograft Nephropathy (CAN) is able to improve renal function. The study is investigating the efficacy of a conversion from a CNI-based to a CNI-free therapy and should show that this switch is safe and well tolerated. &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10023438
Term: Kidney transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican Tabletten&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Other descriptive name: EVEROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.25-&lt;br&gt;&lt;br&gt;Trade Name: Certican Tabletten&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Other descriptive name: EVEROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Trade Name: Certican Tabletten&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Other descriptive name: EVEROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.75-&lt;br&gt;&lt;br&gt;Trade Name: Certican Tabletten&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Other descriptive name: EVEROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.0-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess improvement of renal function of kidney allograft recipients suffering from a chronic allograft nephropathy (CAN) after therapy switch to a CNI-free regimen between Baseline and Month 12 by monitoring the GFR slope using Cockcroft-Gault method&lt;br&gt;;Secondary Objective: To assess improvement of renal function assessed as glomerular filtration rate (GFR) – Nankivell method –  at Month 12&lt;br&gt;&lt;br&gt;To assess each efficacy variable (time to biopsy proven acute rejection, graft loss, death) at Month 12&lt;br&gt;&lt;br&gt;To assess occurrence of treatment failures up to or at Month 12, while treatment failure is defined as a composite endpoint of biopsy proven acute rejection, graft loss, death, loss to follow up and discontinuations due to lack of efficacy or toxicity or conversion to another regimen (at least one condition must be present)&lt;br&gt;&lt;br&gt;To assess safety and tolerability during the trial and finally at Month 12 &lt;br&gt;&lt;br&gt;To assess changes in proteinuria between BL and Month 12&lt;br&gt;&lt;br&gt;Cardiovascular risk factors (blood pressure, cholesterol (HDL, LDL), triglyceride, documentation of antihypertensive drugs)&lt;br&gt;;Primary end point(s): Improvement of renal function between Baseline and Month 12 by monitoring the GFR slope using Cockcroft-Gault method&lt;br&gt;</Primary_outcome>
    <Secondary_ID>KM004EIC</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2590507</Internal_Number>
    <TrialID>EUCTR2010-018791-24-DE</TrialID>
    <Last_Refreshed_on>15 May 2012</Last_Refreshed_on>
    <Public_title>Single-center, single-armed, open-label, prospective study assessing efficacy and safety of a conversion of stable kidney allograft recipients to an Everolimus-based regimen to prevent the development of CAN (Chronic Allograft Nephropathy) and improve renal function - PreCAN</Public_title>
    <Scientific_title>Single-center, single-armed, open-label, prospective study assessing efficacy and safety of a conversion of stable kidney allograft recipients to an Everolimus-based regimen to prevent the development of CAN (Chronic Allograft Nephropathy) and improve renal function - PreCAN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Kliniken der Stadt Koeln gGmbH, Klinikum Merheim</Primary_sponsor>
    <Date_registration3>20110104</Date_registration3>
    <Date_registration>04/01/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-018791-24                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>04/07/2011</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Males or females, aged &gt;18 years&lt;br&gt;2.	Stable maintenance renal transplant recipients defined as having a stable GFR- slope at least 6 months prior to baseline. GFR-slope is calculated for the period from the day of TX until baseline (at least 6 months post transplantation) or at least 6 months before baseline and must not have a significant negative slope as calculated by described statistic method (chapter 10.4.2). At least 5 GFR-values have to be present for slope-calculation. A renal biopsy at Baseline Visit will be performed to exclude the presence of CAN. This renal bisopsy may be taken within 3 months before Baseline visit&lt;br&gt;3.	Allowed time interval between renal transplantation and Baseline Visit is = 6 months&lt;br&gt;4.	Patients receiving Myfortic® / MMF and a CNI (Sandimmun® Optoral or Prograf®) with or without corticosteroids as part of their immunosuppressive regimen for at least 4 weeks prior study start whereas the single doses of the regime partners may vary&lt;br&gt;5.	Females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at baseline, and are required to practice an approved method of birth control for the duration of the study and for a period of 6 weeks following discontinuation of study medication, even where there has been a history of infertility (see also chapter 8.2)&lt;br&gt;6.	Patients who are willing and able to participate in the study and from whom written informed consent has been obtained&lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	More than one previous renal transplantation&lt;br&gt;2.	Multi-organ recipients (e.g., kidney and pancreas) or previous transplant with any other organ, different from kidney&lt;br&gt;3.	Patient with proteinuria &gt; 1g/day total Protein in urine or &gt; 500mg/day Albumin in urine at baseline&lt;br&gt;4.	Patients with hypersensitivity to Certican®, mycophenolic acid, or other components of the formulation (e.g. lactose; see also SPCs)&lt;br&gt;5.	Patients who have received an investigational drug within four weeks prior to baseline&lt;br&gt;6.	Patients who suffered from severe rejection (more than or equal to BANFF II acute rejection), recurrent acute rejection, or steroid resistant rejection within 6 months of enrollment in this trial (baseline). A renal biopsy at Baseline Visit will be performed to exclude any signs of rejection. This renal biopsy may taken within 3 month before Baseline visit &lt;br&gt;7.	Patients with thrombocytopenia (platelets &lt; 100,000/mm³), with an absolute neutrophil count of &lt; 1,500/mm³ or leucopenia (leucocytes &lt; 4,000/mm³), or hemoglobin &lt; 8 g/dL&lt;br&gt;8.	Abnormal physical or laboratory findings of clinical significance within 2 weeks of study inclusion (baseline) which at investigator discretion would interfere with the objectives of the study&lt;br&gt;9.	Patients with symptoms of significant somatic or mental illness. Inability to cooperate or communicate with the investigator, who are unlikely to comply with the study requirements, or who are unable to give informed consent&lt;br&gt;10.	Patients with a history of malignancy during the last five years, except squamos or basal cell carcinoma of the skin&lt;br&gt;11.	Patients who are HIV positive, or Hepatitis C-, or Hepatitis B surface antigen positive&lt;br&gt;12.	Evidence of severe liver disease (incl. abnormal liver enzyme profile, i.e. AST, ALT or total bilirubin &gt; 3 times UNL)&lt;br&gt;13.	Females of childbearing potential who are planning to become pregnant, who are pregnant or lactating and/or who are unwilling to use effective means of contraception &lt;br&gt;14.	Presence of a clinically significant infection requiring continued therapy, severe diarrhea, active peptic ulcer disease or uncontrolled diabetes mellitus that in the opinion of the investigator would interfere with the appropriate conduct of the study&lt;br&gt;15.	Evidence of drug or alcohol abuse&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>This study is designed to assess whether a conversion from a CNI-based therapy to a CNI-free therapy with Certican® in stable renal transplant patients is able to prevent the development of Chronic Allograft Nephropathy (CAN) and to improve renal function. The study investigates the efficacy of a prophylactic conversion from a CNI-based to a CNI-free therapy and should show that the conversion is safe and well tolerated. &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10023438
Term: Kidney transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican Tabletten&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Trade Name: Certican Tabletten&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.75-&lt;br&gt;&lt;br&gt;Trade Name: Certican Tabletten&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.0-&lt;br&gt;&lt;br&gt;Trade Name: Certican Tabletten&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess evolution of renal function of stable renal kidney allograft recipients after therapy switch to a CNI-free regimen between baseline and Month 12 by monitoring the GFR slope using Cockcroft-Gault method.&lt;br&gt;;Secondary Objective: Renal function assessed as glomerular filtration rate (GFR) – Nankivell method –  at Month 12&lt;br&gt;&lt;br&gt;To assess each efficacy variable (time to biopsy proven acute rejection, graft loss, death) at Month 12&lt;br&gt;&lt;br&gt;To assess occurrence of treatment failures up to or at Month 12, while treatment failure is defined as a composite endpoint of biopsy proven acute rejection, graft loss, death, loss to follow up and discontinuations due to lack of efficacy or toxicity or conversion to another regimen (at least one condition must be present)&lt;br&gt;&lt;br&gt;To assess safety and tolerability during the trial and finally at Month 12 &lt;br&gt;&lt;br&gt;To assess changes in proteinuria between BL and Month 12&lt;br&gt;&lt;br&gt;Cardiovascular risk factors (blood pressure, cholesterol (HDL, LDL), triglyceride, documentation of antihypertemsive drugs)&lt;br&gt;;Primary end point(s): Evolution of renal function between Baseline and Month 12 of the study by assessing the GFR-slope using Cockcroft-Gault method. </Primary_outcome>
    <Secondary_ID>KM003EPC</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2603467</Internal_Number>
    <TrialID>EUCTR2007-000410-37-DE</TrialID>
    <Last_Refreshed_on>29 May 2012</Last_Refreshed_on>
    <Public_title>Determination of glomerular filtration rate (GFR) using MR nephrography in patients with chronic kidney disease.</Public_title>
    <Scientific_title>Determination of glomerular filtration rate (GFR) using MR nephrography in patients with chronic kidney disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>University Of Tuebingen</Primary_sponsor>
    <Date_registration3>20070515</Date_registration3>
    <Date_registration>15/05/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-000410-37                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/09/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Chronic kidney disease Stages 1,2 and 3&lt;br&gt;- age over 18 years&lt;br&gt;- stable kidney function 2 weeks prior study&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- chronic kidney disease stages 4 and 5&lt;br&gt;- exclusion for MR: pace maker, metal implant, ICD&lt;br&gt;- pregnancy&lt;br&gt;- known allergy against gadovist or inulin&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic kidney disease &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10064848
Term: Chronic kidney disease
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Gadovist(R)&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Gadobutrol&lt;br&gt;CAS Number: 138071-82-6&lt;br&gt;Concentration unit: mmol/ml millimole(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.0-&lt;br&gt;&lt;br&gt;Trade Name: Inutest&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Sinistrin&lt;br&gt;Concentration unit: % (W/V) percent weight/volume&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Measurement of glomerular filtration rate using magnetic resonance and comparison to the GFR measured by inulin clearance;Secondary Objective: ;Primary end point(s): Agreement between GFR measured by MR and inulin </Primary_outcome>
    <Secondary_ID>310107</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2603951</Internal_Number>
    <TrialID>EUCTR2009-009426-81-DE</TrialID>
    <Last_Refreshed_on>29 May 2012</Last_Refreshed_on>
    <Public_title>Contrast-enhanced Imaging of the Abdomen: Gadovist® vs. Dotarem® – Intraindividual comparison of 0.1mmol/kg bw gadoterate meglumine with 0.1mmol/kg bw gadobutrol for dynamic abdominal imaging in patients with suspected focal liver or renal lesions
 - CIA-GaDo</Public_title>
    <Scientific_title>Contrast-enhanced Imaging of the Abdomen: Gadovist® vs. Dotarem® – Intraindividual comparison of 0.1mmol/kg bw gadoterate meglumine with 0.1mmol/kg bw gadobutrol for dynamic abdominal imaging in patients with suspected focal liver or renal lesions
 - CIA-GaDo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>University Heidelberg</Primary_sponsor>
    <Date_registration3>20090702</Date_registration3>
    <Date_registration>02/07/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009426-81                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/11/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: Evaluation in a blinded read only&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Subjected to MR imaging of the liver or of the kidneys for clinical reasons&lt;br&gt;2.	willing to undergo two MR-exams within 14 days&lt;br&gt;3.	Age: 18 – 85 years&lt;br&gt;4.	Provided written informed consent.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Glomerular filtration rate (GFR) less than 50ml/min/1.73m2, calculated with the MDRD formula. The values must not be older than 1 week before the examination.&lt;br&gt;2.	If female, pregnant or breast-feeding&lt;br&gt;3.	MR contraindications, e.g. pacemaker, magnetic clips or several claustrophobia&lt;br&gt;4.	Intervention or change in therapy between the two MR examinations&lt;br&gt;5.	Known allergy to any ingredient of Gadovist or Dotarem&lt;br&gt;6.	Presenting with history of anaphylactoid or anaphylactic reaction to any allergen including drugs and contrast agents&lt;br&gt;7.	Having received another investigational drug within the last 30 days prior to inclusion into this study&lt;br&gt;8.	Having any physical or mental status that interferes with the informed consent procedure including self-signed consent&lt;br&gt;9.	Close affiliation with the investigational site; e.g. a close relative of the investigator&lt;br&gt;10.	Having been previously enrolled in this study&lt;br&gt;11.	Participating in another clinical trial&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>patients with suspected focal liver or renal lesions &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10039533
Term: Scan NOS abdomen abnormal
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Gadovist 1.0 mmol/ml, Injektionslösung&lt;br&gt;Product Code: V08CA09&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: GADOBUTROL&lt;br&gt;CAS Number: 138071-82-6&lt;br&gt;Concentration unit: mmol/ml millimole(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.0-&lt;br&gt;&lt;br&gt;Trade Name: Dotarem 0,5mmol/ml, Injektionslösung&lt;br&gt;Product Code: V08CA02&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Gadoterate meglumine&lt;br&gt;CAS Number: 92923-44-9&lt;br&gt;Concentration unit: mmol/ml millimole(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of the study is to show in an intra-individual comparison the superiority of Gadovist®-enhanced images over Dotarem®-enhanced images in patients with suspected or known lesions of the liver or the kidneys by two blinded radiologists ;Secondary Objective: The secondary objectives comprise the determination of the technical parameters SNR and CNR:&lt;br&gt;•	Aorta during the first pass (20s post injection)&lt;br&gt;•	Aorta during the portalvenous phase (40s post injection)&lt;br&gt;•	Portal vein during the portalvenous phase (40s post injection)&lt;br&gt;•	Liver during the portalvenous phase (40s post injection)&lt;br&gt;•	Kidney during the portalvenous phase (40s post injection)&lt;br&gt;•	Pancreas during the portalvenous phase (40s post injection)&lt;br&gt;•	Liver, kidney, pancreas during the delayed phase (80s post injection)&lt;br&gt;•	Largest liver mass (20s, 40s and 80s post injection)&lt;br&gt;•	Largest renal mass (20s, 40s and 80s post injection)&lt;br&gt;;Primary end point(s): Technical (quantitative) assessment of the difference  of&lt;br&gt;•	SNR&lt;br&gt;•	CNR&lt;br&gt;- image quality&lt;br&gt;</Primary_outcome>
    <Secondary_ID>CIA-GaDo</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2605309</Internal_Number>
    <TrialID>EUCTR2008-002345-23-DE</TrialID>
    <Last_Refreshed_on>29 May 2012</Last_Refreshed_on>
    <Public_title>Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients</Public_title>
    <Scientific_title>A PHASE 2, MULTICENTER, OPEN-LABEL, ACTIVE COMPARATOR CONTROLLED, EXTENSION TRIAL TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF CP-690,550 IN RENAL ALLOGRAFT RECIPIENTS - N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Pfizer Inc. 235 East 42nd Street, New York, NY10017, USA</Primary_sponsor>
    <Date_registration3>20080915</Date_registration3>
    <Date_registration>15/09/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-002345-23                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>28/11/2008</Date_enrollement>
    <Target_size>300</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 3&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Subjects must meet all of the following criteria to be eligible for enrollment into the trial:&lt;br&gt;1. Subjects must have received a primary renal allograft, enrolled in Study A3921030 and completed 12-months of treatment with trial medications (CP-690,550 or CsA).&lt;br&gt;2. Subjects must have no known contraindications to the continued administration of CP-690,550, CsA, MMF or corticosteroids.&lt;br&gt;3. Subjects must be willing and able to provide written informed consent with evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all the pertinent aspects of the study.&lt;br&gt;4. Subjects must be willing and able to comply with the scheduled visits, treatment plan,laboratory tests, and other study procedures.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: 0&lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 162&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 16&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Subjects with any of the following will not be included in the trial:&lt;br&gt;1. Subjects who are on the waiting list for a second kidney transplant or any non renal organ transplant.&lt;br&gt;2. Subjects who are unwilling to refrain from consumption of grapefruit or grapefruit containing juices for the duration of trial medication period.&lt;br&gt;3. Subjects receiving or expected to receive concomitant medications on the list of prohibited medications.&lt;br&gt;4. Subjects with mental dysfunction or inability to cooperate with the trial.&lt;br&gt;5. Subjects with any condition that may significantly affect drug absorption (eg, gastrectomy or insufficiently treated diabetic gastroparesis).&lt;br&gt;6. Women of childbearing potential who are either pregnant, lactating, planning to become pregnant during this trial, or with a positive serum or urine pregnancy test. Women of childbearing potential must be willing to agree to contraceptive practices.&lt;br&gt;7. Males who are unwilling to abstain from sexual intercourse or use a condom with lactating women.&lt;br&gt;8. Subjects with clinically significant disease (eg, gastrointestinal or hepatic disorders) that places the subject at increased risk for participating in the trial and/or will confound the results of the trial.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Prevention of kidney allograft rejection &lt;br&gt;MedDRA version: 14.1
Level: LLT
Classification code 10066543
Term: Acute allograft rejection
System Organ Class: 10021428 - Immune system disorders
;Therapeutic area: Diseases [C] - Immune System Diseases [C20]</Condition>
    <Intervention>&lt;br&gt;Product Name: CP-690,550&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: tofacitinib&lt;br&gt;CAS Number: 540737-29-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: Ciclosporin&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: Ciclosporin&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: Ciclosporin&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: Ciclosporin&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate the long term safety, tolerability and efficacy of CP 690,550 including the incidence of Biopsy Proven Acute Rejection (BPAR) (as interpreted by the central pathologist) and treated clinical acute rejection, (episodes that are diagnosed clinically and receive anti rejection treatment).;Secondary Objective: • To evaluate additional efficacy measures such as combined Banff rejection categories (of Antibody mediated rejection plus Borderline changes plus Acute rejection, as interpreted by the central pathologist), graft loss, subject death, and efficacy failure (defined as the first occurrence of BPAR or graft loss, including subject death);&lt;br&gt;• To explore relationships between CP 690,550 concentrations and safety and efficacy endpoints.&lt;br&gt;;Primary end point(s): • Adverse events, clinically significant infections, malignancies, measured GFR, and progression of chronic allograft lesions;&lt;br&gt;• BPAR (as interpreted by the central pathologist) and treated clinical acute rejection, (episodes that are diagnosed clinically and receive anti rejection treatment).&lt;br&gt;;Timepoint(s) of evaluation of this end point: Adverse events, clinically significant infections, malignancies, BPAR and treated clinical acute rejection will be evaluated through Month 72 posttransplant, measured GFR and progression of CAN will be evaluated at Month 36.  </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): • Combined Banff rejection categories (of Antibody mediated rejection plus Borderline changes plus Acute rejection, as interpreted by the central pathologist), graft loss, subject death, efficacy failure, and subject discontinuation;
&lt;br&gt;• Safety laboratory tests (including ANC, Hgb, serum lipids, HbA1c, fasting serum glucose, and proteinuria);
&lt;br&gt;• Estimated GFR (GFR derived from equations), pharmacokinetics, and health outcome assessments.
&lt;br&gt;;Timepoint(s) of evaluation of this end point: All secondary endpoints will be evaluated through Month 72 posttransplant.  Health outcomes measures will be evaluated through Month 36 posttransplant.</Secondary_outcome>
    <Secondary_ID>A3921050;NCT00658359</Secondary_ID>
    <Source_Support>Pfizer Inc</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2605458</Internal_Number>
    <TrialID>EUCTR2012-001208-39-AT</TrialID>
    <Last_Refreshed_on>29 May 2012</Last_Refreshed_on>
    <Public_title>A new therapeutic approach to prevent acute complications in type 2 diabetes: The effect of the combination of the GLP-1 Analog Liraglutide and Insulin LEvemir® against the cOnventional insulin therapy: GALILEO</Public_title>
    <Scientific_title>A new therapeutic approach to prevent acute insulin-mediated complications in type 2 diabetes 
Subtitle: The effect of the combination of the GLP-1 Analog Liraglutide and Insulin LEvemir® vs. cOnventional insulin therapy: GALILEO
 - GALILEO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Medizinische Universität Wien, Univ.Klinik für Innere Medizin III, Abt.f.Endokrinologie und Stoffwechsel</Primary_sponsor>
    <Date_registration3>20120417</Date_registration3>
    <Date_registration>17/04/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-001208-39                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>14/05/2012</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: conventionel insulin therapy&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Type 2 diabetes &lt;br&gt;•	Currently under oral glucose lowering medication&lt;br&gt;•	Insufficient metabolic control: HbA1C &gt; 8%&lt;br&gt;•	Patient understands study procedure and gives written informed consent&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 32&lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	Age &lt; 18 years&lt;br&gt;•	Type 1 Diabetes, LADA-Diabetes&lt;br&gt;•	Prior insulin administration/therapy&lt;br&gt;•	Therapy with thiazolidiones&lt;br&gt;•	Known cardiovascular disease (history of myocardial infarction, stroke etc)&lt;br&gt;•	Severe arterial hypertension &lt;br&gt;•	Acute or chronic inflammatory disease within 2 weeks prior the study&lt;br&gt;•	Kidney or liver disease&lt;br&gt;•	Psychiatric disorder&lt;br&gt;•	Tendency towards claustrophobia&lt;br&gt;•	metal devices or other magnetic material in or on the subjects body which will be hazardous for NMR investigation &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>diabetes mellitus type 2, inadequate metabolic control, indication for insulin therapy
myocardial lipid accumulation and left-ventricular function, retinal changes, microabluminuria, beta-cell-function, endothelial dysfunction &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10012607
Term: Diabetes mellitus inadequate control
System Organ Class: 10027433 - Metabolism and nutrition disorders
 &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10012689
Term: Diabetic retinopathy
System Organ Class: 10015919 - Eye disorders
 &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10067585
Term: Type 2 diabetes mellitus
System Organ Class: 10027433 - Metabolism and nutrition disorders
 &lt;br&gt;MedDRA version: 14.1
Level: HLT
Classification code 10012654
Term: Diabetic complications cardiovascular
System Organ Class: 10014698 - Endocrine disorders
 &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10012647
Term: Diabetic cardiomyopathy
System Organ Class: 10007541 - Cardiac disorders
 &lt;br&gt;MedDRA version: 14.1
Level: HLT
Classification code 10012658
Term: Diabetic complications renal
System Organ Class: 10014698 - Endocrine disorders
 &lt;br&gt;MedDRA version: 14.1
Level: HLT
Classification code 10012657
Term: Diabetic complications ophthalmic
System Organ Class: 10014698 - Endocrine disorders
 &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10054044
Term: Diabetic microangiopathy
System Organ Class: 10047065 - Vascular disorders
 &lt;br&gt;MedDRA version: 14.1
Level: HLGT
Classification code 10012653
Term: Diabetic complications
System Organ Class: 10014698 - Endocrine disorders
;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]</Condition>
    <Intervention>&lt;br&gt;Product Name: Insulin Levemir&lt;br&gt;Product Code: EMEA/H/C/000528&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;INN or Proposed INN: INSULIN DETEMIR&lt;br&gt;CAS Number: 169148-63-4&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Name: Victoza&lt;br&gt;Product Code: EMEA/H/C/001026&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;INN or Proposed INN: LIRAGLUTIDE&lt;br&gt;CAS Number: 204656-20-2&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 6-&lt;br&gt;&lt;br&gt;Product Name: insulin aspart&lt;br&gt;Product Code: EMEA/H/C/000308&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;INN or Proposed INN: INSULIN ASPART&lt;br&gt;CAS Number: 116094-23-6&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The aim of the current study is to evaluate the acute effects of gradual, insulin sparing (GLP-1-based therapy) versus acute (insulin-based therapy) glucose lowering on myocardial lipid content (assessed by MR-spectroscopy) in patients with type 2 diabetes.;Secondary Objective: Changes in &lt;br&gt;•	hepato-cellular lipid content &lt;br&gt;•	left ventricular function (ejection fraction, end-systolic volume, end-diastolic volume, stroke volume, cardiac output, mass, wall thickness, E/A-ratio) and remodeling-indices&lt;br&gt;•	retinal morphology, perfusion and function as measured by Optical Coherence Tomography (SD-OCT) and fluorescein angiography&lt;br&gt;•	retinal function measured by microperimetry &lt;br&gt;•	biomarkers of endothelial dysfunction &lt;br&gt;•	microalbuminuria&lt;br&gt;•	beta-cell-function&lt;br&gt;;Primary end point(s): Changes in myocardial lipid content (assessed by MR-spectroscopy)&lt;br&gt;;Timepoint(s) of evaluation of this end point: study day 28</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Changes in:&lt;br&gt;- left-ventricular function&lt;br&gt;- retinopathy&lt;br&gt;- microalbuminuria&lt;br&gt;- beta-cell-function&lt;br&gt;- biomarkers of endothelial dysfunction;Timepoint(s) of evaluation of this end point: study day 28</Secondary_outcome>
    <Secondary_ID>GALILEO242012</Secondary_ID>
    <Source_Support>Medizinische Universität Wien</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2634118</Internal_Number>
    <TrialID>EUCTR2010-019337-10-ES</TrialID>
    <Last_Refreshed_on>12 June 2012</Last_Refreshed_on>
    <Public_title>Estudio piloto abierto, aleatorizado (2:1), prospectivo y unicentrico para evaluar el rechazo agudo y la función renal de una pauta inmunosupresora libre de fármacos  anticalcineurínicos frente a un regimen convencional (basado en fármacos anticalcineurinicos) en receptores de un trasplante renal de riesgo estándar.</Public_title>
    <Scientific_title>Estudio piloto abierto, aleatorizado (2:1), prospectivo y unicentrico para evaluar el rechazo agudo y la función renal de una pauta libre de anticalcineurínicos basada en Sirolimus con doble inducción con timoglobulina y gammaglobulina frente a un regimen convencional basado, en anticalcineurinicos en receptores de un trasplante renal de riesgo estándar.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>SERVICIO NEFROLOGIA HOSPITAL UNIVERSITARIO DE BELLVITGE</Primary_sponsor>
    <Date_registration3>20120328</Date_registration3>
    <Date_registration>28/03/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-019337-10                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/05/2012</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Edad del receptor 18 años.&lt;br&gt;2. Pacientes afectos de insuficiencia renal crónica terminal candidatos a recibir un primer injerto renal de cadáver, de vivo no emparentado o emparentado.&lt;br&gt;3. PAR 20%(panel de antigenos reactivos poblacionales) &lt;br&gt;4. Test cross-match por linfocitotoxicidad negativo pre-trasplante.&lt;br&gt;5. Mujeres con potencial fértil deben tener un test de embarazo negativo antes de la inclusión.&lt;br&gt;5. Mujeres y hombres con potencial fértil deben acceder a utililizar un método anticonceptivo eficaz durante todo el tratamiento y hasta 3 meses de su finalización. &lt;br&gt;6. Consentimiento informado firmado y fechado antes del trasplante.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 25&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 5&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Trasplante de órganos múltiple.&lt;br&gt;2. Receptores de riñones en bloque de adulto o pediátricos, dual o de donante a corazón parado.&lt;br&gt;3. Evidencia de infección sistémica o localizada importante.&lt;br&gt;4. Evidencia de infiltrado, cavitación o consolidación en la placa de torax pre-trasplante.&lt;br&gt;5. Uso de fármacos o tratamientos  en investigación  durante las 4 semanas previas al trasplante renal.&lt;br&gt;6. Tratamiento con  voriconazol, ketoconazol, itraconazol, fluconazol, clotrimoxazol, astemizol, pimozida, terfenadina, erithromicina, claritromicina, telitromicina, troleandomicina, rifampicina, rifabutina, o hierba de San Juan que se discontinuen antes de la inclusión.&lt;br&gt;7. Tratamiento con aminoglucosidos, amfotericina B, cisplatino, cisaprida, metoclopramida, cimetidina, bromocriptina, danazol, o otros fármacos asociados a disfunción renal que no se discontinuen antes de la inclusión en el estudio. &lt;br&gt;8. Individuos con un recuento de leucocitos  2,000/mm3 o neutofilos totales  500, plaquetas 100,000/mm3 pre-trasplante.&lt;br&gt;9.  Resultados de  trigliceridos  400 mg/dL (4.6 mmol/L) o colesterol      total  300 mg/dL (7.8 mmol/L) en ayunas, a pesar de estar recibiendo una adecuada terapia para la misma.&lt;br&gt; 10. Historia de malignidad en los 2 años previos a la inclusión (excepto el carcinoma basocelular o escamoso de piel adecuaamente tratado). &lt;br&gt; 11. Pacientes  infectados por los virus HIV, VHC y VHB.  &lt;br&gt; 12. Indice de masa corporal &gt;30 kg/m2.&lt;br&gt;14. Pacientes con trastornos psiquiátricos activos. &lt;br&gt;15. Pacientes con historia activa de ulcus péptico activo o trastorno en la absorción intestinal.&lt;br&gt;</Exclusion_Criteria>
    <Condition>END STAGE RENAL DISEASE-KIDNEY TRANSPLANTATION &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10070581
Term: Immune tolerance induction
System Organ Class: 10042613 - Surgical and medical procedures
 &lt;br&gt;MedDRA version: 14.1
Level: LLT
Classification code 10023438
Term: Kidney transplant
System Organ Class: 10042613 - Surgical and medical procedures
;Therapeutic area: Diseases [C] - Immune System Diseases [C20]</Condition>
    <Intervention>&lt;br&gt;Trade Name: TIMOGLOBULINA 5mg/ml Polvo para solución para perfusión&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: INMUNOGLOBULINA CONEJO ANTI-LINFOCITOS T HUMANOS&lt;br&gt;Other descriptive name: INMUNOGLOBULINA CONEJO ANTI-LINFOCITOS T HUMANOS&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: PRIVIGEN 100 mg/ml solución para perfusión&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: PROTEINA PLASMATICA HUMANA&lt;br&gt;Other descriptive name: PROTEINA PLASMATICA HUMANA&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Trade Name: RAPAMUNE 1 mg comprimidos recubiertos&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: SIROLIMUS&lt;br&gt;Other descriptive name: SIROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 0.5-2&lt;br&gt;&lt;br&gt;Trade Name: SIMULECT 20 mg polvo y disolvente para sol. iny. o sol. para perfusión&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;INN or Proposed INN: BASILIXIMAB&lt;br&gt;CAS Number: 179045-86-4&lt;br&gt;Other descriptive name: BASILIXIMAB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Trade Name: CELLCEPT 250 MG CAPSULAS&lt;br&gt;Product Name: MICOFENOLATO MOFETIL&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;INN or Proposed INN: MICOFENOLATO DE MOFETILO&lt;br&gt;Other descriptive name: MYCOPHENOLATE MOFETIL&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Trade Name: CELLCEPT 500 MG COMPRIMIDOS&lt;br&gt;Product Name: MICOFENOLATO MOFETIL&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: MICOFENOLATO DE MOFETILO&lt;br&gt;Other descriptive name: MYCOPHENOLATE MOFETIL&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Trade Name: CELLCEPT 500MG, POLVO PARA CONCENTRADO PARA SOL. PARA PERFUSION&lt;br&gt;Product Name: MICOFENOLATO MOFETIL&lt;br&gt;Pharmaceutical Form: Powder for solution for infusion&lt;br&gt;INN or Proposed INN:</Intervention>
    <Primary_outcome>Main Objective: El objetivo es la evaluación prospectiva de si la administración de timoglobulina junto con gammaglobulina seguida de un régimen basado en sirolimus con esteroides permitiria una buena función renal y , no inferior a la del grupo control  basada en anticalcineurinicos.;Secondary Objective: Descripción acumulada de los episodios de rechazo agudo, confirmados por biopsia.&lt;br&gt;- Describir el porcentaje de episodios de rechazo agudo sensibles a esteroides a los 6 meses&lt;br&gt;- Describir la necesidad de tratamiento con anticuerpos policlonales de los episodios de rechazo agudo a los 6 meses.&lt;br&gt;- Describir la incidencia de rechazo agudo mediado por anticuerpos&lt;br&gt;- Describir la proteinuria en g/día en el mes 6 y 12 post-trasplante.&lt;br&gt;- Describir la histología y expresión de FoxP3+Tregs y celulas T. &lt;br&gt;- Describir el porcentaje de pacientes con anticuerpos específicos contra el donante.&lt;br&gt;- Describir el porcentaje de pacientes que requieren la introducción de anticalcineurinicos.&lt;br&gt;- Describir los efectos adversos.&lt;br&gt;- Describir la depleción de linfocitos con diferentes marcadores de célula T (CD3, CD4, CD8, CD25) antes del trasplante y a los 15 días, 1, 3, 6, 12 y 24 meses.&lt;br&gt;- Describir la alorespuesta donante específica Th1 mediante el test ELISPOT pre-trasplante, 6, 12 y 24 meses post-trasp;Primary end point(s): Descripción de la función renal mediante la fórmula MDRD modificada en el mes 6 post-trasplante.</Primary_outcome>
    <Secondary_ID>SIDOTIGA</Secondary_ID>
    <Source_Support>Pfizer;Behring</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2644202</Internal_Number>
    <TrialID>EUCTR2004-000081-13-GB</TrialID>
    <Last_Refreshed_on>26 June 2012</Last_Refreshed_on>
    <Public_title>A randomized, controlled, open-label, multi-center, parallel group study to demonstrate efficacy and safety of RO0503821 when administered with pre-filled syringes for the maintenance treatment of anemia in patients with chronic kidney disease who are on dialysis.</Public_title>
    <Scientific_title>A randomized, controlled, open-label, multi-center, parallel group study to demonstrate efficacy and safety of RO0503821 when administered with pre-filled syringes for the maintenance treatment of anemia in patients with chronic kidney disease who are on dialysis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>F Hoffmann-La Roche Ltd</Primary_sponsor>
    <Date_registration3>20050214</Date_registration3>
    <Date_registration>14/02/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000081-13                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>07/09/2004</Date_enrollement>
    <Target_size>264</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Written informed consent&lt;br&gt;&lt;br&gt;2. Adult patients (=  18 years old) with chronic renal anemia &lt;br&gt;&lt;br&gt;3. Regular long-term hemodialysis or peritoneal dialysis therapy with the same mode of dialysis for at least 12 weeks before screening and during the screening/baseline period&lt;br&gt;&lt;br&gt;4. Kt/V =1.2 or URR =65% for patients on thrice-weekly hemodialysis or weekly Kt/V =1.8 for peritoneal dialysis patients. Hemodialysis patients with fewer or more dialysis sessions per week should have a weekly Kt/V =3.6&lt;br&gt;&lt;br&gt;5. Baseline haemoglobin concentration between 10.5 and 13 g/dL (mean of the weekly haemoglobin values determined in weekly -4 to-1)&lt;br&gt;&lt;br&gt;6.  Stable baseline haemoglobin concentrations (defined as an absolute difference less than or equal to 1g/dL between the mean haemoglobin values determined in weeks -4 and -3 and the mean hemoglobin values determined in weeks -2 and -1)&lt;br&gt;&lt;br&gt;7.  Continuous maintenance Epoetin therapy (Epoetin alfa formulated with human albumin or Epoetin beta) with the same dosing interval (i.e., one, two or three times weekly) and route (intravenous or subcutaneous) for at least 8 weeks before screening (a maximum of one missed does is allowed)&lt;br&gt;&lt;br&gt;8.  Continuous maintenance Epoetin therapy (Epoetin alfa formulated with human albumin or Epoetin beta) with the same dosing interval (i.e., one, two or three times weekly) and route (intravenous or subcutaneous) during screening/baseline period (no missed dose is allowed)&lt;br&gt;&lt;br&gt;9.  Stable maintenance Epoetin therapy (Epoetin alfa formulated with human albumin or Epoetin beta) during screening/baseline period (a maximum of one change of the weekly dose is allowed: this change should not exceed 25% compared to the weekly dose administered in the week preceding screening)&lt;br&gt;&lt;br&gt;10.  Adequate iron status defined as serum ferritin = 100 ng/mL or TSAT = 20% (or percentage of hypochromic red cells &lt; 10%);( mean of two values determined in week -4 and -3).&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.  Overt gastrointestinal bleeding or any other bleeding episode necessitating transfusion within 8 weeks before screening or during the screening/baseline period&lt;br&gt;&lt;br&gt;2.  RBC transfusions within 8 weeks before screening or during the screening/baseline period&lt;br&gt;&lt;br&gt;3.  Hemoglobinopathies (e.g. homozygous sickle-cell disease, thalassemia of all types)&lt;br&gt;&lt;br&gt;4.  Hemolysis&lt;br&gt;&lt;br&gt;5.  Active malignant disease except non-melanoma skin cancer&lt;br&gt;&lt;br&gt;6.  Chronic, uncontrolled or systematic inflammatory disease (e.g. rheumatoid arthritis, systemic lupus erythematosus)&lt;br&gt;&lt;br&gt;7.  Acute infection&lt;br&gt;&lt;br&gt;8.  CRP &gt; 30mg/L&lt;br&gt;&lt;br&gt;9.  Temporary (untunneled) dialysis access catheter&lt;br&gt;&lt;br&gt;10.  Vitamin B12 deficiency&lt;br&gt;&lt;br&gt;11.  Folic acid deficiency&lt;br&gt;&lt;br&gt;12.  Uncontrolled or symptomatic secondary hyperparathyroidism&lt;br&gt;&lt;br&gt;13.  Poorly controlled hypertension necessitating interruption of Epoetin treatment in the 6 months before screening &lt;br&gt;&lt;br&gt;14.  Epileptic seizure in the 6 months prior to screening&lt;br&gt;&lt;br&gt;15.  Platelets &gt; 500x109 /L&lt;br&gt;&lt;br&gt;16.  Pure red cell aplasia&lt;br&gt;&lt;br&gt;17.  Chronic congestive heart failure (New York Heart Association Class IV)&lt;br&gt;&lt;br&gt;18.  High likelihood of early withdrawal or interruption of the study (e.g. myocardial infraction, severe or unstable coronary artery disease, stroke, severe liver disease within the 12 weeks before screening or occurring during the screening period)&lt;br&gt;&lt;br&gt;19.  Planned elective surgery during the study period&lt;br&gt;&lt;br&gt;20.  Life expectation less than 12 months&lt;br&gt;&lt;br&gt;21.  Pregnancy or breast feeding&lt;br&gt;&lt;br&gt;22.  Woman of childbearing potential without effective contraception&lt;br&gt;&lt;br&gt;23.  Previous treatment with RO0503821&lt;br&gt;&lt;br&gt;24.  Administration of another investigational drug within 4 weeks before screening or planned during the study period&lt;br&gt;&lt;br&gt;25.  Know hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any constituents of the study or reference drug formulations &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with Chronic Kidney Disease who are on dialysis</Condition>
    <Intervention>&lt;br&gt;Product Code: RO0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;Current Sponsor code: RO0503821&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50 µg/0.3mL-&lt;br&gt;Current Sponsor code: RO0503821&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100 µg/0.3mL-&lt;br&gt;Current Sponsor code: RO0503821&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 150 µg/0.3mL-&lt;br&gt;Current Sponsor code: RO0503821&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200 µg/0.3mL-&lt;br&gt;Current Sponsor code: RO0503821&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400 µg/0.6mL-&lt;br&gt;&lt;br&gt;Trade Name: NeoRecormon&lt;br&gt;Product Name: NeoRecormon&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;INN or Proposed INN: Epoetin beta&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50,000-&lt;br&gt;INN or Proposed INN: Epoetin beta&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100,000-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To demonstrate that RO0503821 administered in pre-filled syringes maintains hemoglobin concentrations in dialysis patients on prior intravenous or subcutaneous Epoetin maintenance treatment of chronic renal anemia.;Secondary Objective: To assess the safety and tolerability of RO0503821 administered with pre-filled syringes in this patient population.;Primary end point(s): The change in hemoglobin concentration between the baseline and evaluation period.</Primary_outcome>
    <Secondary_ID>BA 17284</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2648250</Internal_Number>
    <TrialID>EUCTR2012-000200-15-ES</TrialID>
    <Last_Refreshed_on>26 June 2012</Last_Refreshed_on>
    <Public_title>Clinical Trial for the assessment of treatment efficacy with a gas mixture of equal parts (50/50) of nitrous oxide (N2O) and oxygen (O2) in renal colic.</Public_title>
    <Scientific_title>PHASE IV RANDOMIZED DOUBLE BLINDED AND MULTICENTER CLINICAL TRIAL FOR THE EVALUATION OF AN OXIGEN AND NITROUS OXIDE 50/50 MIXTURE USE IN RENAL COLIC TREATMENT BY AN EMERGENCY SERVICE. - CLINICAL TRIAL FOR THE EVALUATION OF A MIXTURE O2 + N2O IN RENAL COLIC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Fundación de Investigación Biomédica. Instituto de Investigación Sanitaria del Hospital Universitario de la Princesa.</Primary_sponsor>
    <Date_registration3>20120417</Date_registration3>
    <Date_registration>17/04/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-000200-15                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>29/05/2012</Date_enrollement>
    <Target_size>242</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Age ? 18 years.&lt;br&gt;Low back pain irradiated or not.&lt;br&gt;Colic in nature.&lt;br&gt;Pain by pressure in the same side of pain.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 242&lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients &lt;18 years.&lt;br&gt; ? Patients who do not meet criteria for the diagnosis of renal colic.&lt;br&gt; ? Patients with allergy or intolerance to either drug used in the study (dexketoprofen, metamizol, metoclorpropamida and / or pethidine).&lt;br&gt;Pregnant patients, applying the usual clinical management of patients with suspected renal colic. Be considered as not pregnant the patient who has not presented late in their menstrual cycle and that denies the possibility of pregnancy and / or using effective contraception  or menopausal patient.&lt;br&gt; ? breast feeding patients.&lt;br&gt; ? Patients with clinically significant psychiatric condition at the discretion of the physician.&lt;br&gt; ? Patients with absolute or relative contraindication for the use of N2O/O2 50/50:&lt;br&gt; or unable to work and / or altered level of consciousness.&lt;br&gt; o pneumothorax.&lt;br&gt; or with significant abdominal distension and / or suspected bowel obstruction.&lt;br&gt; o severe bullous emphysema.&lt;br&gt; or a history of recent diving (in the last 7 days).&lt;br&gt; or have suffered a head injury.&lt;br&gt; o those who have made recent intraocular injection of gas (in the last 7 days).&lt;br&gt; o which they have made a surgical procedure in the middle ear.&lt;br&gt; or oxygen saturation &lt;94%.&lt;br&gt; o known deficiency of vitamin B12 or folic&lt;br&gt;</Exclusion_Criteria>
    <Condition>RENAL COLIC;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]</Condition>
    <Intervention>&lt;br&gt;Trade Name: Entonox&lt;br&gt;Product Name: Oxido nitroso&lt;br&gt;Product Code: N01AX63&lt;br&gt;Pharmaceutical Form: Inhalation gas&lt;br&gt;INN or Proposed INN: 71597&lt;br&gt;CAS Number: 10024-97-2&lt;br&gt;Current Sponsor code: Entonox&lt;br&gt;Other descriptive name: NITROUS OXIDE&lt;br&gt;Concentration unit: % percent&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Aire Medicinal&lt;br&gt;Product Name: aire medicinal&lt;br&gt;Pharmaceutical Form: Inhalation gas&lt;br&gt;INN or Proposed INN: 68510&lt;br&gt;CAS Number: 7782-44-7&lt;br&gt;Current Sponsor code: Aire Medicinal&lt;br&gt;Other descriptive name: OXYGEN&lt;br&gt;Concentration unit: % percent&lt;br&gt;Concentration type: not less then&lt;br&gt;Concentration number: 21-&lt;br&gt;INN or Proposed INN: 68510&lt;br&gt;Current Sponsor code: Aire medicinal&lt;br&gt;Other descriptive name: NITROGEN&lt;br&gt;Concentration unit: % percent&lt;br&gt;Concentration type: not less then&lt;br&gt;Concentration number: 78-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Check whether the use of a mixture of oxygen and nitrous oxide 50/50 reduces time to decrease the pain and its intensity compared to conventional analgesic treatment.;Secondary Objective: Check if the gas mixture decreases the number of drugs needed to relieve pain, opioid use, how long the patient stays in the emergency department, the need for admission and performance of ultrasound. Also as an additional objective analyze the economic impact and patient satisfaction using this gas compared to conventional treatment.;Primary end point(s): The main objective is to test whether the use of a mixture of oxygen and nitrous oxide 50/50 reduces the time to reduce pain and its intensity compared to conventional analgesic treatment, and patient satisfaction with treatment given prior at discharge.;Timepoint(s) of evaluation of this end point: Main outcomes: pain intensity measured by VAS  as well as patient satisfaction with treatment given prior to discharge</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Secondary objectives ascertain whether the mixture of gases decreases the number of drugs needed to relieve pain, opioid use, how long the patient stays in the emergency department, the need for admission and performance of ultrasound. Also as an additional objective and analyze the economic impact on patient satisfaction from the use of this gas compared to conventional treatment;Timepoint(s) of evaluation of this end point: Secondary outcomes:&lt;br&gt; - Number of drugs to achieve symptomatic control.&lt;br&gt; - Degree of sedation as measured by Modified Observer's Assessment of Alertness Sedation Scale (OAA / S) .&lt;br&gt; - Number of patients requiring opioids.&lt;br&gt; - Side Effects.&lt;br&gt; - Time elapsed between admission and discharge from the emergency.&lt;br&gt; - Degree of patient satisfaction.&lt;br&gt; - Demographic variables: age, sex and race.&lt;br&gt; - Physical variables: blood pressure, heart rate, temperature and oxygen saturation.&lt;br&gt; - Investigations: X-ray of abdomen, white blood cell count, hemoglobin, creatinine, urinalysis and ultrasound (the latter only in cases deemed necessary by the clinician caring for the patient).</Secondary_outcome>
    <Secondary_ID>PG-ON-09</Secondary_ID>
    <Source_Support>FIB Hospital Universitario La Princesa</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2648624</Internal_Number>
    <TrialID>EUCTR2011-005856-32-ES</TrialID>
    <Last_Refreshed_on>26 June 2012</Last_Refreshed_on>
    <Public_title>Comparison of two treatments rituximab in patients with autoimmune disease resistant to conventional treatments</Public_title>
    <Scientific_title>Comparison of the efficacy of two rituximab treatment regimens in patients with lupus nephropathy
resistant to conventional treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Fundación Progreso y Salud</Primary_sponsor>
    <Date_registration3>20120127</Date_registration3>
    <Date_registration>27/01/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-005856-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>21/05/2012</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Both men and women between 18 and 70 years.&lt;br&gt;&lt;br&gt;-Patient  with active lupus nephritis,  previously treated with the following immunosuppressive unless contraindication: cyclophosphamide, azathioprine and mycophenolate (sodium or mophetil), who have not received rituximab in the two previous years, in  whom regime was ineffective at least 3 months after treatment, or who experienced relapse during this time.&lt;br&gt;&lt;br&gt;- Informed consent form signed.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 30&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 6&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-Active/sepsis serious infections&lt;br&gt;&lt;br&gt;-Known neoplasia&lt;br&gt;&lt;br&gt;- Heart failure with  III/IV functional class&lt;br&gt;&lt;br&gt;-Pregnancy&lt;br&gt;&lt;br&gt;-Nursing&lt;br&gt;&lt;br&gt;-Known anaphylaxis to the product&lt;br&gt;&lt;br&gt;-Cardiovascular disease or uncontrolled hypertension&lt;br&gt;&lt;br&gt;-Chronic hepatitis B &lt;br&gt;&lt;br&gt;-Serious Citopenia (granulocytes &lt; 500/mm3, further &lt; 10000/mm3)&lt;br&gt;&lt;br&gt;-Immunodeficiency (CVI, IgA deficiency)&lt;br&gt;&lt;br&gt;-Infection with HIV&lt;br&gt;</Exclusion_Criteria>
    <Condition>Long-term relapse after treatment of lupus nephritis (LN) resistant to conventional treatment &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10025140
Term: Lupus nephritis
System Organ Class: 10038359 - Renal and urinary disorders
;Therapeutic area: Diseases [C] - Immune System Diseases [C20]</Condition>
    <Intervention>&lt;br&gt;Trade Name: MabThera&lt;br&gt;Product Name: Rituximab&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: RITUXIMAB&lt;br&gt;CAS Number: 174722-31-7&lt;br&gt;Concentration unit: mg/m2 milligram(s)/square meter&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 375-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Rate of complete or partial response to the 12, 18 and 24 months, defined as:&lt;br&gt;-Complete response: proteinuria &lt; 0.75 mg per minute (or equivalent in 24h urine, proteinura or urine protein/creatinine index) while maintaining estimated glomerular filtration rate or serum creatinine within the normal range.&lt;br&gt;- Partial response: improvement ? 50% and stabilization of kidney function (glomerular filtration of ± 25% compared to the basal value or serum creatinine within the normal range ).;Secondary Objective: Proteinuria &lt; 0.75 mg per minute at 12, 18 and 24 months of follow-up. Estimated glomerular filtration or serum creatinine within the normal range at 12, 18 and 24 months of follow-up. Improvement ? 50% of proteinuria, hematuria, or leucoituria 12, 18 and 24 months. &lt;br&gt;Proportion of patients who reach a stabilization of kidney function (glomerular filtration of ±25% compared to the basal value or serum creatinine within the normal range) 12, 18 and 24 months of follow-up. Active urinary sediment in a basal position with an inactive urine sediment at 12, 18 and 24 months of follow-up.;Primary end point(s): Rate of complete or partial response defined as:&lt;br&gt;-Complete response: proteinuria &lt; 0.75 mg per minute (or equivalent in 24h urine, proteinura or urine protein/creatinine index) while maintaining estimated glomerular filtration rate or serum creatinine within the normal range.&lt;br&gt;- Partial response: improvement ? 50% and stabilization of kidney function (glomerular filtration of ± 25% compared to the basal value or serum creatinine within the normal range ).;Timepoint(s) of evaluation of this end point: 12, 18 and 24 months</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): - Proteinuria &lt; 0.75 mg per minute &lt;br&gt;- Estimated glomerular filtration or creatinine albumin within the normal range &lt;br&gt;- Improvement ? 50% of proteinuria, hematuria, or leucoituria &lt;br&gt;- Proportion of patients who reach a stabilization of kidney function glomerular filtrate of ± 25% compared to the basal value or creatinine albumin within the normal range).&lt;br&gt;&lt;br&gt;- Active urinary sediment in basal situation presenting a urine sediment inactive in the follow-up.&lt;br&gt;&lt;br&gt;Active urinary sediment is defined by one of the following (in the absence of an infection of the urinary tract): hematies &gt; 20 U/mcl or leukocytes &gt; 30 U/mcl&lt;br&gt;&lt;br&gt;             - Inactive urine sediment is defined by hematies &lt; 20 U/mcl and leukocytes &lt; 30 U/mcl&lt;br&gt;&lt;br&gt;- Duration of the renal response&lt;br&gt;&lt;br&gt;- Number of cycles of RTX administered in the period of study.&lt;br&gt;&lt;br&gt;- Incidence of adverse events (AA), serious adverse events (AAG), and AA that led to the interruption of the study.;Timepoint(s) of evaluation of this end point: 12, 18 and 24 months</Secondary_outcome>
    <Secondary_ID>RITULUP</Secondary_ID>
    <Source_Support>Ministerio de Sanidad y Politica Social</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2676547</Internal_Number>
    <TrialID>EUCTR2009-015918-22-PT</TrialID>
    <Last_Refreshed_on>10 July 2012</Last_Refreshed_on>
    <Public_title>A 24 months, multi-center, open-label, randomized, controlled trial to investigate efficacy, safety and evolution of cardiovascular parameters in de novo renal transplant recipients after early calcineurin inhibitor to everolimus conversion</Public_title>
    <Scientific_title>A 24 months, multi-center, open-label, randomized, controlled trial to investigate efficacy, safety and evolution of cardiovascular parameters in de novo renal transplant recipients after early calcineurin inhibitor to everolimus conversion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Novartis Pharma AG</Primary_sponsor>
    <Date_registration3>20100315</Date_registration3>
    <Date_registration>15/03/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-015918-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/05/2010</Date_enrollement>
    <Target_size>676</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Male or female renal allograft recipients at least 18 years old.&lt;br&gt;- Patients who have given written informed consent to participate in the study. If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness.&lt;br&gt;- Patient who has received a primary or secondary kidney transplant from a cadaveric or living unrelated-/related donor.&lt;br&gt;- Recipient of a kidney allograft with a cold ischemia time (CIT) &lt; 24 hours.&lt;br&gt;- Female patients must have a negative pregnancy test prior to study enrollment.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Recipient of multiple organ transplants.&lt;br&gt;- Recipient of ABO incompatible allograft or a positive cross-match.&lt;br&gt;- Patient with current Panel Reactive Antibodies (PRA) level = 30 %.&lt;br&gt;- Patient who is human immunodeficiency virus (HIV) positive.&lt;br&gt;- Patient who received an allograft from a Hepatitis B surface Antigen (HBsAg) or a Hepatitis C Virus (HCV) positive donor.&lt;br&gt;- HBsAg and/or a HCV positive patient with evidence of elevated LFTs (ALT/AST levels = 2.5 times ULN). Viral serology results obtained within 6 months prior to randomization are acceptable.&lt;br&gt;- Patient with severe restrictive or obstructive pulmonary disorders.&lt;br&gt;- Patient with severe allergy requiring acute (within 4 weeks of baseline) or chronic treatment that would prevent patient from potential exposure to everolimus, or with hypersensitivity to drugs similar to everolimus (e.g. macrolides).&lt;br&gt;- Patient with severe hypercholesterolemia or hypertriglyceridemia that cannot be controlled.&lt;br&gt;- Patient with white blood cell (WBC) count &lt; 2,000 /mm3 or with platelet count &lt;br&gt;&lt; 50,000 /mm3.&lt;br&gt;- History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.&lt;br&gt;&lt;br&gt;	&lt;br&gt;</Exclusion_Criteria>
    <Condition>renal transplantation</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001A&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Other descriptive name: EVEROLIMUS&lt;br&gt;Concentration unit: IU/mg international unit(s)/milligram&lt;br&gt;Concentration number: 0,25-&lt;br&gt;&lt;br&gt;Trade Name: Myfortic&lt;br&gt;Product Name: Myfortic&lt;br&gt;Product Code: ERL080A&lt;br&gt;Pharmaceutical Form: Gastro-resistant tablet&lt;br&gt;INN or Proposed INN: MYCOPHENOLIC ACID&lt;br&gt;CAS Number: 24280-93-1&lt;br&gt;Concentration unit: IU/mg international unit(s)/milligram&lt;br&gt;Concentration number: 180-&lt;br&gt;&lt;br&gt;Trade Name: Simulect&lt;br&gt;Product Name: Simulect&lt;br&gt;Product Code: ERL080A&lt;br&gt;Pharmaceutical Form: Powder for solution for infusion&lt;br&gt;CAS Number: 179045-86-4&lt;br&gt;Other descriptive name: BASILIXIMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration number: 4-&lt;br&gt;&lt;br&gt;Trade Name: Neoral&lt;br&gt;Product Name: Neoral&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: IU/mg international unit(s)/milligram&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Trade Name: Prograf (tacrolimus)&lt;br&gt;Product Name: tacrolimus&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: IU/mg international unit(s)/milligram&lt;br&gt;Concentration number: 0,5-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001A&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Other descriptive name: EVEROLIMUS&lt;br&gt;Concentration unit: IU/mg international unit(s)/milligram&lt;br&gt;Concentration number: 0,50-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001A&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Other descriptive name: EVEROLIMUS&lt;br&gt;Concentration unit: IU/mg international unit(s)/milligram&lt;br&gt;Concentration number: 0,75-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001A&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Other descriptive name: EVEROLIMUS&lt;br&gt;Concentration unit: IU/mg international unit(s)/milligram&lt;br&gt;Concentration number: 1,0-&lt;br&gt;&lt;br&gt;Trade Name: Myfortic&lt;br&gt;Product Name: Myfortic&lt;br&gt;Product Code: ERL080A&lt;br&gt;Pharmaceutica</Intervention>
    <Primary_outcome>Main Objective: To demonstrate superior renal allograft function in de novo renal transplant recipients after early conversion from CNI to everolimus, assessed by Glomerular Filtration Rate (eGFR) estimated by the Modification of Diet in Renal Disease formula 4 (MDRD4) at Month 12 versus the active control;Secondary Objective: - To demonstrate non-inferior efficacy (defined by a composite efficacy endpoint of treated Biopsy Proven Acute Rejection (BPAR) = IB, graft loss or death) at Month 12.&lt;br&gt;- To demonstrate improvement of Left Ventricular Hypertrophy (LVH) in comparable patients (assessed by LV mass index, LVMi) by echocardiogram at Month 12.&lt;br&gt;;Primary end point(s): To demonstrate superior renal allograft function in de novo renal transplant recipients after early CNI to everolimus conversion assessed by Glomerular Filtration Rate (eGFR) estimated by the Modification of Diet in Renal Disease formula 4 (MDRD4) at Month 12 versus the active control</Primary_outcome>
    <Secondary_ID>CRAD001A2429</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2677307</Internal_Number>
    <TrialID>EUCTR2012-000425-45-NL</TrialID>
    <Last_Refreshed_on>10 July 2012</Last_Refreshed_on>
    <Public_title>Effects of morning vs evening dosing on the pharmacokinetics and pharmacodynamics of sunitinib.</Public_title>
    <Scientific_title>Effects of morning vs evening dosing on the pharmacokinetics and pharmacodynamics of sunitinib.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor />
    <Date_registration3>20120308</Date_registration3>
    <Date_registration>08/03/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-000425-45                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>03/07/2012</Date_enrollement>
    <Target_size>18</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Age = 18 years;
&lt;br&gt;Histological or cytological confirmed diagnosis of advanced clear-cell renal cell carcinoma, GIST or pancreatic neuro-endocrine tumor, treated with sunitinib;
&lt;br&gt;WHO performance score = 1 at study entry (see appendix A);
&lt;br&gt;Any stable dose of sunitinib at study entry, defined as no dose change within 3 weeks prior to pharmacokinetics; 
&lt;br&gt;Adequate hematological functions (ANC &gt; 1.0 x 109/L, platelets &gt; 100 x 1012/L);
&lt;br&gt;Adequate liver and renal function defined as bilirubin concentration = 2 x ULN, AST and ALT = 2.5 x ULN, serum creatinin concentration = 2 x ULN;
&lt;br&gt;Written informed consent;
&lt;br&gt;For patients with reproductive potential a reliable method of contraception (excluding oral contraceptives) must be used
&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 18&lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Pregnant or child nursing patients;
&lt;br&gt;Serious illness or medical unstable condition requiring treatment, symptomatic CNS metastasis or history of psychiatric disorder that would prohibit the understanding and giving of informed consent;
&lt;br&gt;Major surgery within 2 weeks prior to start of the protocol;
&lt;br&gt;Use of CYP3A4 inhibiting or inducing medication as listed in appendix C;
&lt;br&gt;Patients who are unable to collect blood from;
&lt;br&gt;Patients with known allergy to sunitinib or midazolam;
&lt;br&gt;Patients unwilling or unable to give written informed consent
&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal Cell Cancer, GIST, pancreatic neuroendocrine tumor &lt;br&gt;MedDRA version: 14.1
Level: LLT
Classification code 10067518
Term: Pancreatic neuroendocrine tumor
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
 &lt;br&gt;MedDRA version: 14.1
Level: LLT
Classification code 10023400
Term: Kidney cancer
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
 &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10055008
Term: Gastric sarcoma
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
;Therapeutic area: Diseases [C] - Cancer [C04]</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sutent&lt;br&gt;Product Name: Sunitinib&lt;br&gt;Product Code: EU/1/06/347/001-008 &lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;&lt;br&gt;Trade Name: Dormicum&lt;br&gt;Product Name: Midazolam&lt;br&gt;Product Code: PL 29831/0140&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine the influence of morning versus evening administration on&lt;br&gt;the pharmacokinetics of sunitinib and its metabolite;Secondary Objective: To investigate whether daily variation in CYP3A4 activity exists in humans, based on midazolam and 4beta-hydroxycholesterol PK.&lt;br&gt;To investigate if evening dosing of sunitinib affects the side effects of this drug.&lt;br&gt;To investigate the influence of single-nucleotide polymorphisms in PK genes on the exposure to sunitinib (based on the MEC02.1002 protocol).&lt;br&gt;;Primary end point(s): -Determine differences in sunitinib pharmacokinetics during sunitinib administration in the morning compared to administration in the&lt;br&gt;evening.;Timepoint(s) of evaluation of this end point: 1 year</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Determine differences in adverse effects during sunitinib administration in the morning compared to administration in the
&lt;br&gt;evening.;Timepoint(s) of evaluation of this end point: 1 year</Secondary_outcome>
  </Trial>
  <Trial>
    <Internal_Number>2685365</Internal_Number>
    <TrialID>EUCTR2010-020965-26-SK</TrialID>
    <Last_Refreshed_on>24 July 2012</Last_Refreshed_on>
    <Public_title xml:space="preserve">
			</Public_title>
    <Scientific_title>A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy - VEG113387                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>GlaxoSmithKline R&amp;D Ltd</Primary_sponsor>
    <Date_registration3>20100826</Date_registration3>
    <Date_registration>26/08/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-020965-26                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin xml:space="preserve">
			</Inclusion_agemin>
    <Inclusion_agemax xml:space="preserve">
			</Inclusion_agemax>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>28/10/2010</Date_enrollement>
    <Target_size>1500</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1 Signed written informed consent&lt;br&gt;2 Diagnosis of RCC with clear-cell or predominant clear-cell histology.&lt;br&gt;3 Subjects with non-metastatic disease (M0) fulfilling any of the following combinations of pathologic staging based on AJCC TNM staging version 2010 and Fuhrman nuclear grading (pT2, G3 or G4, N0; or pT3, Gany, N0; or pT4, Gany, N0; or pTany, Gany, N1)&lt;br&gt;4 Fulfill all of the following criteria of disease-free status at baseline:&lt;br&gt;• Had complete gross surgical resection of all RCC via radical or partial nephrectomy using either open or laparoscopic technique. &lt;br&gt;• Baseline imaging of chest, abdomen and pelvis shows no metastasis or residual tumor lesions as confirmed centrally by an independent radiologist.&lt;br&gt;5 Received no prior adjuvant or neo-adjuvant treatment for RCC. &lt;br&gt;6 Recovered from nephrectomy: any surgery related toxicities should be reduced to = grade 1 per NCI CTCAE (Version 4)&lt;br&gt;7 Karnofsky performance scale (KPS) of = 80.&lt;br&gt;8 Adequate organ system function&lt;br&gt;9 Male or female, age = 18 years &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1 History of another malignancy.&lt;br&gt;Exception:  Subjects who have had another malignancy and have been disease-free for 5 years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible. &lt;br&gt;2 Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to: &lt;br&gt;• Active peptic ulcer disease&lt;br&gt;• Inflammatory bowel disease (e.g. ulcerative colitis, Crohn’s disease), or other gastrointestinal conditions with increased risk of perforation&lt;br&gt;• History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 28 days prior to beginning study treatment&lt;br&gt;3 Active diarrhea of any grade&lt;br&gt;4 Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:&lt;br&gt;• Malabsorption syndrome &lt;br&gt;• Major resection of the stomach or small bowel&lt;br&gt;5 History of human immunodeficiency virus (HIV) infection&lt;br&gt;6 History of active hepatitis &lt;br&gt;7 Presence of uncontrolled infection.&lt;br&gt;8 History of any one or more of the following cardiovascular conditions within the past 6 months:&lt;br&gt;• Cardiac angioplasty or stenting&lt;br&gt;• Myocardial infarction&lt;br&gt;• Unstable angina&lt;br&gt;• Coronary artery bypass graft surgery&lt;br&gt;• Symptomatic peripheral vascular disease&lt;br&gt;9 History of Class III or IV congestive heart failure, as defined by the New York Heart Association Classification of Congestive Heart Failure &lt;br&gt;10 History of cerebrovascular accident including transient ischemic attack, pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months&lt;br&gt;Note:  Subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible&lt;br&gt;11 Corrected QT interval (QTc) &gt; 480 milliseconds (msec) &lt;br&gt;12 Poorly controlled hypertension, defined as systolic blood pressure (SBP) of =140 mmHg or diastolic blood pressure (DBP) of = 90mmHg&lt;br&gt;Note:  Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry&lt;br&gt;13 Evidence of active bleeding or bleeding diathesis&lt;br&gt;14 Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject’s safety, provision of informed consent, or compliance to study procedures&lt;br&gt;15 Unable or unwilling to discontinue use of prohibited medications for at least 14 days or 5 half-lives of a drug (whichever is longer) prior to the first dose of study treatment and for the duration of the study. &lt;br&gt;16 Concurrent therapy given to treat cancer including treatment with an investigational agent or concurrent participation in another clinical trial involving anti-cancer investigational drug&lt;br&gt;17 Administration of an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study treatment.&lt;br&gt;18 Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib or excipients that in the opinion of the investigator contraindicates their participation.&lt;br&gt;19 Prior or current use of systemic anti-VEGF inhibitors, cytokines. &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal Cell Carcinoma &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10038415
Term: Renal cell carcinoma stage unspecified
 &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10067946
Term: Renal cell carcinoma
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Votrient&lt;br&gt;Product Name: Votrient (GW786034)&lt;br&gt;Product Code: Votrient (GW786034)&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: PAZOPANIB&lt;br&gt;CAS Number: 444731-52-6&lt;br&gt;Current Sponsor code: GW786034&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate disease-free survival (DFS) with pazopanib (800 mg/day for 1-year) as compared to placebo as adjuvant therapy for subjects with localized/locally advanced RCC following nephrectomy.;Primary end point(s): The primary efficacy endpoint of this study is DFS, which is defined as time from randomization to developing local disease recurrence and/or metastasis, or death due to any cause whichever comes first;Secondary Objective: Efficacy objectives include: Evaluation of OS in subjects treated with pazopanib compared to those treated with placebo and DFS rates at yearly time points in subjects treated with pazopanib as compared to those treated with placebo. &lt;br&gt;Safety objective: To evaluate safety and tolerability in subjects treated with pazopanib compared to those treated with placebo&lt;br&gt;Health outcome objective: To evaluate health-related quality of life (HRQoL) in subjects treated with pazopanib compared to those treated with placebo</Primary_outcome>
    <Secondary_ID>VEG113387</Secondary_ID>
    <Source_Support xml:space="preserve">
			</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2685579</Internal_Number>
    <TrialID>EUCTR2008-005925-12-DE</TrialID>
    <Last_Refreshed_on>24 July 2012</Last_Refreshed_on>
    <Public_title xml:space="preserve">
			</Public_title>
    <Scientific_title>Polyomavirus BK nephropathy after renal transplantation: Randomized clinical trial to demonstrate that switching to mTOR inhibitor is more effective than a reduction of immunosuppressive therapy - POLYOMA STUDY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Medizinische Hochschule Hannover</Primary_sponsor>
    <Date_registration3>20101229</Date_registration3>
    <Date_registration>29/12/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005925-12                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin xml:space="preserve">
			</Inclusion_agemin>
    <Inclusion_agemax xml:space="preserve">
			</Inclusion_agemax>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/01/2011</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Preceding transplantation;&lt;br&gt;functioning graft with a permanent glomerular filtration rate of &gt;30mL/min; bioptically confirmed polyomavirus BK nephropathy; &lt;br&gt;age of 19 - 75 years;&lt;br&gt;written consent of the patient.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Pregnancy; &lt;br&gt;known intolerance of the planned medication (e.g. severe diarrhea, angioedema, severe wound healing problem, uncontrolled infectious diseases other than BK virus);&lt;br&gt;leucopenia &lt;2000/µL;&lt;br&gt;permanent glomerular filtration rate of &lt;30mL/min.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Polyoma BK-virus nephropathy is a viral complication after renal transplantation attacking up to 10% of renal transplants and causing transplant failure in 45% of cases. No virustatic treatment exists. Modifying the infection is usually tried by lowering immunosuppression, which may lead to transplant failure by rejection as well. A randomized switch of immunosuppression to everolimus vs general lowering of immunosuppression has to be tested (prospect. random. parallel group comparison). &lt;br&gt;
			</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican 0.25mg&lt;br&gt;Product Name: Everolimus 0.25 mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: EVEROLIMUS&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Current Sponsor code: mTOR-inhibitor&lt;br&gt;Other descriptive name: selective immunosuppressive drug&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.25-&lt;br&gt;Current Sponsor code: mTOR-inhibitor&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1-10&lt;br&gt;Current Sponsor code: mTOR-inhibitor&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1-10&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun 100 mg&lt;br&gt;Product Name: Cyclosporin 100 mg&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Current Sponsor code: 005622-B668&lt;br&gt;Other descriptive name: selective immunosuppressive drug&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Trade Name: Prograf 0.5 mg&lt;br&gt;Product Name: Tacrolimus 0.5 mg&lt;br&gt;Product Code: 001773-Z913&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Current Sponsor code: 001773-Z913&lt;br&gt;Other descriptive name: calcineurin inhibitor&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Trade Name: Certican 0.75mg&lt;br&gt;Product Name: Everolimus 0.75&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: EVEROLIMUS&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Current Sponsor code: mTOR-inhibitor&lt;br&gt;Other descriptive name: selective immunosuppressive drug&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.75-&lt;br&gt;&lt;br&gt;Trade Name: Certican 1.00 mg&lt;br&gt;Product Name: Everolimus 1.0 mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: EVEROLIMUS&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Current Sponsor code: mTOR-inhibitor&lt;br&gt;Other descriptive name: selective immunosuppressive drug&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.0-&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun 25 mg&lt;br&gt;Product Name: Cyclosporin 25 mg&lt;br&gt;Pharmaceutical Form: </Intervention>
    <Primary_outcome>Main Objective: The main objective of the trial is to find out if switch to mTOR inhibitor everolimus will be superior compared to lowering of conventional immunosuppression by calcineurin inhibitor in eliminating polyoma BK virus and thus saving the transplant.&lt;br&gt;Therefore graft survival in the 2 groups will be compared&lt;br&gt;(primary efficacy endpoint: time to death or time to graft loss or permanent decrease of glomerular filtration rate to &lt; 25mL/min whatever occurs first).;Secondary Objective: Surrogate parameters of viral attack are renal function (measured by serum creatinine or eGFR), viral load (measured by serum and urine BK PCR), cytopathic changes in repeat renal biopsy. Side effect of lowering or changing immunosuppression may be transplant rejection.&lt;br&gt;These parameters will be measured and compared in both groups&lt;br&gt;(key secondary endpoints: decrease of polyoma BK serum PCR of &gt;one log; decrease of serum creatinine of &gt;25%; progression of tubular atrophy and interstitial fibrosis in follow-up histology in %; number of rejections under changement of immunosuppression; increase of BKV-specific T-cells).;Primary end point(s): Time to death or time to graft loss or permanent glomerular filtration rate to &lt;25mL/min which ever occurs first.&lt;br&gt;&lt;br&gt;</Primary_outcome>
    <Secondary_ID> polyoma IFB 29</Secondary_ID>
    <Source_Support xml:space="preserve">
			</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2685634</Internal_Number>
    <TrialID>EUCTR2009-010143-13-DE</TrialID>
    <Last_Refreshed_on>24 July 2012</Last_Refreshed_on>
    <Public_title xml:space="preserve">
			</Public_title>
    <Scientific_title>Prospective randomized phase-II trial with Temsirolimus versus Sunitinib 
in previously untreated patients with advanced or metastatic non-clear cell renal carcinoma
 - 
			                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>CESAR Central European Society for Anticancer Drug Research-EWIV</Primary_sponsor>
    <Date_registration3>20090415</Date_registration3>
    <Date_registration>15/04/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-010143-13                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin xml:space="preserve">
			</Inclusion_agemin>
    <Inclusion_agemax xml:space="preserve">
			</Inclusion_agemax>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>03/06/2009</Date_enrollement>
    <Target_size xml:space="preserve">
			</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.Adult males and females:  = 18 years of age.&lt;br&gt;2.Locally advanced or metastatic, histological confirmed, non-clear cell RCC of all subtypes. Patients must have advanced non-clear cell of one of the following subtypes: papillary, chromophobe, collecting duct carcinoma (CDC), renal medullary carcinoma (RMC), or unclassified. &lt;br&gt;3.Patients with measurable disease (at least one uni-dimensionally measurable target lesion by CT-scan or MRI) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) If prior palliative radiotherapy to metastatic lesions: = 1 measurable lesion that has not been irradiated.&lt;br&gt;4.PS 0-2 ECOG&lt;br&gt;5.Signed written informed consent.&lt;br&gt;6.White blood cell count (WBC) = 4x10*9/L with neutrophils =1.5 x 10*9/L, platelet count =100x10*9/L, hemoglobin =9 g/dL.&lt;br&gt;7. Total bilirubin &lt; 2 x upper limit of normal.&lt;br&gt;8. AST and ALT &lt;2.5 x upper limit of normal, or &lt;5 x upper limit of normal in case of liver metastases.&lt;br&gt;9.Serum creatinine &lt;2.0 x upper limit of normal.&lt;br&gt;10.Normal ECG without QT prolongation (QTc &lt; 450 msec ).&lt;br&gt;11.Adequate cardiac function (left ventricular ejection fraction &gt; 40% as assessed by ECHO.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.Predominant clear-cell RCC&lt;br&gt;2.Resectability or other curative options&lt;br&gt;3.Any investigational drug within the 30 days before inclusion.&lt;br&gt;4.Prior systemic treatment for their RCC. &lt;br&gt;5.Known or suspected allergy or hypersensitivity reaction to any of the components of study treatments.&lt;br&gt;6.Radiotherapy within the last 4 weeks.&lt;br&gt;7.Pregnancy (absence to be confirmed by beta-hCG test) or lactation period.	&lt;br&gt;8.Men or women of child-bearing potential who are sexually active and unwilling to use a medically acceptable method of contraception during the trial.&lt;br&gt;9.Clinically symptomatic brain or meningeal metastasis. (known or suspected)&lt;br&gt;10.Cardiac arrhythmias requiring anti-arhythmics (excluding beta blockers or digoxin).&lt;br&gt;11.History of any of the following cardiac events within the past 6 months: &lt;br&gt;•	myocardial infarction (including severe/unstable angina),&lt;br&gt;•	coronary/peripheral artery bypass graft,&lt;br&gt;•	congestive heart failure (CHF),&lt;br&gt;•	cerebrovascular accident,&lt;br&gt;•	transient ischemic attack,&lt;br&gt;•	pulmonary embolism.&lt;br&gt;12.hemorrhage = grade 3 within the past 4 weeks&lt;br&gt;13.Uncontrolled severe hypertension (failure of diastolic blood pressure to fall below 90 mm Hg despite the use of =3 anti-hypertensive drugs &lt;br&gt;14.History of relevant pulmonary hypertension or interstitial lung disease.&lt;br&gt;15.Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease or chronic diarrhea &lt;br&gt;16.Previous malignancy (other than renal cancer cancer) in the last 5 years except basal cell cancer of the skin, pre-invasive cancer of the cervix or superficial bladder tumor [Ta, Tis and T1].&lt;br&gt;17.History of organ allograft&lt;br&gt;18.Significant disease which, in the investigator`s opinion would exclude the patient from the study&lt;br&gt;19.Patients with seizure and epileptic disorder or other conditions requiring medication (such as phenytoin, carbamazepin, phenobarbital) &lt;br&gt;20.Patients under strong inducers or inhibitors to CYP Isoenzymes&lt;br&gt;21.Patients with hypersensitivity to the antihistamine or patients who cannot receive the antihistamine for other medical reasons&lt;br&gt;22.Patients requiring long-term cortisone therapy (replacement doses of corticosteroids and topical/inhaled corticosteroids are allowed)&lt;br&gt;23.Patients requiring oral anticoagulation treatment, such as marcoumar. (Anticoagulation treatment with heparin or low molecular weight heparin [LMWH] is allowed provided that close monitoring is performed).&lt;br&gt;24.Surgery within 2 weeks prior to randomization&lt;br&gt;25.HIV seropositivity.&lt;br&gt;26.Abnormal pulmonary function (DLCO &lt; 50%).[Pulmonary function tests need only to be performed if abnormal pulmonary function present in medical history].&lt;br&gt;27.Poorly controlled diabetes mellitus.&lt;br&gt;28.Liver cirrhosis, chronic hepatitis&lt;br&gt;29.Legal incapacity or limited legal capacity&lt;br&gt;30.Known alcohol or drug abuse.&lt;br&gt;31.Medical or psychological conditions that would not permit the patient to complete the study or sign informed consent.&lt;br&gt;32. Current fistula formation.&lt;br&gt;</Exclusion_Criteria>
    <Condition>advanced or metastatic non-clear cell renal carcinoma &lt;br&gt;MedDRA version: 13.1
Level: LLT
Classification code 10050076
Term: Metastatic renal carcinoma
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
</Condition>
    <Intervention>&lt;br&gt;Trade Name: TORISEL&lt;br&gt;Pharmaceutical Form: Concentrate and solvent for solution for injection&lt;br&gt;INN or Proposed INN: Temsirolimus&lt;br&gt;CAS Number: 162635-04-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Trade Name: Sutent&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Sunitinib&lt;br&gt;CAS Number: 341031-54-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 12.5-&lt;br&gt;&lt;br&gt;Trade Name: Sutent&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Sunitinib&lt;br&gt;CAS Number: 341031-54-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Trade Name: Sutent&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Sunitinib&lt;br&gt;CAS Number: 341031-54-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Primary objective of the study is to demonstrate a statistical significant difference between the two arms in progression free survival (PFS) measured from randomisation until progression or death, whichever occurs first.;Secondary Objective: Secondary objectives are the characterization of objective response, Tolerability/Safety,  One Year Rate of Progression Free Survival (1YPFSR) and overall survival (OS) on both treatment arms and the comparsion of the two arms.;Primary end point(s): PFS: progression free survival (PFS) measured from randomization until progression or death, whichever occurs first. PFS is censored at the last time point of tumor assessment where the patient was SD or better if that patient dropped out between two scheduled assessment time points. </Primary_outcome>
    <Secondary_ID>C-II-006</Secondary_ID>
    <Source_Support xml:space="preserve">
			</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2709542</Internal_Number>
    <TrialID>EUCTR2007-001043-22-NL</TrialID>
    <Last_Refreshed_on>31 July 2012</Last_Refreshed_on>
    <Public_title>A Multicenter, Open-Label Study of Hectorol (doxercalciferol capsules) for the Treatment of Secondary Hyperparathyroidism 
in Stage 3 or Stage 4 Chronic Kidney Disease (CKD) Patients
</Public_title>
    <Scientific_title>A Multicenter, Open-Label Study of Hectorol (doxercalciferol capsules) for the Treatment of Secondary Hyperparathyroidism 
in Stage 3 or Stage 4 Chronic Kidney Disease (CKD) Patients
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Genzyme Europe BV</Primary_sponsor>
    <Date_registration3>20070906</Date_registration3>
    <Date_registration>06/09/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001043-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>21/11/2007</Date_enrollement>
    <Target_size>150</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Male or female, aged 18 years or older. &lt;br&gt;&lt;br&gt;2.	CKD Stage 3 or 4, defined as glomerular filtration rate (GFR) from the abbreviated Modification of Diet in Renal Disease (MDRD) equation between 30 and 59 mL/min/1.73m2 for CKD Stage 3 or between 15 and 29 mL/min/1.73m2 for CKD Stage 4 at the Screening Visit.&lt;br&gt;&lt;br&gt;3.	iPTH &gt; 70 pg/mL (&gt; 7.7 pmol/L) for CKD Stage 3 or &gt; 110 pg/mL (&gt; 12.1 pmol/L) for CKD Stage 4, but &lt; 700 pg/mL (&lt; 77 pmol/L) at Week –1.&lt;br&gt;&lt;br&gt;4.	In the opinion of the Investigator, the patient is willing and able to maintain compliance with phosphate binder therapy (if applicable) throughout the study duration.&lt;br&gt;&lt;br&gt;5.	Willing and able to stop any prior active vitamin D therapy (e.g. alfacalcidiol, calcitriol, or paricalcitol) and/or calcimimetic for 28 days prior to Week –1 and maintain this throughout the study.&lt;br&gt;&lt;br&gt;6.	Willing and able to sign and date an Informed Consent form. &lt;br&gt;&lt;br&gt;7.	The patient, if of childbearing potential, must be willing to use an effective contraceptive method throughout the study, which includes barrier methods, hormones, or intrauterine devices.&lt;br&gt;&lt;br&gt;8.	A level of understanding and willingness to cooperate with all visits and procedures as described by the study personnel.&lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Intact PTH value &gt; 700 pg/mL (&gt; 77.0 pmol/L) at the Week -1 Visit.&lt;br&gt;&lt;br&gt;2.	Corrected serum calcium &gt; 10.0 mg/dL (&gt; 2.5 mmol/L) at Week –1.&lt;br&gt;&lt;br&gt;3.	Serum phosphorus &gt; 5.0 mg/dL (&gt; 1.61 mmol/L) at Week –1.&lt;br&gt;&lt;br&gt;4.	In the opinion of the Investigator, the patient currently has poorly controlled diabetes mellitus, poorly controlled hypertension, active vasculitis, human immunodeficiency virus infection, or any other clinically significant, unstable medical condition.&lt;br&gt;&lt;br&gt;5.	Abnormal liver function as measured by alanine aminotransferase (ALT)/aspartate aminotransferase (AST) greater than three times the upper limit of normal at the Screening Visit.&lt;br&gt;&lt;br&gt;6.	Deemed by the Investigator to have rapidly deteriorating renal function.&lt;br&gt;&lt;br&gt;7.	Spot urine calcium/creatinine ratio &gt; 0.2 at Week –1.&lt;br&gt;&lt;br&gt;8.	Current malabsorption, severe chronic diarrhea, or ileostomy.&lt;br&gt;&lt;br&gt;9.	Any evidence of active malignancy except for basal cell carcinoma of the skin.  A history of malignancy is not an exclusion criterion.&lt;br&gt;&lt;br&gt;10.	Allergic reaction to a drug which, in the opinion of the Investigator, suggests an increased potential for hypersensitivity to vitamin D therapy.&lt;br&gt;&lt;br&gt;11.	Active ethanol or drug abuse, excluding tobacco use.&lt;br&gt;&lt;br&gt;12.	Current use of aluminum or magnesium based binders.&lt;br&gt;&lt;br&gt;13.	Pregnant or breast-feeding women.&lt;br&gt;&lt;br&gt;14.	Anticipated dialysis or planned renal transplant less than 12 months from Week 0.&lt;br&gt;&lt;br&gt;15.	Treatment with an investigational drug during 30 days preceding the start of screening.&lt;br&gt;&lt;br&gt;16.	Prior renal transplant.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Secondary hyperparathyroidism in Stage 3 or Stage 4 Chronic Kidney Disease &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10020708
Term: Hyperparathyroidism secondary
</Condition>
    <Intervention>&lt;br&gt;Product Name: doxercalciferol capsules&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: doxercalciferol&lt;br&gt;CAS Number: 54573-75-0&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5 or 2.5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate the safety and tolerability of Hectorol Capsules during 52 weeks of treatment in patients with Stage 3 or Stage 4 CKD;Secondary Objective: To evaluate the efficacy of Hectorol Capsules during 52 weeks of treatment in patients with Stage 3 or Stage 4 CKD;Primary end point(s): Safety endpoints include the following:&lt;br&gt;•	Incidence of AEs and SAEs.&lt;br&gt;•	Changes in physical examination findings, vital signs, or laboratory evaluations.&lt;br&gt;&lt;br&gt;The efficacy endpoint will be the proportion of patients meeting the iPTH target range (defined as iPTH = 70 pg/mL (= 7.7 pmol/L) for Stage 3 patients and iPTH = 110 pg/mL (= 12.1 pmol/L) for Stage 4 patients) at each timepoint during the Treatment Period.</Primary_outcome>
    <Secondary_ID>HECT01206</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2710341</Internal_Number>
    <TrialID>EUCTR2008-000077-38-BE</TrialID>
    <Last_Refreshed_on>31 July 2012</Last_Refreshed_on>
    <Public_title>A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney</Public_title>
    <Scientific_title>A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Novartis Pharma Services AG</Primary_sponsor>
    <Date_registration3>20080711</Date_registration3>
    <Date_registration>11/07/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000077-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>25/03/2009</Date_enrollement>
    <Target_size>360</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Age = 18 years old
&lt;br&gt;2. Patients with metastatic renal cell carcinoma and with histological or cytological confirmation of clear cell RCC (pathology report based on the tissue from the original diagnosis or more recent biopsy of renal cell cancer is acceptable).  Any percentage of clear cell histology is acceptable.
&lt;br&gt;3. Patients with at least one measurable lesion at baseline as per the RECIST criteria.  If skin lesions are reported as target lesions, they must be documented (at baseline and at every physical exam) using color photography and a measuring device (such as a caliper) in clear focus to allow the size of the lesion(s) to be determined from the photograph.
&lt;br&gt;4. Patients with progressive metastatic renal cell carcinoma. Documentation of radiologically progressive disease by RECIST criteria is required only in patients with lung and/or soft tissue metastases without other sites of metastatic disease.
&lt;br&gt;5. Patients who had a prior partial or complete nephrectomy.  Partial nephrectomy is allowed only if the resection margins were clearly negative.
&lt;br&gt;6. Patients with a Karnofsky Performance Status =70%.
&lt;br&gt;7. Adequate bone marrow function as shown by: ANC = 1.5 x 109/L, Platelets = 100 x 109/L, Hb &gt;9 g/dL.
&lt;br&gt;8. Adequate liver function: serum bilirubin: = 1.5 x ULN, ALT and AST = 2.5x ULN. Patients with known liver metastases: AST and ALT = 5x ULN.
&lt;br&gt;9. Adequate renal function: serum creatinine = 2.0 x ULN.
&lt;br&gt;10. INR &lt; 1.5.  (Anticoagulation is allowed if target INR = 1.5 on a stable dose of warfarin or on a stable dose of LMW heparin for &gt;2 weeks at time of randomization.)
&lt;br&gt;11. Adequate lipid profile:  total cholesterol &lt; 300 mg/dL and triglyceride &lt; 200 mg/dL. 
&lt;br&gt;12. Women of childbearing potential must have had a negative serum pregnancy test 72 hours prior to the administration of the study treatment start.
&lt;br&gt;13. Patients who give a written informed consent obtained according to local guidelines.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 250&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 110&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Patients within 4 weeks post-major surgery, open biopsy, or significant traumatic injury to avoid wound healing complications. Minor procedures and percutaneous biopsies or placement of vascular access device require 7 days prior to study entry.
&lt;br&gt;2. Patients who had radiation therapy within 28 days prior to start of study treatment.
&lt;br&gt;3. Patients in anticipation of the need for major surgical procedure during the course of the study.
&lt;br&gt;4. Patients with a serious non-healing wound, ulcer, or bone fracture.
&lt;br&gt;5. Patients with a history of seizure(s) not controlled with standard medical therapy.
&lt;br&gt;6. Patients who have received prior systemic treatment for their metastatic RCC. Adjuvant immunotherapy (vaccines acceptable, but no cytokines) completed 3 months prior to study treatment start is acceptable.
&lt;br&gt;7. Patients who received prior therapy with VEGF pathway inhibitor, such as sunitinib, sorafenib, and bevacizumab.
&lt;br&gt;8. Patients who have previously received systemic mTOR inhibitors.
&lt;br&gt;9. Patients with a known hypersensitivity to RAD001 or other rapamycins or to its excipients.
&lt;br&gt;10. Patients with evidence or history of central nervous system (CNS) metastases or spinal cord compression.
&lt;br&gt;11. Patients with a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment.
&lt;br&gt;12. Patients with proteinuria at screening as demonstrated by either:
&lt;br&gt;• Urine protein: creatinine (UPC) ratio = 1.0 at screening.
&lt;br&gt;• Urine dipstick for proteinuria = 2+ (patients discovered to have =2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate = 1g of protein in 24 hours to be eligible).
&lt;br&gt;13. Patients with inadequately controlled hypertension (defined as a blood pressure of &gt; 150 mmHg systolic and/or &gt; 100 mmHg diastolic on medication), or any prior history of hypertensive crisis or hypertensive encephalopathy.
&lt;br&gt;14. Patients receiving ongoing or with recent (within 10 days prior to study treatment start) need for full therapeutic dose of oral or parenteral anticoagulants or chronic daily treatment with aspirin (&gt; 325 mg/day) or clopidogrel (&gt;75 mg/day).
&lt;br&gt;15. Patients receiving chronic systemic treatment with corticosteroids (dose of = 10 mg/day methylprednisone equivalent) or another immunosuppressive agent. Inhaled and topical steroids are acceptable.
&lt;br&gt;16. Patients with a known history of HIV seropositivity.
&lt;br&gt;17. Patients with hypersensitivity to interferon alfa-2a or any component of the product.
&lt;br&gt;18. Patients with an active, bleeding diathesis or coagulopathy or recurrent thromboembolism (&gt;1 episode of DVT/PE during the past year).
&lt;br&gt;19. Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:
&lt;br&gt;• unstable angina pectoris (at any time), symptomatic congestive heart failure (NYHA II, III, IV) (at any time), serious uncontrolled cardiac arrhythmia (at any time), myocardial infarction or cerebrovascular accidents = 6 months prior to first study treatment or history of left ventricular dysfunction
&lt;br&gt;• severely impaired lung function as defined as spirometry and DLCO that is 50% of the normal predicted value and/or 02 saturation that is 88% or less at rest on room air
&lt;br&gt;• poorly controlled diabetes as defined by fasting serum glucose &gt;2.0 x ULN
&lt;br&gt;• any active (acute or chronic) or uncontrolled infection/disorders that impair the ability to evaluate the patient </Exclusion_Criteria>
    <Condition>Patients with metastatic clear cell carcinoma of the kidney &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10050513
Term: Metastatic renal cell carcinoma
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Afinitor&lt;br&gt;Product Code: RAD001&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: Avastin&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Bevacizumab&lt;br&gt;CAS Number: 216974-75-3&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Trade Name: Roferon-A&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Interferon alfa-2a&lt;br&gt;CAS Number: 076543-88-9&lt;br&gt;Concentration unit: million IU million international units&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 3-&lt;br&gt;&lt;br&gt;Trade Name: Roferon-A&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Interferon alfa-2a&lt;br&gt;CAS Number: 076543-88-9&lt;br&gt;Concentration unit: million IU million international units&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 6-&lt;br&gt;&lt;br&gt;Trade Name: Roferon-A&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Interferon alfa-2a&lt;br&gt;CAS Number: 076543-88-9&lt;br&gt;Concentration unit: million IU million international units&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 9-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess the treatment effect on progression-free survival (PFS) of RAD001 plus bevacizumab versus patients who receive IFN and bevacizumab based on an estimation of the chance of success of a possible subsequent phase III study.;Secondary Objective: • To estimate the overall survival (OS) treatment effect in patients who receive RAD001 plus bevacizumab versus patients who receive IFN and bevacizumab.&lt;br&gt;• To estimate the objective response rate and response duration differences in patients who receive RAD001 plus bevacizumab versus patients who receive IFN and bevacizumab.&lt;br&gt;• To describe the safety profile of RAD001 plus bevacizumab versus IFN and bevacizumab.&lt;br&gt;• To compare patient reported outcomes on quality of life (QoL) from patients treated with RAD001 plus bevacizumab versus patients treated with IFN and bevacizumab.&lt;br&gt;• To measure the exposure of RAD001 in patients randomized to the treatment combination of RAD001 and bevacizumab.;Primary end point(s): Progression-free survival (PFS).  Progression-free survival (PFS) is the time from the date of randomization to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.</Primary_outcome>
    <Secondary_ID>CRAD001L2201</Secondary_ID>
    <Source_Support>Novartis Pharma Services AG</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2710700</Internal_Number>
    <TrialID>EUCTR2011-006115-59-IT</TrialID>
    <Last_Refreshed_on>31 July 2012</Last_Refreshed_on>
    <Public_title>"A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (IMN)"</Public_title>
    <Scientific_title>"A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (IMN)" - GNM-2011                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA</Primary_sponsor>
    <Date_registration3>20120608</Date_registration3>
    <Date_registration>08/06/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-006115-59                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>11/06/2012</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Biopsy diagnosis of idiopathic MN, performed in the last 24 months
&lt;br&gt;2. Proteinuria&gt; 3.5 g/24h in three measurements (one measurement for 3 weeks)
&lt;br&gt;3. Estimated GFR (MDRD formula) = 50ml/min/1.73m2 treated with ACE inhibitors / ARBs
&lt;br&gt;4. Physiological or surgically menopausal women, women who implement an approved method of contraception
&lt;br&gt;5. Failure in treatment with ACE inhibitors or ARBs to be first 3 months of treatment with RTX&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: 0&lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 60&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 10&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Serum creatinine&gt; 2.0mg/dl; eGFR &lt;50 ml/min/1.73m2,
&lt;br&gt;2. Previous treatment with rituximab, steroids, alkylating agents, calcineurin inhibitor, ACTH, MMF, azathioprine
&lt;br&gt;3. Presence of active infection
&lt;br&gt;4. Secondary causes of MN (eg hepatitis B, SLE, drugs, tumors). Testing for HIV, hepatitis B and C run less than 6 months before study
&lt;br&gt;5. Diabetes mellitus type 1 and 2
&lt;br&gt;6. Pregnancy or breast-feeding for safety&lt;br&gt;</Exclusion_Criteria>
    <Condition>MN is an autoimmune disease, suggesting that the disease may be triggered by isotype specific autoantibodies directed against podocyte enzymes and podocyte receptors that are recognized as antigens. The key role of IgG antibodies formation in the pathogenesis of IMN suggests that B cell depletion may favourably impact the evolution of the glomerular disease and reduce proteinuria. We propose this study in order to test in a randomized controlled trial the hyp &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10018372
Term: Glomerulonephritis membranous
System Organ Class: 10038359 - Renal and urinary disorders
;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]</Condition>
    <Intervention>&lt;br&gt;Trade Name: MABTHERA*EV 1FL 50ML 500MG&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;CAS Number: 174722-31-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;Trade Name: URBASON*IM EV 1F 250MG+1F 5ML&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;CAS Number: 83-43-2&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: MEDROL*10CPR DIV 4MG&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 83-43-2&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: .4-&lt;br&gt;&lt;br&gt;Trade Name: ENDOXAN BAXTER*50CPR RIV 50MG&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;CAS Number: 50-18-0&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: .2-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary outcome was the difference in the probability of complete remission (proteinuria &lt;0.3 g / day) at one year (see design and power considerations).;Secondary Objective: Differences in terms of:&lt;br&gt;Levels of proteinuria at time 0, 6.12, 18, 24 and 36 months;&lt;br&gt;Composite end point of CR (complete remission) or PR (partial remission) at 6, 12, 18, 24, and 36 months;&lt;br&gt;Mortality ';&lt;br&gt;Estimated glomerular filtration rate (MDRD formula) at 6, 12, 18, 24, and 36 months;&lt;br&gt;Value of serum creatinine (mg / dl) at 6, 12, 18, 24, and 36 months;&lt;br&gt;Frequency and number of relapses;&lt;br&gt;Frequency of autoantibodies anti-phospholipase A2 receptor (anti-PLA2R), anti-superoxide dismutase 2 (SOD2 anti-), anti-aldose reductase (anti-AR), anti-alpha-enolase (anti-a-enolase) at time 0 and after 3, 6.12, 18, 24 and 36 months after therapy.;Primary end point(s): The primary outcome was the difference in the probability of complete remission (proteinuria &lt;0.3 g / day) at one year;Timepoint(s) of evaluation of this end point: one year</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Differences in terms of:
&lt;br&gt;Levels of proteinuria at time 0, 6.12, 18, 24 and 36 months;
&lt;br&gt;Composite end point of CR (complete remission) or PR (partial remission) at 6, 12, 18, 24, and 36 months;
&lt;br&gt;Mortality ';
&lt;br&gt;Estimated glomerular filtration rate (MDRD formula) at 6, 12, 18, 24, and 36 months;
&lt;br&gt;Value of serum creatinine (mg / dl) at 6, 12, 18, 24, and 36 months;
&lt;br&gt;Frequency and number of relapses;
&lt;br&gt;Frequency of autoantibodies anti-phospholipase A2 receptor (anti-PLA2R), anti-superoxide dismutase 2 (SOD2 anti-), anti-aldose reductase (anti-AR), anti-alpha-enolase (anti-a-enolase) at time 0 and after 3, 6.12, 18, 24 and 36 months after therapy.;Timepoint(s) of evaluation of this end point: three years</Secondary_outcome>
    <Secondary_ID>GNM-2011</Secondary_ID>
    <Source_Support>Azienda Spedali Civili di Brescia</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2710887</Internal_Number>
    <TrialID>EUCTR2012-001786-32-IT</TrialID>
    <Last_Refreshed_on>31 July 2012</Last_Refreshed_on>
    <Public_title>Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with High-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response</Public_title>
    <Scientific_title>Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with High-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response - IL2HD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI</Primary_sponsor>
    <Date_registration3>20120723</Date_registration3>
    <Date_registration>23/07/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-001786-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/06/2012</Date_enrollement>
    <Target_size>19</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;Number of treatment arms in the trial: 1&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Patients, aged = 18 years, with a diagnosis of histologically confirmed non resectable stage III or IV advanced melanoma or Renal Cell Carcinoma (RCC)   2. Patients with a minimum of two lesions, one of which must be measurable   3. At least one tumor lesion accessible for bioptic sampling.  4. Prior lines (maximum 4) of chemotherapy, immunotherapy or biological therapy for advanced disease are allowed (patients must have finished prior treatments at least 4 weeks before the first IL2 dose);  5. Good performance status (ECOG performance status =1 ) and adequate organ function:   - leukocytes &gt;3,500/microL  - absolute neutrophil count &gt;1,500/microL  - platelets &gt;100,000/microL  - total bilirubin within normal institutional limits  - AST(SGOT)/ALT(SGPT) &lt;2.5 X ULN  - creatinine &lt;1,2 mg/dl  -    hemoglobin &gt;9.0 gm/dl  -    ECG and echocardiogram within normal institutional limits  -     pulmonary function tests within normal institutional limits (to be performed only in patients with lung metastases or history of impaired lung function)  6. No contraindication for the use of vasopressor agents  7. An estimated survival of at least 3 months.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: 0&lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 15&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 4&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Patients with stage I or II melanoma or RCC   2. Previous chemotherapy or radiotherapy or immunotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C).  3. Current brain metastases   4. History of allergic reactions attributed to IL2 or similar compounds  5. Any autoimmune disease which could be exacerbated by IL-2  6. A medical illness requiring chronic treatments with corticosteroids or other immunosuppressive agents  7. A history of significant cardiovascular disease, including myocardial infarction, congestive heart failure, primary cardiac arrhythmias, angina pectoris or cerebrovascular accident  8. Uncontrolled intercurrent illness including ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.  9. Other malignant neoplasia with a disease-free interval of less than 5 years (except for previously treated basal cell carcinoma and in situ carcinoma of the uterine cervix)  10. HIV-positivity&lt;br&gt;</Exclusion_Criteria>
    <Condition>metastatic melanoma or renal cell carcinoma &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10038414
Term: Renal cell carcinoma stage IV
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
 &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10025671
Term: Malignant melanoma stage IV
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
 &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10025670
Term: Malignant melanoma stage III
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
;Therapeutic area: Diseases [C] - Cancer [C04]</Condition>
    <Intervention>&lt;br&gt;Trade Name: PROLEUKIN*EV 1F 18MUI&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;INN or Proposed INN: ALDESLEUKIN&lt;br&gt;CAS Number: 110942-02-4&lt;br&gt;Concentration unit: million IU million international units&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 18-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: 1. to determine the tumor antigen-specific immune response induced by the treatment   2. to prospectively determine the predictive/prognostic value of pretreatment biological features in identifying patients who will benefit from HDIL-2-based therapy;Secondary Objective: 1. Toxicity  2. Response Rate  3. Overall Survival.;Primary end point(s): 1) immunological efficacy, as assessed by quantification of circulating immune effectors specific for a selected panel of tumor antigens.  2) predictive value of pretreatment serum biomarkers in identifying patients who will benefit from high dose IL-2 based therapy.;Timepoint(s) of evaluation of this end point: 36 months</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Secondary endpoints will be toxicity, the response rate (RR) and the overall survival (OS).;Timepoint(s) of evaluation of this end point: 36 months</Secondary_outcome>
    <Secondary_ID>IRST172.03</Secondary_ID>
    <Source_Support>Ministero della Salute-Ricerca Finalizzata 2009 (RF-2009-1547242)</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2718318</Internal_Number>
    <TrialID>EUCTR2012-000250-55-AT</TrialID>
    <Last_Refreshed_on>7 August 2012</Last_Refreshed_on>
    <Public_title>Renin-Angiotensin System Quantification in patients treated with specific medication against hypertension (Aliskiren or Candesartan)</Public_title>
    <Scientific_title>Renin-Angiotensin System Quantification in patients treated with Aliskiren or Candesartan (RASQAL) - RASQAL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Medizinische Universität Wien, Universitätsklinik für innere Medizin III</Primary_sponsor>
    <Date_registration3>20120611</Date_registration3>
    <Date_registration>11/06/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-000250-55                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/07/2012</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Chronic kidney disease stages III-IV (defined by MDRD formula)&lt;br&gt;&lt;br&gt;- Urinary albumin to creatinine ratio (UACR) &gt;300mg/g, UACR &gt;200mg/g if already receiving RAS blockade &lt;br&gt;&lt;br&gt;- Hypertension&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 24&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 24&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Age &lt;18 years, diabetes mellitus type 2 (defined by WHO criteria), UACR &gt;3500mg/g, severe hypertension, pregnancy&lt;br&gt;</Exclusion_Criteria>
    <Condition>- Chronic kidney disease stages III-IV (defined by MDRD formula)
- Hypertension;Therapeutic area: Body processes [G] - Physiological processes [G07]</Condition>
    <Intervention>&lt;br&gt;Trade Name: Rasilez&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;CAS Number: 173334-57-1&lt;br&gt;Other descriptive name: ALISKIREN HEMIFUMARATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 150-&lt;br&gt;&lt;br&gt;Trade Name: Atacand&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: CANDESARTAN CILEXETIL&lt;br&gt;CAS Number: 145040-37-5&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 8-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To demonstrate the quantity of differences in the renin-angiotensin peptide profiles in patients receiving direct renin inhibition or angiotensin receptor blockade.;Secondary Objective: To determine if patients who receive single RAS blockade exhibit  rebound upregulation of potentially beneficial components of the RAS system.&lt;br&gt;To demonstrate if patients receiving aliskiren exhibit complete suppression of the RAS system components.&lt;br&gt;To demonstrate potential additional blood pressure lowering effects in patients receiving direct renin inhibition or angiotensin receptor blockade.&lt;br&gt;To demonstrate potential additional antiproteinuric effects in patients receiving direct renin inhibition or angiotensin receptor blockade.&lt;br&gt;;Primary end point(s): Efficacy: Quantitative RAS peptide changes determined by mass spectrometry after a 2 month treatment with aliskiren or ARB&lt;br&gt;&lt;br&gt;Safety: Number of hypotensive episodes experienced by patients receiving study drugs&lt;br&gt;Number of hospitalizations during study phases&lt;br&gt;;Timepoint(s) of evaluation of this end point: after a 2 month treatment</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Efficacy: Extent of RAS suppression with aliskiren, determined by mass spectrometry measurements after aliskiren study phase&lt;br&gt;Blood pressure reduction, determined by ambulatory blood pressure measurements&lt;br&gt;Proteinuria reduction, measured by UACR after each study phase&lt;br&gt;;Timepoint(s) of evaluation of this end point: after study phase of 2 months</Secondary_outcome>
    <Secondary_ID>RASQAL</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2718323</Internal_Number>
    <TrialID>EUCTR2012-001824-36-AT</TrialID>
    <Last_Refreshed_on>7 August 2012</Last_Refreshed_on>
    <Public_title>ORAL SODIUM BICARBONATE SUPPLEMENTATION IN PATIENTS WITH CHRONIC METABOLIC ACIDOSIS AND CHRONIC KIDNEY DISEASE</Public_title>
    <Scientific_title>ORAL SODIUM BICARBONATE SUPPLEMENTATION IN PATIENTS WITH CHRONIC METABOLIC ACIDOSIS AND CHRONIC KIDNEY DISEASE - Oral SoBic supplementation in patients with CKD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Medizinsiche Universität Wien, Klinik für Innere Medizin III, Abteilung für Nephrologie und Dialyse</Primary_sponsor>
    <Date_registration3>20120611</Date_registration3>
    <Date_registration>11/06/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-001824-36                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/07/2012</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;Other trial design description: Controlled, randomized, open label&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Low dose of the IMP&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;• Age =18 years.&lt;br&gt;• Renal function (measured by eGFR-MDRD) between 60 and 15mL/min/ 1.73m2.&lt;br&gt;• Venous serum HCO3- of &lt;21mml/L on two consecutive measurements, at least one day apart.&lt;br&gt;• Stable condition.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 200&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 200&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;• Malignant disease or &lt;5years after a successfully treated malignant disease (except dermal malignancies and carcinoma in situ of the cervix declared to be cured).&lt;br&gt;• Morbid obesity (BMI &gt;40 kg/m2).&lt;br&gt;• Chronic sepsis (C reactive protein &gt; 10 mg/dL).&lt;br&gt;• Immunosuppressive therapy of any kind.&lt;br&gt;• Poorly controlled blood pressure (&gt;150/90mmHg despite the use of 4 agents)&lt;br&gt;• Overt congestive heart failure.&lt;br&gt;• Known peanut and/or soy allergy.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients classified to have chronic kidney disease of stage 3 and 4 and chronic metabolic acidosis (venous serum HCO3- of &lt;21mml/L on 2 separate measurements at least 1 day apart) should be included into the study. The effect of sodium bicarbonate supplementation on renal function should be evaluated. &lt;br&gt;MedDRA version: 14.1
Level: LLT
Classification code 10066569
Term: Chronic acidosis
System Organ Class: 10027433 - Metabolism and nutrition disorders
 &lt;br&gt;MedDRA version: 14.1
Level: LLT
Classification code 10064848
Term: Chronic kidney disease
System Organ Class: 10038359 - Renal and urinary disorders
;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]</Condition>
    <Intervention>&lt;br&gt;Trade Name: Nephrotrans 840mg&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Natriumhydrogencarbonat&lt;br&gt;CAS Number: 144-55-8&lt;br&gt;Current Sponsor code: 5424.01.00&lt;br&gt;Other descriptive name: SODIUM BICARBONATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 840-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Metabolic acidosis in chronic kidney disease is thought to be the result of an insufficient production of bicarbonate in the renal tubular system. Thus, the intervention of an oral exogenous bicarbonate supplementation to substitute the lacking endogenous bicarbonate seems to be rational. Patients with chronic kidney disease stage III and IV and chronic metabolic acidosis should be randomized to either receive a high dose of oral sodium bicarbonate with a serum target HCO3- level of 24±1 mmol/L or receive a rescue therapy of sodium bicarbonate with a serum target level of 20±1 mmol/L. After two years decline of renal function, as well as mortality rates and time of initiation of renal replacement therapy should be compared across study groups.;Secondary Objective: Secondary objectives of the trail are the rate of adverse events, in particular the effect of the additional daily dietary sodium load on the arterial blood pressure. &lt;br&gt;&lt;br&gt;;Primary end point(s): The primary end point of the study is the effect of sodium bicarbonate supplementation on renal function (eGFR). Thus, the Null hypothesis suggests no difference in renal function across study groups after 2 years. On the contrary, a significantly higher eGFR in the interventional group compared to the control group confirms the alternative hypothesis.;Timepoint(s) of evaluation of this end point: After 24 months</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Secondary end points are death rates between groups and the number of subjects proceeding to RRT (renal transplantation, hemodialysis, peritoneal dialysis) across groups. The alternative hypothesis suggests a significantly higher death rate and higher number of initiation of RRT, respectively, in the control group compared to the intervention group. The Null hypothesis confirms no difference in death rates and rates of initiation of RRT across study groups. ;Timepoint(s) of evaluation of this end point: After 24 months.</Secondary_outcome>
    <Secondary_ID>201201</Secondary_ID>
    <Source_Support>Medizinsiche Universität Wien, Klinik für Innere Medizin III, Abteilung für Nephrologie und Dialyse</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2718595</Internal_Number>
    <TrialID>EUCTR2009-011843-38-DE</TrialID>
    <Last_Refreshed_on>7 August 2012</Last_Refreshed_on>
    <Public_title>Documentation of the efficacy and tolerability of oxybutynin solution applied directly into the bladder in adult patients with incontinence</Public_title>
    <Scientific_title>Documentation of the efficacy and tolerability of intravesically applied oxybutynin solution in adult patients with detrusor hyperactivity caused by neurological disorder - Oxybutynin study in adults                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Grachtenhaus-Apotheke, Inh. Klaus Stegemann e.K.</Primary_sponsor>
    <Date_registration3>20090922</Date_registration3>
    <Date_registration>22/09/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011843-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>07/12/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- patient´s written informed consent
&lt;br&gt;- patients of both gender aged 18 to 70 years
&lt;br&gt;- patients, who are experienced in the performance of clean (or sterile) intermittent catheterization (CIC) and who perform regularly CIC for at least 6 weeks
&lt;br&gt;- patients with detrusor hyperactivity confirmed by urodynamic measurement within the last 24 months and associated with a known neurological deficit&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 36&lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- patients under effective and compatible medication
&lt;br&gt;- diseases like polyuria or nycturia due to heart or renal failure, subvesical organic urinary output failure (e. g. prostataadenom, urethral stricture), constrictions (stenosis) in the area of the remaining urinary passage and gastrointestinal tract, acute angle-closure glaucoma (glaucoma) or complanate anterior chamber, fast and abnormal heartbeat (cardiac tachyarrhythmia), severe colon aneurysma (toxic megacolon), severe arteriosclerotic alteration of the celebral vessels (cerebrosclerosis), intestinal obstruction, hiatal hernia with reflux esophagitis, phlogistic colon ulcer, colon atresia
&lt;br&gt;- Myasthenia gravis
&lt;br&gt;- severe hydronephrosis greater than grade 3; a renal ultrasound performed within 3 months prior to entering the study will be accepted as a baseline measurement if this assessment was performed while the patient was on a stable medication regimen
&lt;br&gt;- severe vesical-renal reflux higher than grade 3 according to Parkkulainen based on urodynamic measurement for diagnosis
&lt;br&gt;- symptomatic (febrile) urinary tract infection
&lt;br&gt;- severe limitations in renal function according to laboratory chemical determination of renal function values (Kreatinin &gt; 2,5 mg/dl)
&lt;br&gt;- pathological intraocular pressure – measured within 12 month prior to entering the study
&lt;br&gt;- clinically significant laboratory abnormalities (based on investigator judgment) or laboratory values greater than 2 times the upper limit of standard range
&lt;br&gt;- liver or renal insufficiency
&lt;br&gt;- intake of warfarin, ranitidine or cimetidine
&lt;br&gt;- intake of CYP3A4 inhibiting pharmaceuticals or substances like clomipramine, itraconazole, ketoconazole, testosterone, troleandomycin or CYP2D6 inhibiting pharmaceuticals like dextromethorphan
&lt;br&gt;- intake of anticholinergic or anticholinergic acting pharmaceuticals enhancing the function of oxybutynin, e. g. amantadin and other Anti-Parkinson’s pharmaceuticals, antihistamines, neuroleptics, chinidin, digitalis, trizyclic antidepressants, atropine and related compounds
&lt;br&gt;- intolerance to the active ingredient oxybutynin
&lt;br&gt;- medical history of allergy/hypersensitivity (including drug and sulfa drug allergy) which is deemed as relevant to the trial as judged by the investigator
&lt;br&gt;- treatment with Botulinum Toxin Type A (Botox) injections for urologic use within 6 months of randomization at screening visit
&lt;br&gt;- drug therapy, or non-drug therapy including electrostimulation for their neuropathic bladder initiated during the four weeks prior to screening or anticipated to initiate during the study
&lt;br&gt;- surgical procedure under general anaesthesia within 30 days prior to screening visit
&lt;br&gt;- participation in another trial with an investigational drug within 30 days prior to screening or during the trial
&lt;br&gt;- pregnant or lactating women; all female patients of child bearing potential, who are sexually active in the opinion of the investigator, have to use one accepted and highly effective agent of birth control with a Pearl Index = 1%
&lt;br&gt;- patients who cannot understand the terms of the informed consent form and/or subject information in the investigator's view
&lt;br&gt;- patients who are or have been committed to an institution by virtue of an order either by the judicial or the administrative authorities&lt;br&gt;</Exclusion_Criteria>
    <Condition>Detrusor hyperactivity caused by neurological dysfunction &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10061011
Term: Bladder disorder
System Organ Class: 10038359 - Renal and urinary disorders
;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]</Condition>
    <Intervention>&lt;br&gt;Product Name: Oxybutynin 0.1% Grachtenhaus&lt;br&gt;Pharmaceutical Form: Solution for intravesical use&lt;br&gt;INN or Proposed INN: Oxybutynin hydrochloride&lt;br&gt;CAS Number: 1508-65-2&lt;br&gt;Concentration unit: % (W/W) percent weight/weight&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.1-&lt;br&gt;&lt;br&gt;Trade Name: Dridase 5 mg Tabletten&lt;br&gt;Product Name: Dridase 5 mg Tabletten&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Oxybutynin hydrochloride&lt;br&gt;CAS Number: 1508-65-2&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5.0-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Determination of the alteration of the maximal cystometric bladder capacity between visit 1 and visit 3 (urodynamic measurement);Secondary Objective: - alteration of the catheterized urine volume between the last 3 days before visit 1 and visit 3 (via patient´s diary)&lt;br&gt;- alteration of the frequency of daily incontinences between the last 3 days before visit 1 and visit 3 (via patient´s diary)&lt;br&gt;- alteration of the subjective assessment of quality of life and treatment satisfaction between the last 3 days before visit 1 and visit 3 (via IQoL)&lt;br&gt;- alteration of urodynamic endpoints between visit 1 and 3&lt;br&gt;- a reduction of the number of daily catheterization between the last three days before visit 1 and visit 3 (via patient's diary)&lt;br&gt;- local tolerability via registration of side effects, urine testing and questions concerning tolerability&lt;br&gt;- local tolerability via cystocopy at end of 12-months follow-up study&lt;br&gt;- safety (kind, frequency and severity of side effects, premature study discontinuation, physical examination, ECG, vital signs, laboratory blood and urine values) ;Primary end point(s): The primary endpoint is:&lt;br&gt;• an alteration of the maximal cystometric bladder capacity between visit 1 and visit 3 (via urodynamic measurement);Timepoint(s) of evaluation of this end point: The primary endpoint is:&lt;br&gt;• an alteration of the maximal cystometric bladder capacity between visit 1 and visit 3 (via urodynamic measurement)</Primary_outcome>
    <Secondary_outcome>Timepoint(s) of evaluation of this end point: Efficacy:
&lt;br&gt;• between 3 untreated days before v1 and last 3 days of treatment before v3 (via patient diary) 
&lt;br&gt;•  between 3 untreated days before v1 and last 3 days of treatment before v3 (via patient diary) 
&lt;br&gt;•  between 3 untreated days before v1 and last 3 days before v3 (via IQol questionaire)
&lt;br&gt;•  between v1 and v3
&lt;br&gt;•  between 3 untreated days before v1 and last 3 days of treatment before v3 (via patient diary)
&lt;br&gt;Tolerability:
&lt;br&gt;• local tolerability via registration of advers events, urine analysises, questions of compatibility
&lt;br&gt;Safety:
&lt;br&gt;• kind, frequency, severity of spontaneous reported adverse events
&lt;br&gt;• early stop of study medication due to adverse events
&lt;br&gt;• physical examination (v0, 1, 3)
&lt;br&gt;• ECG (v0, 1, 3)
&lt;br&gt;• laboratory values of blood and urine (v0, 1, 3)
&lt;br&gt;• vitalparameters (v0, 1, 3);Secondary end point(s): Efficacy:
&lt;br&gt;• a change of the catherizated urine volume between the 3 untreated days before visit 1 and the last 3 days of treatment before visit 3 (via patient diary) 
&lt;br&gt;• a change of the frequency of unvolentary loss of urine between the 3 untreated days before visit 1 and the last 3 days of treatment before visit 3 (via patient diary) 
&lt;br&gt;• a change of the sujective evaluation of quality of life and satisfation with the treatment between the 3 untreated days before visit 1 and the last 3 days before visit 3 (via IQol questionaire)
&lt;br&gt;• a change of urodynamic end points (maximal pressure of detrusor during the filling phase, reflexvolume, detrusor compliance) between visit 1 and visit 3; additional will in patients with loss of urine the urodynamic end points "Leak Point Pressure" and bladder filling volume of loss of urine be recorded
&lt;br&gt;• a reduction of daily catheterization numbers between the last 3 days without treatment before visit 1 and the last 3 days of treatment before visit 3 (via patient diary)
&lt;br&gt;
&lt;br&gt;Tolerability:
&lt;br&gt;• local tolerability via registration of advers events, urine analysises, questions of tolerability
&lt;br&gt;• local tolerability via cystocopy at end of 12-months follow-up study
&lt;br&gt;
&lt;br&gt;Safety:
&lt;br&gt;• kind, frequency and severity of spontaneous reported adverse events
&lt;br&gt;• early stop of study medication because of adverse events
&lt;br&gt;• physical examination
&lt;br&gt;• ECG
&lt;br&gt;• laboratory values of blood and urine
&lt;br&gt;• vitalparameters
&lt;br&gt;</Secondary_outcome>
    <Secondary_ID>STEG-CORP_111804</Secondary_ID>
    <Source_Support>Grachtenhaus-Apotheke, Inh. Klaus Stegemann e.K.</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2722853</Internal_Number>
    <TrialID>EUCTR2010-020968-38-BE</TrialID>
    <Last_Refreshed_on>14 August 2012</Last_Refreshed_on>
    <Public_title>Study to Evaluate Efficacy and Safety of Treatment with CNTO 136 in Subjects with Active Lupus Nephritis</Public_title>
    <Scientific_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment with CNTO 136 Administered Intravenously in Subjects with Active Lupus Nephritis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Janssen-Cilag International N.V.</Primary_sponsor>
    <Date_registration3>20101129</Date_registration3>
    <Date_registration>29/11/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-020968-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/03/2011</Date_enrollement>
    <Target_size>24</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Diagnosis of Systemic lupus erythematosus (SLE), and biopsy-proven International Society of Nephrology/Renal Pathology Society Class III or IV lupus glomerulonephritis within approximately 14 months prior to randomization 
&lt;br&gt;
&lt;br&gt;- Persistently active nephritis defined as, proteinuria greater than 0.5g/day as determined by measurement of total urine protein less than 0.5 g/24- hours or a urine Protein/Creatinine (P/C) ratio greater than 0.5 (mg/mg) in a timed collection of 12 or more hours, for 2 months or more prior to the first administration of study medication and observed during at least 2 visits conducted 1 week apart during the screening period 
&lt;br&gt;
&lt;br&gt;- Active Class III or Class IV lupus nephritis determined by recent biopsy within approximately 6 months prior to screening or at least 1 of the following 3 criteria: hematuria (blood in urine), anti-DNA positivity, or low C3 or C4 complement levels 
&lt;br&gt;
&lt;br&gt;- Stable immunosuppression for at least 9 weeks prior to the first administration of study medication consisting of MMF 1-3 g/day (or equivalent dose of MPA) with/without corticosteroids up to prednisone equivalent of 20 mg/day, or azathioprine 1-3 mg/kg/day with/without corticosteroids up to prednisone equivalent of 20 mg/day 
&lt;br&gt;
&lt;br&gt;- Stable dose of angiotensin-converting enzyme (ACE) inhibitor/angiotensin II receptor blocker (ARB) for at least 9 weeks prior to the first administration of study medication 
&lt;br&gt;
&lt;br&gt;- If using oral corticosteroids, must be on a stable dose equivalent to 20 mg/day or less of prednisone for at least 9 weeks prior to the first administration of study medication &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 24&lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Cyclophosphamide use within 3 months of randomization 
&lt;br&gt;
&lt;br&gt;- B-cell depletion therapy within 6 months of screening, or evidence of persistent B-cell depletion at the time of screening 
&lt;br&gt;
&lt;br&gt;- Greater than 50 percent glomerular sclerosis on renal biopsy 
&lt;br&gt;
&lt;br&gt;- Serum creatinine &gt; 2.5 mg/dL (SI: &gt; 177 µmol/L) - White blood cell count &lt; 3.5 x 10^3 cells/µL (SI: &lt; 3.5 x 10^9 cells/L) or neutrophils &lt; 1.96 x 10^3 cells/µL (SI: &lt; 1.96 x 10^9 cells/L) - Platelets &lt; 140 x 103 cells/ µL (SI: &lt; 140 x 10^9 cells/L)&lt;br&gt;</Exclusion_Criteria>
    <Condition>Active Lupus Nephritis &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10025140
Term: Lupus nephritis
System Organ Class: 10038359 - Renal and urinary disorders
;Therapeutic area: Diseases [C] - Immune System Diseases [C20]</Condition>
    <Intervention>&lt;br&gt;Product Code: CNTO136&lt;br&gt;Pharmaceutical Form: Powder for solution for injection&lt;br&gt;Current Sponsor code: CNTO 136&lt;br&gt;Other descriptive name: fully human anti-IL-6 mAb&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective is to evaluate the efficacy and safety of CNTO 136 administered&lt;br&gt;intravenously (IV) in subjects with active, International Society of Nephrology&lt;br&gt;(ISN)/Renal Pathology Society (RPS) Class III and IV lupus nephritis (LN).;Secondary Objective: - Evaluate the pharmacokinetics and immunogenicity of CNTO 136 following IV&lt;br&gt;administration in subjects with active ISN/RPS Class III and IV LN&lt;br&gt;- Assess the pharmacodynamic effects of CNTO 136 IV in subjects with active&lt;br&gt;ISN/RPS Class III and IV LN;Primary end point(s): The primary endpoint is the percent reduction from baseline in proteinuria at Week 24. A 95% confidence interval of the mean change will be calculated based on normal&lt;br&gt;approximation. The baseline value for proteinuria will be defined as the average of the two most recent proteinuria measurements preceding the first study agent infusion.&lt;br&gt;The major secondary endpoints are proportion of subjects with a reduction from baseline in proteinuria by at least 50% at any time through Week 24; proportion of subjects with a meaningful reduction in proteinuria at any time through Week 24; and proportion of subjects with no worsening in GFR at any time through Week 24.;Timepoint(s) of evaluation of this end point: Week 24</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Change from baseline in Patient’s and Physician’s Global Assessment of Disease Activity at Week 24 will be summarized by treatment group.;Timepoint(s) of evaluation of this end point: Week 24</Secondary_outcome>
    <Secondary_ID>CNTO136LUN2001</Secondary_ID>
    <Source_Support>Janssen R&amp;D Inc.</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2725440</Internal_Number>
    <TrialID>EUCTR2005-002097-30-GB</TrialID>
    <Last_Refreshed_on>21 August 2012</Last_Refreshed_on>
    <Public_title>A SU011248 EXPANDED ACCESS PROTOCOL FOR SYSTEMIC THERAPY OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS BUT MAY DERIVE BENEFIT FROM TREATMENT WITH SU011248</Public_title>
    <Scientific_title>A SU011248 EXPANDED ACCESS PROTOCOL FOR SYSTEMIC THERAPY OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS BUT MAY DERIVE BENEFIT FROM TREATMENT WITH SU011248                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>PFIZER Inc 235 East 42nd Street, New York, NY, 10017</Primary_sponsor>
    <Date_registration3>20050613</Date_registration3>
    <Date_registration>13/06/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-002097-30                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/10/2005</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients must meet all of the following inclusion criteria to be eligible for enrollment into the trial:&lt;br&gt;&lt;br&gt;1.Histopathologically confirmed renal cell carcinoma with metastases.&lt;br&gt;2.Must be ineligible for participation in ongoing SU011248 clinical studies (if any Phase 1, 2 or 3 SU011248 protocols for patients having RCC are open to enrollment at the institution).&lt;br&gt;3.Judged by the treating physician to have the potential to derive clinical benefit from SU011248 treatment.&lt;br&gt;4.Male or female, 18 years of age or older.&lt;br&gt;5.If previously treated for metastatic RCC, resolution of all acute toxic effects of prior systemic therapy, radiotherapy or surgical procedure to NCI CTCAE Version 3.0 grade less/equal to 1.&lt;br&gt;6.Adequate organ function as defined by the following criteria:&lt;br&gt;•Total serum bilirubin less/equal to 2 x ULN (patients with Gilbert’s disease exempt)  &lt;br&gt;•Serum transaminases &lt;5 x ULN&lt;br&gt;•Serum creatinine less/equal 2 x ULN&lt;br&gt;•Absolute neutrophil count (ANC) major/equal to 1000/mL without growth factor support&lt;br&gt;•Platelets major/equal to 75,000/mL &lt;br&gt;•Hemoglobin major/equal to 8.0 g/dL &lt;br&gt;7.Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment.  &lt;br&gt;8.Willingness and ability to comply with scheduled visits, treatment plans and laboratory tests and other study procedures.&lt;br&gt;9. As required by local regulations, eg, United Kingdom, ECOG performance status of 0, 1 or 2.&lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.Current treatment in another therapeutic clinical trial&lt;br&gt;2.Congestive heart failure, myocardial infarction or coronary artery bypass graft in the previous six months, ongoing severe or unstable angina or any unstable arrhythmia requiring medication  &lt;br&gt;3.Previous treatment on a SU011248 trial except for those patients who recieved IFN-alpha therapy in Protocol A6181034 and either had radiographic documentation of disease progression or were IFN-alpha intolerant.&lt;br&gt;4.Pregnancy or breastfeeding.  Patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy.  The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.  Male patients must be surgically sterile or agree to use effective contraception. &lt;br&gt;5.Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Histopathologically confirmed renal cell carcinoma with metastases &lt;br&gt;MedDRA version: 8.0
Level: LLT
Classification code 10038415
</Condition>
    <Intervention>&lt;br&gt;Trade Name: SUTENT&lt;br&gt;Product Name: Sutent&lt;br&gt;Product Code: su011248&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: sunitinib malate&lt;br&gt;CAS Number: 341031-54-7&lt;br&gt;Current Sponsor code: SU011248&lt;br&gt;Other descriptive name: PHA-290940AD&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 12.5-&lt;br&gt;INN or Proposed INN: sunitinib malate&lt;br&gt;CAS Number: 341031-54-7&lt;br&gt;Current Sponsor code: SU011248&lt;br&gt;Other descriptive name: PHA-290940AD&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;INN or Proposed INN: sunitinib malate&lt;br&gt;CAS Number: 341031-54-7&lt;br&gt;Current Sponsor code: SU011248&lt;br&gt;Other descriptive name: PHA-290940AD&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of this protocol is to provide access to SU011248 treatment for patients with metastatic RCC given all of the following conditions are met: &lt;br&gt;&lt;br&gt;a) patients are ineligible for participation in ongoing SU011248 clinical studies (if any Phase 1, 2 or 3 SU011248 protocols for patients having RCC are open to enrollment at the institution) except for those patients who recieved IFN-alpha therapy in Protocol A6181034 and either had radiographic documentation of disease progression or were IFN-alpha intolerant, and&lt;br&gt;&lt;br&gt;b) patients have the potential to derive clinical benefit from treatment with SU011248 based on the judgment of the investigator.  &lt;br&gt;;Secondary Objective: Other objectives include the assessment of:&lt;br&gt;&lt;br&gt;•	Safety and tolerability profile of SU011248&lt;br&gt;•	The antitumor efficacy of single-agent SU011248 given orally at a dose of 50 mg in patients with metastatic RCC&lt;br&gt;&lt;br&gt;;Primary end point(s): The primary objective is to provide access to SU011248 treatment for patients with metastatic RCC according to conditions described in the protocol without formal hypothesis testing.  In addition, the following clinical endpoints will be evaluated.&lt;br&gt;•Safety profile of SU011248&lt;br&gt;•Overall survival (OS)&lt;br&gt;•Time-to-progression (TTP)&lt;br&gt;•Progression-free survival (PFS)&lt;br&gt;•Objective response rate (ORR)</Primary_outcome>
    <Secondary_ID>A6181037</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2725567</Internal_Number>
    <TrialID>EUCTR2004-004884-31-GB</TrialID>
    <Last_Refreshed_on>21 August 2012</Last_Refreshed_on>
    <Public_title>An open label, randomized pilot study evaluating the early conversion from calcineurin inhibitors to Rapamune in patients with impaired renal function following kidney transplantation - Sirolimus Switch Study</Public_title>
    <Scientific_title>An open label, randomized pilot study evaluating the early conversion from calcineurin inhibitors to Rapamune in patients with impaired renal function following kidney transplantation - Sirolimus Switch Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Newcastle upon Tyne Hospitals NHS Trust</Primary_sponsor>
    <Date_registration3>20071031</Date_registration3>
    <Date_registration>31/10/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-004884-31                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/01/2008</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Standard (non-sirolimus) based immunosuppression using Mycophenolate mofetil&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;i.	Male and female patients aged 18 to 75 years.&lt;br&gt;ii.	Patients with a calculated creatinine clearance (GFR, Cockcroft &amp; Gault method) of &gt; 40 ml/min and &lt; 60 ml/min.&lt;br&gt;iii.	Patients with a deterioration of calculated creatinine clearance (GFR, Cockcroft &amp; Gault method)  from 3 to 9 months post renal transplantation.&lt;br&gt;iv.	Patients treated with a calcineurin inhibitor, either cyclosporin or tacrolimus for a minimum of 3 months before study entry.&lt;br&gt;v.	Patients between 6 – 9 months post renal transplantation.&lt;br&gt;vi.	Female patients of childbearing age must have a negative serum pregnancy test and agree to use medically accepted form of contraception for the duration of the study and for 3 months following discontinuation of Rapamune.&lt;br&gt;vii.	Able and willing to give written informed consent to participate in the trial and co-operate with the trial requirements&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;i.	Known hypersensitivity to Rapamune and its derivatives.&lt;br&gt;ii.	Evidence of active systemic or localized infection.&lt;br&gt;iii.	Current use of cimetidine, terfenedine, astemizole, pimozide or azole anti-fungals (medications to be discontinued at least 24 hours before administration of sirolimus).&lt;br&gt;iv.	Baseline fasting cholesterol level &gt; 7.8 mmol/L and or triglycerides &gt; 4.6 mmol/L.&lt;br&gt;v.	Know or suspected malignancy within 5 years prior to study entry (with the exception of adequately treated basal cell or squamous cell carcinomas of the skin) or a history of PTLD.&lt;br&gt;vi.	Use of any investigational drug or treatments within 30 days before study entry.&lt;br&gt;vii.	Multiple organ transplants (e.g. kidney-pancreas)&lt;br&gt;viii.	History of alcohol or drug abuse.&lt;br&gt;ix.	Previous participation in this trial.&lt;br&gt;x.	HIV positive patients&lt;br&gt;xi.             Patients with proteinuria &gt;800mg/24 hours&lt;br&gt;</Exclusion_Criteria>
    <Condition>This study will be conducted in 60 established renal allograft recipients who have suffered from chronic renal failure of any cause.</Condition>
    <Intervention>&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: SIROLIMUS&lt;br&gt;CAS Number: 53123889&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1-20&lt;br&gt;&lt;br&gt;Trade Name: Cellcept&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: MYCOPHENOLATE MOFETIL&lt;br&gt;CAS Number: 115007346&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 2-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Secondary Objective: 1.	Comparison of serum creatinine at 6 and 12 months compared to baseline.&lt;br&gt;2.	To assess the efficacy of the two Groups as measured by the cumulative incidence of biopsy proven acute rejection at 6 and 12 months&lt;br&gt;3.	To assess the cumulative incidence of death, graft loss at 12 months&lt;br&gt;4.	To compare the incidence, and severity of adverse events and serious adverse events at 12 months&lt;br&gt;5.	To compare the diastolic and systolic blood pressure at 6 and 12 months and to compare the use of antihypertensive medication between the two groups.;Primary end point(s): The primary objective of the study is renal function as measured by calculated creatinine clearance (GFR) at 6 and 12 months following conversion and by the comparison of differences between treatment groups as determined by the least squares slopes of 1/creatinine vs. time over 12 months following conversion.;Main Objective: The study will assess whether the conversion from CNI based therapy to Rapamune provides effective immunosuppression but with improved renal function as compared to the standard therapy control group. </Primary_outcome>
    <Secondary_ID>Nuth-2005-3400</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2726162</Internal_Number>
    <TrialID>EUCTR2010-019638-28-FR</TrialID>
    <Last_Refreshed_on>21 August 2012</Last_Refreshed_on>
    <Public_title>INVESTIGATING NEW ONSET DIABETES MELLITUS IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT CORTICOSTEROIDS – 
A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY
 - ADVANCE</Public_title>
    <Scientific_title>INVESTIGATING NEW ONSET DIABETES MELLITUS IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT CORTICOSTEROIDS – 
A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY
 - ADVANCE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Astellas Pharma Europe Ltd.</Primary_sponsor>
    <Date_registration3>20100928</Date_registration3>
    <Date_registration>28/09/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-019638-28                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/11/2010</Date_enrollement>
    <Target_size>1166</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Age = 18 years.&lt;br&gt;2. End stage kidney disease and a suitable candidate for primary renal transplantation or retransplantation (unless the graft was lost from rejection within 6 months).&lt;br&gt;3. Receiving a kidney transplant from a deceased or living (non HLA identical) donor with compatible AB0 blood type.&lt;br&gt;4. Female subjects of childbearing potential must have a negative serum or urine pregnancy test at enrollment and must agree to maintain highly effective birth control during the study.&lt;br&gt;A highly effective method of birth control is defined as those which result in a low failure rate (CPMP/ICH/286/95 modified) of less than 1% per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomized partner.&lt;br&gt;5. Capable of understanding the purpose and risks of the study, fully informed and having given written informed consent (signed Informed Consent has been obtained).&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Receiving or having previously received an organ transplant other than a kidney.&lt;br&gt;2. Cold ischemia time of the donor kidney &gt; 30 hours.&lt;br&gt;3. Panel Reactive Antibody (PRA) &gt;20%.&lt;br&gt;4. Previous renal transplant lost within one year for immunological reasons.&lt;br&gt;5. Receiving a graft from a non-heart-beating donor other than of Maastricht category 3 (withdrawal of support awaiting cardiac arrest).&lt;br&gt;6. Significant liver disease, defined as having continuously elevated SGPT/ALT and/or&lt;br&gt;SGOT/AST and/or total bilirubin levels = 2 times the upper value of the normal range of the investigational site or is receiving a graft from a hepatitis C or B positive donor.&lt;br&gt;7. Diagnosis of Diabetes Mellitus prior to transplantation (treated with prescribed&lt;br&gt;medications or diet controlled) or where there is evidence of a previous positive OGTT in the patients medical history or previous diagnosis of gestational diabetes or Baseline HbA1C =6.5mmol/L.&lt;br&gt;8. Requiring initial sequential or parallel therapy with immunosuppressive antibody&lt;br&gt;preparation(s).&lt;br&gt;9. Requiring ongoing dosing with a systemic immunosuppressive drug prior to&lt;br&gt;transplantation (e.g. for Lupus Disease, FSGN etc) other than minimal levels of&lt;br&gt;immunosuppressant following failure of a previous transplantation without nephrectomy.&lt;br&gt;10. Where Physician considers long term steroid treatment is necessary for the prevention of recurrent auto immune mediated renal disease or if the subject requires ongoing dosing with corticosteroids during the study for any other condition.&lt;br&gt;11. Significant, uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer.&lt;br&gt;12. Pregnant woman or breast-feeding mother.&lt;br&gt;13. Subject or donor known to be HIV positive.&lt;br&gt;14. Known allergy or intolerance to tacrolimus, macrolide antibiotics, corticosteroids,&lt;br&gt;Basiliximab, mycophenolate mofetil or any of the product excipients.&lt;br&gt;15. Evidence of malignant disease within the last 5 years other than Basal Cell Carcinoma or Squamous Cell Carcinoma.&lt;br&gt;16. Currently participating in another clinical trial and/or has taken an investigational drug within 28 days prior to randomization.&lt;br&gt;17. Any form of substance abuse, psychiatric disorder or condition which, in the opinion of the investigator, may complicate communication with the investigator.&lt;br&gt;18. Unlikely to comply with the visits scheduled in the protocol.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Prophylaxis of rejection in kidney allograft recipients (by immunosuppression) &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10050436
Term: Prophylaxis against renal transplant rejection
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Advagraf&lt;br&gt;Pharmaceutical Form: Prolonged-release capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Trade Name: Advagraf&lt;br&gt;Pharmaceutical Form: Prolonged-release capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: Advagraf&lt;br&gt;Pharmaceutical Form: Prolonged-release capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 3-&lt;br&gt;&lt;br&gt;Trade Name: Advagraf&lt;br&gt;Pharmaceutical Form: Prolonged-release capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the two treatment arms with regard to incidence of new onset diabetes Mellitus as per the American Diabetic Association criteria at any point up to 24 weeks after kidney transplantation.&lt;br&gt;Arm 1: Advagraf + Basiliximab + MMF + Steroids (discontinued at 10 days)&lt;br&gt;Arm 2: Advagraf + Basiliximab + MMF + Steroids (optional intra-op Bolus only);Secondary Objective: to compare the safety and efficacy profiles of the two therapy regimens with each other;Primary end point(s): The primary endpoint of the study is the incidence of New Onset Diabetes Mellitus defined as: &lt;br&gt;Occurrence of NODAT as per ADA criteria at any point up to 24 weeks after kidney transplantation: &lt;br&gt;&lt;br&gt;1.  HbA1C =6.5% at or after the week 12 visit.  The test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay.&lt;br&gt;OR&lt;br&gt;2.  FPG =126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 hours prior to blood sampling.* &lt;br&gt;OR &lt;br&gt;3. 2-h plasma glucose =200 mg/dl (11.1 mmol/l) during an OGTT. The test should be performed as described by the World Health Organization, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.* &lt;br&gt;OR &lt;br&gt;4. Symptoms of hyperglycemia and a casual plasma glucose =200 mg/dl (11.1mmol/l). Casual is defined as any time of day without regard to time since last meal. The classic symptoms of hyperglycemia include polyuria, polydipsia, and unexplained weight loss.&lt;br&gt;&lt;br&gt;* In the absence of unequivocal hyperglycemia, criteria 2) &amp; 3) should be confirmed by repeat testing (using the same test) =30 days after the initial positive assessment.  A repeat test is not required for 1) and 4). A single HbA1C result of = 6.5% at or after week 12 or unequivocal hyperglycemia (4) is sufficient to confirm diagnosis of NODAT.&lt;br&gt;&lt;br&gt;For 2) &amp; 3) the diagnosis will be classed as the time of the first test showing above criteria only if confirmed by a second reading using the same test, or if treatment for diabetes has been initiated  &lt;br&gt;As per protocol, HbA1C will be measured at Baseline, Week 12 Week 24.  OGTT will be measured at Week 8 and again at Week 24.  Glucose will be measured at all study visits.  The investigator may perform additional tests using the above methods at their discretion.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>PMR-EC-1211</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2726464</Internal_Number>
    <TrialID>EUCTR2011-000493-56-ES</TrialID>
    <Last_Refreshed_on>21 August 2012</Last_Refreshed_on>
    <Public_title>An evaluation of the investigational drug GDC-0980 in patients with metastatic kidney cancer who have already received up to three therapies, with the approved drug everolimus as a comparison</Public_title>
    <Scientific_title>A PHASE II, OPEN-LABEL, RANDOMIZED STUDY OF GDC-0980 VERSUS EVEROLIMUS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO HAVE PROGRESSED ON OR FOLLOWING VEGF-TARGETED THERAPY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>GENENTECH, Inc.</Primary_sponsor>
    <Date_registration3>20110907</Date_registration3>
    <Date_registration>07/09/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-000493-56                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>15/09/2011</Date_enrollement>
    <Target_size>80</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: everolimus&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;?Histologically or cytologically documented, incurable metastatic renal cell carcinoma with clear-cell component that progressed on or within 6 months of stopping VEGF-targeted therapy&lt;br&gt;?Age ? 18 years &lt;br&gt;?Karnofsky Performance Status Score (KPSS) of ? 70%&lt;br&gt;?Disease that is measurable per RECIST v1.1&lt;br&gt;?Adequate hematologic and end organ function&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 40&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 40&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;?Requirement for chronic antihyperglycemic therapy&lt;br&gt;?Current dyspnea at rest or any requirement for supplemental oxygen therapy to perform activities of daily living&lt;br&gt;?Decreased oxygen saturation with exercise (pulse oximeter &lt;88%)&lt;br&gt;?Previously established diagnosis of pulmonary fibrosis of any cause&lt;br&gt;?Current unstable angina&lt;br&gt;?History of myocardial infarction within 6 months prior to Day 1&lt;br&gt;?New York Heart Association (NYHA) Class II or greater congestive heart failure&lt;br&gt;?Clinically significant liver disease&lt;br&gt;?Known HIV infection&lt;br&gt;?Active infection requiring IV antibiotics&lt;br&gt;?Active autoimmune disease that is not controlled by nonsteroidal anti inflammatory drugs&lt;br&gt;?Pregnancy, lactation, or breastfeeding&lt;br&gt;?Leptomeningeal disease as a manifestation of cancer&lt;br&gt;?Untreated or active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control).&lt;br&gt;</Exclusion_Criteria>
    <Condition>METASTATIC RENAL CELL CARCINOMA &lt;br&gt;MedDRA version: 14.0
Level: LLT
Classification code 10038409
Term: Renal cell carcinoma NOS
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
 &lt;br&gt;MedDRA version: 14.0
Level: LLT
Classification code 10038415
Term: Renal cell carcinoma stage unspecified
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
 &lt;br&gt;MedDRA version: 14.0
Level: LLT
Classification code 10038407
Term: Renal cell cancer
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
;Therapeutic area: Diseases [C] - Cancer [C04]</Condition>
    <Intervention>&lt;br&gt;Product Name: GDC-0980&lt;br&gt;Product Code: GDC-0980 (RO5490254)&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;CAS Number: 1032754-93-0&lt;br&gt;Current Sponsor code: GDC-0980 (RO5490254)&lt;br&gt;Other descriptive name: PI3K/mTOR INHIBITOR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;Trade Name: Afinitor 5 mg tablets&lt;br&gt;Product Name: everolimus&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Other descriptive name: EVEROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: Afinitor 10 mg tablets&lt;br&gt;Product Name: everolimus&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Other descriptive name: EVEROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: ?To evaluate the efficacy of GDC-0980 versus everolimus as measured by progression-free survival (PFS) defined as the time from randomization to disease progression;Secondary Objective: ?To assess the clinical activity of GDC-0980 versus everolimus as measured by response rate, duration of response, and overall survival (OS)&lt;br&gt;?To evaluate the safety and tolerability of GDC-0980 versus everolimus &lt;br&gt;?To assess pharmacokinetic (PK) parameters (Cmax, Cmin) of GDC 0980 and everolimus;Primary end point(s): Progression-free survival (PFS);Timepoint(s) of evaluation of this end point: After approximately 60 PFS events have occurred (estimated to occur approximately 23 months after study start).</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Response rate, duration of response, overall survival, safety, tolerability, PK parameters;Timepoint(s) of evaluation of this end point: Final analyses after approximately 60 PFS events have occurred. Interim analyses for safety and PK parameters after the first 10 patients in each arm have undergone the first tumor assessment while receiving study treatment (GDC-0980 or everolimus); and again when the same is the case for 20 and 30 patients in each arm.</Secondary_outcome>
    <Secondary_ID>PIM4973g</Secondary_ID>
    <Source_Support>Genentech Inc. c/o F. Hoffmann-La Roche Ltd.</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2750109</Internal_Number>
    <TrialID>EUCTR2006-003173-27-FR</TrialID>
    <Last_Refreshed_on>28 August 2012</Last_Refreshed_on>
    <Public_title>A Multi-Center, Single Arm Study Evaluating De Novo Once Monthly (QM) Darbepoetin Alfa Dosing for the Correction of Anemia in Subjects with Chronic Kidney Disease (CKD) Not Receiving Dialysis</Public_title>
    <Scientific_title>A Multi-Center, Single Arm Study Evaluating De Novo Once Monthly (QM) Darbepoetin Alfa Dosing for the Correction of Anemia in Subjects with Chronic Kidney Disease (CKD) Not Receiving Dialysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Amgen Limited</Primary_sponsor>
    <Date_registration3>20060921</Date_registration3>
    <Date_registration>21/09/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-003173-27                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>14/04/2009</Date_enrollement>
    <Target_size>155</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;= 18 years of age&lt;br&gt;Estimated GFR of = 15 mL/min/1.73 m2 - = 60 mL/min/1.73 m2 (MDRD equation)&lt;br&gt;Clinically stable, in the judgment of the investigator&lt;br&gt;The mean of 2 screening Hb values taken at least 7 days apart must be &lt;11.0 g/dL&lt;br&gt;Adequate iron stores (serum ferritin &gt; 100 µg/L)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Scheduled to receive a kidney transplant&lt;br&gt;ESA use within 12 weeks before enrollment&lt;br&gt;Uncontrolled hypertension defined as diastolic BP &gt; 110 mm Hg or systolic BP &gt;180 mm Hg&lt;br&gt;Acute myocardial ischemia; hospitalization for congestive heart failure, myocardial infarction, deep vein thrombosis, stroke or transient ischemic attack within 12 weeks before enrollment&lt;br&gt;Major surgery within 12 weeks before enrollment (excluding vascular access&lt;br&gt;surgery).&lt;br&gt;Currently receiving antibiotic therapy for systemic infection.&lt;br&gt;Known positive HIV antibody or positive hepatitis B surface antigen&lt;br&gt;Clinical evidence of current malignancy and/or receiving systemic chemotherapy/radiotherapy with the exception of basal cell or squamous cell carcinoma of the skin and cervical intraepithelial neoplasia&lt;br&gt;Red blood cell (RBC) transfusions within 8 weeks before enrollment&lt;br&gt;Androgen therapy within 8 weeks before enrollment&lt;br&gt;Systemic hematological disease (eg, sickle cell anemia, myelodysplastic syndromes, hematologic malignancy; myeloma; hemolytic anemia)&lt;br&gt;Any disorder that may impact (in the judgment of the investigator) the ability to give informed consent for participation in this study&lt;br&gt;Pregnant or breast-feeding women. All subjects must practice adequate&lt;br&gt;contraception (in the judgment of the investigator) throughout this study&lt;br&gt;Treatment with an investigational agent or device within 30 days before&lt;br&gt;enrollment or scheduled to receive an investigational agent other than those&lt;br&gt;specified by this protocol during the course of this study&lt;br&gt;Subject has known sensitivity to any of the products to be administered during dosing&lt;br&gt;Grand mal seizure within 6 months before enrollment&lt;br&gt;Upper or lower GI bleeding within 6 months before enrollment&lt;br&gt;Currently receiving immunosuppressive therapy&lt;br&gt;</Exclusion_Criteria>
    <Condition>Anemia in subjects with chronic kidney disease not receiving dialysis</Condition>
    <Intervention>&lt;br&gt;Product Name: Darbepoetin alfa 10 micrograms solution for injection in a pre-filled pen&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: darbepoetin alfa&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Product Name: Darbepoetin alfa 20 micrograms solution for injection in a pre-filled pen&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: darbepoetin alfa&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 40-&lt;br&gt;&lt;br&gt;Product Name: Darbepoetin alfa 30 micrograms solution for injection in a pre-filled pen&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: darbepoetin alfa&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Name: Darbepoetin alfa 40 micrograms solution for injection in a pre-filled pen&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: darbepoetin alfa&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Name: Darbepoetin alfa 50 micrograms solution for injection in a pre-filled pen&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: darbepoetin alfa&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Name: Darbepoetin alfa 60 micrograms solution for injection in a pre-filled pen&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: darbepoetin alfa&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Product Name: Darbepoetin alfa 80 micrograms solution for injection in a pre-filled pen&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: darbepoetin alfa&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Product Name: Darbepoetin alfa 100 micrograms solution for injection in a pre-fille</Intervention>
    <Primary_outcome>Main Objective: To assess the proportion of subjects achieving a Hb = 11.0 g/ dL at any time-point during the study following de novo QM darbepoetin alfa administration.;Secondary Objective: Secondary:&lt;br&gt;• To determine Hb values over the duration of the study&lt;br&gt;• To assess the proportion of subjects achieving a mean Hb = 11.0 g/dL during the&lt;br&gt;evaluation period (weeks 25-33)&lt;br&gt;• To determine QM darbepoetin alfa doses over the duration of the study&lt;br&gt;• To assess the safety of darbepoetin alfa administered de novo QM&lt;br&gt;• To assess the change in health related quality of life (HRQOL) scores between&lt;br&gt;baseline, week 17 and end of study;Primary end point(s): Primary Efficacy Endpoint:&lt;br&gt;Achievement of a Hb = 11.0 g/dL at any time point following de novo QM darbepoetin&lt;br&gt;alfa administration.&lt;br&gt;&lt;br&gt;&lt;br&gt;Secondary Efficacy Endpoints&lt;br&gt;• Hb at each scheduled time-point (Baseline, weeks 3, 5, 7, 9, 11,13, 15, 17, 19,&lt;br&gt;21, 23, 25, 27, 29, 31 and 33)&lt;br&gt;• QM Darbepoetin alfa doses over the duration of the study&lt;br&gt;• Time to first Hb = 11.0 g/dL following de novo QM darbepoetin alfa administration&lt;br&gt;• QM dose at first Hb = 11.0 g/dL following de novo QM darbepoetin alfa&lt;br&gt;administration&lt;br&gt;• Achievement of a mean Hb during the evaluation period = 11.0 g/dL&lt;br&gt;&lt;br&gt;Safety Endpoints&lt;br&gt;• Maximum Hb increase over a 2 week period following de novo QM darbepoetin&lt;br&gt;alfa administration&lt;br&gt;• Adverse events following de novo QM darbepoetin alfa administration&lt;br&gt;• Laboratory parameters and blood pressure at each scheduled time point&lt;br&gt;• Hb ROR and excursions above 14.0 g/dL following de novo QM darbepoetin alfa&lt;br&gt;administration&lt;br&gt;• Anti-erythropoietic protein antibodies&lt;br&gt;&lt;br&gt;HRQOL Endpoint&lt;br&gt;Change in HRQOL scores (SF-36 and EQ-5D) from baseline to week 17 and end of&lt;br&gt;study</Primary_outcome>
    <Secondary_ID>20060163</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2750202</Internal_Number>
    <TrialID>EUCTR2007-000062-20-FR</TrialID>
    <Last_Refreshed_on>28 August 2012</Last_Refreshed_on>
    <Public_title>A Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in Patients
With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy</Public_title>
    <Scientific_title>A Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in Patients
With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Wyeth Research Division of Wyeth Pharmaceuticals Inc. Global Medical Affairs</Primary_sponsor>
    <Date_registration3>20070731</Date_registration3>
    <Date_registration>31/07/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-000062-20                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/11/2007</Date_enrollement>
    <Target_size>440</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Histologically confirmed diagnosis of mRCC (regardless of nephrectomy status) with well-documented radiological progressive disease (PD) by RECIST criteria or clinical PD, as judged by the investigator while receiving first-line sunitinib therapy.  Subjects must have received a minimum of 1 six-week cycle of sunitinib therapy.&lt;br&gt;2.	At least 2 weeks since prior treatment with sunitinib, palliative radiation therapy, and/or surgery and resolution of all toxic effects of prior therapy according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE, version 3.0) Grade &lt; or equal to1.&lt;br&gt;3.	At least 1 measurable lesion that can be accurately measured in at least 1 dimension with the longest diameter (LD) superior or equal to 10 mm when measured by spiral computerized tomography (CT) (5-mm slice thickness contiguous) or &gt; or equal to 20 mm when measured by conventional CT (10-mm slice thickness contiguous).  The lesion must be &gt; or equal to 2 times the size of the slice thickness per RECIST criteria.&lt;br&gt;4.	Age = 18 years.&lt;br&gt;5.	Screening laboratory values within the following limits:	Absolute neutrophil count &gt; or equal to 1.5 x 109/L (1500/mL)	Platelet count &gt; or equal to 100 x 109/L (100,000/mL)	Leukocyte count &gt; or equal to 3 x 109/L (3000/µL)	Hemoglobin &gt; or equal to 80g/L (8.0g/dL) without transfusion within 28 days before randomization	Serum creatinine &lt; or equal to 2.0 x upper limit of normal (UNL)	Total bilirubin &lt; or equal to 1.5 x ULN	Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; or equal to 3 x ULN (&lt; or equal to5 x ULN if liver metastases are present)	Fasting serum cholesterol &lt; or equal to 2.0 x ULN  (therapy permitted)	Fasting serum triglycerides &lt; or equal to 2.0 x ULN  (therapy permitted)	Fasting glycosolated hemoglobin A1c (HbA1c) = 9% (therapy permitted)	Corrected serum calcium &lt; or equal to 1.5 x ULN (corrected calcium = total calcium – 0.707 [albumin – 3.4 g/dL].  If a laboratory reports total calcium in mmol/L, results should be converted to mg/dL using 0.249 as conversion factor	Partial thromboplastin time within normal limits (WNL)and international normalized ratio or prothrombin time or prothrombin activity &lt; 1.3 x ULN	Amylase and lipase &lt; or equal to 1.5 x ULN	Sensitive thyroid stimulating hormone (sTSH) &lt; or equal to 5 x ULN	Serum magnesium &gt; or equal to 0.41 mmol/L (1.0 mg/dL) (therapy permitted)	Serum phosphorus &gt; or equal to 0.78 mmol/L (2.5 mg/dL) (therapy permitted)	Serum uric acid &lt; or equal to 588 mcmol/L (10 mg/dL) (therapy permitted) &lt;br&gt;6.	Adequate cardiac function (left ventricular ejection fraction = 40%) as assessed by electrocardiogram (ECG), and either echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan as judged by the investigator and the sponsor’s medical monitor if abnormal.  &lt;br&gt;7.	Eastern Cooperative Oncology Group (ECOG) performance status 0-1.&lt;br&gt;8.	Ability to swallow whole sorafenib tablets.&lt;br&gt;9.	Life expectancy of at least 3 months.&lt;br&gt;10.	Signed and dated institutional review board (IRB) or independent ethics committee (IEC) approved informed consent form (ICF).&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	History of a central nervous system (CNS) malignancy or metastatic disease to the CNS and subjects with a known, active CNS malignancy (primary or metastatic).&lt;br&gt;2.	Subjects who do not have clear evidence of PD while receiving at least 1 six-week cycle of sunitinib therapy, but who discontinued therapy due to intolerance.  &lt;br&gt;3.	Bone only/non-measurable bone lesions as target lesions.&lt;br&gt;4.	Any prior systemic therapy for mRCC other than sunitinib.  &lt;br&gt;5.	Receiving known strong CYP3A4 isoenzyme inhibitors and/or inducers.  Subjects taking CYP3A4 isoenzyme inhibitors and/or inducers not classified as strong are eligible, provided the subject has been on a stable regimen for at least 4 weeks before screening.&lt;br&gt;6.	Not recovered from prior biopsy, surgery, traumatic injury, and/or radiation therapy, as judged by the investigator. &lt;br&gt;7.	Nonhealing wound or ulcer.&lt;br&gt;8.	Grade &gt; or equal to 3 hemorrhage within the past month.&lt;br&gt;9.	Systolic blood pressure of &gt; 160 mm Hg and/or diastolic pressure &gt; 100 mm Hg (antihypertensive medications are permitted).&lt;br&gt;10.	Unstable coronary artery disease, as judged by the investigator, or recent myocardial infarction (&lt; 180 days).&lt;br&gt;11.	American Heart Association class 3/4 heart disease.&lt;br&gt;12.	QTc interval &gt; 450 ms for men and &gt; 470 ms for women and/or any ventricular arrhythmia and/or any uncontrolled atrial arrhythmia.  &lt;br&gt;13.	Receiving anticoagulation with warfarin (low dose  warfarin for catheter patency is permitted).  Low molecular weight (LMW) heparin is permitted.&lt;br&gt;14.	HbA1c &gt; 9% despite therapy.&lt;br&gt;15.	Active ketonuria, urinary tract infection, or gross hematuria	Urinalysis with &gt; 2+ proteinuria (approximately equivalent to 1 g/L or 100 mg/dL), any ketones, any leukocyte esterase, any nitrites, gross hematuria, or &gt; 1+ glucosuria (approximately equivalent to 1.46 mmol/L or 250 mg/dL)&lt;br&gt;16.	Untreated, symptomatic hypothyroidism.  &lt;br&gt;17.	History of pulmonary hypertension or interstitial lung disease.&lt;br&gt;18.	Receiving immunosuppressive agents within 4 weeks of the screening visit.  Replacement doses of corticosteroids and topical/inhaled steroids are permitted.   &lt;br&gt;19.	Chronic viral/bacterial/fungal illnesses such as human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection. Subjects may be included if they are hepatitis B and/or hepatitis C antibody positive as long as they are hepatitis surface antigen negative and/or hepatitis C RNA negative, respectively.  &lt;br&gt;20.	Active infection(s), receiving active systemic antimicrobial therapy or serious intercurrent illness.&lt;br&gt;21.	A “currently active” second malignancy other than non-melanoma skin cancers.  Subjects are not considered to have a “currently active” malignancy if they have completed anticancer therapy and are considered by their physician to be at less than 30% risk of relapse.  &lt;br&gt;22.	Pregnant or nursing women, women who are of childbearing potential  (biologically capable of becoming pregnant) who are not using a medically acceptable contraceptive method, or men who are not using a medically acceptable contraceptive method with partners of childbearing potential.&lt;br&gt;23.	Refusal to use medically acceptable contraceptive methods for 3 months after the last dose of temsirolimus or sorafenib therapy.&lt;br&gt;24.	Any other major illness that, in the investigator’s judgment, will substantially increase the risk associated with the subject’s participation in this study.&lt;br&gt;25.	Known hypersensitivity to any of the components in the temsirolimus infusion or sorafenib product or other medica</Exclusion_Criteria>
    <Condition>Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy</Condition>
    <Intervention>&lt;br&gt;Product Name: TEMSIROLIMUS &lt;br&gt;Product Code: CCI-779&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TEMSIROLIMUS&lt;br&gt;CAS Number: 162635-04-3&lt;br&gt;Current Sponsor code: CCI-779&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Trade Name: Nexavar 200mg Film Coated Tablets&lt;br&gt;Product Name: NEXAVAR 200MG FILM COATED TABLETS&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: SORAFENIB&lt;br&gt;CAS Number: 284461-73-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: -·To compare the safety and tolerability of temsirolimus and sorafenib when used as single agents in the second-line setting in subjects with advanced RCC who have failed prior first-line treatment with sunitinib.&lt;br&gt;-·To compare the efficacy, as measured by PFS (determined by independent assessment), of temsirolimus and sorafenib when used as single agents in the second-line setting in subjects with advanced RCC who have failed prior first-line treatment with sunitinib;Secondary Objective: - To examine additional efficacy endpoints including:&lt;br&gt;- PFS by investigator assessment&lt;br&gt;- Response rate (CR and PR) by RECIST criteria&lt;br&gt;- OS&lt;br&gt;- SD at 12, 24, and 36 weeks&lt;br&gt;- Duration of response&lt;br&gt;- Best/maximum tumor shrinkage in target lesions;Primary end point(s): PFS by independent assessment</Primary_outcome>
    <Secondary_ID>3066K1-404-WW</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2750221</Internal_Number>
    <TrialID>EUCTR2007-002604-17-FR</TrialID>
    <Last_Refreshed_on>28 August 2012</Last_Refreshed_on>
    <Public_title>Sorafenib Long Term Extension Program (STEP) - STEP</Public_title>
    <Scientific_title>Sorafenib Long Term Extension Program (STEP) - STEP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Bayer HealthCare AG, D-51368 Leverkusen, Germany</Primary_sponsor>
    <Date_registration3>20071017</Date_registration3>
    <Date_registration>17/10/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-002604-17                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>14/12/2009</Date_enrollement>
    <Target_size>2000</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1) Patients, who are participating in a previous Bayer/Onyx sponsored study that has reached its endpoint (statistical and regulatory or study end), and who are, in the opinion of the Investigator, expected to continue to have an overall positive benefit/risk from continuing treatment.&lt;br&gt;2) Patients who have signed informed consent for this long term extension program. &lt;br&gt;3) Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation, including the 30 days period after last study drug dosing.  The investigator should advise the patient how to achieve an adequate contraception.&lt;br&gt;4) Women of childbearing potential who have a negative pregnancy test within 7 days of the first dose of sorafenib in this long term extension program.&lt;br&gt;5) Patients receiving sorafenib (Nexavar®) as a monotherapy in their originating protocol.  Patients who were being treated with sorafenib (Nexavar®) in combination with other chemotherapies in the original study, but continued on single agent sorafenib (Nexavar®) after discontinuation of the combination agent will be eligible.&lt;br&gt;6) Patients who have completed the End of Treatment assessments in their originating study.  Every effort should be made to conduct the End of Treatment visit such that the patient does not have any interruption in sorafenib dosing.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1) Any condition that is unstable or which could jeopardize the safety of the patient (please refer to the Investigator Brochure and product labeling safety sections).&lt;br&gt;2) History of cardiac disease:  congestive heart failure&gt;NYHA Class 2 (Appendix 10.2) or uncontrolled hypertension &lt;br&gt;3) Myocardial infarction (MI) within the last 3 months&lt;br&gt;4) Symptomatic metastatic brain or meningeal tumors &lt;br&gt;5) Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors ( Ta, Tis &amp;T1) or any cancer curatively treated &gt; 5 years prior to study entry.&lt;br&gt;6) Patients with seizure disorder requiring medication (such as steroid  anti-epileptics)&lt;br&gt;7) Substance abuse, medical, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results&lt;br&gt;8) Any condition which could jeopardise the safety of the patient and his/her compliance in the study&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Various cancer indications/types (e.g. Renal Cell Carcinoma, Hepatoma Carcinoma, Melanoma and other cancer types).

Patients who remain actively treated in a Bayer/Onyx sponsored Clinical Trial that has reached its statistical, regulatory and/or study end and who, in the opinion of the Investigator, still benefiting from treatment, will be eligible for entry into this program. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10028980
Term: Neoplasm
</Condition>
    <Intervention>&lt;br&gt;Trade Name: NEXAVAR&lt;br&gt;Product Name: sorafenib&lt;br&gt;Product Code: BAY 43-9006&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: sorafenib&lt;br&gt;CAS Number: 28844-1-73-1&lt;br&gt;Current Sponsor code: BAY 43-9006&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The purpose of this program is to enable patients, currently receiving single agent sorafenib (Nexavar®) in a Bayer/Onyx sponsored clinical trial, to continue sorafenib treatment after their respective study has met its primary endpoint and/or has reached the end as defined in the original protocol.  Patients will be able to continue sorafenib (Nexavar®) treatment until the treating physician feels the patient is no longer benefiting from the treatment or sorafenib (Nexavar®) becomes commercially available, and reimbursed for the respective indication as applicable in the country in which the patient lives or until intolerable/unacceptable toxicity occurs. ;Secondary Objective: Not applicable;Primary end point(s): Not applicable</Primary_outcome>
    <Secondary_ID>BAY 43-9006 / 12311</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2750344</Internal_Number>
    <TrialID>EUCTR2008-000531-18-FR</TrialID>
    <Last_Refreshed_on>28 August 2012</Last_Refreshed_on>
    <Public_title>A 24-month extension to a 12-month, open-label, randomised, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus Neoral® in combination with Certican®, Simulect® and corticosteroids in de novo adult renal transplant recipients</Public_title>
    <Scientific_title>A 24-month extension to a 12-month, open-label, randomised, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus Neoral® in combination with Certican®, Simulect® and corticosteroids in de novo adult renal transplant recipients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Novartis Pharma Services AG</Primary_sponsor>
    <Date_registration3>20080725</Date_registration3>
    <Date_registration>25/07/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000531-18                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/10/2008</Date_enrollement>
    <Target_size>170</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Neoral® plus Certican®&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients eligible for inclusion in this study have to fulfill all of the following criteria:&lt;br&gt;• The patient has given written informed consent to participate in the extension study.&lt;br&gt;• The patient has been maintained on AEB071/Certican® or Neoral®/Certican®, consistent with their original randomisation, at their core study Month 12 visit.&lt;br&gt;• Women capable of becoming pregnant are required to practice a medically approved method of birth control as long as they are on study medication and for a period of 3 months following discontinuation of study drug(s), as per [core study protocol].&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;• Inability or unwillingness to comply with the immunosuppressive regimen or the protocol.&lt;br&gt;• Pregnancy.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>To provide continued treatment and to assess the long term safety, efficacy and tolerability of oral AEB071 plus Certican® vs. Neoral® plus Certican® in de novo renal transplant recipients. 
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10023438
Term: Kidney transplant
</Condition>
    <Intervention>&lt;br&gt;Product Name: AEB071&lt;br&gt;Product Code: AEB071&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: sotrastaurin&lt;br&gt;CAS Number: 425637-18-9&lt;br&gt;Current Sponsor code: AEB071&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Trade Name: Neoral&lt;br&gt;Product Name: NEORAL &lt;br&gt;Product Code: OLO400&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: ciclosporin&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;Trade Name: Neoral&lt;br&gt;Product Name: NEORAL &lt;br&gt;Product Code: OLO400&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: ciclosporin&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Trade Name: Neoral&lt;br&gt;Product Name: NEORAL &lt;br&gt;Product Code: OLO400&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: ciclosporin&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Neoral&lt;br&gt;Product Name: NEORAL &lt;br&gt;Product Code: OLO400&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: ciclosporin&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001 Everolimus&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,25mg-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001 Everolimus&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,50 mg-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001 Everolimus&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,75 mg-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001 Everolimus&lt;br&gt;Pharmaceutical Form: Dispersible tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: e</Intervention>
    <Primary_outcome>Primary end point(s): The key efficacy parameter is the incidence over 36 months of the composite endpoint of BPAR = 1A, graft loss, death, or lost to follow-up in the two study arms.  ;Main Objective: to characterise the general and renal-specific glomerular filtration rate (GFR) (MDRD) safety profile, up to 36 months post transplantation, of renal transplant patients treated with AEB071 in combination with Certican® (CNI free) versus a standard CNI-based regimen.;Secondary Objective: to characterise the efficacy profile, composite endpoint of biopsy proven acute rejection (BPAR) =  IA, graft loss, death, or lost to follow up, up to 36 months post transplantation, of renal transplant patients treated with AEB071 in combination with Certican® (CNI free) versus a standard CNI based regimen.&lt;br&gt;&lt;br&gt;</Primary_outcome>
    <Secondary_ID>CAEB071A2206E1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2753747</Internal_Number>
    <TrialID>EUCTR2006-004024-37-FR</TrialID>
    <Last_Refreshed_on>3 September 2012</Last_Refreshed_on>
    <Public_title>SUNITINIB TREATMENT OF RENAL ADJUVANT CANCER (S-TRAC):  A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF ADJUVANT SUNITINIB VS. PLACEBO IN SUBJECTS WITH HIGH RISK RCC - S-TRAC</Public_title>
    <Scientific_title>SUNITINIB TREATMENT OF RENAL ADJUVANT CANCER (S-TRAC):  A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF ADJUVANT SUNITINIB VS. PLACEBO IN SUBJECTS WITH HIGH RISK RCC - S-TRAC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Pfizer Inc. - 235 East 42nd Street - New York - 10017</Primary_sponsor>
    <Date_registration3>20070515</Date_registration3>
    <Date_registration>15/05/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004024-37                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>05/07/2007</Date_enrollement>
    <Target_size>275</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.Subjects must sign and date IRB/IEC-approved informed consent&lt;br&gt;2.Age = 18 years&lt;br&gt;3.ECOG Performance Status 0 – 2 prior to nephrectomy &lt;br&gt;4.Subjects must be diagnosed in the high risk UISS staging system with one of the following:&lt;br&gt;a.T3 N0 or Nx, M0, Fuhrman’s grade = 2 and ECOG general status = 1, or &lt;br&gt;b.T4 N0 or Nx, M0, any Fuhrman’s grade and any ECOG general status, or&lt;br&gt;c.Any T, N1-2, M0, any Fuhrman’s grade and any ECOG general status&lt;br&gt;5.Subjects must have histologically confirmed preponderant clear cell RCC&lt;br&gt;6.Subjects must have no evidence of macroscopic residual disease or metastatic disease Subjects having evidence for microscopic disease (R1) are acceptable&lt;br&gt;7.Subjects must not have received any specific medical previous systemic treatment for RCC&lt;br&gt;8.Subjects must not have received any previous anti-angiogenic treatment&lt;br&gt;9.Subjects must receive the first oral dose of sunitinib not more than 10 weeks after date of nephrectomy (see Appendix 6 for Nephrectomy Procedure).&lt;br&gt;10.Subjects must have adequate organ function defined as: &lt;br&gt;a.Platelets = 100 x 10e9/L, hemoglobin = 8 g/dl, absolute neutrophil count (ANC) =1.5 x 10e9/L;&lt;br&gt;b.Bilirubin = 3 mg/dL,  aspartate transaminase (AST) and alanine transaminase (ALT) = 2.5 times the upper limit of normal &lt;br&gt;c. International Normalize Ratio (INR) = 1.7 or Prothrombin time (PT) = 6 sec over &lt;br&gt;d.Calculated creatinine clearance = 30 ml/min.&lt;br&gt;11.Sufficient left ventricular ejection function (LVEF) defined as =50%  3 to 10 weeks after date of nephrectomy based on 2-D echocardiogram (ECHO) or multigated acquisition MUGA&lt;br&gt;12.Women and men must use adequate contraception during the study. Acceptable contraception includes implants, injectables, combined oral contraceptives, effective intrauterine devices (IUDs), sexual abstinence, or a vasectomized partner or vasectomy.&lt;br&gt;13.Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.Histologically undifferentiated carcinomas or collecting duct carcinoma, lymphoma, sarcoma or subjects with metastatic renal sites. &lt;br&gt;2.NCI CTCAE grade 3 hemorrhage &lt;4 weeks of date of randomization. &lt;br&gt;3.Diagnosis of any second malignancy within the 5 years from date of randomization, except basal cell carcinoma, squamous cell skin cancer, or in situ carcinoma of the cervix uteri that has been adequately treated with no evidence of recurrent disease for 12 months.&lt;br&gt;4.Any of the following within the 12 months prior to study drug administration: severe/unstable angina, myocardial infarction, coronary artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, including transient ischemic attack, or pulmonary embolism.&lt;br&gt;5.Concurrent medication with known potent CYP3A4 inhibitors and inducers and/or dosing before 7 and 12 days before date of randomization (e.g., ketoconazole, rifampin, etc. respectively).&lt;br&gt;6.Ongoing cardiac dysrhythmias of NCI CTCAE grade = 2, atrial fibrillation of any grade, or prolongation of the QTc interval to &gt; 500 msec.  &lt;br&gt;7.Hypertension that cannot be controlled by medications. &lt;br&gt;8.Treatment with anticoagulant agents and treatment with therapeutic doses of warfarin currently or within 2 weeks prior to first day of sunitinib administration.  Low dose warfarin for deep vein thrombosis (DVT) prophylaxis is permitted (up to 2 mg/day). Low molecular weight heparin or aspirin are allowed.&lt;br&gt;9.Inability to swallow oral medications, or presence of active inflammatory bowel disease, partial or complete bowel obstruction or chronic diarrhea.&lt;br&gt;10.Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.&lt;br&gt;11.Known active hepatitis.&lt;br&gt;12.Pregnancy or breastfeeding.  All female subjects with reproductive potential must have a negative pregnancy test (serum or urine) within the 7 days prior to date of randomization.  &lt;br&gt;13.Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the subject inappropriate for entry into this study.&lt;br&gt;14.Receipt of any investigational oncology or, approved or investigational anti-angiogenic agent prior to study entry.&lt;br&gt;15.Current treatment on another therapeutic clinical trial. Supportive care trials or non-treatment trials, e.g. PRO methods studies, are allowed.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Adjuvant treatment of subjects with “high risk” Renal Cell Carcinoma (RCC) following nephrectomy. &lt;br&gt;MedDRA version: 9.1
Level: HLT
Classification code 10038408
Term: Renal cell carcinomas
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sutent&lt;br&gt;Product Name: Sutent&lt;br&gt;Product Code: SU011248&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Sunitinib Malate&lt;br&gt;CAS Number: 341031-54-7&lt;br&gt;Current Sponsor code: SU-0011248&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 12,5-50&lt;br&gt;Pharmaceutical form of the placebo: Capsule, hard&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To demonstrate an improvement in disease-free survival (DFS) in high risk (per modified UISS criteria) subjects with RCC randomly assigned to adjuvant sunitinib 50 mg schedule 4/2: 4 weeks on, 2 weeks off for 1 year (Arm A), vs. Placebo (Arm B) after nephrectomy. ;Secondary Objective: Compare overall survival (OS) associated with Arm A to that associated with Arm B&lt;br&gt;&lt;br&gt;Assess safety/toxicity profile of  schedule 4/2: 4 weeks on, 2 weeks off administration of sunitinib &lt;br&gt;&lt;br&gt;Assess patient reported outcomes (PROs) &lt;br&gt;&lt;br&gt;Assess the UISS Prognostic Model&lt;br&gt;;Primary end point(s): Disease Free Survival: (DFS), defined as the time interval from the date of randomization to the first date of recurrence or occurrence of a secondary malignancy or death. The primary DFS analysis will be based on independent blinded 3rd party review. A secondary analysis of DFS will be based on the local investigator assessment.&lt;br&gt;&lt;br&gt;Recurrence refers to relapse of the primary tumor in-situ or at metastatic sites. The date of recurrence or occurrence of a secondary malignancy is defined as the date of the independent blinded 3rd party review confirms recurrence or occurrence of a secondary malignancy for the first time. &lt;br&gt;&lt;br&gt;For subjects receiving further anti-tumor therapy before disease recurrence or occurrence of a secondary malignancy or death, the subjects will be assigned with DFS events at the first date of recurrence or occurrence of a second primary cancer or death. In the absence of DFS event, DFS time will be censored at the date of last disease assessment or cutoff date, whichever come first. Subjects alive who do not have post baseline disease assessment will have their DFS times censored at Day 1.</Primary_outcome>
    <Secondary_ID>A6181109</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2753823</Internal_Number>
    <TrialID>EUCTR2007-004391-39-FR</TrialID>
    <Last_Refreshed_on>3 September 2012</Last_Refreshed_on>
    <Public_title>A Phase I/II multi-center, open label study  of TKI258 administered orally on an intermittent schedule in adult patients with advanced or metastatic Renal Cell Cancer (RCC)</Public_title>
    <Scientific_title>A Phase I/II multi-center, open label study  of TKI258 administered orally on an intermittent schedule in adult patients with advanced or metastatic Renal Cell Cancer (RCC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Novartis Pharma Services AG</Primary_sponsor>
    <Date_registration3>20080228</Date_registration3>
    <Date_registration>28/02/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004391-39                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>15/04/2008</Date_enrollement>
    <Target_size>81</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Inclusion criteria --&lt;br&gt;Dose escalation part only&lt;br&gt;• Patients with advanced or metastatic renal cancer for whom no other therapeutic options exist (measurable lesion by RECIST is not required).&lt;br&gt;&lt;br&gt;Dose expansion part only --&lt;br&gt;• Patients that must have been previously treated with sunitinib and/or sorafenib.&lt;br&gt;• Patients with at least one measurable lesion at baseline as per the RECIST criteria, either on physical exam or as determined by Computer Tomography (CT) Scan or Magnetic Resonance Imaging (MRI).&lt;br&gt;&lt;br&gt;Dose escalation and dose expansion parts --&lt;br&gt;• Prior therapy with any prior anti-cancer agent (i.e. IL-2, Interferon, bevacizumab, etc.) is permitted as long as it is administered 28 days (6 weeks for nitrosoureas or mitomycin C) prior to first administration of TKI258 (cycle 1 day 1).  Patients must have recovered from adverse events (to grade 1 or less toxicity according to CTCAE 3.0) due to agents administered more than 28 days earlier (with the exception of the GI toxicities mentioned in the exclusion criteria). The only exception is made for palliative radiotherapy for painful bone metastases.&lt;br&gt;• Patients with measurable histologically or cytology confirmed progressive metastatic renal cell carcinoma with predominant clear cell histology (&gt;50%).&lt;br&gt;• Age at least 18 years.&lt;br&gt;• ECOG performance status 0 or 1.&lt;br&gt;• Required baseline laboratory data includes:&lt;br&gt;     • Absolute neutrophil count (ANC) greater than or equal to 1,500/mm3 [SI units 1.5 x 109/L]&lt;br&gt;     • Platelets greater than or equal to 75,000/mm3 [SI units 75 x 109/L]&lt;br&gt;     • Hemoglobin greater than or equal to 8.0 gm/dL [SI units 80 gm/L]&lt;br&gt;     • Serum creatinine less than or equal to 1.5 x upper limit of normal (ULN)&lt;br&gt;     • Bilirubin less than or equal to 1.5 x ULN&lt;br&gt;     • AST (SGOT) and ALT (SGPT) less than or equal to 2.5 x ULN, except for subjects with tumor involvement of the liver who must have AST and ALT less than or equal to 5 x ULN&lt;br&gt;     • Amylase, Lipase less than or equal to ULN&lt;br&gt;     • Electrolyte levels should be within normal limits (If &lt; LLN should be corrected with supplement prior to dosing)&lt;br&gt;     • Urine dipstick reading: Negative for proteinuria or, if documentation of +1 results for protein on dipstick reading, then total urinary protein less than or equal to 500 mg and measured creatinine clearance greater than or equal to 50 mL/min/1.73m2 from a 24-hour urine collection&lt;br&gt;• Life expectancy greater than or equal to 12 weeks.&lt;br&gt;• Signed and witnessed informed consent form obtained prior to any screening procedures.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;• Concurrent therapy with any other investigational agent at least 28 days prior to baseline.&lt;br&gt;• Women of child-bearing potential who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control. Barrier contraceptives must be used throughout the trial in both sexes. Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this study. Women of child-bearing potential, defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e. who has had menses any time in the preceding 12 consecutive months), must have a negative serum pregnancy test less than or equal to 72 hours prior to starting TKI258.&lt;br&gt;• Clinically significant cardiac disease (New York Heart Association, Class III or IV) or impaired cardiac function or clinically significant cardiac diseases, including any one of the following:&lt;br&gt;     • LVEF &lt; 45% as determined by MUGA scan or echocardiogram&lt;br&gt;     • Complete left bundle branch block&lt;br&gt;     • Obligate use of a cardiac pacemaker&lt;br&gt;     • Congenital long QT syndrome&lt;br&gt;     • History or presence of ventricular tachyarrhythmia&lt;br&gt;     • Presence of unstable atrial fibrillation (ventricular response &gt; 100 bpm). Patients with stable atrial fibrillation are eligible, provided they do not meet any of the other cardiac exclusion criteria&lt;br&gt;     • Clinically significant resting bradycardia (&lt; 50 bpm)&lt;br&gt;     • Hypertension of Grade 2 or above&lt;br&gt;     • QTc &gt; 480 msec on screening ECG&lt;br&gt;     • Right bundle branch block + left anterior hemiblock (bifasicular block)&lt;br&gt;     • Angina pectoris less than or equal to 3 months prior to starting study drug&lt;br&gt;     • Acute Myocardial Infarction less than or equal to 3 months prior to starting study drug &lt;br&gt;     • Other clinically significant heart disease (e.g., CHF, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)&lt;br&gt;• Uncontrolled infection.&lt;br&gt;• Diabetes mellitus (insulin dependent or independent disease, requiring chronic medication) with signs of clinically significant peripheral vascular disease.&lt;br&gt;• Previous pericarditis; clinically significant pleural effusion in the previous 12 months or current ascites requiring two or more interventions/month (in both the dose escalation and dose expansion).&lt;br&gt;• Known pre-existing clinically significant disorder of the hypothalamic-pituitary axis, adrenal or thyroid glands.&lt;br&gt;• Prior acute or chronic pancreatitis of any etiology.&lt;br&gt;• Acute and chronic liver disease and all chronic liver impairment.&lt;br&gt;• Malabsorption syndrome or uncontrolled gastrointestinal toxicities (nausea, diarrhea, vomiting) with toxicity greater than NCI CTCAE grade 2.&lt;br&gt;• Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for this study.&lt;br&gt;• Treatment with any of the medications that have a potential risk of prolonging the QT interval or inducing Torsades de Points and the treatment cannot be discontinued or switched to a different medication prior to starting study drug.&lt;br&gt;• Use of ketoconazole, erythromycin, carbamazapine, phenobarbital, rifampin, phenytoin, </Exclusion_Criteria>
    <Condition>advanced or metastatic renal cell carcinoma &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050513
Term: Metastatic renal cell carcinoma
</Condition>
    <Intervention>&lt;br&gt;Product Name: TKI258&lt;br&gt;Product Code: TKI258&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;CAS Number:  692737-80-7&lt;br&gt;Current Sponsor code: TKI258&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Product Name: TKI258&lt;br&gt;Product Code: TKI258&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;CAS Number:  692737-80-7&lt;br&gt;Current Sponsor code: TKI258&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Secondary Objective: Secondary objectives (both escalation and expansion parts)&lt;br&gt;• To assess the safety profile of TKI258 administered orally on a 5 days on/2 days off schedule in this patient population.&lt;br&gt;• To characterize the single and multiple-dose pharmacokinetic (PK) profiles of oral TKI258 on a 5 days on/2 days off dosing schedule. &lt;br&gt;• To assess the effect of TKI258 on plasma biomarkers pre- and post-treatment:&lt;br&gt;          • To evaluate concentrations of circulating growth factors, soluble receptors (e.g. bFGF, VEGF, PlGF, sVEGFR1 and 2).&lt;br&gt;• To assess the relationship between dose and exposure of TKI258.&lt;br&gt;• To explore the relationship between PK and biomarker responses (PD) of TKI258.;Primary end point(s): Primary endpoints&lt;br&gt;• Dose escalation part: incidence rate of DLT.&lt;br&gt;• Dose expansion part: frequency of clinical responder (R) and stable disease (SD).  Patients will be categorized into one of 3 distinct categories: clinical responders (CR and/or PR) at any time point prior the analysis [R], patients with stable disease for at least 8 weeks excluding clinical responders [SD] and all other patients (No Clinical Benefit [NCB]).;Main Objective: Dose escalation part&lt;br&gt;• To determine the maximum tolerated dose (MTD) based on the incidence of the dose limiting toxicities (DLT) of TKI258, administered orally on a 5 days on/2 days off schedule to adult patients with advanced or metastatic renal cell cancer (RCC) whose diseases have progressed despite standard therapy or for whom no standard anticancer therapy exists.&lt;br&gt;&lt;br&gt;Dose expansion part&lt;br&gt;• To determine the preliminary anti-tumor activity of TKI258 in patients that must have been previously treated with sunitinib and/or sorafenib and have measurable histologically or cytology confirmed progressive advanced or metastatic renal cell carcinoma with predominant clear cell histology (&gt;50%) according to the RECIST criteria.</Primary_outcome>
    <Secondary_ID>CTKI258A2107</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2754395</Internal_Number>
    <TrialID>EUCTR2010-020601-32-BE</TrialID>
    <Last_Refreshed_on>3 September 2012</Last_Refreshed_on>
    <Public_title>A study in patients with overactive bladder to evaluate the efficacy, safety and tolerability of a combination of two drugs (solifenacin succinate and mirabegron) with either drug alone, and to find the best dose for each of the drugs in combination</Public_title>
    <Scientific_title>A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder. - Symphony                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Astellas Pharma Europe BV</Primary_sponsor>
    <Date_registration3>20101220</Date_registration3>
    <Date_registration>20/12/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-020601-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>11/05/2011</Date_enrollement>
    <Target_size>1658</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 12&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Inclusion Criteria at Visit 1/Screening
&lt;br&gt;1.Subject is male or female and at least 18 years of age;
&lt;br&gt;2.Subject has a Body Mass Index (BMI) of between 18 and 35 kg/m2 and a total body weight between 50 and 95 kg;
&lt;br&gt;3.Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written informed consent and privacy language as per national regulations has been obtained from the subject prior to any study-related procedures (including discontinuation of prohibited medication, if applicable);
&lt;br&gt;4.Subject is willing and able to complete the micturition diary and questionnaires correctly and is willing and able to measure his/her vital signs at home at stipulated time points, using the device provided by the study personnel, and to adequately record the readings;
&lt;br&gt;5.Subject has symptoms of OAB (urinary frequency, urgency and/or urgency incontinence) for at least 3 months.
&lt;br&gt;Inclusion Criteria at Visit 2/Placebo Run-In
&lt;br&gt;6. Subject must still fulfill all inclusion criteria and none of the exclusion criteria for Visit 1;
&lt;br&gt;7.Subject is willing and able to complete the micturition diary correctly and is willing and able to measure his/her vital signs at home at stipulated time points, using the device provided by the study personnel, and to adequately record the readings.
&lt;br&gt;Inclusion Criteria at Visit 3/Baseline
&lt;br&gt;8.Subject continues to meet all inclusion criteria and none of the exclusion criteria for Visit 1;
&lt;br&gt;9.Subject has experienced frequency of micturition on average = 8 times per 24-hour period during the 3-day micturition diary period (incontinence episode should not be counted as a micturition);
&lt;br&gt;10.Subject must experience at least 1 episode of urgency (grade 3 or 4) per 24-hour period (with or without urgency incontinence) during the 3 day micturition diary period.
&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 1045&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 613&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.Subject is breastfeeding, pregnant or intends to become pregnant during the study. The pregnancy test (ß-HCG in serum) at Screening must be negative in women of childbearing potential;
&lt;br&gt;2.Female subjects of childbearing potential and not using a highly effective method of birth control during the study and for 30 days after final study drug administration.Male subjects (unless surgically sterile) with female spouses/partners who are of childbearing potential, and not using a barrier method of contraception during the study and for 30 days after final study drug administration. 
&lt;br&gt;3.Subject has significant PVR volume (&gt; 150 mL); 
&lt;br&gt;4.Subject has significant stress incontinence or mixed stress/urgency incontinence where stress is the predominant factor as determined by the Investigator 6.Subject has a neurological cause for detrusor overactivity;
&lt;br&gt;5.Subject has an indwelling catheter or practices intermittent self-catheterization;
&lt;br&gt;6.Subject has diabetic neuropathy;
&lt;br&gt;7.Subject has chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs;
&lt;br&gt;8.Subject has had previous lower urinary tract or pelvic floor surgery (except cystoscopy);
&lt;br&gt;9.Subject has had intravesical treatment in the past 12 months with e.g., botulinum toxin, resiniferatoxin, capsaicin;
&lt;br&gt;10.Subject has uncontrolled narrow angle glaucoma, urinary or gastric retention, severe ulcerative colitis or Crohn’s Disease, toxic megacolon, myasthenia gravis or any other condition which makes the use of anticholinergics contraindicated;
&lt;br&gt;11.Subject has clinically significant cardiovascular or cerebrovascular diseases within 6 months prior to Screening, such as myocardial infarction, uncontrolled angina, significant ventricular arrhythmias, heart failure and stroke;
&lt;br&gt;12.Subject is receiving current non-drug treatment including electro-stimulation therapy 15.Subject is using medications intended to treat OAB or prohibited medications. Subject is excluded if using restricted medications under conditions different to those specified in the 'Concomitant Medication' section;
&lt;br&gt;13.Subject has known or suspected hypersensitivity to solifenacin succinate, mirabegron or any of their excipients;
&lt;br&gt;14.Subject has any significant neurological disease or defect affecting bladder function 
&lt;br&gt;15.Subject has severe hypertension 19.Subject has any clinically significant condition which in the opinion of the Investigator makes the subject unsuitable for the study;
&lt;br&gt;16.Subject who participated in any clinical study or who has been treated with any investigational drug or device within 30 days (90 days in the UK) or the period stipulated by local regulations, whichever is longer, prior to Screening;
&lt;br&gt;Exclusion Criteria at Visit 2/Placebo Run-In
&lt;br&gt;17.Subject has evidence of a UTI (urine culture containing &gt; 100,000 cfu/mL). The subject can be enrolled into the study after successful treatment of the UTI (confirmed by a laboratory result of negative urine culture).  However, the subject must be re-screened if the initial screening visit (Visit 1b) was &gt; 28 days;
&lt;br&gt;18.Subject has a QT interval &gt; 450 ms or is at risk of QT prolongation (e.g., family history of long QT syndrome, hypokalaemia) or is on drug treatment known to be associated with QT prolongation;
&lt;br&gt;19.Subject has clinically significant abnormalities on the 12-lead ECG;
&lt;br&gt;20.Subject has serum creatinine &gt; 150 µmol/L, AST and/or ALT &gt; 2x upper limit of no</Exclusion_Criteria>
    <Condition>Overactive Bladder &lt;br&gt;MedDRA version: 14.0
Level: LLT
Classification code 10059617
Term: Overactive bladder
System Organ Class: 10038359 - Renal and urinary disorders
;Therapeutic area: Body processes [G] - Physical Phenomena [G01]</Condition>
    <Intervention>&lt;br&gt;Product Name: Mirabegron&lt;br&gt;Product Code: YM178&lt;br&gt;Pharmaceutical Form: Modified-release tablet&lt;br&gt;INN or Proposed INN: Mirabegron&lt;br&gt;CAS Number: 223673-61-8&lt;br&gt;Current Sponsor code: YM178&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Product Name: Mirabegron&lt;br&gt;Product Code: YM178&lt;br&gt;Pharmaceutical Form: Modified-release tablet&lt;br&gt;INN or Proposed INN: Mirabegron&lt;br&gt;CAS Number: 223673-61-8&lt;br&gt;Current Sponsor code: YM178&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Vesicare&lt;br&gt;Product Name: Solifenacin succinate&lt;br&gt;Product Code: YM905&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Solifenacin succinate&lt;br&gt;CAS Number: 242478-38-2&lt;br&gt;Current Sponsor code: YM905&lt;br&gt;Other descriptive name: SOLIFENACIN SUCCINATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2.5-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Vesicare&lt;br&gt;Product Name: Solifenacin succinate&lt;br&gt;Product Code: YM905&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Solifenacin succinate&lt;br&gt;CAS Number: 242478-38-2&lt;br&gt;Current Sponsor code: YM905&lt;br&gt;Other descriptive name: SOLIFENACIN SUCCINATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Vesicare&lt;br&gt;Product Name: Solifenacin succinate&lt;br&gt;Product Code: YM905&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Solifenacin succinate&lt;br&gt;CAS Number: 242478-38-2&lt;br&gt;Current Sponsor code: YM905&lt;br&gt;Other descriptive name: SOLIFENACIN SUCCINATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;Pharmaceutical fo</Intervention>
    <Primary_outcome>Main Objective: To evaluate the efficacy of four combinations of solifenacin succinate (2.5 mg or 5 mg) plus mirabegron (25 mg or 50 mg) vs. solifenacin succinate 5 mg monotherapy.;Secondary Objective: To investigate the dose-response surface of combinations of solifenacin succinate (0 mg, 2.5 mg, 5 mg and 10 mg) and mirabegron (0 mg, 25 mg and 50 mg) doses;&lt;br&gt;&lt;br&gt;To compare the safety and tolerability of six combinations of solifenacin succinate and mirabegron vs. solifenacin succinate monotherapy, mirabegron monotherapy, and placebo;&lt;br&gt;&lt;br&gt;To investigate the population pharmacokinetics (PK) and PK/pharmacodynamic (PD) relationship of six combinations of solifenacin succinate and mirabegron and the mirabegron and solifenacin succinate monotherapies.&lt;br&gt;;Primary end point(s): Change from baseline in mean volume voided per micturition after 12 weeks of treatment ;Timepoint(s) of evaluation of this end point: After 12 weeks of treatment</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Change from baseline in mean number of micturitions/24 h
&lt;br&gt;Change from baseline in mean number of incontinence episodes/24 h
&lt;br&gt;;Timepoint(s) of evaluation of this end point: Every 24 hours</Secondary_outcome>
    <Secondary_ID>178-CL-100</Secondary_ID>
    <Source_Support>Astellas Pharma Europe BV</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2755286</Internal_Number>
    <TrialID>EUCTR2007-005365-35-SE</TrialID>
    <Last_Refreshed_on>3 September 2012</Last_Refreshed_on>
    <Public_title>Clinical evaluation of a new low sodium peritoneal dialysis solution on patients with hypertension</Public_title>
    <Scientific_title>Multicentric, parallel, controlled, randomized, single blind clinical evaluation of a new low sodium peritoneal dialysis solution on patients with hypertension treated with  continous ambulatory or automated peritoneal dialysis. - PDOne                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Fresenius Medical Care Deutschland GmbH</Primary_sponsor>
    <Date_registration3>20080522</Date_registration3>
    <Date_registration>22/05/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005365-35                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/07/2008</Date_enrollement>
    <Target_size>140</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: yes&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Chronic renal failure
&lt;br&gt;- Stable patients on CAPD with a minimum of 3 bag exchanges including at least one 4-6 hour dwell or patients on APD with at least one daytime exchange lasting for at least 4-6 hours
&lt;br&gt;- Hypertensive patients with high blood pressure at inclusion (Office SBP =140 mmHg and/or DBP =90 mmHg) or hypertensive patients receiving antihypertensive medication, including diuretics, disregarding blood pressure values.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 40&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 100&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Low blood pressure (Office sitting SBP =120 mmHg and confirmed by ABPM =105 mmHg mean SBP)
&lt;br&gt;- Ortostatic hypotension defined as systolic OBP with a drop of &gt;20 mmHg and symptomatic after 1 minute in standing position
&lt;br&gt;- Natremia &lt;130 mmol/l, after two consecutive measurements
&lt;br&gt;- Peritonits within one month prior to study start
&lt;br&gt;- Exite site and/or tunnel infection
&lt;br&gt;- (Patients unable to tolerate 2 L bag exchanges - Cancelled according to
&lt;br&gt;amendment 1, dated 04.06.2012 on version 6.0, dated 17.02.2011)
&lt;br&gt;- Patients with chronic arrhythmia&lt;br&gt;</Exclusion_Criteria>
    <Condition>Subjects with renal failure treated with peritoneal dialysis &lt;br&gt;MedDRA version: 15.0
Level: LLT
Classification code 10009119
Term: Chronic renal failure
System Organ Class: 10038359 - Renal and urinary disorders
;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]</Condition>
    <Intervention>&lt;br&gt;Product Name: PDsol 12&lt;br&gt;Product Code: PDsol 12&lt;br&gt;Pharmaceutical Form: Solution for peritoneal dialysis&lt;br&gt;INN or Proposed INN: Glucose&lt;br&gt;CAS Number: 50-99-7&lt;br&gt;Concentration unit: mmol/l millimole(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 111-&lt;br&gt;INN or Proposed INN: Sodium Chloride&lt;br&gt;CAS Number: 7647-14-5&lt;br&gt;Concentration unit: mmol/l millimole(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 112-&lt;br&gt;INN or Proposed INN: Calcium Chloride dihydrate&lt;br&gt;CAS Number: 10035-04-8&lt;br&gt;Concentration unit: mmol/l millimole(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.37-&lt;br&gt;INN or Proposed INN: Magnesium Chloride hexahydrate&lt;br&gt;CAS Number: 7791-18-6&lt;br&gt;Concentration unit: mmol/l millimole(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.26-&lt;br&gt;INN or Proposed INN: Sodium Lactate (+)&lt;br&gt;CAS Number: 72-17-3&lt;br&gt;Concentration unit: mmol/l millimole(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 40.4-&lt;br&gt;&lt;br&gt;Trade Name: Gambrosol trio 40, L&lt;br&gt;Pharmaceutical Form: Solution for peritoneal dialysis&lt;br&gt;INN or Proposed INN: Glucose&lt;br&gt;CAS Number: 50-99-7&lt;br&gt;Concentration unit: mmol/l millimole(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 85-&lt;br&gt;INN or Proposed INN: Sodium Chloride&lt;br&gt;CAS Number: 7647-14-5&lt;br&gt;Concentration unit: mmol/l millimole(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 133-&lt;br&gt;INN or Proposed INN: Calcium Chloride dihydrate&lt;br&gt;CAS Number: 10035-04-8&lt;br&gt;Concentration unit: mmol/l millimole(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.38-&lt;br&gt;INN or Proposed INN: Magnesium Chloride hexahydrate&lt;br&gt;CAS Number: 7791-18-6&lt;br&gt;Concentration unit: mmol/l millimole(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.26-&lt;br&gt;INN or Proposed INN: Sodium Lactate S(+)&lt;br&gt;CAS Number: 72-17-3&lt;br&gt;Concentration unit: mmol/l millimole(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 41-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess superiority of the new isotonic low sodium solution in comparison with standard isotonic glucose solution.;Secondary Objective: - To assess safety of low sodium dialysis treatment during a 6 month period (natremia, OBP and urine volume)&lt;br&gt;- To assess changes in sodium removal at 2 months&lt;br&gt;- To assess decrease in total body water (TBW) at 2 months (extra and intra cellular water) &lt;br&gt;&lt;br&gt;Exploratory exams to document the treatment:&lt;br&gt;- Residual renal function&lt;br&gt;- 24h clearance&lt;br&gt;- TBW at 6 months&lt;br&gt;&lt;br&gt;In addition:&lt;br&gt;- ABPM results will be analyzed closely to understand the effect of BP treatment behaviour;Primary end point(s): To increase the respons rate by 25% between patients with conventional isotonic solution Gambrosol trio and PDsol 12.&lt;br&gt;•	Improvement of arterial hypertension by a decrease of =6 mmHg on the mean 24h SBP, measured from ABPM (T2-Baseline) in patients without antihypertensive medication modification or&lt;br&gt;•	Documented occurrence of hypotension requiring a medical action as a decrease of antihypertensive drug medication, confirmed by the DSMB;Timepoint(s) of evaluation of this end point: At 2 months in comparison to baseline</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): -  Safety of the study product (No serious study product related safety issues, Frequency of hyponatremia and other adverse events, Residual Renal Function
&lt;br&gt;- Effect on blood pressure by a detailed analysis of ABPM recording and office blood pressure measurement (Mean 24h ABPM (diastolic) at 2 months compared to Baseline; Office systolic and diastolic blood pressure at month 2 and 6 versus T0; Office systolic and diastolic blood pressure during the 2 months study follow-up period to document the reversibility of product effect
&lt;br&gt;- Effect on over hydration through Sodium Removal during 1 dwell at 2 months compared to T0, Estimation of Sodium Removal during 24h at 2 months compared to T0, Estimations of changes in total body water and repartition (intra/extra cellular) on the 6 month study, Body weight changes
&lt;br&gt;;Timepoint(s) of evaluation of this end point: At 2, 6 or 8 months after baseline according to parameter</Secondary_outcome>
    <Secondary_ID>1449;NCT00794326</Secondary_ID>
    <Source_Support>Fresenius Medical Care Deutschland GmbH</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2755347</Internal_Number>
    <TrialID>EUCTR2011-004562-16-GB</TrialID>
    <Last_Refreshed_on>3 September 2012</Last_Refreshed_on>
    <Public_title>Axitinib Treatment for Widespread Kidney Cancer Unsuitable for Surgery</Public_title>
    <Scientific_title>A Phase II Study of Axitinib in Patients with Metastatic Renal Cell Cancer Unsuitable for Nephrectomy - A-PREDICT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Institute of Cancer Research</Primary_sponsor>
    <Date_registration3>20120509</Date_registration3>
    <Date_registration>09/05/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-004562-16                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>15/05/2012</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Histologically confirmed metastatic renal cell carcinoma of predominant clear cell histology&lt;br&gt;2. Unsuitable for nephrectomy as judged by treating clinician(s)&lt;br&gt;3. Not suitable for ‘watch and wait’ policy as determined by treating clinician(s)&lt;br&gt;4. No prior systemic therapy for renal cell carcinoma&lt;br&gt;5. Measurable metastatic disease using RECIST v1.1 (see Appendix A)&lt;br&gt;6. 18 years of age or older &lt;br&gt;7. Life expectancy of 12 weeks or greater&lt;br&gt;8. ECOG performance status 0 or 1&lt;br&gt;9. Adequate organ function as defined by serum aspartate transaminase (AST) and serum alanine transaminase (ALT) =2.5 x upper limit of normal (ULN), or AST and ALT =5 x ULN if liver function abnormalities are due to liver metastases; total serum bilirubin =1.5 x ULN &lt;br&gt;10. Adequate haematological function as defined by absolute neutrophil count (ANC) =1500/µL, platelets =75,000/µL, haemoglobin =9.0 g/dL and prothrombin time (PT) =1.5 x ULN &lt;br&gt;11. Serum creatinine =1.5 x ULN or calculated creatinine clearance = 60 mL/min;&lt;br&gt;12. Urinary protein &lt;2+ by urine dipstick. If dipstick is =2+ then a 24-hour urine collection can be done and the patient may enter only if urinary protein is &lt;2g per 24 hours. &lt;br&gt;13. No evidence of pre-existing uncontrolled hypertension as documented by 2 baseline blood pressure readings taken at least 1 hour apart. The baseline systolic blood pressure readings must be =140 mm Hg, and the baseline diastolic blood pressure readings must be =90 mm Hg. Patients whose hypertension is controlled by antihypertensive therapies are eligible. &lt;br&gt;14. Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to treatment. &lt;br&gt;15. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures, including tumour biopsies.&lt;br&gt;16. Written informed consent&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: 0&lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 80&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 19&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. The presence of intracranial disease, unless there has been radiological evidence of stable intracranial disease &gt;6 months. In the case of a solitary brain metastasis which has been resected, there must be evidence of a disease-free interval of at least 3 months post-surgery.  All patients previously treated for brain metastases must be stable off corticosteroid therapy for at least 28 days.&lt;br&gt;2. The presence of active second malignancy.  Patients will be eligible if they have adequately treated basal cell carcinoma, squamous cell skin cancer, in situ cervical cancer, stable prostate cancer or if treated with curative intent for any other cancer with no evidence of disease for 2 years.&lt;br&gt;3. Women who are pregnant or are breastfeeding.  Female patients must be surgically sterile, be postmenopausal, or must agree to use effective contraception during the period of therapy.  All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrolment.  &lt;br&gt;4. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy.&lt;br&gt;5. Current signs or symptoms of severe progressive or uncontrolled hepatic, endocrine, pulmonary disease other than directly related to RCC.&lt;br&gt;6. Gastrointestinal abnormalities including: &lt;br&gt;a. inability to take oral medication; &lt;br&gt;b. requirement for intravenous alimentation; &lt;br&gt;c. prior surgical procedures affecting absorption including total gastric resection; &lt;br&gt;d. treatment for active peptic ulcer disease in the past 6 months; &lt;br&gt;e. active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy; &lt;br&gt;f. malabsorption syndromes. &lt;br&gt;7. Current use or anticipated need for treatment with drugs that are known potent CYP3A4 inhibitors (see section 8.12, concomitant therapy). &lt;br&gt;8. Current use or anticipated need for treatment with drugs that are known CYP3A4 or CYP1A2 inducers (see section 8.12, concomitant therapy). &lt;br&gt;9. Requirement of anticoagulant therapy with oral vitamin K antagonists. Low-dose anticoagulants for maintenance of patency of central venous access device or prevention of deep venous thrombosis is allowed. Therapeutic use of low molecular weight heparin is allowed. &lt;br&gt;10. Active seizure disorder, spinal cord compression, or carcinomatous meningitis.  &lt;br&gt;11. Any of the following within 12 months prior to study entry: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack.&lt;br&gt;12. Deep vein thrombosis or pulmonary embolism within 6 months prior to study entry.&lt;br&gt;13. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness. &lt;br&gt;</Exclusion_Criteria>
    <Condition>Metastatic renal cell carcinoma &lt;br&gt;MedDRA version: 15.0
Level: LLT
Classification code 10050076
Term: Metastatic renal carcinoma
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
;Therapeutic area: Diseases [C] - Cancer [C04]</Condition>
    <Intervention>&lt;br&gt;Product Name: Axitinib&lt;br&gt;Product Code: AG-013736&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Axitinib&lt;br&gt;CAS Number: 319460-85-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-5&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Secondary Objective: SECONDARY RESEARCH QUESTIONS:&lt;br&gt;What is the largest reduction in a participant's cancer seen during treatment with axitinib?&lt;br&gt;&lt;br&gt;How long does treatment with axitinib stop participants' cancer from getting worse?&lt;br&gt;&lt;br&gt;How long does treatment with axitinib keep people alive?&lt;br&gt;&lt;br&gt;What are the side effects of treatment with axitinib in this group of patients?&lt;br&gt;&lt;br&gt;How many participants' will be able to have surgery to remove their kidney due to treatment with axitinib?&lt;br&gt;&lt;br&gt;EXPLORATORY QUESTION:&lt;br&gt;Are there biological or genetic markers that could be used to indicate who will respond best to axitinib treatment in future?;Primary end point(s): The proportion of patients treated with axitinib who are free from disease progression 6 months from the commencement of treatment.  Progression will be measured from the date of study entry (registration date) until the first date of either death or confirmed progressive disease according to Response Evaluation Criteria In Solid Tumors (RECIST)v1.1. The main timepoint of interest is 6 months after study entry.;Main Objective: Does treatment with axitinib stop previously untreated widespread kidney cancer that can't be surgically removed from getting worse for at least 6 months?;Timepoint(s) of evaluation of this end point: 6 months from start of treatment.</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): • Best overall response confirmed according to RECIST v1.1.&lt;br&gt;• Progression free survival confirmed according to RECIST v1.1.&lt;br&gt;• Overall survival&lt;br&gt;• Safety and toxicity of axitinib (by NCI CTC grading version 4).&lt;br&gt;• Number of patients who become suitable for nephrectomy as a consequence of therapy with axitinib.&lt;br&gt;&lt;br&gt;All secondary endpoints will be measured from time of registration.&lt;br&gt;;Timepoint(s) of evaluation of this end point: Best overall response - during or within 30 days after termination of axitinib&lt;br&gt;Progression-free survival - first date of either death or confirmed progressive disease - time to last follow-up will be used if patient has not progressed or died and PFS time for the patient will be considered censored.&lt;br&gt;Overall survival will be measured until the date of death due to any cause - time to last follow-up will be used if patient has not died and survival time for the patient will be considered censored.&lt;br&gt;Safety and toxicity will be assessed throughout the treatment period.&lt;br&gt;Number of patients suitable for nephrectomy will be assessed at time of last follow up.</Secondary_outcome>
    <Secondary_ID>ICR-CTSU/2011/10033;CCR3587;ICR-CTSU/2011/10033</Secondary_ID>
    <Source_Support>Pfizer Ltd;Cancer Research UK;See above</Source_Support>
    <Secondary_Sponsor>The Royal Marsden Hospital NHS Foundation Trust</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2758376</Internal_Number>
    <TrialID>EUCTR2008-000107-28-FI</TrialID>
    <Last_Refreshed_on>11 September 2012</Last_Refreshed_on>
    <Public_title>A Phase II uncontrolled study of BAY 73-4506 (DAST) in previously untreated patients with metastatic or unresectable renal cell cancer (RCC)</Public_title>
    <Scientific_title>A Phase II uncontrolled study of BAY 73-4506 (DAST) in previously untreated patients with metastatic or unresectable renal cell cancer (RCC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Bayer HealthCare AG</Primary_sponsor>
    <Date_registration3>20080221</Date_registration3>
    <Date_registration>21/02/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000107-28                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>15/04/2008</Date_enrollement>
    <Target_size>41</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•Male or female patients &gt; 18 years of age.&lt;br&gt;&lt;br&gt;•Patients, who suffer from unresectable and/or metastatic, measurable predominantly clear cell RCC histologically or cytologically documented. Patients with rare subtypes of RCC such as pure papillary cell tumor, mixed tumor containing predominantly sarcomatoid cells, Bellini carcinoma, medullary carcinoma, or chromophobe oncocytic tumors are excluded from study participation.&lt;br&gt;&lt;br&gt;•Patients must be previously untreated for advanced disease.  Prior palliative radiation therapy is allowed if the target lesion(s) are not included within the radiation field and no more than 30% of the bone marrow is irradiated.  &lt;br&gt;&lt;br&gt;•Patients who have at least one uni-dimensional measurable lesion by CT-scan or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST).&lt;br&gt;&lt;br&gt;•Patients with “Intermediate” or “Low” risk per the Motzer score.&lt;br&gt;&lt;br&gt;•Patients who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0 or 1.&lt;br&gt;&lt;br&gt;•Adequate bone marrow, renal and hepatic function as assessed by the following laboratory requirements to be conducted within 7 days prior to study drug treatment:&lt;br&gt;?Total bilirubin &lt; 1.5 x the upper limit of normal.&lt;br&gt;?ALT and AST &lt; 2.5 x upper limit of normal (&lt; 5 x upper limit of normal for patients with liver involvement of their cancer).&lt;br&gt;?Amylase and lipase &lt; 1.5 x the upper limit of normal&lt;br&gt;?Serum creatinine &lt; 2.0 x the upper limit of normal.  &lt;br&gt;?INR/PTT &lt; 1.5 x ULN (Patients who are being prophylactically anti-coagulated with an agent such as coumadin or low molecular weight heparin or therapeutically anticoagulated with LMWH will be allowed to participate provided that they meet these criteria; in addition, these patients must be monitored at appropriate intervals throughout study)&lt;br&gt;?Platelet count ¬&gt; 100000 /mm3, Hb &gt; 9 g/dl, ANC &gt; 1500/mm3&lt;br&gt;?Alkaline phosphatase limit &lt; 2.5 x ULN &lt;br&gt;&lt;br&gt;•Life expectancy of at least 12 weeks.&lt;br&gt;•A signed informed consent must be obtained prior to any study specific procedures.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 39&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 25&lt;br&gt;;Inclusion criteria: &lt;br&gt;•Male or female patients &gt; 18 years of age.&lt;br&gt;&lt;br&gt;•Patients, who suffer from unresectable and/or metastatic, measurable predominantly clear cell RCC histologically or cytologically documented. Patients with rare subtypes of RCC such as pure papillary cell tumor, mixed tumor containing predominantly sarcomatoid cells, Bellini carcinoma, medullary carcinoma, or chromophobe oncocytic tumors are excluded from study participation.&lt;br&gt;&lt;br&gt;•Patients must be previously untreated for advanced disease.  Prior palliative radiation therapy is allowed if the target lesion(s) are not included within the radiation field and no more than 30% of the bone marrow is irradiated.  &lt;br&gt;&lt;br&gt;•Patients who have at least one uni-dimensional measurable lesion by CT-scan or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST).&lt;br&gt;&lt;br&gt;•Patients with “Intermediate” or “Low” risk per the Motzer score.&lt;br&gt;&lt;br&gt;•Patients who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0 or 1.&lt;br&gt;&lt;br&gt;•Adequate bone marrow, renal and hepatic function as assessed by the following laboratory requirements to be conducted within 7 days prior to study drug treatment:&lt;br&gt;?Total bilirubin &lt; 1.5 x the upper limit of normal.&lt;br&gt;?ALT and AST &lt; 2.5 x upper limit of normal (&lt; 5 x upper limit of normal for patients with liver involvement of their cancer).&lt;br&gt;?Amylase and lipase &lt; 1.5 x the upper limit of normal&lt;br&gt;?Serum creatinine &lt; 2.0 x the upper limit of normal.  &lt;br&gt;?INR/PTT &lt; 1.5 x ULN (Patients who are being prophylactically anti-coagulated with an agent such as coumadin or low molecular weight heparin or therapeutically anticoagulated with LMWH will be allowed to participate provided that they meet these criteria; in addition, these patients must be monitored at appropriate intervals throughout study)&lt;br&gt;?Platelet count ¬&gt; 100000 /mm3, Hb &gt; 9 g/dl, ANC &gt; 1500/mm3&lt;br&gt;?Alkaline phosphatase limit &lt; 2.5 x ULN &lt;br&gt;&lt;br&gt;•Life expectancy of at least 12 weeks.&lt;br&gt;•A signed informed consent must be obtained prior to any study specific procedures.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 39&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 25&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis &amp; T1] or any cancer curatively treated &gt; 3 years prior to study entry. &lt;br&gt;&lt;br&gt;•Patients who have received prior systemic treatment regimens for RCC.  Prior systemic therapy is defined as the following:  a single chemotherapy agent (or regimen), a single immunotherapy agent (or regimen) or a single investigational treatment agent (or regimen), any anti-VEGF therapy (including bevacizumab, sunitinib and sorafenib) or any mTOR inhibitor therapy (including temsirolimus).  Megestrol acetate or medroxyprogesterone, used as a single agent for the first line treatment of RCC will not constitute one prior systemic therapy.  &lt;br&gt;&lt;br&gt;•Cardiac arrhythmias requiring anti-arrythmics (excluding beta blockers or digoxin), symptomatic coronary artery disease &lt;br&gt;&lt;br&gt;•History of cardiac disease or congestive heart failure &gt;NYHA class 2.  Patients must not have unstable angina (anginal symptoms at rest) or new-onset angina (began within the last 3 months) or myocardial infarction within the past 6 months&lt;br&gt;&lt;br&gt;•Uncontrolled hypertension defined as systolic blood pressure 150 mmHg or diastolic pressure 90 mmHg, despite optimal medical management.&lt;br&gt;&lt;br&gt;•Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.&lt;br&gt;&lt;br&gt;•Active clinically serious infections (&gt; grade 2 NCI-CTC version 3.0). &lt;br&gt;&lt;br&gt;•History of HIV infection or chronic hepatitis B or C. &lt;br&gt;&lt;br&gt;•Known history or symptomatic metastatic brain or meningeal tumours (head CT or MRI at screening to confirm the absence of CNS disease if patient has symptoms suggestive or consistent with CNS disease).  &lt;br&gt;&lt;br&gt;•Patients with seizure disorder requiring medication (such as steroids or anti-epileptics). &lt;br&gt;&lt;br&gt;•History of organ allograft.&lt;br&gt;&lt;br&gt;•Patients with evidence or history of bleeding diasthesis. Any hemorrhage or bleeding event &gt; CTCAE Grade 3 within 4 weeks of first dose of study.&lt;br&gt;&lt;br&gt;•Serious, non-healing wound, ulcer, or bone fracture.&lt;br&gt;&lt;br&gt;•Patients undergoing renal dialysis.&lt;br&gt;&lt;br&gt;•Substance abuse, medical, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results.&lt;br&gt;&lt;br&gt;•Known or suspected allergy to the investigational agent or any agent given in association with this trial.&lt;br&gt;&lt;br&gt;•Any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study.&lt;br&gt;&lt;br&gt;•Pregnant or breast-feeding patients.  Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment.  Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and for at least 3 months after completion of study drug.    The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.&lt;br&gt;&lt;br&gt;•Investigational drug therapy outside of this trial during or within 4 weeks of study entry&lt;br&gt;&lt;br&gt;•Prior exposure to the study drug.&lt;br&gt;&lt;br&gt;•Radiotherapy during study or within 3 weeks of start of study drug.  Palliative radiotherapy will be allowed as described in the Prior and Concomitant Therapy section.&lt;br&gt;&lt;br&gt;•Major surgery open biopsy or significant traumatic injury within 4 weeks of start of study &lt;br&gt;&lt;br&gt;•Autologous bone marrow transplant or stem cell rescue within 4 months of study&lt;br&gt;&lt;br&gt;•Patients unable to swallow oral medicat;Exclusion criteria: &lt;br&gt;•Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis &amp; T1] or any cancer curatively treated &gt; 3 years prior to study entry. &lt;br&gt;&lt;br&gt;•Patients who have received prior systemic treatment regimens for RCC.  Prior systemic therapy is defined as the following:  a single chemotherapy agent (or regimen), a single immunotherapy agent (or regimen) or a single investigational treatment agent (or regimen), any anti-VEGF therapy (including bevacizumab, sunitinib and sorafenib) or any mTOR inhibitor therapy (including temsirolimus).  Megestrol acetate or medroxyprogesterone, used as a single agent for the first line treatment of RCC will not constitute one prior systemic therapy.  &lt;br&gt;&lt;br&gt;•Cardiac arrhythmias requiring anti-arrythmics (excluding beta blockers or digoxin), symptomatic coronary artery disease &lt;br&gt;&lt;br&gt;•History of cardiac disease or congestive heart failure &gt;NYHA class 2.  Patients must not have unstable angina (anginal symptoms at rest) or new-onset angina (began within the last 3 months) or myocardial infarction within the past 6 months&lt;br&gt;&lt;br&gt;•Uncontrolled hypertension defined as systolic blood pressure 150 mmHg or diastolic pressure 90 mmHg, despite optimal medical management.&lt;br&gt;&lt;br&gt;•Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.&lt;br&gt;&lt;br&gt;•Active clinically serious infections (&gt; grade 2 NCI-CTC version 3.0). &lt;br&gt;&lt;br&gt;•History of HIV infection or chronic hepatitis B or C. &lt;br&gt;&lt;br&gt;•Known history or symptomatic metastatic brain or meningeal tumours (head CT or MRI at screening to confirm the absence of CNS disease if patient has symptoms suggestive or consistent with CNS disease).  &lt;br&gt;&lt;br&gt;•Patients with seizure disorder requiring medication (such as steroids or anti-epileptics). &lt;br&gt;&lt;br&gt;•History of organ allograft.&lt;br&gt;&lt;br&gt;•Patients with evidence or history of bleeding diasthesis. Any hemorrhage or bleeding event &gt; CTCAE Grade 3 within 4 weeks of first dose of study.&lt;br&gt;&lt;br&gt;•Serious, non-healing wound, ulcer, or bone fracture.&lt;br&gt;&lt;br&gt;•Patients undergoing renal dialysis.&lt;br&gt;&lt;br&gt;•Substance abuse, medical, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results.&lt;br&gt;&lt;br&gt;•Known or suspected allergy to the investigational agent or any agent given in association with this trial.&lt;br&gt;&lt;br&gt;•Any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study.&lt;br&gt;&lt;br&gt;•Pregnant or breast-feeding patients.  Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment.  Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and for at least 3 months after completion of study drug.    The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.&lt;br&gt;&lt;br&gt;•Investigational drug therapy outside of this trial during or within 4 weeks of study entry&lt;br&gt;&lt;br&gt;•Prior exposure to the study drug.&lt;br&gt;&lt;br&gt;•Radiotherapy during study or within 3 weeks of start of study drug.  Palliative radiotherapy will be allowed as described in the Prior and Concomitant Therapy section.&lt;br&gt;&lt;br&gt;•Major surgery open biopsy or significant traumatic injury within 4 weeks of start of study &lt;br&gt;&lt;br&gt;•Autologous bone marrow transplant or stem cell rescue within 4 months of study&lt;br&gt;&lt;br&gt;•Patients unable to swallow oral medicat</Exclusion_Criteria>
    <Condition>Renal Cell Carcinoma &lt;br&gt;MedDRA version: 14.0
Level: LLT
Classification code 10038407
Term: Renal cell cancer
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
;Therapeutic area: Diseases [C] - Cancer [C04];Renal Cell Carcinoma &lt;br&gt;MedDRA version: 14.0
Level: LLT
Classification code 10038407
Term: Renal cell cancer
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
;Therapeutic area: Diseases [C] - Cancer [C04]</Condition>
    <Intervention>&lt;br&gt;Product Name: Bay 73-4506 coprecipitate&lt;br&gt;Product Code: Bay 73-4506&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: n/a&lt;br&gt;CAS Number: n/a&lt;br&gt;Current Sponsor code: BAY 73-4506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Name: Bay 73-4506 coprecipitate&lt;br&gt;Product Code: Bay 73-4506&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: n/a&lt;br&gt;CAS Number: n/a&lt;br&gt;Current Sponsor code: BAY 73-4506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Product Name: Bay 73-4506 coprecipitate&lt;br&gt;Product Code: Bay 73-4506&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: n/a&lt;br&gt;CAS Number: n/a&lt;br&gt;Current Sponsor code: BAY 73-4506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 40-&lt;br&gt;&lt;br&gt;;&lt;br&gt;Product Name: Bay 73-4506 coprecipitate&lt;br&gt;Product Code: Bay 73-4506&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: n/a&lt;br&gt;CAS Number: n/a&lt;br&gt;Current Sponsor code: BAY 73-4506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Name: Bay 73-4506 coprecipitate&lt;br&gt;Product Code: Bay 73-4506&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: n/a&lt;br&gt;CAS Number: n/a&lt;br&gt;Current Sponsor code: BAY 73-4506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Product Name: Bay 73-4506 coprecipitate&lt;br&gt;Product Code: Bay 73-4506&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: n/a&lt;br&gt;CAS Number: n/a&lt;br&gt;Current Sponsor code: BAY 73-4506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 40-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The objective of this study is to evaluate the antitumor activity and safety of BAY 73-4506 in previously untreated patients with metastatic or unresectable renal cell cancer (RCC).&lt;br&gt;&lt;br&gt;The primary efficacy endpoint of this study is listed in section 4.6.1.;Secondary Objective: Secondary objectives include the evaluation of pharmacokinetic and biomarker data.  The secondary endpoints of this trial are listed in sections 4.6.1 and 4.6.2.;Primary end point(s): The primary efficacy endpoint of this study is to evaluate the response rate of patients with advanced RCC to BAY 73-4506.  Tumor response and disease progression will be evaluated based on RECIST tumor response criteria.  Measurements will be made at baseline and then every 2 cycles (8 weeks- based on 28 day cycles) during the treatment period until progressive disease is documented, and also at the end of treatment visit if applicable.&lt;br&gt;&lt;br&gt;;Timepoint(s) of evaluation of this end point: Measurements will be made at baseline and then every 2 cycles (8 weeks- based on 28 day cycles) during the treatment period until progressive disease is documented, and also at the end of treatment visit if applicable. &lt;br&gt;;Main Objective: The objective of this study is to evaluate the antitumor activity and safety of BAY 73-4506 in previously untreated patients with metastatic or unresectable renal cell cancer (RCC).&lt;br&gt;&lt;br&gt;The primary efficacy endpoint of this study is listed in section 4.6.1.;Secondary Objective: Secondary objectives include the evaluation of pharmacokinetic and biomarker data.  The secondary endpoints of this trial are listed in sections 4.6.1 and 4.6.2.;Primary end point(s): The primary efficacy endpoint of this study is to evaluate the response rate of patients with advanced RCC to BAY 73-4506.  Tumor response and disease progression will be evaluated based on RECIST tumor response criteria.  Measurements will be made at baseline and then every 2 cycles (8 weeks- based on 28 day cycles) during the treatment period until progressive disease is documented, and also at the end of treatment visit if applicable.&lt;br&gt;&lt;br&gt;;Timepoint(s) of evaluation of this end point: Measurements will be made at baseline and then every 2 cycles (8 weeks- based on 28 day cycles) during the treatment period until progressive disease is documented, and also at the end of treatment visit if applicable. &lt;br&gt;</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Secondary efficacy endpoints include overall survival, progression-free survival, time to progression, duration of response and duration of stable disease. ;Timepoint(s) of evaluation of this end point: Throughout the treatment period, the same lesions to those identified and measured at baseline must be evaluated using the same technique, the identical contrast agent and the same slice thickness. The body areas scanned at baseline should also continue to be scanned throughout the study. The exception to this is a baseline negative head CT/MRI if it was performed to rule out metastatic brain or meningeal tumours. &lt;br&gt;;Secondary end point(s): Secondary efficacy endpoints include overall survival, progression-free survival, time to progression, duration of response and duration of stable disease. ;Timepoint(s) of evaluation of this end point: Throughout the treatment period, the same lesions to those identified and measured at baseline must be evaluated using the same technique, the identical contrast agent and the same slice thickness. The body areas scanned at baseline should also continue to be scanned throughout the study. The exception to this is a baseline negative head CT/MRI if it was performed to rule out metastatic brain or meningeal tumours. &lt;br&gt;</Secondary_outcome>
    <Secondary_ID>11726;11726</Secondary_ID>
    <Source_Support>Bayer HealthCare AG;Bayer HealthCare AG</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2758376</Internal_Number>
    <TrialID>EUCTR2008-000107-28-FI</TrialID>
    <Last_Refreshed_on>11 September 2012</Last_Refreshed_on>
    <Public_title>A Phase II uncontrolled study of BAY 73-4506 (DAST) in previously untreated patients with metastatic or unresectable renal cell cancer (RCC)</Public_title>
    <Scientific_title>A Phase II uncontrolled study of BAY 73-4506 (DAST) in previously untreated patients with metastatic or unresectable renal cell cancer (RCC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Bayer HealthCare AG</Primary_sponsor>
    <Date_registration3>20080221</Date_registration3>
    <Date_registration>21/02/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000107-28                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>15/04/2008</Date_enrollement>
    <Target_size>41</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•Male or female patients &gt; 18 years of age.&lt;br&gt;&lt;br&gt;•Patients, who suffer from unresectable and/or metastatic, measurable predominantly clear cell RCC histologically or cytologically documented. Patients with rare subtypes of RCC such as pure papillary cell tumor, mixed tumor containing predominantly sarcomatoid cells, Bellini carcinoma, medullary carcinoma, or chromophobe oncocytic tumors are excluded from study participation.&lt;br&gt;&lt;br&gt;•Patients must be previously untreated for advanced disease.  Prior palliative radiation therapy is allowed if the target lesion(s) are not included within the radiation field and no more than 30% of the bone marrow is irradiated.  &lt;br&gt;&lt;br&gt;•Patients who have at least one uni-dimensional measurable lesion by CT-scan or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST).&lt;br&gt;&lt;br&gt;•Patients with “Intermediate” or “Low” risk per the Motzer score.&lt;br&gt;&lt;br&gt;•Patients who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0 or 1.&lt;br&gt;&lt;br&gt;•Adequate bone marrow, renal and hepatic function as assessed by the following laboratory requirements to be conducted within 7 days prior to study drug treatment:&lt;br&gt;?Total bilirubin &lt; 1.5 x the upper limit of normal.&lt;br&gt;?ALT and AST &lt; 2.5 x upper limit of normal (&lt; 5 x upper limit of normal for patients with liver involvement of their cancer).&lt;br&gt;?Amylase and lipase &lt; 1.5 x the upper limit of normal&lt;br&gt;?Serum creatinine &lt; 2.0 x the upper limit of normal.  &lt;br&gt;?INR/PTT &lt; 1.5 x ULN (Patients who are being prophylactically anti-coagulated with an agent such as coumadin or low molecular weight heparin or therapeutically anticoagulated with LMWH will be allowed to participate provided that they meet these criteria; in addition, these patients must be monitored at appropriate intervals throughout study)&lt;br&gt;?Platelet count ¬&gt; 100000 /mm3, Hb &gt; 9 g/dl, ANC &gt; 1500/mm3&lt;br&gt;?Alkaline phosphatase limit &lt; 2.5 x ULN &lt;br&gt;&lt;br&gt;•Life expectancy of at least 12 weeks.&lt;br&gt;•A signed informed consent must be obtained prior to any study specific procedures.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 39&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 25&lt;br&gt;;Inclusion criteria: &lt;br&gt;•Male or female patients &gt; 18 years of age.&lt;br&gt;&lt;br&gt;•Patients, who suffer from unresectable and/or metastatic, measurable predominantly clear cell RCC histologically or cytologically documented. Patients with rare subtypes of RCC such as pure papillary cell tumor, mixed tumor containing predominantly sarcomatoid cells, Bellini carcinoma, medullary carcinoma, or chromophobe oncocytic tumors are excluded from study participation.&lt;br&gt;&lt;br&gt;•Patients must be previously untreated for advanced disease.  Prior palliative radiation therapy is allowed if the target lesion(s) are not included within the radiation field and no more than 30% of the bone marrow is irradiated.  &lt;br&gt;&lt;br&gt;•Patients who have at least one uni-dimensional measurable lesion by CT-scan or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST).&lt;br&gt;&lt;br&gt;•Patients with “Intermediate” or “Low” risk per the Motzer score.&lt;br&gt;&lt;br&gt;•Patients who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0 or 1.&lt;br&gt;&lt;br&gt;•Adequate bone marrow, renal and hepatic function as assessed by the following laboratory requirements to be conducted within 7 days prior to study drug treatment:&lt;br&gt;?Total bilirubin &lt; 1.5 x the upper limit of normal.&lt;br&gt;?ALT and AST &lt; 2.5 x upper limit of normal (&lt; 5 x upper limit of normal for patients with liver involvement of their cancer).&lt;br&gt;?Amylase and lipase &lt; 1.5 x the upper limit of normal&lt;br&gt;?Serum creatinine &lt; 2.0 x the upper limit of normal.  &lt;br&gt;?INR/PTT &lt; 1.5 x ULN (Patients who are being prophylactically anti-coagulated with an agent such as coumadin or low molecular weight heparin or therapeutically anticoagulated with LMWH will be allowed to participate provided that they meet these criteria; in addition, these patients must be monitored at appropriate intervals throughout study)&lt;br&gt;?Platelet count ¬&gt; 100000 /mm3, Hb &gt; 9 g/dl, ANC &gt; 1500/mm3&lt;br&gt;?Alkaline phosphatase limit &lt; 2.5 x ULN &lt;br&gt;&lt;br&gt;•Life expectancy of at least 12 weeks.&lt;br&gt;•A signed informed consent must be obtained prior to any study specific procedures.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 39&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 25&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis &amp; T1] or any cancer curatively treated &gt; 3 years prior to study entry. &lt;br&gt;&lt;br&gt;•Patients who have received prior systemic treatment regimens for RCC.  Prior systemic therapy is defined as the following:  a single chemotherapy agent (or regimen), a single immunotherapy agent (or regimen) or a single investigational treatment agent (or regimen), any anti-VEGF therapy (including bevacizumab, sunitinib and sorafenib) or any mTOR inhibitor therapy (including temsirolimus).  Megestrol acetate or medroxyprogesterone, used as a single agent for the first line treatment of RCC will not constitute one prior systemic therapy.  &lt;br&gt;&lt;br&gt;•Cardiac arrhythmias requiring anti-arrythmics (excluding beta blockers or digoxin), symptomatic coronary artery disease &lt;br&gt;&lt;br&gt;•History of cardiac disease or congestive heart failure &gt;NYHA class 2.  Patients must not have unstable angina (anginal symptoms at rest) or new-onset angina (began within the last 3 months) or myocardial infarction within the past 6 months&lt;br&gt;&lt;br&gt;•Uncontrolled hypertension defined as systolic blood pressure 150 mmHg or diastolic pressure 90 mmHg, despite optimal medical management.&lt;br&gt;&lt;br&gt;•Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.&lt;br&gt;&lt;br&gt;•Active clinically serious infections (&gt; grade 2 NCI-CTC version 3.0). &lt;br&gt;&lt;br&gt;•History of HIV infection or chronic hepatitis B or C. &lt;br&gt;&lt;br&gt;•Known history or symptomatic metastatic brain or meningeal tumours (head CT or MRI at screening to confirm the absence of CNS disease if patient has symptoms suggestive or consistent with CNS disease).  &lt;br&gt;&lt;br&gt;•Patients with seizure disorder requiring medication (such as steroids or anti-epileptics). &lt;br&gt;&lt;br&gt;•History of organ allograft.&lt;br&gt;&lt;br&gt;•Patients with evidence or history of bleeding diasthesis. Any hemorrhage or bleeding event &gt; CTCAE Grade 3 within 4 weeks of first dose of study.&lt;br&gt;&lt;br&gt;•Serious, non-healing wound, ulcer, or bone fracture.&lt;br&gt;&lt;br&gt;•Patients undergoing renal dialysis.&lt;br&gt;&lt;br&gt;•Substance abuse, medical, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results.&lt;br&gt;&lt;br&gt;•Known or suspected allergy to the investigational agent or any agent given in association with this trial.&lt;br&gt;&lt;br&gt;•Any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study.&lt;br&gt;&lt;br&gt;•Pregnant or breast-feeding patients.  Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment.  Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and for at least 3 months after completion of study drug.    The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.&lt;br&gt;&lt;br&gt;•Investigational drug therapy outside of this trial during or within 4 weeks of study entry&lt;br&gt;&lt;br&gt;•Prior exposure to the study drug.&lt;br&gt;&lt;br&gt;•Radiotherapy during study or within 3 weeks of start of study drug.  Palliative radiotherapy will be allowed as described in the Prior and Concomitant Therapy section.&lt;br&gt;&lt;br&gt;•Major surgery open biopsy or significant traumatic injury within 4 weeks of start of study &lt;br&gt;&lt;br&gt;•Autologous bone marrow transplant or stem cell rescue within 4 months of study&lt;br&gt;&lt;br&gt;•Patients unable to swallow oral medicat;Exclusion criteria: &lt;br&gt;•Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis &amp; T1] or any cancer curatively treated &gt; 3 years prior to study entry. &lt;br&gt;&lt;br&gt;•Patients who have received prior systemic treatment regimens for RCC.  Prior systemic therapy is defined as the following:  a single chemotherapy agent (or regimen), a single immunotherapy agent (or regimen) or a single investigational treatment agent (or regimen), any anti-VEGF therapy (including bevacizumab, sunitinib and sorafenib) or any mTOR inhibitor therapy (including temsirolimus).  Megestrol acetate or medroxyprogesterone, used as a single agent for the first line treatment of RCC will not constitute one prior systemic therapy.  &lt;br&gt;&lt;br&gt;•Cardiac arrhythmias requiring anti-arrythmics (excluding beta blockers or digoxin), symptomatic coronary artery disease &lt;br&gt;&lt;br&gt;•History of cardiac disease or congestive heart failure &gt;NYHA class 2.  Patients must not have unstable angina (anginal symptoms at rest) or new-onset angina (began within the last 3 months) or myocardial infarction within the past 6 months&lt;br&gt;&lt;br&gt;•Uncontrolled hypertension defined as systolic blood pressure 150 mmHg or diastolic pressure 90 mmHg, despite optimal medical management.&lt;br&gt;&lt;br&gt;•Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.&lt;br&gt;&lt;br&gt;•Active clinically serious infections (&gt; grade 2 NCI-CTC version 3.0). &lt;br&gt;&lt;br&gt;•History of HIV infection or chronic hepatitis B or C. &lt;br&gt;&lt;br&gt;•Known history or symptomatic metastatic brain or meningeal tumours (head CT or MRI at screening to confirm the absence of CNS disease if patient has symptoms suggestive or consistent with CNS disease).  &lt;br&gt;&lt;br&gt;•Patients with seizure disorder requiring medication (such as steroids or anti-epileptics). &lt;br&gt;&lt;br&gt;•History of organ allograft.&lt;br&gt;&lt;br&gt;•Patients with evidence or history of bleeding diasthesis. Any hemorrhage or bleeding event &gt; CTCAE Grade 3 within 4 weeks of first dose of study.&lt;br&gt;&lt;br&gt;•Serious, non-healing wound, ulcer, or bone fracture.&lt;br&gt;&lt;br&gt;•Patients undergoing renal dialysis.&lt;br&gt;&lt;br&gt;•Substance abuse, medical, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results.&lt;br&gt;&lt;br&gt;•Known or suspected allergy to the investigational agent or any agent given in association with this trial.&lt;br&gt;&lt;br&gt;•Any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study.&lt;br&gt;&lt;br&gt;•Pregnant or breast-feeding patients.  Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment.  Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and for at least 3 months after completion of study drug.    The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.&lt;br&gt;&lt;br&gt;•Investigational drug therapy outside of this trial during or within 4 weeks of study entry&lt;br&gt;&lt;br&gt;•Prior exposure to the study drug.&lt;br&gt;&lt;br&gt;•Radiotherapy during study or within 3 weeks of start of study drug.  Palliative radiotherapy will be allowed as described in the Prior and Concomitant Therapy section.&lt;br&gt;&lt;br&gt;•Major surgery open biopsy or significant traumatic injury within 4 weeks of start of study &lt;br&gt;&lt;br&gt;•Autologous bone marrow transplant or stem cell rescue within 4 months of study&lt;br&gt;&lt;br&gt;•Patients unable to swallow oral medicat</Exclusion_Criteria>
    <Condition>Renal Cell Carcinoma &lt;br&gt;MedDRA version: 14.0
Level: LLT
Classification code 10038407
Term: Renal cell cancer
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
;Therapeutic area: Diseases [C] - Cancer [C04];Renal Cell Carcinoma &lt;br&gt;MedDRA version: 14.0
Level: LLT
Classification code 10038407
Term: Renal cell cancer
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
;Therapeutic area: Diseases [C] - Cancer [C04]</Condition>
    <Intervention>&lt;br&gt;Product Name: Bay 73-4506 coprecipitate&lt;br&gt;Product Code: Bay 73-4506&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: n/a&lt;br&gt;CAS Number: n/a&lt;br&gt;Current Sponsor code: BAY 73-4506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Name: Bay 73-4506 coprecipitate&lt;br&gt;Product Code: Bay 73-4506&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: n/a&lt;br&gt;CAS Number: n/a&lt;br&gt;Current Sponsor code: BAY 73-4506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Product Name: Bay 73-4506 coprecipitate&lt;br&gt;Product Code: Bay 73-4506&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: n/a&lt;br&gt;CAS Number: n/a&lt;br&gt;Current Sponsor code: BAY 73-4506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 40-&lt;br&gt;&lt;br&gt;;&lt;br&gt;Product Name: Bay 73-4506 coprecipitate&lt;br&gt;Product Code: Bay 73-4506&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: n/a&lt;br&gt;CAS Number: n/a&lt;br&gt;Current Sponsor code: BAY 73-4506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Name: Bay 73-4506 coprecipitate&lt;br&gt;Product Code: Bay 73-4506&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: n/a&lt;br&gt;CAS Number: n/a&lt;br&gt;Current Sponsor code: BAY 73-4506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Product Name: Bay 73-4506 coprecipitate&lt;br&gt;Product Code: Bay 73-4506&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: n/a&lt;br&gt;CAS Number: n/a&lt;br&gt;Current Sponsor code: BAY 73-4506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 40-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The objective of this study is to evaluate the antitumor activity and safety of BAY 73-4506 in previously untreated patients with metastatic or unresectable renal cell cancer (RCC).&lt;br&gt;&lt;br&gt;The primary efficacy endpoint of this study is listed in section 4.6.1.;Secondary Objective: Secondary objectives include the evaluation of pharmacokinetic and biomarker data.  The secondary endpoints of this trial are listed in sections 4.6.1 and 4.6.2.;Primary end point(s): The primary efficacy endpoint of this study is to evaluate the response rate of patients with advanced RCC to BAY 73-4506.  Tumor response and disease progression will be evaluated based on RECIST tumor response criteria.  Measurements will be made at baseline and then every 2 cycles (8 weeks- based on 28 day cycles) during the treatment period until progressive disease is documented, and also at the end of treatment visit if applicable.&lt;br&gt;&lt;br&gt;;Timepoint(s) of evaluation of this end point: Measurements will be made at baseline and then every 2 cycles (8 weeks- based on 28 day cycles) during the treatment period until progressive disease is documented, and also at the end of treatment visit if applicable. &lt;br&gt;;Main Objective: The objective of this study is to evaluate the antitumor activity and safety of BAY 73-4506 in previously untreated patients with metastatic or unresectable renal cell cancer (RCC).&lt;br&gt;&lt;br&gt;The primary efficacy endpoint of this study is listed in section 4.6.1.;Secondary Objective: Secondary objectives include the evaluation of pharmacokinetic and biomarker data.  The secondary endpoints of this trial are listed in sections 4.6.1 and 4.6.2.;Primary end point(s): The primary efficacy endpoint of this study is to evaluate the response rate of patients with advanced RCC to BAY 73-4506.  Tumor response and disease progression will be evaluated based on RECIST tumor response criteria.  Measurements will be made at baseline and then every 2 cycles (8 weeks- based on 28 day cycles) during the treatment period until progressive disease is documented, and also at the end of treatment visit if applicable.&lt;br&gt;&lt;br&gt;;Timepoint(s) of evaluation of this end point: Measurements will be made at baseline and then every 2 cycles (8 weeks- based on 28 day cycles) during the treatment period until progressive disease is documented, and also at the end of treatment visit if applicable. &lt;br&gt;</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Secondary efficacy endpoints include overall survival, progression-free survival, time to progression, duration of response and duration of stable disease. ;Timepoint(s) of evaluation of this end point: Throughout the treatment period, the same lesions to those identified and measured at baseline must be evaluated using the same technique, the identical contrast agent and the same slice thickness. The body areas scanned at baseline should also continue to be scanned throughout the study. The exception to this is a baseline negative head CT/MRI if it was performed to rule out metastatic brain or meningeal tumours. &lt;br&gt;;Secondary end point(s): Secondary efficacy endpoints include overall survival, progression-free survival, time to progression, duration of response and duration of stable disease. ;Timepoint(s) of evaluation of this end point: Throughout the treatment period, the same lesions to those identified and measured at baseline must be evaluated using the same technique, the identical contrast agent and the same slice thickness. The body areas scanned at baseline should also continue to be scanned throughout the study. The exception to this is a baseline negative head CT/MRI if it was performed to rule out metastatic brain or meningeal tumours. &lt;br&gt;</Secondary_outcome>
    <Secondary_ID>11726;11726</Secondary_ID>
    <Source_Support>Bayer HealthCare AG;Bayer HealthCare AG</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2774313</Internal_Number>
    <TrialID>EUCTR2012-001337-13-ES</TrialID>
    <Last_Refreshed_on>18 September 2012</Last_Refreshed_on>
    <Public_title>A randomized study to explore the efficacy and feasibility of rotations between sunitinib and everolimus versus sequential treatment of sunitinib and everolimus until progression in patients with renal cancer.</Public_title>
    <Scientific_title>A randomized phase II study to explore the efficacy and feasibility of upfront rotations between sunitinib and everolimus versus sequential treatment of first line sunitinib and second line everolimus until progression in patients with metastatic clear cell renal cancer. - SUNRISES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>APRO</Primary_sponsor>
    <Date_registration3>20120529</Date_registration3>
    <Date_registration>29/05/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-001337-13                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/08/2012</Date_enrollement>
    <Target_size>115</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: The same medicinal products under standard regimen&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;-Renal cell carcinoma with a predominant clear cell component confirmed by histology or cytology&lt;br&gt;-Advanced disease: metastatic AND, not suitable for resection&lt;br&gt;-Male or female, aged 18 years or older&lt;br&gt;-ECOG 0 or 1 &lt;br&gt;-Low or intermediate MSKCC prognostic risk score&lt;br&gt;-Target and/or non-target lesions according to RECIST 1.1 &lt;br&gt;-Expected survival of at least 3 months.&lt;br&gt;-No prior systemic treatment.&lt;br&gt;-Adequate bone marrow function&lt;br&gt;-Adequate liver function&lt;br&gt;-Adequate renal function as shown by serum creatinine &lt; 1.5 x ULN&lt;br&gt;-Left ventricular ejection fraction &gt;55% on gated cardiac blood pool scan, or normal left ventricular function and fractional shortening on echocardiogram (according to institutional limits).&lt;br&gt;-Systolic blood pressure &lt;140mmHg and diastolic blood pressure &lt;90mmHg (it is acceptable to initiate antihypertensive treatment prior to registration to achieve these goals).&lt;br&gt;-Able to commence treatment within 7 days of registration.&lt;br&gt;-Willing and able to comply with follow-up and all other protocol requirements.&lt;br&gt;-Written informed consent&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 55&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 60&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-Prior treatment with VEGF-targeting agents  or multi-kinase inhibitors or mTOR-targeting agents&lt;br&gt;-Active central nervous system metastases. &lt;br&gt;-Other malignancy diagnosed within the last 5 years, except the following if adequately treated: superficial squamous cell carcinoma or basal cell carcinoma of skin, superficial bladder cancer (T1 and G1 or T1 and G2), stage 1 cervical cancer.&lt;br&gt;-Treatment with an investigational agent in the last 4 weeks.&lt;br&gt;-Known to be HIV positive &lt;br&gt;-Evidence of chronic hepatitis due to HBV or HCV &lt;br&gt;-Clinically significant heart disease &lt;br&gt;-History of hypertension requiring hospitalization.&lt;br&gt;-Other serious illnesses, e.g. active infection requiring antibiotics, bleeding disorders.&lt;br&gt;-Immunotherapy or chemotherapy in the last 4 weeks &lt;br&gt;-Major surgery in the last 4 weeks, or planned in the next 6 weeks.&lt;br&gt;-Radiation therapy in the last 2 weeks, or planned in the next 6 weeks &lt;br&gt;-grade 3 or worse hemorrhage in last 4 weeks &lt;br&gt;-Any of the following in the last year: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism&lt;br&gt;-Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication&lt;br&gt;-Ongoing cardiac dysrhythmias grade &gt;2, atrial fibrillation of any grade, or prolongation of the corrected QT interval (QTc) to &gt;450 msec for males or &gt;470 msec for females&lt;br&gt;-Uncontrolled diabetes as defined by fasting serum glucose &gt;1.5 X ULN&lt;br&gt;-Pregnancy &lt;br&gt;-Known allergy or hypersensitivity to everolimus, sunitinib or iodine&lt;br&gt;-Medical or psychiatric condition that compromises the patients ability to give informed consent&lt;br&gt;</Exclusion_Criteria>
    <Condition>Metastatic clear cell renal cancer &lt;br&gt;MedDRA version: 14.1
Level: LLT
Classification code 10038416
Term: Renal clear cell carcinoma
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
;Therapeutic area: Diseases [C] - Cancer [C04]</Condition>
    <Intervention>&lt;br&gt;Trade Name: SUTENT&lt;br&gt;Product Name: SUTENT&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: SUNITINIB&lt;br&gt;CAS Number: 341031-54-7&lt;br&gt;Other descriptive name: SUNITINIB MALATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 12.5-&lt;br&gt;&lt;br&gt;Trade Name: AFINITOR&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: AFINITOR&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Other descriptive name: EVEROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: AFINITOR&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: AFINITOR&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Other descriptive name: EVEROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: SUTENT&lt;br&gt;Product Name: SUTENT&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: SUNITINIB&lt;br&gt;CAS Number: 341031-54-7&lt;br&gt;Other descriptive name: SUNITINIB MALATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 12.5-&lt;br&gt;&lt;br&gt;Trade Name: SUTENT&lt;br&gt;Product Name: SUTENT&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: SUNITINIB&lt;br&gt;CAS Number: 341031-54-7&lt;br&gt;Other descriptive name: SUNITINIB MALATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Progression-free survival (PFS);Secondary Objective: a)PFS of sequential arm versus PFS of the 2 lines in control arm.&lt;br&gt;b)Objective tumor response rate (ORR) per arm&lt;br&gt;c)Overall Survival (OS)&lt;br&gt;d)Safety Profile;Primary end point(s): Progression;Timepoint(s) of evaluation of this end point: 1 year</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): a) Progression &lt;br&gt;b) Partial and Complete responses &lt;br&gt;c) Survival &lt;br&gt;d) Adverse events;Timepoint(s) of evaluation of this end point: 1 year</Secondary_outcome>
    <Secondary_ID>CRAD001LIC34T</Secondary_ID>
    <Source_Support>Novartis</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2774556</Internal_Number>
    <TrialID>EUCTR2011-002150-31-FI</TrialID>
    <Last_Refreshed_on>18 September 2012</Last_Refreshed_on>
    <Public_title>Study to Evaluate Darbepoetin alfa in Pediatric Subjects With Anemia Due to Chronic Kidney Disease</Public_title>
    <Scientific_title>An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Darbepoetin alfa in Paediatric Subjects From Birth to Less than 1 Year of Age With Anemia due to Chronic Kidney Disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Amgen Inc</Primary_sponsor>
    <Date_registration3>20120725</Date_registration3>
    <Date_registration>25/07/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-002150-31                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>29/08/2012</Date_enrollement>
    <Target_size>5</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Girls and boys between birth and &lt; 1 year of age at the time of enrollment
&lt;br&gt;Body weight = 3 kg at screening and enrollment
&lt;br&gt;Diagnosis of CKD stage 3 to 5 with an estimated GFR &lt; 60 mL/min/1.73m2 without dialysis using the updated Schwartz Equation at screening; OR on dialysis at screening
&lt;br&gt;Hemoglobin = 9.0 g/dL within 7 days prior to enrollment
&lt;br&gt;Transferrin saturation (TSAT) = 20% at screening
&lt;br&gt;Clinically stable and suitable for participation in this study, in the judgment of the Investigator
&lt;br&gt;Subject’s parent or legally acceptable representative (SPoLAR) has provided informed consent prior to performing any study-specific procedures&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: 5&lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Premature girls and boys (&lt; 37 weeks of gestation, counting from the first day of the mother’s last menstrual period)
&lt;br&gt;Peritoneal dialysis subjects with an episode of peritonitis within 30 days prior to enrollment
&lt;br&gt;History of cardiovascular events or thromboembolism
&lt;br&gt;History of upper or lower GI bleeding
&lt;br&gt;History of seizures
&lt;br&gt;Active liver disease or history of liver disease
&lt;br&gt;Uncontrolled hypertension defined as stage 2 hypertension or greater. This is defined as a systolic or diastolic blood pressure value greater than the
&lt;br&gt;99th percentile + 5 mmHg for a subject’s age. Refer to Blood Pressure Stages defined in the “The Fourth Report on the Diagnosis, Evaluation, and Treatment of
&lt;br&gt;High Blood Pressure in Children and Adolescents” Pediatrics 2004
&lt;br&gt;Major surgery 12 weeks prior to enrollment
&lt;br&gt;Red blood cell transfusions 12 weeks prior to enrollment
&lt;br&gt;Use of any erythropoiesis-stimulating agent within 12 weeks prior to enrollment
&lt;br&gt;Currently receiving antibiotic therapy for systemic infection within 4 weeks prior to enrollment
&lt;br&gt;Current or prior use of immunosuppressants (excluding low-dose corticosteroids, defined as = 0.5 mg/kg per day prednisone or equivalent for = 5 days)
&lt;br&gt;Subject is receiving a dose higher than 0.5 mg/kg per day of prednisone (or equivalent dose of another corticosteroid) for &gt; 5 days within 4 weeks prior to
&lt;br&gt;enrollment
&lt;br&gt;Receiving or has received any investigational drug (or is currently using an investigational device) within the 30 days or 5 half-lives (whichever is longer) prior to enrollment
&lt;br&gt;Subject has known hypersensitivity to darbepoetin alfa, r-HuEPO, or to any of the excipients&lt;br&gt;</Exclusion_Criteria>
    <Condition>Anaemia due to chronic kidney disease &lt;br&gt;MedDRA version: 14.1
Level: LLT
Classification code 10064848
Term: Chronic kidney disease
System Organ Class: 10038359 - Renal and urinary disorders
 &lt;br&gt;MedDRA version: 14.1
Level: LLT
Classification code 10002272
Term: Anemia
System Organ Class: 10005329 - Blood and lymphatic system disorders
;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]</Condition>
    <Intervention>&lt;br&gt;Product Name: darbepoetin alfa 25 micrograms solution for injection in vial&lt;br&gt;Product Code: Not applicable&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: DARBEPOETIN ALFA&lt;br&gt;CAS Number: 209810-58-2&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate the safety and tolerability of darbepoetin alfa following single 1.5 microgram/kg subcutaneous (SC) dose administration in paediatric subjects &lt; 1 year of age with anaemia due to chronic kidney disease;Secondary Objective: Following single 1.5 microgram/kg subcutaneous (SC) dose administration in paediatric subjects &lt; 1 year of age with anaemia due to chronic kidney disease, evaluate the:&lt;br&gt;Pharmacokinetic profile&lt;br&gt;Pharmacodynamic profile&lt;br&gt;Change in iron, ferritin and transferrin saturation (TSAT);Primary end point(s): Subject incidence of treatment-emergent AEs, and clinically significant changes in physical examinations, laboratory safety tests, and vital signs.;Timepoint(s) of evaluation of this end point: AEs throughout the study&lt;br&gt;Physical examinations at screening, pre-dose and day 29&lt;br&gt;Laboratory safety tests at screening and at day 8 and day 29&lt;br&gt;Vital signs at screening, pre-dose and at day 8 and day 29&lt;br&gt;</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): PK parameters (ie, Cmax, Tmax, AUC, t½, and CL)
&lt;br&gt;PD parameters, including change in:
&lt;br&gt;reticulocytes from baseline to day 8, and day 29
&lt;br&gt;hemoglobin concentration from baseline to day 8, and day 29
&lt;br&gt;iron, ferritin, and TSAT from baseline to day 29;Timepoint(s) of evaluation of this end point: PK parameters: days 1, 2, 3, 4 and 8
&lt;br&gt;
&lt;br&gt;
&lt;br&gt;PD parameters:
&lt;br&gt;reticulocytes baseline, day 8, and day 29
&lt;br&gt;hemoglobin concentration baseline, day 8, and day 29
&lt;br&gt;iron, ferritin, and TSAT baseline and day 29</Secondary_outcome>
    <Secondary_ID>20090302</Secondary_ID>
    <Source_Support>Amgen Inc</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2774684</Internal_Number>
    <TrialID>EUCTR2012-002657-30-FI</TrialID>
    <Last_Refreshed_on>18 September 2012</Last_Refreshed_on>
    <Public_title>Comparing the effectivity of two different pneumococcal vaccines against severe pneumococcal diseases in adult kidney and liver transplant patients</Public_title>
    <Scientific_title>Immunogenicity of repeated dose 13-valent pneumococcal conjugate vaccine compared to the existing recommended protocol of pneumococcal polysaccharide vaccine in adult kidney and liver transplant patients - SOT13                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>HYKS-instituutti</Primary_sponsor>
    <Date_registration3>20120817</Date_registration3>
    <Date_registration>17/08/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002657-30                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/09/2012</Date_enrollement>
    <Target_size>150</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 4&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Consecutive adult (&gt;18 years) liver and kidney transplant patients are enrolled as they enter the transplant waiting list&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 125&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 25&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Age&lt; 18 years
&lt;br&gt;Previous Pneumococcal vaccination &lt; 3 years ago
&lt;br&gt;Febrile illness at the time of vaccination
&lt;br&gt;Any sign of graft failure or rejection at the time of vaccination
&lt;br&gt;Splenectomy
&lt;br&gt;Pregnancy
&lt;br&gt;Critically ill patient due to any cause, including terminal uncompensated liver disease&lt;br&gt;</Exclusion_Criteria>
    <Condition>Immunogenicity of pneumococcal vaccines in liver and kidney transplant patients;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]</Condition>
    <Intervention>&lt;br&gt;Trade Name: Prevenar 13&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: PNEUMOCOCCAL CONJUGATE VACCINE&lt;br&gt;Other descriptive name: PNEUMOCOCCAL CONJUGATE VACCINE&lt;br&gt;&lt;br&gt;Trade Name: Pneumovax&lt;br&gt;Product Name: Pneumovax&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: pneumococcal polysaccharide vaccine&lt;br&gt;Other descriptive name: PNEUMOCOCCAL VACCINE&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To show the non-inferiority of Prevenar 13 compared to pneumovax;Secondary Objective: To show the safety of Prevenar 13 in these patient groups. To show possible superiority of the Prevenar 13 compared to Pneumovax and to see if an additive dose of Prevenar13 brings better immunogenicity;Primary end point(s): To detect any difference in immunogenicity (valued as the concenration of sertoype spcific IgG antibodies and their opsonophagocytic activity) between the PCV13 and PPV23 groups before and after the initialvaccination and 7 months after the transplantation ( 1 month after the second PCV vaccination);Timepoint(s) of evaluation of this end point: Before and after the first vaccination (prevener or Pneumovax) and before and after the second Prevenar13 vaccination which is administerated at 6 months posttransplant</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): To detect the safety aspects of repeated PCV13 doses in these patient groups;Timepoint(s) of evaluation of this end point: Patients are followed and monitored for AEs and SAEs throughout the study but especially 8 weeks time after each vaccination</Secondary_outcome>
    <Secondary_ID>WS2287576</Secondary_ID>
    <Source_Support>HYKS instituutti</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2774864</Internal_Number>
    <TrialID>EUCTR2010-020452-64-GB</TrialID>
    <Last_Refreshed_on>18 September 2012</Last_Refreshed_on>
    <Public_title>Iron treatment in patients with known kidney disease</Public_title>
    <Scientific_title>A prospective randomisd open label study to determine the effects of intravenous iron administration on markers of acute kidney injury in chronic kidney disease (CKD) - Effects of intravenous iron therapy on markers of acute kidney injury                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Hull and East Yorkshire Hospitals NHS Trust</Primary_sponsor>
    <Date_registration3>20101008</Date_registration3>
    <Date_registration>08/10/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-020452-64                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>05/10/2010</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients with established chronic kidney disease. (Stages III-V) (GFR using MDRD &lt;60ml/min) who are to undergo iron therapy&lt;br&gt;Male, female over 18 years &lt;br&gt;Written and signed informed patient consent&lt;br&gt;No previous iron administration in the last 6 weeks&lt;br&gt;Serum ferritin levels less than 200 mcg/l and/or transferrin saturation &lt;20%&lt;br&gt;Able to meet all study requrements &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: 0&lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 0&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 0&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Pregnancy&lt;br&gt;Age &lt; 18 years&lt;br&gt;Ferritin greater than 200 mcg/l and Transferrin saturation &gt;40%&lt;br&gt;Known allergy to iron therapy&lt;br&gt;Haemochromatosis&lt;br&gt;Parenteral iron therapy within the previous 6 weeks&lt;br&gt;Inability to co-operate with study protocol&lt;br&gt;Patients with potential confounding factors to NGAL measurement&lt;br&gt;Patients who do not have renal failure (CKD stage I and II)&lt;br&gt;Patients who are unable or do not wish to give consent.&lt;br&gt;Patients being investigated for potential blood loss&lt;br&gt;Patients with a haematological malignancy/ haemolysis&lt;br&gt;Patients with known haemaglobinopathy&lt;br&gt;Patients with a diagnosis of myeloma &lt;br&gt;current smokers&lt;br&gt;Any other contraindications to Monofer, Venofer or Cosmofer therapy listed on SPC&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>patients with known chonic kidney disease with functional or absolute Iron deficiency Anaemia, and are greater than 18 years will be given repleacement iron therapy accoring to current local protocols and NICE guidelines &lt;br&gt;MedDRA version: 15.0
Level: LLT
Classification code 10022973
Term: Iron deficiency anaemias
System Organ Class: 10005329 - Blood and lymphatic system disorders
</Condition>
    <Intervention>&lt;br&gt;Trade Name: COSMOFER&lt;br&gt;Product Name: COSMOFER&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: Iron III hydroxide dextran complex&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 50-50&lt;br&gt;&lt;br&gt;Trade Name: VENOFER&lt;br&gt;Product Name: VENOFER&lt;br&gt;Product Code: B03AB04&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: iron sucrose&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-20&lt;br&gt;&lt;br&gt;Trade Name: MOnofer&lt;br&gt;Product Name: MONOFER&lt;br&gt;Pharmaceutical Form: Solution for infusion in administration system&lt;br&gt;INN or Proposed INN: iron(III) isomaltoside 1000 &lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess whether three preparations of intravenous iron therapy affect markers of kidney injury including NGAL levels in serum and urine as a result of intravenous Iron therapy in patients with chronic kidney disease (CKD).&lt;br&gt;The primary objective of this study is to:&lt;br&gt;•To assess the effects of three preparations of intravenous (IV) iron in a cohort of CKD patients with biochemical functional or absolute iron deficiency (ferritin level less than 200 microg/l or/and transferrin saturation of &lt;20%) on measures renal injury.&lt;br&gt;•To determine whether iron isomaltoside, iron sucrose and iron dextran differ in their effects on markers of renal injury in comparison to baseline measures during the lead in period.&lt;br&gt;•To determine whether IVI iron leads to potential transient AKI from assessment of changes in markers of renal injury from baseline markers prior to iron administration.&lt;br&gt;To determine for iron isomaltoside if there is a difference related to dose of drug (low dose and normal dose);Secondary Objective: Secondary objectives are to determine&lt;br&gt;•The effect (efficacy) of iron supplementation on haematinic profiles and haemoglobin levels.&lt;br&gt;•Incidence of significant side affects&lt;br&gt;•Whether hepcidin measurements are a reliable estimate of iron repletion and deficiency in CKD&lt;br&gt;&lt;br&gt;•Change in urinary protein excretion&lt;br&gt;•Change in patients’ Quality of Life (Measured using the SF-36v2™ questionnaire)&lt;br&gt;•NHS health care resources used;Primary end point(s): The primary outcome variable of this study is the time course of markers of renal injury, their quantification and relationship to proteinuria and renal function and NGAL. Correlation curves will be drawn of serum creatinine/eGFR versus NGAL measurements (serum and urinary), and oxidative stress markers and NGAL and renal&lt;br&gt;dysfunction. Patients will be grouped according to injury status at 24 hours as assessed by NGAL and oxidative stress measurements. Examination of the association between NGAL measurement and AKI status based on measurement at 24 hours will be carried out using logistic regression. Receiver operator analysis will be used to&lt;br&gt;assess the ability of NGAL at various cut off values to discriminate between cases and non cases of injury based on oxidative stress. A cox proportional hazards model will be used to analyze the role of uNGAL in predicting the independent risk for acute kidney injury . Unless stated otherwise, all hypotheses tested are to be conducted at an alpha = 0.05 level of significance, with two-sided analysis.</Primary_outcome>
    <Secondary_ID>version2.0</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2802522</Internal_Number>
    <TrialID>EUCTR2007-003793-26-HU</TrialID>
    <Last_Refreshed_on>25 September 2012</Last_Refreshed_on>
    <Public_title xml:space="preserve">
			</Public_title>
    <Scientific_title>Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus
vs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma - INTORACT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Wyeth Research Division of Wyeth Pharmaceuticals Inc.</Primary_sponsor>
    <Date_registration3>20080318</Date_registration3>
    <Date_registration>18/03/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-003793-26                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin xml:space="preserve">
			</Inclusion_agemin>
    <Inclusion_agemax xml:space="preserve">
			</Inclusion_agemax>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/05/2008</Date_enrollement>
    <Target_size>800</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Male or female subjects greater than or equal to 18 years.&lt;br&gt;2. Subject with histologically and/or cytologically confirmed, advanced (stage IV or recurrent) RCC, for whom a majority component of conventional clear-cell type is mandatory. (Subjects with predominantly papillary or sarcomatoid features, and subjects with chromophobe, oncocytoma, collecting duct tumors, Bellini tumors or transitional cell carcinoma are not allowed.)&lt;br&gt;3. At least 1 measurable lesion (per RECIST).&lt;br&gt;4. Karnofsky Performance Status greater than or equal to 70.&lt;br&gt;5. Screening laboratory values within the following parameters:&lt;br&gt;ANC: &gt; or equal to 1.5 x 109/L (1500/mm3)&lt;br&gt;Platelet count: &gt; or equal to 100 x 109/L (100,000/mm3)&lt;br&gt;Hemoglobin: &gt; or equal to 8.0 g/dL (80g/L) without transfusion or red blood cell growth factors within 2 weeks of first dose of test article&lt;br&gt;Serum creatinine &lt; or equal to 1.5 x upper limit of normal (ULN)&lt;br&gt;Total bilirubin &lt; or equal to 1.5 x upper limit of normal (ULN)&lt;br&gt;AST and ALT &lt; or equal to 2.5 x upper limit of normal (ULN) [&lt; or equal to 5 x upper limit of normal (ULN) with liver metastases]&lt;br&gt;Fasting serum cholesterol &lt; or equal to350 mg/dL (9.0 mmol/L)&lt;br&gt;Fasting serum triglycerides &lt; or equal to 400 mg/dL (4.56 mmol/L)&lt;br&gt;HgbA1c &lt; 10% (optimal therapy permitted)&lt;br&gt;PT and PTT =1.5 x ULN (Anticoagulation is allowed if target INR &lt;3 and INR is therapeutic on a stable dose of a coumarin type anticoagulation, or if the subject is on a stable dose of LMW heparin for &gt;2 weeks at time of randomization.) If site only reports INR and not PT, then INR must be &lt; 1.5.&lt;br&gt;6. QTc interval &lt; or equal to 450 msec for males and &lt; or equal to 470 msec for females.&lt;br&gt;7. Life expectancy of at least 12 weeks.&lt;br&gt;8. Signed and dated institutional review board (IRB) or independent ethics committee (IEC) approved informed consent form before any protocol-specific screening procedures&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Prior systemic treatment for RCC in the neoadjuvant, adjuvant or metastatic setting.  Prior treatment with bevacizumab, temsirolimus, sirolimus, IFN, sunitinib or sorafenib, for any indication.&lt;br&gt;2. Evidence of current or prior central nervous system (CNS) metastases or any imaging abnormality indicative of CNS metastases or spinal cord compression.&lt;br&gt;3. Major surgery (incl. open biopsy) or radiation therapy within 28 days prior to randomization. (Palliative radiotherapy to painful bone lesions is allowed up to 14 days prior to randomization). Subject must have recovered from prior surgery and radiation.&lt;br&gt;4. Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to randomization.&lt;br&gt;5. Cardiovascular disease defined as congestive heart failure (NYHA Class II, III, or IV), angina pectoris requiring nitrate therapy, or myocardial infarction within the last 6 months prior to randomization;&lt;br&gt;6. Inadequately controlled hypertension (defined as a blood pressure of &gt; or equal to 150 mmHg systolic and/or &gt; or equal to 100 mmHg diastolic on medication), or any prior history of hypertensive crisis or hypertensive encephalopathy.&lt;br&gt;7. History of stroke or transient ischemic attack within 6 months prior to randomization&lt;br&gt;8. Significant vascular disease (e.g., aortic aneurysm, aortic dissection), or symptomatic peripheral vascular disease&lt;br&gt;9. Known congenital long QT syndrome, history of torsades de pointes or ventricular tachycardia.&lt;br&gt;10. Known history of pulmonary hypertension or non-infectious interstitial pneumonitis.&lt;br&gt;11. More than 1 episode of DVT/PE within the last 6 months prior to randomization..&lt;br&gt;12. Evidence or history of bleeding diathesis or coagulopathy.&lt;br&gt;13. Chronic daily aspirin &gt;325 mg/day or clopidogrel (&gt;75 mg/day)&lt;br&gt;14. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to randomization&lt;br&gt;15. Any of the following serious, non-healing conditions: wound, ulcer, or bone fracture&lt;br&gt;16. Proteinuria at screening as demonstrated by either:&lt;br&gt;- Urine dipstick &gt; or equal to 2+ (subjects discovered to have a &gt; or equal to 2+ proteinuria on dipstick urinalysis at baseline should undergo 24-hour urine collection and must demonstrate &lt; or equal to 1g of protein in 24 hours to be eligible.&lt;br&gt;- 24-hour urine collection demonstrates &gt; 1g of protein in 24 hours.&lt;br&gt;17. Immunocompromised subjects, including known seropositivity for human immunodeficiency virus (HIV), or current or chronic hepatitis B and/or hepatitis C infection (as detected by positive testing for hepatitis B surface antigen [HbsAg] or antibody to hepatitis C virus [anti HCV] with confirmatory testing.  Note: Testing is not mandatory to be eligible for the study.) However if a subject is at risk for having undiagnosed HCV (due to history of injection drug use or due to geographic location for example), testing at screening should be considered.&lt;br&gt;18. Chronic treatment with corticosteroids (prednisone &gt; 12.5 mg/day or dexamethasone &gt; 2 mg/day) excluding inhaled steroids.&lt;br&gt;19. Pregnant or nursing women, women of childbearing potential not using a medically acceptable contraceptive method, or men not using a medically acceptable contraceptive method with partners of childbearing potential.  A woman of childbearing potential is defined as a woman who is biologically capable of becoming pregnant.  Subjects (men and women) must agree to use medically accepted contraceptive methods during the treat</Exclusion_Criteria>
    <Condition>First-Line Treatment in Subjects with Advanced Renal Cell Carcinoma &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050513
Term: Metastatic renal cell carcinoma
</Condition>
    <Intervention>&lt;br&gt;Trade Name: TORISEL&lt;br&gt;Product Name: TORISEL&lt;br&gt;Product Code: TORISEL&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TEMSIROLIMUS&lt;br&gt;CAS Number: 162635-04-3&lt;br&gt;Current Sponsor code: CCI-779&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;Trade Name: Avastin&lt;br&gt;Product Name: AVASTIN&lt;br&gt;Product Code: AVASTIN&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: BEVACIZUMAB &lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Trade Name: Roferon&lt;br&gt;Product Name: ROFERON&lt;br&gt;Product Code: ROFERON&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: INTERFERON ALFA-2A&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 18000000-&lt;br&gt;&lt;br&gt;Trade Name: Roferon&lt;br&gt;Product Name: ROFERON&lt;br&gt;Product Code: ROFERON&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: INTERFERON ALFA-2A&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 6000000-&lt;br&gt;&lt;br&gt;Trade Name: Roferon&lt;br&gt;Product Name: ROFERON&lt;br&gt;Product Code: ROFERON&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: INTERFERON ALFA-2A&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 12000000-&lt;br&gt;&lt;br&gt;Product Code: CCI-779&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TEMSIROLIMUS&lt;br&gt;CAS Number: 162635-04-3&lt;br&gt;Current Sponsor code: CCI-779&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the independently assessed progression free survival of subjects with clear cell type renal cell carcinoma (all risk groups) treated with bevacizumab + temsirolimus (experimental) versus bevacizumab + interferon-alfa (control) in subjects with advanced renal cell carcinoma.;Secondary Objective: Safety&lt;br&gt;Investigator assessed progression free survival&lt;br&gt;Objective response rate (CR + PR) per RECIST (independently assessed)&lt;br&gt;Overall survival&lt;br&gt;;Primary end point(s): The primary objective of this study is a comparison of independently assessed progression free survival (PFS) of subjects with clear cell type renal cell carcinoma (all risk groups) treated with bevacizumab + temsirolimus (experimental arm) versus bevacizumab + IFN (control arm) in subjects with advanced renal cell carcinoma.</Primary_outcome>
    <Secondary_ID>3066K1-3311-WW</Secondary_ID>
    <Source_Support xml:space="preserve">
			</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2802702</Internal_Number>
    <TrialID>EUCTR2009-015987-32-FR</TrialID>
    <Last_Refreshed_on>25 September 2012</Last_Refreshed_on>
    <Public_title xml:space="preserve">
			</Public_title>
    <Scientific_title>An Extension Treatment Protocol for Subjects who have Participated in a Phase 3 Study of Tivozanib vs. Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301) - 
			                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>AVEO Pharmaceuticals, Inc.</Primary_sponsor>
    <Date_registration3>20091105</Date_registration3>
    <Date_registration>05/11/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-015987-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin xml:space="preserve">
			</Inclusion_agemin>
    <Inclusion_agemax xml:space="preserve">
			</Inclusion_agemax>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>02/04/2010</Date_enrollement>
    <Target_size>500</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;Other specify the comparator: Nexavar (sorafenib)&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. The subject must have participated on Protocol AV-951-09-301, and must meet at least one of the following criteria:&lt;br&gt;- Demonstrated disease progression (DP) per RECIST during treatment with sorafenib, OR&lt;br&gt;- Demonstrated clinical benefit [complete response (CR), partial response (PR), or stable disease (SD) per RECIST] and acceptable tolerability after treatment with tivozanib or sorafenib for up to 2 years on protocol AV-951-09-301&lt;br&gt;2. ECOG performance status = 2 (see Appendix C) and life expectancy = 3 months.&lt;br&gt;3. If female and of childbearing potential, documentation of negative pregnancy test prior to enrollment.&lt;br&gt;4. Ability to give written informed consent&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. More than 4 weeks since discontinuation of tivozanib or sorafenib treatment on Protocol AV-951-09-301&lt;br&gt;2. Any of the following hematologic abnormalities:&lt;br&gt;• Hemoglobin &lt; 9.0 g/dL&lt;br&gt;• ANC &lt; 1500 per mm3&lt;br&gt;• Platelet count &lt; 75,000 per mm3&lt;br&gt;• PT or PTT &gt;1.5 × ULN&lt;br&gt;3. Any of the following serum chemistry abnormalities:&lt;br&gt;• Total bilirubin &gt; 1.5 × ULN (or &gt; 2.5 × ULN for subjects with Gilbert’s syndrome)&lt;br&gt;• AST or ALT &gt; 2.5 × ULN (or &gt; 5 × ULN for subjects with liver metastasis)&lt;br&gt;• Alkaline phosphatase &gt; 2.5 × ULN (or &gt; 5 × ULN for subjects with liver or bone metastasis)&lt;br&gt;• Creatinine &gt; 2.0 × ULN&lt;br&gt;• Proteinuria &gt; 3+ by urinalysis or urine dipstick&lt;br&gt;4 . If female, pregnant or lactating&lt;br&gt;5. Sexually active male and pre-menopausal female subjects (and their partners) unless they agree to use adequate contraceptive measures, while on study and for 30 days after the last dose of study drug. All fertile male and female subjects (and their partners) must agree to use a highly effective method of contraception. Effective birth control includes (a) IUD plus one barrier method; or (b) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm). (Note: Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are not considered effective for this study.)&lt;br&gt;6. Uncontrolled hypertension: systolic blood pressure &gt; 150 mmHg or diastolic blood pressure &gt;100 mmHg on 2 or more antihypertensive medications, documented on 2 consecutive measurements taken at least 24 hours apart.&lt;br&gt;7. Unhealed wounds (including active peptic ulcers)&lt;br&gt;8. Serious/active infection or infection requiring parenteral antibiotics&lt;br&gt;9. Life-threatening illness or organ system dysfunction compromising safety evaluation&lt;br&gt;10. Psychiatric disorder, altered mental status precluding informed consent or necessary testing&lt;br&gt;11. Inability to comply with protocol requirements&lt;br&gt;</Exclusion_Criteria>
    <Condition>Advanced Renal Cell Carcinoma &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10050513
Term: Metastatic renal cell carcinoma
</Condition>
    <Intervention>&lt;br&gt;Product Name: Tivozanib (AV-951)&lt;br&gt;Product Code: 1.0 mg&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;CAS Number: 682745-41-1&lt;br&gt;Current Sponsor code: Tivozanib (AV-951)&lt;br&gt;Other descriptive name: KRN951&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.0-&lt;br&gt;&lt;br&gt;Product Name: Tivozanib (AV-951)&lt;br&gt;Product Code: 1.5 mg&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;CAS Number: 682745-41-1&lt;br&gt;Current Sponsor code: Tivozanib (AV-951)&lt;br&gt;Other descriptive name: KRN951&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.5-&lt;br&gt;&lt;br&gt;Trade Name: Nexavar&lt;br&gt;Product Name: Sorafenib&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: SORAFENIB&lt;br&gt;CAS Number: 284461-73-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: • To allow access to tivozanib for subjects who participated in Protocol AV-951-09-301, and failed sorafenib treatment on protocol.&lt;br&gt;• To allow long-term access to tivozanib for subjects who participated in Protocol AV-951-09-301 and demonstrated clinical benefit and acceptable tolerability to tivozanib&lt;br&gt;• To allow long-term access to sorafenib for subjects who participated in Protocol AV-951-09-301 and demonstrated clinical benefit and acceptable tolerability to sorafenib&lt;br&gt;• To assess long-term safety in subjects who continue treatment with tivozanib;Secondary Objective: • To determine the objective response rate (ORR), duration of response (DR), and progression-free survival (PFS) of subjects who continue treatment with tivozanib or sorafenib&lt;br&gt;• To determine the ORR, DR, and PFS of subjects who receive tivozanib after failure of sorafenib&lt;br&gt;• To determine overall survival (OS) of subjects who continue treatment with tivozanib or sorafenib;Primary end point(s): Study drug may be continued in the absence of disease progression or intolerable toxicities&lt;br&gt;&lt;br&gt;Discontinuation: Subjects experiencing unacceptable toxicities or with documented disease progression will be discontinued from further participation in this study. However, if a subject is continuing on sorafenib from Protocol AV-951-09-301 and demonstrates disease progression on sorafenib during this protocol, the subject may begin treatment with tivozanib and continue treatment until documented disease progression or unacceptable toxicity related to tivozanib. This study will be discontinued when tivozanib becomes commercially available in the country where the subject is being treated. If a subject is experiencing clinical benefit from tivozanib when the study is discontinued, the sponsor will assist the subject in obtaining commercially available tivozanib.</Primary_outcome>
    <Secondary_ID>AV-951-09-902</Secondary_ID>
    <Source_Support xml:space="preserve">
			</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2804387</Internal_Number>
    <TrialID>EUCTR2011-002577-33-GB</TrialID>
    <Last_Refreshed_on>25 September 2012</Last_Refreshed_on>
    <Public_title>Chemotherapy following surgery or close follow up in upper tract urothelial cancer</Public_title>
    <Scientific_title>A Phase III randomised trial of Peri-Operative chemotherapy versus sUrveillance in upper Tract urothelial cancer - POUT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Institute of Cancer Research</Primary_sponsor>
    <Date_registration3>20111209</Date_registration3>
    <Date_registration>09/12/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-002577-33                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin xml:space="preserve">
			</Inclusion_agemin>
    <Inclusion_agemax xml:space="preserve">
			</Inclusion_agemax>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>04/01/2012</Date_enrollement>
    <Target_size>345</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Surveillance for signs of recurrence&lt;br&gt;Number of treatment arms in the trial: 1&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.Written informed consent&lt;br&gt;2.=18 years of age&lt;br&gt;3.Post radical nephroureterectomy for upper tract tumour with predominant TCC component - squamoid differentiation or mixed TCC/SCC is permitted. &lt;br&gt;4.Histologically confirmed TCC staged pT2-pT4 pN0-3 M0 or pTany N1-3 M0 (providing all grossly abnormal nodes are resected). Patients with microscopically positive margins on pathology may be entered (providing all grossly abnormal disease was resected).&lt;br&gt;5.Satisfactory haematological profile (ANC&gt; 1.5 x 109/L, platelet count 100 x 10/L ) and liver function tests (bilirubin &lt; 1.5 x ULN, AST and Alkaline phosphatase &lt; 2.5 x ULN), Glomerular filtration rate = 30 mls/min. &lt;br&gt;6.Fit and willing to receive adjuvant chemotherapy with first cycle to be commenced within 90 days of radical nephro-ureterectomy if allocated&lt;br&gt;7.WHO performance status 0-1.&lt;br&gt;8.Available for long-term follow-up&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: 0&lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 145&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 200&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.Evidence of distant metastases&lt;br&gt;2.Pure adenocarcinoma, squamous cell carcinoma or small cell or other variant histology&lt;br&gt;3.Un-resected macroscopic nodal disease&lt;br&gt;4.Concurrent muscle invasive bladder cancer  (patients with concurrent Non-muscle invasive bladder cancer (NMIBC) will be eligible)&lt;br&gt;5.GFR &lt;30 mls/minute. NB Gemcitabine-carboplatin can only be given for patients with suboptimal renal function for cisplatin ie for  GFR 30-49mls/min. Patients with poor performance status or co-morbidities that would make them unfit for chemotherapy are ineligible for the trial&lt;br&gt;6.Significant co-morbid conditions that would interfere with administration of protocol treatment&lt;br&gt;7.Pregnancy; lactating women or women of childbearing potential unwilling or unable to use adequate non-hormonal contraception (male patients should also use contraception if sexually active);&lt;br&gt;8.Previous malignancy in the last 5 years except for previous NMIBC, adequately controlled non melanoma skin tumours, CIS of cervix or LCIS of breast or localised prostate cancer in patients who have a life expectancy of over 5 years upon trial entry.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Upper urinary tract transitional cell carcinoma &lt;br&gt;MedDRA version: 15.0
Level: PT
Classification code 10044407
Term: Transitional cell cancer of the renal pelvis and ureter
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
;Therapeutic area: Diseases [C] - Cancer [C04]</Condition>
    <Intervention>&lt;br&gt;Product Name: Gemcitabine&lt;br&gt;Pharmaceutical Form: Powder for solution for infusion&lt;br&gt;INN or Proposed INN: Gemcitabine&lt;br&gt;CAS Number: 95058-81-4&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 38-&lt;br&gt;&lt;br&gt;Trade Name: Cisplatin&lt;br&gt;Product Name: Cisplatin&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Cisplatin&lt;br&gt;CAS Number: 15663-27-1&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Product Name: Carboplatin&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Carboplatin&lt;br&gt;CAS Number: 41575-94-4&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;Product Name: Gemcitabine&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Gemcitabine&lt;br&gt;CAS Number: 95058814&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 38-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Does chemotherapy given around the time of surgery (peri-operative) extend the amount of time for which participants remain free of recurrent disease?;Secondary Objective: - Does peri-operative chemotherapy increase overall survival time?&lt;br&gt;&lt;br&gt;- Does peri-operative chemotherapy extend the amount of time for which participants remain free of widespread (metastatic) disease?&lt;br&gt;&lt;br&gt;- Does peri-operative chemotherapy reduce the occurence of second upper urinary tract or bladder carcinomas?&lt;br&gt;&lt;br&gt;- What are the side effects associated with peri-operative chemotherapy?&lt;br&gt;&lt;br&gt;- How well do participants allocated to chemotherapy adhere to the treatment regimen?&lt;br&gt;&lt;br&gt;- How do peri-operative chemotherapy and surveillance affect participants' quality of life?&lt;br&gt;&lt;br&gt;- What impact do the findings of an embedded qualitative research study into recruitment have on accrual rates and study setup at subsequent sites?;Primary end point(s): The primary outcome measure is disease-free survival (DFS).  The main time point of interest is three years after randomisation. DFS is defined as the time from randomisation to the first of:&lt;br&gt;•	Death (any cause)&lt;br&gt;•	Metastases&lt;br&gt;•	Any ureteral or renal bed recurrence (invasive or non-muscle invasive)&lt;br&gt;;Timepoint(s) of evaluation of this end point: The primary analysis of DFS will be event driven. The primary time-point of interest is 3 years and the Independent Monitoring Committee will advise the Trial Management Group when the primary endpoint should be analysed.</Primary_outcome>
    <Secondary_outcome>Timepoint(s) of evaluation of this end point: Trial feasibility will be assessed continuously during the first two years of recruitment. Acute toxicity will be analysed after all patients have completed 6 months of follow up.  All other secondary endpoints will be evaluated after the requirements for analysis of the primary endpoint have been met.;Secondary end point(s): •	Trial feasibility, defined by recruitment rate over first two years&lt;br&gt;•	Overall survival, defined as the time from randomisation to death from any cause&lt;br&gt;•	Recurrence/second primary in the bladder&lt;br&gt;•	Contralateral second primary utTCC&lt;br&gt;•	Acute toxicity (on-treatment / up to 3 months post-randomisation)&lt;br&gt;•	Late toxicity (6 months – 5 years)&lt;br&gt;•	Treatment compliance (in the chemotherapy arm)&lt;br&gt;•	Metastasis free survival&lt;br&gt;•	Quality of life (QoL) as measured by the EORTC QLQ-C30 and EQ5D modules.  Domains of interest include Global health/QL, functioning domains and items relating to fatigue and side-effects associated with Gem-Cis/Gem-Carbo.&lt;br&gt;</Secondary_outcome>
    <Secondary_ID>ICR-CTSU/2011/10031;CCR3675;ICR-CTSU/2011/10031</Secondary_ID>
    <Source_Support>Cancer Research UK</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2807015</Internal_Number>
    <TrialID>EUCTR2007-005460-28-ES</TrialID>
    <Last_Refreshed_on>2 October 2012</Last_Refreshed_on>
    <Public_title>Estudio multicéntrico, abierto, de acceso expandido de RAD001, en pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con  inhibidor de tirosina quinasas del receptor del factor de crecimiento endotelial vascular.</Public_title>
    <Scientific_title>Estudio multicéntrico, abierto, de acceso expandido de RAD001, en pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con  inhibidor de tirosina quinasas del receptor del factor de crecimiento endotelial vascular.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Novartis Farmacéutica, S.A</Primary_sponsor>
    <Date_registration3>20080521</Date_registration3>
    <Date_registration>21/05/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005460-28                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/07/2008</Date_enrollement>
    <Target_size>1000</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;• Age = 18 years old.&lt;br&gt;• Patients with metastatic carcinoma and with histological or cytological confirmation of clear cell RCC (tissue from the original diagnosis of renal cell cancer is acceptable).&lt;br&gt;• Patients must have progression on or after stopping treatment with any component of VEGF receptor tyrosine kinase inhibitor therapy (sunitinib and/or sorafenib).&lt;br&gt;• Prior vaccine therapy or treatment with cytokines (i.e., IL-2, Interferon) and/or VEGF-ligand inhibitors (i.e., bevacizumab) is permitted. &lt;br&gt;• Patients with measurable or non-measurable disease by RECIST criteria.&lt;br&gt;• Patients with history of another distinguishable malignancy (such as non-melanoma skin cancer, or low grade lymphoma, or CLL, or well controlled low grade prostate cancer), which are neither life threatening nor require chemotherapy or radiation. &lt;br&gt;• Patients with history of brain metastasis who are neurologically stable following definitive radiation or surgery and do not require corticosteroids. &lt;br&gt;• Patients with a Karnofsky Performance Status =70%.&lt;br&gt;• Patients with adequate bone marrow function defined as ANC = 1.5 x 109/L, Platelets = 100 x 109/L, Hgb &gt;9 g/dL.&lt;br&gt;• Patients with adequate liver function defined as serum bilirubin = 1.5 x ULN, ALT and AST = 2.5x ULN. Patients with known liver metastases who have an AST and ALT = 5x ULN.&lt;br&gt;• Patients with adequate renal function defined as serum creatinine = 2 x ULN.&lt;br&gt;• Women of childbearing potential must have had a negative serum or urine pregnancy test within 14 days prior to the administration of study drug.&lt;br&gt;• Patients must give written informed consent according to local guidelines.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;• Patients receiving chemotherapy, immunotherapy, radio-therapy or any other investigational agent within 4 weeks of study entry, or sunitinib and/or sorafenib within 1 week of the first dose of RAD001.&lt;br&gt;• Patients who have previously received RAD001 or other mTOR inhibitors.&lt;br&gt;• Patients with a known hypersensitivity to RAD001 or other rapamycin analogs (sirolimus, temsirolimus), or to its excipients.&lt;br&gt;• Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent (except corticosteroids with a daily dosage equivalent to prednisone = 20 mg for adrenal insufficiency). Patients receiving corticosteroids must be on a stable dose = 4 weeks prior to the first dose of RAD001. Topical or inhaled corticosteroids are permitted.&lt;br&gt;• Patients with an active bleeding diathesis.&lt;br&gt;• Patients with any severe and/or uncontrolled medical conditions such as unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction = 6 months, serious uncontrolled cardiac arrhythmia, uncontrolled hyperlipidemia, active or uncontrolled severe infection, cirrhosis, chronic or persistent active hepatitis or severely impaired lung function.&lt;br&gt;• Uncontrolled diabetes (fasting glucose &gt; 2x ULN)&lt;br&gt;• Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods.  If barrier contraceptives are used, they must be continued throughout the study by both sexes.&lt;br&gt;• Patients unwilling to or unable to comply with the protocol.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con inhibidor de tirosina quinasas del receptor del factor de crecimiento endotelial vascular
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050513
Term: Metastatic renal cell carcinoma
</Condition>
    <Intervention>&lt;br&gt;Product Name: RAD001&lt;br&gt;Product Code: RAD001&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Current Sponsor code: RAD001&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5 mg-&lt;br&gt;&lt;br&gt;Product Name: RAD001&lt;br&gt;Product Code: RAD001&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Current Sponsor code: RAD001&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10 mg-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: - To provide expanded access to RAD001 in patients with MRCC whose disease has progressed despite prior VEGF receptor tyrosine kinase inhibitor therapy, until the product is commercially available for MRCC in each participating country.&lt;br&gt;- To evaluate the safety profile of RAD001 in patients with MRCC whose disease has progressed despite prior VEGF receptor tyrosine kinase inhibitor therapy&lt;br&gt;;Secondary Objective: - To evaluate the investigator’s best overall response rate of RAD001 in patients with MRCC whose disease has progressed despite prior VEGF receptor tyrosine kinase inhibitor therapy, until the product is commercially available for MRCC in each participating country.;Primary end point(s): Safety:&lt;br&gt;• Grade 3 and 4 Adverse Events, Serious Adverse Events&lt;br&gt;</Primary_outcome>
    <Secondary_ID>CRAD001L2401</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2807354</Internal_Number>
    <TrialID>EUCTR2009-012259-21-ES</TrialID>
    <Last_Refreshed_on>2 October 2012</Last_Refreshed_on>
    <Public_title>A Long-term, Open-label, Non-comparative Study to Evaluate the
Safety and Efficacy of a Modigraf® Based Immunosuppression
Regimen in Paediatric Solid Allograft Recipients.Estudio abierto, no comparativo, a largo plazo, para evaluar eficacia y seguridad de un régimen inmunosupresor basado en Modigraf® en pacientes pediátricos receptores de un aloinjerto de órgano sólido. - PROGRESSION study</Public_title>
    <Scientific_title>A Long-term, Open-label, Non-comparative Study to Evaluate the
Safety and Efficacy of a Modigraf® Based Immunosuppression
Regimen in Paediatric Solid Allograft Recipients.Estudio abierto, no comparativo, a largo plazo, para evaluar eficacia y seguridad de un régimen inmunosupresor basado en Modigraf® en pacientes pediátricos receptores de un aloinjerto de órgano sólido. - PROGRESSION study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Astellas Pharma Europe Ltd.</Primary_sponsor>
    <Date_registration3>20110107</Date_registration3>
    <Date_registration>07/01/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-012259-21                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>02/03/2011</Date_enrollement>
    <Target_size>36</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;F506-CL-0404A&lt;br&gt;CRITERIOS DE INCLUSIÓN:&lt;br&gt;1.	El paciente era  12 años de edad en el momento de inclusión en el estudio F506-CL-0403.&lt;br&gt;2.	El paciente recibió al menos una dosis de Modigraf® en el estudio F506-CL-0403.&lt;br&gt;3.	En opinión del médico investigador del paciente, éste se beneficiaría si continuara el tratamiento con Modigraf®.&lt;br&gt;4.	Los padres del paciente o sus representantes legales han sido informados y han dado su consentimiento informado por escrito para participar en el estudio. Si procede, el paciente ha dado su consentimiento.&lt;br&gt;F506-CL-0404B&lt;br&gt;CRITERIOS DE INCLUSIÓN:&lt;br&gt;1.	El paciente recibió al menos una dosis de Modigraf® en el estudio F506-CL-0403.&lt;br&gt;2.	El paciente participó en el estudio F506-CL-0404A&lt;br&gt;3.	El paciente ha recibido administración continuada de Modigraf® BID desde la Visita EOS-A del estudio F506-CL-0404A.&lt;br&gt;4.	En opinión del médico investigador del paciente, éste se beneficiaría de la conversión a Prograf®.&lt;br&gt;5.	Los padres del paciente o sus representantes legales han sido informados y han dado su consentimiento informado por escrito para participar en el estudio. Si procede, el paciente ha dado su consentimiento.&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;F506-CL-0404A&lt;br&gt;Como todos los pacientes incluidos en este estudio habrán pasado los criterios de exclusión del estudio F506-CL-0403, no hay criterios de exclusión específicos relevantes para este estudio.&lt;br&gt;&lt;br&gt;F506-CL-0404B&lt;br&gt;No hay criterios de exclusión específicos para este estudio.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Stable paediatric allograft recipients.Pacientes estables receptores de un aloinjerto &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10050432
Term: Prophylaxis against heart transplant rejection
 &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10050434
Term: Prophylaxis against liver transplant rejection
 &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10050436
Term: Prophylaxis against renal transplant rejection
</Condition>
    <Intervention>&lt;br&gt;Trade Name: MODIGRAF 0,2 mg granulado para suspensión oral&lt;br&gt;Pharmaceutical Form: Granules for oral suspension&lt;br&gt;INN or Proposed INN: TACROLIMUS MONOHIDRATO&lt;br&gt;Other descriptive name: TACROLIMUS MONOHIDRATO&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.2-&lt;br&gt;&lt;br&gt;Trade Name: MODIGRAF 1 mg granulado para suspensión oral&lt;br&gt;Pharmaceutical Form: Granules for oral suspension&lt;br&gt;INN or Proposed INN: TACROLIMUS MONOHIDRATO&lt;br&gt;Other descriptive name: TACROLIMUS MONOHIDRATO&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: PROGRAF  0,5 mg cápsulas duras&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;Other descriptive name: TACROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Trade Name: PROGRAF 1 mg cápsulas duras&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;Other descriptive name: TACROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: PROGRAF 5 mg cápsulas duras&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;Other descriptive name: TACROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Este estudio se divide en dos partes, denominadas F506-CL-0404A y F506-CL-0404B.&lt;br&gt;	Monitorizar la seguridad y eficacia de Modigraf® (tacrolimus granulado para suspensión oral) en pacientes pediátricos receptores de aloinjerto en fase estable.&lt;br&gt;&lt;br&gt;	Monitorizar los cambios de dosis y los niveles mínimos de tacrolimus en sangre tras la conversión desde un régimen de inmunosupresión basado en Modigraf® a un régimen de inmunosupresión basado en Prograf®.;Secondary Objective: No procede;Primary end point(s): Variables del F506-CL-0404A&lt;br&gt;La eficacia de Modigraf® se describirá a partir de los siguientes parámetros:&lt;br&gt;	Episodios de rechazo&lt;br&gt;	Supervivencia del paciente y del injerto&lt;br&gt;	La seguridad de Modigraf® se describirá a partir de los siguientes parámetros:&lt;br&gt;	Incidencia de acontecimientos adversos (AA).&lt;br&gt;	Parámetros de laboratorio&lt;br&gt;	Constantes vitales&lt;br&gt;	Variables del F506-CL-0404B&lt;br&gt;Entre la visita 1 y la Visita de EOS -B se registrarán los siguientes parámetros:&lt;br&gt;	Niveles mínimos de tacrolimus en sangre&lt;br&gt;	Número de cambios de dosis&lt;br&gt;	Incidencia de AA&lt;br&gt;	Parámetros de laboratorio (cuando corresponda)&lt;br&gt;	Constantes vitales (cuando corresponda)</Primary_outcome>
    <Secondary_ID>F506-CL-0404</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2807398</Internal_Number>
    <TrialID>EUCTR2009-012258-19-ES</TrialID>
    <Last_Refreshed_on>2 October 2012</Last_Refreshed_on>
    <Public_title>A Multicentre, Open-label, Pharmacokinetic Study of Modigraf® (Tacrolimus granules) in de novo Paediatric Allograft Recipients.Estudio Abierto, Multicéntrico,  Farmacocinético de Modigraf® (Tacrólimus Granulado para suspensión oral) en pacientes pediátricos que reciben un aloinjerto de novo. - OPTION study</Public_title>
    <Scientific_title>A Multicentre, Open-label, Pharmacokinetic Study of Modigraf® (Tacrolimus granules) in de novo Paediatric Allograft Recipients.Estudio Abierto, Multicéntrico,  Farmacocinético de Modigraf® (Tacrólimus Granulado para suspensión oral) en pacientes pediátricos que reciben un aloinjerto de novo. - OPTION study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Astellas Pharma Europe Ltd.</Primary_sponsor>
    <Date_registration3>20110107</Date_registration3>
    <Date_registration>07/01/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-012258-19                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>09/03/2011</Date_enrollement>
    <Target_size>36</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	El paciente tiene 12 o menos de 12 años de edad.&lt;br&gt;2.	El paciente es receptor de un trasplante de órgano sólido (hígado, riñón o corazón). Están permitidos los trasplantes multiorgánicos, siempre que al menos uno de los órganos trasplantados sea hígado, riñón o corazón.&lt;br&gt;3.	Los padres del paciente o sus representantes legales han sido informados y han dado su consentimiento informado por escrito para participar en el estudio. Si procede, el paciente ha dado su consentimiento.&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	El paciente ha recibido previamente otro trasplante de órgano (incluido el retrasplante de hígado, riñón o corazón).&lt;br&gt;2.	El paciente presenta un riesgo inmunológico elevado, definido como una puntuación del estudio de reactividad de anticuerpos (PRA) &gt; 50% en los 6 meses previos (solo aplicable para los receptores de trasplante renal).&lt;br&gt;3.	Tiempo de isquemia fría del riñón donante mayor de 30 horas (solo aplicable para los receptores de trasplante renal).&lt;br&gt;4.	El paciente recibe un órgano de donante con incompatibilidad AB0.&lt;br&gt;5.	El paciente presenta una alteración renal significativa, definida como una creatinina sérica  230 &amp;#956;mol/l ( 2,6 mg/dl) antes del trasplante (no aplicable para los receptores de trasplante renal).&lt;br&gt;6.	El paciente presenta enfermedad hepática significativa, definida como elevación del nivel de ALT y/o AST y/o bilirrubina total 3 veces por encima del valor superior del límite de la normalidad durante los 28 días previos al trasplante (no aplicable para los receptores de trasplante hepático).&lt;br&gt;7.	Paciente con resistencia vascular pulmonar mayor de 4 unidades Wood, que no responde al tratamiento.&lt;br&gt;8.	Paciente con patología cancerígena o historial de cáncer en los últimos 5 años.&lt;br&gt;9.	El paciente presenta infección sistémica significativa no controlada y/o trastorno del tracto gastrointestinal superior activo, vómitos o diarrea grave, que pudiesen alterar la absorción de tacrolimus, o presenta una úlcera péptica.&lt;br&gt;10.	El paciente requiere medicación inmunosupresora sistémica para cualquier otra indicación diferente al trasplante.&lt;br&gt;11.	Se sabe que el receptor o el donante son positivos para VIH, VHC o VHB.&lt;br&gt;12.	Intolerancia o alergia conocida a los esteroides, antibióticos macrólidos, basiliximab o tacrolimus.&lt;br&gt;13.	El paciente participa actualmente en otro ensayo clínico y/o ha estado recibiendo un fármaco en investigación en los 3 meses previos al trasplante.&lt;br&gt;14.	Poca probabilidad de que el paciente acuda a las visitas programadas en el protocolo.&lt;br&gt;15.	Los pacientes reciben o requieren tratamiento con medicación o sustancias prohibidas por este protocolo&lt;br&gt;</Exclusion_Criteria>
    <Condition>De novo allograft transplantation (liver, heart, kidney) in paediatric patients. Pacientes pediátricos que reciben un trasplante de aloinjerto de novo ( hígado, corazón y riñón) &lt;br&gt;MedDRA version: 13.1
Level: LLT
Classification code 10024716
Term: Liver transplantation
System Organ Class: 10042613 - Surgical and medical procedures
 &lt;br&gt;MedDRA version: 13.1
Level: PT
Classification code 10019314
Term: Heart transplant
System Organ Class: 10042613 - Surgical and medical procedures
 &lt;br&gt;MedDRA version: 13.1
Level: LLT
Classification code 10023438
Term: Kidney transplant
System Organ Class: 10042613 - Surgical and medical procedures
</Condition>
    <Intervention>&lt;br&gt;Trade Name: MODIGRAF 0,2 mg granulado para suspensión oral&lt;br&gt;Pharmaceutical Form: Granules for oral suspension&lt;br&gt;INN or Proposed INN: TACROLIMUS MONOHIDRATO&lt;br&gt;Other descriptive name: TACROLIMUS MONOHIDRATO&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.2-&lt;br&gt;&lt;br&gt;Trade Name: MODIGRAF 1 mg granulado para suspensión oral&lt;br&gt;Pharmaceutical Form: Granules for oral suspension&lt;br&gt;INN or Proposed INN: TACROLIMUS MONOHIDRATO&lt;br&gt;Other descriptive name: TACROLIMUS MONOHIDRATO&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Determinar la farmacocinética (PK) de tacrolimus tras la administración oral de Modigraf®, después de la primera dosis oral y en la fase estable, en pacientes pediátricos que reciben un trasplante de aloinjerto de novo.;Secondary Objective: Seguridad y eficacia de Modigraf®.;Primary end point(s): Se determinarán los siguientes parámetros PK de tacrolimus tras la dosis matutina del día 1 y el día 7 (+ 7 días):&lt;br&gt;	AUCtau&lt;br&gt;	Cmáx.&lt;br&gt;	tmáx&lt;br&gt;	Cmín</Primary_outcome>
    <Secondary_ID>F506-CL-0403</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2807619</Internal_Number>
    <TrialID>EUCTR2011-004540-22-BE</TrialID>
    <Last_Refreshed_on>2 October 2012</Last_Refreshed_on>
    <Public_title>Desmopressin melt therapy in nocturnal polyuria patients: pharmacokinetic/dynamic study</Public_title>
    <Scientific_title>Desmopressin melt therapy in nocturnal polyuria patients: pharmacokinetic/dynamic study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Ghent University Hospital</Primary_sponsor>
    <Date_registration3>20110914</Date_registration3>
    <Date_registration>14/09/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-004540-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>25/10/2011</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Written informed consent prior to the performance of any study-related activity
&lt;br&gt;- Patients 18 years and older with an average of = 2 nocturnal voids per night &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 40&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 10&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- hypersensitivity/anaphylactic reaction on desmopressin or one of the other substances
&lt;br&gt;- pregnancy
&lt;br&gt;- genito-urinary tract pathology (infection, tumor,...)
&lt;br&gt;- urolithiasis
&lt;br&gt;- suspicion or evidence of cardiac failure
&lt;br&gt;- moderate to severe renal insufficiency (creatinin clearance &lt; 50 ml/min) 
&lt;br&gt;- psychogenic or habitual polydipsia
&lt;br&gt;- hyponatriemia or predisposition for hyponatriemia
&lt;br&gt;- diabetes insipidus
&lt;br&gt;- syndrome of inadequate ADH production&lt;br&gt;</Exclusion_Criteria>
    <Condition>Nocturia and noctural polyuria &lt;br&gt;MedDRA version: 14.0
Level: LLT
Classification code 10064016
Term: Nocturnal polyuria
System Organ Class: 10038359 - Renal and urinary disorders
;Therapeutic area: Body processes [G] - Biological Phenomena [G16]</Condition>
    <Intervention>&lt;br&gt;Trade Name: Minirin Melt 120 µg&lt;br&gt;Product Name: Desmopressin&lt;br&gt;Pharmaceutical Form: Oral lyophilisate&lt;br&gt;INN or Proposed INN: DESMOPRESSIN ACETATE&lt;br&gt;CAS Number: 62357-86-2&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 120-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine the pharmacokinetic/dynamic (PK/PD) characteristics of desmopressin melt in nocturia patients ;Secondary Objective: To determine the reduction of the urine production;Primary end point(s): Blood levels of desmopressin;Timepoint(s) of evaluation of this end point: After 1,2,3,6 and 12 hours of intake of desmopressin melt</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Urine production;Timepoint(s) of evaluation of this end point: After 1,2,3,6 and 12 hours of intake of desmopressin melt</Secondary_outcome>
    <Secondary_ID>AGO/2011/009</Secondary_ID>
    <Source_Support>Ghent University Hospital</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2808107</Internal_Number>
    <TrialID>EUCTR2011-002267-26-AT</TrialID>
    <Last_Refreshed_on>2 October 2012</Last_Refreshed_on>
    <Public_title>Hepatitis C in renal transplant recipients – Safety and efficacy of a conversion of immunosuppression to high-dose cyclosporine A and its impact on HCV-replication, parameters of liver function and glucose tolerance. An open label trial. 
</Public_title>
    <Scientific_title>Hepatitis C in renal transplant recipients – Safety and efficacy of a conversion of immunosuppression to high-dose cyclosporine A and its impact on HCV-replication, parameters of liver function and glucose tolerance. An open label trial. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Medizinische Universität Wien</Primary_sponsor>
    <Date_registration3>20120319</Date_registration3>
    <Date_registration>19/03/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-002267-26                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/04/2012</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 1&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;-  Written informed consent&lt;br&gt;-  Prior renal transplantation with a current tacrolimus-based immunosuppressive regimen&lt;br&gt;-  Hepatitis C-infection&lt;br&gt;-  Age 18-70 years&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 45&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 5&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-  Current hemodialysis or peritoneal dialysis&lt;br&gt;-  Pregnancy or breastfeeding&lt;br&gt;-  Known CsA-intolerance&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>renal transplant recipients with hepatitis C &lt;br&gt;MedDRA version: 14.1
Level: LLT
Classification code 10057394
Term: Hepatitis C positive
System Organ Class: 10022891 - Investigations
;Therapeutic area: Diseases [C] - Virus Diseases [C02]</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sandimmun Neoral 25 mg&lt;br&gt;Product Name: cyclosporine A&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun Neoral 50 mg&lt;br&gt;Product Name: cyclosporine A&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun Neoral 100 mg&lt;br&gt;Product Name: cyclosporine A&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess the impact of a conversion to a cyclosporine A-based immunosuppressive regimen on HCV-replication and parameters of liver function in renal transplant recipients ;Secondary Objective: To assess the impact of a conversion to a cyclosporine A-based immunosuppressive regimen on parameters of insulin sensitivity and insulin secretion in renal transplant recipients ;Primary end point(s): HCV-RNA;Timepoint(s) of evaluation of this end point: 12 weeks after the conversion of immunosuppression from a tacrolimus- to a cyclosporine a-based regimen</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): liver transaminases, fibroScan-Indices, IL28-SNP, vitamin D, parameters of insulin sensitivity and insulin secretion, plasma adipokine levels&lt;br&gt;;Timepoint(s) of evaluation of this end point: 12 weeks after the conversion of immunosuppression from a tacrolimus- to a cyclosporine a-based regimen</Secondary_outcome>
    <Secondary_ID>13071981</Secondary_ID>
    <Source_Support>Medical University of Vienna</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2808125</Internal_Number>
    <TrialID>EUCTR2011-004560-29-BE</TrialID>
    <Last_Refreshed_on>2 October 2012</Last_Refreshed_on>
    <Public_title>Desmopressin melt therapy in nocturnal polyuria patients: pharmacodynamic study</Public_title>
    <Scientific_title>Desmopressin melt therapy in nocturnal polyuria patients: pharmacodynamic study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Ghent University Hospital</Primary_sponsor>
    <Date_registration3>20110914</Date_registration3>
    <Date_registration>14/09/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-004560-29                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>25/10/2011</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Written informed consent prior to the performance of any study-related activity
&lt;br&gt;- Patients 18 years and older with an average of = 2 nocturnal voids per night 
&lt;br&gt;- Evidence for nocturnal polyuria (nocturnal urine volume &gt;33% of total volume over 24h), determined on frequency/volume chart
&lt;br&gt;- Diuresis &lt; 2,5L
&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 40&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 10&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- hypersensitivity/anaphylactic reaction on desmopressin or one of the other substances
&lt;br&gt;- pregnancy
&lt;br&gt;- genito-urinary tract pathology (infection, tumor,...)
&lt;br&gt;- urolithiasis
&lt;br&gt;- suspicion or evidence of cardiac failure
&lt;br&gt;- suspicion or evidence of liver failure
&lt;br&gt;- moderate to severe renal insufficiency (creatinin clearance &lt; 60 ml/min)
&lt;br&gt;- psychogenic or habitual polydipsia
&lt;br&gt;- hyponatriemia or predisposition for hyponatriemia (sodium &lt; 135 mmol/L) before inclusion
&lt;br&gt;- diabetes insipidus
&lt;br&gt;- syndrome of inadequate ADH production &lt;br&gt;</Exclusion_Criteria>
    <Condition>Noctural polyuria &lt;br&gt;MedDRA version: 14.1
Level: LLT
Classification code 10064016
Term: Nocturnal polyuria
System Organ Class: 10038359 - Renal and urinary disorders
;Therapeutic area: Body processes [G] - Physiological processes [G07]</Condition>
    <Intervention>&lt;br&gt;Trade Name: Minirin Melt 60 µg lyophilisaat voor oraal gebruik&lt;br&gt;Product Name: Desmopressin&lt;br&gt;Pharmaceutical Form: Oral lyophilisate&lt;br&gt;INN or Proposed INN: DESMOPRESSIN ACETATE&lt;br&gt;CAS Number: 62357-86-2&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 60-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine the pharmacodynamic (PD) characteristics of desmopressin melt in nocturia patients;Secondary Objective: Safety;Primary end point(s): Urine production;Timepoint(s) of evaluation of this end point: Everyday during the first fourteen days</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Blood analysis for safety profile ;Timepoint(s) of evaluation of this end point: On day 3, 7 and 30 after the start of the treatment with desmopressin melt</Secondary_outcome>
    <Secondary_ID>AGO/2011/010</Secondary_ID>
    <Source_Support>Ghent University Hospital</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2808184</Internal_Number>
    <TrialID>EUCTR2011-000250-28-BE</TrialID>
    <Last_Refreshed_on>2 October 2012</Last_Refreshed_on>
    <Public_title>The purpose of this study is to evaluate blood levels of solifenacin succinate (the study drug) in children after taking a single oral dose.</Public_title>
    <Scientific_title>A Multicenter, Open-label, Single-dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Solifenacin Succinate Suspension in Pediatric Subjects from 5 to less than 18 years of age with Neurogenic Detrusor Overactivity (NDO) - SINGLE DOSE STUDY TO MEASURE BLOOD LEVELS AND SAFETY OF A DRUG FOR CHILDREN WITH OVERACTIVE BLADDER                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Astellas Pharma Europe B.V.</Primary_sponsor>
    <Date_registration3>20110927</Date_registration3>
    <Date_registration>27/09/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-000250-28                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>15/11/2011</Date_enrollement>
    <Target_size>12</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;At screening:
&lt;br&gt;1. Subject is male or female from 5 to less than 18 years of age.
&lt;br&gt;2. Documented diagnosis of NDO, confirmed by urodynamics.
&lt;br&gt;3. Weight and height are within normal percentiles (3rd to 97th percentile) according to Centers for Disease Control and Prevention (CDC) growth charts.
&lt;br&gt;4. Subject’s bowel function is being actively managed. 
&lt;br&gt;5. Able to swallow the study medication in accordance to the protocol.
&lt;br&gt;6. Female subjects of childbearing potential and sexually active agree to use a reliable form of birth control for the duration of the study and for at least one month after ending study treatment. Sexually active male subjects agree to use a barrier method of birth control for the duration of the study and for at least one month after ending study treatment.
&lt;br&gt;7. Subject and subject’s parent(s)/legal guardian are willing and able to comply with the study requirements and with the concomitant medication restrictions.
&lt;br&gt;8. Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written Informed Consent and privacy language as per national regulations (e.g., HIPAA Authorization for U.S. sites) must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable). In the case of a minor, consent from a parent or guardian must be obtained. In the case of an adolescent, a written assent to participate may also be required per local IRB/IEC rules.&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: 12&lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range 0&lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range 0&lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;At screening:
&lt;br&gt;1. Subject is breastfeeding or pregnant. Subjects of childbearing potential must have a negative serum pregnancy test.
&lt;br&gt;2. Subject with any of the following gastrointestinal (GI)conditions: partial or complete bowel obstruction, decreased motility (e.g., paralytic ileus) or at risk for gastric retention.
&lt;br&gt;3. Current fecal impaction or history of hospitalization for fecal impaction with enema in the past 2 years.
&lt;br&gt;4. Subject has a QTcB interval greater than 440 ms, a history of QTc prolongation or at risk of QT prolongation (e.g., hypokalemia, Long QT Syndrome [LQTS] as can be suspected in case of a family history or exercise induced syncope).
&lt;br&gt;5. Any clinically significant abnormality on ECG.
&lt;br&gt;6. Any clinically significant or unstable medical condition or disorder which, in the opinion of the investigator, precludes the subject from participating in the study.
&lt;br&gt;7. History or current diagnosis of any malignancy.
&lt;br&gt;8. Diagnosis of central or X chromosome-linked diabetes insipidus.
&lt;br&gt;9. Subject has severe renal impairment (glomerular filtration rate &lt;30ml/min).
&lt;br&gt;10. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) is greater than or equal to 2 times the ULN or total bilirubin greater than or equal to 1.5 times the ULN.
&lt;br&gt;11. Any other clinically significant out of range results of urinalysis, biochemistry or hematology.
&lt;br&gt;12. Known or suspected hypersensitivity to solifenacin (or other anticholinergics), any of the excipients used in the current formulation or previous severe hypersensitivity to any drug.
&lt;br&gt;13. Subject has participated in another clinical trial and/or has taken an investigational drug within 30 days (or 5 half-lives of the drug whichever is longer) prior to Day 1.
&lt;br&gt;14. Requires ongoing treatment with any of the following prohibited medications: antimuscarinic therapy, tricyclic/tetracyclic antidepressants, H1 antihistamines, strong CYP3A4 inhibitors, strong CYP3A4 inducers (many antiepileptic drugs like carbamazepine, phenytoin and phenobarbital).
&lt;br&gt;15. Mean systolic blood pressure greater than the 95th percentile according to age and height and/or greater than 140 mmHg [National Institute of Health, 2005], judged as clinically significant by the investigator.
&lt;br&gt;16. Subject’s parent(s)/legal guardian is an employee of the Astellas Group, the Contract Research Organization (CRO) involved, or the investigator site executing the study.
&lt;br&gt;17. Subject has a history of glaucoma.
&lt;br&gt;At Day 1:
&lt;br&gt;1. Consumption of grapefruit and products made of it (e.g., juice), and Seville oranges and products made of it (e.g., marmalade) within 14 days prior to Day 1.
&lt;br&gt;2. Positive drug screen test for drugs of abuse at Day 1.
&lt;br&gt;3. Positive alcohol breath test at Day 1.
&lt;br&gt;4. Use of prohibited prior and concomitant medication:
&lt;br&gt;• Antimuscarinics, tricyclic/tetracyclic antidepressants, H1 antihistamines within 5 half-lives prior to intake of study drug at Day 1
&lt;br&gt;• Prescribed or over the counter (OTC) drugs that are potent cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole), CYP3A4 substrates with higher affinity (e.g., verapamil, diltiazem), or potent CYP3A4 inducers (e.g., rifampicin, phenytoin, carbamazepine), including natural and herbal remedies (e.g., St. John’s Wort) within 14 days prior to intake of study drug at Day 1.
&lt;br&gt;5. Donation of blood or blood products within 3 months prior to Day 1.
&lt;br&gt;6. Positive urine pregnancy test.
&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Neurogenic Detrusor Overactivity (NDO) &lt;br&gt;MedDRA version: 14.1
Level: LLT
Classification code 10012547
Term: Detrusor hyperreflexia
System Organ Class: 10038359 - Renal and urinary disorders
;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]</Condition>
    <Intervention>&lt;br&gt;Product Name: Solifenacin Succinate&lt;br&gt;Product Code: YM905&lt;br&gt;Pharmaceutical Form: Oral suspension&lt;br&gt;CAS Number: 242478-38-2&lt;br&gt;Current Sponsor code: YM905&lt;br&gt;Other descriptive name: SOLIFENACIN SUCCINATE&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Primary end point(s): - Maximum concentration (C max)&lt;br&gt;- Time to attain C max (T max)&lt;br&gt;- Area under the plasma concentration – time curve (AUC) from time of dosing until last measurable concentration (AUC last)- only if non-compartmental approach is used to analyze the data&lt;br&gt;- AUC extrapolated until time is infinity (AUC inf)&lt;br&gt;- Apparent terminal elimination half-life (t 1/2)&lt;br&gt;- Apparent Total Body Clearance (CL/F) &lt;br&gt;- Apparent volume of distribution during the terminal phases (Vz/F)&lt;br&gt;;Main Objective: To evaluate the pharmacokinetics of solifenacin succinate suspension after single-dose administration in children and adolescents with NDO.;Secondary Objective: To evaluate the safety and tolerability of solifenacin succinate suspension after single-dose administration in children and adolescents with NDO.;Timepoint(s) of evaluation of this end point: At each study visit (Day 1, Day 3, Day 5 and Day 7)</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): AEs, clinical laboratory evaluations (hematology, biochemistry, urinalysis), vital signs, ECG and physical examination;Timepoint(s) of evaluation of this end point: At each study visit (Day 1, Day 3, Day 5 and Day 7)</Secondary_outcome>
    <Secondary_ID>905-CL-079;NCT01539707</Secondary_ID>
    <Source_Support>Astellas Pharma Europe B.V.</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2808324</Internal_Number>
    <TrialID>EUCTR2011-000330-11-GB</TrialID>
    <Last_Refreshed_on>2 October 2012</Last_Refreshed_on>
    <Public_title>A study to investigate how a drug is taken up, how long it stays in the body and how effective and safe it is in treating children with symptoms of neurogenic detrusor overactivity (NDO).
</Public_title>
    <Scientific_title>A Phase 3, Open-Label, Baseline-controlled, Multicenter, Sequential Dose Titration Study to Assess the Long-Term Efficacy and Safety, and the Pharmacokinetics of Solifenacin Succinate Suspension in Patients from 5 to Less than 18 years of Age with Neurogenic Detrusor Overactivity (NDO)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Astellas Pharma Europe B.V.</Primary_sponsor>
    <Date_registration3>20120104</Date_registration3>
    <Date_registration>04/01/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-000330-11                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>16/07/2012</Date_enrollement>
    <Target_size>74</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 1&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;-Documented diagnosis of NDO, confirmed by urodynamics &lt;br&gt;-Practicing clean intermittent catheterization (CIC).&lt;br&gt;-Currently on treatment with an antimuscarinic drug &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: 74&lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-Known genitourinary condition (other than NDO) that may cause incontinence&lt;br&gt;-Bladder augmentation surgery.&lt;br&gt;-Current Faecal impaction.&lt;br&gt;-Electro - stimulation therapy within 2 weeks prior to screening and at any time during the study.&lt;br&gt;-Subjects with the following gastro-intestinal problems: partial or complete obstruction, decreased motility like paralytic ileus, subjects at risk of gastric retention.&lt;br&gt;-Reflux grade 3 to 5.&lt;br&gt;-Current UTI&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Neurogenic Detrusor Overactivity (NDO) &lt;br&gt;MedDRA version: 14.1
Level: LLT
Classification code 10012547
Term: Detrusor hyperreflexia
System Organ Class: 10038359 - Renal and urinary disorders
;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]</Condition>
    <Intervention>&lt;br&gt;Product Name: Solifenacin Succinate&lt;br&gt;Product Code: YM905&lt;br&gt;Pharmaceutical Form: Oral suspension&lt;br&gt;INN or Proposed INN: Solifenacin succinate&lt;br&gt;CAS Number: 242478-38-2&lt;br&gt;Current Sponsor code: YM905&lt;br&gt;Other descriptive name: Solifenacin succinate&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate the efficacy, safety and PK of solifenacin succinate suspension after multiple dose administration.;Secondary Objective: ;Primary end point(s): Change in maximum cystometric capacity (MCC);Timepoint(s) of evaluation of this end point: Visit 3, 9, 24, 52.</Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Urodynamic variables&lt;br&gt;Change from baseline in:&lt;br&gt;? Bladder compliance &lt;br&gt;? Bladder volume until first detrusor contraction (&gt; 15 cmH2O);&lt;br&gt;? Number of overactive detrusor contractions (&gt; 15 cmH2O) until leakage or maximum 135% of age-related bladder capacity;&lt;br&gt;? Detrusor pressure at leakage or 135% of age-related cystometric capacity.&lt;br&gt;o Mean number of incontinence episodes&lt;br&gt;o Number of dry (incontinence-free) days/7 days.&lt;br&gt;o Quality of life.&lt;br&gt;&lt;br&gt;Safety: AEs, clinical laboratory evaluations, vital organs, ECG and physical examination.&lt;br&gt;PK variables&lt;br&gt;;Timepoint(s) of evaluation of this end point: At each study visit</Secondary_outcome>
    <Secondary_ID>905-CL-047;NCT01565694;2011-000330-11-BE</Secondary_ID>
    <Source_Support>Astellas Pharma Europe B.V.</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2811302</Internal_Number>
    <TrialID>EUCTR2007-005376-13-FR</TrialID>
    <Last_Refreshed_on>9 October 2012</Last_Refreshed_on>
    <Public_title xml:space="preserve">
			</Public_title>
    <Scientific_title>A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABEL
CLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN A
PROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVE
REGIMEN IN KIDNEY TRANSPLANT SUBJECTS.
Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4)) - Short Title: OSAKA Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Astellas Pharma Europe Ltd.</Primary_sponsor>
    <Date_registration3>20080204</Date_registration3>
    <Date_registration>04/02/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005376-13                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin xml:space="preserve">
			</Inclusion_agemin>
    <Inclusion_agemax xml:space="preserve">
			</Inclusion_agemax>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>27/02/2008</Date_enrollement>
    <Target_size>1200</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Subject is eligible for the study if all of the following apply:&lt;br&gt;1. Age = 18 years.&lt;br&gt;2. End stage kidney disease and a suitable candidate for primary renal transplantation or&lt;br&gt;re-transplantation (unless the graft was lost from rejection within 12 months).&lt;br&gt;3. Receiving a kidney transplant from a cadaveric or living (non HLA identical) donor&lt;br&gt;with compatible ABO blood type.&lt;br&gt;4. Female subject of childbearing potential must have a negative serum pregnancy test at&lt;br&gt;enrollment and must agree to maintain effective birth control during the study.&lt;br&gt;5. Capable of understanding the purpose and risks of the study, fully informed and given written informed consent (signed Informed Consent has been obtained).&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Subject will be excluded from participation if any of the following apply:&lt;br&gt;1. Receiving or having previously received an organ transplant other than a kidney.&lt;br&gt;2. Cold ischemia time of the donor kidney &gt; 30 hours.&lt;br&gt;3. Receiving a graft from a non-heart-beating donor other than of Maastricht category 3&lt;br&gt;(withdrawn of support awaiting cardiac arrest).&lt;br&gt;4. Significant liver disease, defined as having continuously elevated SGPT/ALT and/or&lt;br&gt;SGOT/AST and/or total bilirubin levels = 2 times the upper value of the normal range&lt;br&gt;of the investigational site or is receiving a graft from a hepatitis C or B positive donor.&lt;br&gt;5. Requiring initial sequential or parallel therapy with immunosuppressive antibody&lt;br&gt;preparation(s).&lt;br&gt;6. Requiring ongoing dosing with a systemic immunosuppressive drug prior to&lt;br&gt;transplantation.&lt;br&gt;7. Significant, uncontrolled concomitant infections and/or severe diarrhea, vomiting,&lt;br&gt;active upper gastro-intestinal tract malabsorption or active peptic ulcer.&lt;br&gt;8. Pregnant woman or breast-feeding mother.&lt;br&gt;9. Subject or donor known to be HIV positive.&lt;br&gt;10. Known allergy or intolerance to tacrolimus, macrolide antibiotics, corticosteroids,&lt;br&gt;basiliximab or mycophenolate mofetil or any of the product excipients.&lt;br&gt;11. Diagnosis of new-onset malignancy prior to transplantation, with the exception of&lt;br&gt;basocellular or squamous cell carcinoma of the skin which had been treated&lt;br&gt;successfully.&lt;br&gt;12. Currently participating in another clinical trial, and/or has taken an investigational drug&lt;br&gt;within 28 days prior to enrollment.&lt;br&gt;13. Any form of substance abuse, psychiatric disorder or condition which, in the opinion of&lt;br&gt;the investigator, may complicate communication with the investigator.&lt;br&gt;14. Unlikely to comply with the visits scheduled in the protocol.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Prophylaxis of rejection in kidney allograft recipients (via immunosuppression) &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10023438
Term: Kidney transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Prograf capsules &lt;br&gt;Product Name: Tacrolimus capsules&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987113&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5 -&lt;br&gt;&lt;br&gt;Trade Name: Advagraf prolonged-release hard capsules&lt;br&gt;Product Name: Tacrolimus prolonged-release hard capsules&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987113&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5 -&lt;br&gt;&lt;br&gt;Trade Name: Simulect&lt;br&gt;Product Name: Basiliximab&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;Other descriptive name: BASILIXIMAB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Trade Name: Prograf capsules &lt;br&gt;Product Name: Tacrolimus capsules &lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987113&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1 -&lt;br&gt;&lt;br&gt;Trade Name: Prograf capsules &lt;br&gt;Product Name: Tacrolimus capsules&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987113&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5 -&lt;br&gt;&lt;br&gt;Trade Name: Advagraf prolonged-release hard capsules&lt;br&gt;Product Name: Tacrolimus prolonged-release hard capsules&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987113&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1 -&lt;br&gt;&lt;br&gt;Trade Name: Advagraf prolonged-release hard capsules&lt;br&gt;Product Name: Tacrolimus prolonged-release hard capsules&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987113&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5 -&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of this study is to compare the four therapy regimens with regard to&lt;br&gt;efficacy failure rate.;Secondary Objective: The secondary objective is to compare the efficacy and safety profiles of the four therapy&lt;br&gt;regimens with each other.&lt;br&gt;Efficacy failure rate will be assessed using a composite endpoint consisting of graft loss, biopsy&lt;br&gt;confirmed acute rejection (BCAR) and graft dysfunction.;Primary end point(s): The primary analysis of this study is to demonstrate the non-inferiority&lt;br&gt;of the three Advagraf® Arms vs. the Prograf® Arm 24 weeks after&lt;br&gt;renal transplantation with regard to efficacy failure rate using a&lt;br&gt;composite endpoint consisting of any of the following:&lt;br&gt;a) graft loss (defined as re-transplantation, nephrectomy, death or as&lt;br&gt;dialysis ongoing at study end or at time of discontinuation of the&lt;br&gt;subject from the study unless superseded by follow-up information)&lt;br&gt;b) biopsy confirmed acute rejection (BCAR);&lt;br&gt;c) graft dysfunction (defined as glomerular filtration rate (GFR) &lt; 40&lt;br&gt;mL/min/1.73m2 estimated by MDRD formula 24 weeks after&lt;br&gt;transplantation).&lt;br&gt;The primary composite endpoint of the study is the incidence of and&lt;br&gt;time to first incidence of graft loss or BCAR or graft dysfunction.</Primary_outcome>
    <Secondary_ID>PMR-EC-1210</Secondary_ID>
    <Source_Support xml:space="preserve">
			</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2842150</Internal_Number>
    <TrialID>NCT00003553</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer</Public_title>
    <Scientific_title>A Phase II Study of HLA-Matched Peripheral Blood Mobilized Hematopoietic Progenitor Cell Transplantation for Metastatic Renal Cell Carcinoma Followed by Allogeneic T-Cell Infusion as Adoptive Immunotherapy</Scientific_title>
    <Acronym />
    <Primary_sponsor>National Heart, Lung, and Blood Institute (NHLBI)</Primary_sponsor>
    <Date_registration3>19991101</Date_registration3>
    <Date_registration>01/11/1999</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00003553</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 1999</Date_enrollement>
    <Target_size>80</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        DISEASE CHARACTERISTICS:&lt;br&gt;&lt;br&gt;          -  Histologically proven metastatic renal cell carcinoma not amenable to complete&lt;br&gt;             surgical resection and progressive despite immunotherapy&lt;br&gt;&lt;br&gt;          -  Bidimensionally evaluable clinically or radiographically&lt;br&gt;&lt;br&gt;          -  HLA 6/6 or 5/6 matched family donor available&lt;br&gt;&lt;br&gt;          -  No CNS metastases&lt;br&gt;&lt;br&gt;        PATIENT CHARACTERISTICS:&lt;br&gt;&lt;br&gt;        Age:&lt;br&gt;&lt;br&gt;          -  18 to 80&lt;br&gt;&lt;br&gt;        Performance status:&lt;br&gt;&lt;br&gt;          -  ECOG 0 or 1&lt;br&gt;&lt;br&gt;        Life expectancy:&lt;br&gt;&lt;br&gt;          -  At least 3 months&lt;br&gt;&lt;br&gt;        Hematopoietic:&lt;br&gt;&lt;br&gt;          -  Not specified&lt;br&gt;&lt;br&gt;        Hepatic:&lt;br&gt;&lt;br&gt;          -  Bilirubin no greater than 4 mg/dL&lt;br&gt;&lt;br&gt;          -  Transaminases no greater than 3 times upper limit of normal&lt;br&gt;&lt;br&gt;        Renal:&lt;br&gt;&lt;br&gt;          -  Creatinine no greater than 2.5 mg/dL&lt;br&gt;&lt;br&gt;          -  No malignancy-associated hypercalcemia (&lt; 2.5 mmol/L)&lt;br&gt;&lt;br&gt;        Cardiovascular:&lt;br&gt;&lt;br&gt;          -  Left ventricular ejection fraction greater than 40%&lt;br&gt;&lt;br&gt;        Pulmonary:&lt;br&gt;&lt;br&gt;          -  DLCO greater than 65% of predicted&lt;br&gt;&lt;br&gt;        Other:&lt;br&gt;&lt;br&gt;          -  Not pregnant&lt;br&gt;&lt;br&gt;          -  HIV negative&lt;br&gt;&lt;br&gt;          -  No major organ dysfunction that would preclude transplantation&lt;br&gt;&lt;br&gt;          -  No other malignancies except basal cell or squamous cell skin cancer&lt;br&gt;&lt;br&gt;          -  No psychiatric disorder or mental deficiency that would preclude study participation&lt;br&gt;&lt;br&gt;        PRIOR CONCURRENT THERAPY:&lt;br&gt;&lt;br&gt;        Biologic therapy&lt;br&gt;&lt;br&gt;          -  See Disease Characteristics&lt;br&gt;&lt;br&gt;        Chemotherapy&lt;br&gt;&lt;br&gt;          -  Not specified&lt;br&gt;&lt;br&gt;        Endocrine therapy&lt;br&gt;&lt;br&gt;          -  Not specified&lt;br&gt;&lt;br&gt;        Radiotherapy&lt;br&gt;&lt;br&gt;          -  Not specified&lt;br&gt;&lt;br&gt;        Surgery&lt;br&gt;&lt;br&gt;          -  Not specified&lt;br&gt;&lt;br&gt;        Other&lt;br&gt;&lt;br&gt;          -  At least 1 month since prior treatment for renal cell carcinoma&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Cancer</Condition>
    <Intervention>Biological: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: fludarabine phosphate;Drug: methotrexate;Drug: mycophenolate mofetil</Intervention>
    <Primary_outcome>Graft vs tumor effect as measured by CT scan at days 30, 60, and 100 following  transplant</Primary_outcome>
    <Secondary_outcome>Disease-free survival as measured by CT scan at 6 months and 1 year</Secondary_outcome>
    <Secondary_ID>NHLBI-97-H-0196;CDR0000066610</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2842920</Internal_Number>
    <TrialID>NCT00004495</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Randomized Study of Folic Acid Therapy for Hyperhomocysteinemia in Patients With End Stage Renal Disease Receiving Hemodialysis</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>FDA Office of Orphan Products Development</Primary_sponsor>
    <Date_registration3>19991018</Date_registration3>
    <Date_registration>18/10/1999</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00004495</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>21 Years</Inclusion_agemin>
    <Inclusion_agemax>89 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 1999</Date_enrollement>
    <Target_size>84</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Endpoint Classification:  Efficacy Study, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        PROTOCOL ENTRY CRITERIA:&lt;br&gt;&lt;br&gt;        --Disease Characteristics--&lt;br&gt;&lt;br&gt;          -  Diagnosis of end stage renal disease requiring regular hemodialysis treatment 3 times&lt;br&gt;             weekly&lt;br&gt;&lt;br&gt;          -  Baseline predialysis total homocysteine concentration in plasma greater than 16&lt;br&gt;             micromoles/L&lt;br&gt;&lt;br&gt;          -  No prior or concurrent pernicious anemia&lt;br&gt;&lt;br&gt;          -  No blood smear examination showing unexplained macrocytosis&lt;br&gt;&lt;br&gt;        --Prior/Concurrent Therapy--&lt;br&gt;&lt;br&gt;          -  Chemotherapy: No concurrent chemotherapy for cancer&lt;br&gt;&lt;br&gt;          -  Other: No concurrent levodopa or carbidopa No concurrent penicillamine or&lt;br&gt;             trimethoprim-sulfonamide combination No concurrent antiviral therapy No concurrent&lt;br&gt;             anticonvulsants&lt;br&gt;&lt;br&gt;        --Patient Characteristics--&lt;br&gt;&lt;br&gt;          -  Hematopoietic: Hematocrit at least 25%&lt;br&gt;&lt;br&gt;          -  Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use&lt;br&gt;             effective contraception No Parkinson's disease No convulsions or epilepsy requiring&lt;br&gt;             treatment No lactose intolerance or allergy to milk products No history of allergic&lt;br&gt;             sensitization following administration of folic acid, pyridoxine (vitamin B6), or&lt;br&gt;             cyanocobalamin (vitamin B12) No vitamin B12 concentration below lower limit of normal&lt;br&gt;             (150 picamole/L) No untreated hypothyroidism or psoriasis&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End Stage Renal Disease;Hyperhomocysteinemia</Condition>
    <Intervention>Drug: cyanocobalamin;Drug: folic acid;Drug: pyridoxine</Intervention>
    <Secondary_ID>GUMC-FDR001544;199/14276</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Georgetown University</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2842921</Internal_Number>
    <TrialID>NCT00004496</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Phase I Study of Alpha-Melanocyte Stimulating Hormone in Patients With Acute Renal Failure</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>FDA Office of Orphan Products Development</Primary_sponsor>
    <Date_registration3>19991018</Date_registration3>
    <Date_registration>18/10/1999</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00004496</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>February 1999</Date_enrollement>
    <Target_size>45</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Masking:  Double-Blind, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 1</Phase>
    <Inclusion_Criteria>&lt;br&gt;        PROTOCOL ENTRY CRITERIA:&lt;br&gt;&lt;br&gt;        --Disease Characteristics--&lt;br&gt;&lt;br&gt;        Group 1:  Patients on chronic hemodialysis&lt;br&gt;&lt;br&gt;        Group 2:  Patients at high risk of developing acute renal failure (ARF) after cadaveric&lt;br&gt;        renal transplantation Received high risk allograft Cadaveric kidneys with greater than 24&lt;br&gt;        hours of cold ischemia time Donor had rising creatinine before organ procurement Donor&lt;br&gt;        over 60 years&lt;br&gt;&lt;br&gt;        Group 3:  Patients with ischemic ARF due to hypotension, surgery, or trauma ARF severity&lt;br&gt;        index 20-60% Creatinine clearance 12-14 mL/min Rising creatinine of at least 0.5 mg/dL per&lt;br&gt;        day for 2 days without evidence of recovery despite standard supportive care No drug or&lt;br&gt;        contrast induced renal failure No oliguric renal failure (creatinine clearance 3-4 mL/min)&lt;br&gt;        No prior chronic renal failure Baseline creatinine greater than 2.5 mg/dL (males) or 2.0&lt;br&gt;        mg/dL (females) No ARF due to bacterial or fungal sepsis, nephrotoxins, acute&lt;br&gt;        tubulointerstitial nephritis, cyclosporine toxicity, bilateral renal vascular disease, or&lt;br&gt;        systemic diseases (hepatorenal syndrome, glomerulonephritis, renal vasculitis, etc.)&lt;br&gt;&lt;br&gt;        --Prior/Concurrent Therapy--&lt;br&gt;&lt;br&gt;        Group 1:  No recent immunosuppressive therapy Group 2 and 3:  No prior renal&lt;br&gt;        transplantation No prior alpha-MSH Group 3:  No prior dialysis for this episode of ARF No&lt;br&gt;        anticipated need for dialysis for at least 24 hours At least 12 hours since prior&lt;br&gt;        diuretics, mannitol, or dopamine At least 14 days since prior immunosuppressive drugs&lt;br&gt;&lt;br&gt;        --Patient Characteristics--&lt;br&gt;&lt;br&gt;        No recent infection No known reaction to Terumo T175 dialyzer Not a prisoner Not pregnant&lt;br&gt;        or nursing No allergy to drugs used in study Not mentally impaired Group 3:  No severe&lt;br&gt;        nonrenal medical condition that would interfere with the study (e.g., terminal cancer)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Renal Failure</Condition>
    <Intervention>Drug: alpha-melanocyte stimulating hormone</Intervention>
    <Secondary_ID>UTSMC-FDR001552;UTSMC-129447100;199/14286</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>University of Texas</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2843939</Internal_Number>
    <TrialID>NCT00005767</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Dynamic Aspects of Amino Acid Metabolism</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>National Center for Research Resources (NCRR)</Primary_sponsor>
    <Date_registration3>20000601</Date_registration3>
    <Date_registration>01/06/2000</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00005767</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>55 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2000</Date_enrollement>
    <Target_size />
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Natural History, Time Perspective:  Cross-Sectional</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  normal weight-for-height weight 50-80 kg&lt;br&gt;&lt;br&gt;          -  normal physical activity&lt;br&gt;&lt;br&gt;          -  no significant medical history&lt;br&gt;&lt;br&gt;          -  healthy by medical exam and lab blood testing&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  subjects who exercise vigorously&lt;br&gt;&lt;br&gt;          -  subjects who smoke&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Diseases</Condition>
    <Secondary_ID>M01RR00109;NCRR-M01RR00109-0740</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2844462</Internal_Number>
    <TrialID>NCT00006331</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Prospective Controlled Study of Posttransplant Diabetes</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>National Center for Research Resources (NCRR)</Primary_sponsor>
    <Date_registration3>20001004</Date_registration3>
    <Date_registration>04/10/2000</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00006331</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 1999</Date_enrollement>
    <Target_size />
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Defined Population, Time Perspective:  Longitudinal</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Fasting Plasma Glucose (FPG) &lt;126mg/dl.&lt;br&gt;&lt;br&gt;          -  No history of diabetes mellitus or treatment with oral antidiabetic agent or insulin.&lt;br&gt;&lt;br&gt;          -  ESRD or chronic renal failure with CrCl &lt;= 20cc/min per 1.73m2.&lt;br&gt;&lt;br&gt;          -  Waiting list registration for cadaveric or set date for living donor renal&lt;br&gt;             transplantation.&lt;br&gt;&lt;br&gt;          -  Willingness and ability to understand and give informed consent.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Diabetes Mellitus;Kidney Failure</Condition>
    <Intervention>Procedure: renal transplant</Intervention>
    <Secondary_ID>M01RR00042;NCRR-M01RR00042-1699</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2845018</Internal_Number>
    <TrialID>NCT00012441</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Comparison of Daily Nocturnal Hemodialysis With Daily Hemodialysis</Public_title>
    <Scientific_title>Comparison of Daily Nocturnal Hemodialysis With Daily Hemodialysis</Scientific_title>
    <Acronym />
    <Primary_sponsor>National Center for Research Resources (NCRR)</Primary_sponsor>
    <Date_registration3>20010306</Date_registration3>
    <Date_registration>06/03/2001</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00012441</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>21 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 1999</Date_enrollement>
    <Target_size />
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Efficacy Study, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Adult patients with chronic renal failure requiring intermittent hemodialysis with a life&lt;br&gt;        expectancy of greater than 2 years&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Failure, Chronic</Condition>
    <Intervention>Procedure: hemodialysis</Intervention>
    <Secondary_ID>NCRR-M01RR00036-0781</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2848056</Internal_Number>
    <TrialID>NCT00056095</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer</Public_title>
    <Scientific_title>Phase II Trial in Intrafamilial Allogeneic Cell Transplant in Patients With Metastatic Kidney Cancer</Scientific_title>
    <Acronym />
    <Primary_sponsor>UNICANCER</Primary_sponsor>
    <Date_registration3>20030306</Date_registration3>
    <Date_registration>06/03/2003</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00056095</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>65 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>December 2002</Date_enrollement>
    <Target_size>170</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        DISEASE CHARACTERISTICS:&lt;br&gt;&lt;br&gt;          -  Histologically confirmed metastatic renal cell carcinoma&lt;br&gt;&lt;br&gt;          -  No sarcomatoid, pure papillary, or Bellini renal cell cancer&lt;br&gt;&lt;br&gt;          -  Measurable and/or evaluable disease&lt;br&gt;&lt;br&gt;          -  Disease progression after at least 1 immunotherapy regimen for metastatic disease&lt;br&gt;&lt;br&gt;          -  Localized metastases allowed provided the following are true:&lt;br&gt;&lt;br&gt;               -  At least 3 months since prior treatment for metastases&lt;br&gt;&lt;br&gt;               -  Not considered likely to influence outcome of transplantation&lt;br&gt;&lt;br&gt;          -  No brain metastases unless treated surgically or radiologically and MRI normal&lt;br&gt;&lt;br&gt;          -  Sufficiently healthy, HLA-compatible family member must be available as donor for&lt;br&gt;             patients undergoing stem cell transplantation&lt;br&gt;&lt;br&gt;        PATIENT CHARACTERISTICS:&lt;br&gt;&lt;br&gt;        Age&lt;br&gt;&lt;br&gt;          -  18 to 65&lt;br&gt;&lt;br&gt;        Performance status&lt;br&gt;&lt;br&gt;          -  ECOG 0-1&lt;br&gt;&lt;br&gt;        Life expectancy&lt;br&gt;&lt;br&gt;          -  More than 6 months&lt;br&gt;&lt;br&gt;        Hematopoietic&lt;br&gt;&lt;br&gt;          -  Platelet count at least 100,000/mm^3&lt;br&gt;&lt;br&gt;        Hepatic&lt;br&gt;&lt;br&gt;          -  Transaminases less than 1.5 times upper limit of normal (ULN)*&lt;br&gt;&lt;br&gt;          -  Bilirubin less than 1.5 times ULN* NOTE: *Unless due to Gilbert's disease&lt;br&gt;&lt;br&gt;        Renal&lt;br&gt;&lt;br&gt;          -  No renal insufficiency&lt;br&gt;&lt;br&gt;          -  Calcium less than 10.4 mg/dL&lt;br&gt;&lt;br&gt;          -  Creatinine clearance greater than 50 mL/min&lt;br&gt;&lt;br&gt;        Cardiovascular&lt;br&gt;&lt;br&gt;          -  Ejection fraction greater than 50%&lt;br&gt;&lt;br&gt;        Pulmonary&lt;br&gt;&lt;br&gt;          -  No DLCO that would preclude fludarabine or busulfan therapy&lt;br&gt;&lt;br&gt;        Other&lt;br&gt;&lt;br&gt;          -  Not pregnant or nursing&lt;br&gt;&lt;br&gt;          -  Fertile patients must use effective contraception&lt;br&gt;&lt;br&gt;          -  No physical obstacle to receiving study treatment&lt;br&gt;&lt;br&gt;          -  No known autoimmune disease&lt;br&gt;&lt;br&gt;          -  No other malignancy within the past 5 years except basal cell skin cancer or&lt;br&gt;             carcinoma in situ of the cervix&lt;br&gt;&lt;br&gt;          -  No uncontrolled bacterial, viral, or fungal infection&lt;br&gt;&lt;br&gt;          -  No prior or concurrent psychiatric disease&lt;br&gt;&lt;br&gt;          -  HIV negative&lt;br&gt;&lt;br&gt;          -  HTLV1 negative&lt;br&gt;&lt;br&gt;        PRIOR CONCURRENT THERAPY:&lt;br&gt;&lt;br&gt;        Biologic therapy&lt;br&gt;&lt;br&gt;          -  See Disease Characteristics&lt;br&gt;&lt;br&gt;        Chemotherapy&lt;br&gt;&lt;br&gt;          -  No tolerance to fludarabine and busulfan&lt;br&gt;&lt;br&gt;        Endocrine therapy&lt;br&gt;&lt;br&gt;          -  No concurrent corticosteroids&lt;br&gt;&lt;br&gt;        Radiotherapy&lt;br&gt;&lt;br&gt;          -  Not specified&lt;br&gt;&lt;br&gt;        Surgery&lt;br&gt;&lt;br&gt;          -  Not specified&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Cancer</Condition>
    <Intervention>Biological: therapeutic allogeneic lymphocytes;Drug: cyclophosphamide;Drug: cyclosporine;Drug: fludarabine phosphate;Procedure: allogeneic bone marrow transplantation;Procedure: peripheral blood stem cell transplantation</Intervention>
    <Primary_outcome>Survival rate at 18 months;Objective rate of response;Post-transplant immunological reactions and recuperation;Antitumoral activity</Primary_outcome>
    <Secondary_ID>FRE-FNCLCC-GETUG-11/0105;EU-20234;CDR0000271936</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2851908</Internal_Number>
    <TrialID>NCT00110201</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>The Use of Nesiritide in Thoracic Aneurysm Repair to Prevent Acute Renal Failure</Public_title>
    <Scientific_title>Prophylactic Use of Nesiritide (Brain Natriuretic Peptide, BNP) for the Prevention of Acute Renal Failure in Thoracic Aortic Aneurysm Surgery Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>Ejaz, Abulate A, MD</Primary_sponsor>
    <Date_registration3>20050504</Date_registration3>
    <Date_registration>04/05/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00110201</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2005</Date_enrollement>
    <Target_size>124</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double-Blind, Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age 18 years or older&lt;br&gt;&lt;br&gt;          -  Undergoing thoracic aortic aneurysm surgery&lt;br&gt;&lt;br&gt;          -  Impaired renal function&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Prior history of allergy/adverse reaction to Nesiritide&lt;br&gt;&lt;br&gt;          -  History of any organ transplant&lt;br&gt;&lt;br&gt;          -  Preoperative intra-aortic balloon pump (IABP)&lt;br&gt;&lt;br&gt;          -  Decompensated congestive heart failure (CHF)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Cardiovascular Disease;Acute Renal Failure;Death</Condition>
    <Intervention>Drug: Nesiritide</Intervention>
    <Primary_outcome>Need for dialysis and/or mortality</Primary_outcome>
    <Secondary_outcome>Rise in serum creatinine;blood urea nitrogen</Secondary_outcome>
    <Secondary_ID>20050059;bnpufl2005</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2852081</Internal_Number>
    <TrialID>NCT00112476</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors</Public_title>
    <Scientific_title>A Phase I Study of Intravenous CCI-779 in Combination With Bryostatin-1 in Solid Tumors (10038414)</Scientific_title>
    <Acronym />
    <Primary_sponsor>Fox Chase Cancer Center</Primary_sponsor>
    <Date_registration3>20050602</Date_registration3>
    <Date_registration>02/06/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00112476</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2005</Date_enrollement>
    <Target_size>24</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 1</Phase>
    <Inclusion_Criteria>&lt;br&gt;        DISEASE CHARACTERISTICS:&lt;br&gt;&lt;br&gt;          -  Histologically confirmed solid tumor, including melanoma or renal cell carcinoma&lt;br&gt;&lt;br&gt;               -  Metastatic or unresectable disease&lt;br&gt;&lt;br&gt;                    -  Must have evidence of residual, recurrent, or metastatic disease by&lt;br&gt;                       radiography&lt;br&gt;&lt;br&gt;          -  Measurable disease&lt;br&gt;&lt;br&gt;               -  At least 1 unidimensionally measurable lesion = 20 mm by conventional techniques&lt;br&gt;                  (CT scan, MRI, or x-ray) OR = 10 mm by spiral CT scan&lt;br&gt;&lt;br&gt;               -  Must show clear evidence of disease progression within the lesion if the only&lt;br&gt;                  site of measurable disease is within a previously irradiated volume&lt;br&gt;&lt;br&gt;          -  Standard curative or palliative measures do not exist OR are no longer effective&lt;br&gt;&lt;br&gt;          -  No history of or known brain metastases&lt;br&gt;&lt;br&gt;        PATIENT CHARACTERISTICS:&lt;br&gt;&lt;br&gt;        Age&lt;br&gt;&lt;br&gt;          -  18 and over&lt;br&gt;&lt;br&gt;        Performance status&lt;br&gt;&lt;br&gt;          -  ECOG 0-1&lt;br&gt;&lt;br&gt;        Life expectancy&lt;br&gt;&lt;br&gt;          -  At least 3 months&lt;br&gt;&lt;br&gt;        Hematopoietic&lt;br&gt;&lt;br&gt;          -  WBC = 3,000/mm^3&lt;br&gt;&lt;br&gt;          -  Absolute neutrophil count = 1,500/mm^3&lt;br&gt;&lt;br&gt;          -  Platelet count = 100,000/mm^3&lt;br&gt;&lt;br&gt;        Hepatic&lt;br&gt;&lt;br&gt;          -  AST and ALT = 2.5 times upper limit of normal (ULN)&lt;br&gt;&lt;br&gt;          -  Bilirubin normal&lt;br&gt;&lt;br&gt;        Renal&lt;br&gt;&lt;br&gt;          -  Creatinine = 1.5 times ULN OR&lt;br&gt;&lt;br&gt;          -  Creatinine clearance = 50 mL/min&lt;br&gt;&lt;br&gt;        Cardiovascular&lt;br&gt;&lt;br&gt;          -  No symptomatic congestive heart failure&lt;br&gt;&lt;br&gt;          -  No unstable angina pectoris&lt;br&gt;&lt;br&gt;          -  No cardiac arrhythmia&lt;br&gt;&lt;br&gt;        Other&lt;br&gt;&lt;br&gt;          -  Fasting cholesterol = 350 mg/dL*&lt;br&gt;&lt;br&gt;          -  Triglycerides = 400 mg/dL*&lt;br&gt;&lt;br&gt;          -  Not pregnant or nursing&lt;br&gt;&lt;br&gt;          -  Negative pregnancy test&lt;br&gt;&lt;br&gt;          -  Fertile female patients must use effective contraception for = 1 month before,&lt;br&gt;             during, and for = 3 months after completion of study treatment (during and for = 3&lt;br&gt;             months after completion of study treatment for male patients)&lt;br&gt;&lt;br&gt;          -  No history of allergic reaction attributed to compounds of similar chemical or&lt;br&gt;             biological composition to study drugs&lt;br&gt;&lt;br&gt;          -  No ongoing or active bacterial or viral infection&lt;br&gt;&lt;br&gt;          -  No psychiatric illness or social situation that would preclude study compliance&lt;br&gt;&lt;br&gt;          -  No dementia or altered mental status that would preclude giving informed consent&lt;br&gt;&lt;br&gt;          -  No other uncontrolled illnesses NOTE: *Use of medication to obtain acceptable levels&lt;br&gt;             allowed&lt;br&gt;&lt;br&gt;        PRIOR CONCURRENT THERAPY:&lt;br&gt;&lt;br&gt;        Biologic therapy&lt;br&gt;&lt;br&gt;          -  More than 3 weeks since prior immunotherapy&lt;br&gt;&lt;br&gt;          -  Prior biological therapy (e.g., interferon or interleukin 2, vaccine, antibody-based&lt;br&gt;             and tyrosine kinase inhibitors) allowed&lt;br&gt;&lt;br&gt;          -  No concurrent prophylactic hematopoietic colony-stimulating factors except for&lt;br&gt;             epoetin alfa&lt;br&gt;&lt;br&gt;        Chemotherapy&lt;br&gt;&lt;br&gt;          -  No prior cytotoxic chemotherapy&lt;br&gt;&lt;br&gt;          -  No prior bryostatin 1, temsirolimus, everolimus, or AP23573 for this malignancy&lt;br&gt;&lt;br&gt;          -  More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&lt;br&gt;&lt;br&gt;        Endocrine therapy&lt;br&gt;&lt;br&gt;          -  No concurrent steroids except for topical or inhaled use&lt;br&gt;&lt;br&gt;        Radiotherapy&lt;br&gt;&lt;br&gt;          -  See Disease Characteristics&lt;br&gt;&lt;br&gt;          -  No prior radiotherapy to &gt; 25% of bone marrow&lt;br&gt;&lt;br&gt;          -  More than 3 weeks since prior radiotherapy&lt;br&gt;&lt;br&gt;        Surgery&lt;br&gt;&lt;br&gt;          -  More than 3 weeks since prior major surgery, including nephrectomy&lt;br&gt;&lt;br&gt;               -  Minor surgical procedures allowed&lt;br&gt;&lt;br&gt;        Other&lt;br&gt;&lt;br&gt;          -  Recovered from prior therapy&lt;br&gt;&lt;br&gt;          -  More than 3 weeks since prior other anticancer investigational agents&lt;br&gt;&lt;br&gt;          -  Concurrent CYP3A4 inducers or inhibitors allowed provided patient has been on a&lt;br&gt;             stable dose for = 1 week before study entry&lt;br&gt;&lt;br&gt;          -  No concurrent combination antiretroviral therapy for HIV-positive patients&lt;br&gt;&lt;br&gt;          -  No other concurrent antineoplastic agents or therapies&lt;br&gt;&lt;br&gt;          -  No other concurrent experimental agents&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Cancer;Melanoma (Skin);Unspecified Adult Solid Tumor, Protocol Specific</Condition>
    <Intervention>Drug: bryostatin 1;Drug: temsirolimus</Intervention>
    <Secondary_ID>FCCC-04037;NCI-5785;CDR0000432955</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>National Cancer Institute (NCI)</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2853762</Internal_Number>
    <TrialID>NCT00134797</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Glomerular Filtration Rate (GFR) Reporting on Nephrology Referral Patterns by Internists</Public_title>
    <Scientific_title>The Effect of MDRD GFR Reporting on Nephrology Referral Patterns by Internists</Scientific_title>
    <Acronym />
    <Primary_sponsor>United States Naval Medical Center, San Diego</Primary_sponsor>
    <Date_registration3>20050824</Date_registration3>
    <Date_registration>24/08/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00134797</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>February 2005</Date_enrollement>
    <Target_size>1500</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Defined Population, Primary Purpose:  Screening, Time Perspective:  Longitudinal, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  All patients in the Internal Medicine Clinic at Naval Medical Center, San Diego&lt;br&gt;             (NMCSD) who were sent to the lab to obtain follow up by their primary care providers.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  All patients referred to or being followed by nephrologists.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease</Condition>
    <Secondary_ID>CIP #S-04-058</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2854773</Internal_Number>
    <TrialID>NCT00148174</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Predictors and Intervention for Noncompliance</Public_title>
    <Scientific_title>Predictors and Intervention for Noncompliance</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Minnesota - Clinical and Translational Science Institute</Primary_sponsor>
    <Date_registration3>20050902</Date_registration3>
    <Date_registration>02/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00148174</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>14 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 1998</Date_enrollement>
    <Target_size>500</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Kidney transplant&lt;br&gt;&lt;br&gt;          -  Discharged from hospital with functioning graft&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Risk of recurrent primary renal disease, e.g. hemolytic uremic syndrome, oxalosis,&lt;br&gt;             membranoproliferative glomerulonephritis type II, focal,segmental glomerulosclerosis&lt;br&gt;             with nephrotic syndrome&lt;br&gt;&lt;br&gt;          -  Patients with active psychosis&lt;br&gt;&lt;br&gt;          -  Patients not using azathioprine, sirolimus, or mycophenolate mofetil for&lt;br&gt;             immunosuppression at the time of discharge&lt;br&gt;&lt;br&gt;          -  Patients taking the liquid form of azathioprine or mycophenolate mofetil&lt;br&gt;&lt;br&gt;          -  Patients who are younger than 14 yrs. old&lt;br&gt;&lt;br&gt;          -  Patients who do not speak English&lt;br&gt;&lt;br&gt;          -  Receiving extra-renal organ except for pancreas,either simultaneously or previously&lt;br&gt;&lt;br&gt;          -  Patients who live and will be followed outside of the United States, except Canada&lt;br&gt;&lt;br&gt;          -  Patients who are physically unable to open the MEMS cap&lt;br&gt;&lt;br&gt;          -  Patients who are not responsible for taking their own medications, e.g. living in a&lt;br&gt;             medical care facility&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Transplantation</Condition>
    <Intervention>Behavioral: Intensive telephone followup</Intervention>
    <Primary_outcome>Graft loss</Primary_outcome>
    <Secondary_outcome>Acute rejection;Death</Secondary_outcome>
    <Secondary_ID>2P01DK013083-40A1;9611M11943</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2855321</Internal_Number>
    <TrialID>NCT00155363</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effect of Different Hemodialysis Modality on Adiponectin,Vascular Function and Clinical Prognosis</Public_title>
    <Scientific_title>The Impact of Conventional Hemodialysis, High Flux Hemodialysis and Hemodiafiltration on Adiponectin, Vascular Function and Clinical Prognosis</Scientific_title>
    <Acronym />
    <Primary_sponsor>National Taiwan University Hospital</Primary_sponsor>
    <Date_registration3>20050908</Date_registration3>
    <Date_registration>08/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00155363</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2004</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Intervention Model:  Crossover Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        Clinical diagnosis on ESRD under regular maintenance hemodialysis, no active infection, no&lt;br&gt;        allergy to chosen AK, informed consent acquired&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        Not ESRD, temporary HD, active infection, during admission, allergy to chosen AK, without&lt;br&gt;        informed consent&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End-Stage Renal Disease</Condition>
    <Intervention>Device: conventional artificial kidney (AK) vs. high flux AK</Intervention>
    <Primary_outcome>Adiponectin and inflammatory cytokines level</Primary_outcome>
    <Secondary_outcome>Cardiovascular event</Secondary_outcome>
    <Secondary_ID>9361701293</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2855327</Internal_Number>
    <TrialID>NCT00155441</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effects of Cognitive-Behavioral Therapy on Sleep Disturbance in Peritoneal Dialysis Patients</Public_title>
    <Scientific_title>Effects of Cognitive-Behavioral Therapy on Sleep Disturbance in Peritoneal Dialysis Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>National Taiwan University Hospital</Primary_sponsor>
    <Date_registration3>20050908</Date_registration3>
    <Date_registration>08/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00155441</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2005</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Factorial Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Undergoing peritoneal dialysis (PD) for at least 3 months&lt;br&gt;&lt;br&gt;          -  Older than 18 years&lt;br&gt;&lt;br&gt;          -  Have sleep disturbance subjectively&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Unstable clinical conditions or evidence of malignancy&lt;br&gt;&lt;br&gt;          -  Pregnancy&lt;br&gt;&lt;br&gt;          -  Participation in another study that would interfere with the outcome of this study&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Sleep Disorders;Kidney Diseases</Condition>
    <Intervention>Behavioral: cognitive-behavioral therapy</Intervention>
    <Primary_outcome>Check Pittsburgh Sleep Quality Index and restless leg syndrome index: in 1st and 3rd months</Primary_outcome>
    <Secondary_outcome>The hematologic, biochemical markers, and peritoneal function in 1st and 3rd months</Secondary_outcome>
    <Secondary_ID>9461700509</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Far Eastern Memorial Hospital</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2855528</Internal_Number>
    <TrialID>NCT00158080</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Hemofiltration for Contrast-Induced Nephropathy</Public_title>
    <Scientific_title>Prevention of Contrast-Induced Nephropathy by Real-Time Hemofiltration</Scientific_title>
    <Acronym />
    <Primary_sponsor>Nara Medical University</Primary_sponsor>
    <Date_registration3>20050907</Date_registration3>
    <Date_registration>07/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00158080</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>20 Years</Inclusion_agemin>
    <Inclusion_agemax>90 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2002</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Prevention</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with serum creatinine&gt;2.0mg/dl and/or GFR&lt;50ml/min&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Emergent cardiac catheterization&lt;br&gt;&lt;br&gt;          -  Patients on chronic dialysis&lt;br&gt;&lt;br&gt;          -  Patients with HYHA&gt;III heart failure&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease;Cardiac Catheterization</Condition>
    <Intervention>Procedure: hemofiltration</Intervention>
    <Primary_outcome>Prevention of contrast-induced acute renal failure, Elevation of serum creatinine</Primary_outcome>
    <Secondary_outcome>Need for hemodialysis</Secondary_outcome>
    <Secondary_ID>K0001</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2855863</Internal_Number>
    <TrialID>NCT00162487</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Genetic Determinants of the Hypokalemic and Hyperglycemic Effect of Albuterol Inhalation</Public_title>
    <Scientific_title>Evaluation of ß2 Genetic Polymorphisms and the Effect of Albuterol Inhalation on Potassium and Glucose Plasma Concentration</Scientific_title>
    <Acronym />
    <Primary_sponsor>Hadassah Medical Organization</Primary_sponsor>
    <Date_registration3>20050911</Date_registration3>
    <Date_registration>11/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00162487</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 2002</Date_enrollement>
    <Target_size>150</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Pharmacokinetics/Dynamics Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  patients regularly attending the nephrological clinic or the dialysis unit&lt;br&gt;&lt;br&gt;          -  persistent potassium concentration above 5 mEq/L&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Patients suffering from active ischemic heart disease&lt;br&gt;&lt;br&gt;          2. Patient with a recent history of arrhythmia&lt;br&gt;&lt;br&gt;          3. Patients treated regularly with ß blockers&lt;br&gt;&lt;br&gt;          4. Patients treated regularly with salbutamol or other ß2AR agonists&lt;br&gt;&lt;br&gt;          5. Patients suffering from persistent tachycardia (pulse &gt; 100 beats/min)&lt;br&gt;&lt;br&gt;          6. Patients who are hemodynamically unstable&lt;br&gt;&lt;br&gt;          7. Patients suffering from any acute illness&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Hyperkalemia;Chronic Renal Failure</Condition>
    <Intervention>Drug: Albuterol (1,200 µg) through metered-dose inhaler</Intervention>
    <Primary_outcome>The extent of decrease in plasma potassium concentration;The extent of increase in plasma glucose concentration;Plasma concentration of albuterol</Primary_outcome>
    <Secondary_ID>yc19556-HMO-CTIL</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2856192</Internal_Number>
    <TrialID>NCT00166829</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>The Effect of Sirolimus on the Pharmacokinetics of Tacrolimus</Public_title>
    <Scientific_title>The Effect of Sirolimus on the Pharmacokinetics of Tacrolimus</Scientific_title>
    <Acronym />
    <Primary_sponsor>National Taiwan University Hospital</Primary_sponsor>
    <Date_registration3>20050912</Date_registration3>
    <Date_registration>12/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00166829</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>13 Years</Inclusion_agemin>
    <Inclusion_agemax>65 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2004</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Pharmacokinetics Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  De novo kidney transplant patients&lt;br&gt;&lt;br&gt;          -  Aged 13 - 65 years&lt;br&gt;&lt;br&gt;          -  Having aminotransferase concentrations within 2 times the upper limit of normal&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Pregnancy&lt;br&gt;&lt;br&gt;          -  Tuberculosis&lt;br&gt;&lt;br&gt;          -  Hepatitis B or C carrier status&lt;br&gt;&lt;br&gt;          -  Human immunodeficiency virus-positive status&lt;br&gt;&lt;br&gt;          -  Retransplantation or multi-organ transplantation&lt;br&gt;&lt;br&gt;          -  History of rheumatoid arthritis&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Transplantation</Condition>
    <Intervention>Drug: sirolimus, tacrolimus, mycophenolate mofetil</Intervention>
    <Primary_outcome>The influence of sirolimus on the pharmacokinetics of tacrolimus in renal transplant patients</Primary_outcome>
    <Secondary_outcome>Compare the outcome of tacrolimus/sirolimus and tacrolimus/mycophenolate in rejection prevention</Secondary_outcome>
    <Secondary_ID>920606</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2856694</Internal_Number>
    <TrialID>NCT00173485</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>The Study of Infection and Cell Inflammation in Peritoneal Dialysate</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>National Taiwan University Hospital</Primary_sponsor>
    <Date_registration3>20050912</Date_registration3>
    <Date_registration>12/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00173485</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2005</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Defined Population, Primary Purpose:  Screening, Time Perspective:  Cross-Sectional, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        peritoneal dialysis patients, dialysis period for more than 3 months.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        age younger than 18 years old, Pregnant or lactating women. (Pre-menopause women, capable&lt;br&gt;        of bearing children will undergo pregnancy test)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Peritonitis;Kidney Failure</Condition>
    <Secondary_ID>9461700636</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2856720</Internal_Number>
    <TrialID>NCT00173823</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Malnutrition and Inflammation in Dialysis Patients in Taiwan</Public_title>
    <Scientific_title>Malnutrition and Inflammation in Taiwan: Prospective Outcome Evaluation Method (MIT-POEM) in Dialysis Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>National Taiwan University Hospital</Primary_sponsor>
    <Date_registration3>20050913</Date_registration3>
    <Date_registration>13/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00173823</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>90 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2004</Date_enrollement>
    <Target_size>1500</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Defined Population, Primary Purpose:  Screening, Time Perspective:  Longitudinal, Time Perspective:  Retrospective/Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  On HD three times a week for more than 3 months (minimizing the confounding effects&lt;br&gt;             of residual renal function)&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Malignancy;&lt;br&gt;&lt;br&gt;          -  Obvious infections or inflammatory diseases;&lt;br&gt;&lt;br&gt;          -  Preexisting haematological disorders; and,&lt;br&gt;&lt;br&gt;          -  Clinically significant bleeding, transfusion, hospitalization, surgery, or renal&lt;br&gt;             transplantation&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Hemodialysis;Hypercholesterolemia;Malnutrition;Inflammation;Kidney Failure, Chronic</Condition>
    <Secondary_ID>9461700840</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2856729</Internal_Number>
    <TrialID>NCT00173940</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Collection of Blood and Urine Specimens From Volunteers Utilizing Health Examination Services</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>National Taiwan University Hospital</Primary_sponsor>
    <Date_registration3>20050912</Date_registration3>
    <Date_registration>12/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00173940</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2004</Date_enrollement>
    <Target_size />
    <Study_type>Observational</Study_type>
    <Study_design>N/A</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Persons who sign informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age below 18 years&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Diseases;Hypertension;Diabetes;Obesity;Chronic Renal Failure</Condition>
    <Secondary_ID>9100203282</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2857349</Internal_Number>
    <TrialID>NCT00182117</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Pilot Bleeding Study: Risk and Protective Factors Associated With Bleeding in the Hemodialysis Population</Public_title>
    <Scientific_title>Pilot Bleeding Study</Scientific_title>
    <Acronym />
    <Primary_sponsor>Hamilton Health Sciences Corporation</Primary_sponsor>
    <Date_registration3>20050909</Date_registration3>
    <Date_registration>09/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00182117</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2003</Date_enrollement>
    <Target_size>490</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Defined Population, Primary Purpose:  Screening, Time Perspective:  Longitudinal, Time Perspective:  Retrospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patient is undergoing hemodialysis&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  This is an observational study.  No exclusion criteria required.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Bleeding;End Stage Renal Disease</Condition>
    <Secondary_ID>Division of Nephrology Funds</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>St. Joseph's Healthcare Hamilton</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2857876</Internal_Number>
    <TrialID>NCT00189150</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Pharmacokinetics of Mmf and Valganciclovir</Public_title>
    <Scientific_title>Pharmacokinetics of Mycophenolate Mofetil Alone and in Combination With Valganciclovir in Renal and Heart Transplant Recipients</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Michigan</Primary_sponsor>
    <Date_registration3>20050912</Date_registration3>
    <Date_registration>12/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00189150</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2005</Date_enrollement>
    <Target_size>24</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Pharmacokinetics Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        The subject must be able to give informed consent for the study. Stable renal or cardiac&lt;br&gt;        transplant patients age 18 years and older.  Patients must not have had an acute rejection&lt;br&gt;        episode within the previous 30 days of the 1st PK study.&lt;br&gt;&lt;br&gt;        Renal transplant patients with serum creatinine &lt; 2 mg/dL and with change in serum&lt;br&gt;        creatinine &lt; 25% within the 2 weeks prior to the 1st PK study.&lt;br&gt;&lt;br&gt;        Renal and cardiac transplant patients receiving VGCV for prophylaxis of CMV while&lt;br&gt;        concomitantly receiving MMF.&lt;br&gt;&lt;br&gt;        Stable MMF dose:  the dose of MMF must not have been adjusted within 1 week of the 1st PK&lt;br&gt;        study and must be the same during the 2nd PK study Stable renal function during the study&lt;br&gt;        period (change in serum creatinine ? 25%)&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        Patients who are not prescribed MMF maintenance therapy or are receiving Myfortic.&lt;br&gt;&lt;br&gt;        Patients who do not require VGCV prophylaxis (CMV negative recipients of CMV negative&lt;br&gt;        donor organs).&lt;br&gt;&lt;br&gt;        Patients who have their MMF doses adjusted either &lt; 1 week before the 1st scheduled PK&lt;br&gt;        study or anytime during the study period.&lt;br&gt;&lt;br&gt;        Patients whose serum creatinine changes by &gt; 25% within 2 weeks prior to study initiation.&lt;br&gt;&lt;br&gt;        Patients whose hematocrit &lt; 28%. Patients who received other organ transplants in addition&lt;br&gt;        to a kidney or heart. Patients who are pregnant or breast-feeding. Patients prescribed&lt;br&gt;        bile acids, bile acid sequestrants, potassium binding resins, or&lt;br&gt;        magnesium/aluminum-containing antacids.&lt;br&gt;&lt;br&gt;        -&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Transplant Recipient;Heart Transplant Recipient</Condition>
    <Intervention>Drug: Mycophenolate mofetil;Drug: Valganciclovir</Intervention>
    <Primary_outcome>To determine whether a clinically significant pharmacokinetic drug interaction exists between mycophenolate mofetil and valganciclovir under steady state conditions in renal and heart transplant recipients</Primary_outcome>
    <Secondary_outcome>To determine whether the effects of valganciclovir on mycophenolate mofetil pharmacokinetic parameters are deferent between renal and heart transplant recipients</Secondary_outcome>
    <Secondary_ID>Val060</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Hoffmann-La Roche</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2858684</Internal_Number>
    <TrialID>NCT00199875</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Treatment of Patients With Advanced Renal Cancer With a Radio-labeled Antibody, Yttrium-90 Conjugated Chimeric G250</Public_title>
    <Scientific_title>Cohort Study of Increasing Doses of Yttrium-90 Conjugated to Chimeric Monoclonal Antibody cG250 (90Y-DOTA-cG250) in Patients With Advanced Renal Cancer</Scientific_title>
    <Acronym />
    <Primary_sponsor>Ludwig Institute for Cancer Research</Primary_sponsor>
    <Date_registration3>20050913</Date_registration3>
    <Date_registration>13/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00199875</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2005</Date_enrollement>
    <Target_size>24</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 1</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  All patients must have histologically proven clear cell renal carcinoma.&lt;br&gt;&lt;br&gt;          -  All patients must have a clinical presentation consistent with metastatic renal&lt;br&gt;             carcinoma.&lt;br&gt;&lt;br&gt;          -  Patients must have bidimensionally measurable disease by conventional imaging methods&lt;br&gt;             including radiography, ultrasound, computer tomography, or other anatomic imaging&lt;br&gt;             modalities.&lt;br&gt;&lt;br&gt;          -  Female patients of childbearing age are required to have a negative pregnancy test&lt;br&gt;             carried out the day of and prior to receiving therapy&lt;br&gt;&lt;br&gt;          -  All patients must be ambulatory with a Karnofsky Performance Status of at least 70&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Significant prior radiotherapy to the entire pelvis and/or lumbosacral spine.&lt;br&gt;&lt;br&gt;          -  Clinically significant cardiac disease&lt;br&gt;&lt;br&gt;          -  Serious infection or other serious illness.&lt;br&gt;&lt;br&gt;          -  Evidence of CNS tumor involvement.&lt;br&gt;&lt;br&gt;          -  Patients known to have hepatobiliary disease and/or HIV/AIDS.&lt;br&gt;&lt;br&gt;          -  Pregnancy or breastfeeding.&lt;br&gt;&lt;br&gt;          -  Refusal or inability to use effective means of contraception in men or women of&lt;br&gt;             childbearing potential.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Cell Carcinoma;Kidney Neoplasm;Renal Cancer;Kidney Cancer</Condition>
    <Intervention>Drug: Yttrium-90 conjugated chimeric G250 (90Y-cG250)</Intervention>
    <Primary_outcome>Toxicity defined by NCI Common Toxicity Criteria</Primary_outcome>
    <Secondary_outcome>Assessment of selective uptake of 111In-cG250 in tumor with favorable biodistribution;Radiation absorbed dose to blood and whole body of 90Y-cG250 as determined by measurement of 111-In in serum and whole body;HACA - measured by ELISA</Secondary_outcome>
    <Secondary_ID>MSKCC IRB #: 05-031;LUD2002-022</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Memorial Sloan-Kettering Cancer Center</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2858684</Internal_Number>
    <TrialID>NCT00199875</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Treatment of Patients With Advanced Renal Cancer With a Radio-labeled Antibody, Yttrium-90 Conjugated Chimeric G250</Public_title>
    <Scientific_title>Cohort Study of Increasing Doses of Yttrium-90 Conjugated to Chimeric Monoclonal Antibody cG250 (90Y-DOTA-cG250) in Patients With Advanced Renal Cancer</Scientific_title>
    <Acronym />
    <Primary_sponsor>Ludwig Institute for Cancer Research</Primary_sponsor>
    <Date_registration3>20050913</Date_registration3>
    <Date_registration>13/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00199875</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2005</Date_enrollement>
    <Target_size>24</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 1</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  All patients must have histologically proven clear cell renal carcinoma.&lt;br&gt;&lt;br&gt;          -  All patients must have a clinical presentation consistent with metastatic renal&lt;br&gt;             carcinoma.&lt;br&gt;&lt;br&gt;          -  Patients must have bidimensionally measurable disease by conventional imaging methods&lt;br&gt;             including radiography, ultrasound, computer tomography, or other anatomic imaging&lt;br&gt;             modalities.&lt;br&gt;&lt;br&gt;          -  Female patients of childbearing age are required to have a negative pregnancy test&lt;br&gt;             carried out the day of and prior to receiving therapy&lt;br&gt;&lt;br&gt;          -  All patients must be ambulatory with a Karnofsky Performance Status of at least 70&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Significant prior radiotherapy to the entire pelvis and/or lumbosacral spine.&lt;br&gt;&lt;br&gt;          -  Clinically significant cardiac disease&lt;br&gt;&lt;br&gt;          -  Serious infection or other serious illness.&lt;br&gt;&lt;br&gt;          -  Evidence of CNS tumor involvement.&lt;br&gt;&lt;br&gt;          -  Patients known to have hepatobiliary disease and/or HIV/AIDS.&lt;br&gt;&lt;br&gt;          -  Pregnancy or breastfeeding.&lt;br&gt;&lt;br&gt;          -  Refusal or inability to use effective means of contraception in men or women of&lt;br&gt;             childbearing potential.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Cell Carcinoma;Kidney Neoplasm;Renal Cancer;Kidney Cancer</Condition>
    <Intervention>Drug: Yttrium-90 conjugated chimeric G250 (90Y-cG250)</Intervention>
    <Primary_outcome>Toxicity defined by NCI Common Toxicity Criteria</Primary_outcome>
    <Secondary_outcome>Assessment of selective uptake of 111In-cG250 in tumor with favorable biodistribution;Radiation absorbed dose to blood and whole body of 90Y-cG250 as determined by measurement of 111-In in serum and whole body;HACA - measured by ELISA</Secondary_outcome>
    <Secondary_ID>MSKCC IRB #: 05-031;LUD2002-022</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Memorial Sloan-Kettering Cancer Center</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2858684</Internal_Number>
    <TrialID>NCT00199875</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Treatment of Patients With Advanced Renal Cancer With a Radio-labeled Antibody, Yttrium-90 Conjugated Chimeric G250</Public_title>
    <Scientific_title>Cohort Study of Increasing Doses of Yttrium-90 Conjugated to Chimeric Monoclonal Antibody cG250 (90Y-DOTA-cG250) in Patients With Advanced Renal Cancer</Scientific_title>
    <Acronym />
    <Primary_sponsor>Ludwig Institute for Cancer Research</Primary_sponsor>
    <Date_registration3>20050913</Date_registration3>
    <Date_registration>13/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00199875</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2005</Date_enrollement>
    <Target_size>24</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 1</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  All patients must have histologically proven clear cell renal carcinoma.&lt;br&gt;&lt;br&gt;          -  All patients must have a clinical presentation consistent with metastatic renal&lt;br&gt;             carcinoma.&lt;br&gt;&lt;br&gt;          -  Patients must have bidimensionally measurable disease by conventional imaging methods&lt;br&gt;             including radiography, ultrasound, computer tomography, or other anatomic imaging&lt;br&gt;             modalities.&lt;br&gt;&lt;br&gt;          -  Female patients of childbearing age are required to have a negative pregnancy test&lt;br&gt;             carried out the day of and prior to receiving therapy&lt;br&gt;&lt;br&gt;          -  All patients must be ambulatory with a Karnofsky Performance Status of at least 70&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Significant prior radiotherapy to the entire pelvis and/or lumbosacral spine.&lt;br&gt;&lt;br&gt;          -  Clinically significant cardiac disease&lt;br&gt;&lt;br&gt;          -  Serious infection or other serious illness.&lt;br&gt;&lt;br&gt;          -  Evidence of CNS tumor involvement.&lt;br&gt;&lt;br&gt;          -  Patients known to have hepatobiliary disease and/or HIV/AIDS.&lt;br&gt;&lt;br&gt;          -  Pregnancy or breastfeeding.&lt;br&gt;&lt;br&gt;          -  Refusal or inability to use effective means of contraception in men or women of&lt;br&gt;             childbearing potential.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Cell Carcinoma;Kidney Neoplasm;Renal Cancer;Kidney Cancer</Condition>
    <Intervention>Drug: Yttrium-90 conjugated chimeric G250 (90Y-cG250)</Intervention>
    <Primary_outcome>Toxicity defined by NCI Common Toxicity Criteria</Primary_outcome>
    <Secondary_outcome>Assessment of selective uptake of 111In-cG250 in tumor with favorable biodistribution;Radiation absorbed dose to blood and whole body of 90Y-cG250 as determined by measurement of 111-In in serum and whole body;HACA - measured by ELISA</Secondary_outcome>
    <Secondary_ID>MSKCC IRB #: 05-031;LUD2002-022</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Memorial Sloan-Kettering Cancer Center</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2858684</Internal_Number>
    <TrialID>NCT00199875</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Treatment of Patients With Advanced Renal Cancer With a Radio-labeled Antibody, Yttrium-90 Conjugated Chimeric G250</Public_title>
    <Scientific_title>Cohort Study of Increasing Doses of Yttrium-90 Conjugated to Chimeric Monoclonal Antibody cG250 (90Y-DOTA-cG250) in Patients With Advanced Renal Cancer</Scientific_title>
    <Acronym />
    <Primary_sponsor>Ludwig Institute for Cancer Research</Primary_sponsor>
    <Date_registration3>20050913</Date_registration3>
    <Date_registration>13/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00199875</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2005</Date_enrollement>
    <Target_size>24</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 1</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  All patients must have histologically proven clear cell renal carcinoma.&lt;br&gt;&lt;br&gt;          -  All patients must have a clinical presentation consistent with metastatic renal&lt;br&gt;             carcinoma.&lt;br&gt;&lt;br&gt;          -  Patients must have bidimensionally measurable disease by conventional imaging methods&lt;br&gt;             including radiography, ultrasound, computer tomography, or other anatomic imaging&lt;br&gt;             modalities.&lt;br&gt;&lt;br&gt;          -  Female patients of childbearing age are required to have a negative pregnancy test&lt;br&gt;             carried out the day of and prior to receiving therapy&lt;br&gt;&lt;br&gt;          -  All patients must be ambulatory with a Karnofsky Performance Status of at least 70&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Significant prior radiotherapy to the entire pelvis and/or lumbosacral spine.&lt;br&gt;&lt;br&gt;          -  Clinically significant cardiac disease&lt;br&gt;&lt;br&gt;          -  Serious infection or other serious illness.&lt;br&gt;&lt;br&gt;          -  Evidence of CNS tumor involvement.&lt;br&gt;&lt;br&gt;          -  Patients known to have hepatobiliary disease and/or HIV/AIDS.&lt;br&gt;&lt;br&gt;          -  Pregnancy or breastfeeding.&lt;br&gt;&lt;br&gt;          -  Refusal or inability to use effective means of contraception in men or women of&lt;br&gt;             childbearing potential.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Cell Carcinoma;Kidney Neoplasm;Renal Cancer;Kidney Cancer</Condition>
    <Intervention>Drug: Yttrium-90 conjugated chimeric G250 (90Y-cG250)</Intervention>
    <Primary_outcome>Toxicity defined by NCI Common Toxicity Criteria</Primary_outcome>
    <Secondary_outcome>Assessment of selective uptake of 111In-cG250 in tumor with favorable biodistribution;Radiation absorbed dose to blood and whole body of 90Y-cG250 as determined by measurement of 111-In in serum and whole body;HACA - measured by ELISA</Secondary_outcome>
    <Secondary_ID>MSKCC IRB #: 05-031;LUD2002-022</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Memorial Sloan-Kettering Cancer Center</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2859007</Internal_Number>
    <TrialID>NCT00204191</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Comparison of the Two Immunosuppressive Regimens Based on Tacrolimus and Cyclosporine Following Kidney Transplantation</Public_title>
    <Scientific_title>Open, Prospective, Randomized Study to Compare the Efficacy and Safety of Immunosuppression Regimens Based on Cyclosporine (Neoral®) and Tacrolimus (Prograf®) in Renal Transplant Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>Uniwersytet Mikolaja Kopernika w Toruniu</Primary_sponsor>
    <Date_registration3>20050912</Date_registration3>
    <Date_registration>12/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00204191</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2003</Date_enrollement>
    <Target_size>300</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Crossover Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  First or second cadaveric kidney transplantation&lt;br&gt;&lt;br&gt;          -  Age over 18 years old&lt;br&gt;&lt;br&gt;          -  Specific indications or contraindications for cyclosporine or tacrolimus are absent&lt;br&gt;&lt;br&gt;          -  Informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Specific indications for use of cyclosporine or tacrolimus&lt;br&gt;&lt;br&gt;          -  Specific contraindications for use of cyclosporine or tacrolimus&lt;br&gt;&lt;br&gt;          -  Participation in another interventional clinical trial&lt;br&gt;&lt;br&gt;          -  Pregnancy or lactation&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Transplantation</Condition>
    <Intervention>Drug: tacrolimus</Intervention>
    <Primary_outcome>graft survival;patient survival</Primary_outcome>
    <Secondary_outcome>renal function measured by serum creatinine (SCr);lipid profile;total cost of the treatment</Secondary_outcome>
    <Secondary_ID>IDS PL-02-RG-122;1/25/03</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Astellas Pharma Inc</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2860434</Internal_Number>
    <TrialID>NCT00223067</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Induction of Donor-Specific Tolerance in Renal Allograft Recipients (Living Donor) With TAIZ-Monocytes</Public_title>
    <Scientific_title>A Multi-Center Open-Labeled Study of the Administration of Allogenic and Autologous Regulatory Cells for the Induction of Donor-Specific Tolerance in Renal Allograft Recipients (Living Donor)</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Schleswig-Holstein</Primary_sponsor>
    <Date_registration3>20050914</Date_registration3>
    <Date_registration>14/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00223067</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>65 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2005</Date_enrollement>
    <Target_size>10</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 1</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria&lt;br&gt;&lt;br&gt;        Patients must meet all the following inclusion criteria to be considered for admission to&lt;br&gt;        the trial:&lt;br&gt;&lt;br&gt;          1. Male or female adult patients aged between 18 and 64 years (inclusive). A female of&lt;br&gt;             childbearing potential may be enrolled provided she:&lt;br&gt;&lt;br&gt;               -  has a negative pregnancy test at Screening and&lt;br&gt;&lt;br&gt;               -  is routinely using adequate contraception prior to and during the study and&lt;br&gt;&lt;br&gt;               -  agrees not to attempt to become pregnant during the study and&lt;br&gt;&lt;br&gt;               -  is not lactating A female of non-childbearing potential will be defined as one&lt;br&gt;                  who has been postmenopausal for at least one year or has been surgically&lt;br&gt;                  sterilised.&lt;br&gt;&lt;br&gt;          2. Patients receiving a first renal transplant.&lt;br&gt;&lt;br&gt;          3. Patients who fulfil the criteria to receive an allogenic renal transplant (according&lt;br&gt;             to the Eurotransplant (ET) manual on organ allocation and the Bundesärztekammer&lt;br&gt;             allocation criteria) and who are listed on a waiting list.&lt;br&gt;&lt;br&gt;          4. Patients who, after the nature of the study and the disclosure of their data has been&lt;br&gt;             explained to them, have freely given Informed Consent in writing.&lt;br&gt;&lt;br&gt;          5. In vitro demonstration of the suppressive effect of the donor TAIC for the&lt;br&gt;             donor-recipient pair.&lt;br&gt;&lt;br&gt;        Exclusion Criteria (for the recipient)&lt;br&gt;&lt;br&gt;        Exclusion Criteria (for the recipient):&lt;br&gt;&lt;br&gt;        Patients presenting any of the following exclusion criteria must not be included in the&lt;br&gt;        trial:&lt;br&gt;&lt;br&gt;          1. Patients who have received a renal transplant.&lt;br&gt;&lt;br&gt;          2. Patients who have an active infection at the time of entry into the study&lt;br&gt;             (Screening).&lt;br&gt;&lt;br&gt;          3. Recipient and donor pairs who show the following incompatible EBV or CMV&lt;br&gt;             constellation: the donor is EBV or CMV positive and the recipient is EBV or CMV&lt;br&gt;             negative.&lt;br&gt;&lt;br&gt;          4. Patients and/or donors who have positive evidence of HIV or have active virus&lt;br&gt;             hepatitis B and C.&lt;br&gt;&lt;br&gt;          5. Patients with a history of alcohol and/or drug abuse or sepsis.&lt;br&gt;&lt;br&gt;          6. Patients who are pregnant women or nursing mothers.&lt;br&gt;&lt;br&gt;          7. Known hypersensitivity or contraindication to one of the immunosuppressives&lt;br&gt;             administered during the course of the study: ATG, tacrolimus, or steroids&lt;br&gt;             (prednisolone).&lt;br&gt;&lt;br&gt;          8. Patients with a history or present symptoms of autoimmune vasculitis.&lt;br&gt;&lt;br&gt;          9. Detection of &gt; 5% HLA antibodies (all current and historic values).&lt;br&gt;&lt;br&gt;         10. Patients with a malignancy or history of malignancy.&lt;br&gt;&lt;br&gt;         11. Patients with renal insufficiency due to a vasculitis.&lt;br&gt;&lt;br&gt;         12. Patients whose condition requires continuous systemic administration of&lt;br&gt;             immunosuppressives.&lt;br&gt;&lt;br&gt;         13. Missing immunosuppressive effect of the donor TAIC for the donor-recipient pair in&lt;br&gt;             vitro test.&lt;br&gt;&lt;br&gt;         14. Patients who are simultaneously participating or plan to participate in any other&lt;br&gt;             clinical study.&lt;br&gt;&lt;br&gt;         15. Psychiatric or emotional problems or lack of knowledge of the German language which&lt;br&gt;             would invalidate the giving of Informed Consent or limit the ability of the subject&lt;br&gt;             to comply with study requirements.&lt;br&gt;&lt;br&gt;         16. Unwillingness or inability to provide Informed Consent or to participate&lt;br&gt;             satisfactorily for the entire trial period&lt;br&gt;&lt;br&gt;         17. Patients with corresponding donors presenting any one of the exclusion criteria&lt;br&gt;             documented in the Eurotransplant guidelines ( ) must not be included in the trial.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Transplantation</Condition>
    <Intervention>Drug: TAIZ</Intervention>
    <Primary_outcome>graft survival and reduction or withdrawal of immunosuppressives after treatment with Transplant-Acceptance Inducing Cells (TAIC) and autologous regulatory T cells (tregs);serum creatinine;rejection episodes;necessity for re-introduction of any immunosuppressives.</Primary_outcome>
    <Secondary_outcome>safety and tolerability of the treatment with Transplant-Acceptance Inducing Cells (TAIC) in terms of rejection episodes and Adverse Events (AEs)</Secondary_outcome>
    <Secondary_ID>005</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2860982</Internal_Number>
    <TrialID>NCT00230412</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Study of Heat Shock Proteins as Prognostic Factor of Acute Renal Failure in Children (HSP-Study)</Public_title>
    <Scientific_title>Study of Heat Shock Proteins as Prognostic Factor of Acute Renal Failure in Children (HSP-Study)</Scientific_title>
    <Acronym>HSP</Acronym>
    <Primary_sponsor>University of Munich Children's Clinic</Primary_sponsor>
    <Date_registration3>20050928</Date_registration3>
    <Date_registration>28/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00230412</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>18 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2005</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case Control, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Between 0 and 18 years of age.&lt;br&gt;&lt;br&gt;          -  Either severe sepsis, shock of any origin or asphyxia.&lt;br&gt;&lt;br&gt;          -  Operated patients with operative or post-operative transfusion requirement of at&lt;br&gt;             least 0.5 x 80 ml/kg body weight of erythrocyte concentrate.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Existing affection of the kidney.&lt;br&gt;&lt;br&gt;          -  Kidney transplantation.&lt;br&gt;&lt;br&gt;          -  Missing written consent of the parents or guardian (if applicable).&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Failure, Acute</Condition>
    <Primary_outcome>Acute renal failure.</Primary_outcome>
    <Secondary_ID>Projektnummer 233-05;HSP-233-05</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Ludwig-Maximilians - University of Munich</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2861086</Internal_Number>
    <TrialID>NCT00231803</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>The Canadian Prevention of Renal and Cardiovascular Endpoints Trial</Public_title>
    <Scientific_title>Canadian Collaborative Group for the Prevention of Illness in Chronic Renal Disease. The Canadian Prevention of Renal and Cardiovascular Endpoints Trial</Scientific_title>
    <Acronym />
    <Primary_sponsor>Memorial University of Newfoundland</Primary_sponsor>
    <Date_registration3>20050930</Date_registration3>
    <Date_registration>30/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00231803</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>40 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2005</Date_enrollement>
    <Target_size>500</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Stratum 1 (expected about 50% of trial subjects): Diabetes mellitus (by clinical&lt;br&gt;             history with documented prior plasma glucose levels in the diabetic range, or on&lt;br&gt;             hypoglycemic medications) and CKD as documented by calculated (Cockroft-Gault&lt;br&gt;             equation) creatinine clearance between 25 and 60 mls/min/1.73m2 derived from the&lt;br&gt;             screening serum creatinine value and the next most recent known value from more than&lt;br&gt;             2 weeks prior; OR&lt;br&gt;&lt;br&gt;        Stratum 2 (expected about 20% of trial subjects): Non-diabetic with CKD as defined for&lt;br&gt;        Stratum 1 and proteinuria of &gt; 1g/L by dipstick in random urine at screening; OR&lt;br&gt;&lt;br&gt;        Stratum 3 (expected about 30% of trial subjects): Non-diabetic with CKD as defined for&lt;br&gt;        stratum 1, but without proteinuria as for stratum 2 at screening&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Unwilling to provide informed consent&lt;br&gt;&lt;br&gt;          -  Likely to die of any known existing disease within 6 months&lt;br&gt;&lt;br&gt;          -  Recently unstable/advanced cardiovascular disease (MI or acute coronary syndrome,&lt;br&gt;             hospitalized heart failure, TIA or stroke, leg amputation or gangrene in past 6&lt;br&gt;             months)&lt;br&gt;&lt;br&gt;          -  Currently receiving active treatment for a malignant, neoplastic disease other than&lt;br&gt;             localized non-melanoma skin cancer&lt;br&gt;&lt;br&gt;          -  Progressive kidney disease currently treated by immunotherapy&lt;br&gt;&lt;br&gt;          -  Currently receiving dialysis or likely to do so within 6 months&lt;br&gt;&lt;br&gt;          -  Current organ transplant recipient (or planned within 6 months)&lt;br&gt;&lt;br&gt;          -  Currently receiving ongoing care for CKD, or cardiovascular disease, in a multiple&lt;br&gt;             intervention, disease management program.&lt;br&gt;&lt;br&gt;          -  Currently enrolled in another interventional trial&lt;br&gt;&lt;br&gt;          -  Residing in a location not amenable to follow up for the trial&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease</Condition>
    <Intervention>Procedure: Combined CKD and CVD Prevention;Procedure: Cardiovascular Disease prevention;Procedure: Treatment of Chronic Kidney Disease complications</Intervention>
    <Primary_outcome>Time to major cardiovascular event(myocardial infarction, stroke, coronary or peripheral revascularization, hospitalization for heart failure or unstable angina, or death due to cardiovascular cause);- Time to first major clinical event (ESRD, non-fatal cardiovascular events as in secondary (a) or all cause death)</Primary_outcome>
    <Secondary_outcome>• # patients screened via lab;• # patients seen meeting eligibility criteria;• # patients enrolled over documented period;• OR similar assessment of the success of recruitment if non-laboratory based;• Description of baseline characteristics including care in place at study entry to compare to existing databases on clinic patients and community data;• Description of how the intervention is applied (by chart review, interviews and activity records);• Assessment of the workload and study staff requirements;• The % of patients having a cardiovascular or kidney related clinical outcome event by one and two years of study;• The % of patients lost to follow-up each year from the experimental and control groups;• The % of patients in the experimental and control groups achieving targets for blood pressure, lipids, diabetes control, anemia, and mineral metabolism at six months, one and two years.;• The % of patients in the experimental and control groups smoking at six months, one and two years.;• The quality of life of those in the experimental and control groups at baseline, six, twelve and 24 months.;• The satisfaction with care received in the experimental and control groups</Secondary_outcome>
    <Secondary_ID>CIHR Grant# NET-54003;HIC#04.154</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Canadian Institutes of Health Research  (CIHR);Canadian Diabetes Association;The Kidney Foundation of Canada;Heart and Stroke Foundation;Merck Frosst Canada Ltd.;Amgen;Janssen-Ortho Inc., Canada</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2861350</Internal_Number>
    <TrialID>NCT00235287</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease</Public_title>
    <Scientific_title>Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study</Scientific_title>
    <Acronym />
    <Primary_sponsor>Herlev Hospital</Primary_sponsor>
    <Date_registration3>20051006</Date_registration3>
    <Date_registration>06/10/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00235287</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2005</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Pharmacodynamics Study, Intervention Model:  Crossover Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Creatinine: 150-350 micromol/L&lt;br&gt;&lt;br&gt;          -  Blood pressure &gt; 110 systolic&lt;br&gt;&lt;br&gt;          -  Negative pregnancy test for fertile women&lt;br&gt;&lt;br&gt;          -  Written and oral informed consent from the patient&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Treatment with both ACE-inhibitors (ACE-I) and angiotensin receptor blockers&lt;br&gt;&lt;br&gt;          -  Pregnancy or breastfeeding&lt;br&gt;&lt;br&gt;          -  Treatment with immunosuppressive medication, steroids or non-steroidal&lt;br&gt;             anti-inflammatory drugs (NSAIDs)&lt;br&gt;&lt;br&gt;          -  Serious chronic heart failure (New York Heart Association [NYHA] III-IV)&lt;br&gt;&lt;br&gt;          -  Chronic liver disease&lt;br&gt;&lt;br&gt;          -  Suspicion or verified kidney artery stenosis&lt;br&gt;&lt;br&gt;          -  Cardiac arrhythmia and/or implanted pacemaker&lt;br&gt;&lt;br&gt;          -  Myocardial infarction or cerebrovascular incidence within the last 3 months&lt;br&gt;&lt;br&gt;          -  Allergy towards ACE-I or angiotensin receptor blockers&lt;br&gt;&lt;br&gt;          -  Amputation of a whole extremity or the crural or femoral part of the leg&lt;br&gt;&lt;br&gt;          -  Dementia or a psychological condition that makes understanding of the examination&lt;br&gt;             conditions impossible&lt;br&gt;&lt;br&gt;          -  Dialysis or renal transplantation&lt;br&gt;&lt;br&gt;          -  Treatment with aldosterone antagonists&lt;br&gt;&lt;br&gt;          -  Hyperkalemia &gt; 5.5 mmol/l&lt;br&gt;&lt;br&gt;          -  Another serious chronic non-renal disease&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Failure, Chronic;Cardiovascular Diseases</Condition>
    <Intervention>Drug: Candesartan and enalapril;Drug: candesartan and enalapril;Drug: candesartan and enalapril;Drug: candesartan and enalapril</Intervention>
    <Primary_outcome>pulse wave velocity (aortic and brachial)</Primary_outcome>
    <Secondary_outcome>augmentation index;blood pressure (brachial and aortic);buckbergs index;time to reflection;pulse pressure;change in glomerular filtration rate (GFR);blood parameters</Secondary_outcome>
    <Secondary_ID>RAS-block study</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2861881</Internal_Number>
    <TrialID>NCT00242398</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Hemodialysis Without Anticoagulation in Intensive Care Unit</Public_title>
    <Scientific_title>Heparin Free Hemodialysis for Patients With Bleeding High Risk in ICU. Randomized Study: Heparin Free Dialysis With Intermittent Saline Flushes Versus Heparin Free Dialysis With Nephral 400ST (AN69ST, Hospal, France)</Scientific_title>
    <Acronym />
    <Primary_sponsor>Centre Hospitalier Départemental</Primary_sponsor>
    <Date_registration3>20051018</Date_registration3>
    <Date_registration>18/10/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00242398</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2005</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Crossover Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  age &gt; 18 years&lt;br&gt;&lt;br&gt;          -  patient with high risk bleeding&lt;br&gt;&lt;br&gt;          -  patient requiring dialytic therapy in intensive care unit&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Pregnancy&lt;br&gt;&lt;br&gt;          -  History of heparin-induced thrombocytopenia or serious heparin allergy&lt;br&gt;&lt;br&gt;          -  History of serious membrane dialysis allergy&lt;br&gt;&lt;br&gt;          -  Treatment by any of following medications  24H within  the inclusion:&lt;br&gt;&lt;br&gt;        prophylactic or therapeutic anticoagulation with unfractioned heparin or low molecular&lt;br&gt;        weight heparin nonsteroidal anti-inflammatory agents direct thrombin inhibitors,&lt;br&gt;        antithrombin concentrate, activated protein C, anti-factor Xa pentasaccharide&lt;br&gt;&lt;br&gt;          -  Treatement by acetylsalicylic acid or other antiplatelet agent excluding platelet&lt;br&gt;             glycoprotein IIb/IIIa antagonists  7 days within the inclusion.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Failure;Critically Ill;Hemorrhage</Condition>
    <Intervention>Device: AN69 ST</Intervention>
    <Primary_outcome>Early stop dialysis treatment for rapid and persistent elevations in venous extracorporeal pressure secondary to extracorporeal thrombosis.</Primary_outcome>
    <Secondary_outcome>Blood lost associated with extracorporeal thrombosis or active bleeding;Necessary time of nurse's work;Weight lost patients  during dialysis treatment</Secondary_outcome>
    <Secondary_ID>HDI-FH</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2862001</Internal_Number>
    <TrialID>NCT00243958</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Aluminum and Auditory Function in ESRD</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>National Taiwan University Hospital</Primary_sponsor>
    <Date_registration3>20051023</Date_registration3>
    <Date_registration>23/10/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00243958</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>20 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2005</Date_enrollement>
    <Target_size>80</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case Control, Primary Purpose:  Screening, Time Perspective:  Cross-Sectional, Time Perspective:  Retrospective/Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        ESRD patients and healthy volunteers, without history of occupational noise exposure, ear&lt;br&gt;        infection, ear surgery, active systemic infection, previous ototoxic drugs exposure or&lt;br&gt;        congenital hearing defect&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        Unsuitable to undergo hearing test, with history of occupational noise exposure, ear&lt;br&gt;        infection, ear surgery, active systemic infection, previous ototoxic drugs exposure or&lt;br&gt;        congenital hearing defect&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End-Stage Renal Disease (ESRD)</Condition>
    <Secondary_ID>9461701003</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2862916</Internal_Number>
    <TrialID>NCT00256100</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.</Public_title>
    <Scientific_title>Assessment of the Safety and Efficacy of Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Renal Failure.</Scientific_title>
    <Acronym />
    <Primary_sponsor>Melbourne Health</Primary_sponsor>
    <Date_registration3>20051117</Date_registration3>
    <Date_registration>17/11/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00256100</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2004</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Adult patients (18 years or over) admitted to the ICU and expected to stay for more&lt;br&gt;             than 48 hours.&lt;br&gt;&lt;br&gt;          2. Patients who require continuous renal replacement therapy.&lt;br&gt;&lt;br&gt;          3. Patients who consent or if the patient is not competent, the next of kin who consent&lt;br&gt;             to inclusion in the study.  .&lt;br&gt;&lt;br&gt;             -&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Patients aged less than 18 years of age.&lt;br&gt;&lt;br&gt;          2. Patients who are pregnant&lt;br&gt;&lt;br&gt;          3. Patients with a contraindication to anticoagulation for pre existing bleeding&lt;br&gt;             diathesis&lt;br&gt;&lt;br&gt;          4. Patients or next of kin who do not consent to study inclusion.  -&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Patients Requiring Haemofiltration for Acute Renal Failure.</Condition>
    <Intervention>Drug: Fondaparinux  Sodium</Intervention>
    <Primary_outcome>The study will evaluate the duration of filter patency using fondaparinux as an anticoagulant in haemofiltration and compare this to the current standard haemofilter anticoagulant, enoxaparin.</Primary_outcome>
    <Secondary_outcome>To assess the incidence of complications, primary bleeding with fondaparinux compared to enoxaparin in this setting.</Secondary_outcome>
    <Secondary_ID>2004.066</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2863018</Internal_Number>
    <TrialID>NCT00257439</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Vitamin Metabolism in Kidney Disease</Public_title>
    <Scientific_title>Vitamin Metabolism in Kidney Disease</Scientific_title>
    <Acronym />
    <Primary_sponsor>Aalborg Hospital</Primary_sponsor>
    <Date_registration3>20051121</Date_registration3>
    <Date_registration>21/11/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00257439</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>December 2005</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Admission to the Department of Nephrology, Aalborg Hospital&lt;br&gt;&lt;br&gt;          -  Elevated serum creatinine&lt;br&gt;&lt;br&gt;          -  Proteinuria&lt;br&gt;&lt;br&gt;          -  Informed and written consent&lt;br&gt;&lt;br&gt;        Control subjects:&lt;br&gt;&lt;br&gt;          -  Normal serum creatinine and creatinine clearance&lt;br&gt;&lt;br&gt;          -  No proteinuria&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Vitamin supplementation (exceeding predefined values)&lt;br&gt;&lt;br&gt;          -  Renal replacement therapy (dialysis)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Failure</Condition>
    <Secondary_ID>VN 2005/44</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>University of Aarhus;Aarhus University Hospital</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2864374</Internal_Number>
    <TrialID>NCT00275509</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch</Public_title>
    <Scientific_title>Open Label Randomized Study of Thymoglobulin Versus Daclizumab Induction Therapies for the Reduction of Acute Rejection in Live Donor Kidney Transplant Recipients With a Positive Crossmatch</Scientific_title>
    <Acronym />
    <Primary_sponsor>Johns Hopkins University</Primary_sponsor>
    <Date_registration3>20060110</Date_registration3>
    <Date_registration>10/01/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00275509</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2006</Date_enrollement>
    <Target_size>110</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Adult (18 years or older)&lt;br&gt;&lt;br&gt;          -  End-stage renal disease&lt;br&gt;&lt;br&gt;          -  Identified to have positive lymphocytotoxic crossmatch or flow cytometric&lt;br&gt;             crossmatch with live donor&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Deceased donor recipients&lt;br&gt;&lt;br&gt;          -  Pregnancy&lt;br&gt;&lt;br&gt;          -  Active infection&lt;br&gt;&lt;br&gt;          -  History of cancer within the past two years (with the exception of non-melanomatous&lt;br&gt;             skin cancer)&lt;br&gt;&lt;br&gt;          -  History of heparin induced thrombocytopenia&lt;br&gt;&lt;br&gt;          -  Medical contraindications to transplant procedure&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Failure, Chronic</Condition>
    <Intervention>Drug: Thymoglobulin</Intervention>
    <Primary_outcome>6-month acute cellular and antibody-mediated rejection rate</Primary_outcome>
    <Secondary_ID>05-06-29-03</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2865601</Internal_Number>
    <TrialID>NCT00291863</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Simvastatin Effect on End Stage Renal Failure Patients Treated by Peritoneal Dialysis</Public_title>
    <Scientific_title>Simvastatin Effect on Endothelium Dependent Venodilation in Chronic Renal Failure Patients Treated by Peritoneal Dialysis</Scientific_title>
    <Acronym />
    <Primary_sponsor>Federal University of São Paulo</Primary_sponsor>
    <Date_registration3>20060214</Date_registration3>
    <Date_registration>14/02/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00291863</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>February 2006</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double-Blind, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  end stage renal failure&lt;br&gt;&lt;br&gt;          -  peritoneal dialysis&lt;br&gt;&lt;br&gt;          -  LDL cholesterol &gt; 100mg/dL&lt;br&gt;&lt;br&gt;          -  &gt; 18 years and &lt; 80 years&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  using statin or nitrate&lt;br&gt;&lt;br&gt;          -  liver disease&lt;br&gt;&lt;br&gt;          -  diabetes mellitus&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Failure, End Stage;Peritoneal Dialysis</Condition>
    <Intervention>Drug: Simvastatin</Intervention>
    <Primary_outcome>endothelial venodilation</Primary_outcome>
    <Secondary_outcome>Inflammation markers (C-reactive protein, IL-6, TNF);Lipoproteins;Oxidative stress</Secondary_outcome>
    <Secondary_ID>0089/04</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2865925</Internal_Number>
    <TrialID>NCT00296296</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Immunosuppression Impact on the Metabolic Control of First Kidney Transplant Recipients With Pre-Existing Type 2 Diabetes (DM)</Public_title>
    <Scientific_title>Randomized Open Label Study Comparing the Metabolic Control of First Kidney Transplant Recipients With Pre-Existing Type 2 Diabetes (DM) Receiving Either Prograf or Neoral as Part of a Thymoglobulin Induction, Prednisone Free and Blood Monitored Cellcept Immunosuppressive Drug Regimen.</Scientific_title>
    <Acronym />
    <Primary_sponsor>Stanford University</Primary_sponsor>
    <Date_registration3>20060222</Date_registration3>
    <Date_registration>22/02/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00296296</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>65 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2005</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Crossover Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        Inclusion Criteria&lt;br&gt;&lt;br&gt;          1. Patient is a recipient of a first cadaveric kidney, or a kidney living donor&lt;br&gt;             mismatched (at least one mismatch.)&lt;br&gt;&lt;br&gt;          2. Patient is a minimum of 18 years of age at the time of transplant.&lt;br&gt;&lt;br&gt;          3. Patient has type 2 non-insulin dependent diabetes.&lt;br&gt;&lt;br&gt;          4. Patient or legal guardian has signed and dated an Ethics Committee-approved informed&lt;br&gt;             consent document and is willing and able to follow study procedures.&lt;br&gt;&lt;br&gt;          5. If female and is childbearing potential, patient has a negative pregnancy test and&lt;br&gt;             utilizes adequate contraceptive methods.&lt;br&gt;&lt;br&gt;        Exclusion Criteria&lt;br&gt;&lt;br&gt;          1. Recipients of a transplant graft from a donor age 65 and older.&lt;br&gt;&lt;br&gt;          2. Recipient of a multi-organ transplant.&lt;br&gt;&lt;br&gt;          3. Patients who are being re-transplanted will not be eligible for study.&lt;br&gt;&lt;br&gt;          4. Patients who have lost a previous graft to rejection less than one year from&lt;br&gt;             transplant.&lt;br&gt;&lt;br&gt;          5. Patient has any form of substance abuse, psychiatric disorder, or a condition in the&lt;br&gt;             opinion of the investigator, may invalidate communication with the investigator.&lt;br&gt;&lt;br&gt;          6. PRA &gt; 30%&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Transplant;Diabetes Mellitus, Type 2;Diabetic Nephropathy</Condition>
    <Intervention>Drug: Cyclosporin;Drug: Tacrolimus;Behavioral: Diabetes Education / Management</Intervention>
    <Primary_outcome>Primary Endpoints:;Maintenance of glucose metabolism within the ADA criteria without usage of insulin at 3, 6 and 12 months after kidney transplantation.;Number of class of oral agents required to maintain glycemic control within the ADA criteria at 3, 6 and 12 months after kidney transplantation;Insulin requirements.</Primary_outcome>
    <Secondary_outcome>Markers of glucose tolerance and insulin secretion (OGTT, C-peptide, insulin levels, Glycosylated hemoglobin, fructosamine) at 3, 6 and 12 months after kidney transplantation.;Lipid metabolism, change in BMI and waist measurements at 3, 6 and 12 months after kidney transplantation.;Patient and graft survival at one year post transplantation);Incidence of biopsy proven acute rejection at 6 month post transplantation;Kidney function at one year (creatinine clearance and proteinuria);Infection rate;Re-admission related to diabetes complication</Secondary_outcome>
    <Secondary_ID>95442</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2866799</Internal_Number>
    <TrialID>NCT00307983</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effect of Malnutrition on the Prognosis in Hemodialysis Patients</Public_title>
    <Scientific_title>Effect of Malnutrition on the Prognosis in Hemodialysis Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Shizuoka</Primary_sponsor>
    <Date_registration3>20060327</Date_registration3>
    <Date_registration>27/03/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00307983</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2004</Date_enrollement>
    <Target_size>600</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Defined Population, Observational Model:  Natural History, Time Perspective:  Longitudinal, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  hemodialysis for at least 6 months&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  disabled patients&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Renal Failure;Hemodialysis;Malnutrition</Condition>
    <Secondary_ID>CT2006002</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2866940</Internal_Number>
    <TrialID>NCT00309829</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Vaccine Therapy in Treating Patients With Newly Diagnosed Stage IV Kidney Cancer</Public_title>
    <Scientific_title>A Phase IIa Study Testing the Biologic Activity and Safety of Autologous Renal Cell Carcinoma Total mRNA and huCD40L Newly Diagnosed Stage IV Renal Cell Carcinoma</Scientific_title>
    <Acronym />
    <Primary_sponsor>Jonsson Comprehensive Cancer Center</Primary_sponsor>
    <Date_registration3>20060329</Date_registration3>
    <Date_registration>29/03/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00309829</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2005</Date_enrollement>
    <Target_size>26</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        DISEASE CHARACTERISTICS:&lt;br&gt;&lt;br&gt;          -  Histologically confirmed clear cell renal cell carcinoma (RCC)&lt;br&gt;&lt;br&gt;               -  Newly diagnosed disease&lt;br&gt;&lt;br&gt;               -  Metastatic, stage IV disease (any T, any N, and M1)&lt;br&gt;&lt;br&gt;          -  Confirmed diagnosis following nephrectomy on study OR has undergone nephrectomy for&lt;br&gt;             RCC within the past 3 months AND meets the following criteria:&lt;br&gt;&lt;br&gt;               -  Clear cell histology&lt;br&gt;&lt;br&gt;               -  Metastatic lesion available for RNA isolation&lt;br&gt;&lt;br&gt;               -  Stable disease not requiring any other antitumor treatment modality&lt;br&gt;&lt;br&gt;               -  Prior nephrectomy following &lt; stage IV disease with subsequent development of&lt;br&gt;                  metachronous metastasis allowed&lt;br&gt;&lt;br&gt;          -  No requirement for bilateral nephrectomy for renal cancer&lt;br&gt;&lt;br&gt;          -  Measurable disease, defined as = 1 unidimensionally measurable lesion = 20 mm by&lt;br&gt;             conventional techniques OR = 10 mm by spiral CT scan&lt;br&gt;&lt;br&gt;               -  Bone metastases are not considered measurable disease&lt;br&gt;&lt;br&gt;          -  No brain metastases by MRI&lt;br&gt;&lt;br&gt;        PATIENT CHARACTERISTICS:&lt;br&gt;&lt;br&gt;          -  ECOG performance status 0-1&lt;br&gt;&lt;br&gt;          -  Memorial Sloan Kettering Cancer Center risk group 0-1&lt;br&gt;&lt;br&gt;          -  Body weight = 30 kg&lt;br&gt;&lt;br&gt;          -  Normal renal function in the contralateral kidney (kidney without tumor)&lt;br&gt;&lt;br&gt;          -  Not pregnant or nursing&lt;br&gt;&lt;br&gt;          -  Negative pregnancy test&lt;br&gt;&lt;br&gt;          -  Fertile patients must use effective contraception&lt;br&gt;&lt;br&gt;          -  WBC = 4,000/mm^3&lt;br&gt;&lt;br&gt;          -  Platelet count = 100,000/mm^3&lt;br&gt;&lt;br&gt;          -  Absolute lymphocyte count = 700/mm^3&lt;br&gt;&lt;br&gt;          -  Hemoglobin = 10 g/dL&lt;br&gt;&lt;br&gt;               -  Transfusions for hemoglobin = 10 g/dL allowed prior to or post-nephrectomy and&lt;br&gt;                  for up to 2 weeks prior to the first leukapheresis&lt;br&gt;&lt;br&gt;          -  Creatinine &lt; 1.5 mg/dL&lt;br&gt;&lt;br&gt;          -  Total bilirubin &lt; 2.0 mg/dL&lt;br&gt;&lt;br&gt;          -  AST and ALT &lt; 2 times upper limit of normal&lt;br&gt;&lt;br&gt;          -  PT and PTT &lt; 1.5 times control&lt;br&gt;&lt;br&gt;          -  Corrected calcium &lt; 10.5 mg/dL&lt;br&gt;&lt;br&gt;          -  No cardiopulmonary disease&lt;br&gt;&lt;br&gt;          -  No circulatory compromise&lt;br&gt;&lt;br&gt;          -  No hepatic or renal dysfunction&lt;br&gt;&lt;br&gt;          -  No uncontrolled hypertension&lt;br&gt;&lt;br&gt;          -  No type I diabetes mellitus&lt;br&gt;&lt;br&gt;          -  No active autoimmune disease including, but not limited to the following:&lt;br&gt;&lt;br&gt;               -  Rheumatoid arthritis (RF-positive arthritis with current or recent flare)&lt;br&gt;&lt;br&gt;               -  Inflammatory bowel disease&lt;br&gt;&lt;br&gt;               -  Systemic lupus erythematosus (confirmed with anti-nuclear antibody = 1:80)&lt;br&gt;&lt;br&gt;               -  Ankylosing spondylitis&lt;br&gt;&lt;br&gt;               -  Hashimoto's disease&lt;br&gt;&lt;br&gt;               -  Scleroderma&lt;br&gt;&lt;br&gt;               -  Multiple sclerosis&lt;br&gt;&lt;br&gt;               -  Autoimmune hemolytic anemia&lt;br&gt;&lt;br&gt;               -  Immune thrombocytopenic purpura&lt;br&gt;&lt;br&gt;          -  No other malignancy within the past 5 years except adequately treated carcinoma in&lt;br&gt;             situ of the cervix or nonmelanoma skin cancer&lt;br&gt;&lt;br&gt;          -  No active infections&lt;br&gt;&lt;br&gt;          -  HIV negative&lt;br&gt;&lt;br&gt;          -  No viral hepatitis&lt;br&gt;&lt;br&gt;          -  No history of hypercalcemia or symptomatic hypercalcemia requiring management&lt;br&gt;&lt;br&gt;          -  No known hypersensitivity to dimethyl sulfoxide&lt;br&gt;&lt;br&gt;          -  No other serious medical condition that would preclude study compliance&lt;br&gt;&lt;br&gt;        PRIOR CONCURRENT THERAPY:&lt;br&gt;&lt;br&gt;          -  See Disease Characteristics&lt;br&gt;&lt;br&gt;          -  At least 2 weeks since prior medications containing acetyl salicylic acid&lt;br&gt;&lt;br&gt;          -  No prior therapy for renal cancer&lt;br&gt;&lt;br&gt;          -  At least 2 months since prior and no concurrent chemotherapeutic agents&lt;br&gt;&lt;br&gt;          -  At least 2 months since prior and no concurrent growth factors, cytokines, or white&lt;br&gt;             lineage colony stimulating factors (e.g., filgrastim [G-CSF] and sargramostim&lt;br&gt;             [GM-CSF])&lt;br&gt;&lt;br&gt;          -  At least 2 months since prior and no concurrent immunosuppressive agents or&lt;br&gt;             immunotherapy, including, but not limited to the following:&lt;br&gt;&lt;br&gt;               -  Chronic topical corticosteroids (allowed to small areas of skin not near&lt;br&gt;                  injection sites with investigator approval)&lt;br&gt;&lt;br&gt;               -  Inhaled corticosteroids (allowed for chronic obstructive pulmonary disease)&lt;br&gt;&lt;br&gt;               -  Azathioprine&lt;br&gt;&lt;br&gt;               -  Cyclosporine&lt;br&gt;&lt;br&gt;          -  More than 28 days since participation in another investigational drug study&lt;br&gt;&lt;br&gt;          -  Recovered from prior radiotherapy&lt;br&gt;&lt;br&gt;          -  No planned or elective anticancer surgical treatment including target lesion&lt;br&gt;             intervention&lt;br&gt;&lt;br&gt;          -  Concurrent radiotherapy allowed for treatment of bone lesions&lt;br&gt;&lt;br&gt;          -  Concurrent bisphosphonates allowed&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Cancer</Condition>
    <Intervention>Biological: autologous dendritic cell-autologous tumor mRNA-human CD40L vaccine;Biological: therapeutic autologous dendritic cells</Intervention>
    <Primary_outcome>T-cell response to RNA-loaded dendritic cells as assessed by the ELISpot assay on blood cells at screening, baseline, weeks 6 and 14  and years 1 and 2 after first vaccination, and at completion of study treatment</Primary_outcome>
    <Secondary_outcome>Exploratory monitoring of T-cell functionality in terms of  reverse-transcriptase polymerase chain reaction, cytokine/granzyme secretion, CD4/CD8 T cell proliferation, and CD4/CD8 T cell maturation;Exploratory assessment of immune response as assessed by delayed-type hypersensitivity;Safety;Feasability;Objective tumor response (complete and partial response) as assessed by RECIST criteria;Progression-free and overall survival as assessed by RECIST criteria</Secondary_outcome>
    <Secondary_ID>UCLA-0503099-01;ARGOS-003-004;CDR0000455589</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>National Cancer Institute (NCI)</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2867009</Internal_Number>
    <TrialID>NCT00310739</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Urinary Marker for Oxidative Stress in Human Cisplatin- Induced Renal Injury</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>Hamamatsu University</Primary_sponsor>
    <Date_registration3>20060403</Date_registration3>
    <Date_registration>03/04/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00310739</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2001</Date_enrollement>
    <Target_size />
    <Study_type>Observational</Study_type>
    <Study_design>Additional Descriptors:  Convenience Sample, Observational Model:  Natural History, Time Perspective:  Longitudinal, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Hospitalized patients have neck cancer&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Failure</Condition>
    <Secondary_ID>16-50</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2867507</Internal_Number>
    <TrialID>NCT00317252</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Angiotensin Converting Enzyme Inhibitors &amp; Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization</Public_title>
    <Scientific_title>Angiotensin Converting Enzyme Inhibitors and Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization "The CAPTAIN Trial"</Scientific_title>
    <Acronym />
    <Primary_sponsor>Hamilton Health Sciences Corporation</Primary_sponsor>
    <Date_registration3>20060420</Date_registration3>
    <Date_registration>20/04/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00317252</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2006</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Scheduled for Angiography in &gt;= 24hrs from enrolment&lt;br&gt;&lt;br&gt;          -  Documented Cr &gt;= 150 within 3 months before cardiac catheterization AND/OR documented&lt;br&gt;             Cr &gt;= 132umol/L within 1 week Before Cardiac Catheterization&lt;br&gt;&lt;br&gt;          -  Currently Taking an ACE Inhibitor&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with end stage renal disease (for example, patient on dialysis)&lt;br&gt;&lt;br&gt;          -  Emergency Cardiac Catheterization with insufficient time to hold the ACEI&lt;br&gt;&lt;br&gt;          -  Acute Pulmonary Edema&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Failure</Condition>
    <Intervention>Drug: Hold ACEI or ARB</Intervention>
    <Primary_outcome>Contrast induced nephropathy (creatinine rise of 44umol/L or 25% compared to the pre-randomization creatinine level) at 48-96hrs</Primary_outcome>
    <Secondary_outcome>Change in serum creatinine at 48-96hrs;Change in creatinine clearance at 48-96hrs;Death, Myocardial Infarction, Stroke, Congestive Heart Failure, dialysis, major bleeding, minor bleeding, hypertension, re-hospitalization at 48-96hrs.</Secondary_outcome>
    <Secondary_ID>06-005</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2868116</Internal_Number>
    <TrialID>NCT00325325</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Pharmacokinetic Study on the Combination of Everolimus-Tacrolimus</Public_title>
    <Scientific_title>A Pilot Study to Investigate Pharmacokinetic Characteristics of Everolimus in Patients Treated With Tacrolimus-Based Immunosuppression in De Novo Kidney Transplantation</Scientific_title>
    <Acronym />
    <Primary_sponsor>Hospital Universitario Ramon y Cajal</Primary_sponsor>
    <Date_registration3>20060511</Date_registration3>
    <Date_registration>11/05/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00325325</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>65 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2006</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Pharmacokinetics Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Kidney transplant recipients aged 18-65 years old with a presumed immediately&lt;br&gt;             functioning graft&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Non-functioning kidneys&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Diseases</Condition>
    <Intervention>Drug: everolimus and tacrolimus</Intervention>
    <Primary_outcome>12-hour PK profiles of everolimus and tacrolimus on day 14 post-transplantation with everolimus 1.5 mg versus 3 mg per day</Primary_outcome>
    <Secondary_ID>EVEROTAC</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Novartis;Astellas Pharma Inc</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2868278</Internal_Number>
    <TrialID>NCT00327483</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Web Based Renal Transplant Patient Medication Education</Public_title>
    <Scientific_title>Web Based Renal Transplant Patient Medication Education</Scientific_title>
    <Acronym />
    <Primary_sponsor>Agency for Healthcare Research and Quality (AHRQ)</Primary_sponsor>
    <Date_registration3>20060516</Date_registration3>
    <Date_registration>16/05/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00327483</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>14 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2005</Date_enrollement>
    <Target_size>250</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Educational/Counseling/Training</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:age &gt; 18 or capable of managing own medications&lt;br&gt;&lt;br&gt;        -&lt;br&gt;&lt;br&gt;        Exclusion Criteria:Education level below 10th grade&lt;br&gt;&lt;br&gt;        -&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Transplant Recipients</Condition>
    <Intervention>Behavioral: Internet based education software</Intervention>
    <Primary_outcome>Medication errors</Primary_outcome>
    <Secondary_outcome>Serum creatinine;Rejection episodes;Rehospitalizations;Graft loss</Secondary_outcome>
    <Secondary_ID>RO1-HS15038-03</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2870013</Internal_Number>
    <TrialID>NCT00350974</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>ADMA Levels in End-Stage Renal Disease</Public_title>
    <Scientific_title>Determination of Asymmetrical Dimethylarginine (ADMA) Accumulation in End Stage Renal Disease</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Michigan</Primary_sponsor>
    <Date_registration3>20060710</Date_registration3>
    <Date_registration>10/07/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00350974</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2006</Date_enrollement>
    <Target_size>63</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Defined Population, Observational Model:  Natural History, Time Perspective:  Cross-Sectional, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion&lt;br&gt;&lt;br&gt;        Group 1:&lt;br&gt;&lt;br&gt;          -  are now 18 years of age or older, with end-stage renal disease (ESRD)&lt;br&gt;&lt;br&gt;          -  have been on maintenance hemodialysis therapy three times/week for more then 12&lt;br&gt;             months&lt;br&gt;&lt;br&gt;        Group 2 criteria:&lt;br&gt;&lt;br&gt;          -  are now 18 years of age or older&lt;br&gt;&lt;br&gt;          -  can be matched to a volunteer in Group 1 for age, gender, race, blood pressure and&lt;br&gt;             diabetes history&lt;br&gt;&lt;br&gt;          -  have an eGFR greater then 60 ml/min   (This is a value based on a laboratory blood&lt;br&gt;             test that shows how well your kidneys work.)&lt;br&gt;&lt;br&gt;        Group 3 criteria:&lt;br&gt;&lt;br&gt;          -  are now 18 years of age or older&lt;br&gt;&lt;br&gt;          -  have blood pressure less than 130/80 when you are not taking blood pressure&lt;br&gt;             medication&lt;br&gt;&lt;br&gt;          -  normal kidney function&lt;br&gt;&lt;br&gt;        Exclusion&lt;br&gt;&lt;br&gt;          -  are less then 18 years of age&lt;br&gt;&lt;br&gt;          -  are pregnant or breast feeding&lt;br&gt;&lt;br&gt;          -  unable or unwilling to provide informed consent&lt;br&gt;&lt;br&gt;          -  are currently in another study&lt;br&gt;&lt;br&gt;          -  have a hemoglobin (substance in  red blood cells that carries oxygen) level that is&lt;br&gt;             less than 8 mg/dl&lt;br&gt;&lt;br&gt;          -  have an untreated infection that won’t go away&lt;br&gt;&lt;br&gt;          -  require admission to the hospital&lt;br&gt;&lt;br&gt;          -  have a history of hemolytic diseases (e.g. sickle cell disease)&lt;br&gt;&lt;br&gt;          -  appear unlikely or unable to participate in the required study procedures&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease;Hypertension</Condition>
    <Secondary_ID>HUM 0000 4194</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2870412</Internal_Number>
    <TrialID>NCT00356265</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide</Public_title>
    <Scientific_title>Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Michigan</Primary_sponsor>
    <Date_registration3>20060724</Date_registration3>
    <Date_registration>24/07/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00356265</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>55 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2006</Date_enrollement>
    <Target_size>39</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Pharmacodynamics Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Educational/Counseling/Training</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Men and Women-18 to 55 years of age.&lt;br&gt;&lt;br&gt;          -  There are three groups of volunteers.&lt;br&gt;&lt;br&gt;               -  Group A.  People who are hypertensive with kidney disease.  When not taking&lt;br&gt;                  blood pressure medicines, blood pressure must have a systolic between 140-170&lt;br&gt;                  mmHg.  Diastolic must be between 90-109 mmHg.Kidney function should be around&lt;br&gt;                  half of normal.  Urine protein must be no more than 1 gram in a 24-hour urine&lt;br&gt;                  time period.&lt;br&gt;&lt;br&gt;               -  Group B.  People who are hypertensive without kidney disease. Blood pressure&lt;br&gt;                  must have a systolic between 140-170 mmHg. Diastolic must be between 90-109&lt;br&gt;                  mmHg. Kidney function should be normal. Normal amounts of protein in their&lt;br&gt;                  urine.&lt;br&gt;&lt;br&gt;               -  Group C. People who are normotensive.  Blood pressure must have a systolic below&lt;br&gt;                  131/mmHg.  Diastolic must be below 81 mmHg. Kidney function should be normal. No&lt;br&gt;                  more than normal amounts of protein in their urine.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        People with:&lt;br&gt;&lt;br&gt;          -  Diabetes&lt;br&gt;&lt;br&gt;          -  Lung disease&lt;br&gt;&lt;br&gt;          -  Stomach disease&lt;br&gt;&lt;br&gt;          -  Liver disease&lt;br&gt;&lt;br&gt;          -  Blood vessel disease&lt;br&gt;&lt;br&gt;          -  Heart disease&lt;br&gt;&lt;br&gt;          -  Hereditary blood disorders&lt;br&gt;&lt;br&gt;          -  Hematocrit (amount of red blood cells) less than 30%&lt;br&gt;&lt;br&gt;          -  Current tobacco use&lt;br&gt;&lt;br&gt;          -  Kidney disease who require dialysis&lt;br&gt;&lt;br&gt;          -  Women who are pregnant or breastfeeding&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease;Hypertension</Condition>
    <Intervention>Drug: Procedure: Regional phenylephrine arterial infusion</Intervention>
    <Primary_outcome>Determine if a1-adrenoceptor vasoreactivity is enhanced less by inhibition of endothelial NO;Determine whether a1-adrenoceptor vasoreactivity correlates with plasma levels of the endogenous NO inhibitor, asymmetrical dimethylarginine.</Primary_outcome>
    <Secondary_ID>5R33DK071222-02;HUM 00000261</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2871583</Internal_Number>
    <TrialID>NCT00371904</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Trial of Rituximab Given Pre-Transplant to Sensitised Live Donor Kidney Recipients</Public_title>
    <Scientific_title>A Prospective Open Label Randomised Multicentre Study Evaluating the Efficacy &amp; Safety of Rituximab Given Pre-Transplant to Sensitised Renal Allograft Recipients in Addition to a "Standard" Desensitisation Regimen Consisting of PE/IVIG &amp; MMF</Scientific_title>
    <Acronym>RAPTURE</Acronym>
    <Primary_sponsor>Hunter and New England Health</Primary_sponsor>
    <Date_registration3>20060901</Date_registration3>
    <Date_registration>01/09/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00371904</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2006</Date_enrollement>
    <Target_size>192</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion criteria:&lt;br&gt;&lt;br&gt;          1. Subjects, age &gt; 18 years&lt;br&gt;&lt;br&gt;          2. Subjects receiving a single organ renal transplant from a living donor&lt;br&gt;&lt;br&gt;          3. Positive T-cell and/or B-cell crossmatch by complement dependent cytotoxicity (CDC)&lt;br&gt;             and/or positive flow cytometry crossmatch with confirmed donor-specific antibodies on&lt;br&gt;             solid-phase assay at screening. Positive CDC T-cell and/or B-cell crossmatch titre&lt;br&gt;             must be less than or equal to 1:64.&lt;br&gt;&lt;br&gt;          4. Subjects capable of understanding the purposes and risks of the study and who can&lt;br&gt;             give written informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria at Study Entry (4 weeks prior to transplant):&lt;br&gt;&lt;br&gt;          1. Primary renal transplant lost from acute rejection less than six months prior to&lt;br&gt;             randomisation&lt;br&gt;&lt;br&gt;          2. Women of childbearing potential with a positive serum or urine pregnancy test or&lt;br&gt;             nursing mothers&lt;br&gt;&lt;br&gt;          3. Subjects with history of malignancy (other than non melanoma skin cancer that has&lt;br&gt;             been totally excised with no recurrence for two years)&lt;br&gt;&lt;br&gt;          4. Subjects with known contraindications to treatment with rituximab&lt;br&gt;&lt;br&gt;          5. Subjects with haemoglobin &lt; 8.5 g/dL, WBC value of &lt; 3000/mm3 or a platelet count of&lt;br&gt;             &lt; 50,000/mm3 that is unlikely to resolve prior to randomisation&lt;br&gt;&lt;br&gt;          6. Subjects with a positive ABO crossmatch with donor&lt;br&gt;&lt;br&gt;          7. Subjects with severe diarrhoea or other gastrointestinal disorders that might&lt;br&gt;             interfere with the ability to absorb oral medication and is unlikely to resolve prior&lt;br&gt;             to randomisation&lt;br&gt;&lt;br&gt;          8. Subjects participating in another interventional clinical trial or requiring&lt;br&gt;             treatment with un-marketed investigational drugs or who would be expected to require&lt;br&gt;             other medications prohibited by the protocol&lt;br&gt;&lt;br&gt;          9. Subjects who cannot be followed for the study duration&lt;br&gt;&lt;br&gt;         10. Subjects with disorders or conditions that may interfere with the ability to comply&lt;br&gt;             with study procedures and/or requirements&lt;br&gt;&lt;br&gt;        Additional Exclusion Criteria at Day -2 before Transplantation:&lt;br&gt;&lt;br&gt;          1. All exclusion criteria as at study entry&lt;br&gt;&lt;br&gt;          2. Positive T- and/or B-cell CDC crossmatch at Day -2&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Transplantation</Condition>
    <Intervention>Drug: Rituximab;Drug: Standard Care</Intervention>
    <Primary_outcome>Biopsy proven antibody mediated rejection</Primary_outcome>
    <Secondary_outcome>Elimination of donor specific antibodies (DSA);C4d in biopsies;Plasma exchanges;Death;Treated rejection;Graft loss;Treatment failure;Calculation of glomerular filtration rate (GFR);Slope of 1/serum creatinine (Ser. Cr);24-hour U protein;Safety;Cancer and infections</Secondary_outcome>
    <Secondary_ID>RAPTURE</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Melbourne Health;Princess Alexandra Hospital, Brisbane, Australia;Royal Prince Alfred Hospital, Sydney, Australia;Auckland City Hospital, New Zealand;Monash Medical Centre;Royal Perth Hospital;Westmead Hospital;Royal Adelaide Hospital</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2872261</Internal_Number>
    <TrialID>NCT00380848</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Impact of Different Dialysis on Sleep Apnea in Patients With Renal Failure</Public_title>
    <Scientific_title>Effect of Hemodiafiltration on Sleep-Disordered Breathing in Patients With End-Stage Renal Disease</Scientific_title>
    <Acronym />
    <Primary_sponsor>McGill University Health Center</Primary_sponsor>
    <Date_registration3>20060925</Date_registration3>
    <Date_registration>25/09/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00380848</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2006</Date_enrollement>
    <Target_size>15</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Pharmacokinetics/Dynamics Study, Intervention Model:  Crossover Assignment, Masking:  Single Blind, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients currently stable on a thrice weekly hemodialysis regimen for a minimum of 3&lt;br&gt;             months&lt;br&gt;&lt;br&gt;          -  Patients with vascular access and no contraindications to anticoagulation&lt;br&gt;&lt;br&gt;          -  Presence of sleep-related breathing disorder defined as a mean apnea-hypopnea per&lt;br&gt;             hour of recording greater than 10 based on cardiorespiratory monitoring&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients already on hemodiafiltration therapy&lt;br&gt;&lt;br&gt;          -  Patients already on treatment for sleep disordered breathing.&lt;br&gt;&lt;br&gt;          -  Patients with significant neuromuscular disease&lt;br&gt;&lt;br&gt;          -  Patients with an expected lifespan &lt; 1 year&lt;br&gt;&lt;br&gt;          -  Patients unable to complete sleep related quality of life questionnaires and consent&lt;br&gt;             forms due to language barriers or dementia&lt;br&gt;&lt;br&gt;          -  Patients with known substance abuse&lt;br&gt;&lt;br&gt;          -  Patients with a respiratory disturbance index greater than 30 with active&lt;br&gt;             cardiovascular disease defined by unstable angina, myocardial infarction within 3&lt;br&gt;             months or an Epworth sleepiness score greater than 15 while actively working in a&lt;br&gt;             stress situation (for example bus driver, taxi driver). These patients will be&lt;br&gt;             evaluated by a sleep specialist.&lt;br&gt;&lt;br&gt;          -  Living further than 30 km from dialysis centre&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Sleep Apnea;End Stage Renal Disease</Condition>
    <Intervention>Procedure: Hemodiafiltration</Intervention>
    <Primary_outcome>Reduction in apnea hypopnea index after a treatment period of three months of hemodiafiltration; scored on overnight polysomnography</Primary_outcome>
    <Secondary_outcome>Generic Quality of life;specific quality of life related to sleep apnea;specific quality of life related to Restless leg syndrome;24 hour blood pressure control;Periodic limb movement indices;Validity of a positive screening sleep study;specific quality of life related to sleep;Upper airway neuronal afferent dysfunction;Relationship between cytokine levels and sleep apnea severity;Relationship between dialysis clearance and sleep apnea severity</Secondary_outcome>
    <Secondary_ID>MUHC BMB 05-009</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Gambro Renal Products, Inc.;McGill University</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2872497</Internal_Number>
    <TrialID>NCT00383968</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Prevalence of Chronic KIdney Disease in Hypertensive Patients</Public_title>
    <Scientific_title>Prevalence of Chronic KIdney Disease in Hypertensive Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>Aga Khan University</Primary_sponsor>
    <Date_registration3>20061003</Date_registration3>
    <Date_registration>03/10/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00383968</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>40 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2006</Date_enrollement>
    <Target_size>248</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Defined Population, Primary Purpose:  Screening, Time Perspective:  Cross-Sectional, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion criteria:&lt;br&gt;&lt;br&gt;          -  Known hypertensives aged 40 and above with microalbuminuria and/or elevated serum&lt;br&gt;             creatinine on first evaluation.&lt;br&gt;&lt;br&gt;          -  Hypertension: Systolic blood pressure =140, and /or diastolic blood pressure = 90&lt;br&gt;             with or without antihypertensive drugs.&lt;br&gt;&lt;br&gt;          -  Microalbuminuria:&lt;br&gt;&lt;br&gt;               -  Albumin concentration of 20-200mg/L, with albumin-to-creatinine ratio of&lt;br&gt;                  3-30mg/mmol or 30-300mg/g&lt;br&gt;&lt;br&gt;               -  Female:   3.0-30.0mg/mmol or 30-300mg/g&lt;br&gt;&lt;br&gt;               -  Male:       2.0-20.0mg/mmol or 20&lt;br&gt;&lt;br&gt;          -  Elevated Serum creatinine:&lt;br&gt;&lt;br&gt;               -  Female:      &gt;1.2mg/dl&lt;br&gt;&lt;br&gt;               -  Male:          &gt;1.4mg/dl&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Known diabetics will be excluded.&lt;br&gt;&lt;br&gt;          -  unable to give informed consent&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Hypertension;Chronic Kidney Disease</Condition>
    <Secondary_ID>06GS009CHS</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2873295</Internal_Number>
    <TrialID>NCT00394576</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Assessing Novel Methods of Improving Patient Education of Nutrition</Public_title>
    <Scientific_title>Assessing Novel Methods of Improving Patient Education of Nutrition: eHealth, Health Literacy and Chronic Kidney Disease</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Wisconsin, Madison</Primary_sponsor>
    <Date_registration3>20061030</Date_registration3>
    <Date_registration>30/10/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00394576</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>90 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2006</Date_enrollement>
    <Target_size>180</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Factorial Assignment, Masking:  Open Label</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age greater than or equal to 18 and less than 90&lt;br&gt;&lt;br&gt;          -  Chronic kidney disease stage 3, 4 or 5&lt;br&gt;&lt;br&gt;          -  Adequate visual acuity with correction to allow discrimination of 14-point type&lt;br&gt;&lt;br&gt;          -  Ability to read English&lt;br&gt;&lt;br&gt;          -  Ability to provide informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Anticipated need for renal replacement therapy within 60 days&lt;br&gt;&lt;br&gt;          -  Prison population&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease</Condition>
    <Intervention>Behavioral: Internet-based nutrition module;Behavioral: usual care</Intervention>
    <Primary_outcome>After one month gains in phosphorus knowledge will be assessed by the CKDKAT.;After one month compliance with dietary phosphorus intake will be  measured by mineral metabolism laboratory values (serum phosphorus, calcium, PTH, calcium phosphorus product).;After one month compliance with dietary phosphorus intake will be measured by the 24 hour recall diary.;After all groups have completed their visits, statistical comparisons will be made to determine whether eHealth information was able to improve patient knowledge of and compliance with recommended dietary phosphorous intake.</Primary_outcome>
    <Secondary_outcome>After all groups have completed their visits, correlations between dietary phosporus intake, serum phosphorous levels and CECs will be made.</Secondary_outcome>
    <Secondary_ID>5 K12 RRO17614A;H-2006-0186-1</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2874261</Internal_Number>
    <TrialID>NCT00407368</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Platelets Function and Cardiovascular Events in Patients With End Stage Renal Disease</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>Assaf-Harofeh Medical Center</Primary_sponsor>
    <Date_registration3>20061204</Date_registration3>
    <Date_registration>04/12/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00407368</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2006</Date_enrollement>
    <Target_size>150</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Defined Population, Time Perspective:  Longitudinal, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  The study will include patients with end stage renal disease, age 18 years or older,&lt;br&gt;             treated in the nephrology division of Assaf Harofeh medical center.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients will be excluded if their platelets count will be lower then 50,000 cu/mm,&lt;br&gt;             if they have known hematologic malignancies, other solid malignancy with life&lt;br&gt;             expectancy of less then 1 year or if they are treated with Warfarin (Comadin).&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End Stage Renal Disease;Cardiovascular Disease</Condition>
    <Intervention>Procedure: Blood Sample</Intervention>
    <Secondary_ID>75/06</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2875536</Internal_Number>
    <TrialID>NCT00424320</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Clinical Trial of Sodium Bicarbonate to Prevent Contrast-Induced Nephropathy</Public_title>
    <Scientific_title>Clinical Controlled Trial to Determinate the Role of Sodium Bicarbonate in the Prevention of Contrast-Induced Nephropathy in High-Risk Patients Undergoing to Diagnostic Coronariography and/or Percutaneous Coronary Intervention</Scientific_title>
    <Acronym />
    <Primary_sponsor>Instituto Nacional de Cardiologia Ignacio Chavez</Primary_sponsor>
    <Date_registration3>20070118</Date_registration3>
    <Date_registration>18/01/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00424320</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2006</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double-Blind, Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age over 18 years old&lt;br&gt;&lt;br&gt;          -  Indication for coronariography and/or percutaneous coronary intervention&lt;br&gt;&lt;br&gt;          -  Voluntary written consent for the realization of coronariography and/or percutaneous&lt;br&gt;             intervention and for the participation in this clinical trial&lt;br&gt;&lt;br&gt;          -  A MEHRAN contrast-induced nephropathy score of six or more&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with chronic kidney failure requiring any kind of dialysis&lt;br&gt;&lt;br&gt;          -  Patients unable to complete follow-up&lt;br&gt;&lt;br&gt;          -  Multiple myeloma&lt;br&gt;&lt;br&gt;          -  Exposure to contrast 48 hours prior to study&lt;br&gt;&lt;br&gt;          -  Pregnancy&lt;br&gt;&lt;br&gt;          -  Patients unable to give consent&lt;br&gt;&lt;br&gt;          -  Already receiving sodium bicarbonate solutions&lt;br&gt;&lt;br&gt;          -  Receiving contrast media other than non-ionic&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Kidney Failure</Condition>
    <Intervention>Drug: Sodium bicarbonate</Intervention>
    <Primary_outcome>Contrast-induced nephropathy</Primary_outcome>
    <Secondary_outcome>Hemodialysis</Secondary_outcome>
    <Secondary_ID>06-001</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2876986</Internal_Number>
    <TrialID>NCT00443508</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion</Public_title>
    <Scientific_title>Reduction or Discontinuation of Calcineurine Inhibitors With Conversion to Everolimus-Based Immunosuppresion to Alleviate Chronic Allograft Nephropathy (CAN) in Kidney Transplant Recipients: A Prospective Randomized Study</Scientific_title>
    <Acronym />
    <Primary_sponsor>Rabin Medical Center</Primary_sponsor>
    <Date_registration3>20070304</Date_registration3>
    <Date_registration>04/03/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00443508</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Male</Inclusion_gender>
    <Date_enrollement>February 2007</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients on CNI FK &lt; 5 ng/m"l with MPA / Imuran with or without steroids&lt;br&gt;&lt;br&gt;          -  Renal impairment GFR between 30 - 70 m"l/minute/&lt;br&gt;&lt;br&gt;          -  Patient who signed Informed consent&lt;br&gt;&lt;br&gt;          -  Patient with no contraindication to renal biopsy&lt;br&gt;&lt;br&gt;          -  Women who are not pregnant and will use contraception&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Proteinuria &gt; 100 m"g/mmol Creatinine&lt;br&gt;&lt;br&gt;          -  Acute rejection during 3 months before screening&lt;br&gt;&lt;br&gt;          -  WBC &lt; 2500,  plt &lt; 50,000,&lt;br&gt;&lt;br&gt;          -  Nephropathy due to polyoma virus&lt;br&gt;&lt;br&gt;          -  Patients on other investigational drugs&lt;br&gt;&lt;br&gt;          -  Patients on rapamycin&lt;br&gt;&lt;br&gt;          -  Patients with HIV or other systemic infection&lt;br&gt;&lt;br&gt;          -  Inability to comply with protocol requirements&lt;br&gt;&lt;br&gt;          -  Active or history of malignancy&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Diseases</Condition>
    <Intervention>Drug: adding Certican to therapy;Drug: reducing Tacrolimus</Intervention>
    <Primary_outcome>The primary goal is to assess the change in renal function;at 6 and 12 months after conversion using creatinine levels;and calculated creatinine clearance.</Primary_outcome>
    <Secondary_outcome>The secondary aim is to assess changes in cardiovascular risks at;12 months after conversion (glucose control., cholesterol and;triglyceride levels and hypertension control), incidence of;acute and chronic rejection and graft and patient survival rates.</Secondary_outcome>
    <Secondary_ID>CRAD001AIL01</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Novartis</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2877331</Internal_Number>
    <TrialID>NCT00448071</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Pharmacokinetic and Pharmacodynamic Effects of MTR107 in End-Stage Renal Disease (ESRD) Patients</Public_title>
    <Scientific_title>A Phase II, Randomized Double Blind Placebo-Controlled, Dose Escalating Study to Determine Pharmacokinetic and Pharmacodynamic Effects of MTR107 in End-Stage Renal Disease (ESRD) Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>Wolfson Medical Center</Primary_sponsor>
    <Date_registration3>20070314</Date_registration3>
    <Date_registration>14/03/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00448071</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>20 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2006</Date_enrollement>
    <Target_size>12</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Pharmacokinetics/Dynamics Study, Intervention Model:  Parallel Assignment, Masking:  Double-Blind, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Age 20-75 years, inclusive.&lt;br&gt;&lt;br&gt;          2. Presence of frequent bouts of hypotension defined as 3 or more intradialytic&lt;br&gt;             hypotensive events per month for the last six months prior to baseline, despite&lt;br&gt;             standard adjustments in dry weight.&lt;br&gt;&lt;br&gt;          3. ECG performed up to one month before study start.&lt;br&gt;&lt;br&gt;          4. Well-preserved hepatic function (within normal laboratory ranges) at study entry as&lt;br&gt;             judged by:&lt;br&gt;&lt;br&gt;               -  Serum Bilirubin (Total Bilirubin (direct and indirect) 0.3-1.0 mg/dL, and Direct&lt;br&gt;                  Bilirubin 0.1-0.5 mg/dL)&lt;br&gt;&lt;br&gt;               -  Serum Albumin (&gt;3.6 g/dL),&lt;br&gt;&lt;br&gt;               -  Serum aminotransferases (AST (0-37 U/L) and ALT (0-40 U/L)),&lt;br&gt;&lt;br&gt;               -  GGT (Gamma Glutamine Trans Peptidase)&lt;br&gt;&lt;br&gt;          5. Normal coagulation status at study entry as judged by PT-INR, PTT, fibrinogen and&lt;br&gt;             platelet count.&lt;br&gt;&lt;br&gt;          6. Willingness to participate in the study and adhere to the study design.&lt;br&gt;&lt;br&gt;          7. Willingness to sign an informed consent form.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Uncontrolled hypertension &gt;140/90 mmHg.&lt;br&gt;&lt;br&gt;          2. Unstable angina.&lt;br&gt;&lt;br&gt;          3. Abnormal ECG which may indicate acute disease&lt;br&gt;&lt;br&gt;          4. Variable weight gains.&lt;br&gt;&lt;br&gt;          5. Mental retardation.&lt;br&gt;&lt;br&gt;          6. Pregnancy.&lt;br&gt;&lt;br&gt;          7. Malignancy or other concomitant serious diseases.&lt;br&gt;&lt;br&gt;          8. Current participation in another clinical trial involving an  investigational&lt;br&gt;             drug/device, or participation in such a trial within the last 30 days.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Hypotension;End Stage Renal Disease;Intra Dialytic Hypotension</Condition>
    <Intervention>Drug: MTR107</Intervention>
    <Primary_outcome>A descriptive pharmacokinetic / pharmacodynamic study. No primary end-points apply.</Primary_outcome>
    <Secondary_outcome>Exploratory Efficacy Parameters:;? Number and type of medical interventions required for treatment of hypotension.;? Alleviation of symptoms associated with intradialytic hypotension.;? Efficiency of dialysis as reflected by Kt/V</Secondary_outcome>
    <Secondary_ID>MTR107IL-104</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Meditor Pharmaceuticals Ltd.</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2877582</Internal_Number>
    <TrialID>NCT00451373</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Acute Renal Failure in the Surgical Intense Care Units - NTUH-SICU-ARF (NSARF) Study</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>National Taiwan University Hospital</Primary_sponsor>
    <Date_registration3>20070322</Date_registration3>
    <Date_registration>22/03/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00451373</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2006</Date_enrollement>
    <Target_size>300</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Single Blind, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Postoperative acute renal failure&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with ECMO or IABP&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Renal Failure;Sepsis;Postoperative</Condition>
    <Intervention>Device: CVVH and SLED;Drug: Vancomycin;Drug: Daptomycin;Device: FX60, AV600 (dialyzer)</Intervention>
    <Primary_outcome>the mortality of postoperative acute renal failure</Primary_outcome>
    <Secondary_outcome>the cytokine and free radical change of postoperative renal failure</Secondary_outcome>
    <Secondary_ID>31MD03;9561709099</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2877957</Internal_Number>
    <TrialID>NCT00456365</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)</Public_title>
    <Scientific_title>Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Colorado, Denver</Primary_sponsor>
    <Date_registration3>20070312</Date_registration3>
    <Date_registration>12/03/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00456365</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>8 Years</Inclusion_agemin>
    <Inclusion_agemax>21 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2006</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age 8-21 years&lt;br&gt;&lt;br&gt;          -  Autosomal dominant polycystic kidney disease&lt;br&gt;&lt;br&gt;          -  Normal kidney function&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Abnormal kidney function&lt;br&gt;&lt;br&gt;          -  Past allergic history to medications used in study&lt;br&gt;&lt;br&gt;          -  Liver disease&lt;br&gt;&lt;br&gt;          -  Muscle disease/dystrophy&lt;br&gt;&lt;br&gt;          -  Pregnancy, planned pregnancy, or lactation within study period&lt;br&gt;&lt;br&gt;          -  Inability to cooperate with or clinical contraindication for magnetic resonance&lt;br&gt;             imaging&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Polycystic Kidney, Autosomal Dominant</Condition>
    <Intervention>Drug: pravastatin;Drug: Placebo</Intervention>
    <Primary_outcome>Total renal volume;Left ventricular mass index;Urinary albumin excretion;Endothelial-dependent vasodilation</Primary_outcome>
    <Secondary_outcome>Change in primary outcome measures with respect to LDL cholesterol;Change in primary outcome measures with respect to blood pressure</Secondary_outcome>
    <Secondary_ID>2R01DK058793;05-0704</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2878957</Internal_Number>
    <TrialID>NCT00469625</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>Winthrop University Hospital</Primary_sponsor>
    <Date_registration3>20070503</Date_registration3>
    <Date_registration>03/05/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00469625</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>85 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2006</Date_enrollement>
    <Target_size />
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double-Blind, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Stable chronic kidney disease&lt;br&gt;&lt;br&gt;          2. Urine protein : Creatinine ratio &gt; 0.4&lt;br&gt;&lt;br&gt;          3. Chronic kidney disease stage 2-4 with eGFR 15-90 ml/min&lt;br&gt;&lt;br&gt;          4. PTH (intact) &gt;20 pg/ml and &lt;250 pg/ml&lt;br&gt;&lt;br&gt;          5. Age 18-85&lt;br&gt;&lt;br&gt;          6. If on ACEI/ARB, then dose optimized (BP, K)&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Failure to provide informed consent&lt;br&gt;&lt;br&gt;          2. Glomerunephritis requiring active treatment with immunosuppresive therapy&lt;br&gt;&lt;br&gt;          3. Serum phosphorus &gt; 5.2&lt;br&gt;&lt;br&gt;          4. Serum calcium (adjusted for albumin)&gt; 10.0&lt;br&gt;&lt;br&gt;          5. Active malignancy&lt;br&gt;&lt;br&gt;          6. Likelihood of requiring renal replacement therapy within 1 year&lt;br&gt;&lt;br&gt;          7. Uncontrolled hypertension&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Proteinuric Renal Disease</Condition>
    <Intervention>Drug: paricalcitol (initial dose 1 mcg orally per day)</Intervention>
    <Secondary_ID>Z # 13178</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2879042</Internal_Number>
    <TrialID>NCT00470769</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>The Efficacy of Color-Doppler Ultrasonography to Assess the Renal Blood Flow With the Estimation of GFR</Public_title>
    <Scientific_title>Color-Doppler Ultrasonography vs 99mTc-DTPA Scintigraphy to Assess the Renal Blood Flow</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Roma La Sapienza</Primary_sponsor>
    <Date_registration3>20070507</Date_registration3>
    <Date_registration>07/05/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00470769</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>30 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2006</Date_enrollement>
    <Target_size>2006</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Defined Population, Primary Purpose:  Screening, Time Perspective:  Cross-Sectional, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with hypertension&lt;br&gt;&lt;br&gt;          -  Patients  with moderate renal insufficiency&lt;br&gt;&lt;br&gt;          -  Normal subjects&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with solitary kidney function&lt;br&gt;&lt;br&gt;          -  Patients with renal artery stenosis&lt;br&gt;&lt;br&gt;          -  Patients underwent renal angioplasty and stenting&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Hypertension;Renal Failure</Condition>
    <Intervention>Procedure: Color-Doppler Ultrasound, 99mTc-DTPA scintigraphy</Intervention>
    <Secondary_ID>CR-UR-00001</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2880471</Internal_Number>
    <TrialID>NCT00489723</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Is There is a Role of Prophylactic Therapy With Tamsulosin Before Extracorporeal Shock Wave Lithotripsy to Avoid Development of Steinstrasse ?</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>HaEmek Medical Center, Israel</Primary_sponsor>
    <Date_registration3>20070619</Date_registration3>
    <Date_registration>19/06/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00489723</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>15 Years</Inclusion_agemin>
    <Inclusion_agemax>85 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2007</Date_enrollement>
    <Target_size />
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Defined Population, Primary Purpose:  Screening, Time Perspective:  Longitudinal, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  size of stone 1-2 cm&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  ureteral stricture Presence of internal stent prior use of alfa bloker prior ESWL&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Stones</Condition>
    <Intervention>Drug: tamsulosin 0.4mg</Intervention>
    <Secondary_ID>0056-07-EMC</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2880735</Internal_Number>
    <TrialID>NCT00493194</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Fibrosis in Renal Allografts</Public_title>
    <Scientific_title>Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic)</Scientific_title>
    <Acronym />
    <Primary_sponsor>University Hospital, Antwerp</Primary_sponsor>
    <Date_registration3>20070627</Date_registration3>
    <Date_registration>27/06/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00493194</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2005</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Recipients of a renal allograft, with a minimum age of 18 years.&lt;br&gt;&lt;br&gt;          2. Male or female recipients. Women of child-bearing age must practice adequate&lt;br&gt;             contraception&lt;br&gt;&lt;br&gt;          3. For renal allografts from living donors, at least one HLA-mismatch is required.&lt;br&gt;&lt;br&gt;          4. Written informed consent, compliant with local regulations.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Recipients of a second or third renal allograft, with a past history of graft failure&lt;br&gt;             due to rejection.&lt;br&gt;&lt;br&gt;          2. Recipients of a renal allograft from a haplotype-identical living donor or a&lt;br&gt;             non-heart beating donor.&lt;br&gt;&lt;br&gt;          3. Cold ischemia time &gt; 24 hours&lt;br&gt;&lt;br&gt;          4. Recipients of a kidney from donors = 65 years of age&lt;br&gt;&lt;br&gt;          5. Recipients of multiple organs.&lt;br&gt;&lt;br&gt;          6. Pregnant women.&lt;br&gt;&lt;br&gt;          7. Immunological high-risk recipients, defined as current or historical PRA &gt; 50 %&lt;br&gt;&lt;br&gt;          8. Recipients with focal segmental sclerosis as primary renal disease.&lt;br&gt;&lt;br&gt;          9. Recipients with leucopenia (WBC &lt; 3000/mmÂ³), thrombocytopenia (Thr &lt;&lt;br&gt;             100.000/mmÂ³),or hyperlipidemia (Tot Chol &gt; 300 mg/dl or Triglycerides &gt; 300 mg/dl)&lt;br&gt;&lt;br&gt;         10. Previous history of malignancy, except completely excised basocellular skin tumor&lt;br&gt;&lt;br&gt;         11. Chronic active infection.&lt;br&gt;&lt;br&gt;         12. Inadequate compliance to treatment.&lt;br&gt;&lt;br&gt;         13. Use of specific drugs: Terfenadine, pimozide, astemizole, fluconazole, ketoconazole&lt;br&gt;             and cimetidine.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Failure, Chronic;Transplantation;Immunosuppression;Interstitial Fibrosis</Condition>
    <Intervention>Drug: sirolimus;Drug: cyclosporine;Drug: daclizumab</Intervention>
    <Primary_outcome>The primary end-point of this study will be the cortical fractional interstitial fibrosis volume (V IntFib) in protocol biopsies at 6 months.  The V IntFib will be determined on Sirius red stained slides by means of a computerized image analysis program,</Primary_outcome>
    <Secondary_outcome>Secundary end-points:;-Patient and graft-survival at one year.;-The serum creatinine and the estimated creatinine;clearance at 6 and 12 months.;-The 24 hour proteinuria at 6 and 12 months.;-The intimal area and arterial wall thickness in protocol;biopsies at 6 months.;-The glomerular volume in protocol biopsies at 6 months.;-The incidence of acute rejection episodes during the;first year.;-The severity of acute rejection episodes according to;the Banffâ  97 classification.;-The incidence of infectious complications.;-The incidence of hematological adverse effects.;-The number of antihypertensive and lipid-lowering drugs;at 6 and 12 months.;-The incidence of treatment failure.</Secondary_outcome>
    <Secondary_ID>2004-004115-38</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Wyeth is now a wholly owned subsidiary of Pfizer;Hoffmann-La Roche</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2881357</Internal_Number>
    <TrialID>NCT00501475</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>NAC in Preventing CIN in CRF Patients Who Need Enhanced CT Scan in ED</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>Seoul National University Hospital</Primary_sponsor>
    <Date_registration3>20070713</Date_registration3>
    <Date_registration>13/07/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00501475</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>15 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Investigator), Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  CRF patients who need enhanced CT scan&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  less than 15 years old&lt;br&gt;&lt;br&gt;          -  hypersensitivity to NAC&lt;br&gt;&lt;br&gt;          -  on dialysis&lt;br&gt;&lt;br&gt;          -  no consent from patient or next of kin&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Renal Failure</Condition>
    <Intervention>Drug: NAC Bicarbonate</Intervention>
    <Primary_outcome>the rate of CIN</Primary_outcome>
    <Secondary_outcome>mortality</Secondary_outcome>
    <Secondary_ID>06-2006-084</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2882518</Internal_Number>
    <TrialID>NCT00516880</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Targeting Peroxisome Proliferator-activated Receptor-gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients?</Public_title>
    <Scientific_title>Targeting Peroxisome Proliferator-activated Receptor-gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients?</Scientific_title>
    <Acronym />
    <Primary_sponsor>Hospital Authority, Hong Kong</Primary_sponsor>
    <Date_registration3>20070815</Date_registration3>
    <Date_registration>15/08/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00516880</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>20 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2006</Date_enrollement>
    <Target_size>160</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double-Blind, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Both prevalent patients or patients newly started on continuous ambulatory peritoneal&lt;br&gt;             dialysis with age between 20 - 75 with or without diabetes mellitus will be&lt;br&gt;             considered eligible for study entry. For patients newly started on continuous&lt;br&gt;             ambulatory peritoneal dialysis, they will be suitable for recruitment into the study&lt;br&gt;             after one month on continuous ambulatory peritoneal dialysis.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with underlying malignancy&lt;br&gt;&lt;br&gt;          -  Patients with chronic liver disease or liver cirrhosis&lt;br&gt;&lt;br&gt;          -  Patients with hepatitis B or C positive&lt;br&gt;&lt;br&gt;          -  Patients with active infections&lt;br&gt;&lt;br&gt;          -  Patients with other chronic active inflammatory disease such as systemic lupus&lt;br&gt;             erythematosus, rheumatoid arthritis&lt;br&gt;&lt;br&gt;          -  Patients who refuse study participation&lt;br&gt;&lt;br&gt;          -  Patients with underlying congenital heart disease or rheumatic heart disease&lt;br&gt;&lt;br&gt;          -  Patients with poor general condition&lt;br&gt;&lt;br&gt;          -  Patients with plans for living related kidney transplant within 2 years&lt;br&gt;&lt;br&gt;          -  Female patients with pregnancy&lt;br&gt;&lt;br&gt;          -  Patients with history of recurrent hypoglycemia&lt;br&gt;&lt;br&gt;          -  Patients with Class III and IV congestive heart failure&lt;br&gt;&lt;br&gt;          -  Patients already receiving glitazones treatment at the screening visit&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Disease;Kidney Diseases;Cardiovascular Diseases</Condition>
    <Intervention>Drug: rosiglitazone</Intervention>
    <Primary_outcome>carotid athersclerosis;endothelial function</Primary_outcome>
    <Secondary_outcome>all-cause mortality and cardiovascular event;pulse wave velocity;inflammation</Secondary_outcome>
    <Secondary_ID>HARECCTR0500007;UW05-236T/899</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2883540</Internal_Number>
    <TrialID>NCT00530296</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>CBT to Treat Depression in Renal Patients</Public_title>
    <Scientific_title>Effectiveness of Cognitive Behavioral Therapy in Patients With End-Stage Renal Disease in Hemodialysis and With Depression</Scientific_title>
    <Acronym>CBTRPat</Acronym>
    <Primary_sponsor>Federal University of São Paulo</Primary_sponsor>
    <Date_registration3>20070914</Date_registration3>
    <Date_registration>14/09/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00530296</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2005</Date_enrollement>
    <Target_size>80</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver), Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with a diagnosis of Chronic renal disease (end stage) in hemodialysis for at&lt;br&gt;             least 3 months&lt;br&gt;&lt;br&gt;          -  Diagnosis of Major depression disorder (4 or more clinical criteria in MINI and a BDI&lt;br&gt;             score of 10 or more)&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients in process of renal transplant with (living donor)&lt;br&gt;&lt;br&gt;          -  Psychiatric comorbidity&lt;br&gt;&lt;br&gt;          -  Cognitive impairment or mental retardation&lt;br&gt;&lt;br&gt;          -  Current substance abuse&lt;br&gt;&lt;br&gt;          -  Heart failure, angina pectoris, arrhythmias&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Depression;End Stage Renal Disease</Condition>
    <Intervention>Behavioral: Cognitive Behavioral Therapy</Intervention>
    <Primary_outcome>Mini International Neuropsychiatric Interview (MINI-DSM-IV) Beck Depression Inventory (BDI)</Primary_outcome>
    <Secondary_outcome>Kidney Disease and Quality of Life Short-form (KDQOL-SF)</Secondary_outcome>
    <Secondary_ID>04/08710-8</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Fundação de Amparo à Pesquisa do Estado de São Paulo</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2883633</Internal_Number>
    <TrialID>NCT00531544</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248</Public_title>
    <Scientific_title>A SU011248 Expanded Access Protocol for Metastatic RCC Patients Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248</Scientific_title>
    <Acronym />
    <Primary_sponsor>King Faisal Specialist Hospital &amp; Research Center</Primary_sponsor>
    <Date_registration3>20070917</Date_registration3>
    <Date_registration>17/09/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00531544</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>85 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>February 2007</Date_enrollement>
    <Target_size>350</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with metastatic Renal Cell Carcinoma who are ineligible for participation in&lt;br&gt;             other SU011248 protocols but may derive benefit from treatment with SU011248&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Metastatic Renal Cell Carcinoma</Condition>
    <Intervention>Drug: SU011248</Intervention>
    <Primary_outcome>Efficacy</Primary_outcome>
    <Secondary_ID>RAC#2061 043</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2883713</Internal_Number>
    <TrialID>NCT00532597</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effects of On-Line Hemodiafiltration(HDF) on Vascular Health in Chronic Hemodialysis Patients</Public_title>
    <Scientific_title>Effects of On-Line Hemodiafiltration(HDF) on Endothelial Dysfunction in Chronic Hemodialysis Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>Eulji General Hospital</Primary_sponsor>
    <Date_registration3>20070919</Date_registration3>
    <Date_registration>19/09/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00532597</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2007</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Crossover Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  end stage renal disease on maintenance hemodialysis for more than 3 months&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  diagnosis of active cardiovascular diseases in 6 months&lt;br&gt;&lt;br&gt;          -  elevation of liver enzymes over two fold of upper normal limit in 3 months&lt;br&gt;&lt;br&gt;          -  admission for acute infection in 3 months&lt;br&gt;&lt;br&gt;          -  untreatable stenosis of vascular access&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End Stage Renal Disease;Hemodialysis</Condition>
    <Intervention>Procedure: On-line hemodiafiltration;Procedure: Low flux hemodialysis</Intervention>
    <Primary_outcome>endothelial dysfunction measured by flow-mediated vasodilation</Primary_outcome>
    <Secondary_ID>EMCIRB 07-01</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2883719</Internal_Number>
    <TrialID>NCT00532688</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure</Public_title>
    <Scientific_title>Randomised Control Pilot Trial of n-Acetylcysteine in the Treatment of Chronic Heart Failure With Coexistent Chronic Renal Failure.</Scientific_title>
    <Acronym />
    <Primary_sponsor>Bayside Health</Primary_sponsor>
    <Date_registration3>20070919</Date_registration3>
    <Date_registration>19/09/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00532688</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2007</Date_enrollement>
    <Target_size>10</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Crossover Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2/Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age 18 to 75 years inclusive;&lt;br&gt;&lt;br&gt;          -  Patients with chronic heart failure NYHA II, III and IV and LVEF&lt;40%. Stable&lt;br&gt;             medications for 1 month. Not admitted to hospital in the past month.&lt;br&gt;&lt;br&gt;          -  Chronic renal failure with GFR (as estimated by the Cockroft Gault equation) of &gt;30&lt;br&gt;             ml/min and &lt;50 ml/min not on any form of dialysis.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age &lt;18 and &gt;75 years;&lt;br&gt;&lt;br&gt;          -  Myocardial infarction in the preceding six months;&lt;br&gt;&lt;br&gt;          -  Acute decompensation of renal function or heart failure in the last 30 days;&lt;br&gt;&lt;br&gt;          -  Allergy to n-acetylcysteine or glyceryl trinitrate;&lt;br&gt;&lt;br&gt;          -  Contraindications to the use of glyceryl trinitrate as per the product information&lt;br&gt;             lodged with the PBS (Australia);&lt;br&gt;&lt;br&gt;          -  On treatment with allopurinol, vitamin C or vitamin E or other antioxidant therapy at&lt;br&gt;             time of randomisation (statins are acceptable);&lt;br&gt;&lt;br&gt;          -  Acute decompensation of another organ system in the last 30 days;&lt;br&gt;&lt;br&gt;          -  Current pregnancy.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Heart Failure, Congestive;Kidney Failure, Chronic</Condition>
    <Intervention>Drug: N-acetylcysteine</Intervention>
    <Primary_outcome>Vascular function via non invasive ultrasound measured flow mediated dilatation;Estimated glomerular filtration rate calculated with Cockroft Gault equation.</Primary_outcome>
    <Secondary_outcome>Symptoms of heart failure;Death;Serum BNP (brain natriuretic peptide)</Secondary_outcome>
    <Secondary_ID>132/07</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>The Alfred</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2884350</Internal_Number>
    <TrialID>NCT00541008</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer</Public_title>
    <Scientific_title>Phase II of Sunitinib (SUTENT®) in First Line for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma - SUPAP</Scientific_title>
    <Acronym />
    <Primary_sponsor>UNICANCER</Primary_sponsor>
    <Date_registration3>20071005</Date_registration3>
    <Date_registration>05/10/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00541008</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2007</Date_enrollement>
    <Target_size>92</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        DISEASE CHARACTERISTICS:&lt;br&gt;&lt;br&gt;        Inclusion criteria:&lt;br&gt;&lt;br&gt;          -  Diagnosis of papillary renal cell carcinoma&lt;br&gt;&lt;br&gt;               -  Locally advanced or metastatic disease&lt;br&gt;&lt;br&gt;               -  Type I or type II disease&lt;br&gt;&lt;br&gt;          -  Progressive disease&lt;br&gt;&lt;br&gt;          -  Measurable disease defined by RECIST criteria as at least 1 lesion at least 2 cm in&lt;br&gt;             length by conventional CT scan techniques or at least 1 cm by spiral CT scan&lt;br&gt;&lt;br&gt;          -  No brain metastases including treated and nonprogressive metastases&lt;br&gt;&lt;br&gt;        PATIENT CHARACTERISTICS:&lt;br&gt;&lt;br&gt;        Inclusion criteria:&lt;br&gt;&lt;br&gt;          -  ECOG performance status 0-1&lt;br&gt;&lt;br&gt;          -  Life expectancy = 3 months&lt;br&gt;&lt;br&gt;          -  Absolute neutrophil count = 1,500/mm³&lt;br&gt;&lt;br&gt;          -  Platelet count = 100,000/mm³&lt;br&gt;&lt;br&gt;          -  Hemoglobin = 8 g/dL&lt;br&gt;&lt;br&gt;          -  Total bilirubin = 3 mg/dL&lt;br&gt;&lt;br&gt;          -  AST and ALT = 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases&lt;br&gt;             are present)&lt;br&gt;&lt;br&gt;          -  Serum creatinine &lt; 1.5 times ULN&lt;br&gt;&lt;br&gt;          -  INR = 1.7 or PT = 6 seconds over ULN&lt;br&gt;&lt;br&gt;          -  Not pregnant or nursing&lt;br&gt;&lt;br&gt;          -  Fertile patients must use effective contraception&lt;br&gt;&lt;br&gt;          -  Patients must be affiliated to a Social Security System&lt;br&gt;&lt;br&gt;          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory&lt;br&gt;             tests, and other study procedures&lt;br&gt;&lt;br&gt;        Exclusion criteria:&lt;br&gt;&lt;br&gt;          -  NCI CTC grade 3 hemorrhage within 4 weeks prior to start of study treatment&lt;br&gt;&lt;br&gt;          -  Diagnosis of any second malignancy within the past 3 years except for basal cell&lt;br&gt;             carcinoma, squamous cell skin cancer, or in situ carcinoma of the cervix that has&lt;br&gt;             been adequately treated with no evidence of recurrent disease within the past 12&lt;br&gt;             months&lt;br&gt;&lt;br&gt;          -  Spinal cord compression, carcinomatous meningitis, or leptomeningeal disease&lt;br&gt;&lt;br&gt;          -  Any of the following within the past 12 months prior to study drug administration:&lt;br&gt;&lt;br&gt;               -  Severe/unstable angina&lt;br&gt;&lt;br&gt;               -  Myocardial infarction&lt;br&gt;&lt;br&gt;               -  Coronary artery bypass graft&lt;br&gt;&lt;br&gt;               -  Symptomatic congestive heart failure&lt;br&gt;&lt;br&gt;               -  Cerebrovascular accident including transient ischemic attack&lt;br&gt;&lt;br&gt;               -  Pulmonary embolism&lt;br&gt;&lt;br&gt;          -  Any of the following conditions:&lt;br&gt;&lt;br&gt;               -  Ongoing cardiac dysrhythmias of NCI CTCAE grade = 2&lt;br&gt;&lt;br&gt;               -  Atrial fibrillation of any grade&lt;br&gt;&lt;br&gt;               -  Prolongation of the QTc interval to &gt; 450 msec for males or &gt; 470 msec for&lt;br&gt;                  females&lt;br&gt;&lt;br&gt;          -  Hypertension that cannot be controlled by medications&lt;br&gt;&lt;br&gt;          -  Inability to swallow oral medications or presence of active inflammatory bowel&lt;br&gt;             disease, partial or complete bowel obstruction, or chronic diarrhea&lt;br&gt;&lt;br&gt;          -  Known HIV or AIDS infection&lt;br&gt;&lt;br&gt;          -  Other severe acute or chronic medical or psychiatric condition, or laboratory&lt;br&gt;             abnormality that may increase the risk associated with study participation or study&lt;br&gt;             drug administration&lt;br&gt;&lt;br&gt;          -  Psychological, familial, sociological, or geographical condition potentially&lt;br&gt;             hampering compliance with the study protocol and the follow-up schedule&lt;br&gt;&lt;br&gt;          -  Patients deprived of liberty or placed under the authority of a tutor&lt;br&gt;&lt;br&gt;        PRIOR CONCURRENT THERAPY:&lt;br&gt;&lt;br&gt;          -  Recovered from all toxic effects of any prior local treatment to CTCAE version 3.0&lt;br&gt;             grade = 1&lt;br&gt;&lt;br&gt;          -  At least 4 weeks since prior radiotherapy&lt;br&gt;&lt;br&gt;               -  At least 1 week since prior radiotherapy to &lt; 10% of the whole body allowed&lt;br&gt;                  provided side effects are &lt; grade 2 and there is at least one site for&lt;br&gt;                  evaluation&lt;br&gt;&lt;br&gt;          -  More than 2 weeks since prior and no concurrent anticoagulant agents or therapeutic&lt;br&gt;             doses of warfarin&lt;br&gt;&lt;br&gt;               -  Low-dose warfarin (up to 2 mg/day) for deep vein thrombosis prophylaxis allowed&lt;br&gt;&lt;br&gt;               -  Low molecular weight heparin allowed&lt;br&gt;&lt;br&gt;          -  No prior specific medical systemic therapy (i.e., first-line therapy)&lt;br&gt;&lt;br&gt;          -  No prior sunitinib malate&lt;br&gt;&lt;br&gt;          -  No prior investigational agents&lt;br&gt;&lt;br&gt;          -  No concurrent treatment on another therapeutic clinical trial&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Cancer</Condition>
    <Intervention>Drug: sunitinib malate</Intervention>
    <Primary_outcome>Objective tumor response rate</Primary_outcome>
    <Secondary_outcome>Safety;Overall survival;Time to disease progression;Time to response;Duration of response</Secondary_outcome>
    <Secondary_ID>FRE-FNCLCC-GEP-03-0603;EU-20761;EUDRACT-2006-003339-62;PFIZER-FRE-FNCLCC-GEP-03-0603;CDR0000569863</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2884805</Internal_Number>
    <TrialID>NCT00547040</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Arterial Stiffness and Calcifications in Incident Renal Transplant Recipients</Public_title>
    <Scientific_title>Arterial Stiffness and Calcifications in Incident Renal Transplant Recipients</Scientific_title>
    <Acronym>ASCIT</Acronym>
    <Primary_sponsor>Universitaire Ziekenhuizen Leuven</Primary_sponsor>
    <Date_registration3>20071018</Date_registration3>
    <Date_registration>18/10/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00547040</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>90 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2006</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Incident renal transplant patients or combined renal/pancreas transplant patients&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Transplant;Atherosclerosis;Arterial Stiffness</Condition>
    <Intervention>Other: no intervention</Intervention>
    <Primary_outcome>cardiovascular outcome</Primary_outcome>
    <Secondary_ID>ML3775</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2885432</Internal_Number>
    <TrialID>NCT00555373</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Pediatric Kidney Transplant Study of Sirolimus, Mycophenolate Mofetil, and Corticosteroids vs Calcineurin Inhibitor Based Immunosuppression</Public_title>
    <Scientific_title>Novel Pilot Trial of Sirolimus, Mycophenolate Mofetil, and Corticosteroids Versus a Historic Control Population Receiving Calcineurin Inhibitors Based Immunosuppression</Scientific_title>
    <Acronym>CNI-W</Acronym>
    <Primary_sponsor>Pediatric Nephrology of Alabama</Primary_sponsor>
    <Date_registration3>20071106</Date_registration3>
    <Date_registration>06/11/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00555373</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>19 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2007</Date_enrollement>
    <Target_size>50</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Prevention</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria at Transplant:&lt;br&gt;&lt;br&gt;          -  Age &lt; 19 years  (up to the day of the 19th birthday)&lt;br&gt;&lt;br&gt;          -  Panel Reactive Antibody Level (PRA)  &lt;20% (Flow cytometry method)&lt;br&gt;&lt;br&gt;          -  Recipient of first living donor or deceased donor renal transplantation&lt;br&gt;&lt;br&gt;          -  Signed and dated informed consent (per local IRB standards)&lt;br&gt;&lt;br&gt;        Exclusion Criteria at Transplant:&lt;br&gt;&lt;br&gt;          -  Recipients of multi-organ transplants (e.g. kidney/pancreas transplant, etc.)&lt;br&gt;&lt;br&gt;          -  Peak PRA &gt; 20% at any time&lt;br&gt;&lt;br&gt;          -  Recipient of en-bloc kidneys&lt;br&gt;&lt;br&gt;          -  Recipient of an organ from an HLA identical donor or a non-heart beating donor&lt;br&gt;&lt;br&gt;          -  Pregnant or lactating&lt;br&gt;&lt;br&gt;          -  Positive for HIV or an immunodeficiency virus&lt;br&gt;&lt;br&gt;          -  History of malignancy&lt;br&gt;&lt;br&gt;          -  Use of investigational agents within 4 weeks prior to transplantation&lt;br&gt;&lt;br&gt;          -  Current use of terfenadine, cisapride, astemizole, or pimozide (unless discontinued&lt;br&gt;             before administration of SRL)&lt;br&gt;&lt;br&gt;          -  Known hypersensitivity to sirolimus&lt;br&gt;&lt;br&gt;          -  Known hypersensitivity to Prograf, Cellcept, prednisone, Cremophor, HCO-60, or murine&lt;br&gt;             products&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Transplant</Condition>
    <Intervention>Drug: Sirolimus</Intervention>
    <Primary_outcome>This study has a primary endpoint of allograft function as determined by Schwartz GFR at 18 months after conversion to CNI free protocol (2 years post transplantation).</Primary_outcome>
    <Secondary_outcome>Secondary outcomes will include biopsy proven acute rejection episodes, progression of quantitative interstitial fibrosis as determined by Sirius Red staining and digital image analysis, Allograft survival and patient survival</Secondary_outcome>
    <Secondary_ID>WIRB Pr. No.:  20101428</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Pfizer;The EMMES Corporation</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2885566</Internal_Number>
    <TrialID>NCT00557219</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Fenoldopam and Ketanserin for Acute Kidney Failure Prevention After Cardiac Surgery</Public_title>
    <Scientific_title>Influence of Fenoldopam and Ketanserin on Function and Kidney Injury Parameters in Patients With Increased Risk of Acute Kidney Failure After Cardiac Surgery</Scientific_title>
    <Acronym />
    <Primary_sponsor>Medical University of Gdansk</Primary_sponsor>
    <Date_registration3>20071109</Date_registration3>
    <Date_registration>09/11/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00557219</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2008</Date_enrollement>
    <Target_size>90</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver), Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  cardiac surgery&lt;br&gt;&lt;br&gt;          -  at least one risk factor for acute renal failure:&lt;br&gt;&lt;br&gt;               1. oliguria &lt; 0.5 ml/kg/hour for over 3 hours despite adequate blood volume and&lt;br&gt;                  furosemide intravenously&lt;br&gt;&lt;br&gt;               2. at least 60 mg furosemide/12 hours iv  to maintain diuresis &gt; 1 ml/kg/hour&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  refused or none consent&lt;br&gt;&lt;br&gt;          -  chronic renal failure with chronic renal replacement therapy&lt;br&gt;&lt;br&gt;          -  chronic increase of serum creatinine &gt; 2 mg/dl&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Renal Failure</Condition>
    <Intervention>Drug: fenoldopam (Corlopam);Drug: placebo;Drug: ketanserin (Sufrexal)</Intervention>
    <Primary_outcome>cystatin C and NGAL in serum</Primary_outcome>
    <Secondary_outcome>ß2microglobulin in urine;creatinine increase in serum;frequency of renal replacement therapy</Secondary_outcome>
    <Secondary_ID>AMG-NKEBN/225/2007</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2885883</Internal_Number>
    <TrialID>NCT00561483</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Sequential Cystatin C Levels and Renal Impairment in Acute Heart Failure</Public_title>
    <Scientific_title>Sequential Cystatin C Levels and Renal Impairment in Acute Heart Failure</Scientific_title>
    <Acronym />
    <Primary_sponsor>The Cleveland Clinic</Primary_sponsor>
    <Date_registration3>20071120</Date_registration3>
    <Date_registration>20/11/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00561483</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2007</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Hospital admission within 48 hours for ADHF, with an expected stay over 24 hours.&lt;br&gt;&lt;br&gt;          -  Evidence of fluid overload, including jugular venous distention, pulmonary rales,&lt;br&gt;             peripheral edema, and/or ascites receiving diuretic therapy&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Heart failure due to congenital heart disease or critical aortic stenosis&lt;br&gt;             (potentially different cardio-renal pathophysiology)&lt;br&gt;&lt;br&gt;          -  Acute myocardial infarction or unstable acute coronary syndromes&lt;br&gt;&lt;br&gt;          -  End-stage renal insufficiency on renal replacement therapy (already has underlying&lt;br&gt;             advanced renal failure).&lt;br&gt;&lt;br&gt;          -  Patients with active cancer (cystatin C has been shown to be produced by some tumors)&lt;br&gt;&lt;br&gt;          -  Known exposure to nephrotoxic agents (such as contrast dye) or planned surgery during&lt;br&gt;             hospitalization at the time of enrollment&lt;br&gt;&lt;br&gt;          -  Hemoglobin &lt; 9 mg/dL or clinically significant active bleeding.&lt;br&gt;&lt;br&gt;          -  Unable to comply with protocol or unable to have informed consent&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Heart Failure;Renal Failure</Condition>
    <Primary_outcome>To examine the natural history of cystatin C levels during diuretic therapy in ADHF</Primary_outcome>
    <Secondary_outcome>To determine the predictive value of changes in sequential cystatin C levels to subsequent development of WRF;The combined outcome of either death in hospital or death within 90 days after discharge or readmission to the hospital facility for heart failure within 90 days</Secondary_outcome>
    <Secondary_ID>07-834</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2886177</Internal_Number>
    <TrialID>NCT00565331</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Rituximab for Prevention of Rejection After Renal Transplantation</Public_title>
    <Scientific_title>A Prospective Randomized Study on the Efficacy and Safety of the Prophylactic Use of Rituximab, Added to Standard Immunosuppressive Treatment in Comparison With Standard Immunosuppressive Treatment Alone in Renal Transplantation</Scientific_title>
    <Acronym />
    <Primary_sponsor>Radboud University</Primary_sponsor>
    <Date_registration3>20071128</Date_registration3>
    <Date_registration>28/11/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00565331</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>December 2007</Date_enrollement>
    <Target_size>280</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2/Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Renal transplant recipients&lt;br&gt;&lt;br&gt;          -  Signed, dated, and witnessed IRB approved informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Pregnancy&lt;br&gt;&lt;br&gt;          -  Living donor, who is HLA identical.&lt;br&gt;&lt;br&gt;          -  Hemolytic uremic syndrome as original kidney disease.&lt;br&gt;&lt;br&gt;          -  Focal segmental glomerulosclerosis that had recurred in a previous graft.&lt;br&gt;&lt;br&gt;          -  More than two previously failed grafts and/or PRA &gt; 85%.&lt;br&gt;&lt;br&gt;          -  Previous treatment with anti-CD20 antibodies.&lt;br&gt;&lt;br&gt;          -  Diabetes mellitus that is currently not treated with insulin.&lt;br&gt;&lt;br&gt;          -  Total white blood cell count &lt;3,000/mm3 or platelet count &lt;75,000/mm3.&lt;br&gt;&lt;br&gt;          -  Active infection with hepatitis B, hepatitis C, or HIV.&lt;br&gt;&lt;br&gt;          -  History of tuberculosis&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Transplantation</Condition>
    <Intervention>Drug: Rituximab</Intervention>
    <Primary_outcome>Incidence and severity of biopsy-confirmed acute rejection</Primary_outcome>
    <Secondary_outcome>Renal function as estimated by the endogenous creatinine clearance;Occurrence of chronic allograft nephropathy;Cumulative incidence of infections and malignancies;Patient and graft survival</Secondary_outcome>
    <Secondary_ID>UMC Radboud RI000131;RRT06</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Hoffmann-La Roche;Astellas Pharma GmbH</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2886591</Internal_Number>
    <TrialID>NCT00570882</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)</Public_title>
    <Scientific_title>A Randomized Phase II Trial Of Sunitinib Administered Daily For 4 Weeks, Followed By 2-Week Rest Vs. 2-Week On And 1-Week Off In Metastatic Renal Cell Carcinoma</Scientific_title>
    <Acronym />
    <Primary_sponsor>Asan Medical Center</Primary_sponsor>
    <Date_registration3>20071210</Date_registration3>
    <Date_registration>10/12/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00570882</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2007</Date_enrollement>
    <Target_size>80</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Histologically or cytologically confirmation of renal cell carcinoma with a clear&lt;br&gt;             cell histologic component&lt;br&gt;&lt;br&gt;          2. Patients must present with stage IV disease not amenable to surgery, radiotherapy, or&lt;br&gt;             combined modality therapy with curative intent.&lt;br&gt;&lt;br&gt;          3. Measurable disease according to RECIST criteria are required but patients with&lt;br&gt;             evaluable lesions without measurable lesions are allowed to be enrolled to this study&lt;br&gt;&lt;br&gt;          4. ECOG performance status 2 or better&lt;br&gt;&lt;br&gt;          5. Age 18 years or older&lt;br&gt;&lt;br&gt;          6. Adequate bone marrow, hepatic, and renal function&lt;br&gt;&lt;br&gt;          7. Life expectancy of &gt; 3 months&lt;br&gt;&lt;br&gt;          8. Singed and dated informed consent of document indicating that the patient (or legally&lt;br&gt;             acceptable representative) has been informed of all pertinent aspects of the trial&lt;br&gt;             prior to enrollment&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Known spinal cord compression or carcinomatous meningitis&lt;br&gt;&lt;br&gt;          2. Diagnosis of any serious secondary malignancy within the last 2 years, except for&lt;br&gt;             adequately treated basal cell or squamous cell carcinoma of skin, or in situ&lt;br&gt;             carcinoma of cervix uteri&lt;br&gt;&lt;br&gt;          3. Hypertension that cannot be controlled by medications (blood pressure &gt; 150/90 mmHg&lt;br&gt;             despite optimal medical therapy)&lt;br&gt;&lt;br&gt;          4. Treatment with anticonvulsant agents and treatment with therapeutic doses of coumadin&lt;br&gt;             currently or within 2 weeks prior to first day of sunitinib administration. Low dose&lt;br&gt;             coumadin for DVT prophylaxis is permitted (up to 2 mg/day).&lt;br&gt;&lt;br&gt;          5. Pregnancy or breast feeding.&lt;br&gt;&lt;br&gt;          6. Other severe acute or chronic medical or psychiatric condition&lt;br&gt;&lt;br&gt;          7. Prior treatment on sunitinib, sorafenib, or bevacizumab.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Metastatic Renal Cell Carcinoma</Condition>
    <Intervention>Drug: Sunitinib 2/1;Drug: Sunitinib 4/2</Intervention>
    <Primary_outcome>Treatment failure rate (progressive disease, treatment withdrawal due to unacceptable toxicities, or any death)</Primary_outcome>
    <Secondary_outcome>Overall response rate;quality of life;Progression free survival;Overall survival;Adverse events</Secondary_outcome>
    <Secondary_ID>UOSG_AMC_0701</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2886886</Internal_Number>
    <TrialID>NCT00574808</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Improved Delivery of Cardiovascular Care Through Outreach Facilitation</Public_title>
    <Scientific_title>Improved Delivery of Cardiovascular Preventive Care (IDOCC) Through Outreach Facilitation</Scientific_title>
    <Acronym>IDOCC</Acronym>
    <Primary_sponsor>C. T. Lamont Primary Care Research Centre</Primary_sponsor>
    <Date_registration3>20071214</Date_registration3>
    <Date_registration>14/12/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00574808</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>40 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2007</Date_enrollement>
    <Target_size>210</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Single Blind (Outcomes Assessor), Primary Purpose:  Health Services Research</Study_design>
    <Phase>Phase 1</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Men and women over 40 years of age, who meet at least one of the following criteria:&lt;br&gt;&lt;br&gt;               1. have established cardiovascular disease: Coronary Artery Disease,&lt;br&gt;                  Cerebrovascular disease (documented stroke and/or TIA), and Peripheral Vascular&lt;br&gt;                  Disease;&lt;br&gt;&lt;br&gt;               2. have Diabetes Mellitus;&lt;br&gt;&lt;br&gt;               3. have Chronic Kidney Disease ;&lt;br&gt;&lt;br&gt;               4. are at high risk for CVD based on a presence of at least three of the following&lt;br&gt;                  established cardiovascular risk factors: age (males = 45, females = 55), smoker&lt;br&gt;                  status, hypertension, and dyslipidemia.&lt;br&gt;&lt;br&gt;          -  No restrictions will be imposed on the recruitment process; all practices in the&lt;br&gt;             region will be eligible to participate.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  see above&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Hypertension;Dyslipidemia;Diabetes;Chronic Kidney Disease;Cardiovascular Disease;Stroke;Transient Ischemic Attacks</Condition>
    <Intervention>Other: Outreach Facilitation implementing elements of the Chronic Care Model</Intervention>
    <Primary_outcome>Quality of care process index = ? of recommended services received by patient/ ? of the recommended services for which the patient was eligible</Primary_outcome>
    <Secondary_outcome>Quality of care outcome index = ? of recommended targets reached / ? of the number of targets for which the patient is eligible based on the number of conditions suffered by the patient</Secondary_outcome>
    <Secondary_ID>937200801;IDOCC</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Dept of Family Medicine, Faculty of Medicine, Hebrew University, Jerusalem, Israel;Institute of Population Health, University of Ottawa;University of Ottawa Heart Institute;Ottawa Cardiovascular Centre;Ottawa Regional Stroke Program;Élisabeth Bruyère Research Institute;Champlain Primary Care Practices</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2886938</Internal_Number>
    <TrialID>NCT00575497</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>More Frequent Dialysis (&gt;3 Treatments Per Week)</Public_title>
    <Scientific_title>Study of Clinical Outcomes of More Frequent Hemodialysis</Scientific_title>
    <Acronym>MFD</Acronym>
    <Primary_sponsor>Satellite Healthcare</Primary_sponsor>
    <Date_registration3>20071214</Date_registration3>
    <Date_registration>14/12/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00575497</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2005</Date_enrollement>
    <Target_size>300</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Crossover Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Stable vascular access, i.e., lack of needling difficulties and stable flow rates.&lt;br&gt;             Accesses will include fistulae, grafts, catheters and ports.&lt;br&gt;&lt;br&gt;          -  18 years of age.&lt;br&gt;&lt;br&gt;          -  History of compliance with a dialysis treatment schedule, or if a new patient,&lt;br&gt;             express a willingness to be compliant with a treatment schedule.&lt;br&gt;&lt;br&gt;          -  Plan to continue care and follow-up at the investigational site.&lt;br&gt;&lt;br&gt;          -  Able to sign the informed consent and other relevant documents.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  History of poor compliance with thrice (or twice) weekly dialysis schedules as&lt;br&gt;             manifested by more than three unexplained missed treatments in the past six (6)&lt;br&gt;             months.&lt;br&gt;&lt;br&gt;          -  Pregnancy.&lt;br&gt;&lt;br&gt;          -  Intravenous drug abuser.&lt;br&gt;&lt;br&gt;          -  Expects to receive a transplant or transfer to another facility within six months of&lt;br&gt;             entering the study.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End Stage Renal Disease;Chronic Kidney Disease</Condition>
    <Intervention>Procedure: More frequent hemodialysis;Procedure: More frequent hemodialysis;Procedure: More frequent hemodialysis;Procedure: More frequent hemodialysis;Procedure: More frequent hemodialysis;Procedure: More frequent hemodialysis;Procedure: Conventional Hemodialysis</Intervention>
    <Primary_outcome>Hospitalization days per year</Primary_outcome>
    <Secondary_outcome>Nutritional Status measured by Subjective Global Assessment;Anemia, measured by erythropoetin dose;Control of hypertension, as measured by number of antihypertensive tablets taken per day;Control of hyperphosphatemia, as measured by number of phosphate binder tablets taken per day</Secondary_outcome>
    <Secondary_ID>SR002MFD</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2886938</Internal_Number>
    <TrialID>NCT00575497</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>More Frequent Dialysis (&gt;3 Treatments Per Week)</Public_title>
    <Scientific_title>Study of Clinical Outcomes of More Frequent Hemodialysis</Scientific_title>
    <Acronym>MFD</Acronym>
    <Primary_sponsor>Satellite Healthcare</Primary_sponsor>
    <Date_registration3>20071214</Date_registration3>
    <Date_registration>14/12/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00575497</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2005</Date_enrollement>
    <Target_size>300</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Crossover Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Stable vascular access, i.e., lack of needling difficulties and stable flow rates.&lt;br&gt;             Accesses will include fistulae, grafts, catheters and ports.&lt;br&gt;&lt;br&gt;          -  18 years of age.&lt;br&gt;&lt;br&gt;          -  History of compliance with a dialysis treatment schedule, or if a new patient,&lt;br&gt;             express a willingness to be compliant with a treatment schedule.&lt;br&gt;&lt;br&gt;          -  Plan to continue care and follow-up at the investigational site.&lt;br&gt;&lt;br&gt;          -  Able to sign the informed consent and other relevant documents.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  History of poor compliance with thrice (or twice) weekly dialysis schedules as&lt;br&gt;             manifested by more than three unexplained missed treatments in the past six (6)&lt;br&gt;             months.&lt;br&gt;&lt;br&gt;          -  Pregnancy.&lt;br&gt;&lt;br&gt;          -  Intravenous drug abuser.&lt;br&gt;&lt;br&gt;          -  Expects to receive a transplant or transfer to another facility within six months of&lt;br&gt;             entering the study.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End Stage Renal Disease;Chronic Kidney Disease</Condition>
    <Intervention>Procedure: More frequent hemodialysis;Procedure: More frequent hemodialysis;Procedure: More frequent hemodialysis;Procedure: More frequent hemodialysis;Procedure: More frequent hemodialysis;Procedure: More frequent hemodialysis;Procedure: Conventional Hemodialysis</Intervention>
    <Primary_outcome>Hospitalization days per year</Primary_outcome>
    <Secondary_outcome>Nutritional Status measured by Subjective Global Assessment;Anemia, measured by erythropoetin dose;Control of hypertension, as measured by number of antihypertensive tablets taken per day;Control of hyperphosphatemia, as measured by number of phosphate binder tablets taken per day</Secondary_outcome>
    <Secondary_ID>SR002MFD</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2887275</Internal_Number>
    <TrialID>NCT00579995</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>A Prospective, Randomized TrialComparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate</Public_title>
    <Scientific_title>A Prospective, Randomized Trial Comparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate for the Prevention of Contrast-Induced Nephropathy in High-Risk Patients Undergoing Cardiac Catheterization</Scientific_title>
    <Acronym>PROTECt</Acronym>
    <Primary_sponsor>University of Nebraska</Primary_sponsor>
    <Date_registration3>20071218</Date_registration3>
    <Date_registration>18/12/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00579995</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>19 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2005</Date_enrollement>
    <Target_size>140</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Diagnostic</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria: 19 years of age&lt;br&gt;&lt;br&gt;          -  Baseline serum creatinine or&lt;br&gt;&lt;br&gt;          -  Calculated creatinine&lt;br&gt;&lt;br&gt;          -  Stable Renal Function&lt;br&gt;&lt;br&gt;          -  Left Ventricular ejection fraction&lt;br&gt;&lt;br&gt;          -  Non-pregnant, non-lactating females (all women of childbearing potential must have a&lt;br&gt;             negative serum pregnancy test.  No contraception will be required&lt;br&gt;&lt;br&gt;          -  Able to sign informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Acute renal failure&lt;br&gt;&lt;br&gt;          -  History of Kidney transplant&lt;br&gt;&lt;br&gt;          -  Currently receiving N-acetylcysteine&lt;br&gt;&lt;br&gt;             _ Contraindication of hypersensitivity to N-acetylcysteine or sodium bicarbonate&lt;br&gt;&lt;br&gt;          -  Left ventricular ejection fraction&lt;br&gt;&lt;br&gt;          -  Pregnant, lactating females&lt;br&gt;&lt;br&gt;          -  Allergy to contrast dye&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Preserving Kidney Function in People Who Are at High Risk of Developing Contrast-induced Nephropathy</Condition>
    <Intervention>Drug: Oral N-Acetylcysteine;Drug: Intravenous Sodium Bicarbonate</Intervention>
    <Primary_outcome>to compare the effectiveness of two medications, oral N-acetylcysteine (mucomyst) and intravenous sodium bicarbonate, used to protect the kidneys from contrast injury during a cardiac catheterization</Primary_outcome>
    <Secondary_ID>120-05-FB</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2887578</Internal_Number>
    <TrialID>NCT00583973</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effect of Parenteral Iron Therapy on Inflammatory Response and Oxidative Stress Chronic Hemodialysis</Public_title>
    <Scientific_title>The Effect of Parenteral Iron Therapy on the Systemic Inflammatory Response and Oxidative Stress in Chronic Hemodialysis Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of California, Davis</Primary_sponsor>
    <Date_registration3>20071222</Date_registration3>
    <Date_registration>22/12/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00583973</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2007</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Hemodialysis patients age 18 or greater who are prescribed parenteral iron by their&lt;br&gt;             primary nephrologist&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Hemodialysis;Chronic Kidney Disease;Inflammation</Condition>
    <Secondary_ID>200614206-2</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Dialysis Clinic, Inc.</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2888402</Internal_Number>
    <TrialID>NCT00594919</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Neutrophil Gelatinase-Associated Lipocalin: Biomarker of Acute Kidney Injury After Cardiac Surgery</Public_title>
    <Scientific_title>Neutrophil Gelatinase-Associated Lipocalin(NGAL): Early Biomarker of Acute Kidney Injury After Cardiac Surgery</Scientific_title>
    <Acronym />
    <Primary_sponsor>Hospital de Base</Primary_sponsor>
    <Date_registration3>20080107</Date_registration3>
    <Date_registration>07/01/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00594919</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2007</Date_enrollement>
    <Target_size>150</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients aged greater than 18 years undergoing elective cardiac surgery for coronary&lt;br&gt;             artery bypass grafting and/or valve replacement&lt;br&gt;&lt;br&gt;          -  In need of cardiopulmonary bypass and with the prospect of minimum hospital length&lt;br&gt;             stay of 48 hours in ICU&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with IRA before hospitalization in the ICU&lt;br&gt;&lt;br&gt;          -  Patients with estimated glomerular filtration (MDRD formula simplified) less than 30&lt;br&gt;             ml/min&lt;br&gt;&lt;br&gt;          -  Patients transplanted kidney&lt;br&gt;&lt;br&gt;          -  Patients with chronic renal failure on dialysis&lt;br&gt;&lt;br&gt;          -  Patients anuric the admission in the ICU&lt;br&gt;&lt;br&gt;          -  Refusal to participate in the study.&lt;br&gt;&lt;br&gt;        Definition of IRA:&lt;br&gt;&lt;br&gt;        IRA will be defined according to the new proposal of AKIN (Acute Kidney Injury Network)&lt;br&gt;        (awaiting publication): abrupt elevation (48 hours) of serum creatinine in value greater&lt;br&gt;        than or equal to 0.3 mg / dL or an increase of 50% compared to baseline or reduction of&lt;br&gt;        urinary volume to 0.5 ml / kg / h for more than 6 hours&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Early Acute Kidney Injury</Condition>
    <Primary_outcome>Evaluate the urinary excretion of NGAL as a marker of early development of acute kidney injury in patients undergoing cardiac surgery</Primary_outcome>
    <Secondary_ID>1411 - 2007.;CAAE 0246.0.000.140-07</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Fundação de Amparo à Pesquisa do Estado de São Paulo</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2888562</Internal_Number>
    <TrialID>NCT00597025</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Impact of Providing High Protein Bar to Dialysis Patients With Low Serum Albumin</Public_title>
    <Scientific_title>Impact of Providing High Protein Bar to Dialysis Patients With Low Serum Albumin</Scientific_title>
    <Acronym />
    <Primary_sponsor>Satellite Healthcare</Primary_sponsor>
    <Date_registration3>20080108</Date_registration3>
    <Date_registration>08/01/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00597025</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>December 2007</Date_enrollement>
    <Target_size>375</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Subjects with ESRD undergoing center hemodialysis or peritoneal dialysis for more&lt;br&gt;             than 90 days.&lt;br&gt;&lt;br&gt;          -  18 years of age or older.&lt;br&gt;&lt;br&gt;          -  Must have a reasonable expectation of remaining on treatment for at least 3 months.&lt;br&gt;&lt;br&gt;          -  Must have an average serum albumin of &lt;3.5 g/dL over the three months prior to entry&lt;br&gt;             into the study.&lt;br&gt;&lt;br&gt;          -  Must be able to understand and sign the informed consent.&lt;br&gt;&lt;br&gt;          -  Must be willing and able to participate in nutrition interviews for determination of&lt;br&gt;             nutrient intake from conventional foods.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Allergy to protein, milk, nuts or wheat.&lt;br&gt;&lt;br&gt;          -  Documented ongoing acute infection or inflammatory process including treatment with&lt;br&gt;             antibiotics within a two week time of study entry.&lt;br&gt;&lt;br&gt;          -  Severe acidosis defined as pre-dialysis serum bicarbonate levels of &lt;15 mEq/L.&lt;br&gt;&lt;br&gt;          -  Presence of conditions that would affect normal response to repletion of protein and&lt;br&gt;             calories, such as gastrointestinal disorders including inflammatory bowel disease.&lt;br&gt;&lt;br&gt;          -  Hospitalization for an infectious condition within 4 weeks prior to study entry.&lt;br&gt;&lt;br&gt;          -  Planned surgery within the three month study period including planned kidney&lt;br&gt;             transplantation.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End Stage Renal Disease;Hypoalbuminemia;Malnutrition</Condition>
    <Intervention>Dietary Supplement: Protein Food Bar Intelligent Indulgence;Dietary Supplement: Protein Food Bar Intelligent Indulgence;Dietary Supplement: Protein Food Bar Intelligent Indulgence</Intervention>
    <Primary_outcome>The mean change (from baseline to month 3) in serum albumin levels among study groups and the proportion of patients treated with the protein food bar reaching an increase of 0.3 g/dL over the three month study period.;Incidence of potential adverse events including nausea, vomiting, diarrhea, acidosis, and uremic symptoms as evidenced by clinical symptoms and possible worsening of laboratory measures such as BUN, Kt/V, nPNA and bicarbonate.</Primary_outcome>
    <Secondary_outcome>Proportion of patients who reached the goal albumin of &gt;3.5 g/dL during the study period;Overall acceptance and compliance of bar form medical food over a 3 month period will be assessed via the  proportion of patients who ingested 75% or more of the recommended bars.;Impact of protein intake on laboratory measures such as pre-albumin, CRP and ferritin will be monitored</Secondary_outcome>
    <Secondary_ID>SR017PB</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2888568</Internal_Number>
    <TrialID>NCT00597103</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Comparison of Dialysis Therapies on Cognitive Function</Public_title>
    <Scientific_title>Comparison of Dialysis Therapies on Cognitive Function</Scientific_title>
    <Acronym />
    <Primary_sponsor>Satellite Healthcare</Primary_sponsor>
    <Date_registration3>20080108</Date_registration3>
    <Date_registration>08/01/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00597103</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>December 2007</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case Control, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Diagnosis of ESRD&lt;br&gt;&lt;br&gt;          -  Age 18 years or greater&lt;br&gt;&lt;br&gt;          -  Ability to understand and a willingness to sign an informed consent statement and a&lt;br&gt;             Health Insurance Portability and Accountability Act of 1996 (HIPPA) authorization&lt;br&gt;             statement.&lt;br&gt;&lt;br&gt;          -  Expected survival of at least one year.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Documented non-compliance, defined as missing more than 10% of prescribed treatments&lt;br&gt;             during the month prior to the start of the study.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End Stage Renal Disease;Chronic Kidney Disease</Condition>
    <Intervention>Other: Cognitive Function Testing-10 Tests;Other: Sleep Assessment Testing;Other: Periodic Leg Movement Syndrome Assessment</Intervention>
    <Primary_outcome>Distribution of cognitive function impairment in ESRD patients undergoing more frequent hemodialysis</Primary_outcome>
    <Secondary_outcome>Longitudinal analysis of cognitive function over time to test the hypothesis that more frequent hemodialysis contributes to delay in cognitive function impairment;To test the hypothesis that nightly or daily hemodialysis treatment can ultimately be proven to be cost effective options by preserving cognitive function.;Influence of cognitive function on survival.</Secondary_outcome>
    <Secondary_ID>SR016CF</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2888568</Internal_Number>
    <TrialID>NCT00597103</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Comparison of Dialysis Therapies on Cognitive Function</Public_title>
    <Scientific_title>Comparison of Dialysis Therapies on Cognitive Function</Scientific_title>
    <Acronym />
    <Primary_sponsor>Satellite Healthcare</Primary_sponsor>
    <Date_registration3>20080108</Date_registration3>
    <Date_registration>08/01/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00597103</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>December 2007</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case Control, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Diagnosis of ESRD&lt;br&gt;&lt;br&gt;          -  Age 18 years or greater&lt;br&gt;&lt;br&gt;          -  Ability to understand and a willingness to sign an informed consent statement and a&lt;br&gt;             Health Insurance Portability and Accountability Act of 1996 (HIPPA) authorization&lt;br&gt;             statement.&lt;br&gt;&lt;br&gt;          -  Expected survival of at least one year.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Documented non-compliance, defined as missing more than 10% of prescribed treatments&lt;br&gt;             during the month prior to the start of the study.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End Stage Renal Disease;Chronic Kidney Disease</Condition>
    <Intervention>Other: Cognitive Function Testing-10 Tests;Other: Sleep Assessment Testing;Other: Periodic Leg Movement Syndrome Assessment</Intervention>
    <Primary_outcome>Distribution of cognitive function impairment in ESRD patients undergoing more frequent hemodialysis</Primary_outcome>
    <Secondary_outcome>Longitudinal analysis of cognitive function over time to test the hypothesis that more frequent hemodialysis contributes to delay in cognitive function impairment;To test the hypothesis that nightly or daily hemodialysis treatment can ultimately be proven to be cost effective options by preserving cognitive function.;Influence of cognitive function on survival.</Secondary_outcome>
    <Secondary_ID>SR016CF</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2888737</Internal_Number>
    <TrialID>NCT00599365</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Impact of CAMP in an Ambulatory Renal Clinic</Public_title>
    <Scientific_title>Impact of a Pharmacist's Collaborative Management, Adherence,and Medication Education Program (CAMP) in an Ambulatory Renal Clinic</Scientific_title>
    <Acronym>CAMP</Acronym>
    <Primary_sponsor>San Francisco Veterans Administration Medical Center</Primary_sponsor>
    <Date_registration3>20080104</Date_registration3>
    <Date_registration>04/01/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00599365</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>December 2007</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Prevention</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        Patients will be eligible for enrollment if they are &gt; 18 year old men or women receiving&lt;br&gt;        care from the VAMCSF Renal Clinic with a documented diagnosis of CKD stage 2-5, and are&lt;br&gt;        receiving pharmacological treatment for one or more medical conditions of CKD, including&lt;br&gt;        hypertension, diabetes, CKD-mineral and bone disorders, and/or anemia of chronic disease.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        Patients will be excluded from the study if they obtain medications prescribed for the&lt;br&gt;        above medical conditions from a facility outside the VAMCSF, are enrolled in Medi-Set&lt;br&gt;        clinic, are kidney transplant patients, are diagnosed with CKD stage 1, require assistance&lt;br&gt;        in the administration of their medications (i.e. caregiver), lack adequate transportation&lt;br&gt;        to clinic, and/or lack telephone access.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease</Condition>
    <Intervention>Other: Pharmacy care arm</Intervention>
    <Primary_outcome>MPR cumulative persistence rates  pill counts   blood glucose HgbA1c  hemoglobin concentration iron ferritin transferrin saturation SBP/DBP corrected calcium phosphorous calcium-phosphorus product uAlb/Cr eGFR.</Primary_outcome>
    <Secondary_ID>T0986;H45161-31657-01</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>University of California, San Francisco</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2889112</Internal_Number>
    <TrialID>NCT00604357</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment</Public_title>
    <Scientific_title>A Pilot Study to Determine the Safety and Efficacy of Induction-Therapy, De Novo MPA and Delayed mTOR-Inhibition in Liver Transplant Recipients With Impaired Renal Function. (PATRON-Study)</Scientific_title>
    <Acronym>PATRON07</Acronym>
    <Primary_sponsor>University of Regensburg</Primary_sponsor>
    <Date_registration3>20080117</Date_registration3>
    <Date_registration>17/01/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00604357</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>December 2008</Date_enrollement>
    <Target_size>29</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients undergoing primary liver transplantation.&lt;br&gt;&lt;br&gt;          -  Patients older than 18 years.&lt;br&gt;&lt;br&gt;          -  Patients with a hepatorenal syndrome type I or II&lt;br&gt;&lt;br&gt;          -  eGFR &lt; 50 ml/min at the time point of transplantation&lt;br&gt;&lt;br&gt;          -  Serum creatinine levels &gt; 1.5 mg/dL at the time-point of transplantation&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with pre-transplant renal replacement therapy &gt; 14 days.&lt;br&gt;&lt;br&gt;          -  Patients with hepatocellular carcinoma.&lt;br&gt;&lt;br&gt;          -  Patients with a known hypersensitivity to mTOR-inhibitors.&lt;br&gt;&lt;br&gt;          -  Patients with a known hypersensitivity to mycophenolate acid.&lt;br&gt;&lt;br&gt;          -  Patients with a known hypersensitivity to anti CD 25-monoclonal antibodies.&lt;br&gt;&lt;br&gt;          -  Patients with platelets &lt; 50.000/nl.&lt;br&gt;&lt;br&gt;          -  Patients with triglycerides &gt; 350 mg/dl and cholesterol &gt; 300 mg/dl refractory to&lt;br&gt;             optimal medical treatment prior to initiation of therapy with mTOR inhibition.&lt;br&gt;&lt;br&gt;          -  Severe systemic infections and wound-healing disturbances prior to inclusion.&lt;br&gt;&lt;br&gt;          -  Multiple organ graft recipients.&lt;br&gt;&lt;br&gt;          -  Patients with signs of a hepatic artery stenosis directly prior to initiation of&lt;br&gt;             therapy with Sirolimus.&lt;br&gt;&lt;br&gt;          -  Patients with a psychological, familial, sociologic or geographic condition&lt;br&gt;             potentially hampering compliance with the study protocol and follow-up schedule.&lt;br&gt;&lt;br&gt;          -  Patients under guardianship (e.g. individuals who are not able to freely give their&lt;br&gt;             informed consent).&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End Stage Liver Disease;Impaired Renal Function</Condition>
    <Intervention>Drug: anti-CD 25 mAb, Sirolimus, MMF</Intervention>
    <Primary_outcome>The primary endpoint is defined as the incidence of steroid-resistant acute rejection within the first 30 days after liver transplantation.</Primary_outcome>
    <Secondary_outcome>incidence of acute rejection(s);the number and the timing of acute rejections;the development of renal function at 1 week, 1, 3, 6 and 12 months after liver transplantation;liver allograft function;infectious complications;treatment failures defined as introduction of CNIs;side-effects affecting the hematopoetic system;tolerability;impaired wound-healing;incidence of hepatic artery thrombosis;mortality</Secondary_outcome>
    <Secondary_ID>PATRON07</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2889456</Internal_Number>
    <TrialID>NCT00608998</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Identification of Cardiovascular Risk Factors Linked to Renal Failure Progression</Public_title>
    <Scientific_title>Vascular Risk Factors and Coronary Calcifications in Chronic Renal Failure Patients: Identification of Specific Factors Linked to Renal Failure Progression</Scientific_title>
    <Acronym>Pre-HD</Acronym>
    <Primary_sponsor>University Hospital, Montpellier</Primary_sponsor>
    <Date_registration3>20080123</Date_registration3>
    <Date_registration>23/01/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00608998</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>90 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2007</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case-Only, Time Perspective:  Cross-Sectional</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patient who has signed the written consent form&lt;br&gt;&lt;br&gt;          -  Patient aged &gt; 18 and &lt; 90 years&lt;br&gt;&lt;br&gt;          -  Chronic renal failure defined by glomerular filtration rate (GFR)&lt;br&gt;&lt;br&gt;               -  group 1: GFR &gt;90 mL/min with urinary biological abnormalities and GFR comprised&lt;br&gt;                  between 90 and 60 mL/min&lt;br&gt;&lt;br&gt;               -  group 2: GFR comprised between 60 and 30 mL/min&lt;br&gt;&lt;br&gt;               -  group 3: GFR &lt;30 mL/min but without dialysis therapy&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Chronic renal failure patient requiring dialysis therapy&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Renal Failure</Condition>
    <Primary_outcome>description of osteoprotegerin levels according to chronic renal failure progression</Primary_outcome>
    <Secondary_outcome>calcium score description according to chronic renal failure progression;osteoprotegerin description according to calcium score;relationship between cardiovascular risk factors and calcium score;relationship between cardiovascular risk factors and cardiovascular disease</Secondary_outcome>
    <Secondary_ID>UF 7853</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Ministry of Health, France</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2889526</Internal_Number>
    <TrialID>NCT00609986</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>IV Insulin Protocol in Diabetes and Renal Transplantation</Public_title>
    <Scientific_title>Intravenous Insulin Protocol in Diabetes and Renal Transplantation Study</Scientific_title>
    <Acronym />
    <Primary_sponsor>Medical University of South Carolina</Primary_sponsor>
    <Date_registration3>20080102</Date_registration3>
    <Date_registration>02/01/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00609986</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2007</Date_enrollement>
    <Target_size>90</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  18 years of age and greater,&lt;br&gt;&lt;br&gt;          -  Diabetes diagnosis (Type 1 and Type 2, awaiting a living or cadaveric renal&lt;br&gt;             transplant, renal transplant candidates admitted to MUSC medical center for a donor&lt;br&gt;             kidney, FBG &gt;100 mg/dL per admission screening labs, random BG &gt;120mg/dL per&lt;br&gt;             admission screening labs, and&lt;br&gt;&lt;br&gt;          -  Willing and able to provide informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  History of an active GI bleed in the previous 3 mos,&lt;br&gt;&lt;br&gt;          -  Scheduled to receive a simultaneous pancreas transplant,&lt;br&gt;&lt;br&gt;          -  History of a functioning pancreatic transplant,&lt;br&gt;&lt;br&gt;          -  Patient currently managed on an insulin pump,&lt;br&gt;&lt;br&gt;          -  Unable or unwilling to provide informed consent, and&lt;br&gt;&lt;br&gt;          -  Unable to commit to the study protocol including the outpatient follow-up phase of&lt;br&gt;             care&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Transplantation;Diabetes;Hyperglycemia</Condition>
    <Intervention>Drug: insulin;Drug: NPH Insulin or glargine insulin and aspartame insulin</Intervention>
    <Primary_outcome>Outcome measures for Specific Aim I:  delayed graft function, acute/active rejection, and graft survival.  Secondary endpoints such as hyperglycemia and hypoglycemia, infections and hospital readmissions will be analyzed.</Primary_outcome>
    <Secondary_outcome>Outcome measures for Specific Aim II:  inflammatory cytokines collected during this study will include TNF-a, IL-1ß, IL-6, and IL-10. Acute phase reactants collected during this study will include hsCRP.</Secondary_outcome>
    <Secondary_ID>ADA 7-07-CR-22;HR #17383</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2889557</Internal_Number>
    <TrialID>NCT00610389</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors</Public_title>
    <Scientific_title>Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors</Scientific_title>
    <Acronym />
    <Primary_sponsor>Clinica Universidad de Navarra, Universidad de Navarra</Primary_sponsor>
    <Date_registration3>20080128</Date_registration3>
    <Date_registration>28/01/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00610389</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>February 2008</Date_enrollement>
    <Target_size>27</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Confirmed diagnosis of metastatic melanoma, renal cell carcinoma, or  hepatocarcinoma&lt;br&gt;             (Child´s stage A or B) not amenable of curative treatment. For patients with&lt;br&gt;             hepatocarcinoma, treatment after embolization is allowed&lt;br&gt;&lt;br&gt;          -  Measurable disease&lt;br&gt;&lt;br&gt;          -  ECOG 0, 1 or 2.&lt;br&gt;&lt;br&gt;          -  Adequate renal, hepatic and bone marrow function&lt;br&gt;&lt;br&gt;          -  Availability of tumor tissue, for maturing dendritic cells&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Clinically relevant diseases or infections.&lt;br&gt;&lt;br&gt;          -  concurrent participation in other clinical trial or administration or other&lt;br&gt;             antitumoral treatment&lt;br&gt;&lt;br&gt;          -  Concurrent cancer, with the exceptions allowed by the PI.&lt;br&gt;&lt;br&gt;          -  Pregnant or breast feeding women&lt;br&gt;&lt;br&gt;          -  immunosuppressant treatment&lt;br&gt;&lt;br&gt;          -  known CNS metastasis&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Cell Carcinoma;Melanoma;Carcinoma, Hepatocellular</Condition>
    <Intervention>Biological: immunotherapy with dendritic cells</Intervention>
    <Primary_outcome>Response rate</Primary_outcome>
    <Secondary_outcome>Immunological response</Secondary_outcome>
    <Secondary_ID>CD-2007-01</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2889878</Internal_Number>
    <TrialID>NCT00614679</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>A Novel Catheter Lock Solution for Treatment of Tunneled Hemodialysis Catheter-Associated Bacteremia</Public_title>
    <Scientific_title>A Novel Catheter Lock Solution for Treatment of Tunneled Hemodialysis Catheter-Associated Bacteremia</Scientific_title>
    <Acronym />
    <Primary_sponsor>Baylor College of Medicine</Primary_sponsor>
    <Date_registration3>20080211</Date_registration3>
    <Date_registration>11/02/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00614679</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2006</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 1</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Adult patients who have an indwelling hemodialysis catheter for 10 or more days and&lt;br&gt;             evidence of a catheter associated bloodstream infection as evidenced by&lt;br&gt;             1)quantitative blood cultures obtained through the lumen of the catheter yield&lt;br&gt;             concentrations of bacterial colonies that are 5 or more fold higher than peripheral&lt;br&gt;             blood cultures, or 2)blood cultures obtained through the lumen of the catheter&lt;br&gt;             becomes positive 2 or more hours earlier than peripheral blood cultures.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients will be excluded if 1) they are unable or unwilling to provide informed&lt;br&gt;             consent, 2) have evidence of a complicated bacteremia such as endocarditis, septic&lt;br&gt;             thrombophlebitis, septic emboli, osetoemylitis, deep seated abscesses etc 3)evidence&lt;br&gt;             of an exit site infection around the catheter such as a pus pocket, drainage or&lt;br&gt;             erythema. 4) patient is allergic to NAC or the proposed antibiotic (if patient is&lt;br&gt;             allergic to minocycline, tigecycline will not be used). 5) patient is pregnant or&lt;br&gt;             will become pregnant.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End-Stage Renal Disease;Hemodialysis Catheter-Associated Infection</Condition>
    <Intervention>Drug: catheter lock solution consisting of N-acetylcystein, tigecycline and heparin</Intervention>
    <Primary_outcome>Treatment success within 90 days</Primary_outcome>
    <Secondary_outcome>catheter salvage</Secondary_outcome>
    <Secondary_ID>H-17624</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2890165</Internal_Number>
    <TrialID>NCT00618475</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Cognitive Behavioral Treatment of Depression in ESRD Patients on Dialysis</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</Primary_sponsor>
    <Date_registration3>20080215</Date_registration3>
    <Date_registration>15/02/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00618475</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 2008</Date_enrollement>
    <Target_size>80</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case-Crossover, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        - hemodialysis patient Depression diagnosis&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        (1) presence of current organic mental disorder (2) schizophrenia (3) bipolar disorder (4)&lt;br&gt;        depression with psychotic features (5) current substance abuse or dependence (6) active&lt;br&gt;        suicidal intent or plan (7) active homicidal ideation, intent, or plan  -&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End Stage Renal Disease;Depression</Condition>
    <Intervention>Behavioral: Cognitive behavioral therapy</Intervention>
    <Primary_outcome>Beck Depression Inventory</Primary_outcome>
    <Secondary_outcome>Quality of Life;Clinical biomarkers</Secondary_outcome>
    <Secondary_ID>K23 DK76980</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2890187</Internal_Number>
    <TrialID>NCT00618761</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Insulin Secretory Capacity in Insulin-independent Pancreas-Kidney Recipients Compared to Controls</Public_title>
    <Scientific_title>Insulin Secretory Capacity in Insulin-independent Pancreas-Kidney Recipients Compared to Non-Diabetic Kidney Recipients, Insulin Independent Recipients of Beta-cell Grafts and Healthy Controls.</Scientific_title>
    <Acronym />
    <Primary_sponsor>University Hospital, Gasthuisberg</Primary_sponsor>
    <Date_registration3>20080206</Date_registration3>
    <Date_registration>06/02/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00618761</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>21 Years</Inclusion_agemin>
    <Inclusion_agemax>65 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2004</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Diagnostic</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  kidney pancreas recipients&lt;br&gt;&lt;br&gt;          -  kidney recipients&lt;br&gt;&lt;br&gt;          -  healthy volunteers&lt;br&gt;&lt;br&gt;          -  beta-cell recipients&lt;br&gt;&lt;br&gt;          -  immunosuppression with MMF-Tacrolimus&lt;br&gt;&lt;br&gt;          -  1-4 years after transplantation&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  high doses of steroids&lt;br&gt;&lt;br&gt;          -  insulin dependent&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Transplantation;Pancreas Transplantation</Condition>
    <Intervention>Other: hyperglycemic clamp test</Intervention>
    <Primary_outcome>insulin secretion during clamp test</Primary_outcome>
    <Secondary_ID>JDRF 4/2005/1327;clamp01</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Juvenile Diabetes Research Foundation;Fund for Scientific Research, Flanders, Belgium</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2890419</Internal_Number>
    <TrialID>NCT00621790</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Fenoldopam and Acute Renal Failure</Public_title>
    <Scientific_title>Efficacy of Fenoldopam in Reducing the Need for Renal Replacement Therapy After Cardiac Surgery. A Randomized Controlled Study.</Scientific_title>
    <Acronym>FENO HSR</Acronym>
    <Primary_sponsor>Università Vita-Salute San Raffaele</Primary_sponsor>
    <Date_registration3>20080212</Date_registration3>
    <Date_registration>12/02/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00621790</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>February 2008</Date_enrollement>
    <Target_size>1000</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  adult patients&lt;br&gt;&lt;br&gt;          -  who underwent cardiac surgery&lt;br&gt;&lt;br&gt;          -  have Risk of Acute Renal Failure (R of RIFLE score)&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  glaucoma&lt;br&gt;&lt;br&gt;          -  already on renal replacement therapy&lt;br&gt;&lt;br&gt;          -  study drug in the past 30 days&lt;br&gt;&lt;br&gt;          -  inclusion in other protocols&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Renal Failure</Condition>
    <Intervention>Drug: fenoldopam;Drug: placebo</Intervention>
    <Primary_outcome>Number of patients requiring Renal Replacement Therapy</Primary_outcome>
    <Secondary_outcome>Number of dead patients.</Secondary_outcome>
    <Secondary_ID>GO/URC/ER/mm 64/DG</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2890433</Internal_Number>
    <TrialID>NCT00621972</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>AV Fistula Salvage in Advanced CKD Using Sodium Bicarbonate Prophylaxis</Public_title>
    <Scientific_title>A Prospective Observational Study on the Use of Iodinated Contrast for AV Fistula Salvage in Stage 4/5 CKD Using Bicarbonate Prophylaxis</Scientific_title>
    <Acronym />
    <Primary_sponsor>Maine Medical Center</Primary_sponsor>
    <Date_registration3>20080212</Date_registration3>
    <Date_registration>12/02/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00621972</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2008</Date_enrollement>
    <Target_size>25</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  English speaking&lt;br&gt;&lt;br&gt;          -  &gt;18 yrs age&lt;br&gt;&lt;br&gt;          -  chronic kidney disease, documented GFR&lt;30ml/min by abbreviated MDRD calculation&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Inpatients&lt;br&gt;&lt;br&gt;          -  Pediatric patients&lt;br&gt;&lt;br&gt;          -  Non-English speaking patients&lt;br&gt;&lt;br&gt;          -  established dialysis patients&lt;br&gt;&lt;br&gt;          -  patients receiving iodinated contrast within 30 days of current procedure&lt;br&gt;&lt;br&gt;          -  patients with central arterial manipulation within 30 days of current procedure&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Renal Failure</Condition>
    <Primary_outcome>Assess the impact of conventional dose iodinated contrast on the renal function of stage 4 and 5 chronic kidney disease patients undergoing arteriovenous fistula evaluation using a standard sodium bicarbonate prophylaxis protocol.</Primary_outcome>
    <Secondary_outcome>Assess the impact of conventional dose iodinated contrast on urinary kidney injury marker-1 (KIM-1) levels.;Assess the impact of different patient characteristics on the development of contrast-induced kidney injury, such as diabetes, coronary artery disease, hypertension, and angiotensin converting enzyme inhibitor therapy.</Secondary_outcome>
    <Secondary_ID>0200.178070;MMC3230</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2891157</Internal_Number>
    <TrialID>NCT00631553</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Assessment of Changes in Renal Cortical and Medullary Blood Flow by Contrast Ultrasound</Public_title>
    <Scientific_title>Assessment of Changes in Renal Cortical and Medullary Blood Flow by Contrast Ultrasound</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Virginia</Primary_sponsor>
    <Date_registration3>20080227</Date_registration3>
    <Date_registration>27/02/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00631553</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>65 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2006</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Endpoint Classification:  Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Diagnostic</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Healthy adults&lt;br&gt;&lt;br&gt;          -  Males and females&lt;br&gt;&lt;br&gt;          -  Ages 18-65 years old&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Pregnancy or lactation&lt;br&gt;&lt;br&gt;          -  H/o kidney disease&lt;br&gt;&lt;br&gt;          -  H/o congestive heart failure, ischemic heart disease, severe pulmonary disease or&lt;br&gt;             allergy to the drug&lt;br&gt;&lt;br&gt;          -  H/o any cardiovascular disease&lt;br&gt;&lt;br&gt;          -  Abnormal liver function (liver function tests out of specified ranges)&lt;br&gt;&lt;br&gt;          -  Screening urinalysis which indicates infection or inflammation&lt;br&gt;&lt;br&gt;          -  Taking regular medications (except for over-the-counter vitamins or hormonal&lt;br&gt;             contraceptives.)&lt;br&gt;&lt;br&gt;          -  Taking supplements, like protein shakes&lt;br&gt;&lt;br&gt;          -  Unwilling or unable to eat chicken (used as protein meal)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney</Condition>
    <Intervention>Drug: perflutren lipid microspheres</Intervention>
    <Secondary_ID>12014</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>National Institutes of Health (NIH)</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2892676</Internal_Number>
    <TrialID>NCT00651482</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RADOO1</Public_title>
    <Scientific_title>Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RADOO1</Scientific_title>
    <Acronym />
    <Primary_sponsor>Stanford University</Primary_sponsor>
    <Date_registration3>20080328</Date_registration3>
    <Date_registration>28/03/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00651482</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 2008</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        Patients will be included in the study based on the following criteria:&lt;br&gt;&lt;br&gt;          -  Signed Informed Consent Form&lt;br&gt;&lt;br&gt;          -  Histologically confirmed metastatic RCC that is predominantly clear cell&lt;br&gt;&lt;br&gt;          -  Measurable disease, as defined by RECIST (see Appendix D)&lt;br&gt;&lt;br&gt;          -  Age &gt;= 18 years&lt;br&gt;&lt;br&gt;          -  ECOG performance status of 0 or 1&lt;br&gt;&lt;br&gt;          -  No more than one prior targeted therapy (e.g. sorafenib, sunitinib)&lt;br&gt;&lt;br&gt;             o Prior cytokine therapy allowed&lt;br&gt;&lt;br&gt;          -  No more than two prior systemic therapies&lt;br&gt;&lt;br&gt;          -  Ability and capacity to comply with the study and follow-up procedures&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Disease-Specific Exclusions&lt;br&gt;&lt;br&gt;               -  RCC with predominantly sarcomatoid features&lt;br&gt;&lt;br&gt;               -  Radiotherapy for RCC within 28 days prior to Day 1, with the exception of&lt;br&gt;                  single-fraction radiotherapy given for the indication of pain control&lt;br&gt;&lt;br&gt;               -  Prior treatment with bevacizumab or any mTOR inhibitor (temsirolimus, sirolimus,&lt;br&gt;                  or everolimus)&lt;br&gt;&lt;br&gt;               -  Current need for dialysis&lt;br&gt;&lt;br&gt;          2. General Medical Exclusions&lt;br&gt;&lt;br&gt;        Subjects meeting any of the following criteria are ineligible for study entry:&lt;br&gt;&lt;br&gt;          -  Inability to comply with study and/or follow-up procedures&lt;br&gt;&lt;br&gt;          -  Life expectancy of less than 12 weeks&lt;br&gt;&lt;br&gt;          -  Inadequate organ function, as evidenced by any of the following at screening:&lt;br&gt;&lt;br&gt;               -  Absolute neutrophil count (ANC) &lt; 1500/uL&lt;br&gt;&lt;br&gt;               -  Platelet count &lt;= 100 x 10^9/L&lt;br&gt;&lt;br&gt;               -  Total bilirubin &gt;= 1.5 x ULN&lt;br&gt;&lt;br&gt;               -  Alkaline phosphatase, AST, and/or ALT &gt; 2.5 x the upper limit of normal (ULN)&lt;br&gt;                  for patients without evidence of liver metastases; &gt; 5 X ULN for patients with&lt;br&gt;                  documented liver metastases&lt;br&gt;&lt;br&gt;               -  Serum creatinine &gt; 2.0 mg/dL&lt;br&gt;&lt;br&gt;               -  Hemoglobin &lt; 9 g/dL a. may be transfused or receive epoetin alfa to maintain or&lt;br&gt;                  exceed this level up to the hemoglobin level recommended on the current label&lt;br&gt;                  for for epoetin alfa because of the potential increased risk of thrombotic&lt;br&gt;                  events and increased mortality.   Also, rapid increase in hemoglobin may&lt;br&gt;                  exacerbate hypertension, i.e., a possible adverse event with bevacizumab and to&lt;br&gt;                  a lesser extent with RAD001.&lt;br&gt;&lt;br&gt;          -  Active infection or fever &gt; 38.5°C within 3 days of starting treatment&lt;br&gt;&lt;br&gt;          -  Women who are pregnant or breast feeding, or women/men able to conceive and unwilling&lt;br&gt;             to practice an effective method of birth control.&lt;br&gt;&lt;br&gt;               -  Women of childbearing potential must have a negative urine or serum pregnancy&lt;br&gt;                  test within 7 days prior to the initial administration of RAD001 and the first&lt;br&gt;                  day of each cycle.&lt;br&gt;&lt;br&gt;               -  Oral, implantable, or injectable contraceptives may be affected by cytochrome&lt;br&gt;                  P450 interactions, and are therefore not considered effective methods of birth&lt;br&gt;                  control for this study.&lt;br&gt;&lt;br&gt;          -  History of other malignancies within 5 years prior to Day 1 except for tumors with a&lt;br&gt;             negligible risk for metastasis or death, such as adequately controlled basal cell&lt;br&gt;             carcinoma, squamous-cell carcinoma of the skin, carcinoma in situ of the cervix,&lt;br&gt;             early-stage bladder cancer, or low-grade endometrial cancer&lt;br&gt;&lt;br&gt;          -  Malignancies that have undergone a putative surgical cure (i.e., localized prostate&lt;br&gt;             cancer post-prostatectomy) within 5 years prior to Day 1 may be discussed with the&lt;br&gt;             Principal Investigator.&lt;br&gt;&lt;br&gt;          -  Any other medical conditions (including mental illness or substance abuse) deemed by&lt;br&gt;             the clinician to be likely to interfere with a patient's ability to provide informed&lt;br&gt;             consent, cooperate, or participate in the study, or to interfere with the&lt;br&gt;             interpretation of the results.&lt;br&gt;&lt;br&gt;          -  Current, recent (within 4 weeks of the first infusion of this study), or planned&lt;br&gt;             participation in an experimental drug study c. Bevacizumab-Specific Exclusions&lt;br&gt;&lt;br&gt;          -  Inadequately controlled hypertension (defined as systolic blood pressure &gt;150 and/or&lt;br&gt;             diastolic blood pressure &gt; 100 mmHg on antihypertensive medications)&lt;br&gt;&lt;br&gt;          -  Any prior history of hypertensive crisis or hypertensive encephalopathy&lt;br&gt;&lt;br&gt;          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure (see&lt;br&gt;             Appendix B)&lt;br&gt;&lt;br&gt;          -  History of myocardial infarction or unstable angina within 6 months prior to study&lt;br&gt;             enrollment&lt;br&gt;&lt;br&gt;          -  History of stroke or transient ischemic attack within 6 months prior to study&lt;br&gt;             enrollment&lt;br&gt;&lt;br&gt;          -  Known CNS disease, except for treated brain metastasis&lt;br&gt;&lt;br&gt;             o Treated brain metastases are defined as having no evidence of progression or&lt;br&gt;             hemorrhage after treatment and no ongoing requirement for dexamethasone, as&lt;br&gt;             ascertained by clinical examination and brain imaging (MRI or CT) during the&lt;br&gt;             screening period.  Anticonvulsants (stable dose) are allowed.  Treatment for brain&lt;br&gt;             metastases may include whole brain radiotherapy (WBRT), radiosurgery (RS; Gamma&lt;br&gt;             Knife, LINAC, or equivalent) or a combination as deemed appropriate by the treating&lt;br&gt;             physician.  Patients with CNS metastases treated by neurosurgical resection or brain&lt;br&gt;             biopsy performed within 3 months prior to Day 1 will be excluded&lt;br&gt;&lt;br&gt;          -  Significant  vascular disease (e.g., aortic aneurysm, aortic dissection)&lt;br&gt;&lt;br&gt;          -  Symptomatic peripheral vascular disease&lt;br&gt;&lt;br&gt;          -  Evidence of bleeding diathesis or coagulopathy that is not intentionally&lt;br&gt;             pharmacologically-induced&lt;br&gt;&lt;br&gt;          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&lt;br&gt;             prior to study enrollment or anticipation of need for major surgical procedure during&lt;br&gt;             the course of the study&lt;br&gt;&lt;br&gt;          -  Core biopsy or other minor surgical procedure, excluding placement of a vascular&lt;br&gt;             access device, within 7 days prior to study enrollment&lt;br&gt;&lt;br&gt;          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal&lt;br&gt;             abscess within 6 months prior to study enrollment&lt;br&gt;&lt;br&gt;          -  Serious, non-healing wound, ulcer, or bone fracture&lt;br&gt;&lt;br&gt;          -  Proteinuria at screening as demonstrated by a urine protein: creatinine (UPC) ratio&lt;br&gt;             &gt;= 1.0. If UPC &gt;= 1.0, the patient must undergo a 24 hour urine collection which must&lt;br&gt;             demonstrate &lt;= 1g of protein in 24 hours to be eligible.&lt;br&gt;&lt;br&gt;          -  Known hypersensitivity to any component of bevacizumab&lt;br&gt;&lt;br&gt;             d. RAD001- Specific Exclusions&lt;br&gt;&lt;br&gt;          -  Known hypersensitivity to any component of RAD001&lt;br&gt;&lt;br&gt;          -  Chronic treatment with systemic steroids or another immunosuppressive agent&lt;br&gt;&lt;br&gt;          -  Impairment of gastrointestinal function or gastrointestinal disease that may&lt;br&gt;             significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled&lt;br&gt;             nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)&lt;br&gt;&lt;br&gt;          -  Severely impaired lung function (spirometry and DLCO 50% or less of normal and O2&lt;br&gt;        </Inclusion_Criteria>
    <Condition>Kidney Neoplasms;Kidney (Renal Cell) Cancer</Condition>
    <Intervention>Drug: RAD001;Drug: bevacizumab;Procedure: CT Scan</Intervention>
    <Primary_outcome>To assess the effect of the combination therapy bevacizumab and RAD001 on progression-free survival in treatment-refractory mRCC using Response Evaluation Criteria in Solid Tumors (RECIST</Primary_outcome>
    <Secondary_outcome>To assess the efficacy of combining bevacizumab w/ RADOO1 as 2nd or 3rd-line treatment for patients with metastatic RCC, as measured by objective response, duration of objective response, time to treatment failure, &amp; overall survival;To assess the safety of combining bevacizumab with RAD001.;To assess fasting total cholesterol, &amp; triglyceride levels as potential biomarkers for RAD001 activity.;To assess serum VEGF and glucose as potential biomarkers for bevacizumab &amp; RAD001 activity;To assess serum erythropoietin, reticulocyte counts, &amp; hemoglobin/hematocrit as potential biomarkers for bevacizumab activity;To perform subgroup analysis based on Motzer risk types</Secondary_outcome>
    <Secondary_ID>98593;AVF4304s;RENAL0016;41839;SU-01092008-969</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Genentech;Novartis</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2892676</Internal_Number>
    <TrialID>NCT00651482</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RADOO1</Public_title>
    <Scientific_title>Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RADOO1</Scientific_title>
    <Acronym />
    <Primary_sponsor>Stanford University</Primary_sponsor>
    <Date_registration3>20080328</Date_registration3>
    <Date_registration>28/03/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00651482</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 2008</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        Patients will be included in the study based on the following criteria:&lt;br&gt;&lt;br&gt;          -  Signed Informed Consent Form&lt;br&gt;&lt;br&gt;          -  Histologically confirmed metastatic RCC that is predominantly clear cell&lt;br&gt;&lt;br&gt;          -  Measurable disease, as defined by RECIST (see Appendix D)&lt;br&gt;&lt;br&gt;          -  Age &gt;= 18 years&lt;br&gt;&lt;br&gt;          -  ECOG performance status of 0 or 1&lt;br&gt;&lt;br&gt;          -  No more than one prior targeted therapy (e.g. sorafenib, sunitinib)&lt;br&gt;&lt;br&gt;             o Prior cytokine therapy allowed&lt;br&gt;&lt;br&gt;          -  No more than two prior systemic therapies&lt;br&gt;&lt;br&gt;          -  Ability and capacity to comply with the study and follow-up procedures&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Disease-Specific Exclusions&lt;br&gt;&lt;br&gt;               -  RCC with predominantly sarcomatoid features&lt;br&gt;&lt;br&gt;               -  Radiotherapy for RCC within 28 days prior to Day 1, with the exception of&lt;br&gt;                  single-fraction radiotherapy given for the indication of pain control&lt;br&gt;&lt;br&gt;               -  Prior treatment with bevacizumab or any mTOR inhibitor (temsirolimus, sirolimus,&lt;br&gt;                  or everolimus)&lt;br&gt;&lt;br&gt;               -  Current need for dialysis&lt;br&gt;&lt;br&gt;          2. General Medical Exclusions&lt;br&gt;&lt;br&gt;        Subjects meeting any of the following criteria are ineligible for study entry:&lt;br&gt;&lt;br&gt;          -  Inability to comply with study and/or follow-up procedures&lt;br&gt;&lt;br&gt;          -  Life expectancy of less than 12 weeks&lt;br&gt;&lt;br&gt;          -  Inadequate organ function, as evidenced by any of the following at screening:&lt;br&gt;&lt;br&gt;               -  Absolute neutrophil count (ANC) &lt; 1500/uL&lt;br&gt;&lt;br&gt;               -  Platelet count &lt;= 100 x 10^9/L&lt;br&gt;&lt;br&gt;               -  Total bilirubin &gt;= 1.5 x ULN&lt;br&gt;&lt;br&gt;               -  Alkaline phosphatase, AST, and/or ALT &gt; 2.5 x the upper limit of normal (ULN)&lt;br&gt;                  for patients without evidence of liver metastases; &gt; 5 X ULN for patients with&lt;br&gt;                  documented liver metastases&lt;br&gt;&lt;br&gt;               -  Serum creatinine &gt; 2.0 mg/dL&lt;br&gt;&lt;br&gt;               -  Hemoglobin &lt; 9 g/dL a. may be transfused or receive epoetin alfa to maintain or&lt;br&gt;                  exceed this level up to the hemoglobin level recommended on the current label&lt;br&gt;                  for for epoetin alfa because of the potential increased risk of thrombotic&lt;br&gt;                  events and increased mortality.   Also, rapid increase in hemoglobin may&lt;br&gt;                  exacerbate hypertension, i.e., a possible adverse event with bevacizumab and to&lt;br&gt;                  a lesser extent with RAD001.&lt;br&gt;&lt;br&gt;          -  Active infection or fever &gt; 38.5°C within 3 days of starting treatment&lt;br&gt;&lt;br&gt;          -  Women who are pregnant or breast feeding, or women/men able to conceive and unwilling&lt;br&gt;             to practice an effective method of birth control.&lt;br&gt;&lt;br&gt;               -  Women of childbearing potential must have a negative urine or serum pregnancy&lt;br&gt;                  test within 7 days prior to the initial administration of RAD001 and the first&lt;br&gt;                  day of each cycle.&lt;br&gt;&lt;br&gt;               -  Oral, implantable, or injectable contraceptives may be affected by cytochrome&lt;br&gt;                  P450 interactions, and are therefore not considered effective methods of birth&lt;br&gt;                  control for this study.&lt;br&gt;&lt;br&gt;          -  History of other malignancies within 5 years prior to Day 1 except for tumors with a&lt;br&gt;             negligible risk for metastasis or death, such as adequately controlled basal cell&lt;br&gt;             carcinoma, squamous-cell carcinoma of the skin, carcinoma in situ of the cervix,&lt;br&gt;             early-stage bladder cancer, or low-grade endometrial cancer&lt;br&gt;&lt;br&gt;          -  Malignancies that have undergone a putative surgical cure (i.e., localized prostate&lt;br&gt;             cancer post-prostatectomy) within 5 years prior to Day 1 may be discussed with the&lt;br&gt;             Principal Investigator.&lt;br&gt;&lt;br&gt;          -  Any other medical conditions (including mental illness or substance abuse) deemed by&lt;br&gt;             the clinician to be likely to interfere with a patient's ability to provide informed&lt;br&gt;             consent, cooperate, or participate in the study, or to interfere with the&lt;br&gt;             interpretation of the results.&lt;br&gt;&lt;br&gt;          -  Current, recent (within 4 weeks of the first infusion of this study), or planned&lt;br&gt;             participation in an experimental drug study c. Bevacizumab-Specific Exclusions&lt;br&gt;&lt;br&gt;          -  Inadequately controlled hypertension (defined as systolic blood pressure &gt;150 and/or&lt;br&gt;             diastolic blood pressure &gt; 100 mmHg on antihypertensive medications)&lt;br&gt;&lt;br&gt;          -  Any prior history of hypertensive crisis or hypertensive encephalopathy&lt;br&gt;&lt;br&gt;          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure (see&lt;br&gt;             Appendix B)&lt;br&gt;&lt;br&gt;          -  History of myocardial infarction or unstable angina within 6 months prior to study&lt;br&gt;             enrollment&lt;br&gt;&lt;br&gt;          -  History of stroke or transient ischemic attack within 6 months prior to study&lt;br&gt;             enrollment&lt;br&gt;&lt;br&gt;          -  Known CNS disease, except for treated brain metastasis&lt;br&gt;&lt;br&gt;             o Treated brain metastases are defined as having no evidence of progression or&lt;br&gt;             hemorrhage after treatment and no ongoing requirement for dexamethasone, as&lt;br&gt;             ascertained by clinical examination and brain imaging (MRI or CT) during the&lt;br&gt;             screening period.  Anticonvulsants (stable dose) are allowed.  Treatment for brain&lt;br&gt;             metastases may include whole brain radiotherapy (WBRT), radiosurgery (RS; Gamma&lt;br&gt;             Knife, LINAC, or equivalent) or a combination as deemed appropriate by the treating&lt;br&gt;             physician.  Patients with CNS metastases treated by neurosurgical resection or brain&lt;br&gt;             biopsy performed within 3 months prior to Day 1 will be excluded&lt;br&gt;&lt;br&gt;          -  Significant  vascular disease (e.g., aortic aneurysm, aortic dissection)&lt;br&gt;&lt;br&gt;          -  Symptomatic peripheral vascular disease&lt;br&gt;&lt;br&gt;          -  Evidence of bleeding diathesis or coagulopathy that is not intentionally&lt;br&gt;             pharmacologically-induced&lt;br&gt;&lt;br&gt;          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&lt;br&gt;             prior to study enrollment or anticipation of need for major surgical procedure during&lt;br&gt;             the course of the study&lt;br&gt;&lt;br&gt;          -  Core biopsy or other minor surgical procedure, excluding placement of a vascular&lt;br&gt;             access device, within 7 days prior to study enrollment&lt;br&gt;&lt;br&gt;          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal&lt;br&gt;             abscess within 6 months prior to study enrollment&lt;br&gt;&lt;br&gt;          -  Serious, non-healing wound, ulcer, or bone fracture&lt;br&gt;&lt;br&gt;          -  Proteinuria at screening as demonstrated by a urine protein: creatinine (UPC) ratio&lt;br&gt;             &gt;= 1.0. If UPC &gt;= 1.0, the patient must undergo a 24 hour urine collection which must&lt;br&gt;             demonstrate &lt;= 1g of protein in 24 hours to be eligible.&lt;br&gt;&lt;br&gt;          -  Known hypersensitivity to any component of bevacizumab&lt;br&gt;&lt;br&gt;             d. RAD001- Specific Exclusions&lt;br&gt;&lt;br&gt;          -  Known hypersensitivity to any component of RAD001&lt;br&gt;&lt;br&gt;          -  Chronic treatment with systemic steroids or another immunosuppressive agent&lt;br&gt;&lt;br&gt;          -  Impairment of gastrointestinal function or gastrointestinal disease that may&lt;br&gt;             significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled&lt;br&gt;             nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)&lt;br&gt;&lt;br&gt;          -  Severely impaired lung function (spirometry and DLCO 50% or less of normal and O2&lt;br&gt;        </Inclusion_Criteria>
    <Condition>Kidney Neoplasms;Kidney (Renal Cell) Cancer</Condition>
    <Intervention>Drug: RAD001;Drug: bevacizumab;Procedure: CT Scan</Intervention>
    <Primary_outcome>To assess the effect of the combination therapy bevacizumab and RAD001 on progression-free survival in treatment-refractory mRCC using Response Evaluation Criteria in Solid Tumors (RECIST</Primary_outcome>
    <Secondary_outcome>To assess the efficacy of combining bevacizumab w/ RADOO1 as 2nd or 3rd-line treatment for patients with metastatic RCC, as measured by objective response, duration of objective response, time to treatment failure, &amp; overall survival;To assess the safety of combining bevacizumab with RAD001.;To assess fasting total cholesterol, &amp; triglyceride levels as potential biomarkers for RAD001 activity.;To assess serum VEGF and glucose as potential biomarkers for bevacizumab &amp; RAD001 activity;To assess serum erythropoietin, reticulocyte counts, &amp; hemoglobin/hematocrit as potential biomarkers for bevacizumab activity;To perform subgroup analysis based on Motzer risk types</Secondary_outcome>
    <Secondary_ID>98593;AVF4304s;RENAL0016;41839;SU-01092008-969</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Genentech;Novartis</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2893600</Internal_Number>
    <TrialID>NCT00663559</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy</Public_title>
    <Scientific_title>Study Phase II to Determinate the Efficacy of Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy</Scientific_title>
    <Acronym>SOGUG/0107</Acronym>
    <Primary_sponsor>Spanish Oncology Genito-Urinary Group</Primary_sponsor>
    <Date_registration3>20080421</Date_registration3>
    <Date_registration>21/04/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00663559</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>February 2008</Date_enrollement>
    <Target_size>59</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients must give their written informed consent before any procedure related to the&lt;br&gt;             study is performed.&lt;br&gt;&lt;br&gt;          -  Patients with renal clear cell carcinoma metastatic or locally advanced,&lt;br&gt;             histologically or cytologically documented.The patients with metastasic disease must&lt;br&gt;             be not condidated to curative nefrectomy as investigator criteria.&lt;br&gt;&lt;br&gt;          -  Assessable or measurable disease according to RECIST criteria. The lesions previosly&lt;br&gt;             radiated is not considered as target.&lt;br&gt;&lt;br&gt;          -  Ages equal or superior to 18 years old.&lt;br&gt;&lt;br&gt;          -  ECOG = 1&lt;br&gt;&lt;br&gt;          -  Patients with a life expectancy superior to 12 weeks.&lt;br&gt;&lt;br&gt;          -  Patients with adequate organic function, according to the following criteria:&lt;br&gt;&lt;br&gt;               1. . Medular reserve: Neutrophils absolute count= 1.5 x 10^9/L Platelets = 100 x&lt;br&gt;                  10^9/L Haemoglobin = 9g/dl&lt;br&gt;&lt;br&gt;               2. . Hepatic function: Total bilirubin &lt; 1.5 times the superior limit of normality&lt;br&gt;                  ALT and AST &lt; 2.5 times the superior limit of normality (&lt; 5 times the superior&lt;br&gt;                  limit of normality in case of liver failure due to cancer)&lt;br&gt;&lt;br&gt;               3. . Seric Albumin = 1.5 times the superior limit of normality&lt;br&gt;&lt;br&gt;               4. . Renal Function: Cleary creatinine &gt; 30ml/min&lt;br&gt;&lt;br&gt;               5. . FEVI &gt; LIN according to ECO or MUGA&lt;br&gt;&lt;br&gt;          -  Patients who are capable of accomplishing the study's requirements and without any&lt;br&gt;             impediments to follow the instructions while on study&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Pregnant or breastfeeding women. Women of fertile age must have a negative result in&lt;br&gt;             the pregnancy test performed 7 days before the beginning of the administration of the&lt;br&gt;             study medication. Both men and women included in the study must use an adequate&lt;br&gt;             contraceptive method.&lt;br&gt;&lt;br&gt;          -  Patients that have received sistemic treatment previous to metastasic disease.&lt;br&gt;&lt;br&gt;          -  Previous nefrectomy.&lt;br&gt;&lt;br&gt;          -  Mayor Surgery, radiotherapy or sistemic therapy received in the last 3 weeks previous&lt;br&gt;             to the inclusion of the patient in the study, except paliative radiotherapy upper no&lt;br&gt;             target lesions.&lt;br&gt;&lt;br&gt;          -  Radiotherapy upper &gt; 25% bone marrow.&lt;br&gt;&lt;br&gt;          -  Patients that are participating in any clinical trial.&lt;br&gt;&lt;br&gt;          -  Patients with a primary cancer diagnosis in thast 3 years, except superficial&lt;br&gt;             basaliomas, superficial escamous carcinoma or in situ cervix carcinoma with aducuate&lt;br&gt;             treatment.&lt;br&gt;&lt;br&gt;          -  Following events in the last 12 months previous to begin the treatment:   myocardial&lt;br&gt;             infarction, unstable o severe angina, coronary/periferic place of arterial by-pass,&lt;br&gt;             congestive cardiac insufficiency, brain-vascular accident included transitory&lt;br&gt;             ischemia or lung embolism.&lt;br&gt;&lt;br&gt;          -  Arterial uncontrolled hypertension nor controlated with drugs ( &gt;150/100 mmHg despite&lt;br&gt;             adequate medical treatment).&lt;br&gt;&lt;br&gt;          -  Cardiac arrhythmia with grade NCI CTCAE =2, auricular fibrillation all grade and/or&lt;br&gt;             QTc interval&gt; 450mseg in men and &gt; 470 mseg in women.&lt;br&gt;&lt;br&gt;          -  Actually treatment with therapeutic dose with acenocumarol (except low dose for deep&lt;br&gt;             venous thrombosis).&lt;br&gt;&lt;br&gt;          -  Patients that present previously known positive serology for HIV.&lt;br&gt;&lt;br&gt;          -  Abuse of substances, clinical conditions, psychological or social, that may interfere&lt;br&gt;             with the patient's participation in the study or with the evaluation of the study's&lt;br&gt;             results.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Carcinoma Renal Cells</Condition>
    <Intervention>Drug: Sunitinib</Intervention>
    <Primary_outcome>Progression-free survival</Primary_outcome>
    <Secondary_outcome>Global survival;Response global;Duration of response;Security and tolerability of Sunitinib</Secondary_outcome>
    <Secondary_ID>SOGUG/0107</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2894073</Internal_Number>
    <TrialID>NCT00669721</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>OPG and RANKL Plasma Level After Administration of Unfractionated Heparin (UFH) and Low-Molecular-Weight Heparin (LMWH) in Hemodialysis</Public_title>
    <Scientific_title>Effects of UFH and LMWH on Osteoprotegerin and RANKL Plasma Levels in Hemodialysis Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>St. Orsola Hospital</Primary_sponsor>
    <Date_registration3>20080425</Date_registration3>
    <Date_registration>25/04/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00669721</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2008</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Bio-equivalence Study, Intervention Model:  Crossover Assignment, Masking:  Open Label, Primary Purpose:  Basic Science</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. hemodialysis patients with age &gt; 18 years on regular bicarbonate hemodialysis or&lt;br&gt;             hemodiafiltration treatment three times a week;&lt;br&gt;&lt;br&gt;          2. clinical stability at least three months before the study started;&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. active gastrointestinal bleeding (one ore more positive hemoccult test in the last 8&lt;br&gt;             weeks, melena or proctoraggia in the last 6 months )&lt;br&gt;&lt;br&gt;          2. hemorrhagic stroke&lt;br&gt;&lt;br&gt;          3. Myeloproliferative disorders&lt;br&gt;&lt;br&gt;          4. Hereditary deficiency of coagulation factors, LAC phenomenon or antiphospholipid&lt;br&gt;             syndrome&lt;br&gt;&lt;br&gt;          5. Malignant disease&lt;br&gt;&lt;br&gt;          6. Patient submitted to antithrombotic prophylaxis with LMWH&lt;br&gt;&lt;br&gt;          7. Immunosuppressive therapy&lt;br&gt;&lt;br&gt;          8. Participation in other clinical trials&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Failure;Hemodialysis</Condition>
    <Intervention>Drug: law molecular weigth heparin;Drug: unfractioned heparin</Intervention>
    <Primary_outcome>Levels of osteoprotegerin  after administration of UFH  or LMWH used as anticoagulant therapy for  hemodialysis</Primary_outcome>
    <Secondary_outcome>Secondary aim of the study is to verify the safety of anticoagulation therapy with UFH and LMWH.</Secondary_outcome>
    <Secondary_ID>LWH-INT-79</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2895160</Internal_Number>
    <TrialID>NCT00684034</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Redox State in the Course of Chronic Renal Insufficiency and Hemodialysis: Implications in Morbimortality</Public_title>
    <Scientific_title>Redox State in the Course of Chronic Renal Insufficiency and Hemodialysis: Implications in Morbimortality</Scientific_title>
    <Acronym />
    <Primary_sponsor>Assistance Publique Hopitaux De Marseille</Primary_sponsor>
    <Date_registration3>20080521</Date_registration3>
    <Date_registration>21/05/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00684034</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2008</Date_enrollement>
    <Target_size>130</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Intervention Model:  Parallel Assignment, Masking:  Open Label</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  18 and 80 years old man or woman dialysing at least 3 times a week for at least 6&lt;br&gt;             months and having no residual renal function&lt;br&gt;&lt;br&gt;          -  Rate of haemoglobin &gt; 11 g / dl&lt;br&gt;&lt;br&gt;          -  Clinically stable patient that is having had no considerable event (cardiovascular&lt;br&gt;             problem, infection, surgical operation) with the exception of angioplasty of fistula&lt;br&gt;             or prosthesis vascular, in the previous 3 months the entrance to the study&lt;br&gt;&lt;br&gt;          -  Patient capable of understanding and of following the essay, in particular knowing&lt;br&gt;             how to read the note of information.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Pregnant woman&lt;br&gt;&lt;br&gt;          -  Treatment by corticoids or immunosuppresseurs&lt;br&gt;&lt;br&gt;          -  hemopathy sly&lt;br&gt;&lt;br&gt;          -  chronic cancer or infection in evolution&lt;br&gt;&lt;br&gt;          -  Cardiovascular event (infarct, unstable angor, coronary bypasses, confusions of the&lt;br&gt;             rhythm, AVC, amputation) or infectious (blood-poisoning, pneumopathie, meningitis) or&lt;br&gt;             surgical operation in the previous 3 months the inclusion in the study.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Renal Insufficiency</Condition>
    <Intervention>Other: Sampling of blood;Other: Sampling of blood;Other: Sampling of blood</Intervention>
    <Primary_outcome>This study should allow to clarify the redox state some plasma by quantification of thiols membranous on the surface of lymphocytes at the hemodialysis and insufficient renal chronic not dialysed patients.</Primary_outcome>
    <Secondary_outcome>This study should allow to estimate in a forward-looking longitudinal plan the possible involvement of the parameters of the redox state and the morbidity and the cardiovascular and global mortality in 2 years in 2 studied populations.</Secondary_outcome>
    <Secondary_ID>2007-38;2007-A01179-44</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2896120</Internal_Number>
    <TrialID>NCT00696605</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Assessment of Circulating Copeptin Levels in Healthy Subjects and Patients With Renal Insufficiency After Oral Water Load and Hypertonic Saline Infusion</Public_title>
    <Scientific_title>Assessment of Circulating Copeptin Levels in Healthy Subjects and Patients With Renal Insufficiency After Oral Water Load and Hypertonic Saline Infusion</Scientific_title>
    <Acronym />
    <Primary_sponsor>Hospital Centre Biel/Bienne</Primary_sponsor>
    <Date_registration3>20080610</Date_registration3>
    <Date_registration>10/06/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00696605</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2008</Date_enrollement>
    <Target_size>35</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  chronic renal failure grade I through IV&lt;br&gt;&lt;br&gt;          -  healthy age-matched controls&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  chronic renal failure grade V&lt;br&gt;&lt;br&gt;          -  heart failure&lt;br&gt;&lt;br&gt;          -  liver disease&lt;br&gt;&lt;br&gt;          -  nephrotic syndrome&lt;br&gt;&lt;br&gt;          -  anemia (hemoglobin level &lt; 100 g/L)&lt;br&gt;&lt;br&gt;          -  uncontrolled hypertension (systolic BP &gt; 160 mmHg; diastolic BP &gt; 95 mm Hg)&lt;br&gt;&lt;br&gt;          -  coexisting severe disease&lt;br&gt;&lt;br&gt;          -  known thyroid disease&lt;br&gt;&lt;br&gt;          -  known hypocortisolism&lt;br&gt;&lt;br&gt;          -  known hypercortisolism&lt;br&gt;&lt;br&gt;          -  known diabetes insipidus&lt;br&gt;&lt;br&gt;          -  pregnancy&lt;br&gt;&lt;br&gt;          -  lactation&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Hypoosmolality;Hyperosmolality;Renal Failure</Condition>
    <Secondary_ID>Swiss AVP-Copeptin Trial</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Brahms AG</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2896572</Internal_Number>
    <TrialID>NCT00702559</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Design the Home Care Platform for the Monitoring of A Hemodialysis Arteriovenous Graft by Intelligent Physiological Signal</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>Far Eastern Memorial Hospital</Primary_sponsor>
    <Date_registration3>20080618</Date_registration3>
    <Date_registration>18/06/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00702559</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>16 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2008</Date_enrollement>
    <Target_size>50</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case-Only, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  prosthetic grafts with clinical signs of dysfunctions or malfunctions and were&lt;br&gt;             referred for angiographic evaluations.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  autologous arteriovenous accesses or known thrombosed accesses.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Dialysis</Condition>
    <Secondary_ID>FEMH-96040</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2896967</Internal_Number>
    <TrialID>NCT00707759</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Steroid Withdrawal in Pediatric Renal Transplant Immunosuppression : Impact on Growth, Bone Metabolism and Acute Rejection</Public_title>
    <Scientific_title>Multicenter, Open-Label, Randomized Study on Steroid-Free Immunosuppression, in Comparison With Daily Steroid Therapy, in Pediatric Renal Transplant : Impact on Growth, Bone Metabolism and Acute Rejection</Scientific_title>
    <Acronym />
    <Primary_sponsor>Fondo Nacional de Desarrollo Científico y Tecnológico, Chile</Primary_sponsor>
    <Date_registration3>20080626</Date_registration3>
    <Date_registration>26/06/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00707759</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>1 Year</Inclusion_agemin>
    <Inclusion_agemax>16 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2008</Date_enrollement>
    <Target_size>70</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age &lt; 16.0 years&lt;br&gt;&lt;br&gt;          -  Bone age of boys &lt; 15 years, of girls &lt; 13 years&lt;br&gt;&lt;br&gt;          -  First or second kidney transplant, living or cadaver kidney donation&lt;br&gt;&lt;br&gt;          -  Immunosuppression with Tacrolimus (TAC),Mycophenolate mofetil (MMF)&lt;br&gt;&lt;br&gt;          -  Patients and parents, respectively, have given their written consent after&lt;br&gt;             enlightenment (informed consent)&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Irreversible rejection of former transplant&lt;br&gt;&lt;br&gt;          -  Highly reactive (&gt; 30%) lymphocytotoxic  antibodies within 12 months prior to&lt;br&gt;             transplantation&lt;br&gt;&lt;br&gt;          -  Suspected insufficient medication compliance in dialysis&lt;br&gt;&lt;br&gt;          -  Patients receiving a basic immunosuppression other than that prescribed in this&lt;br&gt;             protocol&lt;br&gt;&lt;br&gt;          -  Simultaneous therapy with growth hormone after renal transplant&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Diseases</Condition>
    <Intervention>Drug: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + Withdrawal Prednisone;Drug: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone</Intervention>
    <Primary_outcome>Stimulation of growth after 12 months</Primary_outcome>
    <Secondary_outcome>Growth-factors by IGF-I, IGFBP-3 plasma levels  Bone metabolism (FA, Ca/Cru, CaxP, 25(OH)VitD, PTH,DXA, pQCT  Insulin-sensitivity by ISI method.   Molecular markers - acute rejection (FOXP3/IL-17).  Acute rejection incidence/protocol renal biopsy</Secondary_outcome>
    <Secondary_ID>Fondecyt1080166</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2897272</Internal_Number>
    <TrialID>NCT00711750</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Immediate Maintained Cannulation of a Newly Implanted Prosthetic Arteriovenous Access for Acute Hemodialysis</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>Far Eastern Memorial Hospital</Primary_sponsor>
    <Date_registration3>20080707</Date_registration3>
    <Date_registration>07/07/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00711750</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2008</Date_enrollement>
    <Target_size>39</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case-Only, Time Perspective:  Retrospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  end-stage renal disease underwent the specific prosthetic arteriovenous access&lt;br&gt;             creation in our hospital from November 2003 to October 2005&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  patients' poor health as long as they did not have other options and needed an access&lt;br&gt;             for acute hemodialysis. Exclusions included shock, active systemic infection, and&lt;br&gt;             rejection by the attending nephrologists&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End-Stage Renal Disease;Prosthetic Arteriovenous Access</Condition>
    <Secondary_ID>FEMH-96042</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2897275</Internal_Number>
    <TrialID>NCT00711789</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Angiotensin in Septic Kidney Injury Trial</Public_title>
    <Scientific_title>A Pilot Crossover Randomised Controlled Trial of Angiotensin II in Critically Ill Patients With Severe Sepsis and Acute Renal Failure</Scientific_title>
    <Acronym>ASK-IT</Acronym>
    <Primary_sponsor>Austin Health</Primary_sponsor>
    <Date_registration3>20080707</Date_registration3>
    <Date_registration>07/07/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00711789</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>February 2010</Date_enrollement>
    <Target_size>12</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Crossover Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  age = 18 years&lt;br&gt;&lt;br&gt;          -  within the first 24 hours of ICU admission&lt;br&gt;&lt;br&gt;          -  an expected duration of ICU admission of at least 72 hours&lt;br&gt;&lt;br&gt;          -  informed consent by patient or by proxy (i.e. next of kin)&lt;br&gt;&lt;br&gt;          -  diagnosis of severe sepsis/septic shock&lt;br&gt;&lt;br&gt;          -  diagnosis of kidney dysfunction (minimum RIFLE criteria - 'R'); and&lt;br&gt;&lt;br&gt;          -  presence of a central venous catheter.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  inability to provide or obtain consent;&lt;br&gt;&lt;br&gt;          -  patient is moribund with expected death within 24 hours;&lt;br&gt;&lt;br&gt;          -  known chronic kidney disease (CKD) or end-stage renal disease (ESRD)      receiving&lt;br&gt;             chronic RRT;&lt;br&gt;&lt;br&gt;          -  confirmed or suspected acute glomerulonephritis, acute interstitial nephritis, renal&lt;br&gt;             vasculitis or post-renal aetiology for kidney dysfunction;&lt;br&gt;&lt;br&gt;          -  patient is already receiving (or is about to start) CRRT for acute renal failure at&lt;br&gt;             the time of enrolment;&lt;br&gt;&lt;br&gt;          -  known or documented allergy to angiotensin II;&lt;br&gt;&lt;br&gt;          -  MAP consistently &gt; 100 mmHg with no pressor support and no easily treatable cause&lt;br&gt;             (eg. pain); and&lt;br&gt;&lt;br&gt;          -  enrolling physician's belief that the study drug could not be administered for the&lt;br&gt;             expected study duration.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Renal Failure;Sepsis;Septic Shock</Condition>
    <Intervention>Drug: Angiotensin II;Drug: Saline placebo</Intervention>
    <Primary_outcome>Urine output;Arterial blood pressure</Primary_outcome>
    <Secondary_outcome>Serum creatinine;Serum urea;Serum Cystatin C;Serum neutrophil gelatinase associated lipocalin (NGAL);Urinary cystatin C;Urinary NGAL;Urinary IL-18;Need for renal replacement therapy;Mortality</Secondary_outcome>
    <Secondary_ID>TNH 23/08</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Northern Health and Social Care Trust;Western Hospital, Australia</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2897290</Internal_Number>
    <TrialID>NCT00711984</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Comparison of Stenting Versus Best Medical Therapy for Treatment of Ostial Renal Artery Stenosis: a Trial in Patients With Advanced Atherosclerosis</Public_title>
    <Scientific_title>Comparison of Stenting Versus Best Medical Therapy for Treatment of Ostial Renal Artery Stenosis: a Randomized Controlled Trial in Patients With Advanced Atherosclerosis.</Scientific_title>
    <Acronym />
    <Primary_sponsor>Medical University of Vienna</Primary_sponsor>
    <Date_registration3>20080703</Date_registration3>
    <Date_registration>03/07/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00711984</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>February 2004</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  PAD and unilateral ostial &gt;60% RAS and hypertension&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Conditions which imply RAS stenting (bilateral significant renal disease, single&lt;br&gt;             functioning kidney, or patients whose conditions cannot be managed medically or by&lt;br&gt;             intervention)&lt;br&gt;&lt;br&gt;          -  Allergy to contrast agents or medication administered for best medical treatment (in&lt;br&gt;             particular ASA and statins)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Artery Stenosis</Condition>
    <Intervention>Device: Herkulink renal artery Stent;Other: best medical therapy</Intervention>
    <Primary_outcome>change in mean blood pressure and renal function occurrence of major cardiovascular events</Primary_outcome>
    <Secondary_outcome>progression of the degree of RAS in the conservative group and restenosis rate in the stent group</Secondary_outcome>
    <Secondary_ID>Version 1.0-2003</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2897424</Internal_Number>
    <TrialID>NCT00713739</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Alfuzosin for Medical Expulsion Therapy of Ureteral Stones</Public_title>
    <Scientific_title>Evaluation of Alfuzosin as Medical Expulsion Therapy for Ureteral Stones</Scientific_title>
    <Acronym>MET</Acronym>
    <Primary_sponsor>United States Naval Medical Center, San Diego</Primary_sponsor>
    <Date_registration3>20080707</Date_registration3>
    <Date_registration>07/07/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00713739</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2008</Date_enrollement>
    <Target_size>240</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age &gt;/= 18 years&lt;br&gt;&lt;br&gt;          -  Single ureteral stone &lt; 1 cm in greatest dimension&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age &lt; 18 years&lt;br&gt;&lt;br&gt;          -  Active unstable angina&lt;br&gt;&lt;br&gt;          -  History of or active postural hypotension (&gt;20 mmHg drop in orthostatic SBP)&lt;br&gt;&lt;br&gt;          -  Allergy to alpha-blockers&lt;br&gt;&lt;br&gt;          -  Acute or Chronic Renal Failure as demonstrated by a serum creatinine of &gt; 1.4 mg/dl&lt;br&gt;&lt;br&gt;          -  Urinary tract infection&lt;br&gt;&lt;br&gt;          -  Multiple ureteral stones&lt;br&gt;&lt;br&gt;          -  Current uncontrolled diabetes&lt;br&gt;&lt;br&gt;          -  Alpha-blocker therapy within 30 days for any reason&lt;br&gt;&lt;br&gt;          -  Current pregnancy or lactation&lt;br&gt;&lt;br&gt;          -  Patient desire for immediate stone removal&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Stones</Condition>
    <Intervention>Drug: Alfuzosin;Drug: nifedipine;Drug: doxazosin;Drug: prazosin</Intervention>
    <Primary_outcome>The primary measures are percent of stones passed and rates of occurrence of various side effects (categorical variables), and time to pass, pain scale, and amount of pain medication taken (continuous variables).</Primary_outcome>
    <Secondary_ID>Office of Naval Research FY08;NMCSD CID 06-050</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2897455</Internal_Number>
    <TrialID>NCT00714142</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Renal Blood Flow Measurement With Positron Emission Tomography (PET)</Public_title>
    <Scientific_title>Renal Blood Flow Measurement With PET</Scientific_title>
    <Acronym />
    <Primary_sponsor>Proportional Technologies, Inc.</Primary_sponsor>
    <Date_registration3>20080710</Date_registration3>
    <Date_registration>10/07/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00714142</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 2008</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Pharmacokinetics Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Diagnostic</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Arm 1.&lt;br&gt;&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  males and females, age 18-40 years&lt;br&gt;&lt;br&gt;          -  willingness to provide written informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  history of coronary artery disease (CAD)&lt;br&gt;&lt;br&gt;          -  history of renal disease&lt;br&gt;&lt;br&gt;          -  risk factors for cardiac disease, renal disease, or atherosclerosis, including&lt;br&gt;             diabetes mellitus, hypertension, tobacco abuse, hyperlipidemia, family history of CAD&lt;br&gt;             or chronic renal failure&lt;br&gt;&lt;br&gt;          -  history of liver disease or other significant disease&lt;br&gt;&lt;br&gt;          -  pregnant females&lt;br&gt;&lt;br&gt;        Arm 2.&lt;br&gt;&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  males and females, age &gt; 18 years&lt;br&gt;&lt;br&gt;          -  active hemodialysis or peritoneal dialysis for at least six months&lt;br&gt;&lt;br&gt;          -  any etiology of chronic renal failure except active glomerular nephritis&lt;br&gt;&lt;br&gt;          -  presence of two kidneys&lt;br&gt;&lt;br&gt;          -  willingness to provide written informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  decompensated heart failure (subjects must be on stable medical therapy for one&lt;br&gt;             month)&lt;br&gt;&lt;br&gt;          -  any previous renal transplant (subjects may be on renal transplant waiting list)&lt;br&gt;&lt;br&gt;          -  history of liver disease&lt;br&gt;&lt;br&gt;          -  pregnant females&lt;br&gt;&lt;br&gt;        Arm 3.&lt;br&gt;&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  males and females, age &gt; 18 years&lt;br&gt;&lt;br&gt;          -  documented evidence of renal artery stenosis equivalent to a 75% stenosis by one of&lt;br&gt;             the following clinical tests: MRA, Doppler, Renal Angiogram, Abnormal captopril renal&lt;br&gt;             scan&lt;br&gt;&lt;br&gt;          -  evidence of renal insufficiency with serum creatinine &gt;= 1.3 mg/dL&lt;br&gt;&lt;br&gt;          -  presence of two kidneys&lt;br&gt;&lt;br&gt;          -  willingness to provide written informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  revascularization of stenotic renal artery&lt;br&gt;&lt;br&gt;          -  decompensated heart failure (subjects must be on stable medical therapy for one&lt;br&gt;             month)&lt;br&gt;&lt;br&gt;          -  any previous renal transplant (subjects may be on renal transplant waiting list)&lt;br&gt;&lt;br&gt;          -  history of liver disease&lt;br&gt;&lt;br&gt;          -  pregnant females&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Failure;Renal Artery Stenosis</Condition>
    <Intervention>Drug: 62Cu-ethylglyoxal bis(thiosemicarbazone);Drug: 15O-water;Procedure: Positron Emission Tomography</Intervention>
    <Primary_outcome>Obtain preliminary information on efficacy for quantification of regional renal perfusion in two target clinical populations with a full range of renal disease using 150-water PET and 62Cu-ETS PET</Primary_outcome>
    <Secondary_outcome>Assess the safety of the drug 62Cu-ETS through expansion to two target patient populations and increase the size of the normal subjects group</Secondary_outcome>
    <Secondary_ID>DK58466;UW HS IRB 2008-0097</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>University of Wisconsin, Madison</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2897455</Internal_Number>
    <TrialID>NCT00714142</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Renal Blood Flow Measurement With Positron Emission Tomography (PET)</Public_title>
    <Scientific_title>Renal Blood Flow Measurement With PET</Scientific_title>
    <Acronym />
    <Primary_sponsor>Proportional Technologies, Inc.</Primary_sponsor>
    <Date_registration3>20080710</Date_registration3>
    <Date_registration>10/07/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00714142</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 2008</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Pharmacokinetics Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Diagnostic</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Arm 1.&lt;br&gt;&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  males and females, age 18-40 years&lt;br&gt;&lt;br&gt;          -  willingness to provide written informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  history of coronary artery disease (CAD)&lt;br&gt;&lt;br&gt;          -  history of renal disease&lt;br&gt;&lt;br&gt;          -  risk factors for cardiac disease, renal disease, or atherosclerosis, including&lt;br&gt;             diabetes mellitus, hypertension, tobacco abuse, hyperlipidemia, family history of CAD&lt;br&gt;             or chronic renal failure&lt;br&gt;&lt;br&gt;          -  history of liver disease or other significant disease&lt;br&gt;&lt;br&gt;          -  pregnant females&lt;br&gt;&lt;br&gt;        Arm 2.&lt;br&gt;&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  males and females, age &gt; 18 years&lt;br&gt;&lt;br&gt;          -  active hemodialysis or peritoneal dialysis for at least six months&lt;br&gt;&lt;br&gt;          -  any etiology of chronic renal failure except active glomerular nephritis&lt;br&gt;&lt;br&gt;          -  presence of two kidneys&lt;br&gt;&lt;br&gt;          -  willingness to provide written informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  decompensated heart failure (subjects must be on stable medical therapy for one&lt;br&gt;             month)&lt;br&gt;&lt;br&gt;          -  any previous renal transplant (subjects may be on renal transplant waiting list)&lt;br&gt;&lt;br&gt;          -  history of liver disease&lt;br&gt;&lt;br&gt;          -  pregnant females&lt;br&gt;&lt;br&gt;        Arm 3.&lt;br&gt;&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  males and females, age &gt; 18 years&lt;br&gt;&lt;br&gt;          -  documented evidence of renal artery stenosis equivalent to a 75% stenosis by one of&lt;br&gt;             the following clinical tests: MRA, Doppler, Renal Angiogram, Abnormal captopril renal&lt;br&gt;             scan&lt;br&gt;&lt;br&gt;          -  evidence of renal insufficiency with serum creatinine &gt;= 1.3 mg/dL&lt;br&gt;&lt;br&gt;          -  presence of two kidneys&lt;br&gt;&lt;br&gt;          -  willingness to provide written informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  revascularization of stenotic renal artery&lt;br&gt;&lt;br&gt;          -  decompensated heart failure (subjects must be on stable medical therapy for one&lt;br&gt;             month)&lt;br&gt;&lt;br&gt;          -  any previous renal transplant (subjects may be on renal transplant waiting list)&lt;br&gt;&lt;br&gt;          -  history of liver disease&lt;br&gt;&lt;br&gt;          -  pregnant females&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Failure;Renal Artery Stenosis</Condition>
    <Intervention>Drug: 62Cu-ethylglyoxal bis(thiosemicarbazone);Drug: 15O-water;Procedure: Positron Emission Tomography</Intervention>
    <Primary_outcome>Obtain preliminary information on efficacy for quantification of regional renal perfusion in two target clinical populations with a full range of renal disease using 150-water PET and 62Cu-ETS PET</Primary_outcome>
    <Secondary_outcome>Assess the safety of the drug 62Cu-ETS through expansion to two target patient populations and increase the size of the normal subjects group</Secondary_outcome>
    <Secondary_ID>DK58466;UW HS IRB 2008-0097</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>University of Wisconsin, Madison</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2897495</Internal_Number>
    <TrialID>NCT00714662</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>High Flux Hemodialysis Thrice Versus Once</Public_title>
    <Scientific_title>Effects of Different Frequencies of High-Flux Membranes on Blood Pressure, Fluid Balance, and Indices of Nutrition, Inflammation, and Dialysis Adequacy in Chronic Hemodialysis Patients - Comparisons Between Thrice vs Once Weekly</Scientific_title>
    <Acronym />
    <Primary_sponsor>National Taiwan University Hospital</Primary_sponsor>
    <Date_registration3>20080709</Date_registration3>
    <Date_registration>09/07/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00714662</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2008</Date_enrollement>
    <Target_size>80</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Crossover Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. ESRD patients under regular thrice weekly HD for more than 3 months in       NTUH HD&lt;br&gt;             center.&lt;br&gt;&lt;br&gt;          2. Age: 18~80 years old.&lt;br&gt;&lt;br&gt;          3. Blood flow during dialysis ? 250ml/min&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Previous allergy to heparin or FX series dialyzer (FX-60, FX-80, FX-100)&lt;br&gt;&lt;br&gt;          2. Pre-dialysis systolic blood pressure ? 100mmHg (2week prior to enrollment)&lt;br&gt;&lt;br&gt;          3. Bacteremia, myocardial infarction or stroke in previous 3 months.&lt;br&gt;&lt;br&gt;          4. Known diagnosis with dialysis related amyloidosis&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End-Stage Renal Disease</Condition>
    <Intervention>Device: high flux hemodialyzer (FX-60, FX-80 or FX-100)</Intervention>
    <Primary_outcome>blood pressure, fluid balance, and indices of nutrition, inflammation, and dialysis adequacy</Primary_outcome>
    <Secondary_ID>200803055R</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Mrs. Hsiu-Chin Lee Kidney Research Fund</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2897852</Internal_Number>
    <TrialID>NCT00719316</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Aliskiren and Muscle Sympathetic Nerve Activity</Public_title>
    <Scientific_title>Effect of Aliskiren on Muscle Sympathetic Nerve Activity (MSNA) in Hypertensive Patients With Chronic Kidney Disease</Scientific_title>
    <Acronym>MSNA</Acronym>
    <Primary_sponsor>UMC Utrecht</Primary_sponsor>
    <Date_registration3>20080717</Date_registration3>
    <Date_registration>17/07/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00719316</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>25 Years</Inclusion_agemin>
    <Inclusion_agemax>95 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2008</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Crossover Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with stable chronic kidney disease and hypertension: i.e. using&lt;br&gt;             antihypertensive drugs and/or blood pressure &gt; 145/90 mmHg when off medication.&lt;br&gt;&lt;br&gt;          -  Patients on ACE inhibitor or ARB&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with diabetes mellitus&lt;br&gt;&lt;br&gt;          -  Patients on renal replacement therapy&lt;br&gt;&lt;br&gt;          -  Pregnant patients Using of antihypertensive which cannot be stopped&lt;br&gt;&lt;br&gt;          -  Patients on immunosuppressive therapy and active nephrotic syndrome&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease;Hypertension;Muscle Sympathetic Nerve Activity</Condition>
    <Intervention>Drug: Aliskiren</Intervention>
    <Primary_outcome>Normalisation of muscle sympathetic nerve activity</Primary_outcome>
    <Secondary_outcome>Blood pressure and Blood tests</Secondary_outcome>
    <Secondary_ID>NL19926.041.07</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2898039</Internal_Number>
    <TrialID>NCT00721773</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Renal Protective Effects of Renin Angiotensin System (RAS) Inhibitor in Peritoneal Dialysis Patients</Public_title>
    <Scientific_title>Effects of Benazepril,Valsartan or Combination of Both on Residual Renal Function in Peritoneal Dialysis Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>Sun Yat-sen University</Primary_sponsor>
    <Date_registration3>20080722</Date_registration3>
    <Date_registration>22/07/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00721773</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>20 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2008</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  All patients received CAPD more than 1 months&lt;br&gt;&lt;br&gt;          -  Subjects of either sex, 20-75 years old&lt;br&gt;&lt;br&gt;          -  Residual GFR of 3mL/min per 1.73 m2 or more&lt;br&gt;&lt;br&gt;          -  With hypertension&lt;br&gt;&lt;br&gt;          -  No history of taking an ACE inhibitor or angiotensin-receptor blockers for at least 1&lt;br&gt;             month&lt;br&gt;&lt;br&gt;          -  Provision of written informed consent by subject or guardian&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Underlying medical conditions, such as congestive heart failure, or therapy with an&lt;br&gt;             ACE inhibitor or ARB&lt;br&gt;&lt;br&gt;          -  Peritonitis or volume overload within the preceding 1 month&lt;br&gt;&lt;br&gt;          -  Myocardial infarction within the preceding 6 months&lt;br&gt;&lt;br&gt;          -  Clinically significant valvular disease&lt;br&gt;&lt;br&gt;          -  Malignant hypertension&lt;br&gt;&lt;br&gt;          -  History of hypertensive encephalopathy or cerebrovascular accident within the&lt;br&gt;             preceding 6 months&lt;br&gt;&lt;br&gt;          -  Any condition that may have precluded a patient from remaining in the study, such as&lt;br&gt;             alcohol or drug abuse, chronic liver disease, malignant disease, or psychiatric&lt;br&gt;             disorder&lt;br&gt;&lt;br&gt;          -  History of allergy or intolerance to an ACE inhibitor or ARB&lt;br&gt;&lt;br&gt;          -  Participation in another clinic trial within 2 weeks prior to screening&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Function Disorder</Condition>
    <Intervention>Drug: Benazepril;Drug: Valsartan;Drug: Benazepril+Valsartan;Drug: Control</Intervention>
    <Primary_outcome>The longitudinal change in residual glomerular filtration rate (GFR)</Primary_outcome>
    <Secondary_outcome>Dialysis adequacy;Peritoneal membrane function;Blood pressure;The time to anuria;Death</Secondary_outcome>
    <Secondary_ID>PDRRF</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2898588</Internal_Number>
    <TrialID>NCT00729014</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>A Study of Drug-Induced Kidney Disease</Public_title>
    <Scientific_title>A Study of Drug-Induced Kidney Disease</Scientific_title>
    <Acronym />
    <Primary_sponsor>National Taiwan University Hospital</Primary_sponsor>
    <Date_registration3>20080801</Date_registration3>
    <Date_registration>01/08/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00729014</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2008</Date_enrollement>
    <Target_size>2000</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Time Perspective:  Retrospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  patient who was newly diagnosed as end stage renal disease who need dialysis&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  started dialysis before 2000&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End Stage Renal Disease</Condition>
    <Primary_outcome>The incidence of herbal nephropathy</Primary_outcome>
    <Secondary_outcome>The epidemiology of primary diagnosis for end stage renal disease in Taiwan</Secondary_outcome>
    <Secondary_ID>200804062R</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Department of Health, Taiwan</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2898604</Internal_Number>
    <TrialID>NCT00729248</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>The Differential Effects of 3 Different Immunosuppressive</Public_title>
    <Scientific_title>The Differential Effects of 3 Different Immunosuppressive Agents, Tacrolimus Mycophenolate Mofetil and Sirolimus on the Generation of Tregs and DCregs in in Vitro MLR and T Cell Activation Assays</Scientific_title>
    <Acronym />
    <Primary_sponsor>Northwestern University</Primary_sponsor>
    <Date_registration3>20080804</Date_registration3>
    <Date_registration>04/08/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00729248</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2008</Date_enrollement>
    <Target_size>12</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Time Perspective:  Cross-Sectional</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Adults 18 years of Age or Older&lt;br&gt;&lt;br&gt;          -  Undergoing living donor renal transplant&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  No active infection or history of malignancy&lt;br&gt;&lt;br&gt;          -  No HIV infection&lt;br&gt;&lt;br&gt;          -  No Hepatitis C (HCV) infection&lt;br&gt;&lt;br&gt;          -  No prior transplant (kidney or other organ)&lt;br&gt;&lt;br&gt;          -  No chromic use of immunosuppressive therapy or history of autoimmune disease&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Immunosuppression;Kidney Transplantation</Condition>
    <Primary_outcome>To Examine the regulatory effects of three IS agents (TAC, MMF, SRL) in an in vitro human model (MLR and Anti-CD3 T cell activation;To determine differences in the effects of various IS doses and drug levels on the generation of regulatory profiles in this model</Primary_outcome>
    <Secondary_ID>KV-08-001</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2898805</Internal_Number>
    <TrialID>NCT00731874</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Thymoglobulin Induction Therapy With Minimal Immunosuppression and Evaluation of Allograft Status</Public_title>
    <Scientific_title>Thymoglobulin Induction Therapy With Minimal Immunosuppression and Evaluation of Allograft Status by Biopsy and mRNA Profiles (TIMELY Study)</Scientific_title>
    <Acronym>TIMELY</Acronym>
    <Primary_sponsor>Weill Medical College of Cornell University</Primary_sponsor>
    <Date_registration3>20080807</Date_registration3>
    <Date_registration>07/08/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00731874</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 2008</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age &gt; 18 years&lt;br&gt;&lt;br&gt;          -  Renal allograft recipients who received a steroid-sparing immunosuppression protocol&lt;br&gt;             with rabbit anti-thymocyte globulin (Thymoglobulin) induction&lt;br&gt;&lt;br&gt;          -  Patient must have previously enrolled in protocol entitled "The use of urinary PCR&lt;br&gt;             test to help detect rejection in kidney transplant patients"&lt;br&gt;&lt;br&gt;          -  Recipients must agree to undergo all standard post-transplant protocol biopsies&lt;br&gt;&lt;br&gt;          -  Recipients must be at least 3 months post-transplant and the three most recent&lt;br&gt;             urinary profiles must demonstrate immunologic quiescence as determined by measurement&lt;br&gt;             of Granzyme B and Perforin copy numbers&lt;br&gt;&lt;br&gt;          -  Patient must provide informed consent to participate in the research study&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patient is a high-risk recipient (defined as peak or current PRA &gt;50% or a&lt;br&gt;             re-transplant recipient who lost prior graft within 1 year due to immunologic&lt;br&gt;             reasons)&lt;br&gt;&lt;br&gt;          -  Patients who require maintenance steroids for another medical condition (such as&lt;br&gt;             asthma)&lt;br&gt;&lt;br&gt;          -  Patients who are taking less than 1 gram/day of mycophenolate mofetil&lt;br&gt;&lt;br&gt;          -  Multiple organ transplant recipients (such as kidney-pancreas)&lt;br&gt;&lt;br&gt;          -  Patients with one or more acute rejection episodes within the first 3 months after&lt;br&gt;             transplant&lt;br&gt;&lt;br&gt;          -  Three-month protocol biopsy showing clinical acute rejection (BANFF grade 1a or&lt;br&gt;             higher)&lt;br&gt;&lt;br&gt;          -  Patient with documented or suspected non-compliance with transplant medications in&lt;br&gt;             the first 3 months after transplant&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Transplant;Immunosuppression</Condition>
    <Intervention>Drug: Tacrolimus</Intervention>
    <Primary_outcome>The primary endpoint will be a composite of the following: biopsy-confirmed acute rejection and progression of histologically proven chronic allograft nephropathy at 15 months after transplantation.</Primary_outcome>
    <Secondary_outcome>Patient survival;Graft survival;Incidence and severity of chronic allograft nephropathy;Renal function (estimated glomerular filtration rate);Perforin and granzyme B mRNA levels in urine;Time to acute rejection;Severity of acute rejection (by Banff criteria and need for anti-lymphocyte agents to treat acute rejection);Incidence of opportunistic infection;Development of new onset diabetes mellitus</Secondary_outcome>
    <Secondary_ID>0608008711</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2898947</Internal_Number>
    <TrialID>NCT00733733</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Anti-T-Lymphocyte Globulin (ATG) in Renal Transplantation of Kidneys With a Non-Heart-Beating (NHB) Donor</Public_title>
    <Scientific_title>A Prospective, Randomized, Open, Multicenter Study to Evaluate the Efficacy and Tolerability of Induction Therapy With a Single High-Dose Anti-T-Lymphocyte Globulin (ATG) in Renal Transplant Patients With a Kidney From a Non-Heart-Beating Donor and Tacrolimus, Mycophenolate Mofetil, and Steroids as Basic Immunosuppression.</Scientific_title>
    <Acronym>ATG</Acronym>
    <Primary_sponsor>Radboud University</Primary_sponsor>
    <Date_registration3>20080812</Date_registration3>
    <Date_registration>12/08/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00733733</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2008</Date_enrollement>
    <Target_size>180</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Non-heart-beating-donors (Maastricht  III/IV)&lt;br&gt;&lt;br&gt;          -  Female patients of childbearing age agree to maintain effective birth control&lt;br&gt;             practice during the study.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Pregnant or lactating women at the time of randomization.&lt;br&gt;&lt;br&gt;          -  Patients and donors are ABO incompatible.&lt;br&gt;&lt;br&gt;          -  Women having had &gt;3 pregnancies (including abortions if no consistent data on PRA or&lt;br&gt;             anti-donor antibodies are available).&lt;br&gt;&lt;br&gt;          -  Patients with hypersensibility to rabbit proteins, previous treatment with rabbit&lt;br&gt;             IgG, or known intolerance to any component of basal immunosuppression.&lt;br&gt;&lt;br&gt;          -  Patients with leukocytes &lt;3,000/mm3 and/or platelets &lt;50,000/mm3 before initiation of&lt;br&gt;             transplant.&lt;br&gt;&lt;br&gt;          -  Patients, who are HIV positive.&lt;br&gt;&lt;br&gt;          -  Patients subjected to previous transplants or candidates for multiple  transplants&lt;br&gt;             (e.g. SKP).&lt;br&gt;&lt;br&gt;          -  Patients, who are unlikely to comply with the visit schedule in the protocol and&lt;br&gt;             patients who cannot communicate reliably with the investigator.&lt;br&gt;&lt;br&gt;          -  Patients with pulmonary oedema or with other signs of overhydration.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Transplant Patients;Recipients of a Kidney From a Non-Heart-Beating Donor</Condition>
    <Intervention>Drug: ATG Fresenius</Intervention>
    <Primary_outcome>Incidence of initial delayed graft function (defined as need for dialysis)</Primary_outcome>
    <Secondary_outcome>Duration of initial delayed graft failure;Incidence of primary never-functioning grafts;Incidence of acute rejections (biopsy proven);Renal function as determined by MDRD;Proteinuria;Percentage of patients with arterial hypertension;Percentage of patients with antihypertensive drugs (and the number of different classes of antihypertensive drugs);Percentage of hyperlipidemic patients;Percentage of post transplant diabetes mellitus;Incidence of cytomegalovirus infection;Incidence of tumours/PTLD;Patient and graft survival;Incidence of other infections;Microalbuminuria</Secondary_outcome>
    <Secondary_ID>Euro-NHB</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Erasmus Medical Center;Maastricht University;Leiden University Medical Center;UMC Utrecht;University Medical Centre Groningen;Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2898947</Internal_Number>
    <TrialID>NCT00733733</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Anti-T-Lymphocyte Globulin (ATG) in Renal Transplantation of Kidneys With a Non-Heart-Beating (NHB) Donor</Public_title>
    <Scientific_title>A Prospective, Randomized, Open, Multicenter Study to Evaluate the Efficacy and Tolerability of Induction Therapy With a Single High-Dose Anti-T-Lymphocyte Globulin (ATG) in Renal Transplant Patients With a Kidney From a Non-Heart-Beating Donor and Tacrolimus, Mycophenolate Mofetil, and Steroids as Basic Immunosuppression.</Scientific_title>
    <Acronym>ATG</Acronym>
    <Primary_sponsor>Radboud University</Primary_sponsor>
    <Date_registration3>20080812</Date_registration3>
    <Date_registration>12/08/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00733733</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2008</Date_enrollement>
    <Target_size>180</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Non-heart-beating-donors (Maastricht  III/IV)&lt;br&gt;&lt;br&gt;          -  Female patients of childbearing age agree to maintain effective birth control&lt;br&gt;             practice during the study.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Pregnant or lactating women at the time of randomization.&lt;br&gt;&lt;br&gt;          -  Patients and donors are ABO incompatible.&lt;br&gt;&lt;br&gt;          -  Women having had &gt;3 pregnancies (including abortions if no consistent data on PRA or&lt;br&gt;             anti-donor antibodies are available).&lt;br&gt;&lt;br&gt;          -  Patients with hypersensibility to rabbit proteins, previous treatment with rabbit&lt;br&gt;             IgG, or known intolerance to any component of basal immunosuppression.&lt;br&gt;&lt;br&gt;          -  Patients with leukocytes &lt;3,000/mm3 and/or platelets &lt;50,000/mm3 before initiation of&lt;br&gt;             transplant.&lt;br&gt;&lt;br&gt;          -  Patients, who are HIV positive.&lt;br&gt;&lt;br&gt;          -  Patients subjected to previous transplants or candidates for multiple  transplants&lt;br&gt;             (e.g. SKP).&lt;br&gt;&lt;br&gt;          -  Patients, who are unlikely to comply with the visit schedule in the protocol and&lt;br&gt;             patients who cannot communicate reliably with the investigator.&lt;br&gt;&lt;br&gt;          -  Patients with pulmonary oedema or with other signs of overhydration.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Transplant Patients;Recipients of a Kidney From a Non-Heart-Beating Donor</Condition>
    <Intervention>Drug: ATG Fresenius</Intervention>
    <Primary_outcome>Incidence of initial delayed graft function (defined as need for dialysis)</Primary_outcome>
    <Secondary_outcome>Duration of initial delayed graft failure;Incidence of primary never-functioning grafts;Incidence of acute rejections (biopsy proven);Renal function as determined by MDRD;Proteinuria;Percentage of patients with arterial hypertension;Percentage of patients with antihypertensive drugs (and the number of different classes of antihypertensive drugs);Percentage of hyperlipidemic patients;Percentage of post transplant diabetes mellitus;Incidence of cytomegalovirus infection;Incidence of tumours/PTLD;Patient and graft survival;Incidence of other infections;Microalbuminuria</Secondary_outcome>
    <Secondary_ID>Euro-NHB</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Erasmus Medical Center;Maastricht University;Leiden University Medical Center;UMC Utrecht;University Medical Centre Groningen;Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2899247</Internal_Number>
    <TrialID>NCT00737659</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>CellCept® Dose Adjustment Versus Fixed Dose (Standard Care) in Renal Transplant Recipients</Public_title>
    <Scientific_title>Phase IV, Open-Label, Multicenter, Randomized Study Comparing Mycophenolate Mofetil (MMF) Dose Adjustment Based on Blood MPA Concentration to Standard Care Treatment With MMF in Renal Transplant Recipients Receiving Tacrolimus</Scientific_title>
    <Acronym>MMF</Acronym>
    <Primary_sponsor>Rabin Medical Center</Primary_sponsor>
    <Date_registration3>20080817</Date_registration3>
    <Date_registration>17/08/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00737659</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 2008</Date_enrollement>
    <Target_size>138</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Male or female subjects, between 18 to 70 years of age at the time of enrollment.&lt;br&gt;&lt;br&gt;          -  Patient who received first or second renal transplant.&lt;br&gt;&lt;br&gt;          -  Patients who are 0-14 days post transplant.&lt;br&gt;&lt;br&gt;          -  Patients capable of understanding the purposes and risks of the study who signed a&lt;br&gt;             written informed consent to participate and to comply with the requirements of the&lt;br&gt;             study.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Women lactating, pregnant or of childbearing potential not using a reliable&lt;br&gt;             contraceptive method before beginning study drug therapy, during therapy and for 4&lt;br&gt;             months following their last dose of the study drug therapy.&lt;br&gt;&lt;br&gt;          -  Patients with severe diarrhea or other gastrointestinal disorders that might&lt;br&gt;             interfere with their ability to absorb oral medication, including diabetic patients&lt;br&gt;             with previously diagnosed diabetic gastroenteropathy.&lt;br&gt;&lt;br&gt;          -  Patients with a history of a psychological illness or condition such as to interfere&lt;br&gt;             with the patient's ability to understand the requirements of the study.&lt;br&gt;&lt;br&gt;          -  Patients with evidence of an active systemic infection requiring the continued use of&lt;br&gt;             antibiotics or evidence of an HIV infection, or the presence of a chronic active&lt;br&gt;             hepatitis B (HBs-Ag positive) or C.&lt;br&gt;&lt;br&gt;          -  Current or historic Panel Reactive Antibody (PRA) &gt;50%&lt;br&gt;&lt;br&gt;          -  Positive crossmatch (irrespective of method).&lt;br&gt;&lt;br&gt;          -  Cold ischemia time of the graft of more than 30 hours.&lt;br&gt;&lt;br&gt;          -  Patients who had received an investigational new drug within the last three months at&lt;br&gt;             the time of enrollment.&lt;br&gt;&lt;br&gt;          -  Multi-organ recipients (e.g. kidney and pancreas) or previous transplant with any&lt;br&gt;             organ other than kidney.&lt;br&gt;&lt;br&gt;          -  Patients with any known hypersensitivity to MPA, EC-MPS or other components of the&lt;br&gt;             formulation (e.g. lactose).&lt;br&gt;&lt;br&gt;          -  Patients with thrombocytopenia (&lt; 75,000/mm3), with an absolute neutrophil count of&lt;br&gt;             &lt;1,500/mm3, and/or leukocytopenia (&lt; 2,500/mm3), and/or hemoglobin &lt; 6 g/dL at&lt;br&gt;             Screening or Baseline.&lt;br&gt;&lt;br&gt;          -  Patients with a history of malignancy within the last five years, except excised&lt;br&gt;             squamous or basal cell carcinoma of the skin.&lt;br&gt;&lt;br&gt;          -  Previous exposure to EC-MPS.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Transplant</Condition>
    <Intervention>Drug: Mycophenolate mofetil (CellCept® );Drug: Mycophenolate mofetil (CellCept® )</Intervention>
    <Primary_outcome>Primary Endpoint Treatment failure defined as a biopsy proven acute rejection, graft loss, death, MMF discontinuation or lost to follow-up.</Primary_outcome>
    <Secondary_ID>ML21706</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2899370</Internal_Number>
    <TrialID>NCT00739284</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>A Prospective Comparison Between Ureteral Stent and Nephrostomy Tube for an Urgent Drainage of Obstructed Kidney</Public_title>
    <Scientific_title />
    <Acronym>JJVsPCN08</Acronym>
    <Primary_sponsor>Rabin Medical Center</Primary_sponsor>
    <Date_registration3>20080820</Date_registration3>
    <Date_registration>20/08/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00739284</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 2008</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria: Patient suffering from obstructed kidney by a stone and at least one&lt;br&gt;        of these situations:&lt;br&gt;&lt;br&gt;          1. fever (above 38c)&lt;br&gt;&lt;br&gt;          2. A rise in creatine to above 1.5&lt;br&gt;&lt;br&gt;          3. Pain resistent to multiple analgetic treatments&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with medical condition that prevent the use of one of the procedures&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Disease</Condition>
    <Intervention>Device: nephrostomy tube and ureteral stent</Intervention>
    <Primary_outcome>quality of life</Primary_outcome>
    <Secondary_ID>JJVsPCN08</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2899411</Internal_Number>
    <TrialID>NCT00739843</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Cognitive and Functional Status and Dialysis Outcomes in Older Hemodialysis Patients</Public_title>
    <Scientific_title>Cognitive and Functional Status and Dialysis Outcomes in Older Hemodialysis Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Chicago</Primary_sponsor>
    <Date_registration3>20080820</Date_registration3>
    <Date_registration>20/08/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00739843</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>60 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2007</Date_enrollement>
    <Target_size>150</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Prevalent and incident hemodialysis patients over the age of 60, receiving&lt;br&gt;             hemodialysis treatments at the University of Chicago outpatient dialysis program.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients 59 and younger, and patients with the following medical conditions:&lt;br&gt;             malignancies currently requiring chemotherapy or radiation therapy, severe heart&lt;br&gt;             failure (NYHA class IV), known HIV infection, or currently active hepatic&lt;br&gt;             encephalopathy.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Dementia;Cognition;End-Stage Renal Disease</Condition>
    <Secondary_ID>15813B</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2899657</Internal_Number>
    <TrialID>NCT00743054</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>microRNA Expression in Renal Cell Carcinoma</Public_title>
    <Scientific_title>microRNA Expression in Renal Cell Carcinoma</Scientific_title>
    <Acronym />
    <Primary_sponsor>Sun Yat-sen University</Primary_sponsor>
    <Date_registration3>20080827</Date_registration3>
    <Date_registration>27/08/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00743054</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2008</Date_enrollement>
    <Target_size>50</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case-Only, Time Perspective:  Cross-Sectional</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with primary renal cell carcinoma.&lt;br&gt;&lt;br&gt;          -  Subjects who agree to participate in the study and sign the informed consent.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with secondary renal cell carcinoma.&lt;br&gt;&lt;br&gt;          -  Subjects who refuse to participate in the study and sign the informed consent.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Carcinoma, Renal Cell</Condition>
    <Secondary_ID>SYSU-MiRNARCC</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2900103</Internal_Number>
    <TrialID>NCT00748904</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Rifaximin Versus Lactulose in Renal Failure</Public_title>
    <Scientific_title>A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Progressive Renal Failure</Scientific_title>
    <Acronym />
    <Primary_sponsor>Weill Medical College of Cornell University</Primary_sponsor>
    <Date_registration3>20080908</Date_registration3>
    <Date_registration>08/09/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00748904</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>65 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2008</Date_enrollement>
    <Target_size>70</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  cirrhosis of liver of any etiology&lt;br&gt;&lt;br&gt;          -  progressive renal failure&lt;br&gt;&lt;br&gt;          -  stage 0-2 hepatic encephalopathy&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  pregnant women&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Liver Cirrhosis;Renal Failure</Condition>
    <Intervention>Drug: Rifaximin;Drug: Lactulose</Intervention>
    <Primary_outcome>slower progression to severe hepatic encephalopathy, stage 3 or 4</Primary_outcome>
    <Secondary_ID>0801009635</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2900345</Internal_Number>
    <TrialID>NCT00752102</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Vitamin D and Coronary Calcification Study</Public_title>
    <Scientific_title>A Phase IV, Randomized, Single-center Study of the Effects of Calcitriol and Paricalcitol on Vascular Calcification in Chronic Kidney Disease Stages 3 and 4</Scientific_title>
    <Acronym>VCOR</Acronym>
    <Primary_sponsor>University of Pennsylvania</Primary_sponsor>
    <Date_registration3>20080911</Date_registration3>
    <Date_registration>11/09/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00752102</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>25 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2008</Date_enrollement>
    <Target_size>50</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  CKD stages 3 or 4 (estimated glomerular filtration rate (eGFR) between 15 and 59)&lt;br&gt;&lt;br&gt;          -  Diagnosis of secondary hyperparathyroidism, which is defined as:&lt;br&gt;&lt;br&gt;               -  Elevated intact PTH (iPTH) as per KDIGO guidelines:&lt;br&gt;&lt;br&gt;                    -  CKD stage 3 (eGFR 30-59) or CKD stage 4 (eGFR 15-29) with iPTH &gt; Upper&lt;br&gt;                       Limit of Normal for lab (6.8 pmol/L)&lt;br&gt;&lt;br&gt;          -  Presence of Coronary Artery Calcium (CAC &gt; 0)&lt;br&gt;&lt;br&gt;          -  Subject will be able to complete the study, to the best of his/her knowledge&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  iPTH &gt;1500 pg/ml&lt;br&gt;&lt;br&gt;          -  Current or previous use of bisphosphonates&lt;br&gt;&lt;br&gt;          -  History of parathyroidectomy or anticipated parathyroidectomy&lt;br&gt;&lt;br&gt;          -  History of cinacalcet use&lt;br&gt;&lt;br&gt;          -  History of a solid organ transplant or scheduled date for transplant surgery&lt;br&gt;&lt;br&gt;          -  History of coronary revascularization (coronary artery bypass surgery or percutaneous&lt;br&gt;             intervention)&lt;br&gt;&lt;br&gt;          -  History of coronary artifact (e.g. pacemaker, intracardiac defibrillator, artificial&lt;br&gt;             valve or biventricular leads)&lt;br&gt;&lt;br&gt;          -  Active atrial fibrillation&lt;br&gt;&lt;br&gt;          -  Weight greater than 300 pounds (due to limitations of equipment)&lt;br&gt;&lt;br&gt;          -  HIV positive&lt;br&gt;&lt;br&gt;          -  Current pregnancy (although pregnancy is very rare in the CKD population)&lt;br&gt;&lt;br&gt;          -  Life expectancy less than two years as judged by primary physician&lt;br&gt;&lt;br&gt;          -  Institutionalized patients (nursing home or prisoners)&lt;br&gt;&lt;br&gt;          -  Language barrier or mental incapacity to consent&lt;br&gt;&lt;br&gt;          -  Inability to swallow tablets or current gastrointestinal disorder that may be&lt;br&gt;             associated with impaired absorption of orally administered medications.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease;Vitamin D Deficiency;Coronary Calcification;Disorders of Calcium and Bone Metabolism</Condition>
    <Intervention>Drug: Calcitriol (Rocaltrol®);Drug: Paricalcitol</Intervention>
    <Primary_outcome>To determine prospectively if there is a differential effect on coronary artery (CAC) score progression between calcitriol and paricalcitol in patients with chronic kidney disease.</Primary_outcome>
    <Secondary_outcome>To determine prospectively if there is a differential effect on aortic and valvular score progression and arterial stiffness in patients with chronic kidney disease receiving calcitriol and paricalcitol.;To determine prospectively if there is a differential effect on biomarkers of vascular calcification and mineral metabolism in patients with chronic kidney disease receiving calcitriol and paricalcitol.</Secondary_outcome>
    <Secondary_ID>Abbott #20128</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Abbott</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2900356</Internal_Number>
    <TrialID>NCT00752245</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Uremic Toxins in the Intensive Care Unit (ICU): Patients With Sepsis</Public_title>
    <Scientific_title>Study of the Kinetics of Uremic Toxins in the ICU Patients With Acute Renal Failure, in Order to Optimize the Dialysis Dose: Patients With Sepsis/Multi-organ Failure</Scientific_title>
    <Acronym />
    <Primary_sponsor>University Hospital, Ghent</Primary_sponsor>
    <Date_registration3>20080912</Date_registration3>
    <Date_registration>12/09/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00752245</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2008</Date_enrollement>
    <Target_size>12</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Crossover Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  ICU patients with sepsis/multi-organ failure with acute renal failure&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Failure;Multi Organ Failure</Condition>
    <Intervention>Procedure: Dialysis during 4 hours;Procedure: Dialysis during 6 hours;Procedure: Dialysis during 8 hours</Intervention>
    <Primary_outcome>Registration of toxin removal efficiency</Primary_outcome>
    <Secondary_ID>2008/373</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2900372</Internal_Number>
    <TrialID>NCT00752453</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Uremic Toxins in the Intensive Care Units (ICU): Patients With Lactate Acidosis</Public_title>
    <Scientific_title>Study of the Kinetics of Uremic Toxins in the ICU Patients With Acute Renal Failure, in Order to Optimize the Dialysis Dose: Patients With Lactate Acidosis</Scientific_title>
    <Acronym />
    <Primary_sponsor>University Hospital, Ghent</Primary_sponsor>
    <Date_registration3>20080912</Date_registration3>
    <Date_registration>12/09/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00752453</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2008</Date_enrollement>
    <Target_size>12</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Crossover Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Includes ICU patients with lactate acidosis with acute     renal failure&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Renal Failure</Condition>
    <Intervention>Procedure: Dialysis during 4 hours;Procedure: Dialysis during 6 hours;Procedure: Dialysis during 8 hours</Intervention>
    <Primary_outcome>Toxin removal</Primary_outcome>
    <Secondary_ID>2008/375</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2900399</Internal_Number>
    <TrialID>NCT00752804</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Uremic Toxins in the ICU: Patients After Cardiac Surgery</Public_title>
    <Scientific_title>Study of the Kinetics of Uremic Toxins in the ICU Patients With Acute Renal Failure, in Order to Optimize the Dialysis Dose: Patients After Cardiac Surgery</Scientific_title>
    <Acronym />
    <Primary_sponsor>University Hospital, Ghent</Primary_sponsor>
    <Date_registration3>20080912</Date_registration3>
    <Date_registration>12/09/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00752804</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2008</Date_enrollement>
    <Target_size>12</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Crossover Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  ICU patients after cardiac surgery with acute renal failure&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Failure</Condition>
    <Intervention>Procedure: Dialysis during 4 hours;Procedure: Dialysis during 6 hours;Procedure: Dialysis during 8 hours</Intervention>
    <Primary_outcome>Toxin removal</Primary_outcome>
    <Secondary_ID>2008/374</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2900650</Internal_Number>
    <TrialID>NCT00756145</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>The Use of Low Molecular Weight Heparin in Hemodiafiltration</Public_title>
    <Scientific_title>The Use of Low Molecular Weight Heparin in Hemodiafiltration</Scientific_title>
    <Acronym />
    <Primary_sponsor>University Hospital, Ghent</Primary_sponsor>
    <Date_registration3>20080918</Date_registration3>
    <Date_registration>18/09/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00756145</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2008</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Crossover Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  chronic kidney disease stade V treated with hemodiafiltration&lt;br&gt;&lt;br&gt;          -  age &gt;18 year&lt;br&gt;&lt;br&gt;          -  Hematocrit &gt; 30%&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  treatment with vitamin K antagonists&lt;br&gt;&lt;br&gt;          -  treatment with other heparin besides the heparin used during dialysis&lt;br&gt;&lt;br&gt;          -  active bleeding&lt;br&gt;&lt;br&gt;          -  heparin associated allergy&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease</Condition>
    <Intervention>Procedure: At start of the session, at the inlet line;Procedure: 5 minutes after the start of the session, at the inlet line;Procedure: At the start of the session, at the outlet line</Intervention>
    <Primary_outcome>Clearance of uremic toxins, clearance of LMWH, transmembrane pressure, prefilter pressure, pressure in efferent and afferent bloodline, clotting parameters</Primary_outcome>
    <Secondary_outcome>Visual inspection of membrane and circuit</Secondary_outcome>
    <Secondary_ID>2008/421</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2900763</Internal_Number>
    <TrialID>NCT00757614</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom</Public_title>
    <Scientific_title>A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Cancer in East Anglia, Trent and West Midlands</Scientific_title>
    <Acronym />
    <Primary_sponsor>Cancer Research UK</Primary_sponsor>
    <Date_registration3>20080922</Date_registration3>
    <Date_registration>22/09/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00757614</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>69 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>February 2008</Date_enrollement>
    <Target_size>14000</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>N/A</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        DISEASE CHARACTERISTICS:&lt;br&gt;&lt;br&gt;          -  Diagnosed with bladder cancer, kidney cancer, esophageal cancer, pancreatic cancer,&lt;br&gt;             brain cancer, malignant melanoma, or lymphoma within the past 5 years&lt;br&gt;&lt;br&gt;          -  Identified through the Cancer Research Network OR through the cancer registry serving&lt;br&gt;             any of the following geographic regions of the United Kingdom:&lt;br&gt;&lt;br&gt;               -  East Anglia&lt;br&gt;&lt;br&gt;               -  West Midlands&lt;br&gt;&lt;br&gt;               -  Trent&lt;br&gt;&lt;br&gt;        PATIENT CHARACTERISTICS:&lt;br&gt;&lt;br&gt;          -  Identified by the patient's general practitioner as fit to contact for this study&lt;br&gt;&lt;br&gt;          -  No serious mental illness or retardation&lt;br&gt;&lt;br&gt;        PRIOR CONCURRENT THERAPY:&lt;br&gt;&lt;br&gt;          -  Not specified&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Bladder Cancer;Brain and Central Nervous System Tumors;Esophageal Cancer;Intraocular Melanoma;Kidney Cancer;Lymphoma;Melanoma (Skin);Pancreatic Cancer;Transitional Cell Cancer of the Renal Pelvis and Ureter</Condition>
    <Intervention>Genetic: DNA analysis;Genetic: polymorphism analysis;Other: laboratory biomarker analysis;Other: questionnaire administration</Intervention>
    <Primary_outcome>Acquisition of epidemiological information and biological material;Identification of novel cancer susceptibility genes;Estimation of the age and sex-specific risks associated with variants in predisposition genes;Evaluation of  interactions between polymorphisms in predisposition genes and potential lifestyle risk factors</Primary_outcome>
    <Secondary_ID>MREC-SEARCH-CANCER;MREC-07/MRE05/17;CDR0000598879</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2900763</Internal_Number>
    <TrialID>NCT00757614</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom</Public_title>
    <Scientific_title>A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Cancer in East Anglia, Trent and West Midlands</Scientific_title>
    <Acronym />
    <Primary_sponsor>Cancer Research UK</Primary_sponsor>
    <Date_registration3>20080922</Date_registration3>
    <Date_registration>22/09/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00757614</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>69 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>February 2008</Date_enrollement>
    <Target_size>14000</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>N/A</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        DISEASE CHARACTERISTICS:&lt;br&gt;&lt;br&gt;          -  Diagnosed with bladder cancer, kidney cancer, esophageal cancer, pancreatic cancer,&lt;br&gt;             brain cancer, malignant melanoma, or lymphoma within the past 5 years&lt;br&gt;&lt;br&gt;          -  Identified through the Cancer Research Network OR through the cancer registry serving&lt;br&gt;             any of the following geographic regions of the United Kingdom:&lt;br&gt;&lt;br&gt;               -  East Anglia&lt;br&gt;&lt;br&gt;               -  West Midlands&lt;br&gt;&lt;br&gt;               -  Trent&lt;br&gt;&lt;br&gt;        PATIENT CHARACTERISTICS:&lt;br&gt;&lt;br&gt;          -  Identified by the patient's general practitioner as fit to contact for this study&lt;br&gt;&lt;br&gt;          -  No serious mental illness or retardation&lt;br&gt;&lt;br&gt;        PRIOR CONCURRENT THERAPY:&lt;br&gt;&lt;br&gt;          -  Not specified&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Bladder Cancer;Brain and Central Nervous System Tumors;Esophageal Cancer;Intraocular Melanoma;Kidney Cancer;Lymphoma;Melanoma (Skin);Pancreatic Cancer;Transitional Cell Cancer of the Renal Pelvis and Ureter</Condition>
    <Intervention>Genetic: DNA analysis;Genetic: polymorphism analysis;Other: laboratory biomarker analysis;Other: questionnaire administration</Intervention>
    <Primary_outcome>Acquisition of epidemiological information and biological material;Identification of novel cancer susceptibility genes;Estimation of the age and sex-specific risks associated with variants in predisposition genes;Evaluation of  interactions between polymorphisms in predisposition genes and potential lifestyle risk factors</Primary_outcome>
    <Secondary_ID>MREC-SEARCH-CANCER;MREC-07/MRE05/17;CDR0000598879</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2900991</Internal_Number>
    <TrialID>NCT00760591</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Change of Neutrophil Gelatinase-Associated Lipocalin(NGAL) Following Sodium Phosphate Bowel Preparation(Pilot Study)</Public_title>
    <Scientific_title>Change of Neutrophil Gelatinase-Associated Lipocalin(NGAL) Following Sodium Phosphate Bowel Preparation(Pilot Study)</Scientific_title>
    <Acronym />
    <Primary_sponsor>Soon Chun Hyang University</Primary_sponsor>
    <Date_registration3>20080925</Date_registration3>
    <Date_registration>25/09/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00760591</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>65 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2008</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Who takes ACE-inhibitor, ARB&lt;br&gt;&lt;br&gt;          -  Has a renal or heart disease&lt;br&gt;&lt;br&gt;          -  Has a serum electrolyte disturbance&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Kidney Failure</Condition>
    <Primary_outcome>NGAL</Primary_outcome>
    <Secondary_ID>2008-41</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2902274</Internal_Number>
    <TrialID>NCT00777504</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors</Public_title>
    <Scientific_title>Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors</Scientific_title>
    <Acronym />
    <Primary_sponsor>Radboud University</Primary_sponsor>
    <Date_registration3>20081021</Date_registration3>
    <Date_registration>21/10/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00777504</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2008</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  metastatic or advanced solid cancer that is treated with an oral angiogenesis&lt;br&gt;             inhibitor, with clinical indication to stop this therapy based on progressive disease&lt;br&gt;             as defined by the RECIST criteria on the CT scan. It needs a minimum of 1 previous&lt;br&gt;             evaluation of stable disease and the patient must have been treated with angiogenesis&lt;br&gt;             inhibitors for at least 12 weeks.&lt;br&gt;&lt;br&gt;          -  age =18 years&lt;br&gt;&lt;br&gt;          -  given informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  pregnant or lactating&lt;br&gt;&lt;br&gt;          -  metastatic sites solely in bone or liver&lt;br&gt;&lt;br&gt;          -  contraindication for CT or Avastin scan (claustrophobia, severe renal function&lt;br&gt;             disorder, allergy for contrast fluids, allergy for Avastin)&lt;br&gt;&lt;br&gt;          -  insufficient condition to continue treatment with angiogenesis inhibitors.&lt;br&gt;&lt;br&gt;          -  contraindication for dynamic contrast MRI (deteriorated renal functions with&lt;br&gt;             clearance &lt;60ml/min, metal in body, claustrophobia, pacemaker, defibrillator)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Cell Carcinoma;Gastrointestinal Stromal Tumor</Condition>
    <Intervention>Drug: usage oral angiogenesis inhibitor;Drug: stop oral angiogenesis inhibitor</Intervention>
    <Primary_outcome>Signs of progressive disease on CT-scan, DCE-MRI or Avastin scan</Primary_outcome>
    <Secondary_outcome>Effect on Quality of life as record by questionaires</Secondary_outcome>
    <Secondary_ID>UMCNONCO200801</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2902459</Internal_Number>
    <TrialID>NCT00779922</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>Poitiers University Hospital</Primary_sponsor>
    <Date_registration3>20081023</Date_registration3>
    <Date_registration>23/10/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00779922</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2008</Date_enrollement>
    <Target_size>46</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Endpoint Classification:  Pharmacokinetics Study</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Documented diagnosis of relapsed or refractory multiple myeloma (MM).&lt;br&gt;&lt;br&gt;          -  Age &gt; 18 years at the time of signing the informed consent form&lt;br&gt;&lt;br&gt;          -  Stable renal function&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Documented amyloidosis&lt;br&gt;&lt;br&gt;          -  Any prior use of Revlimid ®&lt;br&gt;&lt;br&gt;          -  Any contraindication to Revlimid ® and especially:&lt;br&gt;&lt;br&gt;          -  Lack of acceptable method of birth control for female of childbearing potential&lt;br&gt;             (FCPB)&lt;br&gt;&lt;br&gt;               -  Men who don't agree to use condom during the study and 4 weeks after the last&lt;br&gt;                  study drug intake if their partner is a FCPB.&lt;br&gt;&lt;br&gt;               -  Pregnant or breast feeding women&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Multiple Myeloma;Impaired Renal Function</Condition>
    <Intervention>Drug: lenalidomide</Intervention>
    <Secondary_ID>REVIR</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2902636</Internal_Number>
    <TrialID>NCT00782275</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma</Public_title>
    <Scientific_title>A Phase II Trial of Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma</Scientific_title>
    <Acronym />
    <Primary_sponsor>Beth Israel Deaconess Medical Center</Primary_sponsor>
    <Date_registration3>20081029</Date_registration3>
    <Date_registration>29/10/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00782275</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2009</Date_enrollement>
    <Target_size>46</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Histologically confirmed renal cell carcinoma in either primary or metastatic&lt;br&gt;             lesions.  Non-clear histology will be allowed.&lt;br&gt;&lt;br&gt;          -  Disease progression on a VEGF-targeted tyrosine kinase inhibitor as the most recent&lt;br&gt;             therapy or have experienced intolerable toxicity so as require discontinuation.  Only&lt;br&gt;             one prior VEGF-targeted tyrosine kinase inhibitor.&lt;br&gt;&lt;br&gt;          -  Must be off of VEGF-targeted tyrosine kinase inhibitor for 2 weeks or greater.&lt;br&gt;&lt;br&gt;          -  One measurable lesion which is not curable by standard radiation therapy or surgery.&lt;br&gt;&lt;br&gt;          -  The enrolling site must agree to obtain paraffin-embedded tumor blocks or at least 10&lt;br&gt;             unstained, paraffin-embedded slides for submission for correlative studies.&lt;br&gt;&lt;br&gt;          -  18 years of age or older&lt;br&gt;&lt;br&gt;          -  ECOG Performance Status of 0 or 1&lt;br&gt;&lt;br&gt;          -  Baseline laboratory values as outlined in the protocol&lt;br&gt;&lt;br&gt;          -  Life expectancy of greater than 3 months&lt;br&gt;&lt;br&gt;          -  No prior malignancy diagnosed within the past three years, other than superficial&lt;br&gt;             basal cell and superficial squamous cell, or carcinoma in situ of the cervix.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Known CNS disease, except for treated brain metastases&lt;br&gt;&lt;br&gt;          -  Previously treated with avastin or mTOR inhibitors&lt;br&gt;&lt;br&gt;          -  Other then VEFG-targeted TKI, patients may only have had prior immunotherapy or&lt;br&gt;             chemotherapy for stage IV disease&lt;br&gt;&lt;br&gt;          -  History of allergic reaction to Chinese hamster ovary cell products, other&lt;br&gt;             recombinant antibodies, or compounds of similar chemical or biologic composition to&lt;br&gt;             avastin or temsirolimus&lt;br&gt;&lt;br&gt;          -  History of bleeding diathesis or coagulopathy.  Therapeutic anticoagulants are&lt;br&gt;             allowed&lt;br&gt;&lt;br&gt;          -  Patients with clinically significant cardiovascular disease&lt;br&gt;&lt;br&gt;          -  Patients receiving enzyme-inducing antiepileptic drugs or any other CYP3A4 inducer&lt;br&gt;             such as rifampin or St. John's wort&lt;br&gt;&lt;br&gt;          -  No serious non-healing wound, ulcer or bone fracture&lt;br&gt;&lt;br&gt;          -  No uncontrolled intercurrent illness including , but not limited to, ongoing active&lt;br&gt;             infection requiring parental antibiotics or psychiatric illness/social situations&lt;br&gt;             that would limit compliance with study requirements&lt;br&gt;&lt;br&gt;          -  HIV-positive receiving combination anti-retroviral therapy&lt;br&gt;&lt;br&gt;          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&lt;br&gt;             prior to study enrollment or anticipation of need for major surgical procedure during&lt;br&gt;             the course of the study&lt;br&gt;&lt;br&gt;          -  Core biopsy or other minor surgical procedure, excluding placement of vascular access&lt;br&gt;             device, within 7 days prior to enrollment on study&lt;br&gt;&lt;br&gt;          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal&lt;br&gt;             abscess within 6 months prior to study enrollment&lt;br&gt;&lt;br&gt;          -  Known hypersensitivity to any component of avastin or temsirolimus&lt;br&gt;&lt;br&gt;          -  Life expectancy of less than 12 weeks&lt;br&gt;&lt;br&gt;          -  History of hemoptysis within 1 month prior to day 1&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Cell Carcinoma;Kidney Cancer</Condition>
    <Intervention>Drug: avastin;Drug: temsirolimus</Intervention>
    <Primary_outcome>Estimate the median progression-free survival in patients with metastatic RCC who have progressed on VEGF-targeted tyrosine kinase treated with avastin and temsirolimus</Primary_outcome>
    <Secondary_outcome>Assess the objective response rate for the combination of avastin and temsirolimus following TKI failure;To estimate the median overall survival for patients treated with avastin and temsirolimus following TKI failure</Secondary_outcome>
    <Secondary_ID>08-184</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Genentech;Dana-Farber Cancer Institute;Brigham and Women's Hospital;Vanderbilt University</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2902636</Internal_Number>
    <TrialID>NCT00782275</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma</Public_title>
    <Scientific_title>A Phase II Trial of Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma</Scientific_title>
    <Acronym />
    <Primary_sponsor>Beth Israel Deaconess Medical Center</Primary_sponsor>
    <Date_registration3>20081029</Date_registration3>
    <Date_registration>29/10/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00782275</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2009</Date_enrollement>
    <Target_size>46</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Histologically confirmed renal cell carcinoma in either primary or metastatic&lt;br&gt;             lesions.  Non-clear histology will be allowed.&lt;br&gt;&lt;br&gt;          -  Disease progression on a VEGF-targeted tyrosine kinase inhibitor as the most recent&lt;br&gt;             therapy or have experienced intolerable toxicity so as require discontinuation.  Only&lt;br&gt;             one prior VEGF-targeted tyrosine kinase inhibitor.&lt;br&gt;&lt;br&gt;          -  Must be off of VEGF-targeted tyrosine kinase inhibitor for 2 weeks or greater.&lt;br&gt;&lt;br&gt;          -  One measurable lesion which is not curable by standard radiation therapy or surgery.&lt;br&gt;&lt;br&gt;          -  The enrolling site must agree to obtain paraffin-embedded tumor blocks or at least 10&lt;br&gt;             unstained, paraffin-embedded slides for submission for correlative studies.&lt;br&gt;&lt;br&gt;          -  18 years of age or older&lt;br&gt;&lt;br&gt;          -  ECOG Performance Status of 0 or 1&lt;br&gt;&lt;br&gt;          -  Baseline laboratory values as outlined in the protocol&lt;br&gt;&lt;br&gt;          -  Life expectancy of greater than 3 months&lt;br&gt;&lt;br&gt;          -  No prior malignancy diagnosed within the past three years, other than superficial&lt;br&gt;             basal cell and superficial squamous cell, or carcinoma in situ of the cervix.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Known CNS disease, except for treated brain metastases&lt;br&gt;&lt;br&gt;          -  Previously treated with avastin or mTOR inhibitors&lt;br&gt;&lt;br&gt;          -  Other then VEFG-targeted TKI, patients may only have had prior immunotherapy or&lt;br&gt;             chemotherapy for stage IV disease&lt;br&gt;&lt;br&gt;          -  History of allergic reaction to Chinese hamster ovary cell products, other&lt;br&gt;             recombinant antibodies, or compounds of similar chemical or biologic composition to&lt;br&gt;             avastin or temsirolimus&lt;br&gt;&lt;br&gt;          -  History of bleeding diathesis or coagulopathy.  Therapeutic anticoagulants are&lt;br&gt;             allowed&lt;br&gt;&lt;br&gt;          -  Patients with clinically significant cardiovascular disease&lt;br&gt;&lt;br&gt;          -  Patients receiving enzyme-inducing antiepileptic drugs or any other CYP3A4 inducer&lt;br&gt;             such as rifampin or St. John's wort&lt;br&gt;&lt;br&gt;          -  No serious non-healing wound, ulcer or bone fracture&lt;br&gt;&lt;br&gt;          -  No uncontrolled intercurrent illness including , but not limited to, ongoing active&lt;br&gt;             infection requiring parental antibiotics or psychiatric illness/social situations&lt;br&gt;             that would limit compliance with study requirements&lt;br&gt;&lt;br&gt;          -  HIV-positive receiving combination anti-retroviral therapy&lt;br&gt;&lt;br&gt;          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&lt;br&gt;             prior to study enrollment or anticipation of need for major surgical procedure during&lt;br&gt;             the course of the study&lt;br&gt;&lt;br&gt;          -  Core biopsy or other minor surgical procedure, excluding placement of vascular access&lt;br&gt;             device, within 7 days prior to enrollment on study&lt;br&gt;&lt;br&gt;          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal&lt;br&gt;             abscess within 6 months prior to study enrollment&lt;br&gt;&lt;br&gt;          -  Known hypersensitivity to any component of avastin or temsirolimus&lt;br&gt;&lt;br&gt;          -  Life expectancy of less than 12 weeks&lt;br&gt;&lt;br&gt;          -  History of hemoptysis within 1 month prior to day 1&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Cell Carcinoma;Kidney Cancer</Condition>
    <Intervention>Drug: avastin;Drug: temsirolimus</Intervention>
    <Primary_outcome>Estimate the median progression-free survival in patients with metastatic RCC who have progressed on VEGF-targeted tyrosine kinase treated with avastin and temsirolimus</Primary_outcome>
    <Secondary_outcome>Assess the objective response rate for the combination of avastin and temsirolimus following TKI failure;To estimate the median overall survival for patients treated with avastin and temsirolimus following TKI failure</Secondary_outcome>
    <Secondary_ID>08-184</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Genentech;Dana-Farber Cancer Institute;Brigham and Women's Hospital;Vanderbilt University</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2903348</Internal_Number>
    <TrialID>NCT00791648</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery</Public_title>
    <Scientific_title>Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery</Scientific_title>
    <Acronym />
    <Primary_sponsor>Vanderbilt University</Primary_sponsor>
    <Date_registration3>20081112</Date_registration3>
    <Date_registration>12/11/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00791648</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2009</Date_enrollement>
    <Target_size>820</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Prevention</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  open heart surgery&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  acute coronary syndrome with troponin leak or unrelenting angina&lt;br&gt;&lt;br&gt;          -  liver dysfunction (transaminases 2x normal)&lt;br&gt;&lt;br&gt;          -  history of myopathy or liver dysfunction on prior statin therapy&lt;br&gt;&lt;br&gt;          -  use of potent CYP3A4 inhibitors such as antifungal azoles, macrolide antibiotics, HIV&lt;br&gt;             protease inhibitors, and nefazodone.&lt;br&gt;&lt;br&gt;          -  pregnancy or breast feeding&lt;br&gt;&lt;br&gt;          -  cyclosporine use&lt;br&gt;&lt;br&gt;          -  dialysis&lt;br&gt;&lt;br&gt;          -  history of kidney transplant&lt;br&gt;&lt;br&gt;          -  fibrate users who cannot stop fibrate use.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Kidney Injury;Post-Operative Delirium;Icu Delirium;Acute Renal Failure;Delirium</Condition>
    <Intervention>Drug: atorvastatin;Drug: placebo</Intervention>
    <Primary_outcome>acute kidney injury;delirium</Primary_outcome>
    <Secondary_outcome>dialysis;urine markers of renal injury;plasma markers of inflammation;liver enzymes;stroke;death;plasma and urine markers of oxidative stress (f2-Isoprostanes, isofurans);mitochondrial function</Secondary_outcome>
    <Secondary_ID>081238</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2903348</Internal_Number>
    <TrialID>NCT00791648</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery</Public_title>
    <Scientific_title>Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery</Scientific_title>
    <Acronym />
    <Primary_sponsor>Vanderbilt University</Primary_sponsor>
    <Date_registration3>20081112</Date_registration3>
    <Date_registration>12/11/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00791648</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2009</Date_enrollement>
    <Target_size>820</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Prevention</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  open heart surgery&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  acute coronary syndrome with troponin leak or unrelenting angina&lt;br&gt;&lt;br&gt;          -  liver dysfunction (transaminases 2x normal)&lt;br&gt;&lt;br&gt;          -  history of myopathy or liver dysfunction on prior statin therapy&lt;br&gt;&lt;br&gt;          -  use of potent CYP3A4 inhibitors such as antifungal azoles, macrolide antibiotics, HIV&lt;br&gt;             protease inhibitors, and nefazodone.&lt;br&gt;&lt;br&gt;          -  pregnancy or breast feeding&lt;br&gt;&lt;br&gt;          -  cyclosporine use&lt;br&gt;&lt;br&gt;          -  dialysis&lt;br&gt;&lt;br&gt;          -  history of kidney transplant&lt;br&gt;&lt;br&gt;          -  fibrate users who cannot stop fibrate use.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Kidney Injury;Post-Operative Delirium;Icu Delirium;Acute Renal Failure;Delirium</Condition>
    <Intervention>Drug: atorvastatin;Drug: placebo</Intervention>
    <Primary_outcome>acute kidney injury;delirium</Primary_outcome>
    <Secondary_outcome>dialysis;urine markers of renal injury;plasma markers of inflammation;liver enzymes;stroke;death;plasma and urine markers of oxidative stress (f2-Isoprostanes, isofurans);mitochondrial function</Secondary_outcome>
    <Secondary_ID>081238</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2904041</Internal_Number>
    <TrialID>NCT00800878</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Chronic Kidney Disease in Pakistani Population</Public_title>
    <Scientific_title>Chronic Kidney Disease in the Pakistani Population</Scientific_title>
    <Acronym>CKD</Acronym>
    <Primary_sponsor>Aga Khan University</Primary_sponsor>
    <Date_registration3>20081201</Date_registration3>
    <Date_registration>01/12/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00800878</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>40 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>February 2008</Date_enrollement>
    <Target_size>650</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Time Perspective:  Cross-Sectional</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  All individuals aged 40 years and above&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Shortness of breath on minimal to moderate exertion&lt;br&gt;&lt;br&gt;          -  Acute fibril illness&lt;br&gt;&lt;br&gt;          -  Doctor diagnosed liver disease&lt;br&gt;&lt;br&gt;          -  Doctor diagnosed rheumatological disease&lt;br&gt;&lt;br&gt;          -  Heart attack within past three months&lt;br&gt;&lt;br&gt;          -  Pregnancy&lt;br&gt;&lt;br&gt;          -  Mentally incompetent to give informed consent&lt;br&gt;&lt;br&gt;          -  Too frail to travel to clinic&lt;br&gt;&lt;br&gt;          -  Bed ridden subjects&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease</Condition>
    <Primary_outcome>GFR will be measured as the mean of at least two urinary clearance periods of Inulin</Primary_outcome>
    <Secondary_ID>R03TW007588</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>National Institutes of Health (NIH)</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2904071</Internal_Number>
    <TrialID>NCT00801268</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease</Public_title>
    <Scientific_title>Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease (ADPKD)</Scientific_title>
    <Acronym />
    <Primary_sponsor>Zhi-Hong Liu, M.D.</Primary_sponsor>
    <Date_registration3>20081125</Date_registration3>
    <Date_registration>25/11/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00801268</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>15 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2008</Date_enrollement>
    <Target_size>150</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Factorial Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Clinically established ADPKD&lt;br&gt;&lt;br&gt;          -  eGFR&gt;30ml/min.&lt;br&gt;&lt;br&gt;          -  Chinese nationality&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Uncontrolled infections&lt;br&gt;&lt;br&gt;          -  Non-ADPKD complications&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Polycystic Kidney</Condition>
    <Intervention>Drug: tripterygium wilfordii;Drug: Emodin</Intervention>
    <Primary_outcome>MRI calculated kidney volume, eGFR</Primary_outcome>
    <Secondary_outcome>End-stage kidney disease (ESRD)</Secondary_outcome>
    <Secondary_ID>NJCT-0802</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2904483</Internal_Number>
    <TrialID>NCT00806676</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease</Public_title>
    <Scientific_title>Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease</Scientific_title>
    <Acronym />
    <Primary_sponsor>Johns Hopkins University</Primary_sponsor>
    <Date_registration3>20081209</Date_registration3>
    <Date_registration>09/12/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00806676</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>9 Years</Inclusion_agemin>
    <Inclusion_agemax>21 Years</Inclusion_agemax>
    <Inclusion_gender>Female</Inclusion_gender>
    <Date_enrollement>December 2008</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Intervention Model:  Single Group Assignment, Masking:  Open Label</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        Females, aged 9-21 years, in the following groups:&lt;br&gt;&lt;br&gt;          -  CKD (defined as estimated glomerular filtration rate between 90 ml/min/1.73m2 and 15&lt;br&gt;             ml/min/1.73m2, as calculated by the Schwartz formula)&lt;br&gt;&lt;br&gt;          -  ESRD (eGFR &lt; 15 ml/min/1.73m2, or receiving chronic dialysis [peritoneal or&lt;br&gt;             hemodialysis])&lt;br&gt;&lt;br&gt;          -  Status-post kidney transplant&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Within first 3 months post kidney transplant&lt;br&gt;&lt;br&gt;          -  Within 3 months of kidney rejection episode&lt;br&gt;&lt;br&gt;          -  Hypersensitivity to active substances or excipients of Gardasil vaccine&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease</Condition>
    <Intervention>Drug: Gardasil® Vaccine (FDA-approved vaccination regimen)</Intervention>
    <Primary_outcome>Geometric mean antibody titers to HPV 6, 11, 16 and 18.</Primary_outcome>
    <Secondary_ID>MERCK_33610</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Merck</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2904634</Internal_Number>
    <TrialID>NCT00808691</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>National Taiwan University Hospital</Primary_sponsor>
    <Date_registration3>20081215</Date_registration3>
    <Date_registration>15/12/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00808691</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2007</Date_enrollement>
    <Target_size>280</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  &gt; 18 y/o&lt;br&gt;&lt;br&gt;          -  Related diagnosis made within 24h&lt;br&gt;&lt;br&gt;          -  Group 1 - Sepsis&lt;br&gt;&lt;br&gt;          -  Group 2 - Postoperative care&lt;br&gt;&lt;br&gt;          -  Group 3 - ARDS&lt;br&gt;&lt;br&gt;          -  Group 4 - Renal failure&lt;br&gt;&lt;br&gt;          -  Group 5 - Liver failure&lt;br&gt;&lt;br&gt;          -  Group 6 - Brain death&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Pregnant patients&lt;br&gt;&lt;br&gt;          -  Related diagnosis made longer than 24h&lt;br&gt;&lt;br&gt;          -  Patients who have received antioxidants within 24h&lt;br&gt;&lt;br&gt;          -  Patients who have received hyperbaric oxygen therapy&lt;br&gt;&lt;br&gt;          -  Patients who have a hemoglobin value less than 9 g/dl&lt;br&gt;&lt;br&gt;          -  Patients who have received NO&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Sepsis;Postoperative Care;ARDS;Liver Failure;Renal Failure;Brain Death</Condition>
    <Intervention>Other: Critical care</Intervention>
    <Primary_outcome>Mortality Severity of Organ Failure</Primary_outcome>
    <Secondary_ID>200707012</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2906058</Internal_Number>
    <TrialID>NCT00827359</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma</Public_title>
    <Scientific_title>A Phase II Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma</Scientific_title>
    <Acronym />
    <Primary_sponsor>Beth Israel Deaconess Medical Center</Primary_sponsor>
    <Date_registration3>20090121</Date_registration3>
    <Date_registration>21/01/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00827359</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2009</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients must have at least one site of disease which in the opinion of the&lt;br&gt;             investigator is safely accessible by CT guided biopsy or metastasectomy.  Safely&lt;br&gt;             accessible metastatic disease will be defined to include those lesions which are&lt;br&gt;             palpable with no overlying viscera and are at least 2cm in size.  Given the paucity&lt;br&gt;             of subcutaneous lesions in RCC, lesions which are felt to be safe to biopsy will also&lt;br&gt;             be allowed.  These lesions include pleural-based tumors, peripheral liver lesions,&lt;br&gt;             kidney lesions and bone lesions with exophytic soft tissue component.  As with&lt;br&gt;             palpable lesions, these other lesions should be at least 2cm in size with no&lt;br&gt;             overlying viscera.&lt;br&gt;&lt;br&gt;          -  At least one measurable site of disease, other than the biopsy site, according to&lt;br&gt;             RECIST criterial that has not been previously irradiated.  Th the patient has had&lt;br&gt;             previous radiation to the marker lesion(s), there must be evidence of progression&lt;br&gt;             since the radiation&lt;br&gt;&lt;br&gt;          -  Metastatic renal carcinoma with histologic confirmation by the treating center of&lt;br&gt;             either primary or a metastatic lesion.  Non-clear cell histologies will be allowed&lt;br&gt;&lt;br&gt;          -  18 years of age or older&lt;br&gt;&lt;br&gt;          -  Minimum of four weeks since any major surgery, completion of radiation, or completion&lt;br&gt;             of all prior systemic anticancer therapy (adequately recovered from the acute&lt;br&gt;             toxicities of any prior therapy)&lt;br&gt;&lt;br&gt;          -  ECOG Performance status of 1 or less&lt;br&gt;&lt;br&gt;          -  Adequate bone marrow, liver and renal function as outlined in the protocol&lt;br&gt;&lt;br&gt;          -  Fasting serum cholesterol &lt; 300mg/dL OR &lt; 7.75 mmol/L AND fasting triglycerides &lt; 2.5&lt;br&gt;             x ULN&lt;br&gt;&lt;br&gt;          -  Life expectancy of greater than 6 months&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Prior treatment with any investigation drug within the preceding 4 weeks&lt;br&gt;&lt;br&gt;          -  Chronic treatment with systemic steroids or another immunosuppressive agent&lt;br&gt;&lt;br&gt;          -  Patients should not receive immunization with attenuated live vaccines within one&lt;br&gt;             week of study entry or during study period&lt;br&gt;&lt;br&gt;          -  Uncontrolled brain or leptomeningeal metastases, including patients who continue to&lt;br&gt;             require glucocorticoids for brain or leptomeningeal metastases.  Treated brain&lt;br&gt;             metastases will be allowed. Treated brain metastases are defined as having no&lt;br&gt;             evidence of progression or hemorrhage after treatment and no ongoing requirement for&lt;br&gt;             dexamethasone, as ascertained by clinical examination and brain imaging (MRI or CT)&lt;br&gt;             during the screening period.  Anticonvulsants (stable dose) are allowed.  Treatment&lt;br&gt;             for brain metastases may include whole brain radiotherapy (WBRT), radiosurgery (RS:&lt;br&gt;             Gamma Knife, LINAC or equivalent) or a combination as deemed appropriate by the&lt;br&gt;             treating physician.  Patients with CNS metastases treated by neurosurgical resection&lt;br&gt;             performed within 3 months prio to day 1 will be excluded.&lt;br&gt;&lt;br&gt;          -  Other malignancies within the past 3 years except for adequately treated carcinoma of&lt;br&gt;             the cervix or basal or squamous cell carcinomas of the skin&lt;br&gt;&lt;br&gt;          -  Patients who have any severe and/or uncontrolled medical conditions or other&lt;br&gt;             conditions that could affect their participation in the study&lt;br&gt;&lt;br&gt;          -  Uncontrolled diabetes mellitus as defined by a fasting serum &gt; 1.5 x ULN&lt;br&gt;&lt;br&gt;          -  A known history of HIV seropositivity.&lt;br&gt;&lt;br&gt;          -  Impairment of gastrointestinal function or gastrointestinal disease that may&lt;br&gt;             significantly alter the absorption of everolimus&lt;br&gt;&lt;br&gt;          -  Patients with active, bleeding diathesis or on systemic anticoagulation.  Aspirin is&lt;br&gt;             permitted.&lt;br&gt;&lt;br&gt;          -  Women who are pregnant or breast feeding, or women/men able to conceive and unwilling&lt;br&gt;             to practice an effective method of birth control.&lt;br&gt;&lt;br&gt;          -  Patients who have received prior treatment with an mTOR inhibitor.&lt;br&gt;&lt;br&gt;          -  Patients with known hypersensitivity to everolimus or other rapamycins or to its&lt;br&gt;             excipients.&lt;br&gt;&lt;br&gt;          -  History of noncompliance to medical regimens&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Cell Carcinoma;Renal Cancer</Condition>
    <Intervention>Drug: Everolimus</Intervention>
    <Primary_outcome>To prospectively validate the expression of phospho-Akt and phospho-S6 as predictive biomarkers of responsiveness to everolimus.</Primary_outcome>
    <Secondary_outcome>To estimate the progression-free survival in patients with advanced RCC treated with everolimus.;To determine the objective response rate to everolimus in patients with advanced RCC.;To assess in an exploratory fashion the predictive value of PML, phospho-TSC (S664), phospho-PRAS40, eIF4E, and FOXO expression with respect to response to everolimus.</Secondary_outcome>
    <Secondary_ID>08-313</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Dana-Farber Cancer Institute;Duke University;Novartis</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2906058</Internal_Number>
    <TrialID>NCT00827359</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma</Public_title>
    <Scientific_title>A Phase II Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma</Scientific_title>
    <Acronym />
    <Primary_sponsor>Beth Israel Deaconess Medical Center</Primary_sponsor>
    <Date_registration3>20090121</Date_registration3>
    <Date_registration>21/01/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00827359</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2009</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients must have at least one site of disease which in the opinion of the&lt;br&gt;             investigator is safely accessible by CT guided biopsy or metastasectomy.  Safely&lt;br&gt;             accessible metastatic disease will be defined to include those lesions which are&lt;br&gt;             palpable with no overlying viscera and are at least 2cm in size.  Given the paucity&lt;br&gt;             of subcutaneous lesions in RCC, lesions which are felt to be safe to biopsy will also&lt;br&gt;             be allowed.  These lesions include pleural-based tumors, peripheral liver lesions,&lt;br&gt;             kidney lesions and bone lesions with exophytic soft tissue component.  As with&lt;br&gt;             palpable lesions, these other lesions should be at least 2cm in size with no&lt;br&gt;             overlying viscera.&lt;br&gt;&lt;br&gt;          -  At least one measurable site of disease, other than the biopsy site, according to&lt;br&gt;             RECIST criterial that has not been previously irradiated.  Th the patient has had&lt;br&gt;             previous radiation to the marker lesion(s), there must be evidence of progression&lt;br&gt;             since the radiation&lt;br&gt;&lt;br&gt;          -  Metastatic renal carcinoma with histologic confirmation by the treating center of&lt;br&gt;             either primary or a metastatic lesion.  Non-clear cell histologies will be allowed&lt;br&gt;&lt;br&gt;          -  18 years of age or older&lt;br&gt;&lt;br&gt;          -  Minimum of four weeks since any major surgery, completion of radiation, or completion&lt;br&gt;             of all prior systemic anticancer therapy (adequately recovered from the acute&lt;br&gt;             toxicities of any prior therapy)&lt;br&gt;&lt;br&gt;          -  ECOG Performance status of 1 or less&lt;br&gt;&lt;br&gt;          -  Adequate bone marrow, liver and renal function as outlined in the protocol&lt;br&gt;&lt;br&gt;          -  Fasting serum cholesterol &lt; 300mg/dL OR &lt; 7.75 mmol/L AND fasting triglycerides &lt; 2.5&lt;br&gt;             x ULN&lt;br&gt;&lt;br&gt;          -  Life expectancy of greater than 6 months&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Prior treatment with any investigation drug within the preceding 4 weeks&lt;br&gt;&lt;br&gt;          -  Chronic treatment with systemic steroids or another immunosuppressive agent&lt;br&gt;&lt;br&gt;          -  Patients should not receive immunization with attenuated live vaccines within one&lt;br&gt;             week of study entry or during study period&lt;br&gt;&lt;br&gt;          -  Uncontrolled brain or leptomeningeal metastases, including patients who continue to&lt;br&gt;             require glucocorticoids for brain or leptomeningeal metastases.  Treated brain&lt;br&gt;             metastases will be allowed. Treated brain metastases are defined as having no&lt;br&gt;             evidence of progression or hemorrhage after treatment and no ongoing requirement for&lt;br&gt;             dexamethasone, as ascertained by clinical examination and brain imaging (MRI or CT)&lt;br&gt;             during the screening period.  Anticonvulsants (stable dose) are allowed.  Treatment&lt;br&gt;             for brain metastases may include whole brain radiotherapy (WBRT), radiosurgery (RS:&lt;br&gt;             Gamma Knife, LINAC or equivalent) or a combination as deemed appropriate by the&lt;br&gt;             treating physician.  Patients with CNS metastases treated by neurosurgical resection&lt;br&gt;             performed within 3 months prio to day 1 will be excluded.&lt;br&gt;&lt;br&gt;          -  Other malignancies within the past 3 years except for adequately treated carcinoma of&lt;br&gt;             the cervix or basal or squamous cell carcinomas of the skin&lt;br&gt;&lt;br&gt;          -  Patients who have any severe and/or uncontrolled medical conditions or other&lt;br&gt;             conditions that could affect their participation in the study&lt;br&gt;&lt;br&gt;          -  Uncontrolled diabetes mellitus as defined by a fasting serum &gt; 1.5 x ULN&lt;br&gt;&lt;br&gt;          -  A known history of HIV seropositivity.&lt;br&gt;&lt;br&gt;          -  Impairment of gastrointestinal function or gastrointestinal disease that may&lt;br&gt;             significantly alter the absorption of everolimus&lt;br&gt;&lt;br&gt;          -  Patients with active, bleeding diathesis or on systemic anticoagulation.  Aspirin is&lt;br&gt;             permitted.&lt;br&gt;&lt;br&gt;          -  Women who are pregnant or breast feeding, or women/men able to conceive and unwilling&lt;br&gt;             to practice an effective method of birth control.&lt;br&gt;&lt;br&gt;          -  Patients who have received prior treatment with an mTOR inhibitor.&lt;br&gt;&lt;br&gt;          -  Patients with known hypersensitivity to everolimus or other rapamycins or to its&lt;br&gt;             excipients.&lt;br&gt;&lt;br&gt;          -  History of noncompliance to medical regimens&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Cell Carcinoma;Renal Cancer</Condition>
    <Intervention>Drug: Everolimus</Intervention>
    <Primary_outcome>To prospectively validate the expression of phospho-Akt and phospho-S6 as predictive biomarkers of responsiveness to everolimus.</Primary_outcome>
    <Secondary_outcome>To estimate the progression-free survival in patients with advanced RCC treated with everolimus.;To determine the objective response rate to everolimus in patients with advanced RCC.;To assess in an exploratory fashion the predictive value of PML, phospho-TSC (S664), phospho-PRAS40, eIF4E, and FOXO expression with respect to response to everolimus.</Secondary_outcome>
    <Secondary_ID>08-313</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Dana-Farber Cancer Institute;Duke University;Novartis</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2906588</Internal_Number>
    <TrialID>NCT00834301</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>An Open Label Trial to Evaluate the Effects of a Novel Renal Multivitamin on Inflammation and Other Biomarkers in Endstage Renal Disease Patients</Public_title>
    <Scientific_title>An Open Label Trial to Evaluate the Effects of a Novel Renal Multivitamin on Inflammation and Other Biomarkers in Endstage Renal Disease Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>Nephrian</Primary_sponsor>
    <Date_registration3>20090202</Date_registration3>
    <Date_registration>02/02/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00834301</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2009</Date_enrollement>
    <Target_size>25</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  End stage renal disease patients on dialysis for at least 90 days deemed to be at low&lt;br&gt;             risk by the investigator for being hospitalized or have concurrent infections&lt;br&gt;&lt;br&gt;          -  Serum phosphorous level &gt; 5 mg/dl&lt;br&gt;&lt;br&gt;          -  Stable phosphate binder regimen for 2 week prior to enrollment&lt;br&gt;&lt;br&gt;          -  Stable dose of Vitamin D for 4 weeks prior to enrollment&lt;br&gt;&lt;br&gt;          -  Stable calcimimetic dose for 4 week prior to enrollment&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  patients who are pregnant&lt;br&gt;&lt;br&gt;          -  patients who have pre existing thrombocytopenia defined as a platelet count of &lt;100 x&lt;br&gt;             109/L&lt;br&gt;&lt;br&gt;          -  abnormal LFTs&lt;br&gt;&lt;br&gt;          -  baseline CRP &gt; 15 g/dl&lt;br&gt;&lt;br&gt;          -  known sensitivity to any of the active ingredients&lt;br&gt;&lt;br&gt;          -  patients who are currently enrolled in a clinical trial, or who have been in a&lt;br&gt;             clinical trial in the last six months&lt;br&gt;&lt;br&gt;          -  are currently taking any immunosuppressive medications&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Hyperphosphatemia;Inflammation;Renal Disease</Condition>
    <Intervention>Dietary Supplement: Oral Multivitamin</Intervention>
    <Primary_outcome>To assess the efficacy and safety of a novel renal multivitamin on markers of bone and mineral metabolism in an ESRD population.</Primary_outcome>
    <Secondary_outcome>To assess the efficacy and safety of a novel renal multivitamin on markers of inflammation in an ESRD population</Secondary_outcome>
    <Secondary_ID>N0801</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2906761</Internal_Number>
    <TrialID>NCT00836563</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Vascular Changes Following Forearm Loop Arteriovenous Graft Placement</Public_title>
    <Scientific_title>The Natural History of Upper Arm Vessels Following Forearm Loop Arteriovenous</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Nebraska</Primary_sponsor>
    <Date_registration3>20090203</Date_registration3>
    <Date_registration>03/02/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00836563</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>19 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2009</Date_enrollement>
    <Target_size>12</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case-Only, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Age greater than or equal to 19 years&lt;br&gt;&lt;br&gt;          2. Planned forearm loop arteriovenous graft placement for hemodialysis or forearm loop&lt;br&gt;             arteriovenous graft placed within the previous 7 days.&lt;br&gt;&lt;br&gt;          3. Cephalic and/or basilic vein diameter greater than or equal to 2.5 mm at the&lt;br&gt;             antecubital fossa to the axilla prior to AVG placement&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Age less than 19 years&lt;br&gt;&lt;br&gt;          2. Hemodialysis access other than forearm loop graft surgery placement&lt;br&gt;&lt;br&gt;          3. Cephalic and/or basilic vein diameter less than 2.5 mm at any point from the&lt;br&gt;             antecubital fossa to the axilla&lt;br&gt;&lt;br&gt;          4. Prior hemodialysis access surgery in the arm receiving the forearm loop graft&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease</Condition>
    <Primary_outcome>50% increase in upper arm vein diameter</Primary_outcome>
    <Secondary_ID>444-08-FB</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2906784</Internal_Number>
    <TrialID>NCT00836862</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Arteriovenous Fistula Tissue Bank</Public_title>
    <Scientific_title>Arteriovenous Fistula Tissue Bank</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Nebraska</Primary_sponsor>
    <Date_registration3>20090203</Date_registration3>
    <Date_registration>03/02/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00836862</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>19 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>February 2009</Date_enrollement>
    <Target_size>50</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age 19 years of age or greater&lt;br&gt;&lt;br&gt;          -  Arteriovenous fistula placement for hemodialysis access scheduled within 30  days&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Incompetent to provide informed consent&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Failure, Chronic</Condition>
    <Intervention>Other: Biologic specimens</Intervention>
    <Secondary_ID>482-08-EP</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2907274</Internal_Number>
    <TrialID>NCT00843349</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)</Public_title>
    <Scientific_title>Fibroblast Growth Factor-23 Reduction in Predialysis Chronic Kidney Disease</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Miami</Primary_sponsor>
    <Date_registration3>20090212</Date_registration3>
    <Date_registration>12/02/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00843349</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>February 2009</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Factorial Assignment, Masking:  Single Blind (Subject), Primary Purpose:  Prevention</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  We will include stage 3a, 3b and 4 CKD patients, aged 18 years or over with normal&lt;br&gt;             serum phosphate levels (= 4.6 mg/dl)&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with rapidly advancing renal failure who thus might develop&lt;br&gt;             hyperphosphatemia or end stage renal disease requiring initiation of dialysis during&lt;br&gt;             the study period&lt;br&gt;&lt;br&gt;          -  Patients expected to require dialysis initiation within the follow up period&lt;br&gt;&lt;br&gt;          -  Patients with hyperphosphatemia &gt; 4.6 mg/dl&lt;br&gt;&lt;br&gt;          -  Patients with any previous or current treatment with phosphate binders or active&lt;br&gt;             vitamin D (doxercalciferol or calcitriol)&lt;br&gt;&lt;br&gt;          -  Malnutrition, defined as a serum albumin &lt; 3.0 mg/dl&lt;br&gt;&lt;br&gt;          -  Patients with liver disease (ALT or AST &gt; 100 U/L) or cholestasis (direct bilirubin &gt;&lt;br&gt;             1.0 mg/dl) because this can limit their ability to absorb fat soluble vitamins such&lt;br&gt;             as vitamin D&lt;br&gt;&lt;br&gt;          -  Anemia, defined as a hematocrit &lt; 27% at the screening visit&lt;br&gt;&lt;br&gt;          -  Medical conditions impacting Pi metabolism—primary hyper- or hypoparathyroidism;&lt;br&gt;             Patients with previous subtotal parathyroidectomy; gastrointestinal malabsorption&lt;br&gt;             disorders such as Crohn's Disease, ulcerative colitis, celiac disease, or severe&lt;br&gt;             liver dysfunction;&lt;br&gt;&lt;br&gt;          -  Patients with outpatient counseling by a renal nutritionist within the previous 6&lt;br&gt;             months&lt;br&gt;&lt;br&gt;          -  Hospitalization within the previous 4 weeks&lt;br&gt;&lt;br&gt;          -  Pregnancy or breastfeeding mothers&lt;br&gt;&lt;br&gt;          -  Patients unable to independently provide written informed consent - prisoners,&lt;br&gt;             mentally incompetent, minors&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Disease</Condition>
    <Intervention>Drug: Lanthanum Carbonate;Other: Reduced Phosphorus Diet;Drug: Placebo</Intervention>
    <Primary_outcome>FGF-23;calcitriol;PTH</Primary_outcome>
    <Secondary_ID>20080536</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>National Institutes of Health (NIH)</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2907532</Internal_Number>
    <TrialID>NCT00846729</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Comparative Renal Function of Young (18-45 Years) and Ageing (55 Years and Above) Kidney Donors</Public_title>
    <Scientific_title>Preserving Renal Longevity in Living Kidney Donors</Scientific_title>
    <Acronym />
    <Primary_sponsor>Stanford University</Primary_sponsor>
    <Date_registration3>20090217</Date_registration3>
    <Date_registration>17/02/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00846729</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2003</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:1. Patients who are over the age of 18. 2. Patients who are undergoing&lt;br&gt;        surgical uninephrectomy for the purpose of living donation for transplantation 3. Adults&lt;br&gt;        who had a single kidney removed for transplant donation  10-20 years ago.&lt;br&gt;&lt;br&gt;        4. All Patients enrolled in this study must be between the ages of 18 and 45 years or 55&lt;br&gt;        years or older.&lt;br&gt;&lt;br&gt;        5.  Patients undergoing surgery for kidney donation who exhibit mild hypertension&lt;br&gt;        controlled with one medication.  Any age accepted&lt;br&gt;&lt;br&gt;        Exclusion Criteria:1. Patients under the age of 18. 2. Patients between the ages of 46 and&lt;br&gt;        54 3. Patients who are allergic to Inulin, Iothalamate, or PAH. 4. Women who are pregnant.&lt;br&gt;        5.  Other "Vulnerable Subjects"&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Diseases</Condition>
    <Intervention>Procedure: CT angiogram of the remaining kidney.;Procedure: Kidney Function study using Iothalamate &amp; PAH as clearance markers</Intervention>
    <Primary_outcome>Diminished adaptive response to living kidney donation in ageing donors as compared to living donors.</Primary_outcome>
    <Secondary_outcome>Renal Failure &amp; new onset, or worsening, of hypertension in living kidney donors</Secondary_outcome>
    <Secondary_ID>IRB eProtocol #13584;SPO 45339;SU-02092009-1778</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2907574</Internal_Number>
    <TrialID>NCT00847275</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Behaviour and Cognitive Evaluation for Dialysis Elderly Patients (BCDE)</Public_title>
    <Scientific_title>Behaviour and Cognitive Evaluation for Dialysis Elderly Patients</Scientific_title>
    <Acronym>BCDE</Acronym>
    <Primary_sponsor>Nantes University Hospital</Primary_sponsor>
    <Date_registration3>20090217</Date_registration3>
    <Date_registration>17/02/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00847275</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>75 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2008</Date_enrollement>
    <Target_size>500</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients aged of 75 years old or more,&lt;br&gt;&lt;br&gt;          -  Chronic kidney disease stage 5 defined by :&lt;br&gt;&lt;br&gt;          -  either an estimated GFR (MDRD) = 15ml/mn/1,73 m² in a non-dialysis patient whatever&lt;br&gt;             the duration of previous monitoring by the nephrologist("Pre-dialysis cohort"),&lt;br&gt;&lt;br&gt;          -  or a dialysis treatment started for more than 3 months and less than one year,&lt;br&gt;             whatever the duration of pre-dialysis follow-up by the nephrologist("post-dialysis&lt;br&gt;             cohort"),&lt;br&gt;&lt;br&gt;          -  Signed and dated informed consent.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Moderately severe to severe dementia (MMS = 15),&lt;br&gt;&lt;br&gt;          -  Major depression and/or GDS-15 &gt; 10/15,&lt;br&gt;&lt;br&gt;          -  Severe dependency (ADL &lt; 3/6),&lt;br&gt;&lt;br&gt;          -  Psychosis, mutism or aphasia,&lt;br&gt;&lt;br&gt;          -  Malignancy or any pathology with life expectancy &lt; one year,&lt;br&gt;&lt;br&gt;          -  Ongoing specialized geriatric care&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Insufficiency</Condition>
    <Intervention>Other: Exclusive nephrology follow-up;Other: Geriatric follow-up</Intervention>
    <Primary_outcome>First outcome reached among: - death, - occurrence of a severe dementia (MMS &lt; 10),- major depression detected by GDS-15 &gt; 10/15 and confirmed by  DSM-IV criteria,- severe dependency (ADL &lt; 3/6).</Primary_outcome>
    <Secondary_outcome>Secondary outcomes are: - cognitive, psychic and autonomy scores,- cardiovascular morbidity and mortality,- biological follow-up of chronic kidney disease including haemoglobin level.</Secondary_outcome>
    <Secondary_ID>06/12-K</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2908018</Internal_Number>
    <TrialID>NCT00853125</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer</Public_title>
    <Scientific_title>Phase II Study of Sunitinib Plus Extended Courses of Irradiated Allogeneic Lymphocytes for Patients With Renal Cell Carcinoma (SPECIAL Trial)</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Medicine and Dentistry New Jersey</Primary_sponsor>
    <Date_registration3>20090227</Date_registration3>
    <Date_registration>27/02/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00853125</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>February 2009</Date_enrollement>
    <Target_size>35</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Endpoint Classification:  Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        DISEASE CHARACTERISTICS:&lt;br&gt;&lt;br&gt;          -  Histologically confirmed renal cell carcinoma&lt;br&gt;&lt;br&gt;               -  Primary lesion or metastatic site demonstrating clear cell variant with &lt; 25% of&lt;br&gt;                  any other histology&lt;br&gt;&lt;br&gt;          -  Radiographically measurable disease by RECIST criteria&lt;br&gt;&lt;br&gt;          -  Initiated treatment with sunitinib malate = 6 weeks ago&lt;br&gt;&lt;br&gt;          -  No radiographically detectable brain metastases by MRI or CT scan&lt;br&gt;&lt;br&gt;          -  HLA-partially matched related donor available, as determined by serologic and/or DNA&lt;br&gt;             typing&lt;br&gt;&lt;br&gt;               -  Appropriate HLA match (= 2/6 HLA A, B, DR match)&lt;br&gt;&lt;br&gt;        PATIENT CHARACTERISTICS:&lt;br&gt;&lt;br&gt;          -  ECOG performance status 0-1&lt;br&gt;&lt;br&gt;          -  Absolute neutrophil count &gt; 1,500/mm³&lt;br&gt;&lt;br&gt;          -  Platelet count &gt; 100,000/mm³&lt;br&gt;&lt;br&gt;          -  Total bilirubin = 2.0 times upper limit of normal (ULN)&lt;br&gt;&lt;br&gt;          -  AST = 3.0 times ULN&lt;br&gt;&lt;br&gt;          -  Calculated creatinine clearance = 40 mL/min&lt;br&gt;&lt;br&gt;          -  Cardiac ejection fraction = 50%&lt;br&gt;&lt;br&gt;          -  QTc interval &lt; 500 msec by EKG&lt;br&gt;&lt;br&gt;          -  Not pregnant&lt;br&gt;&lt;br&gt;          -  Negative pregnancy test&lt;br&gt;&lt;br&gt;          -  Fertile patients must use effective contraception&lt;br&gt;&lt;br&gt;          -  No known HIV positivity&lt;br&gt;&lt;br&gt;          -  None of the following within the past 6 months:&lt;br&gt;&lt;br&gt;               -  Myocardial infarction&lt;br&gt;&lt;br&gt;               -  Severe/unstable angina&lt;br&gt;&lt;br&gt;               -  Coronary/peripheral artery bypass graft&lt;br&gt;&lt;br&gt;               -  Symptomatic congestive heart failure&lt;br&gt;&lt;br&gt;               -  Cerebrovascular accident or transient ischemic attack&lt;br&gt;&lt;br&gt;               -  Pulmonary embolism&lt;br&gt;&lt;br&gt;          -  No ongoing ventricular cardiac dysrhythmias = grade 2, according to NCI CTCAE v3.0&lt;br&gt;&lt;br&gt;          -  No history of serious ventricular arrhythmia (e.g., ventricular tachycardia &gt; 3 beats&lt;br&gt;             in a row)&lt;br&gt;&lt;br&gt;          -  No ongoing atrial fibrillation&lt;br&gt;&lt;br&gt;          -  No other malignancies within the past 3 years, other than basal cell skin cancer,&lt;br&gt;             squamous cell skin cancer, in situ cervical cancer, or ductal or lobular carcinoma in&lt;br&gt;             situ of the breast&lt;br&gt;&lt;br&gt;          -  No other concurrent serious illness&lt;br&gt;&lt;br&gt;        PRIOR CONCURRENT THERAPY:&lt;br&gt;&lt;br&gt;          -  See Disease Characteristics&lt;br&gt;&lt;br&gt;          -  No prior systemic therapy for metastatic renal cell carcinoma&lt;br&gt;&lt;br&gt;          -  No prior immunotherapy&lt;br&gt;&lt;br&gt;          -  No prior VEGF-targeted or mTOR-targeted therapies&lt;br&gt;&lt;br&gt;          -  No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin,&lt;br&gt;             carbamazepine, or phenobarbital), St. John's wort, ketoconazole, dexamethasone,&lt;br&gt;             dysrhythmic drugs (e.g., terfenadine, quinidine, procainamide, sotalol, probucol,&lt;br&gt;             bepridil, indapamide, or flecainide), haloperidol, risperidone, rifampin, grapefruit,&lt;br&gt;             or grapefruit juice&lt;br&gt;&lt;br&gt;          -  No other concurrent investigational anticancer agents&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Cancer</Condition>
    <Intervention>Biological: therapeutic allogeneic lymphocytes;Drug: sunitinib malate</Intervention>
    <Primary_outcome>Progression-free survival</Primary_outcome>
    <Secondary_outcome>Rates and kinetics of clinical/radiographic response;Toxicity as assessed by NCI CTCAE v3.0;Stable disease at 6 months;Overall survival</Secondary_outcome>
    <Secondary_ID>P30CA072720;CDR0000635763;080708</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>National Cancer Institute (NCI)</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2908086</Internal_Number>
    <TrialID>NCT00854022</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Genetic Susceptibility to Kidney Cancer</Public_title>
    <Scientific_title>Genetic Susceptibility to Renal Cell Carcinoma</Scientific_title>
    <Acronym />
    <Primary_sponsor>Baylor College of Medicine</Primary_sponsor>
    <Date_registration3>20090226</Date_registration3>
    <Date_registration>26/02/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00854022</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2008</Date_enrollement>
    <Target_size>1600</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Adult patients of any ethnicity or sex, who have a been diagnosed with possible Renal&lt;br&gt;             Cell Carcinoma within the past year.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Must not have received chemotherapy, biological therapy or radiation therapy in the 6&lt;br&gt;             months preceding enrollment will&lt;br&gt;&lt;br&gt;          -  Must not have had RCC, or metastatic RCC,&lt;br&gt;&lt;br&gt;          -  Must not have had a renal transplantation&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Cell Carcinoma</Condition>
    <Secondary_ID>H-17150</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>M.D. Anderson Cancer Center</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2908196</Internal_Number>
    <TrialID>NCT00855452</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors</Public_title>
    <Scientific_title>rIL-2 Activated Allogeneic Lymphocytes for the Induction of Graft Versus Tumor Effect (GVT) in Metastatic Solid Tumors</Scientific_title>
    <Acronym>rIL-2(LAK)</Acronym>
    <Primary_sponsor>Hadassah Medical Organization</Primary_sponsor>
    <Date_registration3>20090219</Date_registration3>
    <Date_registration>19/02/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00855452</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>12 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2009</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        Consenting patients (age 12-70) will be eligible for participation in the study involving&lt;br&gt;        anti-tumor immunotherapy provided the following criteria are met:&lt;br&gt;&lt;br&gt;          1. Evidence of cancer not expected to be cured with conventional modalities:&lt;br&gt;&lt;br&gt;             Pediatric patients: Chemotherapy-resistant neuroblastoma stage 4 &amp; sarcomas. Adult&lt;br&gt;             patients: Metastatic breast cancer, malignant melanoma, renal cell cancer and&lt;br&gt;             selected cases of ovary cancer, gastrointestinal cancer, small-cell and non-small&lt;br&gt;             cell lung cancer with non-bulky metastatic disease, metastatic prostate cancer.&lt;br&gt;&lt;br&gt;          2. Patients with measurable disease evaluable for response with anticipated life&lt;br&gt;             expectancy &gt;3 months.&lt;br&gt;&lt;br&gt;          3. Patients must be &gt;2 weeks off anti-cancer or potentially immunosuppressive treatment.&lt;br&gt;&lt;br&gt;          4. Adequate ambulatory performance status (Karnofsky &gt;80%; ECOG 0-1) to enable&lt;br&gt;             outpatient treatment (see Appendix 1).&lt;br&gt;&lt;br&gt;          5. Compliant and cooperative patients anticipated to be evaluable for response according&lt;br&gt;             to investigator's assessment.&lt;br&gt;&lt;br&gt;          6. HLA-noncompatible (partial matched or mismatched) donor available.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        Patients will be excluded from participation in the study if any of the following criteria&lt;br&gt;        are met:&lt;br&gt;&lt;br&gt;          1. Any of the above criteria are not met.&lt;br&gt;&lt;br&gt;          2. Patients with a significant history or current evidence of potentially severe&lt;br&gt;             cardiovascular disease.&lt;br&gt;&lt;br&gt;          3. Hepatic and/or renal failure.&lt;br&gt;&lt;br&gt;          4. Abnormal PT and PTT.&lt;br&gt;&lt;br&gt;          5. Patients with abnormal hemogram (PMN&lt;1.0x109/L; HB&lt;10; Plts&lt;50x109/L)&lt;br&gt;&lt;br&gt;          6. Evidence of serious active infection requiring antibiotic therapy.&lt;br&gt;&lt;br&gt;          7. Evidence of active disease requiring steroid or cytotoxic therapy.&lt;br&gt;&lt;br&gt;          8. Pregnancy.&lt;br&gt;&lt;br&gt;          9. Contraindication for donation due to donor disease: HIV-1; HBsAg positivity.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Metastatic Breast Cancer;Malignant Melanoma;Renal Cell Cancer;Gastrointestinal Cancer</Condition>
    <Intervention>Procedure: one - three cycles of cell therapy during 4-6 weeks (3-5x10^7  cells/kg will be given through IV systemically</Intervention>
    <Primary_outcome>CR:disappearance of disease.PR:&lt;50% decrease in the total tumor load of the lesions SD:&lt;50% reduction and 25% increase in the sum of the products of the longest perpendicular diameters of the measured lesions.PD:&gt;25% increase in the size of lesion.</Primary_outcome>
    <Secondary_ID>0457-08-HMO-CTIL</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2908657</Internal_Number>
    <TrialID>NCT00861536</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Comparison of ATG to Thymoglobuline in Renal Transplantation</Public_title>
    <Scientific_title>An Open, Multicenter, Randomised, Parallel Group Pilot Study to Investigate Two Different Polyclonal Rabbit Immunoglobulin Preparations for Safety and Efficacy:A Comparison of ATG-Fresenius S to Thymoglobulin in Prophylaxis for Immunological High Risk Patients Following Renal Transplantation</Scientific_title>
    <Acronym />
    <Primary_sponsor>University Hospital, Basel, Switzerland</Primary_sponsor>
    <Date_registration3>20090312</Date_registration3>
    <Date_registration>12/03/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00861536</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2009</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Recipients, who are at least 18 years or older and have a high immunological risk&lt;br&gt;             defined by:&lt;br&gt;&lt;br&gt;             The presence of at least one donor-specific antibody (class I and/or II) detected and&lt;br&gt;             specified by flow-technology (FlowPRA and single antigen beads), which are&lt;br&gt;&lt;br&gt;               -  For class I below the threshold of detection of a current CDC T-cell-/ and&lt;br&gt;                  B-cell cross-match&lt;br&gt;&lt;br&gt;               -  For class II below the threshold of detection of a current CDC B-cell&lt;br&gt;                  cross-match.&lt;br&gt;&lt;br&gt;          2. Patient receives a renal allograft only.&lt;br&gt;&lt;br&gt;          3. Female patients of child bearing age agree to maintain effective birth control&lt;br&gt;             practice during the study.&lt;br&gt;&lt;br&gt;          4. Patient has been fully informed and has given written or independent person witnessed&lt;br&gt;             oral informed consent.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Patient is pregnant or breastfeeding.&lt;br&gt;&lt;br&gt;          2. Patient has a low immunological risk constellation, defined by receiving a kidney&lt;br&gt;             from a HLA-identical related living donor.&lt;br&gt;&lt;br&gt;          3. Patient and donor have a positive T-cell crossmatch.&lt;br&gt;&lt;br&gt;          4. Patient and donor are ABO incompatible.&lt;br&gt;&lt;br&gt;          5. Patient with combined transplantation.&lt;br&gt;&lt;br&gt;          6. Age of donor &gt;75 years.&lt;br&gt;&lt;br&gt;          7. Cold ischemia time &gt;40 hours.&lt;br&gt;&lt;br&gt;          8. Patient has leucopenia, defined as having at transplantation less than 3000/mm3&lt;br&gt;             leukocytes.&lt;br&gt;&lt;br&gt;          9. Patient has thrombocytopenia, defined as having at transplantation less than&lt;br&gt;             75000/mm3 thrombocytes.&lt;br&gt;&lt;br&gt;         10. Patient is allergic or intolerant to ATG-Fresenius S, Thymoglobulin, steroids,&lt;br&gt;             Tacrolimus or MMF.&lt;br&gt;&lt;br&gt;         11. EBV risk constellation (recipient EBV negative and donor EBV positive).&lt;br&gt;&lt;br&gt;         12. Patient or donor is known to be HIV positive.&lt;br&gt;&lt;br&gt;         13. Patient has a liver disease, defined as continuously having ASAT (SGOT) and/or ALAT&lt;br&gt;             (SGPT) levels greater than 3fold of the upper value of the normal range of the&lt;br&gt;             investigational site during the past 28 days.&lt;br&gt;&lt;br&gt;         14. Patient with malignancy or history of malignancy &lt;2 years, except non metastatic&lt;br&gt;             basal or squamous cell carcinoma of the skin that has been treated successfully.&lt;br&gt;&lt;br&gt;         15. Patient has uncontrolled concomitant infections and/or severe diarrhea, vomiting, or&lt;br&gt;             active peptic ulcer.&lt;br&gt;&lt;br&gt;         16. Patient is unlikely to comply with the visits schedule in the protocol.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Transplantation, Kidney</Condition>
    <Intervention>Drug: ATG Fresenius;Drug: Thymoglobuline Genzyme</Intervention>
    <Primary_outcome>Adverse events</Primary_outcome>
    <Secondary_outcome>Rejection;Graft function;Patient survival;Graft survival</Secondary_outcome>
    <Secondary_ID>82/06</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2908679</Internal_Number>
    <TrialID>NCT00861822</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Advance Targeted Transfusion in Anemic Cardiac Surgical Patients for Kidney Protection: A Proof of Concept Pilot Study</Public_title>
    <Scientific_title>Advance Targeted Transfusion in Anemic Cardiac Surgical Patients for Kidney Protection: A Proof of Concept Pilot Study</Scientific_title>
    <Acronym />
    <Primary_sponsor>University Health Network, Toronto</Primary_sponsor>
    <Date_registration3>20090312</Date_registration3>
    <Date_registration>12/03/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00861822</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2009</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Single Blind (Outcomes Assessor), Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 1</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients undergoing non-emergent aortocoronary bypass (ACB) surgery,  or valve&lt;br&gt;             surgery, combined ACB and valve, or aortic root repair  requiring CPB with a&lt;br&gt;             preoperative Hb concentration between 100 and 120 g/L.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Any conditions that may limit the ability of patients to tolerate the intervention:&lt;br&gt;&lt;br&gt;          -  Severe aortic or mitral valve stenosis&lt;br&gt;&lt;br&gt;          -  History of congestive heart failure within 30 days of surgery or severe ventricular&lt;br&gt;             dysfunction (ejection fraction &lt; 30%)&lt;br&gt;&lt;br&gt;          -  Severe (&gt; 60%) left main coronary artery stenosis or unstable angina within 30 days&lt;br&gt;             of surgery&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Injury</Condition>
    <Intervention>Other: Advanced red blood cell transfusion</Intervention>
    <Primary_outcome>Effects on perioperative (within 72 hours of termination of CPB)  anemia will be measured by: incidence of profound perioperative anemia (Hb &lt; 70 g/L) and by nadir perioperative Hb concentration.</Primary_outcome>
    <Secondary_outcome>(Primary)Effects on periop RBC transfusion rates measured by: incidence and amount of periop RBC transfusions. Effects on periop coagulation measured by: incidence and amount of coagulation product transfusions and incidence of surgical re-exploration.</Secondary_outcome>
    <Secondary_ID>08-1083-B</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2908714</Internal_Number>
    <TrialID>NCT00862303</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma</Public_title>
    <Scientific_title>Study of Autologous Dendritic Cells (DC) Loaded With Autologous Tumor Lysate (DC-Vaccine) in Combination With Cytokine-Induced Killer Cell (CIK) in Patients With Renal Cell Cancer</Scientific_title>
    <Acronym />
    <Primary_sponsor>Fuzhou General Hospital</Primary_sponsor>
    <Date_registration3>20090313</Date_registration3>
    <Date_registration>13/03/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00862303</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2009</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 1/Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Histologically proven renal cell carcinoma&lt;br&gt;&lt;br&gt;          -  Age: &gt; 18&lt;br&gt;&lt;br&gt;          -  WHO- ECOG Performance Status 0-1&lt;br&gt;&lt;br&gt;          -  At least one measurable tumor lesions according to the RECIST criteria.&lt;br&gt;&lt;br&gt;          -  Life expectancy more than 3 months&lt;br&gt;&lt;br&gt;          -  Written informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with a history of any other neoplastic disease less than 5 years ago&lt;br&gt;             (excepting treated carcinomas in situ of the cervix and basal/squamous cell&lt;br&gt;             carcinomas of the skin).&lt;br&gt;&lt;br&gt;          -  Patients with metastatic disease in the central nervous system (CNS).&lt;br&gt;&lt;br&gt;          -  Patients with other significant illness including severe allergy, asthma, angina&lt;br&gt;             pectoris or congestive heart failure.&lt;br&gt;&lt;br&gt;          -  Patients with acute or chronic infection including HIV.&lt;br&gt;&lt;br&gt;          -  Patients who are pregnant or nursing.&lt;br&gt;&lt;br&gt;          -  Patients who have received antineoplastic therapy including chemotherapy or&lt;br&gt;             immunotherapy less than 4 weeks before beginning the trial.&lt;br&gt;&lt;br&gt;          -  Patients who receive corticosteroids or other immunosuppressive agents.&lt;br&gt;&lt;br&gt;          -  Patients with active autoimmune diseases such as lupus erythematosus, rheumatoid&lt;br&gt;             arthritis or thyroiditis.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Cell Carcinoma</Condition>
    <Intervention>Biological: DC-CIK;Drug: IL-2/IFN-a</Intervention>
    <Primary_outcome>Objective tumor response (complete and partial response), Time to recurrence (TTR), Progression-free(PFS) and overall survival(OS) as measured by RECIST criteria.</Primary_outcome>
    <Secondary_outcome>Immunity as measured by T-cell functionality (immuknow assay )to the tumor. Safety as measured by NCI common toxicity table (CTC) at completion of study.</Secondary_outcome>
    <Secondary_ID>fuzhough0938;fuzhough0938</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2909220</Internal_Number>
    <TrialID>NCT00868972</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Renal Stenting With Distal Atheroembolic Protection</Public_title>
    <Scientific_title>Percutaneous Renal Stenting in Renovascular Disease With or Without Distal Atheroembolic Protection</Scientific_title>
    <Acronym />
    <Primary_sponsor>Universita di Verona</Primary_sponsor>
    <Date_registration3>20090324</Date_registration3>
    <Date_registration>24/03/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00868972</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2009</Date_enrollement>
    <Target_size>150</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Outcomes Assessor), Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 2/Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age &gt;18 years&lt;br&gt;&lt;br&gt;          -  Ostial atherosclerotic renal artery stenosis =70% on intra-arterial angiography&lt;br&gt;&lt;br&gt;          -  Well documented history of hypertension (&gt;140/90 mmHg) non responsive to the use of 2&lt;br&gt;             or more antihypertensive medications and/or&lt;br&gt;&lt;br&gt;          -  Estimated glomerular filtration rate &lt;60 ml/min/1.73m2 according to the MDRD formula,&lt;br&gt;             on two occasions within one month&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Declined informed consent&lt;br&gt;&lt;br&gt;          -  Renal longitudinal diameter &lt; 8 cm&lt;br&gt;&lt;br&gt;          -  Any anatomical reasons that make impossible the PTRA and or the positioning of the&lt;br&gt;             distal embolic protection device&lt;br&gt;&lt;br&gt;          -  Estimated glomerular filtration rate &lt;30 ml/min/1.73m2 according to the MDRD formula&lt;br&gt;             or on dialysis&lt;br&gt;&lt;br&gt;          -  Allergy to the contrast medium used during angiography&lt;br&gt;&lt;br&gt;          -  Other conditions associated with (within 6 months) poor prognosis&lt;br&gt;&lt;br&gt;          -  Myocardial infarction, unstable angina or stroke &lt;1 month before planned date of&lt;br&gt;             inclusion&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Artery Obstruction;Renovascular Hypertension</Condition>
    <Intervention>Procedure: Percutaneous renal stenting intervention;Device: Distal embolic protection</Intervention>
    <Primary_outcome>Differences in renal function loss (measured as Cr clearance and/or cystatin C) after 1 and 3 months of follow-up</Primary_outcome>
    <Secondary_outcome>Acute complications, especially atheroembolism;Evaluations of the covariates associated with a better outcome in the atheroembolic device group;Blood pressure control (number of medication needed to keep BP&lt;140/90 )</Secondary_outcome>
    <Secondary_ID>MOMPF-01</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2909223</Internal_Number>
    <TrialID>NCT00869011</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Exercise for Patients With Renal Cell Cancer Receiving Sunitinib</Public_title>
    <Scientific_title>Effects of Physical Activity on the Endothelial and Cardiac Function of Patients With Renal Cell Carcinoma Receiving a Thyrosine Kinase Inhibitor (Sunitinib)</Scientific_title>
    <Acronym />
    <Primary_sponsor>Charite University, Berlin, Germany</Primary_sponsor>
    <Date_registration3>20090323</Date_registration3>
    <Date_registration>23/03/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00869011</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>December 2009</Date_enrollement>
    <Target_size>70</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Single Blind (Investigator), Primary Purpose:  Supportive Care</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  18 to 75 years&lt;br&gt;&lt;br&gt;          -  Understanding of written German&lt;br&gt;&lt;br&gt;          -  Treatment with Sunitinib&lt;br&gt;&lt;br&gt;          -  Ability to walk&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Cardiovascular, pulmonary or osteoarticular disease which can be aggravated by&lt;br&gt;             exercise&lt;br&gt;&lt;br&gt;          -  BMI &lt; 18 or &gt; 30&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Cell Carcinoma</Condition>
    <Intervention>Other: Endurance exercise</Intervention>
    <Primary_outcome>Fatigue</Primary_outcome>
    <Secondary_outcome>VO2max;Systolic and diastolic blood pressure (24 h);Depression score</Secondary_outcome>
    <Secondary_ID>SUIR8687</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Pfizer</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2909365</Internal_Number>
    <TrialID>NCT00870883</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>N-acetylcysteine Plus Deferoxamine for Patients With Hypotension</Public_title>
    <Scientific_title>Prospective, Randomized, Double-blinded, Placebo-controlled Study of N-acetylcysteine Plus Deferoxamine for Patients With Hypotension as Prophylaxis for Acute Renal Failure</Scientific_title>
    <Acronym />
    <Primary_sponsor>Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude</Primary_sponsor>
    <Date_registration3>20090325</Date_registration3>
    <Date_registration>25/03/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00870883</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2009</Date_enrollement>
    <Target_size>140</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Investigator), Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients admitted to the ICU&lt;br&gt;&lt;br&gt;          -  Presenting hypothesion (MAP &lt; 60mm Hg or the needing to use vasoactive drugs) for at&lt;br&gt;             least 30 min in the last 12h before study inclusion&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age lower than 18 years old&lt;br&gt;&lt;br&gt;          -  Chronic renal failure&lt;br&gt;&lt;br&gt;          -  A known history of allergy to any of the study drugs&lt;br&gt;&lt;br&gt;          -  Using n-acetylcysteine to paracetamol overdose&lt;br&gt;&lt;br&gt;          -  Pregnant women&lt;br&gt;&lt;br&gt;          -  Patients who used iodinated contrast medium&lt;br&gt;&lt;br&gt;          -  Hemoglobin less than 6.5 mg/dl&lt;br&gt;&lt;br&gt;          -  Cancer patients&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Hypotension;Acute Renal Failure</Condition>
    <Intervention>Drug: N-acetylcysteine and deferoxamine</Intervention>
    <Primary_outcome>Development of acute renal failure</Primary_outcome>
    <Secondary_outcome>28 day-mortality;Decrease on plasma oxidative damage and inflammatory parameters</Secondary_outcome>
    <Secondary_ID>FR208621</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Conselho Nacional de Desenvolvimento Científico e Tecnológico</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2909636</Internal_Number>
    <TrialID>NCT00874432</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease</Public_title>
    <Scientific_title>Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Wisconsin, Madison</Primary_sponsor>
    <Date_registration3>20090401</Date_registration3>
    <Date_registration>01/04/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00874432</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>60 Years</Inclusion_agemin>
    <Inclusion_agemax>89 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2009</Date_enrollement>
    <Target_size>90</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Investigator), Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age &gt; 60 years&lt;br&gt;&lt;br&gt;          -  BP 120/80 or higher *(bps will be checked weekly first 4 weeks to ensure     &lt; 130/80&lt;br&gt;             - IF bp remains &gt; 130/80 we will administer other bp meds per JNC VII guidelines)&lt;br&gt;&lt;br&gt;          -  CKD stage 3 (GFR 30 - 59 ml/min) for CKD group; no CKD for control group&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Known significant CVD (history of MI, recurrent stroke, or NYHA class III or&lt;br&gt;             greater).&lt;br&gt;&lt;br&gt;          -  Serum potassium &gt; 5.2 meq/L&lt;br&gt;&lt;br&gt;          -  Known allergy or hypersensitivity to ACE inhibitor or ARB&lt;br&gt;&lt;br&gt;          -  Female of childbearing age not practicing contraception&lt;br&gt;&lt;br&gt;          -  Current treatment with an ACE-I or ARB (Note: can participate if on ACE-I after 6&lt;br&gt;             week washout period)&lt;br&gt;&lt;br&gt;          -  History of ACE-I induced angioedema&lt;br&gt;&lt;br&gt;          -  History of angioedema, hereditary or idiopathic&lt;br&gt;&lt;br&gt;          -  Persons lacking consent capacity&lt;br&gt;&lt;br&gt;               -  500 mg/dL proteinuria on 2 consecutive spot urine protein/creat ratios&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Cardiovascular Disease;Chronic Kidney Disease</Condition>
    <Intervention>Drug: angiotensin converting enzyme inhibitor;Drug: lisinopril</Intervention>
    <Primary_outcome>There may be a statistical correlation between eGFR(estimated glomerular function) and PWV (pulse wave velocity) in patients with CKD, the addition of an ACE inhibitor will decrease PWV in all groups, but to a greater extent in patients wil CKD.</Primary_outcome>
    <Secondary_ID>2008-0221</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2910792</Internal_Number>
    <TrialID>NCT00889629</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Pilot Study Evaluating Doxercalciferol Replacement Therapy in Kidney Transplant Recipients</Public_title>
    <Scientific_title>Pilot Study: Effects of Hectorol (Doxercalciferol) Vitamin D Replacement on Proteinuria, PTH Level and Bone Turnover in Stable Kidney Transplant Recipients: a Single-Blind, Placebo-Controlled Study in Patients Receiving 25-OH Vitamin D3</Scientific_title>
    <Acronym />
    <Primary_sponsor>State University of New York - Downstate Medical Center</Primary_sponsor>
    <Date_registration3>20090423</Date_registration3>
    <Date_registration>23/04/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00889629</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>65 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2008</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Adults of both genders between the ages of 18 and 65.&lt;br&gt;&lt;br&gt;          -  Kidney transplant at least 1 year prior to enrollment&lt;br&gt;&lt;br&gt;          -  Creatinine value of &lt;2.5 mg/dl with no excursion &gt;0.5 within the past 3 months&lt;br&gt;&lt;br&gt;          -  Proteinuria of 500 mg/24 hours or a protein/creatinine ratio of 0.5 or greater&lt;br&gt;&lt;br&gt;          -  Hypovitaminosis D, as defined by a 25-OH Vitamin D value of &lt;25 ng/ml&lt;br&gt;&lt;br&gt;          -  Intact PTH value between 150 and 600 pg/ml&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  History of parathyroidectomy&lt;br&gt;&lt;br&gt;          -  History of prior intolerance to vitamin D therapy (not including hypercalcemia)&lt;br&gt;&lt;br&gt;          -  History of biopsy proven acute rejection over the 3 months preceding enrollment&lt;br&gt;&lt;br&gt;          -  Recent (over the past month) addition of an ACE inhibitor or Angiotensin  -&lt;br&gt;&lt;br&gt;          -  Receptor Blocking agent - patients who have been on a stable dose are acceptable&lt;br&gt;&lt;br&gt;          -  Current use of active Vitamin D supplement (patients in whom therapy has been&lt;br&gt;             discontinued more than 1 month prior to enrollment are acceptable)&lt;br&gt;&lt;br&gt;          -  Postmenopausal woman or women receiving hormone replacement therapy&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease;Kidney Transplantation</Condition>
    <Intervention>Drug: Doxercalciferol;Drug: placebo</Intervention>
    <Primary_outcome>Number of patients achieving the target iPTH value of 100 pg/ml or lower;Change in 1,25 D2 and D3, 25-OH Vitamin D3 levels;iPTH at baseline, 1, 3 and 6 months (absolute value and percent change from baseline);Change in FGF-23 levels at baseline, 1, 3 and 6 months;Change in serum bone turnover markers;Change in Protein/creatinine ratio and/or 24 hour urine for protein at baseline, 1, 3 and 6 months</Primary_outcome>
    <Secondary_ID>08-080</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2910792</Internal_Number>
    <TrialID>NCT00889629</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Pilot Study Evaluating Doxercalciferol Replacement Therapy in Kidney Transplant Recipients</Public_title>
    <Scientific_title>Pilot Study: Effects of Hectorol (Doxercalciferol) Vitamin D Replacement on Proteinuria, PTH Level and Bone Turnover in Stable Kidney Transplant Recipients: a Single-Blind, Placebo-Controlled Study in Patients Receiving 25-OH Vitamin D3</Scientific_title>
    <Acronym />
    <Primary_sponsor>State University of New York - Downstate Medical Center</Primary_sponsor>
    <Date_registration3>20090423</Date_registration3>
    <Date_registration>23/04/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00889629</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>65 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2008</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Adults of both genders between the ages of 18 and 65.&lt;br&gt;&lt;br&gt;          -  Kidney transplant at least 1 year prior to enrollment&lt;br&gt;&lt;br&gt;          -  Creatinine value of &lt;2.5 mg/dl with no excursion &gt;0.5 within the past 3 months&lt;br&gt;&lt;br&gt;          -  Proteinuria of 500 mg/24 hours or a protein/creatinine ratio of 0.5 or greater&lt;br&gt;&lt;br&gt;          -  Hypovitaminosis D, as defined by a 25-OH Vitamin D value of &lt;25 ng/ml&lt;br&gt;&lt;br&gt;          -  Intact PTH value between 150 and 600 pg/ml&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  History of parathyroidectomy&lt;br&gt;&lt;br&gt;          -  History of prior intolerance to vitamin D therapy (not including hypercalcemia)&lt;br&gt;&lt;br&gt;          -  History of biopsy proven acute rejection over the 3 months preceding enrollment&lt;br&gt;&lt;br&gt;          -  Recent (over the past month) addition of an ACE inhibitor or Angiotensin  -&lt;br&gt;&lt;br&gt;          -  Receptor Blocking agent - patients who have been on a stable dose are acceptable&lt;br&gt;&lt;br&gt;          -  Current use of active Vitamin D supplement (patients in whom therapy has been&lt;br&gt;             discontinued more than 1 month prior to enrollment are acceptable)&lt;br&gt;&lt;br&gt;          -  Postmenopausal woman or women receiving hormone replacement therapy&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease;Kidney Transplantation</Condition>
    <Intervention>Drug: Doxercalciferol;Drug: placebo</Intervention>
    <Primary_outcome>Number of patients achieving the target iPTH value of 100 pg/ml or lower;Change in 1,25 D2 and D3, 25-OH Vitamin D3 levels;iPTH at baseline, 1, 3 and 6 months (absolute value and percent change from baseline);Change in FGF-23 levels at baseline, 1, 3 and 6 months;Change in serum bone turnover markers;Change in Protein/creatinine ratio and/or 24 hour urine for protein at baseline, 1, 3 and 6 months</Primary_outcome>
    <Secondary_ID>08-080</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2910840</Internal_Number>
    <TrialID>NCT00890253</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation</Public_title>
    <Scientific_title>A Therapeutic Exploratory Study to Determine the Efficacy and Safety of Calcineurin-Inhibitor-Free De-novo Immunosuppression After Liver Transplantation</Scientific_title>
    <Acronym>CILT</Acronym>
    <Primary_sponsor>Armin Goralczyk</Primary_sponsor>
    <Date_registration3>20090428</Date_registration3>
    <Date_registration>28/04/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00890253</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2010</Date_enrollement>
    <Target_size>29</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Patients undergoing primary liver transplantation.&lt;br&gt;&lt;br&gt;          2. Patients older than 18 years.&lt;br&gt;&lt;br&gt;          3. Patients with a hepatorenal syndrome.&lt;br&gt;&lt;br&gt;          4. Female patients of childbearing potential willing to perform a highly effective&lt;br&gt;             contraception during the study and 12 weeks after conclusion of study participation.&lt;br&gt;&lt;br&gt;          5. eGFR &lt; 50 ml/min at the time point of transplantation.&lt;br&gt;&lt;br&gt;          6. Serum creatinine levels &gt; 1.5 mg/dL at the time-point of transplantation.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Patients with pre-transplant renal replacement therapy &gt; 14 days.&lt;br&gt;&lt;br&gt;          2. Patients with a reason for renal impairment other than a hepatorenal syndrome.&lt;br&gt;&lt;br&gt;          3. Patients with a known hypersensitivity to mTOR-inhibitors.&lt;br&gt;&lt;br&gt;          4. Patients with a known hypersensitivity to mycophenolate acid.&lt;br&gt;&lt;br&gt;          5. Patients with a known hypersensitivity to anti CD 25-monoclonal antibodies.&lt;br&gt;&lt;br&gt;          6. Patients with platelets &lt; 50.000/nl prior to initiation of therapy with mTOR&lt;br&gt;             inhibition.&lt;br&gt;&lt;br&gt;          7. Patients with triglycerides &gt; 350 mg/dl and cholesterol &gt; 300 mg/dl refractory to&lt;br&gt;             optimal medical treatment prior to initiation of therapy with mTOR inhibition.&lt;br&gt;&lt;br&gt;          8. Severe systemic infections and wound-healing disturbances.&lt;br&gt;&lt;br&gt;          9. Multiple organ graft recipients.&lt;br&gt;&lt;br&gt;         10. Patients with signs of a hepatic artery stenosis directly prior to initiation of&lt;br&gt;             therapy with everolimus.&lt;br&gt;&lt;br&gt;         11. Pregnant women will not be included in the study.&lt;br&gt;&lt;br&gt;         12. Patients with a psychological, familial, sociologic or geographic condition&lt;br&gt;             potentially hampering compliance with the study protocol and follow-up schedule.&lt;br&gt;&lt;br&gt;         13. Patients under guardianship (e.g., individuals who are not able to freely give their&lt;br&gt;             informed consent).&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Liver Transplantation;Chronic Renal Insufficiency</Condition>
    <Intervention>Drug: Basiliximab (Simulect);Drug: Myfortic;Drug: everolimus;Drug: Prednisolone</Intervention>
    <Primary_outcome>Steroid resistant rejection</Primary_outcome>
    <Secondary_outcome>Steroid resistant rejection;Liver function;Calculated glomerular filtration rate;Patient survival;Number of days on renal replacement therapy;Graft survival</Secondary_outcome>
    <Secondary_ID>CILT08</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2910842</Internal_Number>
    <TrialID>NCT00890279</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)</Public_title>
    <Scientific_title>Phase II Study for the Second-Line Treatment of Hypertension in Patients With Autosomal Dominant Polycystic Kidney Disease; ACEI vs. CCB</Scientific_title>
    <Acronym />
    <Primary_sponsor>Ministry of Health, Labour and Welfare, Japan</Primary_sponsor>
    <Date_registration3>20090428</Date_registration3>
    <Date_registration>28/04/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00890279</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>20 Years</Inclusion_agemin>
    <Inclusion_agemax>60 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2009</Date_enrollement>
    <Target_size>160</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  ADPKD patients&lt;br&gt;&lt;br&gt;          -  Blood pressure measured at out-patient setting is above 120/80 mmHg&lt;br&gt;&lt;br&gt;          -  Age between 20 and 60 years old&lt;br&gt;&lt;br&gt;          -  eGFR more than 30 ml/min/1.73m2&lt;br&gt;&lt;br&gt;          -  Patients give informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with severe cardiovascular and hepatic disorders&lt;br&gt;&lt;br&gt;          -  Patients with complications of central nervous vascular disorders&lt;br&gt;&lt;br&gt;          -  Women who are breast feeding and females of childbearing potential who are not using&lt;br&gt;             acceptable contraceptive methods&lt;br&gt;&lt;br&gt;          -  Patients currently engaging in other experimental protocol&lt;br&gt;&lt;br&gt;          -  Patients with intracranial aneurysma&lt;br&gt;&lt;br&gt;          -  Patients who must use diuretics&lt;br&gt;&lt;br&gt;          -  Allergic patients to Candesartan or Cilnidipine&lt;br&gt;&lt;br&gt;          -  Patients whose hypertension is not controlled by medication of this protocol&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney, Polycystic, Autosomal Dominant</Condition>
    <Intervention>Drug: Cilnidipine;Drug: Imidapril</Intervention>
    <Primary_outcome>eGFR</Primary_outcome>
    <Secondary_outcome>Kidney Volume measured by MRI;Serum creatinine level;Induction of hemodialysis, cardiovascular events and central nervous vascular events</Secondary_outcome>
    <Secondary_ID>ADPKDhypertension</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2910996</Internal_Number>
    <TrialID>NCT00892359</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Anidulafungin During Continuous Venovenous Hemofiltration (CVVHF)</Public_title>
    <Scientific_title>The Pharmacokinetics of Anidulafungin During Continuous Venovenous Hemofiltration</Scientific_title>
    <Acronym />
    <Primary_sponsor>Medical University of Vienna</Primary_sponsor>
    <Date_registration3>20090430</Date_registration3>
    <Date_registration>30/04/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00892359</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>19 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2009</Date_enrollement>
    <Target_size>10</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Pharmacokinetics Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age 19 to 70 years&lt;br&gt;&lt;br&gt;          -  Suspected or proven infection requiring parenteral antifungal therapy.&lt;br&gt;&lt;br&gt;          -  Continuous venovenous hemofiltration because of an acute renal failure.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Known history of hypersensitivity to echinocandins.&lt;br&gt;&lt;br&gt;          -  An expected survival of less than three days.&lt;br&gt;&lt;br&gt;          -  Known alcohol dependency, epilepsy, pregnancy or liver failure.&lt;br&gt;&lt;br&gt;          -  Neutropenic patients&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Renal Failure;Infection</Condition>
    <Intervention>Drug: Anidulafungin</Intervention>
    <Primary_outcome>Anidulafungin area under the curve (AUC), half-live (t1/2), maximum plasma concentration (Cmax) and elimination fraction.</Primary_outcome>
    <Secondary_ID>1.1 - Leitner</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2912315</Internal_Number>
    <TrialID>NCT00910130</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Insulin Resistance And End Stage Renal Disease: The Role Of Retinol Binding Protein 4</Public_title>
    <Scientific_title>Insulin Resistance And End Stage Renal Disease: The Role Of Retinol Binding Protein 4</Scientific_title>
    <Acronym />
    <Primary_sponsor>IRCCS Policlinico S. Matteo</Primary_sponsor>
    <Date_registration3>20090528</Date_registration3>
    <Date_registration>28/05/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00910130</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2008</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case Control, Time Perspective:  Cross-Sectional</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Hemodialysis for "End Stage Renal Disease group"&lt;br&gt;&lt;br&gt;          -  Normal Renal Function for "Control group"&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Diabetes&lt;br&gt;&lt;br&gt;          -  Malnutrition&lt;br&gt;&lt;br&gt;          -  Malignancy&lt;br&gt;&lt;br&gt;          -  Acute Infection&lt;br&gt;&lt;br&gt;          -  Chronic Active Infection&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Insulin Resistance;Diabetes;End Stage Renal Disease</Condition>
    <Secondary_ID>RBP4</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2912521</Internal_Number>
    <TrialID>NCT00912821</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effect of Different Dialysis Dosage on Prognosis in Maintenance Peritoneal Dialysis Patients</Public_title>
    <Scientific_title>Effect of Different Dialysis Dosage on Prognosis in Maintenance Peritoneal Dialysis Patients - A Prospective, Randomized, Controlled, Multi-Center Clinical Study</Scientific_title>
    <Acronym />
    <Primary_sponsor>Shanghai Jiao Tong University School of Medicine</Primary_sponsor>
    <Date_registration3>20090601</Date_registration3>
    <Date_registration>01/06/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00912821</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2009</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Age from 18 to 80, male or female.&lt;br&gt;&lt;br&gt;          2. End stage renal disease patients (eGFR &lt; 15 ml/min/1.73 m2).&lt;br&gt;&lt;br&gt;          3. Maintenance peritoneal dialysis within 6 months after initiation of PD.&lt;br&gt;&lt;br&gt;          4. With informed consent.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Acute renal injury.&lt;br&gt;&lt;br&gt;          2. Patients with an expected follow up less than 6 months sch as renal transplantation.&lt;br&gt;&lt;br&gt;          3. Transferred from hemodialysis or renal transplantation.&lt;br&gt;&lt;br&gt;          4. Residual renal function eGFR less than 1 ml/min.&lt;br&gt;&lt;br&gt;          5. HIV positive.&lt;br&gt;&lt;br&gt;          6. Cancer patients.&lt;br&gt;&lt;br&gt;          7. Unstable organ disease such as active tuberculosis and severe hepatitis. Patients&lt;br&gt;             with an expected follow up less than 48 weeks, such as planned kidney transplant.&lt;br&gt;&lt;br&gt;          8. Other conditions regarded as unsuitability by investigator, such as pregnancy, severe&lt;br&gt;             malnutrition and recent peritonitis.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End-Stage Renal Disease</Condition>
    <Intervention>Drug: 6 L dialysate;Drug: 8 L dialysate</Intervention>
    <Primary_outcome>clinical outcome including mortality and technical failure</Primary_outcome>
    <Secondary_outcome>complications including cardiovascular disease, nutritional and inflammation status, calcium and phosphorus level, anemia and life quality</Secondary_outcome>
    <Secondary_ID>08dz1900501-b</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2912763</Internal_Number>
    <TrialID>NCT00915993</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>MRI in Predicting Response to Sunitinib Malate in Patients With Stage IV Kidney Cancer</Public_title>
    <Scientific_title>An Imaging and Histopathologic Study to Predict Response to Sunitinib Therapy in Patients With Metastatic Renal Cell Carcinoma</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Pennsylvania</Primary_sponsor>
    <Date_registration3>20090605</Date_registration3>
    <Date_registration>05/06/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00915993</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2009</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Masking:  Open Label, Primary Purpose:  Diagnostic</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        DISEASE CHARACTERISTICS:&lt;br&gt;&lt;br&gt;          -  Histologically confirmed renal cell carcinoma&lt;br&gt;&lt;br&gt;               -  Stage IV disease&lt;br&gt;&lt;br&gt;          -  Has undergone nephrectomy&lt;br&gt;&lt;br&gt;          -  Archival tumor tissue samples available&lt;br&gt;&lt;br&gt;          -  No history or clinical evidence of brain metastasis&lt;br&gt;&lt;br&gt;        PATIENT CHARACTERISTICS:&lt;br&gt;&lt;br&gt;          -  ECOG performance status 0-2&lt;br&gt;&lt;br&gt;          -  WBC = 3,000/mm^3&lt;br&gt;&lt;br&gt;          -  Absolute granulocyte count = 1,500/mm^3&lt;br&gt;&lt;br&gt;          -  Platelet count = 100,000/mm^3&lt;br&gt;&lt;br&gt;          -  Serum creatinine = 2.0 times upper limit of normal (ULN) OR creatinine clearance = 40&lt;br&gt;             mL/min&lt;br&gt;&lt;br&gt;          -  Total bilirubin = 1.5 times ULN (&lt; 3.0 times ULN for patients with Gilbert's disease)&lt;br&gt;&lt;br&gt;          -  AST and ALT = 2.5 times ULN (= 5.0 times ULN for patients with liver metastases)&lt;br&gt;&lt;br&gt;          -  INR = 1.5&lt;br&gt;&lt;br&gt;          -  PTT normal&lt;br&gt;&lt;br&gt;          -  Not pregnant or nursing&lt;br&gt;&lt;br&gt;          -  Negative pregnancy test&lt;br&gt;&lt;br&gt;          -  Fertile patients must use effective contraception&lt;br&gt;&lt;br&gt;          -  No pre-existing thyroid abnormality with thyroid-stimulating hormone that cannot be&lt;br&gt;             maintained in the normal range with medication&lt;br&gt;&lt;br&gt;          -  No hypertension that cannot be controlled with medication (i.e., diastolic blood&lt;br&gt;             pressure = 100 mm Hg despite optimal medical therapy)&lt;br&gt;&lt;br&gt;          -  No cardiac dysrhythmias = grade 2 by NCI CTCAE v3.0&lt;br&gt;&lt;br&gt;          -  No concurrent serious illness including, but not limited to, the following:&lt;br&gt;&lt;br&gt;               -  Ongoing or active infection requiring parenteral antibiotics&lt;br&gt;&lt;br&gt;               -  Clinically significant cardiovascular disease (e.g., uncontrolled hypertension,&lt;br&gt;                  myocardial infarction, or unstable angina)&lt;br&gt;&lt;br&gt;               -  NYHA class II-IV congestive heart failure&lt;br&gt;&lt;br&gt;               -  Serious cardiac arrhythmia requiring medication&lt;br&gt;&lt;br&gt;               -  Peripheral vascular disease = grade 2 within the past year&lt;br&gt;&lt;br&gt;               -  Psychiatric illness and/or social situation that would limit compliance with&lt;br&gt;                  study requirements&lt;br&gt;&lt;br&gt;        PRIOR CONCURRENT THERAPY:&lt;br&gt;&lt;br&gt;          -  See Disease Characteristics&lt;br&gt;&lt;br&gt;          -  No prior antiangiogenesis therapy&lt;br&gt;&lt;br&gt;          -  Prior radiotherapy to a symptomatic site of metastatic disease is allowed&lt;br&gt;&lt;br&gt;          -  At least 2 weeks since prior radiotherapy and recovered&lt;br&gt;&lt;br&gt;          -  No other concurrent investigational therapies&lt;br&gt;&lt;br&gt;          -  No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin,&lt;br&gt;             carbamazepine, or phenobarbital), rifampin, or St. John's wort&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Cancer</Condition>
    <Intervention>Drug: sunitinib malate;Genetic: mutation analysis;Other: immunohistochemistry staining method;Other: laboratory biomarker analysis;Other: pharmacological study;Procedure: dynamic contrast-enhanced magnetic resonance imaging</Intervention>
    <Primary_outcome>Correlation of tumor vascular permeability as measured by  dynamic contrast-enhanced MRI  with clinical outcome and with tumor angiogenesis as measured by IHC;Progression-free survival</Primary_outcome>
    <Secondary_outcome>Tumor regression as measured by RECIST criteria</Secondary_outcome>
    <Secondary_ID>UPCC-03809;809442;PFIZER-UPCC-03809;CDR0000643287</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>National Cancer Institute (NCI)</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2913091</Internal_Number>
    <TrialID>NCT00920309</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy</Public_title>
    <Scientific_title>Rapamycin as Treatment for ADPKD: The Role of Biomarkers in Predicting a Response to Therapy</Scientific_title>
    <Acronym />
    <Primary_sponsor>Yale University</Primary_sponsor>
    <Date_registration3>20090612</Date_registration3>
    <Date_registration>12/06/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00920309</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2009</Date_enrollement>
    <Target_size>45</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2/Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  adult ADPKD patients aged 18-70&lt;br&gt;&lt;br&gt;          -  combined kidney volume &gt;1200 ml&lt;br&gt;&lt;br&gt;          -  estimated creatinine clearance &gt;60 ml/min&lt;br&gt;&lt;br&gt;          -  absence of implanted ferromagnetic objects&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age &gt;70&lt;br&gt;&lt;br&gt;          -  uncontrolled hyperlipidemia&lt;br&gt;&lt;br&gt;          -  Proteinuria &gt;500 mg/day&lt;br&gt;&lt;br&gt;          -  unstable cerebral aneurysm&lt;br&gt;&lt;br&gt;          -  active coronary artery disease&lt;br&gt;&lt;br&gt;          -  diagnosis of another systemic condition affecting kidney function (ie: diabetes,&lt;br&gt;             hepatitis B or C, HIV)&lt;br&gt;&lt;br&gt;          -  diagnosis of cancer other than skin cancer&lt;br&gt;&lt;br&gt;          -  pregnancy or lactation&lt;br&gt;&lt;br&gt;          -  presence of implanted ferromagnetic objects&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Autosomal Dominant Polycystic Kidney Disease</Condition>
    <Intervention>Drug: Rapamycin</Intervention>
    <Primary_outcome>combined kidney volume</Primary_outcome>
    <Secondary_outcome>kidney function;change in biomarkers</Secondary_outcome>
    <Secondary_ID>HIC#0903004934</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2913804</Internal_Number>
    <TrialID>NCT00929760</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Impact of Specialised Renal Care in Patients With Chronic Kidney Disease</Public_title>
    <Scientific_title>Impact of Specialised Renal Care in Patients With Chronic Kidney Disease Stage 3-5: A Prospective Randomised Study. "The Implicate Study"</Scientific_title>
    <Acronym>IMPLICATE</Acronym>
    <Primary_sponsor>University Hospital, Geneva</Primary_sponsor>
    <Date_registration3>20090626</Date_registration3>
    <Date_registration>26/06/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00929760</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2009</Date_enrollement>
    <Target_size>400</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with CKD stage 3, 4 and 5 (CCl &lt; 40 ml/min according to abbreviated MDRD&lt;br&gt;             formula) aged 18-80 years old and enrolled during a hospitalization.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients previously known by nephrologists.&lt;br&gt;&lt;br&gt;          -  Estimated life expectancy &lt; 1 year&lt;br&gt;&lt;br&gt;          -  Refusal or inability to sign writing consent&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease</Condition>
    <Intervention>Behavioral: specialised renal care</Intervention>
    <Primary_outcome>Primary (composite): death, and hospitalisation</Primary_outcome>
    <Secondary_outcome>Secondary: initiation of urgent RRT, decline of renal residual function at 2 years, decline of quality of life</Secondary_outcome>
    <Secondary_ID>08-226</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Schweizerische Nierenliga</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2913825</Internal_Number>
    <TrialID>NCT00930033</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Clinical Trial to Assess the Importance of Nephrectomy</Public_title>
    <Scientific_title>Randomized Phase III Trial Evaluating the Importance of Nephrectomy in Patients Presenting With Metastatic Renal Cell Carcinoma Treated With Sunitinib</Scientific_title>
    <Acronym>CARMENA</Acronym>
    <Primary_sponsor>Assistance Publique - Hôpitaux de Paris</Primary_sponsor>
    <Date_registration3>20090629</Date_registration3>
    <Date_registration>29/06/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00930033</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2009</Date_enrollement>
    <Target_size>576</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age = 18 year&lt;br&gt;&lt;br&gt;          -  ECOG Performance Status 0 - 1&lt;br&gt;&lt;br&gt;          -  Biopsy (primary tumour or metastases) confirming the diagnosis of clear cell&lt;br&gt;             carcinoma&lt;br&gt;&lt;br&gt;          -  Documented metastatic disease&lt;br&gt;&lt;br&gt;          -  Absence of prior systemic treatment for kidney cancer including AA&lt;br&gt;&lt;br&gt;          -  Tumour accessible to nephrectomy (partial or total), according to the patient's&lt;br&gt;             surgical urologist. Patients presenting with an inferior vena cava thrombosis can be&lt;br&gt;             included.&lt;br&gt;&lt;br&gt;          -  Patients for which the indication of Sutent is considered according to the&lt;br&gt;             recommendations rules given by national health authorities of participating&lt;br&gt;             countries. The prescription of Sutent in the circumstances of the study is considered&lt;br&gt;             as a standard treatment.&lt;br&gt;&lt;br&gt;          -  Platelets &gt; or = 100 x 109/L, hemoglobin &gt; or = 9 g/dl, neutrophils &gt; or =1.5 x&lt;br&gt;             109/L;&lt;br&gt;&lt;br&gt;          -  Bilirubin &lt; or = 2 mg/dL, aspartate transaminase (ASAT) and alanine transaminase&lt;br&gt;             (ALAT) &lt; or = 2.5 times the upper normal limit (UNL) or &lt; or = 5 times UNL for&lt;br&gt;             patients with liver metastases&lt;br&gt;&lt;br&gt;          -  Patients of child bearing age should use contraceptive methods&lt;br&gt;&lt;br&gt;          -  Patient able to follow the procedures outlined in the protocol as far as the planning&lt;br&gt;             of visits and exams are concerned.&lt;br&gt;&lt;br&gt;          -  Life expectancy = 3 months&lt;br&gt;&lt;br&gt;          -  Affiliated with social security health insurance&lt;br&gt;&lt;br&gt;          -  Written informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Prior systemic treatment for kidney cancer (including Anti angiogenic)&lt;br&gt;&lt;br&gt;          -  Bilateral kidney cancer&lt;br&gt;&lt;br&gt;          -  Pregnant or breast feeding women&lt;br&gt;&lt;br&gt;          -  Non stabilised coronaropathy or episode of myocardial infarction or severe or&lt;br&gt;             unstable angora within the last 6 months as well as severe diabetes with severe&lt;br&gt;             peripheral arteriopathy or deep phlebitis or arterial thrombosis within the last 3&lt;br&gt;             months&lt;br&gt;&lt;br&gt;          -  Anticoagulants with curative intent&lt;br&gt;&lt;br&gt;          -  Medical, general or psychiatrics difficulties non compatibles with the study&lt;br&gt;&lt;br&gt;          -  Brain metastases&lt;br&gt;&lt;br&gt;          -  Prior radiotherapy for kidney cancer&lt;br&gt;&lt;br&gt;          -  Previous history of gastric disease or of the small intestine, syndrome of&lt;br&gt;             insufficient absorption compromising the absorption of  Sunitinib&lt;br&gt;&lt;br&gt;          -  Experimental treatment within the 28 days preceding inclusion&lt;br&gt;&lt;br&gt;          -  Other cancer within the previous 5 years (except for insitu skin carcinoma and&lt;br&gt;             treated localised prostate cancer with undetectable PSA)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Metastatic Renal Cell Carcinoma</Condition>
    <Intervention>Procedure: Nephrectomy;Other: Sunitinib alone</Intervention>
    <Primary_outcome>The primary endpoint is overall survival.</Primary_outcome>
    <Secondary_outcome>Objective Response (complete or partial) is evaluated according to RECIST 1.1 criteria;Clinical benefit (complete response, partial or stable for at least 12 weeks).;Progression-Free Survival;Non-compliance to Sunitinib treatment is evaluated in arm A (nephrectomy + sunitinib) as the percentage of patients not starting sunitinib treatment within 6 weeks after nephrectomy;Non-compliance to sunitinib treatment is evaluated in arm B (sunitinib alone) as the percentage of patients needing nephrectomy;Post operative morbidity is evaluated as the percentage of deaths within 30 days following nephrectomy</Secondary_outcome>
    <Secondary_ID>P070144</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Pfizer</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2913918</Internal_Number>
    <TrialID>NCT00931255</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Tacrolimus to Sirolimus Conversion for Delayed Graft Function</Public_title>
    <Scientific_title>Delayed Tacrolimus to Sirolimus Conversion in Renal Transplant Recipients With Delayed Graft Function</Scientific_title>
    <Acronym>RAPA</Acronym>
    <Primary_sponsor>University of Maryland</Primary_sponsor>
    <Date_registration3>20090629</Date_registration3>
    <Date_registration>29/06/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00931255</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2009</Date_enrollement>
    <Target_size>80</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Age =&gt; 18.&lt;br&gt;&lt;br&gt;          2. Recipient of a deceased donor kidney transplant.&lt;br&gt;&lt;br&gt;          3. Delayed graft function, defined as need for dialysis during first week after surgery&lt;br&gt;             or slow graft function, defined as creatinine &gt;=3.0 by post-op day 5 without&lt;br&gt;             requiring dialysis&lt;br&gt;&lt;br&gt;          4. Stable serum creatinine for 2 weeks prior to enrollment.&lt;br&gt;&lt;br&gt;          5. Able to give informed consent.&lt;br&gt;&lt;br&gt;          6. Compliant with medical regimen and clinic visits.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Episode of acute rejection within 4 weeks prior to enrollment.&lt;br&gt;&lt;br&gt;          2. Calculated GFR &lt; 30 ml/min.&lt;br&gt;&lt;br&gt;          3. Interstitial fibrosis &amp; tubular atrophy in transplant biopsy higher than grade II&lt;br&gt;             (Banff"05 update).&lt;br&gt;&lt;br&gt;          4. Proteinuria &gt; 500 mg/24 h or spot urine protein/creatinine &gt; 0.5.&lt;br&gt;&lt;br&gt;          5. Total fasting cholesterol level &gt; 300 mg/dl or triglyceride &gt; 500 mg/dl despite&lt;br&gt;             optimal lipid lowering therapy.&lt;br&gt;&lt;br&gt;          6. Recipient of pancreas or liver allografts.&lt;br&gt;&lt;br&gt;          7. Leukopenia (WBC &lt; 3000 mm3) within 2 weeks prior to enrollment.&lt;br&gt;&lt;br&gt;          8. Leukopenia (WBC &lt; 2000 mm3) within 4 weeks prior to enrollment.&lt;br&gt;&lt;br&gt;          9. Thrombocytopenia (platelets count &lt; 100,000/mm3) within 2 weeks prior to enrollment.&lt;br&gt;&lt;br&gt;         10. Unwilling to comply with study protocol.&lt;br&gt;&lt;br&gt;         11. Enrollment in another drug trial that precludes use of sirolimus.&lt;br&gt;&lt;br&gt;         12. Diagnosis of malignancy within 2 years prior to enrollment, except adequately treated&lt;br&gt;             non-melanoma skin cancer.&lt;br&gt;&lt;br&gt;         13. For women, pregnancy.&lt;br&gt;&lt;br&gt;         14. Allergy to iodine&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Transplant;Delayed Graft Function;Slow Graft Function-defined at Creatinine &gt;= 3.0 by Post-op Day 5 Without Requiring Dialysis</Condition>
    <Intervention>Drug: Tacrolimus (FK506, Prograf);Drug: Sirolimus (Rapamune, Rapamycin)</Intervention>
    <Primary_outcome>The composite endpoint of reduction of e eGFR at one year by more than 15% &amp; the progression in fibrosis score at one year by &gt;=20% compared with the baseline values</Primary_outcome>
    <Secondary_outcome>eGFR;Change in eGFR from baseline to 1-year;Graft survival (Actual, Actuarial);Patient survival (Actual and Actuarial);Incidence &amp; severity of acute rejection (Actual, Actuarial);Incidence of development of DSA;Incidence of BK nephropathy (Cumulative);Change in inflammatory markers (including IL-6, MCP, CRP)from baseline</Secondary_outcome>
    <Secondary_ID>04868X1-4515;HP-00042201</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Wyeth is now a wholly owned subsidiary of Pfizer</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2914543</Internal_Number>
    <TrialID>NCT00939445</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Short Daily Hemodialysis and Online HDF: Which One is Better?</Public_title>
    <Scientific_title>Short Daily Hemodialysis and Online HDF: Which One is Better?</Scientific_title>
    <Acronym>SHD</Acronym>
    <Primary_sponsor>Bangkok Metropolitan Administration Medical College and Vajira Hospital</Primary_sponsor>
    <Date_registration3>20090714</Date_registration3>
    <Date_registration>14/07/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00939445</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2009</Date_enrollement>
    <Target_size>10</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Crossover Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  stable ESRD&lt;br&gt;&lt;br&gt;          -  KT/V &gt; 1.2 for thrice weekly or &gt; 1.8 for twice weekly&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Inadequate vascular access flow rate&lt;br&gt;&lt;br&gt;          -  Concurrent medical illnesses&lt;br&gt;&lt;br&gt;          -  History of non-compliance&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End Stage Renal Disease</Condition>
    <Intervention>Procedure: Online HDF;Procedure: Short Daily Hemodialysis</Intervention>
    <Primary_outcome>Adequacy</Primary_outcome>
    <Secondary_outcome>Hematocrit, calcium, phosphorus</Secondary_outcome>
    <Secondary_ID>VJR-NEPHRO001</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2914658</Internal_Number>
    <TrialID>NCT00940940</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation</Public_title>
    <Scientific_title>Safety and Immunogenicity of Live Attenuated Herpes Zoster Vaccine in Patients Undergoing Living Donor Kidney Transplantations</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Alberta</Primary_sponsor>
    <Date_registration3>20090715</Date_registration3>
    <Date_registration>15/07/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00940940</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>65 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2009</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator), Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Age 18-65 years&lt;br&gt;&lt;br&gt;          2. Listed or will likely be listed for live donor kidney transplant within one month&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        1. Previous receipt of Zostavax&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Transplant</Condition>
    <Intervention>Biological: Zostavax (Live attenuated herpes zoster vaccine);Biological: Placebo vaccine</Intervention>
    <Primary_outcome>Immunogenicity</Primary_outcome>
    <Secondary_ID>DKUA-001</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2915160</Internal_Number>
    <TrialID>NCT00947479</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effect of Obstructive Sleep Apnea on Central Blood Pressure and Kidney and Endothelial Function</Public_title>
    <Scientific_title>Effect of Correction of Obstructive Sleep Apnea With Positive Airway Pressure on Central Blood Pressure and Kidney and Endothelial Function</Scientific_title>
    <Acronym>OSA-AKI</Acronym>
    <Primary_sponsor>Medical Universtity of Lodz</Primary_sponsor>
    <Date_registration3>20090727</Date_registration3>
    <Date_registration>27/07/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00947479</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>Male</Inclusion_gender>
    <Date_enrollement>February 2009</Date_enrollement>
    <Target_size>50</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Diagnostic</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Males with high risk of obstructive sleep apnea syndrome as clinically assessed by&lt;br&gt;             coincidence of typical symptoms (e.g. daily somnolence, witnessed apnea,&lt;br&gt;             non-refreshing sleep), obesity and high score on Epworth sleepiness scale (ESS) with&lt;br&gt;             age range from 18 to 70 years&lt;br&gt;&lt;br&gt;          2. Glomerular filtration rate (MDRD formula-based) &gt; 60 ml/min&lt;br&gt;&lt;br&gt;          3. Arterial hypertension diagnosed according to the European Society of Hypertension&lt;br&gt;             2007 Guidelines.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Mental illness&lt;br&gt;&lt;br&gt;          2. Proteinuria &gt;2 g/24h&lt;br&gt;&lt;br&gt;          3. Acute and chronic inflammation&lt;br&gt;&lt;br&gt;          4. Heart failure III or IV grade&lt;br&gt;&lt;br&gt;          5. Uncontrolled diabetes mellitus&lt;br&gt;&lt;br&gt;          6. Severe lipid disturbances (triglyceride and/or total cholesterol concentration &gt; 300&lt;br&gt;             mg/dl)&lt;br&gt;&lt;br&gt;          7. Chronic administration of drugs with confirmed nephrotoxicity and/or&lt;br&gt;             sympathicomimetics&lt;br&gt;&lt;br&gt;          8. Obstructive and restrictive pulmonary diseases which may deteriorate the function of&lt;br&gt;             the respiratory system&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Obstructive Sleep Apnea;Acute Kidney Failure;Chronic Kidney Disease</Condition>
    <Intervention>Other: continuous positive airway pressure (CPAP)</Intervention>
    <Primary_outcome>presence of acute kidney injury</Primary_outcome>
    <Secondary_ID>UMLodz OSA-AKI</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2915160</Internal_Number>
    <TrialID>NCT00947479</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effect of Obstructive Sleep Apnea on Central Blood Pressure and Kidney and Endothelial Function</Public_title>
    <Scientific_title>Effect of Correction of Obstructive Sleep Apnea With Positive Airway Pressure on Central Blood Pressure and Kidney and Endothelial Function</Scientific_title>
    <Acronym>OSA-AKI</Acronym>
    <Primary_sponsor>Medical Universtity of Lodz</Primary_sponsor>
    <Date_registration3>20090727</Date_registration3>
    <Date_registration>27/07/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00947479</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>Male</Inclusion_gender>
    <Date_enrollement>February 2009</Date_enrollement>
    <Target_size>50</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Diagnostic</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Males with high risk of obstructive sleep apnea syndrome as clinically assessed by&lt;br&gt;             coincidence of typical symptoms (e.g. daily somnolence, witnessed apnea,&lt;br&gt;             non-refreshing sleep), obesity and high score on Epworth sleepiness scale (ESS) with&lt;br&gt;             age range from 18 to 70 years&lt;br&gt;&lt;br&gt;          2. Glomerular filtration rate (MDRD formula-based) &gt; 60 ml/min&lt;br&gt;&lt;br&gt;          3. Arterial hypertension diagnosed according to the European Society of Hypertension&lt;br&gt;             2007 Guidelines.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Mental illness&lt;br&gt;&lt;br&gt;          2. Proteinuria &gt;2 g/24h&lt;br&gt;&lt;br&gt;          3. Acute and chronic inflammation&lt;br&gt;&lt;br&gt;          4. Heart failure III or IV grade&lt;br&gt;&lt;br&gt;          5. Uncontrolled diabetes mellitus&lt;br&gt;&lt;br&gt;          6. Severe lipid disturbances (triglyceride and/or total cholesterol concentration &gt; 300&lt;br&gt;             mg/dl)&lt;br&gt;&lt;br&gt;          7. Chronic administration of drugs with confirmed nephrotoxicity and/or&lt;br&gt;             sympathicomimetics&lt;br&gt;&lt;br&gt;          8. Obstructive and restrictive pulmonary diseases which may deteriorate the function of&lt;br&gt;             the respiratory system&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Obstructive Sleep Apnea;Acute Kidney Failure;Chronic Kidney Disease</Condition>
    <Intervention>Other: continuous positive airway pressure (CPAP)</Intervention>
    <Primary_outcome>presence of acute kidney injury</Primary_outcome>
    <Secondary_ID>UMLodz OSA-AKI</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2915209</Internal_Number>
    <TrialID>NCT00948116</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Development of a Biomarker Panel for the Earlier Prediction of Acute Kidney Injury in Patients With Diabetes</Public_title>
    <Scientific_title>Development of a Biomarker Panel for the Earlier Prediction of Acute Kidney Injury in Patients With Diabetes Mellitus Undergoing Coronary Revascularisation</Scientific_title>
    <Acronym>BIOMARKERS</Acronym>
    <Primary_sponsor>Barts &amp; The London NHS Trust</Primary_sponsor>
    <Date_registration3>20090728</Date_registration3>
    <Date_registration>28/07/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00948116</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2009</Date_enrollement>
    <Target_size>250</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Age &gt; 18 years, known diabetes mellitus or BM on arrival consistent with probable&lt;br&gt;             diagnosis of diabetes, eGFR &lt;60 ml/min&lt;br&gt;&lt;br&gt;          2. Undergoing a PCI procedure&lt;br&gt;&lt;br&gt;          3. Agrees to the additional collection of blood and urine samples as outlined above&lt;br&gt;&lt;br&gt;          4. Agrees to access of their clinical records for the collection of relevant medical&lt;br&gt;             data&lt;br&gt;&lt;br&gt;          5. No history or signs of drug abuse&lt;br&gt;&lt;br&gt;          6. Able to understand and sign the written Informed Consent Form&lt;br&gt;&lt;br&gt;          7. Able and willing to follow the Protocol requirements&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Cardiogenic shock&lt;br&gt;&lt;br&gt;          2. Pregnancy&lt;br&gt;&lt;br&gt;          3. Patient on renal replacement therapy (haemodialysis/CAPD/renal transplant)&lt;br&gt;&lt;br&gt;          4. Known clinically significant infection such as HIV, Hepatitis or TB&lt;br&gt;&lt;br&gt;          5. Any patient determined not able to make a reasoned, informed consent prior to the&lt;br&gt;             planned interventional procedure&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Diabetes Mellitus;Renal Impairment</Condition>
    <Primary_outcome>Development of contrast induced nephropathy (CIN) which will be defined as an increase in Cr of =  44 µmol/l within 72 hours post-procedure.</Primary_outcome>
    <Secondary_ID>REC 09/H0703/29;ReDA: 006580 QM;09/H0703/29</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2915243</Internal_Number>
    <TrialID>NCT00948558</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Citrate Pharmacokinetics and Regional Citrate Anticoagulation in CRRT</Public_title>
    <Scientific_title>Citrate Pharmacokinetics in Healthy Individuals and Critically Ill Patients and the Application of Regional Citrate Anticoagulation in Continuous Renal Replacement Therapy(RCA-CRRT).</Scientific_title>
    <Acronym />
    <Primary_sponsor>Huashan Hospital</Primary_sponsor>
    <Date_registration3>20090728</Date_registration3>
    <Date_registration>28/07/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00948558</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2009</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case Control, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  healthy individuals, none-pregnant&lt;br&gt;&lt;br&gt;          -  diagnosed with acute renal failure according to RIFLE criteria&lt;br&gt;&lt;br&gt;          -  ARF with hepatic insufficiency&lt;br&gt;&lt;br&gt;          -  ARF with MODS or sepsis&lt;br&gt;&lt;br&gt;          -  within informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  used drugs with citrate within one week&lt;br&gt;&lt;br&gt;          -  infused with blood,plasma or platelet or undergone plasma exchange therapy  within 48&lt;br&gt;             hours&lt;br&gt;&lt;br&gt;          -  serious alkalosis with PH&gt;7.55&lt;br&gt;&lt;br&gt;          -  serious lactic acidosis&lt;br&gt;&lt;br&gt;          -  not in resuscitation state&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Kidney Failure With or Without:;MODS;Sepsis;Hepatic Insufficiency</Condition>
    <Secondary_ID>KY2009-108</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Shanghai Scientific and technology committe</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2915658</Internal_Number>
    <TrialID>NCT00953992</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Etiology, Epidemiology and Prognostics of Acute Kidney Injury (AKI)</Public_title>
    <Scientific_title>The Study of Etiology, Epidemiology and Prognostic Factors of Acute Kidney Injury</Scientific_title>
    <Acronym />
    <Primary_sponsor>Huashan Hospital</Primary_sponsor>
    <Date_registration3>20090805</Date_registration3>
    <Date_registration>05/08/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00953992</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>16 Years</Inclusion_agemin>
    <Inclusion_agemax>88 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2009</Date_enrollement>
    <Target_size>300</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  age &gt;=16 years and &lt;= 88 years&lt;br&gt;&lt;br&gt;          -  clinically diagnosed with acute kidney injury, according RIFLE criteria.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  acute Renal Failure occurring in the setting of burns, obstructive uropathy, allergic&lt;br&gt;             interstitial nephritis, acute or rapidly progressive glomerulonephritis, vasculitis,&lt;br&gt;             hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura (TTP), malignant&lt;br&gt;             hypertension, scleroderma renal crisis, atheroembolism, functional or surgical&lt;br&gt;             nephrectomy, hepatorenal syndrome, cyclosporin or tacrolimus nephrotoxicity&lt;br&gt;&lt;br&gt;          -  Do Not Resuscitate (DNR) status&lt;br&gt;&lt;br&gt;          -  subjects enrolled in another clinical trial that could affect the outcome of this&lt;br&gt;             study protocol&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Failure;Nutrition</Condition>
    <Primary_outcome>renal function survival rate days in the hospital days in the ICU</Primary_outcome>
    <Secondary_ID>KY2009-107</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2916686</Internal_Number>
    <TrialID>NCT00967577</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors</Public_title>
    <Scientific_title>177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Nonprostate Metastatic Solid Tumors: A Pilot Study</Scientific_title>
    <Acronym />
    <Primary_sponsor>Weill Medical College of Cornell University</Primary_sponsor>
    <Date_registration3>20090826</Date_registration3>
    <Date_registration>26/08/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00967577</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2009</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Histologically, or cytologically documented, advanced stage, malignant adult solid&lt;br&gt;             tumors (except prostate cancer) that are refractory to, or recurrent from, standard&lt;br&gt;             therapy or for which no curative standard therapy exists. This will include, but is&lt;br&gt;             not limited to patients with cancers of the kidney, urothelium, head and neck,&lt;br&gt;             breast, non-small cell lung, colorectal, pancreas, ovary, esophagus and gliomas.&lt;br&gt;&lt;br&gt;          -  Metastatic or recurrent solid tumor malignancy defined by abnormal CT, MRI, PET scan,&lt;br&gt;             CXR and/or bone scan&lt;br&gt;&lt;br&gt;          -  Progressive disease manifest by: Development of new lesions or an increase in size of&lt;br&gt;             preexisting lesions on imaging study or by physical examination.&lt;br&gt;&lt;br&gt;          -  Subjects must have recovered from the acute toxicities of any prior therapy, and not&lt;br&gt;             received chemotherapy, radiation therapy or other investigational anticancer&lt;br&gt;             therapeutic drug for at least 4 weeks prior to J591 administration in this trial&lt;br&gt;&lt;br&gt;          -  All subjects must have archived or current tissue (from a primary or metastatic&lt;br&gt;             focus) available for PSMA determination.&lt;br&gt;&lt;br&gt;          -  Subjects on bisphosphonate therapy must be on a stable dose and must have started&lt;br&gt;             therapy &gt; 4 weeks prior to protocol therapy.&lt;br&gt;&lt;br&gt;          -  Subjects will be informed as to the potential risk of procreation while participating&lt;br&gt;             on this trial and will be advised to use effective contraception during the entire&lt;br&gt;             study period. Females of child-bearing potential must have a negative pregnancy test.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Use of red blood cell or platelet transfusions within 4 weeks of treatment.&lt;br&gt;&lt;br&gt;          -  Use of hematopoietic growth factors within 4 weeks of treatment.&lt;br&gt;&lt;br&gt;          -  Prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment.&lt;br&gt;&lt;br&gt;          -  Prior radiation therapy encompassing &gt;25% of skeleton.&lt;br&gt;&lt;br&gt;          -  Prior treatment with 89Strontium or 153Samarium containing compounds (e.g.&lt;br&gt;             Metastron®, Quadramet®)&lt;br&gt;&lt;br&gt;          -  Platelet count &lt;150,000/mm3 or history of platelet count abnormality or dysfunction.&lt;br&gt;&lt;br&gt;          -  Absolute neutrophil count (ANC) &lt;2,000/mm3&lt;br&gt;&lt;br&gt;          -  Hematocrit &lt;30 percent or Hemoglobin &lt; 10 g/dL&lt;br&gt;&lt;br&gt;          -  Abnormal coagulation profile (PT or INR, PTT) &gt; 1.3x upper limit of normal (ULN)&lt;br&gt;&lt;br&gt;          -  Serum creatinine &gt; 2x ULN&lt;br&gt;&lt;br&gt;          -  AST (SGOT) &gt;2.5x ULN&lt;br&gt;&lt;br&gt;          -  Bilirubin (total) &gt;1.5x ULN&lt;br&gt;&lt;br&gt;          -  Active serious infection&lt;br&gt;&lt;br&gt;          -  Active angina pectoris or NY Heart Association Class III-IV&lt;br&gt;&lt;br&gt;          -  ECOG Performance Status &gt; 2&lt;br&gt;&lt;br&gt;          -  Deep vein thrombosis and/or pulmonary embolus within 1 month of enrollment.&lt;br&gt;&lt;br&gt;          -  Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or&lt;br&gt;             hematological organ systems which might preclude completion of this study or&lt;br&gt;             interfere with determination of causality of any adverse effects experienced in this&lt;br&gt;             study.&lt;br&gt;&lt;br&gt;          -  Prior investigational therapy (medications or devices) within 6 weeks of treatment.&lt;br&gt;&lt;br&gt;          -  Known history of HIV.&lt;br&gt;&lt;br&gt;          -  Known leukemia or myelodysplastic syndrome&lt;br&gt;&lt;br&gt;          -  Prior allergic reaction to Gadolinium contrast.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Cancer;Head and Neck Cancer;Breast Cancer;Non-small Cell Lung Cancer;Colorectal Cancer;Pancreatic Cancer;Ovarian Cancer;Esophageal Cancer;Gliomas</Condition>
    <Intervention>Drug: 177Lu-J591</Intervention>
    <Primary_outcome>Change in tumor perfusion as based on DCE-MRI study as well as changes in cellularity as assessed using DWI.</Primary_outcome>
    <Secondary_outcome>Progression free survival</Secondary_outcome>
    <Secondary_ID>0902010212</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2917507</Internal_Number>
    <TrialID>NCT00978354</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Furosemide in Early Acute Kidney Injury</Public_title>
    <Scientific_title>A Phase II Randomized Blinded Controlled Trial of the Effect of furoSemide in Critically Ill Patients With eARly Acute Kidney Injury (The SPARK Study)</Scientific_title>
    <Acronym>SPARK</Acronym>
    <Primary_sponsor>University of Alberta</Primary_sponsor>
    <Date_registration3>20090914</Date_registration3>
    <Date_registration>14/09/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00978354</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2009</Date_enrollement>
    <Target_size>216</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2/Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Informed and written consent by patient or surrogate&lt;br&gt;&lt;br&gt;          -  Peripheral or central intravenous catheter&lt;br&gt;&lt;br&gt;          -  The presence of early AKI&lt;br&gt;&lt;br&gt;          -  2 or more criteria for the systemic inflammatory response syndrome (SIRS) within 24&lt;br&gt;             hours&lt;br&gt;&lt;br&gt;          -  Achieved immediate resuscitation goals&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Confirmed or suspected pregnancy&lt;br&gt;&lt;br&gt;          -  Age &lt;18 years&lt;br&gt;&lt;br&gt;          -  Stage 4 or greater chronic kidney disease or kidney transplantation&lt;br&gt;&lt;br&gt;          -  Acute pulmonary edema requiring urgent use of furosemide or RRT&lt;br&gt;&lt;br&gt;          -  Patient is moribund with expected death within 24 hours&lt;br&gt;&lt;br&gt;          -  Known or suspected drug allergy to furosemide&lt;br&gt;&lt;br&gt;          -  Enrolled in concomitant randomized trial&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Renal Failure</Condition>
    <Intervention>Drug: Furosemide;Drug: Normal Saline</Intervention>
    <Primary_outcome>Worsening AKI</Primary_outcome>
    <Secondary_outcome>Fluid balance;Renal replacement therapy (RRT);Renal Recovery;Survival</Secondary_outcome>
    <Secondary_ID>AHFMR-0920</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Grey Nuns Community Hospital, Edmonton, Canada;Austin Hospital, Melbourne Australia;Princess Alexandra Hospital, Brisbane, Australia</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2917554</Internal_Number>
    <TrialID>NCT00978965</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Identification of Patients With High Probability of Poorly Responding to Therapy With Mycophenolic Acid Prodrugs</Public_title>
    <Scientific_title>Identification of Patients With High Probability of Not or Poorly Responding to Mycophenolate-mofetil (Cellcept®) or Mycophenolate-natrium (Myfortic®) Therapy</Scientific_title>
    <Acronym />
    <Primary_sponsor>Medical University of Vienna</Primary_sponsor>
    <Date_registration3>20090914</Date_registration3>
    <Date_registration>14/09/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00978965</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2009</Date_enrollement>
    <Target_size>250</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  patients with a de novo kidney graft and age &gt;18 and &lt; 75&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  pregnancy&lt;br&gt;&lt;br&gt;          -  panel of antigens reactivity &gt; 40%&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Transplantation</Condition>
    <Intervention>Genetic: MPA SNP</Intervention>
    <Primary_outcome>Detection of functionally relevant SNPs in IMPDH 2 gene.;The association of detected SNPs in inosine monophosphate dehydrogenase-2 transcript or high IMPDH 2 activity with the lack of response to MPA therapy defined as - number of biopsy proven acute rejections in the first year after transplantation</Primary_outcome>
    <Secondary_ID>MPASNPVienna</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Novartis</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2917582</Internal_Number>
    <TrialID>NCT00979329</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST</Public_title>
    <Scientific_title>Study on the Influence of Sunitinib and Sorafenib on Fatigue, Quality of Life and Depression in Patients With Metastatic Renal Cell Cancer or GIST</Scientific_title>
    <Acronym />
    <Primary_sponsor>Radboud University</Primary_sponsor>
    <Date_registration3>20090917</Date_registration3>
    <Date_registration>17/09/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00979329</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2008</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case-Only, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  patients with metastatic renal cell or GIST for whom treatment with Sunitinib or&lt;br&gt;             Sorafenib is planned&lt;br&gt;&lt;br&gt;          -  Karnofsky score &gt; 70%&lt;br&gt;&lt;br&gt;          -  age &gt; 18 year&lt;br&gt;&lt;br&gt;          -  written informed consent for questionnaires&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  contra-indications for treatment with Sunitinib or Sorafenib&lt;br&gt;&lt;br&gt;          -  patients who do not speak or write the Dutch language adequately&lt;br&gt;&lt;br&gt;          -  previous systemic treatment within the last 7 days before start with the study, with&lt;br&gt;             Sunitinib, Sorafenib or Bevacizumab&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Cell Cancer;Colorectal Cancer;GIST</Condition>
    <Intervention>Other: Questionnaires</Intervention>
    <Secondary_ID>UMCNONCO20082</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2917654</Internal_Number>
    <TrialID>NCT00980317</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Third Parties</Public_title>
    <Scientific_title>A Clinical Study of the Living-unrelated Renal Transplantation With Restored Kidneys (Interventional Trial)</Scientific_title>
    <Acronym />
    <Primary_sponsor>Tokushukai Medical Group</Primary_sponsor>
    <Date_registration3>20090917</Date_registration3>
    <Date_registration>17/09/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00980317</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin>20 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2009</Date_enrollement>
    <Target_size>5</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Recipient:&lt;br&gt;&lt;br&gt;               -  Patients who are on dialysis and are willing to receive a restored kidney from a&lt;br&gt;                  third party&lt;br&gt;&lt;br&gt;               -  Patients who are eligible for general anesthesia&lt;br&gt;&lt;br&gt;               -  Patients who have given written informed consent to participate in the study&lt;br&gt;&lt;br&gt;          2. Donor:&lt;br&gt;&lt;br&gt;               -  Patients who have small tumor (size: &lt;4 cm) in the kidney and have chosen total&lt;br&gt;                  nephrectomy among all the available treatment options and have permitted to&lt;br&gt;                  transplant the nephrectomized kidney to a third party upon its surgical&lt;br&gt;                  restoration&lt;br&gt;&lt;br&gt;               -  Patients who are eligible for general anesthesia&lt;br&gt;&lt;br&gt;               -  Patients who have given written informed consent to participate in the study&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Recipient:&lt;br&gt;&lt;br&gt;               -  Patients who have infectious disease, hemorrhagic ulcer, or malignant cancer&lt;br&gt;&lt;br&gt;               -  Patients who have serious vascular lesions (eg. arteriosclerosis, thromboembolic&lt;br&gt;                  disease) and are currently on treatment&lt;br&gt;&lt;br&gt;               -  Patients who were disapproved by the Institutional Ethics Committee&lt;br&gt;&lt;br&gt;          2. Donor:&lt;br&gt;&lt;br&gt;               -  Patients who have tested positive for serious infectious disease (eg. HIV, HBV,&lt;br&gt;                  or HCV)&lt;br&gt;&lt;br&gt;               -  Patients who were diagnosed with malignant lymphoma or sarcoma&lt;br&gt;&lt;br&gt;               -  Patients who were on chemotherapy or radiation therapy for renal cancer prior to&lt;br&gt;                  the nephrectomy&lt;br&gt;&lt;br&gt;               -  Patients who were disapproved by the Institutional Ethics Committee&lt;br&gt;&lt;br&gt;        (*) Other inclusion/exclusion criteria defined in the protocol for both recipient and&lt;br&gt;        donor may apply.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Neoplasms;Renal Insufficiency;Renal Replacement Therapy</Condition>
    <Intervention>Procedure: Restored Kidney Transplant Between Third Parties</Intervention>
    <Primary_outcome>Evaluation of curative efficacy (renal function and QOL) and safety (side effects, complications or occurence of renal cancer) after renal transplantation with restored donor kidneys to third party recipients</Primary_outcome>
    <Secondary_ID>TW062090715KT</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2917654</Internal_Number>
    <TrialID>NCT00980317</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Third Parties</Public_title>
    <Scientific_title>A Clinical Study of the Living-unrelated Renal Transplantation With Restored Kidneys (Interventional Trial)</Scientific_title>
    <Acronym />
    <Primary_sponsor>Tokushukai Medical Group</Primary_sponsor>
    <Date_registration3>20090917</Date_registration3>
    <Date_registration>17/09/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00980317</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin>20 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2009</Date_enrollement>
    <Target_size>5</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Recipient:&lt;br&gt;&lt;br&gt;               -  Patients who are on dialysis and are willing to receive a restored kidney from a&lt;br&gt;                  third party&lt;br&gt;&lt;br&gt;               -  Patients who are eligible for general anesthesia&lt;br&gt;&lt;br&gt;               -  Patients who have given written informed consent to participate in the study&lt;br&gt;&lt;br&gt;          2. Donor:&lt;br&gt;&lt;br&gt;               -  Patients who have small tumor (size: &lt;4 cm) in the kidney and have chosen total&lt;br&gt;                  nephrectomy among all the available treatment options and have permitted to&lt;br&gt;                  transplant the nephrectomized kidney to a third party upon its surgical&lt;br&gt;                  restoration&lt;br&gt;&lt;br&gt;               -  Patients who are eligible for general anesthesia&lt;br&gt;&lt;br&gt;               -  Patients who have given written informed consent to participate in the study&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Recipient:&lt;br&gt;&lt;br&gt;               -  Patients who have infectious disease, hemorrhagic ulcer, or malignant cancer&lt;br&gt;&lt;br&gt;               -  Patients who have serious vascular lesions (eg. arteriosclerosis, thromboembolic&lt;br&gt;                  disease) and are currently on treatment&lt;br&gt;&lt;br&gt;               -  Patients who were disapproved by the Institutional Ethics Committee&lt;br&gt;&lt;br&gt;          2. Donor:&lt;br&gt;&lt;br&gt;               -  Patients who have tested positive for serious infectious disease (eg. HIV, HBV,&lt;br&gt;                  or HCV)&lt;br&gt;&lt;br&gt;               -  Patients who were diagnosed with malignant lymphoma or sarcoma&lt;br&gt;&lt;br&gt;               -  Patients who were on chemotherapy or radiation therapy for renal cancer prior to&lt;br&gt;                  the nephrectomy&lt;br&gt;&lt;br&gt;               -  Patients who were disapproved by the Institutional Ethics Committee&lt;br&gt;&lt;br&gt;        (*) Other inclusion/exclusion criteria defined in the protocol for both recipient and&lt;br&gt;        donor may apply.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Neoplasms;Renal Insufficiency;Renal Replacement Therapy</Condition>
    <Intervention>Procedure: Restored Kidney Transplant Between Third Parties</Intervention>
    <Primary_outcome>Evaluation of curative efficacy (renal function and QOL) and safety (side effects, complications or occurence of renal cancer) after renal transplantation with restored donor kidneys to third party recipients</Primary_outcome>
    <Secondary_ID>TW062090715KT</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2917654</Internal_Number>
    <TrialID>NCT00980317</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Third Parties</Public_title>
    <Scientific_title>A Clinical Study of the Living-unrelated Renal Transplantation With Restored Kidneys (Interventional Trial)</Scientific_title>
    <Acronym />
    <Primary_sponsor>Tokushukai Medical Group</Primary_sponsor>
    <Date_registration3>20090917</Date_registration3>
    <Date_registration>17/09/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00980317</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin>20 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2009</Date_enrollement>
    <Target_size>5</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Recipient:&lt;br&gt;&lt;br&gt;               -  Patients who are on dialysis and are willing to receive a restored kidney from a&lt;br&gt;                  third party&lt;br&gt;&lt;br&gt;               -  Patients who are eligible for general anesthesia&lt;br&gt;&lt;br&gt;               -  Patients who have given written informed consent to participate in the study&lt;br&gt;&lt;br&gt;          2. Donor:&lt;br&gt;&lt;br&gt;               -  Patients who have small tumor (size: &lt;4 cm) in the kidney and have chosen total&lt;br&gt;                  nephrectomy among all the available treatment options and have permitted to&lt;br&gt;                  transplant the nephrectomized kidney to a third party upon its surgical&lt;br&gt;                  restoration&lt;br&gt;&lt;br&gt;               -  Patients who are eligible for general anesthesia&lt;br&gt;&lt;br&gt;               -  Patients who have given written informed consent to participate in the study&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Recipient:&lt;br&gt;&lt;br&gt;               -  Patients who have infectious disease, hemorrhagic ulcer, or malignant cancer&lt;br&gt;&lt;br&gt;               -  Patients who have serious vascular lesions (eg. arteriosclerosis, thromboembolic&lt;br&gt;                  disease) and are currently on treatment&lt;br&gt;&lt;br&gt;               -  Patients who were disapproved by the Institutional Ethics Committee&lt;br&gt;&lt;br&gt;          2. Donor:&lt;br&gt;&lt;br&gt;               -  Patients who have tested positive for serious infectious disease (eg. HIV, HBV,&lt;br&gt;                  or HCV)&lt;br&gt;&lt;br&gt;               -  Patients who were diagnosed with malignant lymphoma or sarcoma&lt;br&gt;&lt;br&gt;               -  Patients who were on chemotherapy or radiation therapy for renal cancer prior to&lt;br&gt;                  the nephrectomy&lt;br&gt;&lt;br&gt;               -  Patients who were disapproved by the Institutional Ethics Committee&lt;br&gt;&lt;br&gt;        (*) Other inclusion/exclusion criteria defined in the protocol for both recipient and&lt;br&gt;        donor may apply.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Neoplasms;Renal Insufficiency;Renal Replacement Therapy</Condition>
    <Intervention>Procedure: Restored Kidney Transplant Between Third Parties</Intervention>
    <Primary_outcome>Evaluation of curative efficacy (renal function and QOL) and safety (side effects, complications or occurence of renal cancer) after renal transplantation with restored donor kidneys to third party recipients</Primary_outcome>
    <Secondary_ID>TW062090715KT</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2918712</Internal_Number>
    <TrialID>NCT00994188</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Family Members</Public_title>
    <Scientific_title>A Clinical Study of the Living-related Renal Transplantation With Restored Kidneys (Interventional Trial)</Scientific_title>
    <Acronym />
    <Primary_sponsor>Tokushukai Medical Group</Primary_sponsor>
    <Date_registration3>20091009</Date_registration3>
    <Date_registration>09/10/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00994188</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin>20 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2009</Date_enrollement>
    <Target_size>5</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        A) Recipient:&lt;br&gt;&lt;br&gt;          -  Patients who are suffering from renal failure and are willing to receive a restored&lt;br&gt;             kidney from a family member&lt;br&gt;&lt;br&gt;          -  Patients who are eligible for general anesthesia&lt;br&gt;&lt;br&gt;          -  Patients who have given written informed consent to participate in the study&lt;br&gt;&lt;br&gt;        B) Donor:&lt;br&gt;&lt;br&gt;          -  Potential donors who are incidentally diagnosed with small renal tumor (size: &lt;4 cm)&lt;br&gt;             or renal stone, ureteral tumor or ureteral stricture and have permitted to transplant&lt;br&gt;             the kidney to a family member upon its surgical restoration&lt;br&gt;&lt;br&gt;          -  Patients who are eligible for general anesthesia&lt;br&gt;&lt;br&gt;          -  Patients who have given written informed consent to participate in the study&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        A) Recipient:&lt;br&gt;&lt;br&gt;          -  Patients who have infectious disease, hemorrhagic ulcer, or malignant cancer&lt;br&gt;&lt;br&gt;          -  Patients who have serious vascular lesions (eg. arteriosclerosis, thromboembolic&lt;br&gt;             disease) and are currently on treatment&lt;br&gt;&lt;br&gt;          -  Patients who were disapproved by the Institutional Ethics Committee&lt;br&gt;&lt;br&gt;        B) Donor:&lt;br&gt;&lt;br&gt;          -  Patients who have tested positive for serious infectious disease (eg. HIV, HBV, or&lt;br&gt;             HCV)&lt;br&gt;&lt;br&gt;          -  Patients who were diagnosed with malignant lymphoma or sarcoma&lt;br&gt;&lt;br&gt;          -  Patients who were on chemotherapy or radiation therapy for renal cancer prior to the&lt;br&gt;             nephrectomy&lt;br&gt;&lt;br&gt;          -  Patients who were disapproved by the Institutional Ethics Committee&lt;br&gt;&lt;br&gt;        (*) Other inclusion/exclusion criteria defined in the protocol for both recipient and&lt;br&gt;        donor may apply.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Neoplasm;Kidney Stone;Ureteral Tumor;Ureteral Stricture;Renal Insufficiency</Condition>
    <Intervention>Procedure: Restored Kidney Transplant Between Family Members</Intervention>
    <Primary_outcome>Evaluation of curative efficacy (renal function and QOL) and safety (side effects, complications) after renal transplantation with restored kidneys between family members</Primary_outcome>
    <Secondary_ID>TW062090617KT</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2918712</Internal_Number>
    <TrialID>NCT00994188</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Family Members</Public_title>
    <Scientific_title>A Clinical Study of the Living-related Renal Transplantation With Restored Kidneys (Interventional Trial)</Scientific_title>
    <Acronym />
    <Primary_sponsor>Tokushukai Medical Group</Primary_sponsor>
    <Date_registration3>20091009</Date_registration3>
    <Date_registration>09/10/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00994188</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin>20 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2009</Date_enrollement>
    <Target_size>5</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        A) Recipient:&lt;br&gt;&lt;br&gt;          -  Patients who are suffering from renal failure and are willing to receive a restored&lt;br&gt;             kidney from a family member&lt;br&gt;&lt;br&gt;          -  Patients who are eligible for general anesthesia&lt;br&gt;&lt;br&gt;          -  Patients who have given written informed consent to participate in the study&lt;br&gt;&lt;br&gt;        B) Donor:&lt;br&gt;&lt;br&gt;          -  Potential donors who are incidentally diagnosed with small renal tumor (size: &lt;4 cm)&lt;br&gt;             or renal stone, ureteral tumor or ureteral stricture and have permitted to transplant&lt;br&gt;             the kidney to a family member upon its surgical restoration&lt;br&gt;&lt;br&gt;          -  Patients who are eligible for general anesthesia&lt;br&gt;&lt;br&gt;          -  Patients who have given written informed consent to participate in the study&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        A) Recipient:&lt;br&gt;&lt;br&gt;          -  Patients who have infectious disease, hemorrhagic ulcer, or malignant cancer&lt;br&gt;&lt;br&gt;          -  Patients who have serious vascular lesions (eg. arteriosclerosis, thromboembolic&lt;br&gt;             disease) and are currently on treatment&lt;br&gt;&lt;br&gt;          -  Patients who were disapproved by the Institutional Ethics Committee&lt;br&gt;&lt;br&gt;        B) Donor:&lt;br&gt;&lt;br&gt;          -  Patients who have tested positive for serious infectious disease (eg. HIV, HBV, or&lt;br&gt;             HCV)&lt;br&gt;&lt;br&gt;          -  Patients who were diagnosed with malignant lymphoma or sarcoma&lt;br&gt;&lt;br&gt;          -  Patients who were on chemotherapy or radiation therapy for renal cancer prior to the&lt;br&gt;             nephrectomy&lt;br&gt;&lt;br&gt;          -  Patients who were disapproved by the Institutional Ethics Committee&lt;br&gt;&lt;br&gt;        (*) Other inclusion/exclusion criteria defined in the protocol for both recipient and&lt;br&gt;        donor may apply.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Neoplasm;Kidney Stone;Ureteral Tumor;Ureteral Stricture;Renal Insufficiency</Condition>
    <Intervention>Procedure: Restored Kidney Transplant Between Family Members</Intervention>
    <Primary_outcome>Evaluation of curative efficacy (renal function and QOL) and safety (side effects, complications) after renal transplantation with restored kidneys between family members</Primary_outcome>
    <Secondary_ID>TW062090617KT</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2918712</Internal_Number>
    <TrialID>NCT00994188</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Family Members</Public_title>
    <Scientific_title>A Clinical Study of the Living-related Renal Transplantation With Restored Kidneys (Interventional Trial)</Scientific_title>
    <Acronym />
    <Primary_sponsor>Tokushukai Medical Group</Primary_sponsor>
    <Date_registration3>20091009</Date_registration3>
    <Date_registration>09/10/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00994188</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin>20 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2009</Date_enrollement>
    <Target_size>5</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        A) Recipient:&lt;br&gt;&lt;br&gt;          -  Patients who are suffering from renal failure and are willing to receive a restored&lt;br&gt;             kidney from a family member&lt;br&gt;&lt;br&gt;          -  Patients who are eligible for general anesthesia&lt;br&gt;&lt;br&gt;          -  Patients who have given written informed consent to participate in the study&lt;br&gt;&lt;br&gt;        B) Donor:&lt;br&gt;&lt;br&gt;          -  Potential donors who are incidentally diagnosed with small renal tumor (size: &lt;4 cm)&lt;br&gt;             or renal stone, ureteral tumor or ureteral stricture and have permitted to transplant&lt;br&gt;             the kidney to a family member upon its surgical restoration&lt;br&gt;&lt;br&gt;          -  Patients who are eligible for general anesthesia&lt;br&gt;&lt;br&gt;          -  Patients who have given written informed consent to participate in the study&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        A) Recipient:&lt;br&gt;&lt;br&gt;          -  Patients who have infectious disease, hemorrhagic ulcer, or malignant cancer&lt;br&gt;&lt;br&gt;          -  Patients who have serious vascular lesions (eg. arteriosclerosis, thromboembolic&lt;br&gt;             disease) and are currently on treatment&lt;br&gt;&lt;br&gt;          -  Patients who were disapproved by the Institutional Ethics Committee&lt;br&gt;&lt;br&gt;        B) Donor:&lt;br&gt;&lt;br&gt;          -  Patients who have tested positive for serious infectious disease (eg. HIV, HBV, or&lt;br&gt;             HCV)&lt;br&gt;&lt;br&gt;          -  Patients who were diagnosed with malignant lymphoma or sarcoma&lt;br&gt;&lt;br&gt;          -  Patients who were on chemotherapy or radiation therapy for renal cancer prior to the&lt;br&gt;             nephrectomy&lt;br&gt;&lt;br&gt;          -  Patients who were disapproved by the Institutional Ethics Committee&lt;br&gt;&lt;br&gt;        (*) Other inclusion/exclusion criteria defined in the protocol for both recipient and&lt;br&gt;        donor may apply.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Neoplasm;Kidney Stone;Ureteral Tumor;Ureteral Stricture;Renal Insufficiency</Condition>
    <Intervention>Procedure: Restored Kidney Transplant Between Family Members</Intervention>
    <Primary_outcome>Evaluation of curative efficacy (renal function and QOL) and safety (side effects, complications) after renal transplantation with restored kidneys between family members</Primary_outcome>
    <Secondary_ID>TW062090617KT</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2919233</Internal_Number>
    <TrialID>NCT01001000</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Colour Coded Duplex Ultrasound of Native Arterio-venous Fistula for Haemodialysis With Venous Pressure Measurement Using Controlled Compression Ultrasound as a Predictor for Shunt Maturation in the Early Postoperative Phase</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>University of Zurich</Primary_sponsor>
    <Date_registration3>20091022</Date_registration3>
    <Date_registration>22/10/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01001000</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2009</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion criteria:&lt;br&gt;&lt;br&gt;          -  Patients after creation of a native arterio-venous fistula at the cephalic vein for&lt;br&gt;             hemodialysis access;&lt;br&gt;&lt;br&gt;          -  Informed consent.&lt;br&gt;&lt;br&gt;        Exclusion criteria:&lt;br&gt;&lt;br&gt;          -  Former creation of a native arterio-venous fistula at the same arm;&lt;br&gt;&lt;br&gt;          -  Known upper extremity occlusive arterial disease;&lt;br&gt;&lt;br&gt;          -  Situation when ultrasound examination is not suitable: extreme swelling of the arm,&lt;br&gt;             post-operative pain, hematoma, local infections.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Insufficiency</Condition>
    <Intervention>Procedure: Ultrasound (Pressure measurement)</Intervention>
    <Secondary_ID>CT-01-2009-USZ</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2919238</Internal_Number>
    <TrialID>NCT01001065</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Association of the Intrarenal Resistance Index (RI) of Transplanted Kidneys With Generalized Atherosclerosis</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>University of Zurich</Primary_sponsor>
    <Date_registration3>20091022</Date_registration3>
    <Date_registration>22/10/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01001065</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2009</Date_enrollement>
    <Target_size>160</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion criteria:&lt;br&gt;&lt;br&gt;          -  Patients after renal transplantation with stable renal function&lt;br&gt;&lt;br&gt;        Exclusion criteria:&lt;br&gt;&lt;br&gt;          -  Known impairment of renal function (e.g. acute rejection)&lt;br&gt;&lt;br&gt;          -  Known renal artery or carotid artery stenosis&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Transplantation</Condition>
    <Intervention>Procedure: Vascular ultrasound</Intervention>
    <Secondary_ID>CT-03-2009-USZ</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2919381</Internal_Number>
    <TrialID>NCT01002937</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Novel Prognostic Markers in Renal Cancer</Public_title>
    <Scientific_title>Novel Prognostic Markers in Renal Cancer: a Protocol for the Analysis of Paraffin Embedded Tumour Samples</Scientific_title>
    <Acronym />
    <Primary_sponsor>Royal Marsden NHS Foundation Trust</Primary_sponsor>
    <Date_registration3>20091027</Date_registration3>
    <Date_registration>27/10/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01002937</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>December 2008</Date_enrollement>
    <Target_size>500</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Retrospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  The presence of histologically proven renal cell cancer&lt;br&gt;&lt;br&gt;          -  The availability of paraffin embedded tissue&lt;br&gt;&lt;br&gt;          -  Informed consent needed for tissue taken after January 2006 (date of enforcement of&lt;br&gt;             human tissue act)&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Absence of histological tissue&lt;br&gt;&lt;br&gt;          -  Absence of consent to study tissue after January 2006&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Cell Carcinoma</Condition>
    <Primary_outcome>The profiling of the expression of signal transduction biomarkers, gene expression, gene copy numbers and effect of mutations of the VHL gene in renal cancer and their relationship to clinical outcomes.</Primary_outcome>
    <Secondary_ID>CCR3076</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2919917</Internal_Number>
    <TrialID>NCT01009957</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Everolimus on CKD Progression in ADPKD Patients</Public_title>
    <Scientific_title>Everolimus on CKD Progression in ADPKD Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>A. Manzoni Hospital</Primary_sponsor>
    <Date_registration3>20091106</Date_registration3>
    <Date_registration>06/11/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01009957</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2008</Date_enrollement>
    <Target_size>90</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2/Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Subjects over 18 years of both genders&lt;br&gt;&lt;br&gt;          2. Clinical diagnosis of autosomal dominant polycystic kidney disease (ADPKD)&lt;br&gt;&lt;br&gt;          3. GFR, according to MDRD formula, between 30 and 90 ml/min/1.73 mq&lt;br&gt;&lt;br&gt;          4. Previous follow up of two years, with a creatinine evaluation at least once a year&lt;br&gt;&lt;br&gt;          5. GFR reduction of at least 2.5 ml/min/year (according to MDRD formula)&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Pregnancy, lactating, males and females without adequate contraception&lt;br&gt;&lt;br&gt;          2. Leucopenia (&lt; 3,000 leucocytes/mm3) or thrombocytopenia (&lt; 100,000 platelets/mm3)&lt;br&gt;&lt;br&gt;          3. Dyslipidemia (cholesterol or triglycerides &gt; 260 mg/dl with treatment)&lt;br&gt;&lt;br&gt;          4. Urinary tract infection&lt;br&gt;&lt;br&gt;          5. Patients who cannot undergoing NMR&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Polycystic Kidney Diseases</Condition>
    <Intervention>Drug: Everolimus;Drug: Standard Therapy</Intervention>
    <Primary_outcome>Reduction of GFR (according to MDRD formula) during a two-year follow up</Primary_outcome>
    <Secondary_outcome>reduction of creatinine clearance and GFR (according to Cockcroft-Gault formula) during a two-year follow up;changes in kidney size and renal and liver cysts dimensions evaluated by NMR at basal and at the end of the study;safety profile of everolimus (leucopenia, thrombocytopenia, lipid profile and other adverse events;evaluation of phosphatemia, phosphaturia and urinary cytokines on primary end point</Secondary_outcome>
    <Secondary_ID>PolEver</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2920051</Internal_Number>
    <TrialID>NCT01011699</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients</Public_title>
    <Scientific_title>Comparison of Nicotinamide and Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients</Scientific_title>
    <Acronym>NICOREN</Acronym>
    <Primary_sponsor>Centre Hospitalier Universitaire, Amiens</Primary_sponsor>
    <Date_registration3>20091110</Date_registration3>
    <Date_registration>10/11/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01011699</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2010</Date_enrollement>
    <Target_size>180</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Factorial Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Women or men over 18 years&lt;br&gt;&lt;br&gt;          -  Chronic hemodialysis (since more than 3 months)&lt;br&gt;&lt;br&gt;          -  Hyperphosphatemia controlled with only CaCO3&lt;br&gt;&lt;br&gt;          -  PO4 &gt; 1,60 mmol/l, PCa &lt; 2,37 mmol/l&lt;br&gt;&lt;br&gt;          -  patient able to understand and sign informed consent form&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  PTH &lt; 60 ou &gt; 800 pg/ml (PTX)&lt;br&gt;&lt;br&gt;          -  Aluminium intoxication (aluminium level in blood &gt; 0,5 µmol/l)&lt;br&gt;&lt;br&gt;          -  Score of aortic calcifications = 20 (max 24)&lt;br&gt;&lt;br&gt;          -  Characterized intolerance with Renagel and/or Nicobion&lt;br&gt;&lt;br&gt;          -  Pregnant woman&lt;br&gt;&lt;br&gt;          -  Autoimmune disease&lt;br&gt;&lt;br&gt;          -  Patient known to have a bad drug compliance&lt;br&gt;&lt;br&gt;          -  Blood tests abnormality (thrombopenia &lt;150 000, serum albumin &lt;30g)&lt;br&gt;&lt;br&gt;          -  Hepatic tests abnormality&lt;br&gt;&lt;br&gt;          -  Transplant probably within 6 months&lt;br&gt;&lt;br&gt;          -  Patient who will need transplantation within 6 month&lt;br&gt;&lt;br&gt;          -  Patients receiving chemotherapy&lt;br&gt;&lt;br&gt;          -  Patients having a loss of dry weight of 3 kg in 3 months or 6 kg in 6 months.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Renal Failure;Hemodialysis</Condition>
    <Intervention>Drug: nicotinamide;Drug: sevelamer;Drug: cinacalcet</Intervention>
    <Primary_outcome>The comparison between nicotinamide and Sevelamer was primarily to demonstrate the noninferiority of nicotinamide in terms of control of the phosphatemia  observed during the 4th, 5th and 6th months before to introduce Cinacalcet ®.</Primary_outcome>
    <Secondary_outcome>To demonstrate noninferiority of nicotinamide in terms of effect on dyslipidemia (evaluated by the ratio LDL / HDL cholesterol), the risk of hypercalcemia (PCa&gt; 2.37 mmol / l) and increase of phospho-calcic product (&gt; 3 , 79 mmol/l).;To evaluate the difference between nicotinamide and sevelamer on vascular calcification;To evaluate the difference between nicotinamide and sevelamer on bone mass loss and fracture risk;Evaluate the percentage of population requiring use of cinacalcet® to control PTH (75-300 pg/ml). Evaluate his benefit on phosphatemia and calcemia control. Prevent the need for surgical PTX, and evaluate the additional cost of treatment by cinacalcet;Evaluate roles of metabolites of nicotinamide (efficacy and side effects) through another study;Compare the cost-effectiveness ratio of these two treatments</Secondary_outcome>
    <Secondary_ID>Eudract N°2008-004673-17;Amiens NICOREN</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2920081</Internal_Number>
    <TrialID>NCT01012089</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease</Public_title>
    <Scientific_title>Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Oklahoma</Primary_sponsor>
    <Date_registration3>20091109</Date_registration3>
    <Date_registration>09/11/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01012089</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>12 Years</Inclusion_agemin>
    <Inclusion_agemax>17 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2010</Date_enrollement>
    <Target_size>10</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Pharmacokinetics Study, Intervention Model:  Single Group Assignment, Masking:  Open Label</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Children who are between 12-17 years of age who are either on HD or PD and whom the&lt;br&gt;             Pediatric Nephrology Section of the OU Children's Physicians Clinics provide care.&lt;br&gt;&lt;br&gt;          -  In addition to children on chronic HD and PD therapy, patients newly initiated on HD&lt;br&gt;             and PD will also be recruited for this study.&lt;br&gt;&lt;br&gt;          -  Patients with suspected or confirmed cases of dialysis related infection from&lt;br&gt;             gram-positive bacteria and who are receiving standard of care antibiotics.&lt;br&gt;&lt;br&gt;          -  Patients will be eligible for enrollment if they were admitted as an inpatient to the&lt;br&gt;             Children's hospital or as an outpatient to the dialysis clinic&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients &gt; 17 years of age&lt;br&gt;&lt;br&gt;          -  Patients &lt; 12 years of age&lt;br&gt;&lt;br&gt;          -  Total amount of blood drawn as part of standard of care and for pharmacokinetic&lt;br&gt;             analysis exceeds 3 ml/kg over an 8 week period&lt;br&gt;&lt;br&gt;          -  Taking an HMG CoA reductase inhibitor within 7 days of daptomycin administration&lt;br&gt;&lt;br&gt;          -  Having used daptomycin in the 30 days preceding study entry&lt;br&gt;&lt;br&gt;          -  Participating in any experimental procedure in the 30 days preceding study&lt;br&gt;&lt;br&gt;          -  A history of muscular disease or neurological disease&lt;br&gt;&lt;br&gt;          -  Baseline creatine phosphokinase (CPK) values equal to or greater than 1.5 times the&lt;br&gt;             upper limit of normal (normal range 65-370 IU/L)&lt;br&gt;&lt;br&gt;          -  Hemoglobin &lt; 9 g/dl&lt;br&gt;&lt;br&gt;          -  Hemodynamic instability within 72 hours before study enrollment&lt;br&gt;&lt;br&gt;          -  Female subjects with a positive pregnancy test or failure to take a pregnancy test&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease;Bacterial Infection</Condition>
    <Intervention>Drug: Daptomycin</Intervention>
    <Primary_outcome>To evaluate the pharmacokinetic profiles of a single 5 mg/kg dose of daptomycin IV in children who are on hemodialysis or peritoneal dialysis</Primary_outcome>
    <Secondary_outcome>To determine urine, HD and PD clearance of daptomycin</Secondary_outcome>
    <Secondary_ID>14808</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Cubist Pharmaceuticals</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2920233</Internal_Number>
    <TrialID>NCT01014065</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect)</Public_title>
    <Scientific_title>A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients</Scientific_title>
    <Acronym>SUPER</Acronym>
    <Primary_sponsor>Alberta Health Services</Primary_sponsor>
    <Date_registration3>20091112</Date_registration3>
    <Date_registration>12/11/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01014065</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2011</Date_enrollement>
    <Target_size>42</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Histologic diagnosis of metastatic renal cell carcinoma&lt;br&gt;&lt;br&gt;          -  Eligible to receive first-line sunitinib&lt;br&gt;&lt;br&gt;          -  Willingness to attend Cross Cancer Institute and University of Alberta for&lt;br&gt;             study-related assessments&lt;br&gt;&lt;br&gt;          -  Karnofsky Performance Status (KPS)82 = 70&lt;br&gt;&lt;br&gt;          -  Age = 18 years of age&lt;br&gt;&lt;br&gt;          -  Adequate creatinine clearance to receive gadolinium&lt;br&gt;&lt;br&gt;          -  All patients with bone metastases are eligible; those with lesions identified at&lt;br&gt;             weight-bearing bones will undergo plain films to evaluate fracture risk prior to&lt;br&gt;             CPET;&lt;br&gt;&lt;br&gt;          -  Fluent in English language&lt;br&gt;&lt;br&gt;          -  No contraindication to MRI or other concern eg., metallic implants, claustrophobia&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Prior systemic therapy for mRCC&lt;br&gt;&lt;br&gt;          -  Documented history of major cardiac event in last year i.e. MI, unstable angina,&lt;br&gt;             CABG, symptomatic CHF, CVA or TIA, or pulmonary embolism&lt;br&gt;&lt;br&gt;          -  Pregnancy&lt;br&gt;&lt;br&gt;          -  Other severe condition or abnormality that, in the judgement of the investigator or&lt;br&gt;             treating oncologist, would make participation in this study inappropriate&lt;br&gt;&lt;br&gt;          -  Unstable brain metastases&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Cell Carcinoma;Cardiotoxicity;Heart Failure;Hypertension</Condition>
    <Secondary_ID>00028 / 24942</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2920246</Internal_Number>
    <TrialID>NCT01014234</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Rapamycin and Regulatory T Cells in Kidney Transplantation</Public_title>
    <Scientific_title>Rapamycin and Regulatory T Cells in Renal Transplant Patients: a Two-year Randomized Prospective Study</Scientific_title>
    <Acronym />
    <Primary_sponsor>IRCCS Policlinico S. Matteo</Primary_sponsor>
    <Date_registration3>20091113</Date_registration3>
    <Date_registration>13/11/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01014234</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2008</Date_enrollement>
    <Target_size>56</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Male and female aged from 18 to 75 years&lt;br&gt;&lt;br&gt;          -  Transplanted patients from cadaveric donors&lt;br&gt;&lt;br&gt;          -  Patients who has given written informed consensus&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Legally unable patients&lt;br&gt;&lt;br&gt;          -  Patients who have been participated to others studies in the last 3 months&lt;br&gt;&lt;br&gt;          -  Addicted to alcohol or smoking&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Transplantation</Condition>
    <Intervention>Drug: Cyclosporins;Drug: Rapamycin</Intervention>
    <Primary_outcome>The absolute number of T-reg after renal transplant in patients in treatment with rapamycin compared to patients treated with cyclosporine</Primary_outcome>
    <Secondary_outcome>Adverse events developed during the duration of the clinical study, that damage the patient, that is not part of the natural history  of the disease.</Secondary_outcome>
    <Secondary_ID>20070034809</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2920427</Internal_Number>
    <TrialID>NCT01016613</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center</Public_title>
    <Scientific_title>Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center</Scientific_title>
    <Acronym>C-PROBE</Acronym>
    <Primary_sponsor>University of Michigan</Primary_sponsor>
    <Date_registration3>20091118</Date_registration3>
    <Date_registration>18/11/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01016613</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2009</Date_enrollement>
    <Target_size>1500</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  persons of any age who have chronic kidney disease (abnormally high protein in urine&lt;br&gt;             or reduced kidney function determined by blood tests)&lt;br&gt;&lt;br&gt;          -  a small number of people without chronic kidney disease&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  people on hemodialysis or peritoneal dialysis&lt;br&gt;&lt;br&gt;          -  people who have had a kidney transplant&lt;br&gt;&lt;br&gt;          -  people unable or unwilling to provide consent&lt;br&gt;&lt;br&gt;          -  women who are pregnant or nursing&lt;br&gt;&lt;br&gt;          -  people who have polycystic kidney disease&lt;br&gt;&lt;br&gt;          -  people with a hemoglobin of &lt;9 at the time of enrollment&lt;br&gt;&lt;br&gt;          -  institutionalized persons&lt;br&gt;&lt;br&gt;          -  people currently participating in a blinded interventional clinical trial&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease;Glomerulopathy</Condition>
    <Secondary_ID>P30 DK 081943</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>St. John Health System, Michigan;University of Illinois;Wayne State University</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2920871</Internal_Number>
    <TrialID>NCT01022450</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Study of the Causes of the Breakdown of Muscle Fibers in Hospitalized Patients</Public_title>
    <Scientific_title>Rhabdomyolysis - A Retrospective Study in Hospitalized Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>National Taiwan University Hospital</Primary_sponsor>
    <Date_registration3>20091125</Date_registration3>
    <Date_registration>25/11/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01022450</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2009</Date_enrollement>
    <Target_size>2500</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case-Only, Time Perspective:  Retrospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients who admitted to The National Taiwan University Hospital during&lt;br&gt;             2003/1/1~2008/12/31 with the following discharge diagnosis: myoglobinuria,&lt;br&gt;             rhabdomyolysis, myopathy, toxic myopathy, malignant hyperthermia, neuroleptic&lt;br&gt;             malignant syndrome, polymyositis, myalgia and had acute neuromuscular illness&lt;br&gt;             presentations and serum creatinine kinase (CK) more than 5 times the upper limit of&lt;br&gt;             normal (male &gt; 900 IU/L; female &gt; 835 IU/L).&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with recent myocardial infarction or stroke, unless clinical history,&lt;br&gt;             examination, or electromyography showed a concomitant myopathy.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Rhabdomyolysis;Myopathy;Acute Renal Failure;Neuroleptic Malignant Syndrome</Condition>
    <Secondary_ID>200911033R</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2920954</Internal_Number>
    <TrialID>NCT01023542</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>CNI-free "Bottom"-up Immunosuppression in Patients Undergoing Liver Transplantation</Public_title>
    <Scientific_title>A 3-Armed Prospective Randomized Controlled, Open-Labeled Phase II Trial to Evaluate Late Introduction of Cyclosporine or Everolimus Versus a 5-day Delay of Cyclosporine in Combination With MMF in Liver Transplant Recipients With MELD-Scores=25</Scientific_title>
    <Acronym>BUILT_01</Acronym>
    <Primary_sponsor>University of Regensburg</Primary_sponsor>
    <Date_registration3>20091201</Date_registration3>
    <Date_registration>01/12/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01023542</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2011</Date_enrollement>
    <Target_size>45</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2/Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Male and female liver transplant recipients of a primary liver transplant older than&lt;br&gt;             18 years&lt;br&gt;&lt;br&gt;          2. Signed, written informed consent prior to randomization&lt;br&gt;&lt;br&gt;          3. MELD scores =25&lt;br&gt;&lt;br&gt;          4. Lack of relevant exclusion criteria&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Patients transplanted for autoimmune hepatitis&lt;br&gt;&lt;br&gt;          2. HIV positive patients&lt;br&gt;&lt;br&gt;          3. Patients with pre-transplant immunosuppressive treatment&lt;br&gt;&lt;br&gt;          4. Patients who are recipients of multiple solid organ or islet cell tissue transplants,&lt;br&gt;             or have previously received an organ or tissue transplant.&lt;br&gt;&lt;br&gt;          5. Patients with renal failure or CKD/ESRD who require renal replacement therapy for&lt;br&gt;             more than 2 weeks prior to transplantation.&lt;br&gt;&lt;br&gt;          6. Patients with signs of hepatic artery thrombosis.&lt;br&gt;&lt;br&gt;          7. Patients with a hepatic encephalopathy grade of Stadium II, III and IV (somnolence,&lt;br&gt;             sopor and loss of consciousness&lt;br&gt;&lt;br&gt;          8. Patients with a known hypersensitivity to the drugs used on study or their class, or&lt;br&gt;             to any of the excipients.&lt;br&gt;&lt;br&gt;          9. Patients who are recipients of ABO incompatible transplant grafts.&lt;br&gt;&lt;br&gt;         10. Patients with uncontrolled or therapy refractory hypercholesterolemia (&gt;350 mg/dL; &gt;9&lt;br&gt;             mmol/L) or hypertriglyceridemia (&gt;500 mg/dL; &gt;8.5 mmol/L) at time of transplantation.&lt;br&gt;&lt;br&gt;         11. Patients with platelet count &lt;50,000/mm3 at the time of randomization.&lt;br&gt;&lt;br&gt;         12. Patients with an absolute neutrophil count of &lt;1,000/mm³ or white blood cell count of&lt;br&gt;             &lt;2,000/mm³ at the time of randomization.&lt;br&gt;&lt;br&gt;         13. Patients with a creatinine/protein ratio indicating daily urinary protein excretion &gt;&lt;br&gt;             1 g/24h at time of randomization.&lt;br&gt;&lt;br&gt;         14. Women of child-bearing potential (WOCBP), defined as all women physiologically&lt;br&gt;             capable of becoming pregnant, including women whose career, lifestyle, or sexual&lt;br&gt;             orientation precludes intercourse with a male partner and women whose partners have&lt;br&gt;             been sterilized by vasectomy or other means, UNLESS (1) they meet the following&lt;br&gt;             definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6&lt;br&gt;             months of spontaneous amenorrhea with serum FSH levels &gt;40 mIU/m, or (2) have past 6&lt;br&gt;             weeks from surgical bilateral oophorectomy with or without hysterectomy or (3) are&lt;br&gt;             using one or more of the following acceptable methods of contraception: surgical&lt;br&gt;             sterilization (e.g., bilateral tubal ligation, vasectomy), hormonal contraception&lt;br&gt;             (implantable, patch, oral), copper coated IUD and double-barrier methods ( any double&lt;br&gt;             combination of male or female condom with spermicidal gel, diaphragm, sponge,&lt;br&gt;             cervical cap). Periodic abstinence (e.g., calendar, ovulation, symptothermal,&lt;br&gt;             post-ovulation methods) and withdrawal are not acceptable methods of contraception.&lt;br&gt;             Reliable contraception should be maintained throughout the and for 3 months after&lt;br&gt;             study drug discontinuation.&lt;br&gt;&lt;br&gt;         15. Patients with any history of coagulopathy or medical condition requiring long-term&lt;br&gt;             anticoagulation which would preclude liver biopsy after transplantation.&lt;br&gt;&lt;br&gt;         16. Patients with a psychologic, familial, sociologic or geographic condition potentially&lt;br&gt;             hampering compliance with the study protocol and follow-up schedule.&lt;br&gt;&lt;br&gt;         17. Patients under guardianship (e.g. individuals who are not able to freely give their&lt;br&gt;             informed consent).&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Impairment;Liver Transplantation;Everolimus</Condition>
    <Intervention>Drug: delayed, low-dose CNI;Drug: BU-CNI;Drug: BU-Everolimus</Intervention>
    <Primary_outcome>The primary outcome measure of the trial is renal function at 12 months measured by estimated GFR using abbreviated MDRD formula.</Primary_outcome>
    <Secondary_ID>BUILT_01</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Novartis Pharmaceuticals</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2921350</Internal_Number>
    <TrialID>NCT01028703</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effects of a Reduction in Kidney Function on Cardiovascular Structure and Function: A Prospective Study of Kidney Donors</Public_title>
    <Scientific_title>Does a Reduction in Renal Function Increase Arterial Stiffness and Left Ventricular Mass? - A Prospective Study of Kidney Donors</Scientific_title>
    <Acronym />
    <Primary_sponsor>University Hospital Birmingham NHS Foundation Trust</Primary_sponsor>
    <Date_registration3>20091208</Date_registration3>
    <Date_registration>08/12/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01028703</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2010</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case Control, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Potential kidney donor attending University Hospital Birmingham NHS Foundation Trust&lt;br&gt;&lt;br&gt;        Current nationally set Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Diabetes mellitus&lt;br&gt;&lt;br&gt;          -  Atrial fibrillation&lt;br&gt;&lt;br&gt;          -  Left ventricular dysfunction (ejection fraction &lt;40% on transthoracic&lt;br&gt;             echocardiography)&lt;br&gt;&lt;br&gt;          -  History of cardiovascular or pulmonary disease&lt;br&gt;&lt;br&gt;          -  Evidence of hypertensive end-organ damage.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease</Condition>
    <Primary_outcome>Left ventricular mass as measured by CMR and Echocardiography;Arterial stiffness as measured by pulse wave velocity</Primary_outcome>
    <Secondary_outcome>Aortic compliance measured by cardiac magnetic resonance imaging;Left ventricular systolic and diastolic elastance measured by echocardiography;;Oxidative stress, inflammation and collagen turnover measured by blood assays of plasma renin, aldosterone, high sensitivity C-reactive protein (hsCRP), procollagen type III aminoterminal peptide (PIIINP) and C-telopeptide for type I collagen (CITP).</Secondary_outcome>
    <Secondary_ID>RKK3922</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2921373</Internal_Number>
    <TrialID>NCT01029002</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease</Public_title>
    <Scientific_title>The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease</Scientific_title>
    <Acronym />
    <Primary_sponsor>Albert Einstein College of Medicine of Yeshiva University</Primary_sponsor>
    <Date_registration3>20091207</Date_registration3>
    <Date_registration>07/12/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01029002</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2009</Date_enrollement>
    <Target_size>85</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age &gt;18 years&lt;br&gt;&lt;br&gt;          -  Ability to provide informed consent&lt;br&gt;&lt;br&gt;          -  Chronic kidney disease stage 3 and 4&lt;br&gt;&lt;br&gt;          -  On ACE inhibitor or ARB for albuminuria if tolerated&lt;br&gt;&lt;br&gt;          -  Assessed during eligibility screen:&lt;br&gt;&lt;br&gt;          -  Albuminuria &gt;30 mg/g creatinine&lt;br&gt;&lt;br&gt;          -  25(OH) vitamin D level &gt;12.5 and &lt;75 nmol/L&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  On vitamin D in past 4 weeks&lt;br&gt;&lt;br&gt;          -  Plans to relocate out of New York City in the next 6 months&lt;br&gt;&lt;br&gt;          -  25 (OH) Vitamin D level &lt;12.5 nmol/L&lt;br&gt;&lt;br&gt;          -  HIV infection&lt;br&gt;&lt;br&gt;          -  History of hypercalcemia or kidney stones&lt;br&gt;&lt;br&gt;          -  Serum phosphate &gt;5.5 mg/dl in past 3 months&lt;br&gt;&lt;br&gt;          -  Serum calcium &gt;10.0 mg/dl in past 3 months&lt;br&gt;&lt;br&gt;          -  SBP &gt;160 DBP &gt;100 at screening visit&lt;br&gt;&lt;br&gt;          -  Transplanted organ&lt;br&gt;&lt;br&gt;          -  Cancer&lt;br&gt;&lt;br&gt;          -  Polycystic kidney disease&lt;br&gt;&lt;br&gt;          -  Rapidly deteriorating kidney function with the expectation for initiation of dialysis&lt;br&gt;             in less than 6 months&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Renal Insufficiency;Proteinuria</Condition>
    <Intervention>Drug: Vitamin D;Other: Placebo</Intervention>
    <Primary_outcome>To assess the effect of vitamin D supplementation on albuminuria in CKD patients as assessed by urine albumin/creatinine measures.</Primary_outcome>
    <Secondary_outcome>To assess whether repletion doses of vitamin D increase 25(OH) vitamin D levels to above 30 ng/mL in a multi-ethnic sample of patients with CKD as a secondary outcome.;To assess the effect of vitamin D supplementation on mean systolic blood pressure as measured by ambulatory blood pressure in CKD patients as a secondary outcome.</Secondary_outcome>
    <Secondary_ID>NIH grant K23 DK078774;2007-266</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2921418</Internal_Number>
    <TrialID>NCT01029587</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome</Public_title>
    <Scientific_title>Phase 2 Study of the Use of Eculizumab to Prevent Thrombosis After Renal Transplantation in Patients With a History of Catastrophic Antiphospholipid Antibody Syndrome (CAPS)</Scientific_title>
    <Acronym />
    <Primary_sponsor>Johns Hopkins University</Primary_sponsor>
    <Date_registration3>20091209</Date_registration3>
    <Date_registration>09/12/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01029587</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2009</Date_enrollement>
    <Target_size>10</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Endpoint Classification:  Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age 18 years or older&lt;br&gt;&lt;br&gt;          -  History of Catastrophic Antiphospholipid Antibody Syndrome (CAPS)&lt;br&gt;&lt;br&gt;          -  End-stage renal disease&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Any contraindications to transplantation other than CAPS&lt;br&gt;&lt;br&gt;          -  Pregnant women&lt;br&gt;&lt;br&gt;          -  Women who intend to become pregnant over the study period&lt;br&gt;&lt;br&gt;          -  Ongoing or untreated meningococcal infections&lt;br&gt;&lt;br&gt;          -  History of serious adverse reaction to eculizumanb&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Antiphospholipid Antibody Syndrome;End Stage Renal Disease</Condition>
    <Intervention>Drug: Eculizumab</Intervention>
    <Primary_outcome>Prevention of CAPS after kidney transplant</Primary_outcome>
    <Secondary_outcome>Kidney transplant graft survival;Patient survival</Secondary_outcome>
    <Secondary_ID>NA_00032637</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2921823</Internal_Number>
    <TrialID>NCT01034878</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Sunitinib in Metastatic Renal Cancer</Public_title>
    <Scientific_title>Phase II Study of Sunitinib in Metastatic Renal Cancer With Non-clear Cell Histology</Scientific_title>
    <Acronym />
    <Primary_sponsor>Istituto Clinico Humanitas</Primary_sponsor>
    <Date_registration3>20091217</Date_registration3>
    <Date_registration>17/12/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01034878</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>December 2009</Date_enrollement>
    <Target_size>55</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Histologically proven diagnosis of metastatic renal cancer with non-clear cell&lt;br&gt;&lt;br&gt;          -  No previous treatment&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Prior treatment with an antiangiogenetic compound&lt;br&gt;&lt;br&gt;          -  Symptomatic and/or unstable pre-existing brain metastases&lt;br&gt;&lt;br&gt;          -  Severe or uncontrolled cardiovascular diseases&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Metastatic Renal Cancer With Non-clear Cell</Condition>
    <Intervention>Drug: Sunitinib</Intervention>
    <Primary_outcome>The antitumor activity in terms of progression free survival</Primary_outcome>
    <Secondary_outcome>To evaluate the objective response rate;To evaluate the toxicity and the safety profile;To evaluate the overall survival</Secondary_outcome>
    <Secondary_ID>ONC-2008-004</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2922147</Internal_Number>
    <TrialID>NCT01039753</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Analysis of Clinical Outcomes in Patients Undergoing Acute Dialysis Therapy at Intensive Care Units</Public_title>
    <Scientific_title>Analysis of Clinical Outcomes in Patients Undergoing Acute Dialysis Therapy at Intensive Care Units</Scientific_title>
    <Acronym />
    <Primary_sponsor>National Taiwan University Hospital</Primary_sponsor>
    <Date_registration3>20091224</Date_registration3>
    <Date_registration>24/12/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01039753</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2010</Date_enrollement>
    <Target_size>300</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients older than 18 years-old and admitted to intensive care units of National&lt;br&gt;             Taiwan University Hospital&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  End stage renal disease&lt;br&gt;&lt;br&gt;          -  Terminal disease with estimated life span shorter than 28 days&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Kidney Injury</Condition>
    <Secondary_ID>200912015R</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2922279</Internal_Number>
    <TrialID>NCT01041482</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>A Multi-Center, Non-Controlled Clinical Study of Sorafenib Adjuvant Therapy in Advanced Renal-Cell Carcinoma</Public_title>
    <Scientific_title>A Multi-Center, Non-Controlled Clinical Study of Sorafenib Adjuvant Therapy in Locally Advanced Renal-Cell Carcinoma After Radical Nephrectomy</Scientific_title>
    <Acronym>AGuo</Acronym>
    <Primary_sponsor>Chinese Academy of Medical Sciences</Primary_sponsor>
    <Date_registration3>20091230</Date_registration3>
    <Date_registration>30/12/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01041482</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2008</Date_enrollement>
    <Target_size>140</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        Preoperative Criteria&lt;br&gt;&lt;br&gt;          -  Renal local advanced renal cell carcinoma and be suitable to radical nephrectomy.&lt;br&gt;&lt;br&gt;          -  Tumor &gt;=7cm, the lymph nodes in metastasis can be resectable, the renal vein or&lt;br&gt;             inferior caval vein with metastatic thrombus can be resectable also, clinical&lt;br&gt;             staging&gt;=T2anyNMo.&lt;br&gt;&lt;br&gt;          -  Resectable tumor with multiple-lesion in ipsolateral kidney Enrolment Criteria&lt;br&gt;&lt;br&gt;          -  No distant metastasis.&lt;br&gt;&lt;br&gt;          -  Not undergoing any adjuvant or systematic anti-tumor therapy, such as chemotherapy,&lt;br&gt;             biotherapy or radiotherapy.&lt;br&gt;&lt;br&gt;          -  After the nephrectomy 4-12 weeks and should be recovery in the postoperative&lt;br&gt;             complications.&lt;br&gt;&lt;br&gt;          -  ECOG scores 0-1.&lt;br&gt;&lt;br&gt;          -  Referring to the Scoring Algorithm to Predict Metastasis after Radical Nephrectomy in&lt;br&gt;             Patients with clear cell renal cell carcinoma, all the patients score higher than 6.&lt;br&gt;             Metastatic lymph node with clinical diagnosis have been resected, all the resected&lt;br&gt;             specimen edge be negative in pathological detection.&lt;br&gt;&lt;br&gt;        The pathological diagnosis of renal cell carcinoma:&lt;br&gt;&lt;br&gt;          -  No remnant tumor with postoperative imaging screening with CT or MRI.&lt;br&gt;&lt;br&gt;          -  The liver and renal function, hemocytogenesis function meet the below criteria within&lt;br&gt;             the 4 weeks before the enrollment.&lt;br&gt;&lt;br&gt;               -  Granulocytes count &gt;1500/mm3&lt;br&gt;&lt;br&gt;               -  Blood platelet &gt;100000/mm3&lt;br&gt;&lt;br&gt;               -  Creatinine&lt;2 times of the upper of the reference value&lt;br&gt;&lt;br&gt;               -  Total bilirubin&lt;1.5 times of the upper of the reference value&lt;br&gt;&lt;br&gt;               -  Alanine aminotransferase/aspartate aminotransferase&lt;2.5 times of the upper of&lt;br&gt;                  the reference value&lt;br&gt;&lt;br&gt;               -  The informed consent has been endorsed.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Other coincident carcinoma, but not including carcinoma in situ of cervix and basal&lt;br&gt;             cell epithelioma after radical therapy and bladder carcinoma superficially(Ta,Tis,T1)&lt;br&gt;             or carcinoma having been cured 3 years ago.&lt;br&gt;&lt;br&gt;          -  Cardiac dysrhythmia need agent intervention(not including ß-receptor inhibitive or&lt;br&gt;             digoxin treatment), coronary heart disease, myocardial infarction occurred in the&lt;br&gt;             later 6 months, heart failure assessment higher than NYHA II&lt;br&gt;&lt;br&gt;          -  Seriously active infection with bacteria or fungus&lt;br&gt;&lt;br&gt;          -  HIV infection or HBV/HCV infection with IFN-a intervention.&lt;br&gt;&lt;br&gt;          -  Dysfunction in blood coagulation.&lt;br&gt;&lt;br&gt;          -  Epilepsia with drug treatment.&lt;br&gt;&lt;br&gt;          -  Those cannot take tablets orally.&lt;br&gt;&lt;br&gt;          -  Allogeneic organ transplantation.&lt;br&gt;&lt;br&gt;          -  Drug abuse or concomitant conditions such as psychologically or socially factors&lt;br&gt;             which may intervene the assessment.&lt;br&gt;&lt;br&gt;          -  Hypersensitiveness to the studying adjuvant or the trial-relevant drugs.&lt;br&gt;&lt;br&gt;          -  Pregnancy or lactation, pregnancy test must be negative within the 14 days before the&lt;br&gt;             trial beginning, either females or males must be contraceptive during the trial.&lt;br&gt;&lt;br&gt;          -  The following concomitant therapeutics must be excluded:&lt;br&gt;&lt;br&gt;               -  Anti-tumor agents, immunological or hormonal therapy&lt;br&gt;&lt;br&gt;               -  Radiotherapy&lt;br&gt;&lt;br&gt;               -  Biological therapeutics such as G-CSF or GM-CSF&lt;br&gt;&lt;br&gt;               -  Autologous bone marrow transplantation or stem cell treatment&lt;br&gt;&lt;br&gt;               -  The other trial medicine therapeutics&lt;br&gt;&lt;br&gt;               -  Bevacizumab treatment or other agents effected in VEGF or VEGF-receptor, such as&lt;br&gt;                  inhibitive in Raf or MEK&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Cell Carcinoma</Condition>
    <Intervention>Drug: sorafenib</Intervention>
    <Primary_outcome>disease free survival</Primary_outcome>
    <Secondary_outcome>overall survival</Secondary_outcome>
    <Secondary_ID>Bay 43-9006</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Beijing University of Chinese Medicine;China Medical University, China;Peking Union Medical College Hospital;Tianjin Medical University;Shanghai Jiao Tong University School of Medicine;Changhai Hospital;Zhejiang University;Fudan University;Jiangsu Province Centers for Disease Control and Prevention;Central South University;Sichuan University;Huazhong University of Science and Technology</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2922627</Internal_Number>
    <TrialID>NCT01046045</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Everolimus Rescue Immunosuppression in the Treatment of Chronic Allograft Dysfunction in Renal Transplant Recipients</Public_title>
    <Scientific_title>Impact and Efficacy of Everolimus Rescue Immunosuppression in the Treatment of Chronic Allograft Dysfunction in Renal Transplant Recipients</Scientific_title>
    <Acronym />
    <Primary_sponsor>Chinese University of Hong Kong</Primary_sponsor>
    <Date_registration3>20100106</Date_registration3>
    <Date_registration>06/01/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01046045</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>65 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2008</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Aged 18-65 years&lt;br&gt;&lt;br&gt;          -  Biopsy-confirmed chronic allograft dysfunction or chronic allograft nephropathy, in&lt;br&gt;             the absence of acute rejection episode within the preceding 2 months&lt;br&gt;&lt;br&gt;          -  Proteinuria &lt; 0.8 g/day (or spot urine protein &lt; 0.8 g/g-Cr) in 2 consecutive samples&lt;br&gt;             within 8 weeks&lt;br&gt;&lt;br&gt;          -  Serum creatinine &lt; 220 µmol/L or estimated glomerular filtration rate &gt; 40&lt;br&gt;             ml/min/1.73m2 by the Nankivell formula, which had been validated in kidney transplant&lt;br&gt;             recipients; this equation was expressed for use with a standard serum creatinine&lt;br&gt;             assay: glomerular filtration rate = 6.7/(standardized serum creatinine in µmol/L /&lt;br&gt;             1000) + weight (kg)/4 - urea (mmol/L)/2 - 100 / height2 (m) + 35 if the subject is&lt;br&gt;             male (or 25 if the subject is female)&lt;br&gt;&lt;br&gt;          -  Willingness to give written consent and comply with the study protocol&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Pregnancy, lactating or childbearing potential without effective method of birth&lt;br&gt;             control&lt;br&gt;&lt;br&gt;          -  Severe gastrointestinal disorders that interfere with their ability to receive or&lt;br&gt;             absorb oral medication&lt;br&gt;&lt;br&gt;          -  Serum cholesterol &gt; 7.8 mmol/L and/or serum triglycerides &gt; 4.5 mmol/L despite&lt;br&gt;             lipid-lowering agents before conversion&lt;br&gt;&lt;br&gt;          -  Systemic infection requiring therapy at study entry&lt;br&gt;&lt;br&gt;          -  Participation in any previous trial on everolimus or sirolimus&lt;br&gt;&lt;br&gt;          -  Patients receiving treatment of sirolimus or everolimus for other medical reasons&lt;br&gt;             within the past 12 months&lt;br&gt;&lt;br&gt;          -  On other investigational drugs within last 30 days&lt;br&gt;&lt;br&gt;          -  History of a psychological illness or condition such as to interfere with the&lt;br&gt;             patient's ability to understand the requirement of the study&lt;br&gt;&lt;br&gt;          -  History of non-compliance&lt;br&gt;&lt;br&gt;          -  Chronic lung disease&lt;br&gt;&lt;br&gt;          -  Known history of sensitivity or allergy to everolimus&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Allograft Dysfunction in Renal Transplantation</Condition>
    <Intervention>Drug: everolimus</Intervention>
    <Primary_outcome>change in glomerular filtration rate decline rate and histological degree of fibrosis before and after treatment with everolimus</Primary_outcome>
    <Secondary_outcome>estimated glomerular filtration rate at 12 months;morphometric studies;cytokines before and after everolimus conversion</Secondary_outcome>
    <Secondary_ID>CRE-2008.004-T</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2922657</Internal_Number>
    <TrialID>NCT01046448</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>The Cardiovascular Comorbidity in Children With Chronic Kidney Disease Study</Public_title>
    <Scientific_title>The Cardiovascular Morbidity in Children With Chronic Renal Failure Study</Scientific_title>
    <Acronym>4C</Acronym>
    <Primary_sponsor>University of Heidelberg</Primary_sponsor>
    <Date_registration3>20090807</Date_registration3>
    <Date_registration>07/08/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01046448</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>6 Years</Inclusion_agemin>
    <Inclusion_agemax>17 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2009</Date_enrollement>
    <Target_size>650</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age 6 to 17 years&lt;br&gt;&lt;br&gt;          -  GFR 10 to 45 ml/min/1.73m² (CKD stage IIIb to V);&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Active systemic vasculitis&lt;br&gt;&lt;br&gt;          -  Diabetes mellitus&lt;br&gt;&lt;br&gt;          -  Renal vascular anomalies&lt;br&gt;&lt;br&gt;          -  Anomalies of the limbs preventing standardized diagnostic procedures&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease;Pediatric;Cardiovascular Disease</Condition>
    <Primary_outcome>Functional and morphological evidence of cardiovascular disease progression (arterial stiffness, myocardial dysfunction, cIMT, LVMI) and association with clinical, anamnestic, anthropometric, biochemical, drug-related and genetic risk factors</Primary_outcome>
    <Secondary_outcome>Genetic risk factors for early manifesting progressive vascular lesions and  progressive kidney disease by the genome-wide SNP-screening and haplotype analysis.</Secondary_outcome>
    <Secondary_ID>S-32/2009</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>KfH Foundation for Preventive Medicine;German Federal Ministry of Education and Research</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2922730</Internal_Number>
    <TrialID>NCT01047410</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Group Rehabilitation for Renal Patients</Public_title>
    <Scientific_title>Group Rehabilitation for Renal Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>Maastricht University Medical Center</Primary_sponsor>
    <Date_registration3>20100111</Date_registration3>
    <Date_registration>11/01/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01047410</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2010</Date_enrollement>
    <Target_size>320</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age = 18 years;&lt;br&gt;&lt;br&gt;          -  Informed Consent;&lt;br&gt;&lt;br&gt;          -  For renal transplant patients:&lt;br&gt;&lt;br&gt;               -  stable renal function;&lt;br&gt;&lt;br&gt;               -  transplantation at least 3 months before start of the study;&lt;br&gt;&lt;br&gt;          -  For hemodialysis and peritoneal dialysis patients:&lt;br&gt;&lt;br&gt;               -  at least 3 months dependent on dialysis.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Psychopathology;&lt;br&gt;&lt;br&gt;          -  Severe cognitive disorders;&lt;br&gt;&lt;br&gt;          -  Negative advice of the nephrologist and/or cardiologist.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Insufficiency</Condition>
    <Intervention>Other: rehabilitation / physical training</Intervention>
    <Primary_outcome>Quality of life;Exercise capacity, skeletal muscle strength and physical activity level;Cost-effectiveness</Primary_outcome>
    <Secondary_outcome>Nutritional state;Blood pressure;Fatigue;Labour participation</Secondary_outcome>
    <Secondary_ID>MEC 09-02-081</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Dutch Kidney Foundation;Innovation Fund of the Dutch Medical Insurance Companies</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2923168</Internal_Number>
    <TrialID>NCT01053130</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Weight Loss Interventions in Obese Patients With Stages 3-4 Chronic Kidney Disease: a Randomised Controlled Trial</Public_title>
    <Scientific_title>The Effect of Weight Loss Surgery on Preservation of Kidney Function and Cardiovascular Disease Risk Factors in Obese Patients With Stages 3-4 Chronic Kidney Disease: a Randomised Controlled Trial</Scientific_title>
    <Acronym />
    <Primary_sponsor>King's College Hospital NHS Trust</Primary_sponsor>
    <Date_registration3>20100120</Date_registration3>
    <Date_registration>20/01/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01053130</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2010</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Stages 3-4 CKD patients (GFR 20-60 mL/min)&lt;br&gt;&lt;br&gt;          -  Male or female&lt;br&gt;&lt;br&gt;          -  BMI 35-45 kg/m2&lt;br&gt;&lt;br&gt;          -  Aged &gt;18 years&lt;br&gt;&lt;br&gt;          -  Previously attempted weight loss&lt;br&gt;&lt;br&gt;          -  Fit or anesthesia and surgery&lt;br&gt;&lt;br&gt;          -  Written informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Pregnancy&lt;br&gt;&lt;br&gt;          -  History of chronic liver disease&lt;br&gt;&lt;br&gt;          -  Previous gastric surgery or large hiatus hernia&lt;br&gt;&lt;br&gt;          -  Previous bariatric surgery&lt;br&gt;&lt;br&gt;          -  Psychiatric illness, including anxiety, mood and untreated eating disorders&lt;br&gt;&lt;br&gt;          -  Malnutrition (assessed by subjective global assessment)&lt;br&gt;&lt;br&gt;          -  Infection or course of antibiotics within the last month&lt;br&gt;&lt;br&gt;          -  Unwilling to consider surgical treatment&lt;br&gt;&lt;br&gt;          -  Previous kidney transplant&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease;Obesity</Condition>
    <Intervention>Procedure: laparoscopic sleeve gastrectomy;Behavioral: weight management program</Intervention>
    <Primary_outcome>Measured glomerular filtration rate (renal function) using the iohexol clearance method in patients with stages 3-4 chronic kidney disease</Primary_outcome>
    <Secondary_outcome>Composite end point of death and cardiovascular outcomes (stroke, myocardial infarction or congestive heart failure hospitalisation);Quality of life and anxiety and depression assessment;Urinary albumin to creatinine ratio and protein to creatinine ratio;Body composition (weight, BMI, waist and hip circ, BIA);Insulin resistance (HOMA method);Serum adiponectin, leptin, IL-6, TNF-a, hs-CRP, fetuin a;Urinary markers IL-6, MCP-1, IL-1ß, RBP, NAG;Endothelial function (flow mediated dilatation)</Secondary_outcome>
    <Secondary_ID>09/H0806/69;KCH1639</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>King's College London</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2923769</Internal_Number>
    <TrialID>NCT01061008</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Handgrip Exercise for Arteriovenous Fistula Maturation</Public_title>
    <Scientific_title>The Effects of Progressive Handgrip Exercise Training on Arteriovenous Fistula Maturation in Chronic Kidney Disease</Scientific_title>
    <Acronym />
    <Primary_sponsor>Bangor University</Primary_sponsor>
    <Date_registration3>20100122</Date_registration3>
    <Date_registration>22/01/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01061008</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2008</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Single Blind (Outcomes Assessor), Primary Purpose:  Basic Science</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Stage 4-5 chronic kidney disease, attending for arteriovenous fistula creation in&lt;br&gt;             forearm&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Are under the age of 18years;&lt;br&gt;&lt;br&gt;          -  Not able to exercise forearm safely (as decided by the patients consultant)&lt;br&gt;&lt;br&gt;          -  Have any other uncontrolled medical condition&lt;br&gt;&lt;br&gt;          -  Unable to withstand transiently raised systolic blood pressure by 35 mmHg and&lt;br&gt;             diastolic by 25 mmHg&lt;br&gt;&lt;br&gt;          -  Or are unable to give consent&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease</Condition>
    <Intervention>Other: Post operative progressive handgrip exercise;Other: Treatment as usual</Intervention>
    <Primary_outcome>Intra access flow; arterial and venous diameter.</Primary_outcome>
    <Secondary_outcome>Maximum handgrip strength;handgrip endurance;Forearm muscle cross sectional area</Secondary_outcome>
    <Secondary_ID>Macdonald 07/4;REC No : 07/WNo01/4</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Betsi Cadwaladr University Health Board</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2923858</Internal_Number>
    <TrialID>NCT01062178</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Efficacy of Ultrasound Contrast Agent to Assess Renal Masses</Public_title>
    <Scientific_title>The Comparison of Accuracy of Contrast Enhanced Ultrasound on Diagnosis of Small Renal Masses and Distinguishing Renal Cell Carcinomas From Other Renal Masses, With Biopsy</Scientific_title>
    <Acronym />
    <Primary_sponsor>University Health Network, Toronto</Primary_sponsor>
    <Date_registration3>20100122</Date_registration3>
    <Date_registration>22/01/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01062178</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2009</Date_enrollement>
    <Target_size>167</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Diagnostic</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with newly diagnosed Renal mass &lt; 4 cmm, who are going to undergo diagnostic&lt;br&gt;             CT, MRI or biopsy.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Cell Carcinoma</Condition>
    <Intervention>Drug: Definity</Intervention>
    <Primary_outcome>biopsy</Primary_outcome>
    <Secondary_ID>08-0512-CE</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Lantheus Medical Imaging</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2923920</Internal_Number>
    <TrialID>NCT01062984</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Continuous Venovenous Hemofiltration Versus Continuous Venovenuous Hemodialysis</Public_title>
    <Scientific_title>A Comparison of the Efficacy of Continuous Venovenous Hemofiltration Versus Continuous Venovenous Hemodialysis for Renal Replacement Therapy in Acute Kidney Injury</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Chicago</Primary_sponsor>
    <Date_registration3>20100203</Date_registration3>
    <Date_registration>03/02/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01062984</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2009</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age 18 or older and able to sign consent (or surrogate).&lt;br&gt;&lt;br&gt;          -  Must have been referred to the inpatient Nephrology consult service for evaluation of&lt;br&gt;             AKI.&lt;br&gt;&lt;br&gt;          -  Expected survival of at least 48 hours.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Hemoglobin &lt; 8 g/dl&lt;br&gt;&lt;br&gt;          -  Serum potassium =6.5mEq/L&lt;br&gt;&lt;br&gt;          -  Weight &gt; 120kg.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Renal Failure</Condition>
    <Intervention>Procedure: Continuous Venovenous Hemofiltration (CVVH);Procedure: Continuous Venovenous Hemodialysis (CVVHD)</Intervention>
    <Primary_outcome>To compare the clearance of urea and creatinine by RRT using continuous venovenous hemofiltration versus continuous venovenous hemodialysis.</Primary_outcome>
    <Secondary_outcome>To compare the clearance cystatin C and inflammatory cytokines (IL-6 and IL-10) by RRT using continuous venovenous hemofiltration versus continuous venovenous hemodialysis.</Secondary_outcome>
    <Secondary_ID>IRB# 15947A</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>NxStage Medical</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2924050</Internal_Number>
    <TrialID>NCT01064674</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Cardiovascular Evaluation Before Renal Transplantation</Public_title>
    <Scientific_title>Cardiovascular Diagnostic Before Renal Transplantation: a Prospective Study to Assess Cardiovascular Morbidity Before Renal Transplantation and to Improve Standard Diagnostic Procedures.</Scientific_title>
    <Acronym />
    <Primary_sponsor>University Hospital Muenster</Primary_sponsor>
    <Date_registration3>20100205</Date_registration3>
    <Date_registration>05/02/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01064674</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>December 2009</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  endstage renal disease&lt;br&gt;&lt;br&gt;          -  preparing for renal transplantation&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  children (&lt; 18 years)&lt;br&gt;&lt;br&gt;          -  women who are pregnant or nursing&lt;br&gt;&lt;br&gt;          -  patients who are also awaiting heart transplantation or have already a heart&lt;br&gt;             transplant&lt;br&gt;&lt;br&gt;          -  severe mental illness&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease;Coronary Artery Disease</Condition>
    <Intervention>Other: diagnostic procedure</Intervention>
    <Primary_outcome>cardiovascular morbidity</Primary_outcome>
    <Secondary_ID>HerzundNierenMünster;KVDiagnostikpratransplantation</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2924309</Internal_Number>
    <TrialID>NCT01068067</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Validation of Pharmacogenetics Plus Drug Combination Guided Initial Tacrolimus Dosage in Renal Transplant Recipients</Public_title>
    <Scientific_title>Validation of Pharmacogenetics Plus Drug Combination Guided Initial Tacrolimus Dosage in Chinese Renal Transplant Recipients: A Prospective Randomized Controlled Study</Scientific_title>
    <Acronym />
    <Primary_sponsor>Sun Yat-sen University</Primary_sponsor>
    <Date_registration3>20100211</Date_registration3>
    <Date_registration>11/02/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01068067</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>65 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2010</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Adult (both males and females, 18-65 years) recipients underwent single primary renal&lt;br&gt;             transplantation in the First Affiliated Hospital of Sun Yat-sen University&lt;br&gt;&lt;br&gt;          2. Wish to participate in the study&lt;br&gt;&lt;br&gt;          3. Informed consent for the trial&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Patients with abnormal hepatic function, serious infection, malignant tumour, and&lt;br&gt;             diabetes mellitus&lt;br&gt;&lt;br&gt;          2. Patients with ABO-incompatible renal transplantation&lt;br&gt;&lt;br&gt;          3. Panel reactive antibody (PRA) levels greater than 30% before transplantation&lt;br&gt;&lt;br&gt;          4. Underwent combined organ transplantations&lt;br&gt;&lt;br&gt;          5. Except for SchE, other medication known to affect tacrolimus blood levels, such as&lt;br&gt;             diltiazem, verapamil, ketoconazole, itraconazole, erythromycin or clarithromycin was&lt;br&gt;             used&lt;br&gt;&lt;br&gt;          6. Allergic history to study medicines&lt;br&gt;&lt;br&gt;          7. During pregnancy or plan to get pregnant during the study period&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Transplantation</Condition>
    <Intervention>Other: drug (tacrolimus and SchE) and genetics;Drug: tacrolimus</Intervention>
    <Primary_outcome>C0 of tacrolimus after the initial dose, the percentage of out-of-range C0 after initial dose, the number of dose adjustments made to achieve therapeutic range (5-10 ng/ml) and the dose requirement to reach therapeutic range</Primary_outcome>
    <Secondary_outcome>acute rejection rate within two weeks after transplantation;serum creatinine at fourteen days after transplantation</Secondary_outcome>
    <Secondary_ID>TAC+WUZHI</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>First Affiliated Hospital, Sun Yat-Sen University</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2924439</Internal_Number>
    <TrialID>NCT01069770</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)</Public_title>
    <Scientific_title>Neoadjuvant Sunitinib Therapy in Patients With Metastatic Clear Cell Type Renal Cell Carcinoma Patients: a Prospective Study</Scientific_title>
    <Acronym />
    <Primary_sponsor>Korean Urological Oncology Society</Primary_sponsor>
    <Date_registration3>20100212</Date_registration3>
    <Date_registration>12/02/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01069770</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2009</Date_enrollement>
    <Target_size>32</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Biopsy proven RCC with a component of clear cell type histology&lt;br&gt;&lt;br&gt;          -  Clinical stage TxNxM+&lt;br&gt;&lt;br&gt;          -  At least one site of measurable disease as defined by RECIST criteria&lt;br&gt;&lt;br&gt;          -  Potential candidates for cytoreductive nephrectomy&lt;br&gt;&lt;br&gt;          -  Favorable or intermittent risk group according to MSKCC risk factor model&lt;br&gt;&lt;br&gt;          -  ECOG performance status 0 or 1&lt;br&gt;&lt;br&gt;          -  Adequate organ function as defined by:&lt;br&gt;&lt;br&gt;               -  AST or ALT less than or equal to 2.5 times the upper limit of normal&lt;br&gt;&lt;br&gt;               -  Bilirubin less than or equal to 1.5 times the upper limit of normal&lt;br&gt;&lt;br&gt;               -  Absolute neutrophil count (ANC) greater than or equal to 1500/mL&lt;br&gt;&lt;br&gt;               -  Platelets greater than or equal to 100,000/mL&lt;br&gt;&lt;br&gt;               -  Hemoglobin greater than or equal to 9.0 g/dL&lt;br&gt;&lt;br&gt;               -  Serum calcium less than or equal to 12.0 mg/dL&lt;br&gt;&lt;br&gt;               -  Serum creatinine less than or equal to 1.5 times the upper limit of normal&lt;br&gt;&lt;br&gt;          -  Male or female, 18 years of age or older&lt;br&gt;&lt;br&gt;          -  Women of childbearing potential must NOT be pregnant (as confirmed by a negative&lt;br&gt;             pregnancy test)&lt;br&gt;&lt;br&gt;          -  Signed informed consent form indicating that the patient or acceptable representative&lt;br&gt;             has been informed of all parts of the trial prior to Sunitinib administration&lt;br&gt;             (enrollment)&lt;br&gt;&lt;br&gt;          -  Willingness and ability to comply with study procedures&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  History of another primary malignancy within 5 years, with the exception of&lt;br&gt;             non-melanoma skin cancer and in situ carcinoma of the uterine cervix.&lt;br&gt;&lt;br&gt;          -  NCI CTCAE grade 3 hemorrhage within 4 weeks of commence of Sunitinib therapy.&lt;br&gt;&lt;br&gt;          -  Presence of brain metastases during screening period&lt;br&gt;&lt;br&gt;          -  Ongoing cardiac dysrhythmias of NCI CTCAE grade of 2 or more, atrial fibrillation of&lt;br&gt;             any grade or prolongation of QTc interval to more than 450 millisecond (msec) for&lt;br&gt;             male or more than 470 msec for female&lt;br&gt;&lt;br&gt;          -  Hypertension that cannot be controlled by medications&lt;br&gt;&lt;br&gt;          -  Concurrent treatment with therapeutic doses of coumadin but low dose of coumadin up&lt;br&gt;             to 2 mg orally daily for deep vein thrombosis prophylaxis is allowed.&lt;br&gt;&lt;br&gt;          -  Current treatment on another therapeutic clinical trial. Supportive care trials or&lt;br&gt;             non-treatment trials are allowed.&lt;br&gt;&lt;br&gt;          -  Inability to swallow oral medications, or presence of active inflammatory bowel&lt;br&gt;             disease, partial or complete bowel obstruction or chronic diarrhea.&lt;br&gt;&lt;br&gt;          -  Concurrent medication with known potent CYP3A4 inhibitors and inducers and/or dosing&lt;br&gt;             before 7 and 12 days before date of randomization.&lt;br&gt;&lt;br&gt;          -  Other severe acute or chronic medical or psychiatric condition of laboratory&lt;br&gt;             abnormality that may increase the risk associated with study participation or study&lt;br&gt;             drug administration, or may interfere with the interpretation of study results, and&lt;br&gt;             in the judgment of the investigator would make the subject inappropriate for entry&lt;br&gt;             into this study.&lt;br&gt;&lt;br&gt;          -  Any of the following within 12 months prior to study drug administration:&lt;br&gt;&lt;br&gt;        severe/unstable angina, myocardiac infarction, coronary artery bypass graft, symptomatic&lt;br&gt;        congestive heart failure, cerebrovascular accident, including transient ischemic attack,&lt;br&gt;        or pulmonary embolism.&lt;br&gt;&lt;br&gt;          -  Known hypersensitivity to Sunitinib&lt;br&gt;&lt;br&gt;          -  Women who are breast-feeding ? Note At screening, resectability of primary tumor&lt;br&gt;             itself does not influence on patients enrollment. Physicians only have to describe&lt;br&gt;             about the resectability ("resectable" or "unresectable") at screening on their own&lt;br&gt;             discretion, but if they decide that primary tumor is "unresectable", the should&lt;br&gt;             specify reasons for unresectable status as follows: invasion into neighboring organs,&lt;br&gt;             proximity to vital structure or vessels, bulky regional lymph nodes, vascular&lt;br&gt;             invasion, burden of metastatic disease, and others.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Clear Cell Renal Cell Carcinoma;Metastasis</Condition>
    <Intervention>Drug: Sunitinib</Intervention>
    <Primary_outcome>Response rate of primary tumor based on Response Evaluation Criteria In Solid Tumors (RECIST) criteria</Primary_outcome>
    <Secondary_outcome>Overall survival rate after Sunitinib therapy;Pathologic evaluation after Sunitinib therapy;Quality of life (QoL) assessed by EORTC QLQ-C30 questionnaire (Korean version);Resectability based on R0 resection rate</Secondary_outcome>
    <Secondary_ID>Sutent-IIR</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Pfizer</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2925061</Internal_Number>
    <TrialID>NCT01077895</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>The Influence of Fluid Removal Using Continuous Venovenous Hemofiltration (CVVH) on Intra-abdominal Pressure and Kidney Function</Public_title>
    <Scientific_title>The Influence of Fluid Removal Using Continuous Venovenous Hemofiltration (CVVH) on Intra-abdominal Pressure and Kidney Function in Critically Ill Adults With Intra-abdominal Hypertension and Acute Kidney Injury</Scientific_title>
    <Acronym />
    <Primary_sponsor>University Hospital, Ghent</Primary_sponsor>
    <Date_registration3>20100225</Date_registration3>
    <Date_registration>25/02/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01077895</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>February 2010</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Single Blind (Subject), Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Adult patients (&gt;18y old) of either gender&lt;br&gt;&lt;br&gt;          -  Admitted to the ICU&lt;br&gt;&lt;br&gt;          -  Sedated and mechanically ventilated (and expected to remain so for at least 48h)&lt;br&gt;&lt;br&gt;          -  Informed consent given&lt;br&gt;&lt;br&gt;          -  admitted to the ICU for &lt;7 days or during the first 7 days of a new shock episode&lt;br&gt;&lt;br&gt;          -  AKI requiring RRT according to treating physician&lt;br&gt;&lt;br&gt;          -  IAP &gt;12mmHg being attributed to fluid overload by treating physician&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Included in the same study before&lt;br&gt;&lt;br&gt;          -  Vasopressor and/or inotrope dose needed above noradrenaline 1µg/kg/min and dobutamine&lt;br&gt;             10µg/kg/min&lt;br&gt;&lt;br&gt;          -  PaO2/FiO2 ratio &lt;100&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Critically Ill;Intra-Abdominal Hypertension;Abdominal Compartment Syndrome;Acute Kidney Injury</Condition>
    <Intervention>Procedure: CVVH;Procedure: ultrafiltration;Procedure: ultrafiltration control group</Intervention>
    <Primary_outcome>Change in IAP in patients receiving fluid removal during CVVH vs patients receiving CVVH without net fluid removal after 24 and 48h of CVVH treatment</Primary_outcome>
    <Secondary_outcome>Difference between CVVH with fluid removal and CVVH without fluid removal;Difference between both groups in terms of daily fluid balance;The relationship between cumulative fluid balance at the start of each day of CVVH and the fluid balance achieved after 24h of CVVH with fluid removal;Difference between both groups regarding recovery of renal function, need for RRT at discharge from the ICU and from the hospital;Difference between both groups regarding mortality (28d, ICU and hospital) and ICU and hospital length of stay</Secondary_outcome>
    <Secondary_ID>2009/721</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Stuivenberg Hospital Antwerp</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2925135</Internal_Number>
    <TrialID>NCT01078857</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Small-fiber Neuropathy in Chronic Kidney Disease</Public_title>
    <Scientific_title>Small-fiber Neuropathy in Chronic Kidney Disease</Scientific_title>
    <Acronym />
    <Primary_sponsor>National Taiwan University Hospital</Primary_sponsor>
    <Date_registration3>20100228</Date_registration3>
    <Date_registration>28/02/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01078857</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>February 2009</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Diagnostic</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  The patients should fulfill the criteria of CKD according to renal function study and&lt;br&gt;             the patients of end-stage renal disease should receive regular dialysis therapy and&lt;br&gt;             follow-up at outpatient clinics.&lt;br&gt;&lt;br&gt;          -  For disease comparison, patients with peripheral neuropathy of variable etiologies&lt;br&gt;             will also be recruited.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Poor control DM,&lt;br&gt;&lt;br&gt;          -  Severe heart failure,&lt;br&gt;&lt;br&gt;          -  Bleeding tendency,&lt;br&gt;&lt;br&gt;          -  Severe lung disease with respiratory distress,&lt;br&gt;&lt;br&gt;          -  Severe infection,&lt;br&gt;&lt;br&gt;          -  Alcoholism,&lt;br&gt;&lt;br&gt;          -  Amyloidosis,&lt;br&gt;&lt;br&gt;          -  Poor wound healing history.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Small-Fiber Neuropathy;Chronic Kidney Disease</Condition>
    <Intervention>Other: Skin biopsy</Intervention>
    <Primary_outcome>The pathology of skin biopsy;Intraepidermal fiber density;Autonomic function</Primary_outcome>
    <Secondary_outcome>Function of small-fiber sensory nerve</Secondary_outcome>
    <Secondary_ID>200812088R</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2925777</Internal_Number>
    <TrialID>NCT01087255</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Caregivers and Electronic Medication Monitoring in Chronic Kidney Disease</Public_title>
    <Scientific_title>Caregivers and Internet Based Monitoring to Improve Medication Use in HPHC Enrollees With Chronic Kidney Disease</Scientific_title>
    <Acronym />
    <Primary_sponsor>Harvard Pilgrim Health Care</Primary_sponsor>
    <Date_registration3>20100315</Date_registration3>
    <Date_registration>15/03/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01087255</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2009</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Supportive Care</Study_design>
    <Phase>Phase 1/Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  HPHC commercial- or Medicare-insured members with 2 or more distinct outpatient&lt;br&gt;             nephrology chronic kidney disease stage (CKD) III, IV, or V diagnoses in a 6-month&lt;br&gt;             period.&lt;br&gt;&lt;br&gt;          -  18 years old or older at the time they are identified as having CKD.&lt;br&gt;&lt;br&gt;          -  An average of two prescription medications dispensed per month in the prior 6-months.&lt;br&gt;&lt;br&gt;          -  Residence in MA, ME, or NH&lt;br&gt;&lt;br&gt;          -  Residence in an area with MedMinder-participating cellular coverage (includes most&lt;br&gt;             major cellular carriers)&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Dialysis or dialysis-related complication medical service claims in 6-month period&lt;br&gt;             preceding study entry.&lt;br&gt;&lt;br&gt;          -  Atrius Health member&lt;br&gt;&lt;br&gt;          -  Serious mental illness or cognitive dysfunction medical service claim in 6-month&lt;br&gt;             period preceding study entry&lt;br&gt;&lt;br&gt;          -  Primary language other than English&lt;br&gt;&lt;br&gt;          -  Unable to use a pillbox&lt;br&gt;&lt;br&gt;          -  Have no eligible caregiver&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease;Medication Adherence</Condition>
    <Intervention>Device: Electronic Pillbox Monitoring System</Intervention>
    <Primary_outcome>medication adherence</Primary_outcome>
    <Secondary_ID>PF000123</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2925894</Internal_Number>
    <TrialID>NCT01088776</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Omega-3 Fatty Acid Supplementation in Children</Public_title>
    <Scientific_title>Omega-3 Fatty Acid Supplementation to Treat Hypertriglyceridemia in Children With Chronic Kidney Disease</Scientific_title>
    <Acronym />
    <Primary_sponsor>The Hospital for Sick Children</Primary_sponsor>
    <Date_registration3>20100316</Date_registration3>
    <Date_registration>16/03/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01088776</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>2 Years</Inclusion_agemin>
    <Inclusion_agemax>18 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2010</Date_enrollement>
    <Target_size>24</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Crossover Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator), Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  age at randomization: 2.0-17.4 years old (stratified by age: 2-8 yr, 9-13 yr, 14-17.4&lt;br&gt;             yr)&lt;br&gt;&lt;br&gt;          -  CKD stages 3 or 4 (GFR:15-59 ml/min/1.73 m2)&lt;br&gt;&lt;br&gt;          -  established and stable in the CKD 3 and 4 Program for a minimum of 3 months&lt;br&gt;&lt;br&gt;          -  fasting serum TG 95th percentile for age and gender 2 on more than or equal to 2&lt;br&gt;             occasions&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  allergy to fish, corn, soybean&lt;br&gt;&lt;br&gt;          -  anti-coagulant or anti-platelet drugs (heparin, warfarin, therapeutic NSAIDs) or&lt;br&gt;             herbal products (ginko, garlic, feverfew, ginger and ginseng) known to prolong&lt;br&gt;             bleeding&lt;br&gt;&lt;br&gt;          -  currently undergoing treatment for dyslipidemia&lt;br&gt;&lt;br&gt;          -  use of dietary supplements containing n-3FA&lt;br&gt;&lt;br&gt;          -  children with Nephrotic Syndrome, on dialysis, or transplanted&lt;br&gt;&lt;br&gt;          -  planned surgery, dialysis or transplantation within the next 7 months&lt;br&gt;&lt;br&gt;          -  children with diabetes&lt;br&gt;&lt;br&gt;          -  bleeding and clotting disorders:&lt;br&gt;&lt;br&gt;               -  thrombocytopenia (platelet count &lt;100 x 109/L), including ITP, TTP&lt;br&gt;&lt;br&gt;               -  Von Willebrands disease&lt;br&gt;&lt;br&gt;               -  hemophilia&lt;br&gt;&lt;br&gt;               -  thrombophilia&lt;br&gt;&lt;br&gt;               -  vitamin K deficiency&lt;br&gt;&lt;br&gt;               -  severe liver disease&lt;br&gt;&lt;br&gt;               -  unstable patients with shock which can lead to DIC (disseminated intravascular&lt;br&gt;                  coagulation)&lt;br&gt;&lt;br&gt;               -  active Henoch Schonlein Purpura&lt;br&gt;&lt;br&gt;               -  hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber disease)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease;Hypertriglyceridemia</Condition>
    <Intervention>Dietary Supplement: n-3 Fatty Acid supplement;Dietary Supplement: Placebo</Intervention>
    <Primary_outcome>Fasting Blood Lipid Profiles(TG levels)</Primary_outcome>
    <Secondary_outcome>Platelet aggregation;CBC;Cholesterol Levels (LDL and HDL);Tolerability of n-3 fatty acid supplements by our participants</Secondary_outcome>
    <Secondary_ID>1000012569</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2926006</Internal_Number>
    <TrialID>NCT01090232</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Host Responses in Kidney-transplant Recipients With Chronic Hepatitis E Virus Infection</Public_title>
    <Scientific_title>Host Responses in Kidney-transplant Recipients With Chronic Hepatitis E Virus Infection</Scientific_title>
    <Acronym />
    <Primary_sponsor>Assistance Publique Hopitaux De Marseille</Primary_sponsor>
    <Date_registration3>20100318</Date_registration3>
    <Date_registration>18/03/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01090232</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>February 2010</Date_enrollement>
    <Target_size>18</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age &gt; 18 years&lt;br&gt;&lt;br&gt;          -  Transplanted by a functional kidney&lt;br&gt;&lt;br&gt;          -  affected by a hepatitis E chronic&lt;br&gt;&lt;br&gt;          -  Benefiting from a follow-up in the Center of Nephrology and renal Transplantation or&lt;br&gt;             in the service of Hépato-gastro-entérologie of the CHU The Conception in Marseille&lt;br&gt;&lt;br&gt;          -  Having signed a consent informed about participation in the study&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Affected by another sharp or chronic viral infection&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney-transplant Recipients With Chronic Hepatitis E Virus Infection</Condition>
    <Intervention>Other: blood samples;Other: blood samples</Intervention>
    <Primary_outcome>analysethe the host responses in kidney-transplant recipients with chronic HEV infection</Primary_outcome>
    <Secondary_outcome>the incidence of HEV infection in kidney-transplant</Secondary_outcome>
    <Secondary_ID>2009 20;2009-A00945-52</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2926345</Internal_Number>
    <TrialID>NCT01094639</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Periodontal Infection and Systemic Inflammation in Renal Patients</Public_title>
    <Scientific_title>Periodontal Infection and Systemic Inflammation in Renal Patients</Scientific_title>
    <Acronym>PeriRen</Acronym>
    <Primary_sponsor>University of Connecticut Health Center</Primary_sponsor>
    <Date_registration3>20100323</Date_registration3>
    <Date_registration>23/03/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01094639</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>21 Years</Inclusion_agemin>
    <Inclusion_agemax>85 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 2009</Date_enrollement>
    <Target_size>152</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Intervention Model:  Parallel Assignment, Masking:  Single Blind (Outcomes Assessor), Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  dental subjects with periodontitis,&lt;br&gt;&lt;br&gt;          -  at least 10 teeth&lt;br&gt;&lt;br&gt;          -  no periodontal (gum) treatment for the last year,&lt;br&gt;&lt;br&gt;          -  no antibiotic for the last 4 months,&lt;br&gt;&lt;br&gt;          -  no vascular access infection.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  smokers&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Periodontitis;Chronic Kidney Disease</Condition>
    <Intervention>Procedure: Scaling root planing;Procedure: Supragingival Prophylaxis</Intervention>
    <Primary_outcome>Serum Interleukin-6 (IL-6) and C-reactive protein (CRP) levels</Primary_outcome>
    <Secondary_outcome>Changes in periodontal (gum) clinical presentation and status</Secondary_outcome>
    <Secondary_ID>K23DE018689;10-092-2</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>National Institute of Dental and Craniofacial Research (NIDCR)</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2926710</Internal_Number>
    <TrialID>NCT01099423</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer</Public_title>
    <Scientific_title>Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma</Scientific_title>
    <Acronym>SURTIME</Acronym>
    <Primary_sponsor>European Organisation for Research and Treatment of Cancer - EORTC</Primary_sponsor>
    <Date_registration3>20100406</Date_registration3>
    <Date_registration>06/04/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01099423</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2010</Date_enrollement>
    <Target_size>458</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        DISEASE CHARACTERISTICS:&lt;br&gt;&lt;br&gt;          -  Histologically confirmed renal cell cancer (RCC)&lt;br&gt;&lt;br&gt;               -  Clear-cell subtype with a resectable asymptomatic in situ primary&lt;br&gt;&lt;br&gt;                    -  Asymptomatic primary is defined as the absence of symptoms* which can be&lt;br&gt;                       exclusively assigned to the primary tumor such as flank pain and/or gross&lt;br&gt;                       hematuria necessitating blood transfusion NOTE: *Para-neoplastic symptoms&lt;br&gt;                       cannot be assigned to the primary tumor alone in metastatic disease, they&lt;br&gt;                       are not included in this definition.&lt;br&gt;&lt;br&gt;                    -  No symptomatic primary tumor necessitating nephrectomy&lt;br&gt;&lt;br&gt;          -  Resectable primary tumor&lt;br&gt;&lt;br&gt;               -  Bulky locoregional lymph node metastases larger than the primary tumor allowed&lt;br&gt;                  provided resectability of the lymph nodes is surgically feasible&lt;br&gt;&lt;br&gt;          -  Metastatic RCC&lt;br&gt;&lt;br&gt;               -  Distant metastases are not completely resectable at the time of surgery or&lt;br&gt;                  during an additional intervention&lt;br&gt;&lt;br&gt;               -  No multiple distant lesions at one site&lt;br&gt;&lt;br&gt;               -  No bone-only metastases&lt;br&gt;&lt;br&gt;          -  Measurable disease, both primary and metastatic, according to RECIST 1.1 criteria&lt;br&gt;&lt;br&gt;          -  Planning to receive sunitinib malate as background therapy&lt;br&gt;&lt;br&gt;          -  Patients with &gt; 3 of the following surgical risk factors are not eligible:&lt;br&gt;&lt;br&gt;               -  Serum albumin CTCAE v 4.0 grade 2 or worse&lt;br&gt;&lt;br&gt;               -  Serum LDH &gt; 1.5 times upper limit of normal&lt;br&gt;&lt;br&gt;               -  Liver metastases&lt;br&gt;&lt;br&gt;               -  Symptoms at presentation due to metastases&lt;br&gt;&lt;br&gt;               -  Retroperitoneal lymph node involvement&lt;br&gt;&lt;br&gt;               -  Supra-diaphragmatic lymph node involvement&lt;br&gt;&lt;br&gt;               -  Clinical stage T3 or T4 disease&lt;br&gt;&lt;br&gt;          -  No clinical signs of CNS involvement&lt;br&gt;&lt;br&gt;        PATIENT CHARACTERISTICS:&lt;br&gt;&lt;br&gt;          -  See Disease Characteristics&lt;br&gt;&lt;br&gt;          -  WHO performance status 0-1&lt;br&gt;&lt;br&gt;          -  Life expectancy &gt; 3 months&lt;br&gt;&lt;br&gt;          -  WBC &gt; 3.0 x 10^9/L&lt;br&gt;&lt;br&gt;          -  Platelet count &gt; 100 x 10^9/L&lt;br&gt;&lt;br&gt;          -  Hemoglobin &gt; 10.0 g/dL&lt;br&gt;&lt;br&gt;          -  PT/PTT or INR = 1.2 times upper limit of normal (ULN)&lt;br&gt;&lt;br&gt;          -  Bilirubin = 1.5 times ULN&lt;br&gt;&lt;br&gt;          -  ALT = 2.5 times ULN (= 5 times ULN if liver lesions)&lt;br&gt;&lt;br&gt;          -  Serum calcium &lt; 10.0 mg/dL&lt;br&gt;&lt;br&gt;          -  Calculated or measured creatinine clearance &gt; 30 mL/min&lt;br&gt;&lt;br&gt;          -  Not pregnant or nursing&lt;br&gt;&lt;br&gt;          -  Negative pregnancy test&lt;br&gt;&lt;br&gt;          -  Fertile patients must use effective contraception 2 weeks before and during study&lt;br&gt;             treatment&lt;br&gt;&lt;br&gt;          -  LVEF normal by MUGA scan or ECHO&lt;br&gt;&lt;br&gt;          -  12-lead ECG normal&lt;br&gt;&lt;br&gt;          -  No serious cardiac illness (myocardial infarction and/or treatable or untreatable&lt;br&gt;             angina pectoris not responding to treatment) within the past 12 months&lt;br&gt;&lt;br&gt;          -  No uncontrolled, high BP (= 150/100 mm Hg) despite optimal medical therapy&lt;br&gt;&lt;br&gt;          -  No current pulmonary disease&lt;br&gt;&lt;br&gt;          -  No active or uncontrolled infections, serious illnesses, malabsorption syndrome, or&lt;br&gt;             medical conditions, including patients with a history of chronic alcohol abuse,&lt;br&gt;             hepatitis, HIV, and/or cirrhosis&lt;br&gt;&lt;br&gt;          -  No malignancies within the past 5 years except renal cell carcinoma, basal or&lt;br&gt;             squamous cell carcinoma of the skin, carcinoma in situ of the cervix, resected&lt;br&gt;             incidental prostate cancer staged pT2 with Gleason Score = 6 and postoperative PSA &lt;&lt;br&gt;             0.5 ng/mL, or patients with any history of malignancies who are disease-free for more&lt;br&gt;             than 5 years&lt;br&gt;&lt;br&gt;          -  No psychological, familial, sociological, or geographical condition potentially&lt;br&gt;             hampering compliance with the study protocol and follow-up schedule&lt;br&gt;&lt;br&gt;        PRIOR CONCURRENT THERAPY:&lt;br&gt;&lt;br&gt;          -  Prior local radiotherapy for bone lesions allowed&lt;br&gt;&lt;br&gt;          -  No prior systemic therapy for metastatic RCC&lt;br&gt;&lt;br&gt;          -  No prior partial or total nephrectomy&lt;br&gt;&lt;br&gt;          -  No concurrent systemic corticosteroid and/or other immunosuppressive systemic&lt;br&gt;             therapies&lt;br&gt;&lt;br&gt;          -  No concurrent radiotherapy, except palliative radiotherapy&lt;br&gt;&lt;br&gt;          -  No concurrent participation in another clinical trial testing treatments for any&lt;br&gt;             disease including renal cell carcinoma&lt;br&gt;&lt;br&gt;          -  No other concurrent investigational or systemic therapy for metastatic RCC&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Cancer</Condition>
    <Intervention>Procedure: timing of surgery;Genetic: gene expression analysis;Other: biologic sample preservation procedure;Other: laboratory biomarker analysis;Procedure: therapeutic conventional surgery</Intervention>
    <Primary_outcome>Overall progression-free survival</Primary_outcome>
    <Secondary_outcome>Overall survival;Morbidity;Overall response to treatment in the deferred nephrectomy arm including the proportion of patients who become unresectable;Effect of nephrectomy on early progression in both arms</Secondary_outcome>
    <Secondary_ID>EU-21022;PFIZER-EORTC-30073;EORTC-30073</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Wales Cancer Trials Unit;Canadian Urologic Oncology Group;Arbeitsgemeinschaft Urologische Onlogie (AUO);Institute of Cancer Research, United Kingdom</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2926883</Internal_Number>
    <TrialID>NCT01101698</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Vitamin K2 and Vessel Calcification in Chronic Kidney Disease Patients</Public_title>
    <Scientific_title>Influence of Vitamin K2 Administration on Vessel Calcification Markers in Patients With Chronic Kidney Disease</Scientific_title>
    <Acronym>CACSK2</Acronym>
    <Primary_sponsor>Medical Universtity of Lodz</Primary_sponsor>
    <Date_registration3>20100409</Date_registration3>
    <Date_registration>09/04/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01101698</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>30 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2009</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Investigator), Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Subject with chronic kidney disease (creatinine clearance 15-60 ml/min/1,73m2 by&lt;br&gt;             Cockroft-Gault formula)&lt;br&gt;&lt;br&gt;          2. Patient has a life without dialysis therapy of more than 9 months&lt;br&gt;&lt;br&gt;          3. Subject in 30-70 years of age&lt;br&gt;&lt;br&gt;          4. Calcium score &gt;10 (as per Agatston scoring system)&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Atherosclerosis generalisata (myocardial infarction treated with PTCA - Percutaneous&lt;br&gt;             Transluminal Coronary Angioplasty or CABG - Coronary Artery Bypass Graft, symptomatic&lt;br&gt;             heart insufficiency, cerebrovascular accident)&lt;br&gt;&lt;br&gt;          2. Subject with a history of cardiac abnormalities, including symptomatic or&lt;br&gt;             asymptomatic arrhythmias (atrial fibrillation)&lt;br&gt;&lt;br&gt;          3. Patient with cardiac pacemaker&lt;br&gt;&lt;br&gt;          4. Subject requires long-term use of vitamin K antagonists&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Diseases;Coronary Artery Calcification</Condition>
    <Intervention>Drug: Vitamin K2+10µg cholecalciferol;Drug: Vitamin D</Intervention>
    <Primary_outcome>Changes in coronary artery calcification score</Primary_outcome>
    <Secondary_outcome>Changes in common carotid artery intima media thickness</Secondary_outcome>
    <Secondary_ID>CACSK2</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2926989</Internal_Number>
    <TrialID>NCT01103076</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effects of High Cut-off (HCO) Hemodialysis on Central Memory CD4+ T and Treg Cells in Patients With End-stage Kidney Disease</Public_title>
    <Scientific_title>Effects of High Cut-off Hemodialysis on Central Memory CD4+ T Cells and Regulatory T Cells in Patients With End-stage Kidney Disease</Scientific_title>
    <Acronym />
    <Primary_sponsor>Centre Hospitalier du Centre du Valais</Primary_sponsor>
    <Date_registration3>20100413</Date_registration3>
    <Date_registration>13/04/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01103076</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2011</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Crossover Assignment, Masking:  Single Blind (Subject), Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2/Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with ESKD (CKD stage 5D according to K/DOQI guidelines) regularly treated by&lt;br&gt;             bicarbonate HD 3 times a week for at least 4 h at a blood flow rate of 300 ml/min&lt;br&gt;             will be included&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Only non-smokers will be enrolled in the study&lt;br&gt;&lt;br&gt;          -  Patients with recent (&lt; 3 mo) major trauma, surgery, myocardial infarction, coronary&lt;br&gt;             revascularization (coronary angioplasty or bypass surgery), or stroke will be&lt;br&gt;             excluded from the study&lt;br&gt;&lt;br&gt;          -  Diabetes mellitus&lt;br&gt;&lt;br&gt;          -  The presence of an acute or chronic inflammatory process, infection&lt;br&gt;&lt;br&gt;          -  Malnutrition (determined by Subjective Global Nutritional Assessment)&lt;br&gt;&lt;br&gt;          -  The use of immunosuppressive drugs or evidence of malignancy&lt;br&gt;&lt;br&gt;          -  Pregnant women, women who are breast feeding or are of child-bearing potential and&lt;br&gt;             not using adequate contraceptive precautions are excluded&lt;br&gt;&lt;br&gt;          -  A pregnancy test will be performed in female patients before the inclusion&lt;br&gt;&lt;br&gt;          -  Except for aspirin and statin, those patients taking anti-inflammatory medications in&lt;br&gt;             the prior 4 weeks will be excluded.&lt;br&gt;&lt;br&gt;          -  All patients have to be negative for circulating hepatitis B antigen, hepatitis C&lt;br&gt;             antibody (Ab) and HIV&lt;br&gt;&lt;br&gt;          -  They will have no active liver disease&lt;br&gt;&lt;br&gt;          -  No patient will be nephrectomized&lt;br&gt;&lt;br&gt;          -  Arterial blood pH will be between 7.38 and 7.42&lt;br&gt;&lt;br&gt;          -  No patient will receive a blood transfusion in the 6 mo before the study&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End-stage Kidney Disease;CD4 T Cells;Central Memory T Cells;Regulatory T Cells;Uremic Toxins</Condition>
    <Intervention>Device: Polyamide HD membrane</Intervention>
    <Primary_outcome>HCO 1100 membrane effect on T CM and Tregs in patients with ESKD chronically hemodialzed</Primary_outcome>
    <Secondary_outcome>Immunogenicity of the HB-AS04 vaccine in patients dialyzed with HCO 1100 or polyamide membranes</Secondary_outcome>
    <Secondary_ID>HCO study;HighCO Hemo study</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Research Unit CHCVs Hôpital de Sion Switzerland;Immunology ICHV Sion Switzerland;Immunology CHUV University Hospital Lausanne Switzerland;Nephrology CHUV University Hospital Lausanne Switzerland</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2926996</Internal_Number>
    <TrialID>NCT01103167</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Body Composition Monitor in Hemodialysis Patients</Public_title>
    <Scientific_title>The Association Between Body Composition and Biomarkers in Hemodialysis Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>Gachon University Gil Medical Center</Primary_sponsor>
    <Date_registration3>20100409</Date_registration3>
    <Date_registration>09/04/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01103167</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2010</Date_enrollement>
    <Target_size>160</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  6-month or more stable hemodialysis patients&lt;br&gt;&lt;br&gt;          -  18 years or more&lt;br&gt;&lt;br&gt;          -  less than 5% of changes of dry weight for last 3 months&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  pregnancy&lt;br&gt;&lt;br&gt;          -  active malignancy&lt;br&gt;&lt;br&gt;          -  cardiac pacemaker or defibrillator&lt;br&gt;&lt;br&gt;          -  history of extremity amputation&lt;br&gt;&lt;br&gt;          -  active infectious disease within 3 months&lt;br&gt;&lt;br&gt;          -  admission history for complication related to hemodialysis within 3 months&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End Stage Renal Disease</Condition>
    <Intervention>Behavioral: control of ultrafiltration</Intervention>
    <Primary_outcome>blood pressure</Primary_outcome>
    <Secondary_outcome>biomarkers</Secondary_outcome>
    <Secondary_ID>korea_bcm_hd</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Seoul National University Hospital;Seoul National University Bundang Hospital</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2927458</Internal_Number>
    <TrialID>NCT01109186</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Anti-BK Virus Immune Response and Kidney Transplantation</Public_title>
    <Scientific_title>Role of Specific Immune Cellular Response in the Control of BK Virus Infection: Prospective Study, Monocentric and Longitudinal During the First Nine Months After a Kidney Transplantation</Scientific_title>
    <Acronym>BKv</Acronym>
    <Primary_sponsor>Nantes University Hospital</Primary_sponsor>
    <Date_registration3>20100421</Date_registration3>
    <Date_registration>21/04/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01109186</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2010</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Kidney-transplanted patient, since less than 30 days&lt;br&gt;&lt;br&gt;          -  Older than 18 years old&lt;br&gt;&lt;br&gt;          -  Treatment with tacrolimus and mycophénolate mofetil&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  No informed consent&lt;br&gt;&lt;br&gt;          -  Pregnant women&lt;br&gt;&lt;br&gt;          -  Patient under legal guardianship&lt;br&gt;&lt;br&gt;          -  Treated by ciclosporin or mTOR-inhibitor&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Transplantation</Condition>
    <Intervention>Other: biological parameters</Intervention>
    <Primary_outcome>Comparison of the level of response between patient with a "non-controlled infection" and patients for who the blood viral load is under 103 copBKv/ml.</Primary_outcome>
    <Secondary_outcome>Analyse of the other causes that could influence the occurence of a viremia higher than 103 copBKv/ml;Measurement of histological consequences of a BKv non-controlled infection during the first year post-graft;Measurement of increase of immune response due to modifications of immunosuppressive treatment for patient with a non-controlled infection</Secondary_outcome>
    <Secondary_ID>BRD 10/3-ZF</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2927514</Internal_Number>
    <TrialID>NCT01109914</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Mucosal Response in Immunocompromised Host</Public_title>
    <Scientific_title>Immune Response After Inactivated Oral Cholera Vaccine (Dukoral) in Renal Transplant Recipients</Scientific_title>
    <Acronym>MICH</Acronym>
    <Primary_sponsor>Leiden University Medical Center</Primary_sponsor>
    <Date_registration3>20100422</Date_registration3>
    <Date_registration>22/04/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01109914</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2010</Date_enrollement>
    <Target_size>70</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        HEALTHY VOLUNTEERS&lt;br&gt;&lt;br&gt;        Inclusion criteria:&lt;br&gt;&lt;br&gt;          -  Above 18 years of age&lt;br&gt;&lt;br&gt;          -  Informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  History of an auto-immune disease (SLE, ANCA associated vasculitis, Goodpasture,&lt;br&gt;             Henoch Schonlein, cryoglobulinemia, secondary vasculitis, polyarteritis nodosa and&lt;br&gt;             immunodeficiency disorders like IgA deficiency)&lt;br&gt;&lt;br&gt;          -  Chronic infection&lt;br&gt;&lt;br&gt;          -  Past vaccination with Dukoral or another cholera or ETEC vaccine&lt;br&gt;&lt;br&gt;          -  History of infection with Vibrio cholerae&lt;br&gt;&lt;br&gt;          -  Episode of diarrhoea in the 6 months prior to inclusion&lt;br&gt;&lt;br&gt;          -  Allergy to vaccine-specific components&lt;br&gt;&lt;br&gt;          -  History of a severe allergic reaction to any vaccine&lt;br&gt;&lt;br&gt;          -  Treatment with blood products in the 3 months prior to inclusion&lt;br&gt;&lt;br&gt;          -  Current pregnancy or breastfeeding&lt;br&gt;&lt;br&gt;          -  Premenopausal women not willing to use contraceptives during the first 60 days after&lt;br&gt;             vaccination&lt;br&gt;&lt;br&gt;          -  Use of any immunosuppressive drug&lt;br&gt;&lt;br&gt;        RENAL TRANSPLANT RECIPIENTS&lt;br&gt;&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Above 18 years of age&lt;br&gt;&lt;br&gt;          -  Creatinin clearance = 40 ml/min measured in the 6 months prior to inclusion&lt;br&gt;&lt;br&gt;          -  Stable renal function for 1 year prior to inclusion&lt;br&gt;&lt;br&gt;          -  Stable immunosuppressive regimen of a CNI, MMF or mTORi combined with prednisolone&lt;br&gt;             for at least 3 months prior to inclusion&lt;br&gt;&lt;br&gt;          -  Informed Consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  History of an auto-immune disease (SLE, ANCA associated vasculitis, Goodpasture,&lt;br&gt;             Henoch Schonlein, cryoglobulinemia, secondary vasculitis, polyarteritis nodosa and&lt;br&gt;             immunodeficiency disorders like IgA deficiency)&lt;br&gt;&lt;br&gt;          -  Chronic infection&lt;br&gt;&lt;br&gt;          -  Treatment for rejection of the transplant in the past 1 year prior to inclusion&lt;br&gt;&lt;br&gt;          -  Past vaccination with Dukoral or another cholera or ETEC vaccine&lt;br&gt;&lt;br&gt;          -  History of infection with Vibrio cholerae&lt;br&gt;&lt;br&gt;          -  Episode of diarrhoea in the 6 months prior to inclusion&lt;br&gt;&lt;br&gt;          -  Allergy to vaccine-specific components&lt;br&gt;&lt;br&gt;          -  History of a severe allergic reaction to any vaccine&lt;br&gt;&lt;br&gt;          -  Treatment with blood products in the 3 months prior to inclusion&lt;br&gt;&lt;br&gt;          -  Current pregnancy or breastfeeding&lt;br&gt;&lt;br&gt;          -  Premenopausal women not willing to use contraceptives during the first 60 days after&lt;br&gt;             vaccination&lt;br&gt;&lt;br&gt;          -  Use of an immunosuppressive drug other than CNI, MMF, mTORi or prednisolone at the&lt;br&gt;             the time of inclusion&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Vaccination;Kidney Transplantation</Condition>
    <Intervention>Biological: Dukoral</Intervention>
    <Primary_outcome>Percentage seroconversion among all renal transplant recipients.</Primary_outcome>
    <Secondary_outcome>Group differences in geometric mean antibody titers after vaccination</Secondary_outcome>
    <Secondary_ID>MICH P10.011</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Crucell B.V., Leiden, the Netherlands</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2927630</Internal_Number>
    <TrialID>NCT01111422</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Anti-Oxidant Effect on Peritoneal Membrane in Peritoneal Dialysis (PD) Patients</Public_title>
    <Scientific_title>A Randomized Prospective Trial of N-acetyl Cystein in Patients With Peritoneal Dialysis</Scientific_title>
    <Acronym />
    <Primary_sponsor>Ewha Womans University</Primary_sponsor>
    <Date_registration3>20100423</Date_registration3>
    <Date_registration>23/04/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01111422</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2010</Date_enrollement>
    <Target_size>66</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Maintenance peritoneal dialysis at least 3 months&lt;br&gt;&lt;br&gt;          -  Patients who are able and willing to understand, sign and date an informed consent&lt;br&gt;             document, and authorize access to protected health information&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Episode of peritonitis at least 3 months&lt;br&gt;&lt;br&gt;          -  Episodes of admission due to other disease at lease 3 months&lt;br&gt;&lt;br&gt;          -  Liver disease&lt;br&gt;&lt;br&gt;          -  Allergic history with N-acetylcysteine&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End-Stage Kidney Disease;Peritoneal Dialysis</Condition>
    <Intervention>Drug: N-acetylcysteine</Intervention>
    <Primary_outcome>Peritoneal membrane function</Primary_outcome>
    <Secondary_outcome>Oxydative stress status;Mesothelial cell transformation (Epithelial to Mesenchymal Transition);Residual renal function;Peritoneal membrane function</Secondary_outcome>
    <Secondary_ID>Ewha 219-3-40</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2928116</Internal_Number>
    <TrialID>NCT01117779</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Tracking Renal Tumors After Cryoablation Evaluation</Public_title>
    <Scientific_title>Tracking Renal Tumors After Cryoablation Evaluation (TRACE) Registry</Scientific_title>
    <Acronym>TRACE</Acronym>
    <Primary_sponsor>Galil Medical</Primary_sponsor>
    <Date_registration3>20100504</Date_registration3>
    <Date_registration>04/05/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01117779</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2010</Date_enrollement>
    <Target_size>250</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case-Only, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Suggested Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patient is at least 18 years of age.&lt;br&gt;&lt;br&gt;          -  Patient has a renal lesion suspicious for malignancy.&lt;br&gt;&lt;br&gt;          -  Patient is to undergo renal lesion cryoablation via a Galil Medical cryoablation&lt;br&gt;             system using Galil Medical needles for treatment of primary or recurrent disease.&lt;br&gt;&lt;br&gt;          -  Patient is to be available for long-term follow-up per the enrolling physician's&lt;br&gt;             standard care practices.&lt;br&gt;&lt;br&gt;          -  Patient has provided written informed consent.&lt;br&gt;&lt;br&gt;        Suggested Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patient is either currently using or has used within the last 30 days an&lt;br&gt;             investigational product of any type.&lt;br&gt;&lt;br&gt;          -  Patient has metastatic disease to or from the kidney.&lt;br&gt;&lt;br&gt;          -  Patient has had previous therapy on the index lesion (e.g. radiofrequency,&lt;br&gt;             cryoablation, partial nephrectomy).&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Neoplasms</Condition>
    <Intervention>Procedure: Cryoablation</Intervention>
    <Primary_outcome>Short and long term outcomes</Primary_outcome>
    <Secondary_outcome>Procedure method outcomes;Standard of care follow-up procedures</Secondary_outcome>
    <Secondary_ID>CUC10-RNL02-01</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2928171</Internal_Number>
    <TrialID>NCT01118494</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Study of Urinary Angiotensinogen as a Marker to Warn the Deterioration of Renal Function in CKD Patients Early.</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>Fudan University</Primary_sponsor>
    <Date_registration3>20100426</Date_registration3>
    <Date_registration>26/04/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01118494</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2009</Date_enrollement>
    <Target_size>400</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case-Only, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  CKD,  in the stage of 3 or 4, and kidney biopsy is preferred selection;&lt;br&gt;&lt;br&gt;          -  Signed the informed consent;&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Kidney cancer patients;&lt;br&gt;&lt;br&gt;          -  Kidney transplantation;&lt;br&gt;&lt;br&gt;          -  Hereditary kidney disease;&lt;br&gt;&lt;br&gt;          -  Secondary renal disease(diabetic nephropathy and hypertensive nephropathy are&lt;br&gt;             excluded)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease;Urinary Angiotensinogen</Condition>
    <Primary_outcome>Urinary AGT level</Primary_outcome>
    <Secondary_ID>08dz1900603</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2928381</Internal_Number>
    <TrialID>NCT01121237</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5</Public_title>
    <Scientific_title>An International, Prospective, Open-label, Multicenter, Pharmacoepidemiological Study to Determine Predictors of Clinical Outcomes in Haemodialysis Patients With Anaemia Treated With Binocrit(r)</Scientific_title>
    <Acronym>MONITOR-CKD5</Acronym>
    <Primary_sponsor>Matrix45</Primary_sponsor>
    <Date_registration3>20100506</Date_registration3>
    <Date_registration>06/05/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01121237</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2009</Date_enrollement>
    <Target_size>1000</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Male or female adults (age &gt; 18 years).&lt;br&gt;&lt;br&gt;          -  On chronic haemodialysis due to end-stage renal disease (CKD5) of original or grafted&lt;br&gt;             kidneys for any duration.&lt;br&gt;&lt;br&gt;          -  Diagnosed with renal anaemia; i.e., anaemia due to impaired production of endogenous&lt;br&gt;             erythropoietin secondary to kidney failure.&lt;br&gt;&lt;br&gt;          -  Treated with commercially available intravenous BINOCRIT® per physician's best&lt;br&gt;             clinical judgment.&lt;br&gt;&lt;br&gt;          -  Haemoglobin level 10-12 g/dL&lt;br&gt;&lt;br&gt;          -  Female patients must be either post-menopausal for one year or surgically sterile or&lt;br&gt;             using effective contraceptive methods such as barrier method with spermicide or an&lt;br&gt;             intra-uterine device. Oral contraceptive use is allowed.&lt;br&gt;&lt;br&gt;          -  Informed written consent to participate in the study by patients or their legal&lt;br&gt;             guardian.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        Known sensitivity to BINOCRIT® or any other ESA.&lt;br&gt;&lt;br&gt;          -  Solid or hematological neoplasia being treated with chemotherapy.&lt;br&gt;&lt;br&gt;          -  Treatment with any myelosuppressant medications.&lt;br&gt;&lt;br&gt;          -  Blood transfusion dependency.&lt;br&gt;&lt;br&gt;          -  History of pure red cell aplasia.&lt;br&gt;&lt;br&gt;          -  Bleeding episode in 30 days prior to enrollment.&lt;br&gt;&lt;br&gt;          -  Orthopaedic surgery in 30 days prior to enrollment.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease;End-stage Renal Disease;Anaemia</Condition>
    <Intervention>Drug: Recombinant human erythropoietin alfa (biosimilar)</Intervention>
    <Primary_outcome>Haemoglobin outcomes, including haemoglobin levels in g/dL, change in haemoglobin levels over time (in g/dL and %), number and proportion of patients with haematopoietic response, number and proportion of patients reaching target haemoglobin levels.</Primary_outcome>
    <Secondary_outcome>Number and proportion of participants with thrombovascular events, hospitalization,and mortality as measures of safety.</Secondary_outcome>
    <Secondary_ID>HX575-503</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Sandoz</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2928381</Internal_Number>
    <TrialID>NCT01121237</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5</Public_title>
    <Scientific_title>An International, Prospective, Open-label, Multicenter, Pharmacoepidemiological Study to Determine Predictors of Clinical Outcomes in Haemodialysis Patients With Anaemia Treated With Binocrit(r)</Scientific_title>
    <Acronym>MONITOR-CKD5</Acronym>
    <Primary_sponsor>Matrix45</Primary_sponsor>
    <Date_registration3>20100506</Date_registration3>
    <Date_registration>06/05/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01121237</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2009</Date_enrollement>
    <Target_size>1000</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Male or female adults (age &gt; 18 years).&lt;br&gt;&lt;br&gt;          -  On chronic haemodialysis due to end-stage renal disease (CKD5) of original or grafted&lt;br&gt;             kidneys for any duration.&lt;br&gt;&lt;br&gt;          -  Diagnosed with renal anaemia; i.e., anaemia due to impaired production of endogenous&lt;br&gt;             erythropoietin secondary to kidney failure.&lt;br&gt;&lt;br&gt;          -  Treated with commercially available intravenous BINOCRIT® per physician's best&lt;br&gt;             clinical judgment.&lt;br&gt;&lt;br&gt;          -  Haemoglobin level 10-12 g/dL&lt;br&gt;&lt;br&gt;          -  Female patients must be either post-menopausal for one year or surgically sterile or&lt;br&gt;             using effective contraceptive methods such as barrier method with spermicide or an&lt;br&gt;             intra-uterine device. Oral contraceptive use is allowed.&lt;br&gt;&lt;br&gt;          -  Informed written consent to participate in the study by patients or their legal&lt;br&gt;             guardian.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        Known sensitivity to BINOCRIT® or any other ESA.&lt;br&gt;&lt;br&gt;          -  Solid or hematological neoplasia being treated with chemotherapy.&lt;br&gt;&lt;br&gt;          -  Treatment with any myelosuppressant medications.&lt;br&gt;&lt;br&gt;          -  Blood transfusion dependency.&lt;br&gt;&lt;br&gt;          -  History of pure red cell aplasia.&lt;br&gt;&lt;br&gt;          -  Bleeding episode in 30 days prior to enrollment.&lt;br&gt;&lt;br&gt;          -  Orthopaedic surgery in 30 days prior to enrollment.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease;End-stage Renal Disease;Anaemia</Condition>
    <Intervention>Drug: Recombinant human erythropoietin alfa (biosimilar)</Intervention>
    <Primary_outcome>Haemoglobin outcomes, including haemoglobin levels in g/dL, change in haemoglobin levels over time (in g/dL and %), number and proportion of patients with haematopoietic response, number and proportion of patients reaching target haemoglobin levels.</Primary_outcome>
    <Secondary_outcome>Number and proportion of participants with thrombovascular events, hospitalization,and mortality as measures of safety.</Secondary_outcome>
    <Secondary_ID>HX575-503</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Sandoz</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2928686</Internal_Number>
    <TrialID>NCT01125202</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Intervention to Reduce Dietary Sodium in Hemodialysis</Public_title>
    <Scientific_title>Intervention to Reduce Dietary Sodium in Hemodialysis</Scientific_title>
    <Acronym>BalanceWise-HD</Acronym>
    <Primary_sponsor>University of Pittsburgh</Primary_sponsor>
    <Date_registration3>20100514</Date_registration3>
    <Date_registration>14/05/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01125202</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2009</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Supportive Care</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Individuals who are 18 years of age or older,&lt;br&gt;&lt;br&gt;          -  Individuals who are literate,&lt;br&gt;&lt;br&gt;          -  Community-dwelling adults who have been receiving maintenance dialysis for at least 3&lt;br&gt;             months.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Individuals who cannot read or write,&lt;br&gt;&lt;br&gt;          -  Individuals who do not speak English,&lt;br&gt;&lt;br&gt;          -  Individuals who plan to move out of the area or change dialysis centers within the&lt;br&gt;             next 6 months,&lt;br&gt;&lt;br&gt;          -  Individuals who have a life expectancy of less than 12 months,&lt;br&gt;&lt;br&gt;          -  Individuals who are scheduled for a living donor transplant,&lt;br&gt;&lt;br&gt;          -  Individuals who cannot see the PDA screen or use the stylus to make food selections&lt;br&gt;             from the PDA screen, or&lt;br&gt;&lt;br&gt;          -  Individuals who live in an institutional setting in which they would have limited&lt;br&gt;             control over their dietary intake.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Dialysis</Condition>
    <Intervention>Behavioral: Social Cognitive Theory based dietary counseling paired with personal digital assistant based self-monitoring;Behavioral: Attention Control</Intervention>
    <Primary_outcome>Change in interdialytic weight gain over time;Dietary sodium intake;Dietary sodium intake;Dietary sodium intake</Primary_outcome>
    <Secondary_outcome>Blood pressure;Self-efficacy for restricting dietary sodium in hemodialysis;Hemodialysis symptoms;Problems with the dialysis diet;Self-rated global health;Experience with the hemodialysis diet and intervention</Secondary_outcome>
    <Secondary_ID>R01NR010135;PRO08040361</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>University of Iowa;National Institute of Nursing Research (NINR)</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2928908</Internal_Number>
    <TrialID>NCT01128101</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effects of Spironolactone in Dialysis</Public_title>
    <Scientific_title>Assessment of the Effects of the Combination of Spironolactone to Conventional Pharmacotherapy in Dialysis Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>UPECLIN HC FM Botucatu Unesp</Primary_sponsor>
    <Date_registration3>20100516</Date_registration3>
    <Date_registration>16/05/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01128101</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2011</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Investigator), Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        The series will consist of:&lt;br&gt;&lt;br&gt;          1. Patients with at least 18 years of age,&lt;br&gt;&lt;br&gt;          2. Suffering from chronic kidney disease stage V on dialysis,&lt;br&gt;&lt;br&gt;          3. Mean blood pressure residential than 135 x 85 mm Hg and&lt;br&gt;&lt;br&gt;          4. Who present left ventricular mass indexed for height to the 2.7 power greater than 51&lt;br&gt;             g/m2, 7.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. History or evidence of angina or myocardial infarction,&lt;br&gt;&lt;br&gt;          2. Heart failure,&lt;br&gt;&lt;br&gt;          3. Peripheral vascular disease,&lt;br&gt;&lt;br&gt;          4. Hyperkalemia&lt;br&gt;&lt;br&gt;          5. Previous valve atrial fibrillation,&lt;br&gt;&lt;br&gt;          6. Anemia (hemoglobin &lt;10 g/dl),&lt;br&gt;&lt;br&gt;          7. Doses of parathyroid hormone (PTH) greater than 300 pg/mL,&lt;br&gt;&lt;br&gt;          8. Patients being treated with spironolactone and&lt;br&gt;&lt;br&gt;          9. Patients who have suspended or initiated the use of inhibitors of angiotensin&lt;br&gt;             converting enzyme inhibitors, angiotensin receptor blockers (ARBs) renin blockers in&lt;br&gt;             the last six months.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Failure</Condition>
    <Intervention>Drug: Spironolactone</Intervention>
    <Primary_outcome>Reduction of Left Ventricular Hypertrophy</Primary_outcome>
    <Secondary_outcome>To evaluate the safety and efficacy of the use of spironolactone at a dose of 25mg in patients with chronic kidney disease on hemodialysis.</Secondary_outcome>
    <Secondary_ID>3439-2010;upeclin/HC/FMB-Unesp-43</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2929679</Internal_Number>
    <TrialID>NCT01138241</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Tenofovir Renal Toxicity and Glomerular Filtration Rate (GFR) Validation</Public_title>
    <Scientific_title>Incidence and Predictor of TDF Associated Nephrotoxicity and Pharmacokinetic of TDF in HIV-1 Infected Thai Patients: A Sub-study of HIV-NAT 006 Long Term Cohort</Scientific_title>
    <Acronym />
    <Primary_sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Primary_sponsor>
    <Date_registration3>20100604</Date_registration3>
    <Date_registration>04/06/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01138241</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2010</Date_enrollement>
    <Target_size>700</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Cross-Sectional</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. &gt; 18 years old.&lt;br&gt;&lt;br&gt;          2. HIV RNA &lt; 50 copies/ml (For ART-experienced group only).&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. a history of Tc-99m DTPA allergy,&lt;br&gt;&lt;br&gt;          2. malnutrition (BMI &lt;18m2),&lt;br&gt;&lt;br&gt;          3. amputation,&lt;br&gt;&lt;br&gt;          4. bed-ridden,&lt;br&gt;&lt;br&gt;          5. currently taking cotrimoxazole or cimetidine,&lt;br&gt;&lt;br&gt;          6. acute deterioration of renal function within the last 3 months,&lt;br&gt;&lt;br&gt;          7. serum creatinine &gt; 1.5 mg/dl, or&lt;br&gt;&lt;br&gt;          8. pregnant/lactating.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Function;HIV Infection</Condition>
    <Intervention>Other: Tc99mDTPA renal clearance</Intervention>
    <Secondary_outcome>eGFR by C-G formula, MDRD, CKD-EPI;GFR by cystatin C;GFR by urine 24 hours;TDF plasma levels</Secondary_outcome>
    <Secondary_ID>HIV-NAT 114</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Chulalongkorn University;Kirby Institute</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2929680</Internal_Number>
    <TrialID>NCT01138254</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Far Infrared Therapy on AV Fistula Flow, Endothelial Function and Echocardiography in ESRD Patients</Public_title>
    <Scientific_title>The Effect of Far Infrared (FIR) Therapy on Access Flow of Arteriovenous (AV) Fistula, Echocardiographic Parameters and Endothelial Function in Patients With End Stage Renal Disease</Scientific_title>
    <Acronym />
    <Primary_sponsor>Taipei Veterans General Hospital,Taiwan</Primary_sponsor>
    <Date_registration3>20100525</Date_registration3>
    <Date_registration>25/05/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01138254</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>90 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2008</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Single Blind (Outcomes Assessor), Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  (1) age between 18 and 80,&lt;br&gt;&lt;br&gt;          -  (2) chronic kidney disease (CKD) stage 5 with clearance of creatinine (CCr) less than&lt;br&gt;             15 ml/min,&lt;br&gt;&lt;br&gt;          -  (3) not receiving dialysis or renal transplantation,&lt;br&gt;&lt;br&gt;          -  (4) is going to receive creation of AV fistula with the standardized surgical&lt;br&gt;             procedures of venous end-to-arterial side anastomosis in the upper extremity.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  (1) creation of AV graft or Perm catheter as the type of vascular access,&lt;br&gt;&lt;br&gt;          -  (2) heart failure in NYHA Fc III or IV,&lt;br&gt;&lt;br&gt;          -  (3) episode of unstable angina, myocardial infarction, cerebrovascular event or&lt;br&gt;             receiving percutaneous coronary intervention therapy (PCI; including angioplasty or&lt;br&gt;             placement of stent ) within 3 months prior to screening.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End Stage Renal Disease</Condition>
    <Intervention>Device: WSTM TY101 FIR emitter (Far infrared therapy);Other: no intervention</Intervention>
    <Primary_outcome>Access flow monthly for 3 months and 6th month (0,1st,2nd,3rd and 6th months) and Echocardiographic parameters at 6th month ( 0 and 6th months)</Primary_outcome>
    <Secondary_outcome>Plasma asymmetric dimethyl arginine (ADMA) and L-arginine</Secondary_outcome>
    <Secondary_ID>V98C1-045</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2930218</Internal_Number>
    <TrialID>NCT01145274</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>A Pilot Study for Pharmacokinetic/Pharmacodynamic (PK/PD) Parameter of Allopurinol and Its Metabolite-oxypurinol After Once-daily Allopurinol in Chronic Kidney Disease Patient</Public_title>
    <Scientific_title>A Pilot Study for PK/PD Parameter of Allopurinol and Its Metabolite-oxypurinol After Once-daily Allopurinol in Chronic Kidney Disease Patient</Scientific_title>
    <Acronym>Allopurinol</Acronym>
    <Primary_sponsor>Seoul National University Hospital</Primary_sponsor>
    <Date_registration3>20100615</Date_registration3>
    <Date_registration>15/06/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01145274</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2010</Date_enrollement>
    <Target_size>80</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  from 18yrs to 80yrs , man and women&lt;br&gt;&lt;br&gt;          -  the patient who are taking allopurinol&lt;br&gt;&lt;br&gt;          -  On screening, the patient shows that the level of protein/creatinine ratio is over&lt;br&gt;             3.0&lt;br&gt;&lt;br&gt;          -  On screening, the patient shows that MDRD GFR &gt;= 30 ml/min and &lt;= 60 ml/min&lt;br&gt;&lt;br&gt;          -  the patient sign on the concent form&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  the patient have experience to take medication that have an effect on renal function&lt;br&gt;&lt;br&gt;          -  the patient have experience to take cyclosporin within 3month&lt;br&gt;&lt;br&gt;          -  At least, the average level of two separate blood pressure ( 2min interval ) shows&lt;br&gt;             that SBP &lt;= 100 mmHg or &gt;=160 mmHg and DBP &lt;=60 mmHg &gt;=100 mmHg, or Heart rate &lt; 40&lt;br&gt;             beats/min or &gt; 90 beats/min&lt;br&gt;&lt;br&gt;          -  uncontrolled hypertension&lt;br&gt;&lt;br&gt;          -  pregnancy or anticipate pregnancy with 6 month&lt;br&gt;&lt;br&gt;          -  hypersensitivity to allopurinol&lt;br&gt;&lt;br&gt;          -  acute hepatitis or the level of AST or ALT is over 2times of normal range or the&lt;br&gt;             level of bilirubin is over 2.0 mg/dL&lt;br&gt;&lt;br&gt;          -  serum albumin &lt; 3.5 mg/dL or &gt; 5mg/dL&lt;br&gt;&lt;br&gt;          -  urinary retension, prostatic hyperplasia&lt;br&gt;&lt;br&gt;          -  the patient show gout attack on taking allopurinol&lt;br&gt;&lt;br&gt;          -  the patient who have gastro-intestinal disease ( ex, crohn's disease, acute or&lt;br&gt;             chronic pancreatitis, ulcer )or who have the surgical history of gastrointestine.&lt;br&gt;&lt;br&gt;          -  the patient who should take azathioprine, mercaptopurine, cyclophosphamide, Losartan,&lt;br&gt;             benzbromarone,fenofibrate,furosemide ,probenecid&lt;br&gt;&lt;br&gt;          -  the patient who had taken part in the other study within 3months&lt;br&gt;&lt;br&gt;          -  the patient who had gotten blood transfusion&lt;br&gt;&lt;br&gt;          -  pregnant, breast feeding&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease</Condition>
    <Secondary_ID>Allopurinol_2010_1</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2930800</Internal_Number>
    <TrialID>NCT01152892</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Risk Stratification in End Stage Renal Disease (ESRD)</Public_title>
    <Scientific_title>Risk Stratification in End Stage Renal Disease (ISAR)</Scientific_title>
    <Acronym>ISAR</Acronym>
    <Primary_sponsor>Technische Universität München</Primary_sponsor>
    <Date_registration3>20100628</Date_registration3>
    <Date_registration>28/06/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01152892</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2010</Date_enrollement>
    <Target_size>400</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Age 18 or older&lt;br&gt;&lt;br&gt;          2. End-stage renal disease (ESRD) and receiving maintenance hemodialysis&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Any clinically significant infection.&lt;br&gt;&lt;br&gt;          2. disturbances in electrolytes (sodium, potassium, calcium, bicarbonate) before&lt;br&gt;             long-term-ecg measurement&lt;br&gt;&lt;br&gt;          3. pregnancy&lt;br&gt;&lt;br&gt;          4. history of malignant disease with a prognostic life expectancy less than 24 months&lt;br&gt;&lt;br&gt;          5. pace-maker device implantation, AICD implantation&lt;br&gt;&lt;br&gt;          6. missing of written and informed consent&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End Stage Renal Disease;Chronic Kidney Disease;Cardiovascular Event;Sudden Cardiac Death</Condition>
    <Primary_outcome>Mortality of all causes</Primary_outcome>
    <Secondary_outcome>Incidence of cardiovascular events;Blood pressure drops within a dialysis session;Incidence of infections requiring antibiotic treatment;Incidence of shunt thrombosis</Secondary_outcome>
    <Secondary_ID>ISAR ESRD 01 2010</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Else Kröner Fresenius Foundation</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2930800</Internal_Number>
    <TrialID>NCT01152892</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Risk Stratification in End Stage Renal Disease (ESRD)</Public_title>
    <Scientific_title>Risk Stratification in End Stage Renal Disease (ISAR)</Scientific_title>
    <Acronym>ISAR</Acronym>
    <Primary_sponsor>Technische Universität München</Primary_sponsor>
    <Date_registration3>20100628</Date_registration3>
    <Date_registration>28/06/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01152892</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2010</Date_enrollement>
    <Target_size>400</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Age 18 or older&lt;br&gt;&lt;br&gt;          2. End-stage renal disease (ESRD) and receiving maintenance hemodialysis&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Any clinically significant infection.&lt;br&gt;&lt;br&gt;          2. disturbances in electrolytes (sodium, potassium, calcium, bicarbonate) before&lt;br&gt;             long-term-ecg measurement&lt;br&gt;&lt;br&gt;          3. pregnancy&lt;br&gt;&lt;br&gt;          4. history of malignant disease with a prognostic life expectancy less than 24 months&lt;br&gt;&lt;br&gt;          5. pace-maker device implantation, AICD implantation&lt;br&gt;&lt;br&gt;          6. missing of written and informed consent&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End Stage Renal Disease;Chronic Kidney Disease;Cardiovascular Event;Sudden Cardiac Death</Condition>
    <Primary_outcome>Mortality of all causes</Primary_outcome>
    <Secondary_outcome>Incidence of cardiovascular events;Blood pressure drops within a dialysis session;Incidence of infections requiring antibiotic treatment;Incidence of shunt thrombosis</Secondary_outcome>
    <Secondary_ID>ISAR ESRD 01 2010</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Else Kröner Fresenius Foundation</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2931273</Internal_Number>
    <TrialID>NCT01159080</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Treatment of the optImuM Dose of calcineUrin Inhibitor and Mycophenolate Sodium in Kidney Recipients</Public_title>
    <Scientific_title>Organ Function Preservation by the Combination Treatment of the optImuM Dose of calcineUrin Inhibitor and Mycophenolate Sodium in Kidney Recipients: OPTIMUM Study</Scientific_title>
    <Acronym>OPTIMUM</Acronym>
    <Primary_sponsor>Asan Medical Center</Primary_sponsor>
    <Date_registration3>20100706</Date_registration3>
    <Date_registration>06/07/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01159080</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>20 Years</Inclusion_agemin>
    <Inclusion_agemax>65 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2010</Date_enrollement>
    <Target_size>350</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  One to five years after a kidney transplant subjects&lt;br&gt;&lt;br&gt;          -  Subject who is using CNI ± purine synthesis inhibitor + steroid without change within&lt;br&gt;             the past 3 months (except the dosage)&lt;br&gt;&lt;br&gt;          -  serum creatinine &lt; 2 mg/dL and the variation of serum creatinine &lt; 30% during the&lt;br&gt;             past 3 months&lt;br&gt;&lt;br&gt;          -  Proteinuria  = 1g quantified by 24 hour urine or  spot urine protein/creatinine ratio&lt;br&gt;             &lt;1.0&lt;br&gt;&lt;br&gt;          -  Subjects who agree with written informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Subjects who received combined non-renal transplantation.&lt;br&gt;&lt;br&gt;          -  Subject who received re-transplantation&lt;br&gt;&lt;br&gt;          -  deceased donor without a heartbeat&lt;br&gt;&lt;br&gt;          -  Patients with hypersensitivity to Mycophenolate sodium, Mycophenolate acid or&lt;br&gt;             Mycophenolate Mofetil or to any of the excipients.&lt;br&gt;&lt;br&gt;          -  Patient with HGPRT(Hypoxanthin e-guanine phosphoribosyl-transferase) such as&lt;br&gt;             Lesch-Nyhan syndrome and kelley-Seegmiller syndrome.&lt;br&gt;&lt;br&gt;          -  HLA-identical living related donor&lt;br&gt;&lt;br&gt;          -  ABO blood group incompatible&lt;br&gt;&lt;br&gt;          -  HIV, HBsAg, or HCV Ab tests (+)&lt;br&gt;&lt;br&gt;          -  Abnormal liver function test (AST or ALT or total bilirubin&gt; upper normal limit x3)&lt;br&gt;             ANC &lt;1,500/µL or WBC &lt;2,500/µL or platelet &lt;750,000/µL&lt;br&gt;&lt;br&gt;          -  Women who are either pregnant, lactating, planning to become pregnant in the next 12&lt;br&gt;             months.&lt;br&gt;&lt;br&gt;          -  Subjects with history of cancer, except successfully treated, localized&lt;br&gt;             nonmelanocytic skin cancer Subjects with clinically significant infections within the&lt;br&gt;             past 3 months.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Transplantation</Condition>
    <Intervention>Drug: routine dose tacrolimus and myfortic;Drug: low dose tacrolimus and myfortic</Intervention>
    <Primary_outcome>estimated GFR (abbreviated MDRD equation)12 months after randomization</Primary_outcome>
    <Secondary_outcome>12 month creatinine clearance (24 hour urine);graft survival</Secondary_outcome>
    <Secondary_ID>CERL080AKR07T;CERL080AKR07T</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Seoul National University Hospital;Samsung Medical Center</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2931785</Internal_Number>
    <TrialID>NCT01165762</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Combined Blood Stem Cell and Human Leukocyte Antigen (HLA) Haplotype Match Living Donor Kidney Transplantation</Public_title>
    <Scientific_title>Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donor CD34+ and T-cell Transfusion in HLA Haplotype Match Living Donor Kidney Transplantation</Scientific_title>
    <Acronym />
    <Primary_sponsor>Stanford University</Primary_sponsor>
    <Date_registration3>20100713</Date_registration3>
    <Date_registration>13/07/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01165762</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>21 Years</Inclusion_agemin>
    <Inclusion_agemax>60 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2010</Date_enrollement>
    <Target_size>25</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. All consenting adult (&gt; 21 years of age) living donor renal transplant recipients at&lt;br&gt;             Stanford University Medical Center who have a one haplotype match donor.&lt;br&gt;&lt;br&gt;          2. Patients who agree to participate in the study and sign an Informed Consent.&lt;br&gt;&lt;br&gt;          3. Patients who have no known contraindication to administration of rabbit ATG or&lt;br&gt;             radiation.&lt;br&gt;&lt;br&gt;          4. Males and females of reproductive potential who agree to practice a reliable form of&lt;br&gt;             contraception for at least 24 months posttransplant.&lt;br&gt;&lt;br&gt;          5. The donor and the recipient must have an identical blood group.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Previous treatment with rabbit ATG or a known allergy to rabbit proteins.&lt;br&gt;&lt;br&gt;          2. History of malignancy with the exception of non-melanoma skin malignancies.&lt;br&gt;&lt;br&gt;          3. Pregnant women or nursing mothers.&lt;br&gt;&lt;br&gt;          4. Serological evidence of HIV, Hepatitis B or Hepatitis C infection.&lt;br&gt;&lt;br&gt;          5. Seronegative for CMV, if donor is seropositive.&lt;br&gt;&lt;br&gt;          6. Leukopenia (with a white blood cell count &lt; 3000/mm3) or thrombocytopenia (with a&lt;br&gt;             platelet count &lt; 100,000/mm3).&lt;br&gt;&lt;br&gt;          7. PRA greater than 20% or demonstration of donor specific antibody (DSA)&lt;br&gt;&lt;br&gt;          8. Prior organ transplantation&lt;br&gt;&lt;br&gt;          9. High risk of primary kidney disease recurrence (i.e.FSGS)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Transplantation</Condition>
    <Intervention>Procedure: Total Lymphoid Radiation with Donor hematopoietic  stem Cell and Kidney Transplant</Intervention>
    <Primary_outcome>Long term freedom from transplant immunosuppressive drugs, safety, rate of infection, graft survival and patient survival.</Primary_outcome>
    <Secondary_ID>18731;SU-06232010-6408</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2932177</Internal_Number>
    <TrialID>NCT01170858</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effect of Icodextrin Solution on Preservation of Residual Renal Function in Patients on Peritoneal Dialysis</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>Yonsei University</Primary_sponsor>
    <Date_registration3>20100722</Date_registration3>
    <Date_registration>22/07/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01170858</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>20 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 2010</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Patients who were maintained on PD for over 3 months.&lt;br&gt;&lt;br&gt;          2. Patients with residual renal function &gt; 750 ml/day.&lt;br&gt;&lt;br&gt;          3. Patients who give informed consent.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. patients less than 20 years of age,&lt;br&gt;&lt;br&gt;          2. uncontrolled volume status requiring the repeated use of 4.25% glucose PD solutions&lt;br&gt;             in addition to 2.5% glucose PD solution or icodextrin,&lt;br&gt;&lt;br&gt;          3. volume depletion or hypotension (systolic blood pressure &lt; 90 mmHg) caused by 2.5%&lt;br&gt;             glucose PD solution or icodextrin solution,&lt;br&gt;&lt;br&gt;          4. allergic to starch,&lt;br&gt;&lt;br&gt;          5. life expectancy less than 12 months,&lt;br&gt;&lt;br&gt;          6. prior history of kidney transplantation or hemodialysis,&lt;br&gt;&lt;br&gt;          7. patients on automated PD.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End Stage Renal Disease</Condition>
    <Intervention>Drug: Icodextrin PD solution;Drug: glucose solutions</Intervention>
    <Primary_outcome>Residual GFR change at 1-year</Primary_outcome>
    <Secondary_ID>4-2010-0379</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2932391</Internal_Number>
    <TrialID>NCT01173666</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Stenting of Renal Artery Stenosis in Coronary Artery Disease Study</Public_title>
    <Scientific_title>Renal Artery Stenosis in Coronary Artery Disease: Medical Therapy Versus Medical Therapy Plus Renal Artery Stenting in Preventing Cardiac and Renal Outcomes. The Rationale and Study Design of a Prospective,Randomized Trial: the RASCAD Study</Scientific_title>
    <Acronym>RASCAD</Acronym>
    <Primary_sponsor>Azienda Ospedaliera, Universitaria Policlinico Vittorio Emanuele</Primary_sponsor>
    <Date_registration3>20100730</Date_registration3>
    <Date_registration>30/07/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01173666</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>85 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2006</Date_enrollement>
    <Target_size>168</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  ischemic heart disease&lt;br&gt;&lt;br&gt;          -  angiographic diagnosis of atherosclerotic RAS &gt;50% and =80%&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Atherosclerotic RAS&gt;80%&lt;br&gt;&lt;br&gt;          -  RAS secondary to fibromuscular dysplasia&lt;br&gt;&lt;br&gt;          -  AMI&lt;br&gt;&lt;br&gt;          -  single functioning kidney and/or sCr &gt;4 mg/dl&lt;br&gt;&lt;br&gt;          -  severe aortic valve stenosis&lt;br&gt;&lt;br&gt;          -  aortic aneurism necessitating surgery&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Artery Stenosis;Left Ventricular Hypertrophy</Condition>
    <Intervention>Procedure: stenting angioplasty plus medical therapy;Drug: Medical therapy</Intervention>
    <Primary_outcome>Left Ventricular Mass (LVMI, g/m2) changes</Primary_outcome>
    <Secondary_outcome>Cardiovascular mortality and morbidity;Progression of renal function</Secondary_outcome>
    <Secondary_ID>RC-1</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>National Research Council, Italy</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2934198</Internal_Number>
    <TrialID>NCT01197235</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effect of Darbepoetin in Contrast-induced Nephropathy</Public_title>
    <Scientific_title>Prevention of Contrast-induced Nephropathy Using Darbepoetin in High-risk Patients Undergoing Coronary Angiography</Scientific_title>
    <Acronym />
    <Primary_sponsor>Seoul National University Bundang Hospital</Primary_sponsor>
    <Date_registration3>20100908</Date_registration3>
    <Date_registration>08/09/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01197235</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2009</Date_enrollement>
    <Target_size>150</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 2/Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  age over 18 yr&lt;br&gt;&lt;br&gt;          -  calculated glomerular filtration rate (GFR) &lt; 60 ml/min&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  patients on dialysis&lt;br&gt;&lt;br&gt;          -  pregnancy or breast feeding&lt;br&gt;&lt;br&gt;          -  contrast use less than 1 week&lt;br&gt;&lt;br&gt;          -  emergency angiography&lt;br&gt;&lt;br&gt;          -  erythropoietin therapy less than 1 month&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Kidney Injury</Condition>
    <Intervention>Drug: darbepoetin alfa, control</Intervention>
    <Primary_outcome>incidence of contrast-induced nephropathy (CIN)</Primary_outcome>
    <Secondary_ID>SNUBH B- 0811/063-001</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>SMG-SNU Boramae Medical Center</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2934286</Internal_Number>
    <TrialID>NCT01198379</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Aspirin in the Prevention of Cardiovascular Events in Hemodialysis Patients</Public_title>
    <Scientific_title>Efficacy of Monitoring of Aspirin Responsiveness in the Prevention of Cardiovascular Events and Decrease in Bleeding Complications in Patients With End-Stage Kidney Disease Undergoing Hemodialysis</Scientific_title>
    <Acronym />
    <Primary_sponsor>Buddhist Tzu Chi General Hospital, Taipei</Primary_sponsor>
    <Date_registration3>20100824</Date_registration3>
    <Date_registration>24/08/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01198379</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>February 2010</Date_enrollement>
    <Target_size>250</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver), Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  patients with end-stage renal disease who are undergoing long-term hemodialysis.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        Patients will be excluded if there is evidence of&lt;br&gt;&lt;br&gt;          -  a recent history of acute uremia,&lt;br&gt;&lt;br&gt;          -  previous adverse reaction to a aspirin or history of aspirin hypersensitivity (eg,&lt;br&gt;             aspirin-induced asthma or angioedema),&lt;br&gt;&lt;br&gt;          -  concurrent treatment with other antiplatelet agent (clopidogrel or ticlopidine),&lt;br&gt;             steroidal drugs, or nonsteroidal anti-inflammatory drugs,&lt;br&gt;&lt;br&gt;          -  high immediate risk for bleeding (eg, active peptic ulceration, recent injury, or&lt;br&gt;             hemophilia), or&lt;br&gt;&lt;br&gt;          -  life-threatening condition other than end-stage renal disease or vascular disease&lt;br&gt;             (eg, non-skin cancer).&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End-Stage Renal Disease</Condition>
    <Intervention>Drug: aspirin;Drug: Placebo</Intervention>
    <Primary_outcome>the prevalence of aspirin resistance</Primary_outcome>
    <Secondary_outcome>the incidence of vascular events (myocardial infarction, cardiac death, stroke, vascular access thrombosis, or revascularization procedure)</Secondary_outcome>
    <Secondary_ID>BTCGHTN01</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Taipei Veterans General Hospital,Taiwan</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2935508</Internal_Number>
    <TrialID>NCT01214356</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Impact of Vitamin D on Diabetic Kidney Disease in African Americans</Public_title>
    <Scientific_title>Impact of Vitamin D on Diabetic Kidney Disease in African Americans</Scientific_title>
    <Acronym />
    <Primary_sponsor>Medical University of South Carolina</Primary_sponsor>
    <Date_registration3>20101001</Date_registration3>
    <Date_registration>01/10/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01214356</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>February 2010</Date_enrollement>
    <Target_size>102</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Investigator), Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  African American race&lt;br&gt;&lt;br&gt;          -  Diagnosis of Type 2 Diabetes&lt;br&gt;&lt;br&gt;          -  Stage 1 or 2 Kidney Disease with detectable microalbuminuria &gt;4.0 (mg/g) 25(OH)D&lt;br&gt;             level &lt;20 ng/ml&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Type 1 diabetes&lt;br&gt;&lt;br&gt;             --&gt; Stage 3 Kidney Disease, or history of dialysis, kidney transplantation or&lt;br&gt;             nephrolithiasis&lt;br&gt;&lt;br&gt;          -  Unable to provide informed consent or contact information&lt;br&gt;&lt;br&gt;          -  Pre-existing calcium or parathyroid condition, including serum calcium &gt;10.2 mg/dL&lt;br&gt;&lt;br&gt;          -  Sarcoidosis, active tuberculosis, or malignancy&lt;br&gt;&lt;br&gt;          -  Known hypersensitivity to vitamin D or any of its analogues and derivatives&lt;br&gt;&lt;br&gt;          -  Current pregnancy or planning to become pregnant in next 15 months&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Diabetic Kidney Disease</Condition>
    <Intervention>Drug: Vitamin D3;Drug: Vitamin D3</Intervention>
    <Primary_outcome>Progression of Kidney Disease</Primary_outcome>
    <Secondary_outcome>Decrease in Estimated Glomerular Filtration Rate (eGFR)</Secondary_outcome>
    <Secondary_ID>1R03DK089120</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2935732</Internal_Number>
    <TrialID>NCT01217281</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>The Effect of Non-surgical Periodontal Treatment in the Renal Function of Patients With Chronic Kidney Disease: RCT</Public_title>
    <Scientific_title>The Effect of Non-surgical Periodontal Treatment in the Renal Function of Patients With Chronic Kidney Disease: A Randomized Clinical Trial</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Athens</Primary_sponsor>
    <Date_registration3>20101006</Date_registration3>
    <Date_registration>06/10/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01217281</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2010</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Single Blind (Outcomes Assessor), Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Chronic Kidney Disease (Stage I, II, III, IV)&lt;br&gt;&lt;br&gt;          -  At least 12 teeth present in the oral cavity&lt;br&gt;&lt;br&gt;          -  Moderate to severe chronic periodontitis, which is defined as: at least 8 surfaces&lt;br&gt;             with periodontal pocket depth (PPD) =5mm and at least 4 surfaces with Clinical&lt;br&gt;             Attachment Loss (CAL) =4mm, distributed in at least two quadrants.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients that have had a renal transplant or undergoing dialysis&lt;br&gt;&lt;br&gt;          -  Acute infections or use of antibiotics in the past 3 months.&lt;br&gt;&lt;br&gt;          -  Auto-immune diseases, conditions that cause immunosuppression or use of&lt;br&gt;             immunosuppressant medication.&lt;br&gt;&lt;br&gt;          -  Systemic conditions that require antibiotic prophylaxis for routine periodontal&lt;br&gt;             therapy.&lt;br&gt;&lt;br&gt;          -  Non-surgical periodontal therapy in the past 6 months or surgical periodontal therapy&lt;br&gt;             in the past 12 months.&lt;br&gt;&lt;br&gt;          -  Use of medication that can cause gingival hyperplasia such as cyclosporine or&lt;br&gt;             fenintoin.&lt;br&gt;&lt;br&gt;          -  Myocardial infarction or cerebral vascular incident in the past 12 months or&lt;br&gt;             uncontrolled angina.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease;Periodontitis</Condition>
    <Intervention>Procedure: Full Mouth Non-Surgical Periodontal Therapy</Intervention>
    <Primary_outcome>eGFR</Primary_outcome>
    <Secondary_outcome>Cystatin C;CRP;d-8-iso prostaglandin F2a;Level of IgG antibodies in serum against periodontal pathogens;Composition of dental plaque;Il-6;TNF-a</Secondary_outcome>
    <Secondary_ID>143</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2935801</Internal_Number>
    <TrialID>NCT01218178</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Sodium Bicarbonate and N-Acetylcysteine for Nephroprotection in Acute Myocardial Infarction</Public_title>
    <Scientific_title>BIcarbonato di Sodio e N-Acetilcisteina Nella Prevenzione Della Nefropatia da Mezzo di Contrasto Nell'infaRto mIocardico acutO(Registro BINARIO)</Scientific_title>
    <Acronym>BINARIO</Acronym>
    <Primary_sponsor>Catholic University of the Sacred Heart</Primary_sponsor>
    <Date_registration3>20101004</Date_registration3>
    <Date_registration>04/10/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01218178</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>89 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2008</Date_enrollement>
    <Target_size>520</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case Control</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  ST-Segment Elevation Myocardial Infarction (STEMI) as diagnosed according to the ACC&lt;br&gt;             (American College of Cardiology) criteria:&lt;br&gt;&lt;br&gt;          -  ischemic symptoms;&lt;br&gt;&lt;br&gt;          -  ECG variations: ST-elevation (&gt;0,05 mV) in two or more contiguous leads;&lt;br&gt;&lt;br&gt;          -  Increase of the biochemical markers of myocardial necrosis (troponin T, cTNT). •&lt;br&gt;             Indication to urgent coronary angiography and primary or rescue PCI&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with history of allergic reaction to NAC&lt;br&gt;&lt;br&gt;          -  Chronic hemodialysis&lt;br&gt;&lt;br&gt;          -  Age &gt;= 90 years&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Myocardial Infarction;Acute Kidney Injury</Condition>
    <Intervention>Drug: Sodium bicarbonate plus NAC;Drug: Saline hydration plus NAC</Intervention>
    <Primary_outcome>All cause mortality, contrast-induced nephropathy and need of dialysis.</Primary_outcome>
    <Secondary_ID>P/479/CE/2010</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Policlinico Casilino ASL RMB</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2936056</Internal_Number>
    <TrialID>NCT01221506</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)</Public_title>
    <Scientific_title>Assessment of Tumor Perfusion Changes in Response to Pazopanib in Renal Cell Carcinoma</Scientific_title>
    <Acronym />
    <Primary_sponsor>Abramson Cancer Center of the University of Pennsylvania</Primary_sponsor>
    <Date_registration3>20101013</Date_registration3>
    <Date_registration>13/10/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01221506</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2010</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Endpoint Classification:  Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 0</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  18 years of age or older&lt;br&gt;&lt;br&gt;          -  Diagnosis of unresectable and/or metastatic clear cell renal cell carcinoma. 10&lt;br&gt;             patients will be enrolled who have had no prior anti-angiogenic therapy; 10 patients&lt;br&gt;             will be enrolled who have had one prior anti-angiogenic therapy&lt;br&gt;&lt;br&gt;          -  Prior radiation therapy to a symptomatic site of metastatic disease is allowed but&lt;br&gt;             patients must have discontinued/completed radiation therapy at least 2 weeks prior to&lt;br&gt;             entering the study, and have recovered from adverse events due to that treatment.&lt;br&gt;&lt;br&gt;          -  ECOG performance status of 0, 1 or 2.&lt;br&gt;&lt;br&gt;          -  Patients must have measureable disease by RECIST 1.1&lt;br&gt;&lt;br&gt;          -  Archived tumor blocks must be provided for all subjects for correlative analysis&lt;br&gt;             before or during treatment with pazopanib&lt;br&gt;&lt;br&gt;          -  Patient must have normal baseline laboratory values&lt;br&gt;&lt;br&gt;          -  Patients must not receive any other investigational agents while onstudy.&lt;br&gt;&lt;br&gt;          -  Patients must not be taking cytochrome P450 enzyme -inducing antiepileptic drugs&lt;br&gt;             (phenytoin, carbamazepine or phenobarbital), rifampin or St.Johns wort.&lt;br&gt;&lt;br&gt;          -  Females of childbearing potential are eligible to enter and participate in this study&lt;br&gt;             if they have a negative pregnancy test and agree to use medically accepted&lt;br&gt;             contraception throughout the study&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Female subjects who are pregnant or brestfeeding - Patients with active prior&lt;br&gt;             malignancy. Note: Subjects who have had another malignancy and have been disease-free&lt;br&gt;             for 3 years, or subjects with a history of completely resected non-melanomatous skin&lt;br&gt;             carcinoma or successfully treated in situ carcinoma are eligible.&lt;br&gt;&lt;br&gt;          -  Patients with a history or clinical evidence of central nervous system (CNS)&lt;br&gt;             metastases or leptomeningeal carcinomatosis, except for individuals who have&lt;br&gt;             previously-treated CNS metastases, are asymptomatic, and have had no requirement for&lt;br&gt;             steroids or anti-seizure medication for 6 months prior to first dose of study drug.&lt;br&gt;             Screening with CNS imaging studies (computed tomography [CT] or magnetic resonance&lt;br&gt;             imaging [MRI]) is required only if clinically indicated or if the subject has a&lt;br&gt;             history of CNS metastases.&lt;br&gt;&lt;br&gt;          -  Patients with clinically significant gastrointestinal abnormalities that may increase&lt;br&gt;             the risk for gastrointestinal bleeding&lt;br&gt;&lt;br&gt;          -  Patients with clinically significant gastrointestinal abnormalities that may affect&lt;br&gt;             absorption of investigational product&lt;br&gt;&lt;br&gt;          -  Patients the presence of uncontrolled infection.&lt;br&gt;&lt;br&gt;          -  Patient with corrected QT interval (QTc) greater than 480 msecs using Bazetts formula&lt;br&gt;&lt;br&gt;          -  Patients with a history of any one or more of the following cardiovascular conditions&lt;br&gt;             within the past 6 months: Cardiac angioplasty or stenting; Myocardial infarction;&lt;br&gt;             Unstable angina; Coronary artery bypass graft surgery; Symptomatic peripheral&lt;br&gt;             vascular disease; Class III or IV congestive heart failure, as defined by the New&lt;br&gt;             York Heart Association (NYHA) [See Section YYY Appendix Y for description&lt;br&gt;&lt;br&gt;          -  Patient with poorly controlled hypertension [defined as systolic blood pressure (SBP)&lt;br&gt;             of greater or equal to 140 mmHg or diastolic blood pressure (DBP) of greater or equal&lt;br&gt;             to 90mmHg].&lt;br&gt;&lt;br&gt;          -  Patients with a history of cerebrovascular accident including transient ischemic&lt;br&gt;             attack (TIA),pulmonary embolism or untreated deep venous thrombosis (DVT) within the&lt;br&gt;             past 6 months. Note: Subjects with recent DVT who have been treated with therapeutic&lt;br&gt;             anti-coagulating agents for at least 6 weeks are eligible&lt;br&gt;&lt;br&gt;          -  Patients who have had prior major surgery or trauma within 28 days prior to first&lt;br&gt;             dose of study drug and/or presence of any non-healing wound, fracture, or ulcer&lt;br&gt;             (procedures such as catheter placement not considered to be major).&lt;br&gt;&lt;br&gt;          -  Patients who have evidence of active bleeding or bleeding diathesis.&lt;br&gt;&lt;br&gt;          -  Patients with known endobronchial lesions and/or lesions infiltrating major pulmonary&lt;br&gt;             vessels&lt;br&gt;&lt;br&gt;          -  Patients with hemoptysis within 6 weeks of first dose of study drug.&lt;br&gt;&lt;br&gt;          -  Patients with any serious and/or unstable pre-existing medical, psychiatric, or other&lt;br&gt;             condition that could interfere with subjects safety, provision of informed consent,&lt;br&gt;             or compliance to study procedures.&lt;br&gt;&lt;br&gt;          -  Patients who are unable or unwilling to discontinue use of prohibited medications&lt;br&gt;             list in Section4.3 for at least 14 days or five half-lives of a drug (whichever is&lt;br&gt;             longer) prior to the first dose of study drug and for the duration of the study.&lt;br&gt;&lt;br&gt;          -  Treatment with any of the following anti-cancer therapies: radiation therapy, surgery&lt;br&gt;             or tumor embolization within 14 days prior to the first dose of pazopanib; OR&lt;br&gt;             chemotherapy,immunotherapy, biologic therapy, investigational therapy or hormonal&lt;br&gt;             therapy within 14 days prior to the first dose of pazopanib. Treatment with prior&lt;br&gt;             sorafenib, sunitinib, temsirolimus or everolimus is allowed but must be discontinued&lt;br&gt;             at least 5 days prior to beginning pazopanib.&lt;br&gt;&lt;br&gt;          -  Patient who have any ongoing toxicity from prior anti-cancer therapy that is greater&lt;br&gt;             than Grade 1 and/or that is progressing in severity, except alopecia.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Carcinoma, Renal Cell</Condition>
    <Intervention>Drug: Pazopanib;Device: DCE-MRI and Quantitative Doppler Ultrasound</Intervention>
    <Primary_outcome>Evaluate Early Changes in DCE-MRI</Primary_outcome>
    <Secondary_outcome>Correlating Baseline DCE-MRI and early changes in DCE-MRI with other measures of treatment effectiveness</Secondary_outcome>
    <Secondary_ID>UPCC 34809</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2936356</Internal_Number>
    <TrialID>NCT01225458</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Behaviour and Cognitive Evaluation for Dialysis Elderly Patients (BCDE)</Public_title>
    <Scientific_title>Behaviour and Cognitive Evaluation for Dialysis Elderly Patients (BCDE)</Scientific_title>
    <Acronym>BCDE</Acronym>
    <Primary_sponsor>Centre Hospitalier Universitaire de Nice</Primary_sponsor>
    <Date_registration3>20101020</Date_registration3>
    <Date_registration>20/10/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01225458</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>75 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2008</Date_enrollement>
    <Target_size>500</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Prevention</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion criteria :&lt;br&gt;&lt;br&gt;          -  Patients aged of 75 years old or more,&lt;br&gt;&lt;br&gt;          -  Chronic kidney disease stage 5 defined by :&lt;br&gt;&lt;br&gt;          -  either an estimated GFR (MDRD) = 15ml/mn/1,73 m² in a non-dialysis patient with a&lt;br&gt;             nephrology follow-up &gt; 3 months ("Pre-dialysis cohort"),&lt;br&gt;&lt;br&gt;          -  or a dialysis treatment started for more than 3 months and less than one year, after&lt;br&gt;             a pre-dialysis follow-up &gt; 3 months ("post-dialysis cohort"),&lt;br&gt;&lt;br&gt;          -  Signed and dated informed consent.&lt;br&gt;&lt;br&gt;        Exclusion criteria :&lt;br&gt;&lt;br&gt;          -  Moderately severe to severe dementia (MMS = 15),&lt;br&gt;&lt;br&gt;          -  Major depression and/or GDS-15 &gt; 10/15,&lt;br&gt;&lt;br&gt;          -  Severe dependency (ADL &lt; 3/6).,&lt;br&gt;&lt;br&gt;          -  Psychosis, mutism or aphasia,&lt;br&gt;&lt;br&gt;          -  Malignancy or any pathology with life expectancy &lt; one year.&lt;br&gt;&lt;br&gt;          -  Ongoing specialized geriatric care&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Renal Insufficiency;Chronic Kidney Failure;Aged</Condition>
    <Intervention>Other: shorter tests;Other: initial complete geriatric tests;Other: follow-up complete geriatric tests</Intervention>
    <Primary_outcome>death;occurrence of a severe dementia (MMS &lt; 10);major depression detected by GDS-15 &gt; 10/15 and confirmed by  DSM-IV criteria;severe dependency (ADL &lt; 3/6)</Primary_outcome>
    <Secondary_outcome>cognitive, psychic and autonomy scores;cardiovascular morbidity and mortality;bone fracture;nutritional parameters;dialysis parameters;biological follow-up of chronic kidney disease including haemoglobin level</Secondary_outcome>
    <Secondary_ID>BCDE</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2936356</Internal_Number>
    <TrialID>NCT01225458</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Behaviour and Cognitive Evaluation for Dialysis Elderly Patients (BCDE)</Public_title>
    <Scientific_title>Behaviour and Cognitive Evaluation for Dialysis Elderly Patients (BCDE)</Scientific_title>
    <Acronym>BCDE</Acronym>
    <Primary_sponsor>Centre Hospitalier Universitaire de Nice</Primary_sponsor>
    <Date_registration3>20101020</Date_registration3>
    <Date_registration>20/10/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01225458</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>75 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2008</Date_enrollement>
    <Target_size>500</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Prevention</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion criteria :&lt;br&gt;&lt;br&gt;          -  Patients aged of 75 years old or more,&lt;br&gt;&lt;br&gt;          -  Chronic kidney disease stage 5 defined by :&lt;br&gt;&lt;br&gt;          -  either an estimated GFR (MDRD) = 15ml/mn/1,73 m² in a non-dialysis patient with a&lt;br&gt;             nephrology follow-up &gt; 3 months ("Pre-dialysis cohort"),&lt;br&gt;&lt;br&gt;          -  or a dialysis treatment started for more than 3 months and less than one year, after&lt;br&gt;             a pre-dialysis follow-up &gt; 3 months ("post-dialysis cohort"),&lt;br&gt;&lt;br&gt;          -  Signed and dated informed consent.&lt;br&gt;&lt;br&gt;        Exclusion criteria :&lt;br&gt;&lt;br&gt;          -  Moderately severe to severe dementia (MMS = 15),&lt;br&gt;&lt;br&gt;          -  Major depression and/or GDS-15 &gt; 10/15,&lt;br&gt;&lt;br&gt;          -  Severe dependency (ADL &lt; 3/6).,&lt;br&gt;&lt;br&gt;          -  Psychosis, mutism or aphasia,&lt;br&gt;&lt;br&gt;          -  Malignancy or any pathology with life expectancy &lt; one year.&lt;br&gt;&lt;br&gt;          -  Ongoing specialized geriatric care&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Renal Insufficiency;Chronic Kidney Failure;Aged</Condition>
    <Intervention>Other: shorter tests;Other: initial complete geriatric tests;Other: follow-up complete geriatric tests</Intervention>
    <Primary_outcome>death;occurrence of a severe dementia (MMS &lt; 10);major depression detected by GDS-15 &gt; 10/15 and confirmed by  DSM-IV criteria;severe dependency (ADL &lt; 3/6)</Primary_outcome>
    <Secondary_outcome>cognitive, psychic and autonomy scores;cardiovascular morbidity and mortality;bone fracture;nutritional parameters;dialysis parameters;biological follow-up of chronic kidney disease including haemoglobin level</Secondary_outcome>
    <Secondary_ID>BCDE</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2936482</Internal_Number>
    <TrialID>NCT01227122</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>NGAL Predictive Value of Acute Kidney Failure After Cardiac Surgery in Patients With Preoperative Chronic Kidney Failure</Public_title>
    <Scientific_title>Plasmatic Level of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Predictive Marker of Acute Kidney Failure in Patients With Preoperative Chronic Kidney Failure Undergoing Cardiac Surgery.</Scientific_title>
    <Acronym>NGAL-CKF</Acronym>
    <Primary_sponsor>Hopital Jean Minjoz</Primary_sponsor>
    <Date_registration3>20101022</Date_registration3>
    <Date_registration>22/10/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01227122</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 2010</Date_enrollement>
    <Target_size>168</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case-Only, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Renal clearance less than 60 mL/min&lt;br&gt;&lt;br&gt;          -  Able to give written consent&lt;br&gt;&lt;br&gt;          -  Elective valve surgery&lt;br&gt;&lt;br&gt;          -  Elective CABG surgery&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Less than 18 years old&lt;br&gt;&lt;br&gt;          -  Iodine injection within 3 days before surgery&lt;br&gt;&lt;br&gt;          -  Iodine injection within 24 first postoperative hours&lt;br&gt;&lt;br&gt;          -  preoperative infection&lt;br&gt;&lt;br&gt;          -  evolutive cancer disease&lt;br&gt;&lt;br&gt;          -  Refusal&lt;br&gt;&lt;br&gt;          -  Pregnancy&lt;br&gt;&lt;br&gt;          -  Unable to give written consent&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Preoperative Period,;Kidney Failure, Chronic;Postoperative Period,;Kidney Failure, Acute;Cardiac Surgical Procedures</Condition>
    <Primary_outcome>NGAL level</Primary_outcome>
    <Secondary_ID>2010-A00111-38</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2936482</Internal_Number>
    <TrialID>NCT01227122</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>NGAL Predictive Value of Acute Kidney Failure After Cardiac Surgery in Patients With Preoperative Chronic Kidney Failure</Public_title>
    <Scientific_title>Plasmatic Level of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Predictive Marker of Acute Kidney Failure in Patients With Preoperative Chronic Kidney Failure Undergoing Cardiac Surgery.</Scientific_title>
    <Acronym>NGAL-CKF</Acronym>
    <Primary_sponsor>Hopital Jean Minjoz</Primary_sponsor>
    <Date_registration3>20101022</Date_registration3>
    <Date_registration>22/10/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01227122</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 2010</Date_enrollement>
    <Target_size>168</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case-Only, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Renal clearance less than 60 mL/min&lt;br&gt;&lt;br&gt;          -  Able to give written consent&lt;br&gt;&lt;br&gt;          -  Elective valve surgery&lt;br&gt;&lt;br&gt;          -  Elective CABG surgery&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Less than 18 years old&lt;br&gt;&lt;br&gt;          -  Iodine injection within 3 days before surgery&lt;br&gt;&lt;br&gt;          -  Iodine injection within 24 first postoperative hours&lt;br&gt;&lt;br&gt;          -  preoperative infection&lt;br&gt;&lt;br&gt;          -  evolutive cancer disease&lt;br&gt;&lt;br&gt;          -  Refusal&lt;br&gt;&lt;br&gt;          -  Pregnancy&lt;br&gt;&lt;br&gt;          -  Unable to give written consent&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Preoperative Period,;Kidney Failure, Chronic;Postoperative Period,;Kidney Failure, Acute;Cardiac Surgical Procedures</Condition>
    <Primary_outcome>NGAL level</Primary_outcome>
    <Secondary_ID>2010-A00111-38</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2936619</Internal_Number>
    <TrialID>NCT01228903</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Uric Acid and the Endothelium is CKD</Public_title>
    <Scientific_title>Is Uric Acid a Mediator of Endothelial Dysfunction in Patients With Chronic Kidney Disease?</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Colorado, Denver</Primary_sponsor>
    <Date_registration3>20101025</Date_registration3>
    <Date_registration>25/10/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01228903</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2010</Date_enrollement>
    <Target_size>80</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Investigator), Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Individuals with moderate chronic kidney disease (CKD stage III) with estimated&lt;br&gt;             glomerular filtration rates between 30-60 mL/min/ 1.73m2&lt;br&gt;&lt;br&gt;          -  Elevated uric acid levels&lt;br&gt;&lt;br&gt;          -  Age range: more than 18 years old&lt;br&gt;&lt;br&gt;          -  Ability to give informed consent&lt;br&gt;&lt;br&gt;          -  Albumin &gt; 3.0 g/dL&lt;br&gt;&lt;br&gt;          -  BMI &lt; 40 kg/m2&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Life expectancy &lt; 1.0 years&lt;br&gt;&lt;br&gt;          -  Expected to undergo living related kidney transplant in 6 months&lt;br&gt;&lt;br&gt;          -  Pregnant, breast feeding, or unwilling to use adequate birth control&lt;br&gt;&lt;br&gt;          -  History of severe liver disease&lt;br&gt;&lt;br&gt;          -  History of severe congestive heart failure&lt;br&gt;&lt;br&gt;          -  History of hospitalizations within 3 months&lt;br&gt;&lt;br&gt;          -  Active infection, on antibiotics&lt;br&gt;&lt;br&gt;          -  History of Warfarin Use or other medications that are contraindicated with&lt;br&gt;             allopurinol&lt;br&gt;&lt;br&gt;          -  Uncontrolled hypertension&lt;br&gt;&lt;br&gt;          -  History of acute gout on Allopurinol&lt;br&gt;&lt;br&gt;          -  History of adverse reaction to Allopurinol&lt;br&gt;&lt;br&gt;          -  Immunosuppressive therapy within the last 1 yr&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Disease</Condition>
    <Intervention>Drug: Allopurinol;Other: Placebo</Intervention>
    <Primary_outcome>Endothelial Dependent Dilation</Primary_outcome>
    <Secondary_outcome>Systemic inflammation and oxidative stress;Inflammation and oxidative stress in the endothelial cells</Secondary_outcome>
    <Secondary_ID>K23DK088833;10-0625</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>National Institutes of Health (NIH)</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2936755</Internal_Number>
    <TrialID>NCT01230697</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM)</Public_title>
    <Scientific_title>Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib. Multicenter Cohort Study</Scientific_title>
    <Acronym>SORHORM</Acronym>
    <Primary_sponsor>University of Turin, Italy</Primary_sponsor>
    <Date_registration3>20100902</Date_registration3>
    <Date_registration>02/09/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01230697</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2010</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. age over 18 years&lt;br&gt;&lt;br&gt;          2. Histologically documented kidney cancer or hepatocarcinoma&lt;br&gt;&lt;br&gt;          3. Performance status more than / equal to 2&lt;br&gt;&lt;br&gt;          4. Life expectancy &gt; 12 weeks&lt;br&gt;&lt;br&gt;          5. in patients with recent surgery, the wound should be completely healed       before&lt;br&gt;             taking Sorafenib&lt;br&gt;&lt;br&gt;          6. required initial laboratory values: absolute neutrophil count &gt; 1500/ul Platelets &gt;&lt;br&gt;             100,000/ul., Hemoglobin &gt; 9.0 g/dl, Creatinine, SGOT, SGPT less than 2.0 X upper&lt;br&gt;             limit of normal Bilirubin less than/equal to upper limit of normal(ULN)&lt;br&gt;&lt;br&gt;          7. Appropriate patienty compliance&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. myocardial infarction or significant change in anginal pattern within the last 6&lt;br&gt;             months, symptomatic congestive heart failure (NYHA Class III or higher) or&lt;br&gt;             uncontrolled cardiac arrhythmia,&lt;br&gt;&lt;br&gt;          2. previous history of malignant disease with the exception of non melanoma skin cancer&lt;br&gt;             curatively treated,&lt;br&gt;&lt;br&gt;          3. significant neurologic or psychiatric diseases preventing patients to give a valid&lt;br&gt;             informed consent&lt;br&gt;&lt;br&gt;          4. Sintomatic brain metastases&lt;br&gt;&lt;br&gt;          5. because patients with immune deficiency are at increased risk of lethal infections&lt;br&gt;             when treated with marrow-suppressive therapy, HIV-positive patients receiving&lt;br&gt;             combination anti-retroviral therapy are excluded&lt;br&gt;&lt;br&gt;          6. patients with seizures that need medical treatment&lt;br&gt;&lt;br&gt;          7. History of heterologous transplantation&lt;br&gt;&lt;br&gt;          8. Patients with previous or active bleeding&lt;br&gt;&lt;br&gt;          9. Dialysis patients&lt;br&gt;&lt;br&gt;         10. Patients with history of primary hyperparathyroidism&lt;br&gt;&lt;br&gt;         11. Dysphagic patients&lt;br&gt;&lt;br&gt;         12. Taking more than four weeks of entry into the study of other bio-chemotherapy&lt;br&gt;             treatments&lt;br&gt;&lt;br&gt;         13. Previous treatment with Sorafenib&lt;br&gt;&lt;br&gt;         14. Recent (&lt;6 months)or concomitant treatment with biphosphonate&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Cancer;Liver Cancer</Condition>
    <Intervention>Drug: Sorafenib</Intervention>
    <Primary_outcome>Identify the value variations of  hormones involved in phosphate homeostasis during sorafenib administration</Primary_outcome>
    <Secondary_outcome>Identify metabolic differences between renal cells cancer and hepatocarcinoma;Identify variations on bone mass during sorafenib treatment;Identify correlations between phosphate related hormones and side effects during sorafenib treatment as a Measure of safety and tolerability;Identify correlations between phosphate related hormones variations and patients outcome (TTP and overall survival)</Secondary_outcome>
    <Secondary_ID>662010</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2936856</Internal_Number>
    <TrialID>NCT01232010</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Clinical Study to Investigate the Safety and Pharmacokinetics of SK3530 Tablet in Renal Impaired Male Patients</Public_title>
    <Scientific_title>Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients</Scientific_title>
    <Acronym>SK3530_RI_I</Acronym>
    <Primary_sponsor>Asan Medical Center</Primary_sponsor>
    <Date_registration3>20101101</Date_registration3>
    <Date_registration>01/11/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01232010</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>19 Years</Inclusion_agemin>
    <Inclusion_agemax>64 Years</Inclusion_agemax>
    <Inclusion_gender>Male</Inclusion_gender>
    <Date_enrollement>November 2009</Date_enrollement>
    <Target_size>12</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Supportive Care</Study_design>
    <Phase>Phase 1</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Adult males aged 19 to 64 years at screening.&lt;br&gt;&lt;br&gt;          -  Subjects with body weight = 50 kg and within ±30% of the ideal body weight : Ideal&lt;br&gt;             body weight = (height [cm] - 100)x0.9.&lt;br&gt;&lt;br&gt;          -  Subjects who have received and understood completely the information regarding the&lt;br&gt;             current study and given written informed consents to voluntarily participate in the&lt;br&gt;             study and followed all instructions specified in the protocol.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Subjects with the test results of QTc &gt; 430 ms or non-sinus cardiac rhythm by ECG&lt;br&gt;             analysis.&lt;br&gt;&lt;br&gt;          -  Subjects with hypotension or hypertension.&lt;br&gt;&lt;br&gt;          -  Subjects deemed ineligible by investigator based on other reasons, including abnormal&lt;br&gt;             laboratory values or diseases.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Insufficiency;Kidney Diseases;Urologic Diseases</Condition>
    <Intervention>Drug: Mirodenafil</Intervention>
    <Primary_outcome>Pharmacokinetics (AUC and Cmax)</Primary_outcome>
    <Secondary_ID>2007-0445</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>SK Chemicals Co.,Ltd.</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2936856</Internal_Number>
    <TrialID>NCT01232010</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Clinical Study to Investigate the Safety and Pharmacokinetics of SK3530 Tablet in Renal Impaired Male Patients</Public_title>
    <Scientific_title>Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients</Scientific_title>
    <Acronym>SK3530_RI_I</Acronym>
    <Primary_sponsor>Asan Medical Center</Primary_sponsor>
    <Date_registration3>20101101</Date_registration3>
    <Date_registration>01/11/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01232010</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>19 Years</Inclusion_agemin>
    <Inclusion_agemax>64 Years</Inclusion_agemax>
    <Inclusion_gender>Male</Inclusion_gender>
    <Date_enrollement>November 2009</Date_enrollement>
    <Target_size>12</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Supportive Care</Study_design>
    <Phase>Phase 1</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Adult males aged 19 to 64 years at screening.&lt;br&gt;&lt;br&gt;          -  Subjects with body weight = 50 kg and within ±30% of the ideal body weight : Ideal&lt;br&gt;             body weight = (height [cm] - 100)x0.9.&lt;br&gt;&lt;br&gt;          -  Subjects who have received and understood completely the information regarding the&lt;br&gt;             current study and given written informed consents to voluntarily participate in the&lt;br&gt;             study and followed all instructions specified in the protocol.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Subjects with the test results of QTc &gt; 430 ms or non-sinus cardiac rhythm by ECG&lt;br&gt;             analysis.&lt;br&gt;&lt;br&gt;          -  Subjects with hypotension or hypertension.&lt;br&gt;&lt;br&gt;          -  Subjects deemed ineligible by investigator based on other reasons, including abnormal&lt;br&gt;             laboratory values or diseases.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Insufficiency;Kidney Diseases;Urologic Diseases</Condition>
    <Intervention>Drug: Mirodenafil</Intervention>
    <Primary_outcome>Pharmacokinetics (AUC and Cmax)</Primary_outcome>
    <Secondary_ID>2007-0445</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>SK Chemicals Co.,Ltd.</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2937186</Internal_Number>
    <TrialID>NCT01236326</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Conventional Laparoscopic Versus Laparoendoscopic Single Site Donor Nephrectomy in Living Donor Kidney Transplantation</Public_title>
    <Scientific_title>A Randomized, Prospective, Parallel Group Study of Conventional Laparoscopic Donor Nephrectomy (LDN) Versus Laparoendoscopic Single Site Donor Nephrectomy (LESS-DN) in Living Donor Kidney Transplantation</Scientific_title>
    <Acronym />
    <Primary_sponsor>Weill Medical College of Cornell University</Primary_sponsor>
    <Date_registration3>20101104</Date_registration3>
    <Date_registration>04/11/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01236326</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2010</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  All patients scheduled to undergo laparoscopic living donor nephrectomy will be&lt;br&gt;             eligible for the study.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  There are no exclusion criteria.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Living Donors;Nephrectomy;Kidney Transplantation;Surgery, Laparoscopic</Condition>
    <Intervention>Procedure: Laparoendoscopic single site donor nephrectomy;Procedure: Conventional laparoscopic donor nephrectomy</Intervention>
    <Primary_outcome>The primary endpoint of the study will be patient self-reported "return to 100%", as measured by the number of days post-surgery that the patient reports his or her return to 100% functioning capacity.</Primary_outcome>
    <Secondary_ID>1009011249</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2937224</Internal_Number>
    <TrialID>NCT01236820</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>A Study Using L5 as a Risk Factor of Cardiovascular (CV) Disease in Chronic Renal and Dialytic Patients</Public_title>
    <Scientific_title>L5 as a Risk Factor of Cardiovascular Disease in Chronic Kidney Disease and Dialysis Patients</Scientific_title>
    <Acronym>L5</Acronym>
    <Primary_sponsor>China Medical University Hospital</Primary_sponsor>
    <Date_registration3>20101105</Date_registration3>
    <Date_registration>05/11/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01236820</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>20 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2010</Date_enrollement>
    <Target_size>48</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case Control, Time Perspective:  Cross-Sectional</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  clinical diagnosis of CKD&lt;br&gt;&lt;br&gt;          -  clinical diagnosis of HD&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  N/A&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Cardiovascular Disease;Chronic Kidney Disease Patients;Hemodialytic Patients;High LDL Level;High L5 Level</Condition>
    <Secondary_ID>CTCHANG001</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2937691</Internal_Number>
    <TrialID>NCT01242904</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Use of a Bimodal Solution for Peritoneal Dialysis</Public_title>
    <Scientific_title>Randomized Controlled Trial of Bimodal Solution for Peritoneal Dialysis: 24-Hour UF Efficiency Using Bimodal PD Solutions During the Long Dwell</Scientific_title>
    <Acronym />
    <Primary_sponsor>Lawson Health Research Institute</Primary_sponsor>
    <Date_registration3>20101116</Date_registration3>
    <Date_registration>16/11/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01242904</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2011</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Be able to provide informed consent&lt;br&gt;&lt;br&gt;          2. Age greater than 18 years&lt;br&gt;&lt;br&gt;          3. Be stable Automated Peritoneal Dialysis (APD) patients for at least 6 weeks&lt;br&gt;&lt;br&gt;          4. Be APD patients who;&lt;br&gt;&lt;br&gt;               1. Can be managed with an icodextrin long dwell AND&lt;br&gt;&lt;br&gt;               2. Will use 4.25% and/or a 2.5% solution for at least one exchange overnight   in&lt;br&gt;                  at least 5 out of 7 days&lt;br&gt;&lt;br&gt;          5. Have residual urine volume &lt;800 ml/24 hours&lt;br&gt;&lt;br&gt;          6. Long dwell must be or patient must tolerate at least an 8-10 hr long dwell.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Scheduled Transplant in the next 1 year&lt;br&gt;&lt;br&gt;          2. Life expectancy &lt; 3 mo (estimated by physician)&lt;br&gt;&lt;br&gt;          3. Participating in other trial that could influence outcome of this trial&lt;br&gt;&lt;br&gt;          4. Known icodextrin allergy&lt;br&gt;&lt;br&gt;          5. Currently using non-Baxter PD solutions&lt;br&gt;&lt;br&gt;          6. Systolic blood pressure &lt; 90 mm Hg on more than three occasions during a seven day&lt;br&gt;             period, despite discontinuation of non-essential anti-hypertensives&lt;br&gt;&lt;br&gt;        Supplementary Exclusion Criteria (post Run-in phase):&lt;br&gt;&lt;br&gt;        1) Unsuccessfully completed 1 week run-in phase.  Defined as:&lt;br&gt;&lt;br&gt;          1. Not using bimodal solution on 7 consecutive days during the run-in&lt;br&gt;&lt;br&gt;          2. Not tolerating the increased UF anticipated with the bimodal solution. Tolerating&lt;br&gt;             defined as:&lt;br&gt;&lt;br&gt;        i) Blood pressure drop below 90/50 on more than three occasions during a seven day period&lt;br&gt;        that cannot be corrected by reducing anti-hypertensives or other simple measures ii)&lt;br&gt;        Intolerable feeling of fullness with the bimodal solution iii) Allergic reaction (although&lt;br&gt;        all patients have already been exposed to icodextrin)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End Stage Renal Disease</Condition>
    <Intervention>Drug: bimodal solution;Drug: icodextrin</Intervention>
    <Primary_outcome>net ultrafiltration efficiency in mL/g</Primary_outcome>
    <Secondary_outcome>24-hour absolute total carbohydrate absorption;24-hour urine volume;24-hour net sodium removal (in both peritoneal effluent and urine);Volume measures as calculated by bioimpedance analysis;Weight;Mean and pulse arterial pressure;Number of anti-hypertensive agents;Renal (urine) solute clearance (Sodium, Urea, Creatinine);Peritoneal effluent solute clearance (Sodium, Urea, Creatinine)</Secondary_outcome>
    <Secondary_ID>17193;R-10-460</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Baxter Healthcare Corporation</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2937989</Internal_Number>
    <TrialID>NCT01246817</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Temsirolimus-RCC-imaging</Public_title>
    <Scientific_title>Evaluation of the Activity of Temsirolimus With FDG-PET and FLT-PET in Patients With Renal Cell Cancer</Scientific_title>
    <Acronym />
    <Primary_sponsor>Radboud University</Primary_sponsor>
    <Date_registration3>20101122</Date_registration3>
    <Date_registration>22/11/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01246817</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 2009</Date_enrollement>
    <Target_size>51</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Endpoint Classification:  Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. patients with histologically confirmed, advanced (stage IV or recurrent disease) RCC&lt;br&gt;             who have received at least one prior angiogenesis inhibitor for their disease.&lt;br&gt;&lt;br&gt;          2. Karnofsky performance status = 70.&lt;br&gt;&lt;br&gt;          3. At least 1 measurable lesion that can be accurately measured in at least 1 dimension&lt;br&gt;             with the longest diameter = 10-mm when measured by spiral computerized tomography&lt;br&gt;             (CT, 5-mm slice thickness contiguous)&lt;br&gt;&lt;br&gt;          4. Age = 18 years.&lt;br&gt;&lt;br&gt;          5. Absolute neutrophil count (ANC) = 1.5 x 109/L (1500 cells/mm3), platelet count = 100&lt;br&gt;             x 109/ L (100,000 cells/ mm3), hemoglobin = 8.0 g/dL (5.0 mmol/L).&lt;br&gt;&lt;br&gt;          6. Adequate renal function (serum creatinine = 1.5 times the ULN) or creatinin clearance&lt;br&gt;             of = 50 ml/min&lt;br&gt;&lt;br&gt;          7. Adequate hepatic function (bilirubin = 1.5 times the ULN, aspartate transaminase&lt;br&gt;             (AST) = 3 times the ULN [= 5 times the ULN if liver metastases are present]).&lt;br&gt;&lt;br&gt;          8. Fasting serum cholesterol = 350 mg/dL (9.0 mmol/L), triglycerides = 400 mg/dL (4.56&lt;br&gt;             mmol/ L).&lt;br&gt;&lt;br&gt;          9. Subjects receiving cytochrome P450 (CYP) 3A4 inducers or inhibitors must be on stable&lt;br&gt;             doses for at least 1 week prior to randomization.&lt;br&gt;&lt;br&gt;         10. Life expectancy of at least 8 weeks.&lt;br&gt;&lt;br&gt;         11. Negative pregnancy test for female patients of childbearing potential&lt;br&gt;&lt;br&gt;         12. Women and men enrolled into this trial must use adequate birth control measures&lt;br&gt;             during the course of the trial and must continue for 3 months after the last dose of&lt;br&gt;             temsirolimus.&lt;br&gt;&lt;br&gt;         13. Signed and dated written informed consent form&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Subjects with central nervous system (CNS) metastases. Subjects with a prior history&lt;br&gt;             of CNS metastases will be eligible if the screening magnetic resonance imaging&lt;br&gt;             (MRI)/CT (with contrast) indicates no residual disease.&lt;br&gt;&lt;br&gt;          2. Prior investigational therapy/agents within 2 weeks of randomization.&lt;br&gt;&lt;br&gt;          3. Prior treatment with a mTOR inhibitor&lt;br&gt;&lt;br&gt;          4. History of other prior malignancy in past 5 years, other than basal cell carcinoma,&lt;br&gt;             squamous cell carcinoma of the skin, or cervical carcinoma in situ.&lt;br&gt;&lt;br&gt;          5. Not recovered from prior surgery and/or surgery or radiation therapy within 4 weeks&lt;br&gt;             of randomization.&lt;br&gt;&lt;br&gt;          6. Immunocompromised subjects, including subjects known to be human immunodeficiency&lt;br&gt;             virus (HIV) positive, hepatitis B positive, or hepatitis C positive.&lt;br&gt;&lt;br&gt;          7. Active infection or serious intercurrent illness.&lt;br&gt;&lt;br&gt;          8. Presence of unstable angina or myocardial infarction within the previous 6 months&lt;br&gt;             (prior to screening), use of ongoing maintenance therapy for life-threatening&lt;br&gt;             arrhythmia, known pulmonary hypertension, or pneumonitis.&lt;br&gt;&lt;br&gt;          9. Pregnant or nursing women, women who are of childbearing potential who are not using&lt;br&gt;             an effective contraceptive method, or men with partners of childbearing potential who&lt;br&gt;             are not using an effective contraceptive method. (A woman of childbearing potential&lt;br&gt;             is defined as a woman who is biologically capable of becoming pregnant.)&lt;br&gt;&lt;br&gt;         10. Any other major illness that, in the investigator's judgment, will substantially&lt;br&gt;             increase the risk associated with the subject's participation in this study&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Cell Cancer</Condition>
    <Intervention>Drug: Temsirolimus</Intervention>
    <Primary_outcome>Evaluation of the FLT-PET and FDG-PET</Primary_outcome>
    <Secondary_outcome>Progression free survival;response rate;Toxicity;Correlation of pharmacodynamics with PET results</Secondary_outcome>
    <Secondary_ID>UMCNONCO200903</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2938617</Internal_Number>
    <TrialID>NCT01255020</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Renal Protective Effects of Restricted Protein Dietary With a-keto Acid in Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients</Public_title>
    <Scientific_title>Safety and Efficacy Evaluation of Restricted Protein Dietary Supplemented With a-keto Acid on Protecting Residual Renal Function in CAPD Patients——A Prospective, Double Blind Randomized, Parallel Control, Multi-center Clinical Trial</Scientific_title>
    <Acronym />
    <Primary_sponsor>Sun Yat-sen University</Primary_sponsor>
    <Date_registration3>20100811</Date_registration3>
    <Date_registration>11/08/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01255020</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2010</Date_enrollement>
    <Target_size>160</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Patients on peritoneal dialysis (PD) at least three month prior to study entry.&lt;br&gt;&lt;br&gt;          2. Subjects of either sex, more than 18 years old, the range of age is 18 to 70 year&lt;br&gt;             old.&lt;br&gt;&lt;br&gt;          3. Residual GFR = 3 ml/min/1.73m2.&lt;br&gt;&lt;br&gt;          4. Without a-Keto Acid therapy in recent 4 weeks.&lt;br&gt;&lt;br&gt;          5. Subjects who agree to participate in the study and sign the informed consent.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. History of peritonitis or other infection within one month.&lt;br&gt;&lt;br&gt;          2. Patients with insufficient dialysis.&lt;br&gt;&lt;br&gt;          3. History of taking drug which may influence amino acid metabolism within one&lt;br&gt;             month(glucocorticoid, thyroxin, antithyroid drug, androgens,amino acids,et al).&lt;br&gt;&lt;br&gt;          4. Patients with diseases which contraindicate ketosteril.&lt;br&gt;&lt;br&gt;          5. Cannot control diet according to protocol.&lt;br&gt;&lt;br&gt;          6. Alcohol abuse or drug abuse.&lt;br&gt;&lt;br&gt;          7. Having malignant tumor.&lt;br&gt;&lt;br&gt;          8. History of psychiatric or neuropathic dysfunction.&lt;br&gt;&lt;br&gt;          9. Cardiac failure, with NYHA grade III-IV or history of severe heart and&lt;br&gt;             cerebrovascular disease in recent one month(acute stroke, acute heart failure,&lt;br&gt;             Lability angina)&lt;br&gt;&lt;br&gt;         10. Serum albumin &lt; 30g/l.&lt;br&gt;&lt;br&gt;         11. Serum calcium &gt; 2.8mmol/l.&lt;br&gt;&lt;br&gt;         12. Participation in another clinic trial within last three months&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Function Disorder</Condition>
    <Intervention>Drug: a-Keto Acid with restricted protein diet;Drug: Placebo plus restricted protein diet</Intervention>
    <Primary_outcome>The longitudinal change in residual glomerular filtration rate (GFR)</Primary_outcome>
    <Secondary_outcome>Peritoneal membrane transport characteristics;Cardiovascular events;Nutritional status;Hospitalization</Secondary_outcome>
    <Secondary_ID>KAPDRRF</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Beijing Fresenius Kabi Pharmaceutical Co</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2939700</Internal_Number>
    <TrialID>NCT01269112</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Citrate-based Regional Anticoagulation Versus Heparin for Continuous Renal Replacement Therapy</Public_title>
    <Scientific_title>Citrate-based Regional Anticoagulation Versus Heparin for Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Renal Failure: a Randomized Controlled Trial</Scientific_title>
    <Acronym />
    <Primary_sponsor>University Hospital, Geneva</Primary_sponsor>
    <Date_registration3>20110103</Date_registration3>
    <Date_registration>03/01/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01269112</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2010</Date_enrollement>
    <Target_size>190</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with acute kidney injury requiring renal replacement therapy (RIFLE&lt;br&gt;             criteria)&lt;br&gt;&lt;br&gt;          -  Patients (males or females) &gt; 18 yrs old&lt;br&gt;&lt;br&gt;          -  Consent form signed (or in emergency investigator's statement form)&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with active bleeding disorders&lt;br&gt;&lt;br&gt;          -  Patients with past history of heparin-induced thrombocytopenia (HIT)&lt;br&gt;&lt;br&gt;          -  Patients with very severe liver disease ( patients awaiting liver transplant or&lt;br&gt;             factor V &lt; 20%  or MELD score &gt; 25)&lt;br&gt;&lt;br&gt;          -  Pregnancy (negative pregnancy test required in child-bearing age women prior to&lt;br&gt;             inclusion)&lt;br&gt;&lt;br&gt;          -  Enrollment in another concurrent therapeutic trial&lt;br&gt;      </Inclusion_Criteria>
    <Condition>- Effectiveness Ofcitrate-based Regional Anticoagulation in Renal Replacement Therapy .</Condition>
    <Intervention>Device: citrate  regional anticoagulation;Device: citrate regional anticoagulation</Intervention>
    <Primary_outcome>Mean daily dialysis delivered dose during intensive care stay</Primary_outcome>
    <Secondary_outcome>patient survival</Secondary_outcome>
    <Secondary_ID>09-069(NAC 09-27)</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2939881</Internal_Number>
    <TrialID>NCT01271465</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Analysis of Donor Biopsy Tissue Samples at the Time of Kidney Transplant</Public_title>
    <Scientific_title>mRNA and microRNA Profiles in Renal Transplant at the Time of Organ Reperfusion</Scientific_title>
    <Acronym />
    <Primary_sponsor>Weill Medical College of Cornell University</Primary_sponsor>
    <Date_registration3>20110105</Date_registration3>
    <Date_registration>05/01/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01271465</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2010</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Basic Science</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Males and females &lt;80 years of age for kidney&lt;br&gt;&lt;br&gt;          -  Recipients of single abdominal organ transplant&lt;br&gt;&lt;br&gt;          -  Ability to provide written informed consent&lt;br&gt;&lt;br&gt;          -  Donor blood and kidney biopsy tissues specimens are collected at the time of&lt;br&gt;             transplantation&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Need for combined organ transplantation.&lt;br&gt;&lt;br&gt;          -  Inability or unwillingness of a participant or legal guardian to provide written&lt;br&gt;             informed consent&lt;br&gt;&lt;br&gt;          -  Clinical evidence of systemic bacterial infection in the recipient at the time of&lt;br&gt;             transplantation&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Transplantation</Condition>
    <Intervention>Procedure: Kidney Biopsy</Intervention>
    <Primary_outcome>Primary endpoint for Aim 1 is the incidence of early organ dysfunction, defined by standard criteria for each organ defined as the need for dialysis within 7 days after transplant;Primary endpoint for Aim 2 is the incidence of biopsy proven acute cellular rejection within the first 12 months after transplant</Primary_outcome>
    <Secondary_outcome>Serum Creatinine;Incidence of chronic allograft nephropathy</Secondary_outcome>
    <Secondary_ID>1004010988</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2940057</Internal_Number>
    <TrialID>NCT01273753</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effects of Intradialytic Exercise as Assessed by Bioimpedance Analysis and Blood Volume Monitoring</Public_title>
    <Scientific_title>Using Bioimpedance Analysis and Blood Volume Monitoring to Assess the Impact of Intradialytic Exercise</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Michigan</Primary_sponsor>
    <Date_registration3>20110106</Date_registration3>
    <Date_registration>06/01/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01273753</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2011</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Diagnostic</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Adults aged 18yrs and older&lt;br&gt;&lt;br&gt;          2. End-stage renal disease on thrice weekly maintenance hemodialysis for at least 3&lt;br&gt;             months&lt;br&gt;&lt;br&gt;          3. Stable dry weight for the preceding month&lt;br&gt;&lt;br&gt;          4. Stable dialysis prescription for the preceding month&lt;br&gt;&lt;br&gt;          5. Average interdialytic weight gain at least 1kg but less than 4% of total body weight.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Patients receiving dialysis for acute renal failure&lt;br&gt;&lt;br&gt;          2. Hospitalization &gt;1 day in the preceding month&lt;br&gt;&lt;br&gt;          3. Inability to complete exercise regimen or medical contraindication to exercise&lt;br&gt;             regimen&lt;br&gt;&lt;br&gt;          4. Patients in whom a dry weight is yet to be established&lt;br&gt;&lt;br&gt;          5. History of non-compliance with dialysis therapy (defined as &gt; 3 missed treatments in&lt;br&gt;             a month)&lt;br&gt;&lt;br&gt;          6. Inability to remain in horizontal position for duration of a dialysis session.&lt;br&gt;&lt;br&gt;          7. Amputation of a limb other than fingers or toes.&lt;br&gt;&lt;br&gt;          8. Pace maker, defibrillator, implantable pump, artificial joint, pins, plates or other&lt;br&gt;             types of metal objects in the body (other than dental fillings).&lt;br&gt;&lt;br&gt;          9. Coronary stents or metal suture material in the heart.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Failure, Chronic</Condition>
    <Intervention>Other: Intradialytic exercise</Intervention>
    <Primary_outcome>Change in bioimpedance analysis trend during dialysis</Primary_outcome>
    <Secondary_outcome>Blood volume monitoring</Secondary_outcome>
    <Secondary_ID>Heung-BIA1</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Renal Research Institute</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2940097</Internal_Number>
    <TrialID>NCT01274273</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer</Public_title>
    <Scientific_title>A Randomized Phase II Trial of IL-2/IFN-a Plus Bevacizumab Versus IL-2/IFN-a in Metastatic Renal Cell Carcinoma (mRCC) - Danish Renal Cancer Group (DARENCA) Study-1</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Aarhus</Primary_sponsor>
    <Date_registration3>20100629</Date_registration3>
    <Date_registration>29/06/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01274273</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2009</Date_enrollement>
    <Target_size>118</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Signed written informed consent&lt;br&gt;&lt;br&gt;          2. Patient must be willing and able to comply with the protocol.&lt;br&gt;&lt;br&gt;          3. Age = 18 years.&lt;br&gt;&lt;br&gt;          4. Histologic og cytologic biopsy proven locally advanced or metastatic renal cell&lt;br&gt;             carcinoma, considered non-candidates for curative surgery. Nephrectomy is not&lt;br&gt;             mandatory.&lt;br&gt;&lt;br&gt;          5. Patient with renal cell carcinoma (RCC) with a clear-cell histologic component&lt;br&gt;             confirmed by local pathology review.&lt;br&gt;&lt;br&gt;          6. Females with a negative serum pregnancy test unless childbearing potential can be&lt;br&gt;             otherwise excluded&lt;br&gt;&lt;br&gt;          7. Fertile women of childbearing potential (&lt;2 years after last menstruation) and men&lt;br&gt;             must use effective means of contraception&lt;br&gt;&lt;br&gt;          8. Memorial-Sloan-Kettering-Cancer-Centre favourable- and intermediate prognostic group.&lt;br&gt;&lt;br&gt;          9. Measurable or non-measurable disease (as per RECIST1.1 criteria)&lt;br&gt;&lt;br&gt;         10. Karnofsky Performance status of 70% or higher.&lt;br&gt;&lt;br&gt;         11. Life expectancy greater than 4 months.&lt;br&gt;&lt;br&gt;         12. The required laboratory values at baseline are as follows:&lt;br&gt;&lt;br&gt;        Haematology:&lt;br&gt;&lt;br&gt;        WCC = 3.0 x 109/L, Platelet count = 100 x 109/L, Haemoglobin = 6.2 mmol/l,  (INR) = 1.5,&lt;br&gt;        APTT = 1.5 x ULN&lt;br&gt;&lt;br&gt;        Biochemistry:&lt;br&gt;&lt;br&gt;        Total bilirubin = 1.5 x upper limit of normal (ULN), AST, ALT = 2.5 x ULN in patients&lt;br&gt;        without liver metastases, = 5 x ULN in patients with liver metastases, Serum Creatinine  =&lt;br&gt;        150 micromol/L&lt;br&gt;&lt;br&gt;        -&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Prior systemic treatment for metastatic RCC disease&lt;br&gt;&lt;br&gt;          2. Major surgical procedure, open surgical biopsy, or significant traumatic injury&lt;br&gt;             within 28 days prior to randomization.&lt;br&gt;&lt;br&gt;          3. Serious non-healing wound, ulcer or bone fracture.&lt;br&gt;&lt;br&gt;          4. Evidence of current central nervous system (CNS) metastases or spinal cord&lt;br&gt;             compression. Patient must undergo an MRI or CT scan of the brain (with contrast, if&lt;br&gt;             possible) within 28 days prior to randomization.&lt;br&gt;&lt;br&gt;          5. Seizure(s) not controlled with standard medical therapy.&lt;br&gt;&lt;br&gt;          6. Dipstick urine test of protein = 2+.&lt;br&gt;&lt;br&gt;          7. Other malignancies within 5 years prior to randomization (other than curatively&lt;br&gt;             treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix).&lt;br&gt;&lt;br&gt;          8. Evidence of bleeding diathesis or coagulopathy.&lt;br&gt;&lt;br&gt;          9. Ongoing or recent (within 10 days prior to study treatment start) need for full&lt;br&gt;             therapeutic dose of oral anticoagulants or chronic daily treatment with aspirin. Low&lt;br&gt;             molecular weight heparin are allowed&lt;br&gt;&lt;br&gt;         10. Uncontrolled hypertension (= 160 mm Hg systolic and/or =  100 mm Hg diastolic) while&lt;br&gt;             receiving chronic medication.&lt;br&gt;&lt;br&gt;         11. Clinically significant (i.e. active) cardiovascular disease, for example&lt;br&gt;             cerebrovascular accidents (= 6 months before randomisation), myocardial infarction (=&lt;br&gt;             6 months before randomisation), unstable angina, New York Heart Association (NYHA)&lt;br&gt;             grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring&lt;br&gt;             medication.&lt;br&gt;&lt;br&gt;         12. Recent (within the 30 days prior to randomization) treatment with another&lt;br&gt;             investigational drug or participation in another investigational study.&lt;br&gt;&lt;br&gt;         13. Chronic treatment with corticosteroids (dose of = 10 mg/day methylprednisolone&lt;br&gt;             equivalent), excluding inhaled steroids.&lt;br&gt;&lt;br&gt;         14. History or presence of other disease, metabolic dysfunction, physical examination&lt;br&gt;             finding, or clinical laboratory finding giving reasonable suspicion of a disease or&lt;br&gt;             condition that contraindicates use of an investigational drug or patient at high risk&lt;br&gt;             from treatment complications.&lt;br&gt;&lt;br&gt;         15. Known hypersensitivity to interleukin-2, Interferon, alfa or bevacizumab.&lt;br&gt;&lt;br&gt;        Serial blood test, serial tumor biopsies and serial dynamic contrast-enhanced imaging will&lt;br&gt;        be obtained as part of a translational research program integrated in the clinical trial.&lt;br&gt;&lt;br&gt;        Part(s) of the translational research program may be omitted in the individual patient due&lt;br&gt;        to practical, technical or safety reasons, without having consequences for participating&lt;br&gt;        in the additional translational research investigations or the clinical part of the study.&lt;br&gt;&lt;br&gt;        -&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Metastatic Renal Cell Carcinoma</Condition>
    <Intervention>Drug: Interleukin-2;Drug: Interferon Alfa-2b;Drug: Bevacizumab</Intervention>
    <Primary_outcome>Progression free survival, PFS</Primary_outcome>
    <Secondary_outcome>Response rate, RR;Overall survival, (OS);Duration of response;Time to progression, (TTP);Time to treatment failure, (TTTF);Tolerability;Frequency of surgical resection of residual disease;Frequency of no evidence of disease (NED);To explore the immunomodulatory effect of therapy in serial blood samples and serial tumor core biopsies and to correlate these biomarkers with outcome;To assess dynamic contrast-enhanced imaging as a potential biomarker.</Secondary_outcome>
    <Secondary_ID>DARENCA-1</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Danish Renal Cancer Study Group</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2940209</Internal_Number>
    <TrialID>NCT01275729</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>The Effect of Loop Diuretics on Severity and Outcome of Acute Kidney Injury</Public_title>
    <Scientific_title>The Effect of Loop Diuretics on Severity and Outcome of Acute Kidney Injury</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Chicago</Primary_sponsor>
    <Date_registration3>20110110</Date_registration3>
    <Date_registration>10/01/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01275729</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>December 2010</Date_enrollement>
    <Target_size>150</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Diagnostic</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. 18 yrs or older&lt;br&gt;&lt;br&gt;          2. increase in serum creatinine of 0.3 mg/dl within 48 hours or an increase of greater&lt;br&gt;             than or equal to 150% from baselinie or sustained oliguria (UOP &lt; 0.5 cc/kg/hr for 6&lt;br&gt;             hours with the last 48hours)&lt;br&gt;&lt;br&gt;          3. written informed consent&lt;br&gt;&lt;br&gt;          4. patients with an indwelling bladder catheter&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Voluntary refusal&lt;br&gt;&lt;br&gt;          2. Patients with advanced chronic kideny disease - as defined by a baseline GFR &lt; 30&lt;br&gt;             ml/min (MDRD)&lt;br&gt;&lt;br&gt;          3. history of renal transplant&lt;br&gt;&lt;br&gt;          4. Pregnant patients&lt;br&gt;&lt;br&gt;          5. Allegery / Sensitivity to Loop diuretics (furosemide)&lt;br&gt;&lt;br&gt;          6. Pre-renal AKI&lt;br&gt;&lt;br&gt;               -  defined by a FENa of &lt; 1% and no urinary casts&lt;br&gt;&lt;br&gt;               -  under-resuscitatedas per the treating clinical team&lt;br&gt;&lt;br&gt;               -  active bleed&lt;br&gt;&lt;br&gt;          7. Post renal AKI&lt;br&gt;&lt;br&gt;               -  evidence of hydro-ureter&lt;br&gt;&lt;br&gt;               -  clincal scenario wherein obstruction is considered a likely possibility&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Kidney Failure</Condition>
    <Intervention>Drug: Furosemide</Intervention>
    <Primary_outcome>Non-renal recovery</Primary_outcome>
    <Secondary_ID>Uchicago 10-503-B</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2940294</Internal_Number>
    <TrialID>NCT01276834</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Comparison of Immunosuppression on Progression of Arteriosclerosis in Renal Transplantation</Public_title>
    <Scientific_title>Randomised Comparison of Two Different Immunosuppressive Regimens on Progression of Arteriosclerosis in Renal Transplant Patients.</Scientific_title>
    <Acronym>NOCTX-2</Acronym>
    <Primary_sponsor>Dianet Dialysis Centers</Primary_sponsor>
    <Date_registration3>20110112</Date_registration3>
    <Date_registration>12/01/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01276834</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2010</Date_enrollement>
    <Target_size>80</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Bio-equivalence Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age between 18-75 yr&lt;br&gt;&lt;br&gt;          -  Willingness to provide written informed consent&lt;br&gt;&lt;br&gt;          -  Ability to understand the study procedures&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Life expectancy &lt; 3 months&lt;br&gt;&lt;br&gt;          -  Claustrophobia&lt;br&gt;&lt;br&gt;          -  Allergy to iodinated contrast&lt;br&gt;&lt;br&gt;          -  Treatment incompliance&lt;br&gt;&lt;br&gt;          -  Pregnancy&lt;br&gt;&lt;br&gt;          -  Highly HLA-sensitized patients&lt;br&gt;&lt;br&gt;          -  Severe dyslipidemia or proteinuria&lt;br&gt;&lt;br&gt;          -  Severe leucopenia or thrombocytopenia&lt;br&gt;&lt;br&gt;          -  GFR &lt; 30 ml/min&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Transplantation</Condition>
    <Intervention>Drug: everolimus</Intervention>
    <Primary_outcome>change in coronary artery calcification score</Primary_outcome>
    <Secondary_ID>2009-011605-16;NOCTX-2</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>UMC Utrecht</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2940592</Internal_Number>
    <TrialID>NCT01280708</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Protocol DIVAT-Uro</Public_title>
    <Scientific_title>Establishment of a National Thematic Network in Urology for the Extension of the Cohort DIVAT (Données Informatisées et Validées en Transplantation) in Surgical Parameters of Renal and Pancreatic Transplant Patients : An Innovative Tool for the Promotion of Epidemiological Studies, Identification of Risk Factors and Good Practices in the Domain of Transplant Surgery</Scientific_title>
    <Acronym />
    <Primary_sponsor>Nantes University Hospital</Primary_sponsor>
    <Date_registration3>20110119</Date_registration3>
    <Date_registration>19/01/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01280708</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2010</Date_enrollement>
    <Target_size>2000</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients aged over 18 years&lt;br&gt;&lt;br&gt;          -  Patients received a kidney transplant or a simultaneous pancreas-kidney    transplant&lt;br&gt;&lt;br&gt;          -  Patients who read the newsletter and signed the consent form on the computerization&lt;br&gt;             of data&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients aged under 18 years&lt;br&gt;&lt;br&gt;          -  Patients who did not sign the consent form&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Transplantation;Pancreas-kidney Transplantation</Condition>
    <Intervention>Other: Capture data</Intervention>
    <Secondary_ID>09/11-E</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2940592</Internal_Number>
    <TrialID>NCT01280708</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Protocol DIVAT-Uro</Public_title>
    <Scientific_title>Establishment of a National Thematic Network in Urology for the Extension of the Cohort DIVAT (Données Informatisées et Validées en Transplantation) in Surgical Parameters of Renal and Pancreatic Transplant Patients : An Innovative Tool for the Promotion of Epidemiological Studies, Identification of Risk Factors and Good Practices in the Domain of Transplant Surgery</Scientific_title>
    <Acronym />
    <Primary_sponsor>Nantes University Hospital</Primary_sponsor>
    <Date_registration3>20110119</Date_registration3>
    <Date_registration>19/01/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01280708</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2010</Date_enrollement>
    <Target_size>2000</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients aged over 18 years&lt;br&gt;&lt;br&gt;          -  Patients received a kidney transplant or a simultaneous pancreas-kidney    transplant&lt;br&gt;&lt;br&gt;          -  Patients who read the newsletter and signed the consent form on the computerization&lt;br&gt;             of data&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients aged under 18 years&lt;br&gt;&lt;br&gt;          -  Patients who did not sign the consent form&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Transplantation;Pancreas-kidney Transplantation</Condition>
    <Intervention>Other: Capture data</Intervention>
    <Secondary_ID>09/11-E</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2940834</Internal_Number>
    <TrialID>NCT01283880</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Renal Tubular Acidosis in Incident Renal Transplant Recipients</Public_title>
    <Scientific_title>Renal Tubular Acidosis in Incident Renal Transplant Recipients</Scientific_title>
    <Acronym />
    <Primary_sponsor>Universitaire Ziekenhuizen Leuven</Primary_sponsor>
    <Date_registration3>20110125</Date_registration3>
    <Date_registration>25/01/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01283880</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2012</Date_enrollement>
    <Target_size>50</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Recipient of a single kidney transplant included in the protocol biopsy program.&lt;br&gt;&lt;br&gt;          -  eGFR &gt; 30 ml/min&lt;br&gt;&lt;br&gt;          -  Age = 18 years&lt;br&gt;&lt;br&gt;          -  Written informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  none&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Transplant Disorder</Condition>
    <Secondary_ID>ML6919</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2940948</Internal_Number>
    <TrialID>NCT01285375</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Safety and Preliminary Efficacy of the Treatment of Kidney Allografts With Curcumin-containing Preservation Solution</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>Helsinki University Central Hospital</Primary_sponsor>
    <Date_registration3>20110126</Date_registration3>
    <Date_registration>26/01/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01285375</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2011</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 1</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with ESRD assigned for kidney transplantation, written informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  None&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End Stage Renal Failure With Renal Transplant</Condition>
    <Intervention>Device: CDC solution;Device: UW-solution</Intervention>
    <Primary_outcome>Delayed Graft Function</Primary_outcome>
    <Secondary_outcome>Primary non-function;Acute rejection;Graft function eGFR;Graft Survival;Patient Survival;Length of stay in hospital</Secondary_outcome>
    <Secondary_ID>236153;236153</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Helsinki University;Academy of Finland</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2941266</Internal_Number>
    <TrialID>NCT01289548</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effect of Remote Ischaemic Preconditioning on Renal Function in Patients Undergoing Living Donor Kidney Transplantation</Public_title>
    <Scientific_title>Effect of Lower Limb Ischaemic Preconditioning on Renal Function in Patients Undergoing Living Donor Kidney Transplantation</Scientific_title>
    <Acronym />
    <Primary_sponsor>Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration3>20110202</Date_registration3>
    <Date_registration>02/02/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01289548</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2010</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose:  Prevention</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Subject capable of giving written informed consent, with end-stage kidney disease,&lt;br&gt;             who is a suitable candidate for primary kidney transplantation&lt;br&gt;&lt;br&gt;          -  Living donors&lt;br&gt;&lt;br&gt;          -  Compatible ABO blood type&lt;br&gt;&lt;br&gt;          -  PRA &lt; 20%&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Re-transplant patients&lt;br&gt;&lt;br&gt;          -  Those with peripheral vascular disease affecting the lower limbs&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Diseases;Kidney Failure, Chronic;Kidney Failure;Renal Insufficiency;Renal Insufficiency, Chronic;Urologic Diseases</Condition>
    <Intervention>Device: remote ischaemic preconditioning</Intervention>
    <Primary_outcome>renal function of recipients after living-related kidney transplantation</Primary_outcome>
    <Secondary_outcome>hemodynamic parameters;0peration time;warm ischemic time;cold ischemic time;Acute rejection of transplanted kidney;Delayed Graft Function;Length of postoperative hospital stay;Ischemia reperfusion injury of recipients after living-related kidney transplantation</Secondary_outcome>
    <Secondary_ID>TJMZK201001</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>B. Braun Medical SA</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2941266</Internal_Number>
    <TrialID>NCT01289548</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effect of Remote Ischaemic Preconditioning on Renal Function in Patients Undergoing Living Donor Kidney Transplantation</Public_title>
    <Scientific_title>Effect of Lower Limb Ischaemic Preconditioning on Renal Function in Patients Undergoing Living Donor Kidney Transplantation</Scientific_title>
    <Acronym />
    <Primary_sponsor>Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration3>20110202</Date_registration3>
    <Date_registration>02/02/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01289548</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2010</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose:  Prevention</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Subject capable of giving written informed consent, with end-stage kidney disease,&lt;br&gt;             who is a suitable candidate for primary kidney transplantation&lt;br&gt;&lt;br&gt;          -  Living donors&lt;br&gt;&lt;br&gt;          -  Compatible ABO blood type&lt;br&gt;&lt;br&gt;          -  PRA &lt; 20%&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Re-transplant patients&lt;br&gt;&lt;br&gt;          -  Those with peripheral vascular disease affecting the lower limbs&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Diseases;Kidney Failure, Chronic;Kidney Failure;Renal Insufficiency;Renal Insufficiency, Chronic;Urologic Diseases</Condition>
    <Intervention>Device: remote ischaemic preconditioning</Intervention>
    <Primary_outcome>renal function of recipients after living-related kidney transplantation</Primary_outcome>
    <Secondary_outcome>hemodynamic parameters;0peration time;warm ischemic time;cold ischemic time;Acute rejection of transplanted kidney;Delayed Graft Function;Length of postoperative hospital stay;Ischemia reperfusion injury of recipients after living-related kidney transplantation</Secondary_outcome>
    <Secondary_ID>TJMZK201001</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>B. Braun Medical SA</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2941266</Internal_Number>
    <TrialID>NCT01289548</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effect of Remote Ischaemic Preconditioning on Renal Function in Patients Undergoing Living Donor Kidney Transplantation</Public_title>
    <Scientific_title>Effect of Lower Limb Ischaemic Preconditioning on Renal Function in Patients Undergoing Living Donor Kidney Transplantation</Scientific_title>
    <Acronym />
    <Primary_sponsor>Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration3>20110202</Date_registration3>
    <Date_registration>02/02/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01289548</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2010</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose:  Prevention</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Subject capable of giving written informed consent, with end-stage kidney disease,&lt;br&gt;             who is a suitable candidate for primary kidney transplantation&lt;br&gt;&lt;br&gt;          -  Living donors&lt;br&gt;&lt;br&gt;          -  Compatible ABO blood type&lt;br&gt;&lt;br&gt;          -  PRA &lt; 20%&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Re-transplant patients&lt;br&gt;&lt;br&gt;          -  Those with peripheral vascular disease affecting the lower limbs&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Diseases;Kidney Failure, Chronic;Kidney Failure;Renal Insufficiency;Renal Insufficiency, Chronic;Urologic Diseases</Condition>
    <Intervention>Device: remote ischaemic preconditioning</Intervention>
    <Primary_outcome>renal function of recipients after living-related kidney transplantation</Primary_outcome>
    <Secondary_outcome>hemodynamic parameters;0peration time;warm ischemic time;cold ischemic time;Acute rejection of transplanted kidney;Delayed Graft Function;Length of postoperative hospital stay;Ischemia reperfusion injury of recipients after living-related kidney transplantation</Secondary_outcome>
    <Secondary_ID>TJMZK201001</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>B. Braun Medical SA</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2941266</Internal_Number>
    <TrialID>NCT01289548</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effect of Remote Ischaemic Preconditioning on Renal Function in Patients Undergoing Living Donor Kidney Transplantation</Public_title>
    <Scientific_title>Effect of Lower Limb Ischaemic Preconditioning on Renal Function in Patients Undergoing Living Donor Kidney Transplantation</Scientific_title>
    <Acronym />
    <Primary_sponsor>Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration3>20110202</Date_registration3>
    <Date_registration>02/02/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01289548</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2010</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose:  Prevention</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Subject capable of giving written informed consent, with end-stage kidney disease,&lt;br&gt;             who is a suitable candidate for primary kidney transplantation&lt;br&gt;&lt;br&gt;          -  Living donors&lt;br&gt;&lt;br&gt;          -  Compatible ABO blood type&lt;br&gt;&lt;br&gt;          -  PRA &lt; 20%&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Re-transplant patients&lt;br&gt;&lt;br&gt;          -  Those with peripheral vascular disease affecting the lower limbs&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Diseases;Kidney Failure, Chronic;Kidney Failure;Renal Insufficiency;Renal Insufficiency, Chronic;Urologic Diseases</Condition>
    <Intervention>Device: remote ischaemic preconditioning</Intervention>
    <Primary_outcome>renal function of recipients after living-related kidney transplantation</Primary_outcome>
    <Secondary_outcome>hemodynamic parameters;0peration time;warm ischemic time;cold ischemic time;Acute rejection of transplanted kidney;Delayed Graft Function;Length of postoperative hospital stay;Ischemia reperfusion injury of recipients after living-related kidney transplantation</Secondary_outcome>
    <Secondary_ID>TJMZK201001</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>B. Braun Medical SA</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2941266</Internal_Number>
    <TrialID>NCT01289548</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effect of Remote Ischaemic Preconditioning on Renal Function in Patients Undergoing Living Donor Kidney Transplantation</Public_title>
    <Scientific_title>Effect of Lower Limb Ischaemic Preconditioning on Renal Function in Patients Undergoing Living Donor Kidney Transplantation</Scientific_title>
    <Acronym />
    <Primary_sponsor>Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration3>20110202</Date_registration3>
    <Date_registration>02/02/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01289548</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2010</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose:  Prevention</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Subject capable of giving written informed consent, with end-stage kidney disease,&lt;br&gt;             who is a suitable candidate for primary kidney transplantation&lt;br&gt;&lt;br&gt;          -  Living donors&lt;br&gt;&lt;br&gt;          -  Compatible ABO blood type&lt;br&gt;&lt;br&gt;          -  PRA &lt; 20%&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Re-transplant patients&lt;br&gt;&lt;br&gt;          -  Those with peripheral vascular disease affecting the lower limbs&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Diseases;Kidney Failure, Chronic;Kidney Failure;Renal Insufficiency;Renal Insufficiency, Chronic;Urologic Diseases</Condition>
    <Intervention>Device: remote ischaemic preconditioning</Intervention>
    <Primary_outcome>renal function of recipients after living-related kidney transplantation</Primary_outcome>
    <Secondary_outcome>hemodynamic parameters;0peration time;warm ischemic time;cold ischemic time;Acute rejection of transplanted kidney;Delayed Graft Function;Length of postoperative hospital stay;Ischemia reperfusion injury of recipients after living-related kidney transplantation</Secondary_outcome>
    <Secondary_ID>TJMZK201001</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>B. Braun Medical SA</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2941437</Internal_Number>
    <TrialID>NCT01291771</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Myocardial Microvascular Disease in ESRD</Public_title>
    <Scientific_title>Detection and Outcomes of Myocardial Microvascular Disease in Patients With End Stage Renal Disease</Scientific_title>
    <Acronym>MICROCARD</Acronym>
    <Primary_sponsor>Hospices Civils de Lyon</Primary_sponsor>
    <Date_registration3>20110207</Date_registration3>
    <Date_registration>07/02/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01291771</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2011</Date_enrollement>
    <Target_size>210</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Prevention</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients age &gt; 18 years with end stage renal disease under dialysis and/or scheduled&lt;br&gt;             for kidney or kidney + pancreatic transplantation&lt;br&gt;&lt;br&gt;          -  Having a non invasive detection of myocardial ischemia and agreeing to participate&lt;br&gt;             (signed informed consent document)&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        Past medical history of&lt;br&gt;&lt;br&gt;          -  Acute coronary syndrome&lt;br&gt;&lt;br&gt;          -  Hypertrophic cardiomyopathy&lt;br&gt;&lt;br&gt;          -  severe aortic and/or mitral valvular disease (grade = 3)&lt;br&gt;&lt;br&gt;          -  Known contraindications to adenosine injection: AV block grade = 2 and/or sinoatrial&lt;br&gt;             block unless prior implantation of a pace maker, asthma, allergic reaction to&lt;br&gt;             adenosine.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End Stage Renal Disease;Myocardial Microvascular Disease</Condition>
    <Intervention>Procedure: Invasive FFR + CFR measurements are performed during coronary angiography using a pressure guide wire</Intervention>
    <Primary_outcome>Major cardiovascular events</Primary_outcome>
    <Secondary_outcome>Incidence of myocardial microvascular disease detected by FFR + CFR in ESRD patients with myocardial ischemia on non invasive tests.</Secondary_outcome>
    <Secondary_ID>2010.611</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2942699</Internal_Number>
    <TrialID>NCT01308242</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease</Public_title>
    <Scientific_title>Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease</Scientific_title>
    <Acronym />
    <Primary_sponsor>Penn State University</Primary_sponsor>
    <Date_registration3>20110303</Date_registration3>
    <Date_registration>03/03/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01308242</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2011</Date_enrollement>
    <Target_size>55</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Intervention Model:  Single Group Assignment, Masking:  Open Label</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Adults between ages 18-80 years old, with a GFR less than or equal to 50 ml/min/1.73&lt;br&gt;             m2 as determined by the Modification of Diet in Renal Disease (MDRD) formula will be&lt;br&gt;             included.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients will be excluded if they have a history of renal transplant or are pregnant.&lt;br&gt;             In addition, patients with dysphagia, swallowing disorders, severe GI motility&lt;br&gt;             disorders, severe constipation, history of major gastrointestinal surgery and&lt;br&gt;             patients taking levothyroxine for hypothyroidism will be excluded.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease</Condition>
    <Intervention>Drug: Sevelamer Carbonate</Intervention>
    <Primary_outcome>Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease</Primary_outcome>
    <Secondary_ID>33139CS</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Genzyme</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2943219</Internal_Number>
    <TrialID>NCT01315067</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Diagnosis of Acute Rejection in Renal Transplant Patients by Urine Mass Spectrometry</Public_title>
    <Scientific_title>Non-invasive Diagnosis of Acute Rejection in Renal Transplant Patients Using Mass Spectrometry of Urine Samples - a Multicentre Diagnostic Phase III Trial</Scientific_title>
    <Acronym />
    <Primary_sponsor>Hannover Medical School</Primary_sponsor>
    <Date_registration3>20110314</Date_registration3>
    <Date_registration>14/03/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01315067</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2011</Date_enrollement>
    <Target_size>600</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Cross-Sectional</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Adult patients with a kidney or combined kidney/pancreas transplantation&lt;br&gt;&lt;br&gt;          -  Unexplained renal allograft dysfunction within the first year of transplantation&lt;br&gt;&lt;br&gt;          -  Renal allograft biopsy, which is clinically indicated to verify or exclude an acute&lt;br&gt;             rejection&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Lacking consent of the patient to participate in the study&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Rejection of Renal Transplant</Condition>
    <Primary_outcome>Ability of the urine mass spectrometry test to diagnose acute renal allograft rejection, compared to the gold standard 'allograft biopsy'</Primary_outcome>
    <Secondary_outcome>Sensitivity and specificity of the urine test to diagnose acute renal allograft rejection in subgroups with different severity grades of the rejection;Sensitivity and specificity of the urine test to diagnose acute renal allograft rejection in subgroups with kidney transplantation alone and with combined pancreas/kidney transplantation;Sensitivity and specificity of the urine test to diagnose acute renal allograft rejection in subgroups with concurrent infection</Secondary_outcome>
    <Secondary_ID>MS-GW4/6-1</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2943379</Internal_Number>
    <TrialID>NCT01317186</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>The Role of FGF23 and Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease</Public_title>
    <Scientific_title />
    <Acronym />
    <Primary_sponsor>Ankara Education and Research Hospital</Primary_sponsor>
    <Date_registration3>20110316</Date_registration3>
    <Date_registration>16/03/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01317186</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>65 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2011</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  between ages of 18 - 65 years old&lt;br&gt;&lt;br&gt;          -  chronic kidney disease of stage 2-4&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  presence of diabetes mellitus or ischemic hearth disease&lt;br&gt;&lt;br&gt;          -  taking vitamin d therapy&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Metabolic Diseases;Chronic Kidney Disease</Condition>
    <Secondary_ID>NEPH002</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2943502</Internal_Number>
    <TrialID>NCT01318798</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Development and Validation of an Enhanced Prediction Score for Postoperative Acute Renal Failure After Liver Resection</Public_title>
    <Scientific_title>Development and Validation of an Enhanced Prediction Score for Post-operative Acute Renal Failure Following Liver Resection</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Zurich</Primary_sponsor>
    <Date_registration3>20110316</Date_registration3>
    <Date_registration>16/03/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01318798</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>95 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2010</Date_enrollement>
    <Target_size>549</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Retrospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  &gt; 18 years&lt;br&gt;&lt;br&gt;          -  scheduled for liver surgery&lt;br&gt;&lt;br&gt;          -  benign as well as malignant diseases&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  liver trauma&lt;br&gt;&lt;br&gt;          -  incomplete data sets&lt;br&gt;&lt;br&gt;          -  pre-operative chronic renal failure requiring hemodialysis&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Renal Failure</Condition>
    <Primary_outcome>Development of an enhanced prediction score for ARF</Primary_outcome>
    <Secondary_outcome>Decision curve analysis;internal validation of the enhanced prediction score</Secondary_outcome>
    <Secondary_ID>StV 33-2009</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2943503</Internal_Number>
    <TrialID>NCT01318811</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>A Comparison of Dilute Versus Concentrated Heparin for CRRT Anticoagulation</Public_title>
    <Scientific_title>A Comparison of Dilute Unfractionated Heparin and Standard Concentrated Unfractionated Heparin Protocols for Anticoagulation of the Extra-corporeal Circuit During Continuous Renal Replacement Therapy in the ICU</Scientific_title>
    <Acronym />
    <Primary_sponsor>Vanderbilt University</Primary_sponsor>
    <Date_registration3>20110317</Date_registration3>
    <Date_registration>17/03/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01318811</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2011</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age greater than 18 years&lt;br&gt;&lt;br&gt;          -  Renal failure, electrolyte disturbance, or volume overload requiring continuous&lt;br&gt;             venovenous hemodialysis (CVVHD) as determined by the Nephrology consult service&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age less than 18 years&lt;br&gt;&lt;br&gt;          -  Active bleeding&lt;br&gt;&lt;br&gt;          -  Coagulopathy as defined by baseline INR &gt; 1.8, aPTT &gt; 45 seconds, or platelet count &lt;&lt;br&gt;             50 thousand/µL&lt;br&gt;&lt;br&gt;          -  Active administration of systemic anticoagulation (such as warfarin, therapeutic&lt;br&gt;             unfractionated heparin, or therapeutic enoxaparin)&lt;br&gt;&lt;br&gt;          -  Contraindication to heparin (allergy, thrombocytopenia with platelet count &lt; 50,&lt;br&gt;             known or suspected heparin induced thrombocytopenia [HIT])&lt;br&gt;&lt;br&gt;          -  Contraindication to systemic anticoagulation (recent surgical or other invasive&lt;br&gt;             procedure, significant bleeding disorder, concern for intracranial bleeding, or other&lt;br&gt;             contraindication as determined by treating physician)&lt;br&gt;&lt;br&gt;          -  Administration of drotrecogin (Xigris™)&lt;br&gt;&lt;br&gt;          -  Anticipated surgical or other invasive procedure that would necessitate withdrawal of&lt;br&gt;             anticoagulation within 72 hours&lt;br&gt;&lt;br&gt;          -  Expected termination of continuous renal replacement therapy (CRRT) or death in &lt; 24&lt;br&gt;             hours&lt;br&gt;&lt;br&gt;          -  The need for more than 500 cc an hour of IV fluids delivered proximal to the filter&lt;br&gt;             for the purpose of performing continuous venovenous hemofiltration (CVVH) or&lt;br&gt;             continuous venovenous hemodiafiltration (CVVHDF)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Kidney Injury;Acute Renal Failure;Heart Failure</Condition>
    <Intervention>Drug: Dilute unfractionated heparin;Drug: Standard concentration unfractionated heparin</Intervention>
    <Primary_outcome>Filter life</Primary_outcome>
    <Secondary_outcome>Bleeding complications</Secondary_outcome>
    <Secondary_ID>VU 110162</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2943503</Internal_Number>
    <TrialID>NCT01318811</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>A Comparison of Dilute Versus Concentrated Heparin for CRRT Anticoagulation</Public_title>
    <Scientific_title>A Comparison of Dilute Unfractionated Heparin and Standard Concentrated Unfractionated Heparin Protocols for Anticoagulation of the Extra-corporeal Circuit During Continuous Renal Replacement Therapy in the ICU</Scientific_title>
    <Acronym />
    <Primary_sponsor>Vanderbilt University</Primary_sponsor>
    <Date_registration3>20110317</Date_registration3>
    <Date_registration>17/03/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01318811</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2011</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age greater than 18 years&lt;br&gt;&lt;br&gt;          -  Renal failure, electrolyte disturbance, or volume overload requiring continuous&lt;br&gt;             venovenous hemodialysis (CVVHD) as determined by the Nephrology consult service&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age less than 18 years&lt;br&gt;&lt;br&gt;          -  Active bleeding&lt;br&gt;&lt;br&gt;          -  Coagulopathy as defined by baseline INR &gt; 1.8, aPTT &gt; 45 seconds, or platelet count &lt;&lt;br&gt;             50 thousand/µL&lt;br&gt;&lt;br&gt;          -  Active administration of systemic anticoagulation (such as warfarin, therapeutic&lt;br&gt;             unfractionated heparin, or therapeutic enoxaparin)&lt;br&gt;&lt;br&gt;          -  Contraindication to heparin (allergy, thrombocytopenia with platelet count &lt; 50,&lt;br&gt;             known or suspected heparin induced thrombocytopenia [HIT])&lt;br&gt;&lt;br&gt;          -  Contraindication to systemic anticoagulation (recent surgical or other invasive&lt;br&gt;             procedure, significant bleeding disorder, concern for intracranial bleeding, or other&lt;br&gt;             contraindication as determined by treating physician)&lt;br&gt;&lt;br&gt;          -  Administration of drotrecogin (Xigris™)&lt;br&gt;&lt;br&gt;          -  Anticipated surgical or other invasive procedure that would necessitate withdrawal of&lt;br&gt;             anticoagulation within 72 hours&lt;br&gt;&lt;br&gt;          -  Expected termination of continuous renal replacement therapy (CRRT) or death in &lt; 24&lt;br&gt;             hours&lt;br&gt;&lt;br&gt;          -  The need for more than 500 cc an hour of IV fluids delivered proximal to the filter&lt;br&gt;             for the purpose of performing continuous venovenous hemofiltration (CVVH) or&lt;br&gt;             continuous venovenous hemodiafiltration (CVVHDF)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Kidney Injury;Acute Renal Failure;Heart Failure</Condition>
    <Intervention>Drug: Dilute unfractionated heparin;Drug: Standard concentration unfractionated heparin</Intervention>
    <Primary_outcome>Filter life</Primary_outcome>
    <Secondary_outcome>Bleeding complications</Secondary_outcome>
    <Secondary_ID>VU 110162</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2944572</Internal_Number>
    <TrialID>NCT01332799</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Xanthine Oxidase Inhibition in Renal Transplant Recipients</Public_title>
    <Scientific_title />
    <Acronym>XART</Acronym>
    <Primary_sponsor>University of Iowa</Primary_sponsor>
    <Date_registration3>20110407</Date_registration3>
    <Date_registration>07/04/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01332799</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>85 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>February 2011</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  age 18 years or older&lt;br&gt;&lt;br&gt;          -  both genders&lt;br&gt;&lt;br&gt;          -  recipients of living donor or deceased-donor kidney transplant with stable renal&lt;br&gt;             function&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  history of gout&lt;br&gt;&lt;br&gt;          -  allergy to allopurinol&lt;br&gt;&lt;br&gt;          -  use of azathioprine&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Complications of Renal Transplant</Condition>
    <Intervention>Drug: allopurinol or placebo</Intervention>
    <Primary_outcome>Cardiovascular events;Endothelial function</Primary_outcome>
    <Secondary_outcome>Arterial stiffness and markers of inflammation</Secondary_outcome>
    <Secondary_ID>201010787</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2944690</Internal_Number>
    <TrialID>NCT01334333</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients</Public_title>
    <Scientific_title>Comparison of Medication Adherence Between Once Daily Tacrolimus (Advagraf®) and Twice Daily Tacrolimus (Prograf®) Administration in Stable Renal Transplant Recipients - a Randomized Study</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of British Columbia</Primary_sponsor>
    <Date_registration3>20110411</Date_registration3>
    <Date_registration>11/04/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01334333</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>19 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2011</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Supportive Care</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  a minimum of one year post renal transplant with a successful kidney graft and stable&lt;br&gt;             renal function (estimated glomerular filtration rate [GFR] above 25 ml/minute per&lt;br&gt;             1.73 m2).&lt;br&gt;&lt;br&gt;          -  currently prescribed tacrolimus&lt;br&gt;&lt;br&gt;          -  able to swallow pills&lt;br&gt;&lt;br&gt;          -  a minimum of grade six education&lt;br&gt;&lt;br&gt;          -  fluent in the English language.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  refusal to or inability to give written informed consent.&lt;br&gt;&lt;br&gt;          -  any visual, hearing or other sensory/motor impairments which may interfere with the&lt;br&gt;             testing procedures.&lt;br&gt;&lt;br&gt;          -  have had a stroke determined to be of significant severity&lt;br&gt;&lt;br&gt;          -  have had a head injury determined to be of significant severity&lt;br&gt;&lt;br&gt;          -  have a current psychiatric diagnosis determined to be of significant severity&lt;br&gt;&lt;br&gt;          -  have the presence of an acute illness (e.g., metastatic cancer), neurological&lt;br&gt;             disease, and other major organ failure (e.g., end stage liver disease)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Disease;Renal Transplant</Condition>
    <Intervention>Drug: Tacrolimus - Prograf® twice daily formulation;Drug: Tacrolimus - Advagraf® once daily formulation</Intervention>
    <Primary_outcome>electronic monitor of medication taking</Primary_outcome>
    <Secondary_outcome>blood levels of medication;self-reported medication adherence;pharmacy refill data</Secondary_outcome>
    <Secondary_ID>H11-00446</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Simon Fraser University;Astellas Pharma Canada, Inc.</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2944690</Internal_Number>
    <TrialID>NCT01334333</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients</Public_title>
    <Scientific_title>Comparison of Medication Adherence Between Once Daily Tacrolimus (Advagraf®) and Twice Daily Tacrolimus (Prograf®) Administration in Stable Renal Transplant Recipients - a Randomized Study</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of British Columbia</Primary_sponsor>
    <Date_registration3>20110411</Date_registration3>
    <Date_registration>11/04/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01334333</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>19 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2011</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Supportive Care</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  a minimum of one year post renal transplant with a successful kidney graft and stable&lt;br&gt;             renal function (estimated glomerular filtration rate [GFR] above 25 ml/minute per&lt;br&gt;             1.73 m2).&lt;br&gt;&lt;br&gt;          -  currently prescribed tacrolimus&lt;br&gt;&lt;br&gt;          -  able to swallow pills&lt;br&gt;&lt;br&gt;          -  a minimum of grade six education&lt;br&gt;&lt;br&gt;          -  fluent in the English language.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  refusal to or inability to give written informed consent.&lt;br&gt;&lt;br&gt;          -  any visual, hearing or other sensory/motor impairments which may interfere with the&lt;br&gt;             testing procedures.&lt;br&gt;&lt;br&gt;          -  have had a stroke determined to be of significant severity&lt;br&gt;&lt;br&gt;          -  have had a head injury determined to be of significant severity&lt;br&gt;&lt;br&gt;          -  have a current psychiatric diagnosis determined to be of significant severity&lt;br&gt;&lt;br&gt;          -  have the presence of an acute illness (e.g., metastatic cancer), neurological&lt;br&gt;             disease, and other major organ failure (e.g., end stage liver disease)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Disease;Renal Transplant</Condition>
    <Intervention>Drug: Tacrolimus - Prograf® twice daily formulation;Drug: Tacrolimus - Advagraf® once daily formulation</Intervention>
    <Primary_outcome>electronic monitor of medication taking</Primary_outcome>
    <Secondary_outcome>blood levels of medication;self-reported medication adherence;pharmacy refill data</Secondary_outcome>
    <Secondary_ID>H11-00446</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Simon Fraser University;Astellas Pharma Canada, Inc.</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2946111</Internal_Number>
    <TrialID>NCT01353053</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Comparison of Two Immunosuppressive Regimens in Kidney Transplant Recipients With Deceased Donors With the Aim of Preventing the Development of Fibrosis / Atrophy of Reducing the Incidence of Cytomegalovirus Infection</Public_title>
    <Scientific_title>Comparison of Two Immunosuppressive Regimens in Kidney Transplant Recipients With Deceased Donors With the Aim of Preventing the Development of Fibrosis / Atrophy of Reducing the Incidence of Cytomegalovirus Infection</Scientific_title>
    <Acronym />
    <Primary_sponsor>Federal University of São Paulo</Primary_sponsor>
    <Date_registration3>20110511</Date_registration3>
    <Date_registration>11/05/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01353053</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2010</Date_enrollement>
    <Target_size>82</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with BMI below 30,&lt;br&gt;&lt;br&gt;          -  first transplants with PRA &lt; 30,&lt;br&gt;&lt;br&gt;          -  no contraindication for induction Thymoglobuline,&lt;br&gt;&lt;br&gt;          -  age 18 years or younger than 70 years.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  patients with a BMI above 30&lt;br&gt;&lt;br&gt;          -  retransplantation&lt;br&gt;&lt;br&gt;          -  patients hypersensitized with PRA &gt; 30&lt;br&gt;&lt;br&gt;          -  compared with Thymoglobulina indication for induction&lt;br&gt;&lt;br&gt;          -  age under 18 or over 70 years&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Disorder of Transplanted Kidney;Cytomegalovirus Infections</Condition>
    <Secondary_ID>056410</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2946207</Internal_Number>
    <TrialID>NCT01354301</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate</Public_title>
    <Scientific_title>Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate</Scientific_title>
    <Acronym />
    <Primary_sponsor>Hospital do Rim e Hipertensão</Primary_sponsor>
    <Date_registration3>20110513</Date_registration3>
    <Date_registration>13/05/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01354301</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2011</Date_enrollement>
    <Target_size>300</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  low risk adult candidates for first renal transplants from living or deceased donors&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  receiving immunosuppressive therapy before transplantation;&lt;br&gt;&lt;br&gt;          -  have received an investigational medication within the past 30 days;&lt;br&gt;&lt;br&gt;          -  have a known contraindication to the administration of antithymocyte globulin;&lt;br&gt;&lt;br&gt;          -  tested positive for human immunodeficiency virus (HIV);&lt;br&gt;&lt;br&gt;          -  had had cancer (except nonmelanoma skin cancer) within the previous 2 years;&lt;br&gt;&lt;br&gt;          -  Pregnant women, nursing mothers, and women of childbearing potential who will be not&lt;br&gt;             using condoms or oral contraceptives will be excluded;&lt;br&gt;&lt;br&gt;          -  Patients with any panel reactive antibody (PRA) equal to or above 50%, class I or&lt;br&gt;             class II.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Cytomegalovirus Infection;Renal Transplant Failure;Transplant; Complication, Rejection</Condition>
    <Intervention>Drug: Thymoglobulin;Drug: Everolimus;Drug: Basiliximabe;Drug: mycophenolate sodium;Drug: Tacrolimus;Drug: Tacrolimus;Drug: Tacrolimus</Intervention>
    <Primary_outcome>incidence of CMV infection or disease</Primary_outcome>
    <Secondary_outcome>incidence of treatment failure defined as a composite end-point of BCAR, graft loss, death, loss to follow up.</Secondary_outcome>
    <Secondary_ID>CRAD001ABR18T</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2946286</Internal_Number>
    <TrialID>NCT01355341</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Safety and Efficacy of Herbmed Plus in Patients withRenal Calculi</Public_title>
    <Scientific_title>A Phase II, 28 Week, Randomized, Double- Blind, Placebo- Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 'Herbmed Plus' an Ayurvedic Formulation in Patients With Renal Calculi</Scientific_title>
    <Acronym>HerbmedPlus</Acronym>
    <Primary_sponsor>Amai Charitable Trust</Primary_sponsor>
    <Date_registration3>20110516</Date_registration3>
    <Date_registration>16/05/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01355341</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>10 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2010</Date_enrollement>
    <Target_size>84</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Investigator), Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age 10-75 years (Both inclusive)&lt;br&gt;&lt;br&gt;          -  Patients with Renal calculi, diagnosis confirmed by plain X-ray KUB &amp;/or ultrasound&lt;br&gt;             KUB/CT scan Abdomen&lt;br&gt;&lt;br&gt;          -  Size of the calculi ranging from 04 mm -09 mm&lt;br&gt;&lt;br&gt;          -  Able and willing to give written informed consent and comply with the requirements of&lt;br&gt;             the study protocol&lt;br&gt;&lt;br&gt;          -  Patients of reproductive potential (males and females) and willing to use a reliable&lt;br&gt;             means of contraception (e.g hormonal contraceptive patch, intrauterine device and&lt;br&gt;             physical barrier) throughout study participation&lt;br&gt;&lt;br&gt;          -  Patients will to cooperate &amp; give consent for the trial&amp; comes for regular follow up.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients having acute condition of renal calculi.&lt;br&gt;&lt;br&gt;          -  Any systemic disease requiring other medications of surgery for calculus condition.&lt;br&gt;&lt;br&gt;          -  Complicated cases of Renal Calculi requiring surgical condition.&lt;br&gt;&lt;br&gt;          -  Chronic or current infectious disease such as but not limited to chronic renal&lt;br&gt;             infection including active urinary tract infection.Uncontrolled diabetes,&lt;br&gt;             hypertension, symptomatic congestive heart failure, unstable angina pectoris,&lt;br&gt;             myocardial infarction&lt;br&gt;&lt;br&gt;          -  Any other urogenital disorders.&lt;br&gt;&lt;br&gt;          -  Liver dysfunction, defined as total bilirubin more then 1.5  the upper limit of&lt;br&gt;             Normal, aspartate aminotransferase  more then  2.5  upper limit of Normal, or alanine&lt;br&gt;             aminotransferase  more then 2.5  upper limit of Normal,&lt;br&gt;&lt;br&gt;          -  Kidney disease, including serum creatinine level more then 1.5  upper limit of&lt;br&gt;             Normal,&lt;br&gt;&lt;br&gt;          -  Subjects on herbal supplements for stone disease (plant extracts preparations or&lt;br&gt;             herbal medicines etc.) within previous 3 months.&lt;br&gt;&lt;br&gt;          -  Participated in another clinical drug trial within 3 months before recruitment.&lt;br&gt;&lt;br&gt;          -  Pregnancy or breast feeding&lt;br&gt;&lt;br&gt;          -  Evidence of significant uncontrolled concomitant disease which in the&lt;br&gt;             Investigator's opinion would preclude patient participation&lt;br&gt;&lt;br&gt;          -  Currently active alcohol or drug abuse or history of alcohol or drug abuse within 24&lt;br&gt;             weeks prior to baseline&lt;br&gt;&lt;br&gt;          -  Patients with psychiatric illness or other condition that would limit compliance with&lt;br&gt;             study requirements&lt;br&gt;&lt;br&gt;          -  Patients receiving or has received any investigational drug within 30 days before&lt;br&gt;             receiving the first dose of study medication&lt;br&gt;&lt;br&gt;          -  Subjects who refuse to sign the informed consent document .&lt;br&gt;      </Inclusion_Criteria>
    <Condition>RENAL CALCULI</Condition>
    <Intervention>Drug: HERBMED PLUS</Intervention>
    <Primary_outcome>To evaluate  the efficacy of "Herbmed plus"in patients with urinary calculi by  assessing the reduction in the stone size &amp; surface area/ or the expulsion of stone</Primary_outcome>
    <Secondary_outcome>Reduction in the size of stone  Reduction in the density of the stone  Painless expulsion of the stone/fragments  Reduction in pain  Consumption of Analgesics</Secondary_outcome>
    <Secondary_ID>ACE/HMP-01</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2946357</Internal_Number>
    <TrialID>NCT01356277</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Intervention to Improve Adherence in Teen Kidney Transplant</Public_title>
    <Scientific_title>TAKE-IT: Teen Adherence in Kidney Transplant Effectiveness of Intervention Trial</Scientific_title>
    <Acronym>TAKE-IT</Acronym>
    <Primary_sponsor>McGill University Health Center</Primary_sponsor>
    <Date_registration3>20110517</Date_registration3>
    <Date_registration>17/05/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01356277</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>11 Years</Inclusion_agemin>
    <Inclusion_agemax>19 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>February 2012</Date_enrollement>
    <Target_size>176</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Subjects age 11 - 19 years&lt;br&gt;&lt;br&gt;          -  At least 3 months post kidney transplant&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Significant neurocognitive disabilities limiting the subject's ability to understand&lt;br&gt;             and participate on their own&lt;br&gt;&lt;br&gt;          -  Unable to communicate in English or French (Montreal site)&lt;br&gt;&lt;br&gt;          -  Unable to communicate in English (all other sites)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Transplantation;Medication Adherence</Condition>
    <Intervention>Device: Medminder adherence monitoring;Behavioral: Action-focused problem-solving;Device: Medminder dosage reminders</Intervention>
    <Primary_outcome>Taking adherence</Primary_outcome>
    <Secondary_outcome>Timing adherence;Clinical outcomes;Healthcare system factors</Secondary_outcome>
    <Secondary_ID>R01 DK92977-01</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Children's Hospital of Philadelphia;Children's Hospital Medical Center, Cincinnati;Seattle Children's Hospital;University of Florida;Children's &amp; Women's Health Centre of British Columbia;The Hospital for Sick Children</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2946379</Internal_Number>
    <TrialID>NCT01356563</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Efficacy Study of Pharmacist Intervention on Medication-related Problems in Hemodialysis Patients</Public_title>
    <Scientific_title>Effects of Pharmacist on Medication-related Problems in Hemodialysis Patients: a Randomized,Controlled, Double-blind Study</Scientific_title>
    <Acronym />
    <Primary_sponsor>Sin-Lau Hospital</Primary_sponsor>
    <Date_registration3>20110514</Date_registration3>
    <Date_registration>14/05/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01356563</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>20 Years</Inclusion_agemin>
    <Inclusion_agemax>90 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2011</Date_enrollement>
    <Target_size>150</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Caregiver, Outcomes Assessor), Primary Purpose:  Health Services Research</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  20-96 years old hemodialysis patient taking medications prescribed by nephrologists.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients who refused informed consent&lt;br&gt;&lt;br&gt;          -  Cognitive impaired&lt;br&gt;&lt;br&gt;          -  unable to talk or hearing disability&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Failure Chronic Requiring Hemodialysis</Condition>
    <Intervention>Behavioral: pharmaceutical care</Intervention>
    <Primary_outcome>amount of unsolved medication-related problems in each group</Primary_outcome>
    <Secondary_outcome>Patient self-reported medication compliance;pharmaceutical care satisfaction;adverse events;knowledge about medication</Secondary_outcome>
    <Secondary_ID>SLH-100-05</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2946437</Internal_Number>
    <TrialID>NCT01357317</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Dietary Phosphorus Restriction</Public_title>
    <Scientific_title>Changes in Biochemical and Vascular Parameters w/Lanthanum Carbonate &amp; Calcium Acetate Therapy Compared to Dietary Intervention in Pts w/Stage 3 &amp; 4 Chronic Kidney Disease &amp; Abnormal Phosphorus Homeostasis: a Randomized Controlled Trial</Scientific_title>
    <Acronym />
    <Primary_sponsor>Salem Veterans Affairs Medical Center</Primary_sponsor>
    <Date_registration3>20110404</Date_registration3>
    <Date_registration>04/04/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01357317</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2011</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Male or female CKD patients &gt; 18 years old&lt;br&gt;&lt;br&gt;          -  Patients should be willing and able to provide written informed consent and HIPAA&lt;br&gt;             authorization to participate in study&lt;br&gt;&lt;br&gt;          -  Chronic kidney disease Stage 3 or 4 per K-DOQI Guidelines:  estimated glomerular&lt;br&gt;             filtration rate (eGFR) of 15-60 ml/.min/1.73m2 by using modified MDRD equation.&lt;br&gt;&lt;br&gt;          -  Serum phosphorus &gt;4.6 mg/dl or plasma intact PTH (iPTH) level above 65 pg/ml or&lt;br&gt;             tubular reabsorption of phosphorus (TRP) &lt;80%.&lt;br&gt;&lt;br&gt;          -  A negative pregnancy test prior to enrollment in female patients, unless the patient&lt;br&gt;             is 2 years postmenopausal, or has had a documented tubal ligation or total&lt;br&gt;             hysterectomy.&lt;br&gt;&lt;br&gt;          -  Patients need to be off any phosphorus binders for 4 weeks prior to screening&lt;br&gt;&lt;br&gt;          -  Stable dose of vitamin D products for 4 weeks in patients receiving such agents.&lt;br&gt;             Dose changes in patients receiving stable and initiation of vitamin D products in&lt;br&gt;             patients previously not treated will not be permitted during study&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Women who are pregnant, capable of becoming pregnant and not participating in an&lt;br&gt;             acceptable form of birth control, or who are breast feeding&lt;br&gt;&lt;br&gt;          -  Patients currently participating in a clinical trial with another investigational&lt;br&gt;             drug or device or who have receiving an investigational drug or device within 30 days&lt;br&gt;             of enrollment in this study&lt;br&gt;&lt;br&gt;          -  Major surgery within 2 month prior to enrollment in study or planned surgery while&lt;br&gt;             the patient is in the study, other than dialysis vascular access surgery.&lt;br&gt;&lt;br&gt;          -  Presence of coronary stents, artificial heart valves or pacemakers, and history of&lt;br&gt;             CABG&lt;br&gt;&lt;br&gt;          -  Patients with active infections requiring ongoing treatment&lt;br&gt;&lt;br&gt;          -  Patients who have had a malignancy (except for non-melanoma cancer of the skin)&lt;br&gt;             unless the patient has received curative treatment and has been disease free for &gt;2&lt;br&gt;             years&lt;br&gt;&lt;br&gt;          -  Patient who the Investigator determines has a medical status that would preclude the&lt;br&gt;             patient's participation in the study&lt;br&gt;&lt;br&gt;          -  Patients on hemodialysis (HD) or peritoneal dialysis (PD)&lt;br&gt;&lt;br&gt;          -  Patients with a functional renal transplant&lt;br&gt;&lt;br&gt;          -  Patients with allergies to study drugs&lt;br&gt;&lt;br&gt;          -  Patients with serum calcium &gt;10.7 mg/dl.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease</Condition>
    <Intervention>Other: Diet counseling;Other: Diet counseling;Drug: Phosphorus binder</Intervention>
    <Primary_outcome>Designated safety measure; serum calcium;Designated safety measure:  phosphorus</Primary_outcome>
    <Secondary_outcome>Changes in flow;Other Changes</Secondary_outcome>
    <Secondary_ID>CK 0036</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Shire Development LLC</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2946622</Internal_Number>
    <TrialID>NCT01359722</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>N-acetylcysteine to Prevent Renal Failure</Public_title>
    <Scientific_title>N-acetylcysteine to Prevent Renal Failure in Patients With Chronic Kidney Disease Undergoing Coronary Artery Bypass Surgery</Scientific_title>
    <Acronym />
    <Primary_sponsor>Instituto do Coracao</Primary_sponsor>
    <Date_registration3>20110518</Date_registration3>
    <Date_registration>18/05/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01359722</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>30 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2010</Date_enrollement>
    <Target_size>50</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Prevention</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  adult patients aged 30 to 80 years old of both sexes&lt;br&gt;&lt;br&gt;          -  indicated for elective CABG&lt;br&gt;&lt;br&gt;          -  with glomerular filtration rate, assessed with the MDRD &lt;60 mL/min/1, 73 m2 and&gt; 15&lt;br&gt;             mL / min / 1.73 m2 body surface&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  patients on chronic dialysis or with creatinine&gt; 5 mg / dL preoperatively;&lt;br&gt;             individuals allergic or intolerant to N-acetylcysteine&lt;br&gt;&lt;br&gt;          -  pregnant women&lt;br&gt;&lt;br&gt;          -  patients with cancer&lt;br&gt;&lt;br&gt;          -  patients underwent re-surgery within the first 72 hours postoperatively&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Failure, Acute;Oxidative Stress Induction</Condition>
    <Intervention>Drug: N-acetylcysteine;Drug: Control</Intervention>
    <Primary_outcome>Decrease in glomerular filtration defined by at least 30% compared to preoperative levels .</Primary_outcome>
    <Secondary_outcome>Up 50% of preoperative levels of serum creatinine.;Death from any cause.;Need for dialysis;Cardiovascular morbidity.;Increased levels of Cystatin C.;Increased levels of NGAL.;Increased levels of isoprostane.</Secondary_outcome>
    <Secondary_ID>0992/09</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Fundação de Amparo à Pesquisa do Estado de São Paulo</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2946765</Internal_Number>
    <TrialID>NCT01361581</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Metabolic Aspects of Citrate Anticoagulation in Renal Replacement Therapy</Public_title>
    <Scientific_title>Metabolic Aspects of Citrate Anticoagulation in Renal Replacement Therapy</Scientific_title>
    <Acronym>Citrate</Acronym>
    <Primary_sponsor>Charles University, Czech Republic</Primary_sponsor>
    <Date_registration3>20110525</Date_registration3>
    <Date_registration>25/05/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01361581</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>16 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2008</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Acute renal failure on continuous renal replacement therapy for more than 24 hours&lt;br&gt;             (CVVH or CVVHDF).&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Absence of consent.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Renal Failure;Critical Illness</Condition>
    <Secondary_ID>NS/10014-4</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Ministry of Health, Czech Republic</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2946981</Internal_Number>
    <TrialID>NCT01364402</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Prevention of Contrast Induced Nephropathy by Erythropoietin</Public_title>
    <Scientific_title>Prevention of Contrast Induced Nephropathy by Erythropoietin in Patients With Diabetes Mellitus and eGFR&lt;60 ml/Min/1.73m2 Undergoing Percutaneous Coronary Intervention</Scientific_title>
    <Acronym />
    <Primary_sponsor>Western Galilee Hospital-Nahariya</Primary_sponsor>
    <Date_registration3>20110524</Date_registration3>
    <Date_registration>24/05/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01364402</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 2011</Date_enrollement>
    <Target_size>142</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Over 18 years of age.&lt;br&gt;&lt;br&gt;          -  Diabetic patients.&lt;br&gt;&lt;br&gt;          -  eGFR &lt; 60 ml/min/1.73m2.&lt;br&gt;&lt;br&gt;          -  Scheduled for primary or elective PCI.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Non diabetic patients.&lt;br&gt;&lt;br&gt;          -  Patients with eGFR = 60 ml/min/1.73m2.&lt;br&gt;&lt;br&gt;          -  Chronic renal replacement therapy.&lt;br&gt;&lt;br&gt;          -  Subject with active malignancy.&lt;br&gt;&lt;br&gt;          -  Subject with any known history of seizure disorders.&lt;br&gt;&lt;br&gt;          -  Subject with polycythemia.&lt;br&gt;&lt;br&gt;          -  Uncontrolled hypertension.&lt;br&gt;&lt;br&gt;          -  Known allergy or hypersensitivity to EPO.&lt;br&gt;&lt;br&gt;          -  Use of EPO 1 week prior to randomization.&lt;br&gt;&lt;br&gt;          -  Use of long acting EPO (CERA) during 1 month prior to randomization.&lt;br&gt;&lt;br&gt;          -  Use of  NAC or bicarbonate during 3 days prior to randomization.&lt;br&gt;&lt;br&gt;          -  Contrast media exposure during the last 7 days before randomization.&lt;br&gt;&lt;br&gt;          -  Pregnant or lactating women.&lt;br&gt;&lt;br&gt;          -  Participation in other clinical trial.&lt;br&gt;&lt;br&gt;          -  Refusal or inability to give informed consent due to mental or physical state.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Diabetes;Chronic Kidney Insufficiency</Condition>
    <Intervention>Drug: Epoetin beta;Drug: Saline 0.9%</Intervention>
    <Primary_outcome>Incidence of Contrast Induced Nephropathy(CIN)</Primary_outcome>
    <Secondary_outcome>Enzymatic infarct size;Hospital length of stay;Renal replacement therapy;Hospital mortality</Secondary_outcome>
    <Secondary_ID>EPO1</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2947977</Internal_Number>
    <TrialID>NCT01377467</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients</Public_title>
    <Scientific_title>A Phase 3, Investigator-initiated, Randomized, Open-label Single-center Study of the Effect of Denosumab on the Prevention of Bone Mineral Density Loss After Renal Transplantation</Scientific_title>
    <Acronym>POSTOP</Acronym>
    <Primary_sponsor>University of Zurich</Primary_sponsor>
    <Date_registration3>20110620</Date_registration3>
    <Date_registration>20/06/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01377467</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2011</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        The key inclusion criteria are:&lt;br&gt;&lt;br&gt;          1. Male or female adult de novo kidney, kidney-pancreas or kidney-islet transplant&lt;br&gt;             recipients&lt;br&gt;&lt;br&gt;          2. Functioning graft within 14 days after transplantation (creatinine having decreased&lt;br&gt;             to &lt;200 micromol/l without the need for dialysis)&lt;br&gt;&lt;br&gt;          3. Being on standard triple immunosuppression including a calcineurin antagonist&lt;br&gt;             (cyclosporine or tacrolimus), mycophenolate (MMF or MPA) and steroids, with or&lt;br&gt;             without induction treatment with basiliximab or anti-thymocyte globulin&lt;br&gt;&lt;br&gt;        Key exclusion criteria are:&lt;br&gt;&lt;br&gt;          1. Age &lt;18 years&lt;br&gt;&lt;br&gt;          2. Rising creatinine after initial drop &lt;200 micromol/l or creatinine &gt;200 micromol/l at&lt;br&gt;             baseline&lt;br&gt;&lt;br&gt;          3. Evidence of early acute rejection, either suspected clinically and/or proven by&lt;br&gt;             biopsy&lt;br&gt;&lt;br&gt;          4. Presence of severe osteoporosis as evidenced by a T score &lt;-4 at the hip, femoral&lt;br&gt;             neck or any of the 4 vertebrae L1 to L4&lt;br&gt;&lt;br&gt;          5. Evidence of severe hyper- or hypoparathyroidism (iPTH &gt;800 ng/l or &lt;10 ng/l)&lt;br&gt;&lt;br&gt;          6. Hypocalcemia (total calcium &lt;1.8 mmol/l) or hypercalcemia (total calcium &gt;2.7 mmol/l)&lt;br&gt;&lt;br&gt;          7. Steroid-free de novo immunosuppression scheme&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Osteoporosis;Chronic Kidney Disease</Condition>
    <Intervention>Drug: Denosumab (Prolia)</Intervention>
    <Primary_outcome>Total hip bone mineral density (BMD) after one year of treatment</Primary_outcome>
    <Secondary_outcome>Occurrence of fractures</Secondary_outcome>
    <Secondary_ID>UZH-NEP 2.1</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2948170</Internal_Number>
    <TrialID>NCT01380002</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Home-Care Needs in Liver or Renal Transplantation Recipients and Their Spouses</Public_title>
    <Scientific_title>Home-Care Needs in Liver or Renal Transplantation Recipients and Their Spouses</Scientific_title>
    <Acronym />
    <Primary_sponsor>National Taiwan University Hospital</Primary_sponsor>
    <Date_registration3>20110622</Date_registration3>
    <Date_registration>22/06/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01380002</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>December 2010</Date_enrollement>
    <Target_size>400</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Family-Based, Time Perspective:  Cross-Sectional</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  about patients&lt;br&gt;&lt;br&gt;               1. liver transplant recipients or renal transplant recipients who have regular&lt;br&gt;                  follow up in organ transplant outpatient departments.&lt;br&gt;&lt;br&gt;               2. conscious clear.&lt;br&gt;&lt;br&gt;               3. above 18 years old.&lt;br&gt;&lt;br&gt;          -  about spouse&lt;br&gt;&lt;br&gt;               1. who live with patients.&lt;br&gt;&lt;br&gt;               2. conscious clear.&lt;br&gt;&lt;br&gt;               3. above 18 years old.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  about patients&lt;br&gt;&lt;br&gt;               1. who suffer form cancer now.&lt;br&gt;&lt;br&gt;               2. have received transplantation twice.&lt;br&gt;&lt;br&gt;          -  about spouse&lt;br&gt;&lt;br&gt;               1. who liver apart from patients.&lt;br&gt;&lt;br&gt;               2. whose spouse(patient) did not recruited in this research.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Liver Transplant;Renal Transplant</Condition>
    <Secondary_ID>201011063RC</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2948351</Internal_Number>
    <TrialID>NCT01382355</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Prospective Donor Specific Antibody (DSA) Monitoring Protocol</Public_title>
    <Scientific_title>Prospective Donor Specific Antibody (DSA) Monitoring Protocol To Detect Patient Characteristics and /or Changes In Immunosuppression on the Development of De Novo Antibodies</Scientific_title>
    <Acronym />
    <Primary_sponsor>Providence Health &amp; Services</Primary_sponsor>
    <Date_registration3>20110621</Date_registration3>
    <Date_registration>21/06/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01382355</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 2011</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Have received a living donor or deceased donor kidney/kidney pancreas transplant&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Have not received a transplant&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Transplant;Kidney/Pancreas Transplant</Condition>
    <Primary_outcome>Proportion of patients who develop DSA within the first year post-transplant;Risk factors for developing DSA</Primary_outcome>
    <Secondary_outcome>Change in allograft function at 1 year post-transplant compared to baseline (measured by Cockcroft-Gault);Incidence of patient survival at 1 year;Proportion of patients who are DSA negative at 1 year;Percent change of DSA from baseline to 1 year;Proportion of Class I versus Class II detectable DSA that progress to antibody mediated rejection;Incidence of allograft survival at 1 year</Secondary_outcome>
    <Secondary_ID>PDSAM 011</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Washington State University;Paul I Terasaki Foundation Laboratory</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2948351</Internal_Number>
    <TrialID>NCT01382355</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Prospective Donor Specific Antibody (DSA) Monitoring Protocol</Public_title>
    <Scientific_title>Prospective Donor Specific Antibody (DSA) Monitoring Protocol To Detect Patient Characteristics and /or Changes In Immunosuppression on the Development of De Novo Antibodies</Scientific_title>
    <Acronym />
    <Primary_sponsor>Providence Health &amp; Services</Primary_sponsor>
    <Date_registration3>20110621</Date_registration3>
    <Date_registration>21/06/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01382355</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 2011</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Have received a living donor or deceased donor kidney/kidney pancreas transplant&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Have not received a transplant&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Transplant;Kidney/Pancreas Transplant</Condition>
    <Primary_outcome>Proportion of patients who develop DSA within the first year post-transplant;Risk factors for developing DSA</Primary_outcome>
    <Secondary_outcome>Change in allograft function at 1 year post-transplant compared to baseline (measured by Cockcroft-Gault);Incidence of patient survival at 1 year;Proportion of patients who are DSA negative at 1 year;Percent change of DSA from baseline to 1 year;Proportion of Class I versus Class II detectable DSA that progress to antibody mediated rejection;Incidence of allograft survival at 1 year</Secondary_outcome>
    <Secondary_ID>PDSAM 011</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Washington State University;Paul I Terasaki Foundation Laboratory</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2948478</Internal_Number>
    <TrialID>NCT01384006</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Extended Pancreas Donor Program - The EXPAND Study</Public_title>
    <Scientific_title>EXTENDED PANCREAS DONOR PROGRAM - THE EXPAND STUDY</Scientific_title>
    <Acronym>EXPAND</Acronym>
    <Primary_sponsor>University of Regensburg</Primary_sponsor>
    <Date_registration3>20110627</Date_registration3>
    <Date_registration>27/06/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01384006</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2011</Date_enrollement>
    <Target_size>110</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Recipients of standard allocation organs or&lt;br&gt;&lt;br&gt;          -  Recipients of organs from donors between 50 to 60 years OR a BMI 30-34&lt;br&gt;&lt;br&gt;          -  CIT (cold ischemic time) = 12h (only local allocation of organs, optimally the&lt;br&gt;             procuring surgical team should be the transplanting team).&lt;br&gt;&lt;br&gt;        and&lt;br&gt;&lt;br&gt;          -  negative cross-match&lt;br&gt;&lt;br&gt;          -  age &gt; 18 years&lt;br&gt;&lt;br&gt;          -  primary SPK, PAK or PTA&lt;br&gt;&lt;br&gt;          -  Patients on standardized immunosuppressive treatment with Tacrolimus (Prograf®), MPA&lt;br&gt;             (Myfortic®) [aiming at center specific trough-level practice] from day 5 after&lt;br&gt;             transplantation (prior to day 5 MMF (Cell Cept®) can be applied as i.v. medication&lt;br&gt;             due to reduced gastrointestinal passage and insecure absorption of orally applied&lt;br&gt;             medication) and center-specific steroid treatment.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Malignant diseases within 5 years prior to PTA/SPK except for squamous cell carcinoma&lt;br&gt;             and basalioma of the skin.&lt;br&gt;&lt;br&gt;          -  Pancreas retransplantation.&lt;br&gt;&lt;br&gt;          -  Immunized patients with a preformed antibody titer&gt;5%.&lt;br&gt;&lt;br&gt;          -  Women with child bearing potential.&lt;br&gt;&lt;br&gt;          -  Patients with a psychological, familial, sociologic or geographic condition&lt;br&gt;             potentially hampering compliance with the study protocol and follow-up schedule.&lt;br&gt;&lt;br&gt;          -  Patients under guardianship (e.g. individuals who are not able to freely give their&lt;br&gt;             informed consent).&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Pancreas Allograft Recipients w/wo Kidney Transplantation</Condition>
    <Primary_outcome>Pancreas allograft survival at 3 months after transplantation</Primary_outcome>
    <Secondary_ID>EXPAND</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Charite University, Berlin, Germany;Ludwig-Maximilians - University of Munich;University of Jena;Johann Wolfgang Goethe University Hospitals;University Hospital Tuebingen;University Hospital Erlangen;University of Heidelberg Medical Center;University of Leipzig;University Hospital Dresden;University Hospital Bergmannsheil Bochum;Hannover Medical School;Universitätsklinikum Hamburg-Eppendorf;University of Kiel;Transplantationszentrum Köln-Merheim</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2948805</Internal_Number>
    <TrialID>NCT01388270</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effect of a Pre Heparin Coated Dialysis Filter on Coagulation During Hemodialysis</Public_title>
    <Scientific_title>The Effect of a Heparin-coated Dialysis Filter (Evodial) on Clotting and Intravascular Coagulation During Hemodialysis (HD) When Compared to a Conventional Polyflux Filter (170H)</Scientific_title>
    <Acronym />
    <Primary_sponsor>Oslo University Hospital</Primary_sponsor>
    <Date_registration3>20110629</Date_registration3>
    <Date_registration>29/06/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01388270</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>90 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2011</Date_enrollement>
    <Target_size>12</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Endpoint Classification:  Efficacy Study, Intervention Model:  Crossover Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Stable HD patients of at least 18 years of age.&lt;br&gt;&lt;br&gt;          -  HD treatment for at least one month.&lt;br&gt;&lt;br&gt;          -  Dialysis time at least 4 hours three times per week.&lt;br&gt;&lt;br&gt;          -  Stable Hemoglobin value of at least 11 g/dl during the last 4 weeks.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Use of warfarin and/or acetylsalicylic acid.&lt;br&gt;&lt;br&gt;          -  Disseminated malignant disease.&lt;br&gt;&lt;br&gt;          -  Clinical signs of infection.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Failure</Condition>
    <Intervention>Device: a pre-heparin-coated hemodialysis filter; Hepran</Intervention>
    <Primary_outcome>Activation of the intravascular coagulation system during hemodialysis with use of a pre-heparin-coated filter compared to a conventional filter</Primary_outcome>
    <Secondary_outcome>A secondary outcome measure is degree of clot score in the extracorporeal system during hemodialysis with use of a pre-heparin-coated filter compared to the conventional filter.</Secondary_outcome>
    <Secondary_ID>2010/3019-2</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2949050</Internal_Number>
    <TrialID>NCT01391468</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Beneficial Effect of Probiotics on Chronic Kidney Disease</Public_title>
    <Scientific_title>Beneficial Effect of Probiotics on Chronic Kidney Disease</Scientific_title>
    <Acronym />
    <Primary_sponsor>China Medical University Hospital</Primary_sponsor>
    <Date_registration3>20110708</Date_registration3>
    <Date_registration>08/07/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01391468</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 2011</Date_enrollement>
    <Target_size>180</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. receiving peritoneal dialysis for more than 3 months, at least 18 years of age, and&lt;br&gt;             GFR &lt; 15 ml/min.&lt;br&gt;&lt;br&gt;          2. receiving hemodialysis dialysis for more than 3 months, at least 18 years of age, and&lt;br&gt;             GFR &lt; 15 ml/min.&lt;br&gt;&lt;br&gt;          3. Stage 3 and 4 CKD patients&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  active infectious conditions within the last 30 days,&lt;br&gt;&lt;br&gt;          -  pregnancy for female,&lt;br&gt;&lt;br&gt;          -  autoimmune disease e.g. SLE.,&lt;br&gt;&lt;br&gt;          -  cardiovascular events before.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease</Condition>
    <Intervention>Dietary Supplement: Probiotics;Dietary Supplement: Cornstarch</Intervention>
    <Primary_outcome>CVD occurence</Primary_outcome>
    <Secondary_outcome>occurrence of peritonitis and improvement of GI symptoms</Secondary_outcome>
    <Secondary_ID>DMR-99-IRB-308</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2949199</Internal_Number>
    <TrialID>NCT01393418</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Evaluating Erythropoietin as an Indicator for Possible Kidney Injury After Cardiac Surgery</Public_title>
    <Scientific_title>EPO: A Renal Biomarker After Cardiac Surgery</Scientific_title>
    <Acronym>EPO</Acronym>
    <Primary_sponsor>University of Michigan Health System</Primary_sponsor>
    <Date_registration3>20110712</Date_registration3>
    <Date_registration>12/07/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01393418</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2010</Date_enrollement>
    <Target_size>80</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case-Only, Time Perspective:  Cross-Sectional</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Cardiac surgery with cardiopulmonary bypass with DHCA&lt;br&gt;&lt;br&gt;          -  Normal renal function or renal insufficiency-serum creatinine less than 2.5 mg/dL&lt;br&gt;&lt;br&gt;          -  Adult male and female patients 18 years and older&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  VADS&lt;br&gt;&lt;br&gt;          -  Emergent cases&lt;br&gt;&lt;br&gt;          -  Prolonged hypoxemia before, during or after bypass&lt;br&gt;&lt;br&gt;          -  End stage renal disease&lt;br&gt;&lt;br&gt;          -  Patients receive erythropoietin receptor agonists&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Erythropoietin;Acute Kidney Injury;Renal Biomarker</Condition>
    <Secondary_ID>HUM41529</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2949199</Internal_Number>
    <TrialID>NCT01393418</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Evaluating Erythropoietin as an Indicator for Possible Kidney Injury After Cardiac Surgery</Public_title>
    <Scientific_title>EPO: A Renal Biomarker After Cardiac Surgery</Scientific_title>
    <Acronym>EPO</Acronym>
    <Primary_sponsor>University of Michigan Health System</Primary_sponsor>
    <Date_registration3>20110712</Date_registration3>
    <Date_registration>12/07/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01393418</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2010</Date_enrollement>
    <Target_size>80</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case-Only, Time Perspective:  Cross-Sectional</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Cardiac surgery with cardiopulmonary bypass with DHCA&lt;br&gt;&lt;br&gt;          -  Normal renal function or renal insufficiency-serum creatinine less than 2.5 mg/dL&lt;br&gt;&lt;br&gt;          -  Adult male and female patients 18 years and older&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  VADS&lt;br&gt;&lt;br&gt;          -  Emergent cases&lt;br&gt;&lt;br&gt;          -  Prolonged hypoxemia before, during or after bypass&lt;br&gt;&lt;br&gt;          -  End stage renal disease&lt;br&gt;&lt;br&gt;          -  Patients receive erythropoietin receptor agonists&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Erythropoietin;Acute Kidney Injury;Renal Biomarker</Condition>
    <Secondary_ID>HUM41529</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2949964</Internal_Number>
    <TrialID>NCT01403389</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant</Public_title>
    <Scientific_title>Pilot Study of the Clinical Activity of Eculizumab for Prevention of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation</Scientific_title>
    <Acronym />
    <Primary_sponsor>Schroppel, Bernd, M.D.</Primary_sponsor>
    <Date_registration3>20110725</Date_registration3>
    <Date_registration>25/07/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01403389</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 2011</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator), Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age 18 or older&lt;br&gt;&lt;br&gt;          -  Weight &gt; 40 kg&lt;br&gt;&lt;br&gt;          -  Male or Female&lt;br&gt;&lt;br&gt;          -  Recipients of first deceased donor kidneys&lt;br&gt;&lt;br&gt;          -  Able to provide written informed consent&lt;br&gt;&lt;br&gt;          -  Transplant candidate as per site specific guidelines&lt;br&gt;&lt;br&gt;          -  Dialysis dependent renal failure (initiated more than 2 months prior to transplant)&lt;br&gt;&lt;br&gt;          -  Novartis Delayed Graft Function Score 3-8&lt;br&gt;&lt;br&gt;          -  Extended criteria donor with brain death, or standard criteria donor with cold&lt;br&gt;             ischemic time &lt; 24 hours&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Planned to receive multi-organ transplant&lt;br&gt;&lt;br&gt;          -  Kidneys from donors &lt; 6 years of age&lt;br&gt;&lt;br&gt;          -  Dual kidney transplant (from same donor, including en bloc)&lt;br&gt;&lt;br&gt;          -  Living donor kidney&lt;br&gt;&lt;br&gt;          -  Highly sensitized recipients (PRA &gt; 50%)&lt;br&gt;&lt;br&gt;          -  Previous transplant&lt;br&gt;&lt;br&gt;          -  Participation in another investigational trial&lt;br&gt;&lt;br&gt;          -  Recipient BMI &gt; 40&lt;br&gt;&lt;br&gt;          -  ABO incompatible&lt;br&gt;&lt;br&gt;          -  DCD Donor&lt;br&gt;&lt;br&gt;          -  Preemptive kidney transplant&lt;br&gt;&lt;br&gt;          -  Recipients with DGF scores &lt; 3 or &gt; 8&lt;br&gt;&lt;br&gt;          -  Women who are pregnant or breast feeding&lt;br&gt;&lt;br&gt;          -  Women of child bearing potential who are unable or unwilling to use a medically&lt;br&gt;             acceptable form of contraception&lt;br&gt;&lt;br&gt;          -  Patients infected with HIV, HCV or HBV&lt;br&gt;&lt;br&gt;          -  Active bacterial or other infection which is clinically significant in the opinion of&lt;br&gt;             the investigator&lt;br&gt;&lt;br&gt;          -  Patients with history of splenectomy&lt;br&gt;&lt;br&gt;          -  Patients with history of meningococcal disease&lt;br&gt;&lt;br&gt;          -  Patients with known or suspected hereditary complement deficiency&lt;br&gt;&lt;br&gt;          -  Patients with history of cancer (other than non-melanoma skin cancers) within the&lt;br&gt;             last 5 years&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Delayed Function of Renal Transplant</Condition>
    <Intervention>Drug: Eculizumab;Drug: Placebo</Intervention>
    <Primary_outcome>Composite of Delayed Graft Function and Slow Graft Function</Primary_outcome>
    <Secondary_ID>HSM 10-1600</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Alexion Pharmaceuticals</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2949969</Internal_Number>
    <TrialID>NCT01403454</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Web-based Interactive Health Communication Application (IHCA) for Successful Home Dialysis</Public_title>
    <Scientific_title>Web-based IHCA for Successful Home Dialysis</Scientific_title>
    <Acronym>WISHED</Acronym>
    <Primary_sponsor>St. Joseph's Healthcare Hamilton</Primary_sponsor>
    <Date_registration3>20110721</Date_registration3>
    <Date_registration>21/07/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01403454</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2012</Date_enrollement>
    <Target_size>152</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Supportive Care</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  enrolled in Kidney Function Program (KFP)&lt;br&gt;&lt;br&gt;          -  previously received KFP-administered dialysis modality education&lt;br&gt;&lt;br&gt;          -  personal access to a home computer (ie. either their own or a close friend/family&lt;br&gt;             member) with internet access&lt;br&gt;&lt;br&gt;          -  most recent eGFR &lt; or = 20mL/min/1.73m2&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  inability to provide informed consent&lt;br&gt;&lt;br&gt;          -  inability to use a home computer or internet&lt;br&gt;&lt;br&gt;          -  inability to understand English (written or spoke)&lt;br&gt;&lt;br&gt;          -  severe visual or auditory impairment&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease</Condition>
    <Intervention>Behavioral: Interactive Health Communication Application;Behavioral: No Intervention: Usual Care</Intervention>
    <Primary_outcome>Number of patients that start home-based dialysis.</Primary_outcome>
    <Secondary_outcome>Number intended to start home-based dialysis;Increase in dialysis knowledge;Increase in decision making and social support.;Mortality differences</Secondary_outcome>
    <Secondary_ID>Grant;11-3536</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>McMaster University</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2949973</Internal_Number>
    <TrialID>NCT01403506</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Study of the Effect of N-acetyl Cysteine on the Renal Graft Function Biomarkers (IL18, NGAL)</Public_title>
    <Scientific_title>Phase 3 Study of N-acetyl Cysteine as an Antioxidant and Glutathione Synthesis Inducer on Biomarkers of Delayed Renal Graft Function Including NGAL and IL-18</Scientific_title>
    <Acronym />
    <Primary_sponsor>Shaheed Beheshti Medical University</Primary_sponsor>
    <Date_registration3>20110725</Date_registration3>
    <Date_registration>25/07/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01403506</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2011</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Pharmacodynamics Study, Intervention Model:  Parallel Assignment, Masking:  Single Blind (Outcomes Assessor), Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  patient receiving transplantation from living donors&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  having a neoplastic disease&lt;br&gt;&lt;br&gt;          -  brain tumor&lt;br&gt;&lt;br&gt;          -  having inflammatory diseases in their active phase (SLE)&lt;br&gt;&lt;br&gt;          -  an acute infection, meningitis, sepsis&lt;br&gt;&lt;br&gt;          -  Sickle Cell Disease&lt;br&gt;&lt;br&gt;          -  Pregnancy&lt;br&gt;&lt;br&gt;          -  Cardio-renal syndrome&lt;br&gt;&lt;br&gt;          -  endogenous Cushing's syndrome&lt;br&gt;&lt;br&gt;          -  chronic use of cimetidine&lt;br&gt;&lt;br&gt;          -  a history of acute pancreatitis in recent months&lt;br&gt;&lt;br&gt;          -  Multiple Sclerosis&lt;br&gt;&lt;br&gt;          -  cardiac bypass in a recent month&lt;br&gt;&lt;br&gt;          -  cirrhosis due to Hepatitis C&lt;br&gt;&lt;br&gt;          -  having Alzheimer's disease&lt;br&gt;&lt;br&gt;          -  having a untreated major depressive illness or schizophrenia&lt;br&gt;&lt;br&gt;          -  Stroke in recent months&lt;br&gt;&lt;br&gt;          -  Hyperoxaluria&lt;br&gt;&lt;br&gt;          -  sensitivity to sulfonamides&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Disorder Related to Renal Transplantation</Condition>
    <Intervention>Drug: N-acetyl Cysteine</Intervention>
    <Primary_outcome>renal function biomarkers (IL18, NGAL)difference between study and control group in 4 and 24 hr after transplantation</Primary_outcome>
    <Secondary_outcome>dialysis</Secondary_outcome>
    <Secondary_ID>186</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2950102</Internal_Number>
    <TrialID>NCT01405183</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Association Between Hepatitis C Infection and Renal Cell Carcinoma</Public_title>
    <Scientific_title>Association Between Hepatitis C Infection and Renal Cell Carcinoma, a Case Control Study</Scientific_title>
    <Acronym />
    <Primary_sponsor>Henry Ford Health System</Primary_sponsor>
    <Date_registration3>20110728</Date_registration3>
    <Date_registration>28/07/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01405183</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2011</Date_enrollement>
    <Target_size>278</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case Control, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Male and female patients 18 years or older in whom renal cell carcinoma is suspected&lt;br&gt;             and are scheduled for either biopsy or partial or total nephrectomy. Diagnosis within&lt;br&gt;             6 months.&lt;br&gt;&lt;br&gt;          -  Male and female patients 18 years or older in whom colorectal cancer has been&lt;br&gt;             diagnosed within the last 6 months&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients who are unwilling to provide consent&lt;br&gt;&lt;br&gt;          -  Patients who decline to complete a questionnaire&lt;br&gt;&lt;br&gt;          -  Patient in who blood sample cannot be obtained&lt;br&gt;&lt;br&gt;          -  Diagnosis of renal cell carcinoma or colon cancer greater than 6 months&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Hepatitis C;Renal Cell Carcinoma;Colorectal Cancer</Condition>
    <Intervention>Other: Hepatitis C testing</Intervention>
    <Primary_outcome>Prevalence of hepatitis C in renal cell carcinoma patients</Primary_outcome>
    <Secondary_ID>P08406</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Schering-Plough</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2950270</Internal_Number>
    <TrialID>NCT01407367</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Safe Kidney Care Cohort Study</Public_title>
    <Scientific_title>Does Under-recognition of Kidney Disease Affect Patient Safety?</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Maryland</Primary_sponsor>
    <Date_registration3>20110426</Date_registration3>
    <Date_registration>26/04/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01407367</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>21 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2011</Date_enrollement>
    <Target_size>350</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  estimated glomerular filtration rate (eGFR) &lt; 60 ml/min/1.73m2 (using Modified Diet&lt;br&gt;             in Renal Disease (MDRD) equation) based on the 2 out-patient serum creatinines&lt;br&gt;             obtained within the last 18 months and at least 90 days apart&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  &lt; 21 years of age,&lt;br&gt;&lt;br&gt;          -  Expected to need dialysis within 12 months after time of enrollment,&lt;br&gt;&lt;br&gt;          -  Expected to die within 12 months after time of enrollment,&lt;br&gt;&lt;br&gt;          -  Unable to provide informed consent, or is a&lt;br&gt;&lt;br&gt;          -  Prisoner&lt;br&gt;&lt;br&gt;          -  Skin sensitivity or allergy to stainless steel and sterling silver (Phase 1 only)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease</Condition>
    <Primary_outcome>The discrete incidence of any of the chronic kidney disease patient safety indicators (CKD-PSIs) endorsed by the consensus expert panel</Primary_outcome>
    <Secondary_outcome>Rate of all-cause hospitalization;Change in renal function from baseline;Incidence rate of end-stage renal disease (ESRD) defined as need for renal replacement therapy (dialysis or transplant);Incidence rate of all-cause Death</Secondary_outcome>
    <Secondary_ID>R01DK084017;HP-00048532</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2950290</Internal_Number>
    <TrialID>NCT01407627</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Evaluation of Fructose Ingestion and the Renin Angiotensin System in Healthy Humans</Public_title>
    <Scientific_title>Evaluation of Fructose Ingestion and the Renin Angiotensin System in Healthy Humans</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Calgary</Primary_sponsor>
    <Date_registration3>20110729</Date_registration3>
    <Date_registration>29/07/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01407627</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2011</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Pharmacodynamics Study, Intervention Model:  Crossover Assignment, Masking:  Double Blind (Subject, Investigator, Outcomes Assessor)</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  age=18 years,&lt;br&gt;&lt;br&gt;          -  able to comprehend study and comply with high-salt diet&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  cardiovascular disease (symptoms consistent with myocardial ischemia, previously&lt;br&gt;             documented myocardial ischemia, cardiac arrhythmias or valve abnormalities, or&lt;br&gt;             abnormal ECG at screening)&lt;br&gt;&lt;br&gt;          -  cerebrovascular disease (transient ischemic attacks or stroke)&lt;br&gt;&lt;br&gt;          -  kidney disease (estimated GFR&lt;60 using the MDRD formula36, proteinuria or hematuria&lt;br&gt;             on dipstick)&lt;br&gt;&lt;br&gt;          -  hypertension (BP&gt;140/90 or use of antihypertensive medications)&lt;br&gt;&lt;br&gt;          -  diabetes mellitus (defined by history, use of hypoglycemic agents or a fasting&lt;br&gt;             glucose &gt;7mmol/L)&lt;br&gt;&lt;br&gt;          -  hyperlipidemia (LDL &gt;4.5mmol/L or use of lipid-lowering agents)&lt;br&gt;&lt;br&gt;          -  pregnancy&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renin Angiotensin System;Human;Renal Hemodynamics</Condition>
    <Intervention>Dietary Supplement: Fructose</Intervention>
    <Primary_outcome>Change in filtration fraction</Primary_outcome>
    <Secondary_outcome>change in blood pressure in response to angiotensin II challenge</Secondary_outcome>
    <Secondary_ID>AIHS;University of Calgary;UCalgary Sugar Study</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2950380</Internal_Number>
    <TrialID>NCT01408797</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Clonal Deletion on Living-Relative Donor Kidney Transplantation</Public_title>
    <Scientific_title>A Prospective, Open-Label, Pilot Study of Clonal Deletion on Living-Relative Donor Kidney Transplantation</Scientific_title>
    <Acronym>DAWN</Acronym>
    <Primary_sponsor>Fuzhou General Hospital</Primary_sponsor>
    <Date_registration3>20110802</Date_registration3>
    <Date_registration>02/08/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01408797</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>60 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2011</Date_enrollement>
    <Target_size>15</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 1/Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Uremia patient of any race that is greater than or equal to 18 years of age but less&lt;br&gt;             than 60 years old&lt;br&gt;&lt;br&gt;          2. Recipients of a kidney from a certifiable relative donor 18-60 years of age&lt;br&gt;&lt;br&gt;          3. Patient is willing and capable of giving written informed consent for study&lt;br&gt;             participation and able to participate in the study for 12 months&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Women who are pregnant, intend to become pregnant in the next 1 years, breastfeeding,&lt;br&gt;             or have a positive pregnancy test on enrollment or prior to study medication&lt;br&gt;             administration&lt;br&gt;&lt;br&gt;          2. Patient with prior solid organ transplant or cell transplant (e.g. bone marrow or&lt;br&gt;             islet cell).&lt;br&gt;&lt;br&gt;          3. Patient is deemed likely to have a second solid organ transplant or cell transplant&lt;br&gt;             (e.g. bone marrow or islet cell) in next 3 years&lt;br&gt;&lt;br&gt;          4. Patient receiving a concurrent SOT (heart, liver, pancreas) or cell transplant&lt;br&gt;             (islet, bone marrow, stem cell)&lt;br&gt;&lt;br&gt;          5. ABO incompatible donor recipient pair or CDC crossmatch positive transplant&lt;br&gt;&lt;br&gt;          6. Sensitized patients (most recent anti-HLA Class I or II Panel Reactive Antibodies&lt;br&gt;             (PRA)&gt;0% by a CDC-assay) or patients identified a high immunological risk by the&lt;br&gt;             transplant physician&lt;br&gt;&lt;br&gt;          7. Donor with cardiac death (non-heart beating donor)&lt;br&gt;&lt;br&gt;          8. Recipient CMV seronegative receiving a organ from a seropositive donor (CMV&lt;br&gt;             seromismatch)&lt;br&gt;&lt;br&gt;          9. Donor OR Recipient are known hepatitis C antibody-positive or polymerase chain&lt;br&gt;             reaction (PCR) positive for hepatitis C&lt;br&gt;&lt;br&gt;         10. Donors OR Recipient are known hepatitis B surface antigen-positive or PCR positive&lt;br&gt;             for hepatitis B AND recipient is HBV negative&lt;br&gt;&lt;br&gt;         11. Patient and/or donors with known human immunodeficiency virus (HIV) infection&lt;br&gt;&lt;br&gt;         12. Patient at risk for tuberculosis (TB) Current clinical, radiographic, or laboratory&lt;br&gt;             evidence of active or latent TB as determined by local standard of care&lt;br&gt;&lt;br&gt;             History of active TB:&lt;br&gt;&lt;br&gt;             Within the last 2 years, even if treated Greater than 2 years ago, unless there is&lt;br&gt;             documentation of adequate treatment according to locally accepted clinical practice&lt;br&gt;             Patient at risk of reactivation of TB precludes administration of conventional&lt;br&gt;             immunosuppression (as determined by investigator and based upon appropriate&lt;br&gt;             evaluation)&lt;br&gt;&lt;br&gt;         13. Patient with any significant infection or other contraindication that would preclude&lt;br&gt;             transplant&lt;br&gt;&lt;br&gt;         14. Patient with a history of hypercoaguable state&lt;br&gt;&lt;br&gt;         15. Patient with a history of substance abuse (drugs or alcohol) within the past 6&lt;br&gt;             months, or psychotic disorders that are not compatible with adequate study follow-up.&lt;br&gt;&lt;br&gt;         16. Patient with active peptic ulcer disease (PUD), chronic diarrhea, or gastrointestinal&lt;br&gt;             malabsorption&lt;br&gt;&lt;br&gt;         17. Patient with a history of cancer within the last 5 years (exception: non-melanoma&lt;br&gt;             skin cell cancers cured by local resection are permitted)&lt;br&gt;&lt;br&gt;         18. Patient with a chest radiograph (no more than 2 months prior to randomization)&lt;br&gt;             consistent with an acute lung parenchymal process and malignancy&lt;br&gt;&lt;br&gt;         19. Patient with a hypersensitivity to any study drugs&lt;br&gt;&lt;br&gt;         20. Patient who have used any investigational drug within 30 days prior to the Day 1&lt;br&gt;             visit&lt;br&gt;&lt;br&gt;         21. . Patients with autoimmune disease or patient treated with immunosuppressive therapy&lt;br&gt;             (eg methotrexate, abatacept, etc) for indications such as autoimmune disease or&lt;br&gt;             patient with comorbidity to a degree that treatment with such agents is likely during&lt;br&gt;             the trial&lt;br&gt;&lt;br&gt;         22. Prisoner or patient compulsorily detained (involuntarily incarcerated) for treatment&lt;br&gt;             or either a psychiatric or physical (e.g. infectious disease) illness&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Transplantation;Uremia</Condition>
    <Intervention>Procedure: donor specific transfusion;Drug: MMF, Bortezomib;Procedure: drugs added according to the immuno condition of the recipients</Intervention>
    <Primary_outcome>Dosage of immunosuppressants</Primary_outcome>
    <Secondary_outcome>immune event;DSA;DGF;Renal function;Survival</Secondary_outcome>
    <Secondary_ID>DAWN-2011-TJM</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Terasaki Foundation</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2950954</Internal_Number>
    <TrialID>NCT01416298</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Use of Biomarkers to Optimize Fluid Dosing,CRRT Initiation and Discontinuation in Pediatric ICU Patients With AKI</Public_title>
    <Scientific_title>Use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) to Optimize Fluid Dosing, Continuous Renal Replacement Therapy (CRRT) Initiation and Discontinuation in Critically Ill Children With Acute Kidney Injury (AKI)</Scientific_title>
    <Acronym />
    <Primary_sponsor>Children's Hospital Medical Center, Cincinnati</Primary_sponsor>
    <Date_registration3>20110726</Date_registration3>
    <Date_registration>26/07/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01416298</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>1 Year</Inclusion_agemin>
    <Inclusion_agemax>25 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 2011</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Endpoint Classification:  Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Diagnostic</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Age 1-25 years old&lt;br&gt;&lt;br&gt;          2. Must weigh at least 20kg&lt;br&gt;&lt;br&gt;          3. Receiving mechanical ventilation&lt;br&gt;&lt;br&gt;          4. Receiving at least 1 vasoactive medication: dopamine (dose greater then 5&lt;br&gt;             micrograms/kg/min), Dobutamine, Epinephrine, Norepinephrine or Vasopressin&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. History of End Stage Renal Disease, on Dialysis&lt;br&gt;&lt;br&gt;          2. Immediately post renal transplant&lt;br&gt;&lt;br&gt;          3. Within 96 hours of Cardiopulmonary Bypass Surgery&lt;br&gt;&lt;br&gt;          4. Weight less than 20 kg Patient with a DNR order, "do not escalate care" order, or&lt;br&gt;             life expectancy of less than 1 week.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Kidney Injury;Fluid Overload</Condition>
    <Intervention>Other: Continuous Renal Replacement Therapy</Intervention>
    <Primary_outcome>plasma NGAL</Primary_outcome>
    <Secondary_ID>Biomarker/CRRT Study</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2951000</Internal_Number>
    <TrialID>NCT01416896</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>New Needle for Two-Needle Hemodialysis</Public_title>
    <Scientific_title>New Needle for Two-Needle Hemodialysis</Scientific_title>
    <Acronym>BME-1</Acronym>
    <Primary_sponsor>Biomedical Enterprises Inc</Primary_sponsor>
    <Date_registration3>20110809</Date_registration3>
    <Date_registration>09/08/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01416896</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 2011</Date_enrollement>
    <Target_size>70</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Crossover Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2/Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:(1) end stage renal disease  receiving hemodialysis in an ambulatory&lt;br&gt;        outpatient dialysis facility (2) male or female, (3) ages 18-80, (4) arterio-venous graft&lt;br&gt;        or AV fistula as vascular access,&lt;br&gt;&lt;br&gt;        Exclusion Criteria:patients with fever, infection, inflammation or  malignancy will be&lt;br&gt;        excluded&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End Stage Renal Disease</Condition>
    <Intervention>Procedure: Hemodialysis using the standard venous needle;Procedure: Hemodialysis using a new venous  needle, the "BME needle";Procedure: Hemodialysis using a new venous needle, the "BME needle";Procedure: Hemodialysis using the standard venous needle</Intervention>
    <Primary_outcome>Net change in intracellular oxidative stress and intracellular proinflammatory cytokines levels</Primary_outcome>
    <Secondary_outcome>Net change in oxidative stress and proinflammatory cytokines in plasma</Secondary_outcome>
    <Secondary_ID>R44DK059062;BME-1</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2951122</Internal_Number>
    <TrialID>NCT01418508</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effects of Low Protein Diet Supplemented Keto-/Amino Acid in Preventing the Progression of Chronic Kidney Disease (CKD)- ELPD Study</Public_title>
    <Scientific_title>Effects of Low Protein Diet Supplemented Keto-/Amino Acid in Preventing the Progression of Chronic Kidney Disease(CKD)- ELPD Study</Scientific_title>
    <Acronym>ELPD-CKD</Acronym>
    <Primary_sponsor>Peking Union Medical College Hospital</Primary_sponsor>
    <Date_registration3>20110815</Date_registration3>
    <Date_registration>15/08/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01418508</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 2011</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with chronic kidney disease in stage 3b and 4(15ml/min/1.73m2&lt;GFR&lt;45&lt;br&gt;             ml/min/1.73m2, estimated by EPI formula) receiving conservative treatment for CKD&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  With diagnosis of diabetic mellitus;&lt;br&gt;&lt;br&gt;          -  Incapable of following study requirements to control diet;&lt;br&gt;&lt;br&gt;          -  Glomerular filtration rate &lt; 15 ml/min/1.73m2;&lt;br&gt;&lt;br&gt;          -  Hypercalcemia or hyperkalemia (&gt; normal upper limit);&lt;br&gt;&lt;br&gt;          -  Other serious disease(eg.heart,lung,brain) within the last 3 months;&lt;br&gt;&lt;br&gt;          -  Cardiac failure stage IV NYHA;&lt;br&gt;&lt;br&gt;          -  With cirrhosis of liver or obvious symptoms of liver diseases, ALT or AST two times&lt;br&gt;             normal upper limit;&lt;br&gt;&lt;br&gt;          -  Severe edema or serous cavity effusion;&lt;br&gt;&lt;br&gt;          -  Drug abuse;&lt;br&gt;&lt;br&gt;          -  Final diagnosis of malignant tumor;&lt;br&gt;&lt;br&gt;          -  Receiving the long-term systematic steroid hormone or immunosuppressive agents(eg.&lt;br&gt;             Cyclophosphamidum,Cyclosporine, Prograf,Azathioprine) treatment;&lt;br&gt;&lt;br&gt;          -  Gestation already, prepares to be pregnant in the period of the trial, lactating&lt;br&gt;             women;&lt;br&gt;&lt;br&gt;          -  Participate in other product clinical trial within 30 days prior to this trial&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease</Condition>
    <Intervention>Behavioral: low protein diet plus a-keto acid;Behavioral: very low protein diet plus a-keto acid</Intervention>
    <Primary_outcome>changes in glomerular filtration rate</Primary_outcome>
    <Secondary_outcome>Compliance to diet;Quality of life;Cardiovascular morbidity;Nutritional status</Secondary_outcome>
    <Secondary_ID>ELPD-CKD</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2951264</Internal_Number>
    <TrialID>NCT01420354</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Can a Spot Urine Replace or Improve 24 Hour Urine Collections in Kidney Stone Patients</Public_title>
    <Scientific_title>Can a Spot Urine Replace or Improve 24 Hour Urine Collections in Kidney Stone Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of British Columbia</Primary_sponsor>
    <Date_registration3>20101018</Date_registration3>
    <Date_registration>18/10/2010</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01420354</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>19 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>August 2009</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case-Only, Time Perspective:  Cross-Sectional</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients who have been diagnosed as having calcium based urinary stones&lt;br&gt;&lt;br&gt;          -  at least 19 years of age&lt;br&gt;&lt;br&gt;          -  do not have any additional serious disease&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients who do not have calcium based urinary stones (such as: uric acid, cystine,&lt;br&gt;             struvite)&lt;br&gt;&lt;br&gt;          -  less than 19 years of age&lt;br&gt;&lt;br&gt;          -  have a serious alternate disease&lt;br&gt;&lt;br&gt;          -  Pregnancy&lt;br&gt;&lt;br&gt;          -  Positive Urine Culture&lt;br&gt;&lt;br&gt;          -  Active cancer&lt;br&gt;&lt;br&gt;          -  Recurrent urinary infections&lt;br&gt;&lt;br&gt;          -  Gross hematuria&lt;br&gt;&lt;br&gt;          -  Receiving treatment with thiazides (or alternatively can be enrolled if the patient&lt;br&gt;             is willing to stop treatment for 2 weeks prior to study)&lt;br&gt;&lt;br&gt;          -  Inability to provide informed consent&lt;br&gt;&lt;br&gt;          -  Investigator's refusal to include&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Stones</Condition>
    <Primary_outcome>Calcium supersaturation and the risk of Calcium Oxalate crystallization will be compared between individual spot urines and conventional 24-hour urine sample</Primary_outcome>
    <Secondary_outcome>Identified risk factors for kidney stone patients will be compared between individual spot urines and conventional 24-hour urine sample: volume, pH, Urinary calcium, magnesium, oxalate, citrate, creatinine</Secondary_outcome>
    <Secondary_ID>H08-02934</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2951373</Internal_Number>
    <TrialID>NCT01421771</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Blood Pressure in Dialysis Patients</Public_title>
    <Scientific_title>Blood Pressure in Dialysis Patients (BID Study)</Scientific_title>
    <Acronym>BID</Acronym>
    <Primary_sponsor>University of New Mexico</Primary_sponsor>
    <Date_registration3>20110816</Date_registration3>
    <Date_registration>16/08/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01421771</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2011</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria&lt;br&gt;&lt;br&gt;          1. Age = 18 years&lt;br&gt;&lt;br&gt;          2. On thrice weekly maintenance hemodialysis for greater than 90 days&lt;br&gt;&lt;br&gt;          3. Two-week average pre-dialysis RDUSYS BPM &gt;=155 mm Hg or if less than 155 on&lt;br&gt;             antihypertensive medications as follows:  at least 1 med for RDUSYS BPM 150-154, 2&lt;br&gt;             meds for RDUSYS BPM 145-149; 3 meds for RDUSYS BPM 140-144. Patient and physician&lt;br&gt;             must agree to backtitrate medications if RDU SYS BPM &lt;155.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Two- week average, pre-dialysis mid-week SDUSBPM =180 mmHg on maximal doses of = 4&lt;br&gt;             antihypertensive agents;&lt;br&gt;&lt;br&gt;          2. Inability to measure blood pressures in an upper arm;&lt;br&gt;&lt;br&gt;          3. History of inter or post-dialytic hypotension (defined as systolic blood pressure &lt;90&lt;br&gt;             mmHg) within the past 2 weeks or inter- or post- dialytic hypotension requiring&lt;br&gt;             hospitalization (including emergency room visit) and/or the use of midodrine in the&lt;br&gt;             past 6 months;&lt;br&gt;&lt;br&gt;          4. Required one or more urgent, unscheduled dialysis treatment for congestive heart&lt;br&gt;             failure in the past 3 months (other than in an incident patient at the time of&lt;br&gt;             starting dialysis);&lt;br&gt;&lt;br&gt;          5. Acute myocardial infarction, unstable angina or stroke/ TIA in past three the 3&lt;br&gt;             months;&lt;br&gt;&lt;br&gt;          6. Severe aortic valve stenosis (valve area &lt;1cm 2) carotid artery stenosis (&gt;70%&lt;br&gt;             stenosis);&lt;br&gt;&lt;br&gt;          7. Known abdominal aortic aneurysm &gt;5 cm in diameter or thoracic aortic aneurysm of any&lt;br&gt;             diameter;&lt;br&gt;&lt;br&gt;          8. Body mass index &gt;40 kg/m2 or arm circumference &gt; 52 cm, which precludes measuring&lt;br&gt;             blood pressure with the "thigh" blood pressure cuff;&lt;br&gt;&lt;br&gt;          9. Life expectancy &lt;1 year;&lt;br&gt;&lt;br&gt;         10. A living donor, kidney transplant, or switch to peritoneal dialysis scheduled within&lt;br&gt;             the next year;&lt;br&gt;&lt;br&gt;         11. Significant cognitive impairment;&lt;br&gt;&lt;br&gt;         12. spKt/V =1.2 in the past 2 months;&lt;br&gt;&lt;br&gt;         13. Active liver disease;&lt;br&gt;&lt;br&gt;         14. Active alcohol or substance abuse including narcotics within the past year;&lt;br&gt;&lt;br&gt;         15. Contraindication to cardiac MRI;&lt;br&gt;&lt;br&gt;         16. Current or planned pregnancy within the next year;&lt;br&gt;&lt;br&gt;         17. Unwillingness to consent to pregnancy test and/or use of birth control if of&lt;br&gt;             childbearing potential;&lt;br&gt;&lt;br&gt;         18. Suspicion that the participant will not be willing or able to adhere to prescribed&lt;br&gt;             medications and study protocol;&lt;br&gt;&lt;br&gt;         19. Incarcerated;&lt;br&gt;&lt;br&gt;         20. Significant concern about the study expressed by spouse, significant other, family&lt;br&gt;             member primary nephrologist or primary care physician;&lt;br&gt;&lt;br&gt;         21. Participation in another intervention study;&lt;br&gt;&lt;br&gt;         22. Unable to speak or understand English or Spanish;&lt;br&gt;&lt;br&gt;         23. Plan to relocate within one year;&lt;br&gt;&lt;br&gt;         24. participation in another intervention study .&lt;br&gt;&lt;br&gt;        During the screening pre-randomization phase, eligibility of potential subjects will be&lt;br&gt;        documented and evaluated using information in the On-Line Randomization Screen.  Patients&lt;br&gt;        will be instructed in study design, objectives, and procedures, after which informed&lt;br&gt;        consent will be obtained.  The study coordinator and site investigator should review this&lt;br&gt;        pre-randomization data with attention to judging the patient's ability to adhere to study&lt;br&gt;        protocols.  A maximum of 12-weeks will be allowed between the screening visit and&lt;br&gt;        randomization.  If over 12-weeks have elapsed, then potential subjects will need to be&lt;br&gt;        re-screened. Eligible participants will be instructed to bring their medications to the&lt;br&gt;        baseline visit.&lt;br&gt;&lt;br&gt;        The site PI and/or study coordinator will rescreen patients who appear to meet the study&lt;br&gt;        entry criteria using the Blood Pressure in Hemodialysis Pilot Study Eligibility Checking&lt;br&gt;        Form. The Blood Pressure in Hemodialysis Pilot Study Screening Physical Exam and Study&lt;br&gt;        Questionnaire Form will be completed for potential subjects who provide informed consent&lt;br&gt;        to assess eligibility for the study.  For women of childbearing potential, a urine&lt;br&gt;        pregnancy test will be done at a local lab and the results documented on this form.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Hypertension;Renal Failure Chronic Requiring Hemodialysis;Fluid Overload</Condition>
    <Intervention>Drug: Antihypertensive Agents;Other: Dry weight Challenge;Dietary Supplement: Extend dialysis treatment time and re-challenge estimated dry weight</Intervention>
    <Primary_outcome>Feasibility and safety of randomizing patients to a low (110-140 mm Hg) and standard (155-165 m Hg)pre-dialysis BP Goal</Primary_outcome>
    <Secondary_outcome>Change in LV mass;Health-related quality of life;Residual Renal Function;Feasibility of Performing Standardized Dialysis Unit BP Readings;Feasibility of home BP monitoring;Feasibility of ambulatory BP monitoring</Secondary_outcome>
    <Secondary_ID>1R01DK083424-01A1</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Tufts Medical Center;Medical University of South Carolina;University of Pittsburgh</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2951929</Internal_Number>
    <TrialID>NCT01429038</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Mesenchymal Stem Cells After Renal or Liver Transplantation</Public_title>
    <Scientific_title>Infusion of Third-party Mesenchymal Stem Cells After Renal or Liver Transplantation. A Phase I-II, Open-label, Clinical Study</Scientific_title>
    <Acronym />
    <Primary_sponsor>University Hospital of Liege</Primary_sponsor>
    <Date_registration3>20110901</Date_registration3>
    <Date_registration>01/09/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01429038</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>February 2012</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 1/Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Male or female patients between 18 and 75 years of age, who will undergo first Kidney&lt;br&gt;             Transplantation or whole Liver Transplantation from a cadaveric or donation after&lt;br&gt;             cardiac death (DCD) organ donor;&lt;br&gt;&lt;br&gt;          -  Fertile female patients must use a reliable contraception method;&lt;br&gt;&lt;br&gt;          -  Informed consent given by patient or his/next of kin if the patient is unable to give&lt;br&gt;             informed consent, for the complete (MSC + follow-up) or partial(no MSC + follow-up)&lt;br&gt;             study;&lt;br&gt;&lt;br&gt;          -  Successful liver/kidney transplantation, demonstration of organ function (improvement&lt;br&gt;             of INR in liver recipients and of creatinine in kidney recipients at 24-36h) and&lt;br&gt;             normal graft vasculature at Doppler examination.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Past history of malignant disease, with the exception of hepatocarcinoma within the&lt;br&gt;             Milan criteria for the Liver Transplantation patients;&lt;br&gt;&lt;br&gt;          -  Active uncontrolled infection;&lt;br&gt;&lt;br&gt;          -  HIV or HCV positive;&lt;br&gt;&lt;br&gt;          -  EBV-negative;&lt;br&gt;&lt;br&gt;          -  Retransplantation;&lt;br&gt;&lt;br&gt;          -  Combined transplantation;&lt;br&gt;&lt;br&gt;          -  Living related transplantation or split liver transplantation;&lt;br&gt;&lt;br&gt;          -  Autoimmune disease or expected impossibility to wean immunosuppression (Liver&lt;br&gt;             Transplantation) or corticosteroids (Kidney Transplantation);&lt;br&gt;&lt;br&gt;          -  Endotracheal intubation;&lt;br&gt;&lt;br&gt;          -  Postoperative cardiovascular instability, active hemorrhage, or any other serious&lt;br&gt;             clinical complication between transplantation and evaluation for suitability for MSC&lt;br&gt;             infusion;&lt;br&gt;&lt;br&gt;          -  For Kidney Transplantation: panel reactive antibodies (PRA) &gt;50%.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Liver Failure;Kidney Failure</Condition>
    <Intervention>Biological: Mesenchymal Stem Cells</Intervention>
    <Primary_outcome>Infusional toxicity;Incidence of infections (bacterial, viral, fungal, parasitic) and cancers</Primary_outcome>
    <Secondary_outcome>Patient and graft survivals;Effects of MSC on graft function;Biopsy-proven (Banff classification) rejection rates;Feasibility and safety of weaning or decreasing immunosuppression;Recipient's immune function;Anti-MSC donor HLA antibodies.</Secondary_outcome>
    <Secondary_ID>TJT1106P1</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2952113</Internal_Number>
    <TrialID>NCT01431430</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>VITamine D Supplementation in RenAL Transplant Recipients - VITALE</Public_title>
    <Scientific_title>Prospective Double Blind Multicentre Randomized Trial of Vitamine D Estimating the Profit of a Treatment by Vitamin D3 at the Dose of 100000 UI by Comparison With a Treatment in the Dose of 12 000 UI at Renal Transplanted Patients</Scientific_title>
    <Acronym>VITALE</Acronym>
    <Primary_sponsor>Assistance Publique - Hôpitaux de Paris</Primary_sponsor>
    <Date_registration3>20110822</Date_registration3>
    <Date_registration>22/08/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01431430</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2011</Date_enrollement>
    <Target_size>640</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Investigator), Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Renal transplant recipients between 12 and 48 months after transplantation with a&lt;br&gt;             stable renal function during the past 3 months.&lt;br&gt;&lt;br&gt;          -  Vitamine D insufficiency  defined as a concentration of 25OHD lower than 30 ng/ml.&lt;br&gt;&lt;br&gt;          -  Patient between 18 and 75 years old&lt;br&gt;&lt;br&gt;          -  Patient capable of understanding the advantages and the risks of the study.&lt;br&gt;&lt;br&gt;          -  Affiliated with social security health insurance&lt;br&gt;&lt;br&gt;          -  Written informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Calcaemia &gt; 2,7 mmol/l&lt;br&gt;&lt;br&gt;          -  Phosphataemia &gt; 1,5 mmol/l&lt;br&gt;&lt;br&gt;          -  Serum creatinine &gt; 250 µmol/l&lt;br&gt;&lt;br&gt;          -  Treatment by an active form of the vitamin D not being able to be interrupted&lt;br&gt;&lt;br&gt;          -  Transplant of an organ other than the kidney&lt;br&gt;&lt;br&gt;          -  Type I or type II diabetes mellitus&lt;br&gt;&lt;br&gt;          -  Past medical history of granulomatosis&lt;br&gt;&lt;br&gt;          -  Primary hyperoxaluria&lt;br&gt;&lt;br&gt;          -  Malabsorption proved by the liposoluble vitamins&lt;br&gt;&lt;br&gt;          -  Simultaneous participation in another therapeutic essay&lt;br&gt;&lt;br&gt;          -  Patients presenting a drug addiction or a psychiatric disorder&lt;br&gt;&lt;br&gt;          -  Pregnant or breast-feeding women&lt;br&gt;&lt;br&gt;          -  Vitamin D hyper sensibility&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Transplant Candidate for Right Kidney</Condition>
    <Intervention>Drug: Cholecalciferol 100 000 UI;Drug: Cholecalciferol 12 000 UI</Intervention>
    <Primary_outcome>De novo diabetes mellitus;Cardiovascular complications;De novo cancer;Patient death</Primary_outcome>
    <Secondary_outcome>Blood pressure control;Echocardiography findings;Infection including opportunistic;Acute rejection episode;Renal allograft function;Graft survival;Phosphocalcic biological and clinical relevant parameters;Renal lithiasis</Secondary_outcome>
    <Secondary_ID>P100103</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Laboratoire Crinex</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2952520</Internal_Number>
    <TrialID>NCT01436747</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Efficacy and Safety of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients</Public_title>
    <Scientific_title>Efficacy and Safety of Selective Vitamin D Receptor Activation With Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients: a Randomized Controlled Trial</Scientific_title>
    <Acronym />
    <Primary_sponsor>University Medical Centre Ljubljana</Primary_sponsor>
    <Date_registration3>20110914</Date_registration3>
    <Date_registration>14/09/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01436747</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2012</Date_enrollement>
    <Target_size>166</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Investigator), Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Recipients of a deceased donor kidney transplant at least 3 months after&lt;br&gt;             transplantation&lt;br&gt;&lt;br&gt;          -  Urinary protein to creatinine ratio (UPCR) &gt; 200 mg/g (22 mg/mmol) as determined by&lt;br&gt;             the the mean of three second morning void urine specimens&lt;br&gt;&lt;br&gt;          -  Subject is on stable immunosuppression for at least 3 months&lt;br&gt;&lt;br&gt;          -  Subject is on stable doses of antihypertensive medications for at least 3 months&lt;br&gt;&lt;br&gt;          -  Subject is not expected to begin dialysis for at least 6 months&lt;br&gt;&lt;br&gt;          -  Estimated glomerular filtration rate &gt; 15 ml/min/1.73 m2&lt;br&gt;&lt;br&gt;          -  Corrected serum calcium level &lt;= 2.5 mmol/l&lt;br&gt;&lt;br&gt;          -  Intact parathormone value &gt; 35 pg/ml&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Subjects on vitamin D receptor activation therapy within 3 months prior to the first&lt;br&gt;             study visit&lt;br&gt;&lt;br&gt;          -  Diagnosis of primary focal segmental glomerulosclerosis (FSGS)&lt;br&gt;&lt;br&gt;          -  Acute kidney injury within 3 months of the first study visit&lt;br&gt;&lt;br&gt;          -  Subjects with poorly controlled hypertension&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Disorder of Transplanted Kidney;Proteinuria;Albuminuria</Condition>
    <Intervention>Drug: Paricalcitol;Drug: Placebo</Intervention>
    <Primary_outcome>The percentage change in urinary protein to creatinine ratio (UPCR) from baseline to the last measurement during treatment.</Primary_outcome>
    <Secondary_outcome>The percentage change in urinary albumin to creatinine ratio (UACR) from baseline to the last measurement during treatment.;The percentage change in 24-hour urinary protein excretion form baseline to the last measurement during treatment.;The proportion of patients achieving at least a 15% reduction in the last on-treatment UPCR level from the baseline.;Change in estimated glomerular filtration rate, blood pressure and biomarkers, including (but not limited to) C-reactive protein, plasma renin activity, aldosterone.</Secondary_outcome>
    <Secondary_ID>31-06-2011</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Abbott</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2952838</Internal_Number>
    <TrialID>NCT01440881</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Does Nesiritide Provide Renal Protection</Public_title>
    <Scientific_title>Does Nesiritide Provide Renal Protection By Attenuating the Inflammatory Response</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Florida</Primary_sponsor>
    <Date_registration3>20110210</Date_registration3>
    <Date_registration>10/02/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01440881</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2010</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator), Primary Purpose:  Prevention</Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients undergoing surgery on their aortic arch, ascending aorta, or having aortic&lt;br&gt;             valve or mitral valve surgery&lt;br&gt;&lt;br&gt;          -  Baseline MDRD (modification of diet in renal disease) calculated GFR (Glomerular&lt;br&gt;             Filtration Rate) 30-90 ml/min.&lt;br&gt;&lt;br&gt;          -  Signed Informed Consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age &lt;18 or &gt;80&lt;br&gt;&lt;br&gt;          -  Ejection Fraction &lt;30%.&lt;br&gt;&lt;br&gt;          -  Presence of endocarditis or other infection.&lt;br&gt;&lt;br&gt;          -  Presence or anticipated use of an intra-aortic balloon pump.&lt;br&gt;&lt;br&gt;          -  History of an organ transplant.&lt;br&gt;&lt;br&gt;          -  History of an adverse reaction to nesiritide.&lt;br&gt;&lt;br&gt;          -  Surgery performed without cardiopulmonary bypass.&lt;br&gt;&lt;br&gt;          -  Receiving Aprotinin&lt;br&gt;&lt;br&gt;          -  Dopamine administered in doses &lt;5 mcg /kg min.&lt;br&gt;&lt;br&gt;          -  Women of child bearing potential or pregnant or breastfeeding.&lt;br&gt;&lt;br&gt;          -  Participation in any other investigational trial&lt;br&gt;&lt;br&gt;          -  Jehovah Witness&lt;br&gt;&lt;br&gt;          -  Bleeding Disorder&lt;br&gt;&lt;br&gt;          -  Active Endocarditis&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Failure</Condition>
    <Intervention>Drug: Nesiritide;Drug: Placebo</Intervention>
    <Primary_outcome>The examine and measure of Neutrophils,cytokines, endothelin 1 and the urinary NGAL(neutrophil gelatinase associated lipocalin) to measure for Kidney injury.</Primary_outcome>
    <Secondary_outcome>Difference in patients receiving nesiritide and placebo at different time points.;Difference in patients receiving nesiritide and placebo at different time points</Secondary_outcome>
    <Secondary_ID>09KW-03;70-2010</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2952945</Internal_Number>
    <TrialID>NCT01442272</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Value Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D</Public_title>
    <Scientific_title>Clinical Trial, Open, Parallel Groups , Value the Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D</Scientific_title>
    <Acronym>NEFROVID2010</Acronym>
    <Primary_sponsor>Hospital Universitario de Canarias</Primary_sponsor>
    <Date_registration3>20110926</Date_registration3>
    <Date_registration>26/09/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01442272</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2012</Date_enrollement>
    <Target_size>174</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Male/female Patients older 18 years old&lt;br&gt;&lt;br&gt;          -  Patients have signed written informed consent&lt;br&gt;&lt;br&gt;          -  Chronic Kidney Illness phase II-IV plus residual proteinuria &gt;0,5 grams/day (two or&lt;br&gt;             more consecutive occasions) and plus beta blockers treatment from AARS during al&lt;br&gt;             least 3 months.&lt;br&gt;&lt;br&gt;          -  Serum levels of calcifediol in the lack of level (15-30 ng/ml).&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Bad control of high blood pressure (higher or same 180/110 mmHg)&lt;br&gt;&lt;br&gt;          -  Bad control of diabetes (HbA1c higher 9,5 in the last three months period)&lt;br&gt;&lt;br&gt;          -  Hypercalcemia (&lt;10,2 mg/dL) o hyperphosphatemia(&gt;5,5  mg/dL),  CaxPO4&gt;50,&lt;br&gt;             hypercalciuria (urin Ca/Cr quotient &gt; 0,15)&lt;br&gt;&lt;br&gt;          -  Vitamin D treatment or any analogous&lt;br&gt;&lt;br&gt;          -  Hepatic failure ( AST o ALT &gt; 3 times higher than normal limit)&lt;br&gt;&lt;br&gt;          -  medical history of poor nutrient intestinal absorptions or chronic diarrhea&lt;br&gt;&lt;br&gt;          -  Active nephrolithiasis&lt;br&gt;&lt;br&gt;          -  Treatment with medication wich can change vitamin D metabolism (phenobarbital,&lt;br&gt;             phenytoin, rifampicin)&lt;br&gt;&lt;br&gt;          -  Participation in other Clinic Trial in 3 last months&lt;br&gt;&lt;br&gt;          -  Active Alcoholism&lt;br&gt;&lt;br&gt;          -  Neoplasia precedent (except cutaneous no melanoma)&lt;br&gt;&lt;br&gt;          -  Pregnant women  or while breastfeeding&lt;br&gt;&lt;br&gt;          -  Vitamin D hypersensitivity or any its excipient hypersensitivity&lt;br&gt;&lt;br&gt;          -  Any other condition from Research&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Kidney Failure, Chronic;Disorder of Vitamin D</Condition>
    <Intervention>Drug: Hidroferol®;Drug: Paricalcitol: Zemplar®;Drug: Habitual medication</Intervention>
    <Primary_outcome>Protein/creatinine quotient and albumin/creatinine in matinal urine sample: basal and 3 period months after a month of the therapeutic protocol beginning.</Primary_outcome>
    <Secondary_ID>NEFROVID2010</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2952992</Internal_Number>
    <TrialID>NCT01442883</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Renal Nerve Ablation in Chronic Kidney Disease Patients</Public_title>
    <Scientific_title>Understanding the Mechanisms of Progressive Decrease in Blood Pressure After Renal Nerve Ablation</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Erlangen-Nürnberg Medical School</Primary_sponsor>
    <Date_registration3>20110922</Date_registration3>
    <Date_registration>22/09/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01442883</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>85 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2010</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  treatment resistant hypertension&lt;br&gt;&lt;br&gt;          -  chronic kidney disease 3 - 5&lt;br&gt;&lt;br&gt;          -  male of female aged over 18 years&lt;br&gt;&lt;br&gt;          -  written informed consent&lt;br&gt;&lt;br&gt;          -  agreement to attend all study visits as planned in the protocol&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  any contraindications for MRI&lt;br&gt;&lt;br&gt;          -  claustrophobia&lt;br&gt;&lt;br&gt;          -  strabismus&lt;br&gt;&lt;br&gt;          -  severe ocular diseases&lt;br&gt;&lt;br&gt;          -  history of epilepsia&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Hypertension;Chronic Kidney Disease</Condition>
    <Intervention>Device: Simplicity Catheter</Intervention>
    <Primary_outcome>office BP;24-h ABPM;Magnetic resonance imaging (MRI);Albuminuria;local RAS activity;systemic RAS activity;vascular structure and function of large and small arteries</Primary_outcome>
    <Secondary_outcome>BP;local RAS activity;systemic RAS activity;vascular structure and function of large and small arteries;MRI</Secondary_outcome>
    <Secondary_ID>RNA-CKD3-5</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2953177</Internal_Number>
    <TrialID>NCT01445366</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Solute Removal With High Volume Hemodiafiltration Versus Long High Flux Hemodialysis</Public_title>
    <Scientific_title>Solute Removal With High Volume Hemodiafiltration Versus Long High Flux Hemodialysis</Scientific_title>
    <Acronym />
    <Primary_sponsor>University Hospital, Ghent</Primary_sponsor>
    <Date_registration3>20110922</Date_registration3>
    <Date_registration>22/09/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01445366</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2012</Date_enrollement>
    <Target_size>10</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Crossover Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Chronic kidney disease (CKD) stage 5 with hemodialysis or hemodiafiltration treatment&lt;br&gt;             for more than three months.&lt;br&gt;&lt;br&gt;          -  No vascular access related problems (Arteriovenous (A/V) fistula, graft or bi-flow&lt;br&gt;             catheter)&lt;br&gt;&lt;br&gt;          -  Double needle/lumen vascular access&lt;br&gt;&lt;br&gt;          -  No ongoing infection&lt;br&gt;&lt;br&gt;          -  Singed informed consent form&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Inclusion criteria not met&lt;br&gt;&lt;br&gt;          -  Known HIV or active hepatitis B or C infection (Positive Polymerisation Chain&lt;br&gt;             Reaction (PCR))&lt;br&gt;&lt;br&gt;          -  Pregnancy&lt;br&gt;&lt;br&gt;          -  Unstable clinical condition (e.g. cardiac or vascular instability)&lt;br&gt;&lt;br&gt;          -  Known coagulation problems&lt;br&gt;&lt;br&gt;          -  Patients participating in another study interfering with the planned study.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End-stage Renal Disease</Condition>
    <Intervention>Device: High volume post dilution hemodiafiltration;Device: high flux hemodialysis</Intervention>
    <Primary_outcome>Uremic retention solute concentrations from pre and post dialysis blood samples,dialyzer inlet and outlet blood samples,and spent dialysate samples.;Uremic retention solute concentrations from pre and post dialysis blood samples,dialyzer inlet and outlet blood samples,and spent dialysate samples.</Primary_outcome>
    <Secondary_ID>2011/591</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2953258</Internal_Number>
    <TrialID>NCT01446484</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection</Public_title>
    <Scientific_title>Phase 1 Pilot Study Using Autologous CD4+CD25+FoxP3+ T Regulatory Cells and Campath-1H to Induce Renal Transplant Tolerance</Scientific_title>
    <Acronym />
    <Primary_sponsor>The Russian State Medical University</Primary_sponsor>
    <Date_registration3>20111003</Date_registration3>
    <Date_registration>03/10/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01446484</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>1 Year</Inclusion_agemin>
    <Inclusion_agemax>18 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2011</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 1/Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Weight greater than  10  kg (    lbs)&lt;br&gt;&lt;br&gt;          -  Will be receiving a living-related primary kidney allograft&lt;br&gt;&lt;br&gt;          -  Negative B-cell and T-cell cytotoxic and flow cytometry crossmatch&lt;br&gt;&lt;br&gt;          -  Normal echocardiogram (ECG) with an ejection fraction of greater than 50%&lt;br&gt;&lt;br&gt;          -  Received full course of vaccination for hepatitis B virus (HBV), completed at&lt;br&gt;             least 6 weeks before transplantation, OR has naturally acquired immunity&lt;br&gt;&lt;br&gt;          -  Parents willing to comply with the study visits&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Previously received or is receiving an organ transplant other than a kidney&lt;br&gt;&lt;br&gt;          -  Receiving an ABO incompatible donor kidney&lt;br&gt;&lt;br&gt;          -  HIV infected&lt;br&gt;&lt;br&gt;          -  Antibody positive for hepatitis C virus&lt;br&gt;&lt;br&gt;          -  Surface antigen positive for HBV&lt;br&gt;&lt;br&gt;          -  Recipient or donor is positive for tuberculosis (TB), under treatment for suspected&lt;br&gt;             TB, or previously exposed to TB (positive Mantoux test)&lt;br&gt;&lt;br&gt;          -  Current cancer or a history of cancer within the 5 years prior to study entry.&lt;br&gt;             Patients who have had successfully treated nonmetastatic basal or squamous cell&lt;br&gt;             carcinoma of the skin or carcinoma in situ of the cervix are not excluded.&lt;br&gt;&lt;br&gt;          -  Significant liver disease, defined as having continuously elevated AST (SGOT) or ALT&lt;br&gt;             (SGPT) levels greater than 3 times the upper value of the normal range within 28 days&lt;br&gt;             prior to study entry&lt;br&gt;&lt;br&gt;          -  Uncontrolled concomitant infections, severe diarrhea, vomiting, active upper&lt;br&gt;             gastrointestinal tract malabsorption, active peptic ulcer, or any other unstable&lt;br&gt;             medical condition that could interfere with this study&lt;br&gt;&lt;br&gt;          -  Currently receiving an investigational drug or received an investigational drug&lt;br&gt;             within 30 days prior to transplant&lt;br&gt;&lt;br&gt;          -  Currently receiving any immunosuppressive agent&lt;br&gt;&lt;br&gt;          -  Anticipated contraindication to taking medications orally or via nasogastric tube by&lt;br&gt;             the morning of Day 2 following completion of the transplant procedure&lt;br&gt;&lt;br&gt;          -  Require certain medications&lt;br&gt;&lt;br&gt;          -  Known hypersensitivity to any of the study medications,&lt;br&gt;&lt;br&gt;          -  Any form of substance abuse, psychiatric disorder, or other condition that, in&lt;br&gt;             opinion of the investigator, may interfere with the study&lt;br&gt;&lt;br&gt;          -  Anticipated contraindication to study medications administration for longer than 5&lt;br&gt;             days post-transplant&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End-Stage Renal Disease;Kidney Failure</Condition>
    <Intervention>Biological: CD4+CD25+CD127lowFoxP3+  T regulatory cells injection;Drug: Alemtuzumab;Drug: Mycophenolate mofetil;Drug: Sirolimus;Drug: Tacrolimus;Drug: Cyclosporine;Drug: Everolimus;Procedure: Kidney transplantation</Intervention>
    <Primary_outcome>Patient and graft survival</Primary_outcome>
    <Secondary_outcome>Patient and graft survival;Incidence rate of biopsy-proven acute rejection, defined as a renal biopsy demonstrating acute cellular or humoral rejection of Banff Grade IA or greater;Incidence of chronic allograft nephropathy, determined using renal biopsies and laboratory values, including 24-hour urine protein excretion;Incidence of adverse events associated with renal transplantation and immunosuppression</Secondary_outcome>
    <Secondary_ID>RSMU-001</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Russian Academy of Medical Sciences</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2953258</Internal_Number>
    <TrialID>NCT01446484</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection</Public_title>
    <Scientific_title>Phase 1 Pilot Study Using Autologous CD4+CD25+FoxP3+ T Regulatory Cells and Campath-1H to Induce Renal Transplant Tolerance</Scientific_title>
    <Acronym />
    <Primary_sponsor>The Russian State Medical University</Primary_sponsor>
    <Date_registration3>20111003</Date_registration3>
    <Date_registration>03/10/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01446484</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>1 Year</Inclusion_agemin>
    <Inclusion_agemax>18 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2011</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 1/Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Weight greater than  10  kg (    lbs)&lt;br&gt;&lt;br&gt;          -  Will be receiving a living-related primary kidney allograft&lt;br&gt;&lt;br&gt;          -  Negative B-cell and T-cell cytotoxic and flow cytometry crossmatch&lt;br&gt;&lt;br&gt;          -  Normal echocardiogram (ECG) with an ejection fraction of greater than 50%&lt;br&gt;&lt;br&gt;          -  Received full course of vaccination for hepatitis B virus (HBV), completed at&lt;br&gt;             least 6 weeks before transplantation, OR has naturally acquired immunity&lt;br&gt;&lt;br&gt;          -  Parents willing to comply with the study visits&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Previously received or is receiving an organ transplant other than a kidney&lt;br&gt;&lt;br&gt;          -  Receiving an ABO incompatible donor kidney&lt;br&gt;&lt;br&gt;          -  HIV infected&lt;br&gt;&lt;br&gt;          -  Antibody positive for hepatitis C virus&lt;br&gt;&lt;br&gt;          -  Surface antigen positive for HBV&lt;br&gt;&lt;br&gt;          -  Recipient or donor is positive for tuberculosis (TB), under treatment for suspected&lt;br&gt;             TB, or previously exposed to TB (positive Mantoux test)&lt;br&gt;&lt;br&gt;          -  Current cancer or a history of cancer within the 5 years prior to study entry.&lt;br&gt;             Patients who have had successfully treated nonmetastatic basal or squamous cell&lt;br&gt;             carcinoma of the skin or carcinoma in situ of the cervix are not excluded.&lt;br&gt;&lt;br&gt;          -  Significant liver disease, defined as having continuously elevated AST (SGOT) or ALT&lt;br&gt;             (SGPT) levels greater than 3 times the upper value of the normal range within 28 days&lt;br&gt;             prior to study entry&lt;br&gt;&lt;br&gt;          -  Uncontrolled concomitant infections, severe diarrhea, vomiting, active upper&lt;br&gt;             gastrointestinal tract malabsorption, active peptic ulcer, or any other unstable&lt;br&gt;             medical condition that could interfere with this study&lt;br&gt;&lt;br&gt;          -  Currently receiving an investigational drug or received an investigational drug&lt;br&gt;             within 30 days prior to transplant&lt;br&gt;&lt;br&gt;          -  Currently receiving any immunosuppressive agent&lt;br&gt;&lt;br&gt;          -  Anticipated contraindication to taking medications orally or via nasogastric tube by&lt;br&gt;             the morning of Day 2 following completion of the transplant procedure&lt;br&gt;&lt;br&gt;          -  Require certain medications&lt;br&gt;&lt;br&gt;          -  Known hypersensitivity to any of the study medications,&lt;br&gt;&lt;br&gt;          -  Any form of substance abuse, psychiatric disorder, or other condition that, in&lt;br&gt;             opinion of the investigator, may interfere with the study&lt;br&gt;&lt;br&gt;          -  Anticipated contraindication to study medications administration for longer than 5&lt;br&gt;             days post-transplant&lt;br&gt;      </Inclusion_Criteria>
    <Condition>End-Stage Renal Disease;Kidney Failure</Condition>
    <Intervention>Biological: CD4+CD25+CD127lowFoxP3+  T regulatory cells injection;Drug: Alemtuzumab;Drug: Mycophenolate mofetil;Drug: Sirolimus;Drug: Tacrolimus;Drug: Cyclosporine;Drug: Everolimus;Procedure: Kidney transplantation</Intervention>
    <Primary_outcome>Patient and graft survival</Primary_outcome>
    <Secondary_outcome>Patient and graft survival;Incidence rate of biopsy-proven acute rejection, defined as a renal biopsy demonstrating acute cellular or humoral rejection of Banff Grade IA or greater;Incidence of chronic allograft nephropathy, determined using renal biopsies and laboratory values, including 24-hour urine protein excretion;Incidence of adverse events associated with renal transplantation and immunosuppression</Secondary_outcome>
    <Secondary_ID>RSMU-001</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Russian Academy of Medical Sciences</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2953577</Internal_Number>
    <TrialID>NCT01450657</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Observational Study of Kibow Biotics in Chronic Kidney Failure Patients</Public_title>
    <Scientific_title>Observational Clinical Trials of Kibow Biotics (a Patented and Proprietary Probiotic Dietary Supplement) in Chronic Kidney Failure Patients, in Conjunction With Standardized Care of Treatment</Scientific_title>
    <Acronym />
    <Primary_sponsor>Kibow Biotech Inc.</Primary_sponsor>
    <Date_registration3>20110926</Date_registration3>
    <Date_registration>26/09/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01450657</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2011</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age 18 to 75 years&lt;br&gt;&lt;br&gt;          -  CKD Stages 3 and 4 as documented by prior medical history&lt;br&gt;&lt;br&gt;          -  Serum Creatinine &gt;2.5 mg/dL&lt;br&gt;&lt;br&gt;          -  Stable and on CKD status 3 and 4 at least for a year or more&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Pregnant or nursing women&lt;br&gt;&lt;br&gt;          -  Refusal to sign the informed consent form&lt;br&gt;&lt;br&gt;          -  Documented to have HIV/AIDS/Liver disease&lt;br&gt;&lt;br&gt;          -  Active dependency on drugs or alcohol&lt;br&gt;&lt;br&gt;          -  Any non-related medical, debilitating disease/disorder that would interfere with&lt;br&gt;             adherence to this study&lt;br&gt;&lt;br&gt;          -  Currently on anticoagulant therapy&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Failure</Condition>
    <Intervention>Dietary Supplement: Kibow Biotics/Renadyl</Intervention>
    <Primary_outcome>15-20% Changes in BUN.;15-20% Change in Creatinine</Primary_outcome>
    <Secondary_outcome>Quality of life outcome based on questionnaire.;To observe inflammatory and oxidative stress biomarkers.;Observation and analysis of patient fecal matter.</Secondary_outcome>
    <Secondary_ID>KIB002</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Thomas Jefferson University</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2953578</Internal_Number>
    <TrialID>NCT01450670</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Observational Study of Kibow Biotics in Dialysis Patients</Public_title>
    <Scientific_title>Observational Clinical Trials of Kibow Biotics (a Patented and Proprietary Probiotic Dietary Supplement) in Dialysis Patients, in Conjunction With Standardized Care of Treatment</Scientific_title>
    <Acronym />
    <Primary_sponsor>Kibow Biotech Inc.</Primary_sponsor>
    <Date_registration3>20110926</Date_registration3>
    <Date_registration>26/09/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01450670</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2011</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Currently on hemodialysis&lt;br&gt;&lt;br&gt;          -  18 to 75 years of age&lt;br&gt;&lt;br&gt;          -  Willing to give informed consent&lt;br&gt;&lt;br&gt;          -  Baseline serum creatinine &gt;2.5 mg/dL&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Pregnant or nursing women&lt;br&gt;&lt;br&gt;          -  Refusal to sign the informed consent form&lt;br&gt;&lt;br&gt;          -  Documented to have HIV/AIDS/Liver disease&lt;br&gt;&lt;br&gt;          -  Active dependency on drugs or alcohol&lt;br&gt;&lt;br&gt;          -  Currently on anticoagulant therapy&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Failure</Condition>
    <Intervention>Dietary Supplement: Kibow Biotics</Intervention>
    <Primary_outcome>15-20% Changes in BUN.;15-20% Changes in Creatinine;15-20% Changes in CRP;15-20% Change in Uric Acid Levels</Primary_outcome>
    <Secondary_outcome>Quality of life outcome based on SF 36 questionnaire.;To observe inflammatory and oxidative stress biomarkers.</Secondary_outcome>
    <Secondary_ID>KIB003</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Thomas Jefferson University</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2953581</Internal_Number>
    <TrialID>NCT01450709</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Observational Study of Kibow Biotics in Chronic Kidney Failure Patients on Dialysis</Public_title>
    <Scientific_title>Observational Clinical Trials of Kibow Biotics® (a Patented and Proprietary Probiotic Formulation) in Dialysis Patients, in Conjunction With Standardized Care of Treatment</Scientific_title>
    <Acronym />
    <Primary_sponsor>Kibow Biotech Inc.</Primary_sponsor>
    <Date_registration3>20110926</Date_registration3>
    <Date_registration>26/09/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01450709</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2011</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Currently on hemodialysis&lt;br&gt;&lt;br&gt;          -  18 to 75 years of age&lt;br&gt;&lt;br&gt;          -  Willing to give informed consent&lt;br&gt;&lt;br&gt;          -  Baseline serum creatinine &gt;2.5 mg/dL&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Pregnant or nursing women&lt;br&gt;&lt;br&gt;          -  Refusal to sign the informed consent form&lt;br&gt;&lt;br&gt;          -  Documented to have HIV/AIDS/Liver disease&lt;br&gt;&lt;br&gt;          -  Active dependency on drugs or alcohol&lt;br&gt;&lt;br&gt;          -  Currently on anticoagulant therapy&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease</Condition>
    <Intervention>Dietary Supplement: Kibow Biotics</Intervention>
    <Primary_outcome>15-20% Changes in BUN.;15-20% Changes in Creatinine;15-20% Changes in CRP;15-20% Changes in Uric Acid Levels</Primary_outcome>
    <Secondary_outcome>Quality of life outcome based on SF 36 questionnaire.;To observe inflammatory and oxidative stress biomarkers.;Observation and analysis of patient fecal matter.</Secondary_outcome>
    <Secondary_ID>KIB004</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>State University of New York - Downstate Medical Center</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2953712</Internal_Number>
    <TrialID>NCT01452412</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Alkali Therapy in Chronic Kidney Disease</Public_title>
    <Scientific_title>Placebo-controlled Randomized Clinical Trial of Alkali Therapy in Patients With Chronic Kidney Disease</Scientific_title>
    <Acronym />
    <Primary_sponsor>Albert Einstein College of Medicine of Yeshiva University</Primary_sponsor>
    <Date_registration3>20111012</Date_registration3>
    <Date_registration>12/10/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01452412</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>19 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>October 2011</Date_enrollement>
    <Target_size>150</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 2/Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Estimate GFR &lt;= 45 and &gt;15 ml/min/1.73m2&lt;br&gt;&lt;br&gt;          -  Age &gt;18&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Previous chronic treatment with alkali within the last 3 months (including sodium&lt;br&gt;             bicarbonate, calcium carbonate or baking soda)&lt;br&gt;&lt;br&gt;          -  bicarbonate level &lt;20 or &gt;25 mEq/L&lt;br&gt;&lt;br&gt;          -  New York Heart Association Class III or IV heart failure&lt;br&gt;&lt;br&gt;          -  Systolic blood pressure &gt;180 mmHg&lt;br&gt;&lt;br&gt;          -  Initiation of ESRD treatment planned within 6 months&lt;br&gt;&lt;br&gt;          -  Kidney transplantation&lt;br&gt;&lt;br&gt;          -  Treatment with immunosuppressives within the last 3 months&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease;Metabolic Acidosis</Condition>
    <Intervention>Drug: Sodium bicarbonate;Drug: Placebo</Intervention>
    <Primary_outcome>HOMA-IR;Sit to stand to sit speed;DEXA of wrist;Urinary NGAL and KIM-1</Primary_outcome>
    <Secondary_outcome>Glucose disposal rate by euglycemic hyperinsulinemic clamp;Hand-grip strength;Serum PTH;Bone-specific alkaline phosphatase;Serum calcium;Serum phosphate;Serum 1,25-dihydroxyvitamin D;serum creatinine;serum cystatin C;urinary albumin/ creatinine ratio;urinary cystatin</Secondary_outcome>
    <Secondary_ID>R01DK087783;CCI-2009-408</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);National Institutes of Health (NIH)</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2954457</Internal_Number>
    <TrialID>NCT01462097</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Exercise Trial in Chronic Kidney Disease</Public_title>
    <Scientific_title>Randomized Trial of Aerobic Exercise Training on Cognitive and Physical Function in Chronic Kidney Disease</Scientific_title>
    <Acronym>AWARD</Acronym>
    <Primary_sponsor>University of Maryland</Primary_sponsor>
    <Date_registration3>20111026</Date_registration3>
    <Date_registration>26/10/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01462097</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>60 Years</Inclusion_agemin>
    <Inclusion_agemax>85 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2012</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Single Blind (Outcomes Assessor)</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Stage 3-4 Chronic kidney disease (estimated GFR 15-45)&lt;br&gt;&lt;br&gt;          -  Age 60 to 85&lt;br&gt;&lt;br&gt;          -  English Speaking&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Dementia or cognitive impairment&lt;br&gt;&lt;br&gt;          -  Renal transplant&lt;br&gt;&lt;br&gt;          -  NY Heart Association class 3-4 heart failure&lt;br&gt;&lt;br&gt;          -  Severe Chronic Lung Disease&lt;br&gt;&lt;br&gt;          -  Unstable angina or coronary revascularization within the last 3 months&lt;br&gt;&lt;br&gt;          -  Orthopedic problems that would preclude aerobic exercise training&lt;br&gt;&lt;br&gt;          -  Known, untreated infection&lt;br&gt;&lt;br&gt;          -  Disabling arthritis&lt;br&gt;&lt;br&gt;          -  Uncontrolled arrhythmia&lt;br&gt;&lt;br&gt;          -  More than 14 alcoholic drinks per week&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease</Condition>
    <Intervention>Behavioral: Aerobic exercise training;Behavioral: Health Education</Intervention>
    <Primary_outcome>Change in neurocognitive function;Change in peak aerobic capacity;Change in 6 minute walk</Primary_outcome>
    <Secondary_outcome>Change in physical Function;Change in endothelial function;Change in health-related quality of life;Change in cardiovascular disease risk factors</Secondary_outcome>
    <Secondary_ID>1R01DK090401-01A1;HP-00045276</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>National Institutes of Health (NIH);National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2954795</Internal_Number>
    <TrialID>NCT01466504</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Effect of Sorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin</Public_title>
    <Scientific_title>A Study of the Effect of Sorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin</Scientific_title>
    <Acronym />
    <Primary_sponsor>Dartmouth-Hitchcock Medical Center</Primary_sponsor>
    <Date_registration3>20111031</Date_registration3>
    <Date_registration>31/10/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01466504</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>May 2011</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Male or female, 18 years old or older.&lt;br&gt;&lt;br&gt;          2. Histologically or cytologically confirmed diagnosis of a solid tumor(Renal Cell&lt;br&gt;             Carcinoma or Hepatocellular Carcinoma).&lt;br&gt;&lt;br&gt;          3. Participants are planning to initiate treatment with sorafenib as a single&lt;br&gt;             chemotherapeutic agent&lt;br&gt;&lt;br&gt;          4. Able to swallow and retain oral medication and does not have any clinically relevant,&lt;br&gt;             active gastrointestinal disease or other condition that may significantly alter&lt;br&gt;             absorption, distribution, metabolism, or excretion of drugs.&lt;br&gt;&lt;br&gt;          5. Life expectancy of at least four months in the opinion of the investigator.&lt;br&gt;&lt;br&gt;          6. Be able to provide written informed consent.&lt;br&gt;&lt;br&gt;        Exclusion Criteria&lt;br&gt;&lt;br&gt;          1. Patients who are or will be receiving other chemotherapeutic or molecularly targeted&lt;br&gt;             agents in addition to sorafenib&lt;br&gt;&lt;br&gt;          2. Concurrent moderate or severe chronic inflammatory skin condition (eczema, psoriasis)&lt;br&gt;&lt;br&gt;          3. Concurrent blistering skin disorder of any severity (such as pemphigus, bullous&lt;br&gt;             pemphigoid)&lt;br&gt;&lt;br&gt;          4. Connective tissue disorders with skin involvement (systemic lupus erythematosus,&lt;br&gt;             scleroderma, dermatomyositis, etc.)&lt;br&gt;&lt;br&gt;          5. Patients manifesting an allergic skin reaction (such as urticaria) or skin reaction&lt;br&gt;             as a complication of prior chemotherapy&lt;br&gt;&lt;br&gt;          6. Patients with skin lesions of infectious or non-infectious cause, precluding skin&lt;br&gt;             biopsy&lt;br&gt;&lt;br&gt;          7. Patients not willing to undergo skin biopsy&lt;br&gt;&lt;br&gt;          8. Patients who are pregnant or planning to become pregnant during their participation&lt;br&gt;             in the study.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Cell Carcinoma;Hepatocellular Carcinoma</Condition>
    <Intervention>Procedure: skin punch biopsy</Intervention>
    <Primary_outcome>p63 expression levels</Primary_outcome>
    <Secondary_outcome>Tumor response</Secondary_outcome>
    <Secondary_ID>D11004</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2954830</Internal_Number>
    <TrialID>NCT01466959</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>The Effect of Citrasate Dialysate on Heparin Dose in Hemodialysis</Public_title>
    <Scientific_title>The Effect of Citrasate Dialysate on Heparin Dose: A Randomized Cross Over Trial in Hemodialysis Patients.</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Calgary</Primary_sponsor>
    <Date_registration3>20111011</Date_registration3>
    <Date_registration>11/10/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01466959</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2011</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Crossover Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Supportive Care</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  chronic stable HD patients = 18 years&lt;br&gt;&lt;br&gt;          -  on HD at least three times per week for at least 3 months&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  contraindication to heparin&lt;br&gt;&lt;br&gt;          -  currently using heparin-free HD&lt;br&gt;&lt;br&gt;          -  known clotting disorder&lt;br&gt;&lt;br&gt;          -  on warfarin therapy&lt;br&gt;&lt;br&gt;          -  dialyzing with a dysfunctional central venous catheter (blood flow rates consistently&lt;br&gt;             less than 300mL/min and/or frequent use of thrombolytic)&lt;br&gt;&lt;br&gt;          -  history of vascular access dysfunction&lt;br&gt;&lt;br&gt;          -  planned vascular access conversion or procedure during the study period&lt;br&gt;&lt;br&gt;          -  use of high calcium dialysate&lt;br&gt;&lt;br&gt;          -  active medical issue requiring hospitalization&lt;br&gt;&lt;br&gt;          -  planned kidney transplant during the study period&lt;br&gt;&lt;br&gt;          -  planned conversion of dialysis modality (peritoneal dialysis, nocturnal dialysis)&lt;br&gt;             during the study period&lt;br&gt;&lt;br&gt;          -  unable to provide informed consent&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease</Condition>
    <Intervention>Other: citrate dialysate (CD);Other: acetic-acid based dialysate (AD)</Intervention>
    <Primary_outcome>The change from baseline in the cumulative dose of heparin anticoagulation used during conventional HD</Primary_outcome>
    <Secondary_outcome>The change from baseline in the number of bleeding events, and bleeding time after HD.;The change from baseline in the number of intradialytic hypotension episodes and the change from baseline in the QT interval;The change in small and middle solute clearance from baseline.;The change from baseline on laboratory inflammatory markers as well as ionized calcium (iCa), magnesium (Mg), and bicarbonate (HCO3).;The intra-rater and inter-rater reliability of our dialyzer / venous chamber clotting score.</Secondary_outcome>
    <Secondary_ID>ID24009</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2954854</Internal_Number>
    <TrialID>NCT01467271</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Observational Study on the Incidence of NSF in Renal Impaired Patients Following DOTAREM Administration</Public_title>
    <Scientific_title>Observational Study on the Incidence of NSF in Renal Impaired Patients Following DOTAREM Administration</Scientific_title>
    <Acronym>NSsaFe</Acronym>
    <Primary_sponsor>Guerbet</Primary_sponsor>
    <Date_registration3>20111104</Date_registration3>
    <Date_registration>04/11/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01467271</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2011</Date_enrollement>
    <Target_size>1000</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with moderate to severe and end stage renal impairment or dialysis,&lt;br&gt;             scheduled for a contrast enhanced MRI with DOTAREM&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patient who has received a Gadolinium Based Contrast Agent within the past 12 months&lt;br&gt;             prior to inclusion in this study&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Insufficiency</Condition>
    <Primary_outcome>Number of patients with moderate to severe renal impairment who develop Nephrogenic Systemic Fibrosis after administration of DOTAREM</Primary_outcome>
    <Secondary_ID>DGD-55-003</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2955138</Internal_Number>
    <TrialID>NCT01471002</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Study to Evaluate the Efficacy of Percutaneous Cryoablation for Renal Tumours &lt; 4cm in Patients Who Are Not Candidates for Partial Nephrectomy</Public_title>
    <Scientific_title>Prospective Study to Evaluate the Efficacy of Percutaneous Cryoablation for Renal Tumours &lt; 4cm in Patients Who Are Not Candidates for Partial Nephrectomy</Scientific_title>
    <Acronym>CRYOREIN</Acronym>
    <Primary_sponsor>University Hospital, Strasbourg, France</Primary_sponsor>
    <Date_registration3>20111103</Date_registration3>
    <Date_registration>03/11/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01471002</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2011</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        Patients should have the following characteristics:&lt;br&gt;&lt;br&gt;          -  About 75 years, or&lt;br&gt;&lt;br&gt;          -  Whatever the age:&lt;br&gt;&lt;br&gt;               -  A context of family-type tumor (VHL, hereditary carcinoma, tubulo-papillary&lt;br&gt;                  ...);&lt;br&gt;&lt;br&gt;               -  or solitary kidney, when the tumor is not easily accessible for nephron-sparing&lt;br&gt;                  surgery: Malignant centro-hilar or intra-parenchymal;&lt;br&gt;&lt;br&gt;               -  or in a local recurrence (single or multiple) after partial nephrectomy (within&lt;br&gt;                  a limit of 3 tumors to be treated);&lt;br&gt;&lt;br&gt;               -  or in a subject with impaired renal function and therefore at risk of severe&lt;br&gt;                  renal insufficiency (risk defined by a creatinine clearance below 30 ml / min by&lt;br&gt;                  MDRD formula);&lt;br&gt;&lt;br&gt;               -  and who do not present any contra-indication for cryoablation treatment.&lt;br&gt;&lt;br&gt;        The tumor(s) should meet the following criteria:&lt;br&gt;&lt;br&gt;          -  Presence of one to three solid tumors of the native renal parenchyma with a largest&lt;br&gt;             diameter less than (or equal to) 40 mm, which corresponds to a maximum volume of&lt;br&gt;             about 32 cc, as measured by MRI.&lt;br&gt;&lt;br&gt;          -  A preoperative MRI is essential since this technique presents a higher sensitivity.&lt;br&gt;             This control will also give more consistency to the evaluation of the radiological&lt;br&gt;             semiology at follow-up.&lt;br&gt;&lt;br&gt;          -  And its/their location(s) will be accessible to a percutaneous approach.&lt;br&gt;&lt;br&gt;        The search of metastases, including a thoracic CT scan, should be negative.&lt;br&gt;&lt;br&gt;        Exclusion Criter ia:&lt;br&gt;&lt;br&gt;          -  - Partial nephrectomy feasible in good technical and oncologic conditions in patients&lt;br&gt;             under 75 years and in the absence of family tumors.&lt;br&gt;&lt;br&gt;          -  Contraindication to any form of sedation.&lt;br&gt;&lt;br&gt;          -  Irreversible coagulopathy&lt;br&gt;&lt;br&gt;          -  Tumor&gt; 4cm&lt;br&gt;&lt;br&gt;          -  Contraindication to MRI or gadolinium (proven allergy). NB: Patients with a&lt;br&gt;             glomerular filtration rate below 30 ml/min/1, 73 m2 will be injected with a single&lt;br&gt;             dose of the macrocyclic gadolinium with the highest thermodynamic stability (Dotarem&lt;br&gt;             or Prohance), given the united recommendations of AFSSAPS and EMA (European Medicines&lt;br&gt;             Agency) [45].  On the contrary, the linear molecules of gadolinium, due to their&lt;br&gt;             lower stability, will be contra-indicated because of the risk of systemic nephrogenic&lt;br&gt;             fibrosis (FNS).&lt;br&gt;&lt;br&gt;          -  Recurrence on the same location after a procedure performed out of the thermoablation&lt;br&gt;             protocol.&lt;br&gt;&lt;br&gt;          -  Biopsy proven benign tumor&lt;br&gt;&lt;br&gt;          -  Predominantly cystic tumor, defined by a necrotic content constituting over one third&lt;br&gt;             of tumor volume&lt;br&gt;&lt;br&gt;          -  Presence of endo-venous extension, of proven secondary extensions, visceral or in the&lt;br&gt;             lymph nodes (especially lung). In this regard, a thoracic CT scan will be routinely&lt;br&gt;             required before treatment, according to the recommendations of urological societies.&lt;br&gt;&lt;br&gt;          -  Psychiatric disorders and adults under guardianship&lt;br&gt;&lt;br&gt;          -  Pregnancy or breastfeeding&lt;br&gt;&lt;br&gt;          -  Minor patients&lt;br&gt;&lt;br&gt;          -  Legal safeguard&lt;br&gt;&lt;br&gt;          -  Participation in another clinical trial&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Tumors Less Than 4 cm</Condition>
    <Intervention>Device: Galil Medical patented 17G Cryoablation Needles</Intervention>
    <Primary_outcome>Suspicious contrast enhancement and progression in size of the cryolesion detected by MRI</Primary_outcome>
    <Secondary_ID>5062</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2955956</Internal_Number>
    <TrialID>NCT01481688</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Enhancing Dialysis Adequacy: Effects of Intradialytic Exercise</Public_title>
    <Scientific_title>Intradialytic Exercise for Enhanced Dialysis Adequacy and Solute Removal in Chronic Kidney Disease Patients: A Randomised Controlled Trial.</Scientific_title>
    <Acronym />
    <Primary_sponsor>Bangor University</Primary_sponsor>
    <Date_registration3>20111124</Date_registration3>
    <Date_registration>24/11/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01481688</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>November 2011</Date_enrollement>
    <Target_size>14</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Crossover Assignment, Masking:  Single Blind (Outcomes Assessor), Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Stage 5 Chronic Kidney Disease&lt;br&gt;&lt;br&gt;          -  Receiving maintenance haemodialysis for &gt; 3 months&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Unable to give consent&lt;br&gt;&lt;br&gt;          -  Present with contraindications to take part in exercise&lt;br&gt;&lt;br&gt;          -  Haemoglobin &lt;11 g/dL&lt;br&gt;&lt;br&gt;          -  Access recirculation&lt;br&gt;&lt;br&gt;          -  Chronic persistent hypotension with pre dialysis systolic blood pressures &lt;100mgHg.&lt;br&gt;&lt;br&gt;          -  Episodic treatment induced hypotension with frequent drops in intradialytic systolic&lt;br&gt;             blood pressure &gt;30mmgHg&lt;br&gt;&lt;br&gt;          -  Unstable medical condition&lt;br&gt;&lt;br&gt;          -  Currently taking medication affecting urea or creatinine generation&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease</Condition>
    <Intervention>Other: Exercise;Other: Extra time</Intervention>
    <Primary_outcome>Urea clearance</Primary_outcome>
    <Secondary_outcome>Urea clearance</Secondary_outcome>
    <Secondary_ID>Kirkman 11/WA/0112;11/WA/0112</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Betsi Cadwaladr University Health Board (implementation);B.Braun Avitum AG</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2956286</Internal_Number>
    <TrialID>NCT01485978</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome</Public_title>
    <Scientific_title>Early Prospective Therapy Trial to Delay Renal Failure in Children With Alport Syndrome</Scientific_title>
    <Acronym />
    <Primary_sponsor>Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH</Primary_sponsor>
    <Date_registration3>20111202</Date_registration3>
    <Date_registration>02/12/2011</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01485978</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin>24 Months</Inclusion_agemin>
    <Inclusion_agemax>18 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>March 2012</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Investigator), Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 3</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Definitive diagnosis of Alport syndrome: Kidney biopsy (patient or affected&lt;br&gt;             relative/s), and/or mutation analysis (hemizygous X-chromosomal or homozygous&lt;br&gt;             autosomal-recessive) and assessment of criteria for clinical diagnosis (haematuria,&lt;br&gt;             positive family history regarding kidney diseases, ocular changes, labyrinthine&lt;br&gt;             hearing loss)&lt;br&gt;&lt;br&gt;          -  Alport syndrome levels 0 or I at screening (microhaematuria without microalbuminuria&lt;br&gt;             or microalbuminuria [30-300 mg albumin/gCrea])&lt;br&gt;&lt;br&gt;          -  Aged between =24 months and &lt;18 years at screening&lt;br&gt;&lt;br&gt;          -  Assent from patient and informed consent from parents/legal guardian&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Uncertain diagnosis or variants of Alport syndrome such as a heterozygous carrier&lt;br&gt;&lt;br&gt;          -  Alport syndrome levels II, , III, or IV (albuminuria &gt;300 mg/g Crea, creatinine&lt;br&gt;             clearance &lt;60 mL/min, or end stage renal failure [ESRF])&lt;br&gt;&lt;br&gt;          -  Known allergies or intolerances to ramipril or related compounds&lt;br&gt;&lt;br&gt;          -  Known contraindication for ACEi-therapy&lt;br&gt;&lt;br&gt;          -  Additional chronic renal, pulmonary or cardiac diseases&lt;br&gt;&lt;br&gt;          -  Pregnancy and lactation&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Renal Insufficiency, Chronic</Condition>
    <Intervention>Drug: Ramipril;Drug: placebo to ramipril;Drug: Ramipril</Intervention>
    <Primary_outcome>Time to next disease level;Incidence of Adverse Drug Events before progression</Primary_outcome>
    <Secondary_outcome>Albuminuria after three years;Adverse Drug Events over three years</Secondary_outcome>
    <Secondary_ID>EARLY_PRO-TECT_ALPORT</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>University Medical Center Goettingen;German Federal Ministry of Education and Research</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2957647</Internal_Number>
    <TrialID>NCT01503710</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Early Diagnosis of Postoperative Acute Renal Failure-using Biomarker to Predict Outcome of Cardiac Surgery Associated Acute Kidney Injury</Public_title>
    <Scientific_title>Early Diagnosis of Postoperative Acute Renal Failure - Using Biomarker to Predict the Outcome of Cardiac Surgery Associated Acute Kidney Injury</Scientific_title>
    <Acronym>NSARF</Acronym>
    <Primary_sponsor>National Taiwan University Hospital</Primary_sponsor>
    <Date_registration3>20120102</Date_registration3>
    <Date_registration>02/01/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01503710</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2011</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Cross-Sectional</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  AKI is defined as a serum creatinine level greater that 50% more than baseline during&lt;br&gt;             the first 3 postoperative days (PODs), and non-AKI, as a less than 10% increase.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with chronic kidney disease (baseline estimated glomerular filtration rate &lt;&lt;br&gt;             60 mL/min/1.73 m2 as calculated by using the 4-variable Modification of Diet in Renal&lt;br&gt;             Disease Study equation, or protein-creatinine ratio &gt; 100 mg/mmol) are excluded.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Renal Failure;Acute Kidney Injury</Condition>
    <Secondary_ID>201105047RC</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>National Science Council, Taiwan</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2957647</Internal_Number>
    <TrialID>NCT01503710</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Early Diagnosis of Postoperative Acute Renal Failure-using Biomarker to Predict Outcome of Cardiac Surgery Associated Acute Kidney Injury</Public_title>
    <Scientific_title>Early Diagnosis of Postoperative Acute Renal Failure - Using Biomarker to Predict the Outcome of Cardiac Surgery Associated Acute Kidney Injury</Scientific_title>
    <Acronym>NSARF</Acronym>
    <Primary_sponsor>National Taiwan University Hospital</Primary_sponsor>
    <Date_registration3>20120102</Date_registration3>
    <Date_registration>02/01/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01503710</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>June 2011</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Cross-Sectional</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  AKI is defined as a serum creatinine level greater that 50% more than baseline during&lt;br&gt;             the first 3 postoperative days (PODs), and non-AKI, as a less than 10% increase.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with chronic kidney disease (baseline estimated glomerular filtration rate &lt;&lt;br&gt;             60 mL/min/1.73 m2 as calculated by using the 4-variable Modification of Diet in Renal&lt;br&gt;             Disease Study equation, or protein-creatinine ratio &gt; 100 mg/mmol) are excluded.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Acute Renal Failure;Acute Kidney Injury</Condition>
    <Secondary_ID>201105047RC</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>National Science Council, Taiwan</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2957956</Internal_Number>
    <TrialID>NCT01507740</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients</Public_title>
    <Scientific_title>Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>Medical University Innsbruck</Primary_sponsor>
    <Date_registration3>20090918</Date_registration3>
    <Date_registration>18/09/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01507740</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>July 2009</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Case-Only, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age over 18 years&lt;br&gt;&lt;br&gt;          -  Patients with HCC, NSCLC, RCC or CRC treated with an approved antiangiogenic drug&lt;br&gt;             (bevacizumab, sorafenib, sunitinib)*&lt;br&gt;&lt;br&gt;          -  Patients with at least one measurable lesion. Lesions must be measurable by CT-scan&lt;br&gt;             or MRI (Magnetic resonance imaging) according to Response Evaluation Criteria in&lt;br&gt;             Solid Tumours (RECIST)&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Pregnant or breast-feeding patients.  Women of childbearing potential must have a&lt;br&gt;             negative pregnancy test performed within 7 days of the start of treatment.  Both men&lt;br&gt;             and women enrolled in this trial must use adequate birth control measures during the&lt;br&gt;             course of the trial. The definition of effective contraception will be based on the&lt;br&gt;             judgment of the principal investigator or a designated associate.&lt;br&gt;&lt;br&gt;          -  Substance abuse, medical, psychological or social conditions that may interfere with&lt;br&gt;             the patient's participation in the study or evaluation of the study results&lt;br&gt;&lt;br&gt;          -  Known or suspected allergy to the investigational agent or any agent given in&lt;br&gt;             association with this trial -_&gt; allergy&lt;br&gt;&lt;br&gt;          -  MRI contraindications: implants (pacemaker)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Hepatocellular Cancer;Non-small Cell Lung Cancer;Renal Cell Cancer;Colorectal Cancer</Condition>
    <Intervention>Drug: Avastin;Drug: Suntent;Drug: Nexavar</Intervention>
    <Primary_outcome>Progression free survival under antiangiogenic therapy</Primary_outcome>
    <Secondary_ID>Praemarker AAT 08</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2958054</Internal_Number>
    <TrialID>NCT01509027</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Study of the Compliance With Phosphorus Restricted Diet and Phosphate Binder Therapy in Hemodialysis Patients</Public_title>
    <Scientific_title>A Randomized Controlled Trial to Evaluate the Impact of Education on the Knowledge About and Compliance With a Phosphorus Restricted Diet and Phosphate Binder Therapy in Maintenance Dialysis Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>Universitaire Ziekenhuizen Leuven</Primary_sponsor>
    <Date_registration3>20120109</Date_registration3>
    <Date_registration>09/01/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01509027</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2012</Date_enrollement>
    <Target_size>150</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation:  Non-Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Single Blind (Subject), Primary Purpose:  Health Services Research</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  prevalent (&gt;3months) hemodialysis patients&lt;br&gt;&lt;br&gt;          -  aged &gt; 18 years&lt;br&gt;&lt;br&gt;          -  informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  decreased consciousness&lt;br&gt;&lt;br&gt;          -  unstable&lt;br&gt;&lt;br&gt;          -  medical contraindication for phosphorus restricted diet or phsophate binder therapy&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Chronic Kidney Disease</Condition>
    <Intervention>Behavioral: education by DVD;Behavioral: Standard care;Behavioral: Education by DVD and dietician</Intervention>
    <Primary_outcome>compliance;serum phosphate levels</Primary_outcome>
    <Secondary_outcome>risk factors of noncompliance</Secondary_outcome>
    <Secondary_ID>B322201112895</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
  </Trial>
  <Trial>
    <Internal_Number>2958373</Internal_Number>
    <TrialID>NCT01513187</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma</Public_title>
    <Scientific_title>Phase I/II Prospective, Open Label and Multicentric Clinical Trial to Determine the Recommended Dose (Phase I) and Efficacy of Pazopanib in Combination With Interferon Alfa 2-A (Phase II), in Patients With Advanced Renal Cell Carcinoma</Scientific_title>
    <Acronym />
    <Primary_sponsor>Spanish Oncology Genito-Urinary Group</Primary_sponsor>
    <Date_registration3>20120110</Date_registration3>
    <Date_registration>10/01/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01513187</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2010</Date_enrollement>
    <Target_size>57</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</Study_design>
    <Phase>Phase 1/Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Signed informed consent&lt;br&gt;&lt;br&gt;          2. Age = 18 years.&lt;br&gt;&lt;br&gt;          3. Patients diagnosed histologically clear cell carcinoma of the kidney metastatic or&lt;br&gt;             unresectable locally advanced, previously untreated. However, in Phase I may include&lt;br&gt;             patients with primary tumors other than renal cell can benefit from these drugs and&lt;br&gt;             patients with renal cell carcinoma treated before.&lt;br&gt;&lt;br&gt;          4. Performance status (ECOG) 0-1.&lt;br&gt;&lt;br&gt;          5. Patients must have measurable disease by RECIST criteria V 1.1. Progression should be&lt;br&gt;             documented in the two months prior to study entry.&lt;br&gt;&lt;br&gt;          6. Patients may not have received prior treatment with anti-VEGF agents, mTOR inhibitors&lt;br&gt;             or cytokines. However, in Phase I may include patients who have received any previous&lt;br&gt;             treatment.&lt;br&gt;&lt;br&gt;          7. Paraffin tumor sample should be available and collection of serum from all subjects&lt;br&gt;             for biomarker analysis previously and / or during treatment with study medication.&lt;br&gt;&lt;br&gt;          8. Adequate Hematologic, liver and kidney functions.&lt;br&gt;&lt;br&gt;          9. Women of childbearing potential must be using an effective method of birth control&lt;br&gt;             (abstinence, any intrauterine device [IUD] published data showing that the expected&lt;br&gt;             minimum rate of failure is less than 1% per year, or any other method the published&lt;br&gt;             data show that the expected minimum rate of failure is less than 1% per year) before&lt;br&gt;             inclusion in the study and continue using it during the same six months after&lt;br&gt;             completion. Women of childbearing age should get a negative pregnancy test in urine&lt;br&gt;             or serum (minimum sensitivity 25 IU / L or equivalent units of beta fraction of human&lt;br&gt;             chorionic gonadotropin [ß-HCG]) during the seven days prior to the randomization.&lt;br&gt;&lt;br&gt;         10. Able to swallow oral compound.&lt;br&gt;&lt;br&gt;         11. Willingness and ability to attend scheduled visits, to follow the treatment schedule&lt;br&gt;             and to undergo clinical trials and other study procedures&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. History of prior malignancies diagnosed or treated over the past 5 years except basal&lt;br&gt;             cell skin cancer or prostate cancer incidentally detected previously treated.&lt;br&gt;             However, patients with a history of malignancy but free of the disease over the past&lt;br&gt;             5 years, or patients with a history of nonmelanoma skin carcinoma-completely-resected&lt;br&gt;             or carcinoma in situ treated successfully can participate in the study .&lt;br&gt;&lt;br&gt;             In Phase I, patients diagnosed with other previous or concomitant malignant diseases&lt;br&gt;             can be included.&lt;br&gt;&lt;br&gt;          2. Presence of metastases in the central nervous system (CNS) or leptomeningeal&lt;br&gt;             carcinomatosis, except for patients with previously treated CNS metastases,&lt;br&gt;             asymptomatic and have not needed corticosteroids or anticonvulsant drugs in the 3&lt;br&gt;             months prior to administering the first dose of the drug under study. Only is&lt;br&gt;             required CNS imaging studies (computed tomography [CT] or magnetic resonance imaging&lt;br&gt;             [MRI]) if clinically indicated or if the individual has a history of CNS metastases.&lt;br&gt;&lt;br&gt;          3. Clinically significant gastrointestinal disorders may increase the risk of&lt;br&gt;             gastrointestinal bleeding including, but not limited to:&lt;br&gt;&lt;br&gt;             Active peptic ulcer disease Known metastatic lesions with probable intraluminal&lt;br&gt;             bleeding Inflammatory bowel disease (ulcerative colitis, Crohn's disease) or other&lt;br&gt;             gastrointestinal disorders with increased risk of perforation History of abdominal&lt;br&gt;             fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days&lt;br&gt;             before the start of study treatment.&lt;br&gt;&lt;br&gt;          4. Clinically significant gastrointestinal abnormalities may affect the absorption of&lt;br&gt;             the investigational product such as but not limited to:&lt;br&gt;&lt;br&gt;             Malabsorption syndrome Major resection of the stomach or small intestine Grade 3&lt;br&gt;             diarrhea&lt;br&gt;&lt;br&gt;          5. Patients with active infection or other disease or serious medical condition.&lt;br&gt;&lt;br&gt;          6. Prolongation of the corrected QT wave (QTc)&gt; 480 ms on baseline ECG according to the&lt;br&gt;             Bazett formula.&lt;br&gt;&lt;br&gt;          7. Subjects with a history of one or more of the following cardiovascular disease in the&lt;br&gt;             last 6 months prior to the inclusion in the study:&lt;br&gt;&lt;br&gt;             Angioplasty or stent placement Myocardial infarction Unstable Angina Coronary bypass&lt;br&gt;             surgery Symptomatic peripheral vascular disease Congestive heart failure Class II,&lt;br&gt;             III or IV New York Heart Association (NYHA)&lt;br&gt;&lt;br&gt;          8. Poorly controlled hypertension [defined as systolic blood pressure (SBP) = 140 mmHg&lt;br&gt;             or diastolic blood pressure stress (DBP) = 90 mmHg] while the patient is on&lt;br&gt;             antihypertensive therapy.&lt;br&gt;&lt;br&gt;             Note: the commencement or adjustment of antihypertensive medication it is possible&lt;br&gt;             before the patient study start. In the baseline period measure blood pressure at&lt;br&gt;             least twice with a minimum interval of 24 hours. The mean values ??of SBP / DBP in&lt;br&gt;             each blood pressure reading should be &lt;140/90 mmHg to include the subject in the&lt;br&gt;             study.&lt;br&gt;&lt;br&gt;          9. Background, in the last six months prior to the inclusion of stroke (including&lt;br&gt;             transient ischemic attacks), pulmonary embolism or deep vein thrombosis (DVT)&lt;br&gt;             untreated.&lt;br&gt;&lt;br&gt;             Note: may be included subjects with recent DVT who received anticoagulants for at&lt;br&gt;             least 6 months.&lt;br&gt;&lt;br&gt;         10. Surgery or trauma in the last 28 days, or minor surgery (eg., Removal of central&lt;br&gt;             venous catheter) in the last 7 days prior to inclusion or unhealed wound, fracture,&lt;br&gt;             or ulcer.&lt;br&gt;&lt;br&gt;         11. Evidence of active bleeding or bleeding diathesis.&lt;br&gt;&lt;br&gt;         12. Hemoptysis within 6 weeks prior to inclusion.&lt;br&gt;&lt;br&gt;         13. Pregnant or breastfeeding.&lt;br&gt;&lt;br&gt;         14. Any medical condition (eg. Uncontrolled infection), psychiatric or other to be&lt;br&gt;             serious and / or unstable and may interfere with the safety of the patient, obtaining&lt;br&gt;             informed consent or compliance with study procedures.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Advanced Renal Cell Carcinoma</Condition>
    <Intervention>Drug: Pazopanib + interferon alpha 2A</Intervention>
    <Primary_outcome>Maximum tolerated dose (MTD) - Phase I;Efficacy, response rate (Phase II)</Primary_outcome>
    <Secondary_outcome>Progression free survival;Overall Survival;Toxicity;Translational Substudy</Secondary_outcome>
    <Secondary_ID>SOGUG-2010-01</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>GlaxoSmithKline</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2958413</Internal_Number>
    <TrialID>NCT01513707</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>The Effects of Pre-transplant Dialysis Modality on Post-transplant Events</Public_title>
    <Scientific_title>The Effects of Pre-transplant Dialysis Modality on Post-transplant Events</Scientific_title>
    <Acronym>PDMP</Acronym>
    <Primary_sponsor>Ha Young Oh</Primary_sponsor>
    <Date_registration3>20120116</Date_registration3>
    <Date_registration>16/01/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01513707</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>20 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>December 2011</Date_enrollement>
    <Target_size>1040</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Subjects must have end-stage renal disease, have been on one renal replacement&lt;br&gt;             therapy (hemodialysis or peritoneal dialysis) for &gt; 6 months ( Who had been on&lt;br&gt;             hemodialysis for at least 6 months before renal transplant for the hemodialysis&lt;br&gt;             group; Who had been on peritoneal dialysis for at least 6 months before renal&lt;br&gt;             transplant for the peritoneal dialysis group ), and are scheduled to receive a first&lt;br&gt;             kidney transplant from a deceased donor, a living-related donor, or a&lt;br&gt;             living-unrelated donor.&lt;br&gt;&lt;br&gt;          2. Between the ages of 20 and 70 years, inclusive.&lt;br&gt;&lt;br&gt;          3. Either female or male adults&lt;br&gt;&lt;br&gt;          4. Subjects must be willing and able to provide written personal information consent&lt;br&gt;             with evidence of a personally signed and dated personal information consent document&lt;br&gt;             indicating that the subject (or a legally acceptable representative) has been&lt;br&gt;             informed of all pertinent aspects of the study.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Subjects who had combined dialysis (hemodialysis + peritoneal dialysis&lt;br&gt;             simultaneously).&lt;br&gt;&lt;br&gt;          2. Subjects who are recipients for multiple organ transplant.&lt;br&gt;&lt;br&gt;          3. Subjects scheduled for non-heart beating donor transplantation.&lt;br&gt;&lt;br&gt;          4. Subjects scheduled for transplantation using desensitization (plasmapheresis +&lt;br&gt;             Rituximab) process.&lt;br&gt;&lt;br&gt;          5. Subjects with evidence of active infection.&lt;br&gt;&lt;br&gt;          6. Women of childbearing potential who are either pregnant, lactating, planning to&lt;br&gt;             become pregnant in the next 12 months. Women of childbearing potential must be&lt;br&gt;             willing to agree to contraceptive practices.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Delayed Function of Renal Transplant;Primary Nonfunction of Renal Transplant;Acute Rejection of Renal Transplant</Condition>
    <Primary_outcome>composite outcomes (delayed graft function, functional delayed graft function, primary nonfunction, biopsy-proven acute rejection)</Primary_outcome>
    <Secondary_outcome>eGFR;Hospitalization;graft loss;Subject death</Secondary_outcome>
    <Secondary_ID>2011-12-005</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Baxter Healthcare Corporation</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2958413</Internal_Number>
    <TrialID>NCT01513707</TrialID>
    <Last_Refreshed_on>17 October 2012</Last_Refreshed_on>
    <Public_title>The Effects of Pre-transplant Dialysis Modality on Post-transplant Events</Public_title>
    <Scientific_title>The Effects of Pre-transplant Dialysis Modality on Post-transplant Events</Scientific_title>
    <Acronym>PDMP</Acronym>
    <Primary_sponsor>Ha Young Oh</Primary_sponsor>
    <Date_registration3>20120116</Date_registration3>
    <Date_registration>16/01/2012</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01513707</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>20 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>December 2011</Date_enrollement>
    <Target_size>1040</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model:  Cohort, Time Perspective:  Prospective</Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Subjects must have end-stage renal disease, have been on one renal replacement&lt;br&gt;             therapy (hemodialysis or peritoneal dialysis) for &gt; 6 months ( Who had been on&lt;br&gt;             hemodialysis for at least 6 months before renal transplant for the hemodialysis&lt;br&gt;             group; Who had been on peritoneal dialysis for at least 6 months before renal&lt;br&gt;             transplant for the peritoneal dialysis group ), and are scheduled to receive a first&lt;br&gt;             kidney transplant from a deceased donor, a living-related donor, or a&lt;br&gt;             living-unrelated donor.&lt;br&gt;&lt;br&gt;          2. Between the ages of 20 and 70 years, inclusive.&lt;br&gt;&lt;br&gt;          3. Either female or male adults&lt;br&gt;&lt;br&gt;          4. Subjects must be willing and able to provide written personal information consent&lt;br&gt;             with evidence of a personally signed and dated personal information consent document&lt;br&gt;             indicating that the subject (or a legally acceptable representative) has been&lt;br&gt;             informed of all pertinent aspects of the study.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Subjects who had combined dialysis (hemodialysis + peritoneal dialysis&lt;br&gt;             simultaneously).&lt;br&gt;&lt;br&gt;          2. Subjects who are recipients for multiple organ transplant.&lt;br&gt;&lt;br&gt;          3. Subjects scheduled for non-heart beating donor transplantation.&lt;br&gt;&lt;br&gt;          4. Subjects scheduled for transplantation using desensitization (plasmapheresis +&lt;br&gt;             Rituximab) process.&lt;br&gt;&lt;br&gt;          5. Subjects with evidence of active infection.&lt;br&gt;&lt;br&gt;          6. Women of childbearing potential who are either pregnant, lactating, planning to&lt;br&gt;             become pregnant in the next 12 months. Women of childbearing potential must be&lt;br&gt;             willing to agree to contraceptive practices.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Delayed Function of Renal Transplant;Primary Nonfunction of Renal Transplant;Acute Rejection of Renal Transplant</Condition>
    <Primary_outcome>composite outcomes (delayed graft function, functional delayed graft function, primary nonfunction, biopsy-proven acute rejection)</Primary_outcome>
    <Secondary_outcome>eGFR;Hospitalization;graft loss;Subject death</Secondary_outcome>
    <Secondary_ID>2011-12-005</Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors</Source_Support>
    <Secondary_Sponsor>Baxter Healthcare Corporation</Secondary_Sponsor>
  </Trial>
</Trials_downloaded_from_ICTRP>